PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Jenkins, TD; Nakagawa, H; Rustgi, AK				Jenkins, TD; Nakagawa, H; Rustgi, AK			The association of Epstein-Barr virus DNA with esophageal squamous cell carcinoma	ONCOGENE			English	Article						Epstein-Barr virus; esophageal cancer; genomic sequence	LYMPHOEPITHELIOMA-LIKE CARCINOMA; NASOPHARYNGEAL CARCINOMA; GASTRIC ADENOCARCINOMA; HUMAN PAPILLOMAVIRUS; RAS MUTATIONS; CYCLIN D1; EXPRESSION; GENE; CANCER; AMPLIFICATION	The Epstein-Barr virus (EBV), a member of the herpesviruses, is a double stranded 170 kilobase DNA virus important in many human benign and malignant conditions. It has been implicated in the pathogenesis of proliferative diseases of lymphocytes and tumors of epithelial derivation. The etiology and pathogenesis of esophageal squamous cell carcinoma (ESCC) is thought to involve a combination of genetic and environmental events which lead to epithelial cell transformation. The aim of this study was to determine whether an association exists between EBV and ESCC. DNA was extracted from 16 human ESCC cell lines and microdissected tumor specimens from 60 patients. The polymerase chain reaction was used to amplify a 400 base pair fragment corresponding to the BamHIW fragment repeat sequence of EBV. Southern blotting, utilizing an oligonucleotide probe specific for the BamH1W sequence, was used to confirm positive results and increase sensitivity of detection. 5/60 tumor samples and 1/16 ESCC cell Lines were positive for the EBV sequence. Positive tumor samples were estimated to contain one copy of EBV per 20 cellular genomes. Given the role of EBV in other tumors of epithelial derivation, it is possible that EBV may contribute to the molecular pathogenesis of ESCC.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,GASTROINTESTINAL UNIT,BOSTON,MA 02114; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,HEMATOL ONCOL UNIT,BOSTON,MA 02114	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NIDDK NIH HHS [DK40561, T2DK07191D21] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007191, P30DK040561] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRICHACEK B, 1984, JNCI-J NATL CANCER I, V72, P809; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; BUTLER AE, 1989, AM J SURG PATHOL, V13, P632, DOI 10.1097/00000478-198908000-00002; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHANG FJ, 1992, GASTROENTEROLOGY, V103, P1336, DOI 10.1016/0016-5085(92)91526-A; CHOI PHK, 1993, CANCER-AM CANCER SOC, V72, P2873, DOI 10.1002/1097-0142(19931115)72:10<2873::AID-CNCR2820721003>3.0.CO;2-A; COHEN JI, 1993, ANN INTERN MED, V118, P45; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; HAFIZ MA, 1985, OBSTET GYNECOL, V66, P829; HARN HJ, 1995, HUM PATHOL, V26, P267, DOI 10.1016/0046-8177(95)90056-X; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HITT MM, 1989, EMBO J, V8, P2639, DOI 10.1002/j.1460-2075.1989.tb08404.x; HOLLSTEIN MC, 1991, CANCER RES, V51, P4102; HOLLSTEIN MC, 1988, CANCER RES, V48, P5119; HUI PK, 1994, HUM PATHOL, V25, P947, DOI 10.1016/0046-8177(94)90017-5; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1992, CANCER RES, V52, P2980; KIEFF E, 1995, NEW ENGL J MED, V333, P724, DOI 10.1056/NEJM199509143331110; KIEFF E, 1990, VIROLOGY, P1889; KITCHEN VS, 1990, GUT, V31, P1223, DOI 10.1136/gut.31.11.1223; LABRECQUE LG, 1995, CANCER RES, V55, P39; LEWENSOHNFUCHS I, 1994, ANTICANCER RES, V14, P1281; LIU QY, 1995, ONCOGENE, V10, P619; MCGUIRE LJ, 1988, AM J PATHOL, V131, P385; MIN KW, 1991, AM J CLIN PATHOL, V96, P219, DOI 10.1093/ajcp/96.2.219; MORI M, 1994, ARCH PATHOL LAB MED, V118, P998; NAKAGAWA H, 1995, CANCER-AM CANCER SOC, V76, P541, DOI 10.1002/1097-0142(19950815)76:4<541::AID-CNCR2820760402>3.0.CO;2-I; Oikawa Ou, 1995, Hokkaido Journal of Medical Science, V70, P729; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PATHMANATHAN R, 1995, AM J PATHOL, V146, P1355; ROWLANDS DC, 1993, BRIT J CANCER, V68, P1014, DOI 10.1038/bjc.1993.472; SHIBATA D, 1992, AM J PATHOL, V140, P769; SHIBATA D, 1991, AM J PATHOL, V139, P469; SWANSON SA, 1988, MODERN PATHOL, V1, P359; TOGAWA K, 1994, GASTROENTEROLOGY, V107, P128, DOI 10.1016/0016-5085(94)90070-1; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Wong Fen-Hwa, 1992, Chinese Journal of Microbiology and Immunology (Taipei), V25, P59; YOUNG LS, 1992, CANCER SURV, V7, P507	38	28	30	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1809	1813						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895528				2022-12-28	WOS:A1996VM88700027
J	Wang, BL; Mysliwiec, T; Feller, SM; Knudsen, B; Hanafusa, H; Kruh, GD				Wang, BL; Mysliwiec, T; Feller, SM; Knudsen, B; Hanafusa, H; Kruh, GD			Proline-rich sequences mediate the interaction of the Arg protein tyrosine kinase with Crk	ONCOGENE			English	Article						Abl; myristoylation	SRC HOMOLOGY-3 DOMAIN; C-ABL; SH3 DOMAIN; CELL-CYCLE; BINDING; PHOSPHORYLATION; IDENTIFICATION; PRODUCT; GENE; LEUKEMIA	Arg is a ubiquitously expressed member of the Abelson family of nonreceptor protein-tyrosine kinases, Defining the Arg sequences that mediate its interaction with other proteins is essential to elucidating its role in cellular signaling, In this report we demonstrate that Arg associates with c-Crk, an adaptor protein composed of an SH2 domain and two SH3 domains, and examine the molecular mechanism of the interaction, In vitro experiments revealed that three proline-rich sequences with distinct specificities for SH3 domains are located in the Arg C-terminal domain, just C-terminal to the kinase domain, and that two of these sequences bind to the Crk N-terminal SH3 domain, These two sequences conform to the PsLPxK/R motif that has been observed in other proteins that bind the Crk N-terminal SH3 domain, The interaction of Arg with c-Crk in living cells was confirmed by the detection of coimmunoprecipitation in coinfected Sf9 cells, In addition, increased phosphorylation of c-Crk was observed in cotransfected COS cells, indicating that Crk is an Arg substrate, The site of c-Crk phosphorylation by Arg was identified as tyrosine 221, a residue whose modification has been shown to result in an intramolecular SH2 interaction and a folded conformation, These experiments extend the known Arg protein interacting motifs to include SH3 binding sites and suggest that Arg may function as an effector as well as a regulator of Crk activity.	FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; BAVARIAN JULIUS MAXIMILIANS UNIV, INST RADIOBIOL & CELL BIOL, WURZBURG, GERMANY; ROCKEFELLER UNIV, MOL ONCOL LAB, NEW YORK, NY 10021 USA	Fox Chase Cancer Center; University of Pennsylvania; University of Wurzburg; Rockefeller University					NCI NIH HHS [CA44356, CA60453-03S1, CA57273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA060453, R01CA057273, R55CA057273, R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LAEMMLI UK, 1968, MOL GEN GENET, V101, P333, DOI 10.1007/BF00436231; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATTIONI T, 1995, ONCOGENE, V10, P1325; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MORRIS JF, 1991, ONCOGENE, V6, P2339; Mysliwiec T, 1996, ONCOGENE, V12, P631; NICHOLS GL, 1994, BLOOD, V84, P2912; OGAWA S, 1994, ONCOGENE, V9, P1669; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PEREGO R, 1991, ONCOGENE, V6, P1899; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG B, IN PRESS ONCOGENE; Wang BL, 1996, ONCOGENE, V12, P1921; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	44	34	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1379	1385						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875975				2022-12-28	WOS:A1996VL38400002
J	McLure, KG; Lee, PWK				McLure, KG; Lee, PWK			A PAb240(+) conformation of wild type p53 binds DNA	ONCOGENE			English	Article						p53 conformation; DNA binding; PAb 240; dominant negative	2 CELLULAR PROTEINS; MUTANT P53; OLIGOMERIZATION DOMAIN; COMPLEXES; SITE; MODULATION; MUTATIONS	It is generally accepted that wild type (growth suppressing) p53 is capable of binding to a consensus DNA sequence and is in a conformation recognizable by antibody PAb246 (for murine p53), but not by antibody PAb240. Conversely, mutant forms of p53 incapable of DNA binding often assume conformations that display the PAb240, but not the PAb246 epitope, Exposure of these tao epitopes on p53 is therefore believed to be mutually exclusive, We show that mild type p53 translated in vitro in rabbit reticulocyte lysate (RRL) has a PAb240 epitope that is not always cryptic, even on p53 that is bound sequence-specifically to DNA (presumably as a tetramer), All of the DNA-bound, PAb240(+) p53 concurrently displays the PAb246 epitope, and both epitopes can be occupied by antibody while p53 is bound to DNA, This novel 'dual positive' conformation also exists in the absence of DNA and suggests that p53 is not necessarily inactive when the PAb240 epitope is displayed, When the C-terminal 58 amino acids of p53 containing the dimer/tetramerization domains are replaced with a heterologous dimerization domain, the resultant dimeric p53 manifests only the PAb246(+)/PAb240(-) conformation while bound to DNA, Thus, the C-terminal 58 amino acids of p53 are required for the PAb246(+)/PAb240(+) phenotype, possibly due to tetramerization, This novel (dual positive' p53 conformation exists in an excess of wild type p53 that has the PAb246(-)/PAb240(+) 'mutant' conformation, suggesting that the 'mutant' conformation is not dominant negative in and of itself.	UNIV CALGARY,HLTH SCI CTR,CANC BIOL RES GRP,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,HLTH SCI CTR,DEPT MICROBIOL & INFECT DIS,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba								CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHODOSH LA, 1991, CURRENT PROTOCOLS MO; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P553; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FREIDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1994, ONCOGENE, V9, P299; HAINAUT P, 1992, EMBO J, V11, P3515; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	32	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1297	1303						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808704				2022-12-28	WOS:A1996VJ20200021
J	SanchezPrieto, R; Quintanilla, M; Cano, A; Lleonart, M; Martin, P; Anaya, A; Cajal, SR				SanchezPrieto, R; Quintanilla, M; Cano, A; Lleonart, M; Martin, P; Anaya, A; Cajal, SR			Carcinoma cell lines become sensitive to DNA-damaging agents by the expression of the adenovirus E1A gene	ONCOGENE			English	Article						carcinoma cell lines; adenovirus E1a; drug resistance; apoptosis; p53	P53 TUMOR-SUPPRESSOR; WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; IONIZING-RADIATION; P53-INDEPENDENT MECHANISMS; CLINICAL IMPLICATIONS; DIFFERENT ONCOGENES; INDUCE APOPTOSIS; CANCER-THERAPY; PROTEIN	Squamous cell carcinomas can show different oncogenic alterations, histological patterns, and an unpredictable clinical behavior, We previously reported that the adenovirus E1a gene may induce sensitivity to DNA-damaging agents in mouse keratinocytes. In order to study whether E1a expression could be used as a therapeutic agent in different malignant cell lines carrying mutations on the p53 gene and other oncogenic alterations, we transfected and infected several murine and human carcinoma cell lines (HaCa4; MSC11A5; HeLa) with vectors containing the 13S or 12S E1a region, We evaluated the sensitivity to cisplatin (CDDP), doxorubicin (DOX) and gamma irradiation (RX) by the crystal violet method, The induction of apoptosis was assessed by flow cytometry and presence of DNA ladders in agarose gels, The expression of E1a and the tumor suppressor p53 protein was analysed by Western blotting, The carcinoma cell lines expressing E1a were about four- to ten-fold more sensitive to CDDP and RX, respectively, than the control cells, Moreover, the reduction in cell viability and cell growth after exposure to CDDP or RX was very significant in the carcinoma cells expressing E1a, With these results, we conclude that expression of E1a may confer great sensitivity to DNA-damaging agents on squamous cell carcinoma cells independently of the p53 protein status and other oncogenic alterations.	CLIN PUERTA HIERRO,DEPT PATOL,E-28035 MADRID,SPAIN; CSIC,INST INVEST BIOMED,MADRID,SPAIN	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Ramon y Cajal, Santiago/H-4955-2016; LLeonart, Matilde E./Q-2662-2019; Espinosas, Maribel/H-8083-2012; Sanchez-Prieto, Ricardo/AAY-4271-2021; Quintanilla, Miguel/K-9293-2017; Sanchez-Prieto, Ricardo/B-6877-2008; Prieto, Ricardo/AAZ-7221-2021	Ramon y Cajal, Santiago/0000-0002-3867-1390; LLeonart, Matilde E./0000-0002-6196-7405; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; 				AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BARBEAU D, 1994, ONCOGENE, V9, P359; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOUFFLER SD, 1995, CANCER RES, V55, P3883; BOULANGER PA, 1991, BIOCHEM J, V275, P281, DOI 10.1042/bj2750281; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; BURNS PA, 1991, ONCOGENE, V6, P2363; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARUSO M, 1993, ONCOGENE, V8, P267; CHANG FJ, 1995, J CLIN ONCOL, V13, P1009, DOI 10.1200/JCO.1995.13.4.1009; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DOTTO GP, 1989, J CELL BIOL, V109, P3115, DOI 10.1083/jcb.109.6.3115; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1990, ONCOGENE, V5, P75; FRITSCHE M, 1993, ONCOGENE, V8, P307; FURIHATA M, 1995, INT J ONCOL, V6, P1209; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HAVRE PA, 1995, CANCER RES, V55, P4420; HOWE JA, 1992, VIROLOGY, V186, P15, DOI 10.1016/0042-6822(92)90057-V; HUNTER T, 1994, CELL, V79, P547; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MARCHETTI E, 1994, INT J ONCOL, V5, P611; MISSERO C, 1991, P NATL ACAD SCI USA, V88, P1295; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PAULES RS, 1995, CANCER RES, V55, P1763; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; RAMON, 1995, HISTOL HISTOPATHOL, V10, P811; RAMON, 1991, AM J PATHOL, V138, P349; RAMON, 1994, AM J PATHOL, V145, P846; SANCHEZPRIETO R, 1995, ONCOGENE, V11, P675; SANCHEZPRIETO R, 1995, ONCOL REP, V2, P457; SANCHEZPRIETO R, 1995, INT J CANCER, V60, P235; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TATSUKA M, 1989, MUTAT RES, V214, P321; TEODORO JG, 1995, ONCOGENE, V11, P467; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; WHITE P, 1989, CELL, V45, P67; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG YJ, 1995, ONCOGENE, V10, P1947	68	91	96	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1083	1092						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806698				2022-12-28	WOS:A1996VG76600022
J	Bigoni, R; Negrini, M; Veronese, ML; Cuneo, A; Castoldi, GL; Croce, CM				Bigoni, R; Negrini, M; Veronese, ML; Cuneo, A; Castoldi, GL; Croce, CM			Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization	ONCOGENE			English	Article						bcl-1; chromosome translocation; mantle cell lymphoma	CHRONIC LYMPHOCYTIC-LEUKEMIA; CENTROCYTIC LYMPHOMA; T(11-14)(Q13-Q32) TRANSLOCATION; INTERMEDIATE DIFFERENTIATION; CHROMOSOME-TRANSLOCATION; BREAKPOINT REGION; TUMOR-CELLS; BCL-1 GENE; EXPRESSION; KARYOTYPE	Characterization of chromosome abnormalities in leukemia and lymphoma have contributed to the understanding of the molecular basis of these neoplastic diseases, In addition, specific chromosomal aberrations have acquired diagnostic or prognostic value. The t(11;14)(q13;q32) chromosome translocation has been detected in mantle cell lymphomas, However, possibly due to the limits of conventional cytogenetic analysis and the presence of different breakpoints at the molecular level, it is possible that the true percentage of association is underestimated, In our study, we used a yeast artificial chromosome, spanning the entire area where the rearrangements occur on chromosome 11q13, to detect the presence of translocations by fluorescent in situ hybridization experiments. We detected BCL-1 translocations in eight of eight patients with clinical and immunological features of mantle cell lymphoma, suggesting that the t(11;14) translocation is a critical event in the pathogenesis of MCL and may be a primary element for the diagnosis. Since this translocation is associated with poor prognosis, its detection may help to make a correct diagnosis as well as to evaluate residual disease, which is critical to plan a rational chemotherapy regimen.	THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, KIMMEL CANC CTR, BLSB, PHILADELPHIA, PA 19107 USA; UNIV FERRARA, DIPARTIMENTO SCI BIOMED & TERAPIE AVANZATE, SEZ EMATOL, FERRARA, ITALY	Jefferson University; University of Ferrara			Negrini, Massimo/J-2377-2016; Cuneo, Antonio/K-7617-2016; Young, Richard A/F-6495-2012	Negrini, Massimo/0000-0002-0007-1920; Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [R35CA039860] Funding Source: NIH RePORTER; NCI NIH HHS [CA39860] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; BANKS PM, 1992, AM J SURG PATHOL, V16, P637, DOI 10.1097/00000478-199207000-00001; BERGER R, 1979, HUM GENET, V53, P111, DOI 10.1007/BF00289460; BOSCH F, 1994, BLOOD, V84, P2726; BRITO-BABAPULLE V, 1987, Hematologic Pathology, V1, P27; CASTOLDI GL, 1987, CANCER GENET CYTOGEN, V26, P75, DOI 10.1016/0165-4608(87)90135-X; CHAGANTI RSK, 1987, CYTOGENET CELL GENET, V45, P93, DOI 10.1159/000132436; Coignet LJA, 1996, BLOOD, V87, P1512, DOI 10.1182/blood.V87.4.1512.bloodjournal8741512; CROCE CM, 1987, CELL, V49, P155, DOI 10.1016/0092-8674(87)90552-6; CUNEO A, 1995, BRIT J HAEMATOL, V90, P409; CUNEO A, 1994, LEUKEMIA LYMPHOMA, V15, P167, DOI 10.3109/10428199409051693; CUNEO A, 1992, BRIT J HAEMATOL, V81, P192, DOI 10.1111/j.1365-2141.1992.tb08206.x; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; GOULD J, 1988, BLOOD, V71, P453; JULIUSSON G, 1991, LEUKEMIA LYMPHOMA, V5, P21, DOI 10.3109/10428199109103374; JULIUSSON G, 1990, NEW ENGL J MED, V323, P720, DOI 10.1056/NEJM199009133231105; LARDELLI P, 1990, AM J SURG PATHOL, V14, P752, DOI 10.1097/00000478-199008000-00007; LEBEAU MM, 1993, BLOOD, V81, P1979; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MEEKER TC, 1989, BLOOD, V74, P1801; MEEKER TC, 1991, LEUKEMIA, V5, P733; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NEWMAN RA, 1993, BLOOD, V82, P1239; RAYNAUD SD, 1993, GENE CHROMOSOME CANC, V8, P80, DOI 10.1002/gcc.2870080204; RIMOKH R, 1993, BLOOD, V81, P3063; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SETO M, 1992, ONCOGENE, V7, P1401; SZEPETOWSKI P, 1995, CYTOGENET CELL GENET, V69, P101, DOI 10.1159/000133948; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; VANDENBERGHE E, 1991, J PATHOL, V163, P13, DOI 10.1002/path.1711630104; VANDENBERGHE E, 1994, BLOOD REV, V8, P79, DOI 10.1016/S0268-960X(05)80011-6; VANDENBERGHE H, 1979, CANCER, V44, P188, DOI 10.1002/1097-0142(197907)44:1<188::AID-CNCR2820440131>3.0.CO;2-F; WILLIAMS ME, 1992, CANCER RES, V52, pS5541; WILLIAMS ME, 1990, BLOOD, V76, P1387; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; YUNIS JJ, 1984, CANCER GENET CYTOGEN, V13, P17, DOI 10.1016/0165-4608(84)90084-0; YUNIS JJ, 1983, SCIENCE, V221, P227, DOI 10.1126/science.6336310; YUNIS JJ, 1987, NEW ENGL J MED, V79, P316	43	46	47	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					797	802						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761301				2022-12-28	WOS:A1996VD43300015
J	Gibson, L; Holmgreen, SP; Huang, DCS; Bernand, O; Copeland, NG; Jenkins, NA; Sutherland, GR; Baker, E; Adams, JM; Cory, S				Gibson, L; Holmgreen, SP; Huang, DCS; Bernand, O; Copeland, NG; Jenkins, NA; Sutherland, GR; Baker, E; Adams, JM; Cory, S			bcl-w, a novel member of the bcl-2 family, promotes cell survival	ONCOGENE			English	Article						bcl-2; bcl-w; apoptosis; survival; oncogene; chromosome 14	CHROMOSOMAL BREAKPOINT; CAENORHABDITIS-ELEGANS; PROTEIN IDENTIFICATION; ENDOPLASMIC-RETICULUM; PROTOONCOGENE BCL-2; SEQUENCE SIMILARITY; CONSERVED DOMAINS; MOLECULAR-CLONING; NUCLEAR-ENVELOPE; HOMOLOG BAK	The prototypic mammalian regulator of cell death is bcl-2, the oncogene implicated in the development of human follicular lymphoma. Several homologues of bcl-2 are now known. Using a PCR-based strategy we cloned a novel member of this gene family, denoted bcl-w. The gene, which is highly conserved between mouse and human, resides near the T-cell antigen receptor a gene within the central portion of mouse chromosome 14 and on human chromosome 14 at band q11. Enforced expression of bcl-w rendered lymphoid and myeloid cells refractory to several (but not all) cytotoxic conditions. Thus, like Bcl-2 and Bcl-x, the Bcl-w protein promotes cell survival, in contrast to other close homologues, Bar and Bak, which facilitate cell death. Comparison of the expected amino acid sequence of Bcl-w with that of these relatives helps to delineate residues likely to convey survival or anti-survival function. While expression of bcl-w was uncommon in B or T lymphoid cell lines, the mRNA was observed in almost all murine myeloid cell lines analysed and in a wide range of tissues. These findings suggest that bcl-w participates in the control of apoptosis in multiple cell types. Its functional similarity to bcl-2 also makes it an attractive candidate proto-oncogene.	ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; ADELAIDE CHILDRENS HOSP INC, DEPT CYTOGENET & MOL GENET, ADELAIDE, SA 5006, AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Gibson, Leonie/AAM-5917-2021; Cory, Suzanne/E-1642-2013; Huang, David C. S./C-7586-2013; Sutherland, Grant Robert/D-2606-2012; Adams, Jerry M/E-1199-2013	Cory, Suzanne/0000-0002-6818-3451; Huang, David C. S./0000-0002-3101-4873; Gibson, Leonie/0000-0002-0904-8145; Adams, Jerry/0000-0002-4360-8628				BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1995, ONCOGENE, V11, P1921; BRAND SF, 1995, GENE, V154, P187, DOI 10.1016/0378-1119(94)00840-O; CALLEN DF, 1990, ANN GENET-PARIS, V33, P219; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CHOI SS, 1995, ONCOGENE, V11, P1693; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Green EL, 1981, GENETICS PROBABILITY, P77; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HARRIS AW, 1973, J IMMUNOL, V110, P431; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LIN EY, 1993, J IMMUNOL, V151, P1979; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LYNES MA, 1978, J IMMUNOL, V121, P2352; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOORE KJ, 1992, GENOMICS, V12, P388, DOI 10.1016/0888-7543(92)90389-A; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RALPH P, 1975, J IMMUNOL, V114, P898; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; STOKKE T, 1995, GENOMICS, V26, P134, DOI 10.1016/0888-7543(95)80092-Z; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Subramanian T, 1995, ONCOGENE, V11, P2403; TANAKA S, 1993, J BIOL CHEM, V268, P10920; TEH HS, 1989, J EXP MED, V169, P795, DOI 10.1084/jem.169.3.795; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1994, APOPTOSIS, V2, P111; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	73	257	276	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					665	675						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761287				2022-12-28	WOS:A1996VD43300001
J	Packham, G; Porter, CW; Cleveland, JL				Packham, G; Porter, CW; Cleveland, JL			C-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways	ONCOGENE			English	Article						c-Myc; ODC; apoptosis; cell cycle	ORNITHINE DECARBOXYLASE; SIGNALING PATHWAYS; EXPRESSION; PROTEIN; GENE; TRANSCRIPTION; ARREST; GROWTH; DEATH; BCL-2	Enforced c-Myc expression promotes inappropriate cell cycle progression of growth factor deprived cells and triggers concomitant apoptosis. However, it is not clear what role dysregulation of the cell cycle plays in c-Myc induced apoptosis. Ornithine decarboxylase (ODC) is a transcriptional target of c-Myc and contributes to c-Myc induced apoptosis. Here we have established that high levels of ODC overexpression in interleukin-3 (IL-3)dependent 32D.3 myeloid cells induces apoptosis at rates comparable to those induced by enforced c-Myc expression. However, ODC-induced apoptosis was not accompanied by dysregulation of cell cycle controls, indicating that cell death was not triggered by inappropriate cell cycle progression. Nonetheless, ODC was required downstream of c-Myc for myeloid cell growth. These results suggested that c-Myc-induced pathways leading to cell cycle progression and apoptosis are separable, yet that they share common mediators. In agreement with this concept, treatment of cells overexpressing c-Myc with the inhibitory agent dibutyryl cyclic AMP (Bt(2)cAMP) arrested these cells G(1), without inducing apoptosis. However, c-Myc retained the ability to induce apoptosis of Bt(2)cAMP-arrested cells following removal of IL-3, demonstrating that Bt(2)cAMP selectively inhibits c-Myc-induced pathways promoting cell cycle progression but not apoptosis. These results suggest a 'multiple effecters' model in which c-Myc regulates the expression of mediators which alone are sufficient to induce apoptosis in the absence of survival factors, yet are required in concert to promote cell cycle progression.	ST MARYS HOSP, SCH MED, LUDWIG INST CANC RES, LONDON W2 1PG, ENGLAND; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ROSWELL PK CANC INST, GRACE CANC DRUG CTR, BUFFALO, NY 14263 USA; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	Imperial College London; Ludwig Institute for Cancer Research; St Jude Children's Research Hospital; Roswell Park Cancer Institute; University of Tennessee System; University of Tennessee Health Science Center					NCI NIH HHS [P0 CA 21765, CA 22153] Funding Source: Medline; NIDDK NIH HHS [DK 44158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA022153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; BARRETT JF, 1995, J BIOL CHEM, V270, P15923, DOI 10.1074/jbc.270.27.15923; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; CLEVELAND JL, 1994, PEZC S AP, P85; Cleveland John L., 1994, Cancer Bulletin (Houston), V46, P167; DEAN M, 1987, ONCOGENE RES, V1, P279; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Green D R, 1994, Important Adv Oncol, P37; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HARRINGTON H, 1994, SCIENCE, V265, P2091; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KRAMER D, 1995, J BIOL CHEM, V270, P2124, DOI 10.1074/jbc.270.5.2124; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; MAMONT PS, 1978, BIOCHEM BIOPH RES CO, V81, P58, DOI 10.1016/0006-291X(78)91630-3; MCKINNEY JD, 1991, TRENDS BIOCHEM SCI, V16, P430, DOI 10.1016/0968-0004(91)90170-Z; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; Roth P, 1992, Curr Top Microbiol Immunol, V181, P141; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	43	99	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					461	469						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760287				2022-12-28	WOS:A1996VB32800003
J	Mayol, X; Garriga, J; Grana, X				Mayol, X; Garriga, J; Grana, X			G1 cyclin/CDK-independent phosphorylation and accumulation of p130 during the transition from G1 to G0 lead to its association with E2F-4	ONCOGENE			English	Article						cell cycle; E2F; pRB; quiescence; TGF-beta	CELL-CYCLE CONTROL; LARGE-T-ANTIGEN; CDC2-RELATED PROTEIN-KINASE; RETINOBLASTOMA GENE FAMILY; TUMOR-SUPPRESSOR PROTEIN; DEPENDENT KINASES; IN-VIVO; INHIBITORS; MEMBER; EXPRESSION	During the transition from G1 to G0, p130 undergoes a specific phosphorylation event - leading to p130-form 2 - that is mediated by a kinase/s other than the known G1, S and G2/M cyclin/CDKs. Changes in the phosphorylation status of p130 during this transition are responsible, at least in part, for the concomitant formation of p130/E2F4 complexes, which are characteristic of GO. These complexes remain abundant during early G1 upon restimulation, but not after mitosis, and are dissociated in mid G1 when p130 is abruptly hyperphosphorylated to form 3. Subsequently, p130 forms 1 and 2 are no longer detected during the remainder of the cell cycle. Consistently, phosphorylation to form 3 and dissociation from E2F-4 complexes is reproduced by a cyclin/CDK holoenzyme in vitro. TGF-beta-induced G1 arrest abrogates cyclin/CDK phosphorylation of p130 but not phosphorylation to form 2. The cell cycle-dependent phosphorylation pattern of p130 is thus shown to comprise two distinct steps that are catalyzed by different kinases. The differential regulation of p130 and pRB phosphorylation during the transition from G1 to G0 may explain the fact that p130 and E2F-4 are the major components of E2F complexes in quiescent cells. Moreover, the newly described phosphorylation of p130 at the transition from G1 to G0 defines a novel mechanism of cell cycle exit regulation.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Mayol, Xavier/C-1391-2012	Grana, Xavier/0000-0001-7134-0473; Mayol, Xavier/0000-0001-7288-195X				BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GRANA X, 1994, ONCOGENE, V9, P2097; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GRANA X, 1995, ONCOGENE, V11, P211; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harlow E., 1988, ANTIBODIES LAB MANUA; HERZINGER T, 1995, ONCOGENE, V10, P2079; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; JOHNSON DG, 1995, ONCOGENE, V11, P1685; KATO M, 1995, J BIOL CHEM, V270, P12373, DOI 10.1074/jbc.270.21.12373; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; Moberg K, 1996, MOL CELL BIOL, V16, P1436; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NEVINS JR, 1992, SCIENCE, V258, P424; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLF DA, 1995, ONCOGENE, V10, P2067; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0	43	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					237	246						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710362				2022-12-28	WOS:A1996VA25200002
J	Crouch, DH; Fincham, VJ; Frame, MC				Crouch, DH; Fincham, VJ; Frame, MC			Targeted proteolysis of the focal adhesion kinase pp125(FAK) during c-myc-induced apoptosis is suppressed by integrin signalling	ONCOGENE			English	Article						focal adhesion kinase; c-myc; apoptosis	PROTEIN-TYROSINE KINASE; CELL-ADHESION; EXTRACELLULAR-MATRIX; PHOSPHORYLATION; TRANSFORMATION; PP125FAK; DOMAIN	The product of the c-myc proto-oncogene has a central role in induction of apoptosis, a physiological form of cell death characterised in vitro by morphological rounding, detachment and nuclear disintegration. Induction of apoptosis by serum withdrawal from c-Myc-transformed chicken embryo fibroblasts (CEF) results in early proteolysis of focal adhesion kinase (pp125(FAK)), a tyrosine kinase implicated in the conversion of integrin signals into their biological responses. Proteolysis of pp125(FAK) occurs in adherent cells prior to commitment to death, suggesting that it contributes to c-Myc-induced apoptosis, rather than being a consequence of it. Furthermore, c-Myc-induced detachment, cell death and cleavage of pp125(FAK) are coordinately suppressed by treating with insulin or plating on the extracellular matrix components collagen and fibronectin. In addition, proteolysis of pp125(FAK) is suppressed by a beta 1-specific integrin antibody, which promotes cell survival in the face of the oncoprotein-induced signal for apoptosis. These results provide compelling evidence that the c-Myc-induced cell death programme in CEF requires disruption of the integrin signalling pathways which normally function when cells are spread on ECM, and that maintaining cellular pp125(FAK), which couples integrins to their downstream effecters, is closely linked to cell survival.	BEATSON INST CANC RES, CRC, BEATSON LABS, GLASGOW G61 1BD, LANARK, SCOTLAND	Beatson Institute								AKASAKA T, 1995, J INVEST DERMATOL, V105, P104, DOI 10.1111/1523-1747.ep12313396; BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CROUCH DH, 1990, ONCOGENE, V5, P683; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Freshney RI, 1994, CULTURE ANIMAL CELLS; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GIBSON AW, 1995, EXP CELL RES, V218, P351, DOI 10.1006/excr.1995.1166; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LLIC D, 1995, NATURE, V377, P539; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MOGI A, 1995, FEBS LETT, V373, P135, DOI 10.1016/0014-5793(95)01014-6; OWENS LV, 1995, CANCER RES, V55, P2752; ROZENGURT E, 1995, CANCER SURV, V24, P81; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SARIN A, 1993, J EXP MED, V178, P1693, DOI 10.1084/jem.178.5.1693; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLAEPFER DD, 1994, NATURE, V372, P786; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	34	122	122	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2689	2696						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700528				2022-12-28	WOS:A1996UW48700023
J	Rodriguez, MS; Wright, J; Thompson, J; Thomas, D; Baleux, F; Virelizier, JL; Hay, RT; ArenzanaSeisdedos, F				Rodriguez, MS; Wright, J; Thompson, J; Thomas, D; Baleux, F; Virelizier, JL; Hay, RT; ArenzanaSeisdedos, F			Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo	ONCOGENE			English	Article						I-kappa B; NF-kappa B; signal induced proteolysis	BINDING-PROTEIN EBP1; INHIBITOR; ACTIVATION; MEMBERS; FAMILY; DNA	Activation of transcription factor NF-kappa B involves signal-induced degradation of the protein inhibitor I kappa B-alpha and release of NF-kappa B which translocates to the nucleus where it influences transcription of responsive genes, Although multiple regions of I kappa B-alpha are involved in this process, the N-terminal region of the protein has been identified as a regulatory region that is required for signal induced phosphorylation and degradation, The sensitivity of I kappa B-alpha degradation to peptide aldehydes which inhibit of the proteasome and the detection of forms of I kappa B-alpha indicate that I kappa B-alpha is degraded by the ubiquitin-proteasome pathway. To identify lysine residues that represent the ubiquitin addition, a series of lysine to mutations were introduced into I kappa B-alpha and the mutant proteins tested for their ability to function in vivo, Exposure of COS7 cells, cotransfected with I kappa B-alpha and a TNF-responsive NF-kappa B reporter gene, resulted in stimulation of reporter activity as a consequence of I kappa B-alpha degradation, In contrast, this effect was drastically reduced when an I kappa B-alpha mutant carrying serine to alanine changes at amino-acids, 32 and 36, which blocks both signal-induced phosphorylation and ubiquitin conjugation of the protein, was co-transfected with the reporter gene. Likewise, a mutant form of I kappa B-alpha containing lysine to arginine changes at positions 21 and 22 (K21R, K22R) severely reduces TNF-induced activation of the NF-kappa B-dependent reporter gene, Examination of the metabolism of mutant I kappa B-alpha molecules reveals that, while the K21R, K22R mutant inhibits the DNA-binding activity of NF-kappa B and undergoes signal induced phosphorylation, it is neither ubiquitinated nor degraded in response to TNF, Thus, it is likely that after signal-induced phosphorylation of I kappa B-alpha. on serine residues 32 and 36, lysine residues 21 and 22 are major sites of ubiquitin ligation which target the protein for rapid degradation by the proteasome.	INST PASTEUR,UNITE IMMUNOL VIRALE,F-75015 PARIS,FRANCE; INST PASTEUR,UNITE CHIM ORGAN,F-75015 PARIS,FRANCE; UNIV ST ANDREWS,SCH BIOL & MED SCI,ST ANDREWS KY16 9AL,FIFE,SCOTLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of St Andrews			Hay, Ronald T/F-9338-2011; Arenzana-Seisdedos, Fernando/E-5835-2016	Hay, Ronald T/0000-0001-7113-9024; 				ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; CLARK L, 1989, J MOL BIOL, V206, P615, DOI 10.1016/0022-2836(89)90570-6; CLARK L, 1989, NUCLEIC ACIDS RES, V17, P499, DOI 10.1093/nar/17.2.499; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; FEHRENTZ JA, 1985, INT J PEPT PROT RES, V26, P236; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HAY RT, 1993, BIOCHEM SOC T, V21, P926, DOI 10.1042/bst0210926; ISRAEL A, 1995, TRENDS GENET, V11, P203, DOI 10.1016/S0168-9525(00)89045-9; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; RODRIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VLACH J, 1995, VIROLOGY, V208, P753, DOI 10.1006/viro.1995.1207; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	52	126	131	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2425	2435						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649784				2022-12-28	WOS:A1996UQ22000021
J	Berry, DE; Lu, YM; Schmidt, B; Fallon, PG; OConnell, C; Hu, SX; Xu, HJ; Blanck, G				Berry, DE; Lu, YM; Schmidt, B; Fallon, PG; OConnell, C; Hu, SX; Xu, HJ; Blanck, G			Retinoblastoma protein inhibits IFN-gamma induced apoptosis	ONCOGENE			English	Article						retinoblastoma protein; IFN-gamma; apoptosis	TUMOR-NECROSIS-FACTOR; B-CELL LINES; INTERFERON-GAMMA; FLOW-CYTOMETRY; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HUMAN CANCER; DEATH; INDUCTION; ALPHA	Regulation of apoptosis (programmed cell death) is critical for maintaining tissue homeostasis. Recent studies indicate a tight coupling between cellular proliferation and apoptosis as cell cycle regulators such as Cyclin D, E1A and E7 appear to influence both events, Each of these modulators is able to bind to and inhibit the function of the retinoblastoma tumor suppressor protein (RE), RE functions, in part, by binding to and inactivating E2F transcription factors, preventing expression of E2F-activated genes associated with G1/S cell-cycle progression, Loss of functional RB deregulates E2F activity and, depending on cell type and environmental factors, promotes tumorigenesis or apoptotic death, To determine the effect of RB on IFN-gamma induced apoptosis, we treated RB-defective carcinoma cell lines and their respective RB-reconstituted sister clones with IFN-gamma and examined the cells for alterations characteristic of apoptosis, We observed that RB-defective cells, but not the RB-reconstituted clones, decreased in size following IFN-gamma treatment, IFN-gamma treatment caused increased cell detachment in the RB-defective lines but did not affect adherence of the RB-reconstituted clones, Assays for DNA fragmentation revealed lower molecular weight DNA and the apoptosis- associated oligo-nucleosomal ladder following IFN-gamma treatment of the RB-defective cells while higher molecular weight DNA was present in the IFN-gamma treated, RB-reconstituted lines, IFN gamma-induced apoptosis in RB-defective cells was enhanced by serum stimulation, which is also characteristic of p53-dependent E2F-1-mediated apoptosis, However, IFN-gamma induced apoptosis in RB-defective lines does not require wild-type p53 suggesting that, upon IFN-gamma induction, deregulated E2F-mediated apoptosis can also proceed via p53-independent pathways.	UNIV S FLORIDA, COLL MED, DEPT BIOCHEM & MOLEC BIOL, TAMPA, FL 33612 USA; UNIV S FLORIDA, H LEE MOFFITT CANC CTR, COLL MED, TAMPA, FL 33612 USA; BAYLOR COLL MED, CTR BIOTECHNOL, THE WOODLANDS, TX 77381 USA	State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Baylor College of Medicine					NEI NIH HHS [EY06195] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARENDS MJ, 1990, AM J PATHOL, V136, P593; BARTEK J, 1990, ONCOGENE, V5, P893; BLANAR MA, 1988, P NATL ACAD SCI USA, V85, P4672, DOI 10.1073/pnas.85.13.4672; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; BUSCHLE M, 1993, J EXP MED, V177, P213, DOI 10.1084/jem.177.1.213; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COHEN JJ, 1984, J IMMUNOL, V132, P38; COHEN PA, 1993, J IMMUNOTHER, V14, P242, DOI 10.1097/00002371-199310000-00012; DETRICK B, 1991, INVEST OPHTH VIS SCI, V32, P1714; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FREEDMAN AS, 1991, CELL IMMUNOL, V137, P429, DOI 10.1016/0008-8749(91)90091-O; GACZYNSKA M, 1993, NATURE, V365, P264, DOI 10.1038/365264a0; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRAWUNDER U, 1993, EUR J IMMUNOL, V23, P544, DOI 10.1002/eji.1830230237; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAUPT Y, 1995, ONCOGENE, V10, P1563; HOON DSB, 1991, CANCER RES, V51, P2002; HOOPER ML, 1994, J CELL SCI, P13; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUSCHTSCHA LI, 1994, EXP CELL RES, V212, P161, DOI 10.1006/excr.1994.1131; IBRAHIM L, 1993, IMMUNOLOGY, V79, P119; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; ISHII H, 1994, ACTA MED OKAYAMA, V48, P73; JO TS, 1995, ANAT RECORD, V241, P70, DOI 10.1002/ar.1092410110; KARASAKI Y, 1992, J INTERFERON RES, V12, P185, DOI 10.1089/jir.1992.12.185; Kelso A, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209026930; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LOTEM J, 1995, LEUKEMIA, V9, P685; LU Y, 1994, J IMMUNOL, V153, P1495; LU Y, 1996, IN PRESS J IMMUNOL; LU YM, 1994, ONCOGENE, V9, P1015; MARTIN DM, 1993, J NEUROSCI RES, V34, P489, DOI 10.1002/jnr.490340502; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUNN DH, 1995, J EXP MED, V181, P127, DOI 10.1084/jem.181.1.127; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NOVELLI F, 1994, J IMMUNOL, V152, P496; OKUBO K, 1991, Kurume Medical Journal, V38, P57; OSBORNE BA, 1994, IMMUNOL REV, V142, P301, DOI 10.1111/j.1600-065X.1994.tb00894.x; OSTRANDROSENBERG S, 1990, J IMMUNOL, V144, P4068; PANG YB, 1992, BLOOD, V80, P724; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHER RL, 1993, ARCH OTOLARYNGOL, V119, P432; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; Shimada Shinya, 1993, In Vivo (Attiki), V7, P1; SHINAGAWA T, 1991, J PATHOL, V165, P247, DOI 10.1002/path.1711650309; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; TOMITA Y, 1993, AM J PATHOL, V143, P191; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	76	80	82	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1809	1819						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622902				2022-12-28	WOS:A1996UG45800024
J	Rao, G; Alland, L; Guida, P; SchreiberAgus, N; Chen, K; Chin, L; Rochelle, JM; Seldin, MF; Skoultchi, AI; DePinho, RA				Rao, G; Alland, L; Guida, P; SchreiberAgus, N; Chen, K; Chin, L; Rochelle, JM; Seldin, MF; Skoultchi, AI; DePinho, RA			Mouse Sin3A interacts with and can functionally substitute for the aminoterminal repression domain of the Myc antagonist Mxi1	ONCOGENE			English	Article						mSin3A; Mxi1; Myc; repression; cotransformation; PAH domain	C-MYC; ERYTHROLEUKEMIA-CELLS; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; SACCHAROMYCES-CEREVISIAE; LINKAGE MAP; EXPRESSION; PROTEIN; DIFFERENTIATION; ONCOGENE	Mxi1 is a basic region helix-loop-helix leucine zipper (bHLH/LZ) protein that, in association with Max, antagonizes Myc oncogenic activities. A possible mechanistic basis for Mxi1-mediated repression was provided by the recent demonstration that the repressive potential of Mxi1 correlates with its ability to physically associate with mSin3B, one of two mammalian homologues of the yeast transcriptional repressor SIN3. Here, we sought to characterize more fully the physical properties of the second homologue, mSin3A and to determine whether the recruitment of mSin3A by Mxi1 is indeed required for anti-Myc activity. Transient transfection of mammalian cells showed that the mSin3A protein can associate with the strong repressive isoform of Mxi1 (Mxi1-SR) and that, like other Myc superfamily members, both mSin3A and Mxi1-SR localize to the nucleus. From a developmental standpoint, a comparative analysis of Myc, Mxi1-SR and Sin3A expression during postnatal mouse development and in differentiating mouse erythroleukemia (MEL) cells revealed that dramatic and reciprocal changes in Myc and Mxi1-SR mRNA levels are accompanied by minimal stage-specific changes in mSin3A gene expression. This constant expression profile, coupled with the observation that over-expression of mSin3A does not augment the anti-Myc activity of Mxi1-SR in the rat embryo fibroblast (REF) transformation assay, suggests that mSin3A is not a limiting factor in the regulation of Myc superfamily function. Finally, a mSin3A-Mxi1 fusion protein, in which the amino terminal mSin3-interacting domain of Mxi1-SR was replaced with the full-length mSin3A, exhibited a level of repression activity equivalent to, or greater than, the level of repression obtained with Mxi1-SR. Taken together, these observations directly demonstrate that the amino-terminal repression domain of Mxi1-SR functions solely to recruit mSin3A and possibly other proteins like mSin3A and this association is necessary for the anti-Myc activity of Mxi1-SR.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MICROBIOL & IMMUNOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT CELL BIOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DIV PEDIAT HEMATOL ONCOL, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DIV DERMATOL, BRONX, NY 10461 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Duke University; Duke University				DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [R37CA016368, T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000194] Funding Source: NIH RePORTER; NCI NIH HHS [RT32CA-09173, 5R37CA16368] Funding Source: Medline; NIA NIH HHS [2T32AG00194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHIN L, 1995, P NATL ACAD SCI USA, V92, P8488, DOI 10.1073/pnas.92.18.8488; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DELGADO MD, 1995, ONCOGENE, V10, P1659; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; EAGLE LR, 1995, NAT GENET, V9, P249, DOI 10.1038/ng0395-249; EDELHOFF S, 1994, ONCOGENE, V9, P665; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; Green EL, 1981, GENETICS PROBABILITY, P77; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HALLECK MS, 1995, GENOMICS, V26, P403, DOI 10.1016/0888-7543(95)80229-F; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HIRSCHHORN JN, 1992, GENE DEV, V6, P2288, DOI 10.1101/gad.6.12a.2288; HOWARD TA, 1991, GENOMICS, V10, P207, DOI 10.1016/0888-7543(91)90502-6; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LACHMAN HM, 1986, P NATL ACAD SCI USA, V83, P6480, DOI 10.1073/pnas.83.17.6480; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NAWAZ Z, 1994, MOL GEN GENET, V245, P724, DOI 10.1007/BF00297279; NISHIZAWA M, 1994, MOL GEN GENET, V245, P301, DOI 10.1007/BF00290110; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; PULVERER BJ, 1994, ONCOGENE, V9, P59; ROY B, 1985, CELL BIO INT, V19, P307; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SELDIN MF, 1991, GENOMICS, V9, P678, DOI 10.1016/0888-7543(91)90361-H; SHIMIZU E, 1995, GENE, V152, P283, DOI 10.1016/0378-1119(94)00722-5; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WATKINS S, 1995, CURRENT PROTOCOLS MO; WILLIAMS FE, 1991, MOL CELL BIOL, V11, P3307, DOI 10.1128/MCB.11.6.3307; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	63	43	44	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1165	1172						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649810				2022-12-28	WOS:A1996UA88400027
J	Helftenbein, G; Krusekopf, K; Just, U; Cross, M; Ostertag, W; Niemann, H; Tamura, T				Helftenbein, G; Krusekopf, K; Just, U; Cross, M; Ostertag, W; Niemann, H; Tamura, T			Transcriptional regulation of the c-fms proto-oncogene mediated by granulocyte macrophage colony-stimulating factor (GM-CSF) in murine cell lines	ONCOGENE			English	Article						transreceptor control; c-fms proto-oncogene; M-CSF receptor; GM-CSF mediated signal transduction	RECEPTOR GENE FAMILY; FACTOR-I RECEPTOR; SIGNAL-TRANSDUCTION; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; MESSENGER-RNA; BETA-SUBUNIT; EXPRESSION; INTERLEUKIN-3; CLONING	Differentiation of blood cells is paralleled by a timely ordered expression of cytokine receptor genes. We show here that the expression of the c-fms gene which encodes the lineage-specific receptor for macrophage colony-stimulating factor (M-CSF or CSF-1) is directly linked to ligand-mediated activation of the receptor for the granulocyte/macrophage colony-stimulating factor (GMCSF). In interleukin-3 (IL-3) dependent multipotent progenitor cells, FDC-Pmix GMV#2 cells, GM-CSF treatment results in the rapid formation of full-length c-fms transcripts. Surprisingly, this upregulation of c-fms transcripts is also observed in mouse NIH3T3 fibroblasts stably transfected with genes coding for the alpha- and beta-subunits of the GM-CSF receptor. These results indicate a direct control by the GM-CSF receptor that takes place regardless of cell differentiation. Furthermore, a 2.1 kb genomic fragment containing the c-fins proximal promoter directs GM-CSF-inducible expression of a reporter gene, suggesting a regulation of c-fms gene expression on the transcriptional level.	UNIV GIESSEN, INST VIROL, D-35392 GIESSEN, GERMANY; UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY; CHRISTIE HOSP NATL HLTH SERV TRUST, PATERSON INST CANC RES, CANC RES CAMPAIGN DEPT EXPTL HAEMATOL, MANCHESTER M20 8BX, LANCS, ENGLAND; BUNDESFORSCH ANSTALT VIRUSKRANKHEITEN TIERE, D-72076 TUBINGEN, GERMANY	Justus Liebig University Giessen; Heinrich Pette Institute; University of Hamburg; Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research			Just, Ursula/E-6992-2010	Cross, Michael/0000-0002-8815-7621				ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DURONIO V, 1992, P NATL ACAD SCI USA, V89, P1587, DOI 10.1073/pnas.89.5.1587; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GORMAN DM, 1990, P NATL ACAD SCI USA, V87, P5459, DOI 10.1073/pnas.87.14.5459; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JUST U, 1993, GROWTH FACTORS, V9, P291, DOI 10.3109/08977199308991589; JUST U, 1991, CELL, V64, P1163, DOI 10.1016/0092-8674(91)90271-Y; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; OKUDA K, 1992, BLOOD, V79, P2880; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; REDDY MA, 1994, J EXP MED, V180, P2309, DOI 10.1084/jem.180.6.2309; ROBERTS WM, 1992, BLOOD, V79, P586; ROTHWELL VM, 1987, ONCOGENE RES, V1, P311; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHATZMUNDING M, 1992, EUR J BIOCHEM, V204, P705, DOI 10.1111/j.1432-1033.1992.tb16685.x; SHERR CJ, 1990, BLOOD, V75, P1; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SPOONCER E, 1986, DIFFERENTIATION, V31, P111, DOI 10.1111/j.1432-0436.1986.tb00391.x; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WEBER B, 1989, MOL CELL BIOL, V9, P769, DOI 10.1128/MCB.9.2.769; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YUE X, 1993, MOL CELL BIOL, V13, P3191, DOI 10.1128/MCB.13.6.3191; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	35	16	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					931	935						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632916				2022-12-28	WOS:A1996TW68600025
J	Chen, IT; Akamatsu, M; Smith, ML; Lung, FDT; Duba, D; Roller, PP; Fornace, AJ; OConnor, PM				Chen, IT; Akamatsu, M; Smith, ML; Lung, FDT; Duba, D; Roller, PP; Fornace, AJ; OConnor, PM			Characterization of p21(Cip1/Waf1) peptide domains required for cyclin E/Cdk2 and PCNA interaction	ONCOGENE			English	Article						Cip1; cyclin E/Cdk2; GADD45; PCNA; peptide; p53; Waf1	REPLICATION; INHIBITOR; KINASES	The cyclin-dependent kinase inhibitor p21(Cip1/Waf1) is responsible for the p53-dependent growth arrest of cells in G1 phase following DNA damage, In the present study we investigated regions of p21 involved in inhibition of the G(1)/S phase cyclin-dependent kinase, cyclin E/Cdk2, as well as regions of p21 important for binding to this kinase and recombinant PCNA, To perform these studies we synthesized a series of overlapping peptides spanning the entire p21 sequence and used them in in vitro assays with cyclin E/Cdk2-immune complexes and with recombinant p21 and PCNA proteins, One amino-terminal p21 peptide spanning amino acids 15-40, antagonized p21 binding and inhibition of cyclin E/Cdk2 kinase, Antagonism of p21 binding was, however, lost in a similar peptide lacking amino acids 15-20, or in a peptide in which cysteine-18 was substituted for a serine, These results suggest that this peptide region is important for p21 interaction with cyclin E/Cdk2, A second peptide (amino acids 58-77) also antagonized p21-activity, but this peptide did not affect the ability of p21 to interact with cyclin E/Cdk2, A region in p21 larger than 26 amino acids is presumably required for Cdk-inhibition because none of the peptides we tested inhibited cyclin E/Cdk2, We also found that a peptide spanning amino acids 21-45 bound recombinant p21 in ELISA assays, and additional studies revealed a requirement for amino acids 26 through 45 for this interaction, A p21 peptide spanning amino acids 139-164 was found to bind PCNA in a filter binding assay and this peptide suppressed recombinant p21-PCNA interaction, Conformational analysis revealed that peptides spanning amino acids 21-45 and 139-164 tended towards an alpha-helical conformation in trifluoroethanol buffer, indicating that these regions are probably in a coiled conformation in the native protein, Taken together, our results provide an insight into domains of p21 that are involved in cyclin E/Cdk2 and PCNA interaction, Our results also suggest that a potential p21 dimerization domain may lie in the amino-terminus of p21, Continued exploration of these domains could prove useful in assessing p21-mimetic strategies for cancer treatment.	NCI, MOLEC PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA; NCI, MED CHEM LAB, DIV BASIC SCI, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X				BAE IS, 1995, CANCER RES, V55, P2387; BHATIA K, 1995, CANCER RES, V55, P1431; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHEN IT, 1995, IN PRESS ONCOGENE; CHEN J, 1995, UNPUB; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUPPI K, 1994, ONCOGENE, V9, P3017; JIANG HP, 1994, ONCOGENE, V9, P3397; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MICHIELI P, 1994, CANCER RES, V54, P3391; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER M, 1995, CELL, V267, P1024; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; SCHULZ GE, 1990, PRINCIPLE PROTEIN ST, P102; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1995, INT J ONCOL, V6, P937; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	53	84	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					595	607						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637717				2022-12-28	WOS:A1996TV59700017
J	Vogt, A; Qian, YM; McGuire, TF; Hamilton, AD; Sebti, SM				Vogt, A; Qian, YM; McGuire, TF; Hamilton, AD; Sebti, SM			Protein geranylgeranylation, not farnesylation, is required for the G(1) to S phase transition in mouse fibroblasts	ONCOGENE			English	Article						cell cycle; prenylation; Ras; farnesyltransferase; geranylgeranyltransferase	GTP-BINDING PROTEIN; CELLULAR RAS ACTIVITY; ACTIN STRESS FIBERS; FARNESYLTRANSFERASE INHIBITORS; SELECTIVE-INHIBITION; CDC42 GTPASES; MAP KINASE; 3T3 CELLS; GROWTH; LOVASTATIN	In order to assess the relative contributions of farnesylated and/or geranylgeranylated proteins on cell cycle progression from G(1) to S phase we designed potent and selective farnesyltransferase (FTI-277) and geranyl-geranyltransferase-I (GGTI-298) inhibitors. Flow cytometry studies showed that treatment of NIH3T3 cells with GGTI-298 or lovastatin, which inhibits both protein farnesylation and geranylgeranylation, arrested cells in G(0)/G(1) whereas cells treated with FTI-277 progressed normally through the cell cycle. [H-3]thymidine incorporation studies showed that mevalonate and geranylgeraniol, but not farnesol, released the lovastatin G(1) block. Furthermore, mevalonate release of the lovastatin G(1) block was inhibited by GGTI-298 but not by FTI-277, These results demonstrate that geranylgeranylated proteins are required for cells to proceed from G(1) to S phase, and that farnesylated proteins do not play an essential role in the G(1) to S phase transition	UNIV PITTSBURGH,SCH MED,DEPT PHARMACOL,PITTSBURGH,PA 15261; UNIV PITTSBURGH,SCH ARTS & SCI,DEPT CHEM,PITTSBURGH,PA 15261	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NATIONAL CANCER INSTITUTE [R01CA055823, U19CA067771] Funding Source: NIH RePORTER; NCI NIH HHS [U19-CA-67771, CA-55823] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J BIOL CHEM, V267, P20033; ALBERTS AW, 1988, AM J CARDIOL, V62, pJ10, DOI 10.1016/0002-9149(88)90002-1; ARMSTRONG SA, 1995, J BIOL CHEM, V270, P7864, DOI 10.1074/jbc.270.14.7864; CASEY PJ, 1994, RECENT PROG HORM RES, V49, P215; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX AD, 1994, J BIOL CHEM, V269, P19203; DECLUE JE, 1991, CANCER RES, V51, P712; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRUNLER J, 1994, BBA-LIPID LIPID MET, V1212, P259, DOI 10.1016/0005-2760(94)90200-3; HOWE PH, 1993, J BIOL CHEM, V268, P21448; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JAMES GL, 1994, J BIOL CHEM, V269, P27705; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Jani J. P., 1994, Cellular Pharmacology, V1, P67; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770; LU KH, 1992, P NATL ACAD SCI USA, V89, P3889, DOI 10.1073/pnas.89.9.3889; Macchia M, 1996, J MED CHEM, V39, P1352, DOI 10.1021/jm960127s; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGUIRE TF, 1995, BIOCHEM BIOPH RES CO, V214, P295, DOI 10.1006/bbrc.1995.2287; MCGUIRE TF, 1996, IN PRESS ONCOGENE; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Qian YM, 1996, J MED CHEM, V39, P217, DOI 10.1021/jm950414g; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, J CELL SCI S, V18, P127; SEBTI SM, 1991, CANCER COMMUN, V3, P141, DOI 10.3727/095535491820873371; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; STACEY DW, 1991, ONCOGENE, V6, P2297; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; SUN JZ, 1995, CANCER RES, V55, P4243; VOGT A, 1995, J BIOL CHEM, V270, P660, DOI 10.1074/jbc.270.2.660; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; ZUBIAUR M, 1995, J BIOL CHEM, V270, P17221, DOI 10.1074/jbc.270.29.17221	50	158	161	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1991	1999						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934546				2022-12-28	WOS:A1996VR79500019
J	Knippschild, U; Milne, D; Campbell, L; Meek, D				Knippschild, U; Milne, D; Campbell, L; Meek, D			p53 N-terminus-targeted protein kinase activity is stimulated in response to wild type p53 and DNA damage	ONCOGENE			English	Article						p53; DNA damage; protein kinase	TEMPERATURE-SENSITIVE MUTANT; GENE AMPLIFICATION; SARCOMA-CELLS; MOUSE P53; 3T3 CELLS; PHOSPHORYLATION; ANTIGEN; RADIATION; METH; UV	The p53 tumour suppressor protein plays a central role in the cellular defence against agents which cause genetic damage, The activity of p53 is regulated at different levels and is subject to multi-site phosphorylation by a variety of different protein kinases. In this paper me have characterised p53 N-terminus-targeted protein kinase (p53NK) activities, present in a range of cell lines, following fractionation of cellular lysates by ion exchange chromatography on HiTrap Q and Mono Q resins, Three peaks of p53NK activity were observed following fractionation of HeLa cell lysates; these activities were each able to catalyse phosphorylation of up to three residues (serines 4, 6 and 9 in murine p53) within the N-terminus of the p53 protein, Similarly, multiple p53NK activities were detected in the MethAp53(ts) cell line (which expresses the valine 135 temperature-sensitive p53 protein), Strikingly, when these cells were shifted from 38 degrees C (the non-permissive temperature) to 28 degrees C, at which the p53 adopts a mild type conformation, a fivefold stimulation of kinase activity was detected, Moreover, when the DNA damage-inducing drugs etoposide or camptothecin were added to the cells, a further stimulation of kinase activity was observed following growth at 28 degrees C, but not 38 degrees C, These data are consistent with a regulatory model in which p53 is sensitive to stress or DNA damage through phosphorylation at its N-terminus.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND	University of Dundee								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHILLON N, 1994, EMBO J, V13, P2777, DOI 10.1002/j.1460-2075.1994.tb06571.x; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELIYAHU D, 1988, ONCOGENE, V3, P313; GANNON JV, 1991, NATURE, V349, P802; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HOEKSTRA MF, 1991, SCIENCE, V253, P1031, DOI 10.1126/science.1887218; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1991, CANCER RES, V51, P6304; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO KX, 1991, METHOD ENZYMOL, V201, P149; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OTTO A, 1993, ONCOGENE, V8, P2591; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SOUSSI T, 1990, ONCOGENE, V5, P945; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	35	44	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1387	1393						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875976				2022-12-28	WOS:A1996VL38400003
J	Maier, JAM; Mariotti, M; Comoglio, PM; Soria, MR				Maier, JAM; Mariotti, M; Comoglio, PM; Soria, MR			Interleukin 1 induces an autocrine loop hepatocyte growth factor c-Met in murine Kaposi-like spindle cells	ONCOGENE			English	Article						hepatocyte growth factor; c-Met; autocrine loop; interleukin-1 alpha; Kaposi's sarcoma	FACTOR-SCATTER-FACTOR; COLONY-STIMULATING FACTOR; PROTEIN-TYROSINE KINASE; TAT TRANSGENIC MICE; FACTOR-RECEPTOR; MESSENGER-RNA; FACTOR GENE; HUMAN KERATINOCYTES; EXPRESSION; PROTOONCOGENE	Several cytokines, growth factors and the HIV transactivator Tat were shown to be involved in the pathogenesis of Kaposi's sarcoma, BKV/tat transgenic mice develop Kaposi's sarcoma-like lesions, and spindle-shaped cells (TTB) have been derived from these lesions, Here we show that TTB cells co-express hepatocyte growth factor (HGF) and its receptor, the product of the oncogene c-Met. An autocrine loop HGF/Met sustains spindle cell proliferation in vitro; indeed, an antisense oligomer targeted against HGF markedly inhibited cell growth, Moreover, HGF and Met are overexpressed after exposing TTB cells to the proinflammatory cytokine interleukin 1 (IL-1), We argue that upon exposure to IL-1, an HGF/Met autocrine loop is induced which could explain the appearance of multiple foci of uncontrolled growth, In addition, due to its angiogenic activity, HGF may also sustain the neovascularization typical of Kaposi's sarcoma lesions.	SAN RAFFAELE SCI INST,DEPT BIOL & TECHNOL RES,DIBIT,I-20132 MILAN,ITALY; UNIV TURIN,SCH MED,DEPT BIOMED SCI & TECHNOL,I-10126 TURIN,ITALY	University of Turin	Maier, JAM (corresponding author), UNIV MILAN,HSR,DEPT BIOMED SCI & TECHNOL,MILAN,ITALY.		Maier, Jeanette AM/H-4820-2012	Maier, Jeanette AM/0000-0002-6326-9221; Comoglio, Paolo/0000-0002-7056-5328				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARBANTIBRODANO G, 1994, ANTIBIOT CHEMOTHER, V46, P88; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMPIONI D, 1995, AIDS RES HUM RETROV, V11, P1039, DOI 10.1089/aid.1995.11.1039; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Comoglio P M, 1993, EXS, V65, P131; CORALLINI A, 1993, CANCER RES, V53, P5569; DINARELLO CA, 1991, BLOOD, V77, P1627; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; ELLER MS, 1995, J CELL SCI, V108, P2741; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; FALKENBURG JHF, 1990, J IMMUNOL, V144, P4657; FRIESEL R, 1987, J CELL BIOL, V104, P689, DOI 10.1083/jcb.104.3.689; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KUPPER TS, 1986, J EXP MED, V164, P2095, DOI 10.1084/jem.164.6.2095; KUPPER TS, 1988, J CLIN INVEST, V82, P1787, DOI 10.1172/JCI113792; LIBBY P, 1988, J CLIN INVEST, V81, P487, DOI 10.1172/JCI113346; LIU YH, 1993, BIOCHIM BIOPHYS ACTA, V1216, P299, DOI 10.1016/0167-4781(93)90159-B; LIU YH, 1994, J BIOL CHEM, V269, P4152; Maier JAM, 1996, INT J CANCER, V65, P168, DOI 10.1002/(SICI)1097-0215(19960117)65:2<168::AID-IJC7>3.0.CO;2-X; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; MOGHUL A, 1994, ONCOGENE, V9, P2045; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAIDU YM, 1994, P NATL ACAD SCI USA, V91, P5281, DOI 10.1073/pnas.91.12.5281; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NORIOKA K, 1987, BIOCHEM BIOPH RES CO, V145, P969, DOI 10.1016/0006-291X(87)91060-6; OKAJIMA A, 1993, EUR J BIOCHEM, V213, P113, DOI 10.1111/j.1432-1033.1993.tb17740.x; POLVERINI PJ, 1995, ADV CANCER RES, V66, P235, DOI 10.1016/S0065-230X(08)60256-0; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x; Sambrook J., 2002, MOL CLONING LAB MANU; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAMURA M, 1993, J BIOL CHEM, V268, P8140; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; ZARNEGAR R, 1995, J CELL BIOL, V129, P1177, DOI 10.1083/jcb.129.5.1177	56	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1009	1015						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806690				2022-12-28	WOS:A1996VG76600014
J	Liang, YX; Robinson, DF; Kujoth, GC; Fahl, WE				Liang, YX; Robinson, DF; Kujoth, GC; Fahl, WE			Functional analysis of the SIS proximal element and its activating factors: Regulated transcription of the c-SIS/PDGF-B gene in human erythroleukemia cells	ONCOGENE			English	Article						c-sis/PDGF-B; K562; Sp1; Sp3; TPA	BOX-BINDING-PROTEINS; GROWTH-FACTOR; PROMOTER; EXPRESSION; FAMILY; PDGF; CIS; IDENTIFICATION; MEMBERS; CLONING	The SIS proximal element (SPE) is essential for the basal transcription of the c-sis/PDGF-B gene as well as the lineage-specific, activated transcription of this gene seen in megakaryocytes. In gel mobility shift analyses, the SPE element forms three gel-shift complexes; the t(op) and b(ottom) complexes were detected in nuclear extracts from both untreated and phorbol 12-myristate 13-acetate ('tetradecanoylphorbol acetate', TPA) treated K562 cells, whereas the m(iddle) complex was detected only in nuclear extracts from TPA-treated g562 cells. Site-directed mutagenesis of the SPE revealed CCACCC motif that was essential for promoter activity as well as the formation of all three SPE gel-shift complexes. Nested-deletion analyses showed that the SPE was required for TPA-inducibility of c-sis/PDGF-B transcription. Antibody supershift analyses demonstrated that the t gel-shift complex contained both Sp1 and Sp3, and that the b complex contained only Sp3. In vitvo transcription assays demonstrated that both Sp1 and Sp3 could support c-sis/PDGF-B transcription independent of each other in untreated K562 cells. However, overexpression of Sp1/Sp3 failed to significantly increase the c-sis/PDGF-B transcription in K562 cells.	UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL CANCER INSTITUTE [P30CA007175, R37CA042024, T32CA009681] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA07175, T32-CA09681, R37-CA42024] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTONIADES HN, 1991, BAILLIERE CLIN ENDOC, V5, P595, DOI 10.1016/S0950-351X(10)80005-9; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIRKSRPH, 1995, NUCLEIC ACIDS RES, V23, P1119; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FLEMING TP, 1992, ONCOGENE, V7, P1355; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; FRANKLIN GC, 1995, ONCOGENE, V11, P1873; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; MAJELLO B, 1995, ONCOGENE, V10, P1841; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MARTINET Y, 1987, NEW ENGL J MED, V317, P202, DOI 10.1056/NEJM198707233170404; PECH M, 1989, MOL CELL BIOL, V9, P396, DOI 10.1128/MCB.9.2.396; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203	25	8	9	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					863	871						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761308				2022-12-28	WOS:A1996VD43300022
J	Sun, XF; Johannsson, O; Hakansson, S; Sellberg, G; Nordenskjold, B; Olsson, H; Borg, A				Sun, XF; Johannsson, O; Hakansson, S; Sellberg, G; Nordenskjold, B; Olsson, H; Borg, A			A novel p53 germline alteration identified in a late onset breast cancer kindred	ONCOGENE			English	Article						p53; germline mutation; familial breast cancer; Li-Fraumeni syndrome	LI-FRAUMENI SYNDROME; TP53 MUTATIONS; OVARIAN-CANCER; GENE-MUTATIONS; FAMILIES; PREVALENCE; RATES	Germline mutations in the p53 tumor suppressor gene are associated with the Li-Fraumeni syndrome, characterized by childhood sarcoma, leukemia and early onset breast cancer and has occasionally been found also in familial breast-ovarian cancer. Most mutations found are of missense type and located in the central region of the gene (exons 5 to 8). In the present study, a germline p53 alteration was identified in a late onset breast cancer family (kindred Lund 5; mean age 58 years) using single stranded conformation polymorphism and sequence analysis. The mutation (a CCG to CTG transition) at codon 82 in exon 4, resulting in a proline to leucine substitution, has not previously been reported and was not present in a control set of 60 healthy individuals. Three of five woman with breast cancer (45, 57 and 65 years) were carriers of the alteration. Loss of heterozygosity at the p53 locus was not seen in the primary tumors of these women, but appeared as a partial loss of the wildtype allele in subsequent recurrent lesions of two gene carriers. The family manifested no linkage to the p53 gene (a two-point LOD-score of -0.41), and has previously also been excluded for linkage to the BRCA1 and BRCA2 loci, as well as being carrier of a BRCA1 germline mutation. Although it seems unlikely that the p53 germline mutation is the major cause of disease predisposition in Lund 5, the data suggest that some p53 alteration may confer a subtle influence on breast cancer development and progression.	LINKOPING UNIV HOSP,DEPT ONCOL,S-58185 LINKOPING,SWEDEN; UNIV LUND HOSP,DEPT ONCOL,S-22185 LUND,SWEDEN	Linkoping University; Lund University; Skane University Hospital				Olsson, Hakan/0000-0002-8794-9635				BIRCH JM, 1994, CANCER RES, V54, P1298; BORRESEN AL, 1992, CANCER RES, V52, P3234; BORRESEN AL, 1995, GENE CHROMOSOME CANC, V14, P71, DOI 10.1002/gcc.2870140113; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; EASTON DF, 1993, AM J HUM GENET, V52, P678; FREBOURG T, 1995, AM J HUM GENET, V56, P608; HARTMANN A, 1995, ONCOGENE, V10, P681; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Johannsson O, 1996, AM J HUM GENET, V58, P441; JOLLY KW, 1994, ONCOGENE, V9, P97; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; PROSSER J, 1992, BRIT J CANCER, V65, P527, DOI 10.1038/bjc.1992.109; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; RUSSO CL, 1994, MED PEDIATR ONCOL, V23, P354, DOI 10.1002/mpo.2950230407; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001; TORNALETTI S, 1995, ONCOGENE, V10, P1493; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WARREN W, 1992, ONCOGENE, V7, P1043; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231	26	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					407	411						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710380				2022-12-28	WOS:A1996VA25200020
J	Noguchi, K; Naito, M; Kugoh, H; Oshimura, M; Mashima, T; Fujita, N; Yonehara, S; Tsuruo, T				Noguchi, K; Naito, M; Kugoh, H; Oshimura, M; Mashima, T; Fujita, N; Yonehara, S; Tsuruo, T			Chromosome 22 complements apoptosis in Fas- and TNF-resistant mutant UK110 cells	ONCOGENE			English	Article						microcell-fusion; chromosome 22; Fas; TNF; apoptosis	TUMOR-NECROSIS-FACTOR; DEATH GENE CED-3; INSITU HYBRIDIZATION; RECEPTOR; ANTIGEN; INDUCTION; HYBRIDS; HT1080; DOMAIN; ENZYME	Fas and p55 tumor necrosis factor receptor (TNFR) transfer an apoptosis signal when they are crosslinked with their ligands or agonistic antibodies, However, the signal transduction mechanism of apoptosis via Fas and p55 TNFR has not yet been elucidated, We previously described a recessive mutant UK110 from the human monocytic leukemia U937 cell line, that showed resistance against Fas- and p55 TNFR-mediated apoptosis. By cytogenetic analysis and microcell-fusion method, we demonstrate here that introduction of chromosome 22 can specifically restore the sensitivity to Fas- and TNF-mediated apoptosis in UK110 cells, Moreover, introduction of chromosome 22 into UK110 can complement the processing of interleukin-1 beta converting enzyme (ICE)-like proteases, such as CPP32/Yama/Apopain and ICH-1L, after treatment with anti-Pas and anti-p55 TNFR antibodies, These results suggest that the product of a gene located on chromosome 22 participates in the Fas-and p55 TNFR-mediated apoptosis at a point upstream of ICE-like proteases.	UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,LAB BIOMED RES,BUNKYO KU,TOKYO 113,JAPAN; TOTTORI UNIV,DEPT MOLEC & CELL GENET,TOTTORI 683,JAPAN; KYOTO UNIV,INST VIRUS RES,KYOTO 60601,JAPAN; JAPANESE FDN CANC RES,CTR CANC CHEMOTHERAPY,TOKYO 170,JAPAN	University of Tokyo; Tottori University; Kyoto University; Japanese Foundation for Cancer Research								BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; BENEDICT WF, 1984, CANCER RES, V44, P3471; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FUCHS P, 1992, GENOMICS, V13, P219, DOI 10.1016/0888-7543(92)90226-I; GOLSTEIN P, 1995, CELL, V81, P185, DOI 10.1016/0092-8674(95)90327-5; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KATAOKA S, 1994, EXP CELL RES, V215, P199, DOI 10.1006/excr.1994.1332; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KUGOH HM, 1990, ONCOGENE, V5, P1637; KUMAR S, 1995, HUM GENET, V95, P641; KURAHASHI H, 1994, HUM GENET, V93, P248, DOI 10.1007/BF00212017; KURIMASA A, 1994, HUM GENET, V93, P21; LICHTER P, 1990, P NATL ACAD SCI USA, V87, P6634, DOI 10.1073/pnas.87.17.6634; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MASHIMA T, 1995, BIOCHEM BIOPH RES CO, V209, P907, DOI 10.1006/bbrc.1995.1584; Mashima T, 1995, BIOCHEM BIOPH RES CO, V217, P1185, DOI 10.1006/bbrc.1995.2894; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOGUCHI K, 1995, CELL GROWTH DIFFER, V6, P1271; PEREIRA LD, 1991, GENOMICS, V9, P229, DOI 10.1016/0888-7543(91)90246-B; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; UEJIMA H, 1995, GENE CHROMOSOME CANC, V14, P120, DOI 10.1002/gcc.2870140206; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	43	18	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					39	46						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700552				2022-12-28	WOS:A1996UX31900005
J	Suzuki, A; Matsuzawa, A; Iguchi, T				Suzuki, A; Matsuzawa, A; Iguchi, T			Down regulation of Bcl-2 is the first step on Fas-mediated apoptosis of male reproductive tract	ONCOGENE			English	Article						Bcl-2; Fas; 1pr mutant mouse; apoptosis; in vivo apoptosis-model	CELL-DEATH; EXPRESSION; ANTIGEN; RECEPTOR; LIGAND; APO-1; MICE; CLONING; MEMBER; GENE	Suppression of apoptosis by Bcl-2, an oncogene product, has been previously reported, Although the down regulation of Bcl-2 has been encountered in various types of apoptosis, the time course of changes in the expression of Bcl-2 has yet to be determined, In the present study, we established and analysed an in vivo model of apoptosis, The mouse male reproductive tract, specifically the prostate and epididymis, which is regulated by sex steroid hormones, especially testosterone, showed regression induced by chromosomal DNA fragmentation, apoptotic cell death, after gonadectomy, Following this apoptosis, down regulation of Bcl-2 and the new expression of Fas were seen, Using functional Fas-lacking mice, we demonstrated that this regression of the male reproductive tract is triggered by Fas-mediated apoptosis, In addition, time course experiments revealed that down regulation of Bcl-2 when apoptosis occurs heralds Fas expression, We propose here that apoptotic death signal transduction in total involve, a number of steps, the first and most important of which is down regulation of Bcl-2.	UNIV TOKYO,INST MED SCI,LAB ANIM RES CTR,MINATO KU,TOKYO 108,JAPAN; YOKOHAMA CITY UNIV,DEPT BIOL,KANAZAWA KU,YOKOHAMA,KANAGAWA 236,JAPAN	University of Tokyo; Yokohama City University	Suzuki, A (corresponding author), DAIICHI PHARMACEUT CO LTD,DRUG SAFETY RES LAB,TOKYO R&D CTR,EDOGAWA KU,16-13 KITAKASAI 1,TOKYO 134,JAPAN.		Iguchi, Taisen/AAL-4225-2021; Matsuzawa, Atsushi/GLU-1387-2022					AKAO Y, 1994, CANCER RES, V54, P2468; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; IGUCHI T, 1992, INT REV CYTOL, V139, P1, DOI 10.1016/S0074-7696(08)61409-6; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KAMADA S, 1995, CANCER RES, V55, P354; KONDO S, 1994, BRIT J CANCER, V70, P421, DOI 10.1038/bjc.1994.321; LEITHAUSER F, 1993, LAB INVEST, V69, P415; LICHTER P, 1992, GENOMICS, V14, P179, DOI 10.1016/S0888-7543(05)80302-7; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAGATA S, 1994, PHILOS T ROY SOC B, V345, P281, DOI 10.1098/rstb.1994.0107; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OTANI H, 1993, J BIOL CHEM, V268, P22733; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SMITH PK, 1985, ANAL BIOCHEM, V170, P203; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Suzuki A, 1996, EMBO J, V15, P211, DOI 10.1002/j.1460-2075.1996.tb00351.x; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WILSON DL, 1977, ANAL BIOCHEM, V83, P33, DOI 10.1016/0003-2697(77)90506-1; Wyllie A H, 1980, Int Rev Cytol, V68, P251	30	106	112	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					31	37						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700551				2022-12-28	WOS:A1996UX31900004
J	Cosgaya, JM; Aranda, A				Cosgaya, JM; Aranda, A			Ras- and Raf-mediated regulation of transforming growth factor beta 1 gene expression by ligands of tyrosine kinase receptors in PC12 cells	ONCOGENE			English	Article						PC12 cells; TGF-beta 1; Egr-1; Ras; Raf; growth factors	PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; B-RAF; NERVE; DIFFERENTIATION; ONCOGENE; INHIBITION; ACTIVATION; LINE	Different ligands of tyrosine kinase receptors have neurotrophic or mitogenic effects in PC12 cells, NFG and FGF, which-cause morphological differentiation, as well as EGF, that induces cell growth, produce a significant increase of TGF-beta 1 transcripts in PC12 cells. Sequences responsible for the transcriptional effects of the growth factors are located in the 5'-flanking region of the TGF-beta 1 gene, The TGF-beta 1 gene has two promoters and the growth factors significantly enhance the activity of constructs containing either the first or the second promoter, A functional p21(ras) is required for the regulation of TGF-beta 1 by ligands of tyrosine kinase receptors since expression of oncogenic I as in PC12 cells also increases TGF-beta 1 transcripts, and a dominant inhibitory ras mutant blocks activation of TGF-beta 1 gene expression by NGF, Oncogenic raf stimulates the activity of both promoters and a dominant negative raf also significantly inhibits growth factor activation. As determined by Mv1Lu cell proliferation inhibition assay, PC12 cells release a significant amount of TGF-beta 1 in a latent form and incubation with growth factors or expression of oncogenic ras further increase TGF-beta 1 production. These results suggest that during proliferation or growth factor-induced differentiation of sympathetic neurons there is an increase in TGF-beta 1 that could be an important mediator of neural cells function.	CSIC, INST INVEST BIOMED, E-28029 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020; Cosgaya, Jose M/B-4936-2008	Aranda, Ana/0000-0002-8338-9589; Cosgaya, Jose Miguel/0000-0002-6005-2916				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHALAZONITIS A, 1992, DEV BIOL, V152, P121, DOI 10.1016/0012-1606(92)90162-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COSGAYA JM, 1995, J NEUROCHEM, V65, P2484; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DACUNHA A, 1993, J NEUROIMMUNOL, V42, P71, DOI 10.1016/0165-5728(93)90214-J; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DERYNK R, 1996, J BIOL CHEM, V261, P4377; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; GEISER AG, 1991, MOL CELL BIOL, V11, P84, DOI 10.1128/MCB.11.1.84; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALEGOUA S, 1991, CURR TOP MICROBIOL, V165, P119; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MCKINNON RD, 1993, J CELL BIOL, V121, P1397, DOI 10.1083/jcb.121.6.1397; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MUROYA K, 1992, ONCOGENE, V7, P277; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Qui MS, 1991, NEURON, V7, P937, DOI [DOI 10.1016/0896-6273(91)90339-2, 10.1016/0896-6273(91)90339-2]; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROGERS SL, 1992, DEV BIOL, V151, P192, DOI 10.1016/0012-1606(92)90226-7; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TOGARI A, 1983, BIOCHEM BIOPH RES CO, V114, P1189, DOI 10.1016/0006-291X(83)90688-5; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	50	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2651	2660						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700524				2022-12-28	WOS:A1996UW48700019
J	Harhaj, EW; Maggirwar, SB; Sun, SC				Harhaj, EW; Maggirwar, SB; Sun, SC			Inhibition of p105 processing by NF-kappa B proteins in transiently transfected cells	ONCOGENE			English	Article						NF-kappa B; p105; protein processing; RelA; c-Rel	HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; DNA-BINDING SUBUNIT; TRANS-ACTIVATOR PROTEIN; NUCLEAR-LOCALIZATION; PRECURSOR P105; 65-KD SUBUNIT; PHORBOL ESTER; MESSENGER-RNA; REL ONCOGENE	Regulation of the transcription factor NF-kappa B involves proteasome-mediated processing of the NF-kappa B1 p105 precursor protein, which generates the p50 subunit of NF-kappa B. The processing of p105 occurs constitutively in vivo but can be markedly enhanced by various cellular activation agents, although the underlying regulatory mechanism is not yet clear, In the present study, we demonstrate that signal-mediated induction of p105 processing in human T cells is associated with de novo synthesis of this precursor protein, Transient transfection studies performed in COS7 cells revealed that the newly synthesized p105 protein appears to be more rapidly processed compared to its accumulated form that is already associated with the processed product p50, Interestingly, the processing rate of p105 is markedly inhibited in cells co-transfected with p50 or other NF-kappa B subunits, including RelA and c-Rel, that physically interact with p105, These findings suggest that the processing of p105 is subject to negative regulation by the various NF-kappa B subunits, We further demonstrate that p105 undergoes degradation in lipopolysaccharide-stimulated human monocytic cells. However, the inducible degradation of p105 is not coupled with the generation of p50, Together, these studies demonstrate that the processing and inducible degradation of p105 are differentially regulated.	PENN STATE UNIV,MILTON S HERSHEY MED CTR,COLL MED,DEPT MICROBIOL & IMMUNOL,HERSHEY,PA 17033	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health					NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA 68471-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1990, HORMONAL CONTROL REG, P409; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; DOERRE S, 1993, P NATL ACAD SCI USA, V90, P1023, DOI 10.1073/pnas.90.3.1023; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; KAUFMAN JD, 1987, MOL CELL BIOL, V7, P3759, DOI 10.1128/MCB.7.10.3759; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TONGSTARKSEN SE, 1987, P NATL ACAD SCI USA, V84, P6845, DOI 10.1073/pnas.84.19.6845; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; ZHENG S, 1993, J BIOL CHEM, V268, P17233	38	27	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2385	2392						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649779				2022-12-28	WOS:A1996UQ22000016
J	Hecker, D; Page, G; Lohrum, M; Weiland, S; Scheidtmann, KH				Hecker, D; Page, G; Lohrum, M; Weiland, S; Scheidtmann, KH			Complex regulation of the DNA-binding activity of p53 by phosphorylation: Differential effects of individual phosphorylation sites on the interaction with different binding motifs	ONCOGENE			English	Article						DNA-binding; p53; phosphorylation; okadaic acid; tumor suppressor protein	LARGE T-ANTIGEN; TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; CELL-CYCLE CONTROL; WILD-TYPE; RAT-CELLS; 3T3 CELLS; TRANSCRIPTION; SEQUENCE; ONCOGENE	The tumor suppressor protein p53 exists in different phosphorylation states depending on the cellular environment and perhaps the stage of the cell cycle. These different phosphorylation states can be mimicked in the baculovirus expression system by employing the phosphatase inhibitor okadaic acid. Hyperphosphorylation of p53, particularly of Ser313 and/or Ser309, stimulated its DNA binding activity (Fuchs, Hecker and Scheidtmann, Eur. J. Biochem. 228, 625, 1995). Here we show that hyperphosphorylation of p53 has different effects on its DNA-binding activity, depending on the phosphorylation sites and the binding motif: (i) Phosphorylation of amino-terminal sites appeared to reduce binding to the RGC consensus motif, whereas additional phosphorylation of both, Ser313 and Ser309 led to enhanced binding. (ii) Upon hyperphosphorylation, binding to the RGC motif was enhanced whereas binding to the p53 response element of the bax1 gene promoter was diminished. (iii) DNA binding was also greatly enhanced by antibodies Pab 122 and 421 directed against the carboxyl terminus, but this latter effect was superimposed by the phosphorylation state of p53. Thus, the DNA binding activity of p53 appears to be regulated in a complex way in that (i) binding to a given sequence motif may be regulated by differential phosphorylation and/or by interaction with other factors; (ii) binding to different motifs may be modulated in opposite ways. Thus, the different genes that are regulated by p53 may be differently affected by these parameters.	UNIV BONN,INST GENET,ABT MOLEK GENET,D-53117 BONN,GERMANY	University of Bonn								BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BRAIN R, 1994, ONCOGENE, V9, P1775; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HEBEL M, 1986, Z NATURFORSCH C, V41, P94; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAMAL S, 1995, ONCOGENE, V10, P2095; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KLAUSING K, 1988, J VIROL, V62, P1258, DOI 10.1128/JVI.62.4.1258-1265.1988; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO K, 1990, ONCOGENE, V5, P921; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MIYASHITA T, 1995, CELL, V80, P293; MOHR IJ, 1987, EMBO J, V6, P153, DOI 10.1002/j.1460-2075.1987.tb04733.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOSNER B, 1995, EMBO J, V14, P4442; MULLER E, 1995, ONCOGENE, V10, P1175; MULLER E, 1993, ONCOGENE, V8, P2193; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OREN M, 1992, CANCER METAST REV, V11, P141, DOI 10.1007/BF00048060; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SCHEIDTMANN KH, 1994, INT J ONCOL, V5, P1353; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIO Y, 1992, P NATL ACAD SCI USA, V89, P5206; SOUSSI T, 1988, NUCLEIC ACIDS RES, V16, P11384, DOI 10.1093/nar/16.23.11384; STEINMEYER K, 1988, ONCOGENE, V3, P501; STURZBECHER HW, 1990, ONCOGENE, V5, P795; SUMMERS MD, 1987, TEXAS EXP STATION B, V1555; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WEISSKER SN, 1992, ONCOGENE, V7, P1921; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	82	78	80	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					953	961						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649812				2022-12-28	WOS:A1996UA88400002
J	Bonapace, IM; Addeo, R; Altucci, L; Cicatiello, L; Bifulco, M; Laezza, C; Salzano, S; Sica, V; Bresciani, F; Weisz, A				Bonapace, IM; Addeo, R; Altucci, L; Cicatiello, L; Bifulco, M; Laezza, C; Salzano, S; Sica, V; Bresciani, F; Weisz, A			17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation	ONCOGENE			English	Article						estrogen; cell cycle; mevalonate; HMG-CoA reductase; c-fos; ras	HUMAN-BREAST-CANCER; ESTROGEN RESPONSE ELEMENT; C-FOS PROTOONCOGENE; GROWTH-INHIBITION; RECEPTOR; IDENTIFICATION; LOVASTATIN; SERUM; GENE; LINE	HMG-CoA reductase inhibitors, such as Lovastatin and Simvastatin, cause cell cycle arrest by interfering with the mitogenic activity of mitogens present in culture media. Cells are induced to pause in G(1) and can readily resume growth upon removal of the enzymatic block. Estrogens, acting via their nuclear receptor, are mitogens for different normal and transformed cell types, where they foster cell cycle progression and cell division. In estrogen-responsive MCF-7 human breast cancer cells, but not in non responsive cells, 17 beta-estradiol (E(2)) induces cells arrested with Lovastatin or Simvastatin to proliferate in the presence of inhibitor, without restoring HMG-CoA reductase activity or affecting the protein prenylation pattern. Mitogenic stimulation of G(1)-arrested MCF-7 cells with E(2) includes primary transcriptional activation of c-fos, accompanied by transient binding in vivo of the estrogen receptor and/or other factors to the ERE and the estrogen-responsive DNA region of this proto-oncogene, as detected by dimethylsulphate genomic footprinting analysis. Mitogenic stimulation of growth-arrested MCF-7 cells by E(2) occurs, under these conditions, without evident activation of ERK-1 and -2 kinases, and thus independently from the mitogen-responsive signal transduction pathways that converge on these enzymes.	UNIV NAPLES 2, FAC MED & CHIRURG, IST PATOL GEN & ONCOL, I-80138 NAPLES, ITALY; UNIV NAPLES FEDERICO II, CNR, CEOS, NAPLES, ITALY; UNIV REGGIO CALABRIA, DIPARTIMENTO MED SPERIMENTALE & CLIN, CATANZARO, ITALY; UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOL & PATOL CELLULARE & MOL L CALIF, NAPLES, ITALY	Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Universita Mediterranea di Reggio Calabria; University of Naples Federico II			Altucci, Lucia/S-8031-2019; laez, chi/AAW-4437-2020; Weisz, Alessandro/A-1317-2014	Weisz, Alessandro/0000-0003-0455-2083; Bifulco, Maurizio/0000-0002-1771-4531; altucci, lucia/0000-0002-7312-5387; BONAPACE, IAN MARC/0000-0001-6580-8893				ABBONDANZA C, 1993, STEROIDS, V58, P4, DOI 10.1016/0039-128X(93)90011-B; AMBROSINO C, 1993, MOL ENDOCRINOL, V7, P1472, DOI 10.1210/me.7.11.1472; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BARBU V, 1990, ONCOGENE, V5, P1077; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BRIAND P, 1986, ANTICANCER RES, V6, P85; BRUNNER N, 1989, CANCER RES, V49, P1515; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; CICATIELLO L, 1993, RECEPTOR, V3, P17; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DAVIDSON NE, 1989, ONCOGENESIS, V1, P89; DECLUE JE, 1991, CANCER RES, V51, P712; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; DOYLE A, 1994, CELL TISSUE CULTURE; DUBIK D, 1992, ONCOGENE, V7, P1587; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRIECO D, 1990, J BIOL CHEM, V265, P19343; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HU AW, 1994, MOL CELL BIOL, V14, P8202; HYDER SM, 1992, J BIOL CHEM, V267, P18047; IACOBELLI S, 1984, J STEROID BIOCHEM, V20, P747, DOI 10.1016/0022-4731(84)90079-7; INGLESE J, 1995, TRENDS BIOCHEM SCI, V20, P151, DOI 10.1016/S0968-0004(00)88992-6; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KNOWLER JT, 1985, ESSAYS BIOCHEM, V20, P1; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; LARSSON O, 1989, CANCER RES, V49, P5605; LIPPMAN M, 1976, CANCER RES, V36, P4595; MARSHALL E, 1994, SCIENCE, V264, P1524, DOI 10.1126/science.8202702; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; Maxam A M, 1980, Methods Enzymol, V65, P499; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; NEMERE I, 1993, RECEPTOR, V3, P277; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OGASAWARA M, 1988, IN VITRO CELL DEV B, V24, P911; PERILLO B, 1995, J BIOL CHEM, V270, P15237, DOI 10.1074/jbc.270.25.15231; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; PFEIFER GP, 1989, SCIENCE, V246, P810, DOI 10.1126/science.2814502; RICHARDFOY H, 1994, NATURE, V370, P417, DOI 10.1038/370417a0; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SCHULZ S, 1992, CANCER RES, V52, P1372; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SHAFIE SM, 1980, SCIENCE, V209, P701, DOI 10.1126/science.6994231; SOULE HD, 1990, CANCER RES, V50, P6075; TAIT L, 1990, CANCER RES, V50, P6087; TAMANOI F, 1993, TRENDS BIOCHEM SCI, V18, P349, DOI 10.1016/0968-0004(93)90072-U; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; VINCENT TS, 1991, BIOCHEM BIOPH RES CO, V180, P1284, DOI 10.1016/S0006-291X(05)81334-8; WEIGEL RJ, 1993, CANCER RES, V53, P3472; WEISS W, 1991, INDAGAT MATH NEW SER, V2, P115, DOI 10.1016/0019-3577(91)90047-B; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WEISZ A, 1990, NUCLEIC ACIDS RES, V18, P5097, DOI 10.1093/nar/18.17.5097; WEISZ A, 1988, MOL ENDOCRINOL, V2, P816, DOI 10.1210/mend-2-9-816; WEJDE J, 1993, J CELL PHYSIOL, V155, P539, DOI 10.1002/jcp.1041550312	65	54	55	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					753	763						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632897				2022-12-28	WOS:A1996TW68600006
J	Flaman, JM; Waridel, F; Estreicher, A; Vannier, A; Limacher, JM; Gilbert, D; Iggo, R; Frebourg, T				Flaman, JM; Waridel, F; Estreicher, A; Vannier, A; Limacher, JM; Gilbert, D; Iggo, R; Frebourg, T			The human tumour suppressor gene p53 is alternatively spliced in normal cells	ONCOGENE			English	Article						p53; alternative splicing; transcription	WILD-TYPE P53; LYMPHOBLASTIC-LEUKEMIA; TRANSCRIPTION; PROTEIN; MUTATIONS; GROWTH; DNA; APOPTOSIS; ANTIGEN; YEAST	Alternative splicing affecting the p53 carboxy-terminus has previously been described in mouse but not in normal human cells. We report here the detection in normal human lymphocytes of an alternatively spliced form of human p53 mRNA containing an additional 133 bp exon derived from intron 9. This splice variant encodes a truncated protein of 341 amino-acids including 10 new amino-acids derived from the novel exon. The truncated protein, which lacks part of the p53 tetramerization domain, fails to bind DNA in vitro and has transcriptional defect in vivo in both yeast and mammalian cells. Quantitative RT-PCR experiments suggests that the alternatively spliced form is only present in significant amounts in quiescent cells. Considering the numerous functions ascribed to the carboxy-terminus of the p53 protein, this splice variant may have important implications for the biological role of p53 in normal cells.	CHU ROUEN,LAB GENET MOL,F-76031 ROUEN,FRANCE; SWISS INST EXPTL CANC RES,CH-1066 EPALINGES,SWITZERLAND; CHU VAUDOIS,SERV ORL,CH-1011 LAUSANNE,SWITZERLAND; CHU ROUEN,LAB IMMUN PATHOL CLIN & EXPT,F-76031 ROUEN,FRANCE; HOP UNIV,F-67091 STRASBOURG,FRANCE	CHU de Rouen; Swiss Institute Experimental Cancer Research; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); CHU de Rouen; CHU Strasbourg			Frebourg, Thierry/AAK-8390-2020; Flaman, Jean-Michel/K-8415-2018; Iggo, Richard/G-3546-2014	Flaman, Jean-Michel/0000-0003-3544-0199; Estreicher, Anne/0000-0001-6828-2508				ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CALABRETTA B, 1986, CANCER RES, V46, P5738; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHOW VTK, 1993, CANCER LETT, V73, P141, DOI 10.1016/0304-3835(93)90256-9; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FELIX CA, 1992, J CLIN INVEST, V89, P640, DOI 10.1172/JCI115630; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; FLAMAN JM, 1994, NUCLEIC ACIDS RES, V22, P3259, DOI 10.1093/nar/22.15.3259; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARLOW E, 1988, ANTIBODIES LABORATOR; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KULESZMARTIN MF, 1994, MOL CELL BIOL, V14, P1698, DOI 10.1128/MCB.14.3.1698; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; MATLASHEWSKI G, 1987, ONCOGENE RES, V1, P77; MIYASHITA T, 1995, CELL, V80, P293; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; TARUNINA M, 1993, ONCOGENE, V8, P3165; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	47	90	97	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					813	818						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632903				2022-12-28	WOS:A1996TW68600012
J	Ohta, Y; Haire, RN; Amemiya, CT; Litman, RT; Trager, T; Riess, O; Litman, GW				Ohta, Y; Haire, RN; Amemiya, CT; Litman, RT; Trager, T; Riess, O; Litman, GW			Human Txk: Genomic organization, structure and contiguous physical linkage with the Tec gene	ONCOGENE			English	Article						protein tyrosine kinase; gene linkage; Tec gene family; P1 artificial chromosome; DNA sequencing	X-LINKED AGAMMAGLOBULINEMIA; PROTEIN-TYROSINE KINASE; EXPRESSION; SEQUENCE	Txk is a Tec-family tyrosine kinase expressed in mouse and human T lymphocytes. Among the Tec kinases, Txk is unique in that its amino terminal region does not include a pleckstrin homology domain or other known extended functional region. Txk is encoded at human chromosome 4p12 and at a recognized region of conserved synteny on mouse chromosome 5. The genomic organization of Txk consists of 15 exons with strong exon-intron organizational homology to Btk, the only other Tee-family kinase for which the genomic structure is fully known. The human Tec gene also maps to 4p12 and, based on limited studies reported here, possesses organizational homology with Btk and Txk. We have sequenced a continuous region of DNA that contains 3' Tec and 5' Txk exons separated by only a similar to 1.5 kb intergenic region containing the putative promoter region of Txk. The close physical linkage of these Tee-family tyrosine kinases, which are expressed in different hematopoetic cell lineages, suggests their potential for coordinate cis-regulation.	UNIV S FLORIDA,ALL CHILDRENS HOSP,DEPT PEDIAT,ST PETERSBURG,FL 33701; BOSTON UNIV,CTR HUMAN GENET,BOSTON,MA 02118; RUHR UNIV BOCHUM,DEPT HUMAN MOLEC GENET,W-4470 BOCHUM,GERMANY	State University System of Florida; University of South Florida; Boston University; Ruhr University Bochum								BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; DHALLAN RS, 1992, J NEUROSCI, V12, P3248, DOI 10.1523/JNEUROSCI.12-08-03248.1992; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GIBSON S, 1993, BLOOD, V82, P1561; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HAIRE RN, 1995, MAMM GENOME, V6, P476, DOI 10.1007/BF00360659; HAIRE RN, 1994, HUM MOL GENET, V3, P897, DOI 10.1093/hmg/3.6.897; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; LEE ST, 1993, ONCOGENE, V8, P3403; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MAZZARELLA R, 1995, GENOMICS, V26, P629, DOI 10.1016/0888-7543(95)80190-W; Nadeau J H, 1991, Mamm Genome, V1 Spec No, pS461, DOI 10.1007/BF00656504; NAGLE DL, 1995, HUM MOL GENET, V4, P2073, DOI 10.1093/hmg/4.11.2073; OELTJEN JC, 1995, MAMM GENOME, V6, P334, DOI 10.1007/BF00364796; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; OLSEN AS, 1993, BIOTECHNIQUES, V14, P116; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; RIESS O, 1994, CYTOGENET CELL GENET, V65, P238, DOI 10.1159/000133638; ROBERTS WM, 1988, CELL, V55, P655, DOI 10.1016/0092-8674(88)90224-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; SATO K, 1994, LEUKEMIA, V8, P1663; SIDERAS P, 1994, J IMMUNOL, V153, P5607; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SOMMERS CL, 1995, ONCOGENE, V11, P245; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P266	33	17	20	2	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					937	942						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632917				2022-12-28	WOS:A1996TW68600026
J	KhannaGupta, A; Lopingco, MC; Savinelli, T; Zibello, T; Berliner, N; Perkins, AS				KhannaGupta, A; Lopingco, MC; Savinelli, T; Zibello, T; Berliner, N; Perkins, AS			Retroviral insertional activation of the EVI1 oncogene does not prevent G-CSF-induced maturation of the murine pluripotent myeloid cell line 32Dcl3	ONCOGENE			English	Article						G-CSF; myeloid leukemia; evil	COLONY-STIMULATING FACTOR; ZINC FINGER GENE; TRANSFORMING GENE; GRANULOCYTIC DIFFERENTIATION; EXPRESSION; SEQUENCE; LEUKEMIA; BINDING; PROTEIN; DNA	Evil is a myeloid-specific protooncogene that encodes 145 kDa and 88 kDa proteins via alternative splicing, Overexpression of the gene via retroviral insertion in murine tumors or chromosomal rearrangement in human tumors is associated with myeloid leukemias and myelodysplasias; however, the mechanism by which such overexpression leads to transformation is not clear, It has been postulated that overexpression of evil acts to block normal myelopoiesis. In attempts to assess the effect of overexpression of evil on myelopoiesis, we chose to utilize the IL-3-dependent murine 32Dcl3 cell line, which has been shown to differentiate in culture in response to G-CSP. Previous experiments with this cell line, which Ne have confirmed, showed that overexpression of evil, mediated by retroviral vector transfer, caused a block to G-CSF-induced cell survival and differentiation, We report here that the naive 32Dcl3 cell line contains a rearrangement of the evil locus and constitutively overexpresses evil mRNA and protein; this expression is downregulated only slightly during G-CSF-induced myeloid maturation, The steady state levels, molecular weight and DNA binding characteristics of the EVI1 protein in these cells is comparable to that seen in NFS 58, a myeloid leukemia cell line with retroviral insertion at evil, The observed ability of the murine 32Dcl3 cells to fully differentiate in the presence of G-CSF while evil continues to be expressed indicates that, at the levels expressed in naive 32Dcl3, evil does not block G-CSF-induced survival and differentiation, Thus, retroviral insertions at evil may have been selected for in 32Dcl3 cells due to effects other than that on G-CSF-induced cell survival.	YALE UNIV, SCH MED, DEPT PATHOL, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06520 USA	Yale University; Yale University					NIDDK NIH HHS [DK42347] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042347] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORDEREAUX D, 1990, ONCOGENE, V5, P925; CHATTOPADHYAY SK, 1980, J VIROL, V36, P499, DOI 10.1128/JVI.36.2.499-505.1980; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; GREENBERGER JS, 1983, FED PROC, V42, P2762; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVY ER, 1994, BLOOD, V83, P1348; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MORISHITA K, 1990, ONCOGENE, V5, P1419; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OTTEN AD, 1988, MOL ENDOCRINOL, V2, P143, DOI 10.1210/mend-2-2-143; OVAL J, 1992, LEUKEMIA, V6, P446; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROVERA G, 1987, ONCOGENE, V1, P29; RUSSELL M, 1994, BLOOD, V84, P1243, DOI 10.1182/blood.V84.4.1243.bloodjournal8441243; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1994, J BIOL CHEM, V269, P24020; VALTIERI M, 1987, J IMMUNOL, V138, P3829	35	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					563	569						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637713				2022-12-28	WOS:A1996TV59700013
J	Herzog, CR; Soloff, EV; McDoniels, AL; Tyson, FL; Malkinson, AM; HaugenStrano, A; Wiseman, RW; Anderson, MW; You, M				Herzog, CR; Soloff, EV; McDoniels, AL; Tyson, FL; Malkinson, AM; HaugenStrano, A; Wiseman, RW; Anderson, MW; You, M			Homozygous codeletion and differential decreased expression of p15(INK4b) p16(INK4a)-alpha and p16(INK4a)-beta in mouse lung tumor cells	ONCOGENE			English	Article						p15(INK4b); p16(INK4a)-alpha; p16(INK4a)-beta; mouse lung; tumor suppressor gene	KINASE-4 INHIBITOR GENE; SUPPRESSOR GENE; P16 MTS1; FAMILIAL MELANOMA; CDK6 INHIBITOR; HUMAN CANCERS; CYCLE ARREST; MUTATIONS; METHYLATION; DELETIONS	The genes of murine cyclin D-dependent kinase inhibitors, p15(INK4b) and p16(INK4a), are located in a region of chromosome 4 where overlapping deletions were found in lung adenocarcinomas, The p16(INK4a) gene uniquely consists of alternative first exons (E1 alpha and E1 beta), which are spliced to exon 2 in alternative reading frames to either encode p16(INK4a) (alpha form) or another potential tumor suppressor, p19(ARF) (beta form), We examined 99 lung adenocarcinomas of C3H/HeJ x A/J F-1(C3AF(1)) and A/J x C3H/HeJ F-1(AC3F(1)) mouse hybrids and 18 (13 metastatic, 5 nonmetastatic) tumorigenic mouse lung epithelial cell lines for p15(INK4b) and p16(INK4a) gene inactivation, Homozygous codeletion occurred in eight of the 13 (62%) metastatic, four of the five (80%) nonmetastatic cell lines, but in only six of 99 (6%) adenocarcinomas. Neither p15(INK4b) nor p16(INK4a) gene was individually deleted in any of the tumors or cell lines, and all deletions of the p16(INK4a) gene extended into exon 2, which would be expected to disrupt the functions of both p16(INK4a) and p19(ARF). We also detected no intragenic mutations of either gene in 44 tumors that displayed loss of heterozygosity at the p16(INK4a) locus or in any of the cell lines, Transcript levels of p16(INK4a)-alpha, p16(INK4a)-beta and p15(INK4b) also were examined in each of the cell lines that retained copies of these genes, Whereas an immortal mouse lung epithelial cell line (E10) and two metastatic tumor cell lines (LM1 and E9) expressed p16(INK4a)-beta and p15(INK4b) mRNA, the a transcript of p16(INK4a) was detected in only the LM1 cell line. These results suggest that both p15(INK4b) and p16(INK4a) (alpha and beta) are targets of inactivation in mouse lung tumorigenesis.	MED COLL OHIO,DEPT PATHOL,TOLEDO,OH 43699; ST MARYS HOSP,CANC RES INST,GRAND JCT,CO 81501; UNIV COLORADO,HLTH SCI CTR,SCH PHARM,MOL TOXICOL PROGRAM,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,SCH PHARM,COLORADO CANC CTR,DENVER,CO 80262; NIEHS,MOL CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)				Soloff, Erik/0000-0002-4473-6736	NCI NIH HHS [CA58554] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA058554, R01CA058554] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DORNS KA, 1987, BIOCH BIOPHYS RDS CO, V144, P591; FRANKS LM, 1986, CANCER RES, V36, P1049; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HERMAN GJ, 1996, CANCER RES, V56, P722; HERMAN JG, 1995, CANCER RES, V55, P4525; HERZOG CR, 1994, CANCER RES, V54, P4007; HEZOG CR, 1995, ONCOGENE, V11, P1811; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LINDARDOPOULOS S, 1995, CANCER RES, V55, P5168; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; NICKS KM, 1989, CANCER RES, V49, P5191; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OTSUKI T, 1995, CANCER RES, V55, P1436; OTTERSON GA, 1995, ONCOGENE, V11, P1211; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SMITH GJ, 1985, J PATHOL, V147, P165, DOI 10.1002/path.1711470304; STONE S, 1995, CANCER RES, V55, P2988; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; WASHIMI O, 1995, CANCER RES, V55, P514; XIAO S, 1995, ONCOGENE, V11, P511; XIAO S, 1995, CANCER RES, V55, P2968; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	40	69	73	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1885	1891						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934534				2022-12-28	WOS:A1996VR79500007
J	Langenfeld, J; Lonardo, F; Kiyokawa, H; Passalaris, T; Ahn, MJ; Rusch, V; Dmitrovsky, E				Langenfeld, J; Lonardo, F; Kiyokawa, H; Passalaris, T; Ahn, MJ; Rusch, V; Dmitrovsky, E			Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation	ONCOGENE			English	Article						retinoic acid; bronchial epithelial cells; transformation; cyclin E	ACUTE PROMYELOCYTIC LEUKEMIA; 13-CIS-RETINOIC ACID; NEOPLASTIC TRANSFORMATION; DIFFERENTIATION THERAPY; INTERFERON ALPHA-2A; PHASE-TRANSITION; LUNG-CANCER; VITAMIN-A; EXPRESSION; CARCINOMA	The retinoids are reported to reduce second primary aerodigestive tract tumors in patients with prior lung or head and neck carcinomas. Yet, the optimal retinoid useful for chemoprevention and those mechanisms linked to this chemoprevention are not identified. This study reports an in vitro model for carcinogen-induced transformation of immortalized human bronchial epithelial (BEAS-2B) cells that was adapted to study the anticarcinogenic effects of all-trans-retinoic acid (RA). Following exposure to carcinogens: cigarette smoke condensate (CSC) or N-nitrosamine-4-(methylnitrosamino)-1-(3 pyridyl)-1-butanone (NNK), BEAS-2B cells exhibited evidence of transformation. This included an increased anchorage independent growth or acquired ability to form tumors in athymic mice. This transformation was inhibited by RA as demonstrated by a lack of augmented anchorage independent growth or tumor formation in athymic mice for the cells treated with RA. The BEAS-2B cells transformed by NNK exhibited an increase in cyclin E expression which was associated with an increase in the cyclin E-Cdk2 kinase activity. Over-expression of human cyclin E by transfection shows cyclin E enhances the basal clonal growth of BEAS-2B cells. In both the parental and transformed BEAS-2B cells, RA down-regulated cyclin E protein levels which was associated with an inhibition of growth and an accumulation of cells in G1. The data reported here suggest the decline of cyclin E expression represents a potential mechanism for the RA-induced growth suppression which is linked to the anti-carcinogenic effects of RA. Thus, this study reports the adaption of an in vitro model of lung carcinogenesis suitable to test the activity of chemoprevention agents.	MEM SLOAN KETTERING CANC CTR,DEPT MED,MOL MED LAB,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT SURG,THORAC SERV,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MEM HOSP,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOL BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,SLOAN KETTERING INST,MOL PHARMACOL & THERAPEUT PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				Kiyokawa, Hiroaki/0000-0002-7942-6455	NCI NIH HHS [K12-CA01712, R01-CA5 4494-04, T32-CA09512] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054494, K12CA001712, T32CA009512] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn MJ, 1995, ONCOGENE, V11, P2357; BASELGA J, 1993, ONCOGENE, V8, P3257; BURGER C, 1994, J CELL SCI, V107, P2047; CASTAIGNE S, 1990, BLOOD, V76, P1704; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DMITROVSKY E, 1990, ONCOGENE RES, V5, P233; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gudas Lorraine J., 1994, P443; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEYOMARSI K, 1994, CANCER RES, V54, P380; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LECHNER JF, 1982, IN VITRO CELL DEV B, V18, P633; LIPPMAN SM, 1992, J NATL CANCER I, V84, P235, DOI 10.1093/jnci/84.4.235; LIPPMAN SM, 1992, JNCI-J NATL CANCER I, V84, P241, DOI 10.1093/jnci/84.4.241; LOTAN R, 1980, BIOCHIM BIOPHYS ACTA, V605, P33, DOI 10.1016/0304-419X(80)90021-9; MAHAFFEY DT, 1995, FEBS LETT, V370, P109, DOI 10.1016/0014-5793(95)00799-F; MERRIMAN RL, 1979, CANCER RES, V39, P1661; MOASSER MM, 1995, ONCOGENE, V10, P1537; MURRAY A, 1995, CELL, V81, P149, DOI 10.1016/0092-8674(95)90322-4; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PASTORINO U, 1993, J CLIN ONCOL, V11, P1216, DOI 10.1200/JCO.1993.11.7.1216; REDDEL RR, 1988, CANCER RES, V48, P1904; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sgambato A, 1996, CANCER RES, V56, P1389; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; 1994, NEW ENGL J MED, V330, P1029	35	77	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1983	1990						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934545				2022-12-28	WOS:A1996VR79500018
J	Valente, P; Melchiori, A; Paggi, MG; Masiello, L; Ribatti, D; Santi, L; Takahashi, R; Albini, A; Noonan, DM				Valente, P; Melchiori, A; Paggi, MG; Masiello, L; Ribatti, D; Santi, L; Takahashi, R; Albini, A; Noonan, DM			RB1 oncosuppressor gene over-expression inhibits tumor progression and induces melanogenesis in metastatic melanoma cells	ONCOGENE			English	Article						retinoblastoma; melanoma; melanin; tumor progression; invasion	RETINOBLASTOMA SUSCEPTIBILITY GENE; CARCINOMA-CELLS; CYCLE ARREST; PRODUCT; DIFFERENTIATION; PROTEIN; GROWTH; INDUCTION; ANTIGEN; TRANSFORMATION	The retinoblastoma gene (RB1) is frequently deleted or mutated in many tumor types and in all cases of retinoblastoma. Apart from its role in regulation of the cell cycle, the RB1 gene product (p110(RB1)) appears to be involved in control of differentiation, Malignant metastatic cells show many properties of poorly differentiated cells, and are highly invasive in vitro and in vivo. We have transfected the human RB1 cDNA in an expression vector under the control of the beta-actin promoter into B16F10 murine melanoma cells. These cells highly overexpress RB1 mRNA and the p110(RB1) product, show reduced growth rate and increased melanogenesis in vitro. Vector control transfectants showed no alteration of invasiveness. The p110(RB1) over-expressing cells also had a reduced capacity to migrate and invade through an artificial basement membrane, key characteristics of metastatic cells. When injected into nude mice, the p110(RB1) over-expressing cells showed reduced tumor growth and reduced metastatic potential, The few metastasis observed were predominantly melanotic. These data indicate that RB1 gene expression is involved in melanoma cell differentiation and plays a role in downregulation of migration, invasion and metastatic potential of these cells.	IST NAZL RIC CANC, DEPT EXPT ONCOL, I-16132 GENOA, ITALY; IST REGINA ELENA STUDIO & CURA TUMORI, ROME, ITALY; UNIV BARI, IST ANAT UMANA NORMALE & ISTOL EMBRIOL, BARI, ITALY; KYOTO UNIV, KYOTO, JAPAN	University of Genoa; IRCCS AOU San Martino IST; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita degli Studi di Bari Aldo Moro; Kyoto University			Noonan, Douglas M/A-8620-2010; Paggi, Marco G./K-3494-2018	Noonan, Douglas M/0000-0001-8058-0719; Albini, Adriana/0000-0002-9624-5103				ALBINI A, 1989, CLIN EXP METASTAS, V7, P437, DOI 10.1007/BF01753664; ALBINI A, 1987, CANCER RES, V47, P3239; ALLAVENA G, 1988, CANCER METASTASIS, P215; BENNETT DC, 1986, CANCER RES, V46, P3239; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Elias H, 1983, GUIDE PRACTICAL STER, P25; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148, DOI 10.1038/newbio242148a0; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FUNG YKT, 1993, ONCOGENE, V8, P2659; FURUKAWA Y, 1991, ONCOGENE, V6, P1343; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HANSEN M, 1989, CC MOL BIOL, P125; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JIANG HP, 1995, ONCOGENE, V11, P1179; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KARPEH MS, 1995, BRIT J CANCER, V72, P986, DOI 10.1038/bjc.1995.447; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; KREIDER JW, 1975, JNCI-J NATL CANCER I, V55, P641, DOI 10.1093/jnci/55.3.641; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Li J., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P78; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; MAIONE R, 1994, CELL GROWTH DIFFER, V5, P231; MANIATIS T, 1989, MOL CLONING LAB MANU, P133; MARTELLI F, 1994, ONCOGENE, V9, P3579; MENSING H, 1984, INT J CANCER, V33, P43, DOI 10.1002/ijc.2910330109; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUFSON RA, 1979, CANCER RES, V39, P3915; MUNCASTER MM, 1992, CANCER RES, V52, P654; NEVINS JR, 1992, SCIENCE, V258, P424; PAGGI MG, 1994, CANCER RES, V54, P1098; PITKANEN K, 1993, EXP CELL RES, V207, P99, DOI 10.1006/excr.1993.1167; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SUPINO R, 1992, MELANOMA RES, V2, P377, DOI 10.1097/00008390-199212000-00012; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; VARLEY JM, 1989, ONCOGENE, V4, P735; WEINBERG RA, 1992, CANCER SURV, V12, P43; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; WHITTAKER JR, 1963, DEV BIOL, V8, P99, DOI 10.1016/0012-1606(63)90028-9; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YAVUZER U, 1995, ONCOGENE, V10, P123	63	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1169	1178						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808691				2022-12-28	WOS:A1996VJ20200008
J	Bennett, JD; Farlie, PG; Watson, RJ				Bennett, JD; Farlie, PG; Watson, RJ			E2F binding is required but not sufficient for repression of B-myb transcription in quiescent fibroblasts	ONCOGENE			English	Article						B-myb; E2F; cell cycle; transcription repression; p107; p130	CELL-CYCLE PROGRESSION; RETINOBLASTOMA PROTEIN; GROWTH-REGULATION; S-PHASE; IN-VIVO; E2F-CYCLIN-A COMPLEX; FAMILY PROTEINS; GENE PROMOTER; EXPRESSION; ASSOCIATION	We have previously shown in mouse NIH3T3 fibroblasts that transcription of the B-myb gene, which encodes a transcription factor required for S phase entry, is repressed through a promoter E2F site in G(0)/early G(1). Transcription repression at this stage of the cell cycle was correlated with binding of a specific p107/E2F complex to this site, We report here, however, that transfection of cells with the known components of this complex, p107, E2F-4 and DP-1, did not repress the B-myb promoter in cycling NIH3T3 cells, although p107 inhibited transcription transactivation by E2F-4/DP-1. To establish definitively the contribution of E2F to repression, the effects of further mutations within and surrounding the E2F site were examined, It was evident that E2F binding and repression were closely correlated, lending greater weight to the contention that E2F itself is implicated in this activity, These studies also identified a closely linked site, designated the downstream repression site (DRS), which was not required for E2F binding or transactivation but which was necessary for repression, These findings indicated that E2F-dependent repression and activation are independently regulated phenomena and suggest that repression involves additional interactions determined by the promoter context.	LUDWIG INST CANC RES,IMPERIAL COLL,SCH MED ST MARYS,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research								ARROYO M, 1993, MOL CELL BIOL, V13, P6537, DOI 10.1128/MCB.13.10.6537; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DOU QP, 1994, J BIOL CHEM, V269, P1306; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HAGMEIER C, 1993, NUCLEIC ACIDS ERS, V21, P4998; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; PAGANO M, 1992, SCIENCE, V255, P1144, DOI 10.1126/science.1312258; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PORCU P, 1994, ONCOGENE, V9, P2125; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOLF DA, 1995, ONCOGENE, V10, P2067; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	52	51	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1073	1082						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806697				2022-12-28	WOS:A1996VG76600021
J	Sakano, S; Serizawa, R; Inada, T; Iwama, A; Itoh, A; Kato, C; Shimizu, Y; Shinkai, F; Shimizu, R; Kondo, S; Ohno, M; Suda, T				Sakano, S; Serizawa, R; Inada, T; Iwama, A; Itoh, A; Kato, C; Shimizu, Y; Shinkai, F; Shimizu, R; Kondo, S; Ohno, M; Suda, T			Characterization of a ligand for receptor protein-tyrosine kinase HTK expressed in immature hematopoietic cells	ONCOGENE			English	Article						receptor tyrosine kinase; HTK; HTK ligand; BIAcore; hematopoietic cells	MOLECULAR-CLONING; GROWTH-FACTOR; EPH; FAMILY; GENE; B61; SIGNAL; ALPHA; ELF-1; MEK4	HTK is a receptor tyrosine kinase that belongs to the Eph subfamily. An extensive screening using BIAcore system revealed that a colon cancer cell line, C-l, expressed the ligand for HTK. From the conditioned medium of C-l cells, a soluble form of ligand was purified by receptor affinity chromatography, and the isolation of full-length cDNA revealed that this ligand is identical to the human HTK ligand (HTKL) previously reported. HTK receptor tyrosine phosphorylation was induced by membrane-bound or clustered soluble HTKL but not by unclustered soluble HTKL, indicating that HTKL requires cell-to-cell interaction for receptor activation. Binding analysis demonstrated that HTKL binds to HTK with a much higher affinity (K-d: 1.23 nM) than the other transmembrane-type ligand for Eph family, LERK-2/ELKL (K-d: 135 nM). The expression of HTK in cord blood cells was upregulated after the culture in the presence of stem cell factor. Clustered soluble HTKL stimulated the proliferation of sorted HTK+ cord blood cells and a hematopoietic cell line, UT-7/EPO from which HTK was isolated. These findings suggest the involvement of HTK-HTKL system in the proliferation of HTK+ hematopoietic progenitor cells in the hematopoietic environment.	KUMAMOTO UNIV,SCH MED,INST MOL EMBRYOL & GENET,DEPT CELL DIFFERENTIAT,KUMAMOTO 860,JAPAN; ASAHI CHEM IND CO LTD,FUNDAMENTAL RES LAB LIFE SCI,FUJI,SHIZUOKA 416,JAPAN; ASAHI CHEM IND CO LTD,LIFE SCI RES INST,BIOL RES LAB,FUJI,SHIZUOKA 416,JAPAN	Kumamoto University			Shinkai-ouchi, Fumiko/E-3207-2010; Suda, Toshio/H-6761-2013	Shinkai-ouchi, Fumiko/0000-0002-0095-941X; Suda, Toshio/0000-0001-7540-1771				BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BENNETT BD, 1995, P NATL ACAD SCI USA, V92, P1866, DOI 10.1073/pnas.92.6.1866; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; EASTY DJ, 1995, CANCER RES, V55, P2528; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; KOMATSU N, 1993, BLOOD, V82, P456; KOZLOSKY CJ, 1995, ONCOGENE, V10, P299; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAKANO S, 1994, ONCOGENE, V9, P1155; SHAO HN, 1994, J BIOL CHEM, V269, P26606; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; ZETTLMEISSL G, 1990, DNA CELL BIOL, V9, P347, DOI 10.1089/dna.1990.9.347	29	84	91	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					813	822						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761303				2022-12-28	WOS:A1996VD43300017
J	LeNaour, F; Prenant, M; Francastel, C; Rubinstein, E; Uzan, G; Boucheix, C				LeNaour, F; Prenant, M; Francastel, C; Rubinstein, E; Uzan, G; Boucheix, C			Transcriptional regulation of the human CD9 gene: Characterization of the 5'-flanking region	ONCOGENE			English	Article						CD9 antigen; tetraspan; promoter; leukemia; platelets	ACUTE LYMPHOBLASTIC-LEUKEMIA; DIPHTHERIA-TOXIN RECEPTOR; GROWTH-FACTOR; MONOCLONAL-ANTIBODY; CELL-LINE; MEMBRANE-PROTEIN; TRANSMEMBRANE-4 SUPERFAMILY; ENCODING METALLOTHIONEIN; IMMUNOGLOBULIN GENES; MOLECULAR-CLONING	The CD9 antigen, initially discovered on B lineage leukemic cells, belongs to the tetraspan superfamily of surface molecules. If no precise function has been assigned to any of these molecules, there are some indications that they could be involved in cell adhesion and cell migration, as well as malignant progression. The CD9 antigen is associated with surface proteins such as VLA integrins or HB-EGF precursor. Transfection of CD9 in melanoma cells reduces tumor growth and metastasis. The heterogenous distribution of the CD9 antigen suggests a complex regulation of its expression. We have previously characterized the CD9 gene and shown that transcription could be initiated at several sites in the TATA-less 5 '-flanking region. We show here, using as a model two human leukemic cell lines with erythromegakaryocytic potential, HEL and K562, that the [-205,-154] region supports a promoter activity when cloned ahead of a CAT reporter gene. Mutagenesis analysis suggested the presence of a positive element located within the [-170,-154] region. Gel shift experiments using HEL extracts were compatible with the binding of the transcriptional factor Spl to the [-237,-205] region and indicated that a non-identified protein binds to the 3 ' end of the [-205,-154] region.	CENG,INSERM,U217,HEMATOL LAB,F-38054 GRENOBLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	LeNaour, F (corresponding author), HOP PAUL BROUSSE,INSERM,U268,F-94807 VILLEJUIF,FRANCE.		Francastel, Claire/AAI-4798-2021; Rubinstein, Eric/B-4650-2019; Uzan, Georges/M-8199-2018	Rubinstein, Eric/0000-0001-7623-9665; Uzan, Georges/0000-0002-0178-5386; Francastel, Claire/0000-0002-6353-4320; Boucheix, Claude/0000-0003-4184-7008				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; ANTON ES, 1995, J NEUROSCI, V15, P584; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; BOUCHEIX C, 1985, LEUKEMIA RES, V9, P597, DOI 10.1016/0145-2126(85)90139-0; BRACH MA, 1992, BLOOD, V79, P728; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GENG YP, 1993, MOL CELL BIOL, V13, P4894, DOI 10.1128/MCB.13.8.4894; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HADJIARGYROU M, 1995, J NEUROSCI, V15, P574; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALLIGAN BD, 1987, P NATL ACAD SCI USA, V84, P7019, DOI 10.1073/pnas.84.20.7019; HAM J, 1991, TRENDS BIOCHEM SCI, V16, P440, DOI 10.1016/0968-0004(91)90172-R; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; HOTTA H, 1988, CANCER RES, V48, P2955; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; IWAMOTO R, 1994, EMBO J, V13, P2322, DOI 10.1002/j.1460-2075.1994.tb06516.x; JANKOWSKI SA, 1994, ONCOGENE, V9, P1205; KADONAGA JT, 1986, TIBS, V11, P21; KERSEY JH, 1981, J EXP MED, V153, P726, DOI 10.1084/jem.153.3.726; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LABBE S, 1993, NUCLEIC ACIDS RES, V21, P1549, DOI 10.1093/nar/21.7.1549; LABBE S, 1991, NUCLEIC ACIDS RES, V19, P4225, DOI 10.1093/nar/19.15.4225; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MARKEN JS, 1992, P NATL ACAD SCI USA, V89, P3503, DOI 10.1073/pnas.89.8.3503; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; MASELLISSMITH A, 1990, J IMMUNOL, V144, P1607; MIKAELIAN I, 1992, NUCLEIC ACIDS RES, V20, P376, DOI 10.1093/nar/20.2.376; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; NAKAMURA K, 1995, J CELL BIOL, V129, P1691, DOI 10.1083/jcb.129.6.1691; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; RADTKE F, 1993, EMBO J, V12, P1355, DOI 10.1002/j.1460-2075.1993.tb05780.x; RIECKMANN P, 1991, J IMMUNOL, V147, P3994; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; RUBINSTEIN E, 1994, EUR J IMMUNOL, V24, P3005, DOI 10.1002/eji.1830241213; RUBINSTEIN E, 1993, GENOMICS, V16, P132, DOI 10.1006/geno.1993.1150; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT AF, 1994, GENOMICS, V20, P227, DOI 10.1006/geno.1994.1157; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SHAW ARE, 1995, J BIOL CHEM, V270, P24092, DOI 10.1074/jbc.270.41.24092; SHAW S, 1994, LEUCOCYTE TYPING, V5, P16; SHELLEY CS, 1993, P NATL ACAD SCI USA, V90, P5364, DOI 10.1073/pnas.90.11.5364; SI ZY, 1993, INT J CANCER, V54, P37, DOI 10.1002/ijc.2910540107; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; THIELE DJ, 1992, NUCLEIC ACIDS RES, V20, P1183, DOI 10.1093/nar/20.6.1183; TRAVIS A, 1991, MOL CELL BIOL, V11, P5756, DOI 10.1128/MCB.11.11.5756; TROUCHE D, 1991, BLOOD, V77, P55; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; UZAN G, 1991, J BIOL CHEM, V266, P8932; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; ZENZIEGREGORY B, 1992, J BIOL CHEM, V267, P2823	66	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					481	486						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760289				2022-12-28	WOS:A1996VB32800005
J	Thomas, M; Massimi, P; Banks, L				Thomas, M; Massimi, P; Banks, L			HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence	ONCOGENE			English	Article						p53; HPV; DNA binding; TBP	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; CYCLIN-DEPENDENT KINASES; CARCINOMA CELL-LINES; C-TERMINAL DOMAIN; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; IN-VITRO; GROWTH ARREST; MUTANT P53	The E6 proteins of the oncogenic-associated human papillomavirus types 16 (HPV-16) and 18 (HPV-18) function by interfering with the normal cell cycle control mechanisms, particularly those controlled by p53. HPV E6 is able to interfere with p53 function by preventing its binding to DNA target sequences and also by labelling p53 for ubiquitin-mediated degradation. We have previously reported that certain p53 mutants, defective in oligomerisation, vary in their susceptibility to E6-directed labelling for ubiquitin-mediated degradation. In this paper we report that the strength of p53's binding to DNA is dependent upon the precise target sequence, but that E6 is able to disrupt each complex. We also report the binding of different oligomeric forms of p53 to different DNA sequences and correlate this with in vivo transcriptional activity and demonstrate the susceptibility of that DNA binding to disruption by E6. Finally we show that the ability of p53 to bind to TBP is a function of its oligomeric state and correlates in part with its ability to transrepress but not with its ability to transactivate.			Thomas, M (corresponding author), INT CTR GENET ENGN & BIOTECHNOL, PADRICIANO 99, I-34012 TRIESTE, ITALY.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CROOK T, 1991, ONCOGENE, V6, P873; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAINAUT P, 1993, CANCER RES, V53, P4469; HARPER JW, 1993, CELL, V75, P805; Hecker D, 1996, ONCOGENE, V12, P953; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JUVEN T, 1993, ONCOGENE, V8, P3411; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1995, MOL CELL BIOL, V15, P6474; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOLINARI M, 1995, ONCOGENE, V10, P1849; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PIM D, 1994, ONCOGENE, V9, P1869; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shaw P, 1996, ONCOGENE, V12, P921; STEWART N, 1995, ONCOGENE, V10, P109; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; THOMAS M, 1995, ONCOGENE, V10, P261; THUKRAL SK, 1995, MOL CELL BIOL, V15, P5196; TRUANT R, 1993, J BIOL CHEM, V268, P2284; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, ONCOGENE, V9, P2513	68	32	32	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					471	480						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760288				2022-12-28	WOS:A1996VB32800004
J	Burnham, MR; Harte, MT; Richardson, A; Parsons, JT; Bouton, AH				Burnham, MR; Harte, MT; Richardson, A; Parsons, JT; Bouton, AH			The identification of p130(cas)-binding proteins and their role in cellular transformation	ONCOGENE			English	Article						p130(cas); SRC; CRK; SH2 domain; SH3 domain	PHOSPHOTYROSINE-CONTAINING PROTEINS; CRK ONCOGENE PRODUCT; SRC SH2 DOMAIN; STABLE ASSOCIATION; V-CRK; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; BINDING; PP60SRC; CELLS	Adaptor proteins play an important role in signal transduction by regulating the establishment and maintenance of functionally important protein complexes, A recently described member of this group of proteins is p130(cas) (CAS), which contains numerous sequence motifs predicted to be involved in mediating protein-protein interactions, We propose that adaptor molecules like GAS may help determine the response of a cell to a particular signal by interacting with specific subsets of cellular proteins. To test this hypothesis, we have identified potential binding partners of CAS that may play a role in cellular transformation by the oncoproteins v-SRC and/or v-CRK. We show that individual domains of CAS associate with specific subsets of proteins in vitro, and that many of these interactions are dependent on the state of tyrosine-phosphorylation of GAS. Sequences necessary for interacting with the focal adhesion kinase pp125(FAK) (FAK), v-SRC and v-CRK have been mapped to distinct regions of CAS. In addition, the identification of a number of putative GAS-binding partners that are present in crk-transformed cell extracts but undetectable in normal and src-transformed cell extracts supports a model in which unique protein complexes are formed in response to different signals.	UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia			Richardson, Alan/E-7615-2010; Richardson, Alan/I-4631-2015	Richardson, Alan/0000-0003-1825-3375	NATIONAL CANCER INSTITUTE [P01CA040042, R01CA029243, R37CA029243] Funding Source: NIH RePORTER; NCI NIH HHS [CA 29243, CA 40042] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BOUTON AH, 1991, MOL CARCINOGEN, V4, P145, DOI 10.1002/mc.2940040210; BOUTON AH, 1991, MOL CELL BIOL, V11, P945, DOI 10.1128/MCB.11.2.945; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; HARTE MT, 1996, IN PRESS J BIOL CHEM; HILDEBRAND JD, 1995, IN PRESS MOL BIOL CE; HILDEBRAND JD, 1996, IN PRESS MOL CELL BI, V16; Ishino M, 1995, ONCOGENE, V11, P2331; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KAMPS MP, 1988, ONCOGENE, V2, P305; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1989, ONCOGENE, V4, P295; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1991, MOL CELL BIOL, V11, P1607, DOI 10.1128/MCB.11.3.1607; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; OGAWA S, 1994, ONCOGENE, V9, P1669; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; SAKAI R, 1994, J BIOL CHEM, V269, P32740; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHAFFHAUSEN B, 1995, BBA-REV CANCER, V1242, P61, DOI 10.1016/0304-419X(95)00004-Y; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	54	92	93	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2467	2472						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649789				2022-12-28	WOS:A1996UQ22000026
J	Marin, MC; Fernandez, A; Bick, RJ; Brisbay, S; Buja, M; Snuggs, M; McConkey, DJ; vonEschenbach, AC; Keating, MJ; McDonnell, TJ				Marin, MC; Fernandez, A; Bick, RJ; Brisbay, S; Buja, M; Snuggs, M; McConkey, DJ; vonEschenbach, AC; Keating, MJ; McDonnell, TJ			Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+	ONCOGENE			English	Article						apoptosis; cell death; bcl-2; calcium	PROGRAMMED CELL-DEATH; RAT-LIVER NUCLEI; DNA FRAGMENTATION; ENDOPLASMIC-RETICULUM; CA-2+ CONCENTRATION; OXIDATIVE STRESS; PROSTATE-CANCER; CALCIUM; PROTEIN; ONCOPROTEIN	Bcl-2 expression is associated with the progression of prostate cancer from androgen-dependence to androgen-independence, Bcl-2 is an integral membrane protein which localizes to mitochondria, endoplasmic reticulum, and the nuclear envelope, Using spectrofluorometry and laser confocal microscopy, the ability of bcl-2 to modulate intracellular Ca2+ was examined in the Dunning G prostate carcinoma cell line following apoptosis induction by adriamycin, Adriamycin and thapsigargin, an endoplasmic reticulum Ca2+-pump inhibitor, were effective inducers of apoptosis in control, but not bcl-2 transfected, cells, Treatment with adriamycin was accompanied by a sustained rise in cytoplasmic Ca2+ in control and bcl-2 transfected cells, An increase in intranuclear Ca2+ was observed in control cells only, Apoptosis induction by thapsigargin was associated with an increase in cytoplasmic Ca2+ in control cells that was not detected in the resistant bcl-2 transfectants, Ca2+ was excluded from nuclei isolated from bcl-2 expressing cells, but was sequestered in control nuclei, following the addition of ATP, These findings suggest that bcl-2 may regulate levels of intranuclear Ca2+ independently of cytosolic Ca2+ levels, The ability of bcl-2 to modulate, directly or indirectly, sustained increases in both cytosolic and intranuclear Ca2+ may provide a common basis for bcl-2 function in different subcellular compartments.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT UROL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT HEMATOL,HOUSTON,TX 77030; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL & LAB MED,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston			Marín Vieira, María del Carmen/B-8108-2015; Marin, Maria C/G-1040-2010	Marín Vieira, María del Carmen/0000-0002-7149-287X; Marin, Maria C/0000-0002-7149-287X; Buja, Louis Maximilian/0000-0001-8386-7029	NATIONAL CANCER INSTITUTE [R01CA062597] Funding Source: NIH RePORTER; NCI NIH HHS [CA62597, CA09255] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLBRITTON NL, 1994, P NATL ACAD SCI USA, V91, P12458, DOI 10.1073/pnas.91.26.12458; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Bornkamm G W, 1995, Curr Top Microbiol Immunol, V194, P323; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COBBOLD PH, 1987, BIOCHEM J, V248, P313, DOI 10.1042/bj2480313; COLOMBEL M, 1993, AM J PATHOL, V143, P390; CORNELIUSSEN B, 1994, NATURE, V368, P760, DOI 10.1038/368760a0; DEJONG D, 1994, CANCER RES, V54, P256; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ENGLISH HF, 1989, PROSTATE, V15, P233, DOI 10.1002/pros.2990150304; FERNANDEZ A, 1995, J IMMUNOL, V155, P5133; FERNANDEZ A, 1995, ONCOGENE, V10, P769; FURUYA Y, 1994, CANCER RES, V54, P6167; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JONES DP, 1983, J BIOL CHEM, V258, P6390; JONES DP, 1989, J BIOL CHEM, V264, P6398; KAMADA S, 1995, CANCER RES, V55, P354; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KASS GEN, 1992, BIOCHEM PHARMACOL, V44, P1995, DOI 10.1016/0006-2952(92)90102-O; KERR JFR, 1972, BRIT J CANCER, V26, P238; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; KYPRIANOU N, 1990, CANCER RES, V50, P3748; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEEK RD, 1994, BRIT J CANCER, V69, P135, DOI 10.1038/bjc.1994.22; LING YH, 1993, CANCER RES, V53, P1845; LITHGOW T, 1994, CELL GROWTH DIFFER, V5, P411; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARTIKAINEN P, 1990, PROSTATE, V17, P175, DOI 10.1002/pros.2990170302; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1992, CANCER RES, V52, P5407; MOCALI A, 1995, EXP CELL RES, V216, P388, DOI 10.1006/excr.1995.1049; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P255; MUSCHEL RJ, 1995, CANCER RES, V55, P995; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; NICOTERA P, 1988, TOXICOLOGY, V52, P55, DOI 10.1016/0300-483X(88)90196-5; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POTMESIL M, 1988, ANTHRACYCLINE ANTHRA, P447; Powis G., 1987, METABOLISM ACTION AN, P211; ROCHE E, 1994, CELL CALCIUM, V16, P331, DOI 10.1016/0143-4160(94)90097-3; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; SKLADANOWSKI A, 1993, BIOCHEM PHARMACOL, V46, P375, DOI 10.1016/0006-2952(93)90512-U; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; STEINMAN HM, 1995, J BIOL CHEM, V270, P3487; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; TOTI FM, 1983, J CLIN ONCOL, V1, P477; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TU SM, 1995, CANCER LETT, V93, P147, DOI 10.1016/0304-3835(95)03795-X; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1992, DEVELOPMENT, V116, P309	73	158	162	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2259	2266						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649765				2022-12-28	WOS:A1996UQ22000002
J	Fujii, M; Minamino, T; Nomura, M; Miyamoto, KI; Tanaka, J; Seiki, M				Fujii, M; Minamino, T; Nomura, M; Miyamoto, KI; Tanaka, J; Seiki, M			Selective activation of the proto-oncogene c-jun promoter by the transforming protein v-Rel	ONCOGENE			English	Article						v-Rel; transcription; c-jun; NF-kB	NF-KAPPA-B; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTIONAL ACTIVATION; BINDING-PROTEIN; GENE-EXPRESSION; FAMILY; SEQUENCES; DOMAIN; REQUIRES; CELLS	The transcription factor v-Rel is a transforming protein of the reticuloendotheliosis virus. We found that v-Rel activates the promoter of the proto-oncogene c-jun, Two elements in the c-jun promoter were required for the activation by v-Rel, One was a kB-site (v-Rel binding site), and the other was a c-jun promoter region between -52 and +148 (c-jun promoter (-52/+148)). Two promoters with the kB-site(s), those of human immunodeficiency virus (HIV) and SV40, were not activated by v-Rel, but their kB-sites were activated when introduced upstream of the c-jun promoter (-52/+148), Thus, the c-jun promoter (-52/+148) had information for the selective activation of the c-jun promoter by v-Rel, v-Rel bound to the c-jun kB-site with the higher affinity than c-Rel, thereby activating the c-jun promoter more efficiently than c-Rel, Moreover, the activity of v-Rel mutants upon the c-jun promoter correlates with their transforming activity, Thus, the c-jun promoter activation by v-Rel may play a role in the transformation caused by v-Rel.	KANAZAWA UNIV,CANC RES INST,DEPT MOLEC ONCOL & VIROL,KANAZAWA,ISHIKAWA 920,JAPAN; HOKURIKU UNIV,SCH PHARM,RES LAB DEV MED,KANAZAWA,ISHIKAWA 920,JAPAN	Kanazawa University; Hokuriku University			Seiki, Motoharu/K-9443-2015					ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1992, CANCER SURV, V15, P69; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1991, Critical Reviews in Oncogenesis, V2, P293; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; KABRUN N, 1994, SEMIN CANCER BIOL, V5, P103; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MCDONNELL PC, 1992, ONCOGENE, V7, P163; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; SARKAR S, 1993, ONCOGENE, V8, P2245; SHIPP MA, 1987, J IMMUNOL, V139, P2143; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TSUCHIYA H, 1993, J VIROL, V67, P7001, DOI 10.1128/JVI.67.12.7001-7007.1993; UNLAP T, 1992, NUCLEIC ACIDS RES, V20, P897, DOI 10.1093/nar/20.4.897; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984	38	14	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2193	2202						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668346				2022-12-28	WOS:A1996UP28300019
J	Tobin, D; Nilsson, M; Toftgard, R				Tobin, D; Nilsson, M; Toftgard, R			Ras-independent activation of Rel-family transcription factors by UVB and TPA in cultured keratinocytes	ONCOGENE			English	Article						ultraviolet radiation; NF kappa B; transcription factor; keratinocyte; rasGTPase	NF-KAPPA-B; HUMAN IMMUNODEFICIENCY VIRUS; PROTEIN-KINASE-C; VL30 TRANSCRIPTION; INDUCED EXPRESSION; TYROSINE KINASES; GENE-EXPRESSION; REQUIRES RAF-1; PHORBOL ESTER; PHOSPHORYLATION	UV irradiation of mammalian cells results in the activation of transcription factors which mediate induction of early response genes designed to repair and minimise the damage sustained by the cell. Evidence from studies in HeLa cells suggest that UVC regulates NF-kappa B activity via tyrosine kinases and activation of Ras and Raf kinase. In this study we have used a previously characterized TPA-responsive element (VLTRE) that binds Rel/NF-kappa B proteins and a Ras-responsive element (B10 RRE) to analyse the signalling pathway in UVB-stimulated gene transcription in cultured keratinocytes, We demonstrate that the tumour promoters TPA and WB use different signalling intermediates to activate different sets of Rel/NF-kappa B proteins. UVB transactivation is independent of PKC activity but dependent on tyrosine kinase activity whereas TPA stimulation requires PKC but not tyrosine kinase activity. Furthermore, neither UVB- nor TPA-transactivation is mediated through p21 Ras but both stimuli are dependent on a functional Raf protein. A constitutively active Raf-1 kinase however, was unable to induce transactivation through VLTRE. Thus, Raf has an essential but permissive role in UVB activation of Rel proteins. These findings demonstrate that keratinocytes contain a novel Ras-independent pathway for induction of Rel mediated transcription.	KAROLINSKA INST,NOVUM,CTR NUTR & TOXICOL,S-14157 HUDDINGE,SWEDEN	Karolinska Institutet	Tobin, D (corresponding author), KAROLINSKA INST,NOVUM,DEPT BIOSCI,S-14157 HUDDINGE,SWEDEN.							BOHM S, 1993, J BIOL CHEM, V268, P3952; BOHM S, 1991, J BIOL CHEM, V266, P24834; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSCHER M, 1988, ONCOGENE, V3, P301; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; EICHER DM, 1994, J IMMUNOL, V152, P2710; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FINCO TS, 1993, J BIOL CHEM, V268, P17676; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HAYASHI T, 1993, J BIOL CHEM, V268, P26790; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; ISLAM TC, 1993, J BIOL CHEM, V268, P3251; KRUTMANN J, 1990, J INVEST DERMATOL, V95, P127, DOI 10.1111/1523-1747.ep12477839; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MARQUARDT B, 1994, ONCOGENE, V9, P3213; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MILLER CC, 1994, J BIOL CHEM, V269, P3529; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL G, 1990, NATURE, V344, P178, DOI 10.1038/344178b0; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NEUMANN M, 1992, ONCOGENE, V7, P2095; NILSSON M, 1994, J VIROL, V68, P276, DOI 10.1128/JVI.68.1.276-288.1994; NILSSON M, 1995, J BIOL CHEM, V270, P12210, DOI 10.1074/jbc.270.20.12210; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Sambrook J, 1989, MOL CLONING LABORATO; SCHIEVEN GL, 1993, BLOOD, V82, P1212, DOI 10.1182/blood.V82.4.1212.bloodjournal8241212; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; SIMON MM, 1994, J INVEST DERMATOL, V102, P422, DOI 10.1111/1523-1747.ep12372194; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STRUHL K, 1990, CURRENT PROTOCOLS S, V11; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; 1992, IARC MONOGRPAHS EVAL, V55	50	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					785	793						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632900				2022-12-28	WOS:A1996TW68600009
J	Iwashita, T; Asai, N; Murakami, H; Matsuyama, M; Takahashi, M				Iwashita, T; Asai, N; Murakami, H; Matsuyama, M; Takahashi, M			Identification of tyrosine residues that are essential for transforming activity of the ret proto-oncogene with MEN2A or MEN2B mutation	ONCOGENE			English	Article						ret proto-oncogene; receptor tyrosine kinase; MEN2A; MEN2B	KINASE-ACTIVITY; PROTOONCOGENE PRODUCTS; RECEPTOR; PHOSPHORYLATION; NEUROBLASTOMA; ASSOCIATION; PP60C-SRC; SEQUENCE; ABILITY; DOMAINS	The c-ret proto-oncogene with multiple endocrine neoplasia (MEN) 2A or 2B mutation can transform NIH3T3 cells with high efficiencies as a consequence of its constitutive activation. The MEN2A mutation induces ligand-independent homodimerization of the Ret protein on the cell surface while the MEN2B mutation appears to alter the catalytic activity without dimerization. In the present study, we investigated the role of tyrosine residues present in the kinase domain for the transforming activity of the mutant Ret proteins. Substitution of phenylalanine for tyrosine 905 (Y905F) that corresponds to tyrosine 416 of the Src protein abolished the transforming activity of Ret with the MEN2A mutation (MEN2A-Ret) but not with the MEN2B mutation (MEN2B-Ret). On the other hand, the transforming activity of MEN2B-Ret but not MEN2A-Ret significantly decreased by changing tyrosine 864 or 952 to phenylalanine. In addition, double mutations of these tyrosines (Y864/952F) completely abolished the activity of MEN2B-Ret. The Y905F and Y864/952F mutations resulted in severe impairment of the kinase activity of MEN2A-Ret and MEN2B-Ret, respectively. These results thus indicated that tyrosine residues essential for the transforming activity are different between MEN2A-Ret and MEN2B-Ret.	NAGOYA UNIV,SCH MED,DEPT PATHOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Nagoya University			Takahashi, Masahide/AAN-4770-2020; ASAI, Naoya/I-7377-2014; TAKAHASHI, Masahide/I-7244-2014	Takahashi, Masahide/0000-0002-2803-2683; 				ASAI N, 1995, MOL CELL BIOL, V15, P1613; BOLINO A, 1995, ONCOGENE, V10, P2415; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; ENG C, 1995, ONCOGENE, V10, P509; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Geer P.V.D., 1991, MOL CELL BIOL, V11, P4698; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; IWAMOTO T, 1993, ONCOGENE, V8, P1087; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; MARUYAMA S, 1994, JPN J CANCER RES, V85, P879, DOI 10.1111/j.1349-7006.1994.tb02962.x; MORRISON DK, 1990, MOL CELL BIOL, V10, P2359, DOI 10.1128/MCB.10.5.2359; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHUCHARDT A, 1995, ONCOGENE, V10, P641; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAHIRA T, 1990, ONCOGENE, V5, P97; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TAKAHASHI M, 1988, ONCOGENE, V3, P571	27	106	109	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					481	487						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637703				2022-12-28	WOS:A1996TV59700003
J	Plaumann, B; Fritsche, M; Rimpler, H; Brandner, G; Hess, RD				Plaumann, B; Fritsche, M; Rimpler, H; Brandner, G; Hess, RD			Flavonoids activate wild-type p53	ONCOGENE			English	Article						flavonoids; p53; cell cycle; G2M; apoptosis; DNA damage	CELL-CYCLE CHECKPOINTS; DNA-DAMAGE; LIPID-PEROXIDATION; INDUCED APOPTOSIS; GROWTH ARREST; QUERCETIN; EXPRESSION; PROTEIN; DIFFERENTIATION; ACCUMULATION	Flavonoids are diphenyl propanoids widely distributed in edible plants. They play a dual role in mutagenesis and carcinogenesis. Some of them act as anticarcinogens or inhibit the growth of tumour cells, whereas others act as cocarcinogens, are mutagenic or able to induce DNA damage. To further elucidate this dual role, we investigated the influence of apigenin, luteolin and quercetin on the tumour suppressor protein p53, regarding p53 accumulation, cell cycle arrest, apoptosis, and biological activity. We found that incubation of the non-tumour cell line C3H10T1/2CL8 with these flavonoids resulted in induction of p53 accumulation and apoptosis. Apoptosis occurred out of the G(2)/M phase of the cell cycle, The G(2)/M arrest seems to be p53-dependent as it did not occur in p53 knockout fibroblasts which further supports the recent finding that p53 is involved in the G(2)/M checkpoint control. Differences between the flavonoids tested concerned p53 accumulation kinetics as well as the biological activity of accumulated p53 and might be due to different modes of flavonoid action. These data suggest that both aspects of flavonoid effects, i.e. inhibition of tumour growth through cell cycle arrest and induction of apoptosis, are functionally related to p53.	UNIV FREIBURG, INST MED MIKROBIOL & HYG, ABT VIROL, D-79104 FREIBURG, GERMANY; INST EXPT KREBSFORSCH, KLIN TUMORBIOL, D-79106 FREIBURG, GERMANY; UNIV FREIBURG, INST PHARMAZEUT BIOL, D-79104 FREIBURG, GERMANY	University of Freiburg; University of Freiburg								AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AHMAD MS, 1992, CARCINOGENESIS, V13, P605, DOI 10.1093/carcin/13.4.605; AHMED MS, 1994, CARCINOGENESIS, V15, P1627, DOI 10.1093/carcin/15.8.1627; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ASKEW DS, 1991, ONCOGENE, V6, P1915; AUSTIN CA, 1992, BIOCHEM J, V282, P883, DOI 10.1042/bj2820883; BABICH H, 1987, TOXICOL IN VITRO, V1, P3, DOI 10.1016/0887-2333(87)90031-2; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BORENFREUND E, 1988, TOXICOL IN VITRO, V2, P1, DOI 10.1016/0887-2333(88)90030-6; CANADA AT, 1990, FREE RADICAL BIO MED, V9, P441, DOI 10.1016/0891-5849(90)90022-B; CARIA H, 1995, MUTAT RES-GENET TOX, V343, P85, DOI 10.1016/0165-1218(95)90075-6; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ENOCH T, 1995, TRENDS BIOCHEM SCI, V20, P426, DOI 10.1016/S0968-0004(00)89093-3; FIALA ES, 1985, ANNU REV NUTR, V5, P295, DOI [10.1146/annurev.nu.05.070185.001455, 10.1146/annurev.nutr.5.1.295]; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GORCZYCA W, 1993, CANCER RES, V53, P3186; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HENDERSON D, 1995, NAT MED, V1, P525, DOI 10.1038/nm0695-525; HOTZ MA, 1994, CYTOMETRY, V15, P237, DOI 10.1002/cyto.990150309; JUVEN T, 1993, ONCOGENE, V8, P3411; KANTENGWA S, 1991, BIOCHEM BIOPH RES CO, V180, P308, DOI 10.1016/S0006-291X(05)81293-8; KINOSHITA T, 1985, CHEM PHARM BULL, V33, P4109; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LAUGHTON MJ, 1989, BIOCHEM PHARMACOL, V38, P2859, DOI 10.1016/0006-2952(89)90442-5; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANACH C, 1995, J NUTR, V125, P1911, DOI 10.1093/jn/125.7.1911; MARKAVERICH BM, 1983, J BIOL CHEM, V258, P1663; MATSUKAWA Y, 1993, CANCER RES, V53, P1328; MCGREGOR JT, 1986, GENETIC TOXICOLOGY D, P33; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; OCHIAI M, 1984, MUTAT RES, V129, P19, DOI 10.1016/0027-5107(84)90118-0; PENNIE WD, 1992, VIROLOGY, V190, P861, DOI 10.1016/0042-6822(92)90926-G; RAHMAN A, 1989, CARCINOGENESIS, V10, P1833, DOI 10.1093/carcin/10.10.1833; RENZING J, 1995, ONCOGENE, V10, P1865; SAHU SC, 1994, CANCER LETT, V85, P159, DOI 10.1016/0304-3835(94)90269-0; SATO F, 1994, BIOCHEM BIOPH RES CO, V204, P578, DOI 10.1006/bbrc.1994.2498; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHIMOI K, 1994, CARCINOGENESIS, V15, P2669, DOI 10.1093/carcin/15.11.2669; SIEGEL J, 1995, ONCOGENE, V11, P1363; STEWART N, 1995, ONCOGENE, V10, P109; THOMPSON RS, 1972, J CHEM SOC PERK T 1, P1387, DOI 10.1039/p19720001387; TOREL J, 1994, PHYTOCHEMISTRY, V26, P2489; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEI YQ, 1994, CANCER RES, V54, P4952; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG W, 1993, ONCOGENE, V8, P2555	54	216	224	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1605	1614						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895505				2022-12-28	WOS:A1996VM88700004
J	Zhang, N; Shen, WF; Ho, AD; Lu, M				Zhang, N; Shen, WF; Ho, AD; Lu, M			Three distinct domains in the HOX-11 homeobox oncoprotein are required for optimal transactivation	ONCOGENE			English	Article						homeoprotein; leukemia; oncogene; transactivation	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING SPECIFICITY; T-CELL LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; TRANSCRIPTION FACTOR; HOX11 GENE; PROTEIN; PROTOONCOGENE; T(10-14)(Q24-Q11); EXTRADENTICLE	HOX-11 (tcl-3) is a homeobox oncogene isolated from the breakpoint region of the t(10;14) chromosomal translocation recurring in T-cell acute lymphoblastic leukemia. Here we demonstrate that the HOX-11 homeoprotein mediates transactivation of reporter genes through various promoters in both mammalian and yeast cells. By deletion analysis, the transactivation domains of HOX-11 have been mapped to three amino acid stretches in the homeoprotein, the glycine-proline-rich region at the amino terminus, the homeodomain and the glutamine-rich region at the carboxyl terminus. The three distinct functional domains of HOX-11 act in concert for optimal transactivation. In addition, the homeodomain of HOX-11 appears to be differentially utilized in a promoter-dependent manner. Our data support the notion that the HOX-11 homeoprotein functions as an oncogenic transcription activator in leukemogenesis.	UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Francisco								CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; CROCE CM, 1991, CANCER RES, V51, pS5015; DEAR TN, 1993, P NATL ACAD SCI USA, V90, P4431, DOI 10.1073/pnas.90.10.4431; DEAR TN, 1995, DEVELOPMENT, V121, P2909; DUBE ID, 1991, BLOOD, V78, P2996; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; KAGAN J, 1989, P NATL ACAD SCI USA, V86, P4161, DOI 10.1073/pnas.86.11.4161; KAGAN J, 1994, CANCER RES, V54, P226; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LU M, 1992, NUCLEIC ACIDS RES, V20, P263, DOI 10.1093/nar/20.2.263; LU M, 1994, HUM GENE THER, V5, P203, DOI 10.1089/hum.1994.5.2-203; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; LU M, 1990, GENE CHROMOSOME CANC, V2, P217, DOI 10.1002/gcc.2870020309; MING L, 1992, ONCOGENE, V7, P1325; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; PARK JK, 1992, GENE CHROMOSOME CANC, V4, P32, DOI 10.1002/gcc.2870040105; PEERS B, 1995, MOL CELL BIOL, V15, P7091; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; ROBERTS CWM, 1994, NATURE, V368, P747, DOI 10.1038/368747a0; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; ZHANG N, 1995, CANCER RES, V55, P1117; ZHANG N, 1993, ONCOGENE, V8, P3265; ZUTTER M, 1990, P NATL ACAD SCI USA, V87, P3161, DOI 10.1073/pnas.87.8.3161	33	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1781	1787						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895525				2022-12-28	WOS:A1996VM88700024
J	Chen, J; Willingham, T; Shuford, M; Bruce, D; Rushing, E; Smith, Y; Nisen, PD				Chen, J; Willingham, T; Shuford, M; Bruce, D; Rushing, E; Smith, Y; Nisen, PD			Effects of ectopic overexpression of p21WAF1/CIP1 on aneuploidy and the malignant phenotype of human brain tumor cells	ONCOGENE			English	Article						cyclin-dependent kinase inhibitors; cell cycle; tumor suppressors; adenovirus; gene therapy	CYCLIN-DEPENDENT KINASES; P53-MEDIATED G(1) ARREST; WILD-TYPE P53; CANCER-CELLS; PROSTATE-CANCER; DNA-REPLICATION; IN-VIVO; P21; INHIBITOR; GENE	p21(WAF1/CIP1) is downstream effector of the p53 tumor suppressor gene and a universal cyclin-dependent kinase (CDK) inhibitor. To determine the ability of p21(WAF1/CIP1) to function as a tumor suppressor, we constructed a replication-defective adenovirus vector containing p21(WAF1/CIP1) (Adp21(WAF1/CIP1)) to effect ectopic overexpression in a p53-defective human astrocytoma cell line, U-373MG. We observed a marked decrease in CDC2 and CDK2 kinase activity associated with a corresponding decrease in the amount of CDC2 but not CDK2 protein; a decreased growth potential of Adp21(WAF1/CIP1)-infected cells demonstrated by diminished [H-3]thymidine incorporation, increased cell doubling time and G(1)-arrested cell cycle; an association between Adp21(WAF1/CIP1)-infected cells and inhibition of aneuploid cell accumulation; and an alteration of the malignant phenotype of cells was evidenced by the loss of anchorage-independent growth in soft agar and the failure to induce tumorigenesis in both peripheral and intracerebral xenograft models, including the prevention of tumor formation AdP21(WAF1/CIP1) infection 2 days post tumor cell implantation. AdP21(WAF1/CIP1). AdP21(WAF1/CIP1) appears to be a strong candidate for gene therapy studies based on these studies indicating that Adp21(WAF1/CIP1) inhibits proliferation, tumorigenicity and aneuploidy in human brain tumor cells.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT NEUROSURG,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PATHOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL CANCER INSTITUTE [P20CA060173] Funding Source: NIH RePORTER; NCI NIH HHS [CA60173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREW ME, 1981, J IMMUNOL, V127, P1201; CARDER P, 1993, ONCOGENE, V8, P1397; Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN YQ, 1995, CANCER RES, V55, P4536; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EASTHAM JA, 1995, CANCER RES, V55, P5151; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; GAO X, 1995, ONCOGENE, V11, P1395; GOMEZFOIX A, 1992, J BIOL CHEM, V267, P25169; GRAHAM FL, 1991, METHODS MOL BIOL GEN, V1, P109; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; LIU TJ, 1994, CANCER RES, V54, P3662; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; RUSSELL SJ, 1995, CANCER, V75, P1339, DOI 10.1002/1097-0142(19950315)75:6<1339::AID-CNCR2820750616>3.0.CO;2-F; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAM SW, 1994, CANCER RES, V54, P5816; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANG ZY, 1995, NAT MED, V1, P1052, DOI 10.1038/nm1095-1052; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	43	68	78	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1395	1403						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875977				2022-12-28	WOS:A1996VL38400004
J	Pandita, TK; Hall, EJ; Hei, TK; Piatyszek, MA; Wright, WE; Piao, CQ; Pandita, RK; Willey, JC; Geard, CR; Kastan, MB; Shay, JW				Pandita, TK; Hall, EJ; Hei, TK; Piatyszek, MA; Wright, WE; Piao, CQ; Pandita, RK; Willey, JC; Geard, CR; Kastan, MB; Shay, JW			Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with alpha-particles simulating radon progeny	ONCOGENE			English	Article							ATAXIA-TELANGIECTASIA GENE; HUMAN COLORECTAL-CARCINOMA; DNA-DAMAGE; SACCHAROMYCES-CEREVISIAE; CYTOGENETIC ANALYSIS; CELLULAR-RESPONSE; P53; RADIATION; PROTEIN; HYBRIDIZATION	Chromosome end-to-end associations seen at metaphase involve telomeres and are commonly observed in cells derived from individuals with ataxia telangiectasia and most types of human tumors, The associations may arise because of short telomeres and/or alterations of chromatin structure, There is a growing consensus that telomere length is stabilized by the activity of telomerase in immortal cells; however, it is not clear why some immortal cells display chromosome end-to-end associations. In the present study we evaluated chromosome end-to-end associations, telomere length and telomerase activity with the tumorigenic status of human bronchial epithelial cells immortalized with human papillomavirus. Oncogenic transformation was initiated using radon simulated alpha-particles and cells evaluated as primary, secondary and metastatic transformants, The fewest chromosome end associations and lowest telomerase activity were observed in the parental immortalized cells, However, increased levels of telomerase activity were detected in alpha-particle survivors while robust telomerase activity was seen in the tumorigenic cell lines, The tumorigenic cells that mere telomerase positive and had the highest frequency of cells with chromosome end-to-end associations mere also metastatic, No correlation was found between telomere length and the different stages of carcinogenicity.	UNIV TEXAS, SW MED CTR, DEPT CELL BIOL & NEUROSCI, DALLAS, TX 75235 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOL GENET, BRONX, NY 10461 USA; MED COLL OHIO, TOLEDO, OH 43699 USA; JOHNS HOPKINS MED SCH, DEPT PEDIAT ONCOL, BALTIMORE, MD 21287 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Yeshiva University; Albert Einstein College of Medicine; Johns Hopkins University; Johns Hopkins Medicine	Pandita, TK (corresponding author), COLUMBIA UNIV, CTR RADIOL RES, NEW YORK, NY 10032 USA.		Shay, Jerry W/F-7878-2011; Pandita, Tej K/AAM-9188-2020; Piatyszek, Mieczyslaw A./F-9365-2015	Piatyszek, Mieczyslaw A./0000-0003-0502-3239	NATIONAL CANCER INSTITUTE [P01CA012536, P01CA049062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER; NCI NIH HHS [CA12536, CA49062] Funding Source: Medline; NIA NIH HHS [AG07992] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABRUZZO MA, 1991, CYTOGENET CELL GENET, V56, P149, DOI 10.1159/000133072; AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; AGGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BENN PA, 1976, AM J HUM GENET, V28, P465; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DEWALD GW, 1987, MAYO CLIN PROC, V62, P558, DOI 10.1016/S0025-6196(12)62293-9; DUTRILLAUX B, 1978, CYTOGENET CELL GENET, V20, P70, DOI 10.1159/000130841; FANG G, 1995, TELOMERES, P69; FITZGERALD PH, 1984, HUM GENET, V67, P385, DOI 10.1007/BF00291396; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GRIEDER CW, 1985, CELL, V43, P405; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HEI TK, 1994, CARCINOGENESIS, V15, P431, DOI 10.1093/carcin/15.3.431; HITTELMAN WN, 1988, CANCER GENET CYTOGEN, V30, P301, DOI 10.1016/0165-4608(88)90199-9; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KARIN M, 1989, GENES SIGNAL TRANSDU, P415; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOVACS G, 1987, CANCER GENET CYTOGEN, V28, P363, DOI 10.1016/0165-4608(87)90225-1; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS1511; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MANDAHL N, 1985, HUM GENET, V71, P321, DOI 10.1007/BF00388457; MARDER BA, 1993, MOL CELL BIOL, V13, P6667, DOI 10.1128/MCB.13.11.6667; McClintock B, 1941, GENETICS, V26, P234; MEHLA C, 1994, CANCER RES, V554, P236; MOORHEAD PS, 1963, J CELL COMPAR PHYSL, V62, P57, DOI 10.1002/jcp.1030620109; MORGAN R, 1986, HUM GENET, V73, P260, DOI 10.1007/BF00401240; MORROW DM, 1995, CELL, V82, P831, DOI 10.1016/0092-8674(95)90480-8; Muller H., 1938, COLLECT NET, V13, P182; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; *NAT COUNC RAD PRO, 1984, 78 NCRP; PANDITA TK, 1995, CYTOGENET CELL GENET, V71, P86, DOI 10.1159/000134069; PANDITA TK, 1994, CYTOGENET CELL GENET, V67, P94, DOI 10.1159/000133807; PANDITA TK, 1992, RADIAT RES, V130, P94, DOI 10.2307/3578485; PANDITA TK, 1995, CYTOGENET CELL GENET, V68, P95, DOI 10.1159/000133899; PANDITA TK, 1983, HUM GENET, V63, P189, DOI 10.1007/BF00291543; PATHAK S, 1988, CYTOGENET CELL GENET, V47, P227, DOI 10.1159/000132555; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PRICE C M, 1992, Current Opinion in Cell Biology, V4, P379, DOI 10.1016/0955-0674(92)90002-T; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SALTMAN D, 1989, CYTOGENET CELL GENET, V50, P230, DOI 10.1159/000132766; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCOTT D, 1982, INT J RADIAT BIOL, V42, P679, DOI 10.1080/09553008214551661; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; YERGANIAN G., 1962, CYTOGENETICS [BASEL], V1, P314, DOI 10.1159/000129742; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	62	57	60	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1423	1430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875980				2022-12-28	WOS:A1996VL38400007
J	Saxena, A; Robertson, JT; Ali, IU				Saxena, A; Robertson, JT; Ali, IU			Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas	ONCOGENE			English	Article						malignant astrocytomas; recurrent tumors; p16; p15; CDK4	EPIDERMAL GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; DEPENDENT KINASES; FACTOR RECEPTOR; HUMAN CANCERS; GLIAL TUMORS; CYCLIN-D; AMPLIFICATION; EXPRESSION; INHIBITORS	Abnormalities in the p16, p15 and CDK4 genes that regulate transition through the G1 phase of the cell cycle have been implicated in the malignant progression of astrocytomas. The results of the present study demonstrate that dysfunction of these genes also occurs during recurrence of glial tumors that were highly malignant at first presentation. Analysis of 10 matched pairs of high grade malignant astrocytomas and their subsequent recurrences identified three distinct groups. The primary and recurrent tumors in Group A did not show structural alterations in the p16, p15 or CDK4 genes, whereas homozygous codeletion of p16 and p15 was observed in both primary and recurrent tumors in Group B. The primary tumors in Group C had a normal profile of p16, p15 and CDK4 at presentation. Upon recurrence, however, the tumors sustained either deletion of p16 alone or codeletion of both p16 and p15 or amplification of CDK4. Analysis of the molecular differences between primary anaplastic astrocytomas/glioblastomas and their subsequent recurrences, which are clinically indistinguishable, may provide better therapeutic options for treatment.	NCI,FREDERICK CANC RES & DEV CTR,FREDERICK,MD 21702; UNIV TENNESSEE,NINDS,NIH,SURG NEUROL BRANCH,MEMPHIS,TN 38119; UNIV TENNESSEE,DEPT NEUROSURG,MEMPHIS,TN 38119	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center								EKSTRAND AJ, 1991, CANCER RES, V51, P2164; ELAZOUZI M, 1989, P NATL ACAD SCI USA, V86, P7186, DOI 10.1073/pnas.86.18.7186; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLEMING TP, 1992, CANCER RES, V52, P4550; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1990, CANCER RES, V50, P5784; GIANI C, 1994, CANCER RES, V54, P6338; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARBARTH P, 1988, DNA-J MOLEC CELL BIO, V7, P297, DOI 10.1089/dna.1988.7.297; HE J, 1995, CANCER RES, V55, P4833; HERMAN JG, 1995, CANCER RES, V55, P4525; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KHATIB ZA, 1993, CANCER RES, V53, P5535; LOUIS DN, 1995, TRENDS GENET, V11, P412, DOI 10.1016/S0168-9525(00)89125-8; LUKAS J, 1995, CANCER RES, V55, P4818; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; REED JA, 1995, CANCER RES, V55, P2713; SAXENA A, 1992, CANCER RES, V52, P6716; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0	32	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					661	664						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760309				2022-12-28	WOS:A1996VB32800025
J	Zabludoff, SD; Wright, WW; Harshman, K; Wold, BJ				Zabludoff, SD; Wright, WW; Harshman, K; Wold, BJ			BRCA1 mRNA is expressed highly during meiosis and spermiogenesis but not during mitosis of male germ cells	ONCOGENE			English	Article						BRCA1; spermatogenesis; meiosis	ADVANCED SPERMATOGENIC CELLS; ANDROGEN-BINDING PROTEIN; RAT TESTIS; TESTOSTERONE CONCENTRATION; QUANTITATIVE RELATIONSHIP; OVARIAN-CANCER; BREAST-CANCER; MESSENGER-RNA; SERTOLI CELLS; ADULT-RAT	The 17q-linked breast and ovarian cancer susceptibility gene (BRCA1) is believed to function as a tumor suppressor gene (Miki et al., 1994). In this report BRCA1 RNA expression has been analysed in adult mouse tissues with detailed attention to its expression in prepuberal and adult testis. Measurements of BRCA1 mRNA levels in highly purified somatic cells of the testis and in staged germ cells showed that high level BRCA1 mRNA expression is limited to the germ cells. Within the germ cell lineage, the high level expression was detected in meiotic cells, specifically pachytene spermatocytes and in post-meiotic round spermatids. This is in contrast to premeiotic germ cells which were found to express little or no BRCA1 mRNA. These observations, considered together with recent data on the expression of BRCA1 in breast epithelium, argues against a function for BRCA1 in early progenitor cells in both tissues and calls attention instead to roles intimately associated with terminal differentiation or with final rounds of cell division.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT POPULAT DYNAM,DIV REPROD BIOL,BALTIMORE,MD 21205; MYRIAD GENET INC,SALT LAKE CITY,UT 84108	Johns Hopkins University; Myriad Genetics, Inc	Zabludoff, SD (corresponding author), CALTECH,DIV BIOL 156 29,PASADENA,CA 91125, USA.				NIAMS NIH HHS [AR 40780, AR 42671] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040780, P01AR042671] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AWONIYI CA, 1989, ENDOCRINOLOGY, V124, P1217, DOI 10.1210/endo-124-3-1217; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BERNDTSON WE, 1974, J ENDOCRINOL, V62, P125, DOI 10.1677/joe.0.0620125; BREMNER WJ, 1994, ENDOCRINOLOGY, V135, P1227, DOI 10.1210/en.135.3.1227; CHAGANTI RSK, 1994, LANCET, V343, P1130, DOI 10.1016/S0140-6736(94)90235-6; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EASTON DF, 1993, AM J HUM GENET, V52, P678; GERARD A, 1995, J STEROID BIOCHEM, V53, P533, DOI 10.1016/0960-0760(95)00109-D; GERARD H, 1994, ENDOCRINOLOGY, V134, P1515, DOI 10.1210/en.134.3.1515; GOLD B, 1983, DEV BIOL, V98, P392, DOI 10.1016/0012-1606(83)90368-8; GONCZY P, 1994, CELL, V77, P1015, DOI 10.1016/0092-8674(94)90441-3; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; KARZAI AW, 1992, BIOL REPROD, V47, P823, DOI 10.1095/biolreprod47.5.823; KERR JB, 1992, CELL TISSUE RES, V268, P179, DOI 10.1007/BF00338067; KLEENE KC, 1984, DEV BIOL, V105, P71, DOI 10.1016/0012-1606(84)90262-8; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MCLACHLAN RI, 1994, BIOL REPROD, V51, P945, DOI 10.1095/biolreprod51.5.945; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; SHARPER NL, 1990, PNAS, V87, P791; SUN YT, 1989, ENDOCRINOLOGY, V125, P1000, DOI 10.1210/endo-125-2-1000; TAVTIGIAN SV, 1994, MOL BIOL CELL, V5, P375, DOI 10.1091/mbc.5.3.375; THOMAS BJ, 1994, CELL, V77, P1003, DOI 10.1016/0092-8674(94)90440-5; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TUNG PS, 1980, BIOL REPROD, V23, P207, DOI 10.1093/biolreprod/23.1.207; VORNBERGER W, 1994, ENDOCRINOLOGY, V134, P2307, DOI 10.1210/en.134.5.2307; WANG N, 1981, CANCER RES, V41, P2135; ZIRKIN BR, 1989, ENDOCRINOLOGY, V124, P3043, DOI 10.1210/endo-124-6-3043	29	39	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					649	653						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760307				2022-12-28	WOS:A1996VB32800023
J	Schuebel, KE; Bustelo, XR; Nielsen, DA; Song, BJ; Barbacid, M; Goldman, D; Lee, IJ				Schuebel, KE; Bustelo, XR; Nielsen, DA; Song, BJ; Barbacid, M; Goldman, D; Lee, IJ			Isolation and characterization of murine vav2, a member of the vav family of proto-oncogenes	ONCOGENE			English	Article						proto-oncogene; signal transduction; gene expression	GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; T-CELL; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; SH2 DOMAIN; BINDING PROTEINS; POINT MUTATIONS; STEEL FACTOR	We describe the isolation and characterization of a cDNA encoding murine vav2. vav2 shares 63% and 55% identity at the nucleic acid and amino acid levels, respectively, with vav, a proto-oncogene that plays an essential role in embryonic development and hematopoietic signal transduction. The 100 kDa Vav2 protein contains the characteristic array of structural motifs found in Vav. However, unlike vav, vav2 transcripts are widely distributed in both hematopoietic and nonhematopoietic tissues. In the adult, vav2 mRNA is found at high levels in the spleen, liver, testes and placenta. Northern blot analysis reveals two vav2 mRNA species (designated alpha and beta). The alpha species is expressed throughout development while the alpha and beta species are expressed tissue-specifically in adults. Transfection of NIH3T3 cells with expression vectors containing vav2 deletions demonstrate that elimination of 183 amino terminal residues of Vav2 is sufficient to activate its oncogenic potential. Vav2-induced transformation is characterized by the appearance of foci composed of cells in which cytokinesis and karyokinesis are uncoupled. This phenotype is comparable, but not identical, to morphological changes induced by Vav and other members of the Dbl family of oncoproteins. Our results suggest that Vav family members mediate functions important in the regulation of cell architecture and proliferation in most, if not all, tissues.	NIAAA,NEUROGENET LAB,NIH,ROCKVILLE,MD 20852; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL BIOL,PRINCETON,NJ 08543	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010; Nielsen, David A/B-4655-2009; Bustelo, Xose R./AAD-2081-2022; Goldman, David/F-9772-2010; Majid, Salma/AAT-2616-2020	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Goldman, David/0000-0002-1724-5405; Majid, Salma/0000-0002-1724-5405				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HENSKE EP, 1995, ANN HUM GENET, V59, P25, DOI 10.1111/j.1469-1809.1995.tb01603.x; HIGUCHI T, 1995, BIOL REPROD, V53, P840, DOI 10.1095/biolreprod53.4.840; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOBERT O, 1994, J BIOL CHEM, V269, P20225; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOLAKOWSKI J, 1995, BIOCHEM J, V306, P199; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; UDDIN S, 1995, J BIOL CHEM, V270, P7712, DOI 10.1074/jbc.270.13.7712; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WU J, 1995, MOL CELL BIOL, V15, P4337; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; ZHANG R, 1995, NATURE, V374, P470, DOI 10.1038/374470a0; ZMUIDZINAS A, 1995, EMBO J, V14, P1	51	117	119	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					363	371						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710375				2022-12-28	WOS:A1996VA25200015
J	Kanazawa, S; Ilic, D; Hashiyama, M; Okada, M; Noumura, T; Aizawa, S; Suda, T				Kanazawa, S; Ilic, D; Hashiyama, M; Okada, M; Noumura, T; Aizawa, S; Suda, T			Impaired development of CD4(+) CD8(+) thymocytes by csk-(knock-in) into fyn locus	ONCOGENE			English	Article						p59(fyn); p50(csk); p56(lck); knock-in; thymocytes; T cell development	PROTEIN-TYROSINE KINASE; CELL ANTIGEN RECEPTOR; SRC FAMILY KINASES; CROSS-LINKING; MICE LACKING; MUTANT MICE; ACTIVATION; ASSOCIATION; P56(LCK); ZAP-70	p59(fyn) is one of the Src-family kinases thought to play an important role in signaling through T cell receptor, However, Fyn deficiency has caused no overt defects in vivo on T cell development, nor has it caused any changes in the phosphorylation status of molecules such as ZAP-70 which have been proposed as p59(fyn) substrates, This could be explained as being due to compensation of Fyn deficiency by other Src-family kinases, Here, we have 'knocked-in' the csk gene, a negative regulator of Src-family kinases, into fyn locus to challenge the problem of redundant functions among Src-family kinases, The csk-'knock-in' mice displayed atrophy of the thymic cortex and impaired development of CD4(+) CD8(+) thymocytes, This was concomitant with decrease in tyrosine phosphorylation of ZAP-70 and p120(cbl).	KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT MORPHOGENESIS,KUMAMOTO 860,JAPAN; KUMAMOTO UNIV,SCH MED,INST MOLEC EMBRYOL & GENET,DEPT CELL DIFFERENTIAT,KUMAMOTO 860,JAPAN; SAITAMA UNIV,GRAD SCH ENGN SCI,URAWA,SAITAMA 338,JAPAN; OSAKA UNIV,INST PROT RES,DIV PROT METAB,SUITA,OSAKA 565,JAPAN	Kumamoto University; Kumamoto University; Saitama University; Osaka University			Suda, Toshio/H-6761-2013	Suda, Toshio/0000-0001-7540-1771; ILIC, DUSKO/0000-0003-1647-0026				ALLAND L, 1994, J BIOL CHEM, V269, P16701; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BLACK TJ, 1993, EMBO J, V12, P2017; BOLEN JB, 1993, ONCOGENE, V8, P2025; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GROSS JA, 1995, J EXP MED, V181, P463, DOI 10.1084/jem.181.2.463; ILIC D, 1995, BIOCHEM BIOPH RES CO, V209, P300, DOI 10.1006/bbrc.1995.1503; IMAMOTO A, 1993, CELL, V73, P117; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LEVIN SD, 1993, J EXP MED, V178, P245, DOI 10.1084/jem.178.1.245; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OKADA S, 1993, BLOOD, V81, P1720; OLSZOWY MW, 1995, J IMMUNOL, V155, P4236; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; RUDD CE, 1994, IMMUNOL TODAY, V15, P225, DOI 10.1016/0167-5699(94)90248-8; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1993, J EXP MED, V178, P1523, DOI 10.1084/jem.178.5.1523; TAMURA T, 1993, J IMMUNOL, V151, P6051; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WEIL R, 1995, J BIOL CHEM, V270, P2791, DOI 10.1074/jbc.270.6.2791; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YAGI T, 1993, ONCOGENE, V8, P3343; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458; YAGI T, 1994, ONCOGENE, V9, P2433	43	6	6	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					199	204						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700547				2022-12-28	WOS:A1996UX31900023
J	Shimizu, S; Eguchi, Y; Kamiike, W; Waguri, S; Uchiyama, Y; Matsuda, H; Tsujimoto, Y				Shimizu, S; Eguchi, Y; Kamiike, W; Waguri, S; Uchiyama, Y; Matsuda, H; Tsujimoto, Y			Bcl-2 blocks loss of mitochondrial membrane potential while ICE inhibitors act at a different step during inhibition of death induced by respiratory chain inhibitors	ONCOGENE			English	Article						apoptosis; bcl-2; bcl-x; ICE; mitochondrial membrane potential; necrosis	PROGRAMMED CELL-DEATH; HUMAN FOLLICULAR LYMPHOMA; CHROMOSOMAL BREAKPOINT; GROWTH-FACTOR; GENE CED-3; APOPTOSIS; PROTEIN; HEPATOCYTES; EXPRESSION; ENZYME	Bcl-2, Bcl-x(L), CrmA and tetrapeptide ICE inhibitor reduce the extent of necrotic cell death induced by cyanide, which primarily damages mitochondria, Although none of them affects the drastic decrease in ATP levels induced by cyanide, Bcl-2 and Bcl-x(L) but not CrmA or ICE inhibitor inhibit the cyanide-induced decrease in mitochondrial membrane potential, A similar blocking effect is observed on necrotic cell death induced by other respiration inhibitors, rotenone and antimycin A, and on apoptotic cell death induced by etoposide or calcium ionophore. These results indicate that Bcl-2 and Bcl-x(L) protect mitochondria against the loss of function during both apoptosis and at least some forms of necrotic cell death, The ICE family proteases act at a different step other than the loss of mitochondrial membrane potential.	OSAKA UNIV,SCH MED,DEPT MED GENET,CTR BIOMED RES,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT ANAT 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSIOL 1,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University; Osaka University; Osaka University								AKAO Y, 1994, CANCER RES, V54, P2468; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BERGER ML, 1989, HEPATOLOGY, V9, P219, DOI 10.1002/hep.1840090210; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GORES GJ, 1990, HEPATOLOGY, V11, P690, DOI 10.1002/hep.1840110425; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOEK JB, 1980, J BIOL CHEM, V255, P1458; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JOHNSON LV, 1981, J CELL BIOL, V88, P526, DOI 10.1083/jcb.88.3.526; KANE AB, 1985, AM J PHYSIOL, V249, pC256, DOI 10.1152/ajpcell.1985.249.3.C256; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRONER H, 1986, BIOL CHEM H-S, V367, P483, DOI 10.1515/bchm3.1986.367.1.483; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LEMASTERS JJ, 1987, NATURE, V325, P78, DOI 10.1038/325078a0; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PASTORINO JG, 1993, J BIOL CHEM, V268, P13791; PASTORINO JG, 1995, AM J PHYSIOL-CELL PH, V268, pC676, DOI 10.1152/ajpcell.1995.268.3.C676; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIMIZU S, 1996, IN PRESS ONCOGENE; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TAGAWA K, 1988, CALCIUM DEPENDENT PR, P221; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tsujimoto Y, 1996, Prog Mol Subcell Biol, V16, P72; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	58	302	304	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					21	29						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700549				2022-12-28	WOS:A1996UX31900003
J	Zhang, YH; Saez, R; Leal, MA; Chan, AML				Zhang, YH; Saez, R; Leal, MA; Chan, AML			Synergism between two growth regulatory pathways: Cooperative transformation of NIH3T3 cells by G alpha(12) and c-raf-1	ONCOGENE			English	Article						oncogene; NIH3T3; G alpha(12); raf; ras; transformation	EXPRESSION CDNA CLONING; ALPHA-SUBUNITS; GENE-PRODUCT; RAS; ONCOGENES; ACTIVATION; CANCER; TUMORS	The alpha-subunit of the heterotrimeric G-protein, G(12), has been shown to induce cellular transformation when overexpressed or oncogenically activated in rodent fibroblasts. To investigate the interaction between G alpha(12) transforming pathway and the Ras-Raf-MAPK pathway, we examined the ability of mitogenic signaling molecules in cooperating with G alpha(12) in transforming NIH3T3 fibroblasts, We observed a striking cooperative effect on focus-forming ability when G alpha(12) and c-raf-1 cDNAs were co-transfected into NIH3T3 cells, NIH3T3 cells coexpressing both G alpha(12) and c-raf-1 resulted in the constitutive activation of the mitogenic-activated protein kinase (MAPK), In addition, the levels of GTP-bound Ras were elevated in G alpha(12) transformed NIH3T3 cells, Our results provide a model for studying the effects of simultaneous activation of two distinct growth regulatory pathways in cellular transformation.					Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464				BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1989, CANCER RES, V49, P4682; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; FAURE M, 1994, J BIOL CHEM, V269, P7841; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PENDERGAST GC, 1995, ONCOGENE, V10, P2289; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	34	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2377	2383						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649778				2022-12-28	WOS:A1996UQ22000015
J	Zhu, D; Bourguignon, L				Zhu, D; Bourguignon, L			Overexpression of CD44 in p185(neu)-transfected NIH3T3 cells promotes an up-regulation of hyaluronic acid-mediated membrane-cytoskeleton interaction and cell adhesion	ONCOGENE			English	Article						CD44; p184(neu); hyaluronic acid; cytoskeleton; cell adhesion	TRANSMEMBRANE GLYCOPROTEIN; PROTO-ONCOGENE; RECEPTOR CD44; HUMAN-BREAST; EXPRESSION; BINDING; NEU; MOLECULE; GP85; AMPLIFICATION	CD44 is a transmembrane glycoprotein known to bind hyaluronic acid (HA) in its extracellular domain and to contain at least one ankyrin-binding site in its cytoplasmic domain. In this study we have examined CD44 expression in a mouse fibroblast cell line transfected with the p185(neu) oncogene cDNA. The results of RT-PCR and Southern blot analyses reveal that CD44s (CD44 standard form) transcript is expressed in both p185(neu)-transfected cells and untransfected cells. Using surface iodination, anti-CD44 immunoprecipitation and immune-binding assays, we have found that the number of CD44s molecules expressed on the surface of p185(neu)-transfected cells are at least 4.5-fold higher than those detected on untransfected cells. Overexpression of surface CD44s in p185(neu)-transfected cells results in a dramatic enhancement of HA-mediated cell adhesion. Scatchard plot analysis indicates that CD44s in p185(neu)-transfected cells binds directly and specifically to ankyrin. The binding affinity between CD44s and ankyrin in p185(neu)-transfected cells (K-d approximate to 0.19 nM) appears to be somewhat higher than that found in the untransfected cells (K-d approximate to 0.30 nM). Double immunofluorescence staining and confocal microscopic analyses indicate that HA induces the HA receptor (i.e. CD44s) to form adhesion plaque-like structures, and causes an accumulation of intracellular ankyrin directly underneath HA receptor (CD44s)-adhesion plaque-like structures in p185(neu)-transfected cells (but not in untransfected cells). These findings suggest that overexpression of CD44s and up-regulation of CD44s-ankyrin interaction by p185(neu) oncogene may be one of the pre-requisite steps in regulating tumor cell behavior.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami					NATIONAL CANCER INSTITUTE [R01CA066163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036353] Funding Source: NIH RePORTER; NCI NIH HHS [CA66163] Funding Source: Medline; NIGMS NIH HHS [GM36353] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BERGER MS, 1988, CANCER RES, V48, P1238; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; CARTER WG, 1988, J BIOL CHEM, V263, P4193; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; DIGIOVANNA MP, 1995, CANCER RES, V55, P1646; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HIRANO H, 1994, INT IMMUNOL, V6, P49, DOI 10.1093/intimm/6.1.49; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; ISACKE CM, 1994, J CELL SCI, V107, P2353; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JAMAL HH, 1994, ONCOGENE, V9, P417; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KALOMIRIS EL, 1988, J CELL BIOL, V106, P317; KUPPNER MC, 1992, INT J CANCER, V50, P572, DOI 10.1002/ijc.2910500414; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOKESHWAR VB, 1991, J BIOL CHEM, V266, P17983; PADHY LC, 1982, CELL, V28, P865, DOI 10.1016/0092-8674(82)90065-4; PARK JB, 1989, CANCER RES, V49, P6605; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; RALL CJN, 1995, CANCER RES, V55, P1831; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; UNDERHILL C, 1992, J CELL SCI, V103, P293; WELSH CF, 1995, J CELL PHYSIOL, V164, P605, DOI 10.1002/jcp.1041640319; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; YU DH, 1992, J BIOL CHEM, V267, P10203; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1991, ONCOGENE, V6; ZHANG LR, 1995, CANCER RES, V55, P428	45	21	22	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2309	2314						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649770				2022-12-28	WOS:A1996UQ22000007
J	Papin, C; Denouel, A; Calothy, G; Eychene, A				Papin, C; Denouel, A; Calothy, G; Eychene, A			Identification of signalling proteins interacting with B-Raf in the yeast two-hybrid system	ONCOGENE			English	Article						B-Raf; c-Raf-1; Ras; MEK-1; MEK-2; 14-3-3; MAP kinase cascade	COMPLETE CODING SEQUENCE; MAP KINASE KINASE; GENE; FAMILY; EXPRESSION; DOWNSTREAM; ONCOGENE; CLONING; MEK2	Recent studies suggested the existence of Ras/B-Raf/MEK-1 complexes and a critical role for B-Raf in regulating the MAP kinase/ERKs signalling pathway, We report, here, that both Ras and MEK-1 proteins interact physically with B-Raf proteins in the yeast two-hybrid system, In addition, by screening a mouse brain cDNA library, we isolated additional B-Raf interacting proteins, These include three members of the 14-3-3 proteins family (eta, theta and zeta) and the MEK-2 protein, We also show that c-Raf-1, previously reported to interact with beta and zeta 14-3-3 proteins, also interacts with eta and theta 14-3-3 proteins in the two-hybrid system, By using different portions of the B-Raf protein, we mapped the regions of the protein involved in these interactions, Specifically, we have characterized B-Raf specific sequences required for an efficient interaction with MER proteins, We show that, consequently, B-Raf interacts with MEK-1 and MEK-2 with a better affinity than does c-Raf-1, thus strengthening the notion that B-Raf is a stronger MER activator than c-Raf-1, Our results also suggest that a MEK specific sequence, not present in MAP kinase kinases which are not activated by members of the Raf family, is required for the interaction with Raf proteins.	CTR UNIV ORSAY,INST CURIE,UMR 146 CNRS,LAB 110,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Eychene, Alain/M-8838-2017	EYCHENE, Alain/0000-0002-6818-7225				AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; Bartel Paul L., 1993, V131, P153; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRASELMANN S, 1995, EMBO J, V14, P4829; BROTT BK, 1993, CELL GROWTH DIFFER, V4, P921; BRTVA TR, 1995, J BIOL CHEM, V270, P9809, DOI 10.1074/jbc.270.17.9809; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUNET A, 1994, ONCOGENE, V9, P3379; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CATLING AD, 1994, J BIOL CHEM, V269, P30014; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DUFFY JB, 1994, DEV BIOL, V166, P380, DOI 10.1006/dbio.1994.1324; EYCHENE A, 1995, ONCOGENE, V10, P1159; EYCHENE A, 1992, ONCOGENE, V7, P1315; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; HALLBERG B, 1994, J BIOL CHEM, V269, P3913; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; OTSU M, 1993, FEBS LETT, V320, P246, DOI 10.1016/0014-5793(93)80596-M; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PAPIN C, 1995, ONCOGENE, V10, P1647; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; RUSSELL M, 1995, BIOCHEMISTRY-US, V34, P6611, DOI 10.1021/bi00020a005; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUEN KL, 1995, ONCOGENE, V11, P825; TRAVERSE S, 1994, FEBS LETT, V350, P13, DOI 10.1016/0014-5793(94)00723-3; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WATANABE M, 1991, MOL BRAIN RES, V10, P151, DOI 10.1016/0169-328X(91)90105-7; WATANABE M, 1994, MOL BRAIN RES, V25, P113, DOI 10.1016/0169-328X(94)90285-2; WU J, 1993, P NATL ACAD SCI USA, V90, P173, DOI 10.1073/pnas.90.1.173; WU J, 1993, MOL CELL BIOL, V13, P4539, DOI 10.1128/MCB.13.8.4539; WU Y, 1995, GENE DEV, V9, P742, DOI 10.1101/gad.9.6.742; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	71	69	72	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2213	2221						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668348				2022-12-28	WOS:A1996UP28300021
J	Arber, N; Sutter, T; Miyake, M; Kahn, SM; Venkatraj, VS; Sobrino, A; Warburton, D; Holt, PR; Weinstein, IB				Arber, N; Sutter, T; Miyake, M; Kahn, SM; Venkatraj, VS; Sobrino, A; Warburton, D; Holt, PR; Weinstein, IB			Increased expression of cyclin D1 and the RB tumor suppressor gene in c-K-ras transformed rat enterocytes	ONCOGENE			English	Article						retinoblastoma; cyclin D1; ras; colon cancer	HUMAN CANCER; COLORECTAL CARCINOMAS; RETINOBLASTOMA GENE; ESOPHAGEAL CANCER; OVEREXPRESSION; AMPLIFICATION; CELLS; CHROMOSOME-13; ABNORMALITIES; FIBROBLASTS	Activating mutations in the c-g-ras gene occur in about 40% of human colorectal carcinomas, yet the role of this oncogene in tumorigenesis is not known. We have developed a model cell culture system to study this problem, utilizing the immortalized but non-tumorigenic epithelial cell line IEC18, originally derived from normal rat intestine epithelium. These cells were cotransfected with the drug resistance selectable marker tk-neo and the plasmid pMIKcys, which encodes a mini human c-K-vas gene (15 kb) containing a cysteine mutation at codon 12, Drug resistant clones were isolated. Clones which also expressed the activated c-K-ras gene displayed a transformed morphology, decreased doubling time, increased level of diacylglycerol, anchorage independent growth in soft agar and an aneuploid karyotype and they were also tumorigenic when injected into nude mice. These clones also displayed increased expression, at both the mRNA and protein levels, of cyclin D1 and Rb. These findings may be of clinical relevance since human colorectal tumors also frequently display increased expression of both cyclin D1 and Rb. This model system may be useful for understanding the role and interrelationship between activation of the c-K-uas oncogene and increased expression of cyclin D1 and Rb in colorectal tumorigenesis.	COLUMBIA UNIV COLL PHYS & SURG,COLUMBIA PRESBYTERIAN CANC CTR,NEW YORK,NY 10032; COLUMBIA UNIV,CTR RADIOL RES,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT GENET & DEV,NEW YORK,NY 10032; COLUMBIA UNIV,ST LUKES ROOSEVELT HOSP CTR,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Mount Sinai St. Luke's; Mount Sinai West				holt, peter/0000-0002-8469-2766; Arber, Nadir/0000-0001-5283-6991				ARBER N, 1996, IN PRESS GASTROENTER; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BOWCOCK AM, 1989, CYTOGENET CELL GENET, V51, P966; CHAMBERS AF, 1993, CRIT REV ONCOGENESIS, V4, P95; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; FEARON ER, 1993, J NATL CANCER I, V85, P1978, DOI 10.1093/jnci/85.24.1978; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FILMUS J, 1994, ONCOGENE, V9, P3627; GOPE R, 1990, J NATL CANCER I, V82, P310, DOI 10.1093/jnci/82.4.310; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOVIG E, 1992, GENE CHROMOSOME CANC, V5, P97, DOI 10.1002/gcc.2870050202; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; JIANG W, 1992, CANCER RES, V52, P2980; KAHN S, 1987, ANTICANCER RES, V7, P639; KATO J, 1993, GENE DEV, V7, P331; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LEACH FS, 1993, CANCER RES, V53, P1986; LOTHE RA, 1992, J NATL CANCER I, V84, P1100, DOI 10.1093/jnci/84.14.1100; LOVEC H, 1994, ONCOGENE, V9, P323; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MITELMAN F, 1992, ISCN GUIDELINES CA S; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; ONO T, 1993, JPN J GENET, V68, P617, DOI 10.1266/jjg.68.617; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PHAN SC, 1991, CANCER RES, V51, P1571; PINES J, 1994, CELL, V79, P573; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; PRICE BD, 1989, J BIOL CHEM, V264, P16638; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; TUCK AB, 1991, J NATL CANCER I, V83, P485; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WILDRICK DM, 1994, MOL CARCINOGEN, V10, P1, DOI 10.1002/mc.2940100102; ZHANG YJ, 1993, BIOCHEM BIOPH RES CO, V196, P1010, DOI 10.1006/bbrc.1993.2350	38	81	81	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1903	1908						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649851				2022-12-28	WOS:A1996UK49800009
J	Barrett, MT; Galipeau, PC; Sanchez, CA; Emond, MJ; Reid, BJ				Barrett, MT; Galipeau, PC; Sanchez, CA; Emond, MJ; Reid, BJ			Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms	ONCOGENE			English	Article						allelotype; esophageal adenocarcinoma; polymorphisms	BARRETTS-ESOPHAGUS; GENETIC ALTERATIONS; ALLELOTYPE; CANCERS; PROGRESSION; DYSPLASIA	It is well established that the progression to human cancer is characterized by the evolution of clones of cells with accumulated genetic abnormalities. However, technical difficulties limit the ability to study this process in some premalignant and malignant conditions. For example, the progression to esophageal adenocarcinoma in the premalignant condition Barrett's esophagus is characterized by the evolution of genetic and cell cycle abnormalities, but it has been difficult to characterize this process completely because of the small size of biopsies and the relative abundance of genetically normal stromal cells in some esophageal adenocarcinomas and premalignant mucosa. We have combined how cytometric cell sorting to obtain purified populations of neoplastic cells with whole genome amplification and analysis of microsatellite polymorphisms to determine the frequency of allelic loss on every nonacrocentric autosomal arm in 20 esophageal adenocarcinomas and two high-grade dysplasias. DNA samples of purified how-sorted aneuploid and corresponding normal tissue were amplified with a degenerate 15mer primer. Aliquots of these reactions were then screened with forty-three highly polymorphic simple sequence repeat markers in PCR-based assays. Allelic losses were observed at polymorphic loci in 38 of the 40 chromosome arms that were analysed and the median fractional allelic loss (FAL) observed in the samples was 0.28. The background allelic loss frequency was estimated at 0.23 with the highest rates of loss observed at 17p (100%), 5q (80%), 9P (64%), 13q (43%), 18q (43%) acid Ip (41%). These data represent the first comprehensive allelotype of esophageal adenocarcinoma and show the feasibility of multiloci analyses with small highly purified human biopsy material.	UNIV WASHINGTON,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle			Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X; Galipeau, Patricia/0000-0001-7961-7430	NCI NIH HHS [R0 1 CA61202, 5 PO 1 CA42792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042792, R01CA061202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT MT, 1995, NUC ACIDS RES, V23, P3368; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; BOYNTON RF, 1991, CANCER RES, V51, P5766; FULTS D, 1990, CANCER RES, V50, P5784; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HIROHASHI S, 1991, CANCER CELL-MON REV, V3, P49; HUANG Y, 1992, CANCER RES, V52, P6525; MELTZER SJ, 1991, P NATL ACAD SCI USA, V88, P4976, DOI 10.1073/pnas.88.11.4976; MELTZER SJ, 1994, CANCER RES, V54, P3370; NAGAI H, 1995, CANCER RES, V55, P1752; NESHAT K, 1994, COLD SPRING HARB SYM, V59, P577, DOI 10.1101/SQB.1994.059.01.065; PEIFFER SL, 1995, CANCER RES, V55, P1922; PHILLIPS RW, 1991, GASTROENTEROL CLIN N, V20, P791; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; REID BJ, 1992, GASTROENTEROLOGY, V102, P1212; SATO T, 1990, CANCER RES, V50, P7184; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SNABES MC, 1994, P NATL ACAD SCI USA, V91, P6181, DOI 10.1073/pnas.91.13.6181; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; TARMIN L, 1994, CANCER RES, V54, P6094; THRASHBINGHAM CA, 1995, P NATL ACAD SCI USA, V92, P2854, DOI 10.1073/pnas.92.7.2854; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; YAMAGUCHI T, 1992, CANCER RES, V52, P419; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; ZHOU XL, 1994, ONCOGENE, V9, P3737	32	113	116	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1873	1878						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649847				2022-12-28	WOS:A1996UK49800005
J	Fan, GS; Ma, XM; Kren, BT; Steer, CJ				Fan, GS; Ma, XM; Kren, BT; Steer, CJ			The retinoblastoma gene product inhibits TGF-beta 1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells	ONCOGENE			English	Article						retinoblastoma; hepatocyte; apoptosis; transforming growth factor-beta 1 (TGF-beta 1); cell cycle; E2F-1	TRANSFORMING GROWTH FACTOR-BETA-1; TGF-BETA; PROTEIN PHOSPHATASES; LIVER-REGENERATION; DEATH; EXPRESSION; INDUCTION; PHOSPHORYLATION; QUANTIFICATION; PROLIFERATION	Transforming growth factor-beta 1 (TGF-beta 1) can induce rapid growth arrest and apoptosis in hepatic cells. Its growth suppressive effects appear to be linked to decreased phosphorylation of the protein product of the retinoblastoma gene, pRb. To characterize the role of pRb in apoptosis, we examined endogenous retinoblastoma gene (Rb) expression following treatment with TGF-beta 1, okadaic acid, or antisense Rb S-oligonucleotides in cultured primary rat hepatocytes acid human hepatoma HuH-7 cells. We also investigated the effects on apoptosis of Rb overexpression following transfection with vectors containing wild-type Rb in HuH-7 cells. Our results indicated that transfection with Rb antisense S-oligonucleotides blocked the expression of pRb in cultured primary hepatocytes and induced apoptosis. Treatment of HuH-7 cells with TGF-beta 1 inhibited expression and phosphorylation of pRb, and also induced apoptosis. Furthermore, 93% of viable preapoptotic cells were arrested in the G(1) phase of the cell cycle. Incubation with the phosphatase inhibitor okadaic acid maintained pRb in its phosphorylated state, and resulted in significant apoptosis. Overexpression of wild-type Rb inhibited TGF-beta 1 induced apoptosis in HuH-7 cells. In contrast, overexpression of transcription factor E2F-1, a known target for the activity of pRb, caused significant apoptosis. However, coexpression of Rb suppressed E2F-1 induced apoptosis in HuH-7 cells. Our results suggest that inhibition of pRb expression is associated with hepatocyte apoptosis. Furthermore, E2F-1 appears to be a target in the pathway through which pRb modulates the apoptotic threshold in hepatic cells. Finally, the data suggest that these cells exit the cell cycle during the G(1) phase before progressing into apoptosis and pRb may be a negative regulator of this process.	UNIV MINNESOTA, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT CELL BIOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities								ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; BURSCH W, 1993, BRIT J CANCER, V67, P531, DOI 10.1038/bjc.1993.98; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN P, 1989, FEBS LETT, V250, P596, DOI 10.1016/0014-5793(89)80803-8; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FAN GS, 1995, CELL GROWTH DIFFER, V6, P1463; FUKUDA K, 1993, HEPATOLOGY, V18, P945, DOI 10.1002/hep.1840180428; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GRUPPUSO PA, 1990, CANCER RES, V50, P1464; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAUPT Y, 1995, ONCOGENE, V10, P1563; HELVERING LM, 1993, CANCER LETT, V71, P133, DOI 10.1016/0304-3835(93)90108-L; JAKOWLEW SB, 1991, CELL REGUL, V2, P535, DOI 10.1091/mbc.2.7.535; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LOCKSHIN RA, 1990, J GERONTOL, V45, pB135, DOI 10.1093/geronj/45.5.B135; MARIASH CN, 1986, J BIOL CHEM, V261, P9583; Massague J, 1992, CURR OPIN GENET DEV, V2, P28, DOI 10.1016/S0959-437X(05)80317-X; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; OBERHAMMER F, 1991, CANCER RES, V51, P2478; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; ORMEROD MG, 1992, J IMMUNOL METHODS, V153, P57, DOI 10.1016/0022-1759(92)90305-D; ORMEROD MG, 1993, ACTA ONCOL, V32, P417, DOI 10.3109/02841869309093620; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; SCHULTEHERMANN R, 1993, ENVIRON HEALTH PERSP, V101, P87, DOI 10.2307/3431847; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; TRUMP BF, 1995, FASEB J, V9, P219, DOI 10.1096/fasebj.9.2.7781924; TSUKIDATE K, 1993, AM J PATHOL, V143, P918; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WALKER PR, 1993, BIOTECHNIQUES, V15, P1032; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YAN ZF, 1992, ONCOGENE, V7, P801; YATSUNAMI J, 1993, CANCER RES, V53, P239	56	119	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1909	1919						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649852				2022-12-28	WOS:A1996UK49800010
J	Powell, SM; Cummings, OW; Mullen, JA; Asghar, A; Fuga, G; Piva, P; Minacci, C; Megha, T; Tosi, P; Jackson, CE				Powell, SM; Cummings, OW; Mullen, JA; Asghar, A; Fuga, G; Piva, P; Minacci, C; Megha, T; Tosi, P; Jackson, CE			Characterization of the APC gene in sporadic gastric adenocarcinomas	ONCOGENE			English	Article						gastric carcinoma; adenomatous polyposis coli (APC); mutations; loss of heterozygosity; molecular genetics	FAMILIAL ADENOMATOUS POLYPOSIS; PANCREATIC-CANCER; SOMATIC MUTATIONS; COLORECTAL-CANCER; FREQUENT LOSS; COLI GENE; HETEROZYGOSITY; CARCINOMA; LOCI; MCC	The prominent role of the APC gene in colorectal tumor development is well established. However, its role in tumorigenesis in other tissues is not clear. Hence, DNA from 30 primary sporadic gastric adenocarcinomas was obtained from patients living in a high risk area of the world (North-Central Italy) in order to further define APC's role in gastric tumorigenesis. We thoroughly examined that region of APC which is commonly mutated in colorectal tumors using proven sensitive methods. The IVS protein assay and DNA sequence analysis of APC codons 686 through 1693 revealed no intragenic mutations. However, allelic loss of loci near APC was detected in 7 (28%) of 25 informative gastric adenocarcinomas using two 5q dinucleotide repeat markers for LOH analysis. These results suggest that genetic alteration of a region of APC commonly mutated in colorectal cancer is not a common event during sporadic gastric tumor development, at least in patients from North-Central Italy. Further analysis of chromosome 5q might identify another gene to be significantly altered in these gastric cancers.	INDIANA UNIV, SCH MED, DEPT PATHOL, INDIANAPOLIS, IN 46202 USA; UNIV SIENA, IST ANAT EISTOL PATOL, I-53100 SIENA, ITALY; HENRY FORD HOSP, DEPT MED, DETROIT, MI 48202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; University of Siena; Henry Ford Health System; Henry Ford Hospital	Powell, SM (corresponding author), INDIANA UNIV, SCH MED, DEPT MED, 975 W WALNUT ST IB 424, INDIANAPOLIS, IN 46202 USA.				NCI NIH HHS [1R29CA67000-01] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*AM JOINT COMM CAN, 1993, MAN STAG CANC; CHONG JM, 1994, CANCER RES, V54, P4595; CORREA P, 1994, CANCER SURV, V20, P55; DAMICO D, 1992, CANCER RES, V52, P1996; FAWCETT TW, 1991, USB EDITORIAL COMMEN, V17, P19; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAN HJ, 1993, CANCER RES, V53, P5087; HORII A, 1992, CANCER RES, V52, P3231; HORII A, 1992, CANCER RES, V52, P6696; HUANG Y, 1992, CANCER RES, V52, P6525; JACKSON CE, 1980, CANCER, V45, P599, DOI 10.1002/1097-0142(19800201)45:3<599::AID-CNCR2820450328>3.0.CO;2-8; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JEN J, 1994, CANCER RES, V54, P5523; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; MCKIE AB, 1993, INT J CANCER, V55, P598, DOI 10.1002/ijc.2910550414; MIRONOV NM, 1994, CANCER RES, V54, P41; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; NAGASE H, 1993, HUM MUTAT, V2, P425, DOI 10.1002/humu.1380020602; NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1980, DOI 10.1016/0016-5085(92)90322-P; OGASAWARA S, 1994, VIRCHOWS ARCH, V424, P607, DOI 10.1007/BF01069740; PARK JG, 1992, DIS COLON RECTUM, V35, P996, DOI 10.1007/BF02253505; PELTOMAKI P, 1993, CANCER RES, V53, P5853; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1994, GASTROENTEROLOGY, V107, P1759, DOI 10.1016/0016-5085(94)90818-4; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RHYU MG, 1994, GASTROENTEROLOGY, V106, P1584, DOI 10.1016/0016-5085(94)90414-6; SANO T, 1991, CANCER RES, V51, P2926; SEYMOUR AB, 1994, CANCER RES, V54, P2761; SHIAO YH, 1994, AM J PATHOL, V144, P511; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; SPIRIO L, 1991, NUCLEIC ACIDS RES, V19, P6348, DOI 10.1093/nar/19.22.6348; STEMMERMANN G, 1994, HUM PATHOL, V25, P968, DOI 10.1016/0046-8177(94)90056-6; STRICKLER JG, 1994, CANCER RES, V54, P4750; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; TAMURA G, 1993, JPN J CANCER RES, V84, P1015, DOI 10.1111/j.1349-7006.1993.tb02794.x; TAMURA G, 1994, CANCER RES, V54, P1149; UCHINO S, 1993, INT J CANCER, V54, P759, DOI 10.1002/ijc.2910540509; UTSUNOMIYA J, 1990, HEREDITARY COLORECTA, P3; VASEN HFA, 1991, LANCET, V338, P877, DOI 10.1016/0140-6736(91)91520-5; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHELAN SL, 1993, IARC SCI PUBLICATION, V12; WIJNEN J, 1991, NUCLEIC ACIDS RES, V19, P6965, DOI 10.1093/nar/19.24.6965-a	49	20	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1953	1959						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649856				2022-12-28	WOS:A1996UK49800014
J	Algar, EM; Khromykh, T; Smith, SI; Blackburn, DM; Bryson, GJ; Smith, PJ				Algar, EM; Khromykh, T; Smith, SI; Blackburn, DM; Bryson, GJ; Smith, PJ			A WT1 antisense oligonucleotide inhibits proliferation and induces apoptosis in myeloid leukaemia cell lines	ONCOGENE			English	Article						WT1; leukaemia; apoptosis	WILMS-TUMOR; GENE; IDENTIFICATION; MUTATIONS; PROTEINS	The response of the CML-BC cell line, K562, the myelomonocytic cell line MM6 and the promyelocytic leukaemia cell line HL-60, to a 15 mer WT1 antisense oligonucleotide, targeted to the translation initiation site of the WT1 mRNA was examined. K562 cells exposed to 0.4 mu M antisense oligonucleotide showed markedly reduced proliferation which was associated with reduced cell viability. Sense, scrambled and mutant antisense oligonucleotides had no effect on the proliferation of K562 cells. MM6 cells exposed to 0.4 mu M antisense oligonucleotide also showed significantly reduced cellular proliferation which was also accompanied by loss of cell viability. In the K562 and MM6 antisense cultures that exhibited reduced cell viability, both DNA fragmentation and morphological features consistent with apoptosis could be identified. In contrast the growth of HL-60 cells was unaffected by exposure to oligonucleotide. In each of the cell WT1 antisense oligonucleotide abrogated WT1 protein expression, and analysis of WT1 coding sequence in these cells showed that no oncogenic point mutations in the gene were present. We propose therefore that in some myeloid leukaemia cell lines, the expression of a normal WT1 protein is necessary for cell proliferation and that it plays a role in maintaining the viability of some leukaemia cells.	UNIV QUEENSLAND,ROYAL BRISBANE HOSP,DEPT PATHOL,HERSTON,QLD 4006,AUSTRALIA; ROYAL CHILDRENS HOSP,DEPT HAEMATOL & ONCOL,PARKVILLE,VIC 3052,AUSTRALIA	Royal Brisbane & Women's Hospital; University of Queensland; Royal Children's Hospital Melbourne	Algar, EM (corresponding author), UNIV QUEENSLAND,SCH MED,DEPT PATHOL,HERSTON RD,HERSTON,QLD 4006,AUSTRALIA.		Algar, Elizabeth/B-3770-2012; Khromykh, Tatiana/D-3952-2017	Khromykh, Tatiana/0000-0001-6629-6885				BAIRD PN, 1992, ONCOGENE, V7, P2141; CHANDLER D, 1994, HUM PATHOL, V25, P789, DOI 10.1016/0046-8177(94)90248-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HABER DA, 1992, CANCER SURV, V12, P105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOTEM J, 1991, BLOOD, V78, P953; LOTEM J, 1989, BLOOD, V74, P579; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIYAGI T, 1993, LEUKEMIA, V7, P970; MORRIS JF, 1991, ONCOGENE, V6, P2339; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1994, HUM MOL GENET, V3, P1633, DOI 10.1093/hmg/3.9.1633; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SEKIYA M, 1994, BLOOD, V83, P1876; SIMMS L, 1996, IN PRESS EUR J CANC; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WANG ZY, 1995, ONCOGENE, V10, P1243; YAM LT, 1971, AM J CLIN PATHOL, V55, P283	27	138	150	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1005	1014						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649791				2022-12-28	WOS:A1996UA88400008
J	Chen, CH; Nussenzweig, A; Guo, M; Kim, D; Li, GC; Ling, CC				Chen, CH; Nussenzweig, A; Guo, M; Kim, D; Li, GC; Ling, CC			Down-regulation of gadd153 by c-myc in rat fibroblasts and its effect on cell growth and radiation-induced apoptosis	ONCOGENE			English	Article						c-myc; gadd153; growth arrest; apoptosis	DNA-DAMAGING AGENTS; MESSENGER-RNA; DIFFERENTIAL DISPLAY; GENOTOXIC STRESS; EMBRYO CELLS; GENE; PROTEIN; ARREST; BCL-2; INDUCTION	Using differential display reverse transcription PCR (DDRT-PCR), we found that a 360 bp cDNA fragment was absent in several c-myc transfected rat fibroblasts: REC:myc, REC:myc + ras and rat1-myc. These cells also showed enhanced sensitivity to gamma ray-induced apoptosis. This cDNA fragment was present in the parental REC (Rat Embryo Cells) and rat1 cells, and in c-Ha-ras transfected REC (REC:ras), all of which were relatively resistant to gamma ray-induced apoptosis. The cDNA fragment was subsequently cloned and used as a probe to screen a rat1 cDNA library, and identified as one of the growth arrest and DNA damaging-inducible genes, gadd153. In addition to the down-regulation of rat gadd153 in all the c-myc transfectants, methyl methanesulfonate (MMS)-induced transcription of the gadd153 was attenuated. The rat1-myc cells, when successfully transfected with and stably expressing the rat gadd153, showed a significantly longer doubling time compared to the parental cells. However, overexpression of gadd153 in rat1-myc cells did not affect gamma ray-induced apoptosis. Thus, the suppression of gadd153 appears to be inversely correlated with that of myc, but not involved in the myc-dependent apoptotic pathway.	MEM SLOAN KETTERING CANC CTR, DEPT MED PHYS, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Chen, CH (corresponding author), MEM SLOAN KETTERING CANC CTR, LAB RADIAT BIOPHYS, 1275 YORK AVE, NEW YORK, NY 10021 USA.				NATIONAL CANCER INSTITUTE [R01CA052713] Funding Source: NIH RePORTER; NCI NIH HHS [CA52713] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ASKEW DS, 1991, ONCOGENE, V6, P1915; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CHEN CH, 1994, RADIAT RES, V139, P307, DOI 10.2307/3578828; CHOI AMK, 1992, EXP CELL RES, V199, P85, DOI 10.1016/0014-4827(92)90464-J; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ENDLICH B, 1992, RADIAT RES, V132, P301, DOI 10.2307/3578238; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FISHER TC, 1993, CANCER RES, V53, P3321; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GATELY DP, 1994, BRIT J CANCER, V70, P1102, DOI 10.1038/bjc.1994.455; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JACKMAN J, 1994, CANCER RES, V54, P5656; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; LAND H, 1983, NATURE, V297, P474; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LING CC, 1989, RADIAT RES, V120, P267, DOI 10.2307/3577713; LOKE SL, 1988, CURR TOP MICROBIOL, V141, P282; LORD KA, 1990, ONCOGENE, V5, P387; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1993, BLOOD, V81, P151; MIYASHITA T, 1992, CANCER RES, V52, P5407; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PRICE BD, 1992, CANCER RES, V52, P3814; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUN Y, 1994, CANCER RES, V54, P1139; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	48	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1659	1665						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895511				2022-12-28	WOS:A1996VM88700010
J	Feo, S; DiLiegro, C; Mangano, R; Read, M; Fried, M				Feo, S; DiLiegro, C; Mangano, R; Read, M; Fried, M			The amplicons in HL60 cells contain novel cellular sequences linked to MYC locus DNA	ONCOGENE			English	Article						HL60 amplified DNA; c-myc; chromosome band 8q24; homogenous staining regions; double minutes; FISH	HL-60 LEUKEMIA-CELLS; ONCOGENE C-MYC; GENE AMPLIFICATION; CHROMOSOMAL LOCATION; HUMAN NEUROBLASTOMA; BURKITT-LYMPHOMA; TUMOR-CELLS; CARCINOMA; TRANSLOCATION; EXPRESSION	We have previously determined that the amplified DNA present in the HL60 promyelocytic leukaemia cell line contained 70 kb of continuous DNA sequences around the c-myc gene, In the work presented here we have further defined the HL60 amplicon and find it to be of the order of 160 kb and to contain a large region of DNA from chromosome 8q24 that is located at Least 260 kb telomeric to the c-myc gene, joined to the 70 kb of DNA from the c-myc gene region, The novel chromosome 8 DNA coamplified sequences are not lost during multiple passage of HL60 cells since the composition of the chimeric amplicon is the same in both early passage HL60 cells containing only double minutes (DMs) and late passage isolates containing homogeneous staining regions (HSRs) at different chromosomal locations, This shows that the HL60 HSRs found in late passage cells are not generated anew but are directly derived from the precursor DMs. The HL60 cells contain tao copies of chromosome 8, each with different polymorphic markers, Both these chromosome 8 homologues retain a c-myc gene as sell as the region containing the coamplified DNA sequences indicating that the HL60 amplicons were not generated by simple DNA deletion, The constraint to maintain the novel DNA sequences coamplified with c-myc gene DNA suggests that these sequences may play some role in maintaining the growth potential and/or differentiation capacity of the HL60 cells.	IMPERIAL CANC RES FUND,EUKARYOT GENE ORG & EXPRESS LAB,LONDON WC2A 3PX,ENGLAND; DIPARTIMENTO BIOL CELLULARE & SVILUPPO,I-90128 PALERMO,ITALY; CNR,IST BIOL SVILUPPO,I-90123 PALERMO,ITALY	Cancer Research UK; Consiglio Nazionale delle Ricerche (CNR)			Feo, Salvatore/C-1333-2012	Feo, Salvatore/0000-0003-3877-2906; Di Liegro, Carlo Maria/0000-0001-7362-7814				ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BAR AI, 1992, GENE CHROMOSOME CANC, V4, P314; BOEHM T, 1989, EUR J BIOCHEM, V185, P1, DOI 10.1111/j.1432-1033.1989.tb15074.x; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; BRENNAN J, 1986, NUCLEIC ACIDS RES, V14, P9224, DOI 10.1093/nar/14.22.9224; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; CORVI R, 1995, ONCOGENE, V10, P1081; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; DONTI E, 1991, CANCER GENET CYTOGEN, V56, P57, DOI 10.1016/0165-4608(91)90362-X; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; FEO S, 1990, NUCLEIC ACIDS RES, V18, P4949, DOI 10.1093/nar/18.16.4949; FEO S, 1994, ONCOGENE, V9, P955; FEO S, 1986, P NATL ACAD SCI USA, V83, P706, DOI 10.1073/pnas.83.3.706; FRANCIS F, 1994, GENET ANAL-BIOMOL E, V11, P148, DOI 10.1016/1050-3862(94)90035-3; FUKUMOTO M, 1993, SOMAT CELL MOLEC GEN, V19, P21, DOI 10.1007/BF01233951; GALLAGHER R, 1979, BLOOD, V54, P713; GRAHAM M, 1986, EMBO J, V5, P2845, DOI 10.1002/j.1460-2075.1986.tb04578.x; GRAHAM SV, 1985, LEUKEMIA RES, V9, P239, DOI 10.1016/0145-2126(85)90086-4; HALUSKA FG, 1987, ANNU REV GENET, V21, P321, DOI 10.1146/annurev.ge.21.120187.001541; HEARD E, 1991, P NATL ACAD SCI USA, V88, P8242, DOI 10.1073/pnas.88.18.8242; LAFAGE M, 1992, GENE CHROMOSOME CANC, V5, P40, DOI 10.1002/gcc.2870050107; LEHRACH H., 1990, GENOME ANAL, P39; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NOWELL P, 1983, NATURE, V306, P494, DOI 10.1038/306494a0; POLYMEROPOULOS MH, 1992, HUM MOL GENET, V1, P65, DOI 10.1093/hmg/1.1.65; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SHTIVELMAN E, 1989, MOL CELL BIOL, V9, P1148, DOI 10.1128/MCB.9.3.1148; SHTIVELMAN E, 1989, P NATL ACAD SCI USA, V86, P3257, DOI 10.1073/pnas.86.9.3257; TYLERSMITH C, 1981, J MOL BIOL, V153, P237, DOI 10.1016/0022-2836(81)90276-X; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VONHOFF DD, 1990, J CLIN INVEST, V85, P1887, DOI 10.1172/JCI114650; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4038, DOI 10.1093/nar/18.13.4038; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P220; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659	39	8	8	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1521	1529						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875990				2022-12-28	WOS:A1996VL38400017
J	Rao, GN				Rao, GN			Hydrogen peroxide induces complex formation of SHC-Grb2-SOS with receptor tyrosine kinase and activates Ras and extracellular signal-regulated protein kinases group of mitogen-activated protein kinases	ONCOGENE			English	Article						oxidant; receptor tyrosine kinases; signal transduction; vascular smooth muscle cells	EPIDERMAL GROWTH-FACTOR; OXYGEN FREE-RADICALS; SMOOTH-MUSCLE CELLS; I RECEPTOR; C-JUN; PHOSPHORYLATION; SHC; TRANSDUCTION; INSULIN; MOUSE	Protein tyrosine phosphorylation events play determinant roles in cellular processes such as proliferation and differentiation. We have recently reported that hydrogen peroxide, an active oxygen species and a cellular oxidant, stimulates growth response events in vascular smooth muscle cells (VSMC). To understand the mechanisms by which oxidant stress modulates these growth response events, we have studied the effect of hydrogen peroxide on protein tyrosine phosphorylation events in VSMC. Our findings show that hydrogen peroxide stimulates tyrosine phosphorylation of several proteins including epidermal growth factor receptor (EGFR) in VSMC. Hydrogen peroxide-induced tyrosine phosphorylation of EGFR was found to be time dependent; with a threefold increase at 5 min and a 20-fold increase at 30 min of treatment as compared to control levels. Hydrogen peroxide treatment of VSMC also resulted in a time-dependent increase in tyrosine phosphorylation of SHC proteins. In addition, hydrogen peroxide-induced tyrosine-phosphorylated EGFR formed a complex with SHC-Grb2-SOS. These events were followed by activation of Pas and extracellular signal-regulated protein kinases (ERKs) group of mitogen-activated protein kinases (MAPKs). Together these findings demonstrate for the first time that hydrogen peroxide, a cellular oxidant, possess the ability to activate EGFR-mediated signaling events in VSMC. These EGFR-mediated signaling events may be important in oxidant stress-induced cellular responses			Rao, GN (corresponding author), UNIV TEXAS, MED BRANCH,DIV CARDIOL,9138 MED RES BLDG,RT 1064, 301 UNIV BLVD, GALVESTON, TX 77555 USA.							BASU T, 1994, ONCOGENE, V9, P3483; BAUSKIN AR, 1991, CELL, V66, P685, DOI 10.1016/0092-8674(91)90114-E; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COFFER PJ, 1995, ONCOGENE, V11, P561; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRAWFORD D, 1988, ONCOGENE, V3, P27; CRAWFORD DW, 1991, ATHEROSCLEROSIS, V89, P97, DOI 10.1016/0021-9150(91)90049-9; DONALDSON RW, 1992, P NATL ACAD SCI USA, V89, P8477, DOI 10.1073/pnas.89.18.8477; DUQUE I, 1993, J PHARMACOL EXP THER, V267, P612; FANTONE JC, 1982, AM J PATHOL, V107, P397; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; HECHT D, 1992, BIOCHEM BIOPH RES CO, V188, P773, DOI 10.1016/0006-291X(92)91123-8; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JANSSEN YMW, 1993, LAB INVEST, V69, P261; JOLLY SR, 1984, CIRC RES, V54, P277, DOI 10.1161/01.RES.54.3.277; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAKI A, 1992, FASEB J, V6, P919, DOI 10.1096/fasebj.6.3.1740241; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MILLER CC, 1994, J BIOL CHEM, V269, P3529; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; OLIVER CN, 1987, ARCH BIOCHEM BIOPHYS, V253, P62, DOI 10.1016/0003-9861(87)90637-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PETERSON JE, 1994, J BIOL CHEM, V269, P27315; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; QIN SF, 1995, BIOCHEM J, V308, P347, DOI 10.1042/bj3080347; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHIBANUMA M, 1990, ONCOGENE, V5, P1025; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; XIE YM, 1995, ONCOGENE, V10, P2409; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	201	212	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					713	719						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761292				2022-12-28	WOS:A1996VD43300006
J	Wahlstrom, GM; Harbers, M; Vennstrom, B				Wahlstrom, GM; Harbers, M; Vennstrom, B			The oncoprotein P75(gag-v-erbA) represses thyroid hormone induced transcription only via response elements containing palindromic half-sites	ONCOGENE			English	Article						v-erbA; homodimers; repression; transcription factor; response elements	AVIAN ERYTHROBLASTOSIS VIRUS; RETINOIC ACID RECEPTORS; DOMINANT NEGATIVE ACTIVITY; V-ERBA; C-ERBA; CELL-TRANSFORMATION; AUXILIARY PROTEINS; LIGAND-BINDING; DOMAIN; GENE	The v-erbA oncoprotein p75(gag-v-erbA), derived from the thyroid hormone receptor alpha (TR alpha), functions as transdominant transcriptional repressor, The mechanism by which P75(gag-v-erbA) acts is however poorly characterized. Here, we show that repression of TR alpha mediated transcription by P75(gag-v-erbA) in transformed erythroblasts is dependent on the structure of the thyroid hormone response element to which it binds. A very efficient repression was seen with hormone response elements having half-sites organized as everted repeats (ER), whereas repression was inefficient with directly repeated half-sites (DR), Promoters containing half-sites organized as an inverted palindrome (IR) gave an intermediate repression, Although P75(gag-v-erbA) failed to associate with the ligand binding domain of retinoid X (RXR) receptor in a two-hybrid test, the oncoprotein in nuclear extracts from transformed cells heterodimerised quantitatively with RXR upon binding to response elements of the DR type, On the other hand, both RXR/P75(gag-v-erb) heterodimers and other types of dimers formed on ER elements, P75(gag-v-erbA) also failed to bind to elements that contained only one half-site in vivo and in vitro, The data demonstrate that P75(gag-v-erbA) represses gene expression efficiently as a dimer, and suggest that thyroid hormone responsive genes that may be targets for the action of the oncoprotein are repressed most efficiently if they contain elements of the ER type.	KAROLINSKA INST,DEV BIOL LAB,DEPT CELLULAR & MOL BIOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet				Harbers, Matthias/0000-0002-5613-7220				AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P2725; BANIAHMAD A, 1987, EMBO J, V6, P2297, DOI 10.1002/j.1460-2075.1987.tb02504.x; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BEUG H, 1986, J VIROL, V57, P1127, DOI 10.1128/JVI.57.3.1127-1138.1986; BEUG H, 1994, CURR OPIN CELL BIOL, V6, P816, DOI 10.1016/0955-0674(94)90050-7; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CARLBERG C, 1993, BIOCHEM BIOPH RES CO, V195, P1345, DOI 10.1006/bbrc.1993.2191; CASANOVA J, 1994, MOL CELL BIOL, V14, P5756, DOI 10.1128/MCB.14.9.5756; CHEN DJ, 1995, NATURE, V377, P454; CHEN HW, 1993, MOL CELL BIOL, V13, P2366, DOI 10.1128/MCB.13.4.2366; CHEN HW, 1993, MOL CELL BIOL, V13, P5970, DOI 10.1128/MCB.13.10.5970; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; DAMM K, 1987, EMBO J, V6, P375, DOI 10.1002/j.1460-2075.1987.tb04765.x; DAMM K, 1993, P NATL ACAD SCI USA, V90, P10668, DOI 10.1073/pnas.90.22.10668; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DESBOIS C, 1991, ONCOGENE, V6, P2129; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1989, MOL ENDOCRINOL, V3, P1610, DOI 10.1210/mend-3-10-1610; FORREST D, 1990, ONCOGENE, V5, P309; FUERSTENBERG S, 1992, EMBO J, V11, P3355, DOI 10.1002/j.1460-2075.1992.tb05414.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HARBERS H, 1996, NUCLEIC ACIDS RES, V24, P12; HARDING HP, 1993, MOL CELL BIOL, V13, P3113, DOI 10.1128/MCB.13.5.3113; HARDING HP, 1995, MOL CELL BIOL, V15, P4791; HERMANN T, 1993, ONCOGENE, V8, P55; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JOHNSTON RF, 1990, ELECTROPHORESIS, V11, P355, DOI 10.1002/elps.1150110503; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; NELSON CC, 1994, MOL ENDOCRINOL, V8, P829, DOI 10.1210/me.8.7.829; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; RAISHER BD, 1992, J BIOL CHEM, V267, P20264; RASCLE A, 1994, ONCOGENE, V9, P2853; RENKAWITZ R, 1990, TRENDS GENET, V6, P192, DOI 10.1016/0168-9525(90)90176-7; RUIZ MDMV, 1991, EMBO J, V10, P3829, DOI 10.1002/j.1460-2075.1991.tb04952.x; SAATCIOGLU F, 1994, SEMIN CANCER BIOL, V5, P347; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SCHROEDER C, 1992, ONCOGENE, V7, P203; SCHROEDER C, 1990, ONCOGENE, V5, P1445; SCHROEDER C, 1992, ONCOGENE, V7, P217; SELMI S, 1991, J BIOL CHEM, V266, P11589; SHARIF M, 1992, ONCOGENE, V7, P953; SUGAWARA A, 1993, ENDOCRINOLOGY, V133, P965, DOI 10.1210/en.133.3.965; TRAINOR CD, 1995, MOL ENDOCRINOL, V9, P1135, DOI 10.1210/me.9.9.1135; WAHLSTROM GM, 1992, MOL ENDOCRINOL, V6, P1013, DOI 10.1210/me.6.7.1013; ZENKE M, 1988, CELL, V52, P107, DOI 10.1016/0092-8674(88)90535-1; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	60	10	10	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					843	852						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761306				2022-12-28	WOS:A1996VD43300020
J	Sonoda, H; Nishida, K; Yoshioka, T; Ohtani, M; Sugita, K				Sonoda, H; Nishida, K; Yoshioka, T; Ohtani, M; Sugita, K			Oxamflatin: A novel compound which reverses malignant phenotype to normal one via induction of JunD	ONCOGENE			English	Article						transformation; inhibitor; ras; junD; fibronectin	RAS-ONCOGENE; NIH3T3 CELLS; TRANSFORMATION; GENE; EXPRESSION; CANCER; DNA	In the course of screening for inhibitors of tumorigenic phenotype of K-ras-transformed NIH3T3 cells (DT cells), we found a novel compound, oxamflatin, an aromatic sulfonamide hydroxamate derivative, which induces flat phenotype in these cells and suppresses their anchorage-independent growth. In contrast to DT cells, in v-raf-transformed NIH3T3 cells, no change in their morphology and no specific inhibition of their anchorage-independent growth was observed, Interestingly, oxamflatin was effective to NIH3T3 cells transformed by constitutively activated mutant of MEK, indicating the possibility that oncogene-induced morphological change is not necessarily induced by common signaling pathway such as MAP kinase cascade, In oxamflatin-treated DT cells, the expression of transcription factor junD was highly augmented, resulting in trans-activation of fibronectin gene by junD via cyclic AMP responsive element in its promoter, This behavior of junD was confirmed to correlate well with partial blocking of malignant phenotype in DT cells, Thus, oxamflatin can be categorized as the first reagent which induces genes whose products can interfere with oncogene-dependent transformation.			Sonoda, H (corresponding author), SHIONOGI & CO LTD, SHIONOGI RES LABS, FUKUSHIMA KU, SAGISU 5-12-4, OSAKA 553, JAPAN.							ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BOS JL, 1989, CANCER RES, V49, P4682; CASINI A, 1994, ALCOHOL ALCOHOLISM, V29, P303; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COX AD, 1994, J BIOL CHEM, V269, P19203; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FUJITA T, 1986, CELL, V46, P401, DOI 10.1016/0092-8674(86)90660-4; FUTAMURA M, 1995, ONCOGENE, V10, P1119; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HYNES RO, 1990, FIBRONECTINS, pCH12; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KIM JH, 1994, J BIOL CHEM, V269, P13740; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KREISBERG JI, 1994, KIDNEY INT, V46, P105, DOI 10.1038/ki.1994.249; KUO ML, 1995, BIOCHEM BIOPH RES CO, V212, P767, DOI 10.1006/bbrc.1995.2035; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MURRAY MJ, 1981, CELL, V25, P355, DOI 10.1016/0092-8674(81)90054-4; NAKAJIMA T, 1992, MOL CELL BIOL, V12, P2837, DOI 10.1128/MCB.12.6.2837; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OHTANI M, 1993, Patent No. 9312075; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SREBROW A, 1993, FEBS LETT, V327, P25, DOI 10.1016/0014-5793(93)81031-T; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; SUGITA K, 1992, CANCER RES, V52, P168; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; YOSHIDA H, 1992, JPN J CANCER RES, V83, P324, DOI 10.1111/j.1349-7006.1992.tb00109.x; ZHAO JF, 1995, ONCOGENE, V11, P161	35	40	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					143	149						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700540				2022-12-28	WOS:A1996UX31900016
J	Sjoblom, T; Lahdetie, J				Sjoblom, T; Lahdetie, J			Expression of p53 in normal and gamma-irradiated rat testis suggests a role for p53 in meiotic recombination and repair	ONCOGENE			English	Article						p53; testis; spermatocytes; meiosis; rat; gamma-irradiation	TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGING AGENTS; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; GERM-CELLS; X-RAYS; MOUSE; SPERMATOGENESIS; SPERMATOCYTES; CHROMOSOMES	In testis, the expression of tumor suppressor protein p53 is stronger than in other tissues suggesting a role for it in spermatogenesis. We have studied the expression of p53 in both unirradiated and gamma-irradiated rat testis using the stage-specific model of rat seminiferous epithelium, Our results show that p53 is expressed during meiosis in normal rat spermatogenesis and its expression is localized to the preleptotene-early pachytene spermatocytes. The most prominent expression is in zygotene - early pachytene spermatocytes (stages XIII-I of seminiferous epithelium). After irradiation p53 levels increased in a time and a dose-dependent manner being highest with the doses of 6.0 and 12.0 Gy and 4 h after irradiation, This increase occurs in the same cells that normally express elevated levels of p53. These results support the view that p53 is involved in meiosis of the male rat and we suggest that p53 has a role in recombinational processes and/or formation of the synaptonemal complex. We also demonstrate that p53 takes part in the response of primary spermatocytes to gamma-irradiation induced DNA damage.	UNIV TURKU,CTR REPROD & DEV MED,FIN-20520 TURKU,FINLAND	University of Turku	Sjoblom, T (corresponding author), UNIV TURKU,DEPT MED GENET,KIINAMYLLYNKATU 10,FIN-20520 TURKU,FINLAND.							ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; BACKER LC, 1991, RADIAT RES, V125, P187, DOI 10.2307/3577887; BAE IS, 1995, CANCER RES, V55, P2387; BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; COOGAN TP, 1988, MUTAT RES, V194, P183, DOI 10.1016/0167-8817(88)90020-X; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HAN KA, 1992, NUCLEIC ACIDS RES, V20, P1979, DOI 10.1093/nar/20.8.1979; HARPER JW, 1993, CELL, V75, P805; JONES DJ, 1995, TRENDS GENET, V11, P165; KASTAN MB, 1991, CANCER RES, V51, P6304; KIERSZENBAUM AL, 1994, ENDOCR REV, V15, P116, DOI 10.1210/er.15.1.116; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; PARVINEN M, 1993, METHODS TOXICOLOGY A, V3, P142; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RASMUSSEN SW, 1978, CARLSBERG RES COMMUN, V43, P275, DOI 10.1007/BF02906106; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHMID P, 1991, DEVELOPMENT, V113, P857; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SJOBLOM T, 1995, MUTAT RES-FUND MOL M, V331, P181, DOI 10.1016/0027-5107(95)00067-S; SMITH ML, 1995, ONCOGENE, V10, P1053; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; TATES AD, 1983, MUTAT RES, V121, P131, DOI 10.1016/0165-7992(83)90111-2; TISHLER RB, 1993, CANCER RES, V53, P2212; VANDERMEER Y, 1992, RADIAT RES, V130, P296, DOI 10.2307/3578374; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x; ZHAN QM, 1994, ONCOGENE, V9, P3743	56	70	73	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2499	2505						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700508				2022-12-28	WOS:A1996UW48700003
J	Velasco, JA; Zimonjic, DB; Popescu, NC; Cansado, J; DiPaolo, JA; Albor, A; Notario, V				Velasco, JA; Zimonjic, DB; Popescu, NC; Cansado, J; DiPaolo, JA; Albor, A; Notario, V			Tissue-specific expression, evolutionary conservation and localization of the cph proto-oncogene on Syrian hamster chromosome X	ONCOGENE			English	Article						cph oncogene; evolution; FISH; gene expression; gene mapping; Syrian hamster	BANDING PATTERNS; GENES; SEQUENCES; CELLS	Treatment of Syrian hamster embryo fibroblasts with a single dose of 3-methylcholanthrene caused the activation of the transforming potential of cellular sequences (Notario et al,, Oncogene 5: 1425-1430, 1990), which were subsequently isolated by cosmid rescue techniques, and further identified as a novel oncogene, termed cph because of its involvement in the carcinogenic progression of hamster embryo cells (Velasco ed al., Oncogene 9: 2065-2069, 1994), We have analysed the expression of the cph proto-oncogene in adult Syrian hamster tissues by northern hybridization using cph-specific genomic probes, The three cph transcripts expressed in normal and neoplastic Syrian hamster embryo cells in culture (5.0, 3.5 and 2.0 kb) were also present in most adult tissues, although different mRNA species, most likely resulting from alternative splicing events, were expressed in testes, The highest steady-state level of cph mRNA was found in kidney, whereas cph expression was nearly undetectable in skin and skeletal muscle, Southern blot analyses of DNAs from other eucaryotic organisms were performed under moderate stringency conditions with a Syrian hamster-specific cph probe, Discrete cpk-hybridizing sequences were present in genomes from yeast to mammalian species, including humans, thus demonstrating that cph is a highly conserved gene in eucaryotic evolution, Using fluorescence in situ hybridization (FISH), we have determined also the chromosomal Idealization of the cph proto-oncogene in the hamster genome, FISH experiments demonstrated that cph is a single copy gene, localized on the euchromatic short arm of the X chromosome, at region Xpa7, Because chromosome X is frequently involved in structural alterations in neoplastic Syrian hamster cells transformed by chemical carcinogens and oncogenic viruses, the localization of the cph locus on this chromosome supports the notion that the cph oncogene plays a role in the malignant conversion of chemically transformed hamster fibroblasts, The wide range of tissue-specific expression and species-specific distribution of cph strongly suggest that the normal function of the cph protein product(s) may be essential for metabolic processes involved in the regulation of cell proliferation and survival.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007; NCI,BIOL LAB,NIH,BETHESDA,MD	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			/AFP-0764-2022; Cansado, Jose/ABC-6872-2020; /AAB-6461-2022; Cansado, Jose/K-5212-2014; Zimonjic, Drazen/AAX-7513-2020	Cansado, Jose/0000-0002-2342-8152; 	NCI NIH HHS [CA64472] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064472] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBOR A, 1994, CANCER RES, V54, P4502; AVILA MA, 1995, ONCOGENE, V10, P963; AVILA MA, 1994, YEAST, V10, P1003, DOI 10.1002/yea.320100803; BARRETT JC, 1984, PHARMACOL REV, V36, P535; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DiPaolo J A, 1979, Prog Exp Tumor Res, V24, P2; DIPAOLO JA, 1973, CANCER RES, V33, P3250; HAMEISTER H, 1986, HUM GENET, V72, P242; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P3934, DOI 10.1073/pnas.83.11.3934; LI S, 1982, CYTOGENET CELL GENET, V33, P295, DOI 10.1159/000131775; MIYOSHI J, 1984, NUCLEIC ACIDS RES, V12, P1821, DOI 10.1093/nar/12.4.1821; MORTON CC, 1989, GENOMICS, V4, P367, DOI 10.1016/0888-7543(89)90344-3; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; NOTARIO V, 1990, ONCOGENE, V5, P1425; OBRIEN SJ, 1983, NATURE, V302, P839, DOI 10.1038/302839a0; OSHIMURA M, 1985, NATURE, V316, P636, DOI 10.1038/316636a0; PATHAK S, 1974, GENETICS, V78, P703; PATHAK S, 1981, GENES CHROMOSOMES NE, P405; POPESCU NC, 1980, CYTOGENET CELL GENET, V28, P10, DOI 10.1159/000131507; POPESCU NC, 1988, CANCER RES, V48, P7246; POPESCU NC, 1995, CYTOGENET CELL GENET, V68, P71, DOI 10.1159/000133893; POPESCU NC, 1989, ONCOGENE, V4, P517; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SATOH H, 1994, CYTOGENET CELL GENET, V65, P127, DOI 10.1159/000133617; TARUSCIO D, 1991, CHROMOSOMA, V101, P141, DOI 10.1007/BF00355364; TRONICK SR, 1989, GENOMICS, V5, P546, DOI 10.1016/0888-7543(89)90022-0; VELASCO JA, 1993, GENE, V137, P179, DOI 10.1016/0378-1119(93)90004-M; VELASCO JA, 1994, ONCOGENE, V9, P2065; VELASCO JA, 1995, ONCOGENE, V10, P2253; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	31	17	17	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2713	2717						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700531				2022-12-28	WOS:A1996UW48700026
J	Kees, UR; Ranford, PR; Hatzis, M				Kees, UR; Ranford, PR; Hatzis, M			Deletions of the p16 gene in pediatric leukemia and corresponding cell lines	ONCOGENE			English	Article						p16; pediatric leukemia; cell lines	LYMPHOBLASTIC-LEUKEMIA; SHORT ARM; ESTABLISHMENT; ABNORMALITIES; CHROMOSOME-9; PHENOTYPE; RECEPTOR	The p16 gene (MTS1 or CDK41) encoding an inhibitor of cyclin-dependent kinase 4 (cdk4), has been reported to be deleted in various tumor cell lines, including lines derived from leukemic cells, The reported frequency of p16 gene Toss Is much higher in established cell lines than in primary tumor specimens, We investigated the status of the p16 gene in pediatric leukemias using 12 established cell lines of differing phenotypes and their corresponding primary leukemic cells, Six: of 12 cell lines, including acute lymphoblastic leukemia (ALL) lines of T-cell (three of four), of precursor-B cell (two of four) and of mixed phenotype (one of four), showed homozygous deletion of the p16 gene using PCR and Southern blotting, Comparison of the cell lines with their corresponding primary leukemic cells clearly showed that in all 12 paired samples there were identical findings with respect to the presence or absence of the p16 gene, demonstrating that loss of the gene was a feature of the primary leukemic cells, This is the first study to show this correlation using a panel of paired samples, indicating that p16 gene deletions were not an artifact of in vitro cell culture, Furthermore, the survival of ALL patients with p16 gene deletions was significantly inferior to those without deletions, suggesting that this genetic alteration may be a clinical prognostic factor.	TVWT,INST CHILD HLTH RES,DIV CHILDRENS LEUKAEMIA & CANC RES,PERTH,WA,AUSTRALIA	Telethon Kids Institute; University of Western Australia								CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAYUELA JM, 1995, BLOOD, V85, P854, DOI 10.1182/blood.V85.3.854a.bloodjournal853854a; DURO D, 1994, CR ACAD SCI III-VIE, V317, P913; FIZZOTTI M, 1995, BLOOD, V85, P2685, DOI 10.1182/blood.V85.10.2685.bloodjournal85102685; GONZALEZREDONDO JM, 1988, BLOOD, V72, P1007; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEES UR, 1990, LEUKEMIA, V4, P292; KEES UR, 1988, BLOOD, V72, P1524; KEES UR, 1990, CANCER GENET CYTOGEN, V46, P201, DOI 10.1016/0165-4608(90)90105-J; KEES UR, 1989, BLOOD, V74, P369; KEES UR, 1995, GENE CHROMOSOME CANC, V12, P201, DOI 10.1002/gcc.2870120307; KEES UR, 1987, LEUKEMIA RES, V11, P489, DOI 10.1016/0145-2126(87)90082-8; KEES UR, 1987, CANCER RES, V47, P3088; KEES UR, 1993, LEUKEMIA RES, V17, P51, DOI 10.1016/0145-2126(93)90141-7; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OGAWA S, 1995, BLOOD, V86, P1548, DOI 10.1182/blood.V86.4.1548.bloodjournal8641548; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OTSUKI T, 1995, CANCER RES, V55, P1436; POLLAK C, 1987, LEUKEMIA, V1, P541; QUESNEL B, 1995, BLOOD, V85, P657, DOI 10.1182/blood.V85.3.657.bloodjournal853657; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; ZHANG SY, 1994, CANCER RES, V54, P5050	28	18	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2235	2239						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668350				2022-12-28	WOS:A1996UP28300023
J	Larsen, CJ				Larsen, CJ			p16(INK4a): A gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression	ONCOGENE			English	Review						CDK inhibitors; cell cycle; oncogenesis; methylation; mRNA splicing					Larsen, CJ (corresponding author), INSERM U301,INST MOLEC GENET,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.							BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; Cayuela JM, 1996, BLOOD, V87, P2180, DOI 10.1182/blood.V87.6.2180.bloodjournal8762180; COLEMAN A, 1994, CANCER RES, V54, P344; CORDONCARDO C, 1995, AM J PATHOL, V147, P545; DURO D, 1994, CR ACAD SCI III-VIE, V317, P913; DURO D, 1995, ONCOGENE, V11, P21; DURO D, 1996, IN PRESS CANC RES; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MAO L, 1995, CANCER RES, V55, P2995; MERLO A, 1995, NAT MED, V1, P692; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; OLOPADE OI, 1992, GENOMICS, V14, P437, DOI 10.1016/S0888-7543(05)80238-1; OTTERSON GA, 1995, ONCOGENE, V11, P1211; QUELLE DE, 1995, CELL, V83, P993; QUESNEL B, 1995, BLOOD, V85, P657, DOI 10.1182/blood.V85.3.657.bloodjournal853657; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STONE S, 1995, CANCER RES, V55, P2988; STRANKS G, 1995, BLOOD, V85, P893, DOI 10.1182/blood.V85.4.893.bloodjournal854893; TAKEUCHI S, 1995, BLOOD, V86, P755, DOI 10.1182/blood.V86.2.755.bloodjournal862755	37	44	47	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2041	2044						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668328				2022-12-28	WOS:A1996UP28300001
J	Nguyen, HQ; Danilenko, DM; Bucay, N; DeRose, ML; Van, GY; Thomason, A; Simonet, WS				Nguyen, HQ; Danilenko, DM; Bucay, N; DeRose, ML; Van, GY; Thomason, A; Simonet, WS			Expression of keratinocyte growth factor in embryonic liver of transgenic mice causes changes in epithelial growth and differentiation resulting in polycystic kidneys and other organ malformations	ONCOGENE			English	Article						keratinocyte growth factor; transgenic mice; mesenchymal-epithelial interactions; polycystic kidney	FETAL-RAT LUNG; MESENCHYMAL INTERACTIONS; CELLS; RECEPTOR; ORGANOGENESIS; AUTOCRINE; PATHWAYS; GENES; KGF	Expression of human keratinocyte growth factor (KGF/FGF-7) was directed to hepatocytes during the later period of mouse gestation using a human apolipoprotein E (ApoE) gene promoter and its associated liver-specific enhancer, Human KGF was detectable in liver extracts and serum prepared from e(17.5)-e(19.5) embryos, concomitant with the appearance of morphological abnormalities in several organs which express KGF receptor, The most striking phenotypic aberration in the ApoE-hKGF transgenic embryos was marked hyperplasia and cystic dilation of the cortical and medullary kidney collecting duct system, a phenotype resembling infantile polycystic kidney disease in humans, Transgenic embryos had enlarged livers, with prominent biliary epithelial hyperplasia, and also exhibited enhanced bronchiolar epithelial and type II pneumocyte proliferation, There was variable hyperplasia of intestinal epithelia, and urothelium of the urinary bladder and ureters, When compared to age-matched littermate controls, marked epidermal papillomatous acanthosis and hyperkeratosis in the skin, with a notable decrease in the slumber of developing hair follicles was seen in transgenic embryos, The pancreas exhibited significant ductal hyperplasia, with an increase in the number of ductal epithelial cells staining positive for insulin expression, High systemic levels of KGF during the latter stages of embryogenesis causes abnormalities in epithelial growth and differentiation within multiple organ systems and results in perinatal lethality, Correct temporal and spatial expression of KGF during the latter stages of organ development is likely to play a critical role in mesenchymal-epithelial signaling required for normal embryonic growth and development.	AMGEN INC, AMGEN CTR, DEPT DEV BIOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, AMGEN CTR, DEPT EXPTL PATHOL, THOUSAND OAKS, CA 91320 USA; AMGEN INC, AMGEN CTR, DEPT BIOL MOLEC, THOUSAND OAKS, CA 91320 USA	Amgen; Amgen; Amgen				Danilenko, Dimitry/0000-0002-8326-1921; De Rose, Margaret/0000-0001-9481-7334				AARONSON SA, 1989, ANN NY ACAD SCI, V567, P122, DOI 10.1111/j.1749-6632.1989.tb16464.x; AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; AARONSON SA, 1990, AM REV RESPIR DIS, V142, pS7, DOI 10.1164/ajrccm/142.6_Pt_2.S7; ADAMSON IYR, 1986, LAB INVEST, V55, P145; ADAMSON IYR, 1984, LAB INVEST, V50, P461; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; BRODY AR, 1981, EXP LUNG RES, V2, P207, DOI 10.3109/01902148109052316; BRODY AR, 1976, VIRCHOWS ARCH A, V372, P39, DOI 10.1007/BF00429715; CHUNG LWK, 1991, CANCER SURV, V11, P91; DANILENKO DM, 1995, AM J PATHOL, V147, P145; FINCH PW, 1995, DEV DYNAM, V203, P223, DOI 10.1002/aja.1002030210; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; GUO LF, 1993, EMBO J, V12, P973, DOI 10.1002/j.1460-2075.1993.tb05738.x; HOUSLEY RM, 1994, J CLIN INVEST, V94, P1764, DOI 10.1172/JCI117524; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; PANOS RJ, 1993, J CLIN INVEST, V92, P969, DOI 10.1172/JCI116673; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; PETERS KG, 1992, DEVELOPMENT, V114, P233; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; SAXEN L, 1987, PEDIATR NEPHROL, V1, P385, DOI 10.1007/BF00849241; SHOJI S, 1990, AM REV RESPIR DIS, V141, P433, DOI 10.1164/ajrccm/141.2.433; Simonet WS, 1995, P NATL ACAD SCI USA, V92, P12461, DOI 10.1073/pnas.92.26.12461; SIMONET WS, 1994, J CLIN INVEST, V94, P1310, DOI 10.1172/JCI117450; SIMONET WS, 1993, J BIOL CHEM, V268, P8221; SPARGO BH, 1988, PATHOLOGY, P839; STILES AD, 1986, EXP LUNG RES, V11, P165, DOI 10.3109/01902148609064294; THESLEFF I, 1991, J CRAN GENET DEV BIO, V11, P229; ULICH TR, 1994, J CLIN INVEST, V93, P1298, DOI 10.1172/JCI117086; URTREGER AO, 1991, DEVELOPMENT, V113, P1419; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; YI ES, 1994, AM J PATHOL, V145, P80; YI ES, 1994, AM J PATHOL, V145, P1015; YI ES, 1995, IN PRESS J UROLOGY	36	70	80	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2109	2119						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668336				2022-12-28	WOS:A1996UP28300009
J	Wertheim, I; Tangir, J; Muto, MG; Welch, WR; Berkowitz, RS; Chen, WY; Mok, SC				Wertheim, I; Tangir, J; Muto, MG; Welch, WR; Berkowitz, RS; Chen, WY; Mok, SC			Loss of heterozygosity of chromosome 17 in human borderline and invasive epithelial ovarian tumors	ONCOGENE			English	Article						ovary; borderline; loss of heterozygosity; microsatellite instability	GENE-MUTATIONS; FREQUENT LOSS; CANCER LOCUS; P53 GENE; MALIGNANCY; DELETION	Polymerase chain reaction (PCR) analysis of microsatellite polymorphisms corresponding to four loci which map to chromosome 17p and 11 loci which map to chromosome 17q was performed to screen for loss of heterozygosity (LOH) in paired normal and tumor tissues from 27 cases of borderline epithelial ovarian tumors (BEOT) and 32 cases of invasive epithelial ovarian cancers (IOC), LOH was observed in six of 27 (22%) of the borderline tumors and in 29 of 32 (90%) of the invasive ovarian cancers (P<0.001), At all 15 loci studied, a lower percentage of allelic loss was detected in borderline tumors (0-14%) vs invasive cancer (8-93%), At eight loci this difference was statistically significant, For IOC, one common loss region was identified on chromosome 17p and four distinct common loss regions were on chromosome 17q, which supports the notion that multiple tumor suppressors may reside on chromosome 17 in IOC. These data suggest that LOH on chromosome 17 is an infrequent event in BEOT compared with IOC and therefore may not be important in the distinct pathogenesis of BEOT.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GYNECOL ONCOL,LAB GYNECOL ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV WOMENS & PERINATAL PATHOL,BOSTON,MA 02115; CHINESE UNIV HONG KONG,DEPT ANAT,SHATIN,HONG KONG	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Chinese University of Hong Kong			Chan, Wood Yee/R-6692-2018	Chan, Wood Yee/0000-0002-7114-1463	NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERCHUCK A, 1994, GYNECOL ONCOL, V52, P232, DOI 10.1006/gyno.1994.1037; CROPP CS, 1994, CANCER RES, V54, P2548; ECCLES DM, 1992, ONCOGENE, V7, P2069; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GODWIN AK, 1994, AM J HUM GENET, V55, P666; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; International Federation of Gynecology and Obstetrics (FIGO), 1987, AM J OBSTET GYNECOL, V56, P263; JACOBS IJ, 1993, CANCER RES, V53, P1218; KAERN J, 1993, CANCER, V71, P1810, DOI 10.1002/1097-0142(19930301)71:5<1810::AID-CNCR2820710516>3.0.CO;2-V; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LEE JH, 1990, CANCER RES, V50, P2724; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MARKS JR, 1991, CANCER RES, V51, P2979; MOK CH, 1992, CANCER RES, V52, P5119; Mok S. C., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P571; MOK SCH, 1993, CANCER RES, V53, P1489; NAROD SA, 1991, LANCET, V338, P82; PIERETTI M, 1995, HUM PATHOL, V26, P393, DOI 10.1016/0046-8177(95)90139-6; RICE LW, 1990, GYNECOL ONCOL, V39, P195, DOI 10.1016/0090-8258(90)90431-J; RUSSELL SEH, 1990, ONCOGENE, V5, P1581; Sambrook J., 2002, MOL CLONING LAB MANU; SATO T, 1991, CANCER RES, V51, P5118; Serov S., 1973, INT HISTOLOGICAL CLA, V9; TANGIR J, 1996, IN PRESS ONCOGENE; TENERIELLO MG, 1993, CANCER RES, V53, P3103; TSAO SW, 1991, ANTICANCER RES, V11, P1975; WEITZEL JN, 1994, GYNECOL ONCOL, V55, P245, DOI 10.1006/gyno.1994.1285; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549	30	48	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2147	2153						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668340				2022-12-28	WOS:A1996UP28300013
J	Quignon, F; Renard, CA; Tiollais, P; Buendia, MA; Transy, C				Quignon, F; Renard, CA; Tiollais, P; Buendia, MA; Transy, C			A functional N-myc2 retroposon in ground squirrels: Implications for hepadnavirus-associated carcinogenesis	ONCOGENE			English	Article						N-myc; hepadnavirus; carcinogenesis; viral determinants; host determinants	HEPATITIS-B VIRUS; WOODCHUCK LIVER-TUMORS; FOCUS-FORMING VIRUSES; HEPATOCELLULAR-CARCINOMA; C-MYC; ACTIVATION; GENE; EXPRESSION; INFECTION; REGION	Three hepatitis B viruses infecting humans, woodchucks and ground squirrels increase the risk of hepatocellular carcinoma in their respective hosts. The woodchuck hepatitis B virus (WHV), unlike the two other viruses, induces a rapid carcinogenic process characterized by direct activation of myc proto-oncogenes by insertion of viral DNA. The highly preferred target of insertional mutagenesis in woodchucks is N-myc2, an intronless N-myc gene. Strikingly, N-myc2 has no human homolog and the homologous N-myc2 locus previously detected in the ground squirrel genome, remains silent during hepatocarcinogenesis. Therefore, N-myc2 may represent a critical host determinant in the evolution of the disease associated with hepadnavirus infection. To address this question, we performed a structural and functional analysis of the ground squirrel N-myc2 locus. We show that ground squirrel N-myc2 is highly homologous to its woodchuck counterpart and is a functional protooncogene, Existence of a functional N-myc2 gene as a potential target for insertional activation by viral DNA is therefore not restricted to the woodchuck species. This suggests that viral rather than host factors determine the higher oncogenic phenotype of WHV as compared to the two other mammalian hepadnaviruses.	INST PASTEUR,INSERM,UNITE RECOMBINAISON & EXPRESS GENET,U163,F-75724 PARIS 15,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Quignon, Frédérique/P-4249-2017					ATHAS GB, 1994, CRIT REV ONCOGENESIS, V5, P169, DOI 10.1615/CritRevOncog.v5.i2-3.40; BEASLEY RP, 1981, LANCET, V2, P1129; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; DAVIS BR, 1987, P NATL ACAD SCI USA, V84, P4875, DOI 10.1073/pnas.84.14.4875; FOUREL G, 1994, EMBO J, V13, P2526, DOI 10.1002/j.1460-2075.1994.tb06542.x; FOUREL G, 1992, MOL CELL BIOL, V12, P5336, DOI 10.1128/MCB.12.12.5336; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; FOUREL G, 1990, NUCLEIC ACIDS RES, V18, P4918, DOI 10.1093/nar/18.16.4918; HAGIWARA T, 1992, EUR J BIOCHEM, V209, P945, DOI 10.1111/j.1432-1033.1992.tb17367.x; HANSEN LJ, 1993, MOL CELL BIOL, V13, P659, DOI 10.1128/MCB.13.1.659; HOLLAND CA, 1989, J VIROL, V63, P1284, DOI 10.1128/JVI.63.3.1284-1292.1989; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; LAUER U, 1992, J VIROL, V66, P5284, DOI 10.1128/JVI.66.9.5284-5289.1992; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MORRISON HL, 1995, J VIROL, V69, P446, DOI 10.1128/JVI.69.1.446-455.1995; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SEEGER C, 1991, J VIROL, V65, P1673, DOI 10.1128/JVI.65.4.1673-1679.1991; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; TRANSY C, 1994, J VIROL, V68, P5291, DOI 10.1128/JVI.68.8.5291-5295.1994; TSICHLIS PN, 1991, P NATL ACAD SCI USA, V88, P4611, DOI 10.1073/pnas.88.11.4611; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WEI Y, 1992, J VIROL, V66, P5265, DOI 10.1128/JVI.66.9.5265-5276.1992	28	3	5	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					2011	2017						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649862				2022-12-28	WOS:A1996UK49800020
J	Shridhar, V; Rivard, S; Shridhar, R; Mullins, C; Bostick, L; Sakr, W; Grignon, D; Miller, OJ; Smith, DI				Shridhar, V; Rivard, S; Shridhar, R; Mullins, C; Bostick, L; Sakr, W; Grignon, D; Miller, OJ; Smith, DI			A gene from human chromosomal band 3p21.1 encodes a highly conserved arginine-rich protein and is mutated in renal cell carcinomas	ONCOGENE			English	Article						arginine-rich protein; cryptic repeat; 3p21.1 gene; mutations; renal cell carcinoma	LUNG-CANCER; REGION 3P21; SEQUENCE; AMINOACYLASE-1; IDENTIFICATION; POLYMERASE; EXPRESSION	We have identified a gene, called ARP for Arginine-rich protein, in human chromosomal band 3p21. It is approximately 600 Kb telomeric to the ACY1 locus (Miller et al., 1989) and encodes a previously unidentified 234 amino acid long, highly basic protein. This gene is highly conserved at the DNA and RNA level. It is found in all species including hamster, rat, mouse, bovine and yeast. We have detected a point mutation (ATG(50) to AGG) or deletion of ATG(50) in 10 of 21 sporadic renal cell carcinomas. The mutable region is in an imperfect trinucleotide repeat in the coding region which is nonpolymorphic among 50 normal individuals examined. The point mutation (ATG(50) to AGG) or deletion of codon 50 removes a methionine and increases the stretch of arginines encoded by the AGG repeats in the ARP gene.	WAYNE STATE UNIV,SCH MED,DEPT MOLEC BIOL & GENET,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT PATHOL,DETROIT,MI 48201	Wayne State University; Wayne State University; Wayne State University					NATIONAL CANCER INSTITUTE [R01CA048031] Funding Source: NIH RePORTER; NCI NIH HHS [CA48031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AZUMA T, 1989, J BIOL CHEM, V264, P16748; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHUNG MY, 1993, NAT GENET, V5, P254, DOI 10.1038/ng1193-254; DALY MC, 1993, AM J HUM GENET, V53, pA290; DRABKIN H, 1990, GENOMICS, V8, P435, DOI 10.1016/0888-7543(90)90029-T; ECKERT KA, 1990, NUCLEIC ACIDS RES, V18, P3739, DOI 10.1093/nar/18.13.3739; ERLANDSSON R, 1990, ONCOGENE, V5, P1207; GEMMILL RM, 1991, GENOMICS, V11, P93, DOI 10.1016/0888-7543(91)90105-N; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GINZINGER DG, 1992, AM J HUM GENET, V50, P826; GOSTOUT B, 1993, AM J HUM GENET, V52, P1182; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MEARS JG, 1978, P NATL ACAD SCI USA, V75, P1222, DOI 10.1073/pnas.75.3.1222; MILLER YE, 1990, GENOMICS, V8, P149, DOI 10.1016/0888-7543(90)90237-O; MILLER YE, 1989, J CLIN INVEST, V83, P2120, DOI 10.1172/JCI114125; NAGEL S, 1995, CANCER RES, V55, P2866; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; RALL LB, 1987, METHOD ENZYMOL, V146, P239; SHRIDHAR V, 1994, CANCER RES, V54, P2084; SHRIDHAR V, 1994, SOMAT CELL MOLEC GEN, V20, P255, DOI 10.1007/BF02254716; SLEDDENS HFBM, 1992, NUCLEIC ACIDS RES, V20, P1427; SMITH DI, 1989, AM J HUM GENET, V45, P443; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEBER JL, 1993, HUM MOL GENET, V2, P2866; YAMAKAWA K, 1993, AM J HUM GENET, V53, pA390; Young A., 1991, FOCUS, V13, P137	32	40	45	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1931	1939						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649854				2022-12-28	WOS:A1996UK49800012
J	Srivenugopal, KS; AliOsman, F				Srivenugopal, KS; AliOsman, F			Deletions and rearrangements inactivate the p16(INK4) gene in human glioma cells	ONCOGENE			English	Article						p16(INK4); cell cycle; human glioma; CdK inhibitor; retinoblastoma protein		Structural alterations in the p16(INK4) gene were examined in early passage human glioma cell lines and related to the expression of p16 transcripts and protein. Using the Southern blot approach, we observed both homozygous and hemizygous deletions, as well as rearrangements of the p16 and p15 genes in 5 of the 7 cell lines (71%). Two cell lines, MGR3 and HBT28, revealed hemizygous deletion of the p16 and p15 genes combined with indistinguishable rearrangements of the remaining p15-p16 locus that resulted in loss of exon 2 sequences for p15 and p16, but retention of p16 exon 1; neither of these cell lines expressed p16 mRNA. Data for a third cell line, MGR2, indicated a similar, but rearrangement involving the p15 and p16 MGR2, which retained a single wild-type p15-p16 locus, showed expression of p16 transcript, but not of p16 protein as indicated by Western blot analysis. All the glioma cell lines expressed similar levels of the retinoblastoma protein and no amplification of the cyclin-dependent kinase 4 gene. These results demonstrate that human glioma cells contain p16 gene microdeletions and rearrangements that contribute to inactivation of the cell cycle regulatory protein.			Srivenugopal, KS (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPT PEDIAT,BOX 169,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.				NATIONAL CANCER INSTITUTE [R01CA064900] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALIOSMAN F, 1987, J NEUROPATH EXP NEUR, V46, P371, DOI 10.1097/00005072-198705000-00126; ALIOSMAN F, 1990, CANCER RES, V50, P6976; ARAP W, 1995, CANCER RES, V55, P1351; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DURO D, 1995, ONCOGENE, V11, P21; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HE J, 1994, CANCER RES, V54, P5804; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HERMAN JG, 1995, CANCER RES, V55, P4525; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V265, P416, DOI 10.1126/science.265.5170.416; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; LI Y, 1994, CANCER RES, V54, P6078; LI YJ, 1995, ONCOGENE, V11, P597; LIU Q, 1995, ONCOGENE, V10, P1061; MAO L, 1995, CANCER RES, V55, P2995; MEAD LJ, 1994, CANCER RES, V54, P2307; MORI T, 1994, CANCER RES, V54, P3396; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1995, ONCOGENE, V11, P1211; OTTERSON GA, 1994, ONCOGENE, V9, P3375; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SONODA Y, 1995, ONCOGENE, V11, P2145; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; STONE S, 1995, ONCOGENE, V11, P987; STONE S, 1995, CANCER RES, V55, P2988; Ueki K, 1996, CANCER RES, V56, P150; WALKER DG, 1995, CANCER RES, V55, P20; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XU L, 1994, CANCER RES, V54, P5262; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683	40	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					2029	2034						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649864				2022-12-28	WOS:A1996UK49800022
J	Charlesworth, A; Broad, S; Rozengurt, E				Charlesworth, A; Broad, S; Rozengurt, E			The bombesin/GRP receptor transfected into Rat-1 fibroblasts couples to phospholipase C activation, tyrosine phosphorylation of p125(FAK) and paxillin and cell proliferation	ONCOGENE			English	Article						neuropeptides; growth factors; Ca2+ mobilisation; protein kinase C	SWISS 3T3 CELLS; PROTEIN-KINASE-C; GASTRIN-RELEASING PEPTIDE; LUNG-CARCINOMA CELLS; MOLECULAR-CLONING; MAJOR SUBSTRATE; GROWTH-FACTOR; DNA-SYNTHESIS; STIMULATION; VASOPRESSIN	Bombesin elicits multiple signalling pathways in various cell types, It is not clear, however, whether these responses are mediated by a single receptor subtype or by different subtypes that couple preferentially to specific pathways. To resolve this we transfected the mouse bombesin/GRP receptor into Rat-1 fibroblasts and investigated the pathways activated by bombesin, Expression of the transfected receptors was verified by binding of [I-125]GRP and two clones were selected, BOR5 and BOR15. Bombesin stimulation of BOR5 and BOR15 cells caused intracellular Ca2+ mobilisation and increased the phosphorylation of 80K/MARCKS, a prominent protein kinase C substrate, The transfected receptor conferred a proliferative response to bombesin demonstrated by incorporation of [H-3]thymidine after 18 h and an increase in total cell numbers after 1-2 days. In BOR5 and BOR15 cells, bombesin rapidly stimulated the tyrosine phosphorylation of multiple proteins M(r) 110000-130000 and 70000-80000 including p125(FAK) and paxillin, at low concentrations (half maximum 0.3 nM). The specific bombesin/GRP receptor antagonist, D-F-5-Phe(6), D-Ala(11)-Bombesin(6-13)OMe, inhibited an the above responses. These results show that phospholipase C activation, cell growth and tyrosine phosphorylation emanate from a single class of bombesin receptor.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK								ASHKENAZI A, 1987, SCIENCE, V238, P672, DOI 10.1126/science.2823384; BATTEY JF, 1991, P NATL ACAD SCI USA, V88, P395, DOI 10.1073/pnas.88.2.395; BOLD RJ, 1994, J CELL PHYSIOL, V161, P519, DOI 10.1002/jcp.1041610315; BROOKS SF, 1991, EMBO J, V10, P2497, DOI 10.1002/j.1460-2075.1991.tb07789.x; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; CARNEY DN, 1987, CANCER RES, V47, P821; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CORJAY MH, 1991, J BIOL CHEM, V266, P18771; COY DH, 1992, PEPTIDES, V13, P775, DOI 10.1016/0196-9781(92)90186-7; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; FATHI Z, 1993, J BIOL CHEM, V268, P5979; GORBULEV V, 1992, EUR J BIOCHEM, V208, P405, DOI 10.1111/j.1432-1033.1992.tb17201.x; GRADY EF, 1995, J BIOL CHEM, V270, P4603, DOI 10.1074/jbc.270.9.4603; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; NANBERG E, 1988, EMBO J, V7, P2741, DOI 10.1002/j.1460-2075.1988.tb03128.x; RANKIN S, 1994, FEBS LETT, V354, P315, DOI 10.1016/0014-5793(94)01148-6; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; ROZENGURT E, 1995, CANCER SURV, V24, P81; ROZENGURT E, 1995, OXFORD TXB ONCOLOGY, P12; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SECKL M, 1993, J BIOL CHEM, V268, P9548; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SETHI T, 1992, CANCER RES, V52, pS2737; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SPINDEL ER, 1990, MOL ENDOCRINOL, V4, P1956, DOI 10.1210/mend-4-12-1956; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TURNER CE, 1994, J CELL SCI, V107, P1583; WADA E, 1991, NEURON, V6, P421, DOI 10.1016/0896-6273(91)90250-4; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211; ZACHARY I, 1985, P NATL ACAD SCI USA, V82, P7616, DOI 10.1073/pnas.82.22.7616; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577; ZACHARY I, 1991, J BIOL CHEM, V266, P24126; ZACHARY I, 1987, DEV BIOL, V124, P295, DOI 10.1016/0012-1606(87)90483-0; ZACHARY I, 1993, J BIOL CHEM, V268, P22060; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZACHARY I, 1987, EMBO J, V6, P2233, DOI 10.1002/j.1460-2075.1987.tb02495.x; ZACHARY I, 1987, J BIOL CHEM, V262, P3947	45	41	41	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1337	1345						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649836				2022-12-28	WOS:A1996UC06700019
J	Marchetti, A; Doglioni, C; Barbareschi, M; Buttitta, F; Pellegrini, S; Bertacca, G; Chella, A; Merlo, G; Angeletti, CA; DallaPalma, P; Bevilacqua, G				Marchetti, A; Doglioni, C; Barbareschi, M; Buttitta, F; Pellegrini, S; Bertacca, G; Chella, A; Merlo, G; Angeletti, CA; DallaPalma, P; Bevilacqua, G			p21 RNA and protein expression in non-small cell lung carcinomas: Evidence of p53-independent expression and association with tumoral differentiation	ONCOGENE			English	Article						p21/WAF1/CIP1/SDI1/mda-6; p53; lung cancer; histology; differentiation	P53; PROLIFERATION; INHIBITOR; MARKERS; KINASES	p21, the product of the WAF1/CIP1/SDI1/mda-6 gene, is an inhibitor of cyclin-dependent kinases. In cell cultures p21 is induced by p53-dependent and p53-independent pathways by DNA damage and induction of differentiation. We investigated p21 RNA and immunohistochemical expression in 43 non-small cell lung carcinomas and corresponding normal lung samples previously investigated for p53 and WAF1 gene status and p53 protein expression. p21 RNA and protein expression in normal and neoplastic tissues were strictly associated (P=0.0001). In normal tissue p21 RNA was expressed at low levels and p21 immunoreactivity was seen in scattered differentiated bronchial, alveolar and stromal cells. In the majority of neoplasms p21 protein and RNA were expressed at higher levels than in the corresponding normal tissues: p21 overexpression was seen in 27 (63%) and 28 (65%) cases respectively. p21 was expressed independently from p53 gene/protein alterations. p21 overexpression was more frequent in well differentiated tumors (P=0.01 and P=0.022 for RNA and protein respectively), and p21 immunoreactivity was usually seen in foci of more pronounced differentiation. We conclude that p21 expression is related to tumor differentiation, and that p53-independent p21 expression is a common feature of in vivo neoplasms.	UNIV PISA,SERV THORAC SURG,I-56100 PISA,ITALY; CITY HOSP BELLUNO,DEPT HISTOPATHOL,BELLUNO,ITALY; SANTA CHIARA HOSP,DEPT HISTOPATHOL,TRENT,ITALY; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	University of Pisa; ULSS 1 Dolomiti; Ospedale di Belluno; Santa Chiara Hospital; Friedrich Miescher Institute for Biomedical Research	Marchetti, A (corresponding author), UNIV PISA,INST PATHOL & HISTOL,VIA ROME 57,I-56100 PISA,ITALY.		Pellegrini, Silvia/C-3770-2011; PELLEGRINI, SILVIA/ABG-8822-2021; Barbareschi, Mattia/AAF-2043-2020	PELLEGRINI, SILVIA/0000-0003-0556-0165; BEVILACQUA, GENEROSO/0000-0001-8857-2609; DOGLIONI, Claudio/0000-0002-4969-5216				[Anonymous], 1982, Am J Clin Pathol, V77, P123; BARBARESCHI M, 1992, J PATHOL, V166, P343, DOI 10.1002/path.1711660405; BARBARESCHI M, 1992, AM J CLIN PATHOL, V98, P408, DOI 10.1093/ajcp/98.4.408; CATTORETTI G, 1992, J PATHOL, V168, P357, DOI 10.1002/path.1711680404; CHEDID M, 1994, ONCOGENE, V9, P3021; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285; JIANG HP, 1994, ONCOGENE, V9, P3397; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARCHETTI A, 1993, CANCER RES, V53, P4665; MARCHETTI A, 1993, CANCER RES, V53, P2846; MARCHETTI A, 1995, INT J ONCOL, V6, P187; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; STEINMAN RA, 1994, ONCOGENE, V9, P3389; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	24	138	145	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1319	1324						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649834				2022-12-28	WOS:A1996UC06700017
J	Roche, J; Boldog, F; Robinson, M; Robinson, L; VarellaGarcia, M; Swanton, M; Waggoner, B; Fishel, R; Franklin, W; Gemmill, R; Drabkin, H				Roche, J; Boldog, F; Robinson, M; Robinson, L; VarellaGarcia, M; Swanton, M; Waggoner, B; Fishel, R; Franklin, W; Gemmill, R; Drabkin, H			Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin	ONCOGENE			English	Article						chromosome 3; lung cancer; homozygous deletions; human SemaphorinIV	POLYMERASE CHAIN-REACTION; CHROMOSOMAL REGION 3P21; SQUAMOUS-CELL CARCINOMA; HOMOZYGOUS DELETION; DNA-SEQUENCE; LINE U2020; SHORT ARM; PROTEIN; YEAST; LOCALIZATION	Loss of chromosome 3p is a critical event in the pathogenesis of lung cancer. Overlapping homozygous 3p21.3 deletions in lung cancer cell lines involving GNAI2 were characterized and found to involve a region of genomic instability. A new widely expressed Semaphorin, H.SemaIV, was isolated from the GNAI2 deletion region. Reduced H.SemaIV expression allowed identification of additional cell lines with submicroscopic or larger deletions of the locus which occurred in a heterogeneous manner. We also demonstrate the presence of a distinct 3p21.3 homozygous deletion region, adjacent to the DNA mismatch repair gene, hMLH1, and identified deletions in direct tumors. This appears to represent one of the first demonstrations of homozygous deletions affecting 3p in direct lung tumors.	UNIV COLORADO, HLTH SCI CTR, DENVER, CO 80262 USA; UNIV COLORADO, CTR CANC, DENVER, CO 80262 USA; UNIV LYON 1, F-69622 VILLEURBANNE, FRANCE; ELEANOR ROOSEVELT INST, DENVER, CO 80206 USA; UNIV VERMONT, BURLINGTON, VT 05405 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Vermont					NATIONAL CANCER INSTITUTE [R01CA068383, P50CA058187] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA68383, CA58187] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BOLDOG FL, 1993, P NATL ACAD SCI USA, V90, P8509, DOI 10.1073/pnas.90.18.8509; BRAUCH H, 1987, NEW ENGL J MED, V317, P1109, DOI 10.1056/NEJM198710293171803; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; DALY MC, 1993, ONCOGENE, V8, P1721; DODD J, 1995, CELL, V81, P471, DOI 10.1016/0092-8674(95)90066-7; DRABKIN H, 1990, GENOMICS, V8, P435, DOI 10.1016/0888-7543(90)90029-T; DRABKIN HA, 1992, GENE CHROMOSOME CANC, V5, P67, DOI 10.1002/gcc.2870050110; GEMMILL RM, 1995, NATURE, V377, P299; GEMMILL RM, 1991, GENOMICS, V11, P93, DOI 10.1016/0888-7543(91)90105-N; GREEN ED, 1990, P NATL ACAD SCI USA, V87, P1213, DOI 10.1073/pnas.87.3.1213; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; Higgins D G, 1994, Methods Mol Biol, V25, P307; HOOVERS JMN, 1992, GENOMICS, V12, P254, DOI 10.1016/0888-7543(92)90372-Y; IBRAGHIMOVBESKROVNAYA O, 1993, HUM MOL GENET, V2, P1651, DOI 10.1093/hmg/2.10.1651; KILLARY AM, 1992, P NATL ACAD SCI USA, V89, P10877, DOI 10.1073/pnas.89.22.10877; KOK K, 1987, NATURE, V330, P578, DOI 10.1038/330578a0; KOK K, 1993, P NATL ACAD SCI USA, V90, P6071, DOI 10.1073/pnas.90.13.6071; KOK K, 1994, CANCER RES, V54, P4183; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; KOLODNER RD, 1995, CANCER RES, V55, P242; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LATIF F, 1992, GENE CHROMOSOME CANC, V5, P119, DOI 10.1002/gcc.2870050205; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LU YY, 1994, GENE CHROMOSOME CANC, V9, P76, DOI 10.1002/gcc.2870090114; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MAGOVCEVIC I, 1992, GENOMICS, V12, P125, DOI 10.1016/0888-7543(92)90414-N; MENDEZ MJ, 1991, GENOMICS, V10, P661, DOI 10.1016/0888-7543(91)90449-O; MESSERSMITH EK, 1995, NEURON, V14, P949, DOI 10.1016/0896-6273(95)90333-X; MUNROE DJ, 1994, GENOMICS, V19, P506, DOI 10.1006/geno.1994.1100; MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341; NAKAMURA H, 1994, HUM MOL GENET, V11, P157; NAKAMURA H, 1994, LUNG CANCER S4, V11, P157; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PUSCHEL AW, 1995, NEURON, V14, P941, DOI 10.1016/0896-6273(95)90332-1; RABBITTS P, 1990, GENE CHROMOSOME CANC, V2, P231, DOI 10.1002/gcc.2870020312; RIED T, 1994, CANCER RES, V54, P1801; Sherman F., 1986, METHODS YEAST GENETI; TESTA JR, 1994, GENE CHROMOSOME CANC, V11, P178, DOI 10.1002/gcc.2870110307; TODD S, 1995, GENOMICS, V25, P19, DOI 10.1016/0888-7543(95)80105-U; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; YAMAKAWA K, 1993, ONCOGENE, V8, P327; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZEIGER MA, 1994, GENE CHROMOSOME CANC, V11, P15, DOI 10.1002/gcc.2870110104	55	186	192	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1289	1297						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649831				2022-12-28	WOS:A1996UC06700014
J	Boulakia, CA; Chen, G; Ng, FWH; Teodoro, JG; Branton, PE; Nicholson, DW; Poirier, GG; Shore, GC				Boulakia, CA; Chen, G; Ng, FWH; Teodoro, JG; Branton, PE; Nicholson, DW; Poirier, GG; Shore, GC			Bcl-2 and adenovirus E1B 19 kDA protein prevent E1A-induced processing of CPP32 and cleavage of poly(ADP-ribose) polymerase	ONCOGENE			English	Article						apoptosia; E1A; PARP; CPP32; Bcl-2; E1B 19K	PROGRAMMED CELL-DEATH; C-ELEGANS; GENE CED-3; APOPTOSIS; TRANSFORMATION; POLYPEPTIDES; ASSOCIATION; INDUCTION; ENZYME	The E1A oncoproteins of adenovirus type 5 are potent inducers of apoptotic cell death. To manifest growth promoting and transforming properties, therefore, E1A requires the co-expression of a suppressor of apoptosis. During normal viral infection, this function is provided by the E1B 19 kDa protein. However, the cellular suppressor Bcl-2 can substitute for 19K during infection, and both proteins can effectively cooperate with E1A to facilitate transformation of primary cells in culture. How E1A induces apoptosis and at what point(s) on this pathway Bcl-2 and E1B 19K act are not presently known. Here, we demonstrate that E1A-induced apoptosis is accompanied by specific endo-proteolytic cleavage of poly(ADP-ribose) polymerase (PARP), an event that is linked to the Ced-3/ICE apoptotic pathway in other systems. PARP cleavage was also observed in p53-null cells infected with 19K(-) virus expressing 13S EIA. In addition to PARP cleavage, expression of E1A caused processing of the zymogen form of CPP32, a Ced-3/ICE protease that cleaves PARP and is required for apoptosis in mammalian cells. These events were prevented when EIA was co-expressed with E1B 19K or BCL-2, which places these suppressors of apoptosis either at or upstream of processing of pro-CPP32.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; MERCK FROSST CTR THERAPEUT RES,DEPT BIOCHEM & MOLEC BIOL,POINTE CLAIRE,PQ H9R 4P8,CANADA; CHU LAVAL,RES CTR,DEPT MOLEC ENDOCRINOL,POLY ADP RIBOSE METAB GRP,ST FOY,PQ G1V 4G2,CANADA	McGill University; Merck & Company; Laval University			Teodoro, Joe/AFT-2440-2022	Teodoro, Joe/0000-0002-3713-6839; Poirier, Guy/0000-0002-4869-1424				BARBEAU D, 1994, ONCOGENE, V9, P359; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BURKLE A, 1992, EXP CLIN IMMUNOGENET, V9, P230; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EARNSHAW WC, 1995, TRENDS CELL BIOL, V5, P217, DOI 10.1016/S0962-8924(00)89006-6; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1989, ONCOGENE, V4, P383; EGAN C, 1988, MOL CELL BIOL, V8, P869; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARVEY DM, 1991, GENE DEV, V5, P2365; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; JUAREZSALINAS H, 1979, NATURE, V282, P740, DOI 10.1038/282740a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MCLORIE W, 1991, J GEN VIROL, V72, P1467, DOI 10.1099/0022-1317-72-6-1467; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TEODORO JG, 1995, ONCOGENE, V11, P467; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	52	144	149	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					529	535						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637709				2022-12-28	WOS:A1996TV59700009
J	Panagopoulos, I; Hoglund, M; Mertens, F; Mandahl, N; Mitelman, F; Aman, P				Panagopoulos, I; Hoglund, M; Mertens, F; Mandahl, N; Mitelman, F; Aman, P			Fusion of the EWS and CHOP genes in myxoid liposarcoma	ONCOGENE			English	Article						myxoid liposarcoma; translocation; EWS gene; CHOP gene; PCR; fusion gene	TRANSLOCATION; TUMORS	The translocation t(12;16)(q13;pll), which cytogenetically characterizes myxoid liposarcomas (MLS), results in a fusion of the CHOP gene in 12q13 and the I;US gene in 16p11, creating a chimeric FUS/CHOP gene. We have identified two cases of MLS with translocations giving rise to recombination between 12q13 and 22q12. The result was a fusion of the N-terminal part of the EWS gene in 22q12, involved in a number of mesenchymal tumor types, with the CHOP gene and the creation of an EWS/CHOP chimeric gene. The presence of the EWS/CHOP chimeric gene in MLS Shows that (i) the N-terminal part of FUS may be replaced by the N-terminal part of EWS in a CHOP fusion oncoprotein (ii) the two N-terminal parts, when fused to certain transcription factors, have a common or very similar oncogenic potential and (iii) the tumorigenic process in MLS and the morphogenetically distinctly different EWS-associated tumor types may be related.			Panagopoulos, I (corresponding author), UNIV LUND HOSP,DEPT CLIN GENET,S-22185 LUND,SWEDEN.			Panagopoulos, Ioannis/0000-0003-2159-5341; Aman, Pierre/0000-0002-1482-8875; Hoglund, Mattias/0000-0001-9283-4421; Mitelman, Felix/0000-0002-3757-7212; Mertens, Fredrik/0000-0002-6278-5232				AMAN P, 1992, GENE CHROMOSOME CANC, V5, P278, DOI 10.1002/gcc.2870050403; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; GERALD WL, 1995, P NATL ACAD SCI USA, V92, P1028, DOI 10.1073/pnas.92.4.1028; GIOVANNINI M, 1994, J CLIN INVEST, V94, P489, DOI 10.1172/JCI117360; ICHIKAWA H, 1994, CANCER RES, V54, P2865; JEON IS, 1995, ONCOGENE, V10, P1229; LADANYI M, 1994, CANCER RES, V54, P2837; MANDAHL N, 1988, HUM GENET, V79, P203, DOI 10.1007/BF00366238; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; PANAGOPOULOS I, 1994, CANCER RES, V54, P6500; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; ZUCMAN J, 1993, NAT GENET, V4, P341, DOI 10.1038/ng0893-341; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x; 1991, GUIDELINES CANCER CY	19	223	233	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					489	494						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637704				2022-12-28	WOS:A1996TV59700004
J	Leshkowitz, D; Rozenblatt, O; Nakamura, T; Yano, T; Dautry, F; Croce, CM; Canaani, E				Leshkowitz, D; Rozenblatt, O; Nakamura, T; Yano, T; Dautry, F; Croce, CM; Canaani, E			ALL-1 interacts with unr, a protein containing multiple cold shock domains	ONCOGENE			English	Article						yeast two hybrid screening; nucleic acid-binding proteins	NUCLEIC-ACID-BINDING; Y-BOX; N-RAS; DROSOPHILA-TRITHORAX; BACILLUS-SUBTILIS; DNA-BINDING; TRANSCRIPTION FACTOR; ACUTE LEUKEMIAS; GENE; MOTIF	The ALL-1 gene is involved in human acute leukemia through chromosome translocations and fusion to partner genes, or through partial tandem duplications, ALL-1 is the human homologue of Drosophila trithorax which transregulates the homeotic genes of the Antennapedia and bithorax complexes controlling body segment identity, ALL-1 encodes a very large protein of 3968 amino acids which presumably interacts with many proteins, Here we applied yeast two hybrid screening to identify proteins interacting with the N-terminal segment of ALL-1, One protein obtained in this way was the product of the unr gene, This protein consists of multiple repeats homologous to the cold shock domain (CSD), a motif common to some bacterial and eukaryotic nucleic acids-binding proteins, The minimal region on unr required for the interaction with ALL-1 included two CSD and two intervening polypeptides. The interaction was confirmed by in vitro binding studies, and by coimmunoprecipitation from COS cells overexpressing the relevant segments of the two proteins, These results suggest that unr is involved in an interaction of ALL-1 with DNA or RNA.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; INST RECH CANC,CNRS,F-94801 VILLEJUIF,FRANCE	Weizmann Institute of Science; Jefferson University; Centre National de la Recherche Scientifique (CNRS)			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ALLAIN KS, 1990, GENE CHROMOSOME CANC, V2, P53; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; DONIGER J, 1992, NEW BIOL, V4, P389; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fidanza V, 1996, CANCER RES, V56, P1179; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAI XX, 1992, NUCLEIC ACIDS RES, V20, P601, DOI 10.1093/nar/20.3.601; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; JACQUEMINSABLON H, 1994, NUCLEIC ACIDS RES, V22, P2643, DOI 10.1093/nar/22.13.2643; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; NICOLAIEW N, 1991, ONCOGENE, V6, P721; OZER J, 1990, J BIOL CHEM, V265, P22143; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RAIMONDI SC, 1993, BLOOD, V81, P2237; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TILLIB S, 1995, MECH DEVELOP, V52, P1; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WILLIMSKY G, 1992, J BACTERIOL, V174, P6326, DOI 10.1128/JB.174.20.6326-6335.1992; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	36	11	12	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2027	2031						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934551				2022-12-28	WOS:A1996VR79500024
J	Kerr, J; Leary, JA; Hurst, T; Shih, YC; Antalis, TM; Friedlander, M; Crawford, E; Khoo, SK; Ward, B; ChenevixTrench, G				Kerr, J; Leary, JA; Hurst, T; Shih, YC; Antalis, TM; Friedlander, M; Crawford, E; Khoo, SK; Ward, B; ChenevixTrench, G			Allelic loss on chromosome 7q in ovarian adenocarcinomas: Two critical regions and a rearrangement of the PLANH1 locus	ONCOGENE			English	Article						loss of heterozygosity; ovarian adenocarcinomas; tumour suppressor genes; PAI-1	TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL; FREQUENT LOSS; CARCINOMAS; HETEROZYGOSITY; CANCER; EXPRESSION; DELETION; 7Q31.1	The presence of a tumour suppressor gene on chromosome 7q is indicated by cytogenetic, loss of heterozygosity (LOH) and chromosome transfer studies, One candidate gene in this region is Plasminogen Activator Inhibitor-1 (PAI-1), The PAI-1 gene product is involved in proteolysis and may therefore influence tumour spread and invasion, We have analysed a series of 139 ovarian epithelial tumours at four loci in the region 7q21-q31 which includes the PAI-1 gene, The highest rates of loss were found in malignant tumours (FIGO stages I-IV) at markers D7S471 (38%, 20/52 informative cases) and D7S522 (34%, 15/44), No loss was seen in benign tumours and only one out of 27 (4%) informative LMP tumours demonstrated LOH, The smallest region of overlap (SRO) lies between D7S471 and PAI-1, We also identified a rearrangement in one tumour in the PAI-1 gene, suggesting that this may be the inactivated gene in this region, In addition LOH at the more distal marker, D7S522, which lies outside the SRO, shows significant association with stage (P=0.0343) and with LOH on chromosome 13 (P=0.0024), This is in contrast to all other markers examined, These data suggest the presence of two critical regions on 7q which may be important in subsets of epithelial ovarian tumours.	QUEENSLAND INST MED RES, QUEENSLAND CANC FUND RES UNIT, BRISBANE, QLD 4029, AUSTRALIA; UNIV SYDNEY, WESTMEAD HOSP, DEPT MED ONCOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV SYDNEY, WESTMEAD HOSP, DEPT OBSTET & GYNAECOL, SYDNEY, NSW 2006, AUSTRALIA; UNIV QUEENSLAND, ROYAL BRISBANE HOSP, DEPT OBSTET & GYNAECOL, HERSTON, QLD 4029, AUSTRALIA; PRINCE WALES HOSP, DEPT MED ONCOL, SYDNEY, NSW 2031, AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Sydney; University of Sydney; Royal Brisbane & Women's Hospital; University of Queensland			Chenevix-Trench, Georgia/AAV-2014-2020	Chenevix-Trench, Georgia/0000-0002-1878-2587				ATKIN NB, 1993, CANCER GENET CYTOGEN, V67, P123, DOI 10.1016/0165-4608(93)90164-H; CHENEVIXTRENCH G, 1992, ONCOGENE, V7, P1059; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; CHENEVIXTRENCH G, 1996, IN PRESS GENES CHROM; DAWSON S, 1991, ARTERIOSCLER THROMB, V11, P183, DOI 10.1161/01.ATV.11.1.183; ECCLES DM, 1992, ONCOGENE, V7, P2069; FOLLO M, 1989, GENE, V84, P447, DOI 10.1016/0378-1119(89)90519-2; GALLION HH, 1992, GYNECOL ONCOL, V47, P137, DOI 10.1016/0090-8258(92)90096-2; KERE J, 1989, BLOOD, V73, P230; KUPRYJANCZYK J, 1995, HUM PATHOL, V26, P387, DOI 10.1016/0046-8177(95)90138-8; LEARY JA, 1995, INT J CANCER, V64, P189, DOI 10.1002/ijc.2910640308; LEVI S, 1991, CANCER RES, V51, P3497; LOSKUTOFF DJ, 1987, BIOCHEMISTRY-US, V26, P3763, DOI 10.1021/bi00387a004; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OSELLA P, 1992, CANCER GENET CYTOGEN, V59, P73, DOI 10.1016/0165-4608(92)90162-2; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; ROBERTS CG, 1990, CANCER GENET CYTOGEN, V48, P243, DOI 10.1016/0165-4608(90)90127-V; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	25	44	47	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1815	1818						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895529				2022-12-28	WOS:A1996VM88700028
J	Gilmore, TD; Koedood, M; Piffat, KA; White, DW				Gilmore, TD; Koedood, M; Piffat, KA; White, DW			Rel/NF-kappa B/I kappa B proteins and cancer	ONCOGENE			English	Review							T-CELL LEUKEMIA; EPSTEIN-BARR-VIRUS; CHICKEN-EMBRYO FIBROBLASTS; LATENT MEMBRANE-PROTEIN; CHRONIC LYMPHOCYTIC-LEUKEMIA; POLYMERASE CHAIN-REACTION; RECEPTOR FUSION PROTEIN; I TAX-PROTEIN; V-REL; C-REL				Gilmore, TD (corresponding author), BOSTON UNIV,DEPT BIOL,5 CUMMINGTON ST,BOSTON,MA 02215, USA.				NCI NIH HHS [CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBADIE C, 1993, CELL, V75, P899, DOI 10.1016/0092-8674(93)90534-W; Akagi T, 1996, ONCOGENE, V12, P1645; ARSURA M, 1996, IMMUNITY, V5, P1; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAICHWAL VR, 1988, ONCOGENE, V2, P461; Baker SJ, 1996, ONCOGENE, V12, P1; Baldassarre F, 1995, J BIOL CHEM, V270, P31244, DOI 10.1074/jbc.270.52.31244; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BEAUPARLANT P, 1994, ONCOGENE, V9, P3189; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BHAT GV, 1990, ONCOGENE, V5, P625; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BRADY JN, 1992, AIDS RES HUM RETROV, V8, P724; BROWNELL E, 1988, ONCOGENE, V2, P527; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; CHEN W, 1996, J VIROL, V70, P4843; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEJARDIN E, 1995, ONCOGENE, V11, P1835; DeLuca C, 1996, J VIROL, V70, P5183, DOI 10.1128/JVI.70.8.5183-5193.1996; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; FRACCHIOLLA NS, 1993, ONCOGENE, V8, P2839; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; Fujii M, 1996, ONCOGENE, V12, P2193; GELINAS C, 1988, ONCOGENE, V3, P349; GILMAN M, 1993, NATURE, V361, P687, DOI 10.1038/361687a0; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GILMORE TD, 1995, DNA PROVIRUS, P109; GILMORE TD, 1995, FRONTIERS MOL BIOL E, P102; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; GRASSMANN R, 1994, ADV CANCER RES, V63, P211, DOI 10.1016/S0065-230X(08)60401-7; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; GRIMM S, 1994, ONCOGENE, V9, P2391; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1990, ONCOGENE, V5, P1843; HANNINK M, 1991, Critical Reviews in Oncogenesis, V2, P293; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HIMES SR, 1993, ONCOGENE, V8, P3189; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, 1992, ONCOGENE, V7, P1737; HISCOTT J, 1995, VIROLOGY, V214, P3, DOI 10.1006/viro.1995.9960; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Houldsworth J, 1996, BLOOD, V87, P25; HRDLICKOVA R, 1994, J VIROL, V68, P308; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HU HM, 1994, J BIOL CHEM, V269, P30069; HUEN DS, 1995, ONCOGENE, V10, P549; HWANG S, 1995, CANCER BIOCHEM BIOPH, V14, P265; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; ISHIKAWA H, 1993, ONCOGENE, V8, P2889; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KANNO T, 1994, MOL CELL BIOL, V14, P6443, DOI 10.1128/MCB.14.10.6443; KANNO T, 1994, P NATL ACAD SCI USA, V91, P12634, DOI 10.1073/pnas.91.26.12634; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; Khaled Z, 1996, NUCLEIC ACIDS RES, V24, P737, DOI 10.1093/nar/24.4.737; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; KINOSHITA T, 1989, P NATL ACAD SCI USA, V86, P5620, DOI 10.1073/pnas.86.14.5620; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KLAMAN LD, 1995, J VIROL, V69, P871, DOI 10.1128/JVI.69.2.871-881.1995; KLEIN G, 1994, CELL, V77, P791, DOI 10.1016/0092-8674(94)90125-2; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KORBER B, 1991, J VIROL, V65, P5471, DOI 10.1128/JVI.65.10.5471-5476.1991; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; LANOIX J, 1994, ONCOGENE, V9, P841; LEE HY, 1995, J EXP MED, V181, P1169, DOI 10.1084/jem.181.3.1169; LENARDO M, 1994, IMMUNOL TODAY, V15, P145, DOI 10.1016/0167-5699(94)90308-5; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; LIPTAY S, 1992, GENOMICS, V13, P287, DOI 10.1016/0888-7543(92)90244-M; LU D, 1991, ONCOGENE, V6, P1235; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATHEW S, 1993, ONCOGENE, V8, P191; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MOORE BE, 1988, VIROLOGY, V162, P377, DOI 10.1016/0042-6822(88)90478-3; MORIN PJ, 1995, CELL GROWTH DIFFER, V6, P789; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; MUKHOPADHYAY T, 1995, ONCOGENE, V11, P999; MULLER CW, 1995, FEBS LETT, V369, P113, DOI 10.1016/0014-5793(95)00541-G; MUNOZ E, 1994, J VIROL, V68, P8035; MURAKAMI T, 1995, VIROLOGY, V206, P1066, DOI 10.1006/viro.1995.1029; NARAYANAN R, 1992, SCIENCE, V256, P367, DOI 10.1126/science.256.5055.367; NARAYANAN R, 1994, IN VIVO, V8, P787; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; OHNO H, 1993, LEUKEMIA, V7, P2057; Pak J, 1996, J VIROL, V70, P4167, DOI 10.1128/JVI.70.6.4167-4172.1996; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; PETRENKO O, 1995, GENE, V160, P305, DOI 10.1016/0378-1119(95)00210-W; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Romero Paolo, 1994, Journal of Virology, V69, P301; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; Rousset R, 1996, NATURE, V381, P328, DOI 10.1038/381328a0; SALAHUDDIN SZ, 1984, SCIENCE, V223, P703, DOI 10.1126/science.6320367; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; SU F, 1986, J VIROL, V70, P4558; SUZUKI T, 1994, ONCOGENE, V9, P3099; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THAKUR S, 1994, ONCOGENE, V9, P2335; THEILEN GH, 1966, J NATL CANCER I, V37, P731; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; WALKER AK, 1986, ONCOGENE, V12, P2515; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATANABE M, 1993, ONCOGENE, V8, P2949; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, MOL CELL BIOL, V16, P1169; WHITE DW, 1995, ONCOGENE, V10, P857; WHITE DW, 1996, IN PRESS ONCOGENE, V13; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Wilson JB, 1996, EMBO J, V15, P3117, DOI 10.1002/j.1460-2075.1996.tb00674.x; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; YAMASHITA I, 1994, BLOOD, V84, P1573; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; ZAKNOEN SL, 1992, LEUKEMIA, V6, P675; Zhang GQ, 1996, ONCOGENE, V12, P1153; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	171	298	308	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1367	1378						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875974				2022-12-28	WOS:A1996VL38400001
J	Beamish, H; Williams, R; Chen, P; Khanna, KK; Hobson, K; Watters, D; Shiloh, Y; Lavin, M				Beamish, H; Williams, R; Chen, P; Khanna, KK; Hobson, K; Watters, D; Shiloh, Y; Lavin, M			Rapamycin resistance in ataxia-telangiectasia	ONCOGENE			English	Article						ataxia-telangiectasia; rapamycin; Wortmannin; cyclin kinase; cell cycle	CYCLE CHECKPOINT PATHWAY; PHOSPHATIDYLINOSITOL 3-KINASE; IONIZING-RADIATION; PROTEIN-KINASE; IMMUNOSUPPRESSANT RAPAMYCIN; INDUCED INHIBITION; MAMMALIAN PROTEIN; SERINE RESIDUE; LYMPHOMA-CELLS; S6 KINASE	The gene mutated in the human genetic disorder ataxia-telangiectasia (A-T) has been described recently (Savitsky et al., 1995a) and the complete coding sequence of this gene, ATM, has been reported (Savitsky et al., 1995b). The derived amino acid sequence demonstrates significant homologies to several proteins containing a phosphatidylinositol 3-kinase (PI3-kinase) domain, including the yeast TOR proteins and the human protein FRAP. Since the TOR and FRAP proteins are targets for the immunosuppressive drug rapamycin, we have investigated the effects of this compound on A-T cells. We report here that 3 A-T cell lines are more resistant than control cells to rapamycin's growth inhibiting effects but were more sensitive to the PI3-kinase inhibitor wortmannin. As expected rapamycin (1 nM) inhibited the rate of exit of control cells from G(1) phase but failed to perturb the progression of A-T cells. This difference in cell cycle progress after rapamycin treatment is reflected in ribosomal S6 protein kinase (p70(S6K)) by both a downward mobility shift on SDS-PAGE and inhibition of activity. Furthermore, the G, phase cyclin-dependent kinase, cyclin E-cdk2, was rapidly inhibited in control cells post-treatment, whereas in A-T cells it took considerably longer to observe inhibition. There was no evidence that a GST-FKBP12 fusion protein specifically precipitated the ATM protein in the presence of rapamycin in either cell type. These results demonstrate that the ATM protein is not a direct target for rapamycin but its functional loss renders cells more resistant to this compound.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,BANCROFT CTR,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT SURG,HERSTON,QLD,AUSTRALIA; TEL AVIV UNIV,SACKLER SCH MED,DEPT HUMAN GENET,IL-69978 TEL AVIV,ISRAEL	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Tel Aviv University; Sackler Faculty of Medicine			Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014; Watters, Dianne J/E-6007-2010	Lavin, Martin F/0000-0002-5940-4769; Watters, Dianne J/0000-0002-2555-5825; Khanna, Kum Kum/0000-0001-8650-5381				ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALBERS MW, 1993, ANN NY ACAD SCI, V696, P54; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; BIEVER BE, 1990, SCIENCE, V250, P556; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P411; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FAN SJ, 1994, CANCER RES, V54, P5824; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRAUMENI JF, 1967, JNCI-J NATL CANCER I, V38, P593; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; GOTTOFF SP, 1967, AM J DIS CHILD, V114, P617; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HECHT F, 1990, CANC GENET CYTOGENET, V46, P11; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HOULDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709, DOI 10.1093/nar/8.16.3709; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LANGE E, 1995, AM J HUM GENET, V57, P112; LAVIN MF, 1995, TRENDS BIOCHEM SCI, V20, P382, DOI 10.1016/S0968-0004(00)89083-0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MUTHUKKUMAR S, 1995, TRANSPLANTATION, V60, P264, DOI 10.1097/00007890-199508000-00010; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PARK BD, 1994, CANCER RES, V54, P896; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SEHGAL SN, 1975, J ANTIBIOT, V28, P727, DOI 10.7164/antibiotics.28.727; SHILOH Y, 1995, IN PRESS EUR J HUM G; STAN R, 1994, J BIOL CHEM, V269, P32027; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; VI M, 1995, TRENDS BIOCHEM SCI, V20, P303; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	59	22	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					963	970						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806686				2022-12-28	WOS:A1996VG76600010
J	Nikiforov, YE; Nikiforova, MN; Gnepp, DR; Fagin, JA				Nikiforov, YE; Nikiforova, MN; Gnepp, DR; Fagin, JA			Prevalence of mutations of ras and p53 in benign and malignant thyroid tumors from children exposed to radiation after the Chernobyl nuclear accident	ONCOGENE			English	Article						thyroid tumors; radiation; Chernobyl; ras; p53	POINT MUTATIONS; HA-RAS; GENOMIC INSTABILITY; LUNG-CANCER; ONCOGENE; GENE; CARCINOMAS; IRRADIATION; DISASTER; PATTERN	Starting 4 years after the Chernobyl accident, a dramatic increase in incidence of thyroid carcinoma was noticed in children from contaminated areas, The incidence of benign thyroid lesions in the exposed population was also increased, To study the possible role of ras and p53 genes in radiation-induced thyroid tumorigenesis, 33 papillary carcinomas, one follicular carcinoma and 22 benign lesions removed from children aged 5-19 were screened for point mutations of H- K-, and N-ras, as well as of p53 (exons 5-8) using single strand conformation polymorphism (SSCP) analysis, Pas point mutations were detected in 1/1 case of follicular carcinoma (N-ras codon 61 CAA(gln)-->AAA(lys)), and in 3/7 follicular adenomas (N-ras codon 61 CAA(gin)-->CGA(arg) x 2, CAA(gln)-->AAA(lys). None of the cases of papillary thyroid carcinoma was positive for ras oncogene abnormalities, The lack of K-ras mutations was confirmed by allele-specific oligonucleotide hybridization (ASOH), and by sequencing in five cases, Somatic point mutations in p53 were found by SSCP in 2/33 papillary thyroid carcinomas, with one missense mutation (exon 5, codon 160 ATG(met)-->GTG(val)) and another silent mutation (codon 182, TGC(cys)-->TGT(cys)). Immunohistochemically, focally positive p53 staining was found in four papillary carcinomas being primarily confined to solid and poorly-differentiate areas in tumors, These data demonstrate that as opposed to the few reports on tumors arising after therapeutic external irradiation, ras mutations are not primary events in the development of post-Chernobyl thyroid papillary carcinomas, p53 mutations do not appear to be important in the development of these tumors, but may in some cases have a role in progression to a more aggressive phenotype that has not yet fully manifested in these pediatric neoplasms.	UNIV CINCINNATI, COLL MED, DIV ENDOCRINOL & METAB, CINCINNATI, OH 45267 USA; CEDARS SINAI MED CTR, DIV ENDOCRINOL, LOS ANGELES, CA 90048 USA; RHODE ISL HOSP, DEPT PATHOL, PROVIDENCE, RI 02903 USA	University System of Ohio; University of Cincinnati; Cedars Sinai Medical Center; Lifespan Health Rhode Island; Rhode Island Hospital					NATIONAL CANCER INSTITUTE [R01CA050706, R29CA050706] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK042792] Funding Source: NIH RePORTER; NCI NIH HHS [CA 50706] Funding Source: Medline; NIDDK NIH HHS [DK 42792] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOGDANOVA T, 1995, THYROID S1, V5, pS28; CHALLETON C, 1995, ONCOGENE, V11, P601; CHEN CH, 1993, CANCER RES, V53, P1511; CONARD RA, 1970, J AMER MED ASSOC, V214, P316, DOI 10.1001/jama.214.2.316; DENKO N, 1995, SOMAT CELL MOLEC GEN, V21, P241, DOI 10.1007/BF02255779; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; DOBYNS BM, 1992, WORLD J SURG, V16, P126, DOI 10.1007/BF02067128; DONGHI R, 1993, J CLIN INVEST, V91, P1753, DOI 10.1172/JCI116385; DUFFY BJ, 1950, J CLIN ENDOCRINOL, V10, P1296, DOI 10.1210/jcem-10-10-1296; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; FURMANCHUK AW, 1992, HISTOPATHOLOGY, V21, P401, DOI 10.1111/j.1365-2559.1992.tb00423.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; ILYIN LA, 1990, J RADIOL PROTECT, V10, P13; ITO T, 1993, CANCER RES, V53, P2940; KASTAN MB, 1991, CANCER RES, V51, P6304; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; KRONENBERG A, 1994, INT J RADIAT BIOL, V66, P603, DOI 10.1080/09553009414551691; LEMOINE NR, 1988, ONCOGENE, V3, P541; Lemoine NR, 1989, THYROID TUMOURS, P4; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; NAMBA H, 1990, MOL ENDOCRINOL, V4, P1474, DOI 10.1210/mend-4-10-1474; Nikiforov Y, 1996, J CLIN ENDOCR METAB, V81, P9, DOI 10.1210/jc.81.1.9; NIKIFOROV Y, 1994, CANCER-AM CANCER SOC, V74, P748, DOI 10.1002/1097-0142(19940715)74:2<748::AID-CNCR2820740231>3.0.CO;2-H; NIKIFOROV YE, 1995, CANCER-AM CANCER SOC, V76, P900, DOI 10.1002/1097-0142(19950901)76:5<900::AID-CNCR2820760527>3.0.CO;2-X; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; SAMPSON R J, 1969, Journal of the American Medical Association, V209, P65, DOI 10.1001/jama.209.1.65; SCHNEIDER AB, 1980, CANCER, V46, P1218, DOI 10.1002/1097-0142(19800901)46:5<1218::AID-CNCR2820460523>3.0.CO;2-H; SHORE RE, 1985, J NATL CANCER I, V74, P1177; TAYLOR JA, 1994, LANCET, V343, P86, DOI 10.1016/S0140-6736(94)90818-4; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2; WILLIAMS D, 1994, NATURE, V371, P556, DOI 10.1038/371556a0; Winship T, 1970, CLIN P CHILDRENS HOS, V26, P327; WRIGHT PA, 1991, ONCOGENE, V6, P471; ZHANG PL, 1994, MOL CARCINOGEN, V9, P46, DOI 10.1002/mc.2940090109	38	107	111	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					687	693						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761289				2022-12-28	WOS:A1996VD43300003
J	deBruijn, DRH; Baats, E; Zechner, U; deLeeuw, B; Balemans, M; Weghuis, DO; HirningFolz, U; vanKessel, AG				deBruijn, DRH; Baats, E; Zechner, U; deLeeuw, B; Balemans, M; Weghuis, DO; HirningFolz, U; vanKessel, AG			Isolation and characterization of the mouse homolog of SYT, a gene implicated in the development of human synovial sarcomas	ONCOGENE			English	Article						synovial sarcoma; mouse Syt gene SH2-; SH3-binding domains; annexin-like repeats; chromosome 18	KRUPPEL-ASSOCIATED BOX; DICTYOSTELIUM-DISCOIDEUM; BINDING PROTEIN; ANNEXIN-VII; TRANSLOCATION; BREAKPOINT; IDENTIFICATION; CHROMOSOME; CLONING; XP11.2	In a previous study we reported the isolation of the human synovial sarcoma-associated t(X;18) breakpoint. As a result of this translocation, the SYT gene on chromosome 18 fuses to either the SSX1 or the SSX2 gene on the X chromosome, depending on the exact location of the breakpoint within band Xp11.2. As yet, little is known about the modes of action of the SYT and SSX genes and their respective (fusion) products. Here we report the isolation of the mouse homolog of SYT, its full length cDNA sequence, its chromosomal localization, and its spatio-temporal expression patterns in adult and embryonic tissues. The SYT gene was found to be well conserved during evolution and is part of a region of synteny between the human and mouse chromosomes 18. In early embryogenesis, Syt is ubiquitously expressed. In later stages, the expression becomes confined to cartilage tissues, specific neuronal cells and some epithelial derived tissues. In mature testis, expression was specifically observed in primary spermatocytes.	UNIV ULM, DEPT MED GENET, D-7900 ULM, GERMANY	Ulm University	deBruijn, DRH (corresponding author), UNIV NIJMEGEN HOSP, DEPT HUMAN GENET, POB 9101, NL-6500 HB NIJMEGEN, NETHERLANDS.		van Kessel, Ad Geurts/A-2810-2010; Olde Weghuis, Danielle/C-4674-2016; Zechner, Ulrich/G-2116-2010; de Bruijn, D.R.H./L-4233-2015					CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DEBRUIJN DRH, 1994, DIFFERENTIATION, V58, P141; DELEEUW B, 1993, ONCOGENE, V8, P1457; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; DELEEUW B, 1994, HUM MOL GENET, V3, P745, DOI 10.1093/hmg/3.5.745; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; DELEEUW B, 1993, GENE CHROMOSOME CANC, V6, P182, DOI 10.1002/gcc.2870060309; FICKETT JW, 1982, NUCLEIC ACIDS RES, V10, P5303, DOI 10.1093/nar/10.17.5303; GRANT CE, 1990, GENE, V96, P213, DOI 10.1016/0378-1119(90)90255-P; GREENWOOD M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P429, DOI 10.1016/0167-4781(91)90137-B; JANZ M, 1995, J PATHOL, V175, P391, DOI 10.1002/path.1711750405; LICHT JD, 1993, P NATL ACAD SCI USA, V90, P11361, DOI 10.1073/pnas.90.23.11361; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; OVERHAUSER J, 1995, CYTOGENET CELL GENET, V71, P106; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SHIPLEY JM, 1994, ONCOGENE, V9, P1447; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; WEGHUIS DO, 1994, GENE CHROMOSOME CANC, V9, P288; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; ZHANGKECK ZY, 1993, BIOCHEM J, V289, P735, DOI 10.1042/bj2890735	21	47	48	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					643	648						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760306				2022-12-28	WOS:A1996VB32800022
J	Sunitha, I; Avigan, MI				Sunitha, I; Avigan, MI			The apical membranes of maturing gut columnar epithelial cells contain the enzymatically active form of a newly identified fyn-related tyrosine kinase	ONCOGENE			English	Article						gtk; intestinal epithelium; tyrosine kinase	HEPATOCYTE GROWTH-FACTOR; SRC-FAMILY KINASES; SIGNAL TRANSDUCTION; C-SRC; PROTEIN-KINASES; FACTOR-RECEPTOR; SUBCELLULAR-LOCALIZATION; GASTROINTESTINAL-TRACT; TISSUE DISTRIBUTION; ANCHORED PROTEINS	Recently, we isolated a new src family member from a rat small intestinal cDNA library which by RNase protection analysis is selectively expressed in the columnar epithelium of gut. Complete nucleotide sequencing of the gastrointestinal associated tyrosine kinase (gtk) has revealed that it is a rat homologue of frk/rak - a fyn related human tyrosine kinase. Unlike frk/rak, gtk is myristylated, in vivo. Furthermore, by immunohistochemical analysis, the kinase is concentrated in the brush border membranes of epithelial cells, throughout the maturation axis of the adult small intestine. In vitro analysis revealed that gtk kinase activity is present in intestinal cells throughout their maturation, suggesting that the enzyme might influence signal transduction pathways in both mitotic and post-mitotic states. Gtk is expressed in all regions of the gastrointestinal tract which contain columnar epithelium, but is absent in the stratified epithelium of the esophagus. Moreover, during gestation, the kinase dramatically appears at high levels in plasma membranes, at the time of transition of gut cells from an undifferentiated to a simple columnar phenotype. After solubilization of cellular membranes with Triton X-100, sucrose gradient analysis of gtk revealed that it partitions differently than c-yes, demonstrating that the brush border src kinases associate with different components of the plasma membranes. These findings suggest that gtk plays a specialized role in the growth/differentiation of gut columnar epithelial cells.	GEORGETOWN UNIV,SCH MED,DEPT PATHOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,SCH MED,DEPT MED,WASHINGTON,DC 20007	Georgetown University; Georgetown University					NATIONAL CANCER INSTITUTE [R29CA054818] Funding Source: NIH RePORTER; NCI NIH HHS [CA 54818] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ALLAND L, 1994, J BIOL CHEM, V269, P16701; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; ARREAZA G, 1994, J BIOL CHEM, V269, P19123; BERARDI RS, 1983, SURG GYNECOL OBSTET, V156, P521; BOLEN JB, 1992, FASEB J, V6, P3403, DOI 10.1096/fasebj.6.15.1281458; BOLEN JB, 1991, CELL GROWTH DIFFER, V2, P409; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CARTWRIGHT CA, 1993, ONCOGENE, V8, P1033; CHAN AML, 1988, ONCOGENE, V2, P593; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; COURTNEIDGE SA, 1993, DEVELOPMENT, P57; COURTNEIDGE SA, 1991, CELL GROWTH DIFFER, V2, P483; CRAVEN RJ, 1995, CANCER RES, V55, P3969; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; DANIELSEN EM, 1995, J CELL BIOL, V131, P939, DOI 10.1083/jcb.131.4.939; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DENARDI FG, 1992, HISTOLOGY PATHOLOGIS, P515; ENGLE MJ, 1995, J BIOL CHEM, V270, P11935, DOI 10.1074/jbc.270.20.11935; GORDON JI, 1989, J CELL BIOL, V108, P1187, DOI 10.1083/jcb.108.4.1187; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; HANCOCK JF, 1990, EMBO J, V8, P4133; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JOHNS BAE, 1952, J ANAT, V86, P431; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KOBAYASHI N, 1993, P NATL ACAD SCI USA, V90, P4201, DOI 10.1073/pnas.90.9.4201; KOEGL M, 1994, BIOCHEM J, V303, P749, DOI 10.1042/bj3030749; KRUEGER JG, 1980, VIROLOGY, V101, P25, DOI 10.1016/0042-6822(80)90480-8; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LOCK P, 1991, MOL CELL BIOL, V11, P4363, DOI 10.1128/MCB.11.9.4363; LOUVARD D, 1992, ANNU REV CELL BIOL, V8, P157, DOI 10.1146/annurev.cb.08.110192.001105; LOWELL CA, 1994, GENE DEV, V8, P387, DOI 10.1101/gad.8.4.387; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MIRCHEFF AK, 1990, METHOD ENZYMOL, V192, P341; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; MOIJNA A, 1992, NATURE, V357, P161; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; NEUTRA M, 1989, MODERN CELL BIOL, V8, P363; OBERGWELSH C, 1995, GENE, V152, P239, DOI 10.1016/0378-1119(94)00718-8; OKADA M, 1991, J BIOL CHEM, V266, P24249; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1993, BIOCHIM BIOPHYS ACTA, V1155, P307, DOI 10.1016/0304-419X(93)90012-2; RIDER LG, 1994, GENE, V138, P219, DOI 10.1016/0378-1119(94)90811-7; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RUDD CE, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239, DOI 10.1016/0304-419X(93)90007-Y; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPARKOWSKI J, 1994, J VIROL, V68, P6120, DOI 10.1128/JVI.68.9.6120-6123.1994; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUNITHA I, 1994, BBA-MOL CELL RES, V1221, P348, DOI 10.1016/0167-4889(94)90260-7; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; TWAMLEY GM, 1992, ONCOGENE, V7, P1893; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; Walter K., 1974, METHODS ENZYMATIC AN, V2nd ed., P856; WEISER MM, 1973, J BIOL CHEM, V248, P2536; ZARNEGAR R, 1990, P NATL ACAD SCI USA, V87, P1252, DOI 10.1073/pnas.87.3.1252; ZHAO YH, 1990, ONCOGENE, V5, P1629	69	14	15	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					547	559						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760296				2022-12-28	WOS:A1996VB32800012
J	Schryver, B; Hinck, L; Papkoff, J				Schryver, B; Hinck, L; Papkoff, J			Properties of Wnt-1 protein that enable cell surface association	ONCOGENE			English	Article						Wnt-1; basic sequence motif; proteoglycan	FIBROBLAST GROWTH-FACTOR; MAMMARY ONCOGENE INT-1; HEPARAN-SULFATE; EXTRACELLULAR-MATRIX; EPITHELIAL-CELLS; WINGLESS PROTEIN; EXPRESSION; DROSOPHILA; BINDING; TRANSFORMATION	Members of the highly conserved Wnt gene family serve key functions in cellular growth and differentiation. Regulated expression of the murine Wnt-1 protooncogene is essential for normal development of the embryonic nervous system and when misexpressed in the mammary gland leads to hyperplasias and tumorigenic progression. Wnt-1 encodes a cysteine rich glycoprotein that is secreted and tightly associated with the cell surface and/or extracellular matrix. This restricted diffusion of Wnt-1 protein is important for specifying a spatially defined pattern of Wnt-activity necessary for cell to cell signaling in cell growth and differentiation. Since the receptors and cell surface molecules that bind Wnt proteins are as yet unknown we have sought to define the sequences within Wnt-1 protein that enable cell surface association and to define the nature of the cell surface structures with which Wnt-1 protein associates. First, site directed mutagenesis was used to identify a basic amino acid sequence motif within Wnt-1 protein that is required for this protein to accumulate on the cell surface. Second, wild type Wnt-1 protein was expressed in a series of proteoglycan-deficient CHO cell lines to show that, contrary to expectations, cellular glycosaminoglycans are not required for processing, secretion, cell surface association and accumulation of Wnt-1 protein.	STANFORD UNIV,CANC BIOL PROGRAM,STANFORD,CA 94305; SUGEN INC,REDWOOD CITY,CA 94063	Stanford University				Hinck, Lindsay/0000-0002-4009-3913				BAME KJ, 1989, J BIOL CHEM, V264, P8059; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADLEY RS, 1995, MOL CELL BIOL, V15, P4616; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; ESCO JD, 1987, J BIOL CHEM, V262, P12189; ESCO JD, 1986, J BIOL CHEM, V261, P15725; ESCO JD, 1985, P NATL ACAD SCI USA, V82, P3197; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KELLY JL, 1993, J CELL BIOL, V121, P1153, DOI 10.1083/jcb.121.5.1153; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; LAROCHELLE WJ, 1991, GENE DEV, V5, P1191, DOI 10.1101/gad.5.7.1191; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; OLSON DJ, 1991, SCIENCE, V252, P1173, DOI 10.1126/science.252.5009.1173; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; OSTMAN A, 1991, CELL REGUL, V2, P503, DOI 10.1091/mbc.2.7.503; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PEIFER M, 1995, TRENDS CELL BIOL, V5, P224, DOI 10.1016/S0962-8924(00)89015-7; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WILLIAMS LT, 1984, J BIOL CHEM, V259, P5287; WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	52	17	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					333	342						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710372				2022-12-28	WOS:A1996VA25200012
J	Welcker, M; Lukas, J; Strauss, M; Bartek, J				Welcker, M; Lukas, J; Strauss, M; Bartek, J			Enhanced protein stability: A novel mechanism of D-type cyclin over-abundance identified in human sarcoma cells	ONCOGENE			English	Article						cell cycle; proto-oncogene; D-cyclin protein stability; retinoblastoma protein; multistep tumorigenesis	HUMAN BREAST-CANCER; G1 PHASE PROGRESSION; D-CDK COMPLEXES; RETINOBLASTOMA-PROTEIN; DEPENDENT KINASES; GENE-PRODUCT; G(1) CONTROL; EXPRESSION; AMPLIFICATION; LOCALIZATION	The mammalian D-type cyclins promote progression through a G1 checkpoint by phosphorylating the retinoblastoma protein (pRB), and can contribute to oncogenesis via their deregulated expression achieved through gene amplification, chromosomal rearrangement, or retroviral integration. We now report a novel mechanism of tumour-associated D-cyclin over-abundance, resulting from enhanced protein stability. In two human cell lines established from a single uterine sarcoma biopsy, pRB-positive SK-UT-1B and pRB-deficient SK-UT-1, aberrant accumulation of functional cyclins D1, and D2 and D3 occurred in the absence of gene amplification and/or elevated mRNA expression. The abundance of D-cyclin proteins remained elevated throughout the cell cycle, and pulse-chase experiments revealed six to 10-fold prolongation of their protein half-lives as compared with either diploid fibroblasts or control U-2-OS sarcoma cells. These results point to a critical regulatory role of D-type cyclin turnover, and contribute to refinement of current views of the role played by the cyclin D-CDK-p16-pRB pathway in cell cycle control and tumorigenesis.	DANISH CANC SOC, DIV CANC BIOL, DK-2100 COPENHAGEN O, DENMARK; MAX PLANCK GESELL, D-13122 BERLIN, GERMANY	Danish Cancer Society; Max Planck Society			Bartek, Jiri/G-5870-2014	Welcker, Markus/0000-0001-6723-4790; Lukas, Jiri/0000-0001-9087-506X				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTKOVA J, 1995, ONCOGENE, V10, P775; Bartkova J, 1996, INT J CANCER, V65, P323, DOI 10.1002/(SICI)1097-0215(19960126)65:3<323::AID-IJC8>3.0.CO;2-1; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BATES S, 1994, ONCOGENE, V9, P1633; BATES S, 1994, ONCOGENE, V9, P71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; GILLETT C, 1994, CANCER RES, V54, P1812; HUNT T, 1991, NATURE, V349, P100, DOI 10.1038/349100a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; KATO J, 1993, GENE DEV, V7, P331; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEBWOHL DE, 1994, ONCOGENE, V9, P1925; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; LUKAS J, 1995, ONCOGENE, V10, P2125; LUKAS J, 1995, CANCER RES, V55, P4818; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETERS G, 1994, J CELL SCI, P89; SCHUURING E, 1992, ONCOGENE, V7, P355; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; STEWART E, 1994, EMBO J, V13, P584, DOI 10.1002/j.1460-2075.1994.tb06296.x; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TAM SW, 1994, ONCOGENE, V9, P2663; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	47	47	51	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					419	425						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710382				2022-12-28	WOS:A1996VA25200022
J	Vaillancourt, RR; Gardner, AM; Kazlauskas, A; Johnson, GL				Vaillancourt, RR; Gardner, AM; Kazlauskas, A; Johnson, GL			The kinase-inactive PDGF beta-receptor mediates activation of the MAP kinase cascade via the endogenous PDGF alpha-receptor in HepG2 cells	ONCOGENE			English	Article						PDGF receptor; HepG2 cells; MAP kinase; Raf-1	GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-C-GAMMA; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; PROTEIN-KINASE; BINDING-SITE; PHOSPHATIDYLINOSITOL-3 KINASE; AUTOPHOSPHORYLATION SITES; INSULIN-RECEPTORS; CDNA CLONING	The PDGF beta-receptor in which the active-site lysine in the kinase domain has been mutated to arginine (K634R) lacks intrinsic kinase activity, When expressed in HepG2 cells, the kinase-inactive PDGF beta-receptor was tyrosine phosphorylated in response to PDGF-BB. Previously, HepG2 cells were thought to be devoid of PDGF alpha-receptor primarily due to lack of specific antibody which precluded detection of the PDGF alpha-receptor. In fact, these cells express low levels of PDGF alpha-receptor. In HepG2 cells that express the kinase-inactive PDGF beta-receptor, PDGF-BB activates the PDGF alpha-receptors to trans phosphorylate the kinase-inactive PDGF beta-receptor in an intermolecular fashion. As a result, stimulation of HepG2 cells that express the kinase-inactive receptor leads to activation of serine-threonine kinases of the MAP kinase cascade which include RAF-1, MEK-1 and p42 MAP kinase. In contrast, the kinase-inactive receptor does not activate any signaling pathways when it is expressed in PC12 cells which do not express the endogenous PDGF alpha-receptor. Thus, the kinase-inactive K634R PDGF beta-receptor is able to enhance PDGF-BB signaling in HepG2 cells that express the PDGF alpha-receptor.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Vaillancourt, RR (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,DENVER,CO 80206, USA.			Gardner, Anne/0000-0001-7095-772X	NCI NIH HHS [CA58187] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BAZENET CE, 1993, ONCOGENE, V9, P517; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPOSGONZALEZ R, 1992, J BIOL CHEM, V267, P14535; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COKER KJ, 1994, P NATL ACAD SCI USA, V91, P6967, DOI 10.1073/pnas.91.15.6967; COUGHLIN SR, 1989, SCIENCE, V243, P1191; CREWS CM, 1992, SCIENCE, V25; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GRONWALD RGK, 1988, P NATL ACAD SCI USA, V85, P3435, DOI 10.1073/pnas.85.10.3435; HEASLEY LE, 1992, MOL BIOL CELL, V3, P545, DOI 10.1091/mbc.3.5.545; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1990, MOL CELL BIOL, V10, P4035, DOI 10.1128/MCB.10.8.4035; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1990, EMBO J, V9, P3279, DOI 10.1002/j.1460-2075.1990.tb07527.x; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; KELLY JD, 1991, J BIOL CHEM, V266, P8987; KOHLER N, 1974, EXP CELL RES, V87, P297, DOI 10.1016/0014-4827(74)90484-4; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; RUSSELL M, 1995, BIOCHEMISTRY-US, V34, P6611, DOI 10.1021/bi00020a005; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SELVA E, 1993, J BIOL CHEM, V268, P2250; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WESTERMARK B, 1976, EXP CELL RES, V98, P170, DOI 10.1016/0014-4827(76)90476-6; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WRIGHT JD, 1995, J BIOL CHEM, V270, P12085, DOI 10.1074/jbc.270.20.12085; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	73	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					151	159						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700541				2022-12-28	WOS:A1996UX31900017
J	Rickert, P; Seghezzi, W; Shanahan, F; Cho, H; Lees, E				Rickert, P; Seghezzi, W; Shanahan, F; Cho, H; Lees, E			Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II	ONCOGENE			English	Article						cyclin C; CDK8; RNA polymerase II; cell cycle	CARBOXYL-TERMINAL-DOMAIN; HUMAN CELL-CYCLE; PROTEIN-KINASE; CATALYTIC SUBUNIT; SACCHAROMYCES-CEREVISIAE; MAMMALIAN FIBROBLASTS; YEAST; PHOSPHORYLATION; PHASE; G(1)	A number of cyclin/kinase complexes have been identified in mammalian cells that are essential for controlled cell proliferation. Cyclin C was isolated by virtue of its ability to rescue the triple CLN mutation in yeast; however, until now its function has remained unclear. Cyclin C associates with a novel cyclin dependent kinase, CDK8, and we demonstrate that this complex is associated with kinase activity towards the carboxy-terminal domain (CTD) of RNA polymerase II. We have identified at least two distinct cyclin C/CDK8 containing complexes within the cell, a larger complex over 500 kD in size, that also contains the largest subunit of RNA polymerase II, and a smaller 170 kD species. Both of these cyclin C complexes retain potent CTD kinase activity. We further demonstrate that the cyclin C/CDK8 complex associates with the large subunit of RNA polymerase II in vivo, implicating a potential role for cyclin C/CDK8 in regulating its activities.	DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center								BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BATES S, 1994, ONCOGENE, V9, P71; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORDEN JL, 1993, CURR OPIN GENET DEV, V3, P213, DOI 10.1016/0959-437X(93)90025-K; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; EMILI A, 1995, CURR OPIN GENET DEV, V5, P204, DOI 10.1016/0959-437X(95)80009-3; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRANA X, 1995, ONCOGENE, V11, P211; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KUCHIN A, 1995, P NATL ACAD SCI USA, V92, P4006; LEE JM, 1991, GENE EXPRESSION, V1, P149; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MALDONADO E, 1996, IN PRESS NATURE; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKAMURA T, 1995, EXP CELL RES, V221, P534, DOI 10.1006/excr.1995.1406; NEVINS JR, 1992, SCIENCE, V258, P424; NONET ML, 1989, GENETICS, V123, P715; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OSSIPOW V, 1995, CELL, V83, P137, DOI 10.1016/0092-8674(95)90242-2; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PAYNE JM, 1993, J BIOL CHEM, V268, P80; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Pines Jonathon, 1994, Seminars in Cell Biology, V5, P399, DOI 10.1006/scel.1994.1047; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STERNER DE, 1995, MOL CELL BIOL, V15, P5716; TAMURA K, 1993, ONCOGENE, V8, P2113; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON NE, 1989, J BIOL CHEM, V264, P1151; TSAI LH, 1993, ONCOGENE, V8, P1593; WU LT, 1994, ONCOGENE, V9, P2089; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013	72	150	157	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2631	2640						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700522				2022-12-28	WOS:A1996UW48700017
J	Rodenhiser, D; Chakraborty, P; Andrews, J; Ainsworth, P; Mancini, D; Lopes, E; Singh, S				Rodenhiser, D; Chakraborty, P; Andrews, J; Ainsworth, P; Mancini, D; Lopes, E; Singh, S			Heterogeneous point mutations in the BRCA1 breast cancer susceptibility gene occur in high frequency at the site of homonucleotide tracts, short repeats and methylatable CpG/CpNpG motifs	ONCOGENE			English	Article						BRCA1; mutation; mutagenesis; homonucleotides; repeats; CpG	NF1 GENE; DNA; DELETIONS; MUTAGENESIS; DISEASE; COLON	Heterogeneous mutations in the BRCA1 tumour suppressor gene are responsible for a large percentage of inherited breast cancers as well as breast/ovarian cancers in families with a high incidence of both cancer types, Over a hundred BRCA1 mutations have been reported, but little is known of the mechanism(s) responsible for BRCA1 mutagenesis, To determine the significance of specific nucleotide sequences at mutational sites within the BRCA1 gene, are assessed how frequently independent BRCA1 mutations occur at the site of short direct repeats, single nucleotide repeats (homonucleotides) and at CpG and CpNpG motifs, We found that homonucleotide and short direct repeats are commonly associated with small deletions and insertions, Substitution mutations are frequently associated with homonucleotide repeats and with methylatable CpG dinucleotides and CpNpG trinucleotides, Our methylation and sequencing experiments show that CpG and certain CpNpG motifs are methylated, supporting the hypothesis that DNA methylation specificity at these sites may be an important contributor to BRCA1 mutagenesis. We suggest that BRCA1 mutations are acquired by replication errors and are retained by cells through an intricate balancing of replication and repair mechanisms, Such mutations may provide a proliferative advantage for a cell, leading to the tumour phenotype.	UNIV WESTERN ONTARIO, DEPT PAEDIAT, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, DEPT ZOOL, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON, ON, CANADA; VICTORIA HOSP, MOL DIAGNOST LAB, LONDON, ON N6A 4G5, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Victoria; Western University (University of Western Ontario)	Rodenhiser, D (corresponding author), CHILDRENS HOSP WESTERN ONTARIO, CHILD HLTH RES INST, MOL MED GENET PROGRAM, LONDON, ON N6C 2V5, CANADA.							AINSWORTH PJ, 1993, HUM GENET, V91, P151; Andrews JD, 1996, HUM MOL GENET, V5, P503, DOI 10.1093/hmg/5.4.503; BOTTEMA CDK, 1993, HUM GENET, V91, P496; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; CLARK SJ, 1995, NAT GENET, V10, P20, DOI 10.1038/ng0595-20; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CLAUS EB, 1991, AM J HUM GENET, V48, P232; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; FRIEDMAN LS, 1995, AM J HUM GENET, V57, P1284; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; INOUE R, 1995, CANCER RES, V55, P3521; JEGO N, 1993, ONCOGENE, V8, P209; KRAWCZAK M, 1991, HUM GENET, V86, P425; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; PLUMMER SJ, 1995, HUM MOL GENET, V4, P1989, DOI 10.1093/hmg/4.10.1989; REDSTON MS, 1994, CANCER RES, V54, P3025; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; RODENHISER DI, 1993, HUM MOL GENET, V2, P439, DOI 10.1093/hmg/2.4.439; RODENHISER DI, 1995, AM J HUM GENET, V57, P1829; SCHLOTTERER C, 1992, NUCLEIC ACIDS RES, V20, P211, DOI 10.1093/nar/20.2.211; SCHMUTTE C, 1995, CANCER RES, V55, P3742; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; Sinden Richard R., 1992, Current Opinion in Biotechnology, V3, P612, DOI 10.1016/0958-1669(92)90005-4; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TASHEVA ES, 1993, SOMAT CELL MOLEC GEN, V19, P275, DOI 10.1007/BF01233075; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; TORNALETTI S, 1995, ONCOGENE, V10, P1493; UPADHYAYA M, 1994, HUM MUTAT, V4, P83, DOI 10.1002/humu.1380040202; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152	49	37	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2623	2629						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700521				2022-12-28	WOS:A1996UW48700016
J	Vairapandi, M; Balliet, AG; Fornace, AJ; Hoffman, B; Liebermann, DA				Vairapandi, M; Balliet, AG; Fornace, AJ; Hoffman, B; Liebermann, DA			The differentiation primary response gene MyD118, related to GADD45, encodes for a nuclear protein which interacts with PCNA and p21(WAF1/CIP1)	ONCOGENE			English	Article						MyD118; p21(WAF1); PCNA; Gadd45; myeloid differentiation; apoptosis	LEUKEMIA INHIBITORY FACTOR; IMMEDIATE EARLY RESPONSE; CYCLIN-DEPENDENT KINASES; TERMINAL DIFFERENTIATION; GROWTH-ARREST; CELL-DEATH; C-MYC; DNA-REPLICATION; APOPTOSIS; P53	Towards dissecting the regulation of terminal differentiation, including growth arrest and apoptosis, myeloid differentiation primary response (MyD) genes, induced in the absence of de novo protein synthesis following induction of M1 myeloblastic leukemia cells for terminal differentiation have been isolated. MyD118 was one of the novel MyD genes cloned, subsequently observed also to be a primary response gene to TGF-beta, which induces M1 cells for growth arrest and apoptosis uncoupled from differentiation. The MyD118 encoded protein was observed to be remarkably similar to the protein encoded by Gadd45, a growth arrest and DNA damage induced gene, regulated in part by the tumor suppressor p53, Though evidence has accumulated that MyD118 functions as an important modulator of negative growth control both in hematopoietic and non-hematopoietic cells, its mechanism of action is unknown, To better understand the role(s) of MyD118 in negative growth control, we have analysed the expression and biological characteristics of the MyD118 protein, compared to the Gadd45 protein, in distinct pathways of growth arrest and apoptosis, including p53 dependent and independent pathways either coupled or uncoupled from differentiation. It is shown that MyD118 and Gadd45 differentially accumulated upon induction of distinct pathways of growth arrest and apoptosis; notably, MyD118, but not Gadd45, was induced by TGF-beta, whereas Gadd45, but not MyD118, was induced by activating wild type (wt) p53 function, It is also shown that MyD118 is a nuclear protein, which regardless of the pathway induced, predominantly localized within the cell nucleus, and interacted with the DNA replication and repair protein PCNA and the cyclin dependent kinase inhibitor P21(WAF1/CIP1). MyD118 also modestly stimulated DNA repair in vitro. All of these characteristics were shared with Gadd45, Finally, it is demonstrated that MyD118, Gadd45 and p21 synergized in the suppression of colony formation by NIH3T3 cells, Taken together, these findings demonstrate that MyD118 and Gadd45 are representative of a new protein family that share remarkable functional similarities in the control of distinct pathways of negative growth, including the suppression of cellular growth and programmed cell death.	TEMPLE UNIV, SCH MED, FELS INST CANC & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA; NCI, DIV CANC TREATMENT, MOLEC PHARMACOL LAB, NIH, BETHESDA, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X	NATIONAL CANCER INSTITUTE [R01CA043618, P30CA012227] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA43618, 5P30 CA12227] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CARRIER F, 1994, J BIOL CHEM, V269, P32672; CHEN IT, 1995, ONCOGENE, V11, P1931; COWLING GJ, 1994, PHILOS T ROY SOC B, V345, P257, DOI 10.1098/rstb.1994.0103; DIETRICH DR, 1993, CRIT REV TOXICOL, V23, P77, DOI 10.3109/10408449309104075; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; FORNACE AJ, 1992, ANNU REV GENET, V26, P507; GRANA X, 1995, ONCOGENE, V11, P211; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1993, CELL, V75, P805; HAWELY RG, 1994, GENE THER, V1, P36; HE B, IN RPESS J VIROLOGY; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAZANTSEV A, 1995, SCIENCE, V270, P1003, DOI 10.1126/science.270.5238.1003; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KEARSEY JM, 1995, SCIENCE, V270, P1004; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KORSMEYER SJ, 1992, BLOOD, V80, P879; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LORD KA, 1990, CELL GROWTH DIFFER, V1, P637; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARX J, 1993, SCIENCE, V259, P60; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; OLTAVI NZ, 1994, CELL, V79, P189; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; QUENSBERY PJ, 1994, EILLIAMS HEMATOLOGY, pCH22; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SELVAKUMARAN M, 1993, BLOOD, V81, P2257; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SMITH ML, 1995, SCIENCE, V270, P1005; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; ZHAN QM, 1995, INT J ONCOL, V6, P937	78	158	160	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2579	2594						16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700517				2022-12-28	WOS:A1996UW48700012
J	Zornig, M; Schmidt, T; Karsunky, H; Grzeschiezek, A; Moroy, T				Zornig, M; Schmidt, T; Karsunky, H; Grzeschiezek, A; Moroy, T			Zinc finger protein GFI-1 cooperates with MYC and PIM-1 in T-cell lymphomagenesis by reducing the requirements for IL-2	ONCOGENE			English	Article						oncogene cooperation; MoMuLV mutagenesis; proviral integration; zinc finger; IL-2 independence; tumour progression	MURINE LEUKEMIA-VIRUS; E-MU-MYC; C-MYC; TRANSGENIC MICE; N-MYC; PROVIRAL INSERTION; GENE; DNA; RNA; EXPRESSION	The clonality of lymphomas that originate in myc/pim-1 bitransgenic mice due to synergistic action of both oncogenes indicates the requirement of additional events for progression to full malignancy, To isolate genes that cooperate with both myc and pim-1, we have used provirus tagging with E mu L-myc/pim-1 double transgenic mice, We find accelerated tumour formation in infected animals and show that the gfi-1 gene and neighbouring loci on mouse chromosome 5 are occupied by proviruses in about 53% of the tumours leading in all cases to high level gfi-1 expression. In agreement with data from Gilks et al, (1993) we find that forced expression of the gfi-1 encoded zinc finger protein in IL-2 dependent T-cells provokes increased survival upon IL-2 depletion and we present evidence that this occurs at least in part through stimulation of proliferation, Our data suggest that gfi-1 is a proto-oncogene and very efficiently engages in a tripartite oncogene cooperation with both mye and pim-1 genes in T-cell lymphomagenesis.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,D-35037 MARBURG,GERMANY	Philipps University Marburg			Moroy, Tarik/D-9923-2011					ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASKEW DS, 1991, ONCOGENE, V6, P1915; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BERNS A, 1991, Current Biology, V1, P28, DOI 10.1016/0960-9822(91)90118-G; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BREUER ML, 1989, EMBO J, V8, P743, DOI 10.1002/j.1460-2075.1989.tb03434.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUYPERS HT, 1984, CELL, V37, P141; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GOTO Y, 1992, J BIOL CHEM, V267, P15252; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HANAHAN D, 1989, SCIENCE, V246, P1265, DOI 10.1126/science.2686032; HAUPT Y, 1993, ONCOGENE, V8, P3161; HAUPT Y, 1991, CELL, V65, P753, DOI 10.1016/0092-8674(91)90383-A; HOGAN B, 1986, MANIPULATION MOUSE E; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JAENISCH R, 1975, P NATL ACAD SCI USA, V72, P4008, DOI 10.1073/pnas.72.10.4008; LEWIS S, 1982, CELL, V30, P807, DOI 10.1016/0092-8674(82)90285-9; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; LIAO XB, 1995, J VIROL, V69, P7132, DOI 10.1128/JVI.69.11.7132-7137.1995; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MOROY T, 1993, P NATL ACAD SCI USA, V90, P10734, DOI 10.1073/pnas.90.22.10734; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MOROY T, 1991, ONCOGENE, V6, P1941; MOROY T, 1991, MOL F ONCOLOGY, P455; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; REIK W, 1985, P NATL ACAD SCI USA, V82, P1141, DOI 10.1073/pnas.82.4.1141; ROSENBAUM H, 1989, EMBO J, V8, P749, DOI 10.1002/j.1460-2075.1989.tb03435.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; TRIGLIA T, 1988, NUCLEIC ACIDS RES, V16, P8186, DOI 10.1093/nar/16.16.8186; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; VANLOHUIZEN M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P213, DOI 10.1016/0304-419X(90)90005-L; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VERBEEK S, 1991, MOL CELL BIOL, V11, P1176, DOI 10.1128/MCB.11.2.1176	50	94	98	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1789	1801						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622900				2022-12-28	WOS:A1996UG45800022
J	Taniguchi, T; Takaishi, K; Murayama, T; Ito, M; Iwata, N; Chihara, K; Sasaki, T; Takai, Y; Matsui, T				Taniguchi, T; Takaishi, K; Murayama, T; Ito, M; Iwata, N; Chihara, K; Sasaki, T; Takai, Y; Matsui, T			Cholecystokinin-B/gastrin receptors mediate rapid formation of actin stress fibers	ONCOGENE			English	Article						stress fiber; cholecystokinin; gastrin; rho p21; PDGF	PROTEIN RHO GDI; SWISS 3T3 CELLS; TYROSINE KINASE; HUMAN BRAIN; ADP-RIBOSYLTRANSFERASE; CLOSTRIDIUM-BOTULINUM; GASTRIN RECEPTOR; FOCAL ADHESIONS; GROWTH; CLONING	Specific receptors for brain-gut peptide hormones, cholecystokinin (CCK) and gastrin, are expressed in a variety of human tumor cells, CCK and gastrin promote the growth of NIH3T3 cells into which the CCK-B/gastrin receptor had been introduced via a eukaryotic expression vector. In this study, we have examined the effect of CCK-8 on the actin cytoskeleton by using two mouse fibroblast cell lines expressing human CCK-B/gastrin receptors. Treatment with very low concentrations of CCK-8 (10(-10) M) induced the formation of actin stress fibers within one minute. Stress fiber formation increased for 30 min, In contrast, a potent mitogen for fibroblasts, platelet-derived growth factor (PDGF), initially induced membrane ruffling and, later, a weak formation of stress fibers. Microinjection of rho GDP dissociation inhibitor or Clostridium botulinum ADP-ribosyltransferase C3 which is known to impair the function of a small GTP-binding protein, rho p21, inhibited the stress fiber formation by CCK-8 as well as by PDGF. These results indicate that CCK-B/gastrin receptor could regulate stress fiber formation in a rho p21-dependent manner. The signals from CCK-B/gastrin receptor might affect cell growth as well as cell motility or adhesion by regulating the actin cytoskeleton.	KOBE UNIV,SCH MED,DEPT MED,DIV 3,KOBE 650,JAPAN; OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN	Kobe University; Osaka University			Matsui, Toshimitsu/E-8065-2010	Matsui, Toshimitsu/0000-0002-2536-7584				CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; HOOSEIN NM, 1988, CANCER RES, V48, P7179; ISHIZUKA J, 1992, ANN SURG, V215, P528, DOI 10.1097/00000658-199205000-00016; ITO M, 1993, J BIOL CHEM, V268, P18300; ITO M, 1994, CELL GROWTH DIFFER, V5, P1127; JOHNSON LR, 1988, PHYSIOL REV, V68, P456, DOI 10.1152/physrev.1988.68.2.456; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LEE YM, 1993, J BIOL CHEM, V268, P8164; MATSUMORI Y, 1995, CANCER RES, V55, P276; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIURA Y, 1993, J BIOL CHEM, V268, P510; NEMOTO Y, 1991, J BIOL CHEM, V266, P19312; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; PISEGNA JR, 1992, BIOCHEM BIOPH RES CO, V189, P296, DOI 10.1016/0006-291X(92)91557-7; RAUFMAN JP, 1984, AM J PHYSIOL, V247, pG95, DOI 10.1152/ajpgi.1984.247.1.G95; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; Sacerdote P, 1988, Peptides, V9 Suppl 1, P29, DOI 10.1016/0196-9781(88)90219-7; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SETHI T, 1991, CANCER RES, V51, P3621; SILEN ML, 1993, TRENDS ENDOCRIN MET, V4, P131, DOI 10.1016/1043-2760(93)90037-F; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TANIGUCHI T, 1994, ONCOGENE, V9, P861; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628	30	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1357	1360						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649838				2022-12-28	WOS:A1996UC06700021
J	Rose, FV; Barnea, ER				Rose, FV; Barnea, ER			Response of human ovarian carcinoma cell lines to antiprogestin mifepristone	ONCOGENE			English	Article						ovarian cancer; antiprogestin; progesterone receptor; mifepristone; cell cycle	BREAST-CANCER; PROGESTERONE; ENDOMETRIAL; ESTROGEN; SURVIVAL; PHASE; PROLIFERATION; TAMOXIFEN; RECEPTORS; KINETICS	The effects of antiprogestin mifepristone (MF) on the growth, progesterone receptor expression and cell cycle kinetics of several human ovarian epithelial carcinoma (OEC) cell lines were evaluated. MF, a synthetic antiprogestin, has been shown to have some antiproliferative activity in breast tumors and in the endometrium, but its efficacy in ovarian carcinomas has not been explored previously. Continuous exposure of OEC cells to MF resulted in a dose- and time-dependent growth inhibition, as determined by MTT assay. Growth inhibition was apparent by day three following addition of MF to cultures in vitro. All cell lines used in this study expressed a progesterone receptor (PR). MF down regulated PR expression on these cells. Changes in the cell cycle kinetics of OEC cells exposed to MF correlated with the observed antiproliferative effects. MF blocked cells in a G(0)/G(1) phase of the cell cycle and thus reduced the number of cells in the S phase. The efficacy of MF was compared with that of taxol and tamoxifen in the same human OEC cell lines. Continuous exposure of OEC cells to tamoxifen resulted in a varied cytostatic response and a transient change in the cell cycle. Taxol inhibited growth of some but not all of the cell lines. These results indicate that PR-positive human OEC cells are sensitive to MF in vitro and that MF may be an active agent against ovarian epithelial tumors.			Rose, FV (corresponding author), UNIV MED & DENT NEW JERSEY,COOPER HOSP,ROBERT WOOD JOHNSON MED SCH,UNIV MED CTR,CAMDEN,NJ 08103, USA.		Barnea, Eytan/AAC-9910-2021; Barnea, Eytan/AAK-9467-2021	Barnea, Eytan/0000-0003-4677-4370				AHLGREN JD, 1993, J CLIN ONCOL, V11, P1957, DOI 10.1200/JCO.1993.11.10.1957; BAKKER GH, 1990, J STEROID BIOCHEM, V37, P789, DOI 10.1016/0960-0760(90)90421-G; BERTAGNA X, 1994, J CLIN ENDOCR METAB, V78, P375, DOI 10.1210/jc.78.2.375; BRENNER RM, 1994, HUM REPROD, V9, P82, DOI 10.1093/humrep/9.suppl_1.82; DREICER R, 1992, CANCER INVEST, V10, P27, DOI 10.3109/07357909209032786; GALTIERDEREURE F, 1992, J CLIN ENDOCR METAB, V75, P1497, DOI 10.1210/jc.75.6.1497; GEISINGER KR, 1990, CANCER, V65, P1055, DOI 10.1002/1097-0142(19900301)65:5<1055::AID-CNCR2820650502>3.0.CO;2-9; GHOSH D, 1992, HUM REPROD, V7, P1048, DOI 10.1093/oxfordjournals.humrep.a137792; GRAHAM ML, 1989, CANCER RES, V49, P3934; HORWITZ KB, 1992, ENDOCR REV, V13, P146, DOI 10.1210/er.13.2.146; KALLIONIEMI OP, 1988, CANCER, V61, P334, DOI 10.1002/1097-0142(19880115)61:2<334::AID-CNCR2820610224>3.0.CO;2-M; KAUPPILA A, 1984, ACTA OBSTET GYN SCAN, V63, P441, DOI 10.3109/00016348409156700; KLEMI PJ, 1989, OBSTET GYNECOL, V74, P200; KRIGMAN H, 1994, CLIN OBSTET GYNECOL, V37, P475, DOI 10.1097/00003081-199406000-00021; LEBEAU MC, 1994, HUM REPROD, V9, P437, DOI 10.1093/oxfordjournals.humrep.a138524; MAENTAUSTA O, 1993, J CLIN ENDOCR METAB, V77, P913, DOI 10.1210/jc.77.4.913; Milas Luka, 1994, In Vivo (Attiki), V8, P665; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NICOLETTI MI, 1993, ANN ONCOL, V4, P151, DOI 10.1093/oxfordjournals.annonc.a058419; NORDEEN SK, 1993, MOL ENDOCRINOL, V7, P731, DOI 10.1210/me.7.6.731; OZOLS RF, 1991, CANCER TREAT REV, V18, P77, DOI 10.1016/0305-7372(91)90027-W; RAO BR, 1991, ENDOCR REV, V12, P14, DOI 10.1210/edrv-12-1-14; REDDEL RR, 1987, CANCER RES, V47, P5323; ROTELLO RJ, 1992, AM J PATHOL, V140, P449; SATYASWAROOP P, 1992, PRINCIPLES PRACTICE, P151; SAUSVILLE E, 1992, PRINCIPLES PRACTICE, P47; SLOTMAN BJ, 1990, CANCER, V66, P740, DOI 10.1002/1097-0142(19900815)66:4<740::AID-CNCR2820660423>3.0.CO;2-H; THOMPSON MA, 1993, ADV EXP MED BIOL, V330, P155; WOODS LK, 1979, CANCER RES, V39, P4449	29	38	43	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					999	1003						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649817				2022-12-28	WOS:A1996UA88400007
J	Aroca, P; Mahadevan, D; Santos, E				Aroca, P; Mahadevan, D; Santos, E			Functional interactions between isolated SH2 domains and insulin/Ras signaling pathways of Xenopus oocytes: Opposite effects of the carboxy- and amino-terminal SH2 domains of p85 PI 3-kinase	ONCOGENE			English	Article						SH2; Ras; insulin signaling; p85 alpha PI 3-kinase; Xenopus	RECEPTOR TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; MEIOTIC MATURATION; ONCOGENE PRODUCT; BETA-RECEPTOR; HIGH-AFFINITY; RAS PROTEINS; SPECIFICITY; ACTIVATION	Purified amino-terminal Src homology 2 (SH2) domains of GAP, PLC gamma 1 and the p85 alpha subunit of PI 3-kinase, as well as the carboxy-terminal SH2 domain of the latter protein and the unique SH2 domain of Grb2, were injected into full grown, stage VI Xenopus laevis oocytes, None of the injected domains showed any effect when injected alone, nor did they affect the rate of GVBD induced by progesterone, an adenylate cyclase-dependent process, On the other hand, the unique Grb2 SH2 domain and all N-terminal SH2 domains injected inhibited to various degrees the rate of insulin-induced GVBD, a tyrosine kinase dependent pathway, Interestingly, and in contrast to the behavior shown by the N-terminal domain of the same molecule, the C-terminal SH2 domain of p85 did not inhibit, but slightly accelerated the rate of GVBD induced by insulin, Furthermore, whereas the Grb SH2 domain and all N-terminal SH2 domains tested failed to co-operate with normal Ras protein to induce GVBD, the C-terminal SH2 domain of p85 alpha exhibited significant synergy when coinjected with normal Pas protein, indicating that the C- and N-terminal SH2 domains of p85 alpha exert opposite (positive and negative, respectively) regulatory roles in the control of oocyte insulin/Ras signaling pathways, Our results demonstrate that the purified, isolated SH2 domains retain structural and functional specificity and that Xenopus oocytes constitute an useful biological system to analyse their functional role in tyrosine kinase signaling pathways.	NCI, DBS, CELLULAR & MOL BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Aroca, Pilar/P-2141-2017	Aroca, Pilar/0000-0002-7557-6931				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; AROCA P, 1995, J BIOL CHEM, V270, P14229, DOI 10.1074/jbc.270.23.14229; BACKER JM, 1992, J BIOL CHEM, V267, P1367; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; DAAR IO, 1991, MOL CELL BIOL, V11, P5985, DOI 10.1128/MCB.11.12.5985; deMora JF, 1996, J BIOL CHEM, V271, P18272, DOI 10.1074/jbc.271.30.18272; DESHPANDE AK, 1987, MOL CELL BIOL, V7, P1285, DOI 10.1128/MCB.7.3.1285; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; Gotoh N, 1995, ONCOGENE, V11, P2525; GRAZIANI G, 1992, ONCOGENE, V7, P229; GRIGORESCU F, 1994, HORM RES, V42, P55, DOI 10.1159/000184146; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KATZAV S, 1995, ONCOGENE, V11, P1079; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KORN LJ, 1987, SCIENCE, V236, P840, DOI 10.1126/science.3554510; LIU XJ, 1995, MOL CELL BIOL, V15, P3563; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHADEVAN D, 1994, BIOCHEMISTRY-US, V33, P746, DOI 10.1021/bi00169a016; Maller James L., 1994, Seminars in Developmental Biology, V5, P183, DOI 10.1006/sedb.1994.1024; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; NEBREDA AR, 1993, ONCOGENE, V8, P467; NEBREDA AR, 1991, SCIENCE, V252, P558, DOI 10.1126/science.1850550; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PINES J, 1990, New Biologist, V2, P389; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; YOAKIM M, 1994, MOL CELL BIOL, V14, P5929, DOI 10.1128/MCB.14.9.5929; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	52	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1839	1846						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934529				2022-12-28	WOS:A1996VR79500002
J	Phinney, DG; Tseng, SW; Hall, B; Ryder, K				Phinney, DG; Tseng, SW; Hall, B; Ryder, K			Chromosomal integration dependent induction of junB by growth factors requires multiple flanking evolutionarily conserved sequences	ONCOGENE			English	Article						chromatin; regulation; evolutionary conservation	SERUM RESPONSE ELEMENT; C-FOS PROMOTER; TRANSCRIPTION FACTORS; SIGNAL-TRANSDUCTION; GENE; BINDING; COMPLEX; PROTEINS; DIFFERENTIATION; IDENTIFICATION	The junB locus contains nine flanking evolutionarily conserved sequences (FECS) that share 72% to 91% sequence identity between human and mouse, These FECS encompass the same regions of flanking DNA necessary for maximal mitogenic induction of junB, Most of the cis elements reported to date that affect junB regulation also reside within FECS, These observations suggest that the persistence of FECS through evolution reflects a necessary role in junB transcriptional regulation, In this report, we identify specific regulatory cis elements within junB FECS II and III and provide a quantitative analysis of the contribution made by these sequences to junB induction, These cis elements include a Serum Response Element (SRE), two Ets sites previously unrecognized as contributing to junB expression, and two novel Ets-linked motifs (ELMs), In general, mutating any single element significantly impairs junB induction, Moreover, the same mutations alter the structure of junB 5' flanking DNA within chromatin, Collectively, these results suggest that multiple proteins bound within FECS confederate to form a functional promoter complex, the activity of which is dependent upon a specific chromatin architecture.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19007	Fox Chase Cancer Center			Phinney, Donald G/D-2155-2014	Phinney, Donald/0000-0002-8688-2619	NATIONAL CANCER INSTITUTE [R01CA052752, P30CA006927] Funding Source: NIH RePORTER; NCI NIH HHS [CA-06927-31, CA-52752] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER P, 1994, ONCOGENE, V9, P911; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; GARRITY PA, 1994, MOL CELL BIOL, V14, P2159, DOI 10.1128/MCB.14.3.2159; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NORDHEIM A, 1994, FOS JUN FAMILIES TRA, P97; PEREZALBUERNE ED, 1993, P NATL ACAD SCI USA, V90, P11960, DOI 10.1073/pnas.90.24.11960; PHINNEY DG, 1994, ONCOGENE, V9, P2353; PHINNEY DG, 1995, GENOMICS, V28, P228, DOI 10.1006/geno.1995.1135; RAO VN, 1994, ONCOGENE, V9, P1855; RIVERA FM, 1990, GENE DEV, V4, P225; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WOLFFE AP, 1994, SCIENCE, V264, P1100, DOI 10.1126/science.8178167	34	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1875	1883						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934533				2022-12-28	WOS:A1996VR79500006
J	Meloche, S; Beatty, BG; Pellerin, J				Meloche, S; Beatty, BG; Pellerin, J			Primary structure, expression and chromosomal locus of a human homolog of rat ERK3	ONCOGENE			English	Article						protein kinase; MAP kinase; gene cloning; chromosomal mapping	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASES; MAP KINASE; INSITU HYBRIDIZATION; GROWTH-FACTOR; CELLS; DIFFERENTIATION; P44(MAPK); CLONING; FAMILY	We report the cloning and characterization of a human cDNA encoding a novel homolog of rat extracellular signal-regulated kinase 3 (ERK3). The cDNA encodes a predicted protein of 721 amino acids which shares 92% amino acid identity with rat ERK3 over their shared length. Interestingly, the human protein contains a unique extension of 178 amino acids at its carboxy terminal extremity, The human ERK3 protein also displays various degrees of homology to other members of the MAP kinases family, but does not contain the typical TXY regulatory motif between subdomains VII and Vm. Northern blot analysis revealed that ERK3 mRNA is widely distributed in human tissues, with the highest expression detected in skeletal muscle. The human ERK3 gene was mapped by fluorescence lit situ hybridization to chromosome 15q21, a region associated with chromosomal abnormalities in acute nonlymphoblastic leukemias. This information should prove valuable in designing studies to define the cellular function of the ERK3 protein kinase.	UNIV MONTREAL, DEPT PHARMACOL, MONTREAL, PQ H2W 1T8, CANADA; HOSP SICK CHILDREN, DEPT PATHOL, TORONTO, ON M5G 1X8, CANADA	Universite de Montreal; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Meloche, S (corresponding author), HOP HOTEL DIEU, CTR RECH, MONTREAL, PQ H2W 1T8, CANADA.							ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOYLE AL, 1992, GENOMICS, V12, P106, DOI 10.1016/0888-7543(92)90412-L; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHAREST DL, 1993, MOL CELL BIOL, V13, P4679, DOI 10.1128/MCB.13.8.4679; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DUARTE MHO, 1990, CANCER GENET CYTOGEN, V49, P25, DOI 10.1016/0165-4608(90)90160-C; FUKUDA M, 1995, ONCOGENE, V11, P239; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LIND L, 1995, HUM MOL GENET, V4, P109, DOI 10.1093/hmg/4.1.109; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; *OMIM, 1996, ONL MEND INH MAN; OWAKI H, 1992, BIOCHEM BIOPH RES CO, V182, P1416, DOI 10.1016/0006-291X(92)91891-S; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUCIU S, 1990, CANCER GENET CYTOGEN, V44, P15, DOI 10.1016/0165-4608(90)90193-E; YUNIS JJ, 1981, NEW ENGL J MED, V305, P135, DOI 10.1056/NEJM198107163050304; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	36	22	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1575	1579						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875998				2022-12-28	WOS:A1996VL38400025
J	Jeffers, M; Rong, S; Anver, M; VandeWoude, GF				Jeffers, M; Rong, S; Anver, M; VandeWoude, GF			Autocrine hepatocyte growth factor scatter factor-Met signaling induces transformation and the invasive/metastastic phenotype in C127 cells	ONCOGENE			English	Article						hepatocyte growth factor scatter factor; Met; transformation; invasion; metastasis	FACTOR/SCATTER FACTOR; EPITHELIAL-CELLS; CARCINOMA-CELLS; TYROSINE KINASE; PROTOONCOGENE; RECEPTOR; TUMORIGENICITY; EXPRESSION; INDUCTION; INVASION	Hepatocyte growth factor/scatter factor (HGF/SF) is a pleiotropic effector of cells expressing the Met tyrosine kinase receptor. C127 is a non-tumorigenic mouse cell line which expresses negligible levels of HGF/SF and Met proteins. In the present report we have generated C127 cells which overexpress HGP/SF and/or Met proteins, and have analysed the effect of HGF/SF-Met signaling in these cells. We show that this signaling pathway stimulates the growth and invasiveness of C127 cells in vitro and that cells overexpressing both HGF/SF and Met proteins (but neither alone) are phenotypically transformed and highly tumorigenic and metastatic in vivo. Our data unequivocally demonstrates the autocrine dependency of HGF/SF-Met-induced transformation and metastasis in this system and supports the theory that the inappropriate expression of HGF/SF and Met proteins could play a role in the development and spread of human tumors. In addition, this system may be useful for identifying metastasis-associated genes that are activated by HGF/SF-Met signaling.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,SAIC,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								BELLUSCI S, 1994, ONCOGENE, V9, P1091; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; CUADRADO A, 1990, CELL GROWTH DIFFER, V1, P9; DVORETZKY I, 1980, VIROLOGY, V103, P309; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GHERARDI E, 1993, SYM SOC EXP BIOL, V47, P163; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; Higashio K, 1993, EXS, V65, P351; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; JEFFERS M, 1996, UNPUB; KANDA H, 1993, ONCOGENE, V8, P3047; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; Matsumoto K, 1993, HEPATOCYTE GROWTH FA, P225; MATSUMOTO K, 1992, Critical Reviews in Oncogenesis, V3, P27; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PORTEOUS DJ, 1986, INT J CANCER, V38, P603, DOI 10.1002/ijc.2910380422; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROSEN EM, 1994, INT J CANCER, V57, P706, DOI 10.1002/ijc.2910570517; ROSEN EM, 1991, CANCER RES, V51, P5315; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Sambrook J., 2002, MOL CLONING LAB MANU; SANTOS OFP, 1994, DEV BIOL, V163, P525, DOI 10.1006/dbio.1994.1169; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SINGHKAW P, 1995, AM J PHYSIOL-LUNG C, V268, pL1012, DOI 10.1152/ajplung.1995.268.6.L1012; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SORIANO JV, 1995, J CELL SCI, V108, P413; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREIT A, 1995, DEVELOPMENT, V121, P813; SUNITHA I, 1994, CLIN EXP METASTAS, V12, P143, DOI 10.1007/BF01753981; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, 1994, SCIENCE, V263, P98, DOI 10.1126/science.7505952; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; YANG Y, 1995, J CELL BIOL, V131, P1	49	118	121	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					853	861						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761307				2022-12-28	WOS:A1996VD43300021
J	Li, WQ; Michieli, P; Alimandi, M; Lorenzi, MV; Wu, YM; Wang, LH; Heidaran, MA; Pierce, JH				Li, WQ; Michieli, P; Alimandi, M; Lorenzi, MV; Wu, YM; Wang, LH; Heidaran, MA; Pierce, JH			Expression of an ATP binding mutant of PKC-delta inhibits Sis-induced transformation of NIH3T3 cells	ONCOGENE			English	Article						Sis; transformation; PKC-delta	PROTEIN-KINASE-C; SIMIAN SARCOMA-VIRUS; ALPHA-PDGF RECEPTOR; GROWTH-FACTOR; SIGNALING PATHWAYS; 3T3 CELLS; H-RAS; ACTIVATION; LOCALIZATION; SEQUENCE	In an effort to determine the role of protein kinase C-delta (PKC-delta) in cellular transformation mediated by the sis proto-oncogene, we cotransfected expression vectors containing cDNAs that encode for c-sis with an ATP binding mutant of PKC-delta (PKC-delta K376R) or wild type PKC-delta (PKC-delta WT) into NTH3T3 cells, Our results showed that expression of PKC-delta K376R severely impaired Sis-induced focus formation, whereas cotransfection of PKC-delta WT cDNA had no effect on Sis-mediated transformation, Consistent with this result, PKC-delta K376R expression also inhibited PDGF-BB-mediated anchorage-independent colony While cotransfection of a vector containing a dominant negative mutant of uas (N17 ras) cDNA potently inhibited Sis-induced transformation, the expression of PKC-delta K376R did not block transformation mediated by v-H-Ras or v-Raf, In addition, PDGF-BB-induced Raf and mitogen-activated protein kinase activation, which are known to be downstream molecules in the Ras cascade, were not affected by the expression of PKC-delta K376R, indicating that PKC-delta and Ras are segregated in mediating Sis-induced transformation. Interestingly, expression of PKC-delta K376R strongly reduced TPA responsive element (TRE) transactivation induced by PDGF stimulation, suggesting that activation of TRE-containing genes, which may be involved in Sis-mediated transformation, are negatively regulated by expression of PKC-delta K376R.	NIDR,IMMUNOL LAB,BETHESDA,MD 20892; CUNY MT SINAI SCH MED,DEPT MICROBIOL,NEW YORK,NY 10029	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Li, WQ (corresponding author), NCI,CELLULAR & MOL BIOL LAB,BLDG 37,ROOM 1E24,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		Michieli, Paolo/A-2588-2011	Michieli, Paolo/0000-0002-3093-8871; Alimandi, Maurizio/0000-0002-1409-6803				BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BECKMANN R, 1994, EUR J BIOCHEM, V222, P335, DOI 10.1111/j.1432-1033.1994.tb18872.x; BETSHOLTZ C, 1986, NATURE, V320, P695, DOI 10.1038/320695a0; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVARE SG, 1983, P NATL ACAD SCI-BIOL, V80, P731, DOI 10.1073/pnas.80.3.731; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALANG CK, 1994, ONCOGENE, V9, P2913; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KROOK A, 1993, MOL CELL BIOL, V13, P1471, DOI 10.1128/MCB.13.3.1471; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; Li W, 1996, CURR TOP MICROBIOL, V211, P55; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; LLOYD AC, 1989, EMBO J, V8, P1099, DOI 10.1002/j.1460-2075.1989.tb03479.x; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PORRAS A, 1994, J BIOL CHEM, V269, P12741; RAO CD, 1986, P NATL ACAD SCI USA, V83, P2392, DOI 10.1073/pnas.83.8.2392; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SHARMA RV, 1993, AM J PHYSIOL, V264, pC71, DOI 10.1152/ajpcell.1993.264.1.C71; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1995, J BIOL CHEM, V270, P7033, DOI 10.1074/jbc.270.13.7033; YU JC, 1994, J CELL BIOL, V127, P479, DOI 10.1083/jcb.127.2.479; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	38	52	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					731	737						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761294				2022-12-28	WOS:A1996VD43300008
J	Paulin, FEM; West, MJ; Sullivan, NF; Whitney, RL; Lyne, L; Willis, AE				Paulin, FEM; West, MJ; Sullivan, NF; Whitney, RL; Lyne, L; Willis, AE			Aberrant translational control of the c-myc gene in multiple myeloma	ONCOGENE			English	Article						c-myc; translational control; multiple myeloma	MESSENGER-RNA TRANSLATION; 5' UNTRANSLATED REGION; PLASMA-CELLS; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; NONCODING REGION; 1ST EXON; P53 GENE; EXPRESSION; ONCOGENE	We demonstrate a 10- to 25-fold increase in the amount of c-myc protein in several independent cell lines derived from patients with multiple myeloma (MM). This is not accompanied by a corresponding increase in the overall level of the c-my mRNA. There is, however, a 3.4-fold increase in the amount of c-myc mRNA associated with the polysomes in these cell Lines without any detectable change in either the polysome size or the rate of translation elongation, thus suggesting that there is an increase in the extent of mobilisation of c-myc mRNA to the polysomes in MM. Analysis of the 5' untranslated region of c-myc has revealed the presence of a mutation, in all of the MM cell lines examined, in a region which has been implicated previously in the translational control of this mRNA species. These data suggest aberrant translational control of the c-myc gene in cell lines derived from patients with MM, which may contribute towards pathogenesis of the disease.	UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND; NUVENTURES LTD,NEWCASTLE TYNE NE2 4HE,TYNE & WEAR,ENGLAND; JESSOP HOSP WOMEN,DEPT OBSTET & GYNAECOL,SHEFFIELD S3 7RE,S YORKSHIRE,ENGLAND	University of Leicester				West, Michelle/0000-0002-9497-9365; Willis, Anne/0000-0002-1470-8531				BARKER HF, 1992, BRIT J HAEMATOL, V81, P331, DOI 10.1111/j.1365-2141.1992.tb08236.x; CORRADINI P, 1993, BLOOD, V81, P2708; CROCE CM, 1985, BLOOD, V65, P1; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; Davidson E. H., 1986, GENE ACTIVITY EARLY; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GRAY NK, 1994, MOL BIOL REP, V19, P195, DOI 10.1007/BF00986961; GREIL R, 1991, BLOOD, V78, P180; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HATA H, 1993, BLOOD, V81, P3357; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; JOHANNES G, 1992, J BIOL CHEM, V267, P10108; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LAZARUS P, 1992, ONCOGENE, V7, P1037; Lewis J P, 1984, Hematol Oncol, V2, P307; MAZARS GR, 1992, ONCOGENE, V7, P1015; NERI A, 1989, J EXP MED, V170, P1715, DOI 10.1084/jem.170.5.1715; NERI A, 1993, BLOOD, V81, P128; NIESVIZKY R, 1993, BLOOD REV, V7, P24, DOI 10.1016/0268-960X(93)90021-U; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PARKIN NT, 1989, ONCOGENE, V4, P815; PETTERSSON M, 1992, BLOOD, V79, P495; PORTIER M, 1992, ONCOGENE, V7, P2539; PRATS AC, 1992, MOL CELL BIOL, V12, P4796, DOI 10.1128/MCB.12.10.4796; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; SCHWAB M, 1986, MOL CELL BIOL, V6, P2752, DOI 10.1128/MCB.6.7.2752; SELVANAYAGAM P, 1988, BLOOD, V71, P30; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; SULLIVAN NF, 1989, ONCOGENE, V4, P1509; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; VANCAMP B, 1990, BLOOD, V76, P377; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WELSH M, 1986, BIOCHEM J, V235, P459, DOI 10.1042/bj2350459; West MJ, 1995, ONCOGENE, V11, P2515	42	51	51	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					505	513						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760292				2022-12-28	WOS:A1996VB32800008
J	Akagi, T; Ono, H; Shimotohno, K				Akagi, T; Ono, H; Shimotohno, K			Tyrosine kinase inhibitor herbimycin A reduces the stability of cyclin-dependent kinase Cdk6 protein in T-cells	ONCOGENE			English	Article						tyrosine kinase; cell cycle; herbimycin A; cdk6; stability; T-cell	RETINOBLASTOMA SUSCEPTIBILITY GENE; PHOSPHORYLATION; EXPRESSION; PRODUCT; REQUIREMENTS; SPECIFICITY; ACTIVATION; LEUKOCYTES; MUTATIONS; FAMILY	The Cdk6 protein level rapidly decreased after treatment with the tyrosine kinase inhibitor herbimycin A in human T-cell lines. This decrease is fairly specific, because the level of other Cdks such as Cdk2 and Cdk4 and cyclins such as cyclin D2, cyclin E and cyclin A, did not change significantly even after 24 h treatment with herbimycin A. Pulse-chase analysis revealed that the decrease in the Cdk6 protein level results from reduced stability of the protein. Our results suggest that herbimycin A-sensitive protein tyrosine kinase(s) are involved in the regulation of the Cdk6 protein level.	NATL CANC CTR, RES INST, DIV VIROL, CHUO KU, TOKYO 104, JAPAN	National Cancer Center - Japan								AKAGI T, 1993, J VIROL, V67, P1211, DOI 10.1128/JVI.67.3.1211-1217.1993; AKAGI T, 1995, FEBS LETT, V358, P34, DOI 10.1016/0014-5793(94)01390-M; AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; BATES S, 1994, ONCOGENE, V9, P1633; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CUTFORTH T, 1994, CELL, V77, P1027, DOI 10.1016/0092-8674(94)90442-1; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GAZDAR AF, 1980, BLOOD, V55, P409; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; HUNTER T, 1991, CELL, V66, P1071, DOI 10.1016/0092-8674(91)90028-W; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LUCAS JJ, 1995, J IMMUNOL, V154, P6275; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MODIANO JF, 1994, J BIOL CHEM, V269, P32972; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SODROSKI JG, 1985, J VIROL, V55, P831, DOI 10.1128/JVI.55.3.831-835.1985; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; UMEZAWA K, 1991, METHOD ENZYMOL, V201, P379; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; XU HJ, 1991, ONCOGENE, V6, P1139; YAMAMOTO N, 1982, SCIENCE, V217, P737, DOI 10.1126/science.6980467	35	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					399	405						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710379				2022-12-28	WOS:A1996VA25200019
J	Skilling, JS; Sood, A; Niemann, T; Lager, DJ; Buller, RE				Skilling, JS; Sood, A; Niemann, T; Lager, DJ; Buller, RE			An abundance of p53 null mutations in ovarian carcinoma	ONCOGENE			English	Article						p53 gene; ovarian cancer; deletions; insertions	GENE-MUTATIONS; NUCLEAR ACCUMULATION; CANCER; DNA; PROTEIN; OVEREXPRESSION; DELETIONS; SEQUENCE; EVENT	Ovarian cancers from 64 midwestern US women were screened for p53 dysfunction both by immunohistochemical staining (IHCS) and single strand conformation polymorphism (SSCP) analysis of the entire open reading frame (ORF), Forty SSCP abnormalities in 39 tumors included nine deletion, one insertion, two splice junction, two nonsense, one silent and 25 missense mutations were confirmed by direct genomic sequencing, Eight of the insertion/deletion defects may have occurred due to slippage during the course of DNA replication, This observation suggests that genomic instability may play an important role in ovarian carcinogenesis, Fifteen percent of the mutations encountered were located outside exons 5-9 and four of these were null, The sensitivity of IHCS was 96% for missense mutations but only 14% for null mutations, This contrasted with 100% sensitivity of the SSCP screening methodology, The 21% overall incidence of null mutations in the present study far exceeds the reported 6.8% incidence in the world literature (P=0.0003). Explanations for this difference include: (1) our complete analysis of the entire ORF of the p53 gene; (2) the tendency of others to rely upon IHCS to screen tumors prior to mutation analysis; and (3) environmental or endogenous genetic influences.	UNIV IOWA HOSP & CLIN,DEPT OBSTET & GYNECOL,IOWA CITY,IA 52242; UNIV IOWA HOSP & CLIN,DEPT PATHOL,IOWA CITY,IA 52242; UNIV IOWA HOSP & CLIN,DEPT PHARMACOL,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa								BULLER RE, 1993, GYNECOL ONCOL, V51, P160, DOI 10.1006/gyno.1993.1265; BULLER RE, 1995, GYNECOL ONCOL, V58, P368, DOI 10.1006/gyno.1995.1244; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUJITA M, 1994, JPN J CANCER RES, V85, P1247, DOI 10.1111/j.1349-7006.1994.tb02937.x; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARTMANN A, 1995, ONCOGENE, V10, P681; HELLER MJ, 1991, BIOTECHNIQUES, V11, P372; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; INOUE M, 1994, AM J CLIN PATHOL, V102, P665, DOI 10.1093/ajcp/102.5.665; JEGO N, 1993, ONCOGENE, V8, P209; KAPPES S, 1995, INT J CANCER, V64, P52, DOI 10.1002/ijc.2910640111; KASTAN MB, 1991, CANCER RES, V51, P6304; KIHANA T, 1992, JPN J CANCER RES, V83, P978, DOI 10.1111/j.1349-7006.1992.tb02010.x; KIM JW, 1995, GYNECOL ONCOL, V57, P199, DOI 10.1006/gyno.1995.1125; KLEMI PJ, 1995, CANCER, V76, P1201, DOI 10.1002/1097-0142(19951001)76:7<1201::AID-CNCR2820760716>3.0.CO;2-L; KOHLER MF, 1993, OBSTET GYNECOL, V81, P643; KOHLER MF, 1993, J NATL CANCER I, V85, P1513, DOI 10.1093/jnci/85.18.1513; KRAWCZAK M, 1991, HUM GENET, V86, P425; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; KUPRYJANCZYK J, 1995, HUM PATHOL, V26, P387, DOI 10.1016/0046-8177(95)90138-8; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOEB LA, 1994, CANCER RES, V54, P5059; MARKS JR, 1991, CANCER RES, V51, P2979; MAZARS R, 1991, ONCOGENE, V6, P1685; MCMANUS DT, 1994, J PATHOL, V174, P159, DOI 10.1002/path.1711740304; MILNER BJ, 1993, CANCER RES, V53, P2128; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; MOK CH, 1992, CANCER RES, V52, P5119; NAITO M, 1992, JPN J CANCER RES, V83, P1030, DOI 10.1111/j.1349-7006.1992.tb02717.x; NIWA K, 1994, BRIT J CANCER, V70, P1191, DOI 10.1038/bjc.1994.472; OKAMOTO A, 1991, CANCER RES, V51, P5171; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; RUNNEBAUM IB, 1994, HUM GENET, V93, P620; SAITOH S, 1994, ONCOGENE, V9, P2869; Sambrook J., 1989, MOL CLONING LAB MANU; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHERIDAN E, 1994, EUR J CANCER, V30A, P1701, DOI 10.1016/0959-8049(94)00325-Y; SHERIDAN E, 1993, CANCER LETT, V68, P83, DOI 10.1016/0304-3835(93)90223-V; SHIAO YH, 1995, CANCER RES, V55, P1485; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; Skilling JS, 1996, GYNECOL ONCOL, V61, P180, DOI 10.1006/gyno.1996.0122; Skilling JS, 1996, GYNECOL ONCOL, V60, P72, DOI 10.1006/gyno.1996.0014; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TENERIELLO MG, 1993, CANCER RES, V53, P3103; VIDALPUIG A, 1994, BIOTECHNIQUES, V17, P490; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146	52	92	94	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					117	123						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700537				2022-12-28	WOS:A1996UX31900013
J	Jakus, J; Yeudall, WA				Jakus, J; Yeudall, WA			Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells	ONCOGENE			English	Article						epidermal growth factor; p21; WAF1; Cip1; PCNA; cyclin dependent kinase	HUMAN EPIDERMOID CARCINOMA; DEPENDENT KINASES; A431 CELLS; RECEPTOR; CULTURE; PROTEIN; HEAD; NECK; DIFFERENTIATION; OVEREXPRESSION	Previous studies have reported inhibition of A431 squamous carcinoma cell growth by nanomolar concentrations of epidermal growth factor (EGF), a potent mitogen for cells of epithelial origin, In this study, we examined potential mechanisms through which inhibition of keratinocyte growth mediated by EGF might occur by analysing components of the cell cycle regulatory machinery in A431, HN6 and HN30 keratinocytes in the presence of growth inhibitory or growth stimulatory doses of EGF, Treatment of cells with 25 pM EGF produced an increase in [H-3]thymidine incorporation in A431, HN6 and HN30 cells, with respect to control cultures, Exposure to 2.5 nM EGF reduced [H-3]thymidine incorporation in A431 cells and HN6 cells to 11% and 70% of control levels, respectively, whereas HN30 cells continued to proliferate in the presence of EGF, [H-3]thymidine incorporation assays carried out over 24 h revealed repression of DNA synthesis in A431 cells after 12 h exposure to 2.5 nM EGF compared to untreated cells, Flow cytometry studies demonstrated accumulation of cells in G(0)/G(1) after addition of 2.5 nM, but not 25 pM EGF, Western blot analysis revealed elevation of p21 (WAF1/CIP1/SDI1) protein levels in A431 and HN6 cells under growth-inhibitory conditions, Stimulatory doses of EGF did not induce p21 in these cells, Northern blot hybridization demonstrated elevated levels of p21 mRNA within 4 h of exposure of A431 cells to 2.5 nM EGF, which remained elevated above basal levels at 24 h, In vitro kinase assays demonstrated temporal differences in CDK2, and CDK6 activities which were related to EGF concentration, Immunocomplex Western blotting demonstrated increased association of p21 with CDK2 and CDK6 in A431 cells treated with 2.5 nM EGF, Furthermore, temporal alterations in the association of PCNA with p21 and with CDK6 were observed, The data indicate that p21 is a likely mediator of EGF-induced growth-inhibition, probably through mechanisms involving sequestration of PCNA and inhibition of CDK activity.	NIDR,CELLULAR DEV & ONCOL LAB,MOLEC CARCINOGENESIS GRP,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)								BARNES DW, 1982, J CELL BIOL, V93, P1, DOI 10.1083/jcb.93.1.1; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSS JE, 1982, P NATL ACAD SCI-BIOL, V79, P2574, DOI 10.1073/pnas.79.8.2574; CARDINALI M, 1995, INT J CANCER, V61, P98, DOI 10.1002/ijc.2910610117; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; GAME SM, 1992, INT J CANCER, V52, P461, DOI 10.1002/ijc.2910520322; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Harlow E., 1989, ANTIBODIES LAB MANUA; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISHITOYA J, 1989, BRIT J CANCER, V59, P559, DOI 10.1038/bjc.1989.113; JIANG HP, 1994, ONCOGENE, V9, P3397; KEARSLEY JH, 1990, BRIT J CANCER, V61, P821, DOI 10.1038/bjc.1990.184; KONGER RL, 1993, J CELL PHYSIOL, V156, P515, DOI 10.1002/jcp.1041560310; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2261; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MICHIELI P, 1994, CANCER RES, V54, P3391; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PRIME SS, 1994, BRIT J CANCER, V69, P8, DOI 10.1038/bjc.1994.2; RHEINWALD JG, 1977, NATURE, V265, P421, DOI 10.1038/265421a0; ROSDY M, 1988, IN VITRO CELL DEV, V22, P295; SACHS L, 1987, CANCER RES, V47, P1981; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SOMERS KD, 1992, CANCER RES, V52, P5997; STANTON P, 1994, BRIT J CANCER, V70, P427, DOI 10.1038/bjc.1994.322; STEINMAN RA, 1994, ONCOGENE, V9, P3389; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WIRTH PJ, 1987, CANCER RES, V47, P2831; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683	42	85	86	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2369	2376						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649777				2022-12-28	WOS:A1996UQ22000014
J	Harwood, FG; Frazier, MW; Krajewski, S; Reed, JC; Houghton, JA				Harwood, FG; Frazier, MW; Krajewski, S; Reed, JC; Houghton, JA			Acute and delayed apoptosis induced by thymidine deprivation correlates with expression of p53 and p53-regulated genes in colon carcinoma cells	ONCOGENE			English	Article						p53 heterozygosity; apoptosis; cytostasis	WILD-TYPE P53; COLORECTAL-CARCINOMA; MUTANT CONFORMATION; DNA DAMAGE; BCL-2; RESISTANCE; PROTEIN; FLUOROURACIL; AMPLIFICATION; CYTOTOXICITY	The endogenous expression of p53 and p53-regulated genes has been examined in a thymidylate synthase-deficient colon carcinoma cell line (TS-) and a derived mutant clone (Thy4) that exhibit acute or delayed apoptotic responses, respectively, when released from G0 synchrony under conditions of dThd starvation. These cell clones demonstrate heterozygosity in p53, thereby expressing one wt allele and one with an A-->C point mutation at codon 240. Following release from G0, upregulated expression of both alleles occurred. During apoptosis in TS-, a wtp53 phenotype was expressed and in Thy4 during cytostasis, a mp53 phenotype was manifested, as determined from the ratios of wtp53/mp53 proteins, transactivation of p50-2 (a wtp53-responsive CAT reporter construct) and the endogenous expression of MDM2. Neither cytotoxicity nor cytostasis correlated with expression of p21(Waf1/Cip1) ThY4 cells sustained accumulation of high levels of Bax in a wtp53-independent and dThd-independent manner and survival was associated with upregulated expression of Bcl-2. In contrast, Bax expression decreased in TS- during apoptosis, except in a highly resistant subpopulation that retained high levels of Bax. Data suggest that resistant cells (Thy4) can sustain high Bax expression and that Bcl-2 is upregulated in response to an apoptotic stimulus due to the absence of negative regulation by wtp53.	ST JUDE CHILDRENS RES HOSP, DEPT MOLEC PHARMACOL, MEMPHIS, TN 38105 USA; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	St Jude Children's Research Hospital; Sanford Burnham Prebys Medical Discovery Institute					NCI NIH HHS [R37 CA32613, CA60181, CA21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060181, P30CA021765, R37CA032613] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRISTOW RG, 1994, ONCOGENE, V9, P1527; BRONNER MP, 1995, AM J PATHOL, V146, P20; CANMAN CE, 1992, P NATL ACAD SCI USA, V89, P10474, DOI 10.1073/pnas.89.21.10474; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DOLE M, 1994, CANCER RES, V54, P3253; DONCHOWER LA, 1992, NATURE, V356, P215; DOROSHOW JH, 1990, J CLIN ONCOL, V8, P491, DOI 10.1200/JCO.1990.8.3.491; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ERLICHMAN C, 1988, J CLIN ONCOL, V6, P469, DOI 10.1200/JCO.1988.6.3.469; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FISHER TC, 1993, CANCER RES, V53, P3321; FREBOURG T, 1994, CANCER RES, V54, P878; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HOCKENBERY D, 1991, NATURE, V349, P254; HOUGHTON JA, 1994, CANCER RES, V54, P4967; Houghton JA, 1995, CLIN CANCER RES, V1, P723; HOUGHTON PJ, 1989, P NATL ACAD SCI USA, V86, P1377, DOI 10.1073/pnas.86.4.1377; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KAMESAKI S, 1993, CANCER RES, V53, P4251; KASTAN MB, 1991, CANCER RES, V51, P6304; KEURBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEONARDO AD, 1994, GENE DEV, V8, P2540; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU QL, 1993, J PATHOL, V169, P431, DOI 10.1002/path.1711690408; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; OTLVAI ZN, 1993, CELL, V74, P609; PETRELLI N, 1987, J CLIN ONCOL, V5, P1559, DOI 10.1200/JCO.1987.5.10.1559; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIETENPOL JA, 1994, CANCER RES, V54, P3714; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALTON MI, 1993, CANCER RES, V53, P1853; WANG YS, 1993, ONCOGENE, V8, P3427; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHAN QM, 1994, ONCOGENE, V9, P3743	63	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2057	2067						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668331				2022-12-28	WOS:A1996UP28300004
J	Pollock, RE; Lang, AQ; Luo, JX; ElNaggar, AK; Yu, DH				Pollock, RE; Lang, AQ; Luo, JX; ElNaggar, AK; Yu, DH			Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells	ONCOGENE			English	Article						sarcoma; p53 suppressor gene; clonal heterogeneity; metastasis; loss of heterozygosity	MUTATIONS; GENE; BONE	Although soft tissue sarcoma has a high incidence of p53 mutations, it is not clear if such alterations facilitate tumor growth and metastasis. In this study, fresh autologous normal lymphocytes, normal muscle, primary and metastatic sarcoma tissues from a single synovial sarcoma patient were examined for p53-related alterations that potentially associated with sarcoma tumor development and metastasis. Normal tissues contain two wild-type p53 alleles. Primary sarcoma had one chromosome 17p p53 allelic deletion without apparent p53 mutation in the other allele. However, metastatic tumor had deletion of one p53 allele with an exon 5 codon 135 missense mutation in the other allele. This p53 gene point mutation in the metastasis was associated with the production of mutated p53 protein. A small clone of cells harboring the identical p53 gene point mutation was identified in the primary tumor using mutant allele specific PCR amplification, albeit at levels much less than in the metastatic sarcoma. This single patient example indicate that soft tissue sarcoma metastasis can develop from clonal expansion of primary tumor cells bearing p53 mutations.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Pollock, RE (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.			Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R29CA060488, R01CA060488, R01CA067802] Funding Source: NIH RePORTER; NCI NIH HHS [CA60488, CA67802] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVEGARD TA, 1989, J CLIN ONCOL, V7, P1845, DOI 10.1200/JCO.1989.7.12.1845; BEAHRS OH, 1992, MANUAL STAGING CANCE; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DROBNJAK M, 1994, J NATL CANCER I, V86, P549, DOI 10.1093/jnci/86.7.549; FELIX CA, 1992, CANCER RES, V52, P2243; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HU GY, 1992, BRIT J HAEMATOL, V81, P489, DOI 10.1111/j.1365-2141.1992.tb02979.x; KOMURO H, 1993, CANCER RES, V53, P5284; LATRES E, 1994, AM J PATHOL, V145, P345; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PINKEL D, 1986, COLD SPRING HARB SYM, V51, P151, DOI 10.1101/SQB.1986.051.01.018; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; TAKEDA S, 1993, HUM MUTAT, V2, P112, DOI 10.1002/humu.1380020209; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; WADAYAMA B, 1993, BRIT J CANCER, V68, P1134, DOI 10.1038/bjc.1993.493; YANG JC, 1993, CANC PRINCIPLES PRAC, P1436; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	22	38	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					2035	2039						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649865				2022-12-28	WOS:A1996UK49800023
J	Robinson, C; Light, Y; Groves, R; Mann, D; Marais, R; Watson, R				Robinson, C; Light, Y; Groves, R; Mann, D; Marais, R; Watson, R			Cell-cycle regulation of B-Myb protein expression: Specific phosphorylation during the S phase of the cell cycle	ONCOGENE			English	Article						B-Myb; cell cycle; phosphorylation; cyclin dependent kinase	C-MYB; HEMATOPOIETIC-CELLS; A-MYB; PROLIFERATION; TRANSCRIPTION; ACTIVATION; CDC2	Previous studies revealed that transcription of B-Myb, which encodes a transcription factor related to the c-Myb proto-oncoprotein, is cell-cycle regulated by an E2F transcription factor-mediated repression mechanism operating in G(0)/G(1). To begin to determine the consequences of transcriptional regulation on B-Myb function, we report here further studies of B-Myb protein expression in the cell cycle. We found that G(0)-arrest of serum-deprived mouse fibroblasts was achieved without significant reduction in B-Myb levels, moreover, overexpression of B-Myb in stably transfected cells did not prevent their entry into G(0). Following serum-induction of arrested fibroblasts, B-Myb abundance increased as cells entered S phase to levels significantly greater than found in cycling cells. This was accompanied by the appearance of a novel phosphorylated form of B-Myb (112 kDa) of distinctly lower electrophoretic mobility than B-Myb present in G(1) (110 kDa). The 112 kDa species was S phase-specific even in transfected cells overexpressing B-Myb. Consistent with modification in the S phase of the cell cycle, preliminary evidence suggested that a cyclin A/cdk2, but not cyclin E/cdk2 or cyclin D1/cdk4, complex could induce a similar electrophoretic mobility change in baculovirus-specified B-Myb. These findings show that B-Myb expression may be subject to two levels of control during the cell cycle, transcription and protein phosphorylation.	ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Cancer Research UK								ARSURA M, 1992, BLOOD, V79, P2708; BOUWMEESTER T, 1994, ONCOGENE, V9, P1029; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; HARPER JW, 1993, CELL, V75, P805; KITAGAWA M, 1995, ONCOGENE, V10, P229; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; LYON J, 1994, CRIT REV ONCOGENESIS, V5, P373, DOI 10.1615/CritRevOncog.v5.i4.30; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; TAKEMOTO Y, 1994, FEBS LETT, V350, P55, DOI 10.1016/0014-5793(94)00733-0; TASHIRO S, 1995, ONCOGENE, V10, P1699; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2	32	62	65	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1855	1864						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649845				2022-12-28	WOS:A1996UK49800003
J	Farrington, SM; Cunningham, C; Boyle, SM; Wyllie, AH; Dunlop, MG				Farrington, SM; Cunningham, C; Boyle, SM; Wyllie, AH; Dunlop, MG			Detailed physical and deletion mapping of 8p with isolation of YAC clones from tumour suppressor loci involved in colorectal cancer	ONCOGENE			English	Article						chromosome 8p; colorectal cancer; mapping; YAC isolation; TSG	HEPATOCELLULAR-CARCINOMA; ALLELIC LOSS; SHORT ARM; CHROMOSOME-8; MUTATIONS; GENE	Loss of heterozygosity (LOH) of markers at chromosome 8p is frequently noted in many different tumour types, including colorectal cancer, Numerous investigations indicate the presence of more than one tumour suppressor gene (TSG) located on 8p. In this study, we describe a detailed LOH map in colorectal cancer and relate this to physical mapping data from reduced radiation 8p hybrids, yeast artificial chromosome (YAC) co-localisation of markers and fluorescence in situ hybridisation data,;These data indicate the presence of two regions harbouring putative TSG's between the polymorphic markers for the LPL gene-D8S298 (similar to 4 Mb) and the markers D8S136-D8S137 (similar to 8 Mb), Yeast Artificial Chromosomes (YAC) have been isolated from these regions of interest to aid the localisation of the putative TSG's.	UNIV EDINBURGH,SCH MED,DEPT PATHOL,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Farrington, SM (corresponding author), MRC,HUMAN GENET UNIT,CREWE RD,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		Dunlop, Malcolm G/F-1973-2011; Farrington, Susan M/C-7319-2013; Farrington, Susan M/Q-2710-2019	Dunlop, Malcolm G/0000-0002-3033-5851; Farrington, Susan M/0000-0001-5955-7389				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BERGERHEIM USR, 1991, GENE CHROMOSOME CANC, V3, P215, DOI 10.1002/gcc.2870030308; BOOKSTEIN R, 1994, GENOMICS, V24, P317, DOI 10.1006/geno.1994.1622; BOVA GS, 1993, CANCER RES, V53, P3869; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; CUNNINGHAM C, 1994, BRIT J CANCER, V70, P18, DOI 10.1038/bjc.1994.243; EMI M, 1992, CANCER RES, V52, P5368; EMI M, 1993, GENE CHROMOSOME CANC, V7, P152, DOI 10.1002/gcc.2870070307; FANTES J, 1995, HUM MOL GENET, V4, P415, DOI 10.1093/hmg/4.3.415; FANTES JA, 1992, AM J HUM GENET, V51, P1286; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; ICHIKAWA T, 1994, CANCER RES, V54, P2299; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; MACOSKA JA, 1994, CANCER RES, V54, P3824; Maniatis T., 1982, MOL CLONING; MATSUYAMA H, 1994, ONCOGENE, V9, P3071; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; Rogaev E., 1992, Human Molecular Genetics, V1, P781, DOI 10.1093/hmg/1.9.781; SADAKANE Y, 1994, BIOCHEM BIOPH RES CO, V200, P219, DOI 10.1006/bbrc.1994.1437; SAPRU M, 1994, GENOMICS, V21, P208, DOI 10.1006/geno.1994.1244; SCHOENBERG M, 1995, GENE CHROMOSOME CANC, V12, P76, DOI 10.1002/gcc.2870120115; SENGUPTA DN, 1993, SCIENCE, V260, P816; STEINBRUECK T, 1992, SCIENCE, V258, P67; TRAPMAN J, 1994, CANCER RES, V54, P6061; VANDERBOSCH K, 1992, GENE CHROMOSOME CANC, V5, P91, DOI 10.1002/gcc.2870050114; WAGNER MJ, 1991, GENOMICS, V10, P114, DOI 10.1016/0888-7543(91)90491-V; WANG LM, 1992, CANCER RES, V52, P4824; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Wood S, 1993, Cytogenet Cell Genet, V64, P134; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102	38	45	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1803	1808						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622901				2022-12-28	WOS:A1996UG45800023
J	Ohta, M; Nagai, H; Nyunoya, H; Shimotohno, K				Ohta, M; Nagai, H; Nyunoya, H; Shimotohno, K			Src-homology domain 2 is responsible for transcriptional suppression induced by expression of Lck	ONCOGENE			English	Article						Lck; Src; SH2; transcriptional suppression; tyrosine kinase	TYROSINE-PROTEIN-KINASE; RETROVIRUS PROMOTER INSERTION; SIGNAL TRANSDUCTION; CD4 RECEPTOR; SH3 DOMAINS; P56LCK; ACTIVATION; IDENTIFICATION; CELLS; GENE	Overexpression of Lck was shown, by our previous study, to suppress gene transcription from various viral and cellular promoters. The suppression of transcription from human T-cell leukemia virus promoter by Lck was independent of the presence of the enhancer core sequences within the long terminal repeat. The suppression of transcription was observed with Lck mutants that had either diminished or enhanced tyrosine-kinase activity. A mutant lacking the myristylation site also suppressed transcription. From the analysis with various deletion mutants of Lck, it was suggested that Src-homology domain 2 (SH2) is both necessary and sufficient for the suppression of transcription. A similar effect was also observed with the SH2 domain of the v-src gene. Thus, overexpression of Lck could suppress gene expression through a unique function of the SH2 domain.	NATL CANC CTR, RES INST, DIV VIROL, TOKYO 104, JAPAN	National Cancer Center - Japan			Nyunoya, Hiroshi/C-9705-2013	Nyunoya, Hiroshi/0000-0002-3237-9639				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; KAMPS MP, 1988, ONCOGENE, V2, P305; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NYUNOYA H, 1990, AIDS RES HUM RETROV, V6, P1311, DOI 10.1089/aid.1990.6.1311; OHTA M, 1990, JPN J CANCER RES, V81, P440, DOI 10.1111/j.1349-7006.1990.tb02588.x; OHTA M, 1988, J VIROL, V62, P4445, DOI 10.1128/JVI.62.12.4445-4451.1988; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	34	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					989	997						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649816				2022-12-28	WOS:A1996UA88400006
J	McMasters, KM; Luna, RMD; Pena, JR; Lozano, G				McMasters, KM; Luna, RMD; Pena, JR; Lozano, G			mdm2 Deletion does not alter growth characteristics of p53-deficient embryo fibroblasts	ONCOGENE			English	Article						G(1) arrest; genomic instability; p53 null cells	WILD-TYPE P53; SOFT-TISSUE SARCOMAS; GENE AMPLIFICATION; MDM2-DEFICIENT MICE; ONCOPROTEIN MDM2; PROTEIN; ABNORMALITIES; LETHALITY; APOPTOSIS; ONCOGENE	The mdma gene encodes a protein that is necessary for the negative regulation of p53 function in vivo. Deletion of the mdm2 gene in mice results in early embryonic death while concomitant mdm2 and p53 deletion results in viable offspring. The viability of these mice prompted us to ask if MDM2, had an important growth regulatory function independent of p53. We established mouse embryo fibroblasts null for both p53 and mdma and compared them with p53-null fibroblasts. The cells did not differ in their growth rates or their ability to bypass a G(1) arrest. Both cell lines formed colonies efficiently when plated at low density and showed a similar degree of genetic instability. Thus, the analysis of several growth parameters indicated no difference between p53-null and p53/mdm2-null cell lines.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL GENET,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT SURG ONCOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA47296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047296, R29CA047296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CORDONCARDO C, 1994, CANCER RES, V54, P794; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; Godley LA, 1996, GENE DEV, V10, P836, DOI 10.1101/gad.10.7.836; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARVEY M, 1993, ONCOGENE, V8, P2457; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; LADANYI M, 1993, CANCER RES, V53, P16; LEACH FS, 1993, CANCER RES, V53, P2231; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUNA RMD, 1995, NATURE, V378, P203; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; NAKAMURA T, 1995, P NATL ACAD SCI USA, V92, P6142, DOI 10.1073/pnas.92.13.6142; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; QUESNEL B, 1994, EUR J CANCER, V30A, P982, DOI 10.1016/0959-8049(94)90128-7; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SHEIKH MS, 1993, CANCER RES, V53, P3226; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	30	48	49	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1731	1736						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895519				2022-12-28	WOS:A1996VM88700018
J	Gotley, DC; Reeder, JA; Fawcett, J; Walsh, MD; Bates, P; Simmons, DL; Antalis, TM				Gotley, DC; Reeder, JA; Fawcett, J; Walsh, MD; Bates, P; Simmons, DL; Antalis, TM			The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases	ONCOGENE			English	Article						DCC; monoclonal antibodies; colon cancer; Dukes Stage; Western blotting	HUMAN TISSUES; FREQUENT LOSS; CARCINOMAS; CELLS; RNA; DIFFERENTIATION; PROGRESSION; INHIBITION	The DCC (deleted in colorectal cancer) gene was originally identified as a candidate tumour suppressor gene in colon carcinogenesis on the basis of allelic losses in chromosome 18q.21 in 70% of colon cancers, Reverse transcriptase polymerase chain reaction (RT-PCR) of DCC mRNA suggests that DCC expression may also be reduced in colon cancers, We have used monoclonal antibodies generated against the DCC immunoglobulinlike domain to investigate DCC isoforms and DCC protein expression during colon cancer progression, Normal mucosa and colonic tumour specimens representative of the range of colonic tumour progression from benign adenomatous polyps to metastases were compared by Western blot analyses, We show that while M(r) 194 000 DCC is present in normal colonic mucosa and adenomatous polyps, it is also similarly expressed in colorectal carcinomas and colonic metastases in the liver, The presence of DCC protein is consistent with the presence of DCC mRNA transcripts in the same tissue specimens. Notably DCC was not completely lost in any colonic tumour specimens examined, even those that had progressed to metastatic cancers, Quantitation of DCC protein expression in tissue specimens by densitometry demonstrated that both normal and malignant specimens exhibit a wide range of DCC protein levels and there was no significant correlation between diminished DCC protein expression and colon cancer progression, These results demonstrate the pattern of expression of the DCC gene product in colonic tumour progression and show that absence of DCC expression is not associated with colonic tumour progression.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,PRINCESS ALEXANDRA HOSP,DEPT SURG,BRISBANE,QLD 4029,AUSTRALIA; QUEENSLAND CANC FUND EXPT ONCOL UNIT,BRISBANE,QLD 4029,AUSTRALIA; GRIFFITH UNIV,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA; GRIFFITH UNIV,FAC SCI & TECHNOL,BRISBANE,QLD 4029,AUSTRALIA; JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,CELL ADHES LAB,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,MOL ONCOL UNIT,OXFORD OX3 9DU,ENGLAND	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Griffith University; QIMR Berghofer Medical Research Institute; Griffith University; University of Oxford; University of Oxford			Gotley, David/F-5481-2013	Gotley, David/0000-0002-8604-253X				ANTALIS TM, 1992, EUR J BIOCHEM, V205, P203, DOI 10.1111/j.1432-1033.1992.tb16769.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; Ekstrand BC, 1995, ONCOGENE, V11, P2393; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOX SB, 1994, CANCER RES, V54, P4539; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KUAN SF, 1989, J BIOL CHEM, V264, P19271; MIYAKE S, 1994, CANCER RES, V54, P3007; NARAYANAN R, 1992, ONCOGENE, V7, P553; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; REALE MA, 1994, CANCER RES, V54, P4493; SCHECK AC, 1993, CANCER RES, V53, P5605; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; TURLEY H, 1995, CANCER RES, V55, P5628; UCHINO S, 1992, CANCER RES, V52, P3099; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	28	36	36	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					787	795						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761300				2022-12-28	WOS:A1996VD43300014
J	Wang, JK; Xu, H; Li, HC; Goldfarb, M				Wang, JK; Xu, H; Li, HC; Goldfarb, M			Broadly expressed SNT-like proteins link FGF receptor stimulation to activators of Ras	ONCOGENE			English	Article						FGFR; SLP; Sos; p13(suc1)	FIBROBLAST GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; ELIMINATES PHOSPHATIDYLINOSITOL HYDROLYSIS; CELL-CYCLE CONTROL; PC12 CELLS; SIGNAL-TRANSDUCTION; POINT MUTATION; NEURONAL DIFFERENTIATION; NEUROTROPHIC FACTOR; INSULIN-RECEPTOR	SNT was originally described as a similar to 90 kilodalton protein in neuronal precursor cells which bears affinity for the yeast cell cycle protein p13(sucl) and which undergoes rapid tyrosine phosphorylation following stimulation with growth factors which trigger terminal differentiation, but not by other growth factors which promote proliferation (Rabin et al,, 1993), We show here that similarly sized SNT-like proteins (SLPs) are expressed in fibroblast, myoblast, and lymphoid cell lines, and undergo robust tyrosine phosphorylation in response to several mitogenic ligands, including fibroblast growth factors (FGFs). SLPs are tyrosine phosphorylated within 15 s of FGF stimulation, are predominantly membrane-associated, and are weakly associated with activated FGF receptor-1, suggesting that these proteins may be direct targets of the receptor kinase, Kinetic analysis of SLP phosphorylation and studies with serine/threonine kinase and phosphatase inhibitors suggest that SLPs are no larger than 70 000 kilodaltons, and that serine/threonine phosphorylation follows tyrosine phosphorylation to substantially retard gel electrophoretic mobility, SLPs are associated with the Grb-2 adaptor and are the major tyrosine phosphorylated proteins associated with the Ras guanine nucleotide exchange factor Sos in FGF-stimulated fibroblasts, suggesting that SLP-Grb2-Sos complexes modulate the activity of Ras proteins.	MT SINAI SCH MED, BROOKDALE CTR MOL BIOL, NEW YORK, NY 10029 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOL BIOPHYS, NEW YORK, NY 10032 USA; CUNY MT SINAI SCH MED, DEPT BIOCHEM, NEW YORK, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Columbia University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai								BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; LI HC, 1981, ARCH BIOCHEM BIOPHYS, V207, P270, DOI 10.1016/0003-9861(81)90034-5; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MAISONPIERRE PC, 1993, ONCOGENE, V8, P1631; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; RICCI A, 1995, ONCOGENE, V11, P1519; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAUE H, 1995, J BIOL CHEM, V270, P11304, DOI 10.1074/jbc.270.19.11304; SALTON SRJ, 1991, MOL CELL BIOL, V11, P2335, DOI 10.1128/MCB.11.5.2335; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; SQUINTO SP, 1991, CELL, V65, P885, DOI 10.1016/0092-8674(91)90395-F; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; TOGARI A, 1985, J NEUROSCI, V5, P307; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; XU YH, 1984, NATURE, V309, P806, DOI 10.1038/309806a0; ZHANG B, 1991, J BIOL CHEM, V266, P990	58	90	91	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					721	729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761293				2022-12-28	WOS:A1996VD43300007
J	Sastry, KJ; Marin, MC; Nehete, PN; McConnell, K; ElNaggar, AK; McDonnell, TJ				Sastry, KJ; Marin, MC; Nehete, PN; McConnell, K; ElNaggar, AK; McDonnell, TJ			Expression of human immunodeficiency virus type 1 tat results in downregulation of bcl-2 and induction of apoptosis in hematopoietic cells	ONCOGENE			English	Article						HIV-1 tat; apoptosis; bcl-2; bax; Fas	PROTEIN INDUCES APOPTOSIS; HIV-1 TAT; T-CELLS; KAPOSIS-SARCOMA; GENE-EXPRESSION; DEATH; INFECTION; AIDS; LYMPHOCYTES; ACTIVATION	Infection by human immunodeficiency virus type 1 (HIV-1) is characterized by progressive loss of various cell types, mainly CD4(+) T lymphocytes. While a passive role for the virus in cell destruction is recognized, it does not account for the vast amount of cell death including those of uninfected 'bystander' cells. Since in the past we and others have demonstrated the capacity of the Tat protein of HIV-1 to modulate the expression of various cellular genes and that Tat secreted by HIV-infected cells can be readily taken up by various cell types, we have investigated the role of Tat on inducing apoptosis. Our results indicate that T lymphocytes transfected to constitutively express HIV-1 tat, when grown under serum-free conditions results in rapid apoptosis characterized by typical ultrastructural features and DNA fragmentation. Additionally, we observed that in several hematopoietic cell types, including T and B lymphoid cells and monocytoid cells, the expression of HIV-1 tat results in down-regulation of bcl-2, an oncogene with known potential for inhibition of apoptosis. The tat-mediated down-regulation of bcl-2 was observed at both the transcriptional and translational levels. Also, tat-transfected cells expressed increased amounts of bax, a bcl-2 family protein known to induce apoptosis. While these results support reports in the literature of an active role for tnt in inducing cell death in HIV-infected individuals, they point to a new mechanism involving Tat-mediated modulation of bcl-2 and bax.	BAYLOR COLL MED,DEPT MOL PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PATHOL ANAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine	Sastry, KJ (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT VET SCI,SCI PK,ROUTE 2,BOX 151-B1,BASTROP,TX 78602, USA.		Marin, Maria C/G-1040-2010; Marín Vieira, María del Carmen/B-8108-2015	Marin, Maria C/0000-0002-7149-287X; Marín Vieira, María del Carmen/0000-0002-7149-287X; Sastry, Jagannadha/0000-0002-6987-4422	NCI NIH HHS [CA 09255] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; EMBERTSON J, 1993, NATURE, V362, P359; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; GORZYCA W, 1992, INT J ONCOL, V1, P639; GOUGEON ML, 1993, AIDS RES HUM RETROV, V9, P553, DOI 10.1089/aid.1993.9.553; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LEVY JA, 1994, HIV PATHOGENESIS AID, P77; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; MCDONNELL TJ, 1990, MOL CELL BIOL, V10, P1901, DOI 10.1128/MCB.10.5.1901; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MUROCACHO CA, 1995, J IMMUNOL, V154, P5555; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1995, NATURE MED, V2, P118; PURVIS SF, 1995, AIDS RES HUM RETROV, V11, P443, DOI 10.1089/aid.1995.11.443; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; STECK KD, 1995, CYTOMETRY, V20, P154, DOI 10.1002/cyto.990200208; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TORNESELLO ML, 1993, INTERVIROLOGY, V36, P57, DOI 10.1159/000150322; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; YAMADA T, 1994, J VIROL, V68, P3374, DOI 10.1128/JVI.68.5.3374-3379.1994; Yin X M, 1995, Curr Top Microbiol Immunol, V194, P331; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZAULI G, 1993, CANCER RES, V53, P4481	37	92	93	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					487	493						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760290				2022-12-28	WOS:A1996VB32800006
J	Rohde, M; Warthoe, P; Gjetting, T; Lukas, J; Bartek, J; Strauss, M				Rohde, M; Warthoe, P; Gjetting, T; Lukas, J; Bartek, J; Strauss, M			The retinoblastoma protein modulates expression of genes coding for diverse classes of proteins including components of the extracellular matrix	ONCOGENE			English	Article						retinoblastoma protein; gene regulation; thrombospondin; endothelin; differential display; DDRT-PCR	TRANSFORMING GROWTH FACTOR-BETA-1; CELL-CYCLE; SUSCEPTIBILITY GENE; MESSENGER-RNA; DIFFERENTIAL DISPLAY; BINDING PROTEIN; PRODUCT; TRANSCRIPTION; SEQUENCE; CLONING	The product of the retinoblastoma susceptibility gene, pRb, is a negative regulator of cell growth. It functions by regulating the activity of transcription factors. Rb represses some genes by sequestering or inactivating the positive transcription factor E2F and seems to activate some others by interacting with factors like Spl or ATF-2, However, there are only a few examples of genes which are positively regulated by pRb. In order to find out if there are common mechanisms for promoter regulation by pRb, we were interested to identify more genes which are either stimulated or repressed by pRb, Using the method of differential display (DDRT-PCR) in combination with nuclear run-on analyses we were able to detect a number of genes which are upregulated by ectopic expression of the Rb gene in Rb-deficient mammary carcinoma cells, We could demonstrate not only stimulation of the endogenous mutant Rb gene but also positive regulation of genes coding for diverse classes of proteins, including the endothelial growth and the proteoglycans versican and PG40, As a second approach, we investigated gene expression in cell lines established from Rb deficient heterozygous and homozygous knockout mouse embryos and normal mice, We have identified several genes the expression of which correlates positively or negatively with the presence of Rb. These data provide further evidence for pRb being a master regulator of a complex network of gene activities defining the difference between dividing and resting or differentiated cells.	DANISH CANC SOC,DIV TUMOR BIOL,DEPT CELL CYCLE & CANC,DK-2100 COPENHAGEN,DENMARK; HUMBOLDT UNIV BERLIN,MPG GRP,MAX DELBRUCK CTR MOLEC MED,D-13122 BERLIN,GERMANY	Danish Cancer Society; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Humboldt University of Berlin			Gjetting, Torben/A-6066-2012	Warthoe, peterwarthoe@gmail.com/0000-0003-3840-5460; Lukas, Jiri/0000-0001-9087-506X				BALEY PA, 1990, J CLIN INVEST, V85, P1320, DOI 10.1172/JCI114570; BARTEK J, 1992, ONCOGENE, V7, P101; Bauer D, 1994, PCR Methods Appl, V4, pS97; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; BLOCH KD, 1989, J BIOL CHEM, V264, P10851; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0; ECONOMOS K, 1992, CANCER RES, V52, P554; EWEN ME, 1995, GENE DEV, V9, P204, DOI 10.1101/gad.9.2.204; FRAMSON P, 1993, J BIOL CHEM, V268, P4989; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; GJETTING T, 1995, BIOL CHEM H-S, V376, P441; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUNG YK, 1987, SCIENCE, V236, P1675; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; INOUE A, 1989, J BIOL CHEM, V264, P14954; IRUELAARISPE ML, 1993, DEV DYNAM, V197, P40, DOI 10.1002/aja.1001970105; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Lee Hu-Hui, 1995, Gene Expression, V4, P95; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LIANG P, 1995, IN PRESS METHODS ENZ; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; NASO MF, 1994, J BIOL CHEM, V269, P32999; PARK K, 1994, J BIOL CHEM, V269, P6083; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHONHERR E, 1991, J BIOL CHEM, V266, P17640; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; STRAUSS M, 1990, ONCOGENE, V5, P1223; STRAUSS M, 1995, NAT MED, V1, P1245, DOI 10.1038/nm1295-1245; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Warthoe Peter, 1995, P421; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WOLF YG, 1994, J CLIN INVEST, V93, P1172, DOI 10.1172/JCI117070; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	70	24	24	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2393	2401						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649780				2022-12-28	WOS:A1996UQ22000017
J	Distelhorst, CW; Lam, M; McCormick, TS				Distelhorst, CW; Lam, M; McCormick, TS			Bcl-2 inhibits hydrogen peroxide-induced ER Ca2+ pool depletion	ONCOGENE			English	Article						Bcl-2; oxygen radical; apoptosis; programmed cell death; calcium; thapsigargin	PROGRAMMED CELL-DEATH; INTRACELLULAR CALCIUM HOMEOSTASIS; C-FOS; ENDOPLASMIC-RETICULUM; MEMBRANE PROTEIN; CIS-FOS; EXPRESSION; TRANSLOCATION; APOPTOSIS; DNA	The mechanism by which Bcl-2 inhibits apoptosis is unknown, The Bcl-2 protein is localized to intracellular membranes, including the endoplasmic reticulum (ER), The ER is the major intracellular reservoir of Ca2+ in non-muscle cells, sequestering Ca2+ for use in intracellular signaling, and is a prime target of oxidative damage, Because of the recent suggestion that Bcl-2 acts in an antioxidant pathway, we wondered whether Bcl-2 might protect the ER Ca2+ pool in cells exposed to reactive oxygen species. To test this hypothesis, we assessed the effect of hydrogen peroxide (H2O2) treatment on the ER Ca2+ pool in WEH17.2 cells, which do not express Bcl-2, and two stable transfectants, W.Hb13 and W.Hb12, The Bcl-2 level by Western blotting is 4-fold higher in W.Hb12 cells compared to W.Hb13 cells, The ER Ca2+ pool in H2O2-treated and untreated cells was measured according to the amount of Ca2+ mobilized from the ER lumen into the cytoplasm by thapsigargin (TG), a selective inhibitor of the ER Ca2+-ATPase, H2O2 treatment produced a significant reduction in the TG-mobilizable Ca2+ pool in WEH17.2 and W.Hb13 cells, but not in W.Hb12 cells, indicating that overexpression of Bcl-2 preserves the integrity of the ER Ca2+ pool in cells exposed to reactive oxygen species.	CASE WESTERN RESERVE UNIV, DEPT PHARMACOL, CLEVELAND, OH 44106 USA	Case Western Reserve University	Distelhorst, CW (corresponding author), CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, BRB329, 10900 EUCLID AVE, CLEVELAND, OH 44106 USA.			McCormick, Thomas/0000-0002-3294-0326	NCI NIH HHS [T32 CA59366, R01 CA42755-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042755, T32CA059366] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BAFFY G, 1993, J BIOL CHEM, V268, P6511; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; COWAN WM, 1984, SCIENCE, V225, P1258, DOI 10.1126/science.6474175; CRAWFORD D, 1988, ONCOGENE, V3, P27; DUBYAK GR, 1986, ARCH BIOCHEM BIOPHYS, V245, P84, DOI 10.1016/0003-9861(86)90192-X; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JIANG S, 1994, EXP CELL RES, V212, P84, DOI 10.1006/excr.1994.1121; JONES DP, 1983, J BIOL CHEM, V258, P6390; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; LAM M, 1993, MOL ENDOCRINOL, V7, P686, DOI 10.1210/me.7.5.686; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LODISH HF, 1992, J BIOL CHEM, V267, P12753; MIYASHITA T, 1992, CANCER RES, V52, P5407; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MUSCHEL RJ, 1995, CANCER RES, V55, P995; ORRENIUS S, 1992, ANN NEUROL, V32, pS33, DOI 10.1002/ana.410320708; REED DJ, 1990, CHEM RES TOXICOL, V3, P495, DOI 10.1021/tx00018a002; RENARD DC, 1992, BIOCHEM J, V284, P507, DOI 10.1042/bj2840507; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHORT AD, 1993, P NATL ACAD SCI USA, V90, P4986, DOI 10.1073/pnas.90.11.4986; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; WERLEN G, 1993, J BIOL CHEM, V268, P16596; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	44	96	101	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2051	2055						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668330				2022-12-28	WOS:A1996UP28300003
J	Venanzoni, MC; Robinson, LR; Hodge, DR; Kola, I; Seth, A				Venanzoni, MC; Robinson, LR; Hodge, DR; Kola, I; Seth, A			ETS1 and ETS2 in p53 regulation: Spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction	ONCOGENE			English	Article						ETS1; ETS2; p53 promoter; transactivation; gene regulation	TRANSCRIPTION FACTORS; ONCOGENIC ACTIVITY; GENE; PROTOONCOGENE; FAMILY; CELLS; EMBRYOGENESIS; EXPRESSION; PROMOTER	p53 is an extensively studied tumor suppressor gene implicated in the genesis of a large number of varied tumours. However, the pathways of regulation for the wild-type p53 gene and its product are as yet unknown. In situ hybridization analyses of ETS1 and ETS2 expression during mouse embryogenesis, have shown a pattern similar to that of p53 gene expression. Significantly, we have identified several ETS-binding sites (EBS) in the promoter regions of the human and mouse p53 genes. In the human promoter two of these EBS are present in the form of a palindrome, with the two EBS cores being separated by four nucleotides. This report shows that the EBS palindrome of the human p53 promoter has a high affinity for ETS1 and ETS2, and that such binding interaction intracellularly is able to activate the transcription of a CAT reporter gene by 5-10-fold using COS cells. To investigate whether the spacing between the two EBS cores influences the DNA binding activity, we synthesized oligonucleotides with increasing distances (4,12,16 and 20 bases respectively) between the two EBS cores of the palindrome. We observed an inverse correlation between an increasing distance in the two EBS cores of the palindrome and the ETS1 and ETS2 DNA binding activity respectively. Interestingly, optimal DNA binding activity was observed when the distance between the two EBS cores was four bases, identical to that which occurs in the natural promoter. Furthermore we show that the p53 mRNA is expressed at higher levels in NIH3T3 cells over-expressing ETS2 gene product, suggesting that the ETS2 transcription factor is a likely candidate for regulating the expression of p53 in vivo.	UNIV TORONTO, FAC MED, DEPT PATHOL, TORONTO, ON M5S 1B2, CANADA; NCI, FREDERICK CANC RES & DEV CTR, MOLEC ONCOL LAB, FREDERICK, MD 21702 USA; FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; MONASH UNIV, MOL GENET & DEV GRP, MELBOURNE, VIC 3168, AUSTRALIA; UNIV TORONTO, FAC DENT, TORONTO, ON M5S 1B2, CANADA; WOMENS COLL HOSP, TORONTO, ON M5S 1B2, CANADA	University of Toronto; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Monash University; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital			Kola, Ismail/C-5254-2013					ASCIONE R, 1992, INT J ONCOL, V1, P631; ASCIONE R, 1993, GENOME RES MOL MED V, V13, P199; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BIENZTADMOR B, 1985, EMBO J, V4, P3209, DOI 10.1002/j.1460-2075.1985.tb04067.x; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HALL PA, 1993, ONCOGENE, V8, P203; Hodge DR, 1996, ONCOGENE, V12, P11; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMB P, 1986, MOL CELL BIOL, V6, P1379, DOI 10.1128/MCB.6.5.1379; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; LEVINE AJ, 1990, BIOCHIM BIOPHYS ACTA, V1032, P119, DOI 10.1016/0304-419X(90)90015-S; LOUIS JM, 1988, BIOCHIM BIOPHYS ACTA, V950, P395, DOI 10.1016/0167-4781(88)90136-4; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; ROTTER V, 1994, SEMIN CANCER BIOL, V5, P229; SCHMID P, 1991, DEVELOPMENT, V113, P857; SETH A, 1990, ADV AP BIOT, V6, P285; SETH A, 1993, ONCOGENE, V8, P1783; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1994, ONCOGENE, V9, P469; SETH A, 1990, ONCOGENE, V5, P1761; SETH A, 1993, CANCER PRINCIPLES PR, P23; SHOHAT O, 1987, ONCOGENE, V1, P277; TUCK SP, 1989, MOL CELL BIOL, V9, P2163, DOI 10.1128/MCB.9.5.2163; VENANZONI M, 1994, MIAMI SHORT REP, V6, P78; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; WERNERT N, 1992, AM J PATHOL, V140, P119	35	63	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1199	1204						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649821				2022-12-28	WOS:A1996UC06700004
J	Thomas, A; ElRouby, S; Reed, JC; Krajewski, S; Silber, R; Potmesil, M; Newcomb, EW				Thomas, A; ElRouby, S; Reed, JC; Krajewski, S; Silber, R; Potmesil, M; Newcomb, EW			Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance	ONCOGENE			English	Article						bcl-2; bax; chronic lymphocytic leukemia; drug resistance; apoptosis	DEATH; EXPRESSION; DIFFERENTIATION	We investigated the relationship among chemosensitivity to drug-induced apoptosis in vitro, the presence of p53 gene mutations, and the expression of bcl-2 and bax proteins in B-cells from B-cell chronic lymphocytic leukemia (B-CLL) patients. Apoptosis was induced with a camptothecin analogue, 9-amino-20(s)-camptothecin, or a purine analogue, fludarabine. Cell death was monitored by propidium iodide staining and FACS analysis. Drug-induced apoptosis in B-CLL cells was p53-independent. Immunoblot analysis of bcl-2 and bax expression revealed a correlation between drug-induced apoptosis and the ratio of endogenous levels of bcl-2 to bax proteins. B-CLL cells with none to low bcl-2/bax ratios were drug-sensitive as compared to cells with high ratios that were drug-resistant Prior to drug treatment, bax protein migrated as a single species of 21 kDa. Following drug-induced apoptosis, anti-bax specific protein complexes of 36-42 kDa were up-regulated. Using two-dimensional gel electrophoresis, bax complexes were disrupted under reducing conditions to reveal homo- and heterodimers of 18 and 21 kDa suggesting that disulfide interactions were required for complex formation. The de novo appearance of the 18 kDa anti-bax specific protein together with its increased expression in drug-sensitive B-CLL B-cells undergoing cell death suggests a role for this protein in the regulation of apoptosis.	NYU, SCH MED, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT MED, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT RADIOL, NEW YORK, NY 10016 USA; KAPLAN COMPREHENS CANC CTR, NEW YORK, NY 10016 USA; LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	New York University; New York University; New York University; Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [U10CA060138] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; ELROUBY S, 1993, BLOOD, V82, P3452; FOON KA, 1990, ANN INTERN MED, V113, P525, DOI 10.7326/0003-4819-113-7-525; FRANKEL RH, 1992, CANCER RES, V52, P1427; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HANADA M, 1993, BLOOD, V82, P1820; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAPARA MY, 1993, EUR J IMMUNOL, V23, P702, DOI 10.1002/eji.1830230320; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROBERTSON LE, 1993, BLOOD, V81, P143; SCHENA M, 1992, BLOOD, V79, P2981; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SILBER R, 1994, BLOOD, V84, P3440; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; ZHAN QM, 1994, ONCOGENE, V9, P3743	31	277	287	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1055	1062						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649796				2022-12-28	WOS:A1996UA88400013
J	Wang, YP; Becker, D				Wang, YP; Becker, D			Differential expression of the cyclin-dependent kinase inhibitors p16 and p21 in the human melanocytic system	ONCOGENE			English	Article						melanocytes; melanoma progression; cyclin-dependent kinase inhibitors; retinoblastoma gene product	RETINOBLASTOMA PROTEIN; TUMOR PROGRESSION; MELANOMA; HOMOLOGY; BINDING	To determine whether loss or inactivation of the putative tumor-suppressor gene, p16, represents an initiating or a secondary event in the progression of human melanoma, we evaluated the status of this gene in early and advanced-stage melanomas of sporadic origin. The results of this analysis revealed p16 deletions in 4/6 primary and 6/14 metastatic melanoma cell lines but not in 3/3 metastatic melanoma specimens. Surprisingly, p16 deletions were also detected in 8/8 benign compound nevi and in 1/3 normal human melanocyte isolates. To investigate whether these deletions in benign and malignant stages of the human melanocytic system were specific for p16, we analysed the same specimens and cell lines for expression of p21, another cyclin-dependent kinase inhibitor and potential tumor suppressor. In contrast to p16, expression of p21 was detected in 3/3 melanocytes, in 3/3 benign nevi, and in greater than 50% of malignant melanoma cell lines and specimens. Finally, because of the recently documented inverse relationship between expression of p16 and pRb protein in a variety of tumor cell lines, we analysed some of the p16-positive and negative melanoma cell lines for the presence of pRb protein. The results demonstrated pRb protein in each of these cell Lines. Taken together, although this study revealed deletions of the p16 gene in a significant number of sporadic primary and metastatic melanoma cell lines, they were also detected in benign nevus specimens and in some normal human melanocyte isolates. Thus, these findings cast some doubt on the role of this gene as being causal to the onset and progression of human melanoma, in particular, sporadic melanoma.	UNIV PITTSBURGH,DEPT MED,PITTSBURGH,PA 15213	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								ALMENDRAL JM, 1987, P NATL ACAD SCI USA, V84, P1575, DOI 10.1073/pnas.84.6.1575; BECKER D, 1989, GENOMICS, V4, P97, DOI 10.1016/0888-7543(89)90320-0; BECKER D, 1992, ONCOGENE, V7, P2302; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARK WH, 1988, ARCH DERMATOL, V124, P1207, DOI 10.1001/archderm.124.8.1207; CLARK WH, 1986, HUM PATHOL, V17, P443, DOI 10.1016/S0046-8177(86)80032-6; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; CLARK WH, 1991, BRIT J CANCER, V64, P101; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDER DE, 1993, SEMIN DIAGN PATHOL, V10, P18; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HERLYN M, 1987, LAB INVEST, V56, P461; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KATO J, 1993, GENE DEV, V7, P331; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORI T, 1994, CANCER RES, V54, P3396; NIKAJIMAIIJIMA S, 1995, P NATL ACAD SCI USA, V82, P6133; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTA M, 1994, CANCER RES, V54, P5269; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; Parmiter A., 1988, MALIGNANT MELANOMA B, P47; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; REED JA, 1995, CANCER RES, V55, P2713; RODECK U, 1987, INT J CANCER, V40, P687, DOI 10.1002/ijc.2910400520; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TRENT JM, 1992, CUTANEOUS MELANOMA, P1001; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0	43	30	30	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1069	1075						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649798				2022-12-28	WOS:A1996UA88400015
J	Rafferty, JA; Clarke, AR; Sellappan, D; Koref, MS; Frayling, IM; Margison, GP				Rafferty, JA; Clarke, AR; Sellappan, D; Koref, MS; Frayling, IM; Margison, GP			Induction of murine O-6-alkylguanine-DNA-alkyltransferase in response to ionising radiation is p53 gene dose dependent	ONCOGENE			English	Article						p53; ATase; DNA repair induction; animal model	DNA-DAMAGING AGENTS; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; IONIZING-RADIATION; MESSENGER-RNA; RAT-LIVER; CELLS; TISSUES; TUMORS; MICE	Expression of both the DNA repair protein O-6-alkylguanine-DNA-alkyltransferase (ATase) and the p53 tumour suppressor protein are inducible by a number of DNA damaging agents. It is probable that DNA strand breaks are the common inducing signals. This similarity, and the function of p53 as a transcription factor lead us to reason that p53 might be involved in ATase inducibility. We now report that the induction of ATase activity in mouse tissues following gamma-radiation is p53 gene dose dependent. While the extent and kinetics of induction in p53 wildtype mice are consistent with previous reports (a 2-3-fold peak increase at 36 h), no induction is observed in p53 null animals. Importantly the heterozygous mice show an intermediate response but the same kinetics, The basal levels of expression in all tissues examined are unaffected by p53 status. These data represent the first report of a discrete DNA repair function being p53 regulated in vivo and their potential clinical implications are discussed.	UNIV EDINBURGH,SCH MED,CANC RES CAMPAIGN LABS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	Rafferty, JA (corresponding author), CHRISTIE HOSP NATL HLTH SERV TRUST,PATERSON INST CANC RES,DEPT CARCINOGENESIS,CANC RES CAMPAIGN,MANCHESTER M20 9BX,LANCS,ENGLAND.		Clarke, Alan R/A-6256-2008; Margison, Geoff/E-4146-2019; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X; Frayling, Ian/0000-0002-3420-0794				BAER JC, 1993, BRIT J CANCER, V67, P1299, DOI 10.1038/bjc.1993.241; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DINCALCI M, 1988, CANC TREAT REV, V15, P5723; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN SJ, 1994, CANCER RES, V54, P5824; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; FRITZ G, 1991, MOL CELL BIOL, V11, P4660, DOI 10.1128/MCB.11.9.4660; HARKNESS RD, 1957, BRIT MED BULL, V13, P87, DOI 10.1093/oxfordjournals.bmb.a069601; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISHIZAKI K, 1994, INT J CANCER, V58, P254, DOI 10.1002/ijc.2910580218; JELINEK J, 1988, CARCINOGENESIS, V9, P81, DOI 10.1093/carcin/9.1.81; KAINA B, 1991, CARCINOGENESIS, V12, P1857; KLEIHUES P, 1976, NATURE, V259, P153, DOI 10.1038/259153a0; LEFEBVRE P, 1993, DNA CELL BIOL, V12, P233, DOI 10.1089/dna.1993.12.233; LI J-H, 1989, Molecular Toxicology, V2, P1; MARGISON GP, 1985, CARCINOGENESIS, V6, P1699, DOI 10.1093/carcin/6.12.1699; MARGISON GP, 1990, HDB EXPT PHARM, V94, P547; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MONTECUCCO A, 1995, NUCLEIC ACIDS RES, V23, P962, DOI 10.1093/nar/23.6.962; MONTESANO R, 1979, CANCER RES, V39, P1789; NAKATSURU Y, 1993, P NATL ACAD SCI USA, V90, P6468, DOI 10.1073/pnas.90.14.6468; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PEGG AE, 1990, CANCER RES, V50, P6119; POTTER PM, 1991, CARCINOGENESIS, V12, P727, DOI 10.1093/carcin/12.4.727; SMITH ML, 1995, ONCOGENE, V10, P1053; STAMMBERGER I, 1990, CARCINOGENESIS, V11, P219, DOI 10.1093/carcin/11.2.219; VOIGT JM, 1995, CARCINOGENESIS, V16, P1775, DOI 10.1093/carcin/16.8.1775; VONHOFE E, 1988, CARCINOGENESIS, V9, P679, DOI 10.1093/carcin/9.4.679; VONHOFE E, 1992, P NATL ACAD SCI USA, V89, P11199, DOI 10.1073/pnas.89.23.11199; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WILSON RE, 1993, CARCINOGENESIS, V14, P679, DOI 10.1093/carcin/14.4.679; ZHAN QM, 1994, CANCER RES, V54, P2755	36	81	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					693	697						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637727				2022-12-28	WOS:A1996TV59700027
J	Rommel, C; Radziwill, G; Lovric, J; Noeldeke, J; Heinicke, T; Jones, D; Aitken, A; Moelling, K				Rommel, C; Radziwill, G; Lovric, J; Noeldeke, J; Heinicke, T; Jones, D; Aitken, A; Moelling, K			Activated Ras displaces 14-3-3 protein from the amino terminus of c-Raf-1	ONCOGENE			English	Article						Ras; Raf; 14-3-3 protein; signal transduction	KINASE-KINASE; RAF-1 KINASE; PHOSPHORYLATION; AUTOPHOSPHORYLATION; PURIFICATION; ANTIBODIES; ONCOGENE; DOMAIN; BRAIN; MIL	The serine/threonine protein kinase c-Raf-1 interacts with a number of cellular proteins including 14-3-3 isoforms which may be regulators or substrates of c-Raf-1 in signal transduction pathways, In vivo and in vitro binding analyses of c-Raf-1 and mutant proteins with 14-3-3 zeta indicate bivalent binding of 14-3-3 zeta to the amino terminus as well as to the carboxy terminus of c-Raf-1, Although 14-3-3 zeta and Ras use different binding regions on the amino terminal regulatory domain of c-Raf-1 (c-Raf-NT), 14-3-3 zeta is displaced from the amino terminus upon binding of activated Ras, In contrast, if c-Raf-1 full length is analysed instead of the separately expressed c-Raf-NT, binding of 14-3-3 zeta is only slightly effected by co-expression of activated Ras, This is explained by a second binding site of 14-3-3 zeta at the carboxy terminus of c-Raf-1. The mutant c-Raf-NT (S259A) cannot bind 14-3-3 zeta, suggesting a regulatory role of this in vivo phosphorylation site, However, c-Raf-NT phosphorylated or unphosphorylated at S259, is able to bind 14-3-3 zeta, Even though 14-3-3 zeta can be phosphorylated in vivo, only the unphosphorylated form binds to the amino terminus of c-Raf-1, The data presented indicate, that 14-3-3 zeta binds to c-Raf-1 in a bivalent fashion in unstimulated cells, 14-3-3 zeta is displaced from the amino terminus but not from the carboxy terminus of c-Raf-1 by binding of activated Ras to c-Raf-1.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND; NATL INST MED RES, LAB PROT STRUCT, LONDON NW7 1AA, ENGLAND	University of Zurich; MRC National Institute for Medical Research				Lovric, Josip/0000-0002-0338-6581				AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AITKEN A, 1995, TRENDS BIOCHEM SCI, V20, P95, DOI 10.1016/S0968-0004(00)88971-9; AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P498, DOI 10.1016/0968-0004(92)90339-B; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BEIMLING P, 1994, BIOCHEM BIOPH RES CO, V204, P841, DOI 10.1006/bbrc.1994.2536; BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CHOW YH, 1995, J BIOL CHEM, V270, P14100, DOI 10.1074/jbc.270.23.14100; CONKLIN DS, 1995, P NATL ACAD SCI USA, V92, P7892, DOI 10.1073/pnas.92.17.7892; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DENT P, 1995, MOL CELL BIOL, V15, P4125; DENT P, 1994, P NATL ACAD SCI USA, V91, P9544, DOI 10.1073/pnas.91.20.9544; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABIAN JR, 1994, P NATL ACAD SCI USA, V91, P5982, DOI 10.1073/pnas.91.13.5982; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; Gorman CM, 1990, DNA PROTEIN ENG TECH, V2, P1; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JAMAL S, 1995, ONCOGENE, V10, P2095; JOHN J, 1988, J BIOL CHEM, V263, P11792; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1993, J BIOL CHEM, V268, P16009; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; MARX J, 1993, SCIENCE, V262, P988, DOI 10.1126/science.8257559; MCCONNELL JE, 1995, DEV BIOL, V169, P218, DOI 10.1006/dbio.1995.1139; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NIEHOF M, 1995, BIOCHEM BIOPH RES CO, V206, P46, DOI 10.1006/bbrc.1995.1007; NIEHOF M, 1994, BIOCHEM BIOPH RES CO, V203, P1560, DOI 10.1006/bbrc.1994.2364; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; ROBINSON K, 1994, BIOCHEM J, V299, P853, DOI 10.1042/bj2990853; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; SUEN KL, 1995, ONCOGENE, V11, P825; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HG, 1994, ONCOGENE, V9, P2751; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	68	124	126	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					609	619						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637718				2022-12-28	WOS:A1996TV59700018
J	BenYosef, T; Yanuka, O; Benvenisty, N				BenYosef, T; Yanuka, O; Benvenisty, N			ECA39 is regulated by c-Myc in human and by a Jun/Fos homolog, Gcn4, in yeast	ONCOGENE			English	Article						Gcn4; c-Jun; c-Myc; oncogenesis; targets; transcription	HELIX-LOOP-HELIX; DNA-BINDING; CELL-LINE; N-MYC; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; EMBRYONIC LETHALITY; CONTINUOUS CULTURE; GENERAL CONTROL; PROTEIN-KINASE	myc oncogenes are transcription factors regulating the level of expression of other genes, Using a subtraction/coexpression strategy, a murine genetic target for Myc regulation was isolated, To further characterize this target gene, named ECA39, we have recently isolated the human, nematode and budding yeast homologs of the mouse gene, The recognition site for Myc binding, located 3' to the start site of transcription in the mouse gene, is conserved in the human homolog, Transfection experiments demonstrated that the Myc binding site of the human gene, mediates activation of a reporter gene in response to over-expression of c-myc, The activation was better executed when the c-Myc binding element was positioned downstream to the promoter, which is the usual position of the c-Myc DNA binding element in its genetic targets, The tissue specific expression of human ECA39 during embryogenesis is similar to that of the mouse homolog, Moreover, ECA39 is expressed in c-myc induced human tumors, It is expressed in Burkitt's lymphoma (where c-myc is translocated and activated) but not in non Burkitt's B-cell lymphoma or in T-cell lymphoma, Thus, it seems that ECA39 is a target for c-myc oncogenesis in humans, In yeast, where c-myc is absent, the ECA39 sequences lack the c-Myc binding element, However, the promoter region of the yeast ECA39 harbors several Gcn4 binding elements, Moreover, ECA39 is markedly down regulated in cells deleted for gcn4, and deletion of Gcn4 binding elements down regulated the transcription from ECA39 promoter, We thus suggest that ECA39 is a target for c-Myc regulation in mammals, while in yeast the regulator is not c-Myc but the c-Jun/c-Fos homolog - Gcn4.	HEBREW UNIV JERUSALEM,INST LIFE SCI,DEPT GENET,IL-91904 JERUSALEM,ISRAEL	Hebrew University of Jerusalem								AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARNDT K, 1986, P NATL ACAD SCI USA, V83, P8516, DOI 10.1073/pnas.83.22.8516; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; Bello-Fernandez C, 1992, Curr Top Microbiol Immunol, V182, P445; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENBASSAT H, 1977, INT J CANCER, V19, P27, DOI 10.1002/ijc.2910190105; BENBASSAT H, 1980, INT J CANCER, V25, P583, DOI 10.1002/ijc.2910250506; BENBASSAT H, 1992, LEUKEMIA LYMPHOMA, V6, P513, DOI 10.3109/10428199209053591; BENVENISTY N, 1995, GROWTH FACTORS, V12, P49, DOI 10.3109/08977199509003213; BENVENISTY N, 1992, ONCOGENE, V7, P2399; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DAVIS LJ, 1993, ONCOGENE, V8, P125; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUERIN M, 1988, ONCOGENE RES, V3, P21; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; Hinnebusch A. G., 1992, MOL CELLULAR BIOL YE, P319, DOI DOI 10.1016/J.ACA.2008.01.060; HINNEBUSCH AG, 1988, MICROBIOL REV, V52, P248, DOI 10.1128/MMBR.52.2.248-273.1988; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LANDSCHULTZ WH, 1987, SCIENCE, V240, P1759; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MIFFLIN D, 1988, BIOSCIENCE REP, V8, P415, DOI 10.1007/BF01121638; Miller J. H, 1972, EXPT MOL GENETICS; MUELLER PP, 1986, CELL, V45, P201, DOI 10.1016/0092-8674(86)90384-3; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1989, NATURE, V341, P362; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; RONEN D, 1991, P NATL ACAD SCI USA, V88, P4128, DOI 10.1073/pnas.88.10.4128; ROSE M, 1983, METHOD ENZYMOL, V101, P167; Rose MD., 1990, METHODS YEAST GENETI; SARID J, 1988, NUCLEIC ACIDS RES, V16, P4725, DOI 10.1093/nar/16.10.4725; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2765, DOI 10.1128/MCB.13.5.2765; Schuldiner O, 1996, P NATL ACAD SCI USA, V93, P7143, DOI 10.1073/pnas.93.14.7143; SHILO BZ, 1982, P NATL ACAD SCI USA, V78, P6789; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STANTON BR, 1992, GENE DEV, V6, P2235, DOI 10.1101/gad.6.12a.2235; STEINITZ M, 1975, P NATL ACAD SCI USA, V72, P8515; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; WALKER CW, 1992, ONCOGENE, V7, P2007	64	18	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1859	1866						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934531				2022-12-28	WOS:A1996VR79500004
J	Kondo, S; Morimura, T; Barnett, GH; Kondo, Y; Peterson, JW; Kaakaji, R; Takeuchi, J; Toms, SA; Liu, JB; Werbel, B; Barna, BP				Kondo, S; Morimura, T; Barnett, GH; Kondo, Y; Peterson, JW; Kaakaji, R; Takeuchi, J; Toms, SA; Liu, JB; Werbel, B; Barna, BP			The transforming activities of MDM2 in cultured neonatal rat astrocytes	ONCOGENE			English	Article						MDM2; astrocyte; p53; bFGF; PDGF; glioma	FIBROBLAST GROWTH-FACTOR; HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN GLIOBLASTOMA CELLS; HUMAN-MALIGNANT GLIOMAS; TUMOR-SUPPRESSOR GENE; SOFT-TISSUE SARCOMAS; HUMAN-BRAIN-TUMORS; P53 MUTATIONS; MESSENGER-RNA; SV40-TRANSFORMED CELLS	Although the molecular events regulating the pathogenesis of malignant astrocytomas remains unclear, the inactivation of tumor suppressor genes may be a key factor. The inactivation of p53 by mutation or deletion, however, is not the only obligatory step in astrocytoma genesis. The MDM2, protein has been shown to bind to and downmodulate p53 function, and to have oncogenic capacity. The MDM2 gene is also amplified and overexpressed in a subset of malignant astrocytomas without p53 mutation. Here we show that overexpression of MDM2 promoted the DNA synthesis of cultured neonatal rat astrocytes (RNB cells), abrogated the transcriptional activity of wild-type p53, conferred invasive activity, and subsequently induced the transformation from astrocytes to high-grade astrocytomas. Intriguingly, MDM2 enhanced the expression of angiogenic mitogens; basic fibroblast growth factor (bFGF) and platelet-derived growth factor (PDGF) in RNB cells. These results indicate that MDM2 may play an important role in the progression of astrocytomas, by not only conferring invasive activity but also stimulating the expression of angiogenic growth factors.	CLEVELAND CLIN FDN,DEPT NEUROSCI,CLEVELAND,OH 44195; NATL UTANO HOSP,DEPT NEUROSURG,UKYO KU,KYOTO 616,JAPAN	Cleveland Clinic Foundation	Kondo, S (corresponding author), CLEVELAND CLIN FDN,DEPT NEUROSURG S80,BRAIN TUMOR CTR,CTR CANC,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Peterson, John/0000-0002-5528-8561				ANTONIADES HN, 1987, ONCOGENES GENES GROW, P1; BOGLER O, 1995, CANCER RES, V55, P2476; COLLINS MKL, 1983, J BIOL CHEM, V258, P1689; CORDONCARDO C, 1994, CANCER RES, V54, P794; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLAUMENHAFT R, 1989, J CELL PHYSIOL, V140, P75, DOI 10.1002/jcp.1041400110; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FRANKEL RH, 1992, CANCER RES, V52, P1427; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1989, CANCER RES, V49, P6572; FULTS D, 1992, CANCER RES, V52, P674; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GUHA A, 1995, J NEUROL NEUROSUR PS, V58, P711, DOI 10.1136/jnnp.58.6.711; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWASAKI K, 1993, J NEUROSURG, V78, P952, DOI 10.3171/jns.1993.78.6.0952; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; KONDO S, 1995, ONCOGENE, V10, P2001; KONDO S, 1992, NEUROSURGERY, V30, P506; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEACH FS, 1993, CANCER RES, V53, P2231; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MALKIN D, 1993, PRINCIPLES PRACTICE, V7, P1; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MAXWELL M, 1991, CANCER RES, V51, P1345; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MORRISON RS, 1993, J NEUROSCI RES, V34, P502, DOI 10.1002/jnr.490340503; MURPHY PR, 1990, MOL ENDOCRINOL, V4, P196, DOI 10.1210/mend-4-2-196; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Potapova O, 1996, CANCER RES, V56, P280; REIFENBERGER G, 1993, CANCER RES, V53, P2736; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU JK, 1993, NEUROSURGERY, V33, P824; XIANO ZX, 1995, NATURE, V375, P694	51	20	23	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1773	1779						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895524				2022-12-28	WOS:A1996VM88700023
J	Itakura, O; Yamada, S; Narita, M; Kikuta, H				Itakura, O; Yamada, S; Narita, M; Kikuta, H			High prevalence of a 30-base pair deletion and single-base mutations within the carboxy terminal end of the LMP-1 oncogene of Epstein-Barr virus in the Japanese population	ONCOGENE			English	Article						EBV; LMP-1; 30-bp deletion; six point mutations; Japanese population	T-CELL LYMPHOMAS; MEMBRANE-PROTEIN LMP-1; NF-KAPPA-B; NASOPHARYNGEAL CARCINOMA; HODGKINS-DISEASE; BNLF-1 GENE; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; HEMOPHAGOCYTIC SYNDROME; HIGH-FREQUENCY; EBV INFECTION	The presence of 30-base pair (bp) deletion mutants within the carboxy terminal end of the LMP-1 oncogene (BNLF-1 gene) of Epstein-Barr virus (EBV) has been reported in EBV-associated neoplasms. We analysed the 30-bp deletion and the single-base mutations of the LMP-1 gene in 13 spontaneously established lymphoblastoid cell lines (LCLs) from peripheral blood mononuclear cells of three healthy children, four patients with EBV-unrelated acute febrile illnesses, three patients with infectious mononucleosis (IM), and three patients with chronic active EBV infection (CEBV), and six frozen samples from four patients with CEBV and two patients with EBV-associated hemophagocytic syndrome (EBV-AHS). For molecular analysis of the carboxy terminal end of the LMP-1 gene, PCR was performed using primers spanning the carboxy terminal region of the LMP-1 gene. Direct sequence analysis of the PCR products revealed identical 30-bp deletion in 14 of 19 samples (74%). Six point mutations at nucleotide positions 168357, 168355, 168320, 168308, 168295, and 168225 were frequently identified regardless of disease status. Our findings revealed the carboxy terminal end of the LMP-1 gene was mutational hot spots. The 30-bp deletion mutant is widely spread in the Japanese population and is not implicated in EBV-associated lymphoproliferative diseases.	HOKKAIDO UNIV,SCH MED,DEPT PEDIAT,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University								ANAGNOSTOPOULOS I, 1992, BLOOD, V80, P1804; BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; CHEN CL, 1993, J VIROL, V67, P6303, DOI 10.1128/JVI.67.10.6303-6308.1993; Chen WG, 1996, AM J PATHOL, V148, P17; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GREGORY CD, 1988, J EXP MED, V167, P1811, DOI 10.1084/jem.167.6.1811; HARABUCHI Y, 1990, LANCET, V335, P128, DOI 10.1016/0140-6736(90)90002-M; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HENNESSY K, 1984, P NATL ACAD SCI-BIOL, V81, P7207, DOI 10.1073/pnas.81.22.7207; HERBST H, 1991, P NATL ACAD SCI USA, V88, P4766, DOI 10.1073/pnas.88.11.4766; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; HUEN DS, 1995, ONCOGENE, V10, P549; KIKUTA H, 1988, NATURE, V333, P455, DOI 10.1038/333455a0; KIKUTA H, 1993, BLOOD, V82, P3259; KIKUTA H, 1989, J INFECT DIS, V160, P546; KNECHT H, 1995, ONCOGENE, V10, P523; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1995, LEUKEMIA, V9, P458; Liebowitz David, 1993, P107; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MOORTHY R, 1990, J VIROL, V64, P829, DOI 10.1128/JVI.64.2.829-837.1990; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; Palefsky JM, 1996, J INFECT DIS, V173, P710, DOI 10.1093/infdis/173.3.710; PALLESEN G, 1993, ADV CANCER RES, V62, P179, DOI 10.1016/S0065-230X(08)60319-X; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; SANDVEJ K, 1994, BLOOD, V84, P4053, DOI 10.1182/blood.V84.12.4053.bloodjournal84124053; STREISINGER G, 1966, COLD SPRING HARB SYM, V31, P77, DOI 10.1101/SQB.1966.031.01.014; TOBI M, 1982, LANCET, V1, P61; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WEISS LM, 1987, AM J PATHOL, V129, P86; WILSON ER, 1981, J PEDIATR-US, V98, P260, DOI 10.1016/S0022-3476(81)80654-3; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZHOU XG, 1994, HISTOPATHOLOGY, V24, P115, DOI 10.1111/j.1365-2559.1994.tb01289.x; ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0	42	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1549	1553						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875994				2022-12-28	WOS:A1996VL38400021
J	SunHoffman, L; Aurigemma, RE; Sun, B; Ruscetti, SK				SunHoffman, L; Aurigemma, RE; Sun, B; Ruscetti, SK			Transactivation of the GATA-1 promoter by a myb-ets-containing mouse retrovirus is mediated by CACCC elements	ONCOGENE			English	Article						ME26 virus; GATA-1 transactivation; CACCC element; Sp1	TRANSCRIPTION FACTOR GATA-1; ERYTHROPOIETIN RECEPTOR GENE; LEUKEMIA-VIRUS; FACTOR SP1; BINDING; CELLS; PROTEINS; E26	The myb-ets-containing ME26 virus causes erythroleukemia in mice by a novel mechanism involving the inappropriate activation of erythroid-specific genes in hematopoietic precursor cells, We have previously shown that the ME26 viral protein can transactivate the GATA-1 promoter in transient transactivation assays carried out in mouse fibroblasts. The mouse GATA-1 promoter, whose activity is regulated by the GATA-1 protein itself, contains a double GATA consensus sequence at its 5' end and two CACCC elements at its 3' end, both of which are crucial for promoter activity in erythroid cells, as well as a nonconsensus GATA sequence and several putative c-myb and c-ets binding sites, In order to determine which sequences in the GATA-1 promoter are crucial for activation by the ME26 viral protein, we made deletions of the promoter, cloned them into a luciferase expression vector and tested their activity in mouse fibroblasts, which do not express GATA-1, Our results indicate that sequences in the 3' end of the GATA-1 promoter, which include two CACCC elements, are essential for transactivation by ME26 virus, while other upstream sites contribute to full activation by the virus, Mutation of the CACCC sites abolishes ME26 viral transactivation. The interaction of cell extracts containing ME26 viral protein and the GATA-1 promoter fragment containing the two CACCC elements was examined by electrophoretic mobility shift analysis (EMSA) and the results showed no direct interaction between the two, However, we could detect the ubiquitous transcription factor Spl bound to this sequence, These data demonstrate that the CACCC element is necessary for GATA-1 promoter transactivation by ME26 virus and that the viral protein may indirectly transactivate the promoter by binding to Sp1.	NCI,MOL ONCOL LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BARON MH, 1994, MOL CELL BIOL, V14, P3108, DOI 10.1128/MCB.14.5.3108; BRADY HJM, 1989, FEBS LETT, V257, P451, DOI 10.1016/0014-5793(89)81594-7; CHIN K, 1995, NUCLEIC ACIDS RES, V23, P3041, DOI 10.1093/nar/23.15.3041; FISCHER KD, 1993, J BIOL CHEM, V268, P23195; FRAMPTON J, 1990, MOL CELL BIOL, V10, P3838, DOI 10.1128/MCB.10.7.3838; GREGORY RC, 1996, BLOOD, V5, P1793; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MILTENBERGER RJ, 1995, CELL GROWTH DIFFER, V6, P549; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P73, DOI 10.1093/nar/17.1.73; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; Ren SC, 1996, NUCLEIC ACIDS RES, V24, P342, DOI 10.1093/nar/24.2.342; RUSCETTI S, 1992, J VIROL, V66, P20, DOI 10.1128/JVI.66.1.20-26.1992; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; YOUSSOUFIAN H, 1990, MOL CELL BIOL, V10, P3675, DOI 10.1128/MCB.10.7.3675; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638	22	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1037	1042						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806693				2022-12-28	WOS:A1996VG76600017
J	Vairapandi, M; Duker, NJ				Vairapandi, M; Duker, NJ			Partial purification and characterization of human 5-methylcytosine-DNA glycosylase	ONCOGENE			English	Article						5-methylcytosine; DNA; demethylation; glycosylase; apyrimidinic site	TRANSIENT DNA DEMETHYLATION; DEOXYRIBONUCLEIC-ACID; APYRIMIDINIC SITES; ENZYMATIC REMOVAL; NUCLEAR EXTRACTS; MAMMALIAN-CELLS; CHICKEN EMBRYOS; EXCISION-REPAIR; METHYLATION; CYTOSINE	The molecular mechanisms by which DNA 5-methylcytosine content is modulated are incompletely understood, Reduction of DNA 5-methylcytosine content has been correlated with the transition from hyperplasia to adenoma in the genesis of human adenocarcinoma of the colon, 5-methylcytosine-DNA glycosylase removes 5-methylcytosine from DNA as a free base, but its involvement in this process is unknown, The 5-methylcytosine-DNA glycosylase activity in HeLa nuclear extracts has been partially purified, with a 460-fold enrichment, and characterized, This activity is specific for 5-methylcytosine at CpG sites in fully methylated DNA; hemimethylated DNA is not a significant substrate, DIVA containing unmethylated cytosines is not cleaved by the enzyme, There is an absolute requirement for Mg2+ ions for the activity, which is inhibited by EDTA, This 5-methylcytosine-DNA glycosylase activity could be involved in carcinogenesis, transcription, replication, differentiation and development through resultant DNA hypomethylation following enzymatic removal of 5-methylcytosine from DNA.	TEMPLE UNIV,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19122; TEMPLE UNIV,SCH MED,FES INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19122	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University								ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; CELEWICZ L, 1992, PHOTOCHEM PHOTOBIOL, V55, P823, DOI 10.1111/j.1751-1097.1992.tb08530.x; DUKER NJ, 1995, BIOCH LIF SCI ADV, V14, P1; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; GENTIL A, 1992, J MOL BIOL, V227, P981, DOI 10.1016/0022-2836(92)90513-J; JONES PA, 1992, BIOESSAYS, V14, P33, DOI 10.1002/bies.950140107; JOST JP, 1994, J BIOL CHEM, V269, P10040; JOST JP, 1995, J BIOL CHEM, V270, P9734, DOI 10.1074/jbc.270.17.9734; JOST JP, 1993, P NATL ACAD SCI USA, V90, P4684, DOI 10.1073/pnas.90.10.4684; JOST JP, 1993, DNA METHYLATION MOL; KUYKENDALL JR, 1989, CANCER LETT, V47, P149, DOI 10.1016/0304-3835(89)90191-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDAHL T, 1990, MUTAT RES, V238, P305, DOI 10.1016/0165-1110(90)90022-4; Mazin A. L., 1993, Molekulyarnaya Biologiya (Moscow), V27, P160; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NYCE J, 1991, SOMAT CELL MOLEC GEN, V17, P543, DOI 10.1007/BF01233619; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; RAZIN A, 1986, P NATL ACAD SCI USA, V83, P2827, DOI 10.1073/pnas.83.9.2827; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; Sambrook J., 2002, MOL CLONING LAB MANU; SHEN JC, 1994, NUCLEIC ACIDS RES, V22, P972, DOI 10.1093/nar/22.6.972; SHEN JC, 1992, CELL, V71, P1073, DOI 10.1016/S0092-8674(05)80057-1; STEINBERG RA, 1995, NUCLEIC ACIDS RES, V23, P1621, DOI 10.1093/nar/23.9.1621; VAIRAPANDI M, 1993, NUCLEIC ACIDS RES, V21, P5323, DOI 10.1093/nar/21.23.5323; VAIRAPANDI M, 1994, MUTAT RES-DNA REPAIR, V315, P85, DOI 10.1016/0921-8777(94)90009-4; VOLPE P, 1993, FEBS LETT, V329, P233, DOI 10.1016/0014-5793(93)80228-M; WANG RYH, 1982, BIOCHIM BIOPHYS ACTA, V697, P371, DOI 10.1016/0167-4781(82)90101-4; WEISS RB, 1989, BIOCHEMISTRY-US, V28, P1488, DOI 10.1021/bi00430a010; YANG AS, 1995, NUCLEIC ACIDS RES, V23, P1380, DOI 10.1093/nar/23.8.1380	34	13	20	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					933	938						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806682				2022-12-28	WOS:A1996VG76600006
J	Martin, DC; Ruther, U; SanchezSweatman, OH; Orr, FW; Khokha, R				Martin, DC; Ruther, U; SanchezSweatman, OH; Orr, FW; Khokha, R			Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP-1 transgenic mice	ONCOGENE			English	Article						TIMP-1; tumor suppression; T antigen; transgenic mice	B16-F10 MELANOMA-CELLS; TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; METALLOPROTEINASE INHIBITOR; CANCER METASTASIS; GENE-EXPRESSION; TUMOR INVASION; GROWTH-FACTOR; ANGIOGENESIS; COLLAGENASE	The potential of tissue inhibitors of metalloproteinases (TIMPs) to inhibit neoplastic progression has been postulated from studies of genetically manipulated cells. To investigate whether the TIMP-1 expressed in a host tissue suppresses cancer in vivo and to identify the affected stages, we developed transgenic mice with constitutive overexpression or reduction of TIMP-1 in the liver. In double transgenic experiments, the TIMP-1 lines were crossed with a second transgenic line which expresses the Simian Virus 40 t/T antigen (TAg). This viral oncogene leads to heritable development of hepatocellular carcinomas with a 100% incidence. Effects of TIMP-1 coexpression on the TAg-induced neoplasms were determined at the tissue and cellular level. Here, we report that overexpression of hepatic TIMP-1 blocked the development of TAg-induced hepatocellular carcinomas. High TIMP-1 levels inhibited not only the later stages in tumor development (growth and angiogenesis), but also events associated with tumor initiation (altered hepatocyte cytology and tissue architecture). We further show that an antisense-mediated reduction of TIMP-1 resulted in a more rapid tumor initiation and progression. These data demonstrate that intrinsic TIMP-1 levels contribute to a tissue's susceptibility to viral oncogene-induced tumorigenesis.	UNIV WESTERN ONTARIO,LONDON REG CANC CTR,DEPT ONCOL,LONDON,ON N6A 4L6,CANADA; UNIV WESTERN ONTARIO,LONDON REG CANC CTR,DEPT BIOCHEM,LONDON,ON N6A 4L6,CANADA; HANNOVER MED SCH,INST MOL BIOL,D-30655 HANNOVER,GERMANY; HAMILTON REG CANC CTR,HAMILTON,ON L8V 5C2,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Hannover Medical School; McMaster University								ALEXANDER CM, 1992, J CELL BIOL, V118, P727, DOI 10.1083/jcb.118.3.727; BERTAUX B, 1993, CR SOC BIOL, V187, P192; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BISWAS C, 1995, CANCER RES, V55, P434; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BOUJRAD N, 1995, SCIENCE, V268, P1609, DOI 10.1126/science.7777858; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CULLEN JM, 1993, VET PATHOL, V30, P111, DOI 10.1177/030098589303000203; DECLERCK YA, 1992, CANCER RES, V52, P701; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; HARVEY MB, 1995, DEVELOPMENT, V121, P1005; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HOGAN B, 1986, MANIPULATING MOUSE E, P153; JIANG D, 1993, ONCOGENE, V8, P2805; JOHNSON MD, 1994, J CELL PHYSIOL, V160, P194, DOI 10.1002/jcp.1041600122; KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017; KHOKHA R, 1989, SCIENCE, V243, P947, DOI 10.1126/science.2465572; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KOOP S, 1994, CANCER RES, V54, P4791; LECO KJ, 1994, J BIOL CHEM, V269, P9352; LEE GH, 1990, CARCINOGENESIS, V11, P1145, DOI 10.1093/carcin/11.7.1145; LIN CQ, 1993, FASEB J, V7, P737, DOI 10.1096/fasebj.7.9.8330681; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MANENTI G, 1994, GENOMICS, V23, P118, DOI 10.1006/geno.1994.1466; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MIGNATTI P, 1988, MOL CELLULAR BIOL WO, P497; MONTGOMERY AMP, 1994, CANCER RES, V54, P5467; MULLER E, 1995, ONCOGENE, V10, P1175; MURPHY AN, 1993, J CELL PHYSIOL, V157, P351, DOI 10.1002/jcp.1041570219; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; OSTEEN KG, 1994, P NATL ACAD SCI USA, V91, P10129, DOI 10.1073/pnas.91.21.10129; OVERALL CM, 1989, J BIOL CHEM, V264, P1860; RODGERS WH, 1994, J CLIN INVEST, V94, P946, DOI 10.1172/JCI117461; RUTHER U, 1993, ONCOGENE, V8, P87; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHNAPER HW, 1993, J CELL PHYSIOL, V156, P235, DOI 10.1002/jcp.1041560204; STASKUS PW, 1991, J BIOL CHEM, V266, P449; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; TAKIGAWA M, 1990, BIOCHEM BIOPH RES CO, V171, P1264, DOI 10.1016/0006-291X(90)90822-5; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; VLODAVSKY I, 1990, CANCER METAST REV, V9, P203, DOI 10.1007/BF00046361; WATERHOUSE P, 1993, MOL REPROD DEV, V35, P219, DOI 10.1002/mrd.1080350302; WELGUS HG, 1979, J BIOL CHEM, V254, P1938; WERNERT N, 1994, CANCER RES, V54, P5683; WITTY JP, 1995, CANCER RES, V55, P1401	54	79	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					569	576						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760297				2022-12-28	WOS:A1996VB32800014
J	Milne, DM; McKendrick, L; Jardine, LJ; Deacon, E; Lord, JM; Meek, DW				Milne, DM; McKendrick, L; Jardine, LJ; Deacon, E; Lord, JM; Meek, DW			Murine p53 is phosphorylated within the PAb421 epitope by protein kinase C in vitro, but not in vivo, even after stimulation with the phorbol ester o-tetradecanoylphorbol 13-acetate	ONCOGENE			English	Article						p53; phosphorylation; protein kinase C; PAb421 epitope	WILD-TYPE P53; TUMOR SUPPRESSOR PROTEIN; CELL-CYCLE; GENE AMPLIFICATION; IRRADIATION; APOPTOSIS; ARREST	The p53 tumour suppressor protein is thought to play a major role in the defence of the cell against agents which damage DIVA, p53 is phosphorylated at multiple sites in vivo and by several different protein kinases in vitro. In this report, we have examined the phosphorylation of murine p53 by protein kinase C (PKC). Phosphopeptide mapping, phosphoamino acid analysis and radiosequence analysis of p53 phosphorylated by PKC in vitro indicated that serine 370 and threonine 377 were the major targets for phosphorylation and suggested that serine 372 and threonines 365 and 371 were minor phosphorylation sites, Site-directed mutagenesis confirmed that residues 370-372, all of which lie within the epitope for monoclonal antibody PAb421, were phosphorylated in vitro. The p53 from P-32-labelled SV3T3 cells showed a phosphopeptide pattern which includes peptides with mobilities similar to those arising from phosphorylation of residues 370-372 by PKC in vitro. Only two of these in vivo-labelled phosphopeptides co-migrated in two dimensions with peptides labelled in vitro within the PAb421 eptiope and their phosphorylation was not stimulated by the addition of the PKC activator o-tetradecanoylphorbol 13-acetate (TPA) to the cells, even though this treatment led to a fourfold stimulation of p53 phosphorylation by MAP kinase, Moreover, when the p53 proteins containing mutations at residues 370-372 were expressed in COS cells, there was no loss of any of the in vivo phosphopeptides, indicating that phosphorylation within the PAb421 epitope was undetectable in the cell, These data suggest that p53 and PKC may not interact in vivo. The two-dimensional migration pattern of the novel group of peptides is consistent with phosphorylation of previously uncharacterised sites within the central DNA binding region of p53.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, BIOMED RES CTR, DUNDEE DD1 9SY, SCOTLAND; UNIV BIRMINGHAM, SCH MED, DEPT IMMUNOL, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND	University of Dundee; University of Birmingham				Lord, Janet/0000-0003-1030-6786				BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DELPHIN C, 1994, J BIOL CHEM, V269, P29579; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCKENDRICK L, 1994, CELL MOL BIOL RES, V40, P555; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, ONCOGENE, V5, P1683; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Shaw P, 1996, ONCOGENE, V12, P921; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	29	54	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					205	211						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700548				2022-12-28	WOS:A1996UX31900024
J	Murty, VVVS; Reuter, VE; Bosl, GJ; Chaganti, RSK				Murty, VVVS; Reuter, VE; Bosl, GJ; Chaganti, RSK			Deletion mapping identifies loss of heterozygosity at 5p15.1-15.2, 5q11 and 5q34-35 in human male germ cell tumors	ONCOGENE			English	Article						male germ cell tumor; chromosome 5; loss of heterozygosity; monosomy; tumor suppressor gene	HEPATOCELLULAR-CARCINOMA; GENE; CHROMOSOME-5Q	Cytogenetic and loss of heterozygosity (LOH) studies of chromosome 5 in male germ cell tumors (GCTs) previously reported suggested the presence of one or more tumor suppressor genes (TSGs) on this chromosome which may play a role in the development of these tumors, In an attempt to further characterize allelic deletions on chromosome 5, we performed a detailed deletion mapping utilizing 66 normal-tumor DNAs from male GCTs assaying 24 polymorphic markers mapped to both the short and long arms, Thirty-seven (56%) tumors exhibited LOH at one or more loci, Loss of one allele at all informative loci was found in 15 of 37 (40.5%) cases suggesting monosomy of chromosome 5, The pattern of LOH in the remaining 22 (59.5%) tumors revealed regional losses identifying three common sites of deletions at 5p15.1-15.2, 5q11, and 5q34-35, respectively, The distribution of allelic deletions was found to be similar in all histologic subtypes with predominance of monosomy in teratomas, Thus, the present study revealed 2 types of chromosome 5 abnormalities in male GCTs, genetic monosomy and regional deletion, the latter identifying three novel sites of candidate TSGs, These data suggest that loss of genetic information on chromosome 5 plays an important role in male GCT development.	MEM SLOAN KETTERING CANC CTR,PROGRAM GENET & CELL BIOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT HUMAN GENET,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT PATHOL,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,DEPT MED,SOLID TUMOR DIV,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA05826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA005826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALJEHANI RMA, 1995, GENE CHROMOSOME CANC, V13, P249, DOI 10.1002/gcc.2870130404; ASADA Y, 1994, NAT GENET, V6, P363, DOI 10.1038/ng0494-363; DING SF, 1993, CANCER DETECT PREV, V17, P405; DING SF, 1991, BRIT J CANCER, V64, P1083, DOI 10.1038/bjc.1991.468; GODDARD AD, 1993, ADV HUM GENET, V21, P321; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HOSOE S, 1994, CANCER RES, V54, P1787; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MITRA AB, 1994, CANCER RES, V54, P4481; MURTY VVVS, 1994, CANCER RES, V54, P3983; MURTY VVVS, 1992, P NATL ACAD SCI USA, V89, P11006, DOI 10.1073/pnas.89.22.11006; MURTY VVVS, 1994, ONCOGENE, V9, P2245; PENG HQ, 1995, CANCER RES, V55, P2871; RASHEED BKA, 1995, ONCOGENE, V10, P2243; RODRIGUEZ E, 1992, CANCER RES, V52, P2285; Tamura G, 1996, CANCER RES, V56, P612; Wieland I, 1996, ONCOGENE, V12, P97; WIELAND I, 1994, CANCER RES, V54, P1772	20	30	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2719	2723						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700532				2022-12-28	WOS:A1996UW48700027
J	Hankins, GR; DeSouza, AT; Bentley, RC; Patel, MR; Marks, JR; Iglehart, JD; Jirtle, RL				Hankins, GR; DeSouza, AT; Bentley, RC; Patel, MR; Marks, JR; Iglehart, JD; Jirtle, RL			M6P/IGF2 receptor: A candidate breast tumor suppressor gene	ONCOGENE			English	Article						loss of heterozygosity; M6P/IGF2 receptor; breast cancer; mutation; tumor suppressor	FACTOR-II RECEPTOR; MANNOSE 6-PHOSPHATE BINDING; GROWTH-FACTOR-BETA; EXPRESSION CLONING; CANCER; PROTEIN; TAMOXIFEN; KINASE; HETEROZYGOSITY; POLYMORPHISM	The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2r) functions in the activation of TGF beta, a potent growth inhibitor for most cell types, the degradation of the mitogen, IGF2, and the intracellular trafficking of lysosomal enzymes, We have found its expression to be significantly reduced in both rat and human hepatocellular carcinomas (HCCs) and recently reported loss of heterozygosity (LOH) at this locus with mutations in the remaining allele in human liver tumors, Using the polymerase chain reaction, we utilized two polymorphisms in the 3' untranslated region of M6P/IGF2r to screen breast tumors for LOH, Forty of 62 (65%) patients were informative (heterozygous) and 12/40 (30%) breast tumors had LOH; 5/19 (26%) carcinomas in situ (CIS) and 7/21 (33%) invasive carcinomas, To investigate the early molecular genetic events in breast carcinogenesis, we screened the CIS with LOH for mutations, In 2/5 (40%) of these tumors, missense mutations were found in the remaining allele that gave rise to significant amino acid substitutions. These findings provide evidence that M6P/IGF2r allelic loss is an early event in the etiology of breast cancer, and that this gene functions as a tumor suppressor gene in the breast.	DUKE UNIV, MED CTR, DEPT RADIAT ONCOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT SURG, DURHAM, NC 27710 USA; ZENECA PHARMACEUT, DEPT SAFETY MED, MACCLESFIELD SK10 4TG, CHESHIRE, ENGLAND	Duke University; Duke University; Duke University					NATIONAL CANCER INSTITUTE [R01CA025951] Funding Source: NIH RePORTER; NCI NIH HHS [CA 25951] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARNES DM, 1993, J CELL BIOCHEM, P132; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BUTTA A, 1992, CANCER RES, V52, P4261; CATHERINO WH, 1993, DRUG SAFETY, V8, P381, DOI 10.2165/00002018-199308050-00005; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DEBLESER PJ, 1995, HEPATOLOGY, V21, P1429, DOI 10.1016/0270-9139(95)90066-7; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVILEE P, 1991, ONCOGENE, V6, P1705; DICKSON RB, 1990, J STEROID BIOCHEM, V37, P795, DOI 10.1016/0960-0760(90)90422-H; DICKSON RB, 1996, DIS BREAST, P221; DUTRILLAUX B, 1990, CANCER GENET CYTOGEN, V49, P203, DOI 10.1016/0165-4608(90)90143-X; FORSYTH IA, 1991, BAILLIERE CLIN ENDOC, V5, P809, DOI 10.1016/S0950-351X(10)80016-3; GOTO J, 1992, NUCLEIC ACIDS RES, V20, P923, DOI 10.1093/nar/20.4.923; HEBERT E, 1994, BRIT J CANCER, V69, P120, DOI 10.1038/bjc.1994.19; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; Hol F. A., 1992, Human Molecular Genetics, V1, P347, DOI 10.1093/hmg/1.5.347; IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91; JIRTLE RL, 1993, CANCER RES, V53, P3849; JIRTLE RL, 1994, CARCINOGENESIS, V15, P1473, DOI 10.1093/carcin/15.8.1473; JORDAN VC, 1993, CANCER, V72, P1, DOI 10.1002/1097-0142(19930701)72:1<1::AID-CNCR2820720102>3.0.CO;2-F; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KORETH J, 1995, J PATHOL, V176, P11, DOI 10.1002/path.1711760104; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAUREYS G, 1988, GENOMICS, V3, P224, DOI 10.1016/0888-7543(88)90083-3; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; LOUIS DN, 1992, AM J PATHOL, V141, P777; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; MARS WM, 1990, CANCER METAST REV, V9, P35, DOI 10.1007/BF00047587; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MELTZER SJ, 1993, PCR PROTOCOLS CURREN, P137; MENASCE LP, 1993, GENOMICS, V17, P263, DOI 10.1006/geno.1993.1320; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; MORROW M, 1996, DIS BREAST, P355; OMALLEY FP, 1994, LAB INVEST, V71, P67; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OSBORNE CK, 1989, MOL ENDOCRINOL, V3, P1701, DOI 10.1210/mend-3-11-1701; RADFORD DM, 1995, CANCER RES, V55, P3399; SACKS NPM, 1993, EUR J CANCER, V29A, P426, DOI 10.1016/0959-8049(93)90401-Z; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT B, 1995, J BIOL CHEM, V270, P14975, DOI 10.1074/jbc.270.25.14975; SLEAT DE, 1995, CANCER RES, V55, P3424; SMITH HS, 1993, J CELL BIOCHEM, P144; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; SZEBENYI G, 1994, GENOMICS, V19, P120, DOI 10.1006/geno.1994.1021; TROCK BJ, 1996, DIS BREAST, P213; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WESTLUND B, 1991, J BIOL CHEM, V266, P23233; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZHAO Y, 1993, CANCER RES, V53, P2901; ZHUANG ZP, 1995, CANCER RES, V55, P467	68	197	202	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					2003	2009						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649861				2022-12-28	WOS:A1996UK49800019
J	Santoro, M; Chiappetta, G; Cerrato, A; Salvatore, D; Zhang, L; Manzo, G; Picone, A; Portella, G; Santelli, G; Vecchio, G; Fusco, A				Santoro, M; Chiappetta, G; Cerrato, A; Salvatore, D; Zhang, L; Manzo, G; Picone, A; Portella, G; Santelli, G; Vecchio, G; Fusco, A			Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice	ONCOGENE			English	Article						thyroid; oncogene; tyrosine-kinase; mice	RET TYROSINE KINASE; PROTO-ONCOGENE; PROTOONCOGENE; TUMORIGENESIS; MUTATIONS; NEOPLASIA; FUSION; INVIVO; GENE; LINE	Gene rearrangements activating the RET proto-oncogene are frequently associated with human thyroid carcinomas belonging to the papillary subtype, These rearrangements cause the fusion of the tyrosine-kinase domain of RET to the 5-terminal region of different genes creating the RET/PTC chimeric oncogenes. Here we report the generation of transgenic mice lines expressing the RET/PTC1 oncogene under the control of the thyroid-specific rat thyroglobulin promoter. RET/PTC1-transgenic mice developed thyroid tumors displaying the histological aspect of papillary carcinomas. These tumors were slowly progressive and did not cause premature death of the animals. Two additional mice developed areas of thyroid hyperplasia. Immunohistochemical and reverse-transcriptase polymerase chain reaction analyses confirmed the thyroid-specific expression of the transgene. Given the frequency of activating rearrangements of RET in human papillary thyroid carcinomas we conclude that this animal system could be a good model for studying the neoplastic progression of thyroid carcinomas.	FDN SENATORE PASCALE,IST NAZL TUMORI NAPOLI,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	IRCCS Fondazione Pascale; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria	Santoro, M (corresponding author), UNIV NAPLES FEDERICO II,FAC MED & CHIRURG,CNR,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,I-80131 NAPLES,ITALY.		Salvatore, Domenico/D-4881-2013; Portella, Giuseppe/AFU-6826-2022; Cerrato, Aniello/AAY-1484-2020	Fusco, Alfredo/0000-0003-3332-5197; PORTELLA, Giuseppe/0000-0001-8276-9769; SALVATORE, DOMENICO/0000-0002-4556-7620				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BIANCIFIORI C, 1979, 23 IARC, V2, P451; BOND JA, 1994, ONCOGENE, V9, P281; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONISKELLER H, 1993, HUM MOL GENET, V2, P851, DOI 10.1093/hmg/2.7.851; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FAGIN JA, 1992, J CLIN ENDOCR METAB, V75, P1398, DOI 10.1210/jc.75.6.1398; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HOGAN B, 1986, MANIPULATING MOUSE E; IWAMOTO T, 1990, ONCOGENE, V5, P535; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; LANZI C, 1992, ONCOGENE, V7, P2189; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1995, ONCOGENE, V10, P1789; MICHIELS FM, 1994, P NATL ACAD SCI USA, V91, P10488, DOI 10.1073/pnas.91.22.10488; MONACO C, 1995, INT J CANCER, V63, P757, DOI 10.1002/ijc.2910630525; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MUSTI AM, 1987, NUCLEIC ACIDS RES, V15, P8149, DOI 10.1093/nar/15.20.8149; PALMITER RD, 1991, P NATL ACAD SCI USA, V88, P478, DOI 10.1073/pnas.88.2.478; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; PORTELLA G, 1989, ONCOGENE, V4, P181; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SANTELLI G, 1993, CANCER RES, V53, P1; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1994, ONCOGENE, V9, P509; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; TAKAHASHI M, 1988, ONCOGENE, V3, P571; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WILLIAMS DW, 1989, THYROID TUMORS MOL B; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; WYNFORDTHOMAS D, 1993, CRIT REV ONCOGENESIS, V4, P1; [No title captured]	39	207	218	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1821	1826						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622903				2022-12-28	WOS:A1996UG45800025
J	Guthridge, MA; Seldin, M; Basilico, C				Guthridge, MA; Seldin, M; Basilico, C			Induction of expression of growth-related genes by FGF-4 in mouse fibroblasts	ONCOGENE			English	Article						FGFs; transcription; cell cycle; cell proliferation; subtractive hybridization	NUCLEOTIDE-SEQUENCE; ENDOTHELIAL-CELLS; PROTEIN; RECEPTOR; CDNA; DNA; DIFFERENTIATION; CLONING; PHOSPHORYLATION; ORGANIZATION	Cells monitor and respond to extracellular signals from polypeptide growth factors by the induction of a genetic program. Although poorly understood at the molecular level, the biological activity of growth factors is believed to be mediated by the regulation of specific sets of genes. We have isolated a number of cDNAs, the expression of whose corresponding RNAs is induced by FGF-4 (K-FGF) in murine NIH3T3 fibroblasts. The cDNAs (FIN, for FGF-inducible) were isolated using a strategy of subtractive hybridization designed to yield 'late' genes which compared transformed 3T3 cells that constitutively produce FGF-4 with their normal counterpart. The 21 independent cDNAs isolated were found to correspond to known genes (FIN1-12), or novel genes (FIN13-21). Expression of the FIN genes is induced in response to FGF-4 as well as to serum in NIH3T3 cells with delayed kinetics, with maximum stimulation occurring 12-18 h after growth factor treatment. Induction requires protein synthesis and is mostly transcriptional. FIN1-12 encode a broad range of previously described genes, some of which are proposed to have an important role in cell proliferation. The novel clones include a putative serine-threonine phosphatase (FIN13) and a gene with homology to NTP-binding proteins (FIN16). The distribution of expression of the novel FIN clones in adult mouse tissues was highly restricted, although most were expressed in embryos. While expression of novel FIN cDNAs was strongly regulated in NIH3T3 cells, induction of differentiation in PC-12 cells by FGF-4 (as web as by NGF) did not result in significant induction of expression, suggesting that most of the FIN genes are proliferation-specific. Chromosomal localization of novel FIN clones indicated that each segregated independently to separate mouse chromosomes.	NYU,SCH MED,DEPT MICROBIOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	New York University; New York University; Duke University			guthridge, mark a/I-1889-2014	guthridge, mark a/0000-0002-0536-3471	NCI NIH HHS [CA42568] Funding Source: Medline; PHS HHS [H600734] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7; BISHOP D T, 1985, Genetic Epidemiology, V2, P349, DOI 10.1002/gepi.1370020404; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CARTER TC, 1953, J GENET, V51, P441, DOI 10.1007/BF02982937; CARTER TC, 1951, J GENET, V50, P277, DOI 10.1007/BF02996224; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHEN JW, 1988, J BIOL CHEM, V263, P8754; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DONOVIEL DB, 1990, J CELL PHYSIOL, V145, P16, DOI 10.1002/jcp.1041450104; FALK G, 1988, BIOCHEM J, V254, P109, DOI 10.1042/bj2540109; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FELDMAN B, 1995, SCIENCE, V267, P246, DOI 10.1126/science.7809630; GOLDRING M B, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P301; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; Green EL, 1981, GENETICS PROBABILITY, P77; GUALANDRIS A, 1995, J CELL PHYSIOL, V162, P400, DOI 10.1002/jcp.1041620312; HERR W, 1984, J VIROL, V49, P471, DOI 10.1128/JVI.49.2.471-478.1984; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; ISHIDA S, 1993, P NATL ACAD SCI USA, V90, P11152, DOI 10.1073/pnas.90.23.11152; JOHNSON DR, 1979, J EMBRYOL EXP MORPH, V53, P327; KAGHAD M, 1990, NUCLEIC ACIDS RES, V18, P3638, DOI 10.1093/nar/18.12.3638; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; MANN DJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P100, DOI 10.1016/0167-4781(92)90471-B; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MIGNATTI P, 1991, J CELL BIOL, V113, P1193, DOI 10.1083/jcb.113.5.1193; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; NOTARNICOLA SM, 1991, GENE, V97, P77, DOI 10.1016/0378-1119(91)90012-Z; OAKEY RJ, 1991, GENOMICS, V10, P338, DOI 10.1016/0888-7543(91)90317-8; PATEL A, 1995, GENOMICS, V25, P314, DOI 10.1016/0888-7543(95)80146-D; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POTTS JF, 1993, BIOCHEM BIOPH RES CO, V197, P100, DOI 10.1006/bbrc.1993.2446; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; RYDEL RE, 1987, J NEUROSCI, V7, P3639; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5643; SAUNDERS AM, 1990, GENOMICS, V8, P524; SCHERENS B, 1993, YEAST, V9, P1355, DOI 10.1002/yea.320091210; SCHMITT J, 1993, GENE, V132, P267, DOI 10.1016/0378-1119(93)90206-I; SCHWEIZER A, 1993, J CELL SCI, V104, P685; SELDIN MF, 1988, J EXP MED, V167, P688, DOI 10.1084/jem.167.2.688; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; TAIJI M, 1992, MOL CELL BIOL, V12, P2193, DOI 10.1128/MCB.12.5.2193; TAKETO M, 1994, GENOMICS, V21, P251, DOI 10.1006/geno.1994.1252; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; TERASAWA T, 1993, ARCH BIOCHEM BIOPHYS, V307, P342, DOI 10.1006/abbi.1993.1598; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WATSON ML, 1992, MAMM GENOME, V2, P158, DOI 10.1007/BF00302874; WATSON ML, 1994, METH MOL G, V5, P369; WEISS R, 1985, RNA TUMOR VIRUSES, P357; WENK J, 1992, FEBS LETT, V297, P135, DOI 10.1016/0014-5793(92)80344-G; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	68	20	25	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1267	1278						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649829				2022-12-28	WOS:A1996UC06700012
J	Lehar, SM; Naeht, M; Jacks, T; Vater, CA; Chittenden, T; Guild, BC				Lehar, SM; Naeht, M; Jacks, T; Vater, CA; Chittenden, T; Guild, BC			Identification and cloning of EI24, a gene induced by p53 in etoposide-treated cells	ONCOGENE			English	Article						p53; gene induction; differential display; apoptosis	TUMOR-SUPPRESSOR; WILD-TYPE; APOPTOSIS; EXPRESSION; PROTEIN; THYMOCYTES; RECEPTOR; SEQUENCE	To search for candidate genes involved in p53-mediated apoptosis, the differential display technique was used to identify RNA species whose expression was altered in murine NIH3T3 cells treated with the cytotoxic drug etoposide. We report here the isolation and characterization of EI24, a novel gene whose 2.4 kb mRNA is induced following etoposide treatment. Induction of EI24 mRNA by etoposide required expression of wild-type p53 in murine embryonic fibroblasts which had been transformed with the oncogenes E1A and T24 H-ras; and overexpression of functional p53 in these cells was sufficient to induce expression of the EI24 mRNA. The EI24 mRNA was also induced in a p53-dependent manner by ionizing irradiation of primary murine thymocytes. Isolation of a full-length EI24 cDNA revealed that its protein product bears homology to CELF37C12.2, a Caenorhabditis elegans protein of unknown function.	APOPTOSIS TECHNOL INC,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; Sambrook J., 2002, MOL CLONING LAB MANU; SHAKLEFORD GM, 1987, CELL, V50, P89; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; WALKER PR, 1991, CANCER RES, V51, P1078; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1994, ONCOGENE, V9, P3743	36	71	74	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1181	1187						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649819				2022-12-28	WOS:A1996UC06700002
J	Aoki, T; Sano, Y; Yamamoto, T; Inoue, J				Aoki, T; Sano, Y; Yamamoto, T; Inoue, J			The ankyrin repeats but not the PEST-like sequences are required for signal-dependent degradation of I kappa B alpha	ONCOGENE			English	Article						ankyrin repeats; degradation; I kappa-B; PEST sequence; phosphorylation	TUMOR-NECROSIS-FACTOR; DNA-BINDING; TRANSCRIPTION FACTORS; PRECURSOR P105; ACTIVATION; REL; PHOSPHORYLATION; I-KAPPA-B/MAD-3; ASSOCIATION; EXPRESSION	The nuclear activity of Rel/NF kappa B transcription factors is tightly regulated from the cytoplasmic compartment by an inhibitory subunit called I kappa B alpha. I kappa B alpha is rapidly phosphorylated and degraded in response to the stimulation through tumor necrosis factor alpha (TNF alpha) receptor, interleukin-1 receptor or CD40. To explore the molecular mechanisms of signal-induced depletion of I kappa B alpha, we have delineated the domain in I kappa B alpha that is required for TNF alpha-induced phosphorylation and rapid degradation of I kappa B alpha. In contrast to the previous reports, the PEST-like sequences, which are present in the carboxyl-terminal region of I kappa B alpha, are demonstrated here to be dispensable for TNF alpha-induced degradation but could be required for signal-independent degradation, as in the case of Cactus, Drosophila homologue of I kappa B. Furthermore, the ankyrin repeats, which are essential for forming a complex with Rel and RelA, are required for TNF alpha-induced degradation suggesting that the putative I kappa B protease could interact with I kappa B alpha in complex with RelA or could recognize the structure of ankyrin repeats. Our data also indicate that neither the ankyrin repeats nor the PEST-like sequences, are essential for TNF alpha-induced phosphorylation.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN	University of Tokyo								ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; BAUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141; BAUERLE PA, 1988, SCIENCE, V242, P540; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CORDLE SR, 1993, J BIOL CHEM, V268, P11803; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ERNST MK, 1995, MOL CELL BIOL, V15, P872; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; INOUE JI, 1992, P NATL ACAD SCI USA, V89, P4333, DOI 10.1073/pnas.89.10.4333; JAFFRAY E, 1995, MOL CELL BIOL, V15, P2166; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RODIGUEZ MS, 1995, MOL CELL BIOL, V15, P2413; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; TEWARI M, 1992, MOL CELL BIOL, V12, P2898, DOI 10.1128/MCB.12.6.2898; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	43	24	24	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1159	1164						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649809				2022-12-28	WOS:A1996UA88400026
J	Givehchian, M; Woerner, SM; Lacroix, J; Zoller, M; Drings, P; Becker, H; Kayser, K; Ridder, R; Doeberitz, MV				Givehchian, M; Woerner, SM; Lacroix, J; Zoller, M; Drings, P; Becker, H; Kayser, K; Ridder, R; Doeberitz, MV			Expression of CD44 splice variants in normal respiratory epithelium and bronchial carcinomas: No evidence for altered CD44 splicing in metastasis	ONCOGENE			English	Article						lung cancer; bronchial epithelium; adhesion molecules; RT-PCR; immunohistology	SMALL-CELL CARCINOMA; ADHESION MOLECULE; RECEPTOR CD44; LUNG-CANCER; ESTABLISHMENT; HYALURONATE; BEHAVIOR; PRODUCTS; LINES	Expression of alternatively spliced CD44 adhesion molecules has been implicated in metastatic spread of various rodent and human tumors. To determine whether specific CD44 splice variants contribute to metastatic spread of bronchial cancers, we compared the expression of CD44 splice variants in normal bronchial epithelium and bronchial cancers, including tumors which already spread to regional lymph nodes or distant organs. Variant CD44 expression was analysed by immunohistochemistry using variant exon-specific monoclonal antibodies. The precise composition of CD44 transcripts was delineated by exon-specific RT-PCR. The concurring data obtained by both methods revealed that high levels of standard CD44 and variants v5 and v6 as well as low levels of variants v7 and v10 are expressed both in normal bronchial epithelium and squamous cell lung cancers. No CD44 expression was observed in the highly metastatic small cell lung cancers and adenocarcinomas with the exception of bronchioalveolar cancers showing weak expression of standard CD44. These data suggest that expression of alternatively spliced CD44 molecules in the bronchial tract is related to the distinct differentiation of the respiratory epithelium. No correlation between expression of specific CD44 splice variants and metastasis of bronchial cancers was observed.	DEUTSCH KREBSFORSCHUNGSZENTRUM, FSP ANGEW TUMORVIROL 6, NEUENHEIMER FELD 242, D-69120 HEIDELBERG, GERMANY; THORAXKLIN HEIDELBERG, D-69126 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg			Woerner, Stefan/A-2187-2010					ABBASI AM, 1993, EUR J CANCER, V29A, P1995, DOI 10.1016/0959-8049(93)90461-N; [Anonymous], 1982, AM J CLIN PATHOL, V77, P123; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; CARNEY DN, 1985, CANCER RES, V45, P2913; COMBARET V, 1995, EUR J CANCER, V31A, P545, DOI 10.1016/0959-8049(95)00027-G; COOPER DL, 1995, NAT MED, V1, P635, DOI 10.1038/nm0795-635; GAZDAR AF, 1980, CANCER RES, V40, P3502; GROSS N, 1995, EUR J CANCER, V31A, P471, DOI 10.1016/0959-8049(95)00029-I; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HARN HJ, 1991, BIOCHEM BIOPH RES CO, V178, P1127, DOI 10.1016/0006-291X(91)91009-2; HAYNES BF, 1991, CANCER CELL-MON REV, V3, P347; HEIDER KH, 1993, CANCER RES, V53, P4197; HOFMANN M, 1991, CANCER RES, V51, P5292; HONG RL, 1995, ONCOLOGY-BASEL, V52, P334; HONG RL, 1995, CANCER LETT, V89, P81, DOI 10.1016/0304-3835(95)90161-2; ICHIKAWA W, 1994, PATHOBIOLOGY, V62, P172, DOI 10.1159/000163907; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; JACKSON DG, 1994, INT J CANCER, P110; JALKANEN S, 1986, SCIENCE, V233, P556, DOI 10.1126/science.3726548; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; KUGELMAN LC, 1992, J INVEST DERMATOL, V99, P886; LIEBER M, 1976, INT J CANCER, V17, P62, DOI 10.1002/ijc.2910170110; LINNOILA I, 1990, HEMATOL ONCOL CLIN N, V4, P1027; LIU AY, 1994, CANCER LETT, V76, P63, DOI 10.1016/0304-3835(94)90135-X; MANTENHORST E, 1995, INT J CANCER, V64, P182, DOI 10.1002/ijc.2910640307; MATSUMURA Y, 1994, BRIT MED J, V308, P619, DOI 10.1136/bmj.308.6929.619; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; OSTERLIND K, 1986, J CLIN ONCOL, V4, P1307, DOI 10.1200/JCO.1986.4.9.1307; PENNO MB, 1994, CANCER RES, V54, P1381; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; RALL CJN, 1995, CANCER RES, V55, P1831; RISTAMAKI R, 1995, J PATHOL, V176, P259, DOI 10.1002/path.1711760308; RUDY W, 1993, CANCER RES, V53, P1262; SALMI M, 1993, J CELL BIOL, V122, P431, DOI 10.1083/jcb.122.2.431; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; STAUDER R, 1995, BLOOD, V85, P2885, DOI 10.1182/blood.V85.10.2885.bloodjournal85102885; TAKEUCHI K, 1995, JPN J CANCER RES, V86, P292, DOI 10.1111/j.1349-7006.1995.tb03053.x; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; UNDERHILL C, 1992, J CELL SCI, V103, P293; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; WASHIMI O, 1994, JPN J CANCER RES, V85, P1112, DOI 10.1111/j.1349-7006.1994.tb02915.x; Woerner SM, 1995, CLIN CANCER RES, V1, P1125; YOKOZAKI H, 1994, CANCER LETT, V83, P229, DOI 10.1016/0304-3835(94)90324-7; ZOLLER M, 1995, J MOL MED, V73, P425	47	30	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1137	1144						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649806				2022-12-28	WOS:A1996UA88400023
J	Kirsch, KH; Korradi, Y; Johnson, JP				Kirsch, KH; Korradi, Y; Johnson, JP			Mader: A novel nuclear protein over expressed in human melanomas	ONCOGENE			English	Article						delayed early response gene; proline rich; MUC18	MESSENGER-RNA DEGRADATION; HUMAN-MALIGNANT MELANOMA; TUMOR PROGRESSION; CELL-ADHESION; SEQUENCE; IDENTIFICATION; STIMULATION; ACTIVATION; ANTIGEN; DOMAINS	Mader is a novel delayed early response gene encoding a nuclear protein. Upregulation of the Mader 2.7 kb mRNA requires protein synthesis and can be induced in a variety of human cell lines by serum stimulation and in freshly isolated lymphocytes by mitogens. mRNA levels reach a maximum by 2 h and return to basal levels by 6 h. Mader is highly conserved as cross-hybridizing DNA sequences were observed in species as diverse as Rhesus and S. cerevisiae. The Mader protein of approximately 55 kD has two proline rich domains and contains 15 potential phosphorylation sites, a nuclear localization signal, and multiple S(T)PXX motifs that are characteristic of regulatory DNA binding proteins. Monoclonal antibodies produced against Mader confirm that it is localized to the nucleus. These features of Mader suggest that it may play a role in growth regulation. Although Mader mRNA can be detected in most cell lines, only occasional immunoreactive cells were detected in normal human tissues. In contrast, uniform strong nuclear staining was observed in all malignant melanomas examined. The fact that only one of six benign melanocytic nevi examined showed evidence of Mader expression suggests that over-expression of Mader protein may be associated with the malignant transformation of melanocytes.	UNIV MUNICH,INST IMMUNOL,D-80336 MUNICH,GERMANY	University of Munich				Kirsch, Kathrin/0000-0003-1532-1715				ALBELDA SM, 1990, CANCER RES, V50, P6757; ALBINO AP, 1994, MELANOMA RES, V4, P35, DOI 10.1097/00008390-199402000-00006; CANNONALBRIGHT LA, 1992, SCIENCE, V258, P1148, DOI 10.1126/science.1439824; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; GARRIGUES HJ, 1986, J CELL BIOL, V103, P1699, DOI 10.1083/jcb.103.5.1699; GRANA X, 1995, ONCOGENE, V11, P211; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Johnson JP, 1996, CURR TOP MICROBIOL, V213, P95; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KELLY K, 1983, CELL, V35, P306; KLEIN CE, 1991, J INVEST DERMATOL, V96, P281, DOI 10.1111/1523-1747.ep12464485; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEHMANN JM, 1989, P NATL ACAD SCI USA, V86, P9891, DOI 10.1073/pnas.86.24.9891; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIU L, 1995, ONCOGENE, V11, P405; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARSHALL MA, 1991, MOL CELL BIOL, V11, P55, DOI 10.1128/MCB.11.1.55; MARTINPADURA I, 1991, CANCER RES, V51, P2239; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MCGREGOR JM, 1993, BRIT J DERMATOL, V128, P606, DOI 10.1111/j.1365-2133.1993.tb00253.x; MENDELSOHL J, 1995, MOL BASIS CANC; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; NATHANS D, 1988, COLD SPRING HARB SYM, V53, P983; OHTA M, 1994, CANCER RES, V54, P5269; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; REED JA, 1995, CANCER RES, V55, P2713; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUZUKI M, 1989, J MOL BIOL, V207, P61, DOI 10.1016/0022-2836(89)90441-5; SUZUKI M, 1990, NATURE, V344, P562, DOI 10.1038/344562a0; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; [No title captured]	44	28	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					963	971						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649813				2022-12-28	WOS:A1996UA88400003
J	Tsang, SX; Morris, GF; Lu, M; Morris, CB				Tsang, SX; Morris, GF; Lu, M; Morris, CB			TATA-dependent repression of human immunodeficiency virus type-1 transcription by the adenovirus E1A 243R oncoprotein	ONCOGENE			English	Article						transcription; E1A; HIV; gene regulation; TATA	LONG-TERMINAL REPEAT; NUCLEAR ANTIGEN PROMOTER; BINDING PROTEIN; ACTIVATES TRANSCRIPTION; FUNCTIONAL DOMAINS; CELLULAR PROTEINS; T-CELLS; GENE; EXPRESSION; IDENTIFICATION	Human adenovirus E1A oncoprotein activates or represses transcription from a variety of viral and cellular promoters by several complex mechanisms. The E1A products, 289R and 243R, have differential effects on transcription directed by the human immunodeficiency virus type 1 (HIV-1) long terminal repeat (LTR). Previous reports indicate that repression of HIV-1 LTR-directed gene expression by E1A 243R is mediated through the kappa B enhancer elements located between nucleotides -105 and -82 relative to the transcription initiation start site (+1). Results from this study suggest a novel mechanism for transcriptional repression of the HIV-1 LTR by E1A 243R that is enhancer-independent and that is mediated through basal HIV-1 promoter elements. Transient expression assays, in which 5'-truncated or site-directed mutant HIV-1 LTR-CAT reporters were tested for their response to repression mediated by wild-type or mutant 243R, demonstrate that LTR sequences upstream of -31 relative to the transcription initiation start site (+1) and inclusive of the enhancer elements are dispensable for 243R-mediated repression. The ability of 243R to repress HIV-1 basal promoter activity requires both an intact N-terminus of E1A 243R and the TATA element within the HIV-1 promoter. These results support a novel mechanism for E1A 243R-induced transcriptional repression that is enhancer-independent and that targets directly the general transcription machinery.	TULANE UNIV, MED CTR, CTR CANC, DEPT LAB MED & PATHOL, NEW ORLEANS, LA 70112 USA; GEORGIA INST TECHNOL, SCH BIOL, ATLANTA, GA 30332 USA	Tulane University; University System of Georgia; Georgia Institute of Technology					NIAID NIH HHS [AI32880] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032880] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BASU A, 1993, J BIOL CHEM, V268, P4188; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BOYER TG, 1993, GENE DEV, V7, P1810, DOI 10.1101/gad.7.9.1810; CHOW LT, 1979, J MOL BIOL, V134, P265, DOI 10.1016/0022-2836(79)90036-6; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; FANG L, 1994, NATURE, V368, P520; GARCIA JA, 1987, EMBO J, V6, P3761, DOI 10.1002/j.1460-2075.1987.tb02711.x; GIACCA M, 1992, VIROLOGY, V186, P133, DOI 10.1016/0042-6822(92)90067-Y; GLENN GM, 1985, J VIROL, V56, P66, DOI 10.1128/JVI.56.1.66-74.1985; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; HERRMANN CH, 1989, MOL CELL BIOL, V9, P5412, DOI 10.1128/MCB.9.12.5412; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; INOSTROZA JA, 1992, CELL, V70, P477; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JONES K A, 1989, New Biologist, V1, P127; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KANNABIRAN C, 1993, J VIROL, V67, P507, DOI 10.1128/JVI.67.1.507-515.1993; KASHANCHI F, 1994, NATURE, V367, P295, DOI 10.1038/367295a0; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; KRAUS VB, 1994, P NATL ACAD SCI USA, V91, P6279, DOI 10.1073/pnas.91.14.6279; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARGOLIS DM, 1994, J VIROL, V68, P905, DOI 10.1128/JVI.68.2.905-910.1994; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; NEVINS JR, 1991, TRENDS BIOCHEM SCI, V16, P435, DOI 10.1016/0968-0004(91)90171-Q; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NEVINS JR, 1992, SCIENCE, V258, P424; OKAMOTO T, 1990, VIROLOGY, V177, P606, DOI 10.1016/0042-6822(90)90526-W; RICE AP, 1988, P NATL ACAD SCI USA, V85, P4200, DOI 10.1073/pnas.85.12.4200; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SONG CZ, 1995, J VIROL, V69, P2907, DOI 10.1128/JVI.69.5.2907-2911.1995; SOUTHGATE CD, 1991, GENE DEV, V5, P2496, DOI 10.1101/gad.5.12b.2496; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VENTURA AM, 1990, P NATL ACAD SCI USA, V87, P1310, DOI 10.1073/pnas.87.4.1310; VESCHAMBRE P, 1995, J MOL BIOL, V250, P169, DOI 10.1006/jmbi.1995.0368; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHITE RJ, 1994, SCIENCE, V266, P448, DOI 10.1126/science.7939686; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WU F, 1988, J VIROL, V62, P218, DOI 10.1128/JVI.62.1.218-225.1988; YEUNG KC, 1994, GENE DEV, V8, P2097, DOI 10.1101/gad.8.17.2097; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821	58	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					819	826						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632904				2022-12-28	WOS:A1996TW68600013
J	Fueyo, J; GomezManzano, C; Bruner, JM; Saito, Y; Zhang, BH; Zhang, W; Levin, VA; Yung, WKA; Kyritsis, AP				Fueyo, J; GomezManzano, C; Bruner, JM; Saito, Y; Zhang, BH; Zhang, W; Levin, VA; Yung, WKA; Kyritsis, AP			Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas	ONCOGENE			English	Article						p16/CDKN2; glioma; methylation; tumor suppressor genes	CHRONIC MYELOGENOUS LEUKEMIA; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; P16(INK4) EXPRESSION; BRAIN-TUMORS; RETINOBLASTOMA; DELETION; CANCERS; P16	There is considerable evidence that lack of p16 protein expression is a frequent event in human gliomas. Nevertheless, the molecular mechanisms underlying this absence of p16 protein expression are not completely understood. In some gliomas, homozygous deletions are the main cause of p16/CDKN2 gene inactivation. However, other gliomas lacking p16 expression exhibit intact p16/CDKN2 gene, suggesting that p16/CDKN2 is down-regulated at the transcriptional level. In this study we investigated whether aberrant p16/CDKN2 gene methylation correlated with absence of p16 expression in the latter group of gliomas. In a series of 27 gliomas, 12 malignant tumors exhibited loss of p16/CDKN2 expression but not gene deletion. Methylation analysis of the CpG island in the 5' region of the p16/CDKN2 gene showed that exon 1 was extensively methylated in six and partially methylated in the other six of the 12 malignant gliomas. In contrast, no methylation was observed in four other malignant gliomas and two low-grade gliomas that expressed p16 protein. These results indicate that abnormal hypermethylation of the CpG island encompassing the 5' end of the p16/CDKN2 gene may be a mechanism of transcriptional silencing in gliomas without homozygous deletions.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT PATHOL,HOUSTON,TX	University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT NEUROONCOL,HOUSTON,TX 77030, USA.			Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133	NATIONAL CANCER INSTITUTE [P01CA055261] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA55261] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAP W, 1995, CANCER RES, V55, P1351; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BURGER PC, 1991, SURGICAL PATHOLOGY N, P193; Fueyo J, 1996, ONCOGENE, V12, P103; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GERADTS J, 1995, CANCER RES, V55, P6006; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HERMAN JG, 1995, CANCER RES, V55, P4525; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; JEN J, 1994, CANCER RES, V54, P6353; JUNG JM, 1995, ONCOGENE, V11, P2021; Kyritsis AP, 1996, ONCOGENE, V12, P63; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NELKIN BD, 1991, BLOOD, V77, P2431; NISHIKAWA R, 1995, CANCER RES, V55, P1941; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SINGERSAM J, 1990, NUCLEIC ACID METHYLA, V128, P285; Ueki K, 1996, CANCER RES, V56, P150; UEKI K, 1994, HUM MOL GENET, V3, P1841, DOI 10.1093/hmg/3.10.1841; YEAGER T, 1995, CANCER RES, V55, P493; ZION M, 1994, P NATL ACAD SCI USA, V91, P10722, DOI 10.1073/pnas.91.22.10722	28	77	81	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1615	1619						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895506				2022-12-28	WOS:A1996VM88700005
J	Chang, JY; Xia, WY; Shao, RP; Hung, MC				Chang, JY; Xia, WY; Shao, RP; Hung, MC			Inhibition of intratracheal lung cancer development by systemic delivery of E1A	ONCOGENE			English	Article						EIA; HER-2/neu; gene therapy; adenoviral vector; lung cancer	GROWTH-FACTOR RECEPTOR; NEU ONCOGENE; GENE-THERAPY; ADENOVIRUS TYPE-5; CYSTIC-FIBROSIS; OVARIAN-CANCER; SMALL-CELL; EXPRESSION; OVEREXPRESSION; METASTASIS	Amplification or overexpression of HER-2/neu in human lung cancer has been correlated with poor prognosis and chemoresistance, We have previously reported that the adenovirus type 5 early region 1A (E1A) gene product can suppress HER-2/neu-mediated transformation phenotypes through inhibition of HER-2/neu expression. To find an efficient way to treat HER-2/neu-overexpressing lung cancer with ELA, a replication-deficient adenovirus containing the E1A gene, Ad.E1A(+), was used to transduce E1A into HER-2/neu-overexpressing and low expressing human lung cancer cell lines, Tumour cell growth in vitro and colony formation in soft agarose were greatly inhibited by Ad.E1A(+) transduction in HER-2/neu-overexpressing lung cancer cell lines, In HER-2/neu low expressing cell lines, E1A could not inhibit cell growth in vitro but could reduce the colony formation ability in soft agarose, indicating different effects of E1A in these two types of cancer cells. To test the therapeutic efficacy of E1A to lung cancer by systemic delivery in vivo, tumor-bearing mice were established by intratracheal injection of lung cancer cells and treated by i.v. tail injections of Ad.E1A(+). As a result, Ad.E1A(+) suppressed HER-2/neu overexpression and inhibited intratracheal lung cancer growth. However, no significant tumor suppression effect of Ad.E1A(+) was observed in mice bearing HER-2/neu low expressing cell line when the same therapeutic procedure was followed, Thus, we conclude that systemic delivery of Ad.E1A(+) can efficiently achieve therapeutic effect in HER-2/neu-overexpressing lung cancer in vivo.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BREAST CANC BASIC RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [R01-CA60856, R01-CA58880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058880, R01CA060856] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BERCHUCK A, 1990, CANCER RES, V50, P4087; BYRD PJ, 1988, ONCOGENE, V2, P477; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DAVENPORT EA, 1988, ANTICANCER RES, V8, P957; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1995, CANCER RES, V55, P5551; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Graham FL, 1991, METHOD MOL BIOL, P109; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HUNG MC, 1995, GENE, V159, P65, DOI 10.1016/0378-1119(94)00459-6; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KERN JA, 1990, CANCER RES, V50, P5284; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; LESOONWOOD LA, 1995, HUM GENE THER, V6, P395, DOI 10.1089/hum.1995.6.4-395; Minna JD, 1989, CANCER PRINCIPLES PR, P591; PERERA FP, 1991, ORIGINS OF HUMAN CANCER, P219; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SHI DR, 1992, MOL CARCINOGEN, V5, P213, DOI 10.1002/mc.2940050308; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THIERRY AR, 1995, P NATL ACAD SCI USA, V92, P9742, DOI 10.1073/pnas.92.21.9742; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; WEINBERG RA, 1989, CANCER RES, V49, P3713; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; YU DH, 1995, ONCOGENE, V11, P1383; ZHANG YJ, 1995, ONCOGENE, V10, P2263	38	26	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1405	1412						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875978				2022-12-28	WOS:A1996VL38400005
J	Coppee, F; Gerard, AC; Denef, JF; Ledent, C; Vassart, G; Dumont, JE; Parmentier, M				Coppee, F; Gerard, AC; Denef, JF; Ledent, C; Vassart, G; Dumont, JE; Parmentier, M			Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene	ONCOGENE			English	Article						thyroid cancer; metastatic tumors; hyperthyroidism; cyclic AMP cascade; E7 oncogene; transgenic model	FIBROBLAST GROWTH-FACTOR; TISSUE-SPECIFIC EXPRESSION; INVASIVE BREAST-CARCINOMA; THYROTROPIN RECEPTOR; TUMOR-GROWTH; THYROGLOBULIN GENE; CELL GROWTH; CYCLIC-AMP; ANGIOGENESIS; MUTATIONS	We report here the characterization of a transgenic mouse model (Tg-A2aR/Tg-E7) resulting from the coexpression of tao oncogenic transgenes in the thyroid, The two transgenes (Tg-A2aR and Tg-E7) were placed under control of the thyroid specific thyroglobulin gene promoter, and directed the expression of either the A2a adenosine receptor that constitutively activates the cAMP pathway, or the E7 protein of the human papillomavirus type 16, that binds and inactivates the retinoblastoma susceptibility gene product (Rbl), Transgenic mice expressing both transgenes were generated by interbreeding the Tg-A2aR and Tg-E7 transgenic lines, generated and characterized previously (Ledent et al., 1992, 1995), These mice develop a larger goiter than that of the two parental lines, and a severe hyperthyroidism comparable to that observed in the Tg-A2aR parental Line, The main feature of the Tg-A2aR/Tg-E7 mice is the rapid occurrence of malignant lesions, and the dissemination of malignant thyroid tissue through the blood stream, generating multiple differentiated and functional metastases in the lung, These metastases appeared as early as 2 months after birth and their frequency increased to 75% over 3 months, They were associated with the presence of large vascular lakes in the thyroid, Electron microscopy of the malignant cells revealed nuclear features similar to those of human thyroid papillary carcinoma, These mice, in which two oncogenes are co-expressed in the thyroid, represent the first genetic animal model developing metastatic differentiated carcinomas of the thyroid with a high frequency.	UNIV CATHOLIQUE LOUVAIN, SERV HISTOL, B-1200 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, SERV GENET MED, B-1070 BRUSSELS, BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Coppee, F (corresponding author), FREE UNIV BRUSSELS, IRIBHN, CAMPUS ERASME, 808 ROUTE LENNIK, B-1070 BRUSSELS, BELGIUM.			Parmentier, Marc/0000-0001-8081-4685				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ASANO M, 1995, CANCER RES, V55, P5296; BECHTNER G, 1993, ACTA ENDOCRINOL-COP, V129, P458, DOI 10.1530/acta.0.1290458; BERNS A, 1989, INT J CANCER, P22; BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; BOSSI P, 1995, CANCER RES, V55, P5049; BREUER M, 1991, RADIAT ENVIRON BIOPH, V30, P181, DOI 10.1007/BF01226614; CHRISTOPHE D, 1990, TRENDS ENDOCRIN MET, V1, P351, DOI 10.1016/1043-2760(90)90083-F; COLIN IM, 1995, ENDOCRINOLOGY, V136, P5283, DOI 10.1210/en.136.12.5283; DAA T, 1993, ACTA PATHOL JAPON, V43, P582; DENEF JF, 1981, ENDOCRINOLOGY, V108, P2352, DOI 10.1210/endo-108-6-2352; Dumont J E, 1971, Vitam Horm, V29, P287; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; EMOTO N, 1991, ENDOCRINOLOGY, V128, P58, DOI 10.1210/endo-128-1-58; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FEIBERG AP, 1983, ANAL BIOCHEM, V132, P6; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; GREIL W, 1989, MOL ENDOCRINOL, V3, P858, DOI 10.1210/mend-3-5-858; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GUIDI AJ, 1994, J NATL CANCER I, V86, P614, DOI 10.1093/jnci/86.8.614; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; HARVEY M, 1995, CANCER RES, V55, P1146; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAENHAUT C, 1992, J BIOL CHEM, V267, P3000; NEVINS JR, 1992, SCIENCE, V258, P424; NUNEZ J, 1982, VITAM HORM, V39, P175, DOI 10.1016/S0083-6729(08)61137-1; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RANGASWAMY M, 1989, NUCL MED COMMUN, V10, P679, DOI 10.1097/00006231-198909000-00007; ROBBINS J, 1991, ANN INTERN MED, V115, P133, DOI 10.7326/0003-4819-115-2-133; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; SCHERBERG NH, 1981, ENDOCRINOLOGY, V109, P1650, DOI 10.1210/endo-109-5-1650; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SUAREZ HG, 1991, ONCOGENE, V6, P677; THOMAS GA, 1989, AM J PATHOL, V134, P141; THOMAS GA, 1991, BRIT J CANCER, V63, P213, DOI 10.1038/bjc.1991.51; USUKI K, 1989, P NATL ACAD SCI USA, V86, P7427, DOI 10.1073/pnas.86.19.7427; VANHEUVERSWYN B, 1984, P NATL ACAD SCI-BIOL, V81, P5941; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WILLIAMS ED, 1992, TOXICOL LETT, V64-5, P375, DOI 10.1016/0378-4274(92)90210-B; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1; WOEBER KA, 1991, MED CLIN N AM, V75, P169, DOI 10.1016/S0025-7125(16)30477-1; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	65	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1471	1482						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875985				2022-12-28	WOS:A1996VL38400012
J	Rabault, B; Roussel, MF; Quang, CT; Ghysdael, J				Rabault, B; Roussel, MF; Quang, CT; Ghysdael, J			Phosphorylation of Ets1 regulates the complementation of a CSF-1 receptor impaired in mitogenesis	ONCOGENE			English	Article						Ets1; phosphorylation; mitogenesis; mitogen-activated protein kinase	TRANSCRIPTION FACTORS; PROTEIN-KINASE; MAP KINASE; GENE; CELLS; ACTIVATION; EXPRESSION; FAMILY; MYC; IDENTIFICATION	Ets1, the founder member of the Ets transcription factor family, is involved in a variety of developmental and cellular processes, Previous studies have shown that serine phosphorylation of Ets1 inhibits its DNA binding activity, suggesting that phosphorylation is important in the regulation of Ets1 function. To further examine Ets1 phosphorylation, we ectopically expressed Ets1 in fibroblasts and stimulated these cells with serum, Using two-dimensional tryptic phosphopeptide analysis and site-directed mutagenesis, we found that Ets1 was phosphorylated on threonine 38, a residue conserved in several Ets proteins, Substitution of this residue with alanine enhanced CSF-1-dependent colony formation in semi-solid medium of NIH3T3 cells expressing a mitogenically defective CSF-1 receptor [Y809F], Threonine 38 is part of a consensus amino-acid sequence frequently recognized and targeted by members of the MAP kinase family, Moreover, this residue is phosphorylated in vitro by recombinant ERK2, which suggests that the kinase which phosphorylates threonine 38 in vivo is a member of the MAP kinase family, In addition, phosphorylation on threonine 38 seems to negatively regulate Ets1 activity in response to growth-factor stimulation.	CTR UNIV ORSAY, INST CURIE, CNRS UMR 146, LAB ONCOL VIRALE & CELLULAIRE, F-91405 ORSAY, FRANCE; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; St Jude Children's Research Hospital			Roussel, Martine F/F-1469-2016; GHYSDAEL, Jacques/F-3377-2013; QUANG, christine TRAN/G-7508-2016	Roussel, Martine F/0000-0002-1740-8139; 	NCI NIH HHS [CA-56819, CA-21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056819, P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P995; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; FISHER CL, 1991, J IMMUNOL, V146, P1743; FLEISCHMAN LF, 1995, MOL CELL BIOL, V15, P925; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOLA I, 1993, P NATL ACAD SCI USA, V90, P7588, DOI 10.1073/pnas.90.16.7588; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RABAULT B, 1994, J BIOL CHEM, V269, P28143; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; ROUSSEL MF, 1994, ONCOGENE, V9, P405; SAITO Y, 1994, FEBS LETT, V341, P119, DOI 10.1016/0014-5793(94)80252-1; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; Yang BS, 1996, MOL CELL BIOL, V16, P538	26	28	28	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					877	881						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761310				2022-12-28	WOS:A1996VD43300024
J	Moscatello, DK; Montgomery, RB; Sundareshan, P; McDanel, H; Wong, MY; Wong, AJ				Moscatello, DK; Montgomery, RB; Sundareshan, P; McDanel, H; Wong, MY; Wong, AJ			Transformation and altered signal transduction by a naturally occurring mutant EGF receptor	ONCOGENE			English	Article						EGF receptor; mutant; EGFRvIII; neoplastic transformation	GROWTH-FACTOR RECEPTOR; HUMAN-BRAIN-TUMORS; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; PROTEIN-KINASE; HUMAN GLIOMAS; BINDING SITE; GENE; EXPRESSION; RAS	An amino-truncated variant form of the epidermal growth factor receptor (EGFRvIII) has been identified in human brain, breast, lung and ovarian tumors, We have found that overexpression of this mutant EGF receptor in NIH3T3 cells results in transformation as a result of the activation of the receptor kinase via ligand-independent dimerization, Transformation was correlated with tyrosine phosphorylation of only a subset of the proteins observed in cells overexpressing the normal EGF receptor. This suggested that further studies on cells expressing the EGFRvIII might provide insights into the pathways most relevant to transformation, In clones expressing high levels of mutant EGF receptor, the levels of both Grb2 and SHC were decreased, Despite this decrease, much of the endogenous Grb2 immunoprecipitated with EGFRvIII, Interestingly, no increase in ras-GTP loading was found in clones expressing the EGFRvIII and MAP kinase assays indicated only a small increase in activity, These results indicate that high-level expression of the EGFRvIII induces downregulation of the ras-MAP kinase pathway and that other components involved in EGF receptor signal transduction may play a greater role in neoplastic transformation by the EGFRvIII.	THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT PHARMACOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107; VET ADM MED CTR,DIV ONCOL,SEATTLE,WA 98108	Jefferson University; Jefferson University; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL CANCER INSTITUTE [T32CA009678, R01CA051093, R01CA053149] Funding Source: NIH RePORTER; NCI NIH HHS [CA51093, CA53149, 5-T32 CA09678-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASU T, 1994, ONCOGENE, V9, P3483; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAZENET CE, 1993, ONCOGENE, V9, P517; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BERGER MS, 1987, BRIT J CANCER, V56, P533, DOI 10.1038/bjc.1987.238; BIGNER SH, 1990, CANCER RES, V50, P8017; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; BLUMENSTOCK M, 1991, ANTICANCER RES, V11, P1353; BUDAY L, 1993, CELL, V73, P169; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DECKER SJ, 1992, J BIOL CHEM, V267, P1104; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DEPALAZZO IEG, 1993, CANCER RES, V53, P3217; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; EKSTRAND AJ, 1994, ONCOGENE, V9, P2313; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; EKSTRAND AJ, 1995, ONCOGENE, V13, P1455; FAN Z, 1993, J BIOL CHEM, V268, P21073; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; Harris A L, 1989, Recent Results Cancer Res, V113, P70; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1988, CANCER RES, V48, P2231; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAX I, 1991, CELL REGUL, V2, P337, DOI 10.1091/mbc.2.5.337; LAX I, 1989, EMBO J, V8, P421, DOI 10.1002/j.1460-2075.1989.tb03393.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI NX, 1994, ONCOGENE, V9, P3457; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUI H, 1991, CANCER RES, V51, P6170; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; OZANNE B, 1986, J PATHOL, V149, P9, DOI 10.1002/path.1711490104; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REIST CJ, 1995, CANCER RES, V55, P4375; SALGALLER M, 1991, CANCER LETT, V57, P243, DOI 10.1016/0304-3835(91)90164-D; SCHLEGEL J, 1994, INT J CANCER, V56, P72; SCHLOTTER NE, 1990, APPL PHYS LETT, V56, P13, DOI 10.1063/1.102648; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SOLER C, 1994, ONCOGENE, V9, P2207; VELU TJ, 1990, MOL CELL ENDOCRINOL, V70, P205, DOI 10.1016/0303-7207(90)90211-P; WALTON GM, 1990, J BIOL CHEM, V265, P1750; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WIKSTRAND CJ, 1995, CANCER RES, V55, P3140; WILLIAMS R, 1993, J BIOL CHEM, V268, P18213; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; WU DG, 1989, J BIOL CHEM, V264, P17469; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; YAMAZAKI H, 1990, JPN J CANCER RES, V81, P773, DOI 10.1111/j.1349-7006.1990.tb02644.x	64	186	207	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					85	96						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700557				2022-12-28	WOS:A1996UX31900010
J	Wang, BL; Kruh, GD				Wang, BL; Kruh, GD			Subcellular localization of the Arg protein tyrosine kinase	ONCOGENE			English	Article						tyrosine kinase; localization; Arg, Abl	POSITIVE HUMAN LEUKEMIAS; C-ABL; CELL-CYCLE; DROSOPHILA-ABL; SIGNAL-TRANSDUCTION; GENE-PRODUCT; BINDING; PHOSPHORYLATION; TRANSFORMATION; ACTIVATION	and c-Abl are ubiquitously expressed proteins which represent the mammalian members of the Abelson family of nonreceptor protein tyrosine kinases (PTKs), In contrast to most nonreceptor PTKs, c-Abl is located in the nucleus and cytoplasm, In this study the subcellular localization of Arg was examined to gain insight into its possible functions, Using indirect immunofluorescence, Arg was detected in the cytoplasm but not the nucleus of both transiently transfected COS cells and stable NIH3T3 transfectants, Arg is expressed as IA and IB isoforms which bear alternative amino termini, with the IB isoform containing a potential myristic acid acceptor sequence, Modification of ArgIB by myristic acid was confirmed by the detection of [H-3]myristic acid labeling and the observation that labeling was abolished by mutating Gig-2, These results indicate that the subcellular localization of Arg is distinct from that of c-Abl and thus suggest that the two proteins have different functions in intracellular signaling, In addition, Arg, Like c-Abl, is expressed as myristoylated and nonmyristoylated isoforms, suggesting that it may have dual cytoplasmic subcellular localizations, and possibly participate in diverse signaling pathways.	FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA	Fox Chase Cancer Center; University of Pennsylvania					NCI NIH HHS [CA57273] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA057273, R01CA057273] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOLEN JB, 1993, ONCOGENE, V8, P2025; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1989, CURR TOP MICROBIOL, V147, P1; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; MATTIONI T, 1995, ONCOGENE, V10, P1325; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MORRIS JF, 1991, ONCOGENE, V6, P2339; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PEREGO R, 1991, ONCOGENE, V6, P1899; PIENTA KJ, 1992, J CELL BIOCHEM, V49, P357, DOI 10.1002/jcb.240490406; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RESH MD, 1990, ONCOGENE, V5, P1437; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	33	37	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					193	197						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700546				2022-12-28	WOS:A1996UX31900022
J	Petropoulos, CJ; Givol, I; Hughes, SH				Petropoulos, CJ; Givol, I; Hughes, SH			Comparative analysis of the structure and function of the chicken c-myc and v-myc genes: v-myc is a more potent inducer of cell proliferation and apoptosis than c-myc	ONCOGENE			English	Article						c-myc; cell cycle; apoptosis; chicken; transcription initiation; translation initiation	WEIGHT NONMUSCLE TROPOMYOSIN; AVIAN MYELOCYTOMATOSIS VIRUS; NUCLEOTIDE-SEQUENCE; RETROVIRUS VECTORS; TRANSFORMING GENE; INDUCED LYMPHOMAS; BURKITT-LYMPHOMA; BURSAL LYMPHOMAS; GROWTH-FACTOR; 1ST EXON	To gain a more complete understanding of c-myc regulation in chickens, we have completed the structural characterization of the chicken c-myc gene and have begun to investigate c-myc transcription and protein expression. A comparison of c-myc Structure and expression between mammals and birds presents an enigma: there are striking similarities in the pattern of gene expression in the absence of obvious sequence similarities in the controlling elements, We have begun to investigate c-myc and v-myc function using retroviral vectors that differ solely in the Myc proteins that they express. We show that while the overexpression of the smaller c-Myc protein is sufficient to induce morphological transformation in chicken embryo fibroblasts, overexpression of v-Myc provides a stronger signal for cells to enter the cell cycle and is a more potent inducer of apoptosis than c-Myc.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick								ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ARGAUT C, 1991, GENE, V97, P231, DOI 10.1016/0378-1119(91)90056-H; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BONNIEU A, 1990, ONCOGENE, V5, P1585; BRADAC JA, 1989, MOL CELL BIOL, V9, P185, DOI 10.1128/MCB.9.1.185; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; EICK D, 1987, ONCOGENE, V2, P61; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FEDERSPIEL MJ, 1994, VIROLOGY, V203, P211, DOI 10.1006/viro.1994.1478; FORRYSCHAUDIES S, 1990, CELL GROWTH DIFFER, V1, P473; FRYKBERG L, 1987, ONCOGENE, V1, P415; Fulton R, 1996, J VIROL, V70, P1154, DOI 10.1128/JVI.70.2.1154-1162.1996; Givol I, 1995, ONCOGENE, V11, P2609; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HAMLYN PH, 1983, NATURE, V304, P135, DOI 10.1038/304135a0; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1992, GENE DEV, V6, P1229, DOI 10.1101/gad.6.7.1229; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; LAIRDOFFRINGA IA, 1989, NUCLEIC ACIDS RES, V17, P6499, DOI 10.1093/nar/17.16.6499; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; LINIAL M, 1985, P NATL ACAD SCI USA, V82, P53, DOI 10.1073/pnas.82.1.53; NEPVEU A, 1987, ONCOGENE, V1, P243; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NOTTENBURG C, 1986, MOL CELL BIOL, V6, P2800, DOI 10.1128/MCB.6.8.2800; PAPAS TS, 1984, CANCER CELL, V2, P153; PAYNE GS, 1982, NATURE, V295, P209, DOI 10.1038/295209a0; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; PIECHACZYK M, 1988, GENE, V72, P287, DOI 10.1016/0378-1119(88)90154-0; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; REED JC, 1985, P NATL ACAD SCI USA, V82, P4221, DOI 10.1073/pnas.82.12.4221; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHEINESS D, 1979, J VIROL, V31, P514, DOI 10.1128/JVI.31.2.514-521.1979; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SHIH CK, 1984, P NATL ACAD SCI-BIOL, V81, P4697, DOI 10.1073/pnas.81.15.4697; STARTWOUT SG, 1987, MOL CELL BIOL, V7, P2052; STEFFEN DL, 1988, VIROLOGY, V164, P55, DOI 10.1016/0042-6822(88)90619-8; STEWART MA, 1986, VIROLOGY, V154, P121, DOI 10.1016/0042-6822(86)90435-6; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; TRIEZENBERG SJ, 1989, CURRENT PROTOCOLS MO, V1; VANBEVEREN C, 1985, RNA TUMOR VIRUSES MO, V2, P686; VASTRIK I, 1994, CRIT REV ONCOGENESIS, V5, P59, DOI 10.1615/CritRevOncog.v5.i1.30; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WEI Y, 1990, GENE, V93, P301, DOI 10.1016/0378-1119(90)90240-R	59	20	20	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2611	2621						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700520				2022-12-28	WOS:A1996UW48700015
J	Walker, AK; Enrietto, PJ				Walker, AK; Enrietto, PJ			Analysis of the role of v-rel in transcriptional regulation of high mobility group protein 14	ONCOGENE			English	Article						v-rel; oncogenes; gene expression; HMG proteins; chromatin	NF-KAPPA-B; PHENOL-CHLOROFORM EXTRACTION; ENHANCER-BINDING-PROTEIN; RECEPTOR FUSION PROTEIN; SINGLE-STEP METHOD; HUMAN C-REL; CHROMOSOMAL-PROTEINS; NUCLEAR FACTORS; RNA ISOLATION; PROMOTER	The oncogene v-rel is a member of the rel/NF-kappa B family of transcription factors. It causes a rapidly fatal lymphoma in young chicks and is capable of transforming both fibroblasts and primitive hematopoietic cells in culture. To understand the role of v-rel in transformation we constructed an inducible form of v-rel and used it to identify potential cellular target genes for v-rel regulation. In this paper we show that High Mobility Group Protein 14 (HMG 14) is expressed in a wide variety of v-rel transformed cell types. In addition we show that v-rel participates in the transcriptional regulation of HMG 14 and that extracts from v-relER cells interact with the HMG 14 promoter. These experiments suggest a role for v-rel in the regulation of a unique gene whose protein product may influence gene transcription in a global fashion.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R01CA051792, T32CA009176] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 51792, CA 09176] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEUG H, 1982, CELL, V39, P5479; BLANAR MA, 1989, MOL CELL BIOL, V9, P844, DOI 10.1128/MCB.9.2.844; BOEHMELT G, 1995, CELL, V80, P341, DOI 10.1016/0092-8674(95)90417-4; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; BUSTIN M, 1991, NUCLEIC ACIDS RES, V19, P3115, DOI 10.1093/nar/19.11.3115; BUSTIN M, 1990, J BIOL CHEM, V265, P20077; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRIPPA MP, 1991, J BIOL CHEM, V266, P2712; CRIPPA MP, 1993, EMBO J, V12, P3855, DOI 10.1002/j.1460-2075.1993.tb06064.x; DEDRICK RL, 1990, MOL CELL BIOL, V10, P593, DOI 10.1128/MCB.10.2.593; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; Enrietto P J, 1990, Semin Cancer Biol, V1, P399; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1992, CANCER SURV, V15, P69; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRILLI M, 1993, INT REV CYTOL, V143, P1; HRDLICKOVA R, 1994, J VIROL, V68, P308; HRDLICKOVA R, 1994, J VIROL, V68, P2371; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KABRUN N, 1990, MOL CELL BIOL, V10, P4788, DOI 10.1128/MCB.10.9.4788; KABRUN N, 1994, SEMIN CANCER BIOL, V5, P103; KANNO M, 1989, EMBO J, V8, P4205, DOI 10.1002/j.1460-2075.1989.tb08606.x; KAWAKAMI K, 1988, P NATL ACAD SCI USA, V85, P4700, DOI 10.1073/pnas.85.13.4700; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LEE JH, 1991, ONCOGENE, V6, P665; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LU D, 1991, ONCOGENE, V6, P1235; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P677; MORRISON LE, 1992, ONCOGENE, V7, P1137; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; PASH JM, 1993, J BIOL CHEM, V268, P13632; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; ROBINSON FR, 1974, AVIAN DIS, V18, P278, DOI 10.2307/1589142; SAMBROOK PL, 1989, MOL CLONING LAB MANU; SAMBUCETTI LC, 1989, EMBO J, V8, P4251, DOI 10.1002/j.1460-2075.1989.tb08610.x; SCHMID RM, 1991, NATURE, V352, P733, DOI 10.1038/352733a0; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHAKOORI AR, 1993, J CELL BIOCHEM, V51, P479, DOI 10.1002/jcb.2400510413; SHIMIZU H, 1990, MOL CELL BIOL, V10, P561, DOI 10.1128/MCB.10.2.561; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SRIKANTHA T, 1990, J MOL BIOL, V211, P49, DOI 10.1016/0022-2836(90)90010-J; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TRIESCHMANN L, 1995, EMBO J, V14, P1478, DOI 10.1002/j.1460-2075.1995.tb07134.x; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	61	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2515	2525						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700510				2022-12-28	WOS:A1996UW48700005
J	Cavrois, M; Gessain, A; WainHobson, S; Wattel, E				Cavrois, M; Gessain, A; WainHobson, S; Wattel, E			Proliferation of HTLV-1 infected circulating cells in vivo in all asymptomatic carriers and patients with TSP/HAM	ONCOGENE			English	Article						HTLV-1; adult T-cell leukemia; leukemogenesis	VIRUS TYPE-I; TROPICAL SPASTIC PARAPARESIS; POLYMERASE CHAIN-REACTION; BLOOD MONONUCLEAR-CELLS; CYTOTOXIC LYMPHOCYTES-T; PROVIRAL DNA; PERIPHERAL-BLOOD; LEUKEMIA LYMPHOMA; MYELOPATHY; P53	Assuming that the clonal expansion of T cells harbouring the human T-cell leukemia virus type 1 (HTLV-1) provirus is a central feature of HTLV-1 infection, the identification of such cells was sought among a series of 19 asymptomatic carriers and 19 cases of tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) devoid of malignancy, Two PCR based protocols designed to amplify the host cell-HTLV-1 proviral integration sites were used, In all cases large numbers of proliferating clones could be identified, The proportion of some clones was >1/1500 peripheral blood mononuclear cells (PBMCs) with the suggestion that their number increased as a function of age among asymptomatic carriers.	INST RECH CANC LILLE,U124 INSERM,LILLE,FRANCE; INST PASTEUR,UNITE EPIDEMIOL VIRUS ONCOGENES,PARIS,FRANCE; INST PASTEUR,UNITE RETROVIROL MOL,PARIS,FRANCE; CHU,SERV MALAD SANG,LILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Lille - ISITE; CHU Lille								BLATTNER WA, 1989, ANN INTERN MED, V111, P4, DOI 10.7326/0003-4819-111-1-4; CAVROIS M, 1995, RES VIROLOGY, V146, P179, DOI 10.1016/0923-2516(96)80578-4; CESARMAN E, 1992, BLOOD, V80, P3205; CHEN YX, 1995, INT J CANCER, V60, P798; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; DINCAN M, 1994, LEUKEMIA, V8, P682; FURUKAWA Y, 1992, BLOOD, V80, P1012; GESSAIN A, 1990, BLOOD, V75, P428; GESSAIN A, 1985, LANCET, V2, P407; GESSAIN A, 1992, ANN INTERN MED, V117, P933, DOI 10.7326/0003-4819-117-11-933; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; HAUSEN HZ, 1991, SCIENCE, V254, P1167, DOI 10.1126/science.1659743; IKEDA S, 1990, CANCER DETECT PREV, V14, P431; IKEDA S, 1993, BLOOD, V82, P2017; JACOBSON S, 1992, ANN NEUROL, V32, P651, DOI 10.1002/ana.410320508; KIRA J, 1991, ANN NEUROL, V29, P194, DOI 10.1002/ana.410290214; KORBER B, 1991, J VIROL, V65, P5471, DOI 10.1128/JVI.65.10.5471-5476.1991; KUBOTA R, 1993, J NEUROIMMUNOL, V42, P147, DOI 10.1016/0165-5728(93)90004-I; MANNS A, 1991, TRANSFUSION, V31, P67, DOI 10.1046/j.1537-2995.1991.31191096189.x; MATSUMURA M, 1993, INT J CANCER, V55, P220, DOI 10.1002/ijc.2910550209; NAGAI H, 1991, JPN J CANCER RES, V82, P1421, DOI 10.1111/j.1349-7006.1991.tb01815.x; NAKADA K, 1987, INT J CANCER, V40, P145, DOI 10.1002/ijc.2910400203; PARKER CE, 1992, VIROLOGY, V188, P628, DOI 10.1016/0042-6822(92)90517-S; POWERS DC, 1993, J INFECT DIS, V167, P584, DOI 10.1093/infdis/167.3.584; SAKASHITA A, 1992, BLOOD, V79, P477; SHINZATO O, 1991, BLOOD, V78, P2082; SUMMERS BA, 1978, LANCET, V1, P187; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WATTEL E, 1992, J ACQ IMMUN DEF SYND, V5, P943; WATTEL E, 1995, J VIROL, V69, P2863, DOI 10.1128/JVI.69.5.2863-2868.1995; WHANGPENG J, 1985, J NATL CANCER I, V74, P357; WILEY CA, 1988, AM J PATHOL, V133, P355; YAMATO K, 1993, JPN J CANCER RES, V84, P4, DOI 10.1111/j.1349-7006.1993.tb02775.x	33	74	75	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2419	2423						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649783				2022-12-28	WOS:A1996UQ22000020
J	Meazza, R; Verdiani, S; Biassoni, R; Coppolecchia, M; Gaggero, A; Orengo, AM; Colombo, MP; Azzarone, B; Ferrini, S				Meazza, R; Verdiani, S; Biassoni, R; Coppolecchia, M; Gaggero, A; Orengo, AM; Colombo, MP; Azzarone, B; Ferrini, S			Identification of a novel interleukin-15 (IL-15) transcript isoform generated by alternative splicing in human small cell lung cancer cell lines	ONCOGENE			English	Article						human IL-15; small cell lung cancer; RT-PCR; alternative splicing	MESSENGER-RNA PRECURSORS; HUMAN-MELANOMA CELLS; FIBRONECTIN ISOFORM; BETA-CHAIN; RECEPTOR; EXPRESSION	IL-15 is a cytokine promoting growth and differentiation of T, B add NK lymphocytes. By RT-PCR analysis, using primers allowing amplification of the entire IL-15 mRNA coding region, 9/11 small cell lung cancer (SCLC) cell lines displayed detectable IL-15 gene expression, In addition to the expected band sizing 524 bp, a larger band was also observed, Cloning and sequence analysis of the larger cDNA from two SCLC cell lines revealed a size of 643 bp due to the presence of additional 119 bp within the previously reported IL-15 cDNA sequence, The 119 bp sequence matched with an IL-15 genomic sequence downstream the IL-15 second coding exon and may represent a previously unreported alternative exon (exon A), The SCLC-associated IL-15 mRNA isoform has a shorter open reading frame (ORF) due to stop codons in exon A, followed by a new AUG codon, The predicted IL-15 precursor protein displays a shorter signal peptide but shares the same aminoacidic composition of mature IL-15 protein, A possible functional role of IL-15, different from 'IL-2-like' activity, in human tumours, is suggested.	IST NAZL RIC CANC,I-16132 GENOA,ITALY; UNIV GENOA,IST ONCOL CLIN & SPERIMENTALE,I-16132 GENOA,ITALY; IST NAZL TUMORI,I-20133 MILAN,ITALY; HOP PAUL BROUSSE,INSERM U268,F-94800 VILLEJUIF,FRANCE	University of Genoa; IRCCS AOU San Martino IST; University of Genoa; Fondazione IRCCS Istituto Nazionale Tumori Milan; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)			Orengo, Anna Maria/AAC-2108-2020; BIASSONI, ROBERTO/J-4677-2018; Meazza, Raffaella/AAC-2425-2019; Azzarone, Bruno/AAH-9251-2019; Colombo, Mario P./V-7166-2017	Orengo, Anna Maria/0000-0003-2959-6859; BIASSONI, ROBERTO/0000-0002-4365-8166; Meazza, Raffaella/0000-0003-0242-3157; Azzarone, Bruno/0000-0002-5962-3849; Colombo, Mario P./0000-0003-0042-7955; Ferrini, Silvano/0000-0001-7254-2616				ANDERSON DM, 1995, GENOMICS, V25, P701, DOI 10.1016/0888-7543(95)80013-C; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BIASSONI R, 1988, J IMMUNOL, V140, P1685; BORSI L, 1995, J BIOL CHEM, V270, P6243, DOI 10.1074/jbc.270.11.6243; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; CARNEMOLLA B, 1989, J CELL BIOL, V108, P1139, DOI 10.1083/jcb.108.3.1139; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; Carson WE, 1995, J CLIN INVEST, V96, P2578, DOI 10.1172/JCI118321; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; MCMILLAN DN, 1995, INT J CANCER, V60, P766, DOI 10.1002/ijc.2910600606; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.immunol.11.1.245; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PLAISANCE S, 1993, INT J CANCER, V55, P164, DOI 10.1002/ijc.2910550129; QUINN LS, 1995, ENDOCRINOLOGY, V136, P3669, DOI 10.1210/en.136.8.3669; RIMOLDI D, 1993, ANTICANCER RES, V13, P555; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SATO N, 1994, CURR OPIN CELL BIOL, V6, P174, DOI 10.1016/0955-0674(94)90133-3; TANABE KK, 1994, CRIT REV ONCOGENESIS, V5, P201, DOI 10.1615/CritRevOncog.v5.i2-3.50; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; VOSS SD, 1992, J EXP MED, V176, P531, DOI 10.1084/jem.176.2.531; WALDMAN TA, 1995, P AACR SPEC C CYT CY; WEIDMANN E, 1992, CANCER RES, V52, P5963; YASUMURA S, 1994, INT J CANCER, V59, P225, DOI 10.1002/ijc.2910590215; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	30	91	97	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2187	2192						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668345				2022-12-28	WOS:A1996UP28300018
J	Shimizu, S; Eguchi, Y; Kamiike, W; Waguri, S; Uchiyama, Y; Matsuda, H; Tsujimoto, Y				Shimizu, S; Eguchi, Y; Kamiike, W; Waguri, S; Uchiyama, Y; Matsuda, H; Tsujimoto, Y			Retardation of chemical hypoxia-induced necrotic cell death by Bcl-2 and ICE inhibitors: Possible involvement of common mediators in apoptotic and necrotic signal transductions	ONCOGENE			English	Article						bcl-2; bcl-x; apoptosis; necrosis; hypoxia; cell death; mitochondria	GROWTH-FACTOR; GENE CED-3; EXPRESSION; PROTEIN; ENZYME; SURVIVAL; ENCODES; INJURY; LINES	Inhibition of the respiratory chain reaction by cyanide, rotenone or antimycin A (chemical hypoxia) induces necrotic cell death characterized by apparently intact chromatin, remarkable mitochondrial swelling with loss of crista structure, and loss of plasma membrane integrity, The treatments induce no apoptotic cell death, as defined by fragmented nuclei with condensed chromatin, fragmented or condensed cytoplasm, The anti-apoptotic proteins Bcl-2 and Bcl-x(L) effectively retard the chemical hypoxia-induced necrotic cell death, The necrotic cell death is also retarded by inhibitors of ICE(-like) proteases, including interleukin-1 beta converting enzyme (ICE), which are common mediators of apoptosis, These results indicate that Bcl-2/Bcl-x(L) and ICE(-like) proteases modulate apoptotic and at least some forms of necrotic cell death, Both cell death pathways appear to involve some common mediators; however necrotic or apoptotic cell death signals might be transduced through multiple pathways, because Bcl-2/Bcl-x(L) or inhibitors of ICE(-like) proteases are relatively less potent in blocking necrotic cell death than in preventing apoptosis.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT MED GENET, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, DEPT SURG 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, DEPT PHYSIOL 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, DEPT ANAT 1, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University; Osaka University; Osaka University								ALISON MR, 1994, GUT, V35, P577, DOI 10.1136/gut.35.5.577; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GORES GJ, 1990, HEPATOLOGY, V11, P690, DOI 10.1002/hep.1840110425; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HAWKINS HK, 1972, AM J PATHOL, V68, P255; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIMIZU S, 1996, IN PRESS CANC RES; SHIMIZU S, 1996, IN PRESS ONCOGENE; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1995, APOPTOSIS BCL 2 ANTI; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	34	234	237	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2045	2050						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668329				2022-12-28	WOS:A1996UP28300002
J	Janknecht, R; Nordheim, A				Janknecht, R; Nordheim, A			Regulation of the c-fos promoter by the ternary complex factor Sap-1a and its coactivator CBP	ONCOGENE			English	Article						c-fos; coactivator CBP; CREB; Ets protein Sap-1a; signaling; transcription	SERUM RESPONSE ELEMENT; TRANSCRIPTION FACTOR; PROTEIN ELK-1; EXPRESSION; ACTIVATION; PHOSPHORYLATION; INHIBITION; KINASE; BINDS; SRF	The c-fos proto-oncogene is activated by a plethora of signals via the transcription factors Sap-1a and CREB. Recently, the coactivator CBP has been demonstrated to act in concert with CREB when CREB is phosphorylated by protein kinase A. We show that CBP also binds directly to Sap-1a. While phosphorylation of Sap-1a by mitogen-activated protein kinases is not necessary for CBP/Sap-1a interaction, functional cooperation between these two proteins requires Sap-1a to become phosphorylated. CBP-antagonists impair Sap-1a-mediated transactivation. Similarly, the CBP antagonist E1A suppresses c-fos upregulation by phosphorylated CREB, indicating that CBP is a central component of c-fos regulation. Furthermore, CBP is phosphorylated by protein kinase A in vitro and the transactivation potential of the carboxyterminal region of CBP is enhanced in the presence of active protein kinase A in vivo. Thus, CBP, in addition to CREB, is a target for cAMP-dependent signaling. However, combined phosphorylation of CBP by protein kinase A and mitogen-activated protein kinases appears to be non-cooperative, suggesting that CBP serves the function of a dampening integrator of two different signaling pathways.			Janknecht, R (corresponding author), HANNOVER MED SCH,INST MOLEC BIOL,D-30623 HANNOVER,GERMANY.			Janknecht, Ralf/0000-0003-1741-1562				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; Cahill M.A., 1995, INDUCIBLE GENE EXPRE, V2, P39; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CURRAN T, 1992, TRANSCRIPTIONAL REGU, P797; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; FRODIN M, 1994, J BIOL CHEM, V269, P6207; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1995, ONCOGENE, V10, P1209; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JANKNECHT R, 1992, GENE, V121, P321, DOI 10.1016/0378-1119(92)90137-E; JANKNECHT R, 1995, IMMUNOBIOLOGY, V193, P137, DOI 10.1016/S0171-2985(11)80536-X; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JS, 1995, GENE DEV, V9, P1188, DOI 10.1101/gad.9.10.1188; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; PRYWES R, 1988, P NATL ACAD SCI USA, V85, P7206, DOI 10.1073/pnas.85.19.7206; RUTHER U, 1989, ONCOGENE, V4, P861; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHALASTA G, 1990, MOL CELL BIOL, V10, P5558, DOI 10.1128/MCB.10.10.5558; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389	53	122	122	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1961	1969						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649857				2022-12-28	WOS:A1996UK49800015
J	Oridate, N; Esumi, N; Lotan, D; Hong, WK; RochetteEgly, C; Chambon, P; Lotan, R				Oridate, N; Esumi, N; Lotan, D; Hong, WK; RochetteEgly, C; Chambon, P; Lotan, R			Implication of retinoic acid receptor gamma in squamous differentiation and response to retinoic acid in head and neck SqCC/Y1 squamous carcinoma cells	ONCOGENE			English	Article						retinoic acid; squamous differentiation; nuclear receptor; retinoic acid receptor gamma	EPIDERMAL GROWTH-FACTOR; ANCHORAGE-INDEPENDENT GROWTH; GENE-EXPRESSION; TERMINAL DIFFERENTIATION; NEGATIVE REGULATION; MOUSE; PROMOTER; IMMUNODETECTION; PHOSPHORYLATION; TRANSFORMATION	Nuclear retinoic acid receptors are considered to be the mediators of most of the effects of retinoic acid (RA) on gene expression. To explore the role of RA receptor gamma (RAR gamma) in the growth and differentiation of SqCC/Y1 head and neck squamous carcinoma cells, they were transfected with RAR gamma sense and antisense expression vectors and stable clones in which RAR gamma expression was either increased or blocked were isolated. The growth inhibitory effect of RA in monolayer culture was enhanced in the sense transfectants and decreased in the antisense ones. The ability to form colonies in semisolid medium was abolished by RA in the sense transfectants, while the antisense transfected clones exhibited heterogeneous responses. The expression of the squamous differentiation markers cytokeratin K1, transglutaminase type I, and involucrin was increased in the absence of exogenous retinoid in a sense transfected clone and decreased in an antisense transfected clone. RA suppressed squamous differentiation in both types of transfectant. The expression of epidermal growth factor receptor (EGFR) was higher in the antisense and lower in the sense transfectant than in the parental cells and RA decreased EGFR mRNA level in the parental and the sense transfectant but not in the antisense transfectant. In addition activator protein-1 (AP-1) binding activity was decreased by the RA treatment in the sense clones, but not in the antisense ones. These results suggest that RAR gamma mediates the effects of RA on the cell growth both in monolayer culture and in semisolid medium possibly through AP-1 suppression.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT THORAC HEAD & NECK MED ONCOL, HOUSTON, TX 77030 USA; IGBMC, GENET MOLEC EUCARYOTES LAB, F-67085 STRASBOURG, FRANCE	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Institut National de la Sante et de la Recherche Medicale (Inserm)			Oridate, Nobuhiko/G-5365-2012; Oridate, Nobuhiko/ABC-4116-2020	Oridate, Nobuhiko/0000-0002-6968-3028	NCI NIH HHS [P01 CA 52051] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANESKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862, DOI 10.1128/MCB.12.11.4862; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BLUMENBERG M, 1992, J INVEST DERMATOL, V98, pS42, DOI 10.1111/1523-1747.ep12462194; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; ELDER JT, 1991, J INVEST DERMATOL, V96, P425, DOI 10.1111/1523-1747.ep12469889; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FLOYD EE, 1989, MOL CELL BIOL, V9, P4846, DOI 10.1128/MCB.9.11.4846; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Gudas Lorraine J., 1994, P443; HIROSE T, 1995, BIOCHEM BIOPH RES CO, V211, P83, DOI 10.1006/bbrc.1995.1781; HU L, 1991, CANCER RES, V51, P3972; HUDSON LG, 1989, MOL ENDOCRINOL, V3, P400, DOI 10.1210/mend-3-2-400; HUSMANN M, 1991, MOL CELL BIOL, V11, P4097, DOI 10.1128/MCB.11.8.4097; KING I, 1989, CANCER RES, V49, P5677; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LOTAN R, 1982, EXP CELL RES, V141, P79, DOI 10.1016/0014-4827(82)90070-2; LOTAN R, 1993, J CELL BIOCHEM, P167; Mangelsdorf David J., 1994, P319; Maniatis T, 1989, MOL CLONING; MIQUEL C, 1992, MOL BIOL REP, V17, P35; MOASSER MM, 1994, ONCOGENE, V9, P833; MOASSER MM, 1995, ONCOGENE, V10, P1537; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; ORIDATE N, 1995, IN PRESS IN VITRO CE; Oridate Nobuhiko, 1994, Molecular and Cellular Differentiation, V2, P413; Pfahl Magnus, 1994, Seminars in Cell Biology, V5, P95, DOI 10.1006/scel.1994.1013; PITMAN SW, 1983, P AM ASSOC CANC RES, V24, P5; REISS M, 1991, CANCER RES, V51, P6254; REISS M, 1985, J NATL CANCER I, V74, P1015; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUDD CJ, 1993, CANCER LETT, V73, P41, DOI 10.1016/0304-3835(93)90186-D; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SHEIKH MS, 1994, J BIOL CHEM, V269, P21440; STEINERT PM, 1985, J BIOL CHEM, V260, P7142; SUNDQVIST K, 1991, CANCER COMMUN-US, V3, P331, DOI 10.3727/095535491820873731; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VOLLBERG TM, 1992, MOL ENDOCRINOL, V6, P667, DOI 10.1210/mend.6.5.1318502; Wan H., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P510; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; XU XC, 1994, CANCER RES, V54, P3580; ZHANG LX, 1995, J BIOL CHEM, V270, P6022, DOI 10.1074/jbc.270.11.6022; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225; ZHENG ZS, 1990, CANCER RES, V50, P1201; ZOU CP, 1994, CANCER RES, V54, P5479	60	46	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					2019	2028						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649863				2022-12-28	WOS:A1996UK49800021
J	Juang, SH; Carvajal, ME; Whitney, M; Liu, YC; Carraway, CAC				Juang, SH; Carvajal, ME; Whitney, M; Liu, YC; Carraway, CAC			Tyrosine phosphorylation at the membrane-microfilament interface: A p185(neu)-associated signal transduction particle containing Src, Abl and phosphorylated p58, a membrane- and microfilament-associated retroviral gag-like protein	ONCOGENE			English	Article						signal transduction particle; tyrosine kinase; src; Ab1; p185(neu); membrane microfilament	EPIDERMAL GROWTH-FACTOR; RAT MAMMARY ADENOCARCINOMA; TUMOR-CELL MICROVILLI; ROUS-SARCOMA VIRUS; C-ABL; GENE-PRODUCT; ASCITES ADENOCARCINOMA; GLYCOPROTEIN COMPLEX; SIALOMUCIN COMPLEX; PHALLOIDIN SHIFT	Microfilaments are associated with the microvillar membrane in the 13762 ascites rat mammary carcinoma cells by stable interaction with a large, multimeric signal transduction particle (STP) containing the (proto)oncogene receptor p185(neu). In vitro kinase assays on isolated microvilli and microvillar fractions enriched in the putative signal transduction particle showed a high specific activity of tyrosine kinase activity compared to that of membranes from EGF receptor-overexpressing A431 cells maximally activated by EGF. Assays of velocity sedimentation fractions from microvillar lysates in the presence and absence of the exogenous tyrosine kinase substrate poly-glu-tyr polypeptide (poly-E(4)Y) suggested association of the tyrosine kinase activity with STP-enriched microvillar fractions. The particulate fractions also contained discrete endogenous tyrosine-phosphorylated proteins, including prominent bands of approximate to 42 and 58 kDa. Addition of ATP to these fractions resulted in a rapid increase in tyrosine phosphorylation of these and several other proteins, as detected by antiphosphotyrosine blots. Immunoprecipitation and immunoblotting with anti-phosphotyrosine antibody of SDS-solubilized ascites cells and microfilament core fractions showed nine major bands; the electrophoretic mobilities of most of these in the cell immunoprecipitate and microfilament core were the same. In vivo and in situ phosphorylation, phosphoamino acid analysis, immunoprecipitation, 2-dimensional isoelectric focusing/SDS PAGE and immunoblot analysis showed that one of the prominent substrates is p58E(gag), a retroviral Gag-like cytoplasmic STP component implicated in stabilizing microfilament-membrane interactions. Immunoblotting identified two peripheral membrane tyrosine kinases, p60(src) and p120(abl), stably associated with the p185(neu)-containing signal transduction particle. These results provide further evidence for the constitutive activation of this aggressive mammary tumor and suggest a role for phosphorylation of p58S(gag) in organization of the STP at the membrane-microfilament interface in these cells.	UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami; University of Miami			Rolle, Marsha W/D-8286-2012		NATIONAL CANCER INSTITUTE [R01CA052498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033795] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52498] Funding Source: Medline; NIGMS NIH HHS [GM 33795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRAUN S, 1984, J BIOL CHEM, V259, P2051; BURR JG, 1980, P NATL ACAD SCI-BIOL, V77, P3484, DOI 10.1073/pnas.77.6.3484; CARRAWAY C A C, 1992, P123; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1986, BIOCHIM BIOPHYS ACTA, V885, P68, DOI 10.1016/0167-4889(86)90039-X; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1991, J BIOL CHEM, V266, P16238; CARRAWAY CAC, 1985, EXP CELL RES, V157, P71, DOI 10.1016/0014-4827(85)90153-3; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY CAC, 1996, IN PRESS TREATISE CY; CARRAWAY CAC, 1983, EXP CELL RES, V143, P301; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1982, J CELL BIOL, V94, P624, DOI 10.1083/jcb.94.3.624; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CHINKERS M, 1979, J CELL BIOL, V83, P260, DOI 10.1083/jcb.83.1.260; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HUGGINS JW, 1980, EXP CELL RES, V127, P27; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JUANG SH, 1994, J BIOL CHEM, V269, P15067; JUNG G, 1985, J CELL BIOCHEM, V28, P243, DOI 10.1002/jcb.240280402; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; KRUEGER JG, 1983, CURR TOP MICROBIOL I, V107, P52; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LOEB DM, 1987, J VIROL, V61, P2420, DOI 10.1128/JVI.61.8.2420-2427.1987; LUI Y, 1989, J BIOL CHEM, V264, P1208; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OKAMURA H, 1994, ONCOGENE, V9, P2293; PELECH SL, 1986, BIOCHEMISTRY-US, V25, P8348, DOI 10.1021/bi00374a002; PLUSKAL MG, 1986, BIOTECHNIQUES, V4, P272; RIJKEN PJ, 1991, J CELL SCI, V100, P491; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; SOBUE K, 1988, BIOCHEM BIOPH RES CO, V157, P1383, DOI 10.1016/S0006-291X(88)81028-3; SRIVASTAVA AK, 1989, BIOCHIM BIOPHYS ACTA, V996, P13, DOI 10.1016/0167-4838(89)90087-3; TAKATA K, 1988, J CELL BIOL, V106, P1757, DOI 10.1083/jcb.106.5.1757; THOM D, 1977, BIOCHEM J, V168, P187, DOI 10.1042/bj1680187; VANDERPUYE OA, 1988, EXP CELL RES, V178, P211, DOI 10.1016/0014-4827(88)90392-8; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325	54	21	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1033	1042						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649794				2022-12-28	WOS:A1996UA88400011
J	Latham, KE; Cosenza, S; Reichenbach, NL; Mordechai, E; Adelson, ME; Kon, N; Horvath, SE; Charubala, R; Mikhailov, SN; Pfleiderer, W; Suhadolnik, RJ				Latham, KE; Cosenza, S; Reichenbach, NL; Mordechai, E; Adelson, ME; Kon, N; Horvath, SE; Charubala, R; Mikhailov, SN; Pfleiderer, W; Suhadolnik, RJ			Inhibition of growth of estrogen receptor positive and estrogen receptor negative breast cancer cells in culture by AA-etherA, a stable 2-5A derivative	ONCOGENE			English	Article						2-5A; breast cancer; AA-etherA; estrogen receptor; 2D gel	PHOSPHOROTHIOATE ANALOGS; 2',5'-OLIGOADENYLATE-DEPENDENT ENDORIBONUCLEASE; PPP(A2'P)NA-DEPENDENT RNASE; REVERSE-TRANSCRIPTASE; INTERFERON TREATMENT; VACCINIA VIRUS; DIFFERENTIATION; REPLICATION; ACTIVATION; TRIMER	The design, chemical synthesis and biological activities of a nuclease-resistant, nontoxic bioactive 2-5A derivative, AA-etherA [i.e., adenylyl-(2'-5')-adenylyl-(2'-2 '')-9-[(2'-hydroxyethoxy)-methyl]adenine], are described as a new approach to the inhibition of breast cancer cell growth, AA-etherA inhibits DNA replication and cell division of both estrogen receptor positive (MCF-7) and estrogen receptor negative (BT-20) breast cancer cells in culture in a dose-dependent manner. Maximal inhibition in MCF-7 and BT-20 cells was obtained with 100 mu M AA-etherA after four days of treatment, with an GI(50) of 58 and 37 mu M, respectively, AA-etherA is stable in the cytoplasm. Treated cells accumulate within the late G(1)/early S phase of the cell cycle and then progress only very slowly through S phase. AA-etherA does not activate RNase L, as do 2-5A and other 2-5A derivatives, nor does it increase p68 kinase (PKR) content of the cells. High resolution, two-dimensional protein gel electrophoresis reveals twofold or greater inhibition of synthesis of 92 proteins out of 682 proteins that were reproducibly detected as high quality spots with average rates of synthesis of greater than or equal to 20 p.p.m. in untreated cells. The specificity of the effects of AA-etherA on select proteins and its failure to activate RNase L indicate that AA-etherA does not act through a general effect on mRNA translation or stability, but rather inhibits cell proliferation through a block to DNA replication, with a concommitant reduction in the synthesis of specific proteins, some of which may be required for cell cycle transit. Two likely targets to account for the AA-etherA inhibition of DNA replication are DNA topoisomerase I, which is inhibited by AA-etherA in other cell lines, and thymidine kinase, which could be inhibited in a manner similar to the effect of acyclovir. These data indicate that 2-5A analogs, particularly bifunctional 2-5A analogs like AA-etherA, will be useful for controlling cancer cell growth. Further development of such 2-5A analogs may provide highly specific compounds for chemotherapy and chemoprevention.	UNIV KONSTANZ,FAK CHEM,W-7750 CONSTANCE,GERMANY; RUSSIAN ACAD SCI,INST MOLEC BIOL,MOSCOW,RUSSIA; TEMPLE UNIV,DEPT BIOCHEM,SCH MED,PHILADELPHIA,PA 19140	University of Konstanz; Russian Academy of Sciences; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Latham, KE (corresponding author), TEMPLE UNIV,FELS INST CANC RES & MOL BIOL,SCH MED,PHILADELPHIA,PA 19140, USA.		Mikhailov, Sergey/B-4576-2008; Mikhailov, Sergey/F-3414-2013	Mikhailov, Sergey/0000-0002-1363-9706	NATIONAL CANCER INSTITUTE [R01CA065779, P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049489] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA12227, CA65779] Funding Source: Medline; NIGMS NIH HHS [GM49489] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CHARACHON G, 1990, BIOCHEMISTRY-US, V29, P2550, DOI 10.1021/bi00462a017; EPSTEIN DA, 1983, J INTERFERON RES, V3, P305; FERBUS D, 1985, MOL CELL BIOCHEM, V67, P125, DOI 10.1007/BF02370171; GAO WY, 1990, J BIOL CHEM, V265, P20172; GARRELS JI, 1983, METHOD ENZYMOL, V100, P411; GARRELS JI, 1989, J BIOL CHEM, V264, P5283; GARRELS JI, 1989, J BIOL CHEM, V264, P5269; HERDEWIJN P, 1989, HELV CHIM ACTA, V42, P1739; HERSH CL, 1984, J BIOL CHEM, V259, P1731; HUBBELL HR, 1985, INT J CANCER, V36, P389, DOI 10.1002/ijc.1985.36.3.389; KARIKO K, 1987, BIOCHEMISTRY-US, V26, P7136, DOI 10.1021/bi00396a040; KARIKO K, 1987, BIOCHEMISTRY-US, V26, P7127, DOI 10.1021/bi00396a039; KIMCHI A, 1981, EUR J BIOCHEM, V114, P5; KRAUSE D, 1985, J BIOL CHEM, V260, P9501; KRAUSE D, 1985, EUR J BIOCHEM, V146, P611, DOI 10.1111/j.1432-1033.1985.tb08695.x; KVASYUK EI, 1995, HELV CHIM ACTA, V78, P1777, DOI 10.1002/hlca.19950780711; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LENGYEL P, 1982, ANNU REV BIOCHEM, V51, P251, DOI 10.1146/annurev.bi.51.070182.001343; MIKHAILOV SN, 1974, IAN SSSR KH, P2582; MORDECHAI E, 1995, VIROLOGY, V206, P913, DOI 10.1006/viro.1995.1014; MORDECHAI E, UNPUB; MULLER WEG, 1991, BIOCHEMISTRY-US, V30, P2027, DOI 10.1021/bi00222a004; PATTERSON SD, 1993, BIOTECHNIQUES, V15, P1076; PESTKA S, 1981, METHOD ENZYMOL, V78, P79; RICE AP, 1984, J VIROL, V50, P220, DOI 10.1128/JVI.50.1.220-228.1984; ROBINS MJ, 1982, CAN J CHEM, V60, P547, DOI 10.1139/v82-081; SAVINOVA O, 1995, J INTERFERON CYTOKIN, V15, pS167; SCHRODER HC, 1994, CHEM-BIOL INTERACT, V90, P169, DOI 10.1016/0009-2797(94)90101-5; SOBOL RW, 1993, BIOCHEMISTRY-US, V32, P12112, DOI 10.1021/bi00096a023; SOBOL RW, 1995, J BIOL CHEM, V270, P5963, DOI 10.1074/jbc.270.11.5963; TAYLOR JL, 1995, J INTERF CYTOK RES, V15, P27, DOI 10.1089/jir.1995.15.27; VIANO I, 1990, J BIOL REGULATORS HO, V3, P167; VISSER GM, 1986, RECL TRAV CHIM PAY B, V105, P528; WELLS V, 1985, EXP CELL RES, V159, P27, DOI 10.1016/S0014-4827(85)80034-3; WRESCHNER DH, 1981, NUCLEIC ACIDS RES, V9, P1571, DOI 10.1093/nar/9.7.1571	35	14	18	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					827	837						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632905				2022-12-28	WOS:A1996TW68600014
J	Tangir, J; Muto, MG; Berkowitz, RS; Welch, WR; Bell, DA; Mok, SC				Tangir, J; Muto, MG; Berkowitz, RS; Welch, WR; Bell, DA; Mok, SC			A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer	ONCOGENE			English	Article						ovary; cancer; borderline; BRCA1; loss of heterozygosity	HETEROZYGOSITY; TUMORS	Allelic deletions on chromosome 17q21 in sporadic ovarian cancer are common, suggesting that inactivation of a tumor suppressor gene(s) in that region may be important for the etiology of these tumors. The recently identified BRCA1 gene on 17q21, involved in the development of familial breast/ovarian cancer, could be a candidate. However, inactivating mutations on BRCA1 in sporadic ovarian cancer has been rarely described. Furthermore, the potential relationship of BRCA1 gene to ovarian tumors of borderline malignancy remains also unclear. We constructed a highly detailed deletion map of chromosome 17q21 based on PCR amplification of eight polymorphic tandem repeat markers in a 650 kb area including three BRCA1 intragenic markers. DNA from 52 sporadic ovarian cancers and 26 borderline tumors, together with their corresponding normal control tissues were used. Only one borderline tumor showed loss of heterozygosity at one marker, whereas 65% of invasive ovarian cancers displayed allelic loss in at least one of the markers studied. A common deletion unit, located approximately 60 kb centromeric to BRCA1, was revealed. These results suggest that inactivation of the BRCA1 gene may not be responsible for the development of borderline ovarian tumors and that another tumor suppressor gene, located centromeric to the BRCA1 gene, may play a role in sporadic ovarian cancer development.	BRIGHAM & WOMENS HOSP, DEPT OBSTET GYNECOL & REPROD BIOL, LAB GYNECOL ONCOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, MASSACHUSETTS GEN HOSP, DEPT PATHOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1987, Am J Obstet Gynecol, V156, P263; BEWTRA C, 1992, INT J GYNECOL PATHOL, V11, P180, DOI 10.1097/00004347-199207000-00003; BOYD J, 1995, NAT GENET, V9, P335, DOI 10.1038/ng0495-335; COUCH FJ, 1994, GENOMICS, V24, P419, DOI 10.1006/geno.1994.1647; CROOP CS, 1995, CANCER LETT, V90, P51, DOI 10.1016/0304-3835(94)03677-B; CROPP CS, 1994, CANCER RES, V54, P2548; DODSON MK, 1993, CANCER RES, V53, P4456; EASTON DF, 1994, LANCET, V344, P761, DOI 10.1016/S0140-6736(94)92256-X; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; FRIEDMAN LS, 1994, CANCER RES, V54, P6374; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GODWIN AK, 1994, AM J HUM GENET, V55, P666; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; JACOB ANK, 1995, ONCOGENE, V11, P981; JACOBS IJ, 1993, CANCER RES, V53, P1218; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MOK CH, 1992, CANCER RES, V52, P5119; MOK SCH, 1993, CANCER RES, V53, P1489; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; TAKAHASHI H, 1995, CANCER RES, V55, P2998; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; 1995, CANCER FACTS FIGURES, P6	27	45	51	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					735	740						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632895				2022-12-28	WOS:A1996TW68600004
J	Spillman, MA; Bowcock, AM				Spillman, MA; Bowcock, AM			BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen	ONCOGENE			English	Article						estrogen; BRCA1; BRCA2; breast cancer; cycloheximide; cell line	SUSCEPTIBILITY GENE; OVARIAN-CANCER; EXPRESSION; RECEPTOR; PROLIFERATION; GROWTH; DIFFERENTIATION; CARCINOMAS; SEQUENCES; TISSUES	The steady state levels of BRCA1 and BRCA2 mRNAs were shown to be coordinately elevated by the steroid hormone estrogen but not progesterone in the human breast cancer cell lines BT-483 and MCF-7. Two different antiestrogens, trans 4'-hydroxytamoxifen and ICI 182,780, blocked the elevation of BRCA1 and BRCA2 mRNA levels, confirming that the effect was mediated through the estrogen receptor. In BT-483 cells, BRCA1 and BRCA2: mRNA levels were both elevated 18 to 24 h after estrogen stimulation, suggesting that the effect of estrogen was indirect. Cycloheximide blocked the estrogen effect implying that estrogen induces synthesis of an unidentified estrogen-responsive protein(s) that then result in the elevation of BRCA1 and BRCA2 mRNAs.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,MCDERMOTT CTR HUMAN GROWTH & DEV,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Bowcock, Anne/0000-0001-8691-9090	NCI NIH HHS [CA60650] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060650] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; DRIFE JO, 1986, ANN NY ACAD SCI, V464, P58, DOI 10.1111/j.1749-6632.1986.tb15993.x; DUBIK D, 1987, CANCER RES, V47, P6517; EASTON DF, 1993, AM J HUM GENET, V52, P678; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN S, 1990, J STEROID BIOCHEM, V37, P747, DOI 10.1016/0960-0760(90)90415-H; GUDAS JM, 1995, CANCER RES, V55, P4561; GUDAS JM, 1996, CELL GROWTH DIFFER, V7, P171; GUDMUNDSSON J, 1995, CANCER RES, V55, P4830; HECHT JR, 1994, AM J CLIN PATHOL, V102, pS25; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HORWITZ KB, 1978, J BIOL CHEM, V253, P2223; KASID A, 1987, J STEROID BIOCHEM, V27, P465, DOI 10.1016/0022-4731(87)90341-4; KING RJB, 1993, BREAST CANCER RES TR, V27, P3, DOI 10.1007/BF00683189; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; LASFARGUES EY, 1978, J NATL CANCER I, V61, P967; LONGACRE TA, 1986, AM J SURG PATHOL, V10, P382, DOI 10.1097/00000478-198606000-00003; MACLEAN HE, 1995, MOL CELL ENDOCRINOL, V112, P133, DOI 10.1016/0303-7207(95)03608-A; MARCUS JN, 1994, MONOGR NATL CANC I, V16, P23; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MAY FEB, 1986, CANCER RES, V46, P6034; MCGUIRE WL, 1992, J STEROID BIOCHEM, V43, P243, DOI 10.1016/0960-0760(92)90214-4; Merajver SD, 1995, CLIN CANCER RES, V1, P539; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; Phelan CM, 1996, NAT GENET, V13, P120, DOI 10.1038/ng0596-120; REW DA, 1992, BRIT J SURG, V79, P335, DOI 10.1002/bjs.1800790418; Sambrook J., 2002, MOL CLONING LAB MANU; SHI YE, 1994, HUM REPROD, V9, P162, DOI 10.1093/humrep/9.suppl_1.162; Spillman M. A., 1995, American Journal of Human Genetics, V57, pA5; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; WAKELING AE, 1991, CANCER RES, V51, P3867; WAKELING AE, 1989, J MOL ENDOCRINOL, V2, P255; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	40	104	107	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1639	1645						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895509				2022-12-28	WOS:A1996VM88700008
J	Fuchs, SY; Dolan, L; Davis, RJ; Ronai, Z				Fuchs, SY; Dolan, L; Davis, RJ; Ronai, Z			Phosphorylation-dependent targeting of c-jun ubiquitination by Jun N-kinase	ONCOGENE			English	Article						c-jun; c-jun N-kinase; ubiquitination; phosphorylation	SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASE; DELTA-DOMAIN; PROTEASOME PATHWAY; ACTIVATION DOMAIN; HA-RAS; V-JUN; TRANSCRIPTION; CELLS; TRANSFORMATION	Ubiquitination of key cellular regulatory proteins marks them for efficient degradation via the proteasome pathway. The delta domain of c-jun is essential for its ubiquitination and also for the activating phosphorylation of neighboring serines by the stress activated jun-N-terminal kinases (JNK). Using an in vitro model system we demonstrate that JNK is among the hydrophobic binding proteins that target c-jun for efficient ubiquitination. Immunodepletion of JNK markedly inhibits c-jun ubiquitination. Conversely, c-jun ubiquitination is increased by adding purified JNK2 or extracts prepared from cells transfected with JNK2. Although c-jun ubiquitination is enhanced by JNK, the phosphorylation of c-jun on Ser(73) by JNK protects c-jun from ubiquitination and prolongs its half-life. The dual activity of JNK in targeting c-jun for ubiquitination or in protecting c-jun from entering this pathway via phosphorylation points to the role of JNK in the control of c-jun stability in cells exposed to environmental stress or inflammatory cytokines.	AMER HLTH FDN,MOL CARCINOGENESIS PROGRAM,VALHALLA,NY 10595; UNIV MASSACHUSETTS,MED CTR,HOWARD HUGHES MED INST,WORCESTER,MA	American Health Foundation; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester				RONAI, ZEEV/0000-0002-3859-0400; Reinhart, Lisa/0000-0001-6266-3342	NCI NIH HHS [CA59908, CA58396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059908, R01CA058396] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FORNACE AJ, 1989, NUCLEIC ACIDS RES, V17, P1215, DOI 10.1093/nar/17.3.1215; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAMROUDKIDRON E, 1994, FEBS LETT, V337, P239, DOI 10.1016/0014-5793(94)80199-1; MORGAN IM, 1993, ONCOGENE, V8, P1135; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	29	163	167	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1531	1535						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875991				2022-12-28	WOS:A1996VL38400018
J	Gale, NW; Flenniken, A; Compton, DC; Jenkins, N; Copeland, NG; Gilbert, DJ; Davis, S; Wilkinson, DG; Yancopoulos, GD				Gale, NW; Flenniken, A; Compton, DC; Jenkins, N; Copeland, NG; Gilbert, DJ; Davis, S; Wilkinson, DG; Yancopoulos, GD			Elk-L3, a novel transmembrane ligand for the Eph family of receptor tyrosine kinases, expressed in embryonic floor plate, roof plate and hindbrain segments	ONCOGENE			English	Article						Eph; LERK; Sek; Elk; Nuk; Htk; floor plate; roof plate	INSITU HYBRIDIZATION; SONIC-HEDGEHOG; MIDLINE CELLS; MOUSE; GENE; ORGANIZATION; MEMBER; MAP; MOLECULES; POLARITY	The Eph family of receptor tyrosine kinases has 13 distinct members and seven ligands for these receptors have been described to date, These receptors and their ligands have been implicated in regulating neuronal axon guidance and in patterning of the developing nervous system and may also serve a patterning and compartmentalization role outside of the nervous system as well, The ligands are all membrane-attached, and this attachment appears to be crucial for their normal function; five of the known ligands are linked to the membrane,ia a glycosyl phosphotidylinositol (GPI) linkage, while tate of the ligands are transmembrane proteins, Despite the large number of Eph family receptors and ligands, they can be divided into just two major subclasses based on their binding specificities. All the GPI-anchored ligands bind and activate one subclass of the Eph receptors (that represented by Eck) while the two transmembrane ligands bind and activate the other major subclass of receptors (represented by Elk), Here we report the identification and characterization of the third, and most divergent, member of the transmembrane group of Eph ligands, which we term Elk-L3 (ElK-related receptor ligand number 3), Elk-L3 is notable for its remarkably restricted and prominent expression in the Boor plate and roof plate of the developing neural tube and its rhombomere-specific expression in the developing hindbrain, The Elk-L3 gene has been localized to mouse chromosome 11 and human chromosome 17.	REGENERON PHARMACEUT INC,TARRYTOWN,NY 10591; NATL INST MED RES,MRC,DIV DEV NEUROBIOL,LONDON NW7 1AA,ENGLAND; NCI,FREDERICK CANC RES & DEV CTR,ABL,MAMMALIAN GENET LAB,FREDERICK,MD 21702	Regeneron; MRC National Institute for Medical Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick				Wilkinson, David/0000-0001-6757-7080				ALTABA AR, 1995, DEV BIOL, V170, P299; ALTABA ARI, 1992, DEVELOPMENT, V116, P81; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BERGEMANN AD, 1995, MOL CELL BIOL, V15, P4921; BRAUMBLLA R, 1995, MOL CELL NEUROSCI, V6, P487; BUCHBERG AM, 1989, GENETICS, V122, P153; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; ELLIS J, 1995, MECH DEVELOP, V52, P319, DOI 10.1016/0925-4773(95)00411-S; ESPESETH A, 1995, MOL CELL NEUROSCI, V6, P199, DOI 10.1006/mcne.1995.1017; FLENNIKEN A, 1996, UNPUB; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; GANJU P, 1994, ONCOGENE, V9, P1613; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; Green EL, 1981, GENETICS PROBABILITY, P77; Heng Henry H. Q., 1994, V33, P35; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JESSELL TM, 1992, HARVEY LECT, V86, P87; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; NIETO MA, 1992, DEVELOPMENT, V116, P1137; Nieto MA, 1996, METHOD CELL BIOL, V51, P219, DOI 10.1016/S0091-679X(08)60630-5; Ruiz i Altaba A., 1993, CURR OPIN GENE DEV, V3, P633; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; VALENZUELA DM, 1995, GENOMICS, V25, P157, DOI 10.1016/0888-7543(95)80121-2; WINSLOW JW, 1995, NEURON, V14, P973, DOI 10.1016/0896-6273(95)90335-6; XU QL, 1994, DEVELOPMENT, V120, P287; Xu QL, 1995, DEVELOPMENT, V121, P4005	39	108	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1343	1352						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808709				2022-12-28	WOS:A1996VJ20200026
J	Noble, JR; Rogan, EM; Neumann, AA; Maclean, K; Bryan, TM; Reddel, RR				Noble, JR; Rogan, EM; Neumann, AA; Maclean, K; Bryan, TM; Reddel, RR			Association of extended in vitro proliferative potential with loss of p16(INK4) expression	ONCOGENE			English	Article						p16(INK4); RB; telomeres; telomerase; senescence; immortalisation	TUMOR-SUPPRESSOR GENE; FRAUMENI SYNDROME FIBROBLASTS; HUMAN PAPILLOMAVIRUS TYPE-16; KINASE-4 INHIBITOR GENE; SQUAMOUS-CELL CARCINOMA; LARGE T-ANTIGEN; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; HUMAN CANCER; FAMILIAL MELANOMA	This study addresses the question of whether loss of p16(INK4) expression contributes to the immortalization of human cells. in vitro immortalization usually proceeds through two phases. In the first phase (lifespan extension), cells continue proliferating and their telomeres continue shortening beyond the point at which normal cells become senescent. In the second phase (immortalization), the cells activate a telomere maintenance mechanism and acquire an unlimited proliferative potential. It has previously been shown that immortalized cells containing viral oncoproteins that bind and inactivate p110(RB) contain wild-type p16(INK4); we therefore examined the p16(INK4) status Of cell lines that became immortalized in vitro in the absence of these oncoproteins. Three such lines were identified: III-CF/ .2A1 and III-CF/E6A2 (both derived from Li-Fraumeni syndrome fibroblasts, probably by spontaneous immortalization) and MePV-23I (normal mesothelial cells transfected with HPV-16 E6/E7 genes that underwent deletion of these genes before immortalization). In each case p16(INK4) expression was lost at or before immortalization. Further, a cell strain was identified that had an extended but finite lifespan associated with loss of p16(INK4) (and p53) expression. Thus loss of p16(INK4) expression was associated with extended in vitro lifespan but was not sufficient for immortalization, even in the absence of wild-type p53.	CHILDRENS MED RES INST,WESTMEAD,NSW 2145,AUSTRALIA	Children's Medical Research Institute - Australia			Reddel, Roger R/A-6635-2014; Bryan, Tracy M/B-8468-2014; Neumann, Axel/D-3319-2012	Reddel, Roger R/0000-0002-6302-6107; Bryan, Tracy/0000-0002-7990-5501				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; ARAP W, 1995, CANCER RES, V55, P1351; BACCHETTI S, 1995, INT J ONCOL, V7, P423; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BRENNER AJ, 1995, CANCER RES, V55, P2892; BRYAN TM, 1994, CRIT REV ONCOGENESIS, V5, P331, DOI 10.1615/CritRevOncog.v5.i4.10; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHADENEAU C, 1995, CANCER RES, V55, P2533; CHENG JQ, 1994, CANCER RES, V54, P5547; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1995, TELOMERES, P265; DESILVA R, 1994, EXP CELL RES, V213, P418, DOI 10.1006/excr.1994.1218; DREYLING MH, 1995, CANCER RES, V55, P984; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1992, EXP GERONTOL, V27, P375, DOI 10.1016/0531-5565(92)90068-B; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JACOBSON S, 1989, J VIROL, V63, P1756, DOI 10.1128/JVI.63.4.1756-1762.1989; JIN XM, 1995, CANCER RES, V55, P3250; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KE Y, 1989, AM J PATHOL, V134, P979; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LAVECK MA, 1988, IN VITRO CELL DEV B, V24, P1077; LI Y, 1994, CANCER RES, V54, P6078; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; MACLEAN K, 1994, ONCOGENE, V9, P719; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUNGER K, 1989, J VIROL, V63, P4417; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; NILSSON P, 1994, ONCOGENE, V9, P3043; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; REED JA, 1995, CANCER RES, V55, P2713; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROSE BR, 1995, GYNECOL ONCOL, V56, P239, DOI 10.1006/gyno.1995.1039; SCHULZE A, 1994, ONCOGENE, V9, P3475; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TAM SW, 1994, CANCER RES, V54, P5816; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; XU L, 1994, CANCER RES, V54, P5262; YEAGER T, 1995, CANCER RES, V55, P493; ZHANG SY, 1994, CANCER RES, V54, P5050	61	54	57	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1259	1268						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808700				2022-12-28	WOS:A1996VJ20200017
J	Carbone, M; Rizzo, P; Procopio, A; Giuliano, M; Pass, HI; Gebhardt, MC; Mangham, C; Hansen, M; Malkin, DF; Bushart, G; Pompetti, F; Picci, P; Levine, AS; Bergsagel, JD; Garcea, RL				Carbone, M; Rizzo, P; Procopio, A; Giuliano, M; Pass, HI; Gebhardt, MC; Mangham, C; Hansen, M; Malkin, DF; Bushart, G; Pompetti, F; Picci, P; Levine, AS; Bergsagel, JD; Garcea, RL			SV40-like sequences in human bone tumors	ONCOGENE			English	Article						SV40; human bone tumors	HUMAN-BRAIN-TUMORS; T-DELETION MUTANTS; SIMIAN-VIRUS 40; GROWTH-FACTOR-I; SV40; ANTIGEN; SIMIAN-VIRUS-40; MICE; GENE; TRANSFORMATION	Simian virus 40 (SV40) is a monkey virus that induces ependymomas, choroid plexus tumors, mesotheliomas, osteosarcomas, sarcomas and true histiocytic lymphomas when injected in hamsters. Recently, approximately 60% of human ependymomas, choroid plexus tumors and mesotheliomas were reported to contain and express SV40-like sequences (N. Engl. J. Med., 1992, 36, 988-993; Oncogene, 1994, 9, 1781-1790). In this study the presence of SV40-like sequences was investigated in additional types of human tumors. Initially, 200 tumor and normal tissue DNA samples were analysed by polymerase chain reaction (PCR) with primers that were analysed by with primers that amplify a 574 base pair region of SV40 large T antigen (Tag), which includes the Rb-pocket binding domain and the intron of Tag. PCR amplification and Southern blot hybridization with a probe specific for SV40 Tag revealed that 18/200 samples contained SV40-like sequences and, unexpectedly, 11/18 were from patients with osteosarcomas. Additional DNA samples from bone tumors were then analysed. In 40/126 osteosarcomas, and 14/34 other bone-related tumors, Tag sequences could be amplified. Sequence analysis of the DNA amplified from seven different tumors confirmed that the amplified sequences corresponded to SV40 Tag, with some demonstrating deletions in the intron region but not in the Rb-pocket binding domain. The extent of SV40 genome sequences present in the DNA samples was further analysed in two osteosarcomas. PCR amplification, Southern blot hybridization, and sequence analysis revealed that these samples also contained sequences for the carboxy-terminal domain of Tag, the viral regulatory region, and the VP1 capsid protein. These results indicate that SV40-like sequences are present in human bone tumors.	NIH, SECT DNA REPLICAT REPAIR & MUTAGENESIS, BETHESDA, MD 20892 USA; UNIV G DANNUNZIO, EXPT CTR GENE THERAPY & DIAG, CHIETI, ITALY; NCI, THORAC ONCOL SECT, BETHESDA, MD 20892 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, BOSTON, MA 02115 USA; BOSTON UNIV, BOSTON, MA 02215 USA; HOSP SICK CHILDREN, TORONTO, ON M5G 1X8, CANADA; UNIV ULM, D-7900 ULM, GERMANY; IST ORTOPED RIZZOLI, BOLOGNA, ITALY; SCOTTISH RITE HOSP, ATLANTA, GA USA; CHILDRENS HOSP, DENVER, CO 80218 USA	National Institutes of Health (NIH) - USA; G d'Annunzio University of Chieti-Pescara; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Boston Children's Hospital; Harvard Medical School; Boston University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ulm University; IRCCS Istituto Ortopedico Rizzoli; Children's Hospital Colorado	Carbone, M (corresponding author), UNIV CHICAGO, DEPT PATHOL, 5841 S MARYLAND AVE, MC3083, ROOM S-342, CHICAGO, IL 60637 USA.		Bergsagel, Daniel John/I-6464-2019; Malkin, David/AAW-8715-2021; Procopio, Antonio Domenico/AAB-2451-2021; Picci, Piero/J-5979-2016	Procopio, Antonio Domenico/0000-0001-6897-8724; Pass, Harvey/0000-0003-3222-3471; Picci, Piero/0000-0002-8519-4101; rizzo, paola/0000-0001-7174-9674; Giuliano, Mariateresa/0000-0002-7338-9200				ABRAMCZUK J, 1984, J VIROL, V49, P540, DOI 10.1128/JVI.49.2.540-548.1984; AVANTAGGIATI ML, IN PRESS EMBO J; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; BRIGHT RK, 1994, J IMMUNOL, V153, P2064; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; BUCHMAN AR, 1981, DNA TUMOR VIRUSES 2, P799; BUTEL JS, 1994, ENCY VIROLOGY, V2, P1322; CARBONE M, 1994, ONCOGENE, V9, P1781; CARBONE M, 1989, CANCER RES, V49, P1565; CARBONE M, 1991, MOL BASIS HUMAN CANC, P191; CARBONE M, 1995, DNA TUMOR VIRUSES ON, P75; CICALA C, 1993, AM J PATHOL, V142, P1524; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cristaudo A., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P29; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DIXON K, 1982, NATURE, V296, P672, DOI 10.1038/296672a0; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; GEISSLER E, 1983, HUM GENET, V63, P1, DOI 10.1007/BF00285389; GEISSLER E, 1990, PROG MED VIROL, V37, P211; GERBER P, 1962, VIROLOGY, V18, P582, DOI 10.1016/0042-6822(62)90061-2; ILYINSKII PO, 1992, J VIROL, V66, P6353, DOI 10.1128/JVI.66.11.6353-6360.1992; JENSEN F, 1964, J NATL CANCER I, V29, P1123; KE Y, 1989, AM J PATHOL, V134, P979; KOPROWSKI H, 1962, J CELL COMPAR PHYSL, V59, P281, DOI 10.1002/jcp.1030590308; KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446; KRIEG P, 1984, VIROLOGY, V138, P336, DOI 10.1016/0042-6822(84)90357-X; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; LEDNICKY JA, 1995, VIRUS RES, V35, P143, DOI 10.1016/0168-1702(94)00093-R; LEWIS AM, 1979, P NATL ACAD SCI USA, V76, P4299, DOI 10.1073/pnas.76.9.4299; LEWIS AM, 1973, BIOHAZARDS BIOL RES, P96; MARTIN JD, 1991, VIRUS RES, V19, P163, DOI 10.1016/0168-1702(91)90043-U; MARTINI F, 1995, J NATL CANCER I, V87, P1331, DOI 10.1093/jnci/87.17.1331; MAYOL X, 1993, ONCOGENE, V8, P2561; MELNICK JL, 1962, P SOC EXP BIOL MED, V109, P965, DOI 10.3181/00379727-109-27392; MORRIS JA, 1961, P SOC EXP BIOL MED, V108, P56, DOI 10.3181/00379727-108-26843; PASS HI, IN PRESS IMPORTANT A; PASS HI, IN PRESS CANC RES; POMPETTI F, IN PRESS J CELL BIOC; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RABSON AS, 1962, J NATL CANCER I, V29, P1123; Ray F.A., 1995, DNA TUMOR VIRUSES ON, P15; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; SAMBROOK S, 1989, MOL CLONING, V2; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; SHEIN HM, 1962, P NATL ACAD SCI USA, V48, P1164, DOI 10.1073/pnas.48.7.1164; SIMMONS DT, 1995, DNA TUMOR VIRUSES ON, P27; SORIANO F, 1974, NATURE, V249, P421, DOI 10.1038/249421a0; STEWART N, 1991, VIROLOGY, V180, P49, DOI 10.1016/0042-6822(91)90008-Y; TIEMANN F, 1994, ONCOGENE, V9, P1907; TODARO GJ, 1967, P SOC EXP BIOL MED, V124, P1232; VALENTINIS B, 1994, ONCOGENE, V9, P825; WALKER DL, 1986, PAPOVAVIRIDAE, V1, P327; WALSH JW, 1982, NEUROSURGERY, V10, P643, DOI 10.1227/00006123-198205000-00018; WANG R, 1991, J VIROL, V65, P5174, DOI 10.1128/JVI.65.10.5174-5183.1991; WEINER LP, 1972, NEW ENGL J MED, V305, P1517; WILKIE TM, 1994, ONCOGENE, V9, P2889; YOSHIIKE K, 1986, PAPOVAVIRIDAE, V1, P295	60	178	182	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					527	535						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760294				2022-12-28	WOS:A1996VB32800010
J	Payson, RA; Wu, J; Liu, Y; Chiu, IM				Payson, RA; Wu, J; Liu, Y; Chiu, IM			The human FGF-8 gene localizes on chromosome 10q24 and is subjected to induction by androgen in breast cancer cells	ONCOGENE			English	Article						breast cancer; steroid hormone; fibroblast growth factor; cloning; fluorescence in situ hybridization	GROWTH-FACTOR; EXPRESSION; CLONING; MOUSE; TISSUES; FAMILY; ACID	Androgen-induced growth factor (AIGP or FGF-8) was originally isolated from the conditioned medium of an androgen-dependent Shionogi carcinoma, SC-3, cell line, It shares structural similarity with other members of the FGF family, The temporal and spatial expression patterns of the FGF-8 gene suggest its involvement in gastrulation, regionalization of the brain, and organogenesis of the limb and face as an embryonic epithelial factor, In the adult, expression of FGF-8 is restricted to gonads including testes and ovaries, Since FGF-8 is identified as a corroborating gene in MMTV-induced mammary tumors in Wnt-1 transgenic mice and because FGF-8 manifested its autocrine mitogenic activity in SC-3 cells, it is possible that aberrant expression of FGF-8 may be present in human cancers which are hormone dependent. However, very little is known about human FGF-8, To determine whether FGF-8 plays a role in human breast cancer, we have isolated the full-length cDNA from SK-BR-3 breast cancer cells. We have also isolated the corresponding genomic DNA in a P1 cloning vector, The FGF-8 gene has been mapped to chromosome 10q24 using both somatic cell hybrid genetic analysis and fluorescence in situ hybridization. Finally, we show that FGF-8 gene expression in a human breast cancer cell line, MDA-MB-231, is inducible by androgen, The findings presented here will facilitate our understanding of the molecular mechanism underlying hormone-responsive breast and prostate cancers.	OHIO STATE UNIV,DEPT INTERNAL MED,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR COMPREHENS CANC,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University			Chiu, Ing-Ming/B-1534-2008		NATIONAL CANCER INSTITUTE [R01CA045611, K04CA001369] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047506] Funding Source: NIH RePORTER; NCI NIH HHS [K04 CA01369, R01 CA45611] Funding Source: Medline; NIDDK NIH HHS [R01 DK47506] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; HALL RE, 1992, INT J CANCER, V52, P778, DOI 10.1002/ijc.2910520518; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KASID A, 1985, SCIENCE, V228, P725, DOI 10.1126/science.4039465; KOUHARA H, 1994, ONCOGENE, V9, P455; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MYERS RL, 1995, ONCOGENE, V11, P785; MYERS RL, 1995, J BIOL CHEM, V270, P8257, DOI 10.1074/jbc.270.14.8257; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS KG, 1992, DEVELOPMENT, V114, P233; POULIN ML, 1993, DEVELOPMENT, V119, P353; POULIN ML, 1995, DEV DYNAM, V202, P378, DOI 10.1002/aja.1002020407; PRIEST JH, 1977, MED CYTOGENETICS CEL; RUOHOLA JK, 1995, ENDOCRINOLOGY, V136, P2179, DOI 10.1210/en.136.5.2179; Sambrook J., 2002, MOL CLONING LAB MANU; SATO B, 1993, J STEROID BIOCHEM, V47, P91, DOI 10.1016/0960-0760(93)90061-Z; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHEPHERD NS, 1994, P NATL ACAD SCI USA, V91, P2629, DOI 10.1073/pnas.91.7.2629; TABIN C, 1995, CELL, V80, P671, DOI 10.1016/0092-8674(95)90343-7; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG WP, 1989, MOL CELL BIOL, V9, P2387, DOI 10.1128/MCB.9.6.2387; YAMANISHI H, 1995, J STEROID BIOCHEM, V52, P49, DOI 10.1016/0960-0760(94)00148-F; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123	37	39	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					47	53						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700553				2022-12-28	WOS:A1996UX31900006
J	Xu, X; Heidenreich, O; Kitajima, I; McGuire, K; Li, QH; Su, B; Nerenberg, M				Xu, X; Heidenreich, O; Kitajima, I; McGuire, K; Li, QH; Su, B; Nerenberg, M			Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis	ONCOGENE			English	Article						JNK; HTLV-1; tumorigenesis; tax; leukemia	VIRUS TYPE-I; T-CELL LEUKEMIA; NF-KAPPA-B; TRANSCRIPTIONAL ACTIVATOR; TAX; PROTEIN; GENE; KINASE; IDENTIFICATION; TRANSFORMATION	Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell leukiemia (ATL) and HTLV-1 associated myelopathy, also called tropical spastic paraparesis (HAM/TSP). Both clinical and in vitro evidence have demonstrated that the virus or its transactivator Tax, are transforming, However, transformation appears to require additional, as yet poorly characterized, genetic changes in infected cells, JNK is a recently characterized member of the MAP kinase family. Its signaling cascade is distinct from other members and has been demonstrated to play an important role in T-cell activation, at least partially through its downstream targets, c-jun and ATF-2. Here we demonstrate constitutive activation of the JNK cascade in human lymphocytes transformed in vitro by HTLV-1 and also in Tax transformed murine fibroblasts. Such activation is not induced by Tax expression alone, and occurs only when infected lymphocytes become IL-2 independent or immortalized. Constitutive JNK activation was also found in leukocytes isolated from ATL patients. The acquisition of constitutive JNK activation may represent an important later event in HTLV-1 tumorigenesis.	SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA; KAGOSHIMA UNIV, DEPT LAB MED, KAGOSHIMA 890, JAPAN; SAN DIEGO STATE UNIV, DEPT BIOL, SAN DIEGO, CA 92182 USA; SAN DIEGO STATE UNIV, INST MOLEC BIOL, SAN DIEGO, CA 92182 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT IMMUNOL, HOUSTON, TX 77030 USA	Scripps Research Institute; Kagoshima University; California State University System; San Diego State University; California State University System; San Diego State University; University of Texas System; UTMD Anderson Cancer Center			Heidenreich, Olaf/AAP-5045-2021	Heidenreich, Olaf/0000-0001-5404-6483				BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BROWN DA, 1994, TRANSGENICS, V1, P377; BRUNET A, 1994, ONCOGENE, V9, P3379; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; COBB HM, 1995, J BIOL CHEM, V270, P14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1991, ONCOGENE, V6, P1023; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GESSAIN A, 1985, LANCET, V2, P407; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI H, 1992, ONCOGENE, V7, P1737; HOLLSBERG P, 1993, NEW ENGL J MED, V328, P1173, DOI 10.1056/NEJM199304223281608; HOLLSBERG P, 1992, J IMMUNOL, V148, P3256; HSUEH YP, 1995, J BIOL CHEM, V270, P18094, DOI 10.1074/jbc.270.30.18094; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KITAJIMA I, 1992, SCIENCE, V258, P1792, DOI 10.1126/science.1299224; KITAJIMA I, 1992, J BIOL CHEM, V267, P25881; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MAEDA M, 1987, BLOOD, V70, P1407; MCGUIRE KL, 1993, J VIROL, V67, P1590, DOI 10.1128/JVI.67.3.1590-1599.1993; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROHWER F, 1994, INT J ONCOL, V5, P1163; SAGGIORO D, 1990, CANCER RES, V50, P4968; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; XU X, 1995, J CLIN INVEST, V96, P1548, DOI 10.1172/JCI118193; XU X, 1994, MOL CELL BIOL, V14, P5371, DOI 10.1128/MCB.14.8.5371; XU X, 1996, IN PRESS VIROLOGY; YAMAGUCHI K, 1990, HUMAN RETROVIROLOGY : HTLV, P163; YAN MH, 1994, NATURE, V372, P798	49	89	90	1	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					135	142						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700539				2022-12-28	WOS:A1996UX31900015
J	Christiansen, JH; Monkley, SJ; Wainwright, BJ				Christiansen, JH; Monkley, SJ; Wainwright, BJ			Murine WNT11 is a secreted glycoprotein that morphologically transforms mammary epithelial cells	ONCOGENE			English	Article						WNT; mammary tumorigenesis; C57MG	PROTO-ONCOGENE INT-1; EXPRESSION; WNT-1; GENE; LINE; GLAND; HYPERPLASIA; PRODUCTS; INVITRO; VECTOR	Wnt genes encode a set of structurally related cell surface glycoproteins that appear to have roles in cell-cell signalling. The ectopic expression of several murine Wnt genes has been implicated in the transformation of mammary epithelial and the onset of mammary tumours. Wnt11 is expressed in the developing embryo in a variety of structures including the dermatome/myotome junction of the somites, the truncus ateriosus region of the heart and limb mesenchyme. Here we report that Wnt11 encodes a glycoprotein that is secreted from expressing cells and becomes associated with the extracellular matrix. In addition, Rat2 fibroblasts expressing WNT11 (which are not morphologically altered themselves) are able to induce the transformation of adjacent C57MG mammary epithelial cells in co-culture experiments. These results suggest that WNT11 functions via a paracrine signalling mechanism to have a direct effect on the morphology and growth characteristics of mammary epithelial cells.	UNIV QUEENSLAND,CTR CELLULAR & MOLEC BIOL,ST LUCIA,QLD 4072,AUSTRALIA	University of Queensland				Monkley, Susan/0000-0001-9174-6278; Wainwright, Brandon/0000-0003-0406-2092; Christiansen, Jeff/0000-0002-8146-1225				ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADLEY RS, 1990, EMBO J, V9, P1565; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; EDWARDS PAW, 1992, ONCOGENE, V7, P2041; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Harlow E., 1988, ANTIBODIES LAB MANUA; HUBBARD SC, 1981, ANNU REV BIOCHEM, V50, P555, DOI 10.1146/annurev.bi.50.070181.003011; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; KRUMLAUF R, 1991, GENE TRANSFER EXPRES, P307; KU M, 1993, DEVELOPMENT, V119, P1161; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOON RT, 1993, BIOESSAYS, V15, P91, DOI 10.1002/bies.950150204; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V23, P311; OLSON DJ, 1994, CELL GROWTH DIFFER, V5, P197; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PARR BA, 1993, DEVELOPMENT, V119, P247; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROBBINS PW, 1984, J BIOL CHEM, V259, P7577; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SONNENBERG A, 1986, CANCER RES, V46, P5913; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAIDYA AB, 1978, VIROLOGY, V90, P12, DOI 10.1016/0042-6822(78)90328-8; VANHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	42	22	23	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2705	2711						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700530				2022-12-28	WOS:A1996UW48700025
J	Hardin, JD; Boast, S; Mendelsohn, M; delosSantos, K; Goff, SP				Hardin, JD; Boast, S; Mendelsohn, M; delosSantos, K; Goff, SP			Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice	ONCOGENE			English	Article						c-abl, transgene; tyrosine kinase; rescue	TARGETED GENE DISRUPTION; VIRUS TRANSFORMING GENE; TYROSINE KINASE; DIFFERENTIAL EXPRESSION; MESSENGER-RNAS; MOUSE-TISSUES; CELL; DNA; BINDING; RECOMBINATION	Mice carrying homozygous mutations in the c-abl gene (abl(ml) or abl(2)) exhibit severe, though variable phenotypes, including a high rate of postnatal mortality, runting, morphological abnormalities, a susceptibility to infections, and selected immune system defects, To further determine the role of the c-Abl protein in vivo, we have generated three lines of mice expressing c-abl transgenes, These minigenes encode the two major forms of the c-abl gene product (c-Abl types I and IV) and a kinase defective type IV c-Abl. The transgenic lines, in Abl-positive genetic backgrounds, were phenotypically almost indistinguishable from their non-transgene littermates and expressed the c-ab! transgene in a variety of tissues at levels comparable to that of the endogenous c-abl gene. When the transgenes were introduced into a mutant c-abl strain by mating, the mutant c-abl phenotype was almost completely rescued by either of the c-abl type I or type IV transgenes, but not by the kinase-defective transgene, These findings suggest that either of the two alternatively spliced c-abl gene products can provide the in vivo functions of c-Abl, and that these functions are dependent on kinase activity.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University; Columbia University; Howard Hughes Medical Institute			Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NCI NIH HHS [P01 CA23767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA023767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELSON HT, 1970, CANCER RES, V30, P2213; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1988, ONCOGENE, V2, P297; BOULTER CA, 1988, EXP CELL RES, V179, P214, DOI 10.1016/0014-4827(88)90360-6; DALEY GQ, 1992, MOL CELL BIOL, V12, P1864, DOI 10.1128/MCB.12.4.1864; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HARDIN JD, 1995, CELL IMMUNOL, V165, P44, DOI 10.1006/cimm.1995.1185; HARDIN JD, 1995, UNPUB; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HOGAN B, 1986, MANIPULATING MOUSE E; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RAY P, 1991, GENE DEV, V5, P2265, DOI 10.1101/gad.5.12a.2265; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; Sambrook J., 2002, MOL CLONING LAB MANU; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHWARTZBERG PL, 1990, P NATL ACAD SCI USA, V87, P3210, DOI 10.1073/pnas.87.8.3210; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1993, ONCOGENES TUMOR SUPP; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WANG JYJ, 1984, CELL, V36, P349; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2669	2677						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700526				2022-12-28	WOS:A1996UW48700021
J	Ray, ME; Su, YA; Meltzer, PS; Trent, JM				Ray, ME; Su, YA; Meltzer, PS; Trent, JM			Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma	ONCOGENE			English	Article						malignant melanoma; chromosome 6; tumor suppression	LONG ARM; EXPRESSION; IDENTIFICATION; SEARCH	Melanocytic transformation is thought to occur by the sequential accumulation of genetic alterations, Evidence implicating human chromosome-6 as a site for a gene(s) involved in melanoma suppression comes from studies of LOH [loss of heterozygosity], cytogenetics and biologic reversion of tumorigenicity following the introduction of a normal chromosome 6 by microcell-mediated chromosome transfer (Trent et al., 1990), Using a tumorigenic melanoma cell line (UACC 903) and a chromosome-6 suppressed melanoma subline [UACC 903 (+6)], we have isolated a series of genes uniquely expressed in the suppressed subline, A modified PCR-based cDNA subtraction technique was used to generate subtracted cDNA sublibraries for both the parental and (+6) suppressed cells, A total of 32 randomly selected clones from the suppressed sublibrary were isolated and examined, with 24 detecting a transcript by Northern analysis, Of these 24 clones, 21 (88%) demonstrated elevated expressed by Northern analysis in the suppressed subline relative to the tumorigenic parental cell line, In 6/21 differentially expressed clones (29%), expression was exclusive to the suppressed subline, Partial sequence analysis and database searching of these clones indicated that 5/6 were novel with one representing a previously characterized gene, Chromosomal localization of the five novel clones was performed following PCR amplification of a human/rodent somatic cell hybrid mapping panel or fluorescent in situ hybridization, One cDNA (termed AIM1) was localized to a band-region of chromosome 6 frequently deleted in melanomas (6q21), This novel approach should facilitate the identification of genes whose expression is causally related to the suppressed phenotype.	NIH,NATL CTR HUMAN GENOME RES,CANC GENET LAB,BETHESDA,MD 20892; UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Michigan System; University of Michigan								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; *ANN CANC STAT REV, 1988, 882789 NIH NCI; BROWN T, 1993, CURRENT PROTOCOLS GR; ENGEBRECHT J, 1991, CURRENT PROTOCOLS; FUNASAKA Y, 1992, MOL BIOL CELL, V3, P197, DOI 10.1091/mbc.3.2.197; GISH W, 1993, NAT GENET, V3, P266, DOI 10.1038/ng0393-266; HALABAN R, 1993, RECENT RES CANCER, V128, P133; JACKSON IJ, 1994, ANNU REV GENET, V28, P189, DOI 10.1146/annurev.ge.28.120194.001201; KINGSTON RE, 1991, CURRENT PROTOCOLS; LASSAM N, 1992, ONCOGENE, V7, P51; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; MATHEW S, 1992, GENOMICS, V14, P775, DOI 10.1016/S0888-7543(05)80184-3; MELTZER PS, 1993, NAT GENET, V4, P252, DOI 10.1038/ng0793-252; MILLIKIN D, 1991, CANCER RES, V51, P5449; NATALI PG, 1992, INT J CANCER, V52, P197, DOI 10.1002/ijc.2910520207; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; WALKER GJ, 1994, INT J CANCER, V58, P203, DOI 10.1002/ijc.2910580210; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505; WELCH DR, 1994, ONCOGENE, V9, P255	21	51	54	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2527	2533						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700511				2022-12-28	WOS:A1996UW48700006
J	Seyfert, VL; Allman, D; He, YS; Staudt, LM				Seyfert, VL; Allman, D; He, YS; Staudt, LM			Transcriptional repression by the proto-oncogene BCL-6	ONCOGENE			English	Article						BCL-6; repression; lymphoma; POZ domain	GERMINAL-CENTERS; CONSERVED DOMAIN; GENE; DROSOPHILA; PROTEINS; IDENTIFICATION; TRANSLOCATIONS; EXPRESSION; ACTIVATORS; LYMPHOMAS	In up to 45% of reported cases of the non-Hodgkin's lymphoma, diffuse large cell lymphoma, there are translocations of the BCL-6 gene, which are presumed to deregulate its expression, The BCL-6 protein, which is unmutated in these lymphomas, contains six Kruppel-like zinc fingers at its carboxy terminus and a 121 amino acid domain at its amino terminus, termed the POZ domain, which bears homology with amino terminal domains in a subset zinc finger transcription factors, In this study, we tested whether BCL-6 regulates transcription and if the POZ domain has a role in this function. The BCL-6 POZ domain, when fused to the GAL4 DNA binding domain, strongly repressed transcriptional activation initiated from several different promoters including the SV40 enhancer/promoter. Repression was also observed when the fusion protein was bound at a distance of 200 bp 5' of the promoter, When the GAL4/BCL6 POZ domain fusion protein was expressed in yeast, it was able to homodimerize in the nucleus, Nevertheless, in contrast with mammalian cells, the fusion protein did not repress transcription, To test the ability of the full length BCl-6 protein to repress transcription when bound to DNA through its zinc finger DNA binding domain, high affinity BCL-6 binding sites were selected from a pool of random oligonucleotides. Full length BCL-6 was able to strongly repress transcription when bound to its cognate site cloned upstream of the thymidine kinase promoter, This repression was mediated, in large measure, by the POZ domain, although a variant of BCL-6 lacking the POZ domain was able to repress transcription modestly, The ability of BCL-6 to function as a transcriptional repressor may contribute to its ability to transform B lymphocytes in diffuse large cell lymphoma.	NCI,METAB BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Staudt, Louis/AAC-5324-2019					Ausubel FM., 2006, ENZYMATIC MANIPULATI; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; BASTARD C, 1994, BLOOD, V83, P2423; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; CHEN W, 1995, MOL CELL BIOL, V15, P3424; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DALLERY E, 1995, ONCOGENE, V10, P2171; DIBELLO PR, 1991, GENETICS, V129, P385; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAIDANO G, 1994, BLOOD, V84, P397; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; HARRISON SD, 1990, EMBO J, V9, P207, DOI 10.1002/j.1460-2075.1990.tb08097.x; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACOB J, 1991, NATURE, V354, P389, DOI 10.1038/354389a0; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; KAWAMATA N, 1994, BIOCHEM BIOPH RES CO, V204, p3P66; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; LOCOCO F, 1994, BLOOD, V83, P1757, DOI 10.1182/blood.V83.7.1757.bloodjournal8371757; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAGRATH IT, 1990, NONHODGKINS LYMPHOMA, P1; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIKI T, 1994, BLOOD, V83, P217; NAKAMURA Y, 1995, BRIT J HAEMATOL, V90, P404, DOI 10.1111/j.1365-2141.1995.tb05166.x; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; OHNO H, 1994, JPN J CANCER RES, V85, P592, DOI 10.1111/j.1349-7006.1994.tb02401.x; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; Rose MD., 1990, METHODS YEAST GENETI; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SAHA S, 1993, NATURE, V363, P648, DOI 10.1038/363648a0; Sambrook J., 2002, MOL CLONING LAB MANU; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570	47	189	193	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2331	2342						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649773				2022-12-28	WOS:A1996UQ22000010
J	Mautner, J; Behrends, U; Hortnagel, K; Brielmeier, M; Hammerschmidt, W; Strobl, L; Bornkamm, GW; Polack, A				Mautner, J; Behrends, U; Hortnagel, K; Brielmeier, M; Hammerschmidt, W; Strobl, L; Bornkamm, GW; Polack, A			c-myc expression is activated by the immunoglobulin kappa-enhancers from a distance of at least 30 kb but not by elements located within 50 kb of the unaltered c-myc locus in vivo	ONCOGENE			English	Article						chromatin analysis; c-myc; gene expression; immunoglobulin enhancer; locus control	BURKITTS-LYMPHOMA CELLS; REGULATORY ELEMENTS; GENE-EXPRESSION; PROMOTER SHIFT; 1ST EXON; T-CELL; TRANSLOCATIONS; REGION; PROTOONCOGENE; TRANSCRIPTION	50 kb of contiguous DNA sequences covering the human c-myc coding region and approximately 20 kb of flanking upstream and downstream sequences were cloned onto a prokaryotic F-factor derived plasmid, which also contains a selectable marker and the plasmid origin of DNA replication oriP of Epstein Barr virus (EBV). Since these plasmids replicate extrachromosomally after stable transfection into EBV-positive B-cell lines, the gene regulation of c-myc can be analysed independent from chromosomal integration positions, Despite the presence of all known c-myc regulatory elements on these constructs, expression from the stably transfected c-myc gene was barely detectable in either cell line, Hypermethylation of these plasmids could be excluded as a mechanism for the lack of gene expression, Insertion of the immunoglobulin kappa-intron and 3' enhancers, however, activated c-myc transcription, when placed adjacent to pr separated from the c-myc promoters by as far as 30 kh, These results indicate that transcription of c-myc in vivo requires additional and still unidentified control elements located outside this 50 kb fragment, and experimentally demonstrate long range enhancer function in vivo.	GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH, INST KLIN MOL BIOL & TUMORGENET, D-81377 MUNICH, GERMANY; GSF FORSCHUNGSZENTRUM UNWELT & GESUNDHEIT GMBH, INST STRAHLENBIOL, D-85764 OBERSCHLEISSHEIM, GERMANY; UNIV MUNICH, ABT PADIATR GENET, D-80336 MUNICH, GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich			Hammerschmidt, Wolfgang/ABG-3921-2021; Brielmeier, Markus/M-7352-2014; Strobl, Lothar J/M-7357-2014	Hammerschmidt, Wolfgang/0000-0002-4659-0427; Brielmeier, Markus/0000-0002-8715-869X; Strobl, Lothar J/0000-0001-8389-1862				BERGMAN Y, 1984, P NATL ACAD SCI-BIOL, V81, P7041, DOI 10.1073/pnas.81.22.7041; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; CANN AJ, 1988, ONCOGENE, V3, P123; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; FEO S, 1994, ONCOGENE, V9, P955; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; HALUSKA FG, 1988, NUCLEIC ACIDS RES, V16, P2077, DOI 10.1093/nar/16.5.2077; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HORTNAGEL K, 1995, ONCOGENE, V10, P1393; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; JOOS S, 1992, CANCER RES, V52, P6547; JUCKER M, 1992, ONCOGENE, V7, P943; KAVATHAS P, 1980, P NATL ACAD SCI-BIOL, V77, P4251, DOI 10.1073/pnas.77.7.4251; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; LAVENU A, 1994, ONCOGENE, V9, P527; LAZO PA, 1990, P NATL ACAD SCI USA, V87, P170, DOI 10.1073/pnas.87.1.170; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MAGRATH I, 1990, ADV CANCER RES, V55, P134; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MAUTNER J, 1995, NUCLEIC ACIDS RES, V23, P72, DOI 10.1093/nar/23.1.72; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; NISHIKURA K, 1986, MOL CELL BIOL, V6, P4093, DOI 10.1128/MCB.6.11.4093; OCONNOR M, 1989, SCIENCE, V244, P1307, DOI 10.1126/science.2660262; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; PULVERTA.RJ, 1965, J CLIN PATHOL, V18, P261, DOI 10.1136/jcp.18.3.261; Sambrook J, 1989, MOL CLONING LABORATO; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STROBL LJ, 1993, ONCOGENE, V8, P1437; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; TRAVERS AA, 1992, CELL, V69, P573, DOI 10.1016/0092-8674(92)90218-2; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; ZEIDLER R, 1994, GENE CHROMOSOME CANC, V9, P282, DOI 10.1002/gcc.2870090408	40	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1299	1307						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649832				2022-12-28	WOS:A1996UC06700015
J	Wu, HK; Heng, HHQ; Siderovski, DP; Dong, WF; Okuno, Y; Shi, XM; Tsui, LC; Minden, MD				Wu, HK; Heng, HHQ; Siderovski, DP; Dong, WF; Okuno, Y; Shi, XM; Tsui, LC; Minden, MD			Identification of a human LIM-Hox gene, hLH-2, aberrantly expressed in chronic myelogenous Leukaemia and located on 9q33-34.1	ONCOGENE			English	Article						fluorescence in situ hybridization; hematological malignancies; hLH-2; Philadelphia chromosome; reverse transcription polymerase chain reaction	T-CELL LEUKEMIA; HOMEOBOX GENE; TRANSGENIC MICE; BCR-ABL; PROTEINS; TRANSLOCATION; INDUCTION; LYMPHOMA; ELEGANS; MEMBER	We describe the isolation of human LH-2, a putative transcription factor containing two cysteine-rich regions (LIM domains) and a homeobox (Hox) DNA-binding domain. High levels of hLH-2 expression were observed in all cases of chronic myelogenous leukaemia (CML) tested, regardless of disease status. hLH-2 was mapped to chromosome 9q33-34.1, in the same region as the reciprocal translocation that creates the BCR-ABL chimera of the Philadelphia chromosome (Ph'), the hallmark of CML; hLH-2 was retained on the derivative 9 chromosome and is therefore centromeric of c-ABL. The proximity of hLH-2 to the breakpoint on chromosome 9 raises the possibility of cis-activation by the t(9;22)(q34;q11) translocation. In addition to finding hLH-2 expression in all cases of CML, expression was observed in lymphoid malignancies and myeloid cell lines, but not in primary cases of acute myelogenous leukaemia. The role of hLH-2 in the development or progression of leukaemia is not known. However, hLH-2 may prove useful as a marker of CML for monitoring residual disease.	UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED,TORONTO,ON M5G 2M9,CANADA; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; HOSP SICK CHILDREN,DEPT GENET,TORONTO,ON M5G 1X8,CANADA; HOSP SICK CHILDREN,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1X8,CANADA; AMGEN INST,QUANTITAT BIOL LAB,TORONTO,ON M5G 2C1,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)			Siderovski, David Peter/AAA-9603-2019	Siderovski, David Peter/0000-0002-0688-8210				BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; BENDAVID L, 1991, VIROLOGY, V182, P382, DOI 10.1016/0042-6822(91)90686-6; BOEHM T, 1990, ONCOGENE, V5, P1103; BRADY G, 1993, METHOD ENZYMOL, V225, P611; CARLESSO N, 1994, ONCOGENE, V9, P149; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DUBOULE D, 1989, EMBO J, V8, P1497, DOI 10.1002/j.1460-2075.1989.tb03534.x; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FISCH P, 1992, ONCOGENE, V7, P2389; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KAWASAKI ES, 1988, P NATL ACAD SCI USA, V85, P5698, DOI 10.1073/pnas.85.15.5698; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; LI H, 1994, EMBO J, V13, P2876, DOI 10.1002/j.1460-2075.1994.tb06582.x; LI PM, 1991, P NATL ACAD SCI USA, V88, P9210, DOI 10.1073/pnas.88.20.9210; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; MAGLI MC, 1991, P NATL ACAD SCI USA, V88, P6348, DOI 10.1073/pnas.88.14.6348; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MAVILIO F, 1986, NATURE, V324, P664, DOI 10.1038/324664a0; MCGUIRE EA, 1992, MOL CELL BIOL, V12, P4186, DOI 10.1128/MCB.12.9.4186; MINDEN MD, 1979, BLOOD, V54, P186; PERKINS A, 1990, P NATL ACAD SCI USA, V87, P8393; RASSOOL F, 1990, LEUKEMIA, V4, P273; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sambrook J., 2002, MOL CLONING LAB MANU; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIMEONE A, 1987, P NATL ACAD SCI USA, V84, P4914, DOI 10.1073/pnas.84.14.4914; TAKESHITA K, 1993, P NATL ACAD SCI USA, V90, P3535, DOI 10.1073/pnas.90.8.3535; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WU HK, 1995, LEUKEMIA, V9, P1291; XU WM, 1994, BONE MARROW TRANSPL, V14, P299; XU Y, 1993, P NATL ACAD SCI USA, V90, P227, DOI 10.1073/pnas.90.1.227	39	42	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1205	1212						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649822				2022-12-28	WOS:A1996UC06700005
J	Gambarotta, G; Boccaccio, C; Giordano, S; Ando, M; Stella, MC; Comoglio, PM				Gambarotta, G; Boccaccio, C; Giordano, S; Ando, M; Stella, MC; Comoglio, PM			Ets up-regulates MET transcription	ONCOGENE			English	Article						proto-oncogenes; ETS; transcription factors; HGF receptor	HEPATOCYTE GROWTH-FACTOR; DNA-BINDING MOTIF; SCATTER FACTOR; RECEPTOR EXPRESSION; MET/HGF RECEPTOR; EPITHELIAL-CELLS; PROTEIN; OVEREXPRESSION; GENE; PROTOONCOGENE	MET, a potentially harmful oncogene controlling invasive growth, is overexpressed in a significant percentage of human cancers, Since amplification of the MET gene occurs only in a fraction of these cases, we investigated the transcriptional mechanisms responsible for up-regulation of the promoter activity, The transcription driven by the 3.1 kbp DNA fragment containing the minimal promoter was studied by 5' progressive deletion analysis, The patterns of MET promoter activity suggest the presence of weak negative and positive elements in the region between 300 and 840 bp upstream to the transcription start site, The region encompassing the first 300 bp strongly upregulates the promoter, This region contains four putative binding sites for members of the Ets transcription factor family, known to be involved in invasive growth, Transient co-expression of Ets1 resulted in a strong enhancement of the MET promoter activity, Increased expression of the Met protein was observed in cells stably transfected with ETS1, Double stranded oligonucleotides with Ets consensus sequence were used as a 'decoy' to inhibit binding to DNA native sites, They dramatically reduced the amount of Met protein in a human carcinoma cell line overexpressing the oncogene, Interestingly, Met activation induces transcription of ETS1 mRNA, showing that Ets proteins act both upstream and downstream to MET, These data indicate that members of the Ets family promote MET transcription and suggest their contribution to the invasive phenotype through overexpression of MET.	UNIV TURIN,SCH MED,INST CANC RES,IRCC,I-10060 CANDIOLO,TORINO,ITALY	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin			Boccaccio, Carla/AHE-7875-2022; Giordano, Silvia/J-9858-2018; Gambarotta, Giovanna/I-8473-2012	Boccaccio, Carla/0000-0003-2620-9083; Giordano, Silvia/0000-0003-1854-1086; Gambarotta, Giovanna/0000-0002-8380-5925; Comoglio, Paolo/0000-0002-7056-5328				BIELINSKA A, 1990, SCIENCE, V250, P997, DOI 10.1126/science.2237444; BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DIRENZO MF, 1992, ONCOGENE, V7, P2549; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERRACINI R, 1995, ONCOGENE, V10, P739; Ferracini R, 1996, ONCOGENE, V12, P1697; FOLKMAN J, 1992, ADV EXP MED BIOL, V313, P355; GALANG CK, 1994, ONCOGENE, V9, P2913; GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, ONCOGENE, V4, P1383; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; Jeffers M, 1996, MOL CELL BIOL, V16, P115; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kaya M, 1996, ONCOGENE, V12, P221; KRAMER B, 1995, J BIOL CHEM, V270, P65787; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIU C, 1992, ONCOGENE, V7, P181; Mao C, 1996, ONCOGENE, V12, P863; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NERLOV C, 1991, ONCOGENE, V6, P1583; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; PANKOV R, 1994, P NATL ACAD SCI USA, V91, P873, DOI 10.1073/pnas.91.3.873; PEPPER MS, 1992, J BIOL CHEM, V267, P20493; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAPTIS L, 1990, DNA CELL BIOL, V9, P615, DOI 10.1089/dna.1990.9.615; RAPTIS LH, 1995, BIOTECHNOLOGY, V4, P129; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; SACCHI N, 1991, ONCOGENE, V6, P2149; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WASYLYK B, 1993, EUR J BIOCHEM, V211, P8; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WASYLYK C, 1994, ONCOGENE, V9, P3665; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; ZHEN Z, 1994, ONCOGENE, V9, P1691	64	119	127	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1911	1917						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934537				2022-12-28	WOS:A1996VR79500010
J	Muller, S; Sideras, P; Smith, CE; Xanthopoulos, KG				Muller, S; Sideras, P; Smith, CE; Xanthopoulos, KG			Cell specific expression of human Bruton's agammaglobulinemia tyrosine kinase gene (Btk) is regulated by Sp1- and Spi-1/PU.1-family members	ONCOGENE			English	Article						Bruton's tyrosine kinase; transcription factors; cell restricted expression	X-LINKED AGAMMAGLOBULINEMIA; BOX-BINDING-PROTEINS; GENOMIC ORGANIZATION; TRANSCRIPTIONAL ACTIVATION; FAMILY; SITE; MUTATIONS; EVOLUTION; ONCOGENE; LINEAGE	Bruton's agammaglobulinemia tyrosine kinase (Btk) is a cytoplasmic tyrosine kinase involved in the human disease X-linked agammaglobulinemia (XLA), The gene is expressed in all hematopoietic cells with the exception of T-cells and plasma cells, For this expression pattern the first 280 bp upstream of the major transcriptional start site seems to be sufficient, In vitro footprinting analysis within this part of the promoter revealed two Spl binding sites as web as a PU-box, The transcription factor Spi-1/PU.1 as well as the closely related factor Spi-B bound to the PU-box in B-cells, In the erythroleukemia cell line K562, due to the absence of Spi-B, only PU.1 bound to the Btk promoter, Mutation of either site reduced the expression in transient transfection experiments, However, mutation of the PU box had no effect in the T-cell line Jurkat, where none of the Spi-1 family members is expressed, In addition Spi-B as well as PU.1 were able to transactivate Btk expression, Tn fetal liver of PU.1(-)/(-) mice, which lack lymphoid and myeloid cells, expression of Btk was reduced two- to threefold but not abolished, Collectively this study shows that expression of the Btk gene is regulated by the combined action of Sp1- and PU.1-family members.	KAROLINSKA INST, NOVUM, DEPT BIOSCI, CTR BIOTECHNOL, S-14157 HUDDINGE, SWEDEN; UMEA UNIV, DEPT MOL & CELL BIOL, S-90187 UMEA, SWEDEN; HUDDINGE UNIV HOSP, DEPT IMMUNOL MICROBIOL PATHOL & INFECT DIS, DIV CLIN IMMUNOL, S-14186 HUDDINGE, SWEDEN	Karolinska Institutet; Umea University; Karolinska Institutet				SMITH, C. I. Edvard/0000-0003-1907-3392				BRUTON OC, 1952, PEDIATRICS, V9, P722; CHEN HM, 1995, ONCOGENE, V11, P1549; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FLODBY P, 1993, EXP CELL RES, V208, P248, DOI 10.1006/excr.1993.1244; GACHELIN FM, 1993, BIOCHIM BIOPHYS ACTA, V1198, P149; GENEVIER HC, 1994, EUR J IMMUNOL, V24, P3100, DOI 10.1002/eji.1830241228; HAGEMANN TL, 1994, HUM MOL GENET, V3, P1743, DOI 10.1093/hmg/3.10.1743; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Himmelmann A, 1996, BLOOD, V87, P1036, DOI 10.1182/blood.V87.3.1036.bloodjournal8731036; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HROMAS R, 1993, BLOOD, V82, P2998; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KUDO S, 1994, EUR J BIOCHEM, V223, P319, DOI 10.1111/j.1432-1033.1994.tb18997.x; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LAUX G, 1995, EMBO J, V13, P6524; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LETOVSKY J, 1989, NUCLEIC ACIDS RES, V17, P2639, DOI 10.1093/nar/17.7.2639; Maniatis T, 1989, MOL CLONING; Mao C, 1996, ONCOGENE, V12, P863; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NILSSON L, 1995, INT IMMUNOL, V7, P1191, DOI 10.1093/intimm/7.8.1191; NILSSON L, 1993, INT IMMUNOL, V5, P271; OHTA Y, 1994, P NATL ACAD SCI USA, V91, P9062, DOI 10.1073/pnas.91.19.9062; Olson MC, 1995, IMMUNITY, V3, P703, DOI 10.1016/1074-7613(95)90060-8; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROHRER J, 1994, IMMUNOGENETICS, V40, P319, DOI 10.1007/BF01246672; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SIDERAS P, 1992, J IMMUNOL, V149, P244; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; SIDERAS P, 1994, J IMMUNOL, V153, P5607; SMITH CIE, 1994, J IMMUNOL, V152, P557; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Vihinen M, 1996, NUCLEIC ACIDS RES, V24, P160, DOI 10.1093/nar/24.1.160	41	56	56	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1955	1964						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934542				2022-12-28	WOS:A1996VR79500015
J	Albor, A; Thraves, PJ; Dritschilo, A; Notario, V				Albor, A; Thraves, PJ; Dritschilo, A; Notario, V			Oncogenic activation of the tyrosine kinase domain of the human trk protooncogene by fusion to a cell adhesion molecule	ONCOGENE			English	Article						radiation transformation; human keratinocytes; beta-1,4-galactosyltransferase; tumorigenicity assays; cosmid cloning	HUMAN EPIDERMAL-KERATINOCYTES; PAPILLARY THYROID CARCINOMAS; HAMSTER-EMBRYO FIBROBLASTS; NEOPLASTIC TRANSFORMATION; DNA REARRANGEMENT; POINT MUTATION; PROTO-ONCOGENE; GROWTH-FACTOR; GENE; GALACTOSYLTRANSFERASE	To investigate the mechanisms of radiation-induced neoplastic conversion, DNA from X-ray transformed human epidermal keratinocytes (RHEK-1) was used in sequential cycles of NM3T3 transfection followed by nude mice tumorigenicity assays. NM3T3-derived transformants retained discrete DNA fragments hybridizing to human alu probes. Pour clones were isolated from a cosmid library prepared from one of these transformants (49-7G) using human DNA as the probe. Analyses of DNAs from 49-7G cells and the four cosmid clones with probes for a number of human oncogenes demonstrated that the cloned sequences were related to the trk oncogene. Transfection of NM3T3 cells with the cosmid DNAs did not result in the appearance of transformed foci when the murine fibroblasts were cultured on plastic. However, foci developed when transfected cells were cultured on plates coated with various extracellular matrix (ECM) components. Neomycin-resistant cosmid-transfected NIH3T3 cells did induce tumors in nude mice, and their tumorigenicity correlated with their level of trk expression. Nucleotide sequence analyses of cDNA clones isolated from a 49-7G library with a human trk probe revealed that the cloned sequences resulted from the fusion between 5' sequences from the human beta-1,4-galactosyltransferase gene, which encodes a membrane protein involved in cell-cell and cell-matrix interactions, and 3' sequences from the human trk proto-oncogene. The 76 kDa protein product of the chimeric gene, designated bgt-trk, has been identified in NM3T3 cells transfected with cosmid 19/2 or with bgt-trk cDNA expression constructs, and its phosphorylation in tyrosine has been found to increase when the transfected cells were seeded on plates coated with ECM components which also elicited foci formation in NIH3T3 transformation assays. The fusion of the trk tyrosine kinase domain to a cell adhesion molecule may explain tbe ECM dependence for the expression of the full transforming potential of the resulting oncogene product.	GEORGETOWN UNIV,MED CTR,DEPT RADIAT MED,WASHINGTON,DC 20007	Georgetown University			/AAB-6461-2022; /AFP-0764-2022		NATIONAL CANCER INSTITUTE [R01CA052954] Funding Source: NIH RePORTER; NCI NIH HHS [CA52954] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBOR A, 1994, CANCER RES, V54, P4502; ALBOR A, 1994, MOL CARCINOG, V11, P1339; AVILA MA, 1995, ONCOGENE, V10, P963; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARCELLOSHOFF MH, 1992, EXP CELL RES, V201, P225, DOI 10.1016/0014-4827(92)90367-H; BARKER PA, 1993, J BIOL CHEM, V268, P15150; BAYNA EM, 1988, CELL, V53, P145, DOI 10.1016/0092-8674(88)90496-5; BLAIR DG, 1982, SCIENCE, V218, P1122, DOI 10.1126/science.6293052; BUTTI MG, 1995, GENOMICS, V28, P15, DOI 10.1006/geno.1995.1100; CALZONE FJ, 1987, METHOD ENZYMOL, V152, P611; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER GM, 1982, SCIENCE, V218, P801; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; DUNCAN AMV, 1986, BIOCHEM BIOPH RES CO, V141, P1185, DOI 10.1016/S0006-291X(86)80169-3; ECKSTEIN DJ, 1992, EXP CELL RES, V201, P83, DOI 10.1016/0014-4827(92)90350-H; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GONG XH, 1995, SCIENCE, V269, P1718, DOI 10.1126/science.7569899; GRECO A, 1995, MOL CELL BIOL, V15, P6118; GRECO A, 1992, ONCOGENE, V7, P237; GRECO A, 1993, GENOMICS, V18, P397, DOI 10.1006/geno.1993.1482; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; ISHIKAWA F, 1986, P NATL ACAD SCI USA, V83, P3209, DOI 10.1073/pnas.83.10.3209; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KOZMA SC, 1988, EMBO J, V7, P147, DOI 10.1002/j.1460-2075.1988.tb02794.x; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; MECHAM RP, 1991, FASEB J, V5, P2538, DOI 10.1096/fasebj.5.11.1651264; MENGLEGAW L, 1991, BIOCHEM BIOPH RES CO, V176, P1269, DOI 10.1016/0006-291X(91)90423-5; MILLER DJ, 1992, NATURE, V357, P589, DOI 10.1038/357589a0; NOTARIO V, 1990, ONCOGENE, V5, P1425; OHUCHI T, 1992, ONCOGENE, V7, P331; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAPER NL, 1986, SOMAT CELL MOLEC GEN, V12, P633, DOI 10.1007/BF01671948; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; THRAVES P, 1990, P NATL ACAD SCI USA, V87, P1174, DOI 10.1073/pnas.87.3.1174; THRAVES P, 1991, MECH CARCINOGENESIS, P93; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3683, DOI 10.1073/pnas.76.8.3683; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; ZIEMIECKI A, 1990, EMBO J, V9, P191, DOI 10.1002/j.1460-2075.1990.tb08095.x	46	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1755	1763						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895522				2022-12-28	WOS:A1996VM88700021
J	Kudoh, T; Ishidate, T; Nakamura, T; Toyoshima, K; Akiyama, T				Kudoh, T; Ishidate, T; Nakamura, T; Toyoshima, K; Akiyama, T			Constitutive expression of the Wilms tumor suppressor gene WT1 in F9 embryonal carcinoma cells induces apoptotic cell death in response to retinoic acid	ONCOGENE			English	Article						WT1; Wilms tumor; tumor suppressor gene; apoptosis; F9	TERATOCARCINOMA STEM-CELLS; PROMOTER ACTIVITY; BAX GENE; C-MYC; DIFFERENTIATION; P53; PRODUCT; INDUCTION; PROTEIN; LOCUS	The product of the Wilms tumor suppressor gene, WT1, is thought to be a tissue specific transcription factor regulating cell growth and differentiation. To elucidate the function of WT1 in cellular differentiation, we examined the changes in the level of WT1 expression during retinoic acid induced-differentiation of embryonal carcinoma F9 cells into parietal endoderm cells. We found that, in response to retinoic acid addition, the expression of WT1 increased significantly after 12-24 h of incubation, then decreased and finally disappeared after 4 days, by which time most of the cells had differentiated into primitive endoderm cells. To examine the significance of these changes in WT1 expression, we established cell lines constitutively expressing one of the WT1 splicing variants. These cell lines showed a phenotype very similar to parental F9 cells in the absence of retinoic acid. However, in the presence of retinoic acid, they failed to differentiate into primitive endoderm cells and underwent apoptotic death 36 h after the addition of retinoic acid. These results suggest that downregulation of WT1 expression is necessary for normal differentiation of F9 cells into parietal endoderm cells.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT ONCOGENE RES,OSAKA 565,JAPAN; OSAKA MED CTR CANC & CARDIOVASC DIS,OSAKA 537,JAPAN	Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases								BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HOGAN BLM, 1981, NATURE, V291, P235, DOI 10.1038/291235a0; INOUE K, 1994, BLOOD, V84, P3071, DOI 10.1182/blood.V84.9.3071.3071; KLINKEN SP, 1988, EXP CELL RES, V178, P185, DOI 10.1016/0014-4827(88)90390-4; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KUDOH T, 1995, P NATL ACAD SCI USA, V92, P4517, DOI 10.1073/pnas.92.10.4517; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MIWA H, 1992, LEUKEMIA, V6, P405; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORRIS JF, 1991, ONCOGENE, V6, P2339; OSHIMA RG, 1981, J BIOL CHEM, V256, P8124; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PHELAN SA, 1994, CELL GROWTH DIFFER, V5, P677; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUCHER FJ, 1990, SCIENCE, V250, P1259; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SEKIYA M, 1994, BLOOD, V83, P1876; SELLINS KS, 1987, J IMMUNOL, V139, P3199; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; STRICKLAND S, 1980, CELL, V21, P347, DOI 10.1016/0092-8674(80)90471-7; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	45	23	29	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1431	1439						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875981				2022-12-28	WOS:A1996VL38400008
J	GonzalezAgosti, C; Xu, L; Pinney, D; Beauchamp, R; Hobbs, W; Gusella, J; Ramesh, V				GonzalezAgosti, C; Xu, L; Pinney, D; Beauchamp, R; Hobbs, W; Gusella, J; Ramesh, V			The merlin tumor suppressor localizes preferentially in membrane ruffles	ONCOGENE			English	Article						merlin; neurofibromatosis 2; meningioma; vestibular schwannoma; ERM; motility	NEUROFIBROMATOSIS TYPE-2 GENE; ERM FAMILY MEMBERS; PLASMA-MEMBRANE; NF2 GENE; SCHWANN-CELLS; MUSCLE-CELLS; EZRIN; MOESIN; ACTIN; PROTEIN	Merlin is a tumor suppressor whose inactivation underlies the familial schwannomas and meningiomas of neurofibromatosis 2 and their sporadic counterparts. It bears striking similarity to the ERM proteins, ezrin, radixin and moesin, members of the protein 4.1 superfamily that link proteins in the cytoskeleton and the plasma membrane, We have generated polyclonal and monoclonal antibodies that detect merlin as an similar to 66 kD protein in many different cell types, Using indirect immunofluorescence we have for the first time visualized endogenous merlin and localized it to the motile regions, such as leading or ruffling edges, in human fibroblast and meningioma cells. Merlin co-localizes with F-actin in these motile regions but is not associated with stress fibers. Merlin does not localize to the same structures as either ezrin or meosin in human meningioma cells, suggesting a function distinct from these ERMs. Thus, merlin is associated with motile regions of the cell and its participation in these structures may be intimately involved in control of proliferation in Schwann cells and meningeal cells.	MASSACHUSETTS GEN HOSP EAST,MOL NEUROGENET UNIT,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital					NINDS NIH HHS [NS24279] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS024279] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDREOLI C, 1994, J CELL SCI, V107, P2509; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BIRGBAUER E, 1991, THESIS MIT; BIRGBAUER E, 1991, THESIS MIT CAMBRIDGE; BRETSCHER A, 1983, J CELL BIOL, V97, P425, DOI 10.1083/jcb.97.2.425; BROCKES JP, 1979, BRAIN RES, V165, P105, DOI 10.1016/0006-8993(79)90048-9; DENBAKKER MA, 1995, ONCOGENE, V10, P757; FRANCK Z, 1993, J CELL SCI, V105, P219; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; GODA S, 1991, J NEUROCHEM, V56, P1354, DOI 10.1111/j.1471-4159.1991.tb11432.x; GonzalezAgosti C, 1996, CELL MOTIL CYTOSKEL, V34, P122, DOI 10.1002/(SICI)1097-0169(1996)34:2<122::AID-CM4>3.0.CO;2-D; GOSLIN K, 1989, J CELL BIOL, V109, P1621, DOI 10.1083/jcb.109.4.1621; Gusella JF, 1996, CURR OPIN GENET DEV, V6, P87, DOI 10.1016/S0959-437X(96)90016-7; HARLOW E, 1988, ANTIBODIES; HENRY MD, 1995, J CELL BIOL, V129, P1007, DOI 10.1083/jcb.129.4.1007; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGAN JA, 1990, CANCER GENET CYTOGEN, V45, P41, DOI 10.1016/0165-4608(90)90064-H; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; LUTCHMAN M, 1995, CANCER RES, V55, P2270; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PESTONJAMASP K, 1995, MOL BIOL CELL, V6, P247, DOI 10.1091/mbc.6.3.247; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1994, BIOESSAYS, V16, P321, DOI 10.1002/bies.950160506; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; SATO N, 1991, J CELL BIOL, V113, P321, DOI 10.1083/jcb.113.2.321; SATO N, 1992, J CELL SCI, V103, P131; SEKIDO Y, 1995, CANCER RES, V55, P1227; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPERTINI F, 1992, J IMMUNOL, V149, P65; TAKAISHI K, 1995, ONCOGENE, V11, P39; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TIKOO A, 1994, J BIOL CHEM, V269, P23387; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; WELLENREUTHER R, 1995, AM J PATHOL, V146, P827; WINCKLER B, 1994, J CELL SCI, V107, P2523	45	110	112	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1239	1247						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808698				2022-12-28	WOS:A1996VJ20200015
J	Nakamura, T; Sanokawa, R; Sasaki, Y; Ayusawa, D; Oishi, M; Mori, N				Nakamura, T; Sanokawa, R; Sasaki, Y; Ayusawa, D; Oishi, M; Mori, N			N-Shc: A neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway	ONCOGENE			English	Article						Shc family; signal transduction; phosphotyrosine; BDNF; TrkB; EGF receptor	GUANINE-NUCLEOTIDE EXCHANGE; PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; CENTRAL-NERVOUS-SYSTEM; MAP KINASE; MESSENGER-RNAS; BINDING-SITES; CONSTITUTIVE PHOSPHORYLATION; PC12 CELLS; RAS	Shc has been implicated in a variety of growth factor- and cytokine receptor-signaling through its specific binding to phosphotyrosine residues of the activated receptors. In neuronal cells, such as PC12, She has been shown to be involved in Ras-dependent MAP kinase activation following Trk receptor stimulation with NGF. While the ubiquitous role of She as an adaptor molecule in signal transduction is increasing in both neuronal and non-neuronal cells and tissues, the expression level of Shc is suprisingly low in the brain. We demonstrated here the isolation of a neural-specific member of the She family. This novel protein, named N-Shc (neuronal Shc), contains tao potential phosphotyrosine-binding domains, PTB and SH2, and is expressed exclusively in the brain; whereas Shc is present in all other non-neuronal tissues. As in Shc, N-Shc can bind activated EGF receptor, become tyrosine phosphorylated, and form a complex with Grb2 adapter protein following EGF stimulation. Furthermore, N-Shc can bind activated TrkB receptor following the stimulation with brain-derived neurotrophic factor (BDNF), which is the most abundant neurotrophin in the brain. These data suggest that N-Shc, rather than She, mediates neurotrophin and other neuronal signalings in the central nervous system.	UNIV TOKYO,INST MOL CELLULAR & BIOSCI,BUNKYO KU,TOKYO 113,JAPAN; YOKOHAMA CITY UNIV,KIHARA INST BIOL RES,TOTSUKA KU,YOKOHAMA,KANAGAWA 244,JAPAN; RES DEV CORP JAPAN,PRESTO,INHERITANCE & VARIAT GRP,KYOTO 61902,JAPAN	University of Tokyo; Yokohama City University; Japan Science & Technology Agency (JST)	Nakamura, T (corresponding author), SUMITOMO ELECT IND,BIOMED RES & DEV DEPT,SAKAE KU,YOKOHAMA,KANAGAWA 244,JAPAN.		Sasaki, Yasnory/L-7065-2018	Sasaki, Yasnory/0000-0003-2614-7038				ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BURNS LA, 1993, J BIOL CHEM, V268, P17659; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GIOGETTI S, 1994, EUR J BIOCHEM, V223, P195; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HASHIMOTO Y, 1994, ONCOGENE, V9, P869; HEFTI F, 1992, NEUROTROPHIC FACTORS, P25; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HIMI T, 1994, NEUROSCIENCE, V60, P907, DOI 10.1016/0306-4522(94)90271-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015; MERLIO JP, 1992, NEUROSCIENCE, V51, P513, DOI 10.1016/0306-4522(92)90292-A; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; OBERMEIER A, 1993, J BIOL CHEM, V268, P22963; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1994, J BIOL CHEM, V269, P1599; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sasaki Y F, 1994, DNA Res, V1, P91, DOI 10.1093/dnares/1.2.91; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SAXTON TM, 1994, J IMMUNOL, V153, P623; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; SUZUKI K, 1995, FEBS LETT, V364, P283, DOI 10.1016/0014-5793(95)00393-N; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANDERGEER P, 1995, TRENDS BIOCHEM SCI, V20, P277, DOI 10.1016/S0968-0004(00)89043-X; WINITZ S, 1993, J BIOL CHEM, V268, P19196; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	64	109	116	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1111	1121						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808684				2022-12-28	WOS:A1996VJ20200001
J	Hansen, RS; Braithwaite, AW				Hansen, RS; Braithwaite, AW			The growth-inhibitory function of p53 is separable from transactivation, apoptosis and suppression of transformation by E1a and Ras	ONCOGENE			English	Review						p53 cell growth; apoptosis; transformation; transcriptional regulation	WILD-TYPE P53; PROGRAMMED CELL-DEATH; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; TEMPERATURE-SENSITIVE MUTANT; RETINOBLASTOMA GENE-PRODUCT; BREAST-CANCER CELLS; S-PHASE ENTRY; P53-DEPENDENT APOPTOSIS; TUMOR-SUPPRESSOR; ADENOVIRUS E1A	p53 is known to suppress oncogenic cell transformation, inhibit cell growth, induce apoptosis and activate and repress gene transcription, To investigate the relationships between these functions, we have examined various mutant forms of p53 for their abilities to perform each activity, This study has shown that growth inhibition is not a prerequisite for apoptotic cell death as these two functions are separate and alternative activities of p53, Additionally, we have demonstrated that the ability of p53 to suppress transformation (by adenovirus E1a and activated Ras) correlates with its ability to induce apoptosis and not with its ability to inhibit cell growth, Although p53 is thought to inhibit growth through the transactivation of p21(WAF1), Our study has demonstrated that transcriptional activation and repression are neither sufficient nor necessary for growth inhibition, This indicates that p53 has more than ne mechanism for inhibiting cell growth and that anorther type of biochemical function must be involved, Furthermore, we have shown that transcriptional activation and repression may each be necessary, and the combination of these activities may even be sufficient, for p53-dependent apoptosis, In summary, our results have provided new information about the cellular and biochemical mechanisms through which p53 acts as a tumour suppressor.			Hansen, RS (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL & IMMUNOL,CANBERRA,ACT 0200,AUSTRALIA.							AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CASEY G, 1991, ONCOGENE, V6, P1791; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EGAN C, 1989, ONCOGENE, V4, P383; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HALDAR S, 1994, CANCER RES, V54, P2095; Hansen R, 1995, ONCOGENE, V11, P2535; HANSEN RS, 1995, THESIS ANU; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIRANO Y, 1995, ONCOGENE, V10, P1879; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JACKSON P, 1993, ONCOGENE, V8, P589; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KATO J, 1993, GENE DEV, V7, P331; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVY N, 1993, MOL CELL BIOL, V13, P7942, DOI 10.1128/MCB.13.12.7942; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; NEVINS JR, 1992, SCIENCE, V258, P424; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; OROURKE RW, 1990, ONCOGENE, V5, P1829; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PERREM K, 1995, ONCOGENE, V11, P1299; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SANG BC, 1994, ONCOGENE, V9, P853; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEWART N, 1995, ONCOGENE, V10, P109; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZHANG W, 1994, CELL GROWTH DIFFER, V5, P705	112	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					995	1007						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806689				2022-12-28	WOS:A1996VG76600013
J	Pauletti, G; Godolphin, W; Press, MF; Slamon, DJ				Pauletti, G; Godolphin, W; Press, MF; Slamon, DJ			Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization	ONCOGENE			English	Article						HER-2/neu; c-erbB-2; gene amplification; breast cancer; FISH; interphase cytogenetics	INSITU HYBRIDIZATION; C-ERBB-2 AMPLIFICATION; ONCOGENE AMPLIFICATION; PROTO-ONCOGENE; CIRCULAR DNA; CELLS; EXPRESSION; FIXATION; FORMALIN; DISEASE	Amplification and overexpression of the HER-2/neu gene occurs in 25-30% of human breast cancers, This genetic alteration is associated with a poor clinical prognosis in women with either node negative or node positive breast cancers, The initial studies testing this association were somewhat controversial and this controversy was due in large part to significant heterogeneity in both the methods and/or reagents used in testing archival material for the presence of the alteration, These methods included a number of solid matrix blotting techniques for DNA, RNA and protein as well as immunohistochemistry, Fluorescence in situ hybridization (FISH) represents the newest methodologic approach for testing for this genetic alteration, In this study, FISH is compared to Southern, Northern and Western blot analyses as well as immunohistochemistry in a large cohort of archival human breast cancer specimens, FISH was found to be superior to all other methodologies tested in assessing formalin fixed, paraffin embedded material for HER-2/neu amplification, The results from this study also confirm that overexpression of HER-2/neu rarely occurs in the absence of gene amplification in breast cancer (approximately 3% of cases), This method of analysis is rapid, reproducible and extremely reliable in detecting presence of HER-2/neu gene amplification and should have clinical utility.	UNIV CALIF LOS ANGELES,DEPT MED,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; DEPT CLIN CHEM,VANCOUVER,BC V5Z 1M9,CANADA; UNIV SO CALIF,SCH MED,DEPT PATHOL,LOS ANGELES,CA 90033	University of California System; University of California Los Angeles; University of Southern California			Godolphin, William/AAE-2699-2022		NCI NIH HHS [CA36827, CA48780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA048780, R01CA036827] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1988, ONCOGENE RES, V3, P139; BATTIFORA H, 1986, J HISTOCHEM CYTOCHEM, V34, P1095, DOI 10.1177/34.8.2426335; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; CARROLL SM, 1987, MOL CELL BIOL, V7, P1740, DOI 10.1128/MCB.7.5.1740; CLARK GM, 1991, CANCER RES, V51, P944; COWELL JK, 1982, ANNU REV GENET, V16, P21, DOI 10.1146/annurev.ge.16.120182.000321; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DHINGRA K, 1992, BREAST CANCER RES TR, V23, P201, DOI 10.1007/BF01833516; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; GULLICK WJ, 1991, BRIT J CANCER, V63, P434, DOI 10.1038/bjc.1991.100; GUSTERSON BA, 1988, BRIT J CANCER, V58, P453, DOI 10.1038/bjc.1988.239; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; HYYTINEN E, 1994, CYTOMETRY, V16, P93, DOI 10.1002/cyto.990160202; KALLIONIEMI OP, 1992, P NATL ACAD SCI USA, V89, P5321, DOI 10.1073/pnas.89.12.5321; KURY F, 1990, EUR J CANCER, V26, P946, DOI 10.1016/0277-5379(90)90616-2; LIU E, 1992, ONCOGENE, V7, P1027; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATSUMURA K, 1992, CANCER RES, V52, P3474; MAURER BJ, 1987, NATURE, V327, P434, DOI 10.1038/327434a0; MICALE MA, 1994, HUM PATHOL, V25, P29, DOI 10.1016/0046-8177(94)90167-8; MULERIS M, 1995, GENE CHROMOSOME CANC, V14, P155, DOI 10.1002/gcc.2870140302; MURPHY DS, 1995, J NATL CANCER I, V87, P1694, DOI 10.1093/jnci/87.22.1694; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NABER SP, 1990, AM J CLIN PATHOL, V94, P125, DOI 10.1093/ajcp/94.2.125; NUOVO GJ, 1989, AM J PATHOL, V134, P837; PAULETTI G, 1990, P NATL ACAD SCI USA, V87, P2955, DOI 10.1073/pnas.87.8.2955; PENAULTLLORCA F, 1994, J PATHOL, V173, P65, DOI 10.1002/path.1711730111; PERSONS DL, 1993, AM J PATHOL, V142, P733; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PODDIGHE PJ, 1992, J PATHOL, V166, P215, DOI 10.1002/path.1711660303; POPESCU NC, 1989, GENOMICS, V4, P362, DOI 10.1016/0888-7543(89)90343-1; PRESS MF, 1993, CANCER RES, V53, P4960; PRESS MF, 1994, CANCER RES, V54, P2771; RENTROP M, 1986, HISTOCHEM J, V18, P271, DOI 10.1007/BF01676237; RICHNER J, 1990, ANN ONCOL, V1, P263, DOI 10.1093/oxfordjournals.annonc.a057745; SAUTER G, 1993, CANCER RES, V53, P2199; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; SHAPIRO DN, 1993, AM J PATHOL, V142, P1339; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SLAMON DJ, 1989, CANCER CEL, V7, P371; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1988, SCIENCE, V240, P1796, DOI 10.1126/science.240.4860.1796; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THOMPSON CT, 1994, AM J PATHOL, V144, P237; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VISSCHER DW, 1995, CYTOMETRY, V21, P95, DOI 10.1002/cyto.990210117; VONHOFF DD, 1988, P NATL ACAD SCI USA, V85, P4804; WAHL GM, 1989, CANCER RES, V49, P1333; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156; WOLMAN SR, 1983, CANCER METAST REV, V2, P257, DOI 10.1007/BF00048481; ZHOU DJ, 1989, ONCOGENE, V4, P105	54	486	497	0	23	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					63	72						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700555				2022-12-28	WOS:A1996UX31900008
J	Altucci, L; Addeo, R; Cicatiello, L; Dauvois, S; Parker, MG; Truss, M; Beato, M; Sica, V; Bresciani, F; Weisz, A				Altucci, L; Addeo, R; Cicatiello, L; Dauvois, S; Parker, MG; Truss, M; Beato, M; Sica, V; Bresciani, F; Weisz, A			17 beta-Estradiol induces cyclin D-1 gene transcription, p36(D1)-p34(cdk4) complex activation and p105(Rb) phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer	ONCOGENE			English	Article						estrogen; breast cancer; cell cycle; cyclins; HMG-CoA reductase; retinoblastoma protein	MYC ONCOGENE EXPRESSION; CELL-CYCLE; RETINOBLASTOMA PROTEIN; NUCLEAR-PROTEIN; GROWTH-FACTOR; OVEREXPRESSION; PROGRESSION; FIBROBLASTS; INHIBITION; LOVASTATIN	MCF-7 human breast cancer cells express functional estrogen receptor and grow in response to estrogen stimulation. G(1)-synchronized MCF-7 cells, made quiescent by exposure to the HMG-CoA reductase inhibitor Simvastatin in estrogen-free medium, readily resume cell cycle progression up-on stimulation with 17 beta-estradiol (E(2)), even under conditions where polypeptide growth factor-triggered signal transduction pathways are inhibited by the continuous presence of Simvastatin in the culture medium. Under these conditions, cyclin D-1 gene transcription is transiently induced within the first 1-9 h of stimulation, as shown by the accumulation of cyclin D-1 mRNA and protein (p36(D1)) in the cell and by enhanced expression of stably transfected D-1 promoter-luciferase hybrid genes. Estrogen-induced p36(D1) associates readily with p32(cdk2) and p34(cdk4), but not with p31(cdk5) which is however abundantly expressed in these cells. Only p36(D1)-p34(cdk4) complexes are activated by E(2), as detected in cell extracts by immunoprecipitation with anti-D-1 antibodies followed by assessment of phosphotransferase activity toward the retinoblastoma (Rb) gene product and by analysis of p105(Rb) phosphorylation in vivo, An estrogen-responsive regulatory region has been mapped within the first 944 bp upstream of the transcriptional startsite of the human D-1 gene. Sequence analysis of this DNA region reveals that the cis-acting elements responsive to estrogen are likely to be different in this case from the canonical EREs.	UNIV NAPLES 2, FAC MED & CHIRURG, IST PATOL GEN & ONCOL, I-80138 NAPLES, ITALY; IMPERIAL CANC RES FUND, MOLEC ENDOCRINOL LAB, LONDON WC2A 3PX, ENGLAND; UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, D-35037 MARBURG, GERMANY	Universita della Campania Vanvitelli; Cancer Research UK; Philipps University Marburg			Altucci, Lucia/S-8031-2019; Weisz, Alessandro/A-1317-2014; Beato, Miguel/B-5564-2015	Weisz, Alessandro/0000-0003-0455-2083; Beato, Miguel/0000-0002-2878-2222; altucci, lucia/0000-0002-7312-5387				ADDEO R, 1996, IN PRESS BIOCH BIOPH; AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BATES S, 1994, ONCOGENE, V9, P71; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; Bonapace IM, 1996, ONCOGENE, V12, P753; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; DAKSIS JI, 1994, ONCOGENE, V9, P3635; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DOYLE A, 1994, CELL TISSUE CULTURE; DUBIK D, 1987, CANCER RES, V47, P6517; DUBIK D, 1992, ONCOGENE, V7, P1587; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FILMUS J, 1994, ONCOGENE, V9, P3627; GRANA X, 1995, ONCOGENE, V11, P211; HALL FL, 1993, ONCOGENE, V8, P1377; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harlow E., 1988, ANTIBODIES LAB MANUA; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HERBER B, 1994, ONCOGENE, V9, P1295; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JAKOBISIAK M, 1991, P NATL ACAD SCI USA, V88, P3628, DOI 10.1073/pnas.88.9.3628; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; JIANG W, 1993, ONCOGENE, V8, P3447; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1991, CANCER RES, V51, P3602; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; LANDERS J P, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P19; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; LUKAS J, 1995, ONCOGENE, V10, P2125; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESTNITZKY D, 1994, MOL CELL BIOL, V14, P1669; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SUKOVICH DA, 1994, MOL CELL BIOL, V14, P7134, DOI 10.1128/MCB.14.11.7134; TAM SW, 1994, ONCOGENE, V9, P2663; VEDECKIS WV, 1992, P SOC EXP BIOL MED, V199, P1; VINCENT TS, 1991, BIOCHEM BIOPH RES CO, V180, P1284, DOI 10.1016/S0006-291X(05)81334-8; WATTS CKW, 1994, BREAST CANCER RES TR, V31, P95, DOI 10.1007/BF00689680; WEISZ A, 1993, CRIT REV ONCOGENESIS, V4, P361; WEISZ A, 1990, MOL ENDOCRINOL, V4, P1041, DOI 10.1210/mend-4-7-1041; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	68	312	316	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2315	2324						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649771				2022-12-28	WOS:A1996UQ22000008
J	Gutmann, DH; Giordano, MJ; Mahadeo, DK; Lau, N; Silbergeld, D; Guha, A				Gutmann, DH; Giordano, MJ; Mahadeo, DK; Lau, N; Silbergeld, D; Guha, A			Increased neurofibromatosis 1 gene expression in astrocytic tumors: Positive regulation by p21-ras	ONCOGENE			English	Article						tumor suppressor gene; gliomas; p21-ras; neurofibromin; GAP	TYPE-1 GENE; CELL-LINES; NF1 GENE; PRODUCT; GROWTH; NEUROBLASTOMA; MUTATIONS; ONCOGENES; MELANOMA; NEURONS	The neurofibromatosis 1 (NF1) gene has been implicated in astrocyte growth regulation in several studies, To determine whether loss of NF1 expression is associated with progression towards malignancy in sporadic astrocytomas from individuals without NF1, twenty-eight fresh astrocytoma operative specimens (low and high grade tumors) and seven primary human astrocytoma cell lines were examined for NF1 mRNA and protein expression, In all astrocytomas examined, increased NF1 expression was observed in the tumors relative to normal resting astrocytes, This increased neurofibromin expression correlated with elevated levels of activated p21-ras measured in both the fresh tumor specimens and the primary cell lines, Furthermore, when levels of activated p21 ras were decreased in astrocytoma cells expressing the ras inhibitory Asn-17 dominant-negative mutant, levels of neurofibromin expression decreased, In addition, fibroblasts induced to express oncogenic activated p21-ras(val12) had increased expression of NF1. These results suggested that neurofibromin expression is increased in human astrocytic tumors as a result of positive feedback regulation by increased levels of activated p21-ras.	WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT NEUROSURG,ST LOUIS,MO 63110; MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO,ON M5G 1X5,CANADA; TORONTO HOSP,DIV NEUROSURG,TORONTO,ON M5T 2S8,CANADA	Washington University (WUSTL); Washington University (WUSTL); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Gutmann, DH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,BOX 8111,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.			Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001590, R29NS033494] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33494-01, NS01590-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOS JL, 1989, CANCER RES, V49, P4682; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; Duffner P K, 1988, Neurofibromatosis, V1, P201; GIORDANO MJ, 1996, J NEUROSCIENCE RS, V46, P246; GREGORY PE, 1993, SOMAT CELL MOLEC GEN, V13, P487; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Guha A, 1996, ONCOGENE, V12, P507; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; GUTMANN DH, 1995, CELL GROWTH DIFFER, V6, P315; GUTMANN DH, 1994, J NEUROSCI RES, V37, P398, DOI 10.1002/jnr.490370312; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; HEWETT SJ, 1995, NEUROREPORT, V6, P1565, DOI 10.1097/00001756-199507310-00025; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; KIM HA, 1995, ONCOGENE, V11, P325; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; NISTER M, 1991, J BIOL CHEM, V266, P16755; NORDLUND M, 1993, J NEUROSCI, V13, P1588; NORTON KK, 1996, IN PRESS NEUROREPORT; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SERVE H, 1995, EMBO J, V14, P473, DOI 10.1002/j.1460-2075.1995.tb07023.x; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741	30	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2121	2127						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668337				2022-12-28	WOS:A1996UP28300010
J	Li, SN; Chang, YS; Liu, ST				Li, SN; Chang, YS; Liu, ST			Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein-Barr virus	ONCOGENE			English	Article						Epstein-Barr virus; BNLF1; latent membrane protein	NASOPHARYNGEAL CARCINOMA; MAMMALIAN-CELLS; BNLF-1 GENE; TRANSFORMATION; LYMPHOCYTES; EXPRESSION; DNA; REPLICATION; INFECTION; PLASMIDS	A previous study has shown that the BNLF1 of Epstein-Barr virus (EBV),isolated from a nasopharyngeal carcinoma biopsy (BNLF1-1510), was able to transform Balb/3T3 cells,On the other hand, BNLF1 of a prototype virus B95-8 (BNLF1-958) was not transforming unless the gene was transcribed from a strong promoter, In this study, we have generated chimeric BNLF1 by exchanging the DNA fragments between BNLF1-1510 and BNLF1-958 and examined their expression and transformation ability in Balb/3T3 cells, Results showed that transformation of Balb/3T3 cells by BNLF1-1510 was not due to the excessive expression of the gene, Transfection of Balb/3T3 cells with chimeric BNLF1 showed that the genes with 3' 453 bp sequence of BNLF1-1510 were oncogenic to the cells, Study also revealed that changing the numbers of the 33 bp repeats in the 3' region of the two BNLF1s did not affect the transformation characteristics. On the other hand, deletion of a 30 bp sequence of BNLF1-958, which is absent in BNLF1-1510, changed the gene oncogenic to oncogenic and insertion of sequence into BNLF1-1510 abolished the transformation ability, BNLF1 without this 30 bp sequence was also found in the tumours of other EBV-related neoplastic disease, suggesting that absence of this 30 bp sequence in BNLF1 may be associated with the oncogenesis of these diseases.	CHANG GUNG COLL MED & TECHNOL,DEPT IMMUNOL & MICROBIOL,GENET MOLEC LAB,TAYUAN 333,TAIWAN; NATL YANG MING UNIV,GRAD INST MICROBIOL & IMMUNOL,TAIPEI 112,TAIWAN	Chang Gung University; National Yang Ming Chiao Tung University								BAICHWAL VR, 1988, ONCOGENE, V2, P461; BAICHWAL VR, 1989, ONCOGENE, V4, P67; BROUSSET P, 1994, BLOOD, V84, P2447; CHANG YS, 1995, INT J CANCER, V62, P673, DOI 10.1002/ijc.2910620605; CHANG YS, 1990, LEUKEMIA RES, V14, P309, DOI 10.1016/0145-2126(90)90157-5; CHEN ML, 1992, ONCOGENE, V7, P2131; CHEN ML, 1995, VIRUS RES, V37, P75; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EPSTEIN MA, 1964, LANCET, V1, P702, DOI 10.1016/s0140-6736(64)91524-7; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; FINGEROTH JD, 1984, P NATL ACAD SCI-BIOL, V81, P4510, DOI 10.1073/pnas.81.14.4510; GRAHAM F, 1973, VIROLOGY, V52, P452; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HENLE G, 1976, INT J CANCER, V17, P1, DOI 10.1002/ijc.2910170102; HENLE G, 1968, P NATL ACAD SCI USA, V59, P94, DOI 10.1073/pnas.59.1.94; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUEN DS, 1995, ONCOGENE, V10, P549; JENG KCG, 1994, J CLIN MICROBIOL, V32, P28, DOI 10.1128/JCM.32.1.28-31.1994; KAYE KM, 1995, J VIROL, V69, P675, DOI 10.1128/JVI.69.2.675-683.1995; KIEFF E, 1990, VIROLOGY, P1889; KNECHT H, 1995, ONCOGENE, V10, P523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBOWITZ D, 1987, MOL CELL BIOL, V7, P2299, DOI 10.1128/MCB.7.7.2299; LINDAHL T, 1976, J MOL BIOL, V102, P511, DOI 10.1016/0022-2836(76)90331-4; LUPTON S, 1985, MOL CELL BIOL, V5, P2533, DOI 10.1128/MCB.5.10.2533; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MILLER WE, 1994, J GEN VIROL, V75, P2729, DOI 10.1099/0022-1317-75-10-2729; MOORTHY RK, 1993, J VIROL, V67, P1638, DOI 10.1128/JVI.67.3.1638-1646.1993; MOORTHY RK, 1993, J VIROL, V67, P2637, DOI 10.1128/JVI.67.5.2637-2645.1993; MOSIALS G, 1995, CELL, V80, P387; NIEDERMAN JC, 1968, J AMER MED ASSOC, V203, P205; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; PURTILO DT, 1981, CANCER RES, V41, P4226; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANDVEJ K, 1994, BLOOD, V84, P4053, DOI 10.1182/blood.V84.12.4053.bloodjournal84124053; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIXBEY JW, 1984, NEW ENGL J MED, V310, P1225, DOI 10.1056/NEJM198405103101905; SU IJ, 1991, BLOOD, V77, P799; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIVEDI P, 1994, EUR J CANCER, V30A, P84, DOI 10.1016/S0959-8049(05)80024-3; WALLING DM, 1995, J INFECT DIS, V171, P1122, DOI 10.1093/infdis/171.5.1122; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051	47	125	137	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2129	2135						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668338				2022-12-28	WOS:A1996UP28300011
J	vanGrunsven, LA; Billon, N; Savatier, P; Thomas, A; Urdiales, JL; Rudkin, BB				vanGrunsven, LA; Billon, N; Savatier, P; Thomas, A; Urdiales, JL; Rudkin, BB			Effect of nerve growth factor on the expression of cell cycle regulatory proteins in PC12 cells: Dissection of the neurotrophic response from the anti-mitogenic response	ONCOGENE			English	Article						NGF; PC12; cyclin D1; p21(Cip1)/WAFI; cell cycle; differentiation	AFFINITY NGF RECEPTOR; PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; KINASE; LINE; PHOSPHORYLATION; ENCODES; CDC2; RAS	PC12 cells treated with nerve growth factor (NGF) undergo a G1 block and differentiate. Expression of selected cell cycle regulatory proteins was studied under culture conditions which permit observation of differentiation response independently from a mitogenic or anti-mitogenic response. The expression of all cell cycle regulatory proteins studied is modulated by NGF addition to exponentially-growing cultures in the presence of serum. While levels of most of these proteins decrease, accumulation of cyclin D1 and the cyclin-dependent kinase inhibitor p21(Cip1/WAF1) is observed. Cyclin D1-associated kinase activity is inhibited, correlating with an increase in p21 protein. PC12 cells, synchronized by serum starvation, undergo morphological and functional differentiation in the presence of NGF. Neither cyclin D1 nor p21 are present in such cultures, nor is their expression upregulated by NGF, indicating that they are not required for this process. Removal of serum from differentiated PC12 cells results in loss of these proteins, but has no effect on differentiation or the nonproliferative state in presence of NGF, Together, the results indicate that cyclin D1 and p21 are not necessary for differentiation per se, nor are they required for maintenance of the differentiated state in the absence of serum.	ECOLE NORMALE SUPER LYON,DIFFERENTIAT & CELL CYCLE GRP,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,CNRS,UMR 49,VIRAL ONCOGENESIS & CELLULAR DIFFERENTIAT GRP,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON)			SAVATIER, Pierre/J-4663-2014; Urdiales, José Luis/K-1125-2014; van Grunsven, Leo/E-5839-2010	Urdiales, José Luis/0000-0002-2519-9293; van Grunsven, Leo/0000-0002-0990-7034; RUDKIN, Brian B./0000-0003-3700-1982				ALLEN JM, 1984, NEUROSCI LETT, V46, P291, DOI 10.1016/0304-3940(84)90114-9; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FEINSTEIN SC, 1985, P NATL ACAD SCI USA, V82, P5761, DOI 10.1073/pnas.82.17.5761; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GREENE LA, 1983, J CELL BIOL, V96, P76, DOI 10.1083/jcb.96.1.76; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1995, ONCOGENE, V10, P1855; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; KAPLAN DR, 1991, SCIENCE, V252, P4554; KIM SJ, 1994, J BIOL CHEM, V269, P3739; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LI Y, 1994, ONCOGENE, V9, P2261; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2006; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SAVATIER P, 1994, ONCOGENE, V9, P809; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SIMPSON DL, 1991, J NEUROSCI RES, V28, P486, DOI 10.1002/jnr.490280405; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; vanGrunsven LA, 1996, ONCOGENE, V12, P855; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WU BY, 1989, J BIOL CHEM, V264, P9000; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAN G, 1992, J NEUROSCI, V15, P6200; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	64	60	60	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1347	1356						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649837				2022-12-28	WOS:A1996UC06700020
J	Barrett, MT; Sanchez, CA; Galipeau, PC; Neshat, K; Emond, M; Reid, BJ				Barrett, MT; Sanchez, CA; Galipeau, PC; Neshat, K; Emond, M; Reid, BJ			Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus	ONCOGENE			English	Article						9p21; CDKN2/p16; Barrett's esophagus	SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; FREQUENT LOSS; HOMOZYGOUS DELETIONS; LUNG-CANCER; P16 GENE; ADENOCARCINOMA; MELANOMA; CHROMOSOME-9; P16/CDKN2	High frequency allelic loss of chromosome 9p21 has been reported in a number of human cancers, including those of the esophagus, The CDKN2 gene on chromosome 9p21 that encodes the p16 inhibitor of cyclinD/Cdk4 complexes is a target of allelic loss and inactivation in a variety of human cancers and cell lines, However, the roles of 9p21 allelic losses and CDKN2 mutations in human neoplastic progression in vivo remain controversial, We determined the prevalence of allelic loss at 9p21 and mutations in CDKN2 in esophageal adenocarcinomas and investigated the order in which they occurred relative to the development of aneuploidy and cancer during neoplastic progression, Aneuploid cell populations from 32 patients with Barrett's esophagus who had premalignant epithelium, cancer, or both, were purified by DNA content flow cytometric cell sorting and evaluated by polymerase chain reaction, Twenty-four of 32 informative patients (75%) had allelic loss at 9p21 in aneuploid cell populations, Premalignant epithelium was available for seven of the patients who had 9p21 allelic losses in cancer; allelic loss of 9p21 was detected before cancer in all seven (100%), Allelic loss of 9p21 preceded the development of aneuploidy in 13 of 15 patients (87%) who had aneuploid cell populations detected in premalignant epithelium, and the two events were detected simultaneously in the remaining two patients, Five of 22 aneuploid populations (23%) with 9p21 loss had somatic mutations in the remaining CDKN2 allele, The same mutations and 9p21 allelic losses were also found in the corresponding diploid cells from premalignant epithelium in all three cases that were evaluable, However, there was no evidence for mutation or homozygous deletion of p16 in the other 17 patients with 9p21 allelic loss, Our results indicate that 9p21 allelic losses and CDKN2 mutations develop as early lesions in diploid cells before aneuploidy and cancer during neoplastic progression in Barrett's esophagus.	FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT MED,DIV GASTROENTEROL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X; Galipeau, Patricia/0000-0001-7961-7430	NCI NIH HHS [R01CA61202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barrett MT, 1996, ONCOGENE, V12, P1873; BARRETT MT, 1995, NUC ACIDS RES, V23, P3368; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; BLOUNT PL, 1993, P NATL ACAD SCI USA, V90, P3221, DOI 10.1073/pnas.90.8.3221; BLOUNT PL, 1994, CANCER RES, V54, P2292; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1994, CANCER RES, V54, P1422; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; DREYLING MH, 1995, CANCER RES, V55, P984; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; GLENDENING JM, 1995, CANCER RES, V55, P5531; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; HAMILTON SR, 1988, HUM PATHOL, V19, P942, DOI 10.1016/S0046-8177(88)80010-8; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HEREFORD LM, 1974, J MOL BIOL, V84, P445, DOI 10.1016/0022-2836(74)90451-3; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LI YJ, 1995, ONCOGENE, V11, P597; LIU Q, 1995, ONCOGENE, V10, P1061; MERLO A, 1994, CANCER RES, V54, P640; NAKAGAWA K, 1995, ONCOGENE, V11, P1843; NESHAT K, 1994, COLD SPRING HARB SYM, V59, P577, DOI 10.1101/SQB.1994.059.01.065; NISHIKAWA R, 1995, CANCER RES, V55, P1941; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; PHILLIPS RW, 1991, GASTROENTEROL CLIN N, V20, P791; REID BI, 1992, GASTROENTEROLOGY, V102, P1211; RODABAUGH KJ, 1995, ONCOGENE, V11, P1249; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SUZUKI H, 1995, HUM MOL GENET, V4, P1883, DOI 10.1093/hmg/4.10.1883; TARMIN L, 1994, CANCER RES, V54, P6094; VANDERRIET P, 1994, CANCER RES, V54, P1156; WALKER GJ, 1995, HUM MOL GENET, V4, P1845, DOI 10.1093/hmg/4.10.1845; WICK ST, 1995, XU L, V11, P2013; XU L, 1994, CANCER RES, V54, P5262; Zariwala M, 1996, ONCOGENE, V12, P451; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847; ZHANG SY, 1994, CANCER RES, V54, P5050; Zhou P, 1996, CANCER RES, V56, P36	42	150	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1867	1873						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934532				2022-12-28	WOS:A1996VR79500005
J	Latham, KE; Litvin, J; Orth, JM; Patel, B; Mettus, R; Reddy, EP				Latham, KE; Litvin, J; Orth, JM; Patel, B; Mettus, R; Reddy, EP			Temporal patterns of A-myb and B-myb gene expression during testis development	ONCOGENE			English	Article						myb; fertility; sterility; gene expression; testis development; meiosis	C-MYB; TRANSCRIPTIONAL ACTIVATOR; PROTEIN; CELLS; MOUSE; SPERMATOGENESIS; PROLIFERATION; LYMPHOCYTES; SUBUNIT; DOMAINS	We recently reported the cloning and sequencing of the mouse A-myb proto-oncogene cDNA and the abundant expression of this mRNA primarily in the testis of adult mice. The A-myb mRNA is detectable by in situ hybridization specifically in the spermatogenic cells, and is downregulated during terminal differentiation. A low level of expression is observed in a few other tissues, including ovary, spleen and brain. We have extended those studies by examining A-myb and B-myb expression during testis development in the mouse. The A-myb and B-myb genes are both expressed in a cell- and stage-specific manner during testis development. The B-myb mRNA is expressed most highly in gonocytes of the fetal testis and in spermatogonia and early spermatocytes in the adult. B-myb expression decreases at day 18 post partum, coincident with the initial appearance of Late pachytene spermatocytes. B-myb expression was also detectable in some interstitial cells of the fetal and adult testis. The A-myb mRNA was not detectable by in situ hybridization in fetal day 15.5 gonocytes but was detectable at a low abundance by RT-PCR in fetal and newborn mice. A-myb mRNA expression increased at post-natal day 10, when primary spermatocytes first appear. In the adult, the A-myb mRNA was expressed highly in a sub-population of spermatogonia and in primary spermatocytes, but was not detectable in spermatids. This expression of A-myb is consistent with the meiotic arrest that is observed in A-myb-deficient male mice. We conclude that B-myb may play a critical role in controlling the proliferation or differentiation of gonocytes and spermatogonia and possibly the somatic lineages as well, whereas A-myb is required for progression through the first meiotic prophase. These distinct roles for B-myb and A-myb during spermatogenesis may reflect distinct transactivation potentials of the two proteins. Further studies to determine the functions of A-myb and B-myb in the developing testis should improve our understanding of the molecular events associated with spermatogenesis and differentiation of the Sertoli and other somatic cell types of the testis.	TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT ANAT & CELL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Latham, KE (corresponding author), TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140, USA.		Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [P30-CA12227] Funding Source: Medline; NICHD NIH HHS [HD15563] Funding Source: Medline; NIGMS NIH HHS [GM49489] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD015563] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA012227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; BARLETTA C, 1991, CANCER RES, V51, P3821; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GOLAY J, 1994, ONCOGENE, V9, P2469; KLAMPNAUER KH, 1987, EMBO J, V6, P2719; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; METTUS RV, 1994, ONCOGENE, V9, P3077; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; ORTH JM, 1982, ANAT REC, V203, P485, DOI 10.1002/ar.1092030408; ORTH JM, 1996, IN PRESS MOL REPROD; RAMBHATLA L, 1995, MOL REPROD DEV, V41, P314, DOI 10.1002/mrd.1080410306; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; Sitzmann J, 1996, ONCOGENE, V12, P1889; Sitzmann J, 1995, ONCOGENE, V11, P2273; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TOSCANI A, UNPUB NATURE; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; XU LZ, 1995, MOL CELL BIOL, V15, P6572	32	42	45	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1161	1168						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808690				2022-12-28	WOS:A1996VJ20200007
J	Shibata, T; Ochiai, A; Kanai, Y; Akimoto, S; Gotoh, M; Yasui, N; Machinami, R; Hirohashi, S				Shibata, T; Ochiai, A; Kanai, Y; Akimoto, S; Gotoh, M; Yasui, N; Machinami, R; Hirohashi, S			Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells	ONCOGENE			English	Article						beta-catenin; c-erbB-2; protein-protein interaction; metastasis	EPIDERMAL GROWTH-FACTOR; ADHESION MOLECULE UVOMORULIN; HUMAN CARCINOMA-CELLS; HUMAN-BREAST-CANCER; E-CADHERIN; TYROSINE PHOSPHORYLATION; GENE-PRODUCT; EPITHELIAL-CELLS; FACTOR RECEPTOR; CYTOPLASMIC DOMAIN	tyrosine phosphorylation of beta-catenin inactivates the E-cadherin-mediated cell adhesion and invasion suppressor system in cancer cells, Elucidation of the association between beta-catenin and c-erbB-2 protein prompted us to investigate whether interference with this interaction can change the invasive phenotype, In a human gastric cancer cell line, TMK-1, N-terminally deleted beta-catenin, which binds to c-erbB-2 but not to cadherin, inhibited the association between endogenous beta-catenin and c-erbB-2 protein, and suppressed the tyrosine phosphorylation of beta-catenin. Cells expressing truncated beta-catenin exhibited markedly reduced invasiveness in vitro and peritoneal metastasis in vivo, and developed an epithelial morphology, These results suggest that tyrosine phosphorylation of beta-catenin regulated by c-erbB-2 protein may play an important role in the invasion, metastasis and morphogenesis of cancer cells and that inhibition of the aberrant tyrosine phosphorylation of beta-catenin effectively prevents invasion and metastasis of cancer cells.	NATL CANC CTR,RES INST,DIV PATHOL,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,FAC MED,DEPT PATHOL,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; University of Tokyo								ABERLE H, 1994, J CELL SCI, V107, P3655; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BEHRENS J, 1985, J CELL BIOL, V101, P1307, DOI 10.1083/jcb.101.4.1307; BORG A, 1991, ONCOGENE, V6, P137; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; MATSUDA S, 1993, P NATL ACAD SCI USA, V90, P10803, DOI 10.1073/pnas.90.22.10803; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; OCHIAI A, 1994, JPN J CANCER RES, V85, P266, DOI 10.1111/j.1349-7006.1994.tb02092.x; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; OKA H, 1993, CANCER RES, V53, P1696; OYAMA T, 1994, CANCER RES, V54, P6268; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1992, J CELL BIOL, V116, P989, DOI 10.1083/jcb.116.4.989; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; SHIMOYAMA Y, 1991, CANCER RES, V51, P2185; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TANIGUCHI S, 1989, CANCER RES, V49, P6738; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; YU DH, 1992, ONCOGENE, V7, P2263	43	111	111	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					883	889						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806677				2022-12-28	WOS:A1996VG76600001
J	Oates, AJ; Barraclough, R; Rudland, PS				Oates, AJ; Barraclough, R; Rudland, PS			The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model	ONCOGENE			English	Article						mammary metastasis; subtractive hybridization; osteopontin (OPN)	EPITHELIAL-CELL LINE; RAT; HYBRIDIZATION; TRANSFECTION; VARIANTS; PROTEIN; CANCER; BONE	The rat mammary epithelial cell line, Rama 37, yields benign, non-metastasizing adenomatous tumours in syngeneic Furth-Wistar rats. Transfection of this stably diploid cell line with genomic DNA fragments from a human metastasizing breast cancer cell line yields cells which, when injected subcutaneously in syngeneic rats, give rise to secondary tumours in a number of the animals. From one such secondary lung tumour, a cell line was established designated Ca2-5-LT1. This cell line, when introduced into the syngeneic rat host, also showed the ability to metastasise. To determine key changes in gene expression that occur during the progression from Rama 37, the benign tumour-inducing cell line, to the metastatic derivative Ca2-5-LT1, a general method of subtractive hybridization has been employed. This procedure in conjunction with Northern blotting and nucleic acid sequencing has been used to identify mRNAs expressed differentially between the metastatic and nonmetastatic cell lines described above. So far, of the subtracted cDNAs that have been identified which represent differentially expressed mRNAs, a large proportion of these cDNAs corresponded to the mRNA for rat osteopontin (OPN). The mRNA for OPN was expressed at a ninefold higher level in the metastatic Ca2-5-LT1 cell Une when compared to the nonmetastatic parental Rama 37 cell Line. Rama 37 cells transfected with DNA from a human benign cell line failed to show elevated levels of OPN mRNA. Following transfection of Rama 37 cells with an expression-construct producing elevated levels of OPN, the newly-transfected cells, when introduced into the rat host, developed metastases in 55% of the animals that produced primary tumours. These experiments show that increasing the expression of OPN in a previously benign cell line is sufficient to produce a metastatic phenotype in this particular rat mammary model.	UNIV LIVERPOOL,DEPT BIOCHEM,CANC & POLIO RES FUND LABS,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Barraclough, Roger/AAH-6516-2020	Barraclough, Roger/0000-0002-7203-1194				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BEHREND EI, 1994, CANCER RES, V54, P832; BROWN LF, 1992, MOL BIOL CELL, V3, P1169, DOI 10.1091/mbc.3.10.1169; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES BR, 1994, CANCER RES, V54, P2785; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DERRICO JA, 1995, J PERIODONTAL RES, V30, P34, DOI 10.1111/j.1600-0765.1995.tb01250.x; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; FELDINGHABERMANN B, 1992, J BIOL CHEM, V267, P5070; FENG B, 1995, CLIN EXP METASTAS, V13, P453, DOI 10.1007/BF00118184; GARDNER HAR, 1994, ONCOGENE, V9, P2321; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; JAMIESON S, 1990, PATHOBIOLOGY, V58, P329, DOI 10.1159/000163605; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; PRINCE CW, 1987, J BIOL CHEM, V262, P2900; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; RUBENSTEIN JLR, 1990, NUCLEIC ACIDS RES, V18, P4833, DOI 10.1093/nar/18.16.4833; RUDLAND PS, 1985, CANCER RES, V45, P3864; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWEINFEST CW, 1992, INT J ONCOL, V1, P499; SIVE HL, 1988, NUCLEIC ACIDS RES, V16, P10937, DOI 10.1093/nar/16.22.10937	26	155	166	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					97	104						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700559				2022-12-28	WOS:A1996UX31900011
J	Wallace, H; Clarke, AR; Harrison, DJ; Hooper, ML; Bishop, JO				Wallace, H; Clarke, AR; Harrison, DJ; Hooper, ML; Bishop, JO			Ganciclovir-induced ablation of non-proliferating thyrocytes expressing herpesvirus thymidine kinase occurs by p53-independent apoptosis	ONCOGENE			English	Article						herpes simplex virus; thymidine kinase; apoptosis; p53; transgenic mice	CELLS; DNA; GROWTH	In adult mice of the transgenic strain TG66.19, in which expression of herpes simplex type 1 virus thymidine kinase (HSV1-TK) is driven in thyrocytes from the thyroglobulin promoter, the drug Ganciclovir causes the death (ablation) of thyrocytes. Ablation occurred in the absence of thyrocyte proliferation or nuclear DNA synthesis, but was accompanied by transient expression of proliferating cell nuclear antigen and the dying thyrocytes exhibited the ultrastructural features of apoptosis, Control experiments show that the apoptosis is a result of the production of Ganciclovir phosphates in thyrocytes that express HSV1-TK. However, cell death was not dependent upon the presence of a functional copy of the oncosuppressor gene p53, We conclude that the apoptosis is probably not mediated by induction of DNA damage and occurs via a pathway that is independent of p53, The fact that Ganciclovir phosphate can kill cells by a p53-independent apoptotic pathway is encouraging in relation to tumour ablation by methods based on transfection with HSV1-tk genes and administration of Ganciclovir.	UNIV EDINBURGH, CTR GENOME RES, EDINBURGH EH9 3JQ, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, DEPT PATHOL, CRC LABS, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Edinburgh			clarke, alan r/P-2820-2014; Clarke, Alan R/A-6256-2008	Clarke, Alan/0000-0002-4281-426X				BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BURTON K, 1967, METHOD ENZYMOL, V8, P162; CHENG YC, 1983, P NATL ACAD SCI-BIOL, V80, P2767, DOI 10.1073/pnas.80.9.2767; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE AR, 1995, ONCOGENE, V11, P1913; CLARKE AR, 1994, ONCOGENE, V9, P1767; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; COLOMBO BM, 1995, HUM GENE THER, V6, P763, DOI 10.1089/hum.1995.6.6-763; CULVER KW, 1994, TRENDS GENET, V10, P174, DOI 10.1016/0168-9525(94)90095-7; DEMARTYNOFF G, 1987, EUR J BIOCHEM, V164, P591, DOI 10.1111/j.1432-1033.1987.tb11168.x; FARQUHARSON C, 1990, BONE MINER, V10, P121, DOI 10.1016/0169-6009(90)90087-V; FREEMAN SM, 1993, CANCER RES, V53, P5274; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWIE SEM, 1994, CLIN EXP IMMUNOL, V95, P195; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KANEKO Y, 1995, CANCER LETT, V96, P105, DOI 10.1016/0304-3835(95)03919-N; Kato Kyozo, 1994, Neurologia Medico-Chirurgica, V34, P339, DOI 10.2176/nmc.34.339; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; Maxam A M, 1980, Methods Enzymol, V65, P499; MERRITT AJ, 1994, CANCER RES, V54, P614; ROUACH EY, 1991, NATURE, V352, P345; RUBNITZ J, 1985, MOL CELL BIOL, V5, P529, DOI 10.1128/MCB.5.3.529; SAMEJIMA Y, 1995, GENE THER, V2, P50; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMEDS S, 1983, ENDOCRINOLOGY, V112, P1718, DOI 10.1210/endo-112-5-1718; SMEE DF, 1983, ANTIMICROB AGENTS CH, V23, P676, DOI 10.1128/AAC.23.5.676; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P844, DOI 10.1128/AAC.31.6.844; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; WALLACE H, 1995, J ENDOCRINOL, V145, P251, DOI 10.1677/joe.0.1450251; WALLACE H, 1991, ENDOCRINOLOGY, V129, P3217, DOI 10.1210/endo-129-6-3217; WALLACE H, 1994, J ENDOCRINOL, V143, P107, DOI 10.1677/joe.0.1430107; WARTERS RL, 1992, CANCER RES, V52, P883; WOLVETANG EJ, 1994, FEBS LETT, V339, P40, DOI 10.1016/0014-5793(94)80380-3	38	37	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					55	61						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700554				2022-12-28	WOS:A1996UX31900007
J	Spitkovsky, D; JansenDurr, P; Karsenti, E; Hoffmann, I				Spitkovsky, D; JansenDurr, P; Karsenti, E; Hoffmann, I			S-phase induction by adenovirus E1A requires activation of cdc25A tyrosine phosphatase	ONCOGENE			English	Article						E1A; oncogene; cdc25 phosphatase; cell cycle	CELL-CYCLE; PROTEIN-KINASE; PHOSPHORYLATION; IDENTIFICATION; MICROINJECTION; MITOSIS; BINDING; SYSTEM; GROWTH; CDK2	Adenovirus EIA proteins can induce quiescent cells to enter S-phase and also affect the expression of cellular genes including various cell cycle regulators. Here we show that human cdc25A, a tyrosine phosphatase involved in regulation of the G1/S-phase transition of the cell cycle, is a target of the adenovirus E1A protein in virus-infected human fibroblasts, Expression of E1A in quiescent fibroblasts leads to a rapid increase in cdc25A phosphatase activity and also increases both cdc25A and cyclin E gene expression. Inhibition of cdc25A function by antibody injection prevents virus-induced entry into S-phase. These results indicate that induction of high levels of cdc25A and its potential positive regulator cyclin E mediates the ability of E1A to induce S-phase in the presence of antiproliferative signals.	DEUTSCH KREBSFORSCHUNGSZENTRUM, D-69120 HEIDELBERG, GERMANY; EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAMME, D-69012 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); European Molecular Biology Laboratory (EMBL)			Jansen-Dürr, Pidder/ABG-2466-2020	Jansen-Dürr, Pidder/0000-0001-7771-3429				ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HOFFMANN I, 1994, J CELL SCI, P75; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORRIS GF, 1994, MOL CELL BIOL, V14, P543, DOI 10.1128/MCB.14.1.543; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1992, ONCOGENE, V7, P1681; PEPPERKOK R, 1988, P NATL ACAD SCI USA, V85, P6748, DOI 10.1073/pnas.85.18.6748; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; SPITKOVSKY D, 1994, J VIROL, V68, P2206, DOI 10.1128/JVI.68.4.2206-2214.1994; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	32	37	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2549	2554						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700513				2022-12-28	WOS:A1996UW48700008
J	Zippel, R; Orecchia, S; Sturani, E; Martegani, E				Zippel, R; Orecchia, S; Sturani, E; Martegani, E			The brain specific ras exchange factor CDC25(Mm): Modulation of its activity through Gi-protein-mediated signals	ONCOGENE			English	Article						Ras; exchange factors; GEF; LPA; Ras-GRF	NUCLEOTIDE-RELEASING FACTOR; GROWTH-FACTOR; RECEPTOR; GRB2; IDENTIFICATION; P21(RAS); FIBROBLASTS; ACTIVATION; EXPRESSION; COMPLEX	CDC25(Mm) is a mouse guanine nucleotide exchange factor specific for Ras, exclusively expressed in the Brain. We used a reporter gene containing a Ras-responsive fos-promoter in order to gain information on the role played by this exchange factor in signal transduction. Transient expression of CDC25(Mm) in CHO cells activates Ras, Moreover serum, but not insulin, can upregulate the response mediated by CDC25(Mm) and this modulation requires that the CDC25(Mm) maintains its N-terminal region, NIH3T3 fibroblasts, stably overexpressing this exchange factor, show a partially transformed phenotype, suggesting that the Ras-dependent pathway is constitutively active. In these cells serum and lysophosphatidic acid (LPA) stimulate Ras activity above the basal level while PDGF does not. Both serum and LPA-induced Ras activations in CDC25(Mm) overexpressing cells can be completely inhibited by pertussis toxin, Moreover, these responses are strongly reduced by coexpression of a truncated version of CDC25(Mm) lacking the C-terminal catalytic portion, This construct behaves in a dominant negative manner suggesting that it may compete with CDC25(Mm) by sequestering in an unproductive way signalling components activated by these factors, The data presented indicate that CDC25(Mm) does not participate in connecting tyrosine, kinase receptors with Ras, while it could mediate Ras activation induced by pertussis toxin sensitive Gi-coupled receptors.			Zippel, R (corresponding author), UNIV MILAN,DEPT GEN PHYSIOL & BIOCHEM,VIA CELORIA 26,I-20133 MILAN,ITALY.			Martegani, Enzo/0000-0001-9196-4224				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JACQUET E, 1992, J BIOL CHEM, V267, P24181; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTEGANI E, 1993, EUR J HISTHCEM, V37, P73; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; STURANI E, 1989, FEBS LETT, V255, P191, DOI 10.1016/0014-5793(89)81089-0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D; ZIPPEL R, 1986, BIOCHIM BIOPHYS ACTA, V881, P54, DOI 10.1016/0304-4165(86)90096-6; ZIPPEL R, 1994, INT J ONCOL, V4, P175	34	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2697	2703						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700529				2022-12-28	WOS:A1996UW48700024
J	Muller, BF; Paulsen, D; Deppert, W				Muller, BF; Paulsen, D; Deppert, W			Specific binding of MAR/SAR DNA-elements by mutant p53	ONCOGENE			English	Review						oncogenic function of mutant p53; MAR/SAR DNA-elements; binding of MAR/SAR DNA-elements by mutant p53	WILD-TYPE P53; SCAFFOLD-ATTACHED REGIONS; LARGE-T-ANTIGEN; CHROMOSOMAL LOOP ANCHORAGE; TUMOR SUPPRESSOR GENE; AMINO-ACID-SEQUENCE; CELL-CYCLE CONTROL; A MOUSE CELLS; SIMIAN VIRUS-40; MONOCLONAL-ANTIBODY	Inactivation of the tumor suppressor p53 by single missense point mutations characterizes a large number of human tumors, At least some mutant p53 proteins not only have lost the tumor suppressor function, but at the same time reveal a variety of dominant oncogenic properties. The molecular basis of this 'gain of function' is still unknown. In this report we describe a new biochemical activity of mutant p53, the specific high-affinity interaction with MAR/SAR DNA-elements (nuclear matrix/scaffold attachment regions). This DNA-binding activity can be distinguished from the previously reported DNA-binding activities of p53 by its specificity for mutant p53, the high binding affinity, and the domains of the mutant p53 molecule involved in MAR/SAR DNA-binding. The MAR/SAR-binding region of mutant p53 maps to a bipartite domain consisting of the mutated core region and the C-terminal 60 amino acids, carrying the unspecific DNA-binding domain and the oligomerization motif. MAR/SAR elements are considered as important regulatory elements in a variety of nuclear processes. We propose a model according to which the specific interaction of mutant p53 with MAR/SAR elements might interfere with these processes, thereby exerting pleiotropic oncogenic effects.	UNIV HAMBURG, HEINRICH PETTE INST EXPTL VIROL & IMMUNOL, D-20251 HAMBURG, GERMANY	Heinrich Pette Institute; University of Hamburg								AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ANDERSON JN, 1986, NUCLEIC ACIDS RES, V14, P8513, DOI 10.1093/nar/14.21.8513; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARTEK J, 1990, ONCOGENE, V5, P893; BEREZNEY R, 1991, J CELL BIOCHEM, V47, P109, DOI 10.1002/jcb.240470204; BERTHOLD H, 1992, PROTEIN EXPRES PURIF, V3, P50, DOI 10.1016/1046-5928(92)90055-2; BODE J, 1988, BIOCHEMISTRY-US, V27, P4706, DOI 10.1021/bi00413a019; Bode J, 1995, INT REV CYTOL, V162A, P389; BOULIKAS T, 1992, J CELL BIOCHEM, V50, P111, DOI 10.1002/jcb.240500202; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P513, DOI 10.1002/jcb.240550411; Boulikas Teni, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P117; BRAIN R, 1994, ONCOGENE, V9, P1775; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COCKERILL PN, 1987, J BIOL CHEM, V262, P5394; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DELEO AB, 1977, J EXP MED, V146, P720, DOI 10.1084/jem.146.3.720; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DEPPERT W, 1990, ONCOGENE, V5, P1701; DEPPERT W, 1994, INT CONGR SER, V1050, P11; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD OS, 1991, NUCLEIC ACIDS RES, V19, P5191, DOI 10.1093/nar/19.19.5191; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gai X X, 1988, Oncogene Res, V3, P377; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HERBOMEL P, 1990, NEW BIOL, V39, P937; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HINZPETER M, 1986, VIROLOGY, V148, P159, DOI 10.1016/0042-6822(86)90411-3; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIESER A, 1994, ONCOGENE, V9, P963; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; LANE DP, 1983, CELL BIOL INT REP, V7, P513, DOI 10.1016/0309-1651(83)90154-6; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEGROS Y, 1994, ONCOGENE, V9, P3689; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MAH DCW, 1993, J CELL SCI, V105, P807; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MICHALOVITZ D, 1991, J CELL BIOCHEM, V45, P22, DOI 10.1002/jcb.240450108; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIELKE C, 1990, BIOCHEMISTRY-US, V29, P7475, DOI 10.1021/bi00484a017; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1987, ONCOGENE, V1, P453; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; PHIVAN L, 1988, EMBO J, V7, P655, DOI 10.1002/j.1460-2075.1988.tb02860.x; PHIVAN L, 1990, MOL CELL BIOL, V10, P2302, DOI 10.1128/MCB.10.5.2302; PHIVAN L, 1990, PROG MOL SUBCELL BIO, V11, P1; POHL J, 1988, MOL CELL BIOL, V8, P2078, DOI 10.1128/MCB.8.5.2078; POLACK A, 1991, ONCOGENE, V6, P2033; POLJAK L, 1994, NUCLEIC ACIDS RES, V22, P4386, DOI 10.1093/nar/22.21.4386; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Reed Michael, 1993, Gene Expression, V3, P95; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SCHWYZER M, 1977, C INSERM, V69, P63; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULIAN E, 1993, EMBO J, V12, P2789, DOI 10.1002/j.1460-2075.1993.tb05940.x; SHAULSKY G, 1991, CANCER RES, V51, P5232; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STEINMEYER K, 1990, ONCOGENE, V5, P1691; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENGER JE, 1994, EMBO J, V13, P6011, DOI 10.1002/j.1460-2075.1994.tb06947.x; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STIEF A, 1989, NATURE, V341, P343, DOI 10.1038/341343a0; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; VONKRIES JP, 1991, CELL, V64, P123, DOI 10.1016/0092-8674(91)90214-J; VONKRIES JP, 1990, NUCLEIC ACIDS RES, V18, P3881; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WEIDT G, 1994, J IMMUNOL, V153, P2554; WEISSKER SN, 1992, ONCOGENE, V7, P1921; WOLF D, 1985, MOL CELL BIOL, V5, P127, DOI 10.1128/MCB.5.1.127; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAKUTHOURI R, 1983, NATURE, V306, P594, DOI 10.1038/306594a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZASTAWNY RL, 1993, ONCOGENE, V8, P1529; ZERRAHN J, 1992, ONCOGENE, V7, P1371; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2; ZHIVOTOVSKY B, 1994, INT ARCH ALLERGY IMM, V105, P333, DOI 10.1159/000236778; ZHIVOTOVSKY B, 1994, BIOCHEM BIOPH RES CO, V202, P120, DOI 10.1006/bbrc.1994.1901	121	53	53	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1941	1952						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649855				2022-12-28	WOS:A1996UK49800013
J	Knippschild, U; Oren, M; Deppert, W				Knippschild, U; Oren, M; Deppert, W			Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion	ONCOGENE			English	Article						nuclear-cytoplasmic transport; tumor suppressor p53	TUMOR SUPPRESSOR GENE; AUTOREGULATORY FEEDBACK LOOP; LARGE-T-ANTIGEN; CELL-CYCLE; MDM2 GENE; PROTEIN; TRANSPORT; MUTANT; EXPRESSION; CANCER	We used clone 6 cells (rat embryo fibroblasts transformed by the temperature sensitive mutant p53(val135) and an activated H-ras-gene (Michalovitz et al., 1990)), growth arrested at 32 degrees C, as a model to analyse whether and how transformed cells, growth-arrested by an overexpressed wild-type p53, might overcome p53-mediated growth inhibition, When clone 6 cells were kept at 32 degrees C for about 2 weeks, foci of cells appeared which grew temperature-independent. Analysis of individual clones of such cell demonstrated that the ectopically expressed tsp53-gene had not been altered by an additional mutation, but that the tsp53 in these cells at 32 degrees C had lost its ability to upregulate expression of the p53 target genes waf1 and mdm2. This loss of p53-specific transactivation correlated with nuclear exclusion of the tsp53 at 32 degrees C, which was most likely mediated by cytoplasmic retention of the tsp53 protein via short-lived anchor proteins, Cytoplasmic retention of the tsp53 at 32 degrees C was also observed in PC12 pheochromocytoma cells ectopically expressing tsp53(val135), there occurring without specific selection, Also in these exclusion of the tsp53 correlated with mediated growth inhibition, Nuclear exclusion of p53 thus might serve as an epigenetic mechanism to eliminate the growth-inhibitory function of p53.	UNIV HAMBURG,HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Heinrich Pette Institute; University of Hamburg; Weizmann Institute of Science					NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R0I CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1992, EMBO J, V11, P2115, DOI 10.1002/j.1460-2075.1992.tb05270.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHANG FJ, 1993, AM J GASTROENTEROL, V88, P174; CIECHANOVER A, 1994, J BIOL CHEM, V269, P9582; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEFROMENTEL CC, 1992, GENE CHROMOSOME CANC, V4, P1; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; Deppert W., 1993, MOL CELL BIOL METHOD, P27; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELKIND NB, 1995, ONCOGENE, V11, P841; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FLORENES VA, 1994, J NATL CANCER I, V86, P1297, DOI 10.1093/jnci/86.17.1297; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORUS A, 1993, CELL GROWTH DIFFER, V4, P1065; FUKUSAWA K, 1991, MOL CELL BIOL, V11, P3472; GANNON JV, 1991, NATURE, V349, P802; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; JUVEN T, 1993, ONCOGENE, V8, P3411; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALTHOFF H, 1993, ONCOGENE, V8, P289; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KNIPPSCHILD U, 1995, ONCOGENE, V11, P683; LADANYI M, 1993, CANCER RES, V53, P16; LAIMINS LA, 1993, INFECT AGENT DIS, V2, P74; LANDERS JE, 1994, ONCOGENE, V9, P2745; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LANE DP, 1992, NATURE, V359, P486, DOI 10.1038/359486b0; LANFORD RE, 1982, VIROLOGY, V119, P169, DOI 10.1016/0042-6822(82)90074-5; LANFORD RE, 1984, CELL, V37, P801, DOI 10.1016/0092-8674(84)90415-X; LANFORD RE, 1985, VIROLOGY, V147, P72, DOI 10.1016/0042-6822(85)90228-4; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OTTO A, 1993, ONCOGENE, V8, P2591; PATSCHINSKY T, 1990, ONCOGENE, V5, P1071; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; PERRY ME, 1993, CURR OPIN GENET DEV, V3, P50, DOI 10.1016/S0959-437X(05)80340-5; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; Prives C, 1993, CURR OPIN CELL BIOL, V5, P214, DOI 10.1016/0955-0674(93)90105-Y; RIHS HP, 1989, EMBO J, V8, P1479, DOI 10.1002/j.1460-2075.1989.tb03531.x; Sambrook J, 1989, J SAMBROOK MOL CLONI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SELTER H, 1994, INT J BIOCHEM, V26, P145, DOI 10.1016/0020-711X(94)90139-2; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; STAUFENBIEL M, 1983, CELL, V33, P173, DOI 10.1016/0092-8674(83)90346-X; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; STURZBECHER HW, 1990, ONCOGENE, V5, P795; TAKAHASHI K, 1994, ONCOGENE, V9, P183; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, J BIOL CHEM, V269, P10923; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZERRAHN J, 1992, ONCOGENE, V7, P1371	78	49	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1755	1765						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622896				2022-12-28	WOS:A1996UG45800018
J	Chan, AML; Takai, S; Yamada, K; Miki, T				Chan, AML; Takai, S; Yamada, K; Miki, T			Isolation of a novel oncogene, NET1, from neuroepithelioma cells by expression cDNA cloning	ONCOGENE			English	Article						oncogene; expression cloning; neuroepithelioma; GEF; RAS; RHO	INSITU HYBRIDIZATION; GENE-PRODUCT; CDC24; BCR; PROTEINS; SYSTEM; CYCLE; VAV; RAS; DNA	We generated a cDNA expression library from a human neuroepithelioma cell line for detection of novel oncogenes by focus formation assay in NIH3T3 cells. A morphologically unique focus was identified upon transfection and the transforming plasmid was isolated. The transforming gene, designated NET1, encoded a predicted protein species of 54 kDa containing the Dbl-Homology (DH) motif. This motif is also present in other growth regulatory molecules including Bcr, Cdc24, Vav, Ras-Grf, Ect2, Ost, Tim and Tiam1, which have been implicated as regulators of small GTP-binding proteins. NIH3T3 cells transfected with NET1 expression plasmid showed altered growth properties in vitro and were tumorigenic when injected into nude mice. In addition, a 2.5 kb cDNA was isolated from a normal human cDNA library which represented the NET1 proto-oncogene contained a 5' extended open reading frame. The fact that the proto-oncogene failed to induce transformation in NIH3T3 cells suggested that the original NET1 oncogene was activated by 5'-truncation. The 3.0 and 2.4 kilobasepair (kb) transcripts of the NET1 gene was ubiquitously expressed in all tissues examined. Using fluorescence in situ hybridization, we localized the NET1 gene to the short arm of human chromosome 10 at band p15.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; INT MED CTR JAPAN, RES INST, DEPT GENET, SHINJUKU KU, TOKYO 162, JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Center for Global Health & Medicine - Japan			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464				ADAMS JM, 1992, ONCOGENE, V7, P611; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHAN AML, 1994, ONCOGENE, V9, P1057; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIU RG, 1995, NATURE, V374, P457; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIKI T, 1991, SCIENCE, V251, P72, DOI 10.1126/science.1846048; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RON D, 1991, NEW BIOL, V3, P372; SHIH C, 1979, P NATL ACAD SCI USA, V76, P5714, DOI 10.1073/pnas.76.11.5714; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; TAKAHASHI E, 1990, HUM GENET, V86, P14; TAKAI S, 1993, CYTOGENET CELL GENET, V63, P59, DOI 10.1159/000133503; VIEGASPEQUIGNOT E, 1978, ANN GENET-PARIS, V21, P122; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	35	76	82	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1259	1266						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649828				2022-12-28	WOS:A1996UC06700011
J	Nikitin, AY; Jin, JJ; Papewalis, J; Prokopenko, SN; Pozharisski, KM; Winterhager, E; FleskenNikitin, A; Rajewsky, MF				Nikitin, AY; Jin, JJ; Papewalis, J; Prokopenko, SN; Pozharisski, KM; Winterhager, E; FleskenNikitin, A; Rajewsky, MF			Wild type neu transgene counteracts mutant homologue in malignant transformation of rat Schwann cells	ONCOGENE			English	Article						neu (erbB-2); rat schwannomas; ethylnitrosourea; gene dosage; transgenic rats	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; NERVOUS-SYSTEM; NEOPLASTIC TRANSFORMATION; C-ERBB-2 RECEPTOR; PERIPHERAL MYELIN; PROTO-ONCOGENE; HUMAN-BREAST; GENE; EXPRESSION	Mutational activation of the neu (erbB-2) receptor protein tyrosine kinase gene appears to be the triggering event in the process of oncogenesis induced by N-ethyl-N-nitrosourea (EtNU) in immature Schwann cells of the rat peripheral nervous system. Subsequent loss of the wild-type neu allele may represent a critical secondary step towards malignancy. Developmentally-regulated expression of a wild-type rat neu transgene (neu cDNA under the control of the rat P-o promotor) in the Schwann cells of transgenic BDIX and Sprague-Dawley rats exposed to EtNU on postnatal day 1 results in a lower incidence of early atypical proliferates in the trigeminal nerve. Furthermore, re-introduction of the wild-type neu gene into homozygous neu mutant schwannoma cells counteracts the expression of the tumorigenic phenotype. The suppressive action of the wild-type gene over its mutationally activated oncogenic homologue underlines the critical function of the neu gene in the control of differentiation in the Schwann cell lineage, and provides evidence for the responsiveness of cellular phenotypes towards quantitative shifts in the dosage of wild-type vs mutant signal transducing molecules.	UNIV ESSEN GESAMTHSCH,SCH MED,INST CELL BIOL CANC RES,D-45122 ESSEN,GERMANY; UNIV ESSEN GESAMTHSCH,SCH MED,INST ANAT,D-45122 ESSEN,GERMANY; NN PETROV ONCOL RES INST,PATHOL LAB,ST PETERSBURG 189646,RUSSIA	University of Duisburg Essen; University of Duisburg Essen; N.N. Petrov Research Institute of Oncology				Flesken-Nikitin, Andrea/0000-0003-3017-1399				BACUS SS, 1993, CANCER RES, V53, P5251; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, CELL, V45, P549; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CHAZIN VR, 1992, ONCOGENE, V7, P1859; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; DATI C, 1990, ONCOGENE, V5, P1001; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; DOUGALL WC, 1994, ONCOGENE, V9, P2103; DRUCKREY H, 1971, ARZNEI-FORSCHUNG, V21, P1274; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HAYES C, 1992, J NEUROSCI RES, V31, P175, DOI 10.1002/jnr.490310123; HOGAN B, 1986, MANIPULATING MOUSE E; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; KIYOKAWA N, 1995, P NATL ACAD SCI USA, V92, P1092, DOI 10.1073/pnas.92.4.1092; KOKAI Y, 1989, CELL, V58, P287, DOI 10.1016/0092-8674(89)90843-X; LAERUM OD, 1975, J NATL CANCER I, V55, P1177, DOI 10.1093/jnci/55.5.1177; LEMKE G, 1988, NEURON, V1, P73, DOI 10.1016/0896-6273(88)90211-5; LEMKE G, 1985, CELL, V40, P501, DOI 10.1016/0092-8674(85)90198-9; LOFTS FJ, 1993, ONCOGENE, V8, P2813; LOTTI LV, 1992, EXP CELL RES, V202, P274, DOI 10.1016/0014-4827(92)90075-J; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTE BM, 1995, ONCOGENE, V10, P167; MESSERLE K, 1994, MOL CELL ENDOCRINOL, V105, P1, DOI 10.1016/0303-7207(94)90029-9; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MORGAN L, 1991, J CELL BIOL, V112, P457, DOI 10.1083/jcb.112.3.457; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; NIKITIN AY, 1993, VIRCHOWS ARCH B, V64, P151, DOI 10.1007/BF02915108; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; NIKITIN AY, 1991, DIFFERENTIATION, V48, P33, DOI 10.1111/j.1432-0436.1991.tb00240.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; SAMANTA A, 1994, P NATL ACAD SCI USA, V91, P1711, DOI 10.1073/pnas.91.5.1711; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SPORN MB, 1988, NATURE, V332, P217, DOI 10.1038/332217a0; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; SUEN TS, 1990, MOL CELL BIOL, V10, P6303; SWENBERG JA, 1975, J NATL CANCER I, V55, P147, DOI 10.1093/jnci/55.1.147; TAVERNA D, 1991, CELL GROWTH DIFFER, V2, P145; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WINTERHAGER E, 1991, EUR J CELL BIOL, V55, P133; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0	56	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1309	1317						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649833				2022-12-28	WOS:A1996UC06700016
J	Chen, J; Nachabah, A; Scherer, C; Ganju, P; Reith, A; Bronson, R; Ruley, HE				Chen, J; Nachabah, A; Scherer, C; Ganju, P; Reith, A; Bronson, R; Ruley, HE			Germ-line inactivation of the murine Eck receptor tyrosine kinase by gene trap retroviral insertion	ONCOGENE			English	Article						Eck deficient mice; gene trap retrovirus; insertional mutagenesis; node	EMBRYONIC STEM-CELLS; RETINOIC ACID; SIGNAL TRANSDUCTION; PROTO-ONCOGENE; LACZ REPORTER; W-LOCUS; EXPRESSION; HINDBRAIN; DISRUPTION; MICE	The present study characterized a mutation in the Eck receptor tyrosine kinase gene induced by the U3 beta geo gene trap retrovirus. The mutation (eck(i)) was identified during an in vitro screen for proviruses that disrupt developmentally regulated genes in cultured ES cells. The germ-line eck(i) fusion gene was expressed in blastocyst and later restricted to the primitive streak, node and to regions of the hindbrain in 6.5-10.5 day embryos. This is identical to the pattern of Eck gene expression as determined by either in situ hybridization or immunostaining, suggesting that expression of the Eck promoter was not affected by provirus integration. The provirus inserted approximately 8 kb upstream of the 5' end of the published cDNA sequence, and 1.8 kb downstream of an alternatively spliced 5' exon. The eck(i) allele is essentially a null mutation since mutant mice are severely deficient for Eck protein as determined by Western blot analysis and irt vitro kinase assays. Nevertheless, mice homozygous for the mutation did not exhibit any discernable phenotype. These results suggest that other members of the Eph family of receptor tyrosine kinases can functionally compensate for loss of Eck.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND; TUFTS UNIV, SCH MED, HUMAN NUTR RES CTR, BOSTON, MA 02111 USA	Massachusetts Institute of Technology (MIT); Ludwig Institute for Cancer Research; Tufts University	Chen, J (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, NASHVILLE, TN 37232 USA.			Chen, Jin/0000-0002-5557-2079	NIGMS NIH HHS [R01GM84688, 1 F32 GM17003-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM017003] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BECKMANN MP, 1994, EMBO J, V13, P3757, DOI 10.1002/j.1460-2075.1994.tb06685.x; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BOYLAN JF, 1995, MOL CELL BIOL, V15, P843; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHEN J, 1994, METH MOL G, V4, P123; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; COLON FL, 1991, DEVELOPMENT, V111, P969; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEGREGORI J, 1994, GENE DEV, V8, P265, DOI 10.1101/gad.8.3.265; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GANJU P, 1994, ONCOGENE, V9, P1613; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HAFEN E, 1991, DEVELOPMENT S, V112, P123; HEMPSTEAD BL, 1992, NEURON, V9, P883, DOI 10.1016/0896-6273(92)90241-5; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; Hogan B, 1994, MANIPULATING MOUSE E; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; JOYNER AL, 1991, S POSTIMPLANTATION D, P277; KLEIN R, 1992, NEURON, V8, P947, DOI 10.1016/0896-6273(92)90209-V; KURATANI SC, 1993, DEVELOPMENT, V117, P105; LEMOUELLIC H, 1990, P NATL ACAD SCI USA, V87, P4712, DOI 10.1073/pnas.87.12.4712; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LOEB DM, 1991, CELL, V66, P861; LUMSDEN A, 1991, DEVELOPMENT, V113, P1281; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MANSOUR SL, 1990, P NATL ACAD SCI USA, V87, P7688, DOI 10.1073/pnas.87.19.7688; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NODEN DM, 1988, DEVELOPMENT, V103, P121; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PAWSON T, 1990, TRENDS GENET, V6, P350, DOI 10.1016/0168-9525(90)90276-C; REDDY S, 1992, P NATL ACAD SCI USA, V89, P6721, DOI 10.1073/pnas.89.15.6721; REITH AD, 1991, GENOME ANAL, V3, P105; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROGERS MB, 1991, DEVELOPMENT, V113, P815; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; RUIZ JC, 1994, MECH DEVELOP, V46, P87; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SERBEDZIJA GN, 1992, DEVELOPMENT, V116, P297; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; STERNBERG PW, 1991, TRENDS GENET, V7, P336; VONMELCHNER H, 1992, GENE DEV, V6, P919, DOI 10.1101/gad.6.6.919; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	58	64	67	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					979	988						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649815				2022-12-28	WOS:A1996UA88400005
J	Chang, CL; Strahler, JR; Thoraval, DH; Qian, MG; Hinderer, R; Hanash, SM				Chang, CL; Strahler, JR; Thoraval, DH; Qian, MG; Hinderer, R; Hanash, SM			A nucleoside diphosphate kinase A (nm23-H1) serine 120->glycine substitution in advanced stage neuroblastoma affects enzyme stability and alters protein-protein interaction	ONCOGENE			English	Article						NDP kinase; nm23-H1; neuroblastoma	REDUCED EXPRESSION; TUMOR-METASTASIS; MYXOCOCCUS-XANTHUS; ESCHERICHIA-COLI; MESSENGER-RNA; GENE-PRODUCT; DROSOPHILA; CARCINOMA; CELLS; AUTOPHOSPHORYLATION	A high level of nucleoside diphosphate kinase A (NDPK A/nm23-H1) in neuroblastoma is associated with advanced stage disease. We have also found a serine 120-->glycine substitution in NDPK A and/or amplification of the nm23-H1 gene in advanced stage neuroblastomas. Serine 120, a highly conserved residue, is located in proximity to histidine 118 which forms a phosphorylated intermediate essential for NDPK activity. The effect of Ser120-->Gly substitution on the biochemical properties of NDPK A was investigated. Phosphate-transferase activity was lower in the recombinant mutant NDPK A and in the immunoprecipitated complex consisting of NDPK A and NDPK B prepared from a neuroblastoma tumor containing the mutation, relative to the wild-type. There was a significant decrease in the enzyme stability toward urea- or temperature-induced denaturation for the recombinant mutant NDPK A and in an immunoprecipitate from a tumor containing the mutation. Recombinant NDPK A containing the Ser120-->Gly mutation exhibited reduced hexameric and increased dimeric oligomerization relative to the wild-type. Moreover a 28 kDa cellular protein was detected, that co-precipitated with the mutant but not wild-type NDPK A. The altered properties of the mutant protein may have relevance to a role for NDPK A in neuroblastoma progression.	UNIV MICHIGAN, DEPT CHEM, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan	Chang, CL (corresponding author), UNIV MICHIGAN, DEPT PEDIAT, ANN ARBOR, MI 48109 USA.		Chang, Christina/B-9650-2009		NCI NIH HHS [CA32146, CA26803] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA032146, P01CA026803] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agarwal R P, 1978, Methods Enzymol, V51, P376; AGARWAL RP, 1971, J BIOL CHEM, V246, P2258; AYHAN A, 1993, VIRCHOWS ARCH B, V63, P213, DOI 10.1007/BF02899264; BIGGS J, 1988, GENE DEV, V2, P1333, DOI 10.1101/gad.2.10.1333; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; BOMINAAR AA, 1994, FEBS LETT, V353, P5, DOI 10.1016/0014-5793(94)00997-X; CHANG CL, 1994, NATURE, V370, P335, DOI 10.1038/370335a0; CRAIG WS, 1988, METHOD ENZYMOL, V156, P333; DEAROLF C, 1988, DEV BIOL, V129, P139; DUMAS C, 1992, EMBO J, V11, P3203, DOI 10.1002/j.1460-2075.1992.tb05397.x; ENGEL M, 1993, INT J CANCER, V55, P375, DOI 10.1002/ijc.2910550306; FLORENES VA, 1992, CANCER RES, V52, P6088; GARCES E, 1969, BIOCHEMISTRY-US, V8, P633, DOI 10.1021/bi00830a026; GILLES AM, 1991, J BIOL CHEM, V266, P8784; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HEMMERICH S, 1992, BIOCHEMISTRY-US, V31, P4580, DOI 10.1021/bi00134a007; KIMURA N, 1988, J BIOL CHEM, V263, P4647; KIMURA N, 1990, J BIOL CHEM, V265, P15744; KODERA Y, 1994, CANCER, V73, P259, DOI 10.1002/1097-0142(19940115)73:2<259::AID-CNCR2820730205>3.0.CO;2-V; KOYAMA K, 1984, J BIOCHEM-TOKYO, V95, P925, DOI 10.1093/oxfordjournals.jbchem.a134720; LACOMBE ML, 1990, J BIOL CHEM, V265, P10012; LASCU I, 1992, J BIOL CHEM, V267, P12775; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; LEONE A, 1991, CANCER RES, V51, P2490; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MUNOZDORADO J, 1993, J BACTERIOL, V175, P1176; MUNOZDORADO J, 1990, J BIOL CHEM, V265, P2702; NAKAMORI S, 1993, INT J PANCREATOL, V14, P125; NAKAYAMA H, 1993, JPN J CANCER RES, V84, P184, DOI 10.1111/j.1349-7006.1993.tb02853.x; NAKAYAMA T, 1992, J NATL CANCER I, V84, P1349, DOI 10.1093/jnci/84.17.1349; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SCHWAB M, 1990, Critical Reviews in Oncogenesis, V2, P35; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TEPPER AD, 1994, J BIOL CHEM, V269, P32175; TIMMONS L, 1993, DEV BIOL, V158, P364, DOI 10.1006/dbio.1993.1195; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; URANO T, 1993, ONCOGENE, V8, P1371; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; ZHOU M, 1993, BRIT J CANCER, V68, P385, DOI 10.1038/bjc.1993.345; ZINYK DL, 1993, NAT GENET, V4, P195, DOI 10.1038/ng0693-195	52	50	53	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					659	667						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637723				2022-12-28	WOS:A1996TV59700023
J	Berx, G; CletonJansen, AM; Strumane, K; deLeeuw, WJF; Nollet, F; vanRoy, F; Cornelisse, C				Berx, G; CletonJansen, AM; Strumane, K; deLeeuw, WJF; Nollet, F; vanRoy, F; Cornelisse, C			E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain	ONCOGENE			English	Article						lobular breast cancer; E-cadherin; mutations; LOH; tumour suppressor gene	CELL-ADHESION MOLECULE; EPITHELIAL TUMOR-CELLS; SUPPRESSOR GENE; ALPHA-CATENIN; BETA-CATENIN; GASTRIC CARCINOMAS; CPG METHYLATION; EXPRESSION; ASSOCIATION; DNA	We have analysed a series of 49 human breast cancers for mutations in the entire coding region plus flanking intron sequences of the E-cadherin gene, The tumours included 41 infiltrating lobular carcinomas, two infiltrating ducto-lobular carcinomas and six infiltrative ductal carcinomas, In the lobular carcinomas 23 different somatic mutations were detected, of which seven were insertions, 11 deletions, two nonsense mutations and three splice site mutations, The other tumours showed no detectable E-cadherin mutations, All the frameshift and nonsense mutations are expected to generate a secreted E-cadherin fragment instead of a transmembrane protein with cell adhesion activity, The majority of the mutations (21 of 23) were found in combination with loss of heterozygosity of the wild type E-cadherin locus (16q22.1), a hallmark of classical tumour suppressor genes, The mutations were scattered over the whole coding region and no hot spots could be identified, All mutations described here were previously unreported, In conclusion, we have identified up to now E-cadherin mutations in 27 of 48 (56%) infiltrating lobular breast carcinomas and in 0 of 50 breast cancers of other histopathological subtypes, These data provide strong evidence that frequent E-cadherin mutations are involved in the particular etiology of sporadic lobular breast cancers.	STATE UNIV GHENT,MOL CELL BIOL LAB,DEPT BIOL MOL,B-9000 GHENT,BELGIUM; VIB,B-9000 GHENT,BELGIUM; ACAD HOSP LEIDEN,DEPT PATHOL,NL-2300 RC LEIDEN,NETHERLANDS	Ghent University; Flanders Institute for Biotechnology (VIB); Leiden University; Leiden University Medical Center (LUMC)			van Roy, Frans M/C-6123-2009	van Roy, Frans M/0000-0003-4358-1039; Berx, Geert/0000-0001-5770-2458				ABERLE H, 1994, J CELL SCI, V107, P3655; BEAUDET AL, 1993, HUM MUTAT, V2, P245, DOI 10.1002/humu.1380020402; BECKER KF, 1993, HUM MOL GENET, V2, P803, DOI 10.1093/hmg/2.6.803; BECKER KF, 1994, CANCER RES, V54, P3845; BERX G, 1995, GENOMICS, V26, P281, DOI 10.1016/0888-7543(95)80212-5; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BUSSEMAKERS MJG, 1993, MOL BIOL REP, V17, P123, DOI 10.1007/BF00996219; Candidus S, 1996, CANCER RES, V56, P49; CLETONJANSEN AM, 1994, GENE CHROMOSOME CANC, V9, P101, DOI 10.1002/gcc.2870090205; CORNELIS RS, 1994, CANCER RES, V54, P4200; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; DSOUZA B, 1994, P NATL ACAD SCI USA, V91, P7202, DOI 10.1073/pnas.91.15.7202; EWING CM, 1995, CANCER RES, V55, P4813; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; FUJIOKA S, 1995, JPN J CANCER RES, V86, P368, DOI 10.1111/j.1349-7006.1995.tb03066.x; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAMALLO C, 1993, AM J PATHOL, V142, P987; GRAFF JR, 1995, CANCER RES, V55, P5195; Hayashi K, 1991, PCR Methods Appl, V1, P34; HENNIG G, 1995, ONCOGENE, V11, P475; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; KANAI Y, 1994, JPN J CANCER RES, V85, P1035, DOI 10.1111/j.1349-7006.1994.tb02902.x; KATAYAMA M, 1994, BRIT J CANCER, V69, P580, DOI 10.1038/bjc.1994.106; KATAYAMA M, 1994, INT J ONCOL, V5, P1049; KNUDSON AG, 1985, CANCER RES, V45, P1437; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MOLL R, 1993, AM J PATHOL, V143, P1731; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211; RIMM DL, 1995, LAB INVEST, V72, P506; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; ROSEN PP, 1993, ATLAS TUMOUR PATHOLO; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKAYAMA T, 1994, INT J ONCOL, V5, P775; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VLEMINCKX KL, 1994, CANCER RES, V54, P873; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	51	376	385	0	14	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1919	1925						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934538				2022-12-28	WOS:A1996VR79500011
J	Kumar, A; Toscani, A; Rane, S; Reddy, EP				Kumar, A; Toscani, A; Rane, S; Reddy, EP			Structural organization and chromosomal mapping of JAK3 locus	ONCOGENE			English	Article						JAK3 genomic sequence; chromosome 19; intron exon organization	PROTEIN-TYROSINE KINASE; GAMMA SIGNAL-TRANSDUCTION; MICE LACKING JAK3; INSITU HYBRIDIZATION; TRANSCRIPTION FACTOR; LYMPHOID DEVELOPMENT; RECEPTOR; ACTIVATION; CELLS; PHOSPHORYLATION	In this study, we have isolated the genomic DNA clone encoding the murine JAK3 gene and determined its sequence. Partial genomic clones of the JAK1 and JAK2 genes encoding the tyrosine kinase domain were also isolated and compared with JAK3. The genomic structure of JAK3 consists of 23 exons. The exon/intron boundaries and the distribution of coding sequences within the exons of each of the three JAK genes were found to follow a similar pattern suggesting that various members of the JAK family have originated from a single primordial gene by duplication and the structure has been closely maintained through evolution. Using in situ hybridization and FISH analysis, we have mapped the JAK3 gene to human chromosome 19p13.1-p13.2.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOL BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NCI NIH HHS [CA68239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA068239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; HARPUR AG, 1992, ONCOGENE, V7, P1347; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENG HHQ, 1994, HUM MOL GENET, V3, P61, DOI 10.1093/hmg/3.1.61; HUNTER T, 1993, NATURE, V366, P114, DOI 10.1038/366114a0; INOUE M, 1991, P NATL ACAD SCI USA, V88, P2278, DOI 10.1073/pnas.88.6.2278; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Kono DH, 1996, MAMM GENOME, V7, P476, DOI 10.1007/s003359900145; LAI KS, 1995, J BIOL CHEM, V270, P25028, DOI 10.1074/jbc.270.42.25028; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; NICHOLSON SE, 1994, P NATL ACAD SCI USA, V91, P2985, DOI 10.1073/pnas.91.8.2985; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RANE SG, 1994, ONCOGENE, V9, P2415; RUI H, 1994, J BIOL CHEM, V269, P5364; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLINDER C, 1995, ANNU REV BIOCHEM, V64, P621; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	32	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					2009	2014						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934548				2022-12-28	WOS:A1996VR79500021
J	Lin, JC; Scherer, SW; Tougas, L; Traverso, G; Tsui, LC; Andrulis, IL; Jothy, S; Park, M				Lin, JC; Scherer, SW; Tougas, L; Traverso, G; Tsui, LC; Andrulis, IL; Jothy, S; Park, M			Detailed deletion mapping with a refined physical map of 7q31 localizes a putative tumor suppressor gene for breast cancer in the region of MET	ONCOGENE			English	Article						breast cancer; tumor suppressor gene; chromosome 7q31; MET receptor tyrosine kinase; loss of heterozygosity	HEPATOCYTE GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; CYSTIC-FIBROSIS LOCUS; EPITHELIAL-CELLS; SCATTER FACTOR; C-MET; MAMMARY-GLAND; FREQUENT LOSS; ALLELIC LOSS; RET PROTOONCOGENE	In breast cancer, loss of heterozygosity (LOH) has been described on the long arm of chromosome 7 at band q31, suggesting the presence of a tumor suppressor gene in this region. To define the deleted region, we analysed 73 cases of breast cancer and matched normal DNAs with 17 polymorphic markers. A minimal area of LOH was identified as the chromosomal interval flanked by markers D7S687 and metH, spanning a segment of 2 Mb on chromosome 7q31, Of the 73 breast cancer patients studied, all were informative for at least one marker in this region and nine patients showed LOH at one or more loci (12.3%). To define the physical size of the deletion and to ensure the correct interpretation of the LOH deletion studies, we redefined the physical map of markers within this region of 7q31, We present a new physical order for markers at 7q31. More significantly, we have mapped the minimum deletion of 7q31 in the breast cancers studied to date to a physical distance of 1000 kb, contained on a single YAC clone, which includes the MET receptor tyrosine kinase but no other known genes.	MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PATHOL,MONTREAL,PQ,CANADA; UNIV TORONTO,DEPT MOL & MED GENET,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PATHOL,TORONTO,ON,CANADA	McGill University; McGill University; McGill University; McGill University; University of Toronto; University of Toronto			Scherer, Stephen W./B-3785-2013; Andrulis, Irene L./E-7267-2013; Tsui, Lap-chee/A-1081-2010	Scherer, Stephen W./0000-0002-8326-1999; 				BERDICHEVSKY F, 1994, J CELL SCI, V107, P3557; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CALLAHAN R, 1993, CLIN CHIM ACTA, V217, P63, DOI 10.1016/0009-8981(93)90238-Y; CALLAHAN R, 1992, CANCER, V69, P1582, DOI 10.1002/1097-0142(19920315)69:6+<1582::AID-CNCR2820691313>3.0.CO;2-Y; CHAMPEME MH, 1995, GENE CHROMOSOME CANC, V12, P304, DOI 10.1002/gcc.2870120411; CHEN LC, 1992, J NATL CANCER I, V84, P506, DOI 10.1093/jnci/84.7.506; COHEN D, 1993, NATURE, V366, P698, DOI 10.1038/366698a0; DENG G, 1994, CANCER RES, V54, P499; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, CRIT REV ONCOGENESIS, V5, P247, DOI 10.1615/CritRevOncog.v5.i2-3.70; DIRENZO MF, 1991, ONCOGENE, V6, P1997; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMPTON GM, 1994, CANCER RES, V54, P4586; HORN GT, 1990, CLIN CHEM, V36, P1614; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; KERANGUEVEN F, 1995, ONCOL REP, V2, P89; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; Latil A, 1995, CLIN CANCER RES, V1, P1385; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LITT M, 1993, BIOTECHNIQUES, V15, P280; MANIATIS T, 1992, MOL CLONING; MCBRIDE OW, 1986, P NATL ACAD SCI USA, V83, P130, DOI 10.1073/pnas.83.1.130; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MULLER D, 1995, ONCOL REP, V2, P847; NAGY J, 1995, J SURG ONCOL, V60, P95, DOI 10.1002/jso.2930600206; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NIRANJAN B, 1995, DEVELOPMENT, V121, P2897; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PEPPER MS, 1995, EXP CELL RES, V219, P204, DOI 10.1006/excr.1995.1220; Poustka A, 1988, GENOMICS, V2, P337, DOI 10.1016/0888-7543(88)90023-7; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RAHIMI N, 1994, DNA CELL BIOL, V13, P1189, DOI 10.1089/dna.1994.13.1189; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; ROMMENS JM, 1989, AM J HUM GENET, V45, P932; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SATO T, 1990, CANCER RES, V50, P7184; SCHERER S, 1991, P33; SCHERER SW, 1992, MAMM GENOME, V3, P179, DOI 10.1007/BF00352464; SORIANO JV, 1995, J CELL SCI, V108, P413; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAKAHASHI S, 1995, CANCER RES, V55, P4114; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; YANG XM, 1995, LAB INVEST, V73, P483; YANG YM, 1995, J CELL BIOL, V131, P215, DOI 10.1083/jcb.131.1.215; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347	60	50	50	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2001	2008						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934547				2022-12-28	WOS:A1996VR79500020
J	Ou, XL; Campau, S; Slusher, R; Jasti, RK; Mabry, M; Kalemkerian, GP				Ou, XL; Campau, S; Slusher, R; Jasti, RK; Mabry, M; Kalemkerian, GP			Mechanism of all-trans-retinoic acid-mediated L-myc gene regulation in small cell lung cancer	ONCOGENE			English	Article						retinoic acid; myc; lung cancer; transcription	N-MYC; CARCINOMA-CELLS; HIGH-FREQUENCY; RECEPTOR-BETA; C-MYC; EXPRESSION; FAMILY; LINES; ONCOGENES; DIFFERENTIATION	The L-myc oncogene is commonly expressed in small cell lung cancer (SCLC) cells and is associated with SCLC cells with a high level of neuroendocrine differentiation and a relatively low proliferative index, We have previously reported that all-trans-retinoic acid (RA) inhibits the growth of NCI-H82 SCLC cells in association with increased neuroendocrine differentiation, increased L-myc gene expression and decreased c-myc gene expression, In the present report, the mechanism of RA-mediated L-myc up-regulation in NCI-H82 SCLC cells was determined by analysing transcriptional and post-transcriptional control of L-myc gene expression, Increases in steady-state levels of L-myc mRNA occurred in a dose-dependent manner after exposure to RA at a time-point prior to discernible changes in cellular morphology or growth, By nuclear run-on analysis, there was a clear increase in L-myc transcript initiation in NCI-H82 cells treated with 1 mu M RA, but no alteration was noted in the baseline degree of transcript attenuation when compared to control cells, L-myc transcript half-life remained unchanged after exposure to 1 mu M RA, indicating that post-transcriptional regulation is not a major factor in the control of L-myc gene expression, A marked dose-dependent increase in RAR beta expression was also demonstrated in RA-treated NCI-H82 cells, We conclude that RA-mediated up-regulation of L-myc gene expression occurs through stimulation of transcript initiation and that the biological effects of RA in SCLC cells may be mediated through RAR beta-dependent pathways.	WAYNE STATE UNIV, DIV HEMATOL & ONCOL, DETROIT, MI 48201 USA; KARMANOS CANC INST, DETROIT, MI 48201 USA; JOHNS HOPKINS ONCOL CTR, DEPT RADIAT ONCOL, BALTIMORE, MD 21287 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Johns Hopkins University; Johns Hopkins Medicine					NATIONAL CANCER INSTITUTE [R01CA048081, R01CA058974] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007076] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA58974-03, R01CA48081-06] Funding Source: Medline; NIEHS NIH HHS [R01ES07076-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERNARD O, 1992, NEURON, V9, P1217, DOI 10.1016/0896-6273(92)90079-S; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BRENNAN J, 1991, CANCER RES, V51, P1708; BROOKS BJ, 1987, ADV VIRAL ONCOL, V7, P155; CELANO P, 1989, BIOTECHNIQUES, V7, P942; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; DONY C, 1985, NATURE, V317, P636, DOI 10.1038/317636a0; DOYLE LA, 1989, CANCER RES, V49, P6745; GAZZERI S, 1991, CANCER RES, V51, P2566; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; Gudas Lorraine J., 1994, P443; HONG WK, 1993, RETINOIDS ONCOLOGY; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; INGVARSSON S, 1988, ONCOGENE, V3, P679; Jetten A M, 1992, J Natl Cancer Inst Monogr, P93; JOHNSON BE, 1996, LUNG CANC PRINCIPLES, P83; KALEMKERIAN G, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P370; KALEMKERIAN GP, 1994, CELL GROWTH DIFFER, V5, P55; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KIM YH, 1995, CANCER RES, V55, P5603; KRUMM A, 1993, BIOESSAYS, V15, P659, DOI 10.1002/bies.950151005; KRUPITZA G, 1995, INT J CANCER, V61, P649, DOI 10.1002/ijc.2910610511; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LIN X, 1991, MOL CELL BIOL, V11, P6007, DOI 10.1128/MCB.11.12.6007; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P493; MILLER WH, 1990, ONCOGENE, V5, P511; MOROY T, 1991, ONCOGENE, V6, P1941; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; PRINS J, 1993, ANTICANCER RES, V13, P1373; RYGAARD K, 1993, INT J CANCER, V54, P144, DOI 10.1002/ijc.2910540123; SAKSELA K, 1990, J CELL BIOCHEM, V42, P153, DOI 10.1002/jcb.240420306; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Sporn M B, 1984, J Natl Cancer Inst, V73, P1381; TAKAHASHI T, 1989, CANCER RES, V49, P2683; THIELE CJ, 1988, ONCOGENE, V3, P281; WADA RK, 1992, ONCOGENE, V7, P711; Weber E., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P503; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	41	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1893	1899						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934535				2022-12-28	WOS:A1996VR79500008
J	Savio, M; Stivala, LA; Scovassi, AI; Bianchi, L; Prosperi, E				Savio, M; Stivala, LA; Scovassi, AI; Bianchi, L; Prosperi, E			P21(waf1/cip1) protein associates with the detergent-insoluble form of PCNA concomitantly with disassembly of PCNA at nucleotide excision repair sites	ONCOGENE			English	Article						PCNA; p21waf1/cip1; DNA damage; nucleotide excision repair	CELL NUCLEAR ANTIGEN; CYCLIN-DEPENDENT KINASES; DNA-POLYMERASE-DELTA; P53-MEDIATED G(1) ARREST; HUMAN FIBROBLASTS; COMPLEX-FORMATION; BINDING DOMAINS; LEUKEMIA-CELLS; GROWTH ARREST; HELA-CELLS	Evidence is presented that after exposure of normal human fibroblasts to UV-C light, nuclear binding of the proliferating cell nuclear antigen (PCNA) required for nucleotide excision repair, was rapidly triggered in the G(1) and G(2) phases of the cell cycle. Association to repair sites of the detergent-insoluble form of PCNA reached a peak 15-30 min after irradiation, and then decreased to basal levels within 24-48 h. In contrast, the nuclear association of p21 protein showed a slower kinetics, reaching maximal levels between 24 and 48h but, similarly to PCNA, occurring only in G(1) and G(2) phases. Although the two proteins are known to be associated as detergent-soluble proteins, it is unknown whether they associate also in the detergent-insoluble form. To address this question, the chromatin-bound form of PCNA was released by using DNAse I. DNA digestion resulted in the almost complete release of PCNA from its binding sites, while only about 60% of nuclear-bound p21 could be solubilized. Immunoprecipitation of PCNA and p21 released by enzymatic digestion showed that p21 was associated with PCNA bound to late DNA repair sites. These results indicate that during nucleotide excision repair, nuclear binding of PCNA precedes that of p21 protein, and suggest that temporal association of p21 with the detergent-insoluble fraction is coincident with the disassembly of PCNA from DNA repair sites.	CNR,CTR STUDIO ISTOCHIM,I-27100 PAVIA,ITALY; CNR,IST GENET BIOCHIM & EVOLUZIONIST,I-27100 PAVIA,ITALY; UNIV PAVIA,IST PATOL GEN,I-27100 PAVIA,ITALY	Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Pavia			Prosperi, Ennio/A-3439-2014; Scovassi, Anna Ivana/F-2458-2010	Prosperi, Ennio/0000-0001-5391-5157; Scovassi, Anna Ivana/0000-0003-3484-9881				BOHR V A, 1988, Trends in Biochemical Sciences, V13, P429, DOI 10.1016/0968-0004(88)90216-2; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; CELIS JE, 1986, FEBS LETT, V209, P277, DOI 10.1016/0014-5793(86)81127-9; Chen IT, 1996, ONCOGENE, V12, P595; CHEN IT, 1995, ONCOGENE, V11, P1931; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FANG F, 1993, J CELL SCI, V106, P983; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOUBIN F, 1995, ONCOGENE, V10, P2281; HALL PA, 1995, ONCOGENE, V10, P2427; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HAVELY O, 1995, SCIENCE, V267, P1018; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; JAUMOT M, 1994, BIOCHEM BIOPH RES CO, V203, P1527, DOI 10.1006/bbrc.1994.2359; JENSEN KA, 1990, BIOCHEMISTRY-US, V29, P4773, DOI 10.1021/bi00472a005; JIANG HP, 1994, ONCOGENE, V9, P3397; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LANDBERG G, 1991, CANCER RES, V51, P4750; Li R, 1996, CURR BIOL, V6, P189, DOI 10.1016/S0960-9822(02)00452-9; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P2216; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MIURA M, 1992, EXP CELL RES, V201, P541, DOI 10.1016/0014-4827(92)90308-U; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2442; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PROSPERI E, 1993, EXP CELL RES, V205, P320, DOI 10.1006/excr.1993.1092; PROSPERI E, 1994, EXP CELL RES, V215, P352; SADAIE MR, 1986, EXP CELL RES, V163, P423, DOI 10.1016/0014-4827(86)90073-X; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SOBCZAKTHEPOT J, 1993, EXP CELL RES, V206, P43, DOI 10.1006/excr.1993.1118; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TOSCHI L, 1988, J CELL BIOL, V107, P1623, DOI 10.1083/jcb.107.5.1623; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENG XR, 1994, J BIOL CHEM, V269, P24027; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHANG W, 1995, CANCER RES, V55, P668	64	42	43	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1591	1598						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895503				2022-12-28	WOS:A1996VM88700002
J	Dalley, BK; Cannon, JF				Dalley, BK; Cannon, JF			Novel, activated RAS mutations alter protein-protein interactions	ONCOGENE			English	Article						RAS; RAF; NF1; GTPase activating proteins; yeast; genetics	SITE-DIRECTED MUTAGENESIS; ADENYLATE-CYCLASE PATHWAY; SACCHAROMYCES-CEREVISIAE; GUANINE-NUCLEOTIDES; SIGNAL TRANSDUCTION; EFFECTOR RESIDUES; TERMINAL DOMAIN; GTP HYDROLYSIS; YEAST-CELLS; GENE	Random RAS2 mutants of Saccharmoyces cerevisiae were screened for activating traits, A total of 69 distinct mutations were identified, affecting 44 different amino acid residues, Many activated alleles do not bypass the requirement for the nucleotide exchange factor, CDC25, nor is the severity of RAS2 phenotypic traits strictly correlated with the capacity to bypass CDC25, In vivo interactions of mutant RAS2 proteins with RAS effecters (adenylate cyclase and RAF), CDC25 and GTPase activating proteins (IRA2 and NF1) mere assayed to assess how the various amino acid substitutions influence interactions with regulatory and target proteins of RAS, Nearly all activated RAS2 proteins mere observed to interact better with adenylate cyclase and RaF, although some distinct differences were found, Several amino acid substitutions that reduce the affinity of RAS2 for guanine nucleotides apparently elevate the fraction of nucleotide-free RAS2, which has greater CDC25 affinity. Amino acid alterations that reduce the affinity of RAS2 for GTPase activating proteins included substitutions both within the switch I/switch II domain and distinctly outside it, One mutant, RAS2-Y78F, bound a lower fraction of GTP in vivo than the wild-type protein, The Y78F substitution is localized to the switch II domain, a region of the RAS protein that undergoes guanine nucleotide-dependent conformational changes.	UNIV MISSOURI, DEPT MOL MICROBIOL & IMMUNOL, COLUMBIA, MO 65212 USA	University of Missouri System; University of Missouri Columbia				Cannon, John/0000-0001-6698-176X				BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Barnard D, 1995, ONCOGENE, V10, P1283; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROACH JR, 1991, TRENDS GENET, V7, P28, DOI 10.1016/0168-9525(91)90018-L; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CANNON JF, 1994, GENETICS, V136, P485; CASPERSON GF, 1985, P NATL ACAD SCI USA, V82, P5060, DOI 10.1073/pnas.82.15.5060; CHESTER VE, 1968, J GEN MICROBIOL, V51, P47, DOI 10.1099/00221287-51-1-49; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CLANTON DJ, 1987, MOL CELL BIOL, V7, P3092, DOI 10.1128/MCB.7.9.3092; CRECHET JB, 1990, J BIOL CHEM, V265, P1563; DENT P, 1992, EUR J BIOCHEM, V210, P1037, DOI 10.1111/j.1432-1033.1992.tb17509.x; DER CJ, 1986, MOL CELL BIOL, V6, P3291, DOI 10.1128/MCB.6.9.3291; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Eckert K A, 1991, PCR Methods Appl, V1, P17; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FUJITAYOSHIGAKI J, 1995, J BIOL CHEM, V270, P4661, DOI 10.1074/jbc.270.9.4661; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; HARDY TA, 1994, J BIOL CHEM, V269, P27907; HU JS, 1993, BIOCHEMISTRY-US, V32, P6763, DOI 10.1021/bi00077a031; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1993, ONCOGENE, V8, P425; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mittal R, 1996, SCIENCE, V271, P1413, DOI 10.1126/science.271.5254.1413; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PETITJEAN A, 1990, GENETICS, V124, P797; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; RUGGIERI R, 1989, P NATL ACAD SCI USA, V86, P8778, DOI 10.1073/pnas.86.22.8778; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIKORSKI RS, 1989, GENETICS, V122, P19; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1992, MOL CELL BIOL, V12, P631, DOI 10.1128/MCB.12.2.631; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WILSON BA, 1993, ONCOGENE, V8, P3441; WOOD DR, 1994, J BIOL CHEM, V269, P5322; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	60	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1209	1220						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808695				2022-12-28	WOS:A1996VJ20200012
J	Pedley, J; Ablett, EM; Pettit, A; Meyer, J; Dunn, IS; Sturm, RA; Parsons, PG				Pedley, J; Ablett, EM; Pettit, A; Meyer, J; Dunn, IS; Sturm, RA; Parsons, PG			Inhibition of retinoblastoma protein translation by UVB in human melanocytic cells and reduced cell cycle arrest following repeated irradiation	ONCOGENE			English	Article						UVB; melanocytes; retinoblastoma gene product; translation; cycle arrest	GENE-PRODUCT; BILATERAL RETINOBLASTOMA; CUTANEOUS MELANOMA; PHOSPHORYLATION; DIFFERENTIATION; RADIATION; RB; EXPRESSION; IDENTIFICATION; TRANSCRIPTION	In human melanocytes and a human melanoma cell line (MM96L), the level of the retinoblastoma gene product (pRB) detected by Western blotting transiently decreased to 55% and 70% of controls respectively 9-12 h after a noncytostatic exposure (75 Jm(-2)) to UVB (280-315 mm) and to 2% and 14% 48 h after a cytostatic exposure (300 Jm(-2)). The pRB levels in fibroblasts and HeLa showed minimal loss, and under some conditions increased compared with unirradiated cells. Equitoxic doses of gamma radiation, cisplatin or the antimetabolite deoxyinosine had little effect on pRB levels. UVC (254 mn) was less inhibitory compared with equitoxic UVB. No loss of PRB mRNA was found in MM96L after UVB, nor was PRB protein stability significantly affected. Synthesis of new pRB in h MM96L 24 h after UVB was 16% of controls, suggesting that loss of pRB results from a UVB-specific inhibition of translation. Compared with HeLa cells and fibroblasts, MM96L cells exhibited reduced cycle arrest if irradiated when pRB was depleted by a previous WE exposure. These results suggest a mechanism whereby down-regulation of pRB translation by UVB may play a role in genesis of melanoma.	QUEENSLAND INST MED RES,QUEENSLAND CANC FUND LABS,HERSTON,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT PATHOL,BRISBANE,QLD 4072,AUSTRALIA; UNIV QUEENSLAND,CTR MOL & CELL BIOL,BRISBANE,QLD 4072,AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Queensland; University of Queensland			Parsons, Peter G/H-8163-2015; Pettit, Allison/O-4462-2019; Sturm, Richard A/C-9943-2009	Parsons, Peter G/0000-0002-0473-3346; Pettit, Allison/0000-0003-4707-7892; Sturm, Richard A/0000-0003-1301-0294				ABDELMALEK Z, 1994, PIGM CELL RES, V7, P326, DOI 10.1111/j.1600-0749.1994.tb00635.x; ALBERT LS, 1990, J AM ACAD DERMATOL, V23, P1001, DOI 10.1016/0190-9622(90)70322-9; ANDERSON MJ, 1994, GENE CHROMOSOME CANC, V9, P251, DOI 10.1002/gcc.2870090405; AUSUBEL FM, 1989, CURRENT RPOTOCOLS MO; BARKER D, 1995, CANCER RES, V55, P4041; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COFFER PJ, 1995, ONCOGENE, V11, P561; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GALLIE BL, 1990, LAB INVEST, V62, P394; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; HAMEL PA, 1992, TRENDS GENET, V8, P180, DOI 10.1016/0168-9525(92)90221-O; HENTZE MW, 1995, CURR OPIN CELL BIOL, V7, P393, DOI 10.1016/0955-0674(95)80095-6; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOROVITZ M, 1993, NEW STATESMAN SOC, V6, P24; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KHANNA KK, 1995, ONCOGENE, V11, P609; KLEINSZANTO AJP, 1994, CANCER RES, V54, P4569; KRANENBURG O, 1995, ONCOGENE, V10, P87; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEVY R, 1993, PRESSE MED, V22, P878; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MEDRANO EE, 1995, CANCER RES, V55, P4047; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORLEY SJ, 1994, MOL BIOL REP, V19, P221, DOI 10.1007/BF00986964; MUNCASTER MM, 1992, CANCER RES, V52, P654; PARSONS PG, 1985, PHOTOCHEM PHOTOBIOL, V42, P287, DOI 10.1111/j.1751-1097.1985.tb08944.x; POLLOCK PM, 1995, ONCOGENE, V11, P663; PRUSS RM, 1981, CELL, V27, P419, DOI 10.1016/0092-8674(81)90383-4; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; ROSENSTEIN BS, 1995, PHOTOCHEM PHOTOBIOL, V61, P142, DOI 10.1111/j.1751-1097.1995.tb03952.x; SAUNDERS BM, 1989, BRIT J CANCER, V60, P358; SCHWARTZ E, 1995, J INVEST DERMATOL, V105, P65, DOI 10.1111/1523-1747.ep12312576; SIEBERT PD, 1993, BIOTECHNIQUES, V14, P244; Sonenberg N, 1993, CURR OPIN CELL BIOL, V5, P955, DOI 10.1016/0955-0674(93)90076-3; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; STURM RA, 1991, CELL GROWTH DIFFER, V2, P519; TANG A, 1989, ONCOGENE, V4, P401; YAVUZER U, 1995, ONCOGENE, V10, P123; YEN A, 1992, EUR J CELL BIOL, V57, P210; YEN A, 1992, IN VITRO CELL DEV-AN, V28A, P669; ZACHSENHAUS E, 1993, MOL CELL BIOL, V13, P4588	51	13	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1335	1342						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808708				2022-12-28	WOS:A1996VJ20200025
J	Steenbergen, RDM; Walboomers, JMM; Meijer, CJLM; vanderRaaijHelmer, EMH; Parker, JN; Chow, LT; Broker, TR; Snijders, PJF				Steenbergen, RDM; Walboomers, JMM; Meijer, CJLM; vanderRaaijHelmer, EMH; Parker, JN; Chow, LT; Broker, TR; Snijders, PJF			Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: Activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q	ONCOGENE			English	Article						human papillomavirus; keratinocytes; allelotyping; loss of heterozygosity; telomerase; immortalization	SQUAMOUS-CELL CARCINOMAS; EPITHELIAL-CELLS; CERVICAL-CARCINOMA; GENETIC-ANALYSIS; UTERINE CERVIX; CHROMOSOME 3P; CANCER; DIFFERENTIATION; SENESCENCE; HETEROZYGOSITY	This study aimed at resolving cellular genetic alterations in the process of in vitro immortalization of human keratinocytes by human papillomavirus (HPV) types 16 and 18. Four cell lines of primary human foreskin keratinocytes transfected with HPV 16 and HPV 18, respectively, were analysed during the transition from the mortal to immortal state, All cell lines showed strong telomerase activity at the immortal state, whereas no or only weak telomerase activity was detected in mortal precursor cells, This was consistent with telomere stabilization or restoration only observed in immortal cells, HPV physical state and copy number appeared constant during immortalization and HPV E6/E7 transcripts were present throughout, Immortalization was associated with clonal allele losses at 3p combined with either 11q or 18q or at 10p, dependent on the cell line, Moreover, a correlation was evident between the onset of telomerase activity and allele loss at 30 or 10p, All immortalized cells retained the capability to differentiate after growth in the presence of physiological calcium and serum, Moreover, one of the immortal cell lines displayed terminal differentiation after organotypic culturing on collagen rafts, The data suggest that (a) several pathways exist for HPV mediated immortalization that may involve genes residing at 3p, 10p, 11q and/or 18q; (b) 3p and 10p may encode genes involved in telomerase regulation; and (c) immortalization lit vitro can be correlated with a spectrum of morphological changes varying from mild to severe dysplasia.	FREE UNIV AMSTERDAM HOSP, DEPT PATHOL, UNIT MOL PATHOL, NL-1081 HV AMSTERDAM, NETHERLANDS; FREE UNIV AMSTERDAM HOSP, DEPT PATHOL, NL-1081 HV AMSTERDAM, NETHERLANDS; UNIV ALABAMA, DEPT BIOCHEM & MOL GENET, BIRMINGHAM, AL 35294 USA	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Alabama System; University of Alabama Birmingham				Steenbergen, Renske/0000-0002-2327-9839	NATIONAL CANCER INSTITUTE [T32CA009467, R01CA036200] Funding Source: NIH RePORTER; NCI NIH HHS [CA36200, T32 CA09467] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT JC, 1994, COLD SPRING HARB SYM, V59, P411, DOI 10.1101/SQB.1994.059.01.046; BLANTON RA, 1991, AM J PATHOL, V138, P673; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHEN TM, 1993, CANCER RES, V53, P1167; Chung GTY, 1995, ONCOGENE, V11, P2591; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; GARRETT LR, 1993, CARCINOGENESIS, V14, P329, DOI 10.1093/carcin/14.2.329; HAMPTON GM, 1994, P NATL ACAD SCI USA, V91, P6953, DOI 10.1073/pnas.91.15.6953; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAUSEN HZ, 1994, LANCET, V343, P955, DOI 10.1016/S0140-6736(94)90070-1; HERMSEN MAJ, 1996, IN PRESS HUMAN PATHO; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; HUNG J, 1995, JAMA-J AM MED ASSOC, V273, P558, DOI 10.1001/jama.273.7.558; KARLSEN F, 1994, INT J CANCER, V58, P787, DOI 10.1002/ijc.2910580606; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KOHNO T, 1993, ONCOGENE, V8, P1825; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KOPAN R, 1987, J CELL BIOL, V105, P427, DOI 10.1083/jcb.105.1.427; LI SL, 1992, CARCINOGENESIS, V13, P1981, DOI 10.1093/carcin/13.11.1981; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MITRA AB, 1995, J NATL CANCER I, V87, P742, DOI 10.1093/jnci/87.10.742; MITRA AB, 1994, CANCER RES, V54, P4481; Muliokandov MR, 1996, CANCER RES, V56, P197; OHMURA H, 1995, JPN J CANCER RES, V86, P899, DOI 10.1111/j.1349-7006.1995.tb02998.x; PECORARO G, 1989, P NATL ACAD SCI USA, V86, P563, DOI 10.1073/pnas.86.2.563; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; RODRIGUEZ E, 1994, CANCER RES, V54, P3398; SASAKI M, 1994, CANCER RES, V54, P6090; SEAGON S, 1994, CANCER RES, V54, P5593; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Snijders P J, 1994, Curr Top Microbiol Immunol, V186, P177; SRIVATSAN ES, 1991, AM J HUM GENET, V49, P868; STANLEY M, 1994, PAPILLOMAVIRUS REP, V5, P141; STEENBERGEN RDM, 1995, CANCER RES, V55, P5465; VANDENBRULE AJC, 1991, AM J PATHOL, V139, P1037; WALBOOMERS JMM, 1988, AM J PATHOL, V131, P587; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WILSON JL, 1992, CELL GROWTH DIFFER, V3, P471; WOODWORTH CD, 1992, ONCOGENE, V7, P619; WOODWORTH CD, 1990, CANCER RES, V50, P3709	49	124	126	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1249	1257						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808699				2022-12-28	WOS:A1996VJ20200016
J	Cook, JL; Potter, TA; Bellgrau, D; Routes, BA				Cook, JL; Potter, TA; Bellgrau, D; Routes, BA			E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes	ONCOGENE			English	Article						oncogenes; NK cells; cytotoxic-T-lymphocytes; effector molecules; signaling molecules	NECROSIS-FACTOR-ALPHA; MAJOR HISTOCOMPATIBILITY ANTIGENS; ADENOVIRUS-TRANSFORMED CELLS; CELLULAR CYTO-TOXICITY; MEDIATED CYTOTOXICITY; ACTIVATED MACROPHAGES; SURFACE ANTIGEN; MOUSE CELLS; C-MYC; LYSIS	E1A oncogene expression increases the susceptibility of cells from several species to lysis by natural killer lymphocytes (NK cells), We asked whether this E1A-induced cellular phenotypic conversion is specific for NK cell recognition interactions with target cells or whether it results from an E1A effect that is mediated independently of recognition, E1A-positive and E1A-negative cell pairs were compared for cytolytic susceptibility to other types of killer cells that use recognition mechanisms different from those of NK cells, E1A-positive, NK-susceptible target cells were also preferentially lysed by cytotoxic T lymphocytes (CTL) that recognize only foreign MHC molecules, lymphokine-activated T cells that lack recognition specificity, and CTL whose conventional recognition mechanisms were bypassed by lectin treatment of target cells, E1A expression increased cellular susceptibility to both major mechanisms of killer cell lysis-perforin/granzyme lysis and Fas-dependent lysis, Furthermore, anti-Fas antibody lysed E1A-positive, but not E1A-negative, cells expressing comparable levels of cell surface Fas antigen, These results indicate that a major mechanism by which E1A induces cellular susceptibility to lysis involves a stage in the interaction of killer cells with their targets that follows and is independent of cell surface recognition.	NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC IMMUNOL,DEPT MED,DENVER,CO 80206; UNIV COLORADO,HLTH SCI CTR,DEPT IMMUNOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,CTR CANC,DENVER,CO 80262	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cook, JL (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,ROBERT W LISLE RES LAB IMMUNOL & TUMOR CELL BIOL,DENVER,CO 80206, USA.				NCI NIH HHS [CA-43187] Funding Source: Medline; NIAID NIH HHS [AI-28115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028115] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; BELL SM, 1985, EUR J IMMUNOL, V15, P59, DOI 10.1002/eji.1830150112; BELLGRAU D, 1988, J VIROL, V62, P1513, DOI 10.1128/JVI.62.5.1513-1519.1988; BELLGRAU D, 1983, J EXP MED, V157, P1505, DOI 10.1084/jem.157.5.1505; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BONAVIDA B, 1985, J IMMUNOL, V135, P1616; BRADLEY TP, 1984, CELL IMMUNOL, V83, P199, DOI 10.1016/0008-8749(84)90239-9; CHADWICK BS, 1992, J IMMUNOL, V149, P3150; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; COOK JL, 1982, INT J CANCER, V30, P795, DOI 10.1002/ijc.2910300619; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; COOK JL, 1993, ONCOGENE, V8, P625; COOK JL, 1989, J IMMUNOL, V142, P4527; COOK JL, 1987, J VIROL, V61, P2155, DOI 10.1128/JVI.61.7.2155-2161.1987; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; DUERKSENHUGHES PJ, 1991, J VIROL, V65, P1236, DOI 10.1128/JVI.65.3.1236-1244.1991; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; GORMAN KC, 1987, J IMMUNOL, V138, P1014; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; HADDADA H, 1986, P NATL ACAD SCI USA, V83, P9684, DOI 10.1073/pnas.83.24.9684; HADDADA H, 1988, ELL, V61, P2755; HUNIG T, 1984, J EXP MED, V159, P551, DOI 10.1084/jem.159.2.551; HUNIG T, 1989, J EXP MED, V169, P73, DOI 10.1084/jem.169.1.73; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KARRE K, 1995, SCIENCE, V267, P978, DOI 10.1126/science.7863341; Karre K, 1993, Semin Immunol, V5, P127, DOI 10.1006/smim.1993.1016; Karre K, 1985, MECHANISMS CYTOTOXIC, P81; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KENYON DJ, 1991, VIROLOGY, V180, P818, DOI 10.1016/0042-6822(91)90099-W; KEREN Z, 1984, CELL IMMUNOL, V89, P458, DOI 10.1016/0008-8749(84)90347-2; KNALL C, 1995, INT IMMUNOL, V7, P995, DOI 10.1093/intimm/7.6.995; KOHL NE, 1987, ONCOGENE, V2, P41; Krantz CK, 1996, VIROLOGY, V217, P23, DOI 10.1006/viro.1996.0089; LEWIS AM, 1985, SCIENCE, V227, P15, DOI 10.1126/science.3843807; LEWIS AM, 1984, CURR TOP MICROBIOL, V110, P1; LOGAN J, 1981, VIROLOGY, V115, P419, DOI 10.1016/0042-6822(81)90126-4; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OEHM A, 1992, J BIOL CHEM, V267, P10709; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; PHILLIPS JH, 1986, J IMMUNOL, V136, P1579; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROUTES JM, 1990, J IMMUNOL, V144, P2763; ROUTES JM, 1995, VIROLOGY, V210, P421, DOI 10.1006/viro.1995.1358; SHANAHAN F, 1986, J IMMUNOL, V137, P723; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; WALKER TA, 1991, P NATL ACAD SCI USA, V88, P6491, DOI 10.1073/pnas.88.15.6491; WHITE E, 1987, J VIROL, V61, P426, DOI 10.1128/JVI.61.2.426-435.1987; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	51	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					833	842						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761305				2022-12-28	WOS:A1996VD43300019
J	Hofmann, TJ; Cole, MD				Hofmann, TJ; Cole, MD			The TAL1/Scl basic helix-loop-helix protein blocks myogenic differentiation and E-box dependent transactivation	ONCOGENE			English	Article						TAL1; leukemogenesis; bHLH; transactivation; myogenesis	T-CELL LEUKEMIA; DNA-BINDING; TRANSCRIPTIONAL-ACTIVATION; MYELOID DIFFERENTIATION; ENHANCER-BINDING; IN-VIVO; GENE; MOTIF; ONCOPROTEIN; ASSOCIATION	The TAL1 gene is transcriptionally activated by chromosomal translocation in the most common genetic lesion associated with T-cell acute lymphoblastic leukemia. TAL1 encodes a bHLH protein that exhibits sequence-specific DNA binding activity when it forms dimers with another bHLH protein such as E2A. We show that ectopic expression of TAL1 blocks the ability of the bHLH gene myogenin to induce myotube differentiation in C3H10T1/2 cells. Cotransfection of TAL1 with either myogenin or E2-5 suppresses the transcriptional activation function of each gene on its respective reporter constructs. TAL1 was as effective as Id in both transcriptional suppression and inhibition of differentiation. Deletion of the C-terminal domain of TAL1 reduces or eliminates its ability to suppress transcription while preserving the bHLH domain that determines the sequence-specificity of DNA binding. These data suggest that the C-terminal domain of TAL1 may directly mask the transactivation domain of E2A-related proteins. Since E2A-related genes are involved in lymphocyte differentiation, the dominant inhibition of E2A-related proteins may be the primary mechanism by which the TAL1 oncogene promotes leukemia.	PRINCETON UNIV,DEPT MOL BIOL,PRINCETON,NJ 08544	Princeton University								APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BAIN G, 1994, CELL, V79, P85; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DOYLE K, 1994, J BIOL CHEM, V269, P12099; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GOLDFARB AN, 1995, BLOOD, V85, P465; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; OHSAKO S, 1994, GENE DEV, V8, P2743, DOI 10.1101/gad.8.22.2743; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROBB L, 1995, P NATL ACAD SCI USA, V92, P7075, DOI 10.1073/pnas.92.15.7075; ROBB L, 1995, ONCOGENE, V10, P205; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; Sambrook J., 2002, MOL CLONING LAB MANU; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; VALGEARCHER VE, 1994, P NATL ACAD SCI USA, V91, P8617, DOI 10.1073/pnas.91.18.8617; VANDOREN M, 1994, GENE DEV, V8, P2729, DOI 10.1101/gad.8.22.2729; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WEINTRAUB H, 1990, P NATL ACAD SCI USA, V87, P5623, DOI 10.1073/pnas.87.15.5623; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	41	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					617	624						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760303				2022-12-28	WOS:A1996VB32800019
J	Kawamura, M; Yamashita, T; Segawa, K; Kaneuchi, M; Shindoh, M; Fujinaga, K				Kawamura, M; Yamashita, T; Segawa, K; Kaneuchi, M; Shindoh, M; Fujinaga, K			The 273rd codon mutants of p53 show growth modulation activities not correlated with p53-specific transactivation activity	ONCOGENE			English	Article						p53 tumor suppressor gene; codon 273; missense mutant; transactivation; ras-collaborative transformation	WILD-TYPE P53; CELL-CYCLE CONTROL; TRANSCRIPTIONAL ACTIVITY; BINDING-SITE; DNA-BINDING; SUPPRESSOR; MUTATIONS; PROTEIN; GENE; ANTIGEN	Cancer-related mutations of the p53 tumor suppressor gene are clustered in the four so-called 'hot spots', codons 175, 248, 273 and 281/282, By using recombination PCR in vitro mutagenesis, we introduced point mutations into the codon 273 of wild-type (wt) p53 (pC53-SN3) from Arg to His (pC53-273H [273H]), Asp (273D),Pro (273P), Lys (273K), Leu (273L) or Thr (273T), and compared their biological and biochemical activities with wt p53 and cancer-derived 175H, 248W and 273H/309S, Among them, 273H/309S, 273H and 273D as well as wt p53 transactivated the chloramphenicol acetyltransferase (CAT) gene placed downstream of the p53 binding consensus, while none of the other mutants including 273L did, Transcriptions from human c-fos and rat PCNA promoters were suppressed by wt p53 and 273D, while they were enhanced variously by all other mutants in Saos-2 and/or NIH3T3 cells. On the other hand, growth of human squamous carcinoma cell lines measured by the plating efficiency of G418-resistant colonies was enhanced by transfection of 175H, 248W, 273H/309S and 273P, while suppressed by not only wt p53, 273D and 273H but also 273L, Thus, 273H/309S enhanced cell growth in spite of its p53-specific transactivation activity, while 273L suppressed cell growth in spite of its complete loss of the p53-specific transactivation, We concluded that the sequence-specific transactivation of p53 is not always correlated with its growth inhibitory activity.	SAPPORO MED UNIV,SCH MED,CANC RES INST,DEPT MOLEC BIOL,CHUO KU,SAPPORO,HOKKAIDO 060,JAPAN; KEIO UNIV,SCH MED,DEPT MICROBIOL,SHINJUKU KU,TOKYO 160,JAPAN	Sapporo Medical University; Keio University			Shindoh, Masanobu/A-4799-2012	Shindoh, Masanobu/0000-0002-7782-5823				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; CHEN JY, 1993, ONCOGENE, V8, P2159; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JONES DH, 1991, BIOTECHNIQUES, V10, P62; KANDA T, 1994, MOL CELL BIOL, V14, P2651, DOI 10.1128/MCB.14.4.2651; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OHASHI Y, 1992, BIOCHIM BIOPHYS ACTA, V1130, P175, DOI 10.1016/0167-4781(92)90525-5; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAKAI E, 1992, ONCOGENE, V7, P927; SEGAWA K, 1993, ONCOGENE, V8, P543; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; van der Eb A J, 1980, Methods Enzymol, V65, P826; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YAMASHITA T, 1993, ONCOGENE, V8, P2433; YAMASHITA T, 1986, Tumor Research, V21, P67; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHANG W, 1993, ONCOGENE, V8, P2555	58	34	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2361	2367						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649776				2022-12-28	WOS:A1996UQ22000013
J	Varley, JM; McGown, G; Thorncroft, M; Cochrane, S; Morrison, P; Woll, P; Kelsey, AM; Mitchell, ELD; Boyle, J; Birch, JM; Evans, DGR				Varley, JM; McGown, G; Thorncroft, M; Cochrane, S; Morrison, P; Woll, P; Kelsey, AM; Mitchell, ELD; Boyle, J; Birch, JM; Evans, DGR			A previously undescribed mutation within the tetramerisation domain of TP53 in a family with Li-Fraumeni syndrome	ONCOGENE			English	Article						TP53; Li-Fraumeni; codon 344; tetramerisation domain	NORMAL KIDNEY TISSUE; BREAST-CANCER; P53 MUTATIONS; GERM; CHROMOSOME; GENE	We report details of a family with classic Li-Fraumeni syndrome in which there is a mutation in codon 344 of the tumour suppressor gene TP53, Codon 344 is a key residue within the tetramerisation domain, and the amino acid substitution of a proline for a leucine is predicted to have profound implications for tetramerisation and potentially DNA binding, This is the first report of a mutation at this residue in either sporadic tumours or in the germline and the first report of a germline mutation within the tetramerisation domain, The family does not appear to be remarkable in the spectrum of tumours, and there is loss of the wild-type allele in a leiomyosarcoma from the proband. A cell line has been established from the tumour of the proband and cytogenetic and molecular studies carried out, providing an extensive analysis in this family.	CITY HOSP,DEPT CLIN GENET,NOTTINGHAM NG5 1PB,ENGLAND; QUEENS MED CTR,DEPT MED ONCOL,NOTTINGHAM NG7 2UH,ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP,PAEDIAT & FAMILIAL CANC RES GRP,CRC,MANCHESTER M27 4HA,LANCS,ENGLAND; ROYAL MANCHESTER CHILDRENS HOSP,DEPT HISTOPATHOL,MANCHESTER M27 4HA,LANCS,ENGLAND	University of Nottingham; University of Nottingham; Royal Manchester Children's Hospital; Royal Manchester Children's Hospital	Varley, JM (corresponding author), PATERSON INST CANC RES,DEPT CANC GENET,CRC,WILMSLOW RD,MANCHESTER M20 9BX,LANCS,ENGLAND.		Evans, D Gareth/AAB-4308-2022	Evans, D Gareth/0000-0002-8482-5784; Woll, Penella/0000-0002-1118-0831				BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BIRCH JM, 1990, J PATHOL, V161, P1, DOI 10.1002/path.1711610102; BIRCH JM, 1994, EUR J CANCER, V30A, P1935, DOI 10.1016/0959-8049(94)00383-G; BORRESEN AL, 1992, CANCER RES, V52, P3234; CHEN PC, 1995, CANCER GENET CYTOGEN, V82, P106, DOI 10.1016/0165-4608(94)00213-U; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DILLER L, 1995, J CLIN INVEST, V95, P1606, DOI 10.1172/JCI117834; ELFVING P, 1990, CYTOGENET CELL GENET, V53, P123, DOI 10.1159/000132910; EMANUEL A, 1992, GENE CHROMOSOME CANC, V4, P75, DOI 10.1002/gcc.2870040110; FREBOURG T, 1995, AM J HUM GENET, V56, P608; HOGGARD N, 1995, CHROMOSOME RES, V3, P137, DOI 10.1007/BF00710677; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; ISHIOKA C, 1995, ONCOGENE, V10, P1485; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KYRITSIS AP, 1994, JNCI-J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; LI FP, 1988, CANCER RES, V48, P5358; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCINTYRE JF, 1994, J CLIN ONCOL, V12, P925, DOI 10.1200/JCO.1994.12.5.925; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SHISEKI M, 1993, CANCER LETT, V73, P51, DOI 10.1016/0304-3835(93)90187-E; SIDRANSKY D, 1992, CANCER RES, V52, P2984; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; VARLEY JM, 1995, J MED GENET, V32, P946; WAGNER J, 1994, JNCI-J NATL CANCER I, V86, P1707, DOI 10.1093/jnci/86.22.1707	25	48	48	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2437	2442						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649785				2022-12-28	WOS:A1996UQ22000022
J	Gruda, MC; vanAmsterdam, J; Rizzo, CA; Durham, SK; Lira, S; Bravo, R				Gruda, MC; vanAmsterdam, J; Rizzo, CA; Durham, SK; Lira, S; Bravo, R			Expression of FosB during mouse development: Normal development of FosB knockout mice	ONCOGENE			English	Article						FosB expression knockout mice; development; AP-1 activity	EMBRYONIC STEM-CELLS; IMMEDIATE-EARLY GENES; C-FOS; TRANSGENIC MICE; NERVOUS-SYSTEM; JUN PROTEINS; MESSENGER-RNAS; RAT-1A CELLS; SHORT FORM; INDUCTION	FosB, one of the members of the Fos family, is rapidly induced in many cell types upon stimulation and has a stimulatory effect on the proliferation of cultured cells, To understand the tissue distribution of FosB, we have studied its expression pattern my immunohistochemistry in newborn and late embryonic stage mice, These results show that FosB is widely expressed with the highest levels of expression observed in both bony and cartilagenous regions of developing bone, FosB is also detected within whisker follicles, liver, and epidermal tissue, To study the role of FosB in mammalian development we generated embryonic stem mice (ES) cells, mice and mouse embryo fibroblasts (MEFs) that are deficient for FosB, FosB (-/-) mice are born at a normal frequency, are fertile and present no obvious phenotypic or histologic abnormalities, FosB-deficient ES cells and MEFs proliferate and enter the S phase normally and we do not find upregulation of other fos family genes to compensate for the lack of FosB, However, we do find that the induction of two AP-1 containing genes is reduced after stimulation of FosB-deficient cells, demonstrating that FosB does indeed play a functional role in transcriptional regulation.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT ONCOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ANGEL P, 1994, FOS JUN FAMILIES TRA, P3; BELE S, 1994, MOL BRAIN RES, V22, P9, DOI 10.1016/0169-328X(94)90027-2; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; BURKERT U, 1991, NEW BIOL, V3, P698; CARRASCO D, 1995, ONCOGENE, V10, P1069; CAUBET JF, 1989, MOL CELL BIOL, V9, P2269, DOI 10.1128/MCB.9.5.2269; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; DRAGUNOW M, 1994, MOL BRAIN RES, V25, P19, DOI 10.1016/0169-328X(94)90274-7; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FIELD SJ, 1992, P NATL ACAD SCI USA, V89, P9306, DOI 10.1073/pnas.89.19.9306; GASS P, 1993, EUR J NEUROSCI, V5, P933, DOI 10.1111/j.1460-9568.1993.tb00944.x; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; GRIGORIADIS AE, 1995, TRENDS GENET, V11, P436, DOI 10.1016/S0168-9525(00)89142-8; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HERDEGEN T, 1991, J COMP NEUROL, V313, P178, DOI 10.1002/cne.903130113; HERDEGEN T, 1992, MOL BRAIN RES, V14, P155, DOI 10.1016/0169-328X(92)90170-G; HERDEGEN T, 1995, J COMP NEUROL, V354, P39, DOI 10.1002/cne.903540105; HOPE BT, 1994, J NEUROSCI, V14, P4318; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; HUO L, 1995, J IMMUNOL, V154, P3300; JAIN J, 1992, J IMMUNOL, V148, P1240; JAIN JN, 1994, MOL CELL BIOL, V14, P1566, DOI 10.1128/MCB.14.3.1566; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KIMURA E, 1993, MOL ENDOCRINOL, V7, P1463, DOI 10.1210/me.7.11.1463; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, NEW BIOL, V3, P870; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; Liotta L A, 1990, Semin Cancer Biol, V1, P99; LUCIBELLO FC, 1993, ONCOGENE, V8, P1667; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; Matrisian L M, 1990, Semin Cancer Biol, V1, P107; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; METZ R, 1994, EMBO J, V13, P3832, DOI 10.1002/j.1460-2075.1994.tb06694.x; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; MINET ML, 1993, J COMP NEUROL, V333, P223; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MUMBERG D, 1991, GENE DEV, V5, P1212, DOI 10.1101/gad.5.7.1212; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1993, MOL CELL BIOL, V13, P4157, DOI 10.1128/MCB.13.7.4157; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; REDEMANNFIBI B, 1991, DIFFERENTIATION, V46, P43, DOI 10.1111/j.1432-0436.1991.tb00864.x; Robertson E. J., 1987, TERATOCARCINOMAS EMB; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RUTHER U, 1988, CELL, V53, P847, DOI 10.1016/S0092-8674(88)90289-9; RYSECK RP, 1991, ONCOGENE, V6, P533; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDBERG M, 1988, DEVELOPMENT, V102, P461; SCHUERMANN M, 1991, ONCOGENE, V6, P567; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SMEYNE RJ, 1994, NATURE, V368, P246, DOI 10.1038/368246a0; SUTHERLAND JA, 1992, GENE DEV, V6, P1810, DOI 10.1101/gad.6.9.1810; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WILES MV, 1991, DEVELOPMENT, V111, P259; WILES MV, 1993, METHOD ENZYMOL, V225, P900; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; WISDOM R, 1992, GENE DEV, V6, P667, DOI 10.1101/gad.6.4.667; Wurst W., 1993, Gene targeting: a practical approach., P33; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	75	55	55	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2177	2185						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668344				2022-12-28	WOS:A1996UP28300017
J	Jacobs, H; Ossendorp, F; deVries, E; Ungewiss, K; vonBoehmer, H; Borst, J; Berns, A				Jacobs, H; Ossendorp, F; deVries, E; Ungewiss, K; vonBoehmer, H; Borst, J; Berns, A			Oncogenic potential of a pre-T cell receptor lacking the TCR beta variable domain	ONCOGENE			English	Article						lymphomagenesis; T cell receptor; transgenic mice; lymphopoiesis; T cell development; oncogene	TRANSGENIC MICE; MONOCLONAL-ANTIBODY; LYMPHOCYTES-T; C-MYC; GENE; ALPHA; CHAIN; PROTEINS; MUTANT; REARRANGEMENT	In transgenic mice expressing a mutated T cell receptor (TCR) beta chain lacking the variable domain (Delta V-TCR beta) T cell differentiation is arrested at the CD4(+) CD8(+) thymocyte stage, Here, we report that these transgenic animals develop CD4(+), CD8(+), IL-2 receptor alpha-positive T cell lymphomas at a very high incidence. Introduction of a normal TCR beta gene into the Delta V-TCR beta transgenic mice drastically reduces the tumor incidence, while crossing the Delta V-TCR beta transgene onto a recombinase-deficient RAG-1(-/-) background does not prevent tumor development, Therefore, the induction of T cell lymphomas is a property of the mutated TCR beta chain, The Delta V- TCR beta chain appears at the cell surface as a disulfide-linked Delta V-TCR beta/pT alpha dimer in association with CD3 gamma and -epsilon, but not with CD3 delta. This mutated preTCR/CD3 complex is shown to induce pre-T cell proliferation and differentiation, but does not permit formation of a normally sized CD4(+)8(+) thymic compartment, Delta V-TCR beta transgenic mice frequently show an expansion of CD4(+)8(+), IL-2 receptor alpha(+) pre-T cells early in life, These cells likely represent the population that is subject to oncogenic transformation.	NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,1066 CX AMSTERDAM,NETHERLANDS; BASEL INST IMMUNOL,CH-4005 BASEL,SWITZERLAND	Netherlands Cancer Institute; Netherlands Cancer Institute				Jacobs, Heinz/0000-0001-6227-9850; Borst, Jannie/0000-0002-8043-5009				BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; COGNE M, 1989, RES IMMUNOL, V140, P487; CUYPERS HT, 1984, CELL, V37, P141; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DODEMONT HJ, 1982, EMBO J, V1, P167, DOI 10.1002/j.1460-2075.1982.tb01142.x; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; GOODMAN T, 1989, J EXP MED, V170, P1569, DOI 10.1084/jem.170.5.1569; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GU H, 1991, CELL, V65, P47, DOI 10.1016/0092-8674(91)90406-O; HASER WG, 1987, J EXP MED, V166, P1186, DOI 10.1084/jem.166.4.1186; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; JACOBS H, 1994, EUR J IMMUNOL, V24, P934, DOI 10.1002/eji.1830240423; KAPPES DJ, 1995, CURR OPIN IMMUNOL, V7, P441, DOI 10.1016/0952-7915(95)80086-7; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KRIMPENFORT P, 1989, NATURE, V341, P742, DOI 10.1038/341742a0; KUBO RT, 1989, J IMMUNOL, V142, P2736; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; MALISSEN M, 1992, IMMUNOL TODAY, V13, P315, DOI 10.1016/0167-5699(92)90044-8; Maniatis T., 1982, MOL CLONING LAB MANU; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OSSENDORP F, 1992, J IMMUNOL, V148, P3714; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; SELIGMANN M, 1979, IMMUNOL REV, V48, P146; SELTEN G, 1984, EMBO J, V3, P3215, DOI 10.1002/j.1460-2075.1984.tb02281.x; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; UEMATSU Y, 1988, CELL, V52, P831, DOI 10.1016/0092-8674(88)90425-4; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531	38	28	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2089	2099						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668334				2022-12-28	WOS:A1996UP28300007
J	Masuda, A; Takenaga, K; Kondoh, F; Fukami, H; Utsumi, K; Okayama, H				Masuda, A; Takenaga, K; Kondoh, F; Fukami, H; Utsumi, K; Okayama, H			Role of a signal transduction pathway which controls disassembly of microfilament bundles and suppression of high-molecular-weight tropomyosin expression in oncogenic transformation of NRK cells	ONCOGENE			English	Article						tropomyosin; microfilament bundles; EGF; NRK cells; anchorage-independent growth	EPIDERMAL GROWTH-FACTOR; RAF-1 PROTEIN-KINASE; STRESS FIBERS; FIBROBLASTS; ISOFORM-2; ABILITY; ABSENCE; LINES; MOUSE; ACTIN	Role of disassembly of microfilament bundles and suppression of high-molecular-weight tropomyosin (TM) expression in growth factor- and various oncogene-induced transformation was studied by using NRK cells and its transformation-deficient mutants. In NRK cells which show a transformed phenotype by treatment with EGF and TGF-beta, cellular stress fibers became dissociated by EGF or EGF and TGF-beta combination, whereas TGF-beta alone caused thicker appearance of stress fibers, Accompanying these changes, the expression of TM isoforms 1 and 2 was suppressed by treatment with EGF or EGF and TGF-beta, but elevated by TGF-beta with similar time courses, On the other hand, the transformation-deficient mutant cell Lines, 39-1 and 39-3, did not show the transformed phenotypes by treatment with EGF and TGF-beta. Neither EGF nor EGF and TGF-beta combination affected cellular stress fibers and expression of TM isoforms 1 and 2 in both mutant lines, The relationship between the formation of stress fibers and the expression of TM isoforms was consistent in NRK cells, the mutant lines and their various oncogene-expressing sublines under various culture conditions, NRK cells overexpressing exogenous mouse TM isoform 2 showed markedly decreased susceptibility to EGF-induced dissociation of stress fibers and decreased anchorage-independent growth potential in the presence of EGF and TGF-beta. These results indicate that the transformation-deficient NRK mutant lines, 39-1 and 39-3 have defects in an EGF signal transduction pathway which induces suppression of high-molecular-weight TM expression and disassembly of microfilament bundles and suggested that the activation of the pathway is important for morphological transformation and oncogenic growth in growth factors- and various oncogene-induced transformation of NRK cells.	CHIBA CANC CTR,RES INST,DIV CHEMOTHERAPY,CHUOH KU,CHIBA 260,JAPAN; UNIV TOKYO,FAC MED,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	Chiba Cancer Center; University of Tokyo	Masuda, A (corresponding author), AICHI CANC CTR,RES INST,LAB ULTRASTRUCT RES,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN.							BAUM G, 1990, DEV BIOL, V142, P115, DOI 10.1016/0012-1606(90)90155-C; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BISCHEK CB, 1981, CELL, V24, P175; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; GALLOWAY PG, 1990, LAB INVEST, V62, P163; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KIZAKAKONDOH S, 1993, FEBS LETT, V336, P255, DOI 10.1016/0014-5793(93)80814-B; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KUME K, 1992, NEW BIOL, V4, P504; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; Macpherson I, 1969, FUNDAMENTAL TECHNIQU, P214; MASUDA A, 1992, NEW BIOL, V4, P489; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; POLLACK R, 1975, P NATL ACAD SCI USA, V86, P6940; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; ROBERTS AB, 1981, P NATL ACAD SCI-BIOL, V78, P5339, DOI 10.1073/pnas.78.9.5339; TAKENAGA K, 1988, MOL CELL BIOL, V8, P5561, DOI 10.1128/MCB.8.12.5561; TAKENAGA K, 1988, BIOCHEM BIOPH RES CO, V157, P1111, DOI 10.1016/S0006-291X(88)80988-4; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498	36	22	22	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2081	2088						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668333				2022-12-28	WOS:A1996UP28300006
J	Andoniou, CE; Thien, CBF; Langdon, WY				Andoniou, CE; Thien, CBF; Langdon, WY			The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain	ONCOGENE			English	Article						tyrosine kinase; cbl oncogene; cell transformation; crk adaptor	CHRONIC MYELOGENOUS LEUKEMIA; V-CBL; PROTEIN; ONCOGENE; TRUNCATION; RETROVIRUS; GENE; RAS	We recently found that the 120-kD protein product of the c-cbl oncogene is tyrosine phosphorylated in tumor cells generated by bcr-abl or v-abl and that p120(cbl) will associate with these proteins bl vivo, We also found an oncogenic form of cbl protein in the 70Z/3 pre-B cell lymphoma which exhibits deregulated tyrosine phosphorylation. These findings have led us to broaden our study of cbl's involvement in abl-mediated tumorigenesis. Here we show by immunodepletion that cbl is the major 120-kD tyrosine phosphorylated protein in cells which express activated forms of the abl oncogene. We also demonstrate that tyrosine phosphorylation of p120(cbl) in bcr-abl transformed cells does not alter its subcellular localization. In addition we show that the oncogenic 70Z/3 form of cbl exhibits enhanced tyrosine phosphorylation in v-abl infected cells and that cbl is heavily tyrosine phosphorylated in hemopoietic cells transformed by v-src. Finally this study identifies two sites that are essential for the tyrosine phosphorylation of cbl in abl-transformed cells. These sites conform to the preferred abl kinase substrate sequence of YXXP and we show that following phosphorylation they mediate an association with the crkL SH2 domain.	UNIV WESTERN AUSTRALIA, QUEEN ELIZABETH II MED CTR, DEPT PATHOL, NEDLANDS, WA 6009, AUSTRALIA	University of Western Australia			Andoniou, Christopher/B-6296-2013; Thien, Christine/GQP-0424-2022	Andoniou, Christopher/0000-0003-0566-3180; Thien, Christine/0000-0003-3884-5546				AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BLAKE TJ, 1992, ONCOGENE, V7, P757; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; HOLMES KL, 1986, J EXP MED, V164, P443, DOI 10.1084/jem.164.2.443; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; JONGEWARD GD, 1995, GENETICS, V139, P1553; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; MANDANAS RA, 1993, BLOOD, V82, P1838; MANN KP, 1987, J VIROL, V61, P2100, DOI 10.1128/JVI.61.7.2100-2108.1987; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1992, CANCER SURV, V15, P37; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; Wang Y, 1996, J BIOL CHEM, V271, P17, DOI 10.1074/jbc.271.1.17; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	107	108	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1981	1989						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649859				2022-12-28	WOS:A1996UK49800017
J	Harigai, M; Miyashita, T; Hanada, M; Reed, JC				Harigai, M; Miyashita, T; Hanada, M; Reed, JC			A cis-acting element in the BCL-2 gene controls expression through translational mechanisms	ONCOGENE			English	Article						Bcl-2; apoptosis; translation	HUMAN FOLLICULAR LYMPHOMA; MESSENGER-RNA; PROTOONCOGENE EXPRESSION; MAMMALIAN-CELLS; PROTO-ONCOGENE; DNA-SEQUENCE; REGION; NEUROBLASTOMA; INHIBITION; CARCINOMA	The bcl-2 gene becomes activated in many types of human cancers and contributes to neoplastic cell expansion, as well as to resistance to radiation and chemotherapy, by blocking programmed cell death or apoptosis. The expression of this proto-oncogene is regulated at both the transcriptional and post-transcriptional levels. DNA sequence comparisons of human, mouse, rat and chicken bcl-2 cDNAs revealed the presence of an open reading frame (OFR) located upstream of the normal coding region. Because upstream ORFs (uORFs) have been associated with translational repression, we analysed the functional significance of the 11 amino-acid uORF in the human BCL-2 gene (-119 to -84 bp). Deletion of this uORF from chloramphenicol acetyltransferase (CAT) reporter gene constructs that contained the bcl-2 promoter and entire 5'-untranslated region (5'-UTR), as well as introduction of an A --> T mutation at position -119 bp that destroyed the AUG-initiation codon, significantly increased CAT activity in HeLa, CEM, and other cell lines, without producing a corresponding elevation in CAT mRNA levels. Positioning this uORF, together with its accompanying Kozak sequences, between a heterologous promoter from SV40 and a CAT reporter gene resulted in marked inhibition of CAT protein production without a decrease in CAT mRNA, Mutation of the start codon (ATG --> TTG) of this uORF completely abolished its inhibitory activity, consistent with a translational mechanism, Taken together, these findings suggest that the uORF located within the 5'UTR of the bcl-2 gene is necessary and sufficient for translational regulation of bcl-2 gene expression.	LA JOLLA CANC RES FDN,ONCOGENE & TUMOR SUPPRESSOR GENE PROGRAM,LA JOLLA,CA 92037	Sanford Burnham Prebys Medical Discovery Institute								ARRICK BA, 1991, MOL CELL BIOL, V11, P4306, DOI 10.1128/MCB.11.9.4306; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRONNER M, 1994, AM J PATHOL, V146, P20; CAZALSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109, DOI 10.1016/0167-4781(92)90064-7; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P292; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; GAUSS GH, 1992, NUCLEIC ACIDS RES, V20, P6739, DOI 10.1093/nar/20.24.6739; HANADA M, 1993, CANCER RES, V53, P4978; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JACKSON RJ, 1990, TRENDS BIOCHEM SCI, V15, P477, DOI 10.1016/0968-0004(90)90302-R; KONDO E, 1992, BLOOD, V80, P2044; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LU QL, 1993, INT J CANCER, V53, P29, DOI 10.1002/ijc.2910530107; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MAKOVER D, 1991, ONCOGENE, V6, P455; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MIYASHITA T, 1994, CANCER RES, V54, P3131; PANTOPOULOS K, 1994, PROG NUCLEIC ACID RE, V48, P181, DOI 10.1016/S0079-6603(08)60856-9; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; PEABODY DS, 1986, MOL CELL BIOL, V6, P2704, DOI 10.1128/MCB.6.7.2704; PEZZELLA F, 1993, NEW ENGL J MED, V329, P690, DOI 10.1056/NEJM199309023291003; REED JC, 1989, ONCOGENE RES, V4, P271; REED JC, 1991, CANCER RES, V51, P6529; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAKURAGI N, 1994, J SOC GYNECOL INVEST, V1, P164, DOI 10.1177/107155769400100212; SATO T, 1994, GENE, V140, P291, DOI 10.1016/0378-1119(94)90561-4; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SONNENBERG N, 1990, CURR TOP MICROBIOL I, V161, P23; TANAKA S, 1992, BLOOD, V79, P229; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686	41	71	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1369	1374						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649841				2022-12-28	WOS:A1996UC06700024
J	Guerrero, C; Rojas, JM; Chedid, M; Esteban, LM; Zimonjic, DB; Popescu, NC; deMora, JF; Santos, E				Guerrero, C; Rojas, JM; Chedid, M; Esteban, LM; Zimonjic, DB; Popescu, NC; deMora, JF; Santos, E			Expression of alternative forms of Ras exchange factors GRF and SOS1 in different human tissues and cell lines	ONCOGENE			English	Article						Ras; hGRF; hSOS1; expression; alternative splicing	NUCLEOTIDE-RELEASING FACTOR; RECEPTOR TYROSINE KINASES; SACCHAROMYCES-CEREVISIAE; DROSOPHILA SON; SEVENLESS GENE; IDENTIFICATION; HOMOLOGS; PROTEINS; GRB2; CDNAS	DNA probes and antibodies specific for different coding regions of human SOS1 and GRF genes were used to screen expression of these genes in a variety of adult and fetal human tissues and cell lines. Despite previous reports of the exclusive expression of hGRF RNA in brain, we also observed expression of this gene in various other tissues including lung and pancreas, as web as several tumor cell lines. At least three different hGRF mRNA transcripts were observed depending on the probe used, with the larger transcripts being detected by probes corresponding to the 5' end of the gene while smaller transcripts were detected by probes corresponding to the 3' end. Expression of hSOS1-related transcripts was more ubiquitous and homogeneous than with hGRF, with similar levels of specific transcripts being detected in most tissues and cell lines tested. Three to five different transcripts were detected in human tissues when using probes for the 5' end and middle regions of this gene, whereas only two were detected with probes corresponding to the 3' end. Screening of multiple human tumor cell lines showed ubiquitous expression of three specific transcripts, although the level and ratio of each of these transcripts varied widely among individual cell lines. Consistent with the variety of transcripts detected, several protein forms were also identified in Western immunoblots with antisera raised against specific domains of hSOS1 and human Ras-GRF gene products. Fluorescence in situ chromosomal hybridization suggested that, in both cases, the multiple forms arise from single chromosomal loci. The heterogeneity of hGRF and hSOS1 gene products detected (which appear to retain in most cases a functional catalytic domain), suggests that differentially expressed, alternatively spliced hSOS1 and hGRF forms may contribute to fine regulation of Ras activation in different tissues or at different stages of development.	NCI, DBS, CELLULAR & MOLEC BIOL LAB, NATL INST HLTH, BETHESDA, MD 20892 USA; NCI, DBS, BIOL LAB, NATL INST HLTH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Rojas, José M/D-3718-2018; Rojas, José M./AAA-3354-2021; de Mora, Jaime Font/H-6304-2015; Zimonjic, Drazen/AAX-7513-2020; Guerrero, Carmen/F-1776-2010; de Mora, Jaime Font/AAK-7591-2021	Rojas, José M/0000-0002-5383-3482; Rojas, José M./0000-0002-7547-2825; de Mora, Jaime Font/0000-0002-6816-2095; Guerrero, Carmen/0000-0002-8747-6831; de Mora, Jaime Font/0000-0002-6816-2095				BEALL JA, 1986, J IMMUNOL METHODS, V86, P217, DOI 10.1016/0022-1759(86)90456-4; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHARDIN P, 1994, CYTOGENET CELL GENET, V66, P68, DOI 10.1159/000133667; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; DALY RJ, 1994, ONCOGENE, V9, P2723; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; FATH I, 1993, NUCLEIC ACIDS RES, V21, P4398, DOI 10.1093/nar/21.18.4398; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; MUSACCHIO A, 1994, TRENDS BIOCHEM SCI, V19, P349; POPESCU N, 1994, GENOMICS, V20, P333, DOI 10.1006/geno.1994.1182; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; WEBB GC, 1993, GENOMICS, V18, P14, DOI 10.1006/geno.1993.1421; WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; ZIMONJIC DB, 1994, CYTOGENET CELL GENET, V65, P184, DOI 10.1159/000133628; ZIMONJIC DB, 1995, CANCER GENET CYTOGEN, V80, P100, DOI 10.1016/0165-4608(94)00161-4	34	48	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1097	1107						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649802				2022-12-28	WOS:A1996UA88400019
J	Perletti, GP; Folini, M; Lin, HC; Mischak, H; Piccinini, F; Tashjian, AH				Perletti, GP; Folini, M; Lin, HC; Mischak, H; Piccinini, F; Tashjian, AH			Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells	ONCOGENE			English	Article						signal transduction; ras; colon cancer; tumorigenesis	TRANSFORM FIBROBLASTS; HA-RAS; EXPRESSION; GROWTH; ALPHA; MODEL	We have analysed the expression of five protein kinase C [PKC] isoforms in an in vitro model using nontumorigenic rat colonic epithelial cells FRC/TEX CL D [D/ WT] and in the related tumorigenic Ha-ras-transformed FRC/TEX CL D/H-ras line [D/ras]. The PKC subspecies alpha, delta, epsilon and zeta were expressed at the protein level in both D/WT and D/ras cells, while beta PKC was undetectable in both lines. The levels of expression of the delta and zeta isoforms were similar in D/WT and D/ras cells. alpha PKC expression was decreased and epsilon PKC was increased in D/ras cells compared to the D/WT line, To assess whether overexpression of epsilon PKC was linked to the transformed phenotype, we have generated from D/WT cells two clones (D/epsilon-5 and D/epsilon-9) which stably overexpress epsilon PKC about fivefold. Overexpression of epsilon PKC caused marked morphological changes in both transfected clones, which were accompanied by increased saturation densities and anchorage-independent colony formation in semisolid agar. These growth effects were attenuated or reversed by chronic incubation with phorbol 12-myristate 13-acetate. Furthermore, D/epsilon-5 and D/epsilon-9 cells formed tumors in athymic nude mice with 100% incidence while the parental D/WT or vector alone (D/MV12) controls produced no tumors. We conclude that epsilon PKC can act as an oncoprotein when modestly overproduced in nontumorigenic D/WT colonic cells, and that this isoform of PKC may be linked to ras-modulated signal transduction leading to neoplastic transformation in colonic epithelium.	HARVARD UNIV,SCH PUBL HLTH,DEPT MOLEC & CELLULAR TOXICOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; GSF,FORSCHUNGSZENTRUM HAEMATOL,INST CLIN MOL BIOL & TUMOR GENET,D-81377 MUNICH,GERMANY; UNIV MILAN,IST FARMACOL,MILAN,ITALY	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Milan			Mischak, Harald/E-8685-2011; Folini, Marco/B-9607-2017	Folini, Marco/0000-0002-1811-4407; Mischak, Harald/0000-0003-0323-0306	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES00002] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; BORNER C, 1991, NATURE, V353, P78, DOI 10.1038/353078a0; CACACE AM, 1993, ONCOGENE, V8, P2095; CHOI PM, 1990, MOL CELL BIOL, V10, P4650, DOI 10.1128/MCB.10.9.4650; CRAVEN PA, 1992, CANCER RES, V52, P2216; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIDSON LA, 1994, ARCH BIOCHEM BIOPHYS, V312, P547, DOI 10.1006/abbi.1994.1344; DELAGE S, 1993, CANCER RES, V53, P2762; DENT P, 1995, MOL CELL BIOL, V15, P4125; DOI S, 1994, CARCINOGENESIS, V11, P197; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KLINGEL R, 1991, GUT, V62, P1508; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KURANAMI M, 1995, J SURG RES, V58, P233, DOI 10.1006/jsre.1995.1036; KURANAMI M, 1995, AM J SURG, V169, P57, DOI 10.1016/S0002-9610(99)80110-X; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MONNAT M, 1987, INT J CANCER, V40, P293, DOI 10.1002/ijc.2910400302; MONTANER S, 1995, ONCOGENE, V10, P2213; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; PORIES SE, 1993, GASTROENTEROLOGY, V104, P1346, DOI 10.1016/0016-5085(93)90343-B; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SCHAEFFER WI, 1976, CANCER LETT, V1, P259; SPANDIDOS DA, 1984, BRIT J CANCER, V49, P681, DOI 10.1038/bjc.1984.108; TOKER A, 1994, J BIOL CHEM, V269, P32358	31	94	97	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					847	854						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632907				2022-12-28	WOS:A1996TW68600016
J	Evans, MK; Chin, KV; Gottesman, MM; Bohr, VA				Evans, MK; Chin, KV; Gottesman, MM; Bohr, VA			Gene-specific DNA repair and steady state transcription of the MDR1 gene in human tumor cell lines	ONCOGENE			English	Article						DNA repair; drug resistance; tumor cells	COMPLEMENTATION GROUP-C; STRAND-SPECIFIC REPAIR; KB CARCINOMA-CELLS; PYRIMIDINE DIMERS; DEFECTIVE REPAIR; COUPLING FACTOR; ACTIVE GENE; RESISTANT; AMPLIFICATION; FIBROBLASTS	We have explored the relationship between DNA repair and transcription in vivo, A gene-specific repair assay has been employed to study removal of ultraviolet light-induced cyclobutane pyrimidine diners in the MDR1 gene at different levels of MDR1 mRNA expression, The parental human adenocarcinoma cell line, KB-3-1, has very low levels of MDR1 mRNA expression, but its multidrug resistant derivatives KB-8-5 and KB-C1 have 42-fold and 3800-fold increases in MDR1 mRNA expression, respectively, In the KB-3-1 cell line that has a low level of MDR1 mRNA expression, we find a low level of MDR1 gene-specific repair and inefficient repair of the transcribed strand of the gene, In the KB-8-5 cell line that has a modest increase in MDR1 mRNA expression, we find only a minor increase in dimer repair in the MDR1 gene, Here, the repair in the transcribed strand is not significantly higher than that in the KB-3-1 cell line, However, in the KB-C1 derivative, where there is a 3800-fold increase in the level of MDR1 mRNA expression, we find a substantial increase in the level of dimer repair in the MDR1 gene, In addition, the MDR1 transcribed strand repair is markedly more efficient than the repair in the nontranscribed strand, Our data suggest that the rate of transcription in the MDR1 gene must be substantially increased before there is any measurable effect on DNA repair, Repair in the housekeeping gene, dihydrofolate reductase (DHFR), was similar in all three tumor cell lines, Repair in its transcribed strand was markedly lower than previously reported in normal human fibroblasts, We suspect that these human HeLa-derived tumor cell lines have deficient gene-specific DNA repair, This may be an important aspect of their malignant phenotype.	NIA,MOLEC GENET LAB,NIH,BALTIMORE,MD 21224; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CANC INST NEW JERSEY,PISCATAWAY,NJ 08854; NCI,CELL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Evans, Michele Kim/AAE-4776-2019; Bohr, Vilhelm/AAP-5931-2020; Chin, Khew-Voon/F-2670-2013	Evans, Michele/0000-0002-8546-2831				AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700; ARRAND JE, 1982, NUCLEIC ACIDS RES, V10, P1547, DOI 10.1093/nar/10.5.1547; BEECHAM EJ, 1994, MOL CELL BIOL, V14, P1204, DOI 10.1128/MCB.14.2.1204; BEECHAM EJ, 1991, MOL CELL BIOL, V11, P3095, DOI 10.1128/MCB.11.6.3095; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1988, DNA REPAIR LABORATOR, P347; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; EVANS MK, 1993, CANCER RES, V53, P5377; EVANS MK, 1993, J BIOL CHEM, V268, P4839; EVANS MK, 1994, MUTAT RES, V314, P221, DOI 10.1016/0921-8777(94)90067-1; FOJO AT, 1985, P NATL ACAD SCI USA, V82, P7661, DOI 10.1073/pnas.82.22.7661; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; JI J, 1995, P AM ASOCATION CANCE, V36, P550; KANTOR GJ, 1990, MUTAT RES, V235, P171, DOI 10.1016/0921-8777(90)90071-C; LARMINAT F, 1995, ONCOGENE, V10, P1639; MADHANI HD, 1986, CELL, V45, P417, DOI 10.1016/0092-8674(86)90327-2; MAYNE LV, 1984, MUTAT RES, V131, P187, DOI 10.1016/0167-8817(84)90023-3; MELLON I, 1986, P NATL ACAD SCI USA, V83, P8878, DOI 10.1073/pnas.83.23.8878; MELON I, 1987, CELL, V51, P241; MELON I, 1989, NATURE, V342, P95; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10602; OKUMOTO DS, 1987, NUCLEIC ACIDS RES, V15, P10021, DOI 10.1093/nar/15.23.10021; PARSHAD R, 1984, CANCER RES, V44, P5577; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PASTAN I, 1987, NEW ENGL J MED, V316, P1388; RAINBOW AJ, 1989, CARCINOGENESIS, V10, P1073, DOI 10.1093/carcin/10.6.1073; SANFORD KK, 1992, CARCINOGENESIS, V13, P1137, DOI 10.1093/carcin/13.7.1137; SANFORD KK, 1985, ENHANCED G2 CHROMOSO, P811; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHOENLEIN PV, 1992, MOL BIOL CELL, V3, P507, DOI 10.1091/mbc.3.5.507; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SHEN D, 1986, J BIOL CHEM, V216, P7762; SHEN DW, 1986, SCIENCE, V232, P643, DOI 10.1126/science.3457471; Smerdon MJ, 1991, CURR OPIN CELL BIOL, V3, P422, DOI 10.1016/0955-0674(91)90069-B; THIEBAUT F, 1993, FEBS LETT, V319, P133, DOI 10.1016/0014-5793(93)80052-V; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; YAROSH DB, 1985, MUTAT RES, V145, P1, DOI 10.1016/0167-8817(85)90034-3	42	10	10	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					651	658						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637722				2022-12-28	WOS:A1996TV59700022
J	Hirai, S; Izawa, M; Osada, S; Spyrou, G; Ohno, S				Hirai, S; Izawa, M; Osada, S; Spyrou, G; Ohno, S			Activation of the JNK pathway by distantly related protein kinases, MEKK and MUK	ONCOGENE			English	Article						ERK; Jun; MAP kinase; Raf; SAPK	C-JUN; MAP KINASE; TRANSCRIPTIONAL ACTIVATION; DOMAIN; ONCOGENE; PHOSPHORYLATION; IDENTIFICATION; AP-1; RAF; FOS	JNK/SAPKs are identified as new members of the MAPK family; they phosphorylate c-Jun protein in response to several cellular stimuli including ultraviolet irradiation, TNF and osmotic shock. We have identified a protein kinase, MUK, as an activator of the JNK-pathway, whose kinase domain shows significant homology to MAPKKK-related proteins such as c-Raf and MEKK. The over-expression of MUK or MEK kinase (MEKK) in NIH3T3 or COS1 cells results in the activation of JNK1 and the accumulation of a hyper-phosphorylated form of c-Jun. While MEKK also activates the ERK pathway, MUK is a rather selective activator of the JNK pathway, On the other hand, c-Raf activates the JNK pathway only slightly despite its remarkable ability to activate the ERK pathway. Even though we originally identified MUK as a MAPKKK-related protein kinase, a greater similarity to mixed lineage kinase (MLK) is found not only in the catalytic domain but also in the 'leucine-zipper'-like motifs located at the C-terminal side of the catalytic domain. The structural divergence between MUK and MEKK reveals the multiplicity of signaling pathways that activate JNK/SAPKs.	KAROLINSKA INST, MED NOBEL INST BIOCHEM, DEPT MED BIOCHEM & BIOPHYS, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet	Hirai, S (corresponding author), YOKOHAMA CITY UNIV, SCH MED, DEPT MOLEC BIOL, KANAZAWA KU, 3-9 FUKU URA, YOKOHAMA, KANAGAWA 236, JAPAN.		Ohno, Shigeo/B-1768-2010	Ohno, Shigeo/0000-0002-1294-5269; Osada, Shin-Ichi/0000-0001-5387-085X				ADLER V, 1994, J BIOL CHEM, V269, P11186; ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DORROW DS, 1993, EUR J BIOCHEM, V213, P701; EROE K, 1994, ONCOGENE, V9, P935; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HIRAI SI, 1990, ONCOGENE, V5, P39; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; ING YL, 1994, ONCOGENE, V9, P1745; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KATOH M, 1995, ONCOGENE, V10, P1447; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YAN MH, 1994, NATURE, V372, P798; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	51	126	131	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					641	650						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637721				2022-12-28	WOS:A1996TV59700021
J	Casey, G; Lopez, ME; Ramos, JC; Plummer, SJ; Arboleda, MJ; Shaughnessy, M; Karlan, B; Slamon, DJ				Casey, G; Lopez, ME; Ramos, JC; Plummer, SJ; Arboleda, MJ; Shaughnessy, M; Karlan, B; Slamon, DJ			DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies	ONCOGENE			English	Article						p53 tumor suppressor gene; breast cancer; ovarian cancer; lung cancer; mutations; immunohistochemical staining	HUMAN BREAST-CANCER; TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; STRAND CONFORMATION POLYMORPHISM; DENATURANT GEL-ELECTROPHORESIS; LI-FRAUMENI-SYNDROME; PROTEIN EXPRESSION; OVARIAN-CANCER; MUTANT P53; PROGNOSTIC-SIGNIFICANCE	p53 mutations are the most common genetic alterations found in human malignancies, However current estimates of p53 alterations in cancers may be inaccurate because there is evidence that current approaches do not detect all p53 alterations, In this study we determine the status of the p53 gene by complete DNA sequencing of exons 2 through 11 as well as immunohistochemical staining in cohorts of primary human breast, ovarian and non small cell lung cancer, Overall, 24 of 93 (26%) breast cancers, 62 of 108 (57%) ovarian cancers and 88 of 154 (57%) non small cell lung cancers contained DNA sequence mutations, whereas positive immunohistochemical staining was detected in 15 of 64 (23%) breast, 35 of 94 (37%) ovarian, and 63 of 137 (46%) lung cancers, Of those tumors that contained mutations, the mutation occurred outside the 'hot-spot' region in 19% of breast, 18% of ovarian and 17% of lung tumors, indicating that a substantial number of mutations remain undetected in studies that are restricted to exons 5 through 9, We observed a high concordance between the presence of p53 missense mutations and positive immunohistochemical staining, but a poor concordance between other types of mutations and staining in all three types of malignancies. We conclude that a combination of DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known alterations in the p53 gene in human malignancies.	UNIV CALIF LOS ANGELES, DEPT MED, DIV HEMATOL & ONCOL, LOS ANGELES, CA 90024 USA; CEDARS SINAI MED CTR, DEPT OBSTET & GYNECOL, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, SCH MED, LOS ANGELES, CA 90048 USA	University of California System; University of California Los Angeles; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Casey, G (corresponding author), CLEVELAND CLIN FDN, RES INST, DEPT CANC BIOL, 9500 EUCLID AVE, CLEVELAND, OH 44195 USA.							ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BARTEK J, 1991, ONCOGENE, V6, P1699; BARTEK J, 1990, INT J CANCER, V46, P839, DOI 10.1002/ijc.2910460515; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; BHATIA K, 1993, FASEB J, V7, P951, DOI 10.1096/fasebj.7.10.8344493; BIGGS PJ, 1993, MUTAGENESIS, V8, P275, DOI 10.1093/mutage/8.4.275; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; BODNER SM, 1992, ONCOGENE, V7, P743; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; CASEY G, 1991, ONCOGENE, V6, P1791; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; CHIBA I, 1990, ONCOGENE, V5, P1603; CHO KR, 1992, J CELL BIOCHEM, P137; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLES C, 1992, CANCER RES, V52, P5291; CONDIE A, 1993, HUM MUTAT, V2, P58, DOI 10.1002/humu.1380020111; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; DENG G, 1994, CANCER RES, V54, P499; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EELES RA, 1993, CANCER SURV, V18, P57; EELES RA, 1993, ONCOGENE, V8, P1269; ELLEDGE RM, 1994, CANCER RES, V54, P3752; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HALL PA, 1993, ONCOGENE, V8, P203; HARTMANN A, 1995, ONCOGENE, V10, P681; HARTMANN A, 1995, J CLIN INVEST, V95, P686, DOI 10.1172/JCI117714; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORAK E, 1991, ONCOGENE, V6, P2277; HORIO Y, 1993, CANCER RES, V53, P1; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; ISOLA J, 1992, J NATL CANCER I, V84, P1109, DOI 10.1093/jnci/84.14.1109; KOVACH JS, 1991, JNCI-J NATL CANCER I, V83, P1004, DOI 10.1093/jnci/83.14.1004; KUPRYJANCZYK J, 1993, P NATL ACAD SCI USA, V90, P4961, DOI 10.1073/pnas.90.11.4961; LANE DP, 1994, MOL BIOL REP, V19, P23, DOI 10.1007/BF00987319; LEHMAN TA, 1991, CANCER RES, V51, P4090; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1990, BIOESSAYS, V12, P60, DOI 10.1002/bies.950120203; LIPPONEN P, 1993, INT J CANCER, V55, P51, DOI 10.1002/ijc.2910550110; LOHMANN D, 1993, DIAGN MOL PATHOL, V2, P36, DOI 10.1097/00019606-199300020-00006; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARKS JR, 1991, CANCER RES, V51, P2979; MAZARS R, 1992, CANCER RES, V52, P3918; MAZARS R, 1991, ONCOGENE, V6, P1685; MAZUR M, 1988, SOMAT CELL MOLEC GEN, V14, P393, DOI 10.1007/BF01534647; MILNER BJ, 1993, CANCER RES, V53, P2128; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOLES JP, 1993, ONCOGENE, V8, P583; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOYRET C, 1994, ONCOGENE, V9, P1739; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OSBORNE RJ, 1991, CANCER RES, V51, P6194; OSTROWSKI JL, 1991, J PATHOL, V164, P75, DOI 10.1002/path.1711640113; PENG HQ, 1993, CANCER RES, V53, P3574; PLUMMER SJ, 1994, ONCOGENE, V9, P3273; POLLER DN, 1993, HUM PATHOL, V24, P463, DOI 10.1016/0046-8177(93)90157-C; PROSSER J, 1990, ONCOGENE, V5, P1573; PURDIE CA, 1994, ONCOGENE, V9, P603; REIHSAUS E, 1990, ONCOGENE, V5, P137; REISSMANN PT, 1993, ONCOGENE, V8, P1913; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; SAITOH S, 1994, ONCOGENE, V9, P2869; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SOMERS KD, 1992, CANCER RES, V52, P5997; SOMMER SS, 1992, J NATL CANCER I, V84, P246, DOI 10.1093/jnci/84.4.246; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STACK M, 1995, HUM MOL GENET, V4, P2047, DOI 10.1093/hmg/4.11.2047; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI K, 1993, MOL CARCINOGEN, V8, P58, DOI 10.1002/mc.2940080112; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; THOMPSON AM, 1992, INT J CANCER, V50, P528, DOI 10.1002/ijc.2910500405; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845; THORLACIUS S, 1993, CANCER RES, V53, P1637; VARLEY JM, 1991, ONCOGENE, V6, P413; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOJTESEK B, 1993, J CELL SCI, V105, P607; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; WALKER RA, 1991, J PATHOL, V165, P203, DOI 10.1002/path.1711650303; WARNEFORD SG, 1992, CELL GROWTH DIFFER, V3, P839	93	205	207	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1971	1981						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934544				2022-12-28	WOS:A1996VR79500017
J	Janknecht, R; Monte, D; Baert, JL; deLaunoit, Y				Janknecht, R; Monte, D; Baert, JL; deLaunoit, Y			The ETS-related transcription factor ERM is a nuclear target of signaling cascades involving MAPK and PKA	ONCOGENE			English	Article						Ets protein; ERM; phosphorylation; signaling; transcription	ACTIVATED PROTEIN-KINASE; DNA-BINDING; TRANSDUCTION PATHWAYS; C-FOS; MOLECULAR-CLONING; GENE-EXPRESSION; ONCOGENE FAMILY; GROWTH-FACTOR; DOMAIN; PROMOTER	Recent studies support a model for signal transduction from activated receptor tyrosine kinases to Ras which, in turn, activates the pathway of the mitogen-activated protein kinase (MARK), Although some members of the Ets transcription factor family have been shown to be activated by this signaling pathway, no data are available on the activation of the PEA3 group of Ets proteins, This group is composed of three members PEA3, ER81 and ERM - which are very similar in the DNA-binding domain, the ETS domain, in the 32 residue amino-terminal acidic domain and in the 61 residue carboxy-terminal domain, First of all we demonstrated that ERM-transfected cells contain a positive labeling in the nucleus, and rye concluded that a nuclear localization signal might be situated in the ETS domain, We then showed that of four putative reporter plasmids, ERM activated the artificial 3 x TORU plasmid which contains an Ets binding site contiguous to an AP1 one, This transactivation enhancement requires the presence of the ERM amino-terminal domain, In contrast, although the lack of the carboxy-terminal domain induced a decrease in transactivation, this latter domain is not crucial, By using the E74-reporter plasmid system which is not basically activated by ERM, we showed that the activation of the Ras/Raf-1/MAPK pathway significantly enhanced ERM-mediated transactivation, The deletion of the amino-terminal transactivation domain abolished the capacity of stimulated MAPK to activate ERM, We also demonstrated that ERM can also be activated through the protein kinase A (PKA), another signaling pathway, Nevertheless, the MAPK and PKA activation of ERM are not synergistic, Finally, we showed that this Ets transcription factor is in vitro phosphorylated by both activated ERK-2 and activated PKA, ERM has thus been identified as a transcription factor which is a target for two different signaling pathways and might therefore be involved in the mitogenic response of cells.	INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59019 LILLE,FRANCE; HANNOVER MED SCH,INST MOL BIOL,D-30623 HANNOVER,GERMANY	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Hannover Medical School				Janknecht, Ralf/0000-0003-1741-1562; monte, didier/0000-0002-0613-6203				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; COFFER P, 1994, ONCOGENE, V9, P911; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Crepieux Pascale, 1993, Gene Expression, V3, P215; deLaunoit Y, 1996, BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, P115; DICKSON B, 1995, TRENDS GENET, V11, P106, DOI 10.1016/S0168-9525(00)89011-3; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; JANKNECHT R, 1995, ONCOGENE, V10, P1209; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; Laget MP, 1996, ONCOGENE, V12, P1325; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; NAKAE K, 1995, J BIOL CHEM, V270, P23795, DOI 10.1074/jbc.270.40.23795; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PICKETT CA, 1995, MOL CELL BIOL, V15, P6777; RAO VN, 1993, ONCOGENE, V8, P2167; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; Stacey D W, 1988, Adv Exp Med Biol, V234, P141; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	40	79	80	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1745	1754						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895521				2022-12-28	WOS:A1996VM88700020
J	CherbonnelLasserre, C; Gauny, S; Kronenberg, A				CherbonnelLasserre, C; Gauny, S; Kronenberg, A			Suppression of apoptosis by Bcl-2 or Bcl-x(L) promotes susceptibility to mutagenesis	ONCOGENE			English	Article						Bcl-2; Bcl-x(L); apoptosis; mutagenesis; ionizing radiation	PROGRAMMED CELL-DEATH; DIPLOID HUMAN-LYMPHOBLASTS; DNA FRAGMENTATION; INDUCED MUTATION; HPRT LOCUS; P53 STATUS; BAX GENE; B-CELLS; IN-VIVO; PROTEIN	Bcl-2 appears to contribute to neoplasia primarily by promoting cell survival, rather than by stimulating cellular proliferation. Bcl-2, and the related protein Bcl-x(L) each suppress apoptosis induced by a wide variety of stimuli in many different cell types. Here we report that suppression of apoptosis by Bcl-2 or Bcl-x(L) markedly elevates the levels of radiation-induced mutations. This enhanced mutagenesis is the result of an increase in mutation frequency (mutations per survivor) together with a moderate increase in viability. Ectopic expression of either Bcl-2 or Bcl-x(L) enhances radiation mutagenesis in cells with wtp53. Surprisingly, we found that ectopic expression of Bcl-x(L) also promotes mutagenesis in p53(-) cells. These results support the hypothesis that apoptosis plays a crucial role in maintaining genomic integrity by selectively eliminating highly mutated cells from the population.	UNIV CALIF BERKELEY, LAWRENCE BERKELEY LAB, DIV LIFE SCI, BERKELEY, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R01CA062364] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-62364] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMUNDSON SA, 1992, MUTAT RES, V267, P89, DOI 10.1016/0027-5107(92)90113-G; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHAO DT, 1995, J EXP MED, V182, P821, DOI 10.1084/jem.182.3.821; CHEN G, 1995, EXP CELL RES, V221, P55, DOI 10.1006/excr.1995.1351; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOLE MG, 1995, CANCER RES, V55, P2576; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FUKUNAGAJOHNSON N, 1995, CARCINOGENESIS, V16, P1761, DOI 10.1093/carcin/16.8.1761; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; Gauthier ER, 1996, CANCER RES, V56, P1451; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Han ZY, 1996, CANCER RES, V56, P1621; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HAVRE PA, 1995, CANCER RES, V55, P4420; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KRONENBERG A, 1989, MUTAT RES, V211, P215, DOI 10.1016/0027-5107(89)90004-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIBER HL, 1982, MUTAT RES, V94, P467, DOI 10.1016/0027-5107(82)90308-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1992, CANCER RES, V52, P5407; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NELSON SL, 1995, RADIAT RES, V141, P2, DOI 10.2307/3579083; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PHILLIPS EN, 1995, RADIAT RES, V143, P255, DOI 10.2307/3579211; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1994, COLD SPRING HARB SYM, V59, P403, DOI 10.1101/SQB.1994.059.01.045; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; XIA F, 1995, CANCER RES, V55, P12; YANDELL DW, 1990, MUTAT RES, V229, P89, DOI 10.1016/0027-5107(90)90011-R; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YUAN JL, 1995, CARCINOGENESIS, V16, P2295, DOI 10.1093/carcin/16.10.2295; ZHAN QM, 1994, ONCOGENE, V9, P3743	46	85	86	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1489	1497						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875987				2022-12-28	WOS:A1996VL38400014
J	Kao, CT; Lin, M; OSheaGreenfield, A; Weinstein, J; Sakamoto, KM				Kao, CT; Lin, M; OSheaGreenfield, A; Weinstein, J; Sakamoto, KM			Over-expression of p55Cdc inhibits granulocyte differentiation and accelerates apoptosis in myeloid cells	ONCOGENE			English	Article						cell division cycle; granulocyte differentiation; apoptosis; myeloid cells	COLONY-STIMULATING FACTOR; CYCLIN-DEPENDENT KINASES; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; MOLECULAR CONTROLS; SUPPRESSOR GENES; WD-40 REPEAT; PROTEIN; ARREST	p55Cdc is a protein identified in cycling mammalian cells. It is highly expressed in proliferating but not in differentiated or growth-arrested cells. Structurally, p55Cdc is similar to the Cdc4 and Cdc20 proteins, which have been proposed to regulate DNA synthesis and mitosis in Saccharomyces cerevisiae. To define the role of p55Cdc during myelopoiesis, me studied the expression and regulation of this protein in response to the hematopoietic growth factors, granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte-colony stimulating factor (G-CSF). We analysed the time course of expression of p55Cdc in response to GM-CSF and G-CSF stimulation in the murine factor-dependent myeloid leukemic cell line, 32Dc13, and demonstrated differential regulation of p55Cdc in response to these two growth factors, Over-expression of p55Cdc resulted in acceleration of apoptosis in growth factor- and serum-free conditions, although no difference was observed in the rate of cell proliferation, Decreases in p55Cdc protein levels correlated with cells undergoing apoptosis, p55Cdc over-expression also inhibited granulocyte differentiation of 32Dc13 cells treated with G-CSF, Our studies suggest that p55Cdc regulation is critical for normal cell cycle control during myeloid cell proliferation and differentiation.	UNIV CALIF LOS ANGELES,SCH MED,GWYNNE HAZEN CHERRY MEM LABS,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV HEMATOL ONCOL,LOS ANGELES,CA 90095; JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095; AMGEN INC,THOUSAND OAKS,CA 91320	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; Amgen					NCI NIH HHS [R29 CA68221, K08 CA59463-01, 1R55 CA68221-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068221, R55CA068221, K08CA059463] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; ASKEW DS, 1991, ONCOGENE, V6, P1915; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOI WJ, 1994, BIOCHEM BIOPH RES CO, V172, P1324; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DAWSON IA, 1993, DEVELOPMENT, V117, P359; ELLEDGE RM, 1995, BIOESSAYS, V17, P923, DOI 10.1002/bies.950171105; EVAN G, 1995, CURR OPIN CELL BIOL, V6, P825; FEUCHTER AE, 1992, GENOMICS, V13, P1237, DOI 10.1016/0888-7543(92)90041-P; GRANA X, 1995, ONCOGENE, V11, P211; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; HALLEK M, 1994, LEUKEMIA, V8, P740; HENNING KA, 1995, CELL, V82, P555, DOI 10.1016/0092-8674(95)90028-4; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1993, P NATL ACAD SCI USA, V90, P6746, DOI 10.1073/pnas.90.14.6746; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; KORSMEYER SJ, 1992, BLOOD, V80, P879; KOUZARIDES T, 1995, TRENDS CELL BIOL, V5, P448, DOI 10.1016/S0962-8924(00)89109-6; KREIDER BL, 1992, ONCOGENE, V7, P135; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; LEE HJJ, 1995, J BIOL CHEM, V270, P15979, DOI 10.1074/jbc.270.27.15979; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; Nunez Gabriel, 1994, Trends in Cell Biology, V4, P399, DOI 10.1016/0962-8924(94)90053-1; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; SAKAMOTO KM, 1994, RECEPTOR CHANNEL, V2, P175; SAKAMOTO KM, 1994, MOL CELL BIOL, V14, P5975, DOI 10.1128/MCB.14.9.5975; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TKATCH LS, 1993, LYMPHOKINE CYTOK RES, V12, P477; TOMEI LD, 1991, APOPTOSIS MOL BASIS; VANDERVOORN L, 1992, FEBS LETT, V307, P131, DOI 10.1016/0014-5793(92)80751-2; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wong A, 1995, J BIOL CHEM, V270, P30271, DOI 10.1074/jbc.270.51.30271; Xiong Y, 1991, Curr Biol, V1, P362, DOI 10.1016/0960-9822(91)90193-Z	48	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1221	1229						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808696				2022-12-28	WOS:A1996VJ20200013
J	Mangues, R; Symmans, WF; Lu, SY; Schwartz, S; Pellicer, A				Mangues, R; Symmans, WF; Lu, SY; Schwartz, S; Pellicer, A			Activated N-ras oncogene and N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis	ONCOGENE			English	Article						transgenic mice; ras pathway; lymphomas; mammary tumors	MURINE SARCOMA-VIRUS; TRANSGENIC MICE; NEU PROTOONCOGENE; MOUSE EMBRYOS; 3T3 CELLS; HA-RAS; TRANSFORMATION; EXPRESSION; GENE; TUMORS	We compared the tumorigenic effects of the N-ras oncogene and the N-ras proto-oncogene in lymphoid and mammary tissues in an in vivo model, For this purpose, we generated transgenic mice with high levels of N-ras oncogene or N-ras proto-oncogene expression, driven by the complete mouse mammary tumor virus LTR (MMTV-LTR) (MMTV/N-ras(T) and MMTV/N-ras(N) constructs) and transgenic mice with low levels of N-ras oncogene or N-ras proto-oncogene expression, driven by a truncated MMTV-LTR (TMTV/N-ras(T) and TMTV/N-ras(N) constructs), We show that both, the N-ras proto-oncogene and the N-ras oncogene with a C:G-->A:T mutation at codon 61, lead to identical tumor types: lymphoblastic T-cell lymphomas, cleaved B-cell lymphomas and poorly differentiated mammary carcinomas, Nevertheless, there were quantitative differences in tumor incidence and latency and in transgene expression among N-ras oncogene and N-ras proto-oncogene transgenics, Despite these differences in tumor kinetics, the predisposition to identical tumor types is in agreement with the idea that the N-ras oncogene and the N-ras proto-oncogene act through the same pathway for in vivo tumorigenesis in B-cells, T-cells or mammary epithelial cells.	NYU,MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU,MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			MARTINEZ, ANTONIO PELLICER/C-4832-2015; Mangues, Ramon/J-6396-2014; Schwartz, Simo/H-7776-2012	Mangues, Ramon/0000-0003-2661-9525; Schwartz, Simo/0000-0001-8297-7971; Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R37CA036327, T32CA009161, R01CA050434, R01CA036327] Funding Source: NIH RePORTER; NCI NIH HHS [CA50434, 5T32 CA09161, CA36327] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOS JL, 1989, CANCER RES, V49, P4682; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICHUTEK K, 1989, J VIROL, V63, P1377, DOI 10.1128/JVI.63.3.1377-1383.1989; Coffman R L, 1982, Immunol Rev, V69, P5; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GORDON JW, 1980, P NATL ACAD SCI-BIOL, V77, P7380, DOI 10.1073/pnas.77.12.7380; GUERRERO I, 1984, SCIENCE, V225, P1041, DOI 10.1126/science.6089339; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HANCOCK JF, 1988, ONCOGENE, V3, P187; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LUO W, 1992, J IMMUNOL, V148, P1630; MANGUES R, 1994, CANCER RES, V54, P6395; MANGUES R, 1992, ONCOGENE, V7, P2073; MARCU KB, 1980, CELL, V22, P187, DOI 10.1016/0092-8674(80)90167-1; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; MORRIS JDH, 1989, ONCOGENE, V4, P27; QUAIFE CJ, 1987, CELL, V48, P1023, DOI 10.1016/0092-8674(87)90710-0; REDMOND SMS, 1988, ONCOGENE, V2, P259; RICKETTS MH, 1988, MOL CELL BIOL, V8, P1460, DOI 10.1128/MCB.8.4.1460; SEUWEN K, 1988, EMBO J, V7, P161, DOI 10.1002/j.1460-2075.1988.tb02796.x; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SOUYRI M, 1989, J VIROL, V63, P3944, DOI 10.1128/JVI.63.9.3944-3953.1989; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; VELU TJ, 1989, J VIROL, V63, P1384, DOI 10.1128/JVI.63.3.1384-1392.1989; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0	36	29	29	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1053	1063						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806695				2022-12-28	WOS:A1996VG76600019
J	Pelicci, G; Dente, L; DeGiuseppe, A; VerducciGalletti, B; Giuli, S; Mele, S; Vetriani, C; Giorgio, M; Pandolfi, PP; Cesareni, G; Pelicci, PG				Pelicci, G; Dente, L; DeGiuseppe, A; VerducciGalletti, B; Giuli, S; Mele, S; Vetriani, C; Giorgio, M; Pandolfi, PP; Cesareni, G; Pelicci, PG			A family of Shc related proteins with conserved PTB, CH1 and SH2 regions	ONCOGENE			English	Article						Shc related proteins; modular organization; Shc family	PHOSPHOTYROSINE INTERACTION DOMAIN; GROWTH-FACTOR RECEPTOR; GRB2 ADAPTER PROTEINS; TYROSINE KINASES; SIGNAL-TRANSDUCTION; CONSTITUTIVE PHOSPHORYLATION; NUCLEOTIDE EXCHANGE; INSULIN-RECEPTOR; BETA-RECEPTOR; ERBB-2 KINASE	Shc proteins are targets of activated tyrosine kinases and have been implicated in the transmission of activation signals to Ras. Upon phosphorylation, Shc proteins form stable complexes with cellular tyrosine-phosphorylated proteins and with the Grb2 adaptor protein, Two Shc isoforms of 52 and 46 kDa have been characterized. They share a C-terminal SH2 domain, a proline- and glycine-rich region (collagen homologous region 1; CH1) and a N-terminal phospho-tyrosine binding domain (PTB), We report here the initial characterization of two Shc related human cDNAs: ShcB and ShcC. The ShcB and ShcC cDNAs code for proteins that are highly similar and share the same modular organization as Shc. PTB and SH2 domains of ShcB and ShcC have similar binding specificities in vitro and bind to activated EGFR in a phosphotyrosine-dependent manner. Based on these findings we propose to rename Shc as ShcA. Anti-ShcB and anti-ShcC antibodies recognize specific polypeptides of 52, 47 kDa (ShcB) and 54 kDa (ShcC) in mammalian cells. Since these two genes are predominantly expressed in specific brain tissues, these Shc family members may be involved in cell type-specific signaling, in the nervous system.	UNIV ROMA TOR VERGATA, DIPARTIMENTO BIOL, I-00173 ROME, ITALY; MEM SLOAN KETTERING CANC CTR, DEPT GENET, NEW YORK, NY 10021 USA; UNIV PERUGIA, IST MED INTERNA & SCI ONCOL, I-06122 PERUGIA, ITALY	University of Rome Tor Vergata; Memorial Sloan Kettering Cancer Center; University of Perugia	Pelicci, G (corresponding author), DEPT EXPTL ONCOL, IST EUROPEO ONCOL, VIA RIPAMONTI 435, I-20141 MILAN, ITALY.		Pelicci, Pier Giuseppe/AAL-6572-2020; Giorgio, Marco/I-9425-2012; Pelicci, Giuliana/AAA-8921-2022	Giorgio, Marco/0000-0002-5842-6042; Pelicci, Giuliana/0000-0003-0986-8255; DENTE, LUCIANA/0000-0002-9617-0922				BALDARI CT, 1995, ONCOGENE, V10, P1141; BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BORRELLO MG, 1994, ONCOGENE, V9, P1661; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CROWE AJ, 1994, ONCOGENE, V9, P537; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELICI F, 1991, J MOL BIOL, V222, P301, DOI 10.1016/0022-2836(91)90213-P; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAI KMV, 1995, MOL CELL BIOL, V15, P4810; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOTTI LV, 1995, IN PRESS MOL CELL BI; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PELICCI G, 1995, ONCOGENE, V11, P899; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RICCI A, 1995, ONCOGENE, V11, P1519; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SEGATTO O, 1993, ONCOGENE, V8, P2105; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TAUCHI T, 1994, J EXP MED, V179, P167, DOI 10.1084/jem.179.1.167; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	45	119	127	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					633	641						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760305				2022-12-28	WOS:A1996VB32800021
J	Gotz, C; Wagner, P; Issinger, OG; Montenarh, M				Gotz, C; Wagner, P; Issinger, OG; Montenarh, M			p21(WAF1/CIP1) interacts with protein kinase CK2	ONCOGENE			English	Article						p21(WAF1/CIP1); protein kinase CK2; phosphorylation; p53	DNA-BINDING FUNCTION; BETA-SUBUNIT; CASEIN KINASE-2; CELLULAR-REGULATION; SUPPRESSOR PROTEIN; ALPHA-SUBUNITS; XENOPUS-LAEVIS; HUMAN TUMORS; II ACTIVITY; P53	p21(WAF1/CIP1) which belongs to a class of regulatory proteins that interact with cyclin dependent kinases is a potent inhibitor of these kinases. The inhibition of the cyclin dependent kinases induces an arrest of cells in the G(1) phase of the cell cycle. In addition p21(WAF1/CIP1) associates with PCNA and inhibits DNA replication. Here, we show that p21(WAF1/CIP1) binds to the regulatory beta-subunit of protein kinase CK2 but not to the catalytic alpha-subunit. Binding of p21(WAF1/CIP1) down regulates the kinase activity of CK2 with respect to the phosphorylation of the beta-subunit of CK2, casein and the C-terminus of p53. This study demonstrates a new binding partner for the regulatory beta-subunit of protein kinase CK2 which regulates the activity of the holoenzyme.	UNIV SAARLAND, INST MED BIOCHEM, D-66421 HOMBURG, GERMANY; ODENSE UNIV, INST BIOKEM, DK-5230 ODENSE, DENMARK	Saarland University; University of Southern Denmark			Montenarh, Mathias/AAB-6689-2020					ALGHISI GC, 1994, CELL MOL BIOL RES, V40, P563; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; APPEL K, 1995, ONCOGENE, V11, P1971; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BODENBACH L, 1994, EUR J BIOCHEM, V220, P263, DOI 10.1111/j.1432-1033.1994.tb18622.x; BOLDYREFF B, 1994, CELL MOL BIOL RES, V40, P391; BOLDYREFF B, 1993, EUR J BIOCHEM, V218, P515, DOI 10.1111/j.1432-1033.1993.tb18404.x; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN YQ, 1995, INT J ONCOL, V7, P889; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GOTZ C, 1995, EUR J BIOCHEM, V233, P327, DOI 10.1111/j.1432-1033.1995.327_1.x; GOUBIN F, 1995, ONCOGENE, V10, P2281; GRANKOWSKI N, 1991, EUR J BIOCHEM, V198, P25, DOI 10.1111/j.1432-1033.1991.tb15982.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HARPER JW, 1993, CELL, V75, P805; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINRICHS MV, 1993, BIOCHEMISTRY-US, V32, P7310, DOI 10.1021/bi00079a030; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KORDIYAK GJ, 1994, BIOCHEMISTRY-US, V33, P13484, DOI 10.1021/bi00249a037; KRAISS S, 1990, ONCOGENE, V5, P845; KREBS EG, 1988, COLD SPRING HARB SYM, V53, P77, DOI 10.1101/SQB.1988.053.01.012; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LIN WJ, 1994, BIOCHEMISTRY-US, V33, P6998, DOI 10.1021/bi00188a032; LITCHFIELD DW, 1992, J BIOL CHEM, V267, P13943; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; LORENZ A, 1992, INT J ONCOL, V1, P571; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MAENPAA PH, 1977, BIOCHIM BIOPHYS ACTA, V498, P294, DOI 10.1016/0304-4165(77)90267-7; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1995, EUR J BIOCHEM, V230, P1025, DOI 10.1111/j.1432-1033.1995.tb20651.x; MEGGIO F, 1992, EUR J BIOCHEM, V205, P939, DOI 10.1111/j.1432-1033.1992.tb16860.x; MEGGIO F, 1992, EUR J BIOCHEM, V204, P293, DOI 10.1111/j.1432-1033.1992.tb16636.x; MEGGIO F, 1993, BIOCHIM BIOPHYS ACTA, V1164, P223, DOI 10.1016/0167-4838(93)90252-M; MEGGIO F, 1983, FEBS LETT, V160, P203, DOI 10.1016/0014-5793(83)80967-3; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; MUNSTERMANN U, 1990, EUR J BIOCHEM, V189, P251, DOI 10.1111/j.1432-1033.1990.tb15484.x; MURRAY A, 1993, CELL CYCLE; NASTAINCZYK W, 1995, HYBRIDOMA, V14, P335, DOI 10.1089/hyb.1995.14.335; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEPPERKOK R, 1994, J BIOL CHEM, V269, P6986; PINNA LA, 1990, BIOCHIM BIOPHYS ACTA, V1054, P267, DOI 10.1016/0167-4889(90)90098-X; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; PROWALD K, 1984, FEBS LETT, V176, P479, DOI 10.1016/0014-5793(84)81222-3; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SCHMIDTSPANIOL I, 1992, HYBRIDOMA, V11, P53, DOI 10.1089/hyb.1992.11.53; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; STURZBECHER HW, 1990, ONCOGENE, V5, P795; WAGNER P, 1994, INT J ONCOL, V4, P491; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	66	58	59	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					391	398						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710378				2022-12-28	WOS:A1996VA25200018
J	Lipsick, JS				Lipsick, JS			One billion years of Myb	ONCOGENE			English	Review						myb; DNA binding; evolution; gene duplication	DNA-BINDING DOMAIN; AVIAN-MYELOBLASTOSIS VIRUS; HUMAN C-MYB; TPA-INDUCED DIFFERENTIATION; NEGATIVE REGULATORY DOMAIN; HUMAN HEMATOPOIETIC-CELLS; AMINO-TERMINAL REGION; HUMAN LYMPHOCYTES-T; V-MYB; B-MYB	The v-myb oncogene of the avian myeloblastosis virus has led to the discovery of a large and growing family of myb-related genes in a wide variety of eukaryotes including animals, plants, fungi and slime molds. The Myb-related proteins contain a highly conserved sequence, often present in multiple tandem repeats which constitute a DNA-binding domain. These proteins generally function in the regulation of cell growth and differentiation, often by coregulating gene expression along with DNA-binding proteins of other classes. This review focuses on the evolution of the myb gene family and the role of these genes in development.	STANFORD UNIV, SCH MED, PROGRAM MOL & GENET MED, STANFORD, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), STANFORD UNIV, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA.							ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; AMARAVADI L, 1994, ONCOGENE, V9, P971; ARSURA M, 1992, BLOOD, V79, P2708; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BALUDA MA, 1994, ONCOGENE, V9, P2761; BARANOWSKIJ N, 1994, EMBO J, V13, P5383, DOI 10.1002/j.1460-2075.1994.tb06873.x; BAUMANN P, 1995, TRENDS GENET, V11, P279, DOI 10.1016/S0168-9525(00)89075-7; BERBEE ML, 1993, CAN J BOT, V71, P1114, DOI 10.1139/b93-131; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BIN X, 1993, J VIROL, V67, P7332, DOI 10.1128/JVI.67.12.7332-7339.1993; BLACKWELL TK, 1994, SCIENCE, V266, P621, DOI 10.1126/science.7939715; BODEAU JP, 1992, MOL GEN GENET, V233, P379, DOI 10.1007/BF00265434; BORTNER DM, 1991, NUCLEIC ACIDS RES, V19, P1533, DOI 10.1093/nar/19.7.1533; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BRANDL CJ, 1990, MOL CELL BIOL, V10, P4256, DOI 10.1128/MCB.10.8.4256; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CATRON KM, 1992, J IMMUNOL, V148, P934; CHASMAN DI, 1990, GENE DEV, V4, P503, DOI 10.1101/gad.4.4.503; CHEN RH, 1995, ONCOGENE, V11, P1771; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; CONE KC, 1993, PLANT CELL, V5, P1795, DOI 10.1105/tpc.5.12.1795; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; DASGUPTA P, 1989, ONCOGENE, V4, P1419; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DESBIENS X, 1991, DEVELOPMENT, V111, P699; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUDEK H, 1989, ONCOGENE, V4, P1489; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; ENGELKE U, 1994, J VIROL, V68, P2752, DOI 10.1128/JVI.68.4.2752-2755.1994; ENGELKE U, 1995, ONCOGENE, V11, P735; ENGLAND BP, 1992, P NATL ACAD SCI USA, V89, P683, DOI 10.1073/pnas.89.2.683; ERWIN DH, 1991, TRENDS ECOL EVOL, V6, P131, DOI 10.1016/0169-5347(91)90092-C; ESS KC, 1995, MOL CELL BIOL, V15, P5707; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FAVIER D, 1994, ONCOGENE, V9, P305; FENG DF, 1990, METHOD ENZYMOL, V183, P375; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1993, EMBO J, V12, P1333, DOI 10.1002/j.1460-2075.1993.tb05778.x; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRAMPTON J, 1989, NATURE, V342, P134, DOI 10.1038/342134a0; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GARCIA A, 1991, ONCOGENE, V6, P265; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; GOFF SA, 1992, GENE DEV, V6, P864, DOI 10.1101/gad.6.5.864; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, J IMMUNOL, V153, P543; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; GROTEWOLD E, 1994, CELL, V76, P543, DOI 10.1016/0092-8674(94)90117-1; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; GUERIN M, 1990, ONCOGENE, V5, P131; GUERRA J, 1995, BLOOD, V86, P1873, DOI 10.1182/blood.V86.5.1873.bloodjournal8651873; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; HOLLAND PWH, 1994, DEVELOPMENT, P125; HOVRING PI, 1994, J BIOL CHEM, V269, P17663; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HSIANG YHH, 1995, J IMMUNOL, V154, P5195; HU YL, 1991, ONCOGENE, V6, P1549; HULSKAMP M, 1994, CELL, V76, P555, DOI 10.1016/0092-8674(94)90118-X; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1988, J VIROL, V62, P4398, DOI 10.1128/JVI.62.11.4398-4402.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JACKSON D, 1991, PLANT CELL, V3, P115, DOI 10.1105/tpc.3.2.115; JU QD, 1990, MOL CELL BIOL, V10, P5226, DOI 10.1128/MCB.10.10.5226; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; KNOLL AH, 1992, SCIENCE, V256, P622, DOI 10.1126/science.1585174; KU DH, 1993, J BIOL CHEM, V268, P2255; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LANG WH, 1994, CELL, V79, P527, DOI 10.1016/0092-8674(94)90261-5; LEECH MJ, 1993, PLANT J, V3, P51, DOI 10.1111/j.1365-313X.1993.tb00010.x; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; LOOMIS WF, 1990, P NATL ACAD SCI USA, V87, P9093, DOI 10.1073/pnas.87.23.9093; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MANAK JR, 1994, DEVELOPMENT, P61; MARSHALL CR, 1994, P NATL ACAD SCI USA, V91, P12283, DOI 10.1073/pnas.91.25.12283; MCCLINTOCK B, 1949, YB 48; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELOTTI P, 1994, J EXP MED, V179, P1023, DOI 10.1084/jem.179.3.1023; MORROW BE, 1993, MOL CELL BIOL, V13, P1173, DOI 10.1128/MCB.13.2.1173; MOSCOVICI C, 1975, VIROLOGY, V68, P173, DOI 10.1016/0042-6822(75)90159-2; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MOSSING MC, 1990, SCIENCE, V250, P1712, DOI 10.1126/science.2148648; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAZAROV V, 1995, J VIROL, V69, P3885, DOI 10.1128/JVI.69.6.3885-3888.1995; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NICOLAIDES NC, 1991, MOL CELL BIOL, V11, P6166, DOI 10.1128/MCB.11.12.6166; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NODA K, 1994, NATURE, V369, P661, DOI 10.1038/369661a0; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OEHLER T, 1993, ONCOGENE, V8, P1141; OEHLER T, 1990, NUCLEIC ACIDS RES, V18, P1703, DOI 10.1093/nar/18.7.1703; OGATA K, 1995, NAT STRUCT BIOL, V2, P309, DOI 10.1038/nsb0495-309; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OHI R, 1994, EMBO J, V13, P471, DOI 10.1002/j.1460-2075.1994.tb06282.x; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; QUATTROCCHIO F, 1993, PLANT CELL, V5, P1497, DOI 10.1105/tpc.5.11.1497; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; RAMSAY RG, 1992, CELL GROWTH DIFFER, V3, P723; RAMSAY RG, 1995, ONCOGENE, V11, P2113; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RERIE WG, 1994, GENE DEV, V8, P1388, DOI 10.1101/gad.8.12.1388; RHOADES MM, 1984, ANNU REV GENET, V18, P1, DOI 10.1146/annurev.ge.18.120184.000245; ROTH BA, 1991, PLANT CELL, V3, P317, DOI 10.1105/tpc.3.3.317; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHUUR ER, 1993, ONCOGENE, V8, P1839; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SENECA S, 1993, ONCOGENE, V8, P2335; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; SMARDA J, 1994, ONCOGENE, V9, P237; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TASHIRO S, 1995, ONCOGENE, V10, P1699; TAUTH K, 1994, EMBO J, V13, P5994; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TORELLI G, 1987, CANCER RES, V47, P5266; TRAVALI S, 1991, ONCOGENE, V6, P887; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; URAO T, 1993, PLANT CELL, V5, P1529, DOI 10.1105/tpc.5.11.1529; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WIESER J, 1995, GENE DEV, V9, P491, DOI 10.1101/gad.9.4.491	173	295	332	5	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					223	235						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710361				2022-12-28	WOS:A1996VA25200001
J	Shivakumar, CV; Das, GC				Shivakumar, CV; Das, GC			Interaction of human polyomavirus BK with the tumor-suppressor protein p53	ONCOGENE			English	Article						BK virus; p53; p53 binding; p53 transactivation	WILD-TYPE P53; TATA-BINDING PROTEIN; TRANSCRIPTIONAL CONTROL REGION; NUCLEAR FACTOR-I; DNA-BINDING; P53-MEDIATED TRANSACTIVATION; SV40-TRANSFORMED CELLS; ACTIVATION DOMAIN; TRANSFORMING GENE; TRANSGENIC MICE	We have been studying the interaction of the oncogenic human polyomavirus BK (BKV) with the tumor-suppressor protein p53 to understand the biology of this virus as well as to understand the basic mechanisms of p53 transactivation. We here demonstrate that p53 binds specifically to the viral promoter at two different sites, S-I (np 361-383) and S-II (np 314-336) in the late region. Site S-I is a 23 bp domain comprising an unique combination of a 10 bp consensus monomer binding site (Pu Pu Pu C (A/T) (T/A) G Py Py Py) which is contiguous with a GC-rich Sp-1 motif that binds p53 in the SV40 promoter. Site S-II also spans a 23 bp sequence containing two tandem consensus binding sites with three base pair mismatches in each and a one base pair deletion. A dimer of a 100 bp region spanning both the binding sites or the site S-I alone induced p53 responsiveness to a basal promoter when cloned upstream from the TATA box, but a similar construct using S-II did not. One tumor-derived mutant protein, p53-175 H, which is defective in DNA binding, also failed to transactivate the reporter gene. We further show that p53 binding-dependent transactivation is abrogated by BKV large T antigen, thereby suggesting an interaction between these two proteins in vivo. In contrast to the isolated p53 binding site, viral early promoter is repressed by p53 in H 1299 cells and the mutants are defective in this function to varying extent. This is suggestive of an involvement of cellular factors in modulating p53's function in the context of the whole promoter. p53 binding sites in BKV are flanked by the binding sites for transcription factors Sp-1 and NF-1 and we show that these transcription factors are present in the immunocomplex with purified p53, implicating modification of p53's transactivation function by protein-protein interaction. Thus, oncoprotein synthesis in this virus might be modulated by p53 in vivo by a complex mechanism other than simple DIVA binding and sequestration of the TATA binding protein. Together with SV40 and polyomavirus, which also harbor p53 binding sites, this viral system will serve as a model to understand the role of p53 in viral infection.	UNIV TEXAS,CTR HLTH,DEPT MOL BIOL,TYLER,TX 75710	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)					NATIONAL CANCER INSTITUTE [R29CA047611] Funding Source: NIH RePORTER; NCI NIH HHS [CA 47611] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; ARTHUR RR, 1986, NEW ENGL J MED, V315, P230, DOI 10.1056/NEJM198607243150405; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; CHAKRABORTY T, 1989, MOL CELL BIOL, V9, P3821, DOI 10.1128/MCB.9.9.3821; CHAKRABORTY T, 1991, J GEN VIROL, V72, P1935, DOI 10.1099/0022-1317-72-8-1935; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; DALRYMPLE SA, 1990, J VIROL, V64, P1182, DOI 10.1128/JVI.64.3.1182-1191.1990; DAS GC, 1995, ONCOGENE, V10, P449; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DEYERLE KL, 1987, J VIROL, V62, P3378; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P185; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; ELDIERY WS, 1992, NAT GENET, V1, P45; ELDIERY WS, 1993, CELL, V75, P817; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1049; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORRESTER K, 1995, ONCOGENE, V10, P2103; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GARDNER SD, 1971, LANCET, V1, P1253; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUALBERTO A, 1995, J BIOL CHEM, V270, P19680, DOI 10.1074/jbc.270.34.19680; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; JACKSON P, 1993, ONCOGENE, V8, P589; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KUNZ C, 1995, NUCLEIC ACIDS RES, V23, P3710, DOI 10.1093/nar/23.18.3710; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PAVELETICH NP, 1993, GENE DEV, V7, P2556; PERREM K, 1995, ONCOGENE, V11, P1299; PIPAS J, 1992, J VIROL, V66, P1289; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P8974, DOI 10.1073/pnas.91.19.8974; SAMBROOK J, 1993, MOL CLONING LAB MANU; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P10277; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; SAUER F, 1995, SCIENCE, V270, P1825, DOI 10.1126/science.270.5243.1825; SEGHAL PB, 1993, ONCOGENE, V8, P3417; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHIIO Y, 1993, ONCOGENE, V8, P2059; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SHIVAKUMAR CV, 1994, J GEN VIROL, V75, P1281, DOI 10.1099/0022-1317-75-6-1281; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SPANDIDOS DA, 1995, INT J ONCOL, V7, P1029; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG P, 1994, MOL CELL BIOL, V14, P5182, DOI 10.1128/MCB.14.8.5182; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; WATANABE S, 1984, J VIROL, V51, P1; WATANABE S, 1989, VIROLOGY, V169, P204, DOI 10.1016/0042-6822(89)90056-1; WATANABE S, 1985, J VIROL, V55, P823, DOI 10.1128/JVI.55.3.823-825.1985; WATANABE S, 1986, J VIROL, V59, P260, DOI 10.1128/JVI.59.2.260-266.1986; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; ZAMBETTI ZP, 1992, GENE DEV, V6, P1131; ZOUMPOURLIS V, 1995, INT J ONCOL, V7, P1035	93	25	25	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					323	332						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710371				2022-12-28	WOS:A1996VA25200011
J	Huynh, DP; Pulst, SM				Huynh, DP; Pulst, SM			Neurofibromatosis 2 antisense oligodeoxynucleotides induce reversible inhibition of schwannomin synthesis and cell adhesion in STS26T and T98G cells	ONCOGENE			English	Article						schwannomin; merlin; neurofibromatosis 2; antisense oligonucleotides; moesin; Schwann cell	E-CADHERIN; TYROSINE PHOSPHORYLATION; TYPE-2 NEUROFIBROMATOSIS; CYTOPLASMIC DOMAIN; UNITED-KINGDOM; BETA-CATENIN; PROTEIN; EZRIN; GENE; ASSOCIATION	Mutations in the neurofibromatosis 2 (NF2) gene are the predominant cause in the development of sporadic schwannomas and are also involved in the pathogenesis of meningiomas and ependymomas. The product of the NF2 gene, termed merlin or schwannnomin, is thought to act as a tumor suppressor protein. Although its protein sequence shows homology to proteins that are known to link the cytoskeleton to the cell membrane, no direct evidence for this function has been obtained, We used antisense phosphorothioate oligodeoxynucleotides (pODNs) complementary to the human NF2 cDNA sequence and transfected them into Schwann-like STS26T cells permeabilized by streptolysin O. Changes in cell morphology and attachment were observed at 12 to 24 h and continued up to 48 h post transfection. Cells were rounded and easily dislodged from the substratum at 12-24 h. These changes were reversible and cells became bipolar with thin protrusions and began to reattach to the substratum after 48 h. Normal morphology and adhesion were observed at 72 h post transfection. Morphological changes were due to suppression of schwannomin synthesis. Immunoprecipitations with anti-schwannomin antibodies showed schwannomin to be almost absent 3 h after treatment with antisense pODNs and to be significantly suppressed up to 12 h post transfection whereas beta-actin levels remained unchanged. The morphological changes were not the result of cell death, but resulted in increased cell proliferation. These data demonstrate that antisense oligonucleotides can be successfully employed to suppress schwannomin synthesis and indicate that schwannomin may belong to a class of tumor suppressor genes that provide a link between cell adhesion and tumorigenesis.	UNIV CALIF LOS ANGELES, SCH MED, NEUROGENET LAB, LOS ANGELES, CA 90048 USA; UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROL, CSMC BURNS & ALLEN RES INST, LOS ANGELES, CA 90048 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NINDS NIH HHS [NS01428-01A1] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGOSTI CG, 1995, AM J HUM GENET, V57, P114; ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; BARRY ELR, 1993, BIOTECHNIQUES, V15, P1016; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BHAKDI S, 1985, INFECT IMMUN, V47, P52; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; CONBOY J, 1986, P NATL ACAD SCI USA, V83, P9512, DOI 10.1073/pnas.83.24.9512; DAHLBERG WK, 1993, INT J RADIAT BIOL, V63, P191, DOI 10.1080/09553009314550251; DEPREZ RHL, 1994, AM J HUM GENET, V54, P1022; EVANS DGR, 1992, J MED GENET, V29, P847, DOI 10.1136/jmg.29.12.847; EVANS DGR, 1992, J MED GENET, V29, P841, DOI 10.1136/jmg.29.12.841; FRANCK Z, 1990, J CELL BIOL, V111, P2475, DOI 10.1083/jcb.111.6.2475; FUNAYAMA N, 1991, J CELL BIOL, V115, P1039, DOI 10.1083/jcb.115.4.1039; GOULD KL, 1989, EMBO J, V8, P4133, DOI 10.1002/j.1460-2075.1989.tb08598.x; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; HUYNH DP, 1994, DEV BIOL, V161, P538, DOI 10.1006/dbio.1994.1052; IRVING RM, 1993, ARCH OTOLARYNGOL, V119, P1222; JACOBSON AB, 1984, NUCLEIC ACIDS RES, V12, P45, DOI 10.1093/nar/12.1Part1.45; JACOBY LB, 1994, HUM MOL GENET, V3, P413, DOI 10.1093/hmg/3.3.413; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOIKE M, 1995, ONCOGENE, V10, P117; LANKES WT, 1991, P NATL ACAD SCI USA, V88, P8297, DOI 10.1073/pnas.88.19.8297; LUTCHMAN M, 1995, CANCER RES, V55, P2270; MARTUZA RL, 1988, NEW ENGL J MED, V318, P684, DOI 10.1056/NEJM198803173181106; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MAUTNER V, NEUROSURGERY, V38, P880; MURTHY AE, 1995, AM J HUM GENET, V57, P113; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; OKA H, 1993, CANCER RES, V53, P1696; REES DJG, 1990, NATURE, V347, P685, DOI 10.1038/347685a0; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; SAINZ J, 1994, HUM MOL GENET, V3, P885, DOI 10.1093/hmg/3.6.885; Sainz J, 1996, HUM GENET, V97, P121; SAINZ J, 1995, HUM MOL GENET, V4, P137, DOI 10.1093/hmg/4.1.137; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1830; SATO N, 1992, J CELL SCI, V103, P131; SHIOZAKI H, 1994, AM J PATHOL, V144, P667; SHIOZAKI H, 1991, AM J PATHOL, V139, P17; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKESHIMA H, 1994, ONCOGENE, V9, P2135; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1989, J CELL BIOL, V108, P2369, DOI 10.1083/jcb.108.6.2369; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita Shoichiro, 1992, Current Opinion in Cell Biology, V4, P834, DOI 10.1016/0955-0674(92)90108-O; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER RW, 1993, SCIENCE, V260, P1510, DOI 10.1126/science.7684856; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949	52	52	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					73	84						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700556				2022-12-28	WOS:A1996UX31900009
J	Bubb, VJ; Curtis, LJ; Cunningham, C; Dunlop, MG; Carothers, AD; Morris, RG; White, S; Bird, CC; Wyllie, AH				Bubb, VJ; Curtis, LJ; Cunningham, C; Dunlop, MG; Carothers, AD; Morris, RG; White, S; Bird, CC; Wyllie, AH			Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer	ONCOGENE			English	Article						replication errors; sporadic colorectal cancer; hMSH2; prognosis	GENETIC INSTABILITY; GENOMIC INSTABILITY; MUTATIONS; CARCINOMA; HOMOLOG; TUMORS; COLON	Microsatellite instability (MSI) occurs in most tumours from patients with hereditary non-polyposis colorectal cancer (HNPCC) and in around 17% of sporadic colorectal cancers. Germline defects in mismatch repair (MMR) genes are responsible for the majority of large HNPCC families, with hMSH2 accounting for at least 50%. MMR gene defects also occur in a small proportion of sporadic colorectal tumours with MSI. Here we report a systematic analysis of mismatch repair deficiency in 215 Scottish patients with sporadic colorectal tumours. We found that 16.4% of tumours exhibited MSI; survival analysis by Cox proportional hazards method showed a substantial survival advantage for patients with tumours showing MSI, independent of other prognostic factors. Tumours with MSI were screened for hMSH2 mutations and although 61% were found to have alterations, of these only 1/24 was exonic. The majority of these changes were reductions in length at intronic mononucleotide tracts and we postulate that these alterations are the result of a genetic defect elsewhere, although they may compromise hMSH2 function as a second step in tumourigenesis. Our findings indicate that instability confers an improved prognosis in colorectal cancer and, despite the fact that these two groups of tumours share similar biological characteristics, the genetic basis of HNPCC and sporadic colorectal cancer with MSI is different.	UNIV EDINBURGH, ROYAL INFIRM, DEPT SURG, EDINBURGH EH3 9YW, MIDLOTHIAN, SCOTLAND; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND	Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh	Bubb, VJ (corresponding author), UNIV EDINBURGH, SCH MED, DEPT PATHOL, CRC LABS, TEVIOT PL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND.		Dunlop, Malcolm G/F-1973-2011	Dunlop, Malcolm G/0000-0002-3033-5851				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BASSAM BJ, 1991, ANAL BIOCHEM, V196, P80, DOI 10.1016/0003-2697(91)90120-I; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; *CANC RES CAMP, 1993, 181 CANC RES CAMP; CHEN JS, 1995, CANCER RES, V55, P174; CHONG JM, 1994, CANCER RES, V54, P4595; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; CURTIS L, 1994, EUR J CANCER, V30A, P984, DOI 10.1016/0959-8049(94)90129-5; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FONG KM, 1995, CANCER RES, V55, P28; GAO XA, 1994, ONCOGENE, V9, P2999; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL NR, 1994, EUR J CANCER, V30A, P1550, DOI 10.1016/0959-8049(94)00326-Z; HAN HJ, 1993, CANCER RES, V53, P5087; HONCHEL R, 1994, CANCER RES, V54, P1159; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KIM HG, 1994, AM J PATHOL, V145, P148; KOBAYASHI Y, 1988, FOCUS, V10, P73; KOLODNER RD, 1994, GENOMICS, V24, P516, DOI 10.1006/geno.1994.1661; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LOTHE RA, 1993, CANCER RES, V53, P5849; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARY JL, 1994, HUM MOL GENET, V3, P2067; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P2098; MIRONOV NM, 1994, CANCER RES, V54, P41; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PATEL U, 1994, ONCOGENE, V9, P3695; PELTOMAKI P, 1993, CANCER RES, V53, P5853; PERCESEPPE A, 1994, INT J CANCER, V58, P799, DOI 10.1002/ijc.2910580608; PROLLA TA, 1994, MOL CELL BIOL, V14, P407, DOI 10.1128/MCB.14.1.407; PURDIE CA, 1991, AM J PATHOL, V138, P807; RHYU MG, 1994, ONCOGENE, V9, P29; RISINGER JI, 1993, CANCER RES, V53, P5100; SHRIDHAR V, 1994, CANCER RES, V54, P2084; STORTS DR, 1993, PROMEGA NOTES, V42, P10; SUZUKI H, 1994, CANCER RES, V54, P4841; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WIERINGA B, 1984, CELL, V37, P915, DOI 10.1016/0092-8674(84)90426-4; WIJNEN J, 1994, HUM MOL GENET, V3, P2268, DOI 10.1093/hmg/3.12.2268-a; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; WU C, 1994, ONCOGENE, V9, P991; YOUNG J, 1993, HUM MUTAT, V2, P351, DOI 10.1002/humu.1380020505	55	231	235	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2641	2649						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700523				2022-12-28	WOS:A1996UW48700018
J	Kilbey, A; Black, EJ; Unlu, M; Gillespie, DAF				Kilbey, A; Black, EJ; Unlu, M; Gillespie, DAF			The v-Jun oncoprotein replaces p39 c-Jun as the predominant AP-1 constituent in ASV17-transformed fibroblasts: Implications for SAPK/JNK-mediated signal transduction	ONCOGENE			English	Article						v-Jun; AP-1; transformation; SAPK/JNK	CHICKEN-EMBRYO FIBROBLASTS; DNA-BINDING ACTIVITY; TRANSCRIPTIONAL ACTIVATION; MOUSE FIBROBLASTS; G0-TO-G1 TRANSITION; LEUCINE ZIPPER; FOS PROTEINS; TRANSFORMATION; DOMAIN; INVITRO	We have investigated the expression of Jun family proteins and composition of AP-I in chicken embryo fibroblasts before and after transformation by the v-Jun oncoprotein of ASV17, We show that p39 c-Jun is the predominant Jun family protein expressed in normal fibroblasts, and that heterodimers of c-Jun and Fos-related partners (Fra's) account for the majority of the AP-1 DNA binding activity, Unexpectedly, because ASV17-transformed fibroblasts do not express p39 c-Jun, v-Jun replaces c-Jun as the predominant AP-1 constituent in association with similar or identical Fra's, This substitution has little effect on the overall level of TRE-specific DNA binding activity, however it results in a profound reduction in TRE-dependent component of AP-1; whilst agonists of SAPK/JNK kinases trigger transient N-terminal phosphorylation of c-Jun in normal fibroblasts, no corresponding modification of v-Jun occurs in ASV17-transformed cells. Because SAPK/JNK-mediated phosphorylation is thought to regulate c-Jun transcriptional activity and thereby cellular gene expression in response to extracellular signals, we propose that subversion of this signal transduction process by v-Jun is likely to contribute to oncogenesis by ASV17.	BEATSON INST CANC RES,CANC RES CAMPAIGN BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	Beatson Institute			Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BLACK EJ, 1994, ONCOGENE, V9, P2363; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOHMANN D, 1994, CELL, V78, P973, DOI 10.1016/0092-8674(94)90273-9; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CATLING AD, 1993, ONCOGENE, V8, P1875; CROUCH DH, 1990, ONCOGENE, V5, P683; DAI TN, 1995, ONCOGENE, V10, P849; DEAN DC, 1989, MOL CELL BIOL, V9, P1489; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FRAME MC, 1991, ONCOGENE, V6, P205; GOLDSTONE SD, 1994, ONCOGENE, V9, P2305; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HADMAN M, 1993, ONCOGENE, V8, P1895; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN MJ, BIOL CHEM, V270, P16483; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MASOOD K, 1993, J NEUROCHEM, V61, P160, DOI 10.1111/j.1471-4159.1993.tb03551.x; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MORGAN IM, 1993, ONCOGENE, V8, P1135; MORGAN IM, 1992, ONCOGENE, V7, P1119; NISHIMURA T, 1988, ONCOGENE, V3, P659; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; SUZUKI T, 1991, JPN J CANCER RES, V82, P58, DOI 10.1111/j.1349-7006.1991.tb01746.x; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308	54	32	32	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2409	2418						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649782				2022-12-28	WOS:A1996UQ22000019
J	Takahashi, C; Akiyama, N; Matsuzaki, T; Takai, S; Kitayama, H; Noda, M				Takahashi, C; Akiyama, N; Matsuzaki, T; Takai, S; Kitayama, H; Noda, M			Characterization of a human MSX-2 cDNA and its fragment isolated as a transformation suppressor gene against v-Ki-ras oncogene	ONCOGENE			English	Article						MSX-2 homeobox gene; cellular transformation; revertant; ras oncogene; myogenic differentiation; MyoD gene	RETROVIRAL VECTORS; LEUKEMIA-VIRUS; CELL-LINES; EXPRESSION; MOUSE; DNA; FIBROBLASTS; EFFICIENCY; POLYMERASE; MYOGENESIS	A cDNA (termed CT124) encoding a carboxyl-terminal fragment of the human homeobox protein MSX-2 was found to induce flat reversion when expressed in v-Ki-ras-transformed NIH3T3 cells, Although the expression of endogenous MSX-2 gene is low in most of the normal adult tissues examined, it is frequently carcinoma-derived cell Likewise, inactive in NIH3T3 but is transcriptionally activated after transformation v-Ki-ras oncogene, suggesting that the intact MSX-2. may play a positive, rather than suppressive, role in cell transformation, To test this possibility, we isolated a near full-length human and tested its activities in two cell fibroblast and myoblast, In NIH3T3 fibroblasts, although the gene by itself failed to confer a transformed phenotype, antisense MSX-2 cDNA as well as truncated CT124 cDNA interfered with the transforming activities of v-Ki-ras oncogene, In C2C12 myoblasts, MSX-2 was found to suppress MyoD gene expression, as do activated ras oncogenes, under certain culture conditions, and CT124 was found to inhibit the activities of both MSX-2 and ras in this system as well, Our findings not only suggest that CT124 may act as a dominant suppressor of MSX-2 but also raise the possibility that MSX-2 gene may be an important downstream target for the Ras signaling pathways.	KYOTO UNIV,GRAD SCH MED,DEPT MOLEC ONCOL,SAKYO KU,KYOTO 606,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT VIRAL ONCOL,TOSHIMA KU,TOKYO 170,JAPAN; INT MED CTR JAPAN,CLIN RES INST,DEPT GENET,SHINJUKU KU,TOKYO 162,JAPAN	Kyoto University; Japanese Foundation for Cancer Research; National Center for Global Health & Medicine - Japan								ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BASSIN RH, 1970, INT J CANCER, V6, P95, DOI 10.1002/ijc.2910060114; BOS JL, 1989, CANCER RES, V49, P4682; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CATRON KM, 1995, MOL CELL BIOL, V15, P861; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COELHO CND, 1991, MECH DEVELOP, V34, P143, DOI 10.1016/0925-4773(91)90051-7; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DAVIDSON D, 1995, TRENDS GENET, V11, P405, DOI 10.1016/S0168-9525(00)89124-6; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; ERLICH HA, 1991, SCIENCE, V252, P1643, DOI 10.1126/science.2047872; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HOLLAND PWH, 1991, GENE, V98, P253, DOI 10.1016/0378-1119(91)90182-B; HSU IC, 1993, CARCINOGENESIS, V14, P987, DOI 10.1093/carcin/14.5.987; JABS EW, 1993, CELL, V75, P443, DOI 10.1016/0092-8674(93)90379-5; JOWETT AK, 1993, DEVELOPMENT, V117, P461; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; MONTARRAS D, 1991, NEW BIOL, V3, P592; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; MYERS TW, 1991, BIOCHEMISTRY-US, V30, P7661, DOI 10.1021/bi00245a001; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; NODA M, 1989, P NATL ACAD SCI USA, V86, P162, DOI 10.1073/pnas.86.1.162; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; NOSA M, 1993, FASEB J, V7, P834; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; Sambrook J., 2002, MOL CLONING LAB MANU; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SONG KN, 1992, NATURE, V360, P477, DOI 10.1038/360477a0; SUZUKI M, 1993, BIOCHEM BIOPH RES CO, V194, P187, DOI 10.1006/bbrc.1993.1802; TAKAI S, 1994, HUM GENET, V93, P198; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VALENZUELA DM, 1986, NUCLEIC ACIDS RES, V14, P843, DOI 10.1093/nar/14.2.843; WANG YQ, 1995, DEV BIOL, V168, P374, DOI 10.1006/dbio.1995.1087; WOLOSHIN P, 1995, CELL, V82, P611, DOI 10.1016/0092-8674(95)90033-0; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	45	39	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2137	2146						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668339				2022-12-28	WOS:A1996UP28300012
J	VanHouten, JN; Natoli, F; Asch, BB				VanHouten, JN; Natoli, F; Asch, BB			Frequent ectopic expression of a placenta-specific gene at high levels in BALB/c mouse mammary carcinomas	ONCOGENE			English	Article						MIPP; retrotransposon; mammary tumorigenesis; intracisternal A-particle	INTRACISTERNAL-A-PARTICLES; HEMATOPOIETIC-CELLS; DNA REARRANGEMENT; INSERTION; SEQUENCES; RETROTRANSPOSONS; TRANSFORMATION; IDENTIFICATION; TRANSPOSITION; PLASMACYTOMA	A placenta-specific gene, MIPP, is transcriptionally regulated in BALB/c mice by a solo long terminal repeat (LTR) of an intracisternal A-particle (IAP), an endogenous retrotransposon, Expression of IAPs, which is also promoted by LTR sequences, is a frequent aberration in many mouse mammary tumors of BALB/c mice, Given that these retroelements and the placental gene have a common promoter, we hypothesized that the tumors also express the gene, Northern blot analysis and RT-PCR revealed high expression of the placenta-specific gene in BALB/c mouse mammary preneoplasias and carcinomas of diverse etiologies, but not in normal mammary gland from virgin, pregnant and lactating mice, The preneoplasias and tumors expressed two transcripts, one of which is apparently unique to the mammary lesions, The other transcript is the same as one expressed in placenta that is not promoted by the IAP LTR, Despite the parallel expression of the placental gene and IAPs in the mammary tissues, RT-PCR showed that LTR sequences are absent from tumor-associated MIPP transcripts, Southern analysis revealed no gross mutations of the MIPP gene in mammary preneoplasias and tumors, The ectopic expression of the placenta-specific gene in BALB/c mouse mammary preneoplasias and carcinomas raises the possibility that it acts as an oncogene.			VanHouten, JN (corresponding author), ROSWELL PK CANC INST, DEPT EXPTL PATHOL, BUFFALO, NY 14263 USA.				NATIONAL CANCER INSTITUTE [R01CA059906] Funding Source: NIH RePORTER; NCI NIH HHS [CA59906] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGATE PA, 1993, ONCOGENE, V8, P1221; ASCH BB, 1990, CANCER RES, V50, P2404; ASCH BB, 1993, INT J CANCER, V54, P813, DOI 10.1002/ijc.2910540516; BANVILLE D, 1989, J MOL BIOL, V207, P481, DOI 10.1016/0022-2836(89)90458-0; BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; CANAANI E, 1983, P NATL ACAD SCI-BIOL, V80, P7118, DOI 10.1073/pnas.80.23.7118; CARDIFF RD, 1988, ANTICANCER RES, V8, P925; CHANGYEH A, 1993, P NATL ACAD SCI USA, V90, P292, DOI 10.1073/pnas.90.1.292; CHANGYEH A, 1991, NUCLEIC ACIDS RES, V19, P3667, DOI 10.1093/nar/19.13.3667; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHRISTY RJ, 1985, NUCLEIC ACIDS RES, V13, P289, DOI 10.1093/nar/13.1.289; DANDEKAR S, 1986, MOL CELL BIOL, V6, P4104, DOI 10.1128/MCB.6.11.4104; HAWLEY RG, 1984, MOL CELL BIOL, V4, P2565, DOI 10.1128/MCB.4.12.2565; JANMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111, DOI 10.1016/0955-0674(95)80052-2; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LUEDERS KK, 1977, CELL, V12, P963, DOI 10.1016/0092-8674(77)90161-1; MEDINA D, 1987, J NATL CANCER I, V79, P569; MEDINA D, 1970, J NATL CANCER I, V45, P353; MIYAMOTO S, 1990, MOL CELL BIOL, V10, P1593, DOI 10.1128/MCB.10.4.1593; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; SCHMID MF, 1994, J CELL BIOL, V124, P341, DOI 10.1083/jcb.124.3.341; SLAGLE BL, 1987, CELLULAR MOL BIOL MA, P275; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TOHYAMA K, 1990, EMBO J, V9, P1823, DOI 10.1002/j.1460-2075.1990.tb08307.x; VARKEY JP, 1995, GENE DEV, V9, P1074, DOI 10.1101/gad.9.9.1074; VONBULOW M, 1995, EXP CELL RES, V219, P407, DOI 10.1006/excr.1995.1246; WAY M, 1995, J CELL BIOL, V128, P51, DOI 10.1083/jcb.128.1.51; WIVEL NA, 1971, INT J CANCER, V7, P167, DOI 10.1002/ijc.2910070119; WOLF D, 1984, MOL CELL BIOL, V4, P1402, DOI 10.1128/MCB.4.7.1402; WUJCIK KM, 1984, J VIROL, V52, P29, DOI 10.1128/JVI.52.1.29-36.1984; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	35	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	1996	12	10					2241	2245						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668351				2022-12-28	WOS:A1996UP28300024
J	Schulz, RA; Chromey, C; Lu, MF; Zhao, B; Olson, EN				Schulz, RA; Chromey, C; Lu, MF; Zhao, B; Olson, EN			Expression of the D-MEF2 transcription factor in the Drosophila brain suggests a role in neuronal cell differentiation	ONCOGENE			English	Article						D-MEF2 transcription factor; Kenyon cells; muscle; mushroom bodies; neuron differentiation; transcriptional enhancers	TINMAN	D-MEF2 is a MADS domain transcription factor expressed in the cardiac, somatic, and visceral muscle cell lineages in the Drosophila embryo, Genetic studies have demonstrated that D-mef2 gene function is required for the proper differentiation of all three of these muscle types, We show that D-MEF2 is also expressed in a limited number of other cell types during development, including Kenyon cells present in the mushroom bodies of the Drosophila brain, This finding suggests a role for D-mef2 in neuron differentiation, To investigate D-mef2 expression in muscle and Kenyon cells, we assayed 26 kb of D-mef2 5'-flanking and intragenic DNA for regulatory sequences controlling the expression of the gene, Our results show that separable enhancer sequences direct D-mef2 gene expression in the myogenic and neuronal cell lineages. The identification of these regulatory DNAs provides a starting point for the analysis of transcriptional regulators controlling the cell-specific expression of D-mef2 and a means to address the function of D-mef2 in Kenyon cell differentiation.			Schulz, RA (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030, USA.							Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BODMER R, 1993, DEVELOPMENT, V118, P719; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; FERVEUR JF, 1995, SCIENCE, V267, P902, DOI 10.1126/science.7846534; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OBRIEN MA, 1994, GENETICS, V137, P121; ODELL KMC, 1995, NEURON, V15, P55, DOI 10.1016/0896-6273(95)90064-0; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; STOCKER RF, 1990, CELL TISSUE RES, V262, P9, DOI 10.1007/BF00327741; TAYLOR MV, 1995, MECH DEVELOP, V50, P29, DOI 10.1016/0925-4773(94)00323-F; TRUMAN JW, 1993, DEV DROSOPHILA MELAN; YANG MY, 1995, NEURON, V15, P45	21	69	70	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1827	1831						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622904				2022-12-28	WOS:A1996UG45800026
J	Michieli, P; Li, WQ; Lorenzi, MV; Miki, T; Zakut, R; Givol, D; Pierce, JH				Michieli, P; Li, WQ; Lorenzi, MV; Miki, T; Zakut, R; Givol, D; Pierce, JH			Inhibition of oncogene-mediated transformation by ectopic expression of p21(Waf1) in NIH3T3 cells	ONCOGENE			English	Article						cellular transformation; oncogenes; tumor suppressor genes; p53 effectors; cyclin-dependent kinase inhibitors	PROTEIN; FIBROBLASTS; RAS; P21; DIFFERENTIATION; LOCALIZATION; KINASES; P53	The p53-regulated p21(Waf1) protein is a universal inhibitor of cyclin-dependent kinases (CDKs). To study the potential tumor-suppressive properties of CDK inhibitors, the ability of p21(Waf1) to interfere with oncogene-mediated cellular transformation was analysed in the NIH3T3 cell system. Cotransfection of waf1 together with activated ras or several other oncogenes into NIH3T3 cells potently inhibited the formation of transformed foci in a dose-dependent manner, Expression of the CDK-binding N-terminal half of p21(Waf1) (N-p21(Waf1)) was necessary and sufficient to inhibit Ras-induced focus formation. In contrast, expression of the C-terminal domain (C-p21(Waf1)) had no effect on Ras-induced focus formation. Immunofluorescence analysis revealed that ectopically expressed p21(Waf1) and C-p21(Waf1) were localized in the nucleus, while N-p21(Waf1) was found in the cytoplasm, with the tendency to accumulate around the nuclear membrane. Surprisingly, stable NIH3T3 transfectants expressing ectopic p21(Waf1) grew at the same rate and displayed similar cell cycle distribution as NIH3T3 cells transfected with the same vector containing no insert. However ectopic p21(Waf1) expression did inhibit Ras-mediated anchorage-independent colony formation, indicating that p21(Waf1) can selectively interfere with oncogene-mediated transformation without affecting NIH3T3 cell growth, at least at the levels of p21(Waf1) expression experiments. Transient NIH3T3 cells inhibited Ras-indnced transcription from a E2F-responsive element but not from a serum-responsive element, indicating that p21(Waf1) acts downstream of early transcriptional events induced by Ras but upstream of E2F-controlled gene transcription. These results provide evidence that p21(Waf1) potently suppresses oncogene-mediated cellular transformation of NIH3T3 cells and that it may do so by inhibiting E2F-driven transcription of S phase genes.	WEIZMANN INST SCI,DEPT MOLEC CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	Michieli, P (corresponding author), NCI,CELLULAR & MOLEC BIOL LAB,NIH,BLDG 37,BETHESDA,MD 20892, USA.		Michieli, Paolo/A-2588-2011	Michieli, Paolo/0000-0002-3093-8871				ATADJA PW, 1994, MOL CELL BIOL, V14, P4991, DOI 10.1128/MCB.14.7.4991; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BLAM SB, 1988, ONCOGENE, V3, P129; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; CURRAN T, 1984, CELL, V36, P259; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; GRANA X, 1995, ONCOGENE, V11, P211; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; JIANG HP, 1994, ONCOGENE, V9, P3397; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LATHANGUE NB, 1990, NUCLEIC ACIDS RES, V18, P2929, DOI 10.1093/nar/18.10.2929; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; NEVINS JR, 1992, SCIENCE, V258, P424; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE E, 1994, NATURE, V371, P21, DOI 10.1038/371021a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAKUT R, 1995, ONCOGENE, V11, P393; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	49	39	41	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					775	784						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632899				2022-12-28	WOS:A1996TW68600008
J	Santos, J; Perez de Castro, I; Herranz, M; Pellicer, A; FernandezPiqueras, J				Santos, J; Perez de Castro, I; Herranz, M; Pellicer, A; FernandezPiqueras, J			Allelic losses on chromosome 4 suggest the existence of a candidate tumor suppressor gene region of about 0.6 cM in gamma-radiation-induced mouse primary thymic lymphomas	ONCOGENE			English	Article						mouse thymic lymphomas; gamma-radiation; microsatellites; loss of heterozygosity; chromosome 4; tumour suppressor genes	HOMOZYGOUS DELETIONS; N-METHYLNITROSOUREA; GENOME; ONCOGENES; RAS; MICROSATELLITES; HETEROZYGOSITY; CARCINOGENESIS; ABNORMALITIES; IRRADIATION	Mouse chromosome 4 was investigated to assess the involvement of tumor suppressor genes in primary thymic lymphomas induced by gamma-irradiation. PCR analysis using microsatellite DNA polymorphic markers was performed in F1 animals generated from a cross between the strains C57BL/6J and RF/J. Microsatellite markers were selected with focus on chromosome 4 around the region containing the interferon alpha gene cluster (D4Mit17, D4Wsm1, D4Mit9, and D4Mit205 and a more distal region (D4Mit12, D4Mit54, and D4Mit13). Allelic losses were detected in 21/47 (44.7%) gamma-radiation-induced thymic lymphomas, Analysis of markers located on six other chromosomes as well as on the proximal region of chromosome 4 illustrates the specificity of the occurrences of LOH appearing on the former markers. This analysis clearly suggests the existence of a candidate tumor suppressor gene region on mouse chromosome 4 of about 0.6 cM between the markers D4Wsm1 and D4Mit9 (TLSR1, Thymic Lymphoma Suppressor Region 1). In addition, another more distal region centered at the marker D4Mit58 could be also exist (TLSR2), In most tumors, allelic losses on these chromosome regions involved the paternal RF/J allele (19 of 20).	UNIV AUTONOMA MADRID, FAC CIENCIAS, DEPT BIOL, LAB GENET MOLEC HUMANA, E-28049 MADRID, SPAIN; NYU, MED CTR, DEPT PATHOL, NEW YORK, NY 10016 USA; NYU, MED CTR, KAPLAN CANC CTR, NEW YORK, NY 10016 USA	Autonomous University of Madrid; New York University; New York University			Santos, Javier/ABF-5755-2021; MARTINEZ, ANTONIO PELLICER/C-4832-2015; de Castro, Ignacio Pérez/A-6260-2012	Santos, Javier/0000-0002-4168-6251; de Castro, Ignacio Pérez/0000-0002-8822-8274				ABBOTT CM, 1994, MAMM GENOME, V5, pS51; ABBOTT CM, 1992, MAMM GENOME, V3, pS55, DOI 10.1007/BF00648422; AITMAN TJ, 1991, MAMM GENOME, V1, P206, DOI 10.1007/BF00352326; ALLEN ND, 1990, CELL, V61, P853, DOI 10.1016/0092-8674(90)90195-K; BARDI G, 1993, CANCER RES, V53, P1895; BIECHE I, 1994, CANCER RES, V54, P4274; BRATHWAITE O, 1992, CANCER RES, V52, P3791; CAIRNS P, 1994, CANCER RES, V54, P1422; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHENG JQ, 1994, CANCER RES, V54, P5547; CHENG JQ, 1993, CANCER RES, V53, P4761; CHENG NC, 1995, ONCOGENE, V10, P291; CORNALL RJ, 1991, GENOMICS, V10, P874, DOI 10.1016/0888-7543(91)90175-E; DIAMOND LE, 1988, MOL CELL BIOL, V8, P2233, DOI 10.1128/MCB.8.5.2233; DIAZ MO, 1988, P NATL ACAD SCI USA, V85, P5259, DOI 10.1073/pnas.85.14.5259; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; FONG CT, 1992, CANCER RES, V52, P1780; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FOUNTAIN JW, 1992, P NATL ACAD SCI USA, V89, P10557, DOI 10.1073/pnas.89.21.10557; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HARRIS LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4175, DOI 10.1073/pnas.79.13.4175; HEARNE CM, 1991, MAMM GENOME, V1, P273, DOI 10.1007/BF00352339; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HEGI ME, 1994, CANCER RES, V54, P6257; HERZOG CR, 1994, CANCER RES, V54, P4007; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KEEN AJ, 1994, ONCOGENE, V9, P2083; KEMP CJ, 1993, CANCER RES, V53, P6022; KLINGER HP, 1982, CYTOGENET CELL GENET, V32, P68, DOI 10.1159/000131688; KNOWLES MA, 1993, ONCOGENE, V8, P1357; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LO KW, 1995, CANCER RES, V55, P2039; LOVE JM, 1990, NUCLEIC ACIDS RES, V18, P4123, DOI 10.1093/nar/18.14.4123; MCMORROW LE, 1988, LEUKEMIA, V2, P115; MIYASAKA K, 1995, MOL CARCINOGEN, V13, P37, DOI 10.1002/mc.2940130107; MORI T, 1994, CANCER RES, V54, P3396; NEWCOMB EW, 1988, CANCER RES, V48, P5514; NEWCOMB EW, 1989, ANTICANCER RES, V9, P1407; NISHIMORI H, 1994, INT J CANCER, V59, P108, DOI 10.1002/ijc.2910590120; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OBRIEN SJ, 1993, NAT GENET, V3, P103, DOI 10.1038/ng0293-103; OKAMOTO A, 1995, CANCER RES, V55, P1448; OLOPADE OI, 1993, CANCER RES, V53, P2410; OLOPADE OI, 1992, CANCER RES, V52, P2523; OTSUKI T, 1995, CANCER RES, V55, P1436; QUELLE DE, 1995, ONCOGENE, V11, P635; SAEZ GT, 1994, MOL CARCINOGEN, V9, P40, DOI 10.1002/mc.2940090108; SANTOS J, 1995, CYTOGENET CELL GENET, V71, P223, DOI 10.1159/000134114; SAPIENZA C, 1989, DEVELOPMENT, V107, P165; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIMON D, 1991, ONCOGENE, V6, P765; SOKOVA OI, 1992, CANCER GENET CYTOGEN, V58, P24, DOI 10.1016/0165-4608(92)90128-U; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; SREEKANTAIAH C, 1993, AM J PATHOL, V142, P293; SUGAWARA O, 1990, SCIENCE, V247, P707, DOI 10.1126/science.2300822; VANDERRIET P, 1994, CANCER RES, V54, P1156; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759	65	55	55	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					669	676						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637724				2022-12-28	WOS:A1996TV59700024
J	Ambartsumian, NS; Grigorian, MS; Larsen, IF; Karlstrom, O; Sidenius, N; Rygaard, J; Georgiev, G; Lukanidin, E				Ambartsumian, NS; Grigorian, MS; Larsen, IF; Karlstrom, O; Sidenius, N; Rygaard, J; Georgiev, G; Lukanidin, E			Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene	ONCOGENE			English	Article						transgenic mice; mts1 gene; MMTV induced mammary carcinomas; metastasis	CALCIUM-BINDING PROTEIN; TUMOR VIRUS; NONMUSCLE MYOSIN; EXPRESSION; ONCOGENE; INDUCTION; ACTIVATION; INVASION; TISSUES; DISEASE	Transgenic mice, carrying the mts1 gene, one of the genes involved in the acquisition of the metastatic phenotype, were generated, The mts1 gene was placed under the control of the mouse mammary tumor virus (MMTV) long terminal repeat (LTR) promoter leading to overexpression in the lactating mammary gland of transgenic animals, Animals bearing the transgene appear phenotypically normal, Animals of two transgenic lines (Tg463 and Tg507) were crossed with the GRS/A mice, The GRS/A strain is characterized by high incidence of mammary tumors which rarely metastasize, 40% of the tumor bearing hybrid GRS/A mts1 females mere found to develop secondary tumors in the lungs, The Mts1 protein was detected in the transgene primary tumor cells as well as in the corresponding metastases, Nontransgenic littermates expressed the Mts1 protein only in the stromal cells surrounding the tumor but not in the tumor cells by itself, Taken together these observations indicate that overexpression of the mts1 gene in the mouse mammary carcinoma cells gives rise to more aggressive tumors which are able to metastasize.	ARMENIAN ACAD SCI, INST MOL BIOL, YEREVAN 44, ARMENIA; UNIV COPENHAGEN, DEPT MOL CELL BIOL, DK-1353 COPENHAGEN K, DENMARK; KOMMUNE HOSP COPENHAGEN, BARTHOLIN INST, DK-1399 COPENHAGEN K, DENMARK; RUSSIAN ACAD SCI, INST GENE BIOL, MOSCOW, RUSSIA	National Academy of Sciences of Armenia; Institute of Molecular Biology - NAS RA; University of Copenhagen; Russian Academy of Sciences; Institute of Gene Biology (IGB) of Russian Academy of Sciences	Ambartsumian, NS (corresponding author), DANISH CANC SOC, DEPT MOL CANC BIOL, STRANDBLVD 49, DK-2100 COPENHAGEN O, DENMARK.		Sidenius, Nicolai/M-9643-2015	Sidenius, Nicolai/0000-0002-7825-7629				CARDIFF RD, 1993, CANCER SURV, V16, P97; CHOI YW, 1987, J VIROL, V61, P3013, DOI 10.1128/JVI.61.10.3013-3019.1987; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES BR, 1993, ONCOGENE, V8, P999; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FORD HL, 1995, ONCOGENE, V10, P1597; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GRIGORIAN M, 1996, IN PRESS INT J CANC; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HALTER SA, 1992, AM J PATHOL, V140, P1131; HOGAN B, 1986, MANIPULATING MOUSE E; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Lukanidin EM, 1996, CURR TOP MICROBIOL, V213, P171; MACDONALD NJ, 1993, CANCER SURV, V16, P175; MESTER J, 1987, J VIROL, V61, P1073, DOI 10.1128/JVI.61.4.1073-1078.1987; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; NICOLSON GL, 1994, FRONT RADIAT THER ON, V28, P11; NIGAM AK, 1994, GUT, V35, P996, DOI 10.1136/gut.35.7.996; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; ROELINK H, 1992, ONCOGENE, V7, P487; ROLLINI P, 1992, J VIROL, V66, P4580, DOI 10.1128/JVI.66.7.4580-4586.1992; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHUURING E, 1990, ONCOGENE, V5, P459; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAMP G, 1992, CELL GROWTH DIFFER, V3, P929; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; VANDERVALK MA, 1981, MAMMARY TUMORS MOUSE, P46; VANNIE R, 1971, J NATL CANCER I, V46, P885; VANNIE R, 1981, MAMMARY TUMORS MOUSE, P202; VINEY JL, 1995, CANCER METAST REV, V14, P77, DOI 10.1007/BF00665792; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	38	167	169	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1621	1630						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895507				2022-12-28	WOS:A1996VM88700006
J	Kolch, W; Philipp, A; Mischak, H; Dutil, EM; Mullen, TM; Feramisco, JR; Meinkoth, JL; Rose, DW				Kolch, W; Philipp, A; Mischak, H; Dutil, EM; Mullen, TM; Feramisco, JR; Meinkoth, JL; Rose, DW			Inhibition of Raf-1 signaling by a monoclonal antibody, which interferes with Raf-1 activation and with Mek substrate binding	ONCOGENE			English	Article						Raf-1 signaling; antibody microinjection; Mek	PROTEIN-KINASE KINASE; SERINE-THREONINE KINASE; C-FOS PROMOTER; TRANSCRIPTION FACTOR; TERNARY COMPLEX; GROWTH-FACTOR; V-RAF; TYROSINE KINASE; PLASMA-MEMBRANE; EARLY RESPONSE	Raf-1 is a serine/threonine specific kinase that integrates signaling by a large number of mitogens to elicit a transcriptional response in the nucleus, Activated Raf-1 phosphorylates and activates MAPK/ERK kinase (Mek), thus initiating the Mek-->MAP kinase cascade, which ultimately results in the phosphorylation and activation of transcription factors by MAP kinase. Here we have characterized the mechanism by which monoclonal antibody URP26K, which binds to an epitope in the Raf-1 kinase domain, inhibits intracellular signal transduction. This antibody preferentially immunoprecipitated the underphosphorylated, non-activated form of Raf-1 from quiescent cells. Baculovirus-expressed Raf-1 immunoprecipitated with URP26K was Largely refractory to. phosphorylation and activation mediated by protein kinase C (PKC)alpha or the tyrosine kinase Lck. In addition, URP26K reduced the binding of Raf-1 to its vitro, but did not disturb the Ras. Microinjection of with cells blocked DIVA synthesis initiated by serum, insulin and various purified growth factors, but it did not block DNA synthesis initiated by v-ras. Microinjected URP26K also impaired the expression of stably transfected beta-galactosidase reporter genes regulated by minimal promoter elements. These results demonstrate, (i) that the URP26K monoclonal antibody inhibits Raf-1 by preventing activating Raf-1 phosphorylation and/or association with its substrate Mek, (ii) that inhibition of Raf-1 by URP26K does not interfere with Ras-induced DNA synthesis. In contrast to dominant negative Raf-1 mutants, which also block Ras signaling by binding to the Ras effector domain, antibody mediated Raf-1 inhibition thus reveals branchpoint of mitogenic signaling at the level of Ras.	UNIV CALIF SAN DIEGO, WHITTIER DIABET PROGRAM, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, PROGRAM BIOMED SCI, LA JOLLA, CA 92093 USA; UNIV PENN, DEPT PHARMACOL, PHILADELPHIA, PA 19104 USA; GSF MUNICH, HAEMATOLOGIKUM, INST KLIN MOL BIOL & TUMORGENET, D-81377 MUNICH, GERMANY	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of Pennsylvania; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health			Mischak, Harald/E-8685-2011; Meinkoth, Judy L/G-2900-2010; Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022	Mischak, Harald/0000-0003-0323-0306; MULLEN, Tina-Marie/0000-0001-6150-8084; Kolch, Walter/0000-0001-5777-5016				ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BRENNSCHEIDT U, 1994, CELL GROWTH DIFFER, V5, P367; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GHOSH S, 1994, J BIOL CHEM, V269, P30785; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUANG WD, 1993, P NATL ACAD SCI USA, V90, P10947, DOI 10.1073/pnas.90.23.10947; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; KOLCH W, 1990, ONCOGENE, V5, P713; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOLCH W, 1993, ONCOGENE, V8, P361; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KORTENJANN M, 1994, MOL CELL BIOL, V14, P4815, DOI 10.1128/MCB.14.7.4815; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MEINKOTH J, 1990, CIBA F SYMP, V150, P47; MEINKOTH JL, 1991, MOL CELL BIOL, V11, P1759, DOI 10.1128/MCB.11.3.1759; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RAPP UR, 1991, ONCOGENE, V6, P495; RIM M, 1992, ONCOGENE, V7, P2065; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOZERI O, 1992, ONCOGENE, V7, P2259; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VICIANA PR, 1994, NATURE, V370, P527; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; XIAO S, 1994, J BIOL CHEM, V269, P21244	57	18	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1305	1314						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808705				2022-12-28	WOS:A1996VJ20200022
J	Ichimura, K; Schmidt, EE; Goike, HM; Collins, VP				Ichimura, K; Schmidt, EE; Goike, HM; Collins, VP			Human glioblastomas with no alterations of the CDKN2A (p16(INK4A), MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene	ONCOGENE			English	Article						astrocytomas; RB1; cell cycle; cyclin-dependent kinase inhibitor	DEPENDENT KINASE INHIBITORS; TUMOR-SUPPRESSOR GENE; HOMOZYGOUS DELETION; SUSCEPTIBILITY GENE; MALIGNANT GLIOMAS; HUMAN CANCER; CELL-LINES; C-MYC; AMPLIFICATION; EXPRESSION	A series of 195 human gliomas were studied as to the status of their CDKN2A, CDK4 and RB1 genes, Among 120 glioblastomas, 40% had no wild-type CDKN2A gene, 12% amplified the CDK4 gene, and 14% had no wild-type RB1 gene, With two exceptions, each tumour had only one of these abnormalities, Thus the majority of the glioblastomas (64%) had distinct genetic aberrations which would obviously disrupt the control of transition from G(1) to the S-phase of the cell cycle, A further 30% had loss of one allele of the CDKN2A and/or RB1 genes, Only seven (6%) glioblastomas had no abnormalities of these genes, Anaplastic astrocytomas showed similar changes to the glioblastomas but at lower frequencies - 34% showing no aberrations of the genes analysed, The astrocytomas showed solely loss of one allele of the RB1 gene in 28% of tumours, with retention of one wild-type copy, In the glioblastomas with no alterations of CDKN2A, CDK4 or RB1, several other genes (CCND1, CCND2, CCND3, CDK6, E2F, CDK7, MYC and MYCN) whose products take part in cell cycle regulation were examined, No abnormalities were detected, Thus some aberration of the CDKN2A, CDK4 and RB1 genes appears to be almost obligatory in glioblastomas.	KAROLINSKA HOSP,STOCKHOLM BRANCH,INST ONCOL & PATHOL,DIV TUMOR PATHOL,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA HOSP,STOCKHOLM BRANCH,LUDWIG INST CANC RES,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Ludwig Institute for Cancer Research								AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; BLANQUET V, 1995, HUM MOL GENET, V4, P383, DOI 10.1093/hmg/4.3.383; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; GAO X, 1995, ONCOGENE, V11, P1395; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; GRANA X, 1995, ONCOGENE, V11, P211; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAMEL PA, 1993, FASEB J, V7, P846, DOI 10.1096/fasebj.7.10.8344484; HE J, 1994, CANCER RES, V54, P5804; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; HIRAMA T, 1995, BLOOD, V86, P841; HOGG A, 1993, P NATL ACAD SCI USA, V90, P7351, DOI 10.1073/pnas.90.15.7351; ICHIMURA K, 1994, CANCER RES, V54, P3127; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LIU Y, 1995, HUM MOL GENET, V4, P727, DOI 10.1093/hmg/4.4.727; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLEDNAK AP, 1995, CANCER, V75, P330, DOI 10.1002/1097-0142(19950101)75:1+<330::AID-CNCR2820751315>3.0.CO;2-5; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SACHSE R, 1994, ONCOGENE, V9, P39; SAKAI T, 1991, AM J HUM GENET, V48, P880; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCRRANO M, 1993, NATURE, V366, P704; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; SIMPSON JR, 1993, INT J RADIAT ONCOL, V26, P239, DOI 10.1016/0360-3016(93)90203-8; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Ueki K, 1996, CANCER RES, V56, P150; VENTER DJ, 1991, ONCOGENE, V6, P445; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	39	233	235	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1065	1072						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806696				2022-12-28	WOS:A1996VG76600020
J	Ljungman, M; Zhang, FF				Ljungman, M; Zhang, FF			Blockage of RNA polymerase as a possible trigger for uv light-induced apoptosis	ONCOGENE			English	Article						preferential repair; p53; xeroderma pigmentosum; Cockayne's syndrome; uv light; ionizing radiation	TRANSCRIPTION-COUPLED REPAIR; XERODERMA PIGMENTOSUM-CELLS; DNA-DAMAGE; COCKAYNES-SYNDROME; NUCLEAR ACCUMULATION; TORSIONAL TENSION; EXCISION-REPAIR; STRAND BREAKS; ACTIVE GENES; GROUP-C	To study the triggering mechanism(s) of the induction of apoptosis following exposure to u.v. light, we used a genetic approach involving cell strains derived from patients with inherited deficiencies in nucleotide excision repair, It was found that cells from patients with Cockayne's syndrome, which are deficient in the processing of u.v.-induced pyrimidine dimers from the transcribed DNA strand, are induced to undergo apoptosis at much lower doses of u.v. light than cells with proficient strand-specific repair, The induction of apoptosis correlated to the induction of p53 and to the inhibition of total RNA and poly(A) mRNA synthesis, We also show that active p53 proteins accumulate following u.v.-irradiation without any apparent requirement for DNA strand breaks or excision repair intermediates, We propose that the blockage of RNA polymerases at DNA lesions in the transcribed strand triggers the induction of a pathway leading to apoptosis, These findings may help explain a long standing enigma of why, despite the DNA repair deficiency, patients with Cockayne's syndrome do not experience an elevated risk for skin cancer since potentially pre-mutagenic cells are eliminated by an easily triggered apoptotic pathway.			Ljungman, M (corresponding author), UNIV MICHIGAN, MED CTR, DEPT RADIAT ONCOL, DIV CANC BIOL, ANN ARBOR, MI 48109 USA.				NCI NIH HHS [P30-CA46592] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BOOTSMA D, 1995, PHILOS T ROY SOC B, V347, P75, DOI 10.1098/rstb.1995.0012; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; CLEAVER JE, 1995, AM J HUM GENET, V56, P1257; CLEAVER JE, 1975, ANNU REV GENET, V9, P19, DOI 10.1146/annurev.ge.09.120175.000315; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; DUNN WC, 1979, MOL PHARMACOL, V15, P367; ERIXON K, 1979, MUTAT RES, V59, P257, DOI 10.1016/0027-5107(79)90164-7; EVANS MK, 1993, J BIOL CHEM, V268, P4839; FISCELLA M, 1993, ONCOGENE, V8, P1519; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FORNACE AJ, 1983, RADIAT RES, V93, P107, DOI 10.2307/3575948; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FRITSCHE M, 1993, ONCOGENE, V8, P307; GOTTLIEB T, 1994, TIBS             NOV, P500; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; LEHMANN AR, 1979, CANCER RES, V39, P4237; Leonard C J, 1995, Important Adv Oncol, P33; LJUNGMAN M, 1992, P NATL ACAD SCI USA, V89, P6055, DOI 10.1073/pnas.89.13.6055; LJUNGMAN M, 1995, NUCLEIC ACIDS RES, V23, P1782, DOI 10.1093/nar/23.10.1782; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUCHNIK AN, 1988, NUCLEIC ACIDS RES, V16, P5175, DOI 10.1093/nar/16.11.5175; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MAYNE LV, 1982, CANCER RES, V42, P1473; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RODI CP, 1989, J CELL PHYSIOL, V141, P346, DOI 10.1002/jcp.1041410216; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SQUIRES S, 1982, MUTAT RES, V95, P389, DOI 10.1016/0027-5107(82)90273-1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VITO P, 1996, NATURE, V271, P521; WALKER PR, 1993, BIOTECHNIQUES, V15, P1032; WHITACRE CM, 1995, CANCER RES, V55, P3697; WYLLIE AH, 1994, PHILOS T R SOC B, V345, P237, DOI 10.1098/rstb.1994.0099; YAMAIZUMI M, 1994, ONCOGENE, V9, P2775; ZEITLIN S, 1995, NAT GENET, V11, P155, DOI 10.1038/ng1095-155; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	48	313	314	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					823	831						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761304				2022-12-28	WOS:A1996VD43300018
J	Lu, X; Burbidge, SA; Griffin, S; Smith, HM				Lu, X; Burbidge, SA; Griffin, S; Smith, HM			Discordance between accumulated p53 protein level and its transcriptional activity in response to uv radiation	ONCOGENE			English	Article						p53; uv irradiation; protein level; transcription activity	DNA-BINDING FUNCTION; CELLULAR TUMOR-ANTIGEN; TRANSFORMED-CELLS; IRRADIATION; EXPRESSION; MUTATIONS; INDUCTION; ACTIVATE; CANCER	In response to DIVA damage, the transcriptional activity of p53 rises. This has been thought to be due to an increase in the level of p53 protein. By comparing the p53 protein level and its ability to transactivate target genes Waf1/Cip1 and mdm2 in both T22 and NTH3T3 cells irradiated with u.v., a discordance between the p53 protein level and its transcriptional activity was observed. When the cells were irradiated with 10 J/m(2) of u.v., there was a substantial increase in expression of Waf1/Cip1 and mdm2. However, little increase in Waf1/Cip1 and mdm2 expression was observed in T22 and NIH3T3 cells 8 or 9 h after exposure to 50 J/m(2) of u.v., although the p53 protein level accumulated to its highest level under these conditions. Interestingly, a significant increase in Waf1/Cip1 expression was seen 24 h after irradiation in NIH3T3 cells, indicating that the inhibition of p53 transcriptional activity is reversible. Discordance between the transcriptional activity of p53 and its protein level was further studied using a cell line expressing the p53 reporter plasmid RGC Delta fosLacZ. Using double immunofluorescence staining, the coexpression of p53 and beta-galactosidase from the reporter plasmid in the same cells was investigated. The observed lack of correlation between the elevated p53 and beta-galactosidase and expression in u.v. irradiated cells strongly indicates that the ability of p53 to transactivate its target genes is not simply correlated to its protein level. The results indicate that the transcriptional activity of p53 may be negatively regulated.			Lu, X (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,LUDWIG INST CANC RES,SCH MED,NORFOLK PL,LONDON W2 1PG,ENGLAND.			Lu, Xin/0000-0002-6587-1152				DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1992, CANCER RES, V52, P6976; Fredersdorf S, 1996, AM J PATHOL, V148, P825; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MIYASHITA T, 1995, CELL, V80, P293; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OConnor DJ, 1995, EMBO J, V14, P6184, DOI 10.1002/j.1460-2075.1995.tb00309.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; WEINBERG WC, 1995, ONCOGENE, V10, P2271; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	26	78	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					413	418						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710381				2022-12-28	WOS:A1996VA25200021
J	Mahajan, MA; Park, ST; Sun, XH				Mahajan, MA; Park, ST; Sun, XH			Association of a novel GTP binding protein, DRG, with TAL oncogenic proteins	ONCOGENE			English	Article						T cell leukemia; helix-loop-helix protein; GTP-binding protein; erythroid differentiation	LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-BINDING; ENHANCER-BINDING; GENE SCL; EXPRESSION; MOTIF; TRANSLOCATION; TRANSCRIPTION	TAL1 is a basic helix-loop-helix (bHLH) protein involved in hematopoietic development. In T cell acute lymphoblastic leukemic cells, TAL1 is aberrantly overexpressed and is thought to contribute to oncogenesis. To identify proteins that interact with TAL1 in mediating leukemogenesis, we used TAL1 as a bait in a two-hybrid interaction screen, and isolated a cDNA clone that encodes a unique GTP binding protein, DRG. The interaction between DRG and TAL1 was confirmed both in vitro and in vivo, DRG was also shown to bind in vitro to two TAL1-related proteins, TAL2 and Lyl1. Mutational analyses showed that the HLH domain of TAL1 was necessary and sufficient for its interaction with the C-terminus of DRG. Furthermore, while DRG and E47 compete to interact with TAL1, TAL1 binds to DRG and E47 in a mutually exclusive manner. In rat embryonic fibroblast transformation assays, DRG stimulated the cotransforming activity of c-myc and I as. Based on these results, DRG appears to be a potential target for TAL-like oncoproteins.	NYU, MED CTR, DEPT CELL BIOL, NEW YORK, NY 10016 USA	New York University				Mahajan, Muktar/0000-0003-1024-6808	NIAID NIH HHS [AI-33597] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033597, R01AI033597] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; AUSUBAL FM, 1994, CURRENT PROTOCOLS MO; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNARD O, 1992, J EXP MED, V176, P919, DOI 10.1084/jem.176.4.919; BOURNE HR, 1991, NATURE, V349, P118; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, ONCOGENE, V8, P677; CONDORELLI G, 1995, BLOOD, V86, P164, DOI 10.1182/blood.V86.1.164.bloodjournal861164; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; GOLDFARB AN, 1994, LEUKEMIA LYMPHOMA, V12, P157, DOI 10.3109/10428199409059586; GOLDFARB AN, 1992, BLOOD, V80, P2858; GREEN AR, 1991, ONCOGENE, V6, P475; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; KADESCH T, 1992, IMMUNOL TODAY, V13, P31, DOI 10.1016/0167-5699(92)90201-H; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; KUMAR S, 1993, INT J DEV BIOL, V37, P539; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PRENDERGAST GC, 1992, GENE DEV, V6, P2426; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SANCHEZGARCIA I, 1994, P NATL ACAD SCI USA, V91, P7869, DOI 10.1073/pnas.91.17.7869; SAZUKA T, 1992, BIOCHEM BIOPH RES CO, V189, P371, DOI 10.1016/0006-291X(92)91568-B; SAZUKA T, 1992, BIOCHEM BIOPH RES CO, V189, P363, DOI 10.1016/0006-291X(92)91567-A; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; VISVADER J, 1991, ONCOGENE, V6, P187; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; VORONOVA AF, 1994, P NATL ACAD SCI USA, V91, P5952, DOI 10.1073/pnas.91.13.5952; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	39	52	52	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2343	2350						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649774				2022-12-28	WOS:A1996UQ22000011
J	Casciano, I; Marchi, JVM; Muresu, R; Volpi, EV; Rozzo, C; Opdenakker, G; Romani, M				Casciano, I; Marchi, JVM; Muresu, R; Volpi, EV; Rozzo, C; Opdenakker, G; Romani, M			Molecular and genetic studies on the region of translocation and duplication in the neuroblastoma cell line NGP at the 1p36.13-p36.32 chromosomal site	ONCOGENE			English	Article						neuroblastoma; reciprocal translocation; duplication; antioncogenes; chromosome 1	INSITU HYBRIDIZATION; BREAST-CANCER; SHORT ARM; HETEROZYGOSITY; PCR; INTEGRATION; DELETION; 1P	Cytogenic and molecular studies suggest that chromosome 1p might contain oncosuppressor genes involved in the pathogenesis of neuroblastoma and other adult tumors, The isolation of these genes by the 'positional cloning' approach will be facilitated by the characterization of cell lines with well defined chromosomal aberrations, In the present report we provide molecular data on the NGP neuroblastoma cell line which contains a reciprocal t(1;15) translocation, Two regions, possibly hosting oncosuppressor genes, have been identified: one is distal to the ENO1 locus, the other one is comprised between PND and A12M2 and corresponds to that of a constitutional t(1;17) translocation described in a neuroblastoma patient, Genetic data also suggest that the NGP cell line, despite the presence of two chromosomes 1, might be hemizygous for the subtelomeric 1p region.	IST,IST NAZL RIC CANC,LAB POPULAT GENET,ALGHERO,ITALY; CNR,IST GENET MOL,ALGHERO,ITALY; CATHOLIC UNIV LEUVEN,REGA INST,B-3000 LOUVAIN,BELGIUM	University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); KU Leuven			Opdenakker, Ghislain/Q-3130-2017; Rozzo, Carla M/C-4300-2015; Opdenakker, Ghislain/V-8562-2019	Opdenakker, Ghislain/0000-0003-1714-2294; Rozzo, Carla M/0000-0001-6581-2227; Opdenakker, Ghislain/0000-0003-1714-2294; Volpi, Emanuela/0000-0002-2422-9104; casciano, ida/0000-0003-1776-670X				AMLER LC, 1995, ONCOGENE, V10, P1095; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALDINI A, 1992, GENOMICS, V14, P181, DOI 10.1016/S0888-7543(05)80303-9; BALDINI A, 1991, GENOMICS, V9, P770, DOI 10.1016/0888-7543(91)90374-N; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; DEAMBROSIS A, 1992, CANCER GENET CYTOGEN, V60, P1, DOI 10.1016/0165-4608(92)90223-U; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HARNETT PR, 1991, CANCER GENET CYTOGEN, V54, P109, DOI 10.1016/0165-4608(91)90037-U; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LAUREYS G, 1995, ONCOGENE, V10, P1087; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; MARS WM, 1991, CANCER DETECT PREV, V15, P145; MURESU R, 1995, GENE CHROMOSOME CANC, V13, P66, DOI 10.1002/gcc.2870130111; NOBILE C, 1994, MAMM GENOME, V5, P566, DOI 10.1007/BF00354931; ROMANI M, 1990, GENE, V95, P231, DOI 10.1016/0378-1119(90)90366-Y; ROMANI M, 1993, GENE, V135, P153, DOI 10.1016/0378-1119(93)90060-G; ROMANI M, 1994, CYTOGENET CELL GENET, V67, P37, DOI 10.1159/000133793; ROMANI M, 1996, IN PRESS J NEURO ONC; SAVALYEVA L, 1994, AM J HUM GENET, V55, P334; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SIMON D, 1991, ONCOGENE, V6, P765; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; VANDERDRIFT P, 1994, HUM MOL GENET, V3, P2131, DOI 10.1093/hmg/3.12.2131; VANROY N, 1993, GENOMICS, V18, P71, DOI 10.1006/geno.1993.1427; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WHITE PS, 1993, GENE CHROMOSOME CANC, V7, P102, DOI 10.1002/gcc.2870070207; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	35	13	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2101	2108						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668335				2022-12-28	WOS:A1996UP28300008
J	Tashiro, S; Kotomura, N; Shinohara, A; Tanaka, K; Ueda, K; Kamada, N				Tashiro, S; Kotomura, N; Shinohara, A; Tanaka, K; Ueda, K; Kamada, N			S phase specific formation of the human Rad51 protein nuclear foci in lymphocytes	ONCOGENE			English	Article						human Rad51 protein; lymphocyte; S phase	RECOMBINATION; GENES; YEAST; RECA	The Rad51 protein, which is a homologue of the bacterial RecA protein, is involved in mitotic and meiotic recombination and in repair of double-strand breaks of DNA in yeast, The Rad51 homologue is conserved from yeast to human, In this study, the Rad51 protein was shown to be induced in peripheral blood lymphocytes (PBLs) 36 h after phytohemagglutinin (PHA) stimulation, Immunofluorescence study revealed that the distribution of the Rad51 protein in the nucleus was not uniform and focus-like staining was observed, Formation of the Rad51 foci was induced at 36 h after treatment of the cells with PHA. Twenty five percent of the cells had the foci at this time and the number of cells with foci declined thereafter, Cell cycle study using laser microscope by double staining method suggested that the appearance of the Rad51 nuclear foci was S phase specific, Furthermore, double staining study for the Rad51 protein and incorporated BrdU confirmed S phase specific appearance of the Rad51 nuclear foci, Formation of the Rad51 nuclear foci in PHA-stimulated lymphocytes might be involved in DNA recombination or DNA repair in S phase, The roles of RAD51 foci in S-phase will be discussed.	HIROSHIMA UNIV,RES INST RADIAT BIOL & MED,DIV MOLEC BIOL,HIROSHIMA 734,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT PEDIAT,HIROSHIMA 734,JAPAN; OSAKA UNIV,FAC SCI,DEPT BIOL,TOYONAKA,OSAKA 560,JAPAN	Hiroshima University; Hiroshima University; Osaka University								BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; FAED MJW, 1978, MUTAT RES, V49, P437, DOI 10.1016/0027-5107(78)90115-X; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; HOZAK P, 1994, J CELL SCI, V107, P219; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KOGOMA T, 1994, MOL GEN GENET, V244, P557, DOI 10.1007/BF00583907; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; Ogawa H, 1990, Adv Biophys, V26, P33, DOI 10.1016/0065-227X(90)90006-F; PANTHIER JJ, 1991, BIOESSAYS, V13, P351, DOI 10.1002/bies.950130709; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; TAUCHI H, 1994, INT J RADIAT BIOL, V65, P449, DOI 10.1080/09553009414550521; TERASAWA M, 1995, GENE DEV, V9, P925, DOI 10.1101/gad.9.8.925; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131; WITKIN EM, 1969, ANNU REV MICROBIOL, V23, P487, DOI 10.1146/annurev.mi.23.100169.002415; WOLFF S, 1974, MUTAT RES, V25, P73, DOI 10.1016/0165-1218(74)90082-2	17	146	146	1	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2165	2170						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668342				2022-12-28	WOS:A1996UP28300015
J	Hongo, A; DAmbrosio, C; Miura, M; Morrione, A; Baserga, R				Hongo, A; DAmbrosio, C; Miura, M; Morrione, A; Baserga, R			Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor	ONCOGENE			English	Article						IGF-1 receptor; transformation; growth; mutation	SIGNAL-TRANSDUCTION; TYROSINE KINASE; HEMATOPOIETIC-CELLS; RAS; TRANSPHOSPHORYLATION; PHOSPHORYLATION; OVEREXPRESSION; EXPRESSION; MECHANISM; IGF-1	The type 1 insulin-like growth factor receptor (IGF-IR) plays an important role in mitogenesis and transformation. It has been previously shown that mitogenic signaling and transforming activity of the IGF-IR can be dissociated: a receptor truncated at residue 1229 (C-terminus) is fully mitogenic, in terms of its response to IGF-I, but cannot transform 3T3-like cells that are devoid of endogenous IGF-IRs (R(-) cells). We have extended our mutational analysis of the C-terminus of the human IGF-IR, by stably transfecting several mutant receptors into R(-) cells, and testing the resulting cell lines for IGF-I-mediated mitogenic response and formation of colonies in soft agar. The results indicate that the transforming domain of the IGF-IR can be localized between residues 1245 and 1310, these sequences being not required for mitogenic signaling. Within these residues, there are at least two areas that contribute to the transforming activity of the receptor.	THOMAS JEFFERSON UNIV,JEFFERSON CANC CTR,PHILADELPHIA,PA 19107	Jefferson University					NIGMS NIH HHS [GM 33684] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BALLOTTI R, 1989, EMBO J, V8, P3303, DOI 10.1002/j.1460-2075.1989.tb08491.x; BASERGA R, 1995, CANCER RES, V55, P249; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BURGAUD JL, 1995, BIOCHEM BIOPH RES CO, V214, P475, DOI 10.1006/bbrc.1995.2311; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; CAI H, 1992, MOL CELL BIOL, V12, P5329, DOI 10.1128/MCB.12.12.5329; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; CREWS CM, 1993, CELL, V74, P215, DOI 10.1016/0092-8674(93)90411-I; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; DEANGELIS T, 1995, J CELL PHYSIOL, V164, P214, DOI 10.1002/jcp.1041640126; DELALUNA S, 1988, GENE, V62, P121; FALCO JP, 1988, ONCOGENE, V2, P573; FARIA TN, 1994, J BIOL CHEM, V269, P13922; FRATTALI AL, 1993, J BIOL CHEM, V268, P7393; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; KALEBIC T, 1994, CANCER RES, V54, P5531; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KATO H, 1993, J BIOL CHEM, V268, P2655; LAMMERS R, 1990, J BIOL CHEM, V265, P16886; LANGLOIS WJ, 1995, ENDOCRINOLOGY, V136, P1978, DOI 10.1210/en.136.5.1978; LI SW, 1994, J BIOL CHEM, V269, P32558; LIU DL, 1993, J VIROL, V67, P6835, DOI 10.1128/JVI.67.11.6835-6840.1993; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; LONG L, 1995, CANCER RES, V55, P1006; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCCUE JL, 1991, BRIT J SURG, V78, P921, DOI 10.1002/bjs.1800780808; MEDEMA RH, 1993, CRIT REV ONCOGENESIS, V4, P615; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; MIURA M, 1994, CANCER RES, V54, P2472; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1994, CANCER RES, V54, P4848; RESNICOFF M, 1995, CANCER RES, V55, P3739; RESNICOFF M, 1995, CANCER RES, V55, P2463; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SURMACZ E, 1995, EXP CELL RES, V218, P370, DOI 10.1006/excr.1995.1168; TAOUIS M, 1994, J BIOL CHEM, V269, P27762; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAMAUCHI K, 1994, MOL CELL BIOL, V14, P4427, DOI 10.1128/MCB.14.7.4427	63	104	105	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1231	1238						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649825				2022-12-28	WOS:A1996UC06700008
J	Kim, S; Brown, PH; Birrer, MJ				Kim, S; Brown, PH; Birrer, MJ			The inhibitory activity of a transdominant c-jun mutant fused to the ligand binding domain of the estrogen receptor	ONCOGENE			English	Article						transcription factor; jun; fos; AP-1; dominant negative mutant; estrogen receptor	FUSION PROTEIN; TRANSCRIPTIONAL ACTIVATION; EMBRYO FIBROBLASTS; GENE FAMILY; TRANSFORMATION; CELLS; DIFFERENTIATION; ONCOPROTEIN; SUPPRESSION; EXPRESSION	Tam-67 is an amino-terminal deletion mutant of c-Jun (Delta 3-122) lacking most of the c-Jun transactivation domain, which has been shown previously to function in a transdominant fashion to inhibit c-Jun-induced transactivation and cellular transformation. In order to create a ligand-dependent dominant negative repressor of AP-1, we have constructed a fusion of the TAM-67 gene with the ligand binding domain of the estrogen receptor. Fusion of TAM-67 with the ligand binding domain of the estrogen receptor produced a 68 kD protein (TAM-67ER) which was immunoprecipitated by c-Jun-specific and estrogen receptor-specific antisera and shown by gel retardation assay to bind oligonucleotides containing an AP-1 sequence. Cotransfection of TAM-67ER and an AP-1-dependent reporter construct into rat embryo cells demonstrated ligand specific inhibition of AP-1 transactivation. In the absence of hormone, TAM-67ER produced complete inhibition of cJun-induced AP-1 transactivation. This inhibition was relieved by treatment with estradiol but not by treatment with tamoxifen. In addition, TAM-67ER inhibited activated c-Ha-ras- or c- raf-induced transformation of NTH3T3 cells. However, this inhibition of transformation was not relieved by the addition of estrogen. Thus, TAM-67ER inhibits transactivation in a ligand-dependent manner, but inhibits transformation in a ligand-independent manner. The results suggest that the ligand-dependent transactivation domain of the estrogen receptor (TAF-2) can substitute for the cJun transactivation domain absent in TAM-67 to stimulate transactivation. However, TAF-2 cannot substitute for the missing c-Jun transactivation domain to induce cellular transformation.	NCI,DIV CLIN SCI,BIOMARKERS & PREVENT RES BRANCH,ROCKVILLE,MD 20850; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA								ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BEEKMAN JM, 1993, MOL ENDOCRINOL, V7, P1266, DOI 10.1210/me.7.10.1266; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BROWN PH, 1994, ONCOGENE, V9, P791; BROWN PH, 1993, ONCOGENE, V8, P877; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; DOSAKAAKITA H, 1991, ONCOGENE, V6, P371; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FRANCIS MK, 1995, J BIOL CHEM, V270, P11502, DOI 10.1074/jbc.270.19.11502; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GILBERT DM, 1993, MOL CELL BIOL, V13, P462, DOI 10.1128/MCB.13.1.462; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; MATSUI M, 1990, ONCOGENE, V5, P249; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; RAPP UR, 1994, ONCOGENE, V9, P3493; REESE JC, 1992, MOL CELL BIOL, V12, P4531, DOI 10.1128/MCB.12.10.4531; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHUERMANN M, 1993, ONCOGENE, V8, P2781; SUPERTIFURGA G, 1991, P NATL ACAD SCI USA, V88, P5114, DOI 10.1073/pnas.88.12.5114; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; TOMMASINO M, 1994, J VIROL, V68, P2206; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	35	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1043	1053						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649795				2022-12-28	WOS:A1996UA88400012
J	Kazmierczak, B; Rosigkeit, J; Wanschura, S; MeyerBolte, K; VandeVen, WJM; Kayser, K; Krieghoff, B; Kastendiek, H; Bartnitzke, S; Bullerdiek, J				Kazmierczak, B; Rosigkeit, J; Wanschura, S; MeyerBolte, K; VandeVen, WJM; Kayser, K; Krieghoff, B; Kastendiek, H; Bartnitzke, S; Bullerdiek, J			HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: A survey of 30 tumors	ONCOGENE			English	Article						chondroid hamartomas of the lung, 12q14-15; HMGI-C gene	DNA-BINDING DOMAIN; INSITU HYBRIDIZATION; PROTEIN	Pulmonary chondroid hamartomas (PCH) are benign tumors of the lung characterized by a more or less high degree of mesenchymal metaplasia, In our series we investigated 30 PCH by a combination of cytogenetic and molecular methods, 18 tumors (60%) had cytogenetically detectable aberrations involving either 12q14-15 or 6p21 with a clear predominance of chromosomal abnormalities involving 12q14-15 (15 tumors), As in subgroups of pleomorphic adenomas of the salivary glands, leiomyomas of the uterus, and lipomas with 12q14-15 abnormalities the HMGI-C gene is frequently rearranged we tested PCH with either 12q14-15 abnormalities or normal karyotype by FISH and 3' RACE experiments for rearrangements of HMGI-C, Rearrangements were found in all cases with chromosomal 12q14-15 abnormalities and further six cases with an apparently normal karyotype, By the combination of cytogenetics with molecular techniques the percentage of cases with intragenic rearrangements of HMGI-C or rearrangements of its immediate surrounding was thus increased to 70% (21/30 cases), Considering all types of aberrations within this series 80% (24/30) of all PCH were aberrant, This is the first report on a combined molecular and cytogenetic analysis of a large series of pulmonary chondroid hamartomas indicating that rearrangements of HMGI-C, a member of the high mobility group protein gene family, are the;leading molecular events in the genesis of PCH.	UNIV BREMEN,CTR HUMAN GENET & GENET COUNSELLING,ZHG,D-28359 BREMEN,GERMANY; CATHOLIC UNIV LEUVEN,CTR HUMAN GENET,B-3000 LOUVAIN,BELGIUM; LVA BODEN,HOSP PULM DIS,DEPT PATHOL,D-69126 HEIDELBERG,GERMANY; URBAN HOSP ST GEORGE,DEPT PATHOL,D-04129 LEIPZIG,GERMANY; PUBL HOSP HARBURG,DEPT PATHOL,D-21041 HAMBURG,GERMANY	University of Bremen; KU Leuven								ASHAR HR, 1995, CELL, V82, P57; BERLINGIERI MT, 1995, MOL CELL BIOL, V15, P1545; BULLERDIEK J, 1987, CYTOGENET CELL GENET, V45, P187, DOI 10.1159/000132452; DALCIN P, 1993, GENE CHROMOSOME CANC, V8, P131; FLETCHER AJ, 1995, GENE CHROMOSOME CANC, V12, P220; FLETCHER JA, 1992, CANCER RES, V52, P6224; FLETCHER JA, 1991, AM J PATHOL, V138, P1199; JOHANSSON M, 1992, CANCER GENET CYTOGEN, V60, P219, DOI 10.1016/0165-4608(92)90026-5; JOHANSSON M, 1993, BRIT J CANCER, V67, P1236, DOI 10.1038/bjc.1993.231; KAZMIERCZAK B, 1995, CANCER RES, V55, P2497; KAZMIERCZAK B, 1995, AM J PATHOL, V147, P580; KIEVITS T, 1990, CYTOGENET CELL GENET, V53, P134, DOI 10.1159/000132913; KOOLS PFJ, 1995, CANCER GENET CYTOGEN, V79, P1, DOI 10.1016/0165-4608(94)00137-Z; Koss MN, 1990, SURGICAL PATHOLOGY L, P418; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; PATEL UA, 1994, BIOCHEM BIOPH RES CO, V201, P63, DOI 10.1006/bbrc.1994.1669; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1991, P NATL ACAD SCI USA, V88, P1671, DOI 10.1073/pnas.88.5.1671; ROMMEL B, 1988, CYTOMETRY, V9, P504, DOI 10.1002/cyto.990090517; SCHOENMAKERS EFPM, 1994, GENE CHROMOSOME CANC, V11, P106, DOI 10.1002/gcc.2870110207; SCHOENMAKERS EFPM, 1994, GENOMICS, V20, P210, DOI 10.1006/geno.1994.1155; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANDEVEN WJM, 1995, GENE CHROMOSOME CANC, V12, P296	24	115	116	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					515	521						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637707				2022-12-28	WOS:A1996TV59700007
J	Santarelli, R; Tzeng, YJ; Zimmermann, C; Guhl, E; Graessmann, A				Santarelli, R; Tzeng, YJ; Zimmermann, C; Guhl, E; Graessmann, A			SV40 T-antigen induces breast cancer formation with a high efficiency in lactating and virgin WAP-SV-T transgenic animals but with a low efficiency in ovariectomized animals	ONCOGENE			English	Article						transgenic animals; SV40-T-antigen; breast cancer; estrogen receptor; progesterone receptor	MOUSE MAMMARY-GLAND; PROGNOSTIC FACTORS; GENE-EXPRESSION; INVOLUTION; RECEPTORS; LECTURE; RAT	The whey acid protein (WAP) is a major mouse milk protein and its gene expression is induced by various lactotrophic hormones leg, estrogen, progesterone). Transgenic animals harboring the early SV40 coding region (T/t-antigen) under the transcriptional control of the WAP promoter develop breast cancer after the first lactation period. The tumor cells synthesize the SV40 T-antigen with a high efficiency indicating that WAP-SV-T expression escapes down-regulation after the lactation period. However about 5-10% of the tumors became T-antigen negative during tumor progession and WAP-SV-T expression was only demonstrable by PCR analysis. Both T-antigen positive and negative tumor cells expressed the estrogen and progesterone receptor at a comparable rate, indicating that hormone receptor levels do not determine expression of the WAP-SV-T transgene, Furthermore, WAP and WAP-SV-T gene expression are not restricted to the pregnancy-lactation period. Virgin animals also express both genes with a low efficiency and about 70% of these animals also developed T-antigen positive breast tumors, The tumor rate however was strongly reduced in ovariectomized animals, indicating that the ovary hormones play a critical role in breast cancer formation.	FREE UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,D-14195 BERLIN,GERMANY	Free University of Berlin			Santarelli, Roberta/K-5434-2015	Santarelli, Roberta/0000-0002-9416-7594				BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; CLARK GM, 1988, SEMIN ONCOL, V15, P20; Daniel C. W., 1987, The mammary gland. Development, regulation, and function., P3; DIELLA F, 1993, LIFE SCI ADV BIOCH, V12, P47; FREEMAN CS, 1978, ENDOCRINOLOGY, V103, P186, DOI 10.1210/endo-103-1-186; FUNQUA SAW, 1991, CANCER RES, V51, P105; GRAESSMANN A, 1981, ADV CANCER RES, V35, P111, DOI 10.1016/S0065-230X(08)60910-0; GRAESSMANN M, 1976, P NATL ACAD SCI USA, V73, P366, DOI 10.1073/pnas.73.2.366; Haslam S. Z., 1987, The mammary gland. Development, regulation, and function., P499; HASLAM SZ, 1980, J CELL BIOL, V86, P730, DOI 10.1083/jcb.86.3.730; HENDERSON BE, 1988, CANCER RES, V48, P246; HOBBS AA, 1982, J BIOL CHEM, V257, P3598; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KUHN NJ, 1977, COMP ASPECTS LACTATI, P165; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER LJ, 1990, CANCER RES, V50, P4177; LI S, 1994, MOL ENDOCRINOL, V8, P1328, DOI 10.1210/me.8.10.1328; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MCGUIRE WL, 1986, CANCER SURV, V5, P527; Muldoon T. G., 1979, Ontogeny of receptors and reproductive hormone action., P225; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; SAMBROOK J, 1989, MOL CLONINGS LABORAT; SENKITI S, 1979, BIOCHIM BIOPHYS ACTA, V582, P79; SHYAMALA G, 1982, HORMONAL REGULATION, V1, P245; STRANGE R, 1992, DEVELOPMENT, V115, P49; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TOPP WC, 1980, DNA TUMOR VIRUSES, P205; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; TZENG YJ, 1993, ONCOGENE, V8, P1965; WANG SQ, 1990, ENDOCRINOLOGY, V127, P2183, DOI 10.1210/endo-127-5-2183	33	27	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					495	505						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637705				2022-12-28	WOS:A1996TV59700005
J	Malkowicz, SB; Tomaszewski, JE; Linnenbach, AJ; Cangiano, TA; Maruta, Y; McGarvey, TW				Malkowicz, SB; Tomaszewski, JE; Linnenbach, AJ; Cangiano, TA; Maruta, Y; McGarvey, TW			Novel p21(WAF1/CIP1) mutations in superficial and invasive transitional cell carcinomas	ONCOGENE			English	Article						cell cycle; bladder carcinoma; p21(WAF1/CIP1) gene	CYCLIN-DEPENDENT KINASES; HUMAN BLADDER-CANCER; P53 GENE; P53-INDEPENDENT EXPRESSION; TUMOR SUPPRESSION; OVARIAN-CANCER; INHIBITOR P21; WAF1/CIP1; ALLELOTYPE; INDUCTION	Alterations in the p53 gene are a predominant component in the development of transitional cell carcinoma (TCC), but the particular pathways distal to p53 alterations which contribute to urothelial transformation are not defined, Here, the p21(WAF1/CIP1) gene, a p53 inducible and p53 independent gene product, was studied in TCC, p21(WAF1/CIP1) expression was measured by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) from five cell lines and 28 tumor specimens (14 superficial, 14 muscle invasive), This was expressed as a ratio of the gene product to L7, a ribosomal housekeeping gene, In addition, exons 4 through 8 of the p53 gene as well as exon 2 of the p21(WAF1/CIP1) gene were assayed for mutations by polymerase chain reaction/ single stranded conformation polymorphism analysis (PCR/SSCP), Candidate mutations were verified by sequencing, p21(WAF1/CIP1)/L7 expression was significantly decreased in invasive lesions compared to superficial lesions (P<0.002), p53 mutations were detected by PCR/SSCP in seven tumors [25%] (one superficial, six invasive) and p21(WAF1/CIP1)/L7 expression was significantly decreased in all tumors that had p53 mutations (P<0.007), PCR/SSCP analysis of exon 2 in p21(WAF1/CIP1) detected band in tumor specimens (two superficial, two invasive), which sequencing and comparison to autologous normal matched DNA revealed as novel mutations.	VET ADM MED CTR,PHILADELPHIA,PA 19104; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	US Department of Veterans Affairs; Veterans Health Administration (VHA); The Wistar Institute	Malkowicz, SB (corresponding author), UNIV PENN,MED CTR,DEPT PATHOL,DEPT SURG,DIV UROL,1 RHOADS,3400 SPRUCE ST,PHILADELPHIA,PA 19104, USA.							AKAMA Y, 1995, P AM ASSOC CANC RES, V36, pA193; BARBOULE N, 1995, INT J CANCER, V63, P611, DOI 10.1002/ijc.2910630502; BHATIA K, 1995, CANCER RES, V55, P1431; CHEN YQ, 1995, CANCER RES, V55, P4536; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLIBY W, 1993, CANCER RES, V53, P2393; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DIGIUSEPPE JA, 1995, AM J PATHOL, V147, P884; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESRIG D, 1993, AM J PATHOL, V143, P1389; GAO X, 1995, ONCOGENE, V11, P1395; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Hayashi K, 1991, PCR Methods Appl, V1, P34; Horikoshi T, 1993, Methods Mol Biol, V15, P177, DOI 10.1385/0-89603-244-2:177; JIANG HP, 1994, ONCOGENE, V9, P3397; JUNG JM, 1995, ONCOGENE, V11, P2021; KAWASAKI T, 1994, CANCER LETT, V82, P113, DOI 10.1016/0304-3835(94)90154-6; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIANES P, 1994, J NATL CANCER I, V86, P1325, DOI 10.1093/jnci/86.17.1325; LINNENBACH AJ, 1993, HUM MOL GENET, V2, P1407; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1251; LUKEIS R, 1990, GENE CHROMOSOME CANC, V2, P116, DOI 10.1002/gcc.2870020207; MICHIELI P, 1994, CANCER RES, V54, P3391; Michieli P, 1996, ONCOGENE, V12, P775; MORITA R, 1991, CANCER RES, V51, P820; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; Ozcelik H, 1995, CLIN CANCER RES, V1, P907; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RUPPERT JM, 1993, CANCER RES, V53, P5093; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SATO T, 1991, CANCER RES, V51, P5118; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SPRUCK CH, 1994, CANCER RES, V54, P784; VIDAL MJ, 1995, P AM ASS RES, V36, pA1138; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABE H, 1995, BBA-GENE STRUCT EXPR, V1263, P275, DOI 10.1016/0167-4781(95)00110-3; WILLIAMSON MP, 1994, GENE CHROMOSOME CANC, V9, P108, DOI 10.1002/gcc.2870090206	43	38	43	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1831	1837						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934528				2022-12-28	WOS:A1996VR79500001
J	Cannell, EJ; Farrell, PJ; Sinclair, AJ				Cannell, EJ; Farrell, PJ; Sinclair, AJ			Epstein-Barr virus exploits the normal cell pathway to regulate Rb activity during the immortalisation of primary B-cells	ONCOGENE			English	Article						Epstein-Barr virus; phosphorylation; cell cycle; immortalisation; Retinoblastoma protein	DEPENDENT KINASE INHIBITOR; SUSCEPTIBILITY GENE-PRODUCT; D-CDK COMPLEXES; RETINOBLASTOMA PROTEIN; CYCLE CONTROL; SUPPRESSOR GENES; LYMPHOCYTES-B; EXPRESSION; LINES; P16(INK4)	Infection of human primary B-lymphocytes with Epstein-Barr virus (EBV) drives quiescent cells into continual proliferation and results in the outgrowth of immortal cell lines. This requires re-programming of the mechanisms that, in the absence of appropriate antigenic stimulation, normally prevent the proliferation of B-lymphocyes. Since the Retinoblastoma protein (pRb) and its relatives, p107 and p130, play critical roles in controlling the mammalian cell division cycle, we have investigated the expression and phosphorylation status of these proteins following EBV immortalisation of primary B-lymphocytes. In this report, me show that EBV drives the hyperphosphorylation of pRb. This is achieved by a strategy involving the altered expression of several components of the signal transduction pathway that normally regulates the phosphorylation status of pRb, including the up regulation of a number of cyclins and cyclin-dependent kinases and the down regulation of a subset of cyclin-dependent kinase inhibitors. The net result is the formation of active cyclin-dependent kinase complexes that are capable of phosphorylating and inactivating pRb. The results presented here identify the activation of a normal signal transduction pathway as an important component of the strategy used by EBV to drive cell proliferation.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research				Sinclair, Alison/0000-0001-8510-8691; Farrell, Paul/0000-0002-6754-9351				AAGAARD L, 1995, INT J CANCER, V61, P115, DOI 10.1002/ijc.2910610120; ALFIERI C, 1991, VIROLOGY, V181, P595, DOI 10.1016/0042-6822(91)90893-G; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; ARVANITAKIS L, 1995, J IMMUNOL, V155, P1047; BATES S, 1994, ONCOGENE, V9, P1633; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; DEBOER CJ, 1995, ONCOGENE, V10, P1833; FREDERSDORF S, 1996, IN PRESS AM J PATH; FUNDERUD S, 1990, EUR J IMMUNOL, V20, P201, DOI 10.1002/eji.1830200129; GRANA X, 1995, ONCOGENE, V11, P211; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HALVEY O, 1995, SCIENCE, V267, P1018; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARA E, 1996, IN PRESS MOL CELL BI; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HOLLYOAKE M, 1995, CANCER RES, V55, P4784; JEN J, 1994, CANCER RES, V54, P6353; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KEIFF E, 1994, VIRUSES CANC, V51, P123; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; LALLE P, 1995, ONCOGENE, V10, P2447; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI Y, 1994, CANCER RES, V54, P6078; Liebowitz David, 1993, P107; LUDLOW JW, 1989, CELL, V56, P67; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; MAYOL X, 1995, ONCOGENE, V11, P801; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PALMERO I, 1993, ONCOGENE, V8, P1049; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; PENG M, 1992, ONCOGENE, V7, P1175; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; QUELLE DE, 1995, ONCOGENE, V11, P635; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAPIRO GI, 1995, CANCER RES, V55, P505; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SINCLAIR AJ, 1995, METH MOL G, V7, P89; SZEKELY L, 1995, ONCOGENE, V10, P1869; TAM SW, 1994, CANCER RES, V54, P5816; TOYOSHIMA H, 1994, CELL, V78, P64; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WHYTE P, 1995, SEMIN CANCER BIOL, V6, P83, DOI 10.1006/scbi.1995.0011; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU HJ, 1989, ONCOGENE, V4, P807; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	57	44	46	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1413	1421						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875979				2022-12-28	WOS:A1996VL38400006
J	Little, MH; Holmes, G; Pell, L; Caricasole, A; Duarte, A; Law, M; Ward, A; Wainwright, B				Little, MH; Holmes, G; Pell, L; Caricasole, A; Duarte, A; Law, M; Ward, A; Wainwright, B			A novel target for the Wilms' tumour suppressor protein (WT1) is bound by a unique combination of zinc fingers	ONCOGENE			English	Article						Wilms' tumour suppressor protein; Wilms' tumour; transcription factor; Zinc finger binding	DENYS-DRASH SYNDROME; FACTOR-A-CHAIN; GENE-PRODUCT; DNA-BINDING; TRANSCRIPTION FACTOR; UROGENITAL DEVELOPMENT; PROMOTER ACTIVITY; POINT MUTATIONS; SEQUENCE; KIDNEY	All isoforms of the Wilms' tumour suppressor protein, WT1, contain four consecutive zinc fingers which facilitate DNA binding. The predominant WT1 transcript contains a 9 base pair insertion resulting in an additional three amino acids, lysine-threonine-serine (KTS), between zinc fingers 3 and 4. WT1 zinc fingers 2, 3 and 4 are highly homologous to the zinc fingers of the early growth response gene, EGR1. However, only WT1-KTS is capable of binding an EGR1 consensus site. In contrast, the previously described genomic fragment, +P5 (D1S3309E), is bound by both WT1-KTS and WT1+KTS. In this study, the region within +P5 to which both WT1-KTS and WT1+KTS bind was defined as 5-GGAGAGGGAGGATC-3'. EGR1 did not bind +P5. By creating zinc finger deletions, we demonstrate that zinc finger 1, but not zinc finger 4, is critical for +P5 binding; whereas zinc finger 4, but not 1, is necessary for the binding of WT1 target sites within EGR1, PDGF A chain and IGF2 promoters. Thus, zinc finger usage can vary with target and +P5 may represent a novel type of WT1 binding site, the physiological relevance of which must be investigated.	UNIV QUEENSLAND, DEPT BIOCHEM, BRISBANE, QLD 4072, AUSTRALIA; UNIV OXFORD, DEPT ZOOL, CRC, GROWTH FACTORS UNIT, OXFORD OX1 3PS, ENGLAND	University of Queensland; University of Oxford	Little, MH (corresponding author), UNIV QUEENSLAND, CTR CELLULAR & MOL BIOL, BRISBANE, QLD 4072, AUSTRALIA.		Little, Melissa H/A-6170-2010; Duarte, Antonio/V-1178-2018	Little, Melissa H/0000-0003-0380-2263; Duarte, Antonio/0000-0002-9255-3635; Wainwright, Brandon/0000-0003-0406-2092; Ward, Andrew/0000-0001-8311-5695				BAIRD PN, 1992, ONCOGENE, V7, P2141; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BERG JM, 1993, CURR OPIN STRUC BIOL, V3, P11, DOI 10.1016/0959-440X(93)90195-Q; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARICASOLE A, 1996, IN PRESS P NATL ACAD; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAMILTON TB, 1995, NUCLEIC ACIDS RES, V23, P277, DOI 10.1093/nar/23.2.277; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HASTIE ND, 1994, ANNU REV GENET, V28, P523; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; HUFF V, 1991, AM J HUM GENET, V48, P997; KENT J, 1995, ONCOGENE, V11, P1781; KONIG A, 1993, HUM MOL GENET, V2, P1967; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE M, 1995, HUM MOL GENET, V4, P351, DOI 10.1093/hmg/4.3.351; LITTLE MH, 1993, HUM MOL GENET, V2, P259, DOI 10.1093/hmg/2.3.259; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Negus K, 1996, CYTOGENET CELL GENET, V72, P306, DOI 10.1159/000134210; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; REDDY JC, 1996, IN PRESS BIOCH BIOPH; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SCOTT J, 1985, NATURE, V317, P260, DOI 10.1038/317260a0; SLATER RM, 1992, CANCER GENET CYTOGEN, V61, P111, DOI 10.1016/0165-4608(92)90071-F; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; SZABO J, 1995, AM J HUM GENET, V56, P944; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, J BIOL CHEM, V267, P21999; Ward A, 1995, GENE, V167, P239, DOI 10.1016/0378-1119(95)00645-1; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828	47	8	8	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1461	1469						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875984				2022-12-28	WOS:A1996VL38400011
J	Kondo, S; Barna, BP; Kondo, Y; Tanaka, Y; Casey, G; Liu, JB; Morimura, T; Kaakaji, R; Peterson, JW; Werbel, B; Barnett, GH				Kondo, S; Barna, BP; Kondo, Y; Tanaka, Y; Casey, G; Liu, JB; Morimura, T; Kaakaji, R; Peterson, JW; Werbel, B; Barnett, GH			WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis	ONCOGENE			English	Article						apoptosis; cisplatin; glioma; p53/WAF1/CIP1	HUMAN GLIOBLASTOMA CELLS; WILD-TYPE P53; LEUKEMIA-CELLS; COMBINATION THERAPY; ANTICANCER AGENTS; BRAIN-TUMORS; PHASE-II; INDUCTION; GENE; EXPRESSION	Induction of apoptosis in tumor cells is an important determinant in the outcome of therapy. Molecular details of the apoptosis pathway, however, are still poorly defined. The recently discovered WAF1/CIP1 gene is a potent inhibitor of cyclin-dependent kinases and a mediator of tumor-suppressor p53-dependent apoptosis by DNA damage. In addition, WAF1/CIP1 expression is shown to be triggered through the p53-independent pathway. The relationship between WAF1/CIP1 and p53-independent apoptosis by DNA damage, however, remains unclear. In this study, we show that WAF1/CIP1 was induced in p53-dependent apoptosis of U87-MG glioma cells by cis-diamminedichloroplatinum (cisplatin), and overexpression of WAF1/CIP1 induced apoptosis in U87-MG cells without cisplatin treatment. In contrast, the p53-independent apoptosis of GB-1 glioma cells by cisplatin did not express WAF1/CIP1. Overexpression of WAF1/CIP1 inhibited DNA synthesis in GB-1 cells, but did not induce apoptosis. Interestingly, WAF1/CIP1 increased the susceptibility of GB-1 cells to cisplatin-induced apoptosis. These results suggest that overexpression of WAF1/CIP1 may have potential for the treatment of tumors with non-functional p53.	CLEVELAND CLIN FDN,DEPT NEUROSCI,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT MOL BIOL,CLEVELAND,OH 44195; CLEVELAND CLIN FDN,DEPT CANC BIOL,CLEVELAND,OH 44195; NATL UTANO HOSP,DEPT NEUROSURG,KYOTO 616,JAPAN	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Kondo, S (corresponding author), CLEVELAND CLIN FDN,DEPT NEUROSURG S80,BRAIN TUMOR CTR CANC CTR,9500 EUCLID AVE,CLEVELAND,OH 44195, USA.			Peterson, John/0000-0002-5528-8561				ANDREWS PA, 1990, CANCER CELL-MON REV, V2, P35; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BERTOLONE SJ, 1989, J NEURO-ONCOL, V7, P5, DOI 10.1007/BF00149372; CASEY G, 1993, CANCER LETT, V69, P151, DOI 10.1016/0304-3835(93)90168-9; CASEY G, 1991, ONCOGENE, V6, P1791; CHEDID M, 1994, ONCOGENE, V9, P3021; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEAN FD, 1993, J NEUROONCOL, V16, P243; EASTMAN A, 1990, CANCER CELL-MON REV, V2, P275; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; GATELY DP, 1993, BRIT J CANCER, V67, P1171, DOI 10.1038/bjc.1993.221; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JIANG HP, 1994, ONCOGENE, V9, P3397; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAWAI K, 1990, J BIOL CHEM, V265, P13137; KELLEY SL, 1989, EUR J CANCER CLIN ON, V25, P1135, DOI 10.1016/0277-5379(89)90405-7; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KONDO S, 1995, J NEUROSURG, V82, P469, DOI 10.3171/jns.1995.82.3.0469; KONDO S, 1995, BRIT J CANCER, V71, P282, DOI 10.1038/bjc.1995.57; KONDO S, 1995, ONCOGENE, V10, P2001; KONDO S, 1994, CANCER RES, V54, P2928; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAXWELL M, 1990, J CLIN INVEST, V86, P131, DOI 10.1172/JCI114675; MICHIELI P, 1994, CANCER RES, V54, P3391; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PEREZ RP, 1990, PHARMACOL THERAPEUT, V48, P19, DOI 10.1016/0163-7258(90)90015-T; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SEXAUER CL, 1985, CANCER, V56, P1497, DOI 10.1002/1097-0142(19851001)56:7<1497::AID-CNCR2820560703>3.0.CO;2-7; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SOMERS KD, 1992, CANCER RES, V52, P5997; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TANAKA Y, 1995, VIRUS RES, V36, P131, DOI 10.1016/0168-1702(94)00111-O; TIMMERBOSSCHA H, 1989, J NATL CANCER I, V81, P1069, DOI 10.1093/jnci/81.14.1069; VAN MEIR EG, 1994, CANCER RES, V54, P649; WELLER M, 1994, J CLIN INVEST, V94, P954, DOI 10.1172/JCI117462; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN DL, 1994, FEBS LETT, V339, P73, DOI 10.1016/0014-5793(94)80387-0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1995, CANCER RES, V55, P668	49	91	92	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1279	1285						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808702				2022-12-28	WOS:A1996VJ20200019
J	Weber, RG; Sabel, M; Reifenberger, J; Sommer, C; Oberstrass, J; Reifenberger, G; Kiessling, M; Cremer, T				Weber, RG; Sabel, M; Reifenberger, J; Sommer, C; Oberstrass, J; Reifenberger, G; Kiessling, M; Cremer, T			Characterization of genomic alterations associated with glioma progression by comparative genomic hybridization	ONCOGENE			English	Article						CGH; glioma; mutation; p53; progression	HUMAN-MALIGNANT GLIOMAS; HUMAN BRAIN-TUMORS; MOLECULAR CYTOGENETIC ANALYSIS; LOW-GRADE ASTROCYTOMA; CELL-CYCLE CONTROL; WILD-TYPE P53; GLIOBLASTOMA-MULTIFORME; GENE AMPLIFICATION; PROSTATE-CANCER; OLIGODENDROGLIAL TUMORS	Genomic alterations associated with glioma progression were determined by comparative genomic hybridization (CGH) 30 tumors from 15 patients with primary gliomas of World Health Organization (WHO) grade II that on recurrence showed progression to malignant gliomas of WHO grades III or IV (five cases of astrocytoma grade II (A II) to grade III (AA III), five cases of A II to glioblastoma multiforme grade IV (GEM) and five cases of oligodendroglioma grade II (O II) to grade III (AO III)). All tumors were additionally screened for p53 mutations by single strand conformational polymorphism and heteroduplex analysis of exons 5-8, followed by direct sequencing. Mutations of p53 were found in the primary and recurrent tumors of all cases of A II progressing to GEM and three of five cases of A II recurring as AA III. Alterations identified by CGH in more than one primary A II included losses on Xp (3/10) and 5p (2/10), gains on 8q and 19p (2/10 each), and gain/amplification on 12p (2/10). Common progression associated changes found in AA III or GEM were losses on 4q, 9p, 10q, 11p, 13q (4/10 each) and gains on 1q, 6p, 20q (2/10 each). The most frequent amplification site was located on 12p13 (1/10 A II, 3/5 AA III, 1/5 GEM). Other amplified chromosomal regions were 13q32-q34 (1/10 AII, 2/5 GBM), 7q31-qter (1/5 AA III, 1/5 GEM), 12q22-qter and 18p (1/5 AA III), In contrast to the astrocytic gliomas, only one of five oligodendroglial cases showed a p53 mutation. Genetic abnormalities identified by CGH to occur more than once were restricted to four chromosomes (1, 4, 9 and 19). Our results provide a comprehensive overview of the genomic alterations associated with the progression of individual gliomas and substantiate the hypothesis that glioma progression is associated with a cumulative acquisition of multiple genetic changes.	UNIV HEIDELBERG,INST HUMAN GENET,D-69120 HEIDELBERG,GERMANY; UNIV HEIDELBERG,INST NEUROPATHOL,D-69120 HEIDELBERG,GERMANY; UNIV DUSSELDORF,DEPT NEUROPATHOL,D-40225 DUSSELDORF,GERMANY; UNIV DUSSELDORF,CTR BIOL & MED RES,D-40225 DUSSELDORF,GERMANY	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf			Weber, Ruthild/E-2906-2015; Reifenberger, Guido/AAE-3599-2019	Weber, Ruthild/0000-0001-6610-1080; Cremer, Thomas/0000-0001-7135-7216				BELLO MJ, 1995, INT J CANCER, V64, P207; BELLO MJ, 1994, GENE CHROMOSOME CANC, V9, P33; BIGNER SH, 1990, CANCER GENET CYTOGEN, V47, P141, DOI 10.1016/0165-4608(90)90024-5; BOGLER O, 1995, GLIA, V15, P308, DOI 10.1002/glia.440150311; BURGER PC, 1987, CANCER, V59, P1617, DOI 10.1002/1097-0142(19870501)59:9<1617::AID-CNCR2820590916>3.0.CO;2-X; CHER ML, 1994, GENE CHROMOSOME CANC, V11, P153, DOI 10.1002/gcc.2870110304; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; COLLINS VP, 1993, FASEB J, V7, P926, DOI 10.1096/fasebj.7.10.8344489; COLLINS VP, 1995, GLIA, V15, P289, DOI 10.1002/glia.440150309; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; DUMANOIR S, 1995, CYTOMETRY, V19, P27, DOI 10.1002/cyto.990190105; European Chromosome 16 Tuberous Sclerosis C., 1993, CELL, V75, P1305; FRANKEL RH, 1992, CANCER RES, V52, P1427; FULLER GN, 1992, MUTAT RES, V276, P299, DOI 10.1016/0165-1110(92)90016-3; FULTS D, 1992, GENOMICS, V14, P799, DOI 10.1016/S0888-7543(05)80191-0; FULTS D, 1992, CANCER RES, V52, P674; FULTS D, 1990, CANCER RES, V50, P5784; GRANA X, 1995, ONCOGENE, V11, P211; GREEN AJ, 1994, NAT GENET, V6, P192; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; JEN J, 1994, CANCER RES, V54, P6353; JOOS S, 1995, GENE CHROMOSOME CANC, V14, P267, DOI 10.1002/gcc.2870140405; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; KALLIONIEMI OP, 1994, GENE CHROMOSOME CANC, V10, P231, DOI 10.1002/gcc.2870100403; KLEIHUES P, 1993, HIST TYPING TUMORS C; Kondo M, 1996, ONCOGENE, V12, P1365; KRAUS JA, 1995, J NEUROPATH EXP NEUR, V54, P91, DOI 10.1097/00005072-199501000-00011; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LAWS ER, 1984, J NEUROSURG, V61, P665, DOI 10.3171/jns.1984.61.4.0665; LEACH FS, 1993, CANCER RES, V53, P1986; LEENSTRA S, 1994, BRIT J CANCER, V70, P684, DOI 10.1038/bjc.1994.373; LICHTER P, 1992, HUMAN CYTOGENETICS P, V1, P157; LICHTER P, 1995, HUMAN CHROMOSOMES FL, P192; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOUIS DN, 1994, J NEUROPATH EXP NEUR, V53, P11, DOI 10.1097/00005072-199401000-00002; Maniatis T., 1982, MOL CLONING; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MCCORMACK BM, 1992, NEUROSURGERY, V31, P636; Mitelman F., 1995, ISCN INT SYSTEM HUMA; MOHAPATRA G, 1995, GENE CHROMOSOME CANC, V13, P86, DOI 10.1002/gcc.2870130203; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOULTON T, 1995, AM J PATHOL, V146, P613; MULERIS M, 1994, ONCOGENE, V9, P2717; MULLER W, 1977, ACTA NEUROCHIR, V37, P75, DOI 10.1007/BF01401927; NEEL BG, 1982, P NATL ACAD SCI-BIOL, V79, P7842, DOI 10.1073/pnas.79.24.7842; Oberstrass J, 1996, J PATHOL, V179, P151, DOI 10.1002/(SICI)1096-9896(199606)179:2<151::AID-PATH556>3.0.CO;2-0; OHGAKI H, 1991, CANCER RES, V51, P6202; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; PIPER J, 1995, CYTOMETRY, V19, P10, DOI 10.1002/cyto.990190104; PIZON V, 1988, ONCOGENE, V3, P201; RASHEED BKA, 1994, CANCER RES, V54, P1324; RECHT LD, 1992, ANN NEUROL, V31, P431, DOI 10.1002/ana.410310413; REIFENBERGER G, 1995, CANCER RES, V55, P731; REIFENBERGER G, 1994, CANCER RES, V54, P4299; Reifenberger G, 1996, BRAIN TUMOR, P187; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; RIED T, 1994, CANCER RES, V54, P1801; RITLAND SR, 1995, GENE CHROMOSOME CANC, V12, P277, DOI 10.1002/gcc.2870120407; ROUSSEAUMERCK MF, 1990, CYTOGENET CELL GENET, V53, P2, DOI 10.1159/000132883; RUSSELL DS, 1989, PATHOLOGY TUMOURS NE, P83; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHROCK E, 1994, AM J PATHOL, V144, P1203; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONODA Y, 1995, CANCER RES, V55, P2166; SPEICHER MR, 1995, CANCER RES, V55, P1010; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; Ueki K, 1996, CANCER RES, V56, P150; VENTER DJ, 1991, ONCOGENE, V6, P445; VERTOSICK FT, 1991, NEUROSURGERY, V28, P496, DOI 10.1227/00006123-199104000-00002; VISAKORPI T, 1995, CANCER RES, V55, P342; VONDEIMLING A, 1993, BRAIN PATHOL, V3, P19; VONDEIMLING A, 1995, GLIA, V15, P328, DOI 10.1002/glia.440150312; VONDEIMLING A, 1994, CANCER RES, V54, P1397; VONDEIMLING A, 1992, CANCER RES, V52, P2987; VOORTER C, 1995, AM J PATHOL, V146, P1341; WALKER DG, 1995, CANCER RES, V55, P20; Weber RG, 1996, LAB INVEST, V74, P108; WINGER MJ, 1989, J NEUROSURG, V71, P487, DOI 10.3171/jns.1989.71.4.0487; WONG AJ, 1994, SEMIN ONCOL, V21, P139; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	86	146	147	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					983	994						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806688				2022-12-28	WOS:A1996VG76600012
J	Soldi, R; Sanavio, F; Aglietta, M; Primo, L; Defilippi, P; Marchisio, PC; Bussolino, F				Soldi, R; Sanavio, F; Aglietta, M; Primo, L; Defilippi, P; Marchisio, PC; Bussolino, F			Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125(FAK)) in human endothelial cells	ONCOGENE			English	Article						PAF; endothelial cells; FAK; cytoskeleton; cell motility	HEPATOCYTE GROWTH-FACTOR; IN-VIVO ANGIOGENESIS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLOOXYGENASE PRODUCTS; EXTRACELLULAR-MATRIX; CYTOKINE REGULATION; HUMAN NEUTROPHILS; CROSS-TALK; PP125(FAK)	Platelet-activating factor (PAF) is a potent activator of angiogenesis and controls the motility and the shape of vascular endothelium. The mechanism(s) whereby PAF exerts its action are in part known. Here we report that the biological active (R)PAF enantiomer administrated to cultured endothelial cells induces the early phosphorylation in tyrosine residues of focal (p125(FAK)) and paxillin, two molecules early signaling and cytoskeleton assembly in cells that undergo integrin-mediated adhesion or are challenged by neuropeptides or lysophosphatidic acid. The phenomenon is rapidly turned on, lasts for a few minutes and is adhesion-independent indicating that the chain of events induced by (R)PAF, including p125(FAK) activation, precedes adhesion. The inhibitory effect of WEB2086, a PAF receptor antagonist, and the lack of activity exerted by the (S)PAF enantiomer, indicate that (R)PAF-mediated p125(FAK) activation, is PAF receptor-dependent. Calphostin C, an inhibitor of protein kinase C blocks the effect of (R)PAF on p125(FAK); phosphorylation suggesting that protein kinase C activation is up-stream the activation of this tyrosine kinase. When endothelial cells are exposed to a substratum that allows adhesion and spreading. (R)PAF-stimulated cells, change their adhesive phenotype and start migrating. Inhibitors of tyrosine kinases, like 3-(1,4,-dihydroxytetralyl) methy-len-2-oxindole and herbimycin A, reduce the cells migration, the transendothelial flux of albumin and the enhancement of p125(FAK) activity induced by (R)PAF. The observation that increased tyrosine phosphorylation of p125(FAK) and its ensuing association with focal adhesion occurs rapidly upon (R)PAF challenge indicates that this signaling molecule has a primary and independent role also in the signaling cascade initiated by (R)PAF.	UNIV TURIN,DEPT GENET BIOL & MED CHEM,I-10126 TURIN,ITALY; UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,I-10126 TURIN,ITALY; IST SCI SAN RAFFAELE,DEPT BIOL & TECHNOL RES,I-20132 MILAN,ITALY	University of Turin; University of Turin; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele			DEFILIPPI, Paola/L-2232-2014; Bussolino, Federico/AES-3951-2022; Bussolino, Federico/K-2500-2016	Bussolino, Federico/0000-0002-5348-1341; PRIMO, Luca/0000-0002-1294-0441; Defilippi, Paola/0000-0001-6427-4906; AGLIETTA, Massimo/0000-0002-2255-7972				ANDRADE SP, 1994, J LIPID MEDIAT CELL, V9, P117; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BUSSOLINO F, 1994, J BIOL CHEM, V269, P2877; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; BUSSOLINO F, 1995, EUR J BIOCHEM, V229, P327, DOI 10.1111/j.1432-1033.1995.tb20472.x; BUSSOLINO F, 1987, J IMMUNOL, V139, P2439; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DEFILIPPI P, 1995, EXP CELL RES, V221, P141, DOI 10.1006/excr.1995.1361; DERYCKX S, 1992, J IMMUNOL, V148, P1465; DHAR A, 1994, J BIOL CHEM, V269, P9123; DHAR A, 1991, J BIOL CHEM, V266, P18797; DHUMIERES S, 1986, EUR J PHARMACOL, V131, P13, DOI 10.1016/0014-2999(86)90510-8; DURSTIN M, 1994, P NATL ACAD SCI USA, V91, P3142, DOI 10.1073/pnas.91.8.3142; GATES RE, 1994, CELL GROWTH DIFFER, V5, P891; GLASS DB, 1978, ANAL BIOCHEM, V87, P566, DOI 10.1016/0003-2697(78)90707-8; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HANDLEY DA, 1984, IMMUNOPHARMACOLOGY, V8, P137, DOI 10.1016/0162-3109(84)90017-1; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HEUER HO, 1990, J PHARMACOL EXP THER, V255, P962; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; HUMPHREY DM, 1982, LAB INVEST, V46, P422; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; JUNCOS LA, 1993, J CLIN INVEST, V91, P1374, DOI 10.1172/JCI116339; KIM DY, 1995, AM J PHYSIOL-HEART C, V268, pH399, DOI 10.1152/ajpheart.1995.268.1.H399; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; KUIJPERS TW, 1992, J CELL BIOL, V117, P565, DOI 10.1083/jcb.117.3.565; KURUVILLA A, 1994, J IMMUNOL, V153, P5433; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER R, 1988, BIOCHEM BIOPH RES CO, V153, P805, DOI 10.1016/S0006-291X(88)81167-7; LORANT DE, 1993, J CLIN INVEST, V92, P559, DOI 10.1172/JCI116623; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; Mariani M., 1994, Proceedings of the American Association for Cancer Research Annual Meeting, V35, P381; MATSUMOTO K, 1994, J BIOL CHEM, V269, P31807; MCMANUS LM, 1993, LAB INVEST, V69, P639; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; NOURSHARGH S, 1995, BLOOD, V85, P2553, DOI 10.1182/blood.V85.9.2553.bloodjournal8592553; PEPPELENBOSCH MP, 1993, CELL, V74, P565, DOI 10.1016/0092-8674(93)80057-L; RANKIN S, 1994, J BIOL CHEM, V269, P704; ROMER LH, 1994, MOL BIOL CELL, V5, P349, DOI 10.1091/mbc.5.3.349; ROSEN A, 1990, J EXP MED, V172, P1211, DOI 10.1084/jem.172.4.1211; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SCHWERTSCHLAG US, 1988, KIDNEY INT, V34, P779, DOI 10.1038/ki.1988.249; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SILVESTRO L, 1994, SEMIN THROMB HEMOST, V20, P214, DOI 10.1055/s-2007-1001905; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SMITH CS, 1994, J IMMUNOL, V153, P3997; STOSSEL TP, 1994, BLOOD, V84, P367; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; VUORI K, 1993, J BIOL CHEM, V268, P21459; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	67	33	34	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					515	525						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760293				2022-12-28	WOS:A1996VB32800009
J	Shao, NS; Chai, YL; Shyam, E; Reddy, P; Rao, NV				Shao, NS; Chai, YL; Shyam, E; Reddy, P; Rao, NV			Induction of apoptosis by the tumor suppressor protein BRCA1	ONCOGENE			English	Article						BRCA1 proteins; tumor suppressor; breast and ovarian cancers; apoptosis; therapy		The breast and ovarian cancer susceptibility gene BRCA1, is a nuclear phosphoprotein which functions as a tumor suppressor, To investigate the role of BRCA1 in apoptosis, we have developed mouse fibroblast cell lines and human breast cancer cell lines expressing BRCA1, The expression of BRCA1 protein in the BRCA1 transfectants were analysed by immunofluorescence and immunohistochemistry. The BRCA1 transfectants showed a flattened morphology compared to the parental cells, We show that serum deprivation or calcium ionophore treatment of BRCA1 transfectants resulted in programmed cell death, These results indicate that BRCA1 genes may play a critical role in the regulation of apoptosis, Thus, since a wide variety of human malignancies like breast and ovarian cancers have a decreased ability to undergo apoptosis, this could be due to lack/decreased levels of functional BRCA1 proteins, Treatments that are aimed at increasing the apoptotic threshold by BRCA1 gene therapy may have the potential to prevent the progression of these malignancies.	JEFFERSON MED COLL,DEPT MICROBIOL & IMMUNOL,KIMMEL CANC INST,PHILADELPHIA,PA 19107	Jefferson University					NCI NIH HHS [CA58642, CA57322] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058642, R01CA057322] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDALL LJ, 1994, EXP HEMATOL, V22, P1252; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; GUDAS JM, 1995, CANCER RES, V55, P4561; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JIMENEZ B, 1995, ONCOGENE, V10, P811; KONDO S, 1995, ONCOGENE, V10, P2001; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Rao VN, 1996, ONCOGENE, V12, P523; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	16	139	145	0	10	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					1	7						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700535				2022-12-28	WOS:A1996UX31900001
J	Li, WL; Park, JW; Nuijens, A; Sliwkowski, MX; Keller, GA				Li, WL; Park, JW; Nuijens, A; Sliwkowski, MX; Keller, GA			Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells	ONCOGENE			English	Article						heregulin; ErbB2/HER2/neu; growth factor internalization; nuclear transport; c-myc	EPIDERMAL GROWTH-FACTOR; LOCALIZATION; ACTIVATION; RECEPTORS; PROTEINS	Heregulins (neuregulins) are a family of proteins known to interact and activate the receptor tyrosine kinases ErbB2 in association with ErbB3 or ErbB4. Using immunofluorescence microscopy, electron microscopy autoradiography, and SDS-PAGE analysis of nuclear fractions, we show that the heregulin-beta 1(1-244) isoform is rapidly internalized and translocated to the nucleus of SK-BR-3 breast cancer cells as an intact molecule. Heregulin-beta 1(1-244) treatment up-regulated expression of c-myc mRNA and protein, which was also observed to undergo its own translocation from the cytosol to the nucleus. c-myc thus appears to be a cellular target gene of HRG beta 1(1-244) and its induction may be related to the nuclear translocation of heregulin.	GENENTECH INC,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech								BENBARUCH N, 1994, P SOC EXP BIOL MED, V206, P221; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; GARCIA G, 1987, CANCER RES, V49, P6675; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P2165, DOI 10.1073/pnas.90.6.2165; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; PEITRAS RJ, 1995, ONCOGENE, V10, P2435; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SARUP JC, 1991, GROWTH REGULAT, V1, P72; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; WAKAMATSU Y, 1993, NEURON, V10, P1, DOI 10.1016/0896-6273(93)90236-K	20	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2473	2477						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649790				2022-12-28	WOS:A1996UQ22000027
J	Roy, LM; Haccard, O; Izumi, T; Lattes, BG; Lewellyn, AL; Maller, JL				Roy, LM; Haccard, O; Izumi, T; Lattes, BG; Lewellyn, AL; Maller, JL			Mos proto-oncogene function during oocyte maturation in Xenopus	ONCOGENE			English	Article						Mos; MAP kinase; cell cycle; xenopus oocyte; proto-oncogene	MEIOTIC MATURATION; CYTOSTATIC FACTOR; MAP KINASE; PROTOONCOGENE PRODUCT; PROMOTING FACTOR; CELL-CYCLE; EGGS; REQUIREMENT; METAPHASE; ARREST	The function of the Xenopus c-mos proto-oncogene product (Mos(xe)) has been investigated during oocyte maturation, Experiments with a new antibody able to immunoblot Mos(xe) demonstrated the time course of MAP kinase (MAP K) activation in oocytes paralleled Mos(xe) accumulation, and in activated eggs the deactivation of MAP K paralleled the degradation of Mos(xe), Ablation of Mos synthesis by microinjection of antisense oligodeoxynucleotides abolished activation of MAP K by progesterone, but microinjection of GST-Mos fully restored both MAP K activation and germinal vesicle breakdown (GVBD), The Mos(xe) level at metaphase of Meiosis I(MI) was 2-3-fold less than that at metaphase of Meiosis II (MII), but MAP K activation was maximal at metaphase in both MI and MII, In the transition between MI and MII, both cyclin B and Mos(xe) levels rapidly declined in the presence of cycloheximide and injection of exogenous GST-Mos(xe) did not prevent degradation of either protein, although MAP K was activated, Microinjection of GST-Mos(xe) into oocytes was able to activate MAP K before GVBD and H1 kinase activation, and microinjection of constitutively-activated thiophosphorylated MAP K induced de novo synthesis of Mos(xe) before H1 kinase activation, suggesting the existence of a positive feedback loop between MAP K and Mos(xe) accumulation.	UNIV COLORADO,SCH MED,HOWARD HUGHES MED INST,DENVER,CO 80262; UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Haccard, Olivier/0000-0002-4305-2746	NCI NIH HHS [F32CA0981] Funding Source: Medline; NIDDK NIH HHS [DK28353] Funding Source: Medline; NIGMS NIH HHS [GM26743] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; FABIAN JR, 1993, J CELL BIOL, V122, P645, DOI 10.1083/jcb.122.3.645; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FREEMAN RS, 1992, J CELL BIOL, V116, P725, DOI 10.1083/jcb.116.3.725; FURUNO N, 1994, EMBO J, V13, P2399, DOI 10.1002/j.1460-2075.1994.tb06524.x; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GERHART J, 1984, J CELL BIOL, V98, P1247, DOI 10.1083/jcb.98.4.1247; HACCARD O, 1995, DEV BIOL, V168, P677, DOI 10.1006/dbio.1995.1112; HACCARD O, 1993, SCIENCE, V262, P1262, DOI 10.1126/science.8235656; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HUANG WD, 1995, MOL BIOL CELL, V6, P237, DOI 10.1091/mbc.6.3.237; HUCHON D, 1993, BIOL CELL, V77, P133, DOI 10.1016/S0248-4900(05)80181-9; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOBAYASHI H, 1991, J CELL BIOL, V114, P755, DOI 10.1083/jcb.114.4.755; KOSAKO H, 1994, J BIOL CHEM, V269, P28354; KOSAKO H, 1994, EMBO J, V13, P2131, DOI 10.1002/j.1460-2075.1994.tb06489.x; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MINSHULL J, 1991, J CELL BIOL, V114, P767, DOI 10.1083/jcb.114.4.767; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P4197, DOI 10.1128/MCB.13.7.4197; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OCONNELL MJ, 1994, CURR OPIN CELL BIOL, V6, P867, DOI 10.1016/0955-0674(94)90058-2; PIWNICAWORMS H, 1990, CURRENT PROTOCOLS MO; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SHIBUYA EK, 1993, MOL BIOL CELL, V4, P781, DOI 10.1091/mbc.4.8.781; VANRENTERGHEM BB, 1993, J BIOL CHEM, V268, P11935; WASSERMAN WJ, 1982, DEV BIOL, V89, P152, DOI 10.1016/0012-1606(82)90303-7; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEBER M, 1991, DEV BIOL, V148, P393, DOI 10.1016/0012-1606(91)90347-6; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1990, ONCOGENE, V5, P1727	43	88	88	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2203	2211						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668347				2022-12-28	WOS:A1996UP28300020
J	Yang, YM; Dolan, LR; Ronai, Z				Yang, YM; Dolan, LR; Ronai, Z			Expression of dominant negative CREB reduces resistance to radiation of human melanoma cells	ONCOGENE			English	Article						AP1; CREB; dominant negative; melanoma; radiation	ULTRAVIOLET-LIGHT; DNA DAMAGE; PROTEIN; TRANSCRIPTION; P53; IRRADIATION; ACTIVATION; TGACAACA; COMPLEX; KINASE	u.v.-responsive element (URE)-binding proteins were found to include members of the AP1 and ATF transcription factor families, To elucidate the functional contribution of URE-bound proteins to the characteristics of human melanoma, we have used a dominant negative CREB cDNA which is mutated within the DNA-binding domain and cloned into a mammalian expression vector driven by the RSV promoter (KCREB), As such, KCREB is still capable of heterodimerizing with its associated proteins, Set, due to its poor binding affinity to DNA it out competes transcriptional activity mediated by those proteins, Human melanoma cells (MeWo) were transfected with KCREB and three clones, designated K1, K2, and K10 which express KCREB transcripts were then selected for further characterization. When tested for binding activities in gel shift assays, proteins prepared from the three clones exhibited a different set of complexes than the parent MeWo and control MeWo(neo) cells (transfected with empty expression vector) under normal growth conditions, and after u.v.-irradiation, Using CAT vector, driven by a tetramer URE construct, revealed a striking decrease in transcriptional activity in each of the three clones before as well as after u.v.-irradiation, When tested for radiation resistance MeWo cells were found to exhibit 42% survival to a u.v.-dose of 16 J/m(2), whereas, K1, K2 and K10 exhibited only 10.2, 3.9 and 4.2% survival, respectively, Exposure to 2 Gy of X-radiation led to 62.1% survival of MeWo as compared with 18.5% of K1 and 7.7% and 6.5% of K2 and K10, respectively, While no significant differences were noticed in their growth rate, all three clones exhibited fewer, and smaller colonies in soft agar, when compared with parent cells, These findings indicate that through their transcriptional activities, CREB and its associated proteins play an important role in the acquisition of characteristic phenotypes of human melanoma cells including resistance to u.v.-irradiation.	AMER HLTH FDN,MOL CARCINOGENESIS PROGRAM,VALHALLA,NY 10595	American Health Foundation				RONAI, ZEEV/0000-0002-3859-0400; Reinhart, Lisa/0000-0001-6266-3342	NCI NIH HHS [CA51995] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051995, R01CA051995] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; CHOI HS, 1991, J BIOL CHEM, V266, P11858; DESDOUETS C, 1995, MOL CELL BIOL, V15, P3301; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; FORNACE AJ, 1992, ANNU REV GENET, V26, P505; GUIFFRE L, 1988, CANCER, V61, P1132; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HERLYN M, 1992, CUTANEOUS MELANOMA, P82; HERRLICH P, 1994, CURR OPIN CELL BIOL, V6, P425, DOI 10.1016/0955-0674(94)90036-1; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; JUNG M, 1995, SCIENCE, V268, P1619, DOI 10.1126/science.7777860; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KASTAN MB, 1991, CANCER RES, V51, P6304; KENNY JJ, 1994, VIROLOGY, V200, P220, DOI 10.1006/viro.1994.1180; KISSTOTH E, 1993, NUCLEIC ACIDS RES, V21, P3677, DOI 10.1093/nar/21.16.3677; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEONARDO AD, 1994, GENE DEV, V8, P2540; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; RONAI Z, 1994, ENVIRON MOL MUTAGEN, V23, P157, DOI 10.1002/em.2850230302; RONAI Z, 1992, INDUCIBLE RESPONSES, P97; RONAI ZA, 1990, CANCER RES, V50, P5374; RUTBERG SE, 1994, MOL CARCINOGEN, V10, P82, DOI 10.1002/mc.2940100205; RUTBERG SE, 1992, NUCLEIC ACIDS RES, V20, P4305, DOI 10.1093/nar/20.16.4305; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1992, PHOTOCHEM PHOTOBIOL, V55, P409, DOI 10.1111/j.1751-1097.1992.tb04255.x; THOMPSON FJ, 1994, J GEN VIROL, V75, P545, DOI 10.1099/0022-1317-75-3-545; TSUCHIYA H, 1989, JPN J CANCER RES, V80, P1246, DOI 10.1111/j.1349-7006.1989.tb01661.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; WALTON KM, 1992, MOL ENDOCRINOL, V6, P647, DOI 10.1210/me.6.4.647; WANDA T, 1991, J VIROL, V65, P557; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; WOLOSHIN PI, 1992, MOL ENDOCRINOL, V6, P1725, DOI 10.1210/me.6.10.1725; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; YANG YM, 1993, CELL GROWTH DIFFER, V4, P595; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	46	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2223	2233						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668349				2022-12-28	WOS:A1996UP28300022
J	Lenahan, MK; Ozer, HL				Lenahan, MK; Ozer, HL			Induction of c-myc mediated apoptosis in SV40-transformed rat fibroblasts	ONCOGENE			English	Article						apoptosis; p53; T antigen; c-myc; fibroblasts; SV40	WILD-TYPE P53; LARGE-T-ANTIGEN; SIMIAN VIRUS-40; CELLULAR SENESCENCE; GENE; IMMORTALIZATION; TRANSFORMATION; TEMPERATURE; EXPRESSION; PROTEIN	The ability of SV40 T antigen to block apoptosis was investigated in Rat1-A fibroblasts expressing an estrogen-dependent c-myc construct, mycER (filers ed al., 1989). These RatmycER cells undergo apoptosis upon activation of c-myc by estradiol under conditions of serum deprivation. Under such conditions SV40-transfected derivatives of RatmycER undergo apoptosis as evidenced by rapid cell death, characteristic morphological changes and DNA fragmentation in a manner indistinguishable from the parental cell line, indicating that T antigen is not able to protect against myc-induced apoptosis. In as much as it had been reported that myc-mediated apoptosis involves wild-type p53 in other systems and T antigen is known to bind and inhibit p53 function, we examined these two polypeptides under different experimental conditions. In all cases, the great majority of the p53 in the SV40 transfectants was found to be in complexes with T antigen. Furthermore, the residual p53 in the uncomplexed state was not sufficient to transactivate an endogenous promoter, WAF1/p21. These data indicate that the failure of T antigen to block apoptosis cannot be attributed to defective function of T antigen and suggest that myc-mediated apoptosis may involve a p53-independent pathway in these cells.	UNIV MED & DENT NEW JERSEY,NEW JERSEY MED SCH,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103; UNIV MED & DENT NEW JERSEY,GRAD SCH BIOMED SCI,DEPT MICROBIOL & MOLEC GENET,NEWARK,NJ 07103	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE ON AGING [P01AG000378, R01AG004821] Funding Source: NIH RePORTER; NIA NIH HHS [AG00378, AG04821] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DHANARAJ SN, 1996, IN PRESS EXP CELL RE; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELLIS RE, 1991, ANN REV CELL BIOL, V7, P633; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HAYASHI M, 1990, MUTAT RES, V245, P245, DOI 10.1016/0165-7992(90)90153-B; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; HSU B, 1995, ONCOGENE, V11, P175; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IMAI Y, 1994, INT J ONCOL, V5, P945; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; JIANG D, 1993, ONCOGENE, V8, P2805; LI QT, 1995, J BIOL CHEM, V270, P15777, DOI 10.1074/jbc.270.26.15777; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MCCARTHY SA, 1994, P NATL ACAD SCI USA, V91, P3979, DOI 10.1073/pnas.91.9.3979; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OZER HL, 1996, IN PRESS EXP GERONTO; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SMALL MB, 1982, NATURE, V296, P671, DOI 10.1038/296671a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TIEMANN F, 1995, J VIROL, V69, P6115, DOI 10.1128/JVI.69.10.6115-6121.1995; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WHITE E, 1984, J VIROL, V52, P410, DOI 10.1128/JVI.52.2.410-419.1984; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YANAI N, 1994, EXP CELL RES, V211, P296, DOI 10.1006/excr.1994.1090; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHENG DQ, 1994, ONCOGENE, V9, P3345	51	33	33	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1847	1854						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649844				2022-12-28	WOS:A1996UK49800002
J	Augenlicht, LH; Richards, C; Corner, G; Pretlow, TP				Augenlicht, LH; Richards, C; Corner, G; Pretlow, TP			Evidence for genomic instability in human colonic aberrant crypt foci	ONCOGENE			English	Article						colon cancer precursors; premalignant lesions; genomic instability; aberrant crypt foci	QUANTIFICATION; MUTATIONS; CANCER	Aberrant crypt foci (ACF) are morphologically abnormal structures that can be identified in whole mounts of colonic tissue from rodents treated with colon carcinogens and from patients at risk for development of colon tumors, ACF are heterogeneous and exhibit properties, such as altered patterns of cell proliferation, the presence of dysplasia, and mutations in protooncogenes and tumor suppressor genes, consistent with the hypothesis that a subset of these structures are precursors to tumor formation, In this study, we have investigated the presence of genomic instability in DNA isolated from human ACF from patients with colon cancer, Altered allele length detected by electrophoretic separation of PCR amplified oligo A or microsatellite loci was used to identify candidate samples which were then more rigorously investigated by sequence analysis for instability, Of 20 patients examined, two exhibited alterations at two loci, and this instability could be confirmed by sequence analysis, An additional seven of the 20 patients had evidence for instability at a single locus, Quantitative sequence analysis of the DNA from an ACF of one of these seven patients was consistent with alteration of allele length in this patient, but the alteration was not sufficiently different from normal to reach statistical significance, Thus, genomic instability, manifest as altered length of microsatellite and oligo A sequences, is present in some ACF, and therefore can be a very early event in the development of some human colon cancers.	CASE WESTERN RESERVE UNIV,SCH MED,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University	Augenlicht, LH (corresponding author), MONTEFIORE MED CTR,ALBERT EINSTEIN CANC CTR,DEPT ONCOL,111 E 210TH ST,BRONX,NY 10467, USA.				NATIONAL CANCER INSTITUTE [R21CA066642, R01CA048032, R01CA057694] Funding Source: NIH RePORTER; NCI NIH HHS [CA57694, CA66642, CA48032] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AUGENLICHT L, 1994, GASTROENTEROLOGY, V107, P1894, DOI 10.1016/0016-5085(94)90840-0; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; CHEN JS, 1995, CANCER RES, V55, P174; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JEN J, 1994, CANCER RES, V54, P5523; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOEB LA, 1994, CANCER RES, V54, P5059; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PRETLOW TP, 1991, CANCER RES, V51, P1564; PRETLOW TP, 1994, GASTROENTEROLOGY, V107, P1719, DOI 10.1016/0016-5085(94)90812-5; PRETLOW TP, 1993, J NATL CANCER I, V85, P2004, DOI 10.1093/jnci/85.24.2004; PRETLOW TP, 1994, INT J CANCER, V56, P599, DOI 10.1002/ijc.2910560422; RONCUCCI L, 1991, HUM PATHOL, V22, P287, DOI 10.1016/0046-8177(91)90163-J; RONCUCCI L, 1993, CANCER RES, V53, P3726; SMITH AJ, 1994, CANCER RES, V54, P5527; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367	23	63	64	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1767	1772						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622897				2022-12-28	WOS:A1996UG45800019
J	Foster, SA; Galloway, DA				Foster, SA; Galloway, DA			Human papillomavirus type 16 E7 alleviates a proliferation block in early passage human mammary epithelial cells	ONCOGENE			English	Article						HPV; E7; epithelial cells; cell cycle	RETINOBLASTOMA GENE-PRODUCT; MAMMALIAN FIBROBLASTS; CELLULAR-RESPONSE; P53 PROTEIN; DNA DAMAGE; CYCLIN-A; PHOSPHORYLATION; EXPRESSION; E6; IMMORTALIZATION	Human mammary epithelial cells (HMEC) isolated from reduction mammoplasty tissue are proliferative for several passages but then enter a period termed 'selection' or M0 during which the majority of the cells become larger, flattened, and less proliferative. Early passage HMEC (prior to M0) were transduced with human papillomavirus type-16 E6, E7, or E6/E7 by using recombinant retroviral vectors. E7 alone or E6/E7, but not E6 alone, alleviated the M0 proliferation block, suggesting a possible role for Rb or Rb-related proteins, but not p53, in M0. In addition, cells in M0 did not have increased levels of p53 or p21 proteins, further indicating that induction of these proteins is not required for the M0 proliferation block. Early passage cells contained Rb which was primarily hyperphosphorylated while cells in M0 contained Rb protein which was predominantly underphosphorylated. Cells in M0 accumulated in G(1) or G(0) and expressed reduced levels of cyclin A and CDKZ proteins.			Foster, SA (corresponding author), FRED HUTCHINSON CANC RES CTR, CANC BIOL PROGRAM, 1124 COLUMBIA ST, C1-015, SEATTLE, WA 98104 USA.				NATIONAL CANCER INSTITUTE [R01CA064795, F32CA062584] Funding Source: NIH RePORTER; NCI NIH HHS [CA64795, CA62584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; ISHII T, 1993, EXP CELL RES, V208, P407, DOI 10.1006/excr.1993.1262; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1993, ONCOGENE, V8, P1407; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAYLORPAPADIMITRIOU J, 1989, J CELL SCI, V94, P403; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Werness B A, 1991, Important Adv Oncol, P3; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	39	75	77	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1773	1779						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622898				2022-12-28	WOS:A1996UG45800020
J	Tian, MX; Martin, GS				Tian, MX; Martin, GS			Reduced phosphotyrosine binding by the v-Src SH2 domain is compatible with wild-type transformation	ONCOGENE			English	Article						Src; SH2 domain; phosphotyrosine; transformation	TYROSINE-PHOSPHORYLATED PEPTIDES; ROUS-SARCOMA VIRUS; SIGNAL-TRANSDUCTION; HOMOLOGY REGION-2; KINASE-ACTIVITY; C-SRC; MUTAGENESIS; INSERTION; MUTATIONS; MUTANTS	The SH2 domain of v-Src binds phosphotyrosyl-proteins in vivo and in vitro. The function of this domain is necessary for transformation of Rat-2 cells and for morphologically wild-type transformation of chicken embryo fibroblasts (CEF). The phosphate group of phosphotyrosine interacts directly with a conserved arginine residue in the FLVRES motif of the SH2 domain, R175 in v-Src. To examine the role of phosphotyrosine binding in transformation by v-Src, we have characterized the effects of R175 mutations on the transforming ability of v-Src and on the interaction of the v-Src SH2 domain with phosphotyrosyl-proteins. The R175H mutation, and to a lesser extent the R175K mutation, reduced but did not eliminate the binding of phosphotyrosyl-proteins to the v-Src SH2 domain. However neither mutation affected transformation of CEF or Rat-2 cells by v-Src and neither mutation resulted in major changes in the level or pattern of protein-tyrosine phosphorylation in transformed CEF. In contrast, the R175E mutant of v-Src induced fusiform transformation of CEF and failed to transform Rat-2 cells; the mutant SH2 domain was insoluble when expressed in bacteria, suggesting that the R175E mutation disrupts the structure of the v-Src SH2 domain. We conclude that, although the Arg residue in the FLVRES motif is invariant in most if not all SH2 domains, at position 175 in the v-Src SH2 domain residues other than arginine can support the binding of phosphotyrosyl-proteins, albeit at reduced levels. Furthermore under the expression conditions normally used, that is when v-Src is expressed under the-control of a retroviral LTR, the reduced binding of phosphotyrosyl-proteins is compatible with wild-type transformation.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R37CA017542, R01CA017542] Funding Source: NIH RePORTER; NCI NIH HHS [CA17542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BOEUF H, 1995, ONCOGENE, V10, P433; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; COURTNEIDGE SA, 1994, SEMIN CANCER BIOL, V5, P239; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LIEBL EC, 1993, VIROLOGY, V195, P265, DOI 10.1006/viro.1993.1371; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MORTON CJ, 1994, CURR BIOL, V4, P615, DOI 10.1016/S0960-9822(00)00134-2; MURPHY SM, 1993, MOL CELL BIOL, V13, P5290, DOI 10.1128/MCB.13.9.5290; OKAMURA H, 1994, ONCOGENE, V9, P2293; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; TEMIN HM, 1960, VIROLOGY, V10, P182, DOI 10.1016/0042-6822(60)90038-6; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VERDERAME MF, 1994, ONCOGENE, V9, P175; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	13	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					727	734						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632894				2022-12-28	WOS:A1996TW68600003
J	Gress, TM; MullerPillasch, F; Geng, M; Zimmerhackl, F; Zehetner, G; Friess, H; Buchler, M; Adler, G; Lehrach, H				Gress, TM; MullerPillasch, F; Geng, M; Zimmerhackl, F; Zehetner, G; Friess, H; Buchler, M; Adler, G; Lehrach, H			A pancreatic cancer-specific expression profile	ONCOGENE			English	Article						pancreatic cancer; EST; differential expression; cDNA; database	GENE-EXPRESSION; SEQUENCE TAGS; MOLECULAR-CLONING; HUMAN CARCINOMAS; MESSENGER-RNA; GROWTH-FACTOR; HUMAN GENOME; HUMAN BRAIN; CELL-LINES; IDENTIFICATION	We present an approach making use of technology established in the context of the genome project to describe a pancreatic cancer-specific expression profile and to identify new potential disease genes or disease-associated-genes, By use of gridded arrays of pancreatic cancer cDNA libraries and differential hybridizations we show that 4% the gridded cDNA library clones contain sequences preferentially expressed in pancreatic cancer. EST-sequencing of 369 distinct (408 total), differentially expressed sequences identified novel genes (32.5%) or homologs to EST-sequences with unknown function (26.3%). Homologies to known genes allow to determine a pancreatic cancer-specific expression profile, which provides for the first time evidence for complex primary and secondary alterations of gene expression responsible for the development of the phenotype of pancreatic cancer cells. In addition this has led to the identification of novel differentially expressed genes, which represent potential oncogenes or disease-associated markers and may be helpful for the development of therapeutic or diagnostic modalities.	UNIV ULM,DEPT INTERNAL MED 1,D-89081 ULM,GERMANY; MAX PLANCK INST MOL GENET,D-14195 BERLIN,GERMANY; UNIV BERN,INSELSPITAL,DEPT VISZERAL & TRANSPLANTAT SURG,CH-3010 BERN,SWITZERLAND	Ulm University; Max Planck Society; University of Bern; University Hospital of Bern				Gress, Thomas/0000-0002-9333-5461				ADACHI Y, 1994, J BIOL CHEM, V269, P2258; ADAMS MD, 1993, NAT GENET, V4, P256, DOI 10.1038/ng0793-256; ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ADAMS MD, 1991, SCIENCE, V252, P1651, DOI 10.1126/science.2047873; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ALTSCHUL SF, 1990, J MOL BIOL, V215, P402; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; BALDWIN GS, 1994, P NATL ACAD SCI USA, V91, P7593, DOI 10.1073/pnas.91.16.7593; BARTKOVA J, 1995, CANCER RES, V55, P949; BARTSCH S, 1995, FEBS LETT, V357, P255, DOI 10.1016/0014-5793(94)01303-I; CHEN JS, 1995, CANCER RES, V55, P174; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; EDOKIMOVA VM, 1995, J BIOL CHEM, V270, P3186; ELSASSER HP, 1992, VIRCHOWS ARCH B, V61, P295, DOI 10.1007/BF02890431; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; FORNEROD M, 1995, ONCOGENE, V10, P1739; GIBSON S, 1993, BLOOD, V82, P1561; GONZALEZ FA, 1992, FEBS LETT, V304, P170, DOI 10.1016/0014-5793(92)80612-K; GRANT AG, 1992, INT J CANCER, V51, P740; GRESS TM, 1992, MAMM GENOME, V3, P609, DOI 10.1007/BF00352477; GRESS TM, 1994, EUR J CANCER, V30A, P1391, DOI 10.1016/0959-8049(94)90191-0; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HARA E, 1993, ANAL BIOCHEM, V214, P58, DOI 10.1006/abio.1993.1456; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; HOOG C, 1991, NUCLEIC ACIDS RES, V19, P6123, DOI 10.1093/nar/19.22.6123; INKI P, 1994, BRIT J CANCER, V70, P319, DOI 10.1038/bjc.1994.300; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KLEVER P, 1992, LANCET, V340, P1158, DOI 10.1016/0140-6736(92)93183-N; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; KOTHS K, 1993, J BIOL CHEM, V268, P1425; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEWIN B, 1994, GENES, V5; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIU QY, 1995, ONCOGENE, V10, P619; MAIER E, 1992, NAT GENET, V1, P273, DOI 10.1038/ng0792-273; MEIEREWERT S, 1993, NATURE, V361, P375, DOI 10.1038/361375a0; MIYAGI Y, 1995, CANCER LETT, V91, P247, DOI 10.1016/0304-3835(95)03737-H; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURPHY D, 1983, CELL, V35, P865, DOI 10.1016/0092-8674(83)90119-8; MURR MM, 1994, CA-CANCER J CLIN, V44, P304, DOI 10.3322/canjclin.44.5.304; MYERS MH, 1989, CA-CANCER J CLIN, V39, P21, DOI 10.3322/canjclin.39.1.21; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; NEKARDA H, 1994, CANCER RES, V54, P2900; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; SARGENT T D, 1983, Science (Washington D C), V222, P135, DOI 10.1126/science.6688681; SCHRAML P, 1994, CANCER RES, V54, P5236; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCOTT MRD, 1983, CELL, V34, P556; SIMON B, 1994, GASTROENTEROLOGY, V106, P1645, DOI 10.1016/0016-5085(94)90422-7; SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833; TAKAGI S, 1995, INT J CANCER, V61, P706, DOI 10.1002/ijc.2910610519; TAKEDA J, 1993, HUM MOL GENET, V2, P1793, DOI 10.1093/hmg/2.11.1793; TAWARAGI Y, 1988, BIOCHEM BIOPH RES CO, V150, P89, DOI 10.1016/0006-291X(88)90490-1; VANERP HE, 1991, CANCER, V15, P2595; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; Vila Maya R., 1994, Zentralblatt fuer Pathologie, V140, P225; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; Wagner R. P., 1993, CHROMOSOMES SYNTHESI; WATSON MA, 1994, CANCER RES, V54, P4598; WEINHOUSE S, 1983, ADV ENZYME REGUL, V21, P369, DOI 10.1016/0065-2571(83)90024-9; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; ZEHETNER G, 1994, NATURE, V367, P489, DOI 10.1038/367489a0	64	158	184	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1819	1830						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895530				2022-12-28	WOS:A1996VM88700029
J	Mymryk, JS				Mymryk, JS			Tumour suppressive properties of the adenovirus 5 E1A oncogene	ONCOGENE			English	Review						E1A; cancer; adenovirus; tumour-suppressor	NECROSIS-FACTOR-ALPHA; NATURAL-KILLER-CELLS; TOXIC LYMPHOCYTES-T; RAT EMBRYO CELLS; RETINOBLASTOMA GENE-PRODUCT; PROTEINS INDUCE APOPTOSIS; F9 TERATOCARCINOMA CELLS; OVARIAN-CANCER CELLS; NERVE GROWTH-FACTOR; C-TERMINAL DOMAIN	The transforming oncogenes of DNA tumour viruses have proven useful as tools to dissect the mechanisms of complex cellular processes. In particular, studies of the multifunctional proteins encoded by the early region 1A (EIA) of human adenovirus types 2 and 5 have provided insight into the regulation of cellular gene expression, growth and differentiation. Despite their well known ability to immortalize primary rodent cells and transform them in cooperation with a second oncogene, the EIA proteins also exhibit significant anti-tumour/tumour suppressive activity. This review focuses on the surprising ability of EIA to function as a tumour suppressor gene.	UNIV WESTERN ONTARIO, LONDON REG CANC CTR, DEPT OBSTET & GYNAECOL, LONDON, ON N6A 4L6, CANADA	Western University (University of Western Ontario)	Mymryk, JS (corresponding author), UNIV WESTERN ONTARIO, LONDON REG CANC CTR, DEPT PHARMACOL & TOXICOL, 790 COMMISSIONERS RD E, LONDON, ON N6A 4L6, CANADA.							ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P4387, DOI 10.1093/nar/19.16.4387; AMES RS, 1990, J VIROL, V64, P4115, DOI 10.1128/JVI.64.9.4115-4122.1990; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; BAYLEY ST, 1994, INT J ONCOL, V5, P425; BELLGRAU D, 1988, J VIROL, V62, P1513, DOI 10.1128/JVI.62.5.1513-1519.1988; BERK AJ, 1986, CANCER SURV, V5, P367; BERLINGIERI MT, 1993, ONCOGENE, V8, P249; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERNHARD EJ, 1995, INT J CANCER, V60, P718, DOI 10.1002/ijc.2910600525; Boulakia CA, 1996, ONCOGENE, V12, P529; BOULUKOS KE, 1993, ONCOGENE, V8, P237; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRAITHWAITE A, 1990, VIROLOGY, V177, P595, DOI 10.1016/0042-6822(90)90525-V; BRANTON PE, 1984, BIOCHIM BIOPHYS ACTA, V780, P67, DOI 10.1016/0304-419X(84)90007-6; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHATTERJEE PK, 1988, EMBO J, V7, P835, DOI 10.1002/j.1460-2075.1988.tb02882.x; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Coffman FD, 1989, GROWTH FACTORS, V1, DOI 10.3109/08977198909000259; COOK JL, 1986, P NATL ACAD SCI USA, V83, P6965, DOI 10.1073/pnas.83.18.6965; COOK JL, 1993, ONCOGENE, V8, P625; COOK JL, 1989, J IMMUNOL, V142, P4527; COOK JL, 1987, J VIROL, V61, P3510, DOI 10.1128/JVI.61.11.3510-3520.1987; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENHARDT DT, 1993, PHARMACOL THERAPEUT, V59, P329, DOI 10.1016/0163-7258(93)90074-N; DOUGLAS JL, 1995, J VIROL, V69, P8061, DOI 10.1128/JVI.69.12.8061-8065.1995; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; DUERKSENHUGHES PJ, 1991, J VIROL, V65, P1236, DOI 10.1128/JVI.65.3.1236-1244.1991; DYSON N, 1992, CANCER SURV, V12, P161; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EGAN C, 1989, ONCOGENE, V4, P383; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FERGUSON B, 1985, MOL CELL BIOL, V5, P2653, DOI 10.1128/MCB.5.10.2653; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; FRISCH SM, 1990, ONCOGENE, V5, P75; GARBISA S, 1987, CANCER RES, V47, P1523; GILLES AM, 1991, J BIOL CHEM, V266, P8784; GOODING LR, 1991, J VIROL, V65, P4114, DOI 10.1128/JVI.65.8.4114-4123.1991; GOODING LR, 1988, CELL, V53, P341, DOI 10.1016/0092-8674(88)90154-7; GOPALAKRISHNAN S, 1995, CELL GROWTH DIFFER, V6, P985; GRAHAM FL, 1984, ADENOVIRUSES, P339; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUTCH MJ, 1991, P NATL ACAD SCI USA, V88, P7913, DOI 10.1073/pnas.88.18.7913; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x; HEASLEY LE, 1991, CELL REGUL, V2, P479, DOI 10.1091/mbc.2.6.479; HENNIG G, 1995, ONCOGENE, V11, P475; HOFMANN M, 1993, CANCER RES, V53, P1516; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUGHES PD, 1989, J IMMUNOL, V143, P4193; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; JONES NC, 1992, MALIGNANT TRANSFORMA, P87; KALMAN D, 1993, MOL BIOL CELL, V4, P353, DOI 10.1091/mbc.4.4.353; KALVAKOLANU DVR, 1991, P NATL ACAD SCI USA, V88, P7459, DOI 10.1073/pnas.88.17.7459; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAST WM, 1989, CELL, V59, P603, DOI 10.1016/0092-8674(89)90006-8; KIMELMAN D, 1985, J VIROL, V53, P399, DOI 10.1128/JVI.53.2.399-409.1985; Krantz CK, 1996, VIROLOGY, V217, P23, DOI 10.1006/viro.1996.0089; KUPPUSWAMY M, 1988, ONCOGENE, V2, P567; KUPPUSWAMY MN, 1987, VIROLOGY, V159, P31, DOI 10.1016/0042-6822(87)90344-8; LASTER SM, 1988, J IMMUNOL, V141, P2629; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LINDER S, 1992, ONCOGENE, V7, P439; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MAGUIRE K, 1991, ONCOGENE, V6, P1417; MARUYAMA K, 1987, ONCOGENE, V1, P361; MAYOL X, 1993, ONCOGENE, V8, P2561; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; MORAN E, 1986, J VIROL, V57, P765, DOI 10.1128/JVI.57.3.765-775.1986; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MYMRYK JS, 1994, ONCOGENE, V9, P1187; MYMRYK JS, 1992, MOL BIOL CELL, V3, P1107, DOI 10.1091/mbc.3.10.1107; NELSON CC, 1990, P NATL ACAD SCI USA, V87, P8041, DOI 10.1073/pnas.87.20.8041; NERLOV C, 1991, ONCOGENE, V6, P1583; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PEREIRA DS, 1995, VIROLOGY, V211, P268, DOI 10.1006/viro.1995.1400; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; POZZATTI R, 1988, MOL CELL BIOL, V8, P2984, DOI 10.1128/MCB.8.7.2984; PRIETO RS, 1995, ONCOGENE, V11, P675; PRIETO RS, 1995, INT J CANCER, V60, P235; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; ROUTES JM, 1991, J VIROL, V65, P1450, DOI 10.1128/JVI.65.3.1450-1457.1991; Routes JM, 1996, J IMMUNOL, V156, P1055; ROUTES JM, 1993, J IMMUNOL, V150, P4315; SANTORO M, 1994, EXP CELL RES, V213, P398, DOI 10.1006/excr.1994.1215; SAWADA Y, 1994, INT J CANCER, V57, P598, DOI 10.1002/ijc.2910570426; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SCHEIDER JF, 1987, EMBO J, V6, P2053; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHEIL JM, 1984, J IMMUNOL, V132, P1578; SHENK T, 1991, ADV CANCER RES, V57, P47; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; SLACK RS, 1995, ONCOGENE, V10, P19; Somasundaram K, 1996, P NATL ACAD SCI USA, V93, P3088, DOI 10.1073/pnas.93.7.3088; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; SUBRAMANIAN T, 1991, ONCOGENE, V6, P1171; SUBRAMANIAN T, 1989, ONCOGENE, V4, P415; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; SVENSSON C, 1991, VIROLOGY, V182, P553, DOI 10.1016/0042-6822(91)90596-4; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TEODORO JG, 1995, ONCOGENE, V11, P467; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUJI Y, 1993, J IMMUNOL, V150, P1897; URBANELLI D, 1989, VIROLOGY, V173, P607, DOI 10.1016/0042-6822(89)90572-2; VANDAM H, 1989, ONCOGENE, V4, P1207; VANORMONDT H, 1980, GENE, V12, P63, DOI 10.1016/0378-1119(80)90016-5; VELCICH A, 1988, MOL CELL BIOL, V8, P2177, DOI 10.1128/MCB.8.5.2177; VELCICH A, 1989, ONCOGENE, V4, P707; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; WEIGEL RJ, 1990, NUCLEIC ACIDS RES, V18, P6107, DOI 10.1093/nar/18.20.6107; WEIGEL RJ, 1990, P NATL ACAD SCI USA, V87, P9878, DOI 10.1073/pnas.87.24.9878; WHITE E, 1993, P SOC EXP BIOL MED, V204, P30; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YOUNG KS, 1989, MOL CELL BIOL, V9, P3109, DOI 10.1128/MCB.9.7.3109; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1994, CELL GROWTH DIFFER, V5, P431; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1995, ONCOGENE, V11, P1383; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	153	93	97	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1581	1589						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895502				2022-12-28	WOS:A1996VM88700001
J	Obata, M; Nishimori, H; Ogawa, K; Lee, GH				Obata, M; Nishimori, H; Ogawa, K; Lee, GH			Identification of the Par2 (Pulmonary adenoma resistance) locus on mouse chromosome 18, a major genetic determinant for lung carcinogen resistance in BALB/cByJ mice	ONCOGENE			English	Article						lung tumor; resistance gene; urethane; mouse	K-RAS ONCOGENE; TUMOR SUSCEPTIBILITY; INTESTINAL NEOPLASIA; COLORECTAL CANCERS; ACTIVATION; MAP; PROTOONCOGENE; MUTATIONS; MODIFIER; LOSSES	The A/J mouse strain is 14 times more susceptible to urethane-induction of lung carcinogenesis than the BALB/cByJ strain (BALE). The relative resistance of BALE is dominant over the high sensitivity of A/J, since (BALBxA/J)F-1 mice are phenotypically similar to the parental BALE mice. BALE mice must thus possess modifier genes suppressing phenotypic expression of the Pas (Pulmonary adenoma susceptibility) genes, which are known to be dominant genetic determinants for lung carcinogenesis in A/J mice. In order to genetically dissect the dominant resistance of the BALB mouse, we performed a linkage analysis to chromosomally map modifier genes by using 130 (A/JxBALB)F(1)xA/J backcross mice. Each backcross mouse was injected i.p. with urethane (1 mg/g bw) at 6 weeks of age and lung tumors were enumerated after 120 days. When the backcross mice were genotyped at multiple simple sequence repeat marker loci distributed on all the chromosomes, a significant linkage between the presence of a BALE allele and resistance to lung tumor induction was found on distal chromosome 18 (maximum LOD = 12.2). Thus, distal chromosome 18 of the BALE mouse contains a modifier gene for lung carcinogenesis: The locus, designated Par2 (Pulmonary adenoma resistance), accounted for 38% of the phenotypic variance in the backcross population, indicating a major role in protection against lung tumor development.	ASAHIKAWA MED COLL,DEPT PATHOL,ASAHIKAWA,HOKKAIDO 078,JAPAN	Asahikawa Medical College								ATCHLEY WR, 1991, SCIENCE, V254, P554, DOI 10.1126/science.1948030; BELINSKY SA, 1989, CANCER RES, V49, P5305; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIETRICH W, 1992, GENETICS, V131, P423; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DRAGANI TA, 1991, CANCER RES, V51, P6299; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; FIJNEMAN RJA, 1994, ONCOGENE, V9, P1417; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HEGI ME, 1994, CANCER RES, V54, P6257; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JOHNSON KR, 1994, MAMM GENOME, V5, pS259; JUSTICE MJ, 1992, GENOMICS, V13, P1281, DOI 10.1016/0888-7543(92)90047-V; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1995, GENETICS, V139, P387; LEE GH, 1995, CARCINOGENESIS, V16, P1993, DOI 10.1093/carcin/16.8.1993; LUONGO C, 1993, GENOMICS, V15, P3, DOI 10.1006/geno.1993.1002; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; MALKINSON AM, 1984, J NATL CANCER I, V73, P925; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; OREFFO VI, 1996, SPEC C AM ASS CANC R, pA34; PITOT HC, 1987, CARCINOGENESIS, V8, P1491, DOI 10.1093/carcin/8.10.1491; RYAN J, 1987, J NATL CANCER I, V79, P1351; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; SUZUKI Y, 1990, ONCOGENE, V5, P1037; WISEMAN RW, 1994, P NATL ACAD SCI USA, V91, P3759, DOI 10.1073/pnas.91.9.3759; Wright S., 1968, EVOLUTION GENETICS P, P373; YAMAMOTO F, 1984, NUCLEIC ACIDS RES, V12, P8873, DOI 10.1093/nar/12.23.8873; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804	41	49	49	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1599	1604						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895504				2022-12-28	WOS:A1996VM88700003
J	Kuroda, H; White, PS; Sulman, EP; Manohar, CF; Reiter, JL; Cohn, SL; Brodeur, GM				Kuroda, H; White, PS; Sulman, EP; Manohar, CF; Reiter, JL; Cohn, SL; Brodeur, GM			Physical mapping of the DDX1 gene to 340 kb 5' of MYCN	ONCOGENE			English	Article						DDX1; DEAD box protein; MYCN; neuroblastoma; amplification	DEAD BOX PROTEIN; N-MYC; HUMAN NEUROBLASTOMAS; CELL-LINES; AMPLIFICATION; EXPRESSION; DNA; COAMPLIFICATION; ASSOCIATION; HOMOLOGY	One of the most important prognostic factors in neuroblastoma is amplification of the MYCN gene, which is strongly associated with advanced stages of disease and a poor prognosis. Although the MYCN amplicon sometimes spans more than 1 Mb, no other consistently expressed sequences from the MYCN amplicon have been reported. However, DDX1, a gene encoding a DEAD box protein, was recently mapped to chromosome 2p24 and is frequently co-amplified with MYCN. Therefore, we performed genomic mapping with YACs to determine the physical relationship between DDX1 and MYCN, and whether DDX1 was contained within the core region of amplification, Based on YAC restriction mapping and content analysis, DDX1 maps 340 kb 5' of MYCN, outside the core domain of consistent amplification. Interestingly, we also determined by sequence analysis and detailed restriction mapping that G21, previously isolated as a 'neuroblastoma-specific' cDNA clone from an MYCN amplicon, is a partial cDNA of DDX1. Our data confirm that DDX1 is amplified in some but not all MYCN-amplified tumors, and that it is rearranged in other cases. This suggests that the co-amplification of DDX1 is due to its proximity to MYCN.	CHILDRENS HOSP PHILADELPHIA, DIV ONCOL, PHILADELPHIA, PA 19104 USA; NORTHWESTERN UNIV, DEPT PEDIAT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, ROBERT H LURIE CANC CTR, CHICAGO, IL 60611 USA; MAYO CLIN, DEPT BIOCHEM & MOL BIOL, ROCHESTER, MN USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Mayo Clinic			Reiter, Jill/AGZ-7331-2022; Cohn, Susan/AAB-6010-2021; Reiter, Jill L/J-3335-2013	Reiter, Jill/0000-0001-5460-2355; Reiter, Jill L/0000-0001-5460-2355; Sulman, Erik/0000-0003-4933-9120; Cohn, Susan/0000-0001-5749-7650	NATIONAL CANCER INSTITUTE [R01CA039771] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA K, 1991, NUCLEIC ACIDS RES, V19, P6887, DOI 10.1093/nar/19.24.6887; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; Amler LC, 1996, GENE CHROMOSOME CANC, V15, P134, DOI 10.1002/(SICI)1098-2264(199602)15:2<134::AID-GCC9>3.0.CO;2-4; BRODEUR GM, 1994, SEMIN DIAGN PATHOL, V11, P118; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; George RE, 1996, ONCOGENE, V12, P1583; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; GODBOUT R, 1994, GENE, V138, P243, DOI 10.1016/0378-1119(94)90816-8; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; MANOHAR CF, 1995, GENE CHROMOSOME CANC, V14, P196, DOI 10.1002/gcc.2870140307; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; Noguchi T, 1996, GENE CHROMOSOME CANC, V15, P129, DOI 10.1002/(SICI)1098-2264(199602)15:2<129::AID-GCC8>3.3.CO;2-M; Reiter JL, 1996, GENOMICS, V32, P97, DOI 10.1006/geno.1996.0081; REITER JL, 1996, UNPUB GENOMICS; Reynolds C P, 1988, Prog Clin Biol Res, V271, P291; Sambrook J., MOL CLONING LAB MANU; SCHNEIDER SS, 1992, MOL CELL BIOL, V12, P5563, DOI 10.1128/MCB.12.12.5563; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SQUIRE JA, 1995, ONCOGENE, V10, P1417	26	17	17	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1561	1565						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875996				2022-12-28	WOS:A1996VL38400023
J	Gunning, KB; Cohn, SL; Tomlinson, GE; Strong, LC; Huff, V				Gunning, KB; Cohn, SL; Tomlinson, GE; Strong, LC; Huff, V			Analysis of possible abnormal WT1 RNA processing in primary Wilms tumors	ONCOGENE			English	Article						WT1; RNA; editing; aberrant splicing; Wilms tumor	GENE; EXPRESSION; DELETION; MUTATIONS; CELLS	WT1 RNA processing abnormalities have been suggested to play a role in the development of Wilms tumor by reports of editing at codon 280 in the rat WT1 transcript (codon 281 in humans) and aberrant splicing of exon 2 in WT1 transcripts from Wilms tumor xenograft cell lines, Both events result in a functionally changed WT1 protein and are potential mechanisms of altering normal protein function in the absence of WT1 DNA mutations, To determine whether either of these RNA processing events occurs in primary Wilms tumors, we analysed WT1 mRNA from 15 primary tumors, There was no evidence of WT1 RNA editing at codon 281, and only one primary tumor displayed aberrant splicing of exon 2, Sequence and Southern analysis of DNA from this tumor did not reveal any alteration in or around exon 2, These results suggest that neither RNA editing at codon 281 nor abberant exon 2 splicing is a frequent mechanism of WT1 alteration during tumorigenesis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPT PEDIAT,HOUSTON,TX 77030; NORTHWESTERN UNIV,SCH MED,DEPT PEDIAT,CHICAGO,IL 60611; CHILDRENS MEM HOSP,CHICAGO,IL 60614; UNIV TEXAS,SW MED SCH,DEPT PEDIAT HEMATOL ONCOL & FAMILY GENET,DALLAS,TX	University of Texas System; UTMD Anderson Cancer Center; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650	NATIONAL CANCER INSTITUTE [P01CA034936, U01CA060114] Funding Source: NIH RePORTER; NCI NIH HHS [CA34936, CA60114] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BROWN KW, 1993, GENE CHROMOSOME CANC, V8, P74, DOI 10.1002/gcc.2870080203; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HUFF V, 1991, AM J HUM GENET, V48, P997; HUFF V, 1990, HUM GENET, V84, P253; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; NICHOLS KE, 1995, CANCER RES, V55, P4540; SHARMA PM, 1994, GENE DEV, V8, P720, DOI 10.1101/gad.8.6.720; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; ZUPPAN CW, 1988, HUM PATHOL, V19, P1199, DOI 10.1016/S0046-8177(88)80152-7	17	9	10	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1179	1185						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808692				2022-12-28	WOS:A1996VJ20200009
J	Li, HM; Lahti, JM; Kidd, VJ				Li, HM; Lahti, JM; Kidd, VJ			Alternatively spliced cyclin C mRNA is widely expressed, cell cycle regulated, and encodes a truncated cyclin box	ONCOGENE			English	Article						cyclin C; alternative splicing; cell cycle	ACUTE LYMPHOBLASTIC-LEUKEMIA; RNA-POLYMERASE-II; PROTEIN-KINASE; CLN FUNCTION; GENE; CHILDHOOD; YEAST; IDENTIFICATION; ARREST	The cyclin C protein has recently been shown to associate with a unique cyclin dependent protein kinase (cdk8) and it has been proposed that this complex may regulate RNA transcription during the cell cycle. In addition, the human cyclin C gene has been localized to human chromosome 6q21 and it was found to be frequently deleted in a subset of acute lymphoblastic leukemias (ALL's). Screening of an avian T-cell cDNA library resulted in the isolation of a cyclin C homologue as well as an abundant, yet distinct, cyclin C-related cDNA. The predicted open reading frame (ORF) of the cyclin C cDNA predicted a 283 amino acid protein that was >99% identical to the human protein and 72% identical to the Drosophila melanogaster protein. However, the predicted ORF of the cyclin C-related cDNA predicted a much smaller 105 amino acid protein that was identical to cyclin C well into the cyclin-box region (amino acid residue 98), where it abruptly diverges and then terminates. Using PCR analysis of cDNA derived from a range of cell lines and tissues, alternative splicing of the avian cyclin C gene has been demonstrated. Furthermore, a smaller similar to 19 kDa protein that co-migrates with the in vitro transcribed and translated truncated cyclin C protein was detected in normal and virally-transformed avian cells with a cyclin C-specific antibody, Expression of alternatively spliced cyclin C mRNA and protein is regulated in a cell cycle-dependent manner reminiscent of cyclin B2. The function of this truncated cyclin C protein is not known, but its expression in avian cells suggest that this truncated cyclin C protein may participate as an early endogenously encoded cyclin C inhibitor.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital					NATIONAL CANCER INSTITUTE [P30CA021765, R01CA067938] Funding Source: NIH RePORTER; NCI NIH HHS [CA 67938, CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; BETTICHER DC, 1995, ONCOGENE, V11, P1005; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUNNELL BA, 1990, P NATL ACAD SCI USA, V87, P7467, DOI 10.1073/pnas.87.19.7467; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DEMETRICK DJ, 1995, CYTOGENET CELL GENET, V69, P190, DOI 10.1159/000133960; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; EIPERS PG, 1992, GENOMICS, V13, P613, DOI 10.1016/0888-7543(92)90132-C; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; KEYOMARSI K, 1995, ONCOGENE, V15, P2612; KIDD VJ, 1991, CELL GROWTH DIFFER, V2, P85; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KOWALCZYK JR, 1985, CANCER GENET CYTOGEN, V15, P47, DOI 10.1016/0165-4608(85)90130-X; LAHTI JM, 1994, NAT GENET, V7, P370, DOI 10.1038/ng0794-370; LAHTI JM, 1991, P NATL ACAD SCI USA, V88, P10595; LAHUE EE, 1991, GENE DEV, V5, P2166, DOI 10.1101/gad.5.12a.2166; Leclerc V, 1996, MOL BIOL CELL, V7, P505, DOI 10.1091/mbc.7.4.505; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; Li HM, 1996, GENOMICS, V32, P253, DOI 10.1006/geno.1996.0112; LI HM, 1995, GENE, V153, P237, DOI 10.1016/0378-1119(94)00801-X; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; ONEILL EM, 1995, NATURE, V374, P121, DOI 10.1038/374121a0; PIETENPOL JA, 1995, CANCER RES, V55, P1206; PRIGOGINA EL, 1988, CANCER GENET CYTOGEN, V32, P183, DOI 10.1016/0165-4608(88)90281-6; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; XIANG JL, 1994, J BIOL CHEM, V269, P15786	29	17	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					705	712						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761291				2022-12-28	WOS:A1996VD43300005
J	Loughran, O; Malliri, A; Owens, D; Gallimore, PH; Stanley, MA; Ozanne, B; Frame, MC; Parkinson, EK				Loughran, O; Malliri, A; Owens, D; Gallimore, PH; Stanley, MA; Ozanne, B; Frame, MC; Parkinson, EK			Association of CDKN2A/p16(INK4A) with human head and neck keratinocyte replicative senescence: Relationship of dysfunction to immortality and neoplasia	ONCOGENE			English	Article						CDKN2; p16; immortality; keratinocyte; senescence; SCC	SQUAMOUS-CELL CARCINOMA; HUMAN-DIPLOID FIBROBLASTS; PRIMARY TUMORS; GENE-PRODUCT; TELOMERASE ACTIVITY; CYCLE INHIBITION; P16/CDKN2 GENE; LUNG-CANCER; LINES; EXPRESSION	We have previously suggested that a gene mapping to chromosome 9p21 could contribute to replicative senescence and suppress cullular immortality in squamous neoplasia. Two candidate genes, the cyclin D-1/cyclin-dependent kinase inhibitors CDKN2A/p16(INK4A) (p16) and CDKN2B/p15(INK4B) (p15) have now been identified in this region and we show here that p16 is upregulated when normal human keratinocytes undergo replicative senescence but not when they undergo differentiation. Furthermore, all of 19 immortal neoplastic keratinocyte head and neck lines, including nine showing loss of heterozygosity (LOH) at 9p21, showed undetectable p16 expression, whereas five of six senescent neoplastic cultures showed normal levels of expression. The retinoblastoma protein (pRb) appeared functional in all the cell lines and cultures examined. The mechanism of p16 inactivation appeared to be transcriptional silencing in 10 of 18 lines and homozygous deletions in the rest. Treatment of two of the immortal cell lines which had transcriptionally silent wild type p16 genes with 5aza-2deoxycytidine resulted in the re-expression of p16, thus implicating DNA methylation as one mechanism of transcriptional silencing in the immortal SCC-HN lines. We observed no cases of p16 point mutation. In contrast, the p15 gene was rarely transcriptionally silent and was not deleted in any of the cell lines which showed p16 deletions. Our results show that p16 dysfunction correlates strongly with keratinocyte immortalisation but less strongly with the stage of tumour progression. P16 dysfunction was not related to the neoplastic state or the length of time spent in vitro. The results also suggest that p16 but not p15 is involved in the keratinocyte replicative senescence programme. However, two neoplastic cell cultures which lacked p16 expression were still mortal, suggesting that the loss of p16 is a necessary but insufficient condition for human keratinocyte immortality.	BEATSON INST CANC RES,CRC BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND; UNIV BIRMINGHAM,SCH MED,CRC INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,CAMBRIDGE CB2 1QP,ENGLAND	Beatson Institute; University of Birmingham; University of Cambridge								ARAP W, 1995, CANCER RES, V55, P1351; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BERRY IJ, 1994, MOL CARCINOGEN, V9, P134, DOI 10.1002/mc.2940090305; BROWN KW, 1987, BRIT J CANCER, V56, P545, DOI 10.1038/bjc.1987.240; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; BURNS JE, 1994, BRIT J CANCER, V70, P591, DOI 10.1038/bjc.1994.356; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; CHANG SE, 1992, INT J CANCER, V52, P896, DOI 10.1002/ijc.2910520612; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; EDINGTON KG, 1995, MOL CARCINOGEN, V13, P254, DOI 10.1002/mc.2940130408; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KAUFMANN WF, 1995, CANCER RES, V55, P493; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LI Y, 1994, CANCER RES, V54, P6078; LOIS AF, 1995, CANCER RES, V55, P4010; LOUGHRAN O, 1994, CANCER RES, V54, P5045; LOUGHRAN O, 1996, UNPUB; LUCIBELLO FC, 1993, J CELL SCI, V105, P123; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; LYDIATT WM, 1995, GENE CHROMOSOME CANC, V13, P94, DOI 10.1002/gcc.2870130204; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NAGAGAWA K, 1995, ONCOGENE, V11, P1843; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OKAMOTO A, 1995, CANCER RES, V55, P1448; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OTTERSON GA, 1994, ONCOGENE, V9, P3375; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; QUELLE DE, 1995, CELL, V83, P993; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RHEINWALD JG, 1980, CELL, V22, P629, DOI 10.1016/0092-8674(80)90373-6; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; VANDERRIET P, 1994, CANCER RES, V54, P1156; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WILKE MS, 1988, LAB INVEST, V58, P660; WILLE JJ, 1984, J CELL PHYSIOL, V121, P31, DOI 10.1002/jcp.1041210106; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YEAGER T, 1995, CANCER RES, V55, P493; YEUDALL WA, 1994, CARCINOGENESIS, V15, P2683, DOI 10.1093/carcin/15.12.2683; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; ZHANG SY, 1994, CANCER RES, V54, P5050	59	127	127	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					561	568						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760298				2022-12-28	WOS:A1996VB32800013
J	Tarunina, M; Grimaldi, M; Ruaro, E; Pavlenko, M; Schneider, C; Jenkins, JR				Tarunina, M; Grimaldi, M; Ruaro, E; Pavlenko, M; Schneider, C; Jenkins, JR			Selective loss of endogenous p21(waf1/cip1) induction underlies the G(1) checkpoint defect of monomeric p53 proteins	ONCOGENE			English	Article						p53; oligomerisation; G(1) checkpoint; p21(waf1/cip1); induction; apoptosis	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL NUCLEAR ANTIGEN; DNA-BINDING DOMAIN; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; TRANS-ACTIVATION; GENE; APOPTOSIS; TRANSFORMATION	Wild-type p53 protein displays a spectrum of activities including the ability to suppress transformed cell growth, to direct apoptotic cell death and to mediate G(1) checkpoint in response to cellular DNA damage. Earlier work showed that a self-association defective p53 protein retained transformation suppressor activity in rat embryo fibroblast based assays, but that monomerisation of tumour mutant p53 proteins resulted in loss of dominant transforming activity. In order to acquire a more detailed understanding of the biological consequences attendant on disruption of p53:p53 association we have carried out a study of the wild-type-like activities that are retained by monomeric p53 proteins and which are associated with the suppression of transformation. Here we show that monomeric p53 proteins are G(1) checkpoint defective. Although able to stimulate transcription via a p53 DNA binding motif from the p21(waf1/cip1) gene promoter in episome based assays these p53 proteins are unable to transactivate the chromosomal p21(waf1/cip1) gene and are sensitive both to degeneracy of consensus binding site and to half site spacing. Monomeric p53 proteins fail to trigger apoptosis in a BRK cell line transformed with E7 and ras. However, they retain wild type transformation suppressor activity in BRK cell based transformation assays. Our results indicate that p21(waf1/cip1) induction and all related p53 dependent G(1) checkpoint activities are dispensable for the p53 directed suppression of transformed cell growth, and that such transformation suppression by monomeric p53 proteins may occur in the absence of an apoptotic response.	MARIE CURIE RES INST,CELL PROLIFERAT LAB,OXTED RH8 0TL,SURREY,ENGLAND; LAB NAZL CONSORZIO INTERUNIV BIOTECNOL,I-34012 TRIESTE,ITALY; RUSSIAN ACAD SCI,INST CYTOL,ST PETERSBURG 194064,RUSSIA	Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS								BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HIRANO Y, 1995, ONCOGENE, V10, P1879; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KENT RB, 1987, SCIENCE, V237, P901, DOI 10.1126/science.3039660; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LI YJ, 1995, ONCOGENE, V10, P599; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MIYASHITA T, 1995, CELL, V80, P293; MURTHY SCS, 1985, P NATL ACAD SCI USA, V82, P2230, DOI 10.1073/pnas.82.8.2230; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PELLEGATA NS, 1995, ONCOGENE, V11, P337; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sambrook J., 2002, MOL CLONING LAB MANU; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEIKH MS, 1995, ONCOGENE, V11, P1899; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TARUNINA M, 1993, ONCOGENE, V8, P3165; TARUNINA M, 1993, CHALL MOD MED, V1, P221; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YonishRouach E, 1995, ONCOGENE, V11, P2197; YOUDALE T, 1975, J CELL PHYSIOL, V86, P495, DOI 10.1002/jcp.1040860306; ZAKUT R, 1995, ONCOGENE, V11, P393; ZHANG W, 1994, ONCOGENE, V9, P2513	68	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					589	598						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760300				2022-12-28	WOS:A1996VB32800016
J	Niikura, M; Dornadula, G; Zhang, H; Mukhtar, M; Duan, LX; Khalili, K; Bagasra, O; Pomerantz, RJ				Niikura, M; Dornadula, G; Zhang, H; Mukhtar, M; Duan, LX; Khalili, K; Bagasra, O; Pomerantz, RJ			Mechanisms of transcriptional transactivation and restriction of human immunodeficiency virus type I replication in an astrocytic glial cell	ONCOGENE			English	Article						HIV-1; astrocytes; glia; transcription; tat	IMMUNE-DEFICIENCY SYNDROME; LONG TERMINAL REPEAT; HIV-1 TAT PROTEIN; CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; RNA-BINDING PROTEIN; TRANS-ACTIVATION; HUMAN-BRAIN; INDEPENDENT ACTIVATION; GENE-EXPRESSION	Unique transcriptional transactivation by the human immunodeficiency virus type 1 (HIV-1) Tat protein of long terminal repeat (LTR)-driven RNA expression, in the absence of the transactivator responsive element (TAR), was previously demonstrated in central nervous system (CNS)-derived astrocytic cell-lines, including U87MG. In the present study, RNase protection assays were utilized to reveal the molecular mechanism(s) underlying transactivation of the HIV-1-LTR in these cells. Short transcripts, which represent abortive HIV-1 transcription, could not be detected either in the absence or presence of Tat, and no differences in transcript levels were detected using 5' probes, as compared to 3' probes, in the experiments. Thus, the transactivational effects of Tat, in U87MG cells, were potentially based on the increase of transcriptional initiation, both in TAR-dependent and -independent states. Further, by using newly established stable cellular transformant, containing HIV-1-LTR-reporter gene constructs, TAR-independent transactivation was demonstrated to efficiently function primarily in transiently-transfected U87MG cells. U87MG cells, stably-transfected with the intact HIV-1 proviral genome, produced very low levels of virus after long-term culture, as previously reported in other astrocytic cells. These cells demonstrated profoundly restricted transcription of the HIV-1 genome, with no detectable levels of HIV-1-specific RNA by Northern blotting, indicating that the restriction of viral production in these cells is principally due to the low level of overall transcription from the 5' HIV-1-LTR. Transcription of HIV-1 RNA in this cell could not be significantly up-regulated by various stimulators, such as phorbol 12-myristate 13-acetate (PMA), tumor necrosis factor-alpha (TNF-alpha) and sodium butyrate. These data suggest that the restriction of HIV-1 transcription in these cells may be controlled by different mechanism(s) from those in lymphocytic or monocytic cells.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,DORRANCE H HAMILTON LABS,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOL BIOL,JEFFERSON INST MOL MED,MOL NEUROVIROL SECT,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS030916] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31836] Funding Source: Medline; NINDS NIH HHS [NS30916] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; ALDOVINI A, 1990, TECHNIQUES HIV RES, P147; BAGASRA O, 1992, J VIROL, V66, P7522, DOI 10.1128/JVI.66.12.7522-7528.1992; BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BLUMBERG BM, 1994, VIRUS RES, V32, P253, DOI 10.1016/0168-1702(94)90044-2; BRACKWERNER R, 1992, AIDS, V6, P273, DOI 10.1097/00002030-199203000-00003; CHENGMAYER C, 1987, P NATL ACAD SCI USA, V84, P3526, DOI 10.1073/pnas.84.10.3526; CHIODI F, 1987, J VIROL, V61, P1244, DOI 10.1128/JVI.61.4.1244-1247.1987; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DUAN LX, 1994, VIROLOGY, V199, P474, DOI 10.1006/viro.1994.1148; DUAN LX, 1994, J VIROL, V68, P4302, DOI 10.1128/JVI.68.7.4302-4313.1994; EPSTEIN LG, 1993, ANN NEUROL, V33, P429, DOI 10.1002/ana.410330502; FEINBERG MB, 1991, P NATL ACAD SCI USA, V88, P4045, DOI 10.1073/pnas.88.9.4045; FUNKE I, 1987, J EXP MED, V165, P1230, DOI 10.1084/jem.165.4.1230; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; HARRICH D, 1994, J VIROL, V68, P5899, DOI 10.1128/JVI.68.9.5899-5910.1994; HARRICH D, 1990, EMBO J, V9, P4417, DOI 10.1002/j.1460-2075.1990.tb07892.x; JEANG KT, 1993, J BIOL CHEM, V268, P24940; JEANG KT, 1992, J B IOL CHEM, V25, P17891; Jones KA, 1993, CURR OPIN CELL BIOL, V5, P461, DOI 10.1016/0955-0674(93)90012-F; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KESSLER M, 1991, P NATL ACAD SCI USA, V88, P10018, DOI 10.1073/pnas.88.22.10018; KOVAL V, 1995, J VIROL, V69, P1645, DOI 10.1128/JVI.69.3.1645-1651.1995; LASPIA MF, 1990, GENE DEV, V4, P2397, DOI 10.1101/gad.4.12b.2397; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LAUGHLIN MA, 1993, VIROLOGY, V196, P496, DOI 10.1006/viro.1993.1505; LEE SHC, 1993, AM J PATHOL, V143, P1032; LU XB, 1993, J VIROL, V67, P1752, DOI 10.1128/JVI.67.4.1752-1760.1993; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MERRILL JE, 1991, FASEB J, V5, P2391, DOI 10.1096/fasebj.5.10.2065887; MICHAELS J, 1988, ACTA NEUROPATHOL, V76, P373, DOI 10.1007/BF00686974; MOSES AV, 1993, P NATL ACAD SCI USA, V90, P10474, DOI 10.1073/pnas.90.22.10474; NAHREINI P, 1995, J VIROL, V69, P1296, DOI 10.1128/JVI.69.2.1296-1301.1995; NEUMANN M, 1995, J VIROL, V69, P2159, DOI 10.1128/JVI.69.4.2159-2167.1995; NEWSTEIN M, 1990, J VIROL, V64, P4565, DOI 10.1128/JVI.64.9.4565-4567.1990; NUOVO GJ, 1994, AM J PATHOL, V144, P659; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; PEUDENIER S, 1991, ANN NEUROL, V29, P152, DOI 10.1002/ana.410290207; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; RATNASABAPATHY R, 1990, GENE DEV, V4, P2061, DOI 10.1101/gad.4.12a.2061; RHODES RH, 1993, HUM PATHOL, V24, P1189, DOI 10.1016/0046-8177(93)90215-3; Sambrook J., 2002, MOL CLONING LAB MANU; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SESHAMMA T, 1992, J VIROL METHODS, V40, P331, DOI 10.1016/0166-0934(92)90091-Q; SHAHABUDDIN M, 1992, PATHOBIOLOGY, V60, P195, DOI 10.1159/000163723; SHAW GM, 1984, SCIENCE, V226, P1165, DOI 10.1126/science.6095449; SHELDON M, 1993, MOL CELL BIOL, V13, P1251, DOI 10.1128/MCB.13.2.1251; SONG CZ, 1994, P NATL ACAD SCI USA, V91, P9357, DOI 10.1073/pnas.91.20.9357; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SOUTHGATE C, 1990, NATURE, V345, P640, DOI 10.1038/345640a0; SUNE C, 1995, J VIROL, V69, P3098; SWINGLER S, 1994, BIOCHEM BIOPH RES CO, V203, P623, DOI 10.1006/bbrc.1994.2228; TAYLOR JP, 1992, EMBO J, V11, P3395, DOI 10.1002/j.1460-2075.1992.tb05418.x; TAYLOR JP, 1995, ONCOGENE, V10, P395; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TORNATORE C, 1994, J VIROL, V68, P93, DOI 10.1128/JVI.68.1.93-102.1994; TORNATORE C, 1991, J VIROL, V65, P6094, DOI 10.1128/JVI.65.11.6094-6100.1991; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; ZHANG H, 1993, AIDS RES HUM RETROV, V9, P1287, DOI 10.1089/aid.1993.9.1287; ZHU M, 1996, IN PRESS AIDS RES HU	66	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					313	322						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710370				2022-12-28	WOS:A1996VA25200010
J	Wolthuis, RMF; Bauer, B; vantVeer, LJ; deVriesSmits, AMM; Cool, RH; Spaargaren, M; Wittinghofer, A; Burgering, BMT; Bos, JL				Wolthuis, RMF; Bauer, B; vantVeer, LJ; deVriesSmits, AMM; Cool, RH; Spaargaren, M; Wittinghofer, A; Burgering, BMT; Bos, JL			RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein	ONCOGENE			English	Article						Rlf; Rap 1A; Ras; RalGDS; exchange factor; two-hybrid	NUCLEOTIDE DISSOCIATION STIMULATOR; RAS-P21 GTPASE; R-RAS; KINASE; INTERACTS; DOMAIN; ACTIVATION; RAF-1; IDENTIFICATION; RECOGNITION	The small GTPase Rap 1A is a close relative of Ras that, when overexpressed, is able to revert oncogenic transformation induced by active Ras. We screened a mouse embryonic cDNA library using the yeast two-hybrid system and isolated the cDNA of a novel Rap 1A-interacting protein. The open reading frame encodes for an 84 kDa protein with a Cdc25-homology domain which shares approximately 30% identity with Ral guanine nucleotide dissociation stimulator (RalGDS) and RalGDS-like (Rg1). The C-terminal region reveals a striking conservation of sequences with the Ras-binding domain of RalGDS. We designated this protein Rlf, for RalGDS-like factor. In the yeast system, Rlf interacts with Rap 1A, H-Ras and R-Ras, but not with Rac and Rho. In addition, we found that Rlf interacts with Rap 1A(Val12) but not with Rap 1A(Asn17). In vitro binding studies revealed that a C-terminally located 91 amino acid region of Rlf is sufficient for direct association with the GTP-bound form of Ras and Rap 1A. The observed dissociation constants are 0.6 mu M and 0.4 mu M, respectively. No significant association with Ras-GDP or Rap 1A-GDP could be detected. These binding characteristics indicate that Rlf is a putative effector for Ras and Rap 1A.	UNIV UTRECHT, PHYSIOL CHEM LAB, NL-3508 TA UTRECHT, NETHERLANDS; MAX PLANCK INST F MOL PHYSIOL, ABT STRUKT BIOL, D-44139 DORTMUND, GERMANY; NETHERLANDS CANC INST, DIV MOLEC PATHOL, NL-1066 CX AMSTERDAM, NETHERLANDS	Utrecht University; Max Planck Society; Netherlands Cancer Institute			Spaargaren, Marcel/AAU-1298-2021	Spaargaren, Marcel/0000-0002-3135-5109; Wolthuis, Rob/0000-0002-3109-1588; Cool, Robbert/0000-0002-9845-2202				ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; CAVENER DR, 1991, NUCLEIC ACIDS RES, V19, P3185, DOI 10.1093/nar/19.12.3185; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HARIHARAN IK, 1991, CELL, V67, P717, DOI 10.1016/0092-8674(91)90066-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; IKEDA M, 1995, FEBS LETT, V375, P37, DOI 10.1016/0014-5793(95)01169-F; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kikuchi A, 1996, J BIOL CHEM, V271, P588, DOI 10.1074/jbc.271.1.588; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEROSEY I, 1991, BIOCHEM BIOPH RES CO, V175, P430, DOI 10.1016/0006-291X(91)91582-W; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LopezBarahona M, 1996, ONCOGENE, V12, P463; MCCABE PC, 1992, MOL CELL BIOL, V12, P4084, DOI 10.1128/MCB.12.9.4084; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; SPAARGAREN M, 1994, BIOCHEM J, V300, P303, DOI 10.1042/bj3000303; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	37	131	133	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					353	362						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710374				2022-12-28	WOS:A1996VA25200014
J	Konishi, H; Ochiya, T; Yasuda, Y; Sakamoto, H; Muto, T; Sugimura, T; Terada, M				Konishi, H; Ochiya, T; Yasuda, Y; Sakamoto, H; Muto, T; Sugimura, T; Terada, M			HST-1/FGF-4 stimulates proliferation of megakaryocyte progenitors synergistically and promotes megakaryocyte maturation	ONCOGENE			English	Article						FGF-4 (fibroblast growth factor 4); adenovirus-mediated gene transfer; megakaryocytopoiesis; maturation; proliferation	C-KIT LIGAND; BINDING GROWTH-FACTOR; HUMAN BONE-MARROW; TRANSFORMING GENE; FGF RECEPTOR; CELL-LINE; K-FGF; EXPRESSION; INVITRO; HST	Megakaryocyte (MK) development is dependent on the complex interaction of MK progenitors, various cytokines and stromal elements, We previously reported that an injection of replication-deficient adenovirus containing HST-1/FGF-4 cDNA (Adex1HST-1) into mice caused a twofold increase in peripheral platelet count for 30 days without any other hematological or histological abnormality, In the present study using Adex1HST-1-infected human megakaryocytic Dami cells, we demonstrated for the first time that HST-1/FGF-4 promoted MK maturation, inducing increases in DNA ploidy, cytoplasmic and membrane maturation, and platelet-like particle release, Moreover, HST-1/FGF-4 acted on megakaryocytic cells to induce secretion of IL-6 and TNF-alpha, and increased adhesion of megakaryocytic cells to human endothelial cells primarily via VLA-4 and LFA-1 molecules; both mechanisms have been shown to lead to MK maturation, We also showed that HST-1/FGF-4 stimulates the proliferation of MK progenitors not alone but synergistically with IL-3 via IL-6 and with c-mpl ligand (thrombopoietin) not via IL-6, This result supports the hypothesis of the presence of two distinct populations of MK progenitors: IL-3-dependent and Tpo-dependent. All these results suggest that HST-1/FGF-4 can regulate MK development not only as an MK potentiating factor, but also as an inducer of cytokine secretion from MK, and as a modulator of adhesive interations with endothelial cells.	NATL CANC CTR, RES INST, DIV GENET, CHUO KU, TOKYO 104, JAPAN; UNIV TOKYO, SCH MED, DEPT SURG 1, BUNKYO KU, TOKYO 113, JAPAN; INST PASTEUR KYOTO, SAKYO KU, KYOTO 606, JAPAN	National Cancer Center - Japan; University of Tokyo			Ochiya, Takahiro/AAH-7585-2019					ADELAIDE J, 1988, ONCOGENE, V2, P413; AVRAHAM H, 1992, BLOOD, V79, P365; AVRAHAM H, 1992, BLOOD, V80, P1679; AVRAHAM H, 1993, J CLIN INVEST, V91, P2378, DOI 10.1172/JCI116470; AVRAHAM H, 1994, BLOOD, V83, P2126; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BIKFALVI A, 1992, BLOOD, V80, P1905; BLAM SB, 1988, ONCOGENE, V3, P129; BOVI PD, 1987, P NATL ACAD SCI USA, V84, P5660, DOI 10.1073/pnas.84.16.5660; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BRANDT JE, 1994, BLOOD, V83, P1507; BRIDDELL RA, 1991, BLOOD, V78, P2854; BROUDY VC, 1995, BLOOD, V85, P1719, DOI 10.1182/blood.V85.7.1719.bloodjournal8571719; BRUNNER G, 1993, BLOOD, V81, P631; BRUNO E, 1993, BLOOD, V82, P430, DOI 10.1182/blood.V82.2.430.bloodjournal822430; BURSTEIN SA, 1992, J CELL PHYSIOL, V153, P305, DOI 10.1002/jcp.1041530210; DEGABRIELE G, 1967, BRIT J HAEMATOL, V13, P202; GONSKY R, 1991, MOL ENDOCRINOL, V5, P1687, DOI 10.1210/mend-5-11-1687; GREENBERG SM, 1988, BLOOD, V72, P1968; GURNEY AL, 1994, SCIENCE, V265, P1445, DOI 10.1126/science.8073287; HOFFMAN R, 1989, BLOOD, V74, P1196; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; JACKSON CW, 1973, BLOOD, V42, P413, DOI 10.1182/blood.V42.3.413.413; KATOH O, 1992, BIOCHEM BIOPH RES CO, V183, P83, DOI 10.1016/0006-291X(92)91612-T; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; KAUSHANSKY K, 1995, P NATL ACAD SCI USA, V92, P3234, DOI 10.1073/pnas.92.8.3234; KISHI T, 1994, BIOCHEM BIOPH RES CO, V202, P1387, DOI 10.1006/bbrc.1994.2084; KONISHI H, 1995, J CLIN INVEST, V96, P1125, DOI 10.1172/JCI118099; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; MIYAGAWA K, 1988, ONCOGENE, V3, P383; NAVARRO S, 1991, BLOOD, V77, P461; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OCHIYA T, 1995, J CELL BIOL, V130, P997, DOI 10.1083/jcb.130.4.997; OGAWA M, 1993, BLOOD, V81, P2844; PAUL CC, 1993, BLOOD, V81, P1193; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; QUARTO N, 1989, ONCOGENE RES, V5, P101; QUESENBERRY PJ, 1991, EXP HEMATOL, V19, P35; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SAKAMOTO H, 1994, P NATL ACAD SCI USA, V91, P12368, DOI 10.1073/pnas.91.26.12368; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TERAMURA M, 1992, BLOOD, V79, P327; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELCICH A, 1989, ONCOGENE RES, V5, P31; WICKENHAUSER C, 1995, BLOOD, V85, P685, DOI 10.1182/blood.V85.3.685.bloodjournal853685; YANAI N, 1994, BLOOD, V83, P2844, DOI 10.1182/blood.V83.10.2844.2844; YOSHIDA MC, 1988, P NATL ACAD SCI USA, V85, P4861, DOI 10.1073/pnas.85.13.4861; YOSHIDA T, 1991, METHOD ENZYMOL, V198, P124; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; YOSHIDA T, 1988, BIOCHEM BIOPH RES CO, V155, P1324, DOI 10.1016/S0006-291X(88)81286-5	54	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					9	19						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700558				2022-12-28	WOS:A1996UX31900002
J	Wang, YS; Okan, I; Pokrovskaja, K; Wiman, KG				Wang, YS; Okan, I; Pokrovskaja, K; Wiman, KG			Abrogation of p53-induced G1 arrest by the HPV 16 E7 protein does not inhibit p53-induced apoptosis	ONCOGENE			English	Article						HPV16 E7; p53-induced G1 arrest; apoptosis	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; ERYTHROLEUKEMIA-CELLS; E6 ONCOPROTEIN; TUMOR-ANTIGEN; LINE; GENE; SUPPRESSION; IRRADIATION; INDUCTION	Wild type (wt) p53 expressed from a temperature-sensitive construct (ts p53) can induce both G1 cell cycle arrest and apoptosis in the p53-negative J3D mouse T lymphoma line (Wang et al., 1995). The human papillomavirus (HPV) 16 E7 protein has been shown to prevent p53-induced G1 cell cycle arrest following DNA damage. We asked whether inhibition of p53-induced G1 arrest by overexpression of the HPV16 E7 protein in the ts p53-transfected J3D cells would interfere with p53-induced apoptosis. Whereas a majority of the ts p53-expressing J3D cells were arrested in the G1 phase 22 h after induction of wt p53 by temperature shift to 32 degrees C, the E7/ts p53-expressing cells showed only a minor increase in the number of cells in G1 at this time point. In addition, the E7/ts p53-expressing cells showed a much less dramatic reduction in number of cells in S phase than the ts p53-expressing cells. This demonstrates that E7 at least partially rescues the cells from p53-induced G1 arrest. In contrast, overexpression of HPV16 E7 did not have any effect on the kinetics nor the frequency of p53-triggered apoptotic death, as shown by PACS analysis, trypan blue exclusion, and DNA fragmentation analysis. These findings support the notion that p53-induced G1 arrest and p53-induced apoptosis are two separate independent pathways.			Wang, YS (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN.		Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Pokrovskaja Tamm, Katja/0000-0001-6359-1256				CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRITSCHE M, 1993, ONCOGENE, V8, P307; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAMQVIST T, 1993, ONCOGENE, V8, P1495; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; Sambrook J., 2002, MOL CLONING LAB MANU; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELIVANOVA G, 1995, ADV CANCER RES, V66, P143, DOI 10.1016/S0065-230X(08)60253-5; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WANG YS, 1995, CELL GROWTH DIFFER, V6, P1071; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	47	15	15	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2731	2735						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700534				2022-12-28	WOS:A1996UW48700029
J	Bringuier, PP; Tamimi, Y; Schuuring, E; Schalken, J				Bringuier, PP; Tamimi, Y; Schuuring, E; Schalken, J			Expression of cyclin D1 and EMS1 in bladder tumours; Relationship with chromosome 11q13 amplification	ONCOGENE			English	Article						contactin; cyclin D1; EMS1; amplification; bladder tumor	HUMAN CARCINOMAS; GENES; IDENTIFICATION; SUBSTRATE; OVEREXPRESSION; CANCER; ONCOGENE; TUMORS; INT-2; HST	11q13 amplifications have been found in several cancers, including bladder tumours,However, the biological significance of this genetic alteration is not yet fully understood, To get more insight into the role of 11q13 amplification in bladder tumour development, we have studied the level of amplification and expression of 4 (protoonco)genes lying within the amplicon: cyclin D1, FGF3, FGF4 and EMS1 DNA amplification was found in 5/46 tumours, There was no correlation between amplification and clinico-pathological data. No expression of FGF3 and FGF4 was detected whereas both cyclin D1 and EMS1 were expressed at higher level in tumours with amplifications, Thus cyclin D1 and EMS1, but not FGF3 and FGF4, are likely to play a pathogenic role in the 11q13 amplification in bladder cancer, However, amplification is not the unique way of activation of these genes, Indeed, in situ hybridisation and Northern blot analysis have shown that most bladder tumours have a fair to high expression of cyclin D1 and EMS1 in contrast to normal urothelium with a moderate expression, Interestingly, a trend towards higher expression occurs in superficial versus invasive tumours (8.8+/-2.0 versus 1.9+/-0.4; P approximate to 13% for cyclin D1 and 4.5 +/- 1.4 versus 2.0 +/- 0.4; P approximate to 8% for EMS1), Moreover, the 9 tumours with low expression are all highly malignant, leading to the hypothesis that the tumours developing through a cyclin D1/EMS1 independent pathway are more aggressive.	UNIV LEIDEN HOSP, DEPT PATHOL, 2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	Bringuier, PP (corresponding author), UNIV NIJMEGEN HOSP, UROL RES LAB, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.		Schalken, Jack A/B-1277-2014	Schalken, Jack A/0000-0001-8274-7797				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARTKOVA J, 1994, INT J CANCER, V58, P568, DOI 10.1002/ijc.2910580420; BIANCHI AB, 1993, ONCOGENE, V8, P1127; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COOMBS LM, 1991, BRIT J CANCER, V63, P601, DOI 10.1038/bjc.1991.139; DETAISNE C, 1984, NATURE, V310, P581, DOI 10.1038/310581a0; GILLETT C, 1994, CANCER RES, V54, P1812; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JARES P, 1994, CANCER RES, V54, P4813; JIANG W, 1993, P NATL ACAD SCI USA, V90, P9026, DOI 10.1073/pnas.90.19.9026; JIANG W, 1993, ONCOGENE, V8, P3447; KANDA Y, 1994, INT J CANCER, V58, P291, DOI 10.1002/ijc.2910580224; KNOWLES MA, 1994, CANCER RES, V54, P531; LOVEC H, 1994, ONCOGENE, V9, P323; MAA MC, 1992, ONCOGENE, V7, P2429; MANSOURI A, 1988, DIFFERENTIATION, V38, P67, DOI 10.1111/j.1432-0436.1988.tb00593.x; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mostofi FK, 1973, INT HISTOLOGICAL CLA; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; NISHIDA N, 1994, CANCER RES, V54, P3107; PETERS G, 1994, J CELL SCI, P89; PROCTOR AJ, 1991, ONCOGENE, V6, P789; SCHAUER IE, 1994, P NATL ACAD SCI USA, V91, P7827, DOI 10.1073/pnas.91.16.7827; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, ONCOGENE, V7, P355; TAIRA M, 1987, P NATL ACAD SCI USA, V84, P2980, DOI 10.1073/pnas.84.9.2980; TAMIMI Y, 1993, CANCER RES, V53, P5512; THEILLET C, 1989, ONCOGENE, V4, P915; TSURUTA H, 1993, BIOCHEM BIOPH RES CO, V196, P1529, DOI 10.1006/bbrc.1993.2425; TSUTSUMI M, 1988, JPN J CANCER RES, V79, P428, DOI 10.1111/j.1349-7006.1988.tb01609.x; *UICC, 1992, TNM CLASS INT UN CAN; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	36	126	127	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	1996	12	8					1747	1753						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622895				2022-12-28	WOS:A1996UG45800017
J	Enders, GH; Koh, J; Missero, C; Rustgi, AK; Harlow, E				Enders, GH; Koh, J; Missero, C; Rustgi, AK; Harlow, E			p16 inhibition of transformed and primary squamous epithelial cells	ONCOGENE			English	Article						p16; esophageal squamous cell carcinoma; retinoblastoma protein; squamous epithelial	RETINOBLASTOMA PROTEIN; CYCLE CONTROL; PHOSPHORYLATION; DIFFERENTIATION; MOUSE; GENE	We and others have recently shown that p16 can potently and specifically inhibit progression through the G1 phase of the replicative cycle in cells that express the retinoblastoma protein (pRB). However, none of these studies examined cell types in which p16 has been firmly implicated in tumorigenesis. We predicted that such cells would show sensitivity to p16 inhibition, perhaps conferred by proteins in addition to or other than pRB. Intragenic, inactivating mutations of p16 have been found at significant frequency in primary tumors derived from squamous epithelial cells of the esophagus (ESCC). We therefore examined p16 function in ESCC lines and in primary squamous epithelial cells cultured from mouse skin. We find that seven of eight ESCC lines tested are inhibited by p16 and fail to express the protein endogenously. The lone p16-resistant line expresses endogenous p16 but lacks functional pRB. Primary squamous epithelial cells are also inhibited by p16. These data suggest that squamous epithelial cells are generally sensitive to inhibition by a regulatory pathway that involves p16 and pRB, and that, by the time of establishment in culture, there is nearly universal inactivation of this pathway in ESCCs.	MASSACHUSETTS GEN HOSP,GASTROINTESTINAL UNIT,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Enders, GH (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129, USA.			Missero, Caterina/0000-0003-0905-5123				ARAP W, 1995, CANCER RES, V55, P1351; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; FILVAROFF E, 1990, MOL CELL BIOL, V10, P1164, DOI 10.1128/MCB.10.3.1164; GRUIS NA, 1995, NAT GENET, V10, P351, DOI 10.1038/ng0795-351; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARLOW E, 1988, ANTIBODIES; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; IGAKI H, 1994, BIOCHEM BIOPH RES CO, V203, P1090, DOI 10.1006/bbrc.1994.2294; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEES JA, 1992, EMBO J, V359, P288; LIU QY, 1995, ONCOGENE, V10, P619; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; MORI T, 1994, CANCER RES, V54, P3396; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1995, CANCER RES, V55, P1448; OTTERSON GA, 1994, ONCOGENE, V9, P3375; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REED JA, 1995, CANCER RES, V55, P2713; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEW JY, 1989, ONCOGENE RES, V4, P205; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; TSAI LH, 1993, ONCOGENE, V8, P1593; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; ZHOU XL, 1994, ONCOGENE, V9, P3737; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	36	43	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1239	1245						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649826				2022-12-28	WOS:A1996UC06700009
J	Laget, MP; Defossez, PA; Albagli, O; Baert, JL; Dewitte, F; Stehelin, D; deLaunoit, Y				Laget, MP; Defossez, PA; Albagli, O; Baert, JL; Dewitte, F; Stehelin, D; deLaunoit, Y			Two functionally distinct domains responsible for transactivation by the Ets family member ERM	ONCOGENE			English	Article						Ets gene; ERM; DNA-binding; transactivation	TRANSCRIPTIONAL ACTIVATION DOMAINS; HOMEODOMAIN-DNA INTERACTIONS; GENE FAMILY; C-FOS; CRYSTAL-STRUCTURE; LEUKEMIA-VIRUS; V-ETS; BINDING; PROTEIN; C-ETS-1	The recently cloned human Ets transcription factor ERM is closely related to the ER81 and PEA3 genes. Here, we report the functional analysis of the DNA-binding and transactivation properties of ERM. Specific DNA-binding by ERM requires the ETS domain, conserved in all members of the Ets family and is inhibited by an 84 residue long central region and the carboxy-terminal tail. Two fragments of ERM are transferrable activation domains: alpha, which sits in the 72 first residues and encompasses the acidic domain conserved between ERM, ER81 and PEA3, and the carboxy-terminal tail which also bears a DNA-binding inhibition function. Deletion of alpha strongly reduces transactivation by ERM. Moreover, alpha and the carboxyterminal tail exhibit functional synergism, suggesting that they activate transcription through different mechanisms. In support of this idea, we demonstrate that VP16 squelches transactivation by alpha but not by the carboxyterminal tail. This result also indicates that alpha and VP16 may share common limiting cofactors. alpha and the carboxy-terminal tail do not seem to be conserved within the whole Ets family, indicating that the specificity of ERM may rely on interactions with distinct cofactors.	INST PASTEUR,CNRS,URA 1160,UNITE ONCOL MOL,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille				Defossez, Pierre-Antoine/0000-0002-6463-9263				ALBAGLI O, 1994, ONCOGENE, V9, P3259; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BHATTACHARYA G, 1993, ONCOGENE, V8, P3459; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CHEN ZQ, 1992, SCIENCE, V250, P1416; CHUMAKOV AM, 1993, J VIROL, V67, P2421, DOI 10.1128/JVI.67.4.2421-2425.1993; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; Crepieux Pascale, 1993, Gene Expression, V3, P215; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEGNAN BM, 1993, NUCLEIC ACIDS RES, V21, P3479, DOI 10.1093/nar/21.15.3479; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; JANKNECHT R, 1994, ONCOGENE, V9, P1273; JEON IS, 1995, ONCOGENE, V10, P1229; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LIM F, 1992, EMBO J, V11, P643, DOI 10.1002/j.1460-2075.1992.tb05096.x; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; QIAN YQ, 1989, CELL, V59, P573, DOI 10.1016/0092-8674(89)90040-8; RAO VN, 1993, ONCOGENE, V8, P2167; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SIDDIQUE HR, 1993, ONCOGENE, V8, P1751; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WASYLYK C, 1993, NUCLEIC ACIDS RES, V21, P523, DOI 10.1093/nar/21.3.523; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	72	51	51	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1325	1336						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649835				2022-12-28	WOS:A1996UC06700018
J	Mysliwiec, T; Perego, R; Kruh, GD				Mysliwiec, T; Perego, R; Kruh, GD			Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain	ONCOGENE			English	Article						tyrosine kinase; Arg/Abl chimera; transforming activity	MURINE LEUKEMIA-VIRUS; ABL TYROSINE KINASE; CHRONIC MYELOGENOUS LEUKEMIA; ONCOGENIC ACTIVATION; TRANSFORMING ABILITY; GENE-PRODUCT; PROTEIN; BINDING; CELLS; BCR	Arg and c-Abl represent the mammalian member of the Abelson family of nonreceptor protein tyrosine kinases. The two proteins are composed of SH2, SH3, kinase and C-terminal domains, To examine Arg structure-function relationships we analysed a Gag-Arg fusion protein, analogous to the oncogenic Gag-Abl fusion protein of Abelson Murine Leukaemia Virus and found that in contrast to Gag-Abl, it lacked transforming activity, Three observations indicated that the difference in the transforming activity was mediated by the distinct Arg and Abl C-terminal domains, (1) The analysis of chimeric Gag-Arg/Abl molecules revealed that the Arg C-terminal domain completely abrogated Gag-Abl transforming activity and that the Abl C-terminus conferred transforming activity to Gag-Arg, Substitutions of SH2 and kinase domains did not affect activity, (2) Alterations in the Arg C-terminus were observed in spontaneous foci that developed in transfections of two nontransforming chimera. (3) An engineered Gag-Arg molecule containing a truncation of almost the entire C-terminal domain, including three SH3 domain-binding sites, was oncogenic, whereas a slightly smaller truncation that deleted two of three SH3 domain-binding sites, lacked transforming activity, These observations indicate that the C-terminal domain regulates Arg biological activity in a manner distinct from c-Abl and suggest that this effect may be mediated in part by SH3 domain-binding sites.	FOX CHASE CANC CTR,DEPT MED ONCOL,PHILADELPHIA,PA 19111; UNIV MILAN,INST GEN PATHOL,MILAN,ITALY; CNR,CTR RES CELL PATHOL,MILAN,ITALY	Fox Chase Cancer Center; University of Milan; Consiglio Nazionale delle Ricerche (CNR)					NATIONAL CANCER INSTITUTE [R55CA057273, P30CA006927, R01CA057273, F32CA060453] Funding Source: NIH RePORTER; NCI NIH HHS [CA-60453, CA06927, CA-57273] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1994, CURRENT PROTOCOLS MO, V2; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOLEN J, 1993, ONCOGENE, V3, P2025; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON PK, 1993, ONCOGENE, V8, P1943; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUH GD, 1986, SCIENCE, V234, P1545, DOI 10.1126/science.3787260; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LUGO TG, 1990, SCIENCE, V237, P532; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PEREGO R, 1991, ONCOGENE, V6, P1899; PRYWES R, 1983, CELL, V34, P569, DOI 10.1016/0092-8674(83)90389-6; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SRINIVASAN A, 1982, P NATL ACAD SCI-BIOL, V79, P5508, DOI 10.1073/pnas.79.18.5508; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	46	19	19	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					631	640						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637720				2022-12-28	WOS:A1996TV59700020
J	Wu, SJ; Pena, A; Korcz, A; Soprano, DR; Soprano, KJ				Wu, SJ; Pena, A; Korcz, A; Soprano, DR; Soprano, KJ			Overexpression of Mxi1 inhibits the induction of the human ornithine decarboxylase gene by the Myc/Max protein complex	ONCOGENE			English	Article						Mxi1; ODC; c-myc/max; cell growth; cell cycle	C-MYC; MESSENGER-RNA; GROWTH ARREST; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; CELL-TRANSFORMATION; SENSITIVE METHOD; MAMMALIAN-CELLS; MOUSE KIDNEY; EXPRESSION	We have previously shown that the Myc/Max protein complex plays a role in the growth-associated expression of the human ornithine decarboxylase gene. Mxi1 and Mad, novel Max-associated proteins have been identified and shown to form heterodimers with Max which bind efficiently to the Myc/Max consensus recognition sequence, CACGTG, in vitro. However, formation of Max/Mxi1 or Max/Mad heterodimers results in a reduction in Myc/Max dependent transcriptional activation of reporter plasmid constructs containing the consensus element. In light of the evidence that ODC is transcriptionally regulated in vitro and in vivo by the Myc/Max protein complex and the potential role of Mxi1 and Mad as antagonists of Myc transactivation activity, we set out to determine if one of these Max associated proteins, Mxi1, could affect the regulation of ODC expression by Myc/Max and if this regulation was correlated to growth status, Our results show that overexpression of Mxi1 does in fact inhibit ODC gene expression in a dose-dependent manner both in vivo and in vitro. In addition, evidence is presented which shows that levels of Mxi1 are up-regulated during long term quiescence and down-regulated following growth stimulation by serum. These results suggest that alterations in the levels of Max-associated proteins such as Mxi1 can modulate critical levels of functional Myc/Max protein complexes. This can alter transcriptional transactivation of Myc-regulated targets and as a consequence affect levels of genes essential for initiation and/or maintenance of growth.	TEMPLE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Korcz, Aleksandra/0000-0002-9501-3343	NCI NIH HHS [CA 56309, CA 64945] Funding Source: Medline; NIDDK NIH HHS [DK 49045] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064945, P01CA056309] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049045] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAMSEN MS, 1990, MOL CELL BIOL, V10, P5525, DOI 10.1128/MCB.10.10.5525; ALBAROSA R, 1995, HUM GENET, V95, P709; AUGENLICHT LH, 1974, EXP CELL RES, V89, P255, DOI 10.1016/0014-4827(74)90789-7; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERGER FG, 1984, J BIOL CHEM, V259, P7941; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER R, 1991, ONCOGENE, V6, P229; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HOLTTA E, 1993, J CELL BIOL, V122, P903, DOI 10.1083/jcb.122.4.903; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATZ A, 1987, MOL CELL BIOL, V7, P2641, DOI 10.1128/MCB.7.7.2641; KONTULA KK, 1984, P NATL ACAD SCI-BIOL, V81, P731, DOI 10.1073/pnas.81.3.731; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LORD KA, 1990, ONCOGENE, V5, P387; LU L, 1991, BIOCHEM J, V277, P671, DOI 10.1042/bj2770671; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MCCONLOGUE L, 1984, P NATL ACAD SCI-BIOL, V81, P540, DOI 10.1073/pnas.81.2.540; MOONSLEHNER K, 1991, MOL CELL BIOL, V11, P886; MOSHIER JA, 1993, CANCER RES, V53, P2618; OWEN TA, 1987, J BIOL CHEM, V262, P15111; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1988, CANCER RES, V48, P759; PENA A, 1995, J CELL PHYSIOL, V162, P234, DOI 10.1002/jcp.1041620209; PENA A, 1993, J BIOL CHEM, V268, P27277; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REDDY CD, 1992, ONCOGENE, V7, P2085; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1986, GENE, V42, P49, DOI 10.1016/0378-1119(86)90149-6; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; SISTONEN L, 1989, EMBO J, V8, P815, DOI 10.1002/j.1460-2075.1989.tb03442.x; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SOPRANO KJ, 1987, MOL CELL BIOCHEM, V75, P61, DOI 10.1007/BF00231609; SOPRANO KJ, 1994, J CELL BIOCHEM, V54, P405, DOI 10.1002/jcb.240540407; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; THOMAS P, 1980, P NATL ACAD SCI USA, V77, P54201; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; WETTERS TV, 1989, MOL CELL BIOL, V9, P5484, DOI 10.1128/MCB.9.12.5484; WETTERS TV, 1989, NUCLEIC ACIDS RES, V17, P9843, DOI 10.1093/nar/17.23.9843; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	54	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					621	629						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637719				2022-12-28	WOS:A1996TV59700019
J	Fornerod, M; Boer, J; vanBaal, S; Morreau, H; Grosveld, G				Fornerod, M; Boer, J; vanBaal, S; Morreau, H; Grosveld, G			Interaction of cellular proteins with the leukemia specific fusion proteins DEK-CAN and SET-CAN and their normal counterpart, the nucleoporin CAN	ONCOGENE			English	Article						DEK-CAN; SET-CAN; can proto-oncogene; nucleoporins; acute leukemia	NUCLEAR-PORE COMPLEX; ACUTE NONLYMPHOCYTIC LEUKEMIA; MYELOID LEUKEMOGENESIS; PUTATIVE ONCOGENE; IDENTIFICATION; LOCALIZATION; EXPRESSION; SEQUENCE; IMPORT; GENE	The recurrent chromosomal translocation (6;9) is associated with acute myeloid leukemia and results in expression of the DER-CAN fusion protein. This oncoprotein consists of almost the entire DEK protein fused to the C-terminal two-thirds of the CAN protein. In much the same way, CAN is fused to SET in a patient with acute undifferentiated leukemia, producing a SET-CAN fusion protein. Interestingly, CAN is associated with the nuclear pore complex (NPC) and we recently established its crucial role in nucleocytoplasmic transport processes and cell cycle progression. As a first step in the biochemical analysis of the oncogenic mechanism associated with translocation (6;9), we set out to identify proteins that interact with CAN and its fusion proteins. We found that two proteins specifically co-immunoprecipitate with CAN. One had a molecular mass of 88 kDa protein (CC88) and was determined to associate with the central region of CAN that contains several protein interaction motifs. A second protein of 112 kDa (CC112) was found to interact with the C-terminal nucleoporin-specific repeat of CAN, a region that is supposed to function in nucleocytoplasmic transport. CC112 also interacts with the DEK-CAN and SET-CAN fusion proteins. This finding suggests that CC112 may contribute an essential function to the leukemogenic effect of DEK-CAN and SET-CAN.	ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital			Fornerod, Maarten/A-7503-2010; Boer, Judith/A-7546-2010	Fornerod, Maarten/0000-0002-6166-3030	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA-21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOGERD HP, 1995, CELL, V82, P485, DOI 10.1016/0092-8674(95)90437-9; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BYRD DA, 1994, J CELL BIOL, V127, P1515, DOI 10.1083/jcb.127.6.1515; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; FORNEROD M, 1995, ONCOGENE, V10, P1739; Fornerod M, 1996, BIOTECHNIQUES, V20, P876; FRITZ CC, 1995, NATURE, V376, P530, DOI 10.1038/376530a0; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1995, NATURE, V377, P246, DOI 10.1038/377246a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRANDI P, 1995, J CELL BIOL, V130, P1263, DOI 10.1083/jcb.130.6.1263; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HURT EC, 1989, J CELL SCI, P243; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; KOEFFLER HP, 1978, SCIENCE, V200, P1153, DOI 10.1126/science.306682; KRAEMER D, 1994, P NATL ACAD SCI USA, V91, P1519, DOI 10.1073/pnas.91.4.1519; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MOROIANU J, 1995, P NATL ACAD SCI USA, V92, P6532, DOI 10.1073/pnas.92.14.6532; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; RADU A, 1995, P NATL ACAD SCI USA, V92, P1769, DOI 10.1073/pnas.92.5.1769; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; ROWLEY JD, 1976, BLOOD, V47, P705; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SOEKARMAN D, 1992, BLOOD, V79, P2990; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; STUTZ F, 1995, CELL, V82, P495, DOI 10.1016/0092-8674(95)90438-7; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; VANDEURSEN J, 1996, IN PRESS EMBO J; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; VONLINDERN M, 1990, MOL CELL BIOL, V10, P4016, DOI 10.1128/MCB.10.8.4016; VONLINDERN M, 1992, MOL CELL BIOL, V12, P1687, DOI 10.1128/MCB.12.4.1687; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WIMMER C, 1992, EMBO J, V11, P5051, DOI 10.1002/j.1460-2075.1992.tb05612.x	39	68	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1801	1808						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895527				2022-12-28	WOS:A1996VM88700026
J	Stoppler, H; Koval, D; Schlegel, R				Stoppler, H; Koval, D; Schlegel, R			The serine protease inhibitors TLCK and TPCK inhibit the in vitro immortalization of primary human keratinocytes by HPV-18 DNA	ONCOGENE			English	Article						HPV-immortalization; E7-Rb binding; serine protease inhibitors (TLCK/TPCK)	HUMAN PAPILLOMAVIRUS TYPE-16; LYSINE CHLOROMETHYL KETONE; RAT EMBRYO FIBROBLASTS; CATALYTIC SUBUNIT; TRANSFORMING GENE; E6 ONCOPROTEIN; KINASE-C; E7 GENE; HA-RAS; CELLS	The human papillomaviruses (HPV) which are commonly found in anogenital malignancies express viral E7 oncoprotein which possesses both immortalizing and transforming activities. The E7 protein forms a complex with the cellular tumor suppressor protein Rb and alters its interaction with transcription factor E2F, presumably interfering with cell cycle control and contributing to cellular transformation/immortalization. We demonstrated earlier that the serine protease inhibitors tosyl-L-phenylalanine chloromethyl ketone (TPCK) and tosyl-L-lysine chloromethyl ketone (TLCK) modified the HPV type 18 E7 protein in cell extracts as well as in Living cells and abrogated its ability to form a complex with Rb. In the present study we evaluated the effect of TLCK or TPCK treatment on the immortalization of primary keratinocytes by transfected HPV-18 DNA. Supplementing the medium of primary foreskin keratinocytes with TLCK or TPCK during their immortalization with HPV 18 DNA demonstrated that either TLCK (5-10 mu M) or TPCK (0.25 mu M) could inhibit cellular immortalization by 50-100% without altering keratinocyte proliferation, suggesting that the topical application of these reagents in ripe could significantly interfere with HPV-mediated cellular transformation.	GEORGETOWN UNIV, MED CTR, DEPT PATHOL, MOL PATHOBIOL PROGRAM, WASHINGTON, DC 20007 USA	Georgetown University								BARBOSA MS, 1989, ONCOGENE, V4, P1529; BEDELL MA, 1989, J VIROL, V63, P1247, DOI 10.1128/JVI.63.3.1247-1255.1989; CHESTERS PM, 1989, J GEN VIROL, V70, P353, DOI 10.1099/0022-1317-70-2-353; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HAUSEN HZ, 1988, MOL CARCINOGEN, V1, P147, DOI 10.1002/mc.2940010302; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KANDA T, 1988, VIROLOGY, V165, P321, DOI 10.1016/0042-6822(88)90694-0; KINZEL V, 1980, BIOCHEM BIOPH RES CO, V93, P349, DOI 10.1016/0006-291X(80)91083-9; KUPFER A, 1979, P NATL ACAD SCI USA, V76, P3073, DOI 10.1073/pnas.76.7.3073; LALOU CI, 1993, BIOCHIMIE, V75, P443, DOI 10.1016/0300-9084(93)90109-6; LIU ZJ, 1994, VIROLOGY, V201, P388, DOI 10.1006/viro.1994.1306; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MUNGER K, 1989, J VIROL, V63, P4417; PEACOCK JW, 1990, ONCOGENE, V5, P1769; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLEGEL R, 1988, EMBO J, V7, P3181, DOI 10.1002/j.1460-2075.1988.tb03185.x; SCHNEBLI HP, 1972, P NATL ACAD SCI USA, V69, P3825, DOI 10.1073/pnas.69.12.3825; SCHOELLMANN G, 1963, BIOCHEMISTRY-US, V2, P252, DOI 10.1021/bi00902a008; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SHAW E, 1970, PHYSIOL REV, V50, P244, DOI 10.1152/physrev.1970.50.2.244; SOLOMON DH, 1985, FEBS LETT, V190, P342, DOI 10.1016/0014-5793(85)81315-6; Stoppler H, 1996, VIROLOGY, V217, P542, DOI 10.1006/viro.1996.0149; STOPPLER H, 1994, INTERVIROLOGY, V37, P168; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; TANAKA A, 1989, J VIROL, V63, P1465, DOI 10.1128/JVI.63.3.1465-1469.1989; TROLL W, 1970, SCIENCE, V169, P1211, DOI 10.1126/science.169.3951.1211; VILLA LL, 1991, VIROLOGY, V181, P374; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167	36	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1545	1548						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875993				2022-12-28	WOS:A1996VL38400020
J	Boddy, MN; Howe, K; Etkin, LD; Solomon, E; Freemont, PS				Boddy, MN; Howe, K; Etkin, LD; Solomon, E; Freemont, PS			PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia	ONCOGENE			English	Article						APL; PML; interacting clone; ubiquitin-like	ZINC-FINGER; RAR-ALPHA; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; RING FINGER; GROWTH-SUPPRESSOR; FUSION PROTEINS; NUCLEAR MATRIX; SEQUENCE MOTIF; MESSENGER-RNAS	Acute promyelocytic leukaemia (APL) arises following a reciprocal translocation t(15;17) that fuses PML with retinoic acid receptor alpha (PAPA), The PML-RARA fusion protein targets and disrupts nuclear multiprotein complexes called PODs, ND10 or NBs, a process which is associated with a block in myeloid differentiation leading to APL, A human B-cell cDNA library was screened for PML-interacting clones and :I single positive clone (PIC1) was isolated, The sequence of PIC1 shows 52% identity to a S. cerevisiae ubiquitin-like protein that was cloned as a suppressor of mutations in MIF2, a protein required for mitotic spindle integrity during anaphase, Transient transfection of NIH3T3 cells with PIC1 results in a nuclear staining pattern coincident with that of endogenous mouse PML, Further, cotransfection of PIC1 with human PML produces a completely overlapping staining pattern between the two proteins, An antibody raised against PIC1 detects a punctate staining pattern in HeLa cells that is coincident with endogenous human PML. There is no significant colocalisation observed between the staining of PML/PML-RARA and PIC1 in an APL-derived cell line NB4, as compared to cells expressing only wild type PML. However, following all trans retinoic acid treatment of NB4 cells a significant relocalisation of PIC1 and PML is observed, PIC1 is the first identified NB-associated protein that interacts with PML, the function of which may lead to a fuller understanding of the molecular events leading to APL.	IMPERIAL CANC RES FUND, PROT STRUCT LAB, LONDON WC2A 3PX, ENGLAND; IMPERIAL CANC RES FUND, SOMAT CELL GENET LAB, LONDON WC2A 3PX, ENGLAND; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOL GENET, HOUSTON, TX 77030 USA	Cancer Research UK; Cancer Research UK; University of Texas System; UTMD Anderson Cancer Center			Boddy, Michael/A-7214-2009					ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BANERJI J, 1990, P NATL ACAD SCI USA, V87, P2374, DOI 10.1073/pnas.87.6.2374; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1992, BRIT J HAEMATOL, V82, P529, DOI 10.1111/j.1365-2141.1992.tb06463.x; BROCARD MP, 1994, EUR J BIOCHEM, V221, P421, DOI 10.1111/j.1432-1033.1994.tb18754.x; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DANIEL MT, 1993, BLOOD, V82, P1858; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; JOHNS MB, 1989, ANAL BIOCHEM, V180, P276, DOI 10.1016/0003-2697(89)90430-2; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; KORIOTH F, 1995, J CELL BIOL, V130, P1, DOI 10.1083/jcb.130.1.1; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KUMAR S, 1993, BIOCHEM BIOPH RES CO, V195, P393, DOI 10.1006/bbrc.1993.2056; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LINNEN JM, 1993, GENE, V128, P181, DOI 10.1016/0378-1119(93)90561-G; MEEKSWAGNER D, 1986, CELL, V44, P53, DOI 10.1016/0092-8674(86)90484-8; MELUH PB, 1995, MOL BIOL CELL, V6, P2095; MEREDITH M, 1995, VIROLOGY, V209, P174, DOI 10.1006/viro.1995.1241; MICHIELS L, 1993, ONCOGENE, V8, P2537; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MOSCOW JA, 1994, GENE, V144, P229, DOI 10.1016/0378-1119(94)90382-4; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NAKAMURA M, 1995, P NATL ACAD SCI USA, V92, P3463, DOI 10.1073/pnas.92.8.3463; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PUVIONDUTILLEUL F, 1995, EXP CELL RES, V218, P9, DOI 10.1006/excr.1995.1125; RANGANATHAN G, 1995, J BIOL CHEM, V270, P7149, DOI 10.1074/jbc.270.13.7149; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; STUURMAN N, 1992, J CELL SCI, V101, P773; SUDO K, 1994, GENOMICS, V24, P276, DOI 10.1006/geno.1994.1616; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TONIOLO D, 1988, P NATL ACAD SCI USA, V85, P851, DOI 10.1073/pnas.85.3.851; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	57	320	328	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					971	982						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806687				2022-12-28	WOS:A1996VG76600011
J	Knecht, H; McQuain, C; Martin, J; Rothenberger, S; Drexler, HG; Berger, C; Bachmann, E; Kittler, ELW; Odermatt, BF; Quesenberry, PJ				Knecht, H; McQuain, C; Martin, J; Rothenberger, S; Drexler, HG; Berger, C; Bachmann, E; Kittler, ELW; Odermatt, BF; Quesenberry, PJ			Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology	ONCOGENE			English	Article						LMP1; oncoprotein; Reed-Sternberg cells; giant cells; NF-kappa B; L-428 cell line; 293 cells	EPSTEIN-BARR-VIRUS; LATENT MEMBRANE-PROTEIN; NF-KAPPA-B; NASOPHARYNGEAL CARCINOMA; ONCOGENE; GENE; ACTIVATION; DOMAIN; DNA; MEMBRANE-PROTEIN-1	The latent membrane protein 1 (LMP1) oncogene is one of the major proteins synthesized by the Epstein-Barr virus (EBV) and is expressed in Reed-Sternberg (RS) cells of EBV-associated Hodgkin's disease (HD), We have studied the effect of this oncoprotein on the formation of RS cells in the EBV-negative HD cell lines L-428 and KM-H2 as well as on the formation of multinucleated cells in the mononuclear human embryonic kidney cell line 293. LMP1 prototype (B95-8) and its naturally occurring carboxy terminal 30 base pair deletion variant LMP1-del were transfected into the cell lines and cytocentrifuge preparations were analysed after 24, 48, 72, 144, 216, and 240 h. While no oncoprotein expression was seen in the KM-H2 cell lines, expression of LMP1 and LMP1-del was observed in the L-428 and 293 cell lines, In the HD cell line L-428 oncoprotein expression was infrequent but when observed was very strong and preferentially associated with multinucleated RS cell morphology (71% of LMP1 positive cells), This is in contrast with the untransfected or transfected but not expressing cells where intermediate mononuclear elements predominated over multinucleated RS cells (< 3%), Frequent oncoprotein expression was observed in the 293 cells and again was associated with multinuclearity, These LMP1 expressing 293 giant cells showed strong expression of ICAM-1 (CD54), not detectable in the untransfected cells, In the LMP1-del transfectants giant cells with more than four nuclei were frequently observed, However, giant cells were much less frequent in 293 cells transfected with the amino terminal deletion variant of LMP1 or the lytic form of LMP1, known to induce low NF-kappa B activation compared to the LMP1 prototype, Therefore, LMP1 mediated NF-kappa B activation appears to be involved in polycaria formation, The strong association of LMP1 expression with multinuclearity in a genetically unstable condition - the L-428 and 293 cells show multiple chromosomal abnormalities - suggests that this oncoprotein including its naturally occurring carboxy terminal deletion variant promote the formation of multinuclear cells, in particular of RS cells in EBV-associated HD.	PURDUE UNIV,DEPT PHARMACOL,W LAFAYETTE,IN 47907; UNIV LAUSANNE,INST PHARMACOL,LAUSANNE,SWITZERLAND; GERMAN COLLECT MICROORGANISMS & CELL CULTURES,BRAUNSCHWEIG,GERMANY; INST PATHOL,LAB IMMUNOHISTOCHEM,ZURICH,SWITZERLAND	Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Lausanne; Leibniz Institut fur Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ)	Knecht, H (corresponding author), UNIV MASSACHUSETTS,MED CTR,CTR CANC,LINK LABS,DIV HEMATOL ONCOL,55 LAKE AVE N,WORCESTER,MA 01655, USA.			Rothenberger, Sylvia/0000-0001-8633-2994	NATIONAL CANCER INSTITUTE [R29CA064610] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64610] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BAICHWAL VR, 1987, J VIROL, V61, P866, DOI 10.1128/JVI.61.3.866-875.1987; Bankier A T, 1983, Mol Biol Med, V1, P425; BROUSSET P, 1992, LAB INVEST, V67, P457; CHEN ML, 1992, ONCOGENE, V7, P2131; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DIEHL V, 1995, NEW ENGL J MED, V332, P461, DOI 10.1056/NEJM199502163320709; DREXLER HG, 1994, LEUKEMIA LYMPHOMA, V3, P201; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FENNEWALD S, 1984, J VIROL, V51, P411, DOI 10.1128/JVI.51.2.411-419.1984; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HALUSKA FG, 1994, BLOOD, V84, P1005, DOI 10.1182/blood.V84.4.1005.bloodjournal8441005; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; HAMMERSCHMIDT W, 1989, J VIROL, V63, P2469, DOI 10.1128/JVI.63.6.2469-2475.1989; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HU LF, 1991, J GEN VIROL, V72, P2399, DOI 10.1099/0022-1317-72-10-2399; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; HUEN DS, 1995, ONCOGENE, V10, P549; JOSKE D, 1993, BLOOD REV, V7, P215, DOI 10.1016/0268-960X(93)90008-R; KAMESAKI H, 1986, BLOOD, V68, P285; KAZAZI F, 1994, J GEN VIROL, V75, P2795, DOI 10.1099/0022-1317-75-10-2795; KNECHT H, 1995, ONCOGENE, V10, P523; KNECHT H, 1993, BLOOD, V82, P2937; KNECHT H, 1993, ACTA HAEMATOL-BASEL, V90, P167; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; MARTIN J, 1991, J VIROL, V65, P3246, DOI 10.1128/JVI.65.6.3246-3258.1991; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PENG M, 1992, ONCOGENE, V7, P1775; PENGPILON M, 1995, J GEN VIROL, V76, P767, DOI 10.1099/0022-1317-76-4-767; Rothenberger S., 1995, Blood, V86, p741A; SCHAADT M, 1979, BLUT, V38, P185, DOI 10.1007/BF01007965; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WEBERMATTHIESEN K, 1995, BLOOD, V86, P1464, DOI 10.1182/blood.V86.4.1464.bloodjournal8641464; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B	38	38	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					947	953						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806684				2022-12-28	WOS:A1996VG76600008
J	Garcia, P; Cales, C				Garcia, P; Cales, C			Endoreplication in megakaryoblastic cell lines is accompanied by sustained expression of G1/S cyclins and downregulation of cdc25C	ONCOGENE			English	Article						cell cycle; endoreplication; megakaryocyte differentiation; cyclins; cdc2; cdc25C	DEPENDENT KINASE-4 CDK4; FISSION YEAST CDC25; S-PHASE; DROSOPHILA EMBRYOGENESIS; RETINOBLASTOMA PROTEIN; ACTIVATING KINASE; DEVELOPMENTAL CONTROL; DNA-REPLICATION; MITOTIC INDUCER; G(1) CYCLINS	In most eukaryotic cells, a link between S and M phases of the cell cycle must be assured in order to maintain the ploidy of newly divided cells. However, in some cell types, e.g. the precursors of platelets megakaryocytes, extra S-phases can occur in the absence of concomitant mitoses, resulting in polyploidy, We have used two established cell lines with megakaryoblastic characteristics (HEL and MEG-01) to investigate the molecular events that lead these cells to bypass the regular control checkpoints that govern the interdependency of S and M phases. In the presence of the phorbol ester TPA, both cell lines stopped proliferating and displayed additional megakaryocytic features, including polyploidization. Analysis of key cell cycle regulatory factors implicated in the control of G1/S and G2/M transitions revealed a number of differences compared to normally cycling cells. Differentiating megakaryocytes were found to maintain high levels of cdk2, and cyclins E and A, This was accompanied by the appearance of the retinoblastoma protein in the hyperphosphorylated, functionally inactivated form, In addition, TPA-treated cells showed high levels of cyclin B and cdc2 proteins, however no activation of cdc2 was detected, This lack of cdc2 activation which should occur for entry into M phase appeared to be related to the down regulation of cdc25C phosphatase found in both differentiated HEL and MEG-01 cells, Together, our results suggest that in differentiating megakaryoblastic cells endoreplication is accompanied by sustained levels of cyclins A and E, and a lack of cdc2 activation, which is probably mediated through down regulation of cdc25C protein phosphatase.	UNIV AUTONOMA MADRID,CSIC,INST INVEST BIOMED,DEPT BIOQUIM,MADRID 28029,SPAIN	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Calés, Carmela/AAB-1595-2019	Garcia, Paloma/0000-0001-5582-8575; Cales, Carmela/0000-0002-6987-2259				BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DESHAIES R, 1995, CURR OPIN CELL BIOL, V7, P781, DOI 10.1016/0955-0674(95)80061-1; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; DUCOMMUN B, 1990, BIOCHEM BIOPH RES CO, V167, P301, DOI 10.1016/0006-291X(90)91765-K; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; DURONIO RJ, 1994, DEVELOPMENT, V120, P1503; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; EDGAR B, 1995, CURR OPIN CELL BIOL, V7, P815, DOI 10.1016/0955-0674(95)80065-4; EDGAR BA, 1994, GENE DEV, V8, P440, DOI 10.1101/gad.8.4.440; EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FUSE N, 1994, GENE DEV, V8, P2270, DOI 10.1101/gad.8.19.2270; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GRAFI G, 1995, SCIENCE, V269, P1262, DOI 10.1126/science.269.5228.1262; GREENBERG SM, 1990, BLOOD, V76, P533; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HANDELI S, 1992, CELL, V71, P599, DOI 10.1016/0092-8674(92)90594-3; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HAYASHI S, 1993, DEVELOPMENT, V118, P105; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HOFFMAN R, 1989, BLOOD, V74, P1196; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Krishan A, 1990, Methods Cell Biol, V33, P121; KUTER DJ, 1992, BLOOD, V79, P619; LARRICK JW, 1980, J IMMUNOL, V125, P6; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LEES E, 1995, CURR OPIN CELL BIOL, V7, P773, DOI 10.1016/0955-0674(95)80060-3; LEHNER CF, 1990, CELL, V61, P535, DOI 10.1016/0092-8674(90)90535-M; LONG MW, 1990, J CLIN INVEST, V85, P1072, DOI 10.1172/JCI114538; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Martin-Castellanos C, 1996, EMBO J, V15, P839, DOI 10.1002/j.1460-2075.1996.tb00419.x; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; MORUZZI EV, 1993, BIOCHEM BIOPH RES CO, V196, P1248; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; NURSE P, 1994, CURR OPIN CELL BIOL, V6, P867; OGURA M, 1988, BLOOD, V72, P49; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; RICHARDSON HE, 1993, DEVELOPMENT, V119, P673; ROBERTS JR, 1990, CANCER RES, V50, P710; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SMITH AV, 1991, DEVELOPMENT, V112, P997; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STERN B, 1993, DEVELOPMENT, V117, P219; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; VANDERLOO B, 1993, EUR J CLIN INVEST, V23, P621; VARMUZA S, 1988, DEVELOPMENT, V102, P127; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YEN A, 1993, CANCER RES, V53, P3085; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X	75	52	52	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					695	703						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761290				2022-12-28	WOS:A1996VD43300004
J	Theile, M; Seitz, S; Arnold, W; Jandrig, B; Frege, R; Schlag, PM; Haensch, W; Guski, H; Winzer, KJ; Barrett, JC; Scherneck, S				Theile, M; Seitz, S; Arnold, W; Jandrig, B; Frege, R; Schlag, PM; Haensch, W; Guski, H; Winzer, KJ; Barrett, JC; Scherneck, S			A defined chromosome 6q fragment (at D6S310) harbors a putative tumor suppressor gene for breast cancer	ONCOGENE			English	Article						breast cancer; tumor suppressor genes; chromosome 6q; LOH analysis; microcell-mediated chromosome transfer; estrogen receptor	ESTROGEN-RECEPTOR GENE; IMMORTAL HUMAN FIBROBLASTS; HUMAN OVARIAN CARCINOMAS; HUMAN-MALIGNANT MELANOMA; 2 DISTINCT REGIONS; FREQUENT LOSS; LINKAGE MAP; CELL-LINES; HUMAN GENOME; WILD-TYPE	Recent evidence obtained by cytogenetic and molecular studies indicates that in breast cancer chromosome 6q is often affected by genetic changes suggesting the existence of putative tumor suppressor genes (TSGs). However the function of gene(s) on this chromosome in breast cancer suppession is not understood. To substantiate further the presence of breast cancer related TSGs at 60 and to define their location, we first performed microcell-mediated transfer of chromosome 6 to CAL51 breast cancer cells for studying possible suppression of malignant phenotype and secondly, we analysed DNAs from 46 primary breast cancers for loss of constitutive heterozygosity (LOH) using 24 polymorphic microsatellite markers, The chromosome transfer resulted in loss of tumorigenicity and reversion of other neoplastic properties of the microcell hybrids. Polymorphism analysis of single hybrids revealed that they harbored only a small donor chromosome fragment defined by the marker D6S310 (6q23.3-q25) and flanked by D65292 and D6S311, The LOH data suggest that four tumor suppressor gene loci mapped to the central and distal portion of 6q may be independently deleted in breast cancer. One of these regions corresponds to the region identified by chromosome transfer.	MAX DELBRUCK CTR MOL MED,FORSCH GRP ONKOL & TUMORIMMUNOL,D-13122 BERLIN,GERMANY; FREE UNIV BERLIN,ROBERT ROSSLE KLIN,ABT CHIRURG & CHIRURG ONKOL,D-13122 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,D-10117 BERLIN,GERMANY; NIEHS,MOL CARCINOGENESIS LAB,NIH,RES TRIANGLE PK,NC 27709	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Theile, M (corresponding author), MAX DELBRUCK CTR MOL MED,ARBEITSGRP TUMORGENET,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.							ANDERSEN TI, 1994, HUM GENET, V94, P665; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BRAVARD A, 1992, INT J CANCER, V51, P476, DOI 10.1002/ijc.2910510323; CASTLES CG, 1995, BRIT J CANCER, V71, P974, DOI 10.1038/bjc.1995.188; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; COX LA, 1994, BREAST CANCER RES TR, V32, P19, DOI 10.1007/BF00666203; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Del Senno L., 1992, Human Molecular Genetics, V1, P354; DESOUZA AT, 1995, ONCOGENE, V10, P1725; DEVILEE P, 1991, ONCOGENE, V6, P1705; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; FUQUA SAW, 1990, J NATL CANCER I, V82, P858, DOI 10.1093/jnci/82.10.858; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HAINSWORTH PJ, 1991, CANCER GENET CYTOGEN, V52, P205; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; LASTOWSKA MA, 1994, CANCER GENET CYTOGEN, V77, P99, DOI 10.1016/0165-4608(94)90222-4; LEBEAU MM, 1986, BLOOD, V67, P844; LEE JH, 1990, CANCER RES, V50, P2724; LU YJ, 1993, CANCER GENET CYTOGEN, V69, P91, DOI 10.1016/0165-4608(93)90081-V; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MENASCE LP, 1993, GENOMICS, V17, P263, DOI 10.1006/geno.1993.1320; MILLIKIN D, 1991, CANCER RES, V51, P5449; MORITA R, 1991, CANCER RES, V51, P5817; NEGRINI M, 1994, CANCER RES, V54, P1331; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; ROODI N, 1995, JNCI-J NATL CANCER I, V87, P446, DOI 10.1093/jnci/87.6.446; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sandhu AK, 1996, ONCOGENE, V12, P247; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; STEINARSDOTTIR M, 1995, GENE CHROMOSOME CANC, V13, P239, DOI 10.1002/gcc.2870130403; THEILE M, 1995, ONCOGENE, V10, P439; THEILE M, 1994, INT J ONCOL, V4, P1067; THOMPSON F, 1993, GENE CHROMOSOME CANC, V7, P185, DOI 10.1002/gcc.2870070402; TRENT JM, 1989, CANCER RES, V49, P420; TRENT JM, 1990, SCIENCE, V247, P568, DOI 10.1126/science.2300817; VIDAL F, 1993, P NATL ACAD SCI USA, V90, P208, DOI 10.1073/pnas.90.1.208; VISAKORPI T, 1995, CANCER RES, V55, P342; VOLZ A, 1994, GENOMICS, V21, P464, DOI 10.1006/geno.1994.1302; WAN MH, 1994, INT J ONCOL, V5, P1043; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WELCH DR, 1994, ONCOGENE, V9, P255; YAICH L, 1992, CANCER RES, V52, P77; YAMADA H, 1990, ONCOGENE, V5, P1141; ZUPPAN P, 1991, AM J HUM GENET, V48, P1065	60	118	118	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					677	685						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761288				2022-12-28	WOS:A1996VD43300002
J	Pereira, DS; Kushner, DB; Ricciardi, RP; Graham, FL				Pereira, DS; Kushner, DB; Ricciardi, RP; Graham, FL			Testing NF-kappa B1-p50 antibody specificity using knockout mice	ONCOGENE			English	Article						NF-kappa B; p50; antibody specificity; knockout mice	SUBUNIT	Cell extracts from knockout mice can provide definitive proof of antibody specificity. Two NF-kappa B1-p50 antibodies, sc-114 (a commercial antibody) and NR1157, were observed to recognize proteins having distinct electrophoretic mobilities of 52-55 kD and 50 Kd, respectively, by Western blot analysis. In order to discriminate the specificity of these antibodies for NF-kappa B1-p50, whole cell extracts derived from NF-kappa B1-p105 knockout mice were employed. While the NR1157 antibody completely failed to recognize its 50 kD product in p105-/- knockout extracts, the sc-114 antibody still strongly recognized its 52-55 kD product. These data demonstrate that NR1157, but not sc-114, is highly specific for NF-kappa B1-p50 by Western blot analysis. In addition, these results highlight the utility of knockout cell extracts for discerning antibody specificity.	MCMASTER UNIV,DEPT BIOL,HAMILTON,ON L8S 4K1,CANADA; MCMASTER UNIV,DEPT PATHOL,HAMILTON,ON L8S 4K1,CANADA; UNIV PENN,SCH DENT MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104; UNIV PENN,GRAD GRP MOLEC BIOL,PHILADELPHIA,PA 19104	McMaster University; McMaster University; University of Pennsylvania; University of Pennsylvania				Kushner, David B/0000-0002-6260-5094	NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29797] Funding Source: Medline; NIAID NIH HHS [5-T32-AI0735] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Kushner DB, 1996, ONCOGENE, V12, P143; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; *SANT CRUZ BIOT, 9495 SANT CRUZ BIOT; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8	5	8	8	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					445	446						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710386				2022-12-28	WOS:A1996VA25200026
J	Rehman, I; Takata, M; Wu, YY; Rees, JL				Rehman, I; Takata, M; Wu, YY; Rees, JL			Genetic change in actinic keratoses	ONCOGENE			English	Article						loss of heterozygosity; allelotype; squamous cell carcinoma; p21(WAF1/CIP1); p53; Ki67	SQUAMOUS-CELL CARCINOMA; P53 MUTATIONS; SOLAR KERATOSES; BREAST-CANCER; SKIN-CANCER; ALLELOTYPE; BIOLOGY; PROGRESSION; COMMON	Actinic keratoses (AKs) are small scaly red areas of skin characterised histologically by dysplasia, a minority of which are thought to be precursors of squamous cell carcinoma (SCC), and which show a high frequency of regression. Surprisingly, in view of their benign clinical course, they show a high frequency of loss of heterozygosity (LOH) with a median loss of four loci with almost 20% of lesions showing loss of eight or more alleles, as well as frequent p53 mutation. Loss was common on 3p (31%), 9p (39%), 9q (22%), 13q (52%), 17p (64%) and 17q (46%), and allele loss correlated with dysplasia. Topological disturbance of p21(WAF1/CIP1) expression correlated with allele loss but was also seen together with increased wild-type p53 expression and an increase in the fraction of cycling cells in the absence of allele loss or p53 mutation, and is likely to represent an early change, P21(WAF1/CIP1) expression appeared independent of p53 status. The frequency of LOH in AKs exceeded that of (invasive) SCCs suggesting that the relation between the accumulation of genetic change and behaviour for non-melanoma skin cancer is not straightforward.	UNIV NEWCASTLE UPON TYNE,ROYAL VICTORIA INFIRM,DEPT DERMATOL,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	Newcastle University - UK								AHSEE KW, 1994, CANCER RES, V54, P1617; ANTONIADES HN, 1994, J CLIN INVEST, V93, P2206, DOI 10.1172/JCI117217; BOYLE JO, 1993, CANCER RES, V53, P4477; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; BROWN DC, 1990, HISTOPATHOLOGY, V17, P489, DOI 10.1111/j.1365-2559.1990.tb00788.x; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; CAMPBELL C, 1993, SKIN CANC, V8, P245; CLIBY W, 1993, CANCER RES, V53, P2393; COLES C, 1992, CANCER RES, V52, P5291; DUMAZ N, 1994, MUTAT RES, V307, P375, DOI 10.1016/0027-5107(94)90311-5; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; GAILANI MR, 1992, CELL, V69, P111, DOI 10.1016/0092-8674(92)90122-S; GALLAGHER RP, 1990, J AM ACAD DERMATOL, V23, P413, DOI 10.1016/0190-9622(90)70234-9; GOUDIE DR, 1993, NAT GENET, V3, P165, DOI 10.1038/ng0293-165; HEALY E, 1994, J INVEST DERMATOL, V103, P493, DOI 10.1111/1523-1747.ep12395637; HEALY E, 1994, J INVEST DERMATOL, V105, P274; JACKSON DP, 1995, PCR PRACTICAL APPROA, P29; JIANG HP, 1994, ONCOGENE, V9, P3397; KNOWLES MA, 1994, CANCER RES, V54, P531; KWA RE, 1992, J AM ACAD DERMATOL, V26, P1, DOI 10.1016/0190-9622(92)70001-V; LEE YS, 1994, CANCER-AM CANCER SOC, V73, P2317, DOI 10.1002/1097-0142(19940501)73:9<2317::AID-CNCR2820730913>3.0.CO;2-0; MARKS R, 1986, BRIT J DERMATOL, V115, P649, DOI 10.1111/j.1365-2133.1986.tb06644.x; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; MARKS R, 1991, ARCH DERMATOL, V127, P1031, DOI 10.1001/archderm.127.7.1031; MARKS R, 1988, LANCET, V1, P795, DOI 10.1016/s0140-6736(88)91658-3; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P161, DOI 10.1016/0190-9622(91)70022-T; MILLER SJ, 1991, J AM ACAD DERMATOL, V24, P1, DOI 10.1016/0190-9622(91)70001-I; MOLES JP, 1993, J INVEST DERMATOL, V101, P100, DOI 10.1111/1523-1747.ep12360920; MOLES JP, 1993, ONCOGENE, V8, P583; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NAWROZ H, 1994, CANCER RES, V54, P1152; NEWTON JA, 1987, BRIT J DERMATOL, V117, P169, DOI 10.1111/j.1365-2133.1987.tb04113.x; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; QUINN AG, 1994, GENE CHROMOSOME CANC, V11, P222, DOI 10.1002/gcc.2870110404; QUINN AG, 1994, CANCER RES, V54, P4756; REES J, 1994, J INVEST DERMATOL, V103, P747, DOI 10.1111/1523-1747.ep12412256; REES JL, 1995, J INVEST DERMATOL, V104, P883, DOI 10.1111/1523-1747.ep12606149; REHMAN I, 1994, LANCET, V344, P788, DOI 10.1016/S0140-6736(94)92343-4; REID T, 1994, CANCER RES, V54, P1801; SATO S, 1994, CANCER RES, V54, P5652; SATO T, 1990, CANCER RES, V50, P7184; SMITH MD, 1995, BRIT J DERMATOL, V132, P359, DOI 10.1111/j.1365-2133.1995.tb08668.x; SOBER AJ, 1995, CANCER, V75, P645, DOI 10.1002/1097-0142(19950115)75:2+<645::AID-CNCR2820751405>3.0.CO;2-1; TAGUCHI M, 1994, J INVEST DERMATOL, V103, P500, DOI 10.1111/1523-1747.ep12395643; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VANDERRIET P, 1994, CANCER RES, V54, P25; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; YOUNG AR, 1987, PHOTODERMATOLOGY, V4, P127; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	53	77	79	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2483	2490						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700506				2022-12-28	WOS:A1996UW48700001
J	Mok, SC; Chan, WY; Wong, KK; Muto, MG; Berkowitz, RS				Mok, SC; Chan, WY; Wong, KK; Muto, MG; Berkowitz, RS			SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells	ONCOGENE			English	Article						ovarian cancer; SPARC; tumor suppressor; RNA fingerprinting	MESSENGER-RNA; INSITU HYBRIDIZATION; ENDOTHELIAL-CELLS; OSTEONECTIN; EXPRESSION; GLYCOPROTEIN; GENE; SEQUENCES; SECRETION; TISSUES	SPARC, also termed osteonectin, BM-40 and 43K protein, is an acidic, cysteine-rich component of the extracellular matrix that has been shown to be directly regulated by progesterone and dexamethasone and indirectly by cytokines. By RNA fingerprinting technique, we cloned a SPARC homolog from the normal human ovarian surface epithelial (HOSE) cells and demonstrated that it is expressed at high levels in the normal HOSE cells but at much lower levels in ovarian carcinoma cells in vitro and in vivo. Subsequently, we transfected the full length SPARC cDNA into an ovarian carcinoma cell line SKOV3 and showed that it reduced the growth rate of the cancer cell line in culture and reduced the cell's ability to induce tumours in nude mice. These results suggest that SPARC may play an important role in growth and and differentiation of the HOSE cells and support the hypothesis that SPARC functions as a tumor suppressor.	PACIFIC NW LAB, RICHLAND, WA 99352 USA; CHINESE UNIV HONG KONG, DEPT ANAT, SHA TIN, HONG KONG	United States Department of Energy (DOE); Pacific Northwest National Laboratory; Chinese University of Hong Kong	Mok, SC (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, LAB GYNECOL ONCOL, DEPT OBSTET GYNECOL & REPROD BIOL, BOSTON, MA 02115 USA.		Chan, Wood Yee/R-6692-2018; Wong, K.-k./AAA-6589-2020	Chan, Wood Yee/0000-0002-7114-1463; Wong, K.-k./0000-0002-0375-6669	NATIONAL CANCER INSTITUTE [R01CA063381] Funding Source: NIH RePORTER; NCI NIH HHS [CA63381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BOLANDER ME, 1988, P NATL ACAD SCI USA, V85, P1919; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOMENICUCCI C, 1988, BIOCHEM J, V253, P139, DOI 10.1042/bj2530139; DZIADEK M, 1986, EUR J BIOCHEM, V161, P455, DOI 10.1111/j.1432-1033.1986.tb10466.x; ENGEL J, 1987, BIOCHEMISTRY-US, V26, P6958, DOI 10.1021/bi00396a015; HOLLAND PWH, 1987, J CELL BIOL, V105, P473, DOI 10.1083/jcb.105.1.473; HOWE CC, 1990, EXP CELL RES, V188, P185, DOI 10.1016/0014-4827(90)90158-7; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANKAT-BUTTGEREIT B, 1991, Journal of Dermatological Science, V2, P300, DOI 10.1016/0923-1811(91)90054-2; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; MASON IJ, 1986, EMBO J, V5, P1465, DOI 10.1002/j.1460-2075.1986.tb04383.x; MASON IJ, 1986, EMBO J, V5, P1831, DOI 10.1002/j.1460-2075.1986.tb04434.x; MOK CH, 1992, CANCER RES, V52, P5119; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MUNDLOS S, 1992, J HISTOCHEM CYTOCHEM, V40, P283, DOI 10.1177/40.2.1552170; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; NERI M, 1992, EUR J BIOCHEM, V205, P569, DOI 10.1111/j.1432-1033.1992.tb16814.x; NG KW, 1989, MOL ENDOCRINOL, V3, P2079, DOI 10.1210/mend-3-12-2079; NOMURA S, 1989, J BIOL CHEM, V264, P12201; NOMURA S, 1988, J CELL BIOL, V106, P441, DOI 10.1083/jcb.106.2.441; PIVER MS, 1992, GYNECOL ONCOL, P250; REED MJ, 1993, J HISTOCHEM CYTOCHEM, V41, P1467, DOI 10.1177/41.10.8245406; SAGE EH, 1992, BIOCHEM CELL BIOL, V70, P579, DOI 10.1139/o92-089; SAGE H, 1986, J CELL PHYSIOL, V127, P373, DOI 10.1002/jcp.1041270305; SAGE H, 1989, J HISTOCHEM CYTOCHEM, V37, P819, DOI 10.1177/37.6.2723400; SAGE H, 1984, J BIOL CHEM, V259, P3993; SUN LZ, 1994, J BIOL CHEM, V269, P26449; TERMINE JD, 1981, CELL, V26, P99, DOI 10.1016/0092-8674(81)90037-4; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; VILLARREAL XC, 1989, BIOCHEMISTRY-US, V28, P6483, DOI 10.1021/bi00441a049	31	124	130	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1895	1901						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649850				2022-12-28	WOS:A1996UK49800008
J	Biggs, PJ; Chapman, P; Lakhani, SR; Burn, J; Stratton, MR				Biggs, PJ; Chapman, P; Lakhani, SR; Burn, J; Stratton, MR			The cylindromatosis gene (cyld1) on chromosome 16q may be the only tumour suppressor gene involved in the development of cylindromas	ONCOGENE			English	Article						cylindroma; cylindromatosis; tumour suppressor gene	BASAL-CELL ADENOMA; TURBAN TUMOR; PAROTID-GLAND; DERMAL CYLINDROMAS; RETINOBLASTOMA; PATIENT; CANCER	Hereditary cylindromatosis is a rare autosomal dominant disease characterised by the development of multiple benign neoplasms of the skin, We recently localised the gene responsible for this disease (cyld1) to chromosome 16q12-q13 and provided evidence that it is a tumour suppressor gene (Biggs et al., 1995). We have now examined polymorphic markers on every chromosome, some of which are close to known tumour suppressor genes, in 25 tumours from 4 individuals with familial cylindromatosis, No loss of heterozygosity (LOH) was detected other than at loci on chromosome 16q. This observation suggests that the cyld1 gene may be the only tumour suppressor gene implicated in the development of cylindromas. We have also demonstrated LOH using markers on chromosome 16q in 8/14 (57%) sporadic cylindromas, indicating that the cyld1 gene is likely to be involved in the genesis of both familial and sporadic cylindromas.	INST CANC RES,HADDOW LABS,MOLEC CARCINOGENESIS SECT,SUTTON SM2 5NG,SURREY,ENGLAND; UNIV NEWCASTLE,DIV HUMAN GENET,NEWCASTLE TYNE NE2 4AA,TYNE & WEAR,ENGLAND; ROYAL MARSDEN NHS TRUST,DEPT HISTOPATHOL,SUTTON SM2 5PT,SURREY,ENGLAND	University of London; Institute of Cancer Research - UK; Newcastle University - UK; Royal Marsden NHS Foundation Trust			Lakhani, Sunil R/I-1970-2018; Biggs, Patrick Jon/H-3355-2014	Lakhani, Sunil R/0000-0003-4067-2760; Biggs, Patrick Jon/0000-0002-0285-4101; Burn, John/0000-0002-9823-2322				ABENOZA P, 1990, NEOPLASMS ECCRINE DI, P253; ALAWI MH, 1982, BRIT J PLAST SURG, V35, P167, DOI 10.1016/0007-1226(82)90157-6; AUTIOHARMAINEN H, 1988, CANCER-AM CANCER SOC, V61, P161, DOI 10.1002/1097-0142(19880101)61:1<161::AID-CNCR2820610127>3.0.CO;2-1; BIGGS PJ, 1995, IN PRESS NATURE GENE; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COLLINS N, 1995, ONCOGENE, V10, P1673; DEVILEE P, 1994, BBA-REV CANCER, V1198, P113, DOI 10.1016/0304-419X(94)90009-4; FABIAN RL, 1981, HEAD NECK SURG, V4, P165, DOI 10.1002/hed.2890040214; FERRANDIZ C, 1985, J CUTAN PATHOL, V12, P72, DOI 10.1111/j.1600-0560.1985.tb00432.x; FREEDMAN AM, 1989, ANN PLAS SURG, V22, P50, DOI 10.1097/00000637-198901000-00010; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Harper P S, 1971, Birth Defects Orig Artic Ser, V7, P338; HYMA BA, 1988, ARCH PATHOL LAB MED, V112, P209; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; Lever W. F., 1990, HISTOPATHOLOGY SKIN; PINGITORE R, 1984, TUMORI, V70, P385, DOI 10.1177/030089168407000415; REINGOLD IM, 1977, CANCER, V40, P1702, DOI 10.1002/1097-0142(197710)40:4<1702::AID-CNCR2820400446>3.0.CO;2-A; SATO S, 1994, CANCER RES, V54, P5652; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; VERNON HJ, 1988, J AM ACAD DERMATOL, V19, P397, DOI 10.1016/S0190-9622(88)70186-3; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	23	54	54	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1375	1377						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649842				2022-12-28	WOS:A1996UC06700025
J	Kondo, M; Matsuoka, S; Uchida, K; Osada, H; Nagatake, M; Takagi, K; Harper, JW; Takahashi, T; Elledge, SJ; Takahashi, T				Kondo, M; Matsuoka, S; Uchida, K; Osada, H; Nagatake, M; Takagi, K; Harper, JW; Takahashi, T; Elledge, SJ; Takahashi, T			Selective maternal-allele loss in human lung cancers of the maternally expressed p57(KIP2) gene at 11p15.5	ONCOGENE			English	Article						lung cancer; genomic imprinting; allele loss; p57(KIP2); cyclin dependent kinase inhibitor	SPORADIC WILMS-TUMOR; CHROMOSOME-11; HETEROZYGOSITY; P53; ABNORMALITIES; SUPPRESSION	Genomic imprinting at 11p15 is suggested to play a role in certain pediatric tumors such as Wilms' tumor, based on the findings of selective maternal loss of this chromosomal region, Although the allele loss at 11p15 is also frequent in a number of cancers of adults including lung, breast, and bladder cancers, possible involvement of genomic imprinting in these tumors has not been investigated extensively, p57(KIP2), a newly described member of the p21 cyclin-dependent kinase (CDK) inhibitor family which is thought to negatively regulate the cell cylce at the G(1) checkpoint, has been mapped to 11p15, In the present study, we searched for somatic p57(KIP2) mutations in lung cancer, but failed to find such alterations, Interestingly, however, we found that the p57(KIP2) gene is imprinted with maternal expression and that the maternal alleles had been selectively lost in 11 of 13 (85%) lung cancer cases carrying 11p15 deletions, this being a significant bias (P=0.01), These data provide the first evidence that genomic imprinting may play a role in the oncogenesis of not only rare pediatric tumors but also this common cancer of adults, suggesting that the imprinted p57(KIP2) CDK inhibitor gene is a potential target for maternally biased 11p15 deletions.	AICHI CANC CTR,RES INST,LAB ULTRASTRUCT RES,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT HUMAN & MOL GENET,HOUSTON,TX 77030; NAGOYA UNIV,SCH MED,DEPT INTERNAL MED 2,SHOWA KU,NAGOYA,AICHI 466,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Baylor College of Medicine; Baylor College of Medicine; Nagoya University			Osada, Hiroyuki/AAY-6254-2020; Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014	Takahashi, Takashi/0000-0003-0615-7001; Harper, Jeffrey/0000-0002-6944-7236				DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARPER JW, 1993, CELL, V75, P805; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; HIBI K, 1994, ONCOGENE, V9, P611; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1995, ONCOGENE, V10, P1193; KONDO M, 1994, ONCOGENE, V9, P3063; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; MANNENS M, 1988, HUM GENET, V81, P41, DOI 10.1007/BF00283727; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MOUTLON T, 1994, NAT GENET, V7, P440; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; PAL N, 1990, ONCOGENE, V5, P1665; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SCHROEDER WT, 1987, AM J HUM GENET, V40, P413; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SURANI MA, 1993, NATURE, V366, P302, DOI 10.1038/366302a0; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WADEY RB, 1990, ONCOGENE, V5, P901; WASHIMI O, 1995, CANCER RES, V55, P514; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099	31	113	126	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1365	1368						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649840				2022-12-28	WOS:A1996UC06700023
J	Zubiaur, M; Forman, LW; Stice, LL; Faller, DV				Zubiaur, M; Forman, LW; Stice, LL; Faller, DV			A role for activated p21(ras) in inhibition regulation of platelet-derived growth factor (PDGF) type-beta receptor activation	ONCOGENE			English	Article						Ras; signal transduction; tyrosine phosphorylation; EGF; grb-2; syp	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PROTEIN-TYROSINE KINASES; PHOSPHOLIPASE-C-GAMMA; EJ-RAS ONCOGENE; SIGNAL TRANSDUCTION; CDNA CLONING; TRANSFORMED CELLS; PHOSPHORYLATION; EXPRESSION; BINDING	Ligand-stimulated Platelet-Derived Growth Factor [PDGF] type-beta receptor autophosphorylation, and tyrosine phosphorylation of receptor-associated signalling proteins, is blocked in cells expressing activated Ras genes. A factor present in membrane fractions of v-ras-expressing fibroblasts (Kbalb cells) dominantly inhibits the autophosphorylation of the PDGF type-beta receptor. Purification of this factor, via ion exchange, reveals that the inhibitor can be physically separated from the PDGF type-beta receptor, with reconstitution of PDGF type-beta receptor kinase activity in response to ligand binding. The inhibitor exhibited specificity for the PDGF type-beta receptor, and consistently co-purified with activated p21(ras), with Syp/PTP-2, and with Grb2. Neutralization of the p21(ras) protein from the Kbalb cell membranes by p21(ras)-specific monoclonal antibodies, however, completely removed the inhibition of PDGF type-beta receptor, rendering the PDGF type-beta receptor molecule capable of autophosphorylation in response to ligand. These results indicate that activated p21(ras) either interacts directly with the PDGF type-beta receptor to inhibit autokinase activity, or complexes with different molecules such as Syp and/or Grb2 at the cell membrane to act on another effector which then inhibits PDGF type-beta receptor function.	BOSTON UNIV,SCH MED,CTR CANC RES,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL & LAB MED,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University			Zubiaur, Mercedes/AAC-5792-2021; Zubiaur, Mercedes/K-9390-2014	Zubiaur, Mercedes/0000-0002-4127-3027; Zubiaur, Mercedes/0000-0002-4127-3027				BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BENJAMIN CW, 1987, P NATL ACAD SCI USA, V84, P546, DOI 10.1073/pnas.84.2.546; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN S, 1980, J BIOL CHEM, V255, P4834; DOWNING JR, 1991, ONCOGENE, V6, P607; EGAN SE, 1993, NATURE, V363, P15; ESCOBEDO JA, 1991, CELL, V65, P75, DOI 10.1016/0092-8674(91)90409-R; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KUMJIAN DA, 1989, P NATL ACAD SCI USA, V86, P8232, DOI 10.1073/pnas.86.21.8232; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIN AH, 1988, MOL CELL BIOL, V18, P5052; LOWE PN, 1991, J BIOL CHEM, V266, P1672; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; QUINONES MA, 1991, J BIOL CHEM, V266, P14055; RAKE JB, 1991, J BIOL CHEM, V266, P5348; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TOMASKA L, 1993, BIOCHEM J, V293, P215, DOI 10.1042/bj2930215; TONKS NK, 1989, TRENDS BIOCHEM SCI, V14, P497, DOI 10.1016/0968-0004(89)90184-9; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WATERS SB, 1995, J BIOL CHEM, V270, P20883, DOI 10.1074/jbc.270.36.20883; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIAO S, 1994, J BIOL CHEM, V269, P21244; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZULLO JN, 1988, MOL CELL BIOL, V8, P5080, DOI 10.1128/MCB.8.12.5080	49	9	9	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1213	1222						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649823				2022-12-28	WOS:A1996UC06700006
J	Zhang, GQ; Humphries, EH				Zhang, GQ; Humphries, EH			v-rel and c-rel induce a membrane protein, p75, on avian hematopoietic cells	ONCOGENE			English	Article						rel oncogene; p75; ectopic expression	NF-KAPPA-B; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; TRANSCRIPTIONAL ACTIVATOR; ONCOGENIC TRANSFORMATION; GENE-EXPRESSION; LYMPHOID-CELLS; LINES; IDENTIFICATION; REPRESSION	v-rel-induced neoplasias are thought to be caused by the aberrant expression of cellular genes. Using a monoclonal antibody we detected a 75 kDa-protein (p75) on vrel-transformed chicken hematopoietic cells. This protein is normally expressed only on a certain type of non-T, non-B cells in the chicken caecal tonsils. Overexpression of v-rel in two B-cell lines and in splenic cells induced the expression of p75. In contrast, overexpression of c-rel in these cells resulted in variable expression of p75. These data indicated that p75 is ectopically expressed on v-rel-transformed hematopoietic cells and that it responds differently to v-rel and c-rel induction.	W VIRGINIA UNIV,HLTH SCI CTR,MARY BABB RANDOLPH CANC CTR,MORGANTOWN,WV 26506; W VIRGINIA UNIV,HLTH SCI CTR,DEPT MICROBIOL & IMMUNOL,MORGANTOWN,WV 26506	West Virginia University; West Virginia University					NATIONAL CANCER INSTITUTE [R01CA041450] Funding Source: NIH RePORTER; NCI NIH HHS [CA41450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA Y, 1974, BIKEN J, V17, P105; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BARTH CF, 1988, J EXP MED, V167, P89, DOI 10.1084/jem.167.1.89; BARTH CF, 1988, MOL CELL BIOL, V8, P5358, DOI 10.1128/MCB.8.12.5358; BARTH CF, 1990, J VIROL, V64, P6054, DOI 10.1128/JVI.64.12.6054-6062.1990; BOEHMELT G, 1992, EMBO J, V11, P4641, DOI 10.1002/j.1460-2075.1992.tb05566.x; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN CH, 1988, EUR J IMMUNOL, V18, P539, DOI 10.1002/eji.1830180408; CHEN CLH, 1986, J EXP MED, V164, P375, DOI 10.1084/jem.164.1.375; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GRILLI M, 1993, INT REV CYTOL, V143, P1; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HANNINK M, 1991, Critical Reviews in Oncogenesis, V2, P293; Harlow E., 1988, ANTIBODIES LAB MANUA; HOELZER JD, 1980, VIROLOGY, V100, P462, DOI 10.1016/0042-6822(80)90536-X; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HUFFNAGLE GB, 1989, HYBRIDOMA, V8, P589, DOI 10.1089/hyb.1989.8.589; HUMPHRIES EH, 1992, CURRENT TOPIC MICROB, V18, P475; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; LEWIS RB, 1981, CELL, V25, P421, DOI 10.1016/0092-8674(81)90060-X; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; NAZERIAN K, 1982, J GEN VIROL, V58, P351, DOI 10.1099/0022-1317-58-2-351; NEHYBA J, 1994, J VIROL, V68, P2039, DOI 10.1128/JVI.68.4.2039-2050.1994; OKAZAKI W, 1980, AVIAN PATHOL, V9, P311, DOI 10.1080/03079458008418416; OLSON LD, 1967, AM J VET RES, V28, P1501; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806	34	7	7	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1153	1157						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649808				2022-12-28	WOS:A1996UA88400025
J	Guha, A; Lau, N; Huvar, I; Gutmann, D; Provias, J; Pawson, T; Boss, G				Guha, A; Lau, N; Huvar, I; Gutmann, D; Provias, J; Pawson, T; Boss, G			Ras-GTP levels are elevated in human NF1 peripheral nerve tumors	ONCOGENE			English	Article						NF1; Ras-GDP; Ras	NEUROFIBROMATOSIS TYPE-1 GENE; NUCLEOTIDE EXCHANGE FACTOR; SIGNAL TRANSDUCTION; ACTIVATING PROTEIN; GRB2; PRODUCT; CELLS; TRANSFORMATION; NEUROBLASTOMA; ONCOGENES	Neurofibromin, the gene product of NF1, is a Pas GTPase Activating Protein. The absence of neurofibromin leads to increased levels of Ras-GTP, which contributes to the proliferation of NF1 neurogenic sarcoma cell lines. Whether this pathogenic mechanism is applicable to benign and malignant peripheral nerve tumours from NF1 and non NF1 patients is not known, due to lack of a tissue based assay, We have adapted a colorimetric enzymatic assay for determining levels of Pas bound guanine nucleotides in tissues, Ras-GTP levels were increased in NF1 neurogenic sarcomas (15 times) and benign NF1 neurofibromas (four times), compared to non NF1 schwannomas. Neurofibromin was not expressed in NF1 sarcomas, in support of its important negative Ras regulatory role in the pathogenesis of NF1 peripheral nerve tumors.	UNIV TORONTO,ONTARIO CANC INST,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,TORONTO HOSP,DIV NEUROPATHOL,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5S 1A1,CANADA; UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92103; WASHINGTON UNIV,SCH MED,DEPT NEUROL PEDIAT & GENET,ST LOUIS,MO 63130; UNIV TORONTO,TORONTO HOSP,DIV NEUROSURG & SURG ONCOL,TORONTO,ON M5S 1A1,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of California System; University of California San Diego; Washington University (WUSTL); University of Toronto; University Toronto Affiliates; University Health Network Toronto	Guha, A (corresponding author), MT SINAI HOSP,SAMUEL LUNENFELD RES INST,PROGRAMME MOLEC BIOL & CANC,600 UNIV AVE,TORONTO,ON M5G 1X5,CANADA.		Pawson, Tony J/E-4578-2013	Boss, Gerry/0000-0002-9758-8714; Gutmann, David/0000-0002-3127-5045	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001590] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49360] Funding Source: Medline; NINDS NIH HHS [NS-01590-05] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; ATKINSON DE, 1968, BIOCHEMISTRY-US, V7, P4030, DOI 10.1021/bi00851a033; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOLLAG G, 1992, CANCER BIOL, V3, P199; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GUHA A, 1995, NEUROLOGICAL SURGERY; GUTMANN DH, 1994, GENE CHROMOSOME CANC, V10, P55, DOI 10.1002/gcc.2870100109; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; GUTMANN DH, 1994, METABOLIC MOL BASIS; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LOWENSTEIN E, 1942, CELL, V70, P431; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90063-V; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NAKAFUKU M, 1993, P NATL ACAD SCI USA, V90, P6706, DOI 10.1073/pnas.90.14.6706; NUREKAMAL MSA, 1993, J BIOL CHEM, V268, P22331; PELTONEN J, 1983, ACTA NEUROPATHOL, V61, P275, DOI 10.1007/BF00691998; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; Sambrook J, 1989, MOL CLONING LABORATO; SCHEELE JS, 1995, P NATL ACAD SCI USA, V92, P1097, DOI 10.1073/pnas.92.4.1097; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; XU G, 1990, CELL, V463, P835; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	40	139	140	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					507	513						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637706				2022-12-28	WOS:A1996TV59700006
J	Rao, VN; Shao, NS; Ahmad, M; Reddy, ESP				Rao, VN; Shao, NS; Ahmad, M; Reddy, ESP			Antisense RNA to the putative tumor suppressor gene BRCA1 transforms mouse fibroblasts	ONCOGENE			English	Article						BRCA1 proteins; antisense RNA; tumor suppressor; breast and ovarian cancers	FAMILIAL BREAST; OVARIAN-CANCER; CHROMOSOME; REGION	Recently, BRCA1, a familial breast and ovarian cancer susceptible gene has been cloned and shown to be either lost or mutated in families with breast and ovarian cancers, BRCA1 has been postulated to encode a tumor suppressor, a protein that acts as a negative regulator of tumor growth, We have characterized the BRCA1 gene products by Western blot and immunoprecipitation analysis in mouse and tumor cells. Multiple BRCA1 polypeptides of approximately 225, 185, 160, 145, 100, 52 and 38 kD were identified in these cells, BRCA1 proteins were found to be localized mainly in the nucleus of normal Rat1 cells and human breast cancer cells, Tn order to understand the role of BRCA1 in cell transformation, we have established a stable NIH3T3 cell line expressing BRCA1 antisense RNA. The inhibition of expression of endogenous BRCA1 protein was detected in NIH3T3 transfectants by Western blot analysis, The antisense BRCA1 expressing NIH3T3 cells showed accelerated growth rate, anchorage independent growth and tumorigenicity in nude mice unlike the parental and sense transfectants, These results provide the first direct biological evidence for the possible function of BRCA1 as a tumor suppressor gene.			Rao, VN (corresponding author), THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT MICROBIOL & IMMUNOL, 233 S 10TH ST, PHILADELPHIA, PA 19107 USA.				NATIONAL CANCER INSTITUTE [P01CA050507, R01CA057322, R01CA057157] Funding Source: NIH RePORTER; NCI NIH HHS [CA 57322, CA 57157, CA 50507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLAUS EB, 1991, AM J HUM GENET, V48, P232; EASTON DF, 1993, AM J HUM GENET, V52, P678; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; ISZAT JG, 1984, CELL, V36, P1007; KELSELL DP, 1993, HUM MOL GENET, V2, P1823; LOVELAND BE, 1992, BIOCHEM INT, V27, P501; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; RAO VN, 1993, CANCER RES, V53, P215; SMITH HS, 1993, J CELL BIOCHEM, P144; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; TAKAHASHI H, 1995, CANCER RES, V55, P2998; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444	15	99	101	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					523	528						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637708				2022-12-28	WOS:A1996TV59700008
J	Soprano, DR; Chen, LX; Wu, S; Donigan, AM; Borghaei, RC; Soprano, KJ				Soprano, DR; Chen, LX; Wu, S; Donigan, AM; Borghaei, RC; Soprano, KJ			Overexpression of both RAR and RXR restores AP-1 repression in ovarian adenocarcinoma cells resistant to retinoic acid-dependent growth inhibition	ONCOGENE			English	Article						retinoic acid receptor; retinoic acid resistance; ovarian carcinoma cells; AP-1 antagonism	RECEPTOR-ALPHA; X RECEPTOR; EXPRESSION; LINES; CARCINOMA; COMPLEX; GAMMA; BETA; MICE; GENE	Retinoids including retinoic acid (RA) have been demonstrated to be effective growth inhibitors of a number of human cancer cell lines including ovarian adenocarcinoma cells, To begin to determine the mechanism of action by which RA inhibits the growth of ovarian carcinoma cells, we have examined AP-1 activity in two representative cell lines: CaOV-3 a RA-sensitive cell line and SK-OV-3 a RA-resistant cell line, AP-1 activity was found to be inhibited by 50% upon RA treatment of the RA-sensitive cells while there was no change in AP-1 activity following RA treatment of the RA-resistant cells, Maximal inhibition of AP-1 activity could be achieved in the RA-resistant SK-OV-3 cells by overexpression of any one of the three retinoic acid receptor (RAR) subtypes in conjunction with retinoid X receptor (RXR) alpha. This inhibition of AP-1 activity was nearly comparable to that of the RA-sensitive cells, A similar change in AP-1 complex formation in vitro has also been observed, These results suggest that one mechanism by which RA inhibits growth of RA-sensitive ovarian carcinoma cells is by repressing AP-1 activity, Moreover, in the RA-resistant cells the RAR/RXR signalling pathway leading to inhibition of AP-1 activity is impaired however overexpression of one of the RAR subtypes along with RXR alpha is sufficient to restore this pathway.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Borghaei, Ruth/0000-0003-4206-0231	NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517, R01DK049045] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64945] Funding Source: Medline; NIDDK NIH HHS [DK44517, DK 49045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Baserga R, 1969, AUTORADIOGRAPHY TECH; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; CARTER R, 1991, ONCOGENE, V6, P229; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; GRUNT TW, 1991, J CELL SCI, V100, P657; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hong Waun Ki, 1994, P597; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; LANGDON SP, 1988, CANCER RES, V48, P6161; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mangelsdorf David J., 1994, P319; MARTH C, 1989, ANTICANCER RES, V9, P461; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2723; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; OWEN TA, 1987, J BIOL CHEM, V262, P15111; PAN LY, 1992, NUCLEIC ACIDS RES, V20, P3105, DOI 10.1093/nar/20.12.3105; PAN LY, 1995, J CELL BIOCHEM, V57, P575, DOI 10.1002/jcb.240570402; PENA A, 1993, J BIOL CHEM, V268, P27277; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839	32	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					577	584						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637715				2022-12-28	WOS:A1996TV59700015
J	Cheng, NC; Beitsma, M; Chan, A; denCamp, IO; Westerveld, A; Pronk, J; Versteeg, R				Cheng, NC; Beitsma, M; Chan, A; denCamp, IO; Westerveld, A; Pronk, J; Versteeg, R			Lack of class I HLA expression in neuroblastoma is associated with high N-myc expression and hypomethylation due to loss of the MEMO-1 locus	ONCOGENE			English	Article						class I HLA; MEMO-1; methylation; neuroblastoma; N-myc; tumour suppressor gene	BLASTOMA CELL-LINES; NEURO-BLASTOMA; ANTIGEN EXPRESSION; LEUKOCYTE ANTIGEN; DNA METHYLATION; C-MYC; GENE; AMPLIFICATION; TUMOR; SEQUENCE	Class I HLA expression is low in neuroblastoma tumours and cell lines. We have recently mapped a modifier of methylation for HLA-C (MEMO-1) to chromosomal bands 1p35-36.1, a region deleted in many neuroblastomas. Hypomethylation of HLA-C is strongly correlated with allelic loss of the MEMO-1 locus. Here, we show that loss of MEMO-1 is associated with hypomethylation of both the 5' and 3' regions of class I KLA loci. We next investigated the relationship between methylation and expression of class I HLA in 28 cell lines of neuroectodermal tumours. Cell lines with hypermethylated HLA-C and HLA-A loci have relatively high expression, while most cell lines with hypomethylated loci have no or a reduced expression. It was reported earlier that high expression of c- or N-myc can suppress class I HLA expression. Remarkably, also N-myc amplification in neuroblastomas is associated with allelic loss of 1p35-36. Therefore, we have analysed the relationships between allelic loss of the MEMO-1 locus, class I HLA methylation and expression, and N-myc amplification and expression. This study shows a tight inter-relationship between these phenomena. Our data suggest a model in which hypomethylation of class I HLA due to loss of the MEMO-1 locus and high N-myc expression could collaborate in the down-regulation of class I HLA expression.	UNIV AMSTERDAM,ACAD MED CTR,DEPT HUMAN GENET,NL-1100 DE AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam			Versteeg, Rogier/AAQ-1765-2020	Versteeg, Rogier/0000-0001-7172-0388				BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BRODEUR GM, 1981, CANCER RES, V41, P4678; CAMPBELL RD, 1993, IMMUNOL TODAY, V14, P349, DOI 10.1016/0167-5699(93)90234-C; CARON H, 1995, HUM MOL GENET, V4, P535, DOI 10.1093/hmg/4.4.535; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHENG NC, 1995, ONCOGENE, V10, P291; Cheng NC, 1996, HUM MOL GENET, V5, P309, DOI 10.1093/hmg/5.3.309; COOPER MJ, 1990, CANCER RES, V50, P3694; DAAR AS, 1984, TRANSPLANTATION, V38, P287, DOI 10.1097/00007890-198409000-00018; EMMOUR J, 1991, IMMUNOBIOLOGY, V187, P70; FAVROT MC, 1991, INT J CANCER, V48, P502, DOI 10.1002/ijc.2910480405; FELTNER DE, 1989, J IMMUNOL, V143, P4292; GILBERT F, 1984, CANCER RES, V44, P5444; GROSS N, 1994, INT J CANCER, V59, P141, DOI 10.1002/ijc.2910590124; GUSSOW D, 1987, IMMUNOGENETICS, V25, P313, DOI 10.1007/BF00404424; KOLLER BH, 1985, J IMMUNOL, V134, P2727; LAMPSON LA, 1983, J IMMUNOL, V130, P2471; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; REIN RS, 1987, J IMMUNOL, V138, P1178; REYNOLDS CP, 1988, ADV NEUROBLASTOMA RE, V2, P291; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SODOYER R, 1984, EMBO J, V3, P879, DOI 10.1002/j.1460-2075.1984.tb01900.x; SUMMERS CW, 1993, EUR J IMMUNOGENET, V20, P201, DOI 10.1111/j.1744-313X.1993.tb00111.x; TANAKA K, 1986, P NATL ACAD SCI USA, V83, P7598, DOI 10.1073/pnas.83.20.7598; TANAKA K, 1983, CELL, V35, P457, DOI 10.1016/0092-8674(83)90179-4; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; VERSTEEG R, 1988, EMBO J, V7, P1023, DOI 10.1002/j.1460-2075.1988.tb02909.x; VERSTEEG R, 1989, J EXP MED, V170, P621, DOI 10.1084/jem.170.3.621; VERSTEEG R, 1990, MOL CELL BIOL, V10, P5416, DOI 10.1128/MCB.10.10.5416	29	27	28	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1737	1744						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895520				2022-12-28	WOS:A1996VM88700019
J	Vairo, G; Innes, KM; Adams, JM				Vairo, G; Innes, KM; Adams, JM			Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival	ONCOGENE			English	Article						bcl-2; differentiation; cell cycle; G(0); haemopoiesis; apoptosis	C-MYC; GROWTH-FACTORS; PROTOONCOGENE EXPRESSION; LEUKEMIA-CELLS; HL-60 CELLS; DIFFERENTIATION; APOPTOSIS; PROTEIN; DEATH; INDUCTION	Myeloid maturation appears to require exit from the cell cycle and leads to activation of apoptosis in the differentiated cells. The level of Bcl-2, which is known to promote cell survival, is shown here to influence both these critical steps. Bcl-2 function during myelomonocytic differentiation was investigated by introducing a deregulated bcl-2 gene into HL60 promyelocytic luekaemia cells, which can be induced to exit the cell cycle and differentiate into granulocytes or monocytes. Deregulated Bcl-2 expression did not itself promote differentiation but extended the lifespan of mature cells elicited by granulocytic or monocytic inducers. Unexpectedly, in response to induction, Bcl-2 overexpression markedly potentiated and hastened cell cycle withdrawal into G(0). Enhanced survival cannot account for the elevated numbers of G(0) cells, because they arose under induction conditions that did not kill control cells. Since the cell cycle status and growth of uninduced cells was not affected by Bcl-2-overexpression, its cell cycle inhibitory activity must require an induction signal. While cell cycle withdrawal may be necessary for maturation, it was not sufficient, implicating a requirement for specific differentiative signals. These results identify, for the first time, a function for the bcl-2 proto-oncogene that is separable from its enhancement of cell survival.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628	NCI NIH HHS [CA12421] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; BENITO A, 1995, AM J PATHOL, V146, P481; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BREITMAN TR, 1990, METHOD ENZYMOL, V190, P118; Cochrane C. G., 1968, Advances in Immunology, V9, P97, DOI 10.1016/S0065-2776(08)60442-3; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COLLINS MKL, 1994, BIOESSAYS, V16, P133, DOI 10.1002/bies.950160210; COLLINS SJ, 1987, BLOOD, V70, P1233; CORY S, 1994, COLD SPRING HARB SYM, V59, P365, DOI 10.1101/SQB.1994.059.01.041; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; Crissman H A, 1990, Methods Cell Biol, V33, P305; DANDREA AD, 1994, CURR OPIN CELL BIOL, V6, P804, DOI 10.1016/0955-0674(94)90048-5; DARZYNKIEWICZ Z, 1990, FLOW CYTOMETRY SORTI, P469; DELIA D, 1992, BLOOD, V79, P1291, DOI 10.1182/blood.V79.5.1291.bloodjournal7951291; DURO D, 1995, ONCOGENE, V11, P21; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Guy CT, 1996, MOL CELL BIOL, V16, P685; HENSON PM, 1987, J CLIN INVEST, V79, P669, DOI 10.1172/JCI112869; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; KIYOKAWA H, 1994, MOL CELL BIOL, V14, P7195, DOI 10.1128/MCB.14.11.7195; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; Lin EY, 1996, BLOOD, V87, P983, DOI 10.1182/blood.V87.3.983.bloodjournal873983; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; LONDON L, 1987, J EXP MED, V166, P1419, DOI 10.1084/jem.166.5.1419; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; MARVEL J, 1994, ONCOGENE, V9, P1117; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAUMOVSKI L, 1994, BLOOD, V83, P2261; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARK JR, 1994, BLOOD, V84, P440; PEZZELLA F, 1990, AM J PATHOL, V137, P225; PIETENPOL JA, 1994, CANCER RES, V54, P3714; PILZ RB, 1987, J CLIN INVEST, V79, P1006, DOI 10.1172/JCI112867; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSER A, 1996, IN PRESS EMBO J; TERUI Y, 1995, J CELL PHYSIOL, V164, P74, DOI 10.1002/jcp.1041640110; Uhlmann EJ, 1996, CANCER RES, V56, P2506; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; ZUCKER RM, 1983, CYTOMETRY, V3, P414, DOI 10.1002/cyto.990030605	60	161	171	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1511	1519						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875989				2022-12-28	WOS:A1996VL38400016
J	Zhao, JQ; Schmieg, FI; Logsdon, N; Freedman, D; Simmons, DT; Molloy, GR				Zhao, JQ; Schmieg, FI; Logsdon, N; Freedman, D; Simmons, DT; Molloy, GR			p53 binds to a novel recognition sequence in the proximal promoter of the rat muscle creatine kinase gene and activates its transcription	ONCOGENE			English	Article						p53; creatine kinase genes; energy metabolism; in vitro transactivation	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL NUCLEAR ANTIGEN; DNA-BINDING; RESPONSIVE ELEMENT; INDUCED APOPTOSIS; MDM2 EXPRESSION; MICE DEFICIENT; BRAIN; IDENTIFICATION	The rat muscle creatine kinase (CKM) gene promoter is unusual since it is one of the few cellular promoters containing a p53 response element which is located proximally (bp -168 to -57) to the transcription start site. We have previously shown that p53wt transactivates transcription in vivo of rat CKM, in CV-1 monkey kidney cells, through this 112 bp promoter-proximal fragment which contains at least five degenerate p53-binding elements. In this report, we employed the gel-shift assay and demonstrated that recombinant, immunoaffinity-purified mouse p53wt binds to this 112 bp CKM sequence and activates the in vitro transcription of the proximal CKM promoter by nuclear extracts from CV-1 cells. Also, a competitor plasmid containing this 112 bp CKM fragment interferred with the in vivo transactivation of CKM by p53. This CKM fragment, when cloned upstream of the rat br ain creatine kinase (CKB) promoter, mediated the p53 transactivation of CKB. Analyses of p53 wt and a series of missense mutants (altered in conserved region II of p53) showed that binding of p53 to the CKM promoter was required but was not sufficient for transactivation. The results are discussed in relation to the possible role of p53wt in the expression of CKM in cell types which may not express the myogenic transcription factors.	UNIV DELAWARE,DEPT BIOL,NEWARK,DE 19716	University of Delaware					NCI NIH HHS [CA 55234] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA055234] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V250, P1576; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; EDMONDOSN EG, 1993, J BIOL CHEM, V268, P755; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GASDAR AF, 1981, CANCER RES, V41, P2773; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAMES BD, 1993, IRL PRESS, V136; HARPER JW, 1993, CELL, V75, P805; HEMMER W, 1993, DEV NEUROSCI-BASEL, V15, P249, DOI 10.1159/000111342; HEMMER W, 1994, EUR J NEUROSCI, V6, P538, DOI 10.1111/j.1460-9568.1994.tb00298.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KERN SE, 1991, SCIENCE, V252, P1707; KLEY N, 1992, NUCLEIC ACIDS RES, V17, P3645; KLEY SE, 1992, SCIENCE, V17, P3645; KUZHIKANDATHIL EV, 1994, J NEUROSCI RES, V39, P70, DOI 10.1002/jnr.490390110; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3219; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MANOS P, 1993, DEV NEUROSCI-BASEL, V15, P271, DOI 10.1159/000111344; MANOS P, 1991, J NEUROCHEM, V56, P2101, DOI 10.1111/j.1471-4159.1991.tb03472.x; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MITCHELL MT, 1990, J BIOL CHEM, V265, P8259; MIYASHITA T, 1995, CELL, V80, P293; MOLLOY GR, 1992, J NEUROCHEM, V59, P1925, DOI 10.1111/j.1471-4159.1992.tb11028.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; WALLIMANN T, 1994, MOL CELL BIOCHEM, V133, P193, DOI 10.1007/BF01267955; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WILSON CD, 1993, J NEUROSCI RES, V35, P92, DOI 10.1002/jnr.490350111; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	79	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					293	302						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710368				2022-12-28	WOS:A1996VA25200008
J	Ogawa, S; Kurokawa, M; Tanaka, T; Mitani, K; Inazawa, J; Hangaishi, A; Tanaka, K; Matsuo, Y; Minowada, J; Tsubota, T; Yazaki, Y; Hirai, H				Ogawa, S; Kurokawa, M; Tanaka, T; Mitani, K; Inazawa, J; Hangaishi, A; Tanaka, K; Matsuo, Y; Minowada, J; Tsubota, T; Yazaki, Y; Hirai, H			Structurally altered Evi-1 protein generated in the 3q21q26 syndrome	ONCOGENE			English	Article						Evi-1; inv(3)(q21q26); 3q21q26; syndrome CML; blastic crisis	ECOTROPIC VIRAL INTEGRATION; ACUTE MYELOGENOUS LEUKEMIAS; COLONY-STIMULATING FACTOR; MURINE MYELOID TUMORS; ZINC FINGER GENE; COMMON SITE; EV11 GENE; EXPRESSION; REARRANGEMENTS; TRANSLOCATIONS	Overexpression of the Evi-1 gene appears to be a consistent feature of the 3q21q26 syndrome, an association of myeloid leukemias/myelodysplastic syndrome with a specific chromosomal aberration involving both 3q21 and 3q26, such as t(3;3)(q21;q26) or inv(3)(q21a26). The rearrangement in 3q26 has been reported to occur near the Evi-1 locus, implicating that it is the critical gene deregulated in the 3q21q26 syndrome, Here we present a structural abnormality of Evi-1 protein in a case with the 3q21q26 syndrome, In this case carrying typical inv(3)(q21q26), the 3q26 breakpoint is located within an intron of the Evi-1 gene, and resulted in overexpression of normally unexpressed, an aberrant form of Evi-1 protein, in which the C-terminal 44 amino acids of wild-type Evi-1 protein were truncated and replaced by five amino acids, The truncated Evi-1 protein is shown to increase AP1 activity when expressed in NIH3T3 cells as its wild-type counterpart, We also show that the origin of this peculiar type of rearrangement of the Evi-1 gene is not an artifact during establishment of the cell line, but is the event that occurred in the primary leukemic cells, Our results strongly support that the primary target for the 3q21q26 syndrome is the Evi-1 gene, and provide the first evidence that the structurally altered Evi-1 gene may be involved in the 3q21q26 syndrome.	UNIV TOKYO, FAC MED, DEPT INTERNAL MED 3, BUNKYO KU, TOKYO 113, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT HYG, KYOTO 602, JAPAN; HAYASHIBARA BIOCHEM LABS INC, FUJISAKI CELL CTR, OKAYAMA 702, JAPAN; OKAYAMA CITY HOSP, DEPT INTERNAL MED, OKAYAMA 700, JAPAN	University of Tokyo; Kyoto Prefectural University of Medicine; Hayashibara Biochemical Laboratories, Inc.			Tanaka, Tomoyuki U/A-4775-2008; Tanaka, Kozo/Y-6566-2018	Tanaka, Kozo/0000-0001-6086-2858				BARTHOLOMEW C, 1989, ONCOGENE, V4, P529; BITTER MA, 1985, BLOOD, V66, P1362; BORDEREAUX D, 1990, ONCOGENE, V5, P925; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DREYFUS F, 1995, LEUKEMIA, V9, P203; FICHELSON S, 1992, LEUKEMIA, V6, P93; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JENKINS RB, 1989, CANCER GENET CYTOGEN, V39, P167, DOI 10.1016/0165-4608(89)90182-9; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; KUROKAWA M, 1995, ONCOGENE, V11, P833; LEVY ER, 1994, BLOOD, V83, P1348; Matsuo Y, 1991, Hum Cell, V4, P261; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MORISHITA K, 1990, ONCOGENE, V5, P963; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, ONCOGENE RES, V2, P219; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA S, 1994, ONCOGENE, V9, P1669; OGAWA S, 1996, IN PRESS LEUKEMIA; OHYASHIKI JH, 1995, BLOOD, V85, P3713, DOI 10.1182/blood.V85.12.3713.bloodjournal85123713; OHYASHIKI K, 1994, LEUKEMIA, V8, P2169; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RUSSELL M, 1993, LEUKEMIA, V7, P1654; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TANAKA T, 1991, BLOOD, V77, P2597	30	50	52	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					183	191						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700545				2022-12-28	WOS:A1996UX31900021
J	Matoskova, B; Wong, WT; Nomura, N; Robbins, KC; DiFiore, PP				Matoskova, B; Wong, WT; Nomura, N; Robbins, KC; DiFiore, PP			RN-tre specifically binds to the SH3 domain of eps8 with high affinity and confers growth advantage to NIH3T3 upon carboxy-terminal truncation	ONCOGENE			English	Article						eps8; SH3; tre; signal transduction	GUANINE-NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; TYROSINE KINASE; EGF RECEPTOR; GRB2; RAS; ONCOGENE; CELLS; SOS; ACTIVATOR	We isolated a cDNA encoding a protein, RN-tre, which shows homology to the N-terminus of the tre oncogene product and has SH3-binding ability as well as an evolutionarily conserved domain, termed TrH, with protein-binding ability in vitro. In the present study, we identify the product of the RN-tre gene as a 97 - 100 kDa protein. We demonstrate stable association in vivo and in vitro between RN-tre and eps8, mediated by the SH3 domain of the latter. In vitro, RN-tre displayed remarkable preference for binding to the eps8-SH3, as compared to eight other SH3s. The Kd for the in vitro interaction between RN-tre and eps8-SH3 was between 10(-8) and 10(-7) M. A role for RN-tre in cell proliferation was suggested by the finding that a C-terminal truncated mutant was able to confer proliferative advantage and reduced serum-requirement to NIH3T3 fibroblasts. Finally, comparison of the structure and biological activities of RN-tre and of the tre oncogene product, provided insight into the mechanism of oncogenic activation of tre.	IST EUROPEO ONCOL, DEPT EXPTL ONCOL, I-20141 MILAN, ITALY; NIDR, CELLULAR DEV & ONCOL LAB, NIH, BETHESDA, MD 20892 USA; NCI, LAB CELLULAR & MOL BIOL, NIH, BETHESDA, MD 20892 USA; KAZASA DNA RES INST, CHIBA 292, JAPAN; FAC MED & CHIRURG, IST MICROBIOL, BARI, ITALY	IRCCS European Institute of Oncology (IEO); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FINAN P, 1994, J BIOL CHEM, V269, P13752; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HUEBNER K, 1988, ONCOGENE, V3, P449; KARLSSON T, 1995, IN PRESS ONCOGENE; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Matoskova B, 1996, ONCOGENE, V12, P2563; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RICHARDSON PM, 1995, ONCOGENE, V11, P1139; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG WT, 1994, ONCOGENE, V9, P3057	31	36	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2679	2688						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700527				2022-12-28	WOS:A1996UW48700022
J	Duprez, E; Lillehaug, JR; Gaub, MP; Lanotte, M				Duprez, E; Lillehaug, JR; Gaub, MP; Lanotte, M			Differential changes of retinoid-X-receptor (RXR alpha) and its RAR alpha and PML-RAR alpha partners induced by retinoic acid and cAMP distinguish maturation sensitive and resistant t(15;17) promyelocytic leukemia NB4 cells	ONCOGENE			English	Article						acute promyelocytic leukemia; retinoic acid; nuclear receptor superfamily; transcription factors; differentiation; NB4 cells	TRANSLOCATION; PROTEIN; EXPRESSION; GENE; LINE; RNA; BREAKPOINT; EXTRACTION; LOCUS	The expression of retinoid receptors (RXR alpha, RAR alpha and the chimeric form PML-RAR alpha) was analysed both at the mRNA and protein level in the maturation sensitive NB4 and resistant NB4-R1 cell lines of t(15;17) promyelocytic leukemia (APL), All-trans RA and cAMP which show synergistic activity in inducing maturation of NB4 cells and maturation triggering of the RA 'primed' NB4-R1 resistant cells, distinctly modulate RXR alpha, RAR alpha and PML-RAR alpha mRNA. In the NB4 and NB4-R1 cells, RXR alpha mRNA was downregulated by RA, but only in RA-primed NB4-R1 cells a release from RXR alpha mRNA downregulation was obtained by cAMP treatment, RXR alpha protein (53 kDa) was decreased to the western-blot detection limit (97.5%) by RA in NB4 cells, but in NB4-R1 cells although it was frankly decreased (85%), the signal for RXR alpha protein remained very significant, More importantly, while cAMP slightly upregulated RXR alpha protein in RA-treated NB4 cells, it caused an increase of RXR alpha protein in RA-treated NB4-R1 cells bringing RXR alpha to the initial control level, RXR alpha partners in heterodimers (PML-RAR alpha, RAR alpha) were also analysed, In contrast to RXR alpha, RAR alpha and PML-RAR alpha mRNA were not modulated by RA and/or cAMP, while significant changes were observed at the protein levels, A putatively phosphorylated form of RAR alpha (52 kDa) during maturation of NB4 cells, but was in resistant NB4-R1 cells, Conversely, while PML-RAR alpha remained stable during RA-induced NB4 maturation, RA treatment which failed to induce maturation of NB4-R1 cells significantly down-regulated the chimeric receptor (120 kDa), These likely results from translational and post-translational regulation, This work reveals complex pattern of subtle changes at the protein level distinguishing RA-sensitive and RA-resistant cells, Our data show that the RA-cAMP synergistic effect on NB4 cell maturation and cooperation in triggering maturation of RA-primed NB4-R1 cells operate changes in the RXR/ PML-RAR alpha ratio which are both favouring RXR alpha. In both cell lines, variations of PML-RAR alpha and RXR alpha may result in a decrease in the formation of the PML-RAR alpha/RXR alpha heterodimers which are supposed involved in the block of maturation, This may prove crucial to embark cells on maturation.	HOP ST LOUIS,CTR G HAYEM,INSERM U301,F-75010 PARIS,FRANCE; IGBMC,INSERM U184,F-67404 ILLKIRCH GRAFFENS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)			duprez, estelle a/R-2357-2016					ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BAIN G, 1994, BIOCHEM BIOPH RES CO, V200, P1252, DOI 10.1006/bbrc.1994.1585; BORDEN K, 1985, EMBO J, V14, P1532; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRUEL A, 1995, LEUKEMIA, V9, P1173; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; CHEN Z, 1990, LEUKEMIA, V5, P288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGMAN JDL, 1983, NUCLEIC ACIDS RES, V11, P1495; Duprez E, 1996, ONCOGENE, V12, P2451; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; EVERETT RD, 1994, EMBO J, V13, P5062, DOI 10.1002/j.1460-2075.1994.tb06835.x; FAGIOLI M, 1992, ONCOGENE, V7, P1083; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Gudas Lorraine J., 1994, P443; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; KAKIZUKA A, 1991, CELL, V66, P653; Kastner P., 1994, Vitamin A in health and disease., P189; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KIZAKI M, 1993, BLOOD, V82, P3592; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1080; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; Mangelsdorf David J., 1994, P319; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; MUINDI J, 1992, BLOOD, V79, P299; OLSON IL, 1982, CANCER RES, V42, P3922; PEMRICK SM, 1994, LEUKEMIA, V8, P1797; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; WAN YJY, 1994, EXP CELL RES, V210, P56, DOI 10.1006/excr.1994.1009; WARRELL RP, 1993, BLOOD, V82, P1949, DOI 10.1182/blood.V82.7.1949.bloodjournal8271949; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0	53	43	43	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2443	2450						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649786				2022-12-28	WOS:A1996UQ22000023
J	Massimi, P; Pim, D; Storey, A; Banks, L				Massimi, P; Pim, D; Storey, A; Banks, L			HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation	ONCOGENE			English	Article						CKII; HPV; E7; TBP	HUMAN PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; HUMAN KERATINOCYTES; ACTIVATION DOMAIN; MOUSE CELLS; CYCLIN-A; EJ-RAS; TRANSFORMATION; TRANSACTIVATION	The major transforming protein of HPV-16 is encoded by the E7 gene. This has been shown to cooperate with EJ-ras in the immortalisation of primary rodent cells and with the viral E6 gene in the immortalisation of primary human keratinocytes. HPV-16 E7 protein has been shown to bind to a number of cellular proteins involved in the control of cell growth; including pRB, p107 and cyclin A, Loss of pRb or p107 binding results in the loss of transforming activity. In this paper we demonstrate that HPV-16 E7 can also complex with the core component of TFIID, the TATA Box Binding Protein (TBP). This interaction is partly dependent upon phosphorylation of the E7 protein by cellular casein kinase II (CKII), since phosphorylation of E7 by CKII increases the affinity with which E7 binds TBP. Similar results are also obtained with the Adenovirus Ela protein, indicating a conservation of function between these two viral oncoproteins. Mutation of the CKII site to two acidic amino acids significantly increases the affinity of E7 for TBP, indicating that the incorporation of two negative charges at this region of E7 is important in regulating the interaction with TBP.	INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY; ROYAL LONDON HOSP, DEPT EXPTL DERMATOL, LONDON, ENGLAND	International Center for Genetic Engineering & Biotechnology (ICGEB); Barts Health NHS Trust; Royal London Hospital				Storey, Alan/0000-0003-2001-9772				ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANKS L, 1988, VIROLOGY, V165, P326, DOI 10.1016/0042-6822(88)90695-2; BANKS L, 1990, ONCOGENE, V5, P1383; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARPER JW, 1993, CELL, V75, P805; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; HUDSON JB, 1990, J VIROL, V64, P519, DOI 10.1128/JVI.64.2.519-526.1990; IMAI Y, 1991, J VIROL, V65, P4966, DOI 10.1128/JVI.65.9.4966-4972.1991; KERR LD, 1993, NATURE, V336, P646; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; METZ R, 1994, MOL CELL BIOL, V14, P6021, DOI 10.1128/MCB.14.9.6021; MUNGER K, 1989, J VIROL, V63, P4417; PHELPS WC, 1991, J VIROL, V65, P6922, DOI 10.1128/JVI.65.12.6922-6930.1991; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PIM D, 1994, ONCOGENE, V9, P1869; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; STOREY A, 1990, J GEN VIROL, V71, P965, DOI 10.1099/0022-1317-71-4-965; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; STOREY A, 1995, J GEN VIROL, V76, P819, DOI 10.1099/0022-1317-76-4-819; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; TOMMASINO M, 1993, ONCOGENE, V8, P195; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; zur Hausen H, 1987, PAPILLOMAVIRUSES, P245	41	74	78	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2325	2330						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649772				2022-12-28	WOS:A1996UQ22000009
J	Rojas, JM; Coque, JJR; Guerrero, C; Aroca, P; deMora, JF; delaCruz, X; Lorenzi, MV; Esteban, LM; Santos, E				Rojas, JM; Coque, JJR; Guerrero, C; Aroca, P; deMora, JF; delaCruz, X; Lorenzi, MV; Esteban, LM; Santos, E			A 15 amino acid stretch close to the Grb2-binding domain defines two differentially expressed hSos1 isoforms with markedly different Grb2 binding affinity and biological activity	ONCOGENE			English	Article						hSos1; isoforms; Ras activation; Grb2 binding; differential expression	RECEPTOR TYROSINE KINASES; GUANINE-NUCLEOTIDE EXCHANGE; GROWTH-FACTOR RECEPTORS; SIGNAL TRANSDUCTION; SEVENLESS GENE; SH3 DOMAINS; RAS; PROTEIN; CELLS; IDENTIFICATION	We compared structure, expression and functional properties of two hSos1 cDNA isoforms (IsfI and Isf II) isolated, respectively, from human fetal brain and adult skeletal muscle libraries, IsfI and IsfII nucleotide sequences differ only by the presence in IsfII of an in-frame 45 bp insertion located near the first proline-rich motif required for Grb2 binding, Some human tissues express only one isoform whereas others express different proportions of both in fetal and adult stages, In vitro binding assays and in vivo functional studies showed that IsfII exhibits significantly higher Grb2 binding affinity and biological activity than IsfI, These results suggest that functionally different hSos1 isoforms, with differential tissue expression and distribution, play important regulatory roles in the mechanisms controlling Ras activation in different tissues and/or developmental stages.	NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, MOLEC BIOL LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Aroca, Pilar/P-2141-2017; Rojas, José M/D-3718-2018; de Mora, Jaime Font/H-6304-2015; Guerrero, Carmen/F-1776-2010; Coque, Juan Jose Rubio/AAV-2049-2021; Rojas, José M./AAA-3354-2021; de Mora, Jaime Font/AAK-7591-2021	Aroca, Pilar/0000-0002-7557-6931; Rojas, José M/0000-0002-5383-3482; de Mora, Jaime Font/0000-0002-6816-2095; Guerrero, Carmen/0000-0002-8747-6831; Coque, Juan Jose Rubio/0000-0001-8221-7817; Rojas, José M./0000-0002-7547-2825; de Mora, Jaime Font/0000-0002-6816-2095; De la Cruz Montserrat, Fco. Xavier/0000-0002-9738-8472				ADHUBEI AA, 1993, J MOL BIOL, V229, P472; ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHU CS, 1991, EMBO J, V10, P1355, DOI 10.1002/j.1460-2075.1991.tb07655.x; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HERTOG J, 1994, EMBO J, V13, P3020; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LEGRAIN P, 1993, GENE DEV, V7, P1390, DOI 10.1101/gad.7.7b.1390; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NISHI T, 1991, ONCOGENE, V6, P1555; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	58	10	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2291	2300						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649768				2022-12-28	WOS:A1996UQ22000005
J	Das, R; Reddy, EP; Chatterjee, D; Andrews, DW				Das, R; Reddy, EP; Chatterjee, D; Andrews, DW			Identification of a novel Bcl-2 related gene, BRAG-1, in human glioma	ONCOGENE			English	Article						apoptosis; Bcl-2; BRAG-1; glioma	APOPTOTIC CELL-DEATH; RNA; PROTEIN	Programmed cell death (apoptosis) plays a major role in embryogenesis, in mature organ homeostasis and in many disease states including cancer. Apoptosis occurs as an orderly cell-intrinsic suicide program regulated by a family of genes related to Bcl-2. Here, we describe the cloning and molecular characterization of a gene homologous to Bcl-2 from a human glioma. This gene named BRAG-1 (for brain-related apoptosis gene) has an open reading frame that encodes for a protein of 31 kDa sharing significant sequence homology with the Bcl-2 family of genes in the BH1 and BH2 regions. Northern blot analyses revealed that BRAG-1 is expressed in human gliomas as a 1.8 kb message. This gene, interestingly, was found to be expressed predominantly in normal human brain as a 4.5 kb transcript which is different in size from the message found in tumor tissues. These results suggest that BRAG-1 may be rearranged in human gliomas leading to its over-expression as a truncated transcript. Utilizing a bacterial expression vector, we produced BRAG-1 protein which was found to cross-react with a Bcl-2 monoclonal antibody, further suggesting structural and immunological similarity to Bcl-2.	THOMAS JEFFERSON UNIV HOSP, WILLS NEUROSENSORY INST, DEPT NEUROSURG, NEUROONCOL LAB, PHILADELPHIA, PA 19107 USA; THOMAS JEFFERSON UNIV HOSP, JEFFERSON CANC INST, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA	Jefferson University; Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [K11CA001514] Funding Source: NIH RePORTER; NCI NIH HHS [NIHK11-CA01514] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALDERSON LM, 1995, CANCER RES, V55, P999; ANDREWS AT, 1986, MONOGRAPHS PHYSICAL; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; CHOI SS, 1995, ONCOGENE, V11, P1693; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; FARWELL J, 1984, NEW ENGL J MED, V311, P749, DOI 10.1056/NEJM198409203111201; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; LIN EY, 1993, J IMMUNOL, V151, P1979; MALONE M, 1986, CANCER, V57, P1979, DOI 10.1002/1097-0142(19860515)57:10<1979::AID-CNCR2820571016>3.0.CO;2-R; Maniatis T., 1982, MOL CLONING; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RICCIARDI RP, 1977, P NATL ACAD SCI USA, V74, P5461; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	28	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					947	951						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649811				2022-12-28	WOS:A1996UA88400001
J	Shin, KH; Tannyhill, RJ; Liu, X; Park, NH				Shin, KH; Tannyhill, RJ; Liu, X; Park, NH			Oncogenic transformation of HPV-immortalized human oral keratinocytes is associated with the genetic instability of cells	ONCOGENE			English	Article						genetic stability; oral cancer; p53; HPV; carcinogenesis	WILD-TYPE P53; HUMAN PAPILLOMAVIRUS TYPE-16; SIMPLEX VIRUS TYPE-1; DNA-DAMAGING AGENTS; SHUTTLE VECTOR; GROWTH ARREST; MUTAGENESIS; MUTATIONS; IRRADIATION; INDUCTION	HPV-immortalized human oral keratinocytes can convert to tumorigenic cells when exposed to N-methyl-N-nitro-N-nitrosoguanidine (MNNG), but normal human oral keratinocytes cannot transform with a similar exposure. The different responses of these cells could be due to different genetic stability of cells. In as much as genetic stability is determined by cell cycle control and of repair of damaged DNA, we studied the effect of MNNG exposure upon cell cycle progression, expression of p53, WAF1/CIP1 and gadd45, and the mutation frequency of a shuttle vector pS189 in normal human oral keratinocytes, in HPV-immortalized oral keratinocytes, and in an oral cancer cell line expressing mutant p53. Normal cells demonstrated transient cell cycle arrest after exposure to MNNG, but the other tested cells did not. While MNNG exposure significantly increased the levels of intranuclear wt p53 protein and the expression of WAF1/CIP1 and gadd45 genes in normal cells, it did not alter them in the immortalized and cancer cells. The mutation frequency of pS189 plasmid was significantly lower in normal cells than in the other tested cells. These data indicate that malignant conversion of HPV-immortalized oral keratinocytes may, in part, be associated with the cells' genetic instability. The genetic instability may be due to cells' (1) inability to accumulate intranuclear wt p53 to a threshold level at which p53 upregulates the transcription of WAF1/CIP1 and gadd45, resulting in the loss of cell cycle control and (2) inefficient repair of DNA damage caused by genotoxic agents.	UNIV CALIF LOS ANGELES, SCH DENT, DENT RES INST, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles			Tannyhill, R. John/AAE-7432-2019	Tannyhill, R. John/0000-0003-3172-0345	NIDCR NIH HHS [K15 DE00371, R01 DE 10049, DE11229] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010049, R01DE011229, K15DE000371] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAEK JH, 1994, INT J ONCOL, V5, P1023; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; BURNS PA, 1987, J MOL BIOL, V194, P385, DOI 10.1016/0022-2836(87)90668-1; CANMAN CE, 1994, CANCER RES, V54, P5054; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUKUSHIMA A, 1994, GENOMICS, V22, P127, DOI 10.1006/geno.1994.1353; GUJULUVA CN, 1994, ONCOGENE, V9, P1819; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HWANG CBC, 1991, VIROLOGY, V181, P620, DOI 10.1016/0042-6822(91)90895-I; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, MOL CELL BIOL, V13, P4242; KIM MS, 1993, ANTICANCER RES, V13, P1405; KIM S, 1986, MUTAT RES, V173, P141, DOI 10.1016/0165-7992(86)90092-8; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI SL, 1992, ORAL ONCOL, V28B, P129, DOI 10.1016/0964-1955(92)90041-X; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEIDMAN M, 1989, MUTAT RES, V220, P55, DOI 10.1016/0165-1110(89)90010-9; SEIDMAN MM, 1987, P NATL ACAD SCI USA, V84, P4944, DOI 10.1073/pnas.84.14.4944; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHILLITOE EJ, 1993, VIRUS RES, V27, P239, DOI 10.1016/0168-1702(93)90036-M; SHIN KH, 1994, MOL CARCINOGEN, V9, P76, DOI 10.1002/mc.2940090205; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STARY A, 1992, MUTAT RES, V272, P101, DOI 10.1016/0165-1161(92)90038-N; SUN XG, 1995, MOL CELL BIOL, V15, P4489; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YEUNG MC, 1993, BIOTECHNIQUES, V15, P381; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	43	29	30	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1089	1096						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649801				2022-12-28	WOS:A1996UA88400018
J	Gollahon, LS; Shay, JW				Gollahon, LS; Shay, JW			Immortalization of human mammary epithelial cells transfected with mutant p53 (273(his))	ONCOGENE			English	Article						telomerase; telomeres; senescence; life span	HUMAN PAPILLOMAVIRUS TYPE-16; HUMAN-DIPLOID FIBROBLASTS; LARGE TUMOR-ANTIGEN; LARGE T-ANTIGEN; BREAST-CANCER; CELLULAR SENESCENCE; PROTEIN; TRANSFORMATION; GENE; DNA	Normal human breast epithelial cells were transfected with expression vectors containing the p53 gene mutated at either codon 143, 175, 248 or 273, or by infection with a recombinant retroviral vector containing the p53 gene mutated at codons 143, 175, 248, or 273. The breast epithelial cells were monitored for extension of in vitro lifespan and immortalization. Expression of some, but not all, p53 mutants resulted in an extension of in vitro lifespan. Experiments with the p53 temperature sensitive mutant 143(ala) revealed that at 32 degrees C, the nonpermissive temperature, the growth of breast epithelial cells was inhibited. At 37 degrees C, the mutant conformation, there was increased proliferation of cells, resulting in extension of in vitro lifespan. Breast epithelial cells expressing p53 mutant 273(his) maintained DNA binding and transcriptional activities and one clone immortalized after a period of growth arrest (crisis). The progression of this immortalization event was characterized by the reactivation of telomerase using the telomeric repeat amplification protocol (TRAP), and terminal restriction fragment analysis (TRF). This is the first reported immortalization of human mammary epithelial cells transfected with a mutant 53.	UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Shay, Jerry W/F-7878-2011					ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BOND JA, 1994, ONCOGENE, V9, P1885; CALLAHAN R, 1989, J NATL CANCER I, V81, P780; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; EYFJORD JE, 1995, CANCER RES, V55, P646; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORRESTER K, 1995, ONCOGENE, V10, P2103; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GILLESPIE P, 1991, P NATL ACAD SCI USA, V88, P2593; GOTZ C, 1995, INT J ONCOL, V6, P1129; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HIYAMA K, 1995, ONCOGENE, V10, P937; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUANGE HJS, 1988, SCIENCE, V292, P1563; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSLER LG, 1992, CANCER-AM CANCER SOC, V69, P1896, DOI 10.1002/1097-0142(19920401)69:7+<1896::AID-CNCR2820691704>3.0.CO;2-1; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KULJU KS, 1995, EXP CELL RES, V217, P336, DOI 10.1006/excr.1995.1095; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LI FP, 1988, CANCER RES, V48, P5358; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU ZJ, 1995, VIROLOGY, V207, P260, DOI 10.1006/viro.1995.1075; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MUNGER K, 1989, J VIROL, V63, P4417; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; PEREIRASMITH OM, 1987, MOL CELL BIOL, V7, P1541, DOI 10.1128/MCB.7.4.1541; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; Pollock Raphael E., 1992, Cancer Bulletin (Houston), V44, P268; REW DA, 1994, BRIT J SURG, V81, P1416, DOI 10.1002/bjs.1800811005; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SHAY JW, 1992, MUTAT RES, V277, P163, DOI 10.1016/0165-1110(92)90003-R; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, INT J ONCOL, V3, P559; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SHAY JW, 1993, BREAST CANCER RES TR, V25, P83, DOI 10.1007/BF00662404; SMITH JK, 1992, AM J OBSTET GYNECOL, V167, P1883, DOI 10.1016/0002-9378(92)91791-8; SMITH ML, 1995, ONCOGENE, V10, P1053; TSUTSUI T, 1995, CARCINOGENESIS, V16, P25, DOI 10.1093/carcin/16.1.25; VANDERHAEGEN BA, 1993, IN VITRO CELL DEV-AN, V29A, P180, DOI 10.1007/BF02634177; WATANABE S, 1989, SCIENCE, V248, P76; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; WYNFORDTHOMAS D, 1995, MOL CARCINOGEN, V12, P119; ZHANG W, 1992, ONCOGENE, V7, P1644	78	74	76	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					715	725						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632893				2022-12-28	WOS:A1996TW68600002
J	vanGrunsven, LA; Thomas, A; Urdiales, JL; Machenaud, S; Choler, P; Durand, I; Rudkin, BB				vanGrunsven, LA; Thomas, A; Urdiales, JL; Machenaud, S; Choler, P; Durand, I; Rudkin, BB			Nerve growth factor-induced accumulation of PC12 cells expressing cyclin D1: Evidence for a G1 phase block	ONCOGENE			English	Article						NGF; PC12; cyclin D1; flow cytometry; cell cycle; differentiation	PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; DNA; OVEREXPRESSION; PROGRESSION; FIBROBLASTS; METABOLISM; PROTEIN; G(1); LINE	The anti-proliferative effect of nerve growth factor (NGF) on the rat pheochromocytoma cell line PC12 has been previously shown to be accompanied by the accumulation of cells in either the G1 phase with a 2c DNA content, or with a 4c DNA content characteristic for G2/M, as evidenced by flow cytometric analysis of DNA distribution using propidium iodide. Herein, these apparently conflicting results are clarified. The present studies indicate that a simple DNA distribution profile obtained by this technique can confound interpretation of the biological effects of NGF on cell-cycle distribution due to the presence of tetraploid cells. Using cyclin D1 and incorporation of bromodeoxyuridine as markers of respectively, G1 and S phase, we show that PC12 cultures can have a considerable amount of tetraploid cells which, when in the G1 phase, have a 49 DNA content and express cyclin D1. During exposure to NGF, this population increases, reflecting the accumulation of cells in the G1 phase of the cell cycle. The data presented, support the possibility that events affecting the expression or action of G1 regulatory proteins may be involved in the molecular mechanism of the antimitogenic effect of NGF.	ECOLE NORMALE SUPER LYON,BIOL CELLULAIRE & MOLEC LAB,UMR CNRS 49,F-69364 LYON 07,FRANCE; SCHERING PLOUGH CORP,LAB RECH IMMUNOL,F-69570 DARDILLY,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Merck & Company; Schering Plough Corporation			van Grunsven, Leo/E-5839-2010; Urdiales, José Luis/K-1125-2014; Choler, Philippe/A-7270-2008	van Grunsven, Leo/0000-0002-0990-7034; Urdiales, José Luis/0000-0002-2519-9293; Choler, Philippe/0000-0002-9062-2721; RUDKIN, Brian B./0000-0003-3700-1982				BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Barde Y A, 1994, Prog Clin Biol Res, V390, P45; BOCCHINI V, 1969, P NATL ACAD SCI USA, V64, P787, DOI 10.1073/pnas.64.2.787; BUCHKOVICH KJ, 1994, MOL BIOL CELL, V5, P1225, DOI 10.1091/mbc.5.11.1225; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; DAHMER MK, 1988, ENDOCRINOLOGY, V122, P2109, DOI 10.1210/endo-122-5-2109; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; FUJITA K, 1989, ENVIRON HEALTH PERSP, V80, P127, DOI 10.2307/3430738; GRECO A, 1993, CELL GROWTH DIFFER, V4, P539; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J NEUROSCI, V1, P368; IGNATIUS MJ, 1985, J NEUROSCI, V5, P343; JIANG W, 1993, ONCOGENE, V8, P3447; KATO J, 1993, GENE DEV, V7, P331; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUKAS J, 1994, ONCOGENE, V9, P2159; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MILANI D, 1993, J GEN VIROL, V74, P2587, DOI 10.1099/0022-1317-74-12-2587; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RAUSCH DM, 1989, J NEUROSCI RES, V24, P49, DOI 10.1002/jnr.490240108; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; SCHUBERT D, 1977, P NATL ACAD SCI USA, V74, P2579, DOI 10.1073/pnas.74.6.2579; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; SUZUKI T, 1994, EMBO J, V13, P1114, DOI 10.1002/j.1460-2075.1994.tb06360.x; TAMARU T, 1994, NEUROSCI LETT, V168, P229, DOI 10.1016/0304-3940(94)90457-X; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103	34	48	48	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					855	862						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632908				2022-12-28	WOS:A1996TW68600017
J	Reddy, UR; Phatak, S; Pleasure, D				Reddy, UR; Phatak, S; Pleasure, D			Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains	ONCOGENE			English	Article						splicing; truncated-Ror1; neural tissues	GROWTH-FACTOR RECEPTOR; HUMAN CELL-LINE; NTERA-2 CELLS; FAMILY; GENE; RNA	Human heart, lung and kidney express a 6 kb mRNA encoding Ror1, a member of the receptor tyrosine kinase (RTK) family with as yet unknown ligand specificity. We used a Ror1 cDNA probe to screen a cDNA library prepared from the human neuronogenic teratocarcinoma line, NTera2, and cloned a 2373 nucleotide transcript, This transcript contains an open reading frame that encodes a 388 amino acid protein identical with the cytosolic, C-terminal region of ror1 but lacking the ror1 transmembrane and entire extracellular domains, Northern blots demonstrate that mRNA encoding this truncated Ror1 ('t-Ror1') is abundantly expressed in fetal and adult human CNS, in human leukemia, lymphoma cell. lines, and in a variety of human cancers derived from neuroectoderm. While previous studies have documented alternative splicing patterns within 5' and 3' regions of mRNAs encoding various RTKs altering their ligand binding specificity or their intracellular signaling, the present report is the first to demonstrate tissue-specific alternative mRNA splicing causing loss of the entire extracellular and transmembrane regions of an RTK.	UNIV PENN,DEPT NEUROL,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PEDIAT,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	Reddy, UR (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV NEUROL RES,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS008075, P20NS031102, R01NS025044, P50NS008075] Funding Source: NIH RePORTER; NINDS NIH HHS [NS08075, NS31102, NS25044] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKER DL, 1989, CANCER RES, V49, P4142; BARKER PA, 1993, J BIOL CHEM, V268, P15150; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUKUNAGA R, 1990, P NATL ACAD SCI USA, V87, P8702, DOI 10.1073/pnas.87.22.8702; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILSON C, 1993, P NATL ACAD SCI USA, V90, P7109, DOI 10.1073/pnas.90.15.7109; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOUNKIN DP, 1993, P NATL ACAD SCI USA, V90, P2174, DOI 10.1073/pnas.90.6.2174	18	27	34	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1555	1559						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875995				2022-12-28	WOS:A1996VL38400022
J	Farina, A; Gaetano, C; Crescenzi, M; Puccini, F; Manni, I; Sacchi, A; Piaggio, G				Farina, A; Gaetano, C; Crescenzi, M; Puccini, F; Manni, I; Sacchi, A; Piaggio, G			The inhibition of cyclin B1 gene transcription in quiescent NIH3T3 cells is mediated by an E-box	ONCOGENE			English	Article						Max; cyclin B1 promoter; cell cycle	DNA-BINDING; BREAST-CANCER; MESSENGER-RNA; MYC; MAX; EXPRESSION; PROTEIN; DIFFERENTIATION; AMPLIFICATION; DIMERIZATION	Cyclin B1 plays an important role in cell proliferation. Its expression is tightly regulated at the mRNA and protein levels during the cell cycle and is found to be deregulated in various malignancies. To enlighten the signalling pathways which lead to the cell cycle dependent expression of the cyclin B1 gene, we studied its transcriptional regulation in quiescent and proliferating NIH3T3 cells. We previously showed that the transcriptional activity of the cyclin B1 promoter decreases in quiescent cells. Here, we map a quiescence-responsive element of the human cyclin B1 promoter to an E-box sequence, CACGTG, which spans positions -124/-119. Nuclear proteins protect this sequence in a DNase I digestion assay and bind, in electromobility shift assays, an oligonucleotide spanning positions -133/-110. Max-specific antibodies block the DNA-binding activity of protein complexes to this probe. A mutation in the E-box core sequence abolishes the decrease in transcription that occurs during quiescence. Finally, we find that over-expression of Max protein in proliferating cells specifically inhibits cyclin B1 promoter activity through this E-box. Moreover, Max overexpression in proliferating NIH3T3 cells leads to down-regulation of the endogenous cyclin B1 protein. In conclusion, these data support a model whereby E-box-binding proteins mediate the decrease in the transcriptional activity of the cyclin B1 promoter observed in quiescent cells and suggest that Max contributes to this response.	IST REGINA ELENA,CTR RICERCA SPERIMENTALE,LAB ONCOGENESI MOL,I-00158 ROME,ITALY	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena			Crescenzi, Marco/J-3603-2018; Piaggio, Giulia/J-7214-2018; Piaggio, Giulia/AAD-7336-2022; Manni, Isabella/ABH-6460-2020; Gaetano, Carlo/P-9997-2019	Crescenzi, Marco/0000-0003-0156-1494; Piaggio, Giulia/0000-0003-2114-1892; Manni, Isabella/0000-0003-4823-0596; Gaetano, Carlo/0000-0002-5238-1832				AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; BAXEVANIS AD, 1993, CURR OPIN GENET DEV, V3, P278, DOI 10.1016/0959-437X(93)90035-N; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P3467; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; GALLANT P, 1994, EMBO J, V13, P595, DOI 10.1002/j.1460-2075.1994.tb06297.x; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GONG JP, 1994, CANCER RES, V54, P4285; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOPEWELL R, 1995, MOL CELL BIOL, V15, P3470; Hurlin P. J., 1994, V59, P109; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LAROCCA SA, 1994, ONCOGENE, V9, P3499; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	36	25	26	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1287	1296						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808703				2022-12-28	WOS:A1996VJ20200020
J	Tantravahi, R; Dudek, H; Patel, G; Reddy, EP				Tantravahi, R; Dudek, H; Patel, G; Reddy, EP			Murine myeloid leukemic cells with disrupted myb loci show splicing anomalies that account for heterogeneous sizes in myb proteins	ONCOGENE			English	Article						ABPL tumors; Myb protein heterogeneity; RNA splicing	C-MYB; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; DNA-BINDING; V-MYB; DIFFERENTIAL EXPRESSION; STRUCTURAL ORGANIZATION; CELLULAR PROGENITOR; ONCOGENE ACTIVATION; GENE	The ABPL tumor cell lines represent a group of myeloid cell lines which contain an altered myb locus due viral insertional mutagenesis within the third exon of c-myb. Immunoprecipitation analysis of the proteins produced in three ABPL lines revealed an interesting anomaly. Despite the invariant position of the virus integration event, the three ABPL tumor cell lines me examined (ABPL-1, ABPL-2 and ABPL-4) produced three different sized proteins. In this report, we examined the molecular basis for this protein size heterogeneity. Molecular cloning and sequence analysis of the cDNAs derived from the myb transcripts show that ABPL-1 tumor produces a tripartate mRNA containing sequences derived from the viral gag and Env genes fused to the myb coding region. This results in the synthesis of a 74 kd protein. In the ABPL-2 tumor line, a gag-myb fusion protein is produced which is of 68 kd. In ABPL-4 cell line a gag-myb fusion protein is produced which contains an internal deletion of coding sequences derived from exons 13 and 14. This deletion results in the synthesis of a 59 kd protein in ABPL-4 tumor cell line,These observations were further confirmed by RNase protection assays which demonstrate the presence of aberrantly spliced mRNAs in ABPL-1 and ABPL-4 tumor cells but not in cells containing an undisrupted c-myb locus. In vitro translation and immuno-precipitation analysis of the cRNAs derived from the ABPL-1, ABPL-2 and ABPL-4 cDNAs show the synthesis of protein products that mere identical to Myb proteins produced by these tumors in vivo. These results suggest that integration of Mo-MuLV within the c-myb locus not only results in deletions of the 5' end of the transcript but splicing aberrations within the encoded mRNA, which results in the synthesis of a heterogeneous array of proteins, not seen in normal hematopoietic cells.	TEMPLE UNIV, SCH MED, FELS INST CANC RES & MOL BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NATIONAL CANCER INSTITUTE [P01CA052009] Funding Source: NIH RePORTER; NCI NIH HHS [CA52009] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANFOSSI G, 1989, P NATL ACAD SCI USA, V86, P3379, DOI 10.1073/pnas.86.9.3379; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BADING H, 1987, ONCOGENE, V1, P395; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; CASTLE S, 1985, BIOCHEM BIOPH RES CO, V132, P688, DOI 10.1016/0006-291X(85)91187-8; CRAIG RW, 1984, CANCER RES, V44, P442; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GERWITZ AM, 1989, SCIENCE, V242, P1303; GILMAN M, 1988, CURRENT PROTOCOLS MO; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Kawasaki ES, 1990, PCR PROTOCOLS GUIDE; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LAVU S, 1984, CURR TOP MICROBIOL, V113, P37; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROVERA G, 1987, ONCOGENE, V1, P29; RUSHLOW KE, 1982, SCIENCE, V216, P1421, DOI 10.1126/science.6283631; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1987, EMBO J, V6, P4035, DOI 10.1002/j.1460-2075.1987.tb02748.x; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; URBANEK P, 1988, NUCLEIC ACIDS RES, V16, P11521, DOI 10.1093/nar/16.24.11521; WATSON RJ, 1988, ONCOGENE, V2, P267; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	37	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1187	1196						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808693				2022-12-28	WOS:A1996VJ20200010
J	Spitkovsky, D; Aengeneyndt, F; Braspenning, J; Doeberitz, MV				Spitkovsky, D; Aengeneyndt, F; Braspenning, J; Doeberitz, MV			p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene	ONCOGENE			English	Article						p53; low risk and high risk HPV E6; p21 dexamethasone; transactivation; growth arrest	P53 PROTEIN; CELLULAR-RESPONSE; CARCINOMA CELLS; DNA DAMAGE; E7; ONCOPROTEINS; SUPPRESSION; EXPRESSION; APOPTOSIS; INDUCTION	Growth of cervical carcinoma cells depends on continuous expression of high risk type human papillomavirus oncogenes E6 and E7, E6 destabilizes p53, a tumor-suppressive transcription factor, which activates expression of the inhibitor of cell cycle progression p21 and other genes, E6-mediated p53 degradation can therefore result in cell cycle deregulation, It has, however, not yet been determined whether p53 inactivation is sufficient to provoke cell cycle progression in established cervical carcinoma cells, Moreover, it has not yet been clarified whether E6 confers additional p53-independent growth stimuli in cancer cells, To address these questions, we analysed p53 functions in SW 756 cervical cancer cells in which the expression of endogenous HPV 18 E6-E7 genes be downregulated by dexamethasone. This results significantly increased p53 levels and sequent cell cycle arrest in the G(1) phase, Surprisingly, p53 activities were suppressed rather than enhanced in these cervical cancer cells, However, if high risk papillomavirus type 16 E6 genes, including a mutant which does not degrade p53, were expressed in dexamethasone-treated SW 756 cells with suppressed endogenous HPV type 18 E6-E7 expression, the cells reentered the cell cycle even in the absence of a cooperating viral E7 gene, In contrast, the non oncogenic papillomavirus type 6 E6 gene did not release the cells from growth arrest under these conditions, These data indicate that suppression of p53 functions is not sufficient to provoke cell cycle progression in E6-E7-depleted cervical cancer cells and point to a p53-independent mitotic activity to oncogenic papillomavirus type E6 genes in cervical carcinoma cells.	UNIV HEIDELBERG, DIV MOL DIAGNOST & THERAPY, DEPT SURG, D-69120 HEIDELBERG, GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM, FSP6 ANGEW TUMORVIROL, D-69120 HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)								BUTZ K, 1995, ONCOGENE, V10, P927; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRAKER PJ, 1995, METHOD CELL BIOL, V46, P57; FRITSCHE M, 1993, ONCOGENE, V8, P307; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAVRE PA, 1995, CANCER RES, V55, P4420; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MULLER M, 1992, VIROLOGY, V187, P508; MUNGER K, 1992, CANCER SURV, V12, P197; SCHAUB LBO, 1995, MOL CELL BIOL, V15, P3032; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; SEEDORF K, 1987, EMBO J, V6, P139, DOI 10.1002/j.1460-2075.1987.tb04731.x; SEYLER FH, 1991, NUCLEIC ACIDS RES, V19, P5080; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; VONKNEBELDOEBERITZ M, 1994, J VIROL, V68, P2811, DOI 10.1128/JVI.68.5.2811-2821.1994; ZHAN QM, 1994, CANCER RES, V54, P2755; ZHAN QM, 1994, ONCOGENE, V9, P3743; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	29	31	33	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					1027	1035						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806692				2022-12-28	WOS:A1996VG76600016
J	Wienecke, R; Maize, JC; Shoarinejad, F; Vass, WC; Reed, J; Bonifacino, JS; Resau, JH; deGunzburg, J; Yeung, RS; DeClue, JE				Wienecke, R; Maize, JC; Shoarinejad, F; Vass, WC; Reed, J; Bonifacino, JS; Resau, JH; deGunzburg, J; Yeung, RS; DeClue, JE			Co-localization of the TSC2 product tuberin with its target Rap1 in the golgi apparatus	ONCOGENE			English	Article						tuberous sclerosis; tuberin; localization Rap1; Golgi apparatus	EKER RAT MODEL; DOMINANTLY INHERITED CANCER; SCLEROSIS TSC2; CYTOPLASMIC DOMAIN; HUMAN NEUTROPHILS; PLASMA-MEMBRANE; MANNOSIDASE-II; GENE-PRODUCT; PROTEINS; COMPLEX	Tuberin is the protein product of the tuberous sclerosis-2 (TSC2) gene, which is associated with tuberous sclerosis (TSC), a human genetic syndrome characterized by the development of tumors in a variety of tissues, We have previously shown that tuberin is a widely expressed 180 kDa protein which exhibits specific GTPase activating activity in vitro towards the Ras-related Rap1 study we have used affinity-purified antibodies against tuberin to analyse its expression in human and rat tissues and to examine its subcellular localization, Tuberin expression was detected in all adult human tissues tested, with the highest levels found in brain, heart and kidney, organs that are commonly affected in TSC patients, By contrast, in adult rats the highest levels of tuberin were found in brain, liver and testis, Indirect immunofluorescence of tuberin in various cultured cell lines revealed a punctate, mostly perinuclear staining pattern, Double-indirect immunofluorescence analysis sera and anti-tuberin sera and antisera against known Golgi markers (mannosidase-II and furin) revealed that the staining of tuberin was consistent with its localization in the stacks of the Golgi apparatus, In support of this, treatment of cells with brefeldin A, a drug known to cause disassembly of the Golgi apparatus: abolished the perinuclear staining of tuberin, Moreover, conventional and confocal immunofluorescence demonstrated co-localization of tuberin with Rap1, which has previously been localized to the Golgi apparatus, The colocalization of tuberin and Rap1 in vivo strengthens the likelihood that the in vitro catalytic activity of tuberin toward Rap1 plays a physiologically relevant role in the tumor suppressor function of tuberin.	NCI, CELLULAR ONCOL LAB, BETHESDA, MD 20892 USA; FOX CHASE CANC CTR, DIV MED SCI, PHILADELPHIA, PA 19111 USA; CORNELL UNIV, MED CTR, NEW YORK HOSP, DEPT DERMATOPATHOL, NEW YORK, NY 10021 USA; NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, ADV BIOSCI LABS, BASIS RES PROGRAM, FREDERICK, MD 21702 USA; INST CURIE, SECT RECH, F-74231 PARIS 05, FRANCE	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Fox Chase Cancer Center; Cornell University; NewYork-Presbyterian Hospital; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie				Bonifacino, Juan S./0000-0002-5673-6370				BERANGER F, 1991, P NATL ACAD SCI USA, V88, P1606, DOI 10.1073/pnas.88.5.1606; BOKOCH GM, 1993, BIOCHEM J, V289, P17, DOI 10.1042/bj2890017; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; Carbonara C, 1996, GENE CHROMOSOME CANC, V15, P18, DOI 10.1002/(SICI)1098-2264(199601)15:1<18::AID-GCC3>3.0.CO;2-7; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GEIST RT, 1995, CELL GROWTH DIFFER, V6, P1477; Givol I, 1995, ONCOGENE, V11, P2609; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; Gomez MR, 1988, TUBEROUS SCLEROSIS; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Harlow E., 1988, ANTIBODIES LAB MANUA; HENSKE EP, 1995, GENE CHROMOSOME CANC, V13, P295, DOI 10.1002/gcc.2870130411; HINO O, 1995, MOL CARCINOGEN, V14, P23, DOI 10.1002/mc.2940140106; JANSSEN B, 1994, HUM GENET, V94, P437, DOI 10.1007/BF00201608; JIN F, 1996, IN PRESS P NATL ACAD; KAMEYAMA Y, 1994, LIFE SCI, V55, P213, DOI 10.1016/0024-3205(94)00882-5; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOBAYASHI T, 1995, NUCLEIC ACIDS RES, V23, P2608, DOI 10.1093/nar/23.14.2608; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KUMAR A, 1995, HUM MOL GENET, V4, P1471, DOI 10.1093/hmg/4.8.1471; KWIATKOWSKI DJ, 1993, CYTOGENET CELL GENET, V64, P94; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; MARIDONNEAUPARINI I, 1992, J BIOL CHEM, V267, P6396; MOLLINEDO F, 1993, FEBS LETT, V326, P209, DOI 10.1016/0014-5793(93)81792-X; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; MOREMEN KW, 1991, J CELL BIOL, V115, P1521, DOI 10.1083/jcb.115.6.1521; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NELLIST M, 1993, CELL, V75, P1305; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVIKOFF PM, 1983, P NATL ACAD SCI-BIOL, V80, P4364, DOI 10.1073/pnas.80.14.4364; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1994, J CELL SCI, V107, P1661; QUARCK R, 1994, FEBS LETT, V342, P159, DOI 10.1016/0014-5793(94)80492-3; Tsuchiya H, 1996, CANCER RES, V56, P429; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; Wilson PJ, 1996, HUM MOL GENET, V5, P249, DOI 10.1093/hmg/5.2.249; XIAO GH, 1995, ONCOGENE, V11, P81; XIAO GH, 1995, CELL GROWTH DIFFER, V6, P1185; XU L, 1995, GENOMICS, V27, P475, DOI 10.1006/geno.1995.1079; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YEUNG RS, 1995, MOL CARCINOGEN, V14, P28, DOI 10.1002/mc.2940140107; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	49	96	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					913	923						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806680				2022-12-28	WOS:A1996VG76600004
J	Gurniak, CB; Berg, LJ				Gurniak, CB; Berg, LJ			A new member of the Eph family of receptors that lacks protein tyrosine kinase activity	ONCOGENE			English	Article						Eph family tyrosine kinase; catalytically inactive tyrosine kinase; alternatively spliced receptor; thymus; brain	T-CELL DEVELOPMENT; SIGNAL-TRANSDUCTION; IL-2 RECEPTOR; JANUS KINASE; GAMMA-CHAIN; ZETA-CHAIN; IDENTIFICATION; ASSOCIATION; EXPRESSION; ACTIVATION	Using a PCR-based screen to identify tyrosine kinases involved in T cell development, we have cloned a new member of the Eph-family of receptor tyrosine kinases (Mep, for murine eph-family protein). At the amino acid level Mep is 60% identical to the chicken embyronic kinase Cek9. Sequence analysis indicates that the predicted extracellular portion of Mep bears an Ig-like domain, a cysteine-rich region, and sequences homologous to fibronectin type III. The transmembrane region of Mep is followed by a kinase domain. Surprisingly, this kinase domain carries amino acid substitutions in the highly conserved consensus motifs found in all protein tyrosine kinases and known to be crucial for kinase activity. We demonstrate that a bacterial fusion protein of the Mep kinase domain does not have protein tyrosine kinase activity. Analysis of Mep mRNA levels in a variety of mouse tissues shows that Mep is highly expressed in thymus and brain. We have also isolated two additional Mep cDNA clones from thymocytes which are predicted to encode secreted forms of the Mep extracellular domain; mRNAs encoding these secreted isoforms are also expressed in mouse brain.	HARVARD UNIV,DEPT MOL & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDERSON G, 1993, NATURE, V362, P70, DOI 10.1038/362070a0; BASU A, 1989, MOL CELL BIOL, V9, P671, DOI 10.1128/MCB.9.2.671; BRAMBILLA R, 1995, EMBO J, V14, P3116, DOI 10.1002/j.1460-2075.1995.tb07314.x; BURGESS KE, 1992, P NATL ACAD SCI USA, V89, P9311, DOI 10.1073/pnas.89.19.9311; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DRESCHER U, 1995, CELL, V82; Gurniak CB, 1996, BLOOD, V87, P3151, DOI 10.1182/blood.V87.8.3151.bloodjournal8783151; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARRIS WA, 1995, NEURON, V15, P241, DOI 10.1016/0896-6273(95)90000-4; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HOZUMI K, 1994, INT IMMUNOL, V6, P1451, DOI 10.1093/intimm/6.9.1451; HUEBER AO, 1994, BRAZ J MED BIOL RES, V27, P275; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIRKEN RA, 1994, J BIOL CHEM, V269, P19136; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LETWIN K, 1988, ONCOGENE, V3, P621; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1988, ONCOGENE, V3, P629; LU YL, 1992, J IMMUNOL, V149, P24; MACNEIL I, 1993, J IMMUNOL, V151, P6913; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MOTT R, 1992, B MATH BIOL, V54, P59, DOI 10.1007/BF02458620; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SAJJADI FG, 1991, NEW BIOL, V3, P769; SAMELSON LE, 1990, J IMMUNOL, V145, P2448; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SHAO HN, 1995, J BIOL CHEM, V270, P5636, DOI 10.1074/jbc.270.10.5636; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TAYLOR V, 1994, NEUROSCIENCE, V63, P163, DOI 10.1016/0306-4522(94)90014-0; TESSIERLAVIGNE M, 1995, CELL, V82, P345, DOI 10.1016/0092-8674(95)90421-2; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VONBOEHMER H, 1988, IMMUNOL REV, V101, P21; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	57	84	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					777	786						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761299				2022-12-28	WOS:A1996VD43300013
J	Milia, E; DiSomma, MM; Baldoni, F; Chiari, R; Lanfrancone, L; Pelicci, PG; Telford, JL; Baldari, CT				Milia, E; DiSomma, MM; Baldoni, F; Chiari, R; Lanfrancone, L; Pelicci, PG; Telford, JL; Baldari, CT			The aminoterminal phosphotyrosine binding domain of Shc associates with ZAP-70 and mediates TCR dependent gene activation	ONCOGENE			English	Article						Shr; ZAP-70; PTB domain; TCR; T-cell	CELL ANTIGEN RECEPTOR; SEVERE COMBINED IMMUNODEFICIENCY; PROTEIN-TYROSINE KINASE; GRB2 ADAPTER PROTEIN; JURKAT T-CELLS; SIGNAL-TRANSDUCTION; ZETA-CHAIN; LYMPHOCYTE-ACTIVATION; NUCLEOTIDE EXCHANGE; PHOSPHORYLATION	T-cell antigen receptor stimulation results in recruitment to the zeta chain and phosphorylation both of the syk family protein tyrosine kinase ZAP-70 and of the She adaptor protein, which transduces activating signals to Pas, Both ZAP-70 and Pas are required for T-cell activation. We have investigated the functional link between these two molecules in TCR signaling, She was found to associate with ZAP-70 in response to TCR triggering. This association was dependent on the presence of the aminoterminal phosphotyrosine binding (PTB) domain of She. The analysis of She binding to a potential PTB domain binding site on ZAP-70 confirmed the interaction of the She PTB domain with ZAP-70 and identified the ZAP-70 phosphotyrosine residue involved in this interaction, To test the role of the She PTB domain in transducing TCR derived signals we measured the effects of the isolated She PTB domain on the activation of the T-cell specific transcription factor NF-AT, The isolated She PTB domain was designed to compete non productively with endogenous She for binding to upstream tyrosine phosphorylated proteins and thus interfere with coupling to regulators of Pas activation, A significant inhibition of NP-AT activation by TCR triggering was observed, showing a functional involvement of She in TCR signaling through its PTB domain and suggesting an important role for She association with ZAP-70.	UNIV SIENA,DEPT EVOLUTIONARY BIOL,I-53100 SIENA,ITALY; IRIS,I-53100 SIENA,ITALY; MONTELUCE POLICLIN,MED CLIN 1,I-06100 PERUGIA,ITALY; IST EUROPEO ONCOL,MILAN,ITALY	University of Siena; Novartis; IRCCS European Institute of Oncology (IEO)			Telford, John Laird/ABG-8144-2020; Lanfrancone, Luisa/AAC-8671-2019; Pelicci, Pier Giuseppe/AAL-6572-2020	Lanfrancone, Luisa/0000-0002-4523-3815; chiari, rita/0000-0002-7649-273X	Telethon [E.0207] Funding Source: Medline	Telethon(Fondazione Telethon)		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BALDARI CT, 1993, J BIOL CHEM, V268, P2693; BALDARI CT, 1995, EUR J IMMUNOL, V25, P1843, DOI 10.1002/eji.1830250708; BALDARI CT, 1992, FEBS LETT, V304, P261, DOI 10.1016/0014-5793(92)80633-R; BALDARI CT, 1995, ONCOGENE, V10, P1141; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BORST J, 1990, HUM IMMUNOL, V2, P175; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; DEMARTIN R, 1993, GENE, V124, P137, DOI 10.1016/0378-1119(93)90776-Y; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; IZQUIERDO M, 1992, MOL CELL BIOL, V12, P3305, DOI 10.1128/MCB.12.7.3305; JANEWAY CA, 1994, CELL, V76, P275, DOI 10.1016/0092-8674(94)90335-2; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOYASU S, 1992, J BIOL CHEM, V267, P3375; LAMINET A, 1996, IN PRESS J BIOL CHEM; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; OSMAN N, 1995, EUR J IMMUNOL, V25, P2863, DOI 10.1002/eji.1830251023; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	53	41	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					767	775						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761298				2022-12-28	WOS:A1996VD43300012
J	Zhang, N; Song, QZ; Lu, H; Lavin, MF				Zhang, N; Song, QZ; Lu, H; Lavin, MF			Induction of p53 and increased sensitivity to cisplatin in ataxia-telangiectasia cells	ONCOGENE			English	Article						ataxia-telangiectasia; cisplatin; p53 stability; functional assays	WILD-TYPE P53; DNA-DAMAGING AGENTS; IONIZING-RADIATION; GENE-EXPRESSION; PROTEIN; UV; ACCUMULATION; APOPTOSIS; ARREST; GROWTH	Several reports have demonstrated a defective p53 response to ionizing radiation exposure in ataxia-telangiectasia (A-T) cells. On the other hand, p53 induction was normal after u.v. irradiation, an agent to which A-T cells are not hypersensitive. We show here that A-T cells are more sensitive than normal lymphoblastoid cells to cisplatin treatment but the rate of induction of p53 by cisplatin is similar in both cell types. In addition, the half-life of p53, both in the induced and uninduced forms, is the same in A-T and normal lymphoblastoid cells. The use of a reporter assay to determine the functional status of p53 confirmed the results obtained in the induction experiments with cisplatin. These results demonstrate that p53 induction status in A-T cells does not correlate with sensitivity to the inducting agent and there is no inherent defect in the turn-over of p53 in the induced or uninduced states in A-T.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,QUEENSLAND CANC FUND RES UNIT,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,ROYAL BRISBANE HOSP,DEPT SURG,BRISBANE,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; Royal Brisbane & Women's Hospital; University of Queensland			Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769				ABRAHAMS PJ, 1995, MUTAT RES-DNA REPAIR, V336, P169, DOI 10.1016/0921-8777(94)00049-C; ALLDAY MJ, 1995, EMBO J, V14, P1382, DOI 10.1002/j.1460-2075.1995.tb07124.x; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; AURIAS A, 1980, MUTAT RES, V69, P369, DOI 10.1016/0027-5107(80)90101-3; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRITSCHE M, 1993, ONCOGENE, V8, P307; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MEYN MS, 1994, INT J RADIAT BIOL, V66, P141; MIRZAYANS R, 1989, CANCER RES, V49, P5523; MORGAN JL, 1968, AM J DIS CHILD, V116, P557, DOI 10.1001/archpedi.1968.02100020561022; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; WOOD KV, 1991, BIOLUMINESCENCE CHEM, pP543; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	33	19	19	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					655	659						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760308				2022-12-28	WOS:A1996VB32800024
J	Kralova, J; Schatzle, JD; Liss, AS; Bargmann, W; Bose, HR				Kralova, J; Schatzle, JD; Liss, AS; Bargmann, W; Bose, HR			Synergistic stimulation of avian I kappa B alpha transcription by rel and fos/jun factors	ONCOGENE			English	Article						I kappa B alpha; Rel/NF-kappa B; AP-1; transcription synergy	DNA-BINDING PROTEIN; FAMILY MEMBERS; V-REL; INHIBITOR; GENE; SUBUNIT; EXPRESSION; ACTIVATION; DORSAL; P50	Rel/NF-kappa B transcription factors and I kappa B alpha function in an autoregulatory network. Avian I kappa B alpha transcription is increased in response to both c-Rel and v-Rel. This study shows that I kappa B alpha transcription is synergistically stimulated by Rel and AP-1 factors (c-Fos and c-Jun). However, the response to v-Rel and the AP-1 factors was not as vigorous as that of c-Rel and AP-1. A 386 bp region of the I kappa B alpha promoter (containing two NF-kappa B and one AP-1 binding sites) was shown to be both necessary and sufficient for response to both Rel factors alone or Rel factors in conjunction with the AP-1 proteins. In addition, an imperfect NF-kappa B binding site was found to overlap the AP-1 binding site. Mutation of either of the NF-kappa B binding sites or the AP-1 binding site dramatically decreased the response of the I kappa B alpha promoter to Rel proteins alone or Rel and AP-1 factors. Overexpression of c-Rel or v-Rel resulted in the formation of DNA binding complexes associated with the imperfect NF-kappa B binding site which overlaps the AP-1 site. v-Rel associated with the imperfect NF-kappa B site stronger than c-Rel, and overexpression of v-Rel also resulted in the formation of a v-Rel containing complex bound to a consensus AP-1 site. These studies address the difference in c-Rel and v-Rel's ability to synergistically stimulate I kappa B alpha expression in conjunction with the AP-1 factors.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712; UNIV TEXAS,CELL RES INST,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Liss, Andrew/L-9696-2019; Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	NATIONAL CANCER INSTITUTE [F32CA063767, R01CA033192] Funding Source: NIH RePORTER; NCI NIH HHS [CA 33192, CA 63767-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; GUILIANI C, 1995, J BIOL CHEM, V270, P11453; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HRDLICKOVA R, 1995, J VIROL, V69, P3369; IP YT, 1991, CELL, V64, P439; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KRISHNAN A, 1995, IN PRESS GENE; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MURR, 1991, LIO, V5, P1464; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	44	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2595	2604						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700518				2022-12-28	WOS:A1996UW48700013
J	Rockow, S; Tang, JP; Xiong, W; Li, W				Rockow, S; Tang, JP; Xiong, W; Li, W			Nck inhibits NGF and basic FGF induced PC12 cell differentiation via mitogen-activated protein kinase-independent pathway	ONCOGENE			English	Article						receptor tyrosine kinases; src-homology domains; adapter molecules; signal transduction	NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; SIGNAL-TRANSDUCTION; FACTOR RECEPTOR; SH3 DOMAINS; MAP KINASE; SRC; PHOSPHOTYROSINE; PHOSPHORYLATION; TYROSINE	Proto-oncogene Nck, an adapter molecule containing three SH3 and one SH2 domains, binds to cell surface receptors and mediate mitogenic effects in the cells. Overexpression of Nck caused cell transformation in vitro and tumor formation in the nude mice. The mechanism of this action by Nck, however, remained unclear. Rat adrenal pheochromocytoma cell line PC12 provides a useful system for studying growth factor-regulated cell proliferation and differentiation. Serum and epidermal growth factor (EGF) stimulate proliferation, whereas nerve growth factor (NGF) and basic fibroblast growth factor (bFGF) cause growth arrest and sympathetic neurite outgrowth in these cells. To study the function of Nck, we generated stable clones of PC12 cells overexpressing the human Nck. We report here that the overexpressed Nck caused continued proliferation of PC12 cells even in the presence of NGF and blocked both the NGF- and bFGF-induced neurite outgrowth. Anti-sense but not sense oligonucleotides to the human Nck resumed the NGF-induced differentiation, indicating the specific inhibitory effect of Nck. Interestingly, Nck did not interfere with the kinetics of NGF- and EGF-stimulated protein tyrosine phosphorylation and the mitogen-activated protein kinase (MAPK) activation, suggesting that Nck inhibited the induced PC12 cell differentiation via a MAPK-independent mechanism. This study has provided a useful system for further understanding the function of Nck.	UNIV CHICAGO, BEN MAY INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT PHARMACOL & PHYSIOL SCI, CHICAGO, IL 60637 USA	University of Chicago; University of Chicago					NCI NIH HHS [CA65567] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065567] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAO MV, 1992, CELL, V68, P995, DOI 10.1016/0092-8674(92)90068-N; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COHEN P, 1992, BIOCHEM SOC T, V20, P671, DOI 10.1042/bst0200671; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; HU QJ, 1995, MOL CELL BIOL, V15, P1169; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KWAN SP, 1995, P NATL ACAD SCI USA, V92, P4706, DOI 10.1073/pnas.92.10.4706; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEHMANN JM, 1990, NUCLEIC ACIDS RES, V18, P1048, DOI 10.1093/nar/18.4.1048; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA M, 1992, J VIROL, V66, P115, DOI 10.1128/JVI.66.1.115-121.1992; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1990, J VIROL, V64, P3581, DOI 10.1128/JVI.64.8.3581-3589.1990; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PAWSON T, 1993, CURR BIOL, V3, P343; PAWSON T, 1995, NATURE, V373, P575; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RIVEROLEZCANO OM, 1995, MOL CELL BIOL, V15, P5725; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; THOMAS SM, 1992, CELL, V68, P1030; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	42	34	34	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2351	2359						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649775				2022-12-28	WOS:A1996UQ22000012
J	Roemer, K; MuellerLantzsch, N				Roemer, K; MuellerLantzsch, N			p53 transactivation domain mutant Q22, S23 is impaired for repression of promoters and mediation of apoptosis	ONCOGENE			English	Article						programmed cell death; transcription; transfection; MDM-2	WILD-TYPE P53; GENE-EXPRESSION; CELL-GROWTH; PROTEIN; SUPPRESSION; DNA; INHIBITION; CARCINOMA; ONCOGENE; KINASES	p53 is multifunctional, To assess exactly what function is critical for the prevention of neoplastic transformation has proven difficult, Mutants with substitutions at positions 22 and 23 promised to address the relevance of transcription transactivation since they seemed to be defective specifically for this function, We report here that p53 mutant Q22, S23 [p53 (22,23)] is not only impaired for transactivation but for the repression of the fos promoter and SV40 early promoter, Furthermore, whereas p53 (22,23) fails to efficiently transactivate reporter genes in two p53-negative cell lines, it stimulates reporters and suppresses proliferation in two wild-type (wt) p53-positive cell lines strongly above the levels induced by the transfection procedure alone, This transactivation is refractory to inhibition by MDM-2, Finally, p53 (22,23) expressed from large plasmid quantity (1 mu g) is crippled for the mediation of apoptosis in p53-negative Hep3B hepatocarcinoma cells, Nevertheless, at a quantity of only 10 ng, both mutant and wt p53 plasmids but not control plasmid, are able to induce some cell death which is not inhibitable by MDM-2, Thus, a correlation exists between p53's functions to regulate promoters and to efficiently mediate apoptosis in Hep3B cells.			Roemer, K (corresponding author), UNIV SAARLAND,DEPT VIROL,INST MED MICROBIOL,BLDG 47,D-66421 HOMBURG,GERMANY.							ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KLEY N, 1992, NUCLEIC ACIDS RES, V20, P4083, DOI 10.1093/nar/20.15.4083; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIU X, 1995, MOL CELL BIOL, V15, P6474; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OREN M, 1994, SEMIN CANCER BIOL, V5, P221; PERREM K, 1995, ONCOGENE, V11, P1299; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; RENZING J, 1995, ONCOGENE, V10, P1865; ROLLEY N, 1995, ONCOGENE, V11, P763; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SANG BC, 1994, ONCOGENE, V9, P853; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; VAN MEIR EG, 1994, CANCER RES, V54, P649; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; XU L, 1989, VIROLOGY, V171, P331, DOI 10.1016/0042-6822(89)90600-4; YEE PR, 1994, GENE DEV, V8, P190; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	65	28	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2069	2079						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668332				2022-12-28	WOS:A1996UP28300005
J	Levkowitz, G; Klapper, LN; Tzahar, E; Freywald, A; Sela, M; Yarden, Y				Levkowitz, G; Klapper, LN; Tzahar, E; Freywald, A; Sela, M; Yarden, Y			Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins	ONCOGENE			English	Article						tyrosine kinase; growth factor; signal transduction; Neu differentiation factor	GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; EGF RECEPTOR; V-CBL; NEU RECEPTOR; SH2 DOMAINS; BINDING; KINASE; GENE	The ErbB family of transmembrane tyrosine kinases includes the receptor for EGF (ErbB-1), two receptors for NDF/heregulin (ErbB-3 and ErbB-4) and an orphan receptor (ErbB-2). In order to examine the possibility that distinct signal transduction pathways are coupled to each ErbB protein, we examined the interaction of individual ligand-stimulated receptors with the c-Cbl protein, a protooncogene-encoded signaling molecule previously identified in hematopoietic cells. We report that c-Cbl undergoes rapid and sustained phosphorylation on tyrosine residues upon stimulation of fibroblast and epithelial cell lines with ligands of ErbB-1. By contrast, activation of either ErbB-3 or ErbB-4 by NDF did not affect tyrosine phosphorylation of c-Cbl. Likewise, activation of a chimeric ligand-stimulatable ErbB-2 by a heterologous ligand was ineffective. Despite rapidity of the EGF effect, we observed no association of c-Cbl with activated ErbB-1, implying that the interaction is indirect. Our in vitro experiments suggest that a candidate mediator of the interaction is the Grb-2/Ash adaptor protein, which is constitutively bound to c-Cbl. These results indicate that different ErbB proteins can couple to distinct signaling pathways, and therefore their physiological functions are probably non-redundant.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Levkowitz, Gil/AAB-9441-2019; YARDEN, YOSEF/K-1467-2012	Levkowitz, Gil/0000-0002-3896-1881; 	NATIONAL CANCER INSTITUTE [R01CA051712] Funding Source: NIH RePORTER; NCI NIH HHS [CA51712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BATEWELL DDL, 1995, ONCOGENE, V11, P1561; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BENLEVY R, 1992, J BIOL CHEM, V267, P17304; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EAGAN SE, 1993, NATURE, V363, P45; FAJARDO JE, 1993, MOL CELL BIOL, V13, P7295, DOI 10.1128/MCB.13.12.7295; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FAZIOLI F, 1991, MOL CELL BIOL, V11, P2040, DOI 10.1128/MCB.11.4.2040; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FEDI P, 1994, MOL CELL BIOL, V14, P492, DOI 10.1128/MCB.14.1.492; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HSU JC, 1994, GENE DEV, V8, P2176, DOI 10.1101/gad.8.18.2176; KEANE MM, 1995, ONCOGENE, V10, P2367; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MEISENHELDER J, 1992, MOL CELL BIOL, V12, P5843, DOI 10.1128/MCB.12.12.5843; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PARK D, 1992, MOL CELL BIOL, V12, P5816, DOI 10.1128/MCB.12.12.5816; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1992, J BIOL CHEM, V267, P12266; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUTLEDGE BJ, 1992, GENE DEV, V6, P1503, DOI 10.1101/gad.6.8.1503; SEGATTO O, 1993, ONCOGENE, V8, P2105; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; VEGA QC, 1992, MOL CELL BIOL, V12, P128, DOI 10.1128/MCB.12.1.128; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	61	139	142	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1117	1125						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649804				2022-12-28	WOS:A1996UA88400021
J	Sattler, M; Salgia, R; Okuda, K; Uemura, N; Durstin, MA; Pisick, E; Xu, G; Li, JL; Prasad, KV; Griffin, JD				Sattler, M; Salgia, R; Okuda, K; Uemura, N; Durstin, MA; Pisick, E; Xu, G; Li, JL; Prasad, KV; Griffin, JD			The proto-oncogene product p120(CBL) and the adaptor proteins CRKL and c-CRK link c-ABL, p190(BCR/ABL) and p210(BCR/ABL) to the phosphatidylinositol-3' kinase pathway	ONCOGENE			English	Article						BCR/ABL; c-CBL; c-CRK; CRKL; phosphatidylinositol-3' kinase	ACUTE LYMPHOBLASTIC-LEUKEMIA; V-CBL; FUSED TRANSCRIPT; 3-KINASE; BINDING; DOMAIN; TRANSFORMATION; FIBROBLASTS; TRUNCATION; CELLS	Chronic myelogenous leukemia (CML) and some acute lymphoblastic leukemias (ALL) are caused by the t(9;22) chromosome translocation, which produces the constitutively activated BCR/ABL tyrosine kinase. When introduced into factor dependent hematopoietic cell lines, BCR/ABL induces the tyrosine phosphorylation of many cellular proteins. One prominent BCR/ABL substrate is p120(CBL), the cellular homolog of the v-Cbl oncoprotein. In an effort to understand the possible contribution of p120(CBL) to transformation by BCR/ABL, we looked for cellular proteins which associate with p120(CBL) in hematopoietic cell lines transformed by BCR/ABL. In addition to p210(BCR/ABL) and c-ABL, p120(CBL) coprecipitated with an 85 kDa phosphoprotein, which was identified as the p85 subunit of PI3K. Anti-p120(CBL) immunoprecipitates from BCR/ABL-transformed, but not from untransformed, cell lines contained PI3K lipid kinase activity. Interestingly, the adaptor proteins CRKL and c-CRK were also found in these complexes. In vitro binding studies indicated that the SH2 domains of CRKL and c-CRK bound directly to p120(CBL), while the SH3 domains of c-CRK and CRKL bound to BCR/ABL and c-ABL. The N-terminal and the C-terminal SH2 and the SH3 domain of p85(PI3K) bound directly in vitro to p120(CBL). The ABL-SH2, but not ABL-SH3, could also bind to p120(CBL). These data suggest that BCR/ABL may induce the formation of multimeric complexes of signaling proteins which include p120(CBL), PI3K, c-CRK or CRKL, c-ABL and BCR/ABL itself.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV TUMOR IMMUNOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Li, Jian-Liang/AAE-9315-2019	Li, Jian-Liang/0000-0002-6487-081X	NCI NIH HHS [CA36167, CA60821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA036167, R01CA036167, K08CA060821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BEDI A, 1994, BLOOD, V83, P2038; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FREDERICKSON TN, 1994, J NATL CANCER I, V72, P447; Langdon W Y, 1992, Curr Top Microbiol Immunol, V182, P467; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; SALGIA R, 1995, J BIOL CHEM, V270, P29145, DOI 10.1074/jbc.270.49.29145; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SATTLER M, 1995, EXP HEMATOL, V23, P1040; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; TENHOEVE J, 1993, ONCOGENE, V8, P2469; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; XIAO HY, 1995, INT J ONCOL, V6, P405; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	48	259	264	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					839	846						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632906				2022-12-28	WOS:A1996TW68600015
J	Nikiforov, MA; Hagen, K; Ossovskaya, VS; Connor, TMF; Lowe, SW; Deichman, GI; Gudkov, AV				Nikiforov, MA; Hagen, K; Ossovskaya, VS; Connor, TMF; Lowe, SW; Deichman, GI; Gudkov, AV			p53 Modulation of anchorage independent growth and experimental metastasis	ONCOGENE			English	Article						anchorage dependence; apoptosis; metastasis; p53	TUMOR-SUPPRESSOR GENES; WILD-TYPE P53; DRUG-RESISTANCE; EXTRACELLULAR-MATRIX; ADHESION MOLECULES; BREAST-CARCINOMA; BCL-2 EXPRESSION; CANCER; APOPTOSIS; CELLS	Death in circulation is one of the natural barriers preventing dissemination of tumor cells and formation of metastases. One of the negative factors acting in circulation is the loss of cell contact with natural substrate which can be imitated in vitro by the incubation of cells in suspension or in semi-solid media. Normal mouse fibroblasts (MEFs) stay viable in suspension and undergo p53-independent G(1) growth arrest. Transformation with Ela and ras oncogenes leads to the abrogation of this arrest and to the p53-dependent apoptosis occurring in G, phase of the cell cycle. Suppression of apoptosis by p53 gene knock-out, transduction of dominant negative p53 mutant or bcl-2 prevents death in suspension and greatly induces frequency of colony formation in semi-solid media. The ability of cells to undergo apoptosis does not correlate with their tumorigenicity in nude mice but does correlate with their ability to survive in lungs of intravenously injected mice and to form experimental metastases. We suggest that abrogation of a p53-mediated apoptosis facilitates experimental metastasis by promoting survival of tumor cells in circulation.	UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60607 USA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; CTR CANC RES, INST CARCINOGENESIS, MOSCOW 115478, RUSSIA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Cold Spring Harbor Laboratory				Gudkov, Andrei/0000-0003-2548-0154	FOGARTY INTERNATIONAL CENTER [R03TW000475] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R21CA062045, R01CA060730] Funding Source: NIH RePORTER; FIC NIH HHS [R03TW00475] Funding Source: Medline; NCI NIH HHS [R01-CA60730, R21CA62045] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383; BATES RC, 1994, J CELL BIOL, V125, P403, DOI 10.1083/jcb.125.2.403; BENZEEV A, 1980, CELL, V21, P365, DOI 10.1016/0092-8674(80)90473-0; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BERTORELLE R, 1995, AM J SURG PATHOL, V19, P463, DOI 10.1097/00000478-199504000-00008; CARRIER F, 1992, MOL CELL BIOL, V12, P1856, DOI 10.1128/MCB.12.4.1856; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; FRISCH SM, 1994, J CELL BIOL, V127, P1085, DOI 10.1083/jcb.127.4.1085; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HAGUE A, 1994, ONCOGENE, V9, P3367; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HAYES DF, 1995, SEMIN ONCOL, V22, P5; HELLMAN K, 1991, MICROCIRCULATION CAN, P67; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HIMELSTEIN BP, 1994, INVAS METAST, V14, P246; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; KASTRINAKIS WV, 1995, ONCOGENE, V11, P647; KERBEL RS, 1994, INVAS METAST, V14, P50; KERBEL RS, 1994, J CELL BIOCHEM, V56, P37, DOI 10.1002/jcb.240560108; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Lafrenie R M, 1993, Cell Biophys, V23, P3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MARCHETTI A, 1993, CANCER RES, V53, P2846; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MYERS RB, 1994, PROSTATE, V25, P243, DOI 10.1002/pros.2990250504; NEIMAN PE, 1994, MOL BIOL CELL, V5, P763, DOI 10.1091/mbc.5.7.763; NOONAN KD, 1977, J CELL PHYSIOL, V91, P201, DOI 10.1002/jcp.1040910206; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERRY ME, 1992, MUTAT RES, V276, P189, DOI 10.1016/0165-1110(92)90008-W; POUPON MF, 1992, AIDS RES HUM RETROV, V8, P796; PROSS HF, 1993, NAT IMMUN, V12, P279; SIERRA A, 1995, INT J CANCER, V60, P54, DOI 10.1002/ijc.2910600108; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; THOMPSON TC, 1995, ONCOGENE, V10, P869; UHLMAN DL, 1994, J NATL CANCER I, V86, P1470, DOI 10.1093/jnci/86.19.1470; ULBRIGHT TM, 1994, MODERN PATHOL, V7, P64; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; WEISS L, 1989, CLIN EXP METASTAS, V7, P127, DOI 10.1007/BF01787020; WEISS L, 1994, INVAS METAST, V14, P192; Weiss L., 1985, PRINCIPLES METASTASI; WHITESIDE TL, 1994, IMMUNOL SER, V61, P159; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YOKOYAMA M, 1994, ANTICANCER RES, V14, P2477; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255	57	73	76	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1709	1719						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895517				2022-12-28	WOS:A1996VM88700016
J	Patel, G; Tantravahi, R; Oh, IH; Reddy, EP				Patel, G; Tantravahi, R; Oh, IH; Reddy, EP			Transcriptional activation potential of normal and tumor-associated myb isoforms does not correlate with their ability to block GCSF-induced terminal differentiation of murine myeloid precursor cells	ONCOGENE			English	Article						c-myb; ABPL tumor myb; transactivation; myeloid cell differentiation	COLONY-STIMULATING FACTOR; C-MYB; V-MYB; GRANULOCYTIC DIFFERENTIATION; HEMATOPOIETIC-CELLS; FUNCTIONAL DOMAINS; VIRAL INTEGRATION; GENE-EXPRESSION; LEUKEMIA-VIRUS; MIM-1 GENE	The myb gene has been shown to be an important regulator of hematopoietic cell proliferation, differentiation and apoptosis, Activation of the myb gene into an oncogenic form has involved structural alterations to the coding sequences, Thus, the v-myb gene encoded by the Avian Myeloblastosis Virus, is truncated at both the 5' and 3' ends, Additionally, tumor cells containing rearrangements in the myb locus, such as the ABPL tumors or NFS60 tumor cell line have recently been shown to display a heterogeneity of structure, In this study, we examined the growth and differentiation properties of clonal cell lines derived from 32Dcl3 which harbor myb transgenes derived from v-myb, and the ABPL-1, ABPL-2, ABPL-4 and NFS-60 cell Lines, Retroviral vectors containing the appropriate myb cDNAs were produced, transfected into packaging cell lines, and the viruses were used to generate the 32D derivative cell clones, Abrogation of IL-3 dependence was never observed in any cell line, Expression of c-my6, ABPL1-myb and ABPL-2-myb isoforms in 32D cells resulted in a block to their ability to terminally differentiate into granulocytes at the pro-myelocytic stage, However, expression of ABPL-4-myb or NFS60-myb in these cells failed:to result in a similar effect, These cells differentiated into granulocytes in the presence of G-CSF, albeit more slowly than control 32Dcl3 cells, We also examined the ability of various Myb-isoforms to transactivate transcription of reporter genes containing Myb-binding elements in their promoter/enhancer sequences, to determine whether the phenotypic effects produced by these various isoforms correlate with their ability to transactivate transcription, Our results show that while v-myb and c-myb transactivated transcription equally well, the MFS60-myb exhibited the highest levels of transcriptional transactivation. The ABPL-1, ABPL-2 and ABPL-4-myb isoforms showed very low levels of transcriptional transactivation potential with the same reporter genes. These results suggest that the ability of various Myb-isoforms to transactivate transcription does not by itself correlate with their ability to induce a block to G-CSF-induced terminal differentiation of myeloid precursor cells.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALUDA MA, 1994, ONCOGENE, V9, P2761; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GERWITZ AM, 1988, SCIENCE, V242, P1303; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Harlow E., 1988, ANTIBODIES LAB MANUA; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; MAGLI MC, 1987, P NATL ACAD SCI USA, V84, P789, DOI 10.1073/pnas.84.3.789; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1995, ONCOGENE, V11, P525; ROVERA G, 1987, ONCOGENE, V1, P29; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V84, P3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; TANTRAVAHI R, 1996, IN PRESS ONCOGENE; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	51	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1197	1208						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808694				2022-12-28	WOS:A1996VJ20200011
J	Yu, DH; Liu, BL; Tan, M; Li, JZ; Wang, SS; Hung, MC				Yu, DH; Liu, BL; Tan, M; Li, JZ; Wang, SS; Hung, MC			Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms	ONCOGENE			English	Article						c-erbB-2/HER-2; oncogene; breast cancer; drug resistance; Taxol	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE-ACTIVITY; PHASE-II TRIAL; NEU ONCOGENE; PROTO-ONCOGENE; MULTIDRUG RESISTANCE; MEDICAL PROGRESS; P-GLYCOPROTEIN; OVARIAN-CANCER; DNA-REPAIR	It has been reported that breast tumors that overexpress c-erbB-2/neu are less responsive to certain adjuvant chemotherapy regimens than those that express a normal amount of the gene product, To investigate whether overexpression of the c-erbB-2/neu-encoded p185 can indeed lead to increased chemoresistance in breast cancers, we introduced the human c-erbB-2/neu gene into the very low p185-expressing MDA-MB-435 human breast cancer cells and examined Taxol sensitivities among the parental MDA-MB-435 cells and stable transfectants which express increased levels of p185. The p185-overexpressing MDA-MB-435 transfectants were more resistant to Taxol than the parental cells. The increased Taxol resistance was not accompanied by changes in doubling time and S-phase fraction. The increased Taxol resistance was independent from oncogenic transformation since it was observed only in c-erbB-2/neu-transformed cells and not ras-transformed cells when oncogene-transformed NIH3T3 cells were examined. To study whether p185 induced Taxol resistance through the mdr-1 pathway, we examined the mdr-1-encoded p170 levels in these transfectants. The MDA-MB-435 cells expressed very low levels of p170 and there was no increase of p170 expression in the p185-overexpressing MDA-MB-435 transfectants. Furthermore, these transfectants were not sensitized to Taxol treatment by mdr-1 blocker thioradazine. These data demonstrated that overexpression of c-erbB-2/neu can lead to intrinsic Taxol resistance independent from mdr-1 mechanisms.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,BREAST CANC BAS RES PROGRAM,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Yu, DH (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT SURG ONCOL,BOX 107,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Tan, Ming/ABD-5847-2021; Hung, Mien-Chie/ABD-5911-2021	Tan, Ming/0000-0003-2007-9898; Hung, Mien-Chie/0000-0003-4317-4740; Liu, Bolin/0000-0003-0150-8650; Yu, Dihua/0000-0001-6231-9381	NATIONAL CANCER INSTITUTE [R01CA058880, R29CA060488, R01CA060856, R01CA060488] Funding Source: NIH RePORTER; NCI NIH HHS [CA58880, CA60488, CA60856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1986, SCIENCE, V232, P1644, DOI 10.1126/science.3012781; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; CHEVALLIER B, 1995, J CLIN ONCOL, V13, P314, DOI 10.1200/JCO.1995.13.2.314; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CREE IA, 1995, ANTI-CANCER DRUG, V6, P398, DOI 10.1097/00001813-199506000-00006; EFFERTH T, 1993, CANCER LETT, V70, P197, DOI 10.1016/0304-3835(93)90231-W; GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARRIS JR, 1992, NEW ENGL J MED, V327, P473, DOI 10.1056/NEJM199208133270706; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; HARRIS JR, 1992, NEW ENGL J MED, V327, P319, DOI 10.1056/NEJM199207303270505; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG M-C, 1988, Cancer Bulletin (Houston), V40, P300; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; LACROIX H, 1989, ONCOGENE, V4, P145; MOSCOW JA, 1988, J NATL CANCER I, V80, P14, DOI 10.1093/jnci/80.1.14; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; NOOTER K, 1991, BRIT J CANCER, V63, P663, DOI 10.1038/bjc.1991.152; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; *PROM, 1991, TECHN B PROM CORP, V169; SCHNEIDER J, 1994, J NATL CANCER I, V86, P850, DOI 10.1093/jnci/86.11.850; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1986, MOL CELL BIOL, V6, P1729, DOI 10.1128/MCB.6.5.1729; TAUCHI K, 1989, VIRCHOWS ARCH A, V416, P65, DOI 10.1007/BF01606471; Tsai CM, 1996, CANCER RES, V56, P206; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; TSAI CM, 1995, J NATL CANCER I, V87, P685; WALL ME, 1995, CANCER RES, V55, P753; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260	37	212	223	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1359	1365						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808711				2022-12-28	WOS:A1996VJ20200028
J	Bates, S; Rowan, S; Vousden, KH				Bates, S; Rowan, S; Vousden, KH			Characterisation of human cyclin G(1) and G(2): DNA damage inducible genes	ONCOGENE			English	Article						cyclins; p53; DNA damage	PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; GROWTH ARREST; G1 ARREST; BAX GENE; APOPTOSIS	Several genes have been identified as targets for transcriptional activation by the p53 tumour suppressor protein. Rodent cyclin G was previously identified as a p53 responsive gene and in order to assess the role played by cyclin G as a mediator of p53 function in humans cells we have isolated full length human cyclin G(1) and identified a related gene designated cyclin G(2). Both human G-cyclins are induced by the DNA damaging agent actinomycin-D and although the induction of cyclin G(1) is clearly p53 dependent, activation of cyclin G(2) expression was observed in the absence of p53. Based on sequence similarity, the G-cyclins and the recently identified cyclin I form a distinct sub-group within the larger cyclin family, possibly reflecting some degree of functional similarity.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick			Rowan, Sheldon/AAA-3271-2019	Rowan, Sheldon/0000-0002-1123-6743				ALLDAY MJ, 1995, EMBO J, V14, P4994, DOI 10.1002/j.1460-2075.1995.tb00182.x; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GRANA X, 1995, ONCOGENE, V11, P211; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HAFFNER R, 1995, CURR OPIN GENET DEV, V5, P84, DOI 10.1016/S0959-437X(95)90058-6; HARPER JW, 1993, CELL, V75, P805; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; KATO J, 1993, GENE DEV, V7, P331; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobayashi T, 1995, ONCOGENE, V11, P2311; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; LEW DJ, 1991, CELL, V66, P1191; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NAKAMURA T, 1995, EXP CELL RES, V21, P534; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POON RYC, 1994, J CELL SCI, V107, P2789; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOLOMON MJ, 1994, TRENDS BIOCHEM SCI, V19, P496, DOI 10.1016/0968-0004(94)90137-6; TAMURA K, 1993, ONCOGENE, V8, P2113; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WALDMAN T, 1995, CANCER RES, V55, P5187; WU LT, 1994, ONCOL REP, V1, P705; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZHAN QM, 1994, ONCOGENE, V9, P3743	52	130	139	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1103	1109						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806701				2022-12-28	WOS:A1996VG76600025
J	Vater, CA; Bartle, LM; Dionne, CA; Littlewood, TD; Goldmacher, VS				Vater, CA; Bartle, LM; Dionne, CA; Littlewood, TD; Goldmacher, VS			Induction of apoptosis by tamoxifen-activation of a p53-estrogen receptor fusion protein expressed in E1A and T24 H-ras transformed p53(-/-) mouse embryo fibroblasts	ONCOGENE			English	Article						p53; apoptosis; tamoxifen	WILD-TYPE P53; P53-DEPENDENT GROWTH ARREST; TUMOR-SUPPRESSOR GENE; BREAST-CANCER CELLS; P53-DEFICIENT MICE; MUTANT P53; COLORECTAL-CARCINOMA; FUNCTION MUTATIONS; ESTROGEN-RECEPTOR; BINDING DOMAIN	A fusion gene consisting of wild-type p53 linked to a modified ligand binding domain of the murine estrogen receptor has been constructed and should be a useful tool for studying controlled activation of wild-type p53 function in a variety of experimental cell systems, The protein product of this gene, p53ER(TM), is expressed in cells constitutively but is not functional unless associated with tamoxifen or 4-hydroxytamoxifen, p53ER(TM) was introduced into p53-deficient mouse embryo fibroblasts (MEFs) expressing the EIA and T24 H-ras oncogenes, Activation of p53 in these transformed cells by the addition of tamoxifen or 4-hydroxytamoxifen resulted in apoptosis, In addition to engaging the apoptotic machinery, the tamoxifen-activated fusion protein exhibited other functions characteristic of wild-type p53, such as induction of WAF1 and MDM2 gene expression and activation of the p53-dependent spindle checkpoint in cells treated with nocodazole. Activation of p53ER(TM) expressed in p53-positive MEFs coexpressing E1A and ras had, at most, only a small cytotoxic effect, When three cell Lines of transformed p53(+/+) fibroblasts not expressing p53ER(TM) were tested for sensitivity to the DNA-damaging drug doxorubicin, the p53(+/+) clones displayed either comparable sensitivity, or at most an increase in drug sensitivity of less than fourfold, as compared to several p53(-/-) cell lines, Our data show that restoration of wild-type p53 activity is sufficient to trigger apoptosis in p53(-/-) MEFs transformed with EIA and T24 H-ras and suggest that rare propagable clones of p53-normal MEPs expressing the EIA and T24 H-ras oncogenes have suffered compensatory alterations that compromise the ability to undergo p53-dependent apoptosis.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	Vater, CA (corresponding author), APOPTOSIS TECHNOL INC,148 SIDNEY ST,CAMBRIDGE,MA 02139, USA.			Goldmakher, Viktor/0000-0001-6130-4436				ALDERSON LM, 1995, CANCER RES, V55, P999; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BOND JA, 1994, ONCOGENE, V9, P1885; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHILOSI M, 1994, BLOOD, V84, P4295, DOI 10.1182/blood.V84.12.4295.bloodjournal84124295; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CRIPPS KJ, 1994, ONCOGENE, V9, P2739; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANIELIAN PS, 1993, MOL ENDOCRINOL, V7, P232, DOI 10.1210/me.7.2.232; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELROUBY S, 1993, BLOOD, V82, P3452; ESRIG D, 1994, NEW ENGL J MED, V331, P1259, DOI 10.1056/NEJM199411103311903; FURTH EE, 1981, ANAL BIOCHEM, V110, P1, DOI 10.1016/0003-2697(81)90103-2; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARVEY M, 1993, ONCOGENE, V8, P2457; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; HSIAO M, 1994, AM J PATHOL, V145, P702; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDERS JE, 1994, ONCOGENE, V9, P2745; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OTTO A, 1993, ONCOGENE, V8, P2591; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RENZING J, 1995, ONCOGENE, V10, P1865; ROEMER K, 1993, P NATL ACAD SCI USA, V90, P9252, DOI 10.1073/pnas.90.20.9252; RUNNEBAUM IB, 1994, ANTICANCER RES, V14, P1137; Sambrook J., 2002, MOL CLONING LAB MANU; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; THOMPSON TC, 1995, ONCOGENE, V10, P869; TSUKADA T, 1993, ONCOGENE, V8, P3313; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZIGLER A, 1994, NATURE, V372, P773	55	44	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					739	748						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761295				2022-12-28	WOS:A1996VD43300009
J	Hawker, KL; Vass, JK; Ozanne, BW				Hawker, KL; Vass, JK; Ozanne, BW			Isolation of novel, transcriptionally active AP-1 binding sites: Implications for cellular transformation	ONCOGENE			English	Article						c-fos; v-fos; transformation; AP-1	C-FOS; GROWTH-FACTOR; PHYSICAL ASSOCIATION; JUN ONCOGENE; V-JUN; DNA; GENE; PROTEIN; TRANSACTIVATION; COMPLEXES	Increased AP-1 DNA-binding activity, in the context of TRE-binding, is not a consequence of Fos transformation. In this report we investigate the possibility of a change in binding site preference by vFosAP-1 compared with AP-1 from an untransformed cell. Fos binding sites mere immunoselected from random sequence oligonucleotides using a pan Fos anti-serum with nuclear protein from quiescent FBRp75(v-fos)-transformed (FBR) and normal (208F) rat fibroblasts. The selected oligonucleotides were aligned by computer and a consensus described for the sequences bound by AP-1 from the two cell lines. The vFos binding site is shown to be a consensus TRE, whereas the sequence ACCACATC is described as the cellular Fos protein family consensus. We demonstrate that sequences differing from the TRE consensus can bind AP-1 and direct transcription. AP-1 DNA-binding activity differs between normal and transformed cells with several of the selected oligonucleotides. These sequences also demonstrate differential transcriptional activation between normal and transformed cells. In particular, the 208F consensus has no transcriptional activity in FBR cells. Further, EGF differentially influences the transcriptional activity of the oligonucleotides in 208F and FBR cells. Our results suggest that AP-1 may change its preferred binding site depending on the proteins available at any given time, the sequences flanking a non-consensus TRE or even the environment in which the cell exists. These differences in binding site preference and transcriptional activation may result in the increased transforming ability. of the v-fos oncogene compared with the c-fos proto-oncogene and may extend the potential target genes beyond those with an AP-1 consensus binding site.	BEATSON INST CANC RES,CRC,BEATSON LABS,GLASGOW G61 1BD,LANARK,SCOTLAND	Beatson Institute								ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BOHMAN D, 1989, CELL, V52, P705; CARICASOLE A, 1993, NUCLEIC ACIDS RES, V21, P1873, DOI 10.1093/nar/21.8.1873; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; CHUI R, 1988, CELL, V54, P541; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; DOBRZANSKI P, 1991, MOL CELL BIOL, V11, P5470, DOI 10.1128/MCB.11.11.5470; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; FINKEL MP, 1975, FRONTIERS RADIATION, V10, P28; FRAME MC, 1991, ONCOGENE, V6, P205; GOLDBERG Y, 1994, J BIOL CHEM, V269, P16566; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GROSKOPF JC, 1994, MOL CELL BIOL, V14, P6013, DOI 10.1128/MCB.14.9.6013; HADMAN M, 1993, ONCOGENE, V8, P1895; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HERTZ GZ, 1990, COMPUT APPL BIOSCI, V6, P81; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JOOSS K, 1992, ONCOGENE, V7, P1933; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kataoka K, 1996, ONCOGENE, V12, P53; KERPPOLA TK, 1993, MOL CELL BIOL, V13, P3782, DOI 10.1128/MCB.13.6.3782; KERPPOLA TK, 1994, ONCOGENE, V9, P3149; KIZAKAKONDOH S, 1992, MOL CELL BIOL, V12, P5078, DOI 10.1128/MCB.12.11.5078; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KRAMER B, 1995, J BIOL CHEM, V270, P6577; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCIBELLO FC, 1991, NEW BIOL, V3, P671; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MORGAN IM, 1993, ONCOGENE, V8, P1135; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; MULLER U, 1992, J VIROL, V66, P5867; NEUBERG M, 1991, ONCOGENE, V6, P1325; OEHLER T, 1993, ONCOGENE, V8, P1141; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Ransone Lynn J., 1993, Gene Expression, V3, P37; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P553; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SZABO E, 1991, CELL GROWTH DIFFER, V2, P475; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429	56	5	5	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					283	292						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710367				2022-12-28	WOS:A1996VA25200007
J	Wang, H; Grand, RJA; Milner, AE; Armitage, RJ; Gordon, J; Gregory, CD				Wang, H; Grand, RJA; Milner, AE; Armitage, RJ; Gordon, J; Gregory, CD			Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: Relationship to the cell-cycle and role of the retinoblastoma protein	ONCOGENE			English	Article						Burkitt-lymphoma; cell-survival; anti-Ig; phosphorylation	TUMOR-SUPPRESSOR PROTEIN; MYC-INDUCED APOPTOSIS; C-MYC; BURKITT-LYMPHOMA; GERMINAL-CENTERS; TRANSGENIC MICE; GROWTH ARREST; ANTI-MU; DEATH; INDUCTION	Using a Burkitt lymphoma cell line to model human B-cell apoptosis in vitro, we observed that crosslinking, by antibody, of cell surface immunoglobulin induced G(1) growth-arrest followed by apoptosis. By contrast, cells treated with the Ca2+-ionophore, ionomycin, generated apoptotic signals in G(2)/M as well as in G(1). Both ionomycin and anti-immunoglobulin treatment induced rapid dephosphorylation of Rb prior to apoptosis. Apoptosis was repressed following exposure to CD40-ligand and was accompanied by hyperphosphorylation of Rb and cell-cycle progression but not Bcl-2 expression. Expression of Bcl-2 protein in stable bcl-2-transfectants, also resulted in repression of apoptosis and anti-immunoglobulin-treated cells no longer underwent growth-arrest. In Bcl-2-expressing cells in which apoptosis was repressed, Rb remained hyperphosphorylated, even during G(1)-arrest induced by ionomycin. TGF beta treatment of Bcl-2-expressing cells induced G(1)-arrest, de-phosphorylation of Rb and apoptosis. These results suggest that the functional activity of Bcl-2 in B-lymphoma cells is dependent upon, or leads to, sustained hyperphosphorylation of Rb and that Rb hyperphosphorylation can be uncoupled from cell-cycle progression.	UNIV BIRMINGHAM,SCH MED,DEPT IMMUNOL,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,SCH MED,INST CANC STUDIES,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND; IMMUNEX RES & DEV CORP,SEATTLE,WA	University of Birmingham; University of Birmingham								ASKEW DS, 1991, ONCOGENE, V6, P1915; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; DOU QP, 1995, P NATL ACAD SCI USA, V92, P9019, DOI 10.1073/pnas.92.20.9019; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; GREGORY CD, 1994, INT J CANCER, V57, P419, DOI 10.1002/ijc.2910570321; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOLDER MJ, 1993, EUR J IMMUNOL, V23, P2368, DOI 10.1002/eji.1830230948; ISHIDA T, 1995, J IMMUNOL, V155, P5527; JOSEPH LF, 1995, CELL GROWTH DIFFER, V6, P51; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LIU YJ, 1989, NATURE, V342, P929, DOI 10.1038/342929a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU YM, 1994, ONCOGENE, V9, P1015; MacDonald I, 1996, BLOOD, V87, P1147, DOI 10.1182/blood.V87.3.1147.bloodjournal8731147; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MAHESWARAN S, 1991, ONCOGENE, V6, P1965; MERINO R, 1995, J IMMUNOL, V155, P3830; MILNER AE, 1992, INT J CANCER, V52, P636, DOI 10.1002/ijc.2910520424; MILNER AE, 1993, ONCOGENE, V8, P3385; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NEVINS JR, 1992, SCIENCE, V258, P424; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; Scott David W., 1995, P187; SCOTT DW, 1986, J EXP MED, V164, P156, DOI 10.1084/jem.164.1.156; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; VALENTINE MA, 1992, EUR J IMMUNOL, V22, P3141, DOI 10.1002/eji.1830221217; VISVADER JE, 1992, EMBO J, V11, P4557, DOI 10.1002/j.1460-2075.1992.tb05557.x; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	48	67	68	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					373	379						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710376				2022-12-28	WOS:A1996VA25200016
J	Capaccioli, S; Quattrone, A; Schiavone, N; Calastretti, A; Copreni, E; Bevilacqua, A; Canti, G; Gong, L; Morelli, S; Nicolin, A				Capaccioli, S; Quattrone, A; Schiavone, N; Calastretti, A; Copreni, E; Bevilacqua, A; Canti, G; Gong, L; Morelli, S; Nicolin, A			A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in human follicular lymphoma t(14;18) cell lines	ONCOGENE			English	Article						antisense RNA; hybrid RNA; synthetic oligonucleotides; apoptosis; bcl-2 regulation	MESSENGER-RNA DEGRADATION; FIBROBLAST GROWTH-FACTOR; 3' UNTRANSLATED REGION; AU-RICH SEQUENCES; C-MYC GENE; BURKITTS-LYMPHOMA; CHROMOSOMAL TRANSLOCATION; IN-VITRO; B-CELLS; GM-CSF	The 14;18 chromosome translocation, characteristic of most human follicular B-cell lymphomas, juxtaposes the bcl-2 gene with the IgH locus, creating a bcl-2/IgH hybrid gene, By mechanisms that are still under investigation, this event increases the cellular levels of the bcl-2 mRNA and thereby induces an overproduction of the antiapoptotic BCL-2 protein which is likely responsible for neoplastic transformation, In an effort to identify potential upregulators of bcl-2 activity in t(14;18) cells, we found, by strand-specific RT-PCR, a bcl-2 antisense transcript that is present in the t(14;18) DOHHZ and SU-DHL-4 but not in the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on the bcl-2/IgH fusion, This antisense transcript is a hybrid bcl-2/IgH RNA, that originates in the IgH locus, encompasses the t(14;18) fusion site and spans at least the complete 3' UTR region of the bcl-2 mRNA, To achieve some insight into its biological function, we treated the t(14;18) DOHH2 cell line with oligonucleotides (ODNs) by specifically targeting the bcl-2/IgH antisense strand, These ODNs lowered bcl-2 gene expression, inhibited neoplastic cell growth by inducing apoptosis, We would like to propose the hypothesis that the bcl-2/IgH antisense transcript may contribute, by an unknown mechanism, to upregulation of bcl-2 gene expression in t(14;18) cells. The possibility has been considered that the hybrid antisense transcript mask AU-rich motifs present in the 3' UTR of the bcl-2 mRNA characterized in other genes as mRNA destabilizing elements.	SCH MED, DEPT PHARMACOL, I-20129 MILAN, ITALY; UNIV FLORENCE, INST GEN PATHOL, I-50134 FLORENCE, ITALY	University of Florence			Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424; Quattrone, Alessandro/0000-0003-3333-7630; Schiavone, Nicola/0000-0002-1592-4244				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AIELLO A, 1992, CYTOMETRY, V13, P502, DOI 10.1002/cyto.990130509; AIELLO A, 1990, HEMATOL ONCOL, V8, P229, DOI 10.1002/hon.2900080407; APEL TW, 1992, ONCOGENE, V7, P1267; ASSONBATRES MA, 1994, ANN NY ACAD SCI, V712, P34, DOI 10.1111/j.1749-6632.1994.tb33560.x; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; CAPACCIOLI S, 1993, BIOCHEM BIOPH RES CO, V197, P818, DOI 10.1006/bbrc.1993.2552; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARBONARI M, 1994, BLOOD, V83, P1268; CELANO P, 1992, J BIOL CHEM, V267, P15092; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; CORNELISSEN M, 1989, NUCLEIC ACIDS RES, V17, P7203, DOI 10.1093/nar/17.18.7203; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COTTER FE, 1994, ONCOGENE, V9, P3049; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DELIA D, 1993, CANCER RES, V53, P6036; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; GESSANI S, 1993, VIROLOGY, V193, P507, DOI 10.1006/viro.1993.1154; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; GREENBERG ME, 1990, ENZYME, V44, P181, DOI 10.1159/000468756; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HALDAR S, 1994, CANCER RES, V54, P2095; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOB CO, 1993, NUCLEIC ACIDS RES, V21, P2761, DOI 10.1093/nar/21.11.2761; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; JOCHUM C, 1990, J VIROL, V64, P1956, DOI 10.1128/JVI.64.5.1956-1963.1990; KHOCHBIN S, 1992, ANN NY ACAD SCI, V660, P77, DOI 10.1111/j.1749-6632.1992.tb21060.x; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KITADA S, 1994, ANTISENSE RES DEV, V4, P71, DOI 10.1089/ard.1994.4.71; Kitada S, 1993, Antisense Res Dev, V3, P157; KLUINNELEMANS HC, 1991, LEUKEMIA, V5, P221; KNEBA M, 1991, CANCER RES, V51, P3243; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KORSMEYER SJ, 1990, CURR TOP MICROBIOL, V166, P203; KRYSTAL GW, 1990, MOL CELL BIOL, V10, P4180, DOI 10.1128/MCB.10.8.4180; LENOIR GM, 1982, NATURE, V298, P474, DOI 10.1038/298474a0; LERNER A, 1993, J IMMUNOL, V151, P3152; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MUNIR MI, 1992, ANTISENSE RNA PRODUC; MURPHY PR, 1994, MOL ENDOCRINOL, V8, P852, DOI 10.1210/me.8.7.852; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; NOGUCHI M, 1994, J BIOL CHEM, V269, P29161; NOWELL PC, 1987, DEV RECOGNITION TRAN; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PETERSON JA, 1993, NUCLEIC ACIDS RES, V21, P5500, DOI 10.1093/nar/21.23.5500; PEZZELLA F, 1990, AM J PATHOL, V137, P225; POLACK A, 1993, EMBO J, V12, P3913, DOI 10.1002/j.1460-2075.1993.tb06069.x; QUATTRONE A, 1995, CANCER RES, V55, P90; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; RAYMOND V, 1989, ONCOGENE RES, V5, P1; REED JC, 1989, ONCOGENE RES, V4, P271; REED JC, 1990, CANCER RES, V50, P6565; RIVKIN M, 1993, MOL REPROD DEV, V35, P394, DOI 10.1002/mrd.1080350413; ROWLEY JD, 1990, CANCER RES, V50, P3816; ROY N, 1992, NUCLEIC ACIDS RES, V20, P5753, DOI 10.1093/nar/20.21.5753; SCHULER GD, 1988, CELL, V55, P1115, DOI 10.1016/0092-8674(88)90256-5; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIANG R, 1993, AM J HUM GENET, V53, P836; SILVERMAN TA, 1992, J BIOL CHEM, V267, P9738; SPICER DB, 1992, MOL CELL BIOL, V12, P1324, DOI 10.1128/MCB.12.3.1324; STANBRIDGE EJ, 1990, CELL, V63, P867, DOI 10.1016/0092-8674(90)90490-6; TAYLOR ER, 1991, J MOL ENDOCRINOL, V7, P145, DOI 10.1677/jme.0.0070145; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VOLK R, 1989, EMBO J, V8, P2983, DOI 10.1002/j.1460-2075.1989.tb08448.x; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WHITTEMORE LA, 1990, P NATL ACAD SCI USA, V87, P7799, DOI 10.1073/pnas.87.20.7799; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZHOU BS, 1992, CANCER RES, V52, P4280; ZUNIGA A, 1993, DEV BIOL, V157, P110, DOI 10.1006/dbio.1993.1116	80	59	64	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					105	115						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700536				2022-12-28	WOS:A1996UX31900012
J	Leiter, LM; Chen, JJ; Marathe, T; Tanaka, M; Dutta, A				Leiter, LM; Chen, JJ; Marathe, T; Tanaka, M; Dutta, A			Loss of transactivation and transrepression function, and not RPA binding, alters growth suppression by p53	ONCOGENE			English	Article						p53; RPA; transcription; cell cycle; DNA replication	WILD-TYPE P53; DNA-REPLICATION INVITRO; SIMIAN VIRUS-40 DNA; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; GENE AMPLIFICATION; MULTIPLE STAGES; SV40 ORIGIN; PROTEIN-A; INHIBITION	The tumor suppressor protein p53 activates transcription from promoters with specific p53 binding elements, represses transcription from promoters without such elements and interacts with and inhibits the single-stranded DNA binding activity of the human DNA replication factor RPA, All these activities involve the N terminal 70 amino acids of p53, Dissection of the domains of p53 which,bind RPA suggest that multiple sub-domains of the protein synergize to give strong RPA binding, Point-mutations in one of these sub-domains of p53 significantly diminish its ability to interact with RPA, A multimer of a peptide from p53 which includes these residues, or of a peptide from the acidic activation domain of the prototypic trans-activator protein VP16, can itself bind to RPA, Comparison of sequences of these multimeric peptides suggests that aromatic amino acids flanked by negatively charged residues are important for binding RPA, Several alleles of p53 with point mutations in the N terminal region were analysed for their relative abilities to bind RPA, activate or repress transcription, and suppress growth of p53 null SaOs2 and H1299 cells, Both mutants of p53 with decreased RPA binding suppressed cell growth as well as wild-type p53, suggesting that p53 can suppress growth without interacting with RPA, The allele that lost most of the transcription activation function also lost most of its transcription repression activity suggesting that interaction with the same basal transcription factors are involved in both functions, This same allele bound RPA well but was defective in growth suppression. Therefore, transcription activation and/or repression appear to be more important for the growth suppression function of p53 than RPA binding.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV MOL ONCOL,BOSTON,MA 02115; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Cold Spring Harbor Laboratory			Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073	NCI NIH HHS [CA 60499, R01 CA060499, R01 CA060499-02S1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060499] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DELSAL G, 1995, MOL CELL BIOL, V15, P7152; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; EL DW, 1993, CELL, V75, P817; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HEYER WD, 1990, EMBO J, V9, P2321, DOI 10.1002/j.1460-2075.1990.tb07404.x; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; ISHIMI Y, 1988, J BIOL CHEM, V263, P19723; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Sambrook J., 2002, MOL CLONING LAB MANU; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shen F, 1996, J BIOL CHEM, V271, P4819; Shen F, 1996, J BIOL CHEM, V271, P4827; Steel RGD, 1980, PRINCIPLES PROCEDURE; SUBLER MA, 1994, ONCOGENE, V9, P1351; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; WU X, 1993, GENE DEV, V8, P1126; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	43	21	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2661	2668						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700525				2022-12-28	WOS:A1996UW48700020
J	Duprez, E; Lillehaug, JR; Naoe, T; Lanotte, M				Duprez, E; Lillehaug, JR; Naoe, T; Lanotte, M			cAMP signalling is decisive for recovery of nuclear bodies (PODs) during maturation of RA-resistant t(15;17) promyelocytic leukemia NB4 cells expressing PML-RAR alpha	ONCOGENE			English	Article						acute promyelocytic leukemia; cAMP; NB4; retinoic acid; nuclear receptors; transcription factors; nuclear bodies; differentiation	ACID RECEPTOR-ALPHA; RETINOIC ACID; TRANSLOCATION; PROTEIN; EXTRACTION; ISOFORMS; GENES; LINE	We analysed the expression of retinoid receptors and PML in relation to the morphology of PML-containing nuclear bodies (PODs) in maturation sensitive (NB4) and resistant subclones (NB4-R1 and R2) of the promyelocytic NB4 cell line, The basal level of RAR alpha, RXR alpha and PML mRNA and protein were roughly the same in the three cell lines, While NB4 and NB4-R1 cells express comparable amounts of PML-RAR alpha mRNA and 120 kDa protein, NB4-R2 cells despite normal mRNA levels the 120 kDa protein was not detectable, In NB4-R2 cells however, two novel PML-related entities of 65 kDa and 85 kDa were detected with a anti-PML antibody, in addition to the two PML isoforms of 78 and 97 kDa found in any NB4 cells, Despite the 120 kDa PML-RAR alpha defect, NB4-R2 cells show micropunctuated nuclear bodies typical of APL cells, Contrasting with NS4 cells, neither NB4-R1 cells which express PML-RAR alpha, nor NB4-R2 cells lacking the 120 kDa PML-RAR alpha reorganised nuclear bodies (PODs) in response to RA, Importantly, in RA-primed NB4-R1 cells, a secondary event triggered by cAMP restored PODs, concomitant to maturation, This indicates that the recovery of nuclear bodies in APL is dissociated from the early action of RA in cell maturation, Finally, the key finding of this work is that cAMP signalling ultimately determines the recovery of nuclear bodies associated to cell maturation.	HOP ST LOUIS,CTR G HAYEN,INSERM U301,F-75010 PARIS,FRANCE; NAGOYA UNIV,SCH MED,NAGOYA,AICHI 466,JAPAN	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Nagoya University			Naoe, Tomoki/I-1888-2012; duprez, estelle a/R-2357-2016					ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRUEL A, 1995, LEUKEMIA, V9, P1173; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHEN A, 1994, BLOOD, V84, P2122, DOI 10.1182/blood.V84.7.2122.bloodjournal8472122; CHEN Z, 1990, LEUKEMIA, V5, P288; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DERMIME S, 1993, BLOOD, V82, P1573; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGMAN JDL, 1983, NUCLEIC ACIDS RES, V11, P1495; Duprez E, 1996, ONCOGENE, V12, P2443; DUPREZ E, 1992, LEUKEMIA, V6, P1281; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAGIOLI M, 1992, ONCOGENE, V7, P1083; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GIANNI M, 1995, BLOOD, V85, P3619, DOI 10.1182/blood.V85.12.3619.bloodjournal85123619; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HUGGENVIK JI, 1993, MOL ENDOCRINOL, V7, P543, DOI 10.1210/me.7.4.543; KAKIZUKA A, 1991, CELL, V66, P653; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LANOTTE M, 1991, BLOOD, V77, P1082; LAVAU C, 1994, LEUKEMIA, V8, P1615; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Maniatis T, 1989, DECONTAMINATION DILU; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; OLSON IL, 1982, CANCER RES, V42, P3922; ROCHETTEEGLY C, 1994, BIOCHEM BIOPH RES CO, V204, P525, DOI 10.1006/bbrc.1994.2491; ROWLEY JD, 1977, LANCET, V1, P549; RUCHAUD S, 1994, P NATL ACAD SCI USA, V91, P8428, DOI 10.1073/pnas.91.18.8428; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; ZHU J, 1995, LEUKEMIA, V9, P302	38	40	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2451	2459						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649787				2022-12-28	WOS:A1996UQ22000024
J	CorbalanGarcia, S; Degenhardt, KR; BarSagi, D				CorbalanGarcia, S; Degenhardt, KR; BarSagi, D			Insulin-induced dissociation of Sos from Grb2 does not contribute to the down regulation of Ras activation	ONCOGENE			English	Article						Sos; Grb2; ras; insulin; MAP kinase	GUANINE-NUCLEOTIDE EXCHANGE; RECEPTOR TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; DEPENDENT ACTIVATION; POLYACRYLAMIDE GELS; PROTEIN; INHIBITION; P21RAS; BINDS; CAMP	Activation of Ras by a number of receptor tyrosine kinases is mediated by the guanine nucleotide exchange factor Sos. This activation is thought to occur as a result of the recruitment to the plasma membrane of a complex consisting of Sos and the adaptor molecule Grb2. Growth factor stimulation has been shown to induce the rapid phosphorylation of Sos on serine and threonine residues. In rat L6 cells, insulin-induced Sos phosphorylation is accompanied by a partial dissociation of the Grb2-Sos complex. In this study we have investigated the relationship between Sos phosphorylation and Grb2 association. To this end, we have utilized cAMP because it has been demonstrated that elevation of cytoplasmic levels of cAMP inhibits growth factor-induced Sos phosphorylation. We show that in rat L6 cells, cAMP treatment prevents both the insulin-stimulated Sos phosphorylation and Grb2 dissociation. However, cAMP treatment has no effect on the duration of insulin-induced Ras activation. These results suggest that the kinetics of Ras activation are independent of the phosphorylation-induced dissociation of Sos from Grb2.	SUNY STONY BROOK, DEPT MOLEC GENET & MICROBIOL, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook			Corbalan-Garcia, Senena/C-6477-2009	Corbalan-Garcia, Senena/0000-0003-1840-5578; Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA055360, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUDAY L, 1995, CELL, V11, P1327; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; ROZAKISADCOCK M, 1995, ONCOGENE, V11, P1417; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	28	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1063	1068						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649797				2022-12-28	WOS:A1996UA88400014
J	Pocard, M; Chevillard, S; Villaudy, J; Poupon, MF; Dutrillaux, B; Remvikos, Y				Pocard, M; Chevillard, S; Villaudy, J; Poupon, MF; Dutrillaux, B; Remvikos, Y			Different p53 mutations produce distinct effects on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation	ONCOGENE			English	Article						p53 mutations; colon carcinoma; cell cycle arrest; transfection	WILD-TYPE P53; COLORECTAL TUMORIGENESIS; TUMOR SUPPRESSION; BREAST-CANCER; GROWTH ARREST; MUTANT P53; PROTEIN; DNA; GENE; INSTABILITY	The LoVo colon carcinoma cell line that presents two wild type p53 alleles was used as the recipient for a series of transfections with p53 expression vectors coding for wild-type or three different mutants (143ala, 175his or 273his). The parental cell line as well as all clones that had rearranged the plasmid with consequent loss of p53 c-DNA were readily blocked at the G1/S boundary following 10 Gy of irradiation. For each mutation two clones with different levels of mutant protein expression were selected. Confirmation of the integration of the exogenous sequence was obtained by the expression of the mutant m-RNA, established by reverse transcription and DGGE or Southern blot. Flow cytometric measurements of 5-bromodeoxyuridine incorporation revealed a total G(1)/S block of the 143ala transfectants, similarly to the parental and control transfectant cells, but little or no cell cycle block for the 175his and 273his clones. Although it has been shown in vitro that all three mutations interfere with transcriptional activation by the wild-type protein, not only did we observe p53 protein induction and nuclear accumulation following irradiation, but WAF-1/CIP-1 m-RNA was increased in some of the clones for which the G1/S block was abolished. Our results show that mutant p53 proteins are to some extent submitted to the control of the cellular environment in cancer cells with wild type p53 alleles, but with an efficacy that depends on the mutation.	INST CURIE,UMR CYTOGENET MOLEC & ONCOL 147,F-75231 PARIS 05,FRANCE	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie				Chevillard, Sylvie/0000-0001-5889-4041				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DEAN SW, 1989, EXP CELL RES, V183, P473, DOI 10.1016/0014-4827(89)90406-0; DEPPERT W, 1994, SEMIN CANCER BIOL, V5, P187; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HALL PA, 1993, ONCOGENE, V8, P203; HANN, 1995, NAT GENET, V9, P221; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLSTEIN M, 1991, SCIENCE, V253, P49; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1994, INT J CANCER, V57, P623, DOI 10.1002/ijc.2910570502; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHIELI P, 1994, CANCER RES, V54, P3391; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MULERIS M, 1988, CANCER GENET CYTOGEN, V32, P43, DOI 10.1016/0165-4608(88)90310-X; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TOMINAGA O, 1993, ONCOGENE, V8, P2653; TOMINAGA O, 1992, Critical Reviews in Oncogenesis, V3, P257; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VSOJTESEK B, 1993, J CELL SCI, V105, P607; WILLIAMS AC, 1995, ONCOGENE, V11, P141; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	38	62	62	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					875	882						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632910				2022-12-28	WOS:A1996TW68600019
J	Okada, K; Urano, T; Baba, H; Furukawa, K; Furukawa, K; Shiku, H				Okada, K; Urano, T; Baba, H; Furukawa, K; Furukawa, K; Shiku, H			Independent and differential expression of two isotypes of human Nm23: Analysis of the promoter regions of the nm23-H1 and H2 genes	ONCOGENE			English	Article						nm23; NDP kinase; promoter; transcription; metastasis	NUCLEOSIDE DIPHOSPHATE KINASE; TUMOR-METASTASIS; RNA; DNA; AMPLIFICATION; CARCINOMAS; SUPPRESSOR; CELLS; LINE; RAT	We isolated genomic clones of two isotypes of human NDP kinase, nm23-H1 and H2, The nm23-H1 and H2 genes located in a tandem array contained 5 exons and most of the splicing sites in the exon-intron junctions of two isotypes were essentially identical, The regulatory elements of nm23-H1 and H2 genes were also analysed, One major and several minor transcriptional initiation sites were detected in the two isotypes by 5' RACE analysis in HeLa cell, We also identified them by means of an RNase protection assay and primer extension Promoter activities were found in the 5' sequences of the two genes when placed upstream of the chloramphenicol acetyltransferase gene, Transcriptional activities of nm23-H1 and H2 regulatory regions were measured in a series of human cancer lines, The nm23-H1/nm23-H2 gene transcriptional activity ratio varied depending on the cell line, DNA sequencing of these two genes showed that their promoter regions contain distinct binding sites for known transcriptional factors, These studies suggest that the two isotypes of the nm23 genes might be regulated dissimilarly, and in cell type specific manner.	NAGASAKI UNIV,SCH MED,DEPT ONCOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT ORTHOPAED SURG,NAGASAKI 852,JAPAN; MIE UNIV,SCH MED,DEPT INTERNAL MED 2,TSU,MIE 514,JAPAN; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Nagasaki University; Nagasaki University; Mie University; Tufts University				Urano, Takeshi/0000-0003-3383-3554				BABA H, 1995, CANCER RES, V55, P1977; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BIGGS J, 1990, CELL, V63, P933, DOI 10.1016/0092-8674(90)90496-2; CHEN HC, 1994, ONCOGENE, V9, P2905; FISHMAN JR, 1994, J UROLOGY, V152, P202, DOI 10.1016/S0022-5347(17)32862-8; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HAMA H, 1991, GENE, V105, P31, DOI 10.1016/0378-1119(91)90510-I; HIGASHIYAMA M, 1992, BRIT J CANCER, V66, P533, DOI 10.1038/bjc.1992.308; KIMURA N, 1990, J BIOL CHEM, V265, P15744; LEONE A, 1993, ONCOGENE, V8, P2325; LEONE A, 1993, ONCOGENE, V8, P855; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; OKABEKADO J, 1992, BIOCHEM BIOPH RES CO, V182, P987, DOI 10.1016/0006-291X(92)91829-F; OKADA K, 1994, CANCER RES, V54, P3979; POSTEL EH, 1993, SCIENCE, V261, P478, DOI 10.1126/science.8392752; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEIFERT M, 1995, BIOCHEM BIOPH RES CO, V215, P910, DOI 10.1006/bbrc.1995.2550; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TOKUNAGA Y, 1993, INT J CANCER, V55, P66, DOI 10.1002/ijc.2910550113; URANO T, 1992, FEBS LETT, V309, P358, DOI 10.1016/0014-5793(92)80807-S; URANO T, 1992, INT J ONCOL, V1, P425; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; YAMASHIRO S, 1994, ONCOGENE, V9, P2461	26	19	21	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1937	1943						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934540				2022-12-28	WOS:A1996VR79500013
J	Miyazaki, Y; Sun, X; Uchida, H; Zhang, J; Nimer, S				Miyazaki, Y; Sun, X; Uchida, H; Zhang, J; Nimer, S			MEF, a novel transcription factor with an Elf-1 like DNA binding domain but distinct transcriptional activating properties	ONCOGENE			English	Article						transcriptional activator; ets protein; cytokine genes	STIMULATING FACTOR PROMOTER; ETS ONCOGENE FAMILY; EWINGS-SARCOMA TRANSLOCATION; T-CELLS; FACTOR PU.1; GM-CSF; RESTRICTED EXPRESSION; MOLECULAR-CLONING; NUCLEAR FACTORS; TEL GENE	To isolate novel ETS genes expressed in hematopoietic cells we used a nested, degenerate oligonucleotide PCR based technique to obtain a cDNA fragment that encodes an ETS domain from a human megakaryocytic cell line. This fragment was used to isolate a full length, 4.2 kb cDNA that encodes a 663 amino acid protein which we call MEF (myeloid elf-1-like factor). MEF contains a central ETS domain and is expressed in a variety of myeloid leukemia cell lines and in normal adult hematopoietic tissue such as spleen, thymus and peripheral blood, as well as non-hematopoietic tissue such as ovary, placenta and colon. Using an oligonucleotide binding selection assay, and bacterially expressed MEF, we demonstrated that MEF recognizes a consensus DNA binding sequence nearly identical to elf-1 (..WGGA..) and then showed that MEF specifically bound to known elf-1 binding sites in the human GMCSF and IL-3 promoters. To characterize the functional effect of MEF on transcription, we performed cotransfection experiments in myeloid cells, and T cells, and demonstrated transactivation of both promoters by MEF, but not by elf-1. MEF is a new member of the elf-1/E74 family of ETS proteins, that has DNA binding properties similar to elf-1 but distinct transcriptional activating effects in several hematopoietic cell lineages.	MEM SLOAN KETTERING CANC CTR, SLOAN KETTERING INST CANC RES, LAB MOL ASPECTS HEMATOPOIESIS, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, DIV HEMATOL ONCOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 43025] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BORLES JC, 1995, NATURE, V377, P635; BUIJS A, 1995, ONCOGENE, V10, P1511; Chomczynski P, 1987, ANAL BIOCH, V162, P156; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; FRASER JK, 1994, BLOOD, V84, P2523; FRASER JK, 1994, MOL CELL BIOL, V14, P2213, DOI 10.1128/MCB.14.3.2213; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; HROMAS R, 1994, INT J HEMATOL, V59, P257; HROMAS R, 1993, BLOOD, V82, P2998; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; JEON IS, 1995, ONCOGENE, V10, P1229; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LU Q, 1994, MOL CELL BIOL, V14, P3938, DOI 10.1128/MCB.14.6.3938; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MONTE D, 1994, ONCOGENE, V9, P1397; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; NIMER S, 1990, MOL CELL BIOL, V10, P6084, DOI 10.1128/MCB.10.11.6084; Nimer SD, 1996, BLOOD, V87, P3694, DOI 10.1182/blood.V87.9.3694.bloodjournal8793694; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; OVAL J, 1990, BLOOD, V76, P1369; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1992, CELL GROWTH DIFFER, V3, P327; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; THOMAS RS, 1995, ONCOGENE, V11, P2135; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WANG CY, 1992, J EXP MED, V175, P1391, DOI 10.1084/jem.175.5.1391; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WOLIN M, 1993, ONCOGENE, V8, P1905; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	47	64	67	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1721	1729						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895518				2022-12-28	WOS:A1996VM88700017
J	Jongmans, W; Artuso, M; Vuillaume, M; Bresil, H; Jackson, SP; Hall, J				Jongmans, W; Artuso, M; Vuillaume, M; Bresil, H; Jackson, SP; Hall, J			The role of Ataxia telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionising radiation	ONCOGENE			English	Article						DNA-PK; ataxia-telangiectasia; DNA-repair; cell cycle; WAF1/CIP1 (p21); Ku	IONIZING-RADIATION; V(D)J RECOMBINATION; BINDING FUNCTION; TERMINAL DOMAIN; SINGLE STRANDS; P53 PROTEIN; GENE; PHOSPHORYLATION; CELLS; INDUCTION	The DNA-dependent protein kinase (DNA-PK), whose catalytic subunit shows structural similarities to the Ataxia telangiectasia (AT) gene product (ATM), has also been implicated in the p53-mediated signal transduction pathway that activates the cellular response to DNA damage produced by ionizing radiation, DNA-PK activity however was not found to be related to the transcriptional induction of WAF1/CIP1(21) in AT lymphoblastoid cell lines, following treatment with ionizing radiation, Normal protein and transcription levels of Ku70 and Ku80, as sell as DNA-PK activity, mere found-in sis different AT cell lines, 1-4 h following exposure to ionizing radiation, timepoints where reduced and delayed transcriptional induction of WAF1/CIP1 (p21) was observed, WAF1/CIP1 (p21) was found to be transcriptionally induced by p53 in normal cell lines over this same time period following exposure to ionizing radiation, These results suggest that despite the findings that in vitro DNA-PK may phosphorylate p53, in vivo it mould not appear to play a central role in the activation of p53 as a transcription factor nor can it substitute for the ATM gene product in the cellular response following exposure to ionizing radiation.	INT AGCY RES CANC,UNIT MECH CARCINOGENESIS,F-69372 LYON 08,FRANCE; UNIV CAMBRIDGE,WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND	World Health Organization; International Agency for Research on Cancer (IARC); University of Cambridge			Jackson, Stephen Philip/R-4548-2019; Dry, Kate/I-2328-2014; hall, janet/G-1372-2013	Jackson, Stephen Philip/0000-0001-9317-7937; hall, janet/0000-0002-4397-6295	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARTUSO M, 1995, ONCOGENE, V11, P1427; BALKALKIN G, 1994, P NATL ACAD SCI USA, V94, P413; BLUNT T, 1995, CELL, V80, P1; Bogue MA, 1996, GENE DEV, V10, P553, DOI 10.1101/gad.10.5.553; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Errami A, 1996, MOL CELL BIOL, V16, P1519; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, ONCOGENE, V10, P789; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1995, ONCOGENE, V11, P609; KHANNA KK, 1993, ONCOGENE, V8, P3307; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; SHILOH Y, 1995, EUR J HUM GENET, V3, P116; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	29	44	44	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1133	1138						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808686				2022-12-28	WOS:A1996VJ20200003
J	Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM				Klugbauer, S; Lengfelder, E; Demidchik, EP; Rabes, HM			A new form of RET rearrangement in thyroid carcinomas of children after the Chernobyl reactor accident	ONCOGENE			English	Article						RET oncogene; RT-PCR; 5'RACE; RET/PTC3; RET/Delta PTC3; papillary thyroid carcinoma	MOLECULAR CHARACTERIZATION; PROTOONCOGENE; ACTIVATION; ONCOGENE; RET/PTC3; D10S170; FUSION; CANCER; GENE; PTC	Intrachromosomal rearrangements involving the RET and the adjacent H4 or ELE1 gene are very frequent events in thyroid cancer of children from Belarus after the Chernobyl reactor accident (Klugbauer et al., 1995), The fusion product between ELE1 and RET (RET/PTC3) seems to be the prevailing type of rearrangement as shown in a recently published study using a novel RT multiplex PCR approach in combination with the identification of the rearrangement type by RT-PCR and direct sequencing. Now we found a new type of RET rearrangement: By the 5'RACE method we demonstrated in cDNA the fusion of the tyrosine kinase domain of RET with a truncated ELE1 gene shorter than the ELE1 in RET/PTC3, Sequencing of genomic DNA revealed a rearrangement breakpoint at position 41 of a new ELE1 intron (522 bp in length), The new oncogene RET/Delta PTC3 is shortened by one ELE1 exon of 144 bp in length, Structural considerations of the ele1 amino terminal of RET/Delta PTC3 suggest that the transforming activity of the fusion protein is apparently not affected by this truncation, The exon lacking in RET/Delta PTC3 was found to code in the reciprocal transcript RET/Delta ELE1 and increased its size by 144 bp, Obviously the new and possibly additional ELE/RET fusion molecules might even increase the high prevalence of ELE1/RET rearrangements in thyroid carcinomas of children after the Chernobyl reactor accident.	UNIV MUNICH, INST PATHOL, D-80337 MUNICH, GERMANY; UNIV MUNICH, INST RADIAT BIOL, MUNICH, GERMANY; MED HIGH SCH MINSK, CHAIR ONCOL, MINSK, BELARUS	University of Munich; University of Munich								BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; EZAKI H, 1991, J RADIAT RES, V32, P193, DOI 10.1269/jrr.32.SUPPLEMENT_193; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; ITO T, 1993, CANCER RES, V53, P2940; JHIANG SM, 1992, ONCOGENE, V7, P1331; JHIANG SM, 1994, CANCER LETT, V78, P69, DOI 10.1016/0304-3835(94)90033-7; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; Klugbauer S, 1995, ONCOGENE, V11, P2459; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; SANTORO M, 1994, ONCOGENE, V9, P509; SHORE RE, 1993, AM J EPIDEMIOL, V137, P1068, DOI 10.1093/oxfordjournals.aje.a116610; TONG Q, 1995, ONCOGENE, V10, P1781; TSUZUKI T, 1995, ONCOGENE, V10, P191	17	56	60	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					1099	1102						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806700				2022-12-28	WOS:A1996VG76600024
J	Jiang, MC; YangYen, HF; Lin, JK; Yen, JJY				Jiang, MC; YangYen, HF; Lin, JK; Yen, JJY			Differential regulation of p53, c-Myc, Bcl-2 and Bax protein expression during apoptosis induced by widely divergent stimuli in human hepatoblastoma cells	ONCOGENE			English	Article						apoptosis; p53; c-Myc; Bcl-2; Bax; hepatoma	WILD-TYPE P53; MYELOID LEUKEMIC-CELLS; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; CYCLE ARREST; IN-VIVO; HEPATOMA-CELLS; CURCUMA-LONGA; DNA-BINDING; DEATH	Apoptosis of HepG2 cells triggered by various agents is characterized in an attempt to delineate the common apoptosis signaling pathway in human hepatoma cells. Several hallmarks of apoptosis, including DNA laddering, chromatin condensation and fragmentation, and an apoptosis specific cleavage of 28S and 18S ribosomal RNA were observed after treatment with curcumin. Curcumin treatment however did not alter the expression levels of Bcl-2 and Bax proteins, p53 protein accumulated slowly and decreased abruptly after reaching the maximum. Conversely, c-Myc protein decreased initially and subsequently increased preceding the onset of apoptosis. The accumulation of p53 protein is not due to increased levels of p53 mRNA and does not result in growth arrest. Staurosporine, quinacrine, ultraviolet irradiation, hydrogen peroxide, and cyclohexamide are all capable of triggering apoptosis in HepG2 cells. While most of these agents affect the expression levels of p53 and c-Myc similarly, none of them altered the expression levels of the Bcl-2 and Bax proteins. In conclusion, these data suggest that p53 and c-Myc may play a more important role in the apoptosis signaling pathway in HepG2 cells, than the bcl-2 gene family.	ACAD SINICA, INST BIOMED SCI, TAIPEI 11529, TAIWAN; ACAD SINICA, INST MOL BIOL, TAIPEI 11529, TAIWAN; NATL TAIWAN UNIV, SCH MED, INST BIOCHEM, TAIPEI 10764, TAIWAN	Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University			Yen, Jeffrey Jong-Young/Q-5134-2018; Yang-Yen, Hsin-Fang/ABA-5808-2021	Yen, Jeffrey Jong-Young/0000-0001-6299-1995; Yang-Yen, Hsin-Fang/0000-0001-9048-4800				AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMMON HPT, 1991, PLANTA MED, V57, P1, DOI 10.1055/s-2006-960004; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CAMPOS L, 1993, BLOOD, V81, P3091; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; COLOMBEL M, 1992, CANCER RES, V52, P4313; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; DIVE C, 1991, BRIT J CANCER, V64, P192, DOI 10.1038/bjc.1991.269; ERAY M, 1994, INT IMMUNOL, V6, P1817, DOI 10.1093/intimm/6.12.1817; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FUJIMOTO Y, 1994, CANCER RES, V54, P281; GILLARDON F, 1994, ONCOGENE, V9, P3219; GOVINDARAJAN VS, 1980, CRC CR REV FOOD SCI, V12, P199, DOI 10.1080/10408398009527278; GUILLOUF C, 1995, BLOOD, V85, P2691, DOI 10.1182/blood.V85.10.2691.bloodjournal85102691; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOSONO S, 1993, ONCOGENE, V8, P491; HOUGE G, 1995, MOL CELL BIOL, V15, P2051; HOUGE G, 1993, FEBS LETT, V315, P16, DOI 10.1016/0014-5793(93)81123-H; HUBER BE, 1987, CANCER RES, V47, P3414; ITO N, 1990, JPN J CANCER RES, V81, P216, DOI 10.1111/j.1349-7006.1990.tb02552.x; JIANG MC, 1996, IN PRESS NUTR CANC; KANEKO Y, 1992, CANCER LETT, V66, P155, DOI 10.1016/0304-3835(92)90228-N; KASTAN MB, 1991, CANCER RES, V51, P6304; KUTTAN R, 1985, CANCER LETT, V29, P197, DOI 10.1016/0304-3835(85)90159-4; LENNON SV, 1991, CELL PROLIFERAT, V24, P203, DOI 10.1111/j.1365-2184.1991.tb01150.x; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MAKINO R, 1984, BIOCHEM BIOPH RES CO, V119, P1096, DOI 10.1016/0006-291X(84)90887-8; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; NERENSTONE SR, 1988, CANCER TREAT REV, V15, P1, DOI 10.1016/0305-7372(88)90007-2; OCONNOR PM, 1993, CANCER RES, V53, P4776; OLAH E, 1990, CANCER BIOCHEM BIOPH, V11, P107; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; ROH M S, 1990, Current Opinion in Oncology, V2, P725; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SAITO H, 1991, INT J CANCER, V48, P291, DOI 10.1002/ijc.2910480223; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEU JC, 1992, CANCER RES, V52, P6098; STRANGE R, 1992, DEVELOPMENT, V115, P49; TAKEDA T, 1991, BIOCHEM BIOPH RES CO, V178, P378, DOI 10.1016/0006-291X(91)91824-V; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; TISHLER RB, 1993, CANCER RES, V53, P2212; VENOOK AP, 1994, J CLIN ONCOL, V12, P1323, DOI 10.1200/JCO.1994.12.6.1323; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YAP EPH, 1993, LANCET, V341, P251, DOI 10.1016/0140-6736(93)90124-Y; YEN JJY, 1995, J IMMUNOL, V154, P2144; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZHANG XK, 1990, ONCOGENE, V5, P909	63	95	106	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					609	616						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760302				2022-12-28	WOS:A1996VB32800018
J	Shuai, K; Halpern, J; tenHoeve, J; Rao, XP; Sawyers, CL				Shuai, K; Halpern, J; tenHoeve, J; Rao, XP; Sawyers, CL			Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia	ONCOGENE			English	Article						JAK kinases; tyrosine phosphorylation; signal transduction	COLONY-STIMULATING FACTOR; DNA-BINDING ACTIVITY; PROTEIN-TYROSINE KINASES; EPIDERMAL GROWTH-FACTOR; PHILADELPHIA-CHROMOSOME; TRANSCRIPTION FACTOR; INTERFERON ACTIVATION; SIGNAL-TRANSDUCTION; HEMATOPOIETIC-CELLS; TRANSFORMATION	Using chronic myelogenous leukemia (CML) as a model, we tested the hypothesis that cytokine-independent growth of leukemia cells results from aberrant activation of cytokine signaling pathways. The STAT5 (signal transducer and activator of transcription) protein, which is activated transiently in normal myeloid cells by cytokines such as GM-CSF (granulocyte-macrophage colony stimulating factor), was constitutively activated in cell lines derived from CML patients, even in the absence of GM-CSF. STAT5 was also activated in primary mouse bone marrow cells acutely transformed by the CML-specific BCR-ABL oncogene, but not by the serine kinase oncogene v-MOS. Reconstitution experiments in non-hematopoietic cells show that STAT5 activation by BCR-ABL occurs independent of cytokines. Results using BCR-ABL mutants which specifically uncouple connections to known signal transduction pathways show that STATS activation is kinase dependent and correlates directly with ability to confer cytokine independent growth in hematopoietic cells. BCR-ABL also activates JAK kinases, which may a STAT activation. These provide mechanism for findings are consistent with hematopoietic transformation by BCR-ABL.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, SCH MED, INST MOL BIOL, LOS ANGELES, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Anderson SM, 1996, BLOOD, V87, P238; AZAM M, 1995, EMBO J, V14, P1402, DOI 10.1002/j.1460-2075.1995.tb07126.x; CARLESSO N, 1994, ONCOGENE, V9, P149; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; KEATING A, 1983, NORMAL NEOPLASTIC HE, P513; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LANGE B, 1987, BLOOD, V70, P192; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEV S, 1994, CRIT REV ONCOGENESIS, V5, P141, DOI 10.1615/CritRevOncog.v5.i2-3.30; LOZZIO BB, 1976, J NATL CANCER I, V56, P627, DOI 10.1093/jnci/56.3.627; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA T, 1994, BLOOD, V83, P3457; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PEDOGARO L, 1983, J NATL CANCER I, V70, P447; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QUELLE FW, 1995, J BIOL CHEM, V270, P20775, DOI 10.1074/jbc.270.35.20775; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SIRARD C, 1994, BLOOD, V83, P1575; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THOMPSON BJ, 1981, BIOCHIM BIOPHYS ACTA, V662, P125, DOI 10.1016/0005-2744(81)90232-1; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; VARTICOVSKI L, 1991, MOL CELL BIOL, V11, P1107, DOI 10.1128/MCB.11.2.1107; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; YAMAMOTO K, 1994, MOL CELL BIOL, V14, P4342, DOI 10.1128/MCB.14.7.4342; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	57	391	401	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					247	254						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710363				2022-12-28	WOS:A1996VA25200003
J	Lane, DP; Stephen, CW; Midgley, CA; Sparks, A; Hupp, TR; Daniels, DA; Greaves, R; Reid, A; Vojtesek, B; Picksley, SM				Lane, DP; Stephen, CW; Midgley, CA; Sparks, A; Hupp, TR; Daniels, DA; Greaves, R; Reid, A; Vojtesek, B; Picksley, SM			Epitope analysis of the murine p53 tumour suppressor protein	ONCOGENE			English	Article						murine p53; p53; monoclonal antibodies; epitopes	TRANSFORMATION-ASSOCIATED PROTEIN; PHAGE-DISPLAYED PEPTIDES; MONOCLONAL-ANTIBODY; DISCONTINUOUS EPITOPES; SV40-TRANSFORMED CELLS; ACTIVATING MUTATIONS; EXPRESSION; ANTIGEN; MIMICKING; PRODUCE	The identification and characterisation of the p53 tumour suppressor has relied extensively on the use of immunological reagents, To facilitate further characterisation of the murine p53 protein (Mp53), and its interaction with other proteins, we have characterised the antigenic sites of Mp53 in fine detail, Using an overlapping Mp53 peptide library we report the identification by Pepscan ELISA of the epitopes of nine antibodies, We have also used this technique to determine whether corresponding epitopes were present in a human p53 (Hp53) peptide library, This comparison was extended to include polyclonal sera of mice immunized with either Mp53 or Hp53, to compare the overall range of antigenic sites, The range of antigenic sites identified by polyclonal sera is very similar, although the N-terminus of Mp53 is clearly not an immunodominant region, in contrast to the N-terminus of Hp53, However, the N-terminus of Mp53 is immunogenic in rabbits as demonstrated by the Pepscan ELISA of CM5 serum (a rabbit anti-Mp53 serum used in analysing p53 expression in mice), Since, very few new antigenic sites were identified in either Mp53 or Hp53, new approaches will have to be employed to identify novel immunological reagents against human and murine p53.	NINEWELLS HOSP & MED SCH, DEPT PATHOL, DUNDEE DD1 9SY, SCOTLAND; STANFORD UNIV, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA; MASARYK MEM CANC INST, CR-65653 BRNO, CZECH REPUBLIC	University of Dundee; Stanford University; Masaryk Memorial Cancer Institute	Lane, DP (corresponding author), UNIV DUNDEE, DEPT BIOCHEM, CELL TRANSFORMAT RES GRP, CRC, DUNDEE DD1 4HN, SCOTLAND.		Lane, David P/C-4920-2008	Lane, David/0000-0003-0551-3545	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARTEK J, 1993, J PATHOL, V169, P27, DOI 10.1002/path.1711690106; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; FELICI F, 1993, GENE, V128, P21, DOI 10.1016/0378-1119(93)90148-V; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GREAVES R, 1988, THESIS U LONDON; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; LANE DP, 1994, MOL BIOL REP, V19, P23, DOI 10.1007/BF00987319; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEGROS Y, 1994, ONCOGENE, V9, P2071; LEGROS Y, 1994, ONCOGENE, V9, P3689; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; MIDGLEY CA, 1992, J CELL SCI, V101, P183; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; MILNER J, 1986, VIROLOGY, V154, P21, DOI 10.1016/0042-6822(86)90426-5; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; PEZZELLA F, 1994, J CLIN PATHOL, V47, P592, DOI 10.1136/jcp.47.7.592; PICKSLEY SM, 1994, CURR OPIN CELL BIOL, V6, P853, DOI 10.1016/0955-0674(94)90056-6; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; SOUSSI T, 1990, ONCOGENE, V5, P945; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; VOJTESEK B, 1995, ONCOGENE, V10, P389; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	32	40	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2461	2466						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649788				2022-12-28	WOS:A1996UQ22000025
J	Shiio, Y; Sawada, JI; Handa, H; Yamamoto, T; Inoue, JI				Shiio, Y; Sawada, JI; Handa, H; Yamamoto, T; Inoue, JI			Activation of the retinoblastoma gene expression by Bcl-3: Implication for muscle cell differentiation	ONCOGENE			English	Article						Bcl-3; E4TF1; GABP; muscle differentiation; Rb	NF-KAPPA-B; CANDIDATE PROTOONCOGENE BCL-3; EMBRYONAL CARCINOMA-CELLS; BETA INTERFERON GENE; NEGATIVE REGULATION; DNA-BINDING; ONCOPROTEIN BCL-3; MOLECULAR-CLONING; PROMOTER REGION; C-MYC	The retinoblastoma (Rb) protein is a master regulator of cell cycle. Accumulating evidence suggests that elevation of Rb expression is a key event in differentiation of various cell types. However the mechanism of regulation of Rb expression is poorly understood. Here we report that the candidate oncoprotein Bcl-3, previously characterized as a member of the I kappa B family, activates transcription of the Rb gene, whose promoter has no typical kappa B sites. A target element for Bcl-3 that matches the consensus for the E4TF1/GABP transcription factor was identified. Bcl-3 was shown to promote tetramer formation of E4TF1. During muscle cell differentiation, increased bcl-3 expression was observed before the induction of the Rb mRNA. Transient expression of Bcl-3 in myoblasts was shown to induce expression of the endogenous Rb. Furthermore, expression of the antisense bcl-3 RNA in myoblasts suppressed induction of Rb and myogenic differentiation. These results suggest that Bcl-3 is an upstream regulator of Rb expression during differentiation of muscle cells.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	University of Tokyo; Tokyo Institute of Technology								BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BHATIA K, 1991, ONCOGENE, V6, P1569; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOLWIG GM, 1992, NUCLEIC ACIDS RES, V20, P6555, DOI 10.1093/nar/20.24.6555; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HAUPT Y, 1995, ONCOGENE, V10, P1563; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; INOUE J, 1993, ONCOGENE, V8, P2067; ISHIDA T, 1993, BIOCHEM BIOPH RES CO, V191, P831, DOI 10.1006/bbrc.1993.1292; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KANEIISHII C, 1989, NUCLEIC ACIDS RES, V17, P1521, DOI 10.1093/nar/17.4.1521; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SHIROKI K, 1988, J VIROL, V62, P325, DOI 10.1128/JVI.62.1.325-330.1988; SLACK RS, 1993, ONCOGENE, V8, P1585; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	52	12	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1837	1845						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649843				2022-12-28	WOS:A1996UK49800001
J	Trapasso, F; Martelli, ML; Battaglia, C; Angotti, E; Mele, E; Stella, A; Samarut, J; Avvedimento, VE; Fusco, A				Trapasso, F; Martelli, ML; Battaglia, C; Angotti, E; Mele, E; Stella, A; Samarut, J; Avvedimento, VE; Fusco, A			The v-erbA oncogene selectively inhibits iodide uptake in rat thyroid cells	ONCOGENE			English	Article						v-erbA; thyroid; differentiation; uptake; rat cells	AVIAN ERYTHROBLASTOSIS VIRUS; MURINE SARCOMA-VIRUS; HORMONE RECEPTOR; RETINOIC ACID; EPITHELIAL-CELLS; MESSENGER-RNA; MAMMALIAN-CELLS; GENE-EXPRESSION; BINDING DOMAIN; TRANSFORMATION	v-erbA is the oncogenic form of the c-erbA protooncogene, which encodes the receptor for thyroid hormones. The expression of the v-erbA oncogene in thyroid differentiated cells, PC Cl 3, inhibits iodide uptake and thyrotropin-dependent growth, whereas it has no effect on the expression of the other thyroid specific markers, i.e. thyroglobulin, thyroperoxidase and thyrotropin receptor. The activity of transcription factor AP-1, evaluated by a specific DNA binding assay and by transcription of AP-induced promoter (TRE) is enhanced in PC v-erbA cells, v-erbA mutants in the DNA binding domain do not affect the iodide uptake of thyroid cells nor AP-1 activity. We suggest that this transcriptional activation mediates the selective effects of v-erbA on the expression of thyroid specific markers.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,CNRS,UMR49,INRA,F-69364 LYON 7,FRANCE	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE			Samarut, Jacques/AAD-2587-2019	Fusco, Alfredo/0000-0003-3332-5197				AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; BATTAGLIA C, 1993, CELL GROWTH DIFFER, V4, P185; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BERLINGIERI MT, 1992, ONCOGENE, V8, P249; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P226; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; FUSCO A, 1983, J VIROL, V56, P284; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GANDRILLON O, 1995, INT J ONCOL, V6, P215; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL BL, 1992, CELL GROWTH DIFFER, V3, P207; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; LOMBARDI A, 1988, ENDOCRINOLOGY, V123, P1544, DOI 10.1210/endo-123-3-1544; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Mangelsdorf David J., 1994, P319; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; PEREZ P, 1993, J BIOL CHEM, V268, P23538; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; ZARRILLI R, 1990, MOL ENDOCRINOL, V4, P39, DOI 10.1210/mend-4-1-39; [No title captured]	56	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1879	1888						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649848				2022-12-28	WOS:A1996UK49800006
J	Bosher, JM; Totty, NF; Hsuan, JJ; Williams, T; Hurst, HC				Bosher, JM; Totty, NF; Hsuan, JJ; Williams, T; Hurst, HC			A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma	ONCOGENE			English	Article						c-erbB-2; AP-2; transcription; mammary carcinoma	TRANSCRIPTION FACTOR AP-2; POSITIVE BREAST-CANCER; RNA POLYMERASE-II; NEU ONCOGENE; DNA-BINDING; RECEPTOR; OVEREXPRESSION; ACTIVATION; AMPLIFICATION; EMBRYOGENESIS	The proto-oncogene c-erbB-2 is overexpressed in 25-30% of breast cancers through increased transcription and amplification of the gene, We have previously described a factor, OB2-1 which upregulates c-erbB-2 transcription and which is closely related to the developmentally regulated transcription factor, AP-2. Further analysis of affinity purified OB2-1 has now shown that it is in fact a combination of proteins from three AP-2-related genes, the previously described AP-2 alpha gene and two new human family members, AP-2 beta and AP-2 gamma whose cloning and characterisation are described here. All three AP-2 proteins show a high degree of homology and are capable of binding to the c-erbB-2 promoter as homo- or heterodimers. The three proteins can also activate a c-erbB-2 reporter construct, but AP-2 alpha and AP-2 gamma are 3-4 times more active in this regard than AP-2 beta. In addition both AP-2 alpha and AP-2 gamma are expressed at elevated levels in the majority of c-erbB-2 overexpressing mammary tumour lines examined. Mechanisms which may have led to the increased AP-2 levels in these cells are discussed.	HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,ONCOL UNIT,GENE TRANSPORTAT LAB,LONDON W12 0NN,ENGLAND; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT BIOCHEM & MOL BIOL,LONDON WC1E 6BT,ENGLAND; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	Cancer Research UK; Imperial College London; Ludwig Institute for Cancer Research; University of London; University College London; Yale University			Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564	NIGMS NIH HHS [GM46770] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046770] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; BORG A, 1994, CANCER LETT, V81, P137, DOI 10.1016/0304-3835(94)90194-5; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chazaud C, 1996, MECH DEVELOP, V54, P83, DOI 10.1016/0925-4773(95)00463-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DSOUZA B, 1993, ONCOGENE, V8, P1797; HOLLYWOOD DP, 1993, EMBO J, V12, P2369, DOI 10.1002/j.1460-2075.1993.tb05891.x; HOLLYWOOD DP, 1995, BRIT J CANCER, V71, P753, DOI 10.1038/bjc.1995.146; HUDSON DL, 1992, HYBRIDOMA, V11, P367, DOI 10.1089/hyb.1992.11.367; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEASK A, 1991, P NATL ACAD SCI USA, V88, P7948, DOI 10.1073/pnas.88.18.7948; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MARCHIONNI MA, 1995, NATURE, V378, P334, DOI 10.1038/378334a0; MEIER P, 1995, DEV BIOL, V169, P1, DOI 10.1006/dbio.1995.1121; MITCHELL PJ, 1991, GENE DEV, V5, P105, DOI 10.1101/gad.5.1.105; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MOSER M, 1995, DEVELOPMENT, V121, P2779; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLATTERY E, 1983, J BIOL CHEM, V258, P5955; SNAPE AM, 1991, DEVELOPMENT, V113, P283; TETU B, 1994, CANCER, V73, P2359, DOI 10.1002/1097-0142(19940501)73:9<2359::AID-CNCR2820730919>3.0.CO;2-9; TOTTY NF, 1972, SCIENCE, V1, P1215; WILLIAMS T, 1991, SCIENCE, V251, P1067, DOI 10.1126/science.1998122; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Williamson JA, 1996, GENOMICS, V35, P262, DOI 10.1006/geno.1996.0351; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	34	204	210	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1701	1707						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895516				2022-12-28	WOS:A1996VM88700015
J	Cook, DM; Hinkes, MT; Bernfield, M; Rauscher, FJ				Cook, DM; Hinkes, MT; Bernfield, M; Rauscher, FJ			Transcriptional activation of the syndecan-1 promoter by the Wilms' tumor protein WT1	ONCOGENE			English	Article						Wilms' tumor; DNA-binding protein; zincfinger; WT1; kidney development; syndecan-1	ZINC FINGER PROTEIN; GENE-PRODUCT; KIDNEY DEVELOPMENT; SUPPRESSOR WT1; MAMMALIAN-CELLS; DNA-BINDING; EXPRESSION; REPRESSION; GROWTH; LOCUS	The Wilms' tumor suppressor gene (wt1) encodes a zinc finger DNA binding protein (WT1) which functions as a transcriptional regulator and is essential for normal urogenital development. WT1 has previously been shown to repress the transcription of a variety of target genes whose products stimulate growth, such as growth factors, growth factor receptors and other transcription factors. In this study, we identify syndecan-1 as a target gene for WT1-mediated activation. Syndecan-1 is a cell surface proteoglycan whose induction is coincident with epithelial differentiation during kidney development and whose loss of expression is correlated with the loss of the epithelial phenotype and malignant transformation. The murine syndecan-1 promoter contains several potential binding sites for WT1. We demonstrate that both WT1 (-KTS) and WT1 (+KTS) isoforms bind to multiple sites in this highly G+C-rich region, as detected by gel-shift analyses. These WT1 isoforms function as transcriptional activators of syndecan-1 expression in transient transfection assays. Activation of syndecan-1 by WT1 is dependent on an intact zinc-finger region as well as a 179 amino acid proline-rich region in the amino terminus of the protein. Moreover, the endogenous syndecan-1 gene is activated by WT1 in a novel inducible cell line based upon the sheep metallothionein promoter. These results highlight an emerging role for WT1 as an activator of genes like syndecan-1 which may potentiate epithelial differentiation and maintenance in the developing kidney.	WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104; HARVARD UNIV,SCH MED,JOINT PROGRAM NEONATOL,BOSTON,MA 02115	The Wistar Institute; Harvard University; Harvard Medical School					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD006763, R01HD006763] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA028735] Funding Source: NIH RePORTER; NCI NIH HHS [CA09171, CA28735] Funding Source: Medline; NICHD NIH HHS [HD06763] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; COPPES MJ, 1993, FASEB J, V7, P886, DOI 10.1096/fasebj.7.10.8393819; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HINKES MT, 1993, J BIOL CHEM, V268, P11440; Inaba T, 1996, NATURE, V382, P541, DOI 10.1038/382541a0; INKI P, 1991, AM J PATHOL, V139, P1333; JALKANEN M, 1991, BIOCHEM SOC T, V19, P1069, DOI 10.1042/bst0191069; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KATO M, 1995, MOL CELL BIOL, V6, P554; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LELONGT B, 1988, DEV BIOL, V128, P256, DOI 10.1016/0012-1606(88)90289-8; LEPPA S, 1992, P NATL ACAD SCI USA, V89, P932, DOI 10.1073/pnas.89.3.932; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MORRIS JF, 1991, ONCOGENE, V6, P2339; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PARK S, 1993, CANCER RES, V53, P457; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; ROTHSTEIN JL, 1992, GENE DEV, V6, P1190, DOI 10.1101/gad.6.7.1190; RYAN G, 1995, DEVELOPMENT, V121, P867; Sambrook J., 2002, MOL CLONING LAB MANU; SAUER F, 1995, NATURE, V375, P162, DOI 10.1038/375162a0; SAUNDERS S, 1989, J CELL BIOL, V108, P1547, DOI 10.1083/jcb.108.4.1547; Saxen L., 1987, ORGANOGENESIS KIDNEY; SPAETE RR, 1985, J VIROL, V56, P136; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; VAINIO S, 1989, DEV BIOL, V134, P382, DOI 10.1016/0012-1606(89)90110-3; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WANG ZY, 1992, P NATL ACAD SCI USA, V89, P10984; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; ZHOU P, 1995, ONCOGENE, V11, P571	57	90	90	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1789	1799						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895526				2022-12-28	WOS:A1996VM88700025
J	Puthenveettil, JA; Frederickson, SM; Reznikoff, CA				Puthenveettil, JA; Frederickson, SM; Reznikoff, CA			Apoptosis in human papillomavirus16 E7-, but not E6-immortalized human uroepithelial cells	ONCOGENE			English	Article						HPV16 E7; apoptosis; p53; BAX; BCL-2; human uroepithelial cells	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; P53-DEPENDENT APOPTOSIS; RETINOBLASTOMA PROTEIN; HUMAN FIBROBLASTS; CYCLE REGULATION; DNA-DAMAGE; BAX GENE; E6; BLADDER	We compared the ability of E6-, versus E7-, immortalized human uroepithelial cells (HUC) to undergo apoptosis in response to gamma (gamma) radiation. Two independent HPV16 E6-immortalized cell lines, alpha E6#1 and alpha E6#2, that showed low or undetectable p53 levels, failed to undergo apoptosis in response to 18 Gray (Gy) gamma radiation as determined by DNA fragmentation. In contrast, two independent HPV16 E7-immortalized cell lines, alpha E7#1 and alpha E7#2, both of which showed stabilized wildtype p53, underwent apoptosis in the same experiment. Interestingly, both alpha E7#1 and alpha E7#2 showed constitutively elevated BAX and lowered BCL-2 levels, compared to either alpha E6#1 or alpha E6#2. However, elevated BAX and reduced BCL-2 per se were insufficient to trigger apoptosis, as apoptosis occurred only after exposure to gamma radiation. These results support a model in which HPV16 E7-immortalized cells are primed to undergo apoptosis, given an appropriate trigger. This apoptotic response was not observed in alpha E6/E7#1 cells which, like alpha E6-HUCs, showed low p53 levels, nor in late passage alpha E7#1 with spontaneously mutated TP53. These results suggest that E7 immortalization primes HUC for apoptosis in response to gamma radiation, and that this enhanced apoptotic response is p53 dependent.	UNIV WISCONSIN, SCH MED, DEPT HUMAN ONCOL, MADISON, WI 53792 USA; UNIV WISCONSIN, SCH MED, CTR ENVIRONM TOXICOL, MADISON, WI 53792 USA; UNIV WISCONSIN, CTR COMPREHENS CANC, MADISON, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NCI NIH HHS [CA 67158-01, CA-29525-16] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067158, R01CA029525] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN JJ, 1995, SCIENCE, V269, P529, DOI 10.1126/science.7624774; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; FRITSCHE M, 1993, ONCOGENE, V8, P307; GORCZYCA W, 1993, CANCER RES, V53, P3186; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; KAUFMANN WK, 1993, FASEB J, V7, P1188, DOI 10.1096/fasebj.7.12.8375618; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LARUE H, 1995, CLIN CANCER RES, V1, P435; LEONARDO AD, 1994, GENE DEV, V8, P2540; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLUMI AF, 1990, CANCER RES, V50, P7081; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAN HC, 1995, GENE DEV, V9, P2157, DOI 10.1101/gad.9.17.2157; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; REZNIKOFF CA, 1996, IN PRESS SEM ONC; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SMITH ML, 1995, ONCOGENE, V10, P1053; SPRUCK CH, 1994, CANCER RES, V54, P784; TEODORO JG, 1995, ONCOGENE, V11, P467; VOUSDEN K, 1993, FASEB J, V7, P872, DOI 10.1096/fasebj.7.10.8393818; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHAN QM, 1994, ONCOGENE, V9, P3743	50	44	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1123	1131						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808685				2022-12-28	WOS:A1996VJ20200002
J	Dorfman, K; Carrasco, D; Gruda, M; Ryan, C; Lira, SA; Bravo, R				Dorfman, K; Carrasco, D; Gruda, M; Ryan, C; Lira, SA; Bravo, R			Disruption of the erp/mkp-1 gene does not affect mouse development: Normal MAP kinase activity in ERP/MKP-1-deficient fibroblasts	ONCOGENE			English	Article						erp; mkp-1 knockout; development; Erk1, Erk2 MAP kinases	PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; IMMEDIATE-EARLY GENE; EMBRYONIC STEM-CELLS; HEAT-SHOCK; IN-VIVO; MESODERM INDUCTION; GROWTH-FACTORS; EXPRESSION; ACTIVATION	Externally regulated phosphatase (ERP or MKP-1) is a dual specificity phosphatase that has been implicated in the dephosphorylation of mitogen activated protein kinases (MAP kinases), MAP kinase is activated in response to external signals and in turn phosphorylates proteins essential to the regulation of cell growth, To study the role of ERP/MKP-1 protein in mammalian development and its function in signal transduction we have generated mice, embryonic stem (ES), cells and mouse embryo fibroblasts (MEFs) that are deficient in the ERP/MKP-1 protein, ERP/MKP-1-deficient mice are born at normal frequency, are fertile and present no phenotypic or histologic abnormalities, MAP kinase activity and the induction of c-fos mRNA is unaltered in MEFs lacking the ERP/MKP-1 protein, indicating no alteration of the MAP kinase pathway, In addition, ERP/MKP-1 deficient MEFs grow and enter DNA synthesis at the same rate as control cells, Our results demonstrate that the activity of ERP/MKP-1 is not essential for embryo development and indicate that the lack of ERP/MKP-1 activity can be compensated by other phosphatases in vivo.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT ONCOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BURKERT U, 1991, NEW BIOL, V3, P698; CARRASCO D, 1993, CELL GROWTH DIFFER, V4, P849; CHARLES CH, 1992, ONCOGENE, V7, P187; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DUFF JL, 1993, J BIOL CHEM, V268, P26037; EMSLIE EA, 1994, HUM GENET, V93, P513; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KWAK SP, 1994, J BIOL CHEM, V269, P3596; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MELOCHE S, 1992, MOL ENDOCRINOL, V6, P845, DOI 10.1210/me.6.5.845; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Robertson E. J., 1987, TERATOCARCINOMAS EMB; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WILES MV, 1991, DEVELOPMENT, V111, P259; WU J, 1994, FEBS LETT, V353, P9, DOI 10.1016/0014-5793(94)01000-5; Wurst W., 1993, Gene targeting: a practical approach., P33; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	49	179	182	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					925	931						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806681				2022-12-28	WOS:A1996VG76600005
J	Fugazzola, L; Pierotti, MA; Vigano, E; Pacini, F; Vorontsova, TV; Bongarzone, I				Fugazzola, L; Pierotti, MA; Vigano, E; Pacini, F; Vorontsova, TV; Bongarzone, I			Molecular and biochemical analysis of RET/PTC4 a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer	ONCOGENE			English	Article						Chernobyl tumors; papillary thyroid carcinoma; RET arrangements; RET/PTC4	TRANSFORMING SEQUENCE; DNA REARRANGEMENT; ACTIVATION; PROTOONCOGENE; CARCINOMAS; CHILDREN; ACCIDENT; FUSION	A post-Chernobyl papillary thyroid cancer, displaying a novel ELE1/RET oncogenic rearrangement with an anomalous fusion transcript, was molecularly characterized, In spite of the presence of a normal breakpoint in exon 5 of the activating ELE1 gene, the sequence of the rearranged genomic DNA showed a previously unreported intra-exonic breakpoint in the RET proto-oncogene, As a consequence, a cDNA sequence 93 nucleotides larger than the regular one, and with the exon 5 of ELE1 joined to exon 11 instead of exon 12 of RET, is formed, To characterize the product of this new oncogenic ELE1/RET rearrangement, here designated as RET/PTC4, we performed an immunoprecipitation and Western blot analysis on cell extracts from NIH3T3 transfectants, The results showed the presence of two isoforms of the chimeric protein, displaying a constitutive tyrosine phosphorylation, As expected, the molecular weight of this protein was higher than that of RET/PTC3 protein (p80 and p85, instead of p76 and p81), Previous reports, from our and other laboratories, showed that post-Chernobyl papillary thyroid carcinomas are characterized by a high frequency (about 60%) of RET oncogenic rearrangements (Fugazzola et al., 1995; Klugbauer et al., 1995; Ito et al,, 1994), These events predominantly involve ELE1 activating sequence, thus producing RET/PTC3 oncogene (Fugazzola et al,, 1995; Klugbauer ef al., 1995), Hence, this elevated frequency of RET rearrangements could increase the probability of selecting unusual events as that here described, Alternatively, targeted radiation effects could be responsible for the atypical RET rearrangement producing RET/PTC4 oncogene.	IST NAZL TUMORI, DIV EXPT ONCOL A, I-20133 MILAN, ITALY; UNIV PISA, INST ENDOCRINOL, I-56018 PISA, ITALY; INST RADIAT MED, MINSK, BELARUS	Fondazione IRCCS Istituto Nazionale Tumori Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa			Fugazzola, Laura/F-2846-2011; Bongarzone, Italia/B-9544-2017	Bongarzone, Italia/0000-0003-2530-9170; Pierotti, Marco Alessandro/0000-0002-7431-8332				Bongarzone I, 1996, J CLIN ENDOCR METAB, V81, P2006, DOI 10.1210/jc.81.5.2006; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; ISHIZAKA Y, 1989, ONCOGENE, V4, P789; ITO T, 1994, LANCET, V344, P259; Klugbauer S, 1995, ONCOGENE, V11, P2459; KUNIEDA T, 1991, GENE, V107, P323, DOI 10.1016/0378-1119(91)90334-8; MINOLETTI F, 1994, GENE CHROMOSOME CANC, V11, P51, DOI 10.1002/gcc.2870110108; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOZZI G, 1994, GENE CHROMOSOME CANC, V9, P244, DOI 10.1002/gcc.2870090404; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1	15	98	120	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					1093	1097						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806699				2022-12-28	WOS:A1996VG76600023
J	Karlsson, T; Welsh, M				Karlsson, T; Welsh, M			Apoptosis of NIH3T3 cells overexpressing the Src homology 2 domain protein Shb	ONCOGENE			English	Article						Shb; Src homology 2 domain; Src homology 3 domain; NIH3T3 fibroblasts; apoptosis	DNA FRAGMENTATION; TYROSINE KINASE; NUCLEAR-DNA; FIBROBLASTS; ACTIVATION; RECEPTOR; DEATH	To understand the role of the Src homology 2 (SH2) domain protein Shb in the signal transduction of tyrosine kinase receptors, NIH3T3 cells were transfected with a DNA construct expressing the Shb cDNA (NIHSHB cells), The NIHSHB cells expressed elevated levels of proteins with the estimated molecular weights of 77, 66 and 55 kDa as determined by immunoblotting, In contrast to the control cells, the NIHSHB cells failed to increase in cell number in the presence of 1% serum, This effect was largely due to apoptosis, since staining of pyknotic nuclei was observed using the terminal transferase labeling method, The NIHSHB cells displayed similar levels of c-myc mRNA and decreased contents of the p53 protein after culture in 1% serum compared with control cells, The addition of platelet-derived growth factor (PDGF-BB) restored the growth of the NIHSHB cells, whereas insulin-like growth factor-1 (IGF-1) failed to affect the proliferation of Shb overexpressing cells in 1% serum, We conclude that Shb overexpression is associated with cell degeneration under certain conditions, and that Shb could transduce apoptotic signals from tyrosine kinase receptors.	UNIV UPPSALA,BIOMEDICUM,DEPT MED CELL BIOL,S-75123 UPPSALA,SWEDEN	Uppsala University			Welsh, Michael/AAF-8564-2020	Welsh, Michael/0000-0002-5467-9755				BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FATH I, 1994, SCIENCE, V264, P971, DOI 10.1126/science.8178156; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; KARLSSON T, 1995, ONCOGENE, V10, P1475; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAKELA TP, 1992, GENE, V118, P293, DOI 10.1016/0378-1119(92)90203-2; Maniatis T, 1982, MOL CLONING LABORATO; OBERHAMMER F, 1993, J CELL SCI, V104, P317; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; WELSH M, 1994, ONCOGENE, V9, P19; WESTERMARK B, 1990, P NATL ACAD SCI USA, V87, P128, DOI 10.1073/pnas.87.1.128	23	30	31	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					955	961						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806685				2022-12-28	WOS:A1996VG76600009
J	Lutz, W; Stohr, M; Schurmann, J; Wenzel, A; Lohr, A; Schwab, M				Lutz, W; Stohr, M; Schurmann, J; Wenzel, A; Lohr, A; Schwab, M			Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells	ONCOGENE			English	Article						tetracycline; cell cycle; Myc; immediate early gene; neuroblastoma	HUMAN NEURO-BLASTOMA; C-MYC; GENE-EXPRESSION; MAMMALIAN-CELLS; TRANSGENIC MICE; GROWTH-FACTOR; CYCLE ARREST; PROTEIN; AMPLIFICATION; APOPTOSIS	To elucidate the contribution of the N-Myc protein to neuroblastomas we have used a synthetic inducible expression system on the basis of the tetracycline repressor of E coli to reversibly express N-myc in a human neuroblastoma cell line in which expression of endogenous N-myc is barely detectable. Like the c-Myc protein, N-Myc up-regulates the expression of both alpha-prothymosin and ornithine decarboxylase. Induction of N-myc increases both the rate of DNA-synthesis and the proliferation rate, and shortens the G(1) phase of the cell cycle. A comparison of cell populations in which the presence of N-Myc protein was restricted to different parts of G(0)/G(1) revealed that N-Myc is rate-limiting for cell cycle progression during the first 5 h after serum stimulation of quiescent cells providing direct evidence that Myc-proteins act early after mitogenic stimulation of quiescent cells.	GERMAN CANC RES CTR, DIV CELL CYCLE & PHENOTYPE, DEPT CYTOGENET 0825, D-69120 HEIDELBERG, GERMANY; GERMAN CANC RES CTR, DIV CELL CYCLE & PHENOTYPE, DEPT APPL IMMUNOL, D-69120 HEIDELBERG, GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)								AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; ASKEW DS, 1991, ONCOGENE, V6, P1915; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERNARD HU, 1985, EXP CELL RES, V158, P237, DOI 10.1016/0014-4827(85)90446-X; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRONDYK WH, 1991, ONCOGENE, V6, P1269; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; CORVI R, 1995, CANCER RES, V55, P3471; CROUCH DH, 1993, ONCOGENE, V8, P1849; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DILDROP R, 1989, EMBO J, V8, P1121, DOI 10.1002/j.1460-2075.1989.tb03482.x; DOBROWOLSKI S, 1994, MOL CELL BIOL, V14, P5441, DOI 10.1128/MCB.14.8.5441; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; GAUBATZ S, 1994, MOL CELL BIOL, V14, P3853, DOI 10.1128/MCB.14.6.3853; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HENRIKSSON M, 1996, IN PRESS; HERMEKING H, 1995, ONCOGENE, V11, P1409; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KARN J, 1989, ONCOGENE, V4, P773; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MORROW MA, 1992, GENE DEV, V6, P61, DOI 10.1101/gad.6.1.61; MURGRAUER G, 1988, J CELL BIOL, V107, P1325; NEGRONI A, 1991, CELL GROWTH DIFFER, V2, P511; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENA A, 1993, J BIOL CHEM, V268, P27277; Peverali FA, 1996, ONCOGENE, V12, P457; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETERNELLA CM, 1995, MOL CELL BIOL, V15, P6999; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; ROSS RA, 1983, J NATL CANCER I, V71, P741; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1985, TRENDS GENET, V1, P271, DOI 10.1016/0168-9525(85)90103-9; Schwab M, 1995, NEUROSCIENTIST, V1, P277; SCHWEIGERER L, 1990, CANCER RES, V50, P4411; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STOHR M, 1978, STAIN TECHNOL, V53, P205; SZABO P, 1992, BIOCHEM BIOPH RES CO, V185, P953, DOI 10.1016/0006-291X(92)91719-7; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; WADA RK, 1993, CANCER, V72, P3346, DOI 10.1002/1097-0142(19931201)72:11<3346::AID-CNCR2820721134>3.0.CO;2-E; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455; ZERLIN M, 1987, ONCOGENE, V1, P19; ZORNIG M, 1995, ONCOGENE, V11, P2165	61	273	277	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	1996	13	4					803	812						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761302				2022-12-28	WOS:A1996VD43300016
J	Braverman, RH; Cooper, HL; Lee, HS; Prasad, GL				Braverman, RH; Cooper, HL; Lee, HS; Prasad, GL			Anti-oncogenic effects of tropomyosin: Isoform specificity and importance of protein coding sequences	ONCOGENE			English	Article						tropomyosin; isoforms; tumor suppressor	STIMULATES TYROSINE PHOSPHORYLATION; CHICKEN-EMBRYO FIBROBLASTS; MAMMARY EPITHELIAL-CELLS; NON-MUSCLE TROPOMYOSINS; CARDIAC TROPONIN-T; TRANSFORMED-CELLS; ALPHA-TROPOMYOSIN; BETA-TROPOMYOSIN; GROWTH-FACTOR; HYPERTROPHIC CARDIOMYOPATHY	Suppression of muscle type isoforms of tropomyosin (TM) is a common biochemical event in malignantly transformed cells. To evaluate the role of TM proteins and isoform specificity in cellular transformation, cDNAs that consist of coding sequences of TM1 (product of beta gene) and TM2 (product of alpha gene), but lacking untranslated regions (UTRs), have been expressed separately in DT (v-Ki-ras transformed NIH3T3) cells, and elevated levels of the corresponding proteins were detected. DT cells which over express TM2 manifest growth in soft agar. Elevated levels of TM1 protein in DT cells resulted in flattened cell morphology and complete abolition of anchorage independent growth. Tumorigenesis in athymic nude mice was observed in the absence of transduced TM1 mRNA. Thus, expression of TM1 protein is sufficient for tumor suppression: the UTRs of TM1 are not required for the tumor suppressive effects. Expression of TM2 protein, on the other hand, has no effect on the transformed phenotype of DT cells. These data indicate that isoforms 1 and 2 of TMs perform distinct physiological roles.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ADEREM A, 1992, TRENDS BIOCHEM SCI, V17, P438, DOI 10.1016/0968-0004(92)90016-3; BHATTACHARYA B, 1988, ONCOGENE RES, V3, P51; BHATTACHARYA B, 1990, CANCER RES, V50, P2105; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; CANONNEHERGAUX F, 1994, NEUROCHEM INT, V25, P545, DOI 10.1016/0197-0186(94)90153-8; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLAYTON L, 1988, J MOL BIOL, V201, P507, DOI 10.1016/0022-2836(88)90633-X; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; COTE GP, 1983, MOL CELL BIOCHEM, V57, P127, DOI 10.1007/BF00849190; DREES B, 1995, J CELL BIOL, V128, P383, DOI 10.1083/jcb.128.3.383; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GRAMATIKOFF K, 1995, BIOL CHEM H-S, V376, P321; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hammell RL, 1996, J BIOL CHEM, V271, P4236; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HENDRICKS M, 1981, P NATL ACAD SCI-BIOL, V78, P5633, DOI 10.1073/pnas.78.9.5633; HITCHCOCKDEGREGORI SE, 1994, ADV EXP MED BIOL, V358, P85; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; JAMMEY PA, 1995, CURR OPIN CELL BIOL, V7, P111; KAHN P, 1979, J CELL BIOL, V82, P1, DOI 10.1083/jcb.82.1.1; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; LEAVITT J, 1986, MOL CELL BIOL, V6, P2721, DOI 10.1128/MCB.6.7.2721; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; LIANG NG, 1995, NAT GENET, V9, P75; LIBRI D, 1990, MOL CELL BIOL, V10, P5036, DOI 10.1128/MCB.10.10.5036; LIBRI D, 1990, J BIOL CHEM, V265, P3471; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; MACLEOD AR, 1987, BIOESSAYS, V6, P208, DOI 10.1002/bies.950060504; MAEKAWA S, 1994, BIOCHEM MOL BIOL INT, V33, P661; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MCINNES C, 1988, BIOCHIM BIOPHYS ACTA, V951, P117, DOI 10.1016/0167-4781(88)90031-0; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MULLAUER L, 1993, ONCOGENE, V8, P2531; MUTHUCHAMY M, 1993, MOL CELL BIOL, V13, P3311, DOI 10.1128/MCB.13.6.3311; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V25, P267, DOI 10.1002/cm.970250307; NOVY RE, 1993, CELL MOTIL CYTOSKEL, V26, P248, DOI 10.1002/cm.970260308; Payne M R, 1985, Cell Muscle Motil, V6, P141; PITTENGER MF, 1995, J CELL SCI, V108, P3253; PITTENGER MF, 1994, CURR OPIN CELL BIOL, V6, P96, DOI 10.1016/0955-0674(94)90122-8; PRASAD GL, 1994, EUR J BIOCHEM, V224, P1, DOI 10.1111/j.1432-1033.1994.tb19988.x; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; PRASAD GL, 1991, BIOCHEM BIOPH RES CO, V177, P1068, DOI 10.1016/0006-291X(91)90647-P; PRENDERGAST GC, 1993, ADV CANCER RES, V62, P19, DOI 10.1016/S0065-230X(08)60314-0; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUIZOPAZO N, 1987, J BIOL CHEM, V262, P4755; SECKL MJ, 1995, J BIOL CHEM, V270, P6984, DOI 10.1074/jbc.270.12.6984; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; STAMM S, 1993, P NATL ACAD SCI USA, V90, P9857, DOI 10.1073/pnas.90.21.9857; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; TAKENAGA K, 1988, MOL CELL BIOL, V8, P5561, DOI 10.1128/MCB.8.12.5561; TAKENAGA K, 1994, CANCER LETT, V87, P47, DOI 10.1016/0304-3835(94)90408-1; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TIKOO A, 1994, J BIOL CHEM, V269, P23387; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WEINBERGER RP, 1993, J CELL BIOL, V120, P205, DOI 10.1083/jcb.120.1.205; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WHITTLE N, 1987, PROTEIN ENG, V1, P499, DOI 10.1093/protein/1.6.499; WIRTH PJ, 1992, ELECTROPHORESIS, V13, P305, DOI 10.1002/elps.1150130163	66	47	50	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					537	545						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760295				2022-12-28	WOS:A1996VB32800011
J	Smit, L; vanderHorst, G; Borst, J				Smit, L; vanderHorst, G; Borst, J			Formation of Shc/Grb2- and Crk adaptor complexes containing tyrosine phosphorylated Cbl upon stimulation of the B-cell antigen receptor	ONCOGENE			English	Article						B-cell antigen receptor; adaptor protein; Cbl; Shc/Grb2; Crk; Ras activation	NUCLEOTIDE EXCHANGE FACTOR; GTPASE-ACTIVATING PROTEIN; PROTOONCOGENE C-CBL; PHOSPHATIDYLINOSITOL 3-KINASE; LYMPHOCYTES-B; GRB2 ADAPTER; KINASE LYN; T-CELLS; SIGNAL TRANSDUCTION; EGF STIMULATION	B-cell antigen receptor (BCR) stimulation induces tyrosine phosphorylation of the She adaptor protein and its association with Grb2. The Shc/Grb2 complex may be involved in Ras activation, since Grb2 interacts with the guanine nucleotide exchange factor Sos. We reveal here an additional complexity of the BCR-induced Shc/Grb2 complex: it contains tyrosine phosphorylated proteins of 130, 110 and 75 kDa. The 130 kDa molecule inducibly associates with She, while the 75 kDa protein interacts with the carboxy-terminal SH3 domain of Grb2. The 110 kDa molecule is defined as Cbl, the product of the c-cbl oncogene, which is strongly phosphorylated on tyrosine upon BCR stimulation. Cbl constitutively interacts with the SH3 domains of Grb2, with a preference for the amino-terminal domain, and is in this way recruited to She upon BCR stimulation. Immunodepletion studies showed that Grb2-associated Cbl can be phosphorylated by BCR-induced tyrosine kinases independent of a Shc/Grb2 interaction. This indicates that the BCR can also couple to a Grb2 complex without the involvement of She. Cbl not only interacts with Grb2, but also with the adaptor protein Crk. In contrast to its constitutive interaction with Grb2, tyrosine-phosphorylated Cbl only associates with Crk after BCR stimulation. In summary, we observe that the BCR activates Shc/Grb2-, Grb2- and Crk adaptor complexes of distinct composition, which may allow selective coupling to different signal transduction cascades. Cbl participates in all three adaptor complexes and is tyrosine phosphorylated upon BCR stimulation, pointing to a central role for this molecule in the regulation of antigen receptor-induced B cell responses.	NETHERLANDS CANC INST,DIV CELLULAR BIOCHEM,NL-1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute				Smit, Linda/0000-0003-0025-269X; Borst, Jannie/0000-0002-8043-5009				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BLAKE TJ, 1991, ONCOGENE, V6, P653; BORST J, 1993, IMMUNOL REV, V132, P49, DOI 10.1111/j.1600-065X.1993.tb00837.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; BUDAY L, 1994, J BIOL CHEM, V269, P9019; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHARDIN P, 1995, FEBS LETT, V369, P47, DOI 10.1016/0014-5793(95)00578-W; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COGGESHALL KM, 1992, P NATL ACAD SCI USA, V89, P5660, DOI 10.1073/pnas.89.12.5660; CORY GOC, 1995, J EXP MED, V182, P611, DOI 10.1084/jem.182.2.611; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DEWEERS M, 1994, J BIOL CHEM, V269, P23857; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Fournel M, 1996, J EXP MED, V183, P301, DOI 10.1084/jem.183.1.301; FUKUZAWA T, 1995, J BIOL CHEM, V270, P19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOLD MR, 1993, J IMMUNOL, V150, P377; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLD MR, 1992, J IMMUNOL, V148, P2012; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HARWOOD AE, 1993, J IMMUNOL, V151, P4513; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; LANKESTER AC, 1994, EUR J IMMUNOL, V24, P2818, DOI 10.1002/eji.1830241136; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU L, 1994, MOL CELL BIOL, V14, P6926, DOI 10.1128/MCB.14.10.6926; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; REIF K, 1994, J BIOL CHEM, V269, P14081; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; SAWASDIKOSOL S, 1995, J BIOL CHEM, V270, P2893, DOI 10.1074/jbc.270.7.2893; SAXTON TM, 1994, J IMMUNOL, V153, P623; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SMIT L, 1994, J BIOL CHEM, V269, P20209; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VANNOESEL CJM, 1993, INT IMMUNOL, V5, P699; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	61	45	46	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					381	389						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710377				2022-12-28	WOS:A1996VA25200017
J	Bacus, SS; Yarden, Y; Oren, M; Chin, DM; Lyass, L; Zelnick, CR; Kazarov, A; Toyofuku, W; GrayBablin, J; Beerli, RR; Hynes, NE; Nikiforov, M; Haffner, R; Gudkov, A; Keyomarsi, K				Bacus, SS; Yarden, Y; Oren, M; Chin, DM; Lyass, L; Zelnick, CR; Kazarov, A; Toyofuku, W; GrayBablin, J; Beerli, RR; Hynes, NE; Nikiforov, M; Haffner, R; Gudkov, A; Keyomarsi, K			Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells	ONCOGENE			English	Article						heregulin; Neu; p53; p21(WAF1/CIP1); cell cycle; erbB-2	EPIDERMAL GROWTH-FACTOR; HUMAN-BREAST-CANCER; MONOCLONAL-ANTIBODIES; MAMMARY-TUMORS; P53; PROTEIN; GENE; PHOSPHORYLATION; IDENTIFICATION; AMPLIFICATION	Previously we reported that neu differentiation factor (NDF)/heregulin (HRG) elevates tyrosine phosphorylation of its receptors erbB-3, erbB-4, and erbB-2 (through heterodimer formation). We also showed that both NDF/HRG and antibodies to erbB-2 can arrest growth and induce differentiation in breast cancer cells. In this study, we report on the mechanism of NDF/HRG-induced cellular effects. We show that NDF/HRG and antibodies to erbB-2 receptors up-regulate expression of p53 by stabilizing the protein. This is accompanied by upregulation of the p53 inducible gene, p21(CIP1/WAF1), in a variety of cell lines: MCF7 and their derivatives (MCF7/HER2, MN1 and MCF-7-puro), ZR75T and LnCap cells, The induction of p21 is further enhanced when cells are treated with both NDF/HRG and DNA-damaging chemotherapeutic agents (i.e. doxorubicin). The NDF/HRG mediated induction of p21 is dependent on wildtype p53, as it fails to occur in cells expressing dominant negative p53 (MDD2). Furthermore, p21 induction is capable of inactivating cdk2 complexes as measured by Histone H1 phosphorylation assays. Finally, we show that in primary cultures of breast and other cancers, p21 is significantly induced in response to NDF/HRG treatment. Collectively, these observations suggest that the mechanism of breast cancer cell growth inhibition and differentiation via erbB receptors activation is through a p53-mediated pathway.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR, ALBANY, NY 12201 USA; ADV CELLULAR DIAGNOST INC, ELMHURST, IL 60126 USA; UNIV ILLINOIS, CHICAGO, IL 60612 USA; WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	State University of New York (SUNY) System; Wadsworth Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Weizmann Institute of Science; Friedrich Miescher Institute for Biomedical Research			Keyomarsi, Khandan/H-2716-2016; YARDEN, YOSEF/K-1467-2012	Keyomarsi, Khandan/0000-0002-5440-0849; Gudkov, Andrei/0000-0003-2548-0154	NATIONAL CANCER INSTITUTE [R21CA062045, R01CA060730] Funding Source: NIH RePORTER; NCI NIH HHS [CA62045, CA60730] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMAGASE H, 1990, J PHARMACOBIO-DYNAM, V13, P263, DOI 10.1248/bpb1978.13.263; ARTEAGA CL, 1994, CANCER RES, V54, P3758; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CANCER RES, V52, P2580; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; DOLBEARE F, 1983, P NATL ACAD SCI-BIOL, V80, P5573, DOI 10.1073/pnas.80.18.5573; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUDAS J, 1995, ONCOGENE, V11, P253; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANCOCK MC, 1991, CANCER RES, V51, P4575; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KASTAN MB, 1991, CANCER RES, V51, P6304; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KWOK TT, 1991, INT J CANCER, V49, P73, DOI 10.1002/ijc.2910490114; KWOK TT, 1989, J NATL CANCER I, V81, P1020, DOI 10.1093/jnci/81.13.1020; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Liu Y, 1996, CANCER RES, V56, P31; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1994, ONCOGENE, V9, P1829; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Ronen D, 1996, CELL GROWTH DIFFER, V7, P21; SACHS L, 1987, CANCER RES, V47, P1981; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SIEGALL CB, 1995, J BIOL CHEM, V270, P7625, DOI 10.1074/jbc.270.13.7625; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAGLIABUE E, 1991, INT J CANCER, V47, P933, DOI 10.1002/ijc.2910470625; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668; ZIANG H, 1993, MOL BIOL CELL DIFF, V1, P285	67	72	75	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2535	2547						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700512				2022-12-28	WOS:A1996UW48700007
J	Khwaja, A; Hallberg, B; Warne, PH; Downward, J				Khwaja, A; Hallberg, B; Warne, PH; Downward, J			Networks of interaction of p120(cbl) and p130(cas) with Crk and Grb2 adaptor proteins	ONCOGENE			English	Article						Cb1; Grb2; Crk; oncogene; tyrosine phosphorylation	RECEPTOR TYROSINE KINASES; V-CBL ONCOGENE; SH3 DOMAINS; IDENTIFICATION; TRANSFORMATION; ASSOCIATION; TRUNCATION; BINDS; CELLS	P120(cbl), the product of the c-cbl proto-oncogene, has previously been shown to become tyrosine phosphorylated following EGF stimulation of cells, and to bind constitutively to the SH3 domain of the adaptor protein Grb2. Here we show that another adaptor protein, Crk, binds through its SH2 domain to tyrosine phosphorylated p120(cbl). In addition, Crk becomes phosphorylated on tyrosine and serine following EGF treatment of PC12 and other cell lines. In unstimulated cells, while Grb2 is not bound to any tyrosine phosphoprotein, Crk is bound via its SH2 domain to tyrosine phosphorylated p130(cas), the Crk-associated v-Src substrate. Following EGF treatment, Crk dissociates from p130(cas), possibly due to a higher affinity of Crk SH2 for p120(cbl) compared with p130(cas). Interaction between Grb2 and p120(cbl) increases threefold following EGF treatment of cells; in vitro, this induction of Grb2 association with unphosphorylated p120(cbl) can be mimicked by the addition of tyrosine phosphorylated She, suggesting a transfer of information between the SH2 and SH3 domains of Grb2. These data indicate that adaptor proteins can exchange binding partners in response to stimuli, and that different adaptor proteins can bind to the same partners by different mechanisms.	IMPERIAL CANC RES FUND, LONDON WC2A 3PX, ENGLAND	Cancer Research UK			Khwaja, Asim/C-1509-2008	Downward, Julian/0000-0002-2331-4729				ADCOCK MR, 1993, NATURE, V363, P83; ADCOCK MR, 1992, NATURE, V360, P689; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOCH CA, 1992, MOL CELL BIOL, V12, P1366, DOI 10.1128/MCB.12.3.1366; LEZCANO OMR, 1994, J BIOL CHEM, V269, P17363; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PATCH LA, 1995, J CELL SCI, V108, P1371; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; REGNIER DC, 1989, J VIROL, V63, P3678, DOI 10.1128/JVI.63.9.3678-3682.1989; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P9345; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAUCHI T, 1994, J BIOL CHEM, V269, P25206; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556; ZACHARY I, 1992, J BIOL CHEM, V267, P19031; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	48	48	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2491	2498						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700507				2022-12-28	WOS:A1996UW48700002
J	Momand, J; Zambetti, GP				Momand, J; Zambetti, GP			Analysis of the proportion of p53 bound to mdm-2 in cells with defined growth characteristics	ONCOGENE			English	Article						cell cycle; immortalized; post-translational; tumorigenic	GENE-EXPRESSION; 3T3 CELLS; PROTEIN; DNA; PHOSPHORYLATION; TRANSFORMATION; ONCOGENE; PRODUCT; COMPLEX; FORMS	A critical parameter affecting cell growth properties is the relative levels of the p53 tumor suppressor protein and the mdm-2 oncoprotein. Because mdm-2 overexpression is observed in several types of human cancers and its physical association with p53 appears essential for down-regulating p53 activity the proportion of p53 bound to mdm-2 was examined in four types of cells with divergent growth properties: (1) Growth arrested cells (Al) expressing high levels of wild-type p53 activity; (2) Tumorigenic cells (3T3DM) expressing high levels of mdm-2; (3) Immortalized non tumorigenic cells (Swiss3T3 and Balb/c3T3); and (4) Normal murine fibroblasts. In Al cells, greater than 78% of the p53 was not bound to mdm-2, demonstrating that excess free p53 is available for cell cycle arrest. In 3T3DM cells 100% of the p53 was bound to mdm-2 and these cells were unable to support p53-mediated transactivation, a p53 function essential for cell growth inhibition, In Swiss3T3 cells 75% of the p53 was bound to mdm-2. In Balb/c3T3 cells and normal cells no detectable mdm-2 was bound to p53. Since free p53 was detected in several of these cell lines the possibility that mdm-2 is completely titrated by p53 was investigated. However, free mdm-2 was present in all these cells. Phosphorylation of p53 does not appear to control complex formation since the free and the mdm-2-bound form of p53 from Al cells had identical phosphorylation maps. These data suggest that a high proportion of p53 bound to mdm-2 is observed in some cells with a more transformed phenotype and that p53-mdm-2 complex formation is controlled by a posttranslational event other than p53 phosphorylation.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	St Jude Children's Research Hospital	Momand, J (corresponding author), CITY HOPE NATL MED CTR, DEPT CELL & TUMOR BIOL, 1500 E DUARTE RD, DUARTE, CA 91010 USA.		Zambetti, Gerard/N-8093-2018; Momand, Jamil/F-8154-2012	Zambetti, Gerard/0000-0002-0929-5007; 	NCI NIH HHS [5 P30CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAHILLYSNYDER L, 1987, SOMAT CELL MOLEC GEN, V13, P235, DOI 10.1007/BF01535205; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CORDONCARDO C, 1994, CANCER RES, V54, P794; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAKHARZADEH SS, 1991, EMBO J, V10, P1565, DOI 10.1002/j.1460-2075.1991.tb07676.x; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1993, MOL CELL BIOL, V13, P301, DOI 10.1128/MCB.13.1.301; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRUDAS JM, 1995, CLIN CANCER RES, V1, P71; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MELTZER PS, 1994, J NATL CANCER I, V86, P1265, DOI 10.1093/jnci/86.17.1265; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MONTALVO EA, 1991, J VIROL, V65, P3647, DOI 10.1128/JVI.65.7.3647-3655.1991; MOSNER J, 1994, ONCOGENE, V9, P3321; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OLSON DC, 1993, ONCOGENE, V8, P2353; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PICKSLEY SM, 1992, ONCOGENE, V7, P1649; PICKSLEY SM, 1994, ONCOGENE, V9, P2523; RITTLING SR, 1992, ONCOGENE, V7, P935; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	61	30	30	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	1996	12	11					2279	2289						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649767				2022-12-28	WOS:A1996UQ22000004
J	Kato, MV; Sato, H; Tsukada, T; Ikawa, Y; Aizawa, S; Nagayoshi, M				Kato, MV; Sato, H; Tsukada, T; Ikawa, Y; Aizawa, S; Nagayoshi, M			A follistatin-like gene, mac25, may act as a growth suppressor of osteosarcoma cells	ONCOGENE			English	Article						mac25; follistatin; p53; growth suppressor	ACTIVIN-BINDING PROTEIN; MICE; P53; PROTEOGLYCANS; INHIBITION; RECEPTOR; KINASES; P21	mac25, a retinoic acid-inducible gene that is expressed at high levels in senescent epithelial cells, was initially cloned as a gene that is differentially expressed in meningioma, Although the homology of its product with members of family of insulin-like growth factor-binding proteins was suggested, the product also exhibits strong homology to follistatin, an activin-binding protein, However, a domain corresponding to the carboxyl terminus of follistatin is not found in mac25, The carboxyl-terminally truncated form of follistatin, generated by alternative splicing, has stronger activin-binding activity than the complete form, This result suggests that mac25 might act as an activated follistatin, Clonal growth of a p53-deficient osteosarcoma cell line was strongly inhibited when the murine mac25 gene, as well as the p53 gene, was introduced, Resembling activins that belong to the transforming growth factor-beta (TGF-beta) superfamily, mac25 and p53 might associate with similar but distinct targets, namely cyclin-dependent kinase inhibitors. However, there is no evidence for compensation of p53 function by mac25 in the development of p53-deficient mice, as judged from the pattern of expression of mac25 in mice, mac25 might act as a tumor suppressor, modulating signaling of the TGF-beta family, as does alpha-inhibin.	SAITAMA UNIV,FAC SCI,DEPT REGULAT BIOL,URAWA,SAITAMA 338,JAPAN; TOKYO MED & DENT UNIV,DEPT RETROVIRAL REGULAT,DIV MED RES,BUNKYO KU,TOKYO 113,JAPAN; KUMAMOTO UNIV,SCH MED,INST EMBRYOL & GENET,DEPT MORPHOGENESIS,KUMAMOTO 860,JAPAN	Saitama University; Tokyo Medical & Dental University (TMDU); Kumamoto University	Kato, MV (corresponding author), RIKEN,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,3-1-1 KOYODAI,TSUKUBA,IBARAKI 305,JAPAN.		Kato, Mitsuo/D-5411-2009	Kato, Mitsuo/0000-0002-1783-1084				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MATHER JP, 1992, P SOC EXP BIOL MED, V201, P1; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MURPHY M, 1993, CELL GROWTH DIFFER, V4, P715; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SATO H, 1995, BIOCHEM BIOPH RES CO, V214, P468, DOI 10.1006/bbrc.1995.2310; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHIMASAKI S, 1988, P NATL ACAD SCI USA, V85, P4218, DOI 10.1073/pnas.85.12.4218; SUGINO K, 1993, J BIOL CHEM, V268, P15579; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSUKADA T, 1993, ONCOGENE, V8, P3313; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	30	56	60	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1361	1364						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649839				2022-12-28	WOS:A1996UC06700022
J	Wick, W; Petersen, I; Schmutzler, RK; Wolfarth, B; Lenartz, D; Bierhoff, E; Hummerich, J; Muller, DJ; Stangl, AP; Schramm, J; Wiestler, OD; vonDeimling, A				Wick, W; Petersen, I; Schmutzler, RK; Wolfarth, B; Lenartz, D; Bierhoff, E; Hummerich, J; Muller, DJ; Stangl, AP; Schramm, J; Wiestler, OD; vonDeimling, A			Evidence for a novel tumor suppressor gene on chromosome 15 associated with progression to a metastatic stage in breast cancer	ONCOGENE			English	Article						tumor suppressor gene; breast carcinoma; metastasis; allelic loss; chromosome 15	CELL CARCINOMA; ALLELOTYPE; THROMBOSPONDIN; NM23; HETEROZYGOSITY; ANGIOGENESIS; INHIBITION; EXPRESSION	Loss of heterozygosity (LOH) studies have emerged as a valuable indicator for tumor suppressor genes involved in the formation or progression of carcinomas. We here present data indicating that human chromosome 15 harbours a novel putative tumor suppressor gene which appears to play a role during later stages of carcinogenesis and which may be associated with metastasis in breast cancer. In this study, 153 primary and metastatic carcinomas from 101 patients have been analysed for LOH with 13 polymorphic microsatellite markers on chromosome 15. The tumors included carcinoma of the lung in 49 patients, breast carcinoma in 29, colorectal carcinoma in nine, renal carcinoma in five, pancreatic carcinoma in five, urinary bladder carcinoma in two and prostate carcinoma and ovarial carcinoma in one patient each. LOH15 was seen in 42/99 (42%) informative patients. Tn metastatic tumors, LOH15 was observed in 37/68 (54%). High incidences of allelic losses were detected in metastases from lung (56%), breast (70%) and colorectal (67%) carcinomas. In carcinomas of the breast, there was a significant difference (P<0.01) in LOH15 frequencies between non-metastatic tumors (11%) and brain metastases (70%). Such a difference was not observed on the chromosomal arm 17p which yielded high proportions of LOH in both non metastatic breast tumor (73%) and breast carcinoma metastases (90%). In 16 patients, interstitial deletions could be detected. The common region of overlap extended from D15S231 to D15S641, thus mapping this putative tumor suppressor gene to chromosome 15q14. Our data indicate that a gene on chromosome 15 contributes to the pathogenesis of metastatic carcinoma.	UNIV BONN,MED CTR,DEPT NEUROPATHOL,D-53105 BONN,GERMANY; CHARITE,DEPT PATHOL,BERLIN,GERMANY; UNIV BONN,MED CTR,DEPT OBSTET & GYNECOL,D-53105 BONN,GERMANY; UNIV HOSP FREIBURG,INST PATHOL,FREIBURG,GERMANY; HOSP COLOGNE MERHEIM,DEPT NEUROSURG,D-51109 COLOGNE,GERMANY; UNIV HOSP BONN,DEPT PATHOL,D-53105 BONN,GERMANY; UNIV HOSP BONN,DEPT NEUROSURG,D-53105 BONN,GERMANY	University of Bonn; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Bonn; University of Freiburg; University of Bonn; University of Bonn			Müller, Daniel J./L-4159-2016; Wick, Wolfgang/AAA-2545-2020; Mueller, Daniel Josef/GVT-7899-2022; von Deimling, Andreas/F-7774-2013	Müller, Daniel J./0000-0003-4978-4400; Wick, Wolfgang/0000-0002-6171-634X; Mueller, Daniel Josef/0000-0003-4978-4400; von Deimling, Andreas/0000-0002-5863-540X				BAGAVANDOSS P, 1990, BIOCHEM BIOPH RES CO, V170, P867, DOI 10.1016/0006-291X(90)92171-U; BENDER B, 1994, BIOTECHNIQUES, V16, P204; BEVILACQUA G, 1989, CANCER RES, V49, P5185; BOUKAMP P, 1995, ONCOGENE, V11, P961; BUDOWLE B, 1991, AM J HUM GENET, V48, P137; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CLIBY W, 1993, CANCER RES, V53, P2393; DEVILEE P, 1991, ONCOGENE, V6, P1705; FIDLER IJ, 1982, SCIENCE, V217, P998, DOI 10.1126/science.7112116; FUJIMORI M, 1991, CANCER RES, V51, P89; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HAHN M, 1993, CLIN CHEM, V39, P549; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; LEONE A, 1991, CANCER RES, V51, P2490; LOUIS DN, 1992, AM J PATHOL, V141, P777; MORITA R, 1991, CANCER RES, V51, P820; RASHEED BKA, 1995, ONCOGENE, V10, P2243; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; Sambrook J., 1989, MOL CLONING; SATO S, 1994, CANCER RES, V54, P5652; SATO T, 1990, CANCER RES, V50, P7184; SHISEKI M, 1994, CANCER RES, V54, P5643; STEEG PS, 1988, CANCER RES, V48, P6550; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; TARABOLETTI G, 1990, J CELL BIOL, V111, P765, DOI 10.1083/jcb.111.2.765; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047; VONDEIMLING A, 1993, NEUROPATH APPL NEURO, V19, P524; VONDEIMLING A, 1994, INT J CANCER, V57, P676, DOI 10.1002/ijc.2910570511; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504	32	101	104	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					973	978						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649814				2022-12-28	WOS:A1996UA88400004
J	Hwang, ES; Naeger, LK; DiMaio, D				Hwang, ES; Naeger, LK; DiMaio, D			Activation of the endogenous p53 growth inhibitory pathway in HeLa cervical carcinoma cells by expression of the bovine papillomavirus E2 gene	ONCOGENE			English	Article						tumour suppressor protein; growth arrest; human papillomavirus	WILD-TYPE P53; MOUSE B-MYB; CELLULAR-RESPONSE; DNA DAMAGE; PROTEIN; E6; TRANSCRIPTION; PRODUCT; RB; KERATINOCYTES	We previously showed that expression of the bovine papillomavirus (BPV) E2 gene results in a dramatic inhibition of the proliferation of several human cervical carcinoma cell lines, including HeLa cells which contain human papillomavirus (HPV) type 18 DNA. We have assessed the status of endogenous G1 cell cycle regulatory proteins, including the tumor suppressor proteins, p53 and p105Rb, in order to investigate growth regulatory pathways in HeLa expression. The p53 tumor suppressor stabilized following the introduction of the E2 gene into HeLa cells. This results in the induction of the p53-responsive gene encoding the cyclin dependent kinase (cdk) inhibitor, p21/WAF1, complex formation between p21/WAF1 and cdk2 and reduction of in vitro cdk2/cyclin E kinase activity. The reduced cdk kinase activity is accompanied by the accumulation of the growth inhibitory hypophosphorylated form of the tumor suppressor protein, p105Rb. The level of the p105Rb-regulated transcription factor, E2F1, is reduced, as is transcription of a variety of E2F1-regulated genes, including B-myb. Thus, the p53 growth inhibitory pathway has evidently not accumulated mutations in HeLa cells but rather appears intact. However, this pathway remains dormant, until it is mobilized by appropriate manipulations, such as the expression of the BPV E2 protein.	YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University					NATIONAL CANCER INSTITUTE [P01CA016038] Funding Source: NIH RePORTER; NCI NIH HHS [CA16038] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUTZ K, 1995, ONCOGENE, V10, P927; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROOK T, 1991, ONCOGENE, V6, P873; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUJITA M, 1992, CANCER RES, V52, P5323; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HAVRE PA, 1995, CANCER RES, V55, P4420; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HURLIN PJ, 1991, P NATL ACAD SCI USA, V88, P570, DOI 10.1073/pnas.88.2.570; HWANG ES, 1993, J VIROL, V67, P3720, DOI 10.1128/JVI.67.7.3720-3729.1993; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PECORARO G, 1991, AM J PATHOL, V138, P1; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THIERRY F, 1987, EMBO J, V6, P3391, DOI 10.1002/j.1460-2075.1987.tb02662.x; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	52	83	84	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					795	803						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632901				2022-12-28	WOS:A1996TW68600010
J	Matsuda, S; KawamuraTsuzuku, J; Ohsugi, M; Yoshida, M; Emi, M; Nakamura, Y; Onda, M; Yoshida, Y; Nishiyama, A; Yamamoto, T				Matsuda, S; KawamuraTsuzuku, J; Ohsugi, M; Yoshida, M; Emi, M; Nakamura, Y; Onda, M; Yoshida, Y; Nishiyama, A; Yamamoto, T			Tob, a novel protein that interacts with p185(erbB2), is associated with antiproliferative activity	ONCOGENE			English	Article						c-erbB-2; receptor tyrosine kinase; BTG1; growth suppression; chromosome 17q21	EPIDERMAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; NEU ONCOGENE; C-ERBB-2; DOMAIN; PROTOONCOGENE; PRODUCTS; CLONING; ERBB-2; BREAST	We have molecularly cloned a cDNA for a novel protein termed Tob (Transducer of ErbB-2) that interacts with the c-erbB-2 gene product p185(erbB2). Nucleotide sequencing reveals that the Tob protein is a 45 kDa protein that does not contain either SH2 (Src Homology 2) or SH3 domain but is homologous to the previously characterized anti-proliferative gene product BTG-1 at its amino-terminal half. The carboxyl-terminal half of Tob is characterized by the presence of a sequence rich in proline and glutamine and shows no homology to known proteins. Like BTG-1, exogenously expressed Tob is able to suppress growth of NIH3T3 cells, but the growth suppression is hampered by the presence of kinase-active p185(erbB2). By using the GST-Tob protein that contains either full length or amino-terminal half of Tob, we show that the carboxyl-terminal half of Tob is relevant to its interaction with p185(erbB2). Furthermore, we could co-immunoprecipitate the Tob protein with anti-ErbB-2 antibody, and reciprocally the p185(erbB2). With anti-Tob antibodies. These data suggest that p185(erbB2) negatively regulates the Tob-mediated anti-proliferative pathway through its interaction with Tob, resulting possibly in growth stimulation by p185(erbB2). Finally, expression of the Tob mRNA is observed in various cell types and is not correlated with expression of c-erbB-2, suggesting that other receptor-type protein-tyrosine kinases are also involved in the Tob-mediated regulation of cell growth.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; UNIV TOKYO,INST MED SCI,MOLEC MED LAB,MINATO KU,TOKYO 108,JAPAN; 2ND HOSP,NIPPON MED SCH,NAKAHARA KU,KAWASAKI,KANAGAWA 211,JAPAN; HOKKAIDO UNIV,FAC SCI,SAPPORO,HOKKAIDO 060,JAPAN	University of Tokyo; University of Tokyo; Nippon Medical School; Hokkaido University				Ohsugi, Miho/0000-0003-0288-3428				AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FUJIMOTO A, 1991, BIOCHEM BIOPH RES CO, V17, P724; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTER P, 1990, SCIENCE, V247, P63; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASUKO T, 1989, JPN J CANCER RES, V80, P10, DOI 10.1111/j.1349-7006.1989.tb02237.x; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mossmann T., 1983, J IMMUNOL METHODS, V65, P55; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEGATTO O, 1990, New Biologist, V2, P187; SEGATTO O, 1993, ONCOGENE, V8, P2105; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI M, 1993, J BIOL CHEM, V268, P27413; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; YAMAMOTO T, 1986, NATURE, V45, P649; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YOKOTA J, 1986, LANCET, V1, P765	35	166	180	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					705	713						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632892				2022-12-28	WOS:A1996TW68600001
J	Goruppi, S; Ruaro, E; Schneider, C				Goruppi, S; Ruaro, E; Schneider, C			Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts	ONCOGENE			English	Article						gas6; axl; growth arrest; growth factors	ARREST-SPECIFIC GENE; GROWTH ARREST; PROTEIN-S; SIGNAL-TRANSDUCTION; CELL-DEATH; MURINE FIBROBLASTS; BLOOD-COAGULATION; SYSTEM; PURIFICATION; EXPRESSION	Reversible growth arrest has been characterised for enhanced expression of a set of genes called gas (growth arrest specific). gas6 product (Gas6) is a secreted protein that was identified as the ligand for the tyrosine kinase receptor Axl. Here we report that Gas6 is able to induce cell cycle division entry in serum starved NIH3T3 cells. This mitogenic activity of Gas6 strictly correlates with its ability to interact with NIH3T3 endogenous Axl receptor since it can be abolished by soluble Axl extracellular domain and activates both Axl intrinsic kinase activity and the downstream MAPK pathway. Moreover when ectopic Axl overexpression is performed by microinjection in serum starved NIH3T3 cells, addition of a non mitogenic level of Gas6 induces selective entry into S phase in Axl overexpressing cells. Interestingly, Axl overexpression per se is not able to induce S phase entry. Finally we present evidences indicating that Gas6 is able to protect serum starved NIH3T3 cells from cell death by apoptosis as induced by complete growth factor depletion. The reported survival activity seems to be independent of Gas6 mitogenic activity, thus implicating a double and separable activity for Gas6 during growth arrest.	LAB NAZL CONSORZIO INTERUNIV BIOTECNOL, I-34012 TRIESTE, ITALY; INT CTR GENET ENGN & BIOTECHNOL, I-34012 TRIESTE, ITALY	International Center for Genetic Engineering & Biotechnology (ICGEB)								AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRANCOLINI C, 1992, J CELL BIOL, V117, P1251, DOI 10.1083/jcb.117.6.1251; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CORDONCARDO C, 1991, CELL, V66, P173, DOI 10.1016/0092-8674(91)90149-S; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; DAHLBACK B, 1983, BIOCHEM J, V209, P837, DOI 10.1042/bj2090837; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DELSAL G, 1994, BIOTECHNIQUES, V16, P134; DOWNING JR, 1989, MOL CELL BIOL, V9, P2890, DOI 10.1128/MCB.9.7.2890; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FAUST M, 1992, ONCOGENE, V7, P1287; FUJIMOTO J, 1994, ONCOGENE, V9, P693; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; GODOWSKI PJ, 1995, CELL, V82, P355, DOI 10.1016/0092-8674(95)90424-7; GORUPPI S, 1994, ONCOGENE, V9, P1537; GRAHAM DK, 1994, CELL GROWTH DIFFER, V5, P647; GRAHAM DK, 1995, ONCOGENE, V10, P2349; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JIA R, 1994, J BIOL CHEM, V269, P1839; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; LAI C, 1991, NEURON, V6, P691, DOI 10.1016/0896-6273(91)90167-X; LIN YZJ, 1991, ONCOGENE, V6, P639; LUNDWALL A, 1986, P NATL ACAD SCI USA, V83, P6716, DOI 10.1073/pnas.83.18.6716; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1994, J BIOL CHEM, V269, P10720; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; NEUBAUER A, 1994, BLOOD, V84, P1931; OBRYAN JP, 1995, J BIOL CHEM, V270, P551, DOI 10.1074/jbc.270.2.551; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OHASHI K, 1994, ONCOGENE, V9, P699; PELICCI G, 1995, ONCOGENE, V10, P1631; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RESCIGNO J, 1991, ONCOGENE, V6, P1909; Sambrook J, 1989, MOL CLONING LABORATO; SCHER CD, 1982, J CELL PHYSIOL, V113, P211, DOI 10.1002/jcp.1041130205; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SCHNEIDER C, 1988, CELL, V54, P787, DOI 10.1016/S0092-8674(88)91065-3; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; TAMM I, 1990, J CELL PHYSIOL, V143, P494, DOI 10.1002/jcp.1041430314; TAMM I, 1991, J CELL PHYSIOL, V148, P85, DOI 10.1002/jcp.1041480111; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251	59	244	253	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					471	480						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637702				2022-12-28	WOS:A1996TV59700002
J	Weintraub, M; Lin, AY; Franklin, J; Tucker, MA; Magrath, IT; Bhatia, KG				Weintraub, M; Lin, AY; Franklin, J; Tucker, MA; Magrath, IT; Bhatia, KG			Absence of germline p53 mutations in familial lymphoma	ONCOGENE			English	Article						p53; germline mutations; familial lymphoma	TUMOR-SUPPRESSOR GENE; ABNORMAL EXPRESSION; MALIGNANT-LYMPHOMAS; HODGKINS-DISEASE; BREAST-CANCER; LEUKEMIA; RELATIVES; NEOPLASMS; PROTEIN; CELLS	p53, a tumor suppressor gene, is frequently mutated in sporadic human cancer, and inherited mutations in p53 predispose to the early onset of cancer, p53 mutations occur frequently in sporadic lymphoma, and, in mice deficient for p53, lymphoma is the most common type of malignancy, Families with an increased incidence of lymphoma have been described, suggesting an inherited predisposition to lymphoma in these circumstances, To determine whether the predisposition to lymphoma in these families results from germline mutations in p53, we analysed exons 4-11 of the p53 gene in 35 individuals from 19 lymphoma-prone kindreds, We found no germline p53 mutations in any of the individuals tested, However, p53 expression assessed by immunohistochemistry, which suggests mutation, was observed in 35% of the tumor samples from the familial Hodgkin's disease cases and in 13% of the familial non-Hodgkin's lymphoma cases, These results suggest that p53 mutations do not play a critical role in heritable susceptibility to lymphoma, p53 may act by different, non-mutation related mechanisms in this setting, or be involved in late events in the pathogenesis of these tumors.	NCI,PEDIAT BRANCH,NIH,BETHESDA,MD 20892; NCI,GENET EPIDEMIOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Tucker, Margaret A/B-4297-2015					BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BHATIA K, 1993, FASEB J, V7, P951, DOI 10.1096/fasebj.7.10.8344493; BHATIA KG, 1992, CANCER RES, V52, P4273; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BJERRUM OW, 1986, SCAND J HAEMATOL, V36, P398; CESARMAN E, 1993, AM J PATHOL, V143, P845; CHILOSI M, 1994, BLOOD, V84, P4295, DOI 10.1182/blood.V84.12.4295.bloodjournal84124295; DOGLIONI C, 1991, HEMATOL PATHOL, V5, P67; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUPTA RK, 1993, P NATL ACAD SCI USA, V90, P2817, DOI 10.1073/pnas.90.7.2817; HAIM N, 1982, CANCER, V49, P2197, DOI 10.1002/1097-0142(19820515)49:10<2197::AID-CNCR2820491036>3.0.CO;2-9; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HARVEY M, 1993, FASEB J, V7, P918; HILDESHEIM A, 1995, EUR J CANCER, V31A, P125, DOI 10.1016/0959-8049(94)00465-H; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; JOLLY KW, 1994, ONCOGENE, V9, P97; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; OHGAKI H, 1993, INT J CANCER, V54, P408, DOI 10.1002/ijc.2910540310; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; POTTERN LM, 1991, LEUKEMIA RES, V15, P305, DOI 10.1016/0145-2126(91)90005-E; PROKOCIMER M, 1994, BLOOD, V84, P2391; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; SAID JW, 1992, AM J PATHOL, V141, P1343; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SANDER CA, 1993, BLOOD, V82, P1994; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; TRUMPER LH, 1993, BLOOD, V81, P3097; VILLUENDAS R, 1993, BLOOD, V82, P3151; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	39	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					687	691						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637726				2022-12-28	WOS:A1996TV59700026
J	Zhang, LS; Hung, MC				Zhang, LS; Hung, MC			Sensitization of HER-2/neu-overexpressing non-small cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin	ONCOGENE			English	Article						emodin; HER-2/neu; tyrosine kinase; lung cancer; combination therapy	GROWTH-FACTOR-RECEPTOR; NEU ONCOGENE; GENE; EXPRESSION; ADENOCARCINOMA; ACTIVATION; SURVIVAL; P185NEU; ASSAY; LINES	Overexpression of the HER-2/neu proto-oncogene which encodes tyrosine kinase receptor p185(neu), has been observed frequently in many human cancers, including non-small cell lung cancer (NSCLC), and is correlated with poor patient survival in these cancers, In addition, HER-2/neu overexpression in NSCLC is known to induce chemoresistance, Recently, we demonstrated that emodin, a tyrosine kinase inhibitor, suppresses HER-2/neu tyrosine kinase activity in HER-2/neu-overexpressing breast cancer cells and preferentially represses proliferation of these cells, The work described here was carried out to examine (1) whether the tyrosine kinase activity of p185(neu) is required for resistance to chemotherapeutic drugs of HER-2/neu-overexpressing NSCLC cells and (2) whether the tyrosine kinase inhibitor emodin can sensitize these cells to chemotherapeutic drugs. We found that emodin decreased tyrosine phosphorylation of HER-2/neu and preferentially suppressed proliferation of HER-2/neu-overexpressing NSCLC cells. Furthermore, the combination of emodin with cisplatin, doxorubicin or etoposide (VP16) synergistically inhibited the proliferation of HER-2/neu-overexpressing lung cancer cells, whereas low doses of emodin, cisplatin, doxorubicin, or VP16 alone had only minimal antiproliferative effects on these cells, These results indicate that tyrosine kinase activity is required for the chemoresistant phenotype of HER-2/neu-overexpressing NSCLC cells and that tyrosine kinase inhibitors such as emodin can sensitize these cells to chemotherapeutic drugs, The results may have important implications in chemotherapy for HER-2/neu-overexpressing cancers.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA058880, P30CA016672, R01CA060856] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 58880, CA 60856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CHAN TCK, 1993, BIOCHEM BIOPH RES CO, V193, P1152, DOI 10.1006/bbrc.1993.1746; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; HATA Y, 1994, ONCOL RES, V6, P19; HUNG MC, 1989, P NATL ACAD SCI USA, V86, P2545, DOI 10.1073/pnas.86.8.2545; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; JAYASURIYA H, 1992, J NAT PROD, V55, P696, DOI 10.1021/np50083a026; KERN JA, 1990, CANCER RES, V50, P5184; KUPCHAN SM, 1976, LLOYDIA, V39, P223; Minna JD, 1989, CANCER PRINCIPLES PR, P591; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; RUBINSTEIN LV, 1990, J NATL CANCER I, V82, P1113, DOI 10.1093/jnci/82.13.1113; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCHNEIDER PM, 1989, CANCER RES, V49, P4968; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; Silverberg E., 1988, CA-CANCER J CLIN, V38, P5; SISTONEN L, 1989, J CELL BIOL, V109, P1911, DOI 10.1083/jcb.109.5.1911; TSAI CM, 1995, J NATL CANCER I, V87, P682, DOI 10.1093/jnci/87.9.682; TSAI CM, 1993, J NATL CANCER I, V85, P897, DOI 10.1093/jnci/85.11.897; UDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159; WEBB JL, 1963, ENZYMES METABOL INH, V1, P507; WEINER DB, 1990, CANCER RES, V50, P421; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YEH SF, 1988, PLANTA MED, P413, DOI 10.1055/s-2006-962484; YU DH, 1993, CANCER RES, V53, P891; YU DH, 1991, ONCOGENE, V6, P1991; YU DH, 1994, CANCER RES, V54, P3260; ZHANG LS, 1995, CANCER RES, V55, P3890	30	113	127	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					571	576						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637714				2022-12-28	WOS:A1996TV59700014
J	Huang, K; Sommers, CL; Grinberg, A; Kozak, CA; Love, PE				Huang, K; Sommers, CL; Grinberg, A; Kozak, CA; Love, PE			Cloning and characterization of PTP-K1, a novel nonreceptor protein tyrosine phosphatase highly expressed in bone marrow	ONCOGENE			English	Article						protein tyrosine phosphatase; cDNA cloning; signal transduction	NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; SEQUENCE HOMOLOGY; RICH SEQUENCES; PROLINE-RICH; RECEPTOR; FAMILY; CDNA; IDENTIFICATION; DOMAINS	A novel nonreceptor protein tyrosine phosphatase (PTP), PTP-K1, was identified using a consensus polymerase chain reaction-based approach, The full length cDNA encompasses an open reading frame of 1362 base pairs, predicting a protein of 453 amino acid residues with a molecular mass of 54 kDa, The PTP domain is located in the N-terminal portion of the molecule and shares similar to 50% amino acid identify with two other nonreceptor PTPs: PEP and PTP-PEST, PTP-K1 is preferentially expressed in mouse bone marrow with transcripts of 1.7 kb, 1.9 kb and 3.5 kb, The 1.7 kb transcript was also detected in kidney, lung and ovary, The PTP domain of PTP-K1 was expressed as a fusion protein in bacteria and had intrinsic PTP catalytic activity, Indirect immunofluorescence microscopy in COS-7 cells showed that PTP-K1 was localized to the cytoplasm, Ptp-k1 was mapped to mouse chromosome 1, and was closely linked to the interleukin-1 receptor gene, The high level expression of PTP-K1 mRNA in bone marrow suggests that PTP-K1 may be involved in signal transduction in growth and differentiation of hematopoietic cells.	NICHHD,NIH,LAB MAMMALIAN GENES & DEV,BETHESDA,MD 20892; NIAID,MOL MICROBIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								Adachi M, 1996, CELL, V85, P15; ADAMSON MC, 1991, VIROLOGY, V183, P778, DOI 10.1016/0042-6822(91)91010-E; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; CHANG HL, 1991, J IMMUNOL, V147, P1687; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHAREST A, 1995, BIOCHEM J, V308, P425, DOI 10.1042/bj3080425; DENHERTOG J, 1992, BIOCHEM BIOPH RES CO, V184, P1241, DOI 10.1016/S0006-291X(05)80015-4; ELSON A, 1995, J BIOL CHEM, V270, P26116, DOI 10.1074/jbc.270.44.26116; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FLORES E, 1994, MOL CELL BIOL, V14, P4938, DOI 10.1128/MCB.14.7.4938; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Green EL, 1981, GENETICS PROBABILITY, P77; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; HIGASHITSUJI H, 1995, ONCOGENE, V10, P407; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KOZAK CA, 1994, GENOMICS, V21, P659, DOI 10.1006/geno.1994.1331; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; MATTHEWS RJ, 1990, P NATL ACAD SCI USA, V87, P4444, DOI 10.1073/pnas.87.12.4444; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MIYASAKA H, 1992, BIOCHEM BIOPH RES CO, V185, P818, DOI 10.1016/0006-291X(92)91700-Z; MIZUNO K, 1993, MOL CELL BIOL, V13, P5513, DOI 10.1128/MCB.13.9.5513; MOSINGER B, 1992, P NATL ACAD SCI USA, V89, P499, DOI 10.1073/pnas.89.2.499; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAGA Y, 1986, P NATL ACAD SCI USA, V83, P6940, DOI 10.1073/pnas.83.18.6940; SCHEPENS J, 1992, MOL BIOL REP, V16, P241, DOI 10.1007/BF00419663; SELDIN MF, 1994, MAMM GENOME, V5, pS1; SOMMERS CL, 1995, ONCOGENE, V11, P245; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TONKS NK, 1992, COLD SPRING HARB SYM, V57, P87, DOI 10.1101/SQB.1992.057.01.012; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; YANG Q, 1991, P NATL ACAD SCI USA, V88, P5949, DOI 10.1073/pnas.88.14.5949; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134	41	16	19	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1567	1573						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875997				2022-12-28	WOS:A1996VL38400024
J	Aronica, MG; Brizzi, MF; Dentelli, P; Rosso, A; Yarden, Y; Pegoraro, L				Aronica, MG; Brizzi, MF; Dentelli, P; Rosso, A; Yarden, Y; Pegoraro, L			p91 STAT1 activation in interleukin-3-stimulated primary acute myeloid leukemia cells	ONCOGENE			English	Article						leukemia; growth factors; signaling; STATs	COLONY-STIMULATING FACTOR; ACUTE MYELOBLASTIC-LEUKEMIA; JAK2 TYROSINE KINASE; COMMON BETA-SUBUNIT; GM-CSF RECEPTOR; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; BLAST CELLS; PROLIFERATIVE RESPONSE; TRANSCRIPTION FACTOR	Interleukin-3 (IL-3) stimulates in vitro blast cell proliferation in a consistent proportion of acute myeloid leukemia (AML) cases, however the degree of response varies from case to case and it is not related to the FAB subtype or to other clinical parameters, IL-3-induced proliferation of myeloid cells is mediated by the interaction with an heterodimeric receptor (IL-3R) comprised of a ligand binding subunit denoted alpha and a common transducing subunit designated as beta (beta(c)). Ligand binding to the receptor activates a number of signaling molecules including proteins of the STATs (signal transducing and activators of transcription) family, To elucidate the mechanisms responsible for the abnormal proliferative response of AML cells to IL-3, we evaluated, both in the IL-3-dependent M-07e cell line and in 20 AML cases, the activation of STAT1 p91 and its association with the beta(c) subunit, On the basis of the in vitro proliferation assay, 11 out of 20 cases were found to be responsive to IL-3 and eight out of 16 to GM-CSF, Our results demonstrated that in M-07e cells and in six AML cases (five IL-3 responsive and one unresponsive) p91 tyrosine phosphorylation was ligand dependent, Ligand independent p91 tyrosine phosphorylation was detected in 10 AML cases (five responsive and five unresponsive), p91 association with the beta(c) subunit was consistent with its ligand dependent activation and with the ability to form a DNA-binding complex containing p91, In the remaining four cases (three unresponsive and one responsive) no p91 tyrosine phosphorylation and/or association were detected, These findings, together with the observation that in five IL-3 responsive cases p91 was constitutively phosphorylated, suggest that IL-3-mediated AML proliferation is only partially sustained by p91 activation and that other post-receptor molecules are required to achieve maximal proliferative response, Moreover structural abnormalities of the receptor or of post-receptor signaling proteins may account for the constitutive p91 phosphorylation and growth factor independent proliferation observed in the unresponsive AML cases.	UNIV TURIN,DIPARTIMENTO SCI BIOMED & ONCOL UMANA,TURIN,ITALY; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	University of Turin; Weizmann Institute of Science			Brizzi, Maria Felice/J-7882-2016; YARDEN, YOSEF/K-1467-2012					AVANZI GC, 1990, J CELL PHYSIOL, V145, P458, DOI 10.1002/jcp.1041450310; AVANZI GC, 1991, CANCER RES, V51, P1741; BASHEY A, 1992, BLOOD, V79, P981; BEGLEY CG, 1987, LEUKEMIA, V1, P1; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; BRIZZI MF, 1995, BRIT J HAEMATOL, V90, P258, DOI 10.1111/j.1365-2141.1995.tb05145.x; Brizzi MF, 1996, J BIOL CHEM, V271, P3562; BUDEL LM, 1990, BLOOD, V75, P1439; BUDEL LM, 1989, BLOOD, V74, P565; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DELWEL R, 1988, BLOOD, V72, P1944; DELWEL R, 1987, BLOOD, V70, P333; GAVOSTO F, 1964, NATURE, V203, P92, DOI 10.1038/203092a0; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GouilleuxGruart V, 1996, BLOOD, V87, P1692; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GRIFFIN JD, 1986, BLOOD, V67, P1448; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HOANG T, 1986, BLOOD, V68, P313; HORIE M, 1993, J BIOL CHEM, V268, P968; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IKEDA H, 1991, BLOOD, V78, P2962; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; JUBINSKY PT, 1994, BLOOD, V84, P4174, DOI 10.1182/blood.V84.12.4174.bloodjournal84124174; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEARY AG, 1987, BLOOD, V70, P1343; MCCOLL SR, 1991, BLOOD, V78, P1842; MIYAUCHI J, 1987, BLOOD, V70, P657; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; OKUDA K, 1992, BLOOD, V79, P2880; PAZDRAK K, 1995, J IMMUNOL, V155, P397; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; RADICH JP, 1990, BLOOD, V76, P801; REILLY IAG, 1989, BRIT J HAEMATOL, V72, P363, DOI 10.1111/j.1365-2141.1989.tb07717.x; REILLY IAG, 1989, LEUKEMIA, V3, P145; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SADOWSKI HB, 1993, NATURE, V366, P580; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOKSOZ D, 1987, ONCOGENE, V1, P409; TSUJIMURA T, 1994, BLOOD, V83, P2619; VANDERBRUGGEN T, 1995, BLOOD, V85, P1442, DOI 10.1182/blood.V85.6.1442.bloodjournal8561442; VELLENGA E, 1987, LEUKEMIA, V1, P584; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; YOUNG DC, 1986, BLOOD, V68, P1178; ZHONG Z, 1994, SCIENCE, V265, P1701; [No title captured]	62	15	15	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1017	1026						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806691				2022-12-28	WOS:A1996VG76600015
J	Huang, TS; Kuo, ML; Shew, JY; Chou, YW; Yang, WK				Huang, TS; Kuo, ML; Shew, JY; Chou, YW; Yang, WK			Distinct p53-mediated G(1)/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents	ONCOGENE			English	Article						apoptosis; cell growth arrest; G(1)/S checkpoint; MMS; gamma-radiation; TPA	CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR P53; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; CELLULAR-RESPONSE; GENE-EXPRESSION; BAX GENE; IN-VIVO; PROTEIN; APOPTOSIS	N-3T3 and P-3T3 cells, originally isolated from a NIH3T3 cell clone on the basis of their negative and positive transformation by v-Abl, v-Src and Bcr-Abl, were previously found to show distinct cyclin activity changes following 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment, which is anti-mitogenic for N-3T3 cells and mitogenic for P-3T3 cells. We have found in this study that, while the G(1)/S arrest and cell death induced by serum starvation and TPA treatment in N-3T3 cells did not involve p53-mediated checkpoint or apoptosis, N-3T3 and P-3T3 cells evidently responded differently in these aspects of cell cycle regulation to DNA-damaging agents, methylmethane sulfonate (MMS) and gamma-radiation. In N-3T3 cells, DNA damages elicit cell growth arrest at G(1)/S transition with concomitant accumulation of p53 and p53-inducible Waf1/Cip1 proteins and also signs of apoptosis such as DNA ladder patterns and apoptotic (subgenomic) peak in flow cytograph. Conversely, P-3T3 cells treated with the DNA-damaging agents showed no cell cycle interruption nor accumulation of p53 or Waf1/Cip1. However, both P-3T3 and N-3T3 cells showed the same p53 protein half-life of 40 min or less, the same wild-type p53 DNA sequence and the same co-immunoprecipitable cellular proteins in complexes with p53, suggesting that an alteration in a signal transduction pathway upstream of p53 might account for the evasion of p53-mediated G(1) checkpoint in P-3T3 cells.	ACAD SINICA,NATL HLTH RES INST,CLIN RES INST,TAIPEI,TAIWAN; ACAD SINICA,INST BIOMED SCI,VGH TAIPEI,COOPERAT CLIN RES LAB,TAIPEI,TAIWAN; NATL TAIWAN UNIV,COLL MED,INST TOXICOL,TAIPEI 10764,TAIWAN; NATL TAIWAN UNIV,COLL MED,INST BIOCHEM,TAIPEI 10764,TAIWAN	Academia Sinica - Taiwan; National Health Research Institutes - Taiwan; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University			Kuo, Min-Liang/C-4872-2009; Huang, Tze-Sing/E-3667-2010; Huang, Tze-Sing/C-9361-2013	Huang, Tze-Sing/0000-0001-8736-4330; KUO, MIN-LIANG/0000-0002-7139-0144				CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; KADOHAMA T, 1994, ONCOGENE, V9, P2845; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLSON DC, 1993, ONCOGENE, V8, P2353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	34	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					625	632						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760304				2022-12-28	WOS:A1996VB32800020
J	Thomas, M; Matlashewski, G; Pim, D; Banks, L				Thomas, M; Matlashewski, G; Pim, D; Banks, L			Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation	ONCOGENE			English	Article						apoptosis; HPV; p53; transactivation; growth suppression	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CELL-CYCLE REGULATION; DNA-BINDING; TRANSCRIPTIONAL ACTIVATION; GROWTH ARREST; TRANSFORMING ACTIVITY; MUTATIONAL ANALYSIS; GENE-EXPRESSION; TUMOR-ANTIGEN	Inhibition of p53 function is a common feature of many DNA tumour viruses. Human papillomavirus (HPV) E6 proteins from the oncogenic HPVs inhibit p53 function either by blocking its ability to bind DNA or by labelling newly synthesised p53 as a target for ubiquitin mediated degradation. In this study we have investigated the role of the degradation function of E6 with respect to p53 function. Using a panel of previously characterised p53 mutant proteins we have been able to establish a series of assays which separates p53 growth suppression from transformation suppression and from induction of apoptosis. Only wild type p53 inhibits the growth of p53 null 10(1) cells, whereas wild type, dimeric and monomeric mutants of p53 suppress transformed cell growth of both Saos-2 cells and baby rat kidney cells. Cells expressing the different oligomeric forms of p53 all retain the ability to induce apoptosis upon u.v. treatment. Using HPV E6 and E7 we have been able to show that E7 will overcome p53 growth suppressor activity with an efficiency similar to that observed with E6. However, in contrast to E6, E7 has no effect on the ability of p53 to suppress transformed cell growth. Finally, we show that the ability of E6 to label p53 for ubiquitin mediated degradation is prerequisite for its ability to overcome p53 inhibition of transformed cell growth and induction of apoptosis. These observations argue that E6 inhibits p53 mediated apoptosis and suppression of transformation while E7 inhibits p53 suppression of cell proliferation.	INT CTR GENET ENGN & BIOTECHNOL,I-34012 TRIESTE,ITALY; MCGILL UNIV,INST PARASITOL,MONTREAL,PQ,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL,PQ,CANADA	International Center for Genetic Engineering & Biotechnology (ICGEB); McGill University; McGill University								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, P NATL ACAD SCI USA, V91, P2026, DOI 10.1073/pnas.91.6.2026; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PIM D, 1992, ONCOGENE, V7, P27; PIM D, 1994, ONCOGENE, V9, P1869; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; STEWART N, 1995, ONCOGENE, V10, P109; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; STOREY A, 1993, ONCOGENE, V8, P919; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TARUNINA M, 1993, ONCOGENE, V8, P3165; THOMAS M, 1995, ONCOGENE, V10, P261; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOUSDEN KH, 1993, ONCOGENE, V8, P1697; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	61	64	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					265	273						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710365				2022-12-28	WOS:A1996VA25200005
J	Krishnan, K; Yan, H; Lim, JTE; Krolewski, JJ				Krishnan, K; Yan, H; Lim, JTE; Krolewski, JJ			Dimerization of a chimeric CD4-interferon-alpha receptor reconstitutes the signaling events preceding STAT phosphorylation	ONCOGENE			English	Article						interferon; signaling; receptor; tyrosine phosphorylation; STAT	INTERFERON-ALPHA RECEPTOR; PROTEIN-TYROSINE KINASE; GROWTH-FACTOR RECEPTOR; TRANSCRIPTION FACTOR; TRANSDUCTION; CLONING; FAMILY; MEMBER; MPL	Interferon-alpha induces the rapid tyrosine phosphorylation of a number of molecules, including the cognate receptors, JAK-family kinases (Jak1 and tyk2), and latent transcription factors (STATs 1 and 2), Here, we describe the use of chimeric molecules composed of the extracellular domain of CD4 fused to the intracellular domain of the interferon-alpha receptor subunit 1 (IFNaR1), Antibody mediated crosslinking dimerizes the transfected chimeras, activates tyk2 and induces a tyk2-dependent tyrosine phosphorylation of the intracellular domain of the chimera, We further define the major site of IFNaR1 phosphorylation, and show that phosphorylation of this site is required for association with STAT2, Finally, we show that homodimerization of IFNaR1 is not sufficient to activate the STATs, suggesting a role for the IFNaR2 subunit and Jak1 in the transduction of the interferon-alpha signal.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,CTR CANC,NEW YORK,NY 10032	Columbia University; Columbia University					NATIONAL CANCER INSTITUTE [R01CA056862] Funding Source: NIH RePORTER; NCI NIH HHS [CA56862] Funding Source: Medline; NIGMS NIH HHS [GM07367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVICH C, 1994, EMBO J, V13, P5871, DOI 10.1002/j.1460-2075.1994.tb06932.x; BARBIERI G, 1994, EUR J BIOCHEM, V223, P427, DOI 10.1111/j.1432-1033.1994.tb19010.x; COLAMONICI O, 1994, MOL CELL BIOL, V14, P8133, DOI 10.1128/MCB.14.12.8133; COLAMONICI OR, 1994, J BIOL CHEM, V269, P3518; COLAMONICI OR, 1991, PHARMACOL THERAPEUT, V52, P227, DOI 10.1016/0163-7258(91)90010-J; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Davis E, 1996, LEUKEMIA, V10, P543; DOMANSKI P, 1995, J BIOL CHEM, V270, P21606, DOI 10.1074/jbc.270.37.21606; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GUPTA S, 1996, EMBO J, V15; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; LUO KX, 1990, MOL CELL BIOL, V10, P5305, DOI 10.1128/MCB.10.10.5305; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; PLATANIAS LC, 1994, J BIOL CHEM, V269, P17761; Sambrook J., 2002, MOL CLONING LAB MANU; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SOH JM, 1994, J BIOL CHEM, V269, P18102; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SUDOL M, 1993, NONRECEPTOR TYROSINE, P203; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; UZE G, 1995, J INTERF CYTOK RES, V15, P3, DOI 10.1089/jir.1995.15.3; VANDERKUUR JA, 1994, J BIOL CHEM, V269, P21709; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; VIGON I, 1993, ONCOGENE, V8, P2607; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Yan H, 1996, EMBO J, V15, P1064, DOI 10.1002/j.1460-2075.1996.tb00444.x; YAN H, 1995, ANAL BIOCHEM, V231, P455, DOI 10.1006/abio.1995.0080; Yan H, 1996, MOL CELL BIOL, V16, P2074	43	24	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					125	133						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700538				2022-12-28	WOS:A1996UX31900014
J	Mehle, C; Piatyszek, MA; Ljungberg, B; Shay, JW; Roos, G				Mehle, C; Piatyszek, MA; Ljungberg, B; Shay, JW; Roos, G			Telomerase activity in human renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; telomerase; clinical course	TUMOR HETEROGENEITY	Telomeres have a vital role in maintaining chromosome stability and are essential for long term viability, Since the very ends of linear chromosomes cannot replicate, telomeres shorten in normal somatic cells eventually resulting in growth inhibition, However, most immortal cell lines maintain stable telomeres indicating that mechanisms exist to compensate for the end replication problem, Telomerase activity, leading to synthesis of telomeric DNA repeats, has been proposed to be an important step in the immortalization process of tumor cells, In the present study, 56 renal cell carcinomas were tested for telomerase activity using the sensitive TRAP (telomeric repeat amplification protocol), Forty of the analysed tumors (71%) were positive for telomerase activity, whereas none of the 56 corresponding normal kidney samples showed telomerase activity, All telomerase negative tumors had a reduction in mean telomere restriction fragment (TRF) length and a decrease in total telomere repeat hybridization signal, though cases were observed with an increase in peak TRF lengths, No obvious association between the presence of telomerase activity and clinicopathological parameters (histopathologic grade, DNA-ploidy, stage and clinical outcome) was found, The high frequency of detection of telomerase activity in the renal cell carcinomas indicates that this enzyme is likely to be an important factor involved in the evolution of this tumor type.	UMEA UNIV,DEPT UROL & ANDROL,S-90187 UMEA,SWEDEN; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	Umea University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mehle, C (corresponding author), UMEA UNIV,DEPT PATHOL,S-90187 UMEA,SWEDEN.				NATIONAL INSTITUTE ON AGING [R01AG007992] Funding Source: NIH RePORTER; NIA NIH HHS [AG07992] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; ALLSOPP RC, 1995, EXP CELL RES, V219, P130, DOI 10.1006/excr.1995.1213; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; BRYAN MT, 1995, EMBO J, V14, P4240; CHADENEAU C, 1995, CANCER RES, V55, P2533; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; HIYAMA E, 1995, CANCER RES, V55, P3258; HIYAMA E, 1995, NAT MED, V1, P249, DOI 10.1038/nm0395-249; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; HOLT SE, 1996, IN PRESS MOL CELL BI; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1995, TELOMERE, P1; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; LANGFORD LA, 1995, LANCET, V346, P1267, DOI 10.1016/S0140-6736(95)91865-5; LARSSON P, 1993, INT J CANCER, V55, P566, DOI 10.1002/ijc.2910550408; LJUNGBERG B, 1985, CANCER, V56, P503, DOI 10.1002/1097-0142(19850801)56:3<503::AID-CNCR2820560316>3.0.CO;2-N; LJUNGBERG B, 1996, IN PRESS BR J CANC; MEHLE C, 1994, CANCER RES, V54, P236; MEHLE C, 1993, GENE CHROMOSOME CANC, V6, P86, DOI 10.1002/gcc.2870060204; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; NILSSON P, 1994, ONCOGENE, V9, P3043; NORDENSON I, 1988, CANCER GENET CYTOGEN, V32, P35, DOI 10.1016/0165-4608(88)90309-3; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; ROBSON CJ, 1969, J UROLOGY, V101, P239; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; SKINNER DG, 1971, CANCER-AM CANCER SOC, V28, P1165, DOI 10.1002/1097-0142(1971)28:5<1165::AID-CNCR2820280513>3.0.CO;2-G; Sommerfeld HJ, 1996, CANCER RES, V56, P218; Strahl C, 1996, MOL CELL BIOL, V16, P53; TAHARA H, 1995, CANCER RES, V55, P2734; WHITAKER NJ, 1995, ONCOGENE, V11, P971; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794	40	98	105	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					161	166						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700542				2022-12-28	WOS:A1996UX31900018
J	Liu, PK; Kraus, E; Wu, TA; Strong, LC; Tainsky, MA				Liu, PK; Kraus, E; Wu, TA; Strong, LC; Tainsky, MA			Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations	ONCOGENE			English	Review						tumor suppressor gene; germline mutations; chromosome instability; shuttle vector mutagenesis; DNA replication	DNA-POLYMERASE-ALPHA; SIMIAN VIRUS-40 DNA; LARGE-T-ANTIGEN; SHUTTLE VECTOR PLASMID; CELLULAR TUMOR-ANTIGEN; INDUCED POINT MUTATIONS; WILD-TYPE P53; HUMAN-CELLS; ATAXIA-TELANGIECTASIA; REPLICATION INVITRO	Germline p53 mutations are frequently observed in the normal DNA of cancer-prone patients with Li-Fraumeni syndrome (LFS), Fibroblasts from LFS patients develop chromosomal aberrations, loss of cell cycle control, and spontaneous immortalization, We transfected four different mutant p53 genes into human skin fibroblasts from normal donors with two copies of wild-type p53 (p53(wt/wt)), Each mutant p53 expression-plasmid induced genomic instability equivalent to that seen in LFS cells, To test the role of wild-type and mutant p53 alleles in DNA replication and fidelity in LFS cells, we analysed the replication of the SV40-based shuttle vector pZ189 in four types of cells, We used p53(wt/mut) and p53(mut/-) LFS fibroblasts, and p53(-/-) non-LFS cells, Replication of pZ189 in vivo was significantly reduced by the presence of a p53(wt) allele, To show that this was not just due to inhibition of the function of T-antigen in SV40-based replication, we constructed a shuttle vector, pZ402, that contains a mutation in SV40 T-antigen which blocks its ability to interact with p53, Replication of pZ402 in LFS cells was also reduced by the presence of p53(wt), indicating that p53 can inhibit replication by interacting with proteins within the cellular replication machinery, Replicative errors in this shuttle vector are detected as mutations in a marker gene, supF: In addition to supF: mutations, we observed deletion of a portion of the SV40 T-antigen gene in 100% of replicated plasmid pZ189 mutants (supF(-)) from the p53(wt/mut) fibroblasts and in 88% of the supF(-) mutants from the p53(mut/-) (amino acid 175 arg to his) LFS cells, In one cell strain of immortal LFS cells, p53(mut/-), containing a p53 frameshift mutation at amino acid 184, pZ189 replication yielded very few of these deleted shuttle vector plasmids (15%), These large deletions were not detected in plasmids replicated in p53(-/-) non-LFS cells, Saos-2 cells, Replicated plasmids with a normal supF gene were never found to have this large deletion regardless of the cell from which they were derived, Because the supF; gene is not in the same region of the shuttle vector as the T-antigen gene it appears that second, independent gene deletions are frequent when replicative errors in supF occur in cells with a mutant p53, We conclude, therefore, that p53(wt/mut) LFS cells contain an activity that promotes mutations, Such an activity, which is likely to be due to the p53(mut), could result in the high rate of chromosomal instability and allelic loss of the wild-type p53 observed as these cells spontaneously immortalize.	UNIV TEXAS,MD ANDERSON CANC CTR,DIV LAB MED,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT EXPTL PEDIAT,HOUSTON,TX 77030; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center				Tainsky, Michael/0000-0002-0261-831X	NATIONAL CANCER INSTITUTE [P01CA034936, P30CA016672, T32CA009299] Funding Source: NIH RePORTER; NCI NIH HHS [CA-16672, P01 CA034936, CA-09299, P01 CA034936-14A1, P30 CA016672, T32 CA009299, CA-P01 34936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; AIZAWA S, 1987, MOL GEN GENET, V208, P342, DOI 10.1007/BF00330463; ARIGA H, 1983, J VIROL, V48, P481, DOI 10.1128/JVI.48.2.481-491.1983; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BEETT WP, 1994, CANC PERTURBATIONS C; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BISHOP M, 1986, SCIENCE, V235, P305; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BREDBERG A, 1987, CARCINOGENESIS, V8, P1923, DOI 10.1093/carcin/8.12.1923; BUBLEY GJ, 1991, MOL CARCINOGEN, V4, P397, DOI 10.1002/mc.2940040512; CARTY MP, 1993, MOL CELL BIOL, V13, P533, DOI 10.1128/MCB.13.1.533; CARTY MP, 1990, MUTAT RES, V232, P141, DOI 10.1016/0027-5107(90)90119-O; CHAN JYH, 1979, P NATL ACAD SCI USA, V76, P814, DOI 10.1073/pnas.76.2.814; CHANG CC, 1981, SOMAT CELL GENET, V7, P235; CLARKE P, 1991, VIROLOGY, V182, P597, DOI 10.1016/0042-6822(91)90600-G; CLEAVER JE, 1989, MUTAT RES, V220, P161, DOI 10.1016/0165-1110(89)90022-5; COMINGS DE, 1973, P NATL ACAD SCI USA, V70, P3324, DOI 10.1073/pnas.70.12.3324; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DRESLER SL, 1982, BIOCHEMISTRY-US, V21, P2557, DOI 10.1021/bi00539a040; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREEN AP, 1993, BIOCHEM BIOPH RES CO, V190, P111, DOI 10.1006/bbrc.1993.1018; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HARLOW E, 1981, J VIROL, V37, P564, DOI 10.1128/JVI.37.2.564-573.1981; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; HARVEY M, 1993, ONCOGENE, V8, P2457; HAY RT, 1989, BIOCHEM J, V258, P3, DOI 10.1042/bj2580003; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JABERABOANSARI A, 1991, RADIAT RES, V127, P202, DOI 10.2307/3577966; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENNINGS PA, 1987, EMBO J, V6, P3043, DOI 10.1002/j.1460-2075.1987.tb02610.x; KARASUYAMA H, 1989, J EXP MED, V169, P13, DOI 10.1084/jem.169.1.13; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KIENZLE H, 1989, EUR J BIOCHEM, V184, P181, DOI 10.1111/j.1432-1033.1989.tb15005.x; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LAVIGUEUR A, 1991, ONCOGENE, V6, P2197; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LIN J, 1991, J VIROL, V64, P2066; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIU PK, 1993, MUTAT RES, V288, P229, DOI 10.1016/0027-5107(93)90089-X; LIU PK, 1983, P NATL ACAD SCI-BIOL, V80, P797, DOI 10.1073/pnas.80.3.797; LIU PK, 1984, SCIENCE, V254, P833; LOEB LA, 1991, CANCER RES, V51, P3075; LOEB LA, 1974, CANCER RES, V34, P2311; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MAH MCM, 1989, CARCINOGENESIS, V10, P2321, DOI 10.1093/carcin/10.12.2321; MAHER VM, 1989, MUTAT RES, V220, P83, DOI 10.1016/0165-1110(89)90013-4; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MCCORMICK F, 1980, J VIROL, V34, P213, DOI 10.1128/JVI.34.1.213-224.1980; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILLER SD, 1995, MOL CELL BIOL, V15, P6554; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MURAKAMI Y, 1992, P NATL ACAD SCI USA, V89, P952, DOI 10.1073/pnas.89.3.952; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; MURIEL WJ, 1991, MUTAT RES, V254, P119, DOI 10.1016/0921-8777(91)90002-7; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PARK CH, 1995, J BIOL CHEM, V270, P4896, DOI 10.1074/jbc.270.9.4896; PARRIS CN, 1992, EXP CELL RES, V201, P462, DOI 10.1016/0014-4827(92)90295-J; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; RUNGER TM, 1992, MUTAT RES, V293, P47, DOI 10.1016/0921-8777(92)90007-P; RUSCETTI SK, 1983, J VIROL, V46, P1022, DOI 10.1128/JVI.46.3.1022-1026.1983; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEETHARAM S, 1991, NUCLEIC ACIDS RES, V19, P1601, DOI 10.1093/nar/19.7.1601; SEIDMAN MM, 1985, GENE, V38, P233, DOI 10.1016/0378-1119(85)90222-7; SHAY JW, 1995, MOL CELL BIOL, V15, P425, DOI 10.1128/MCB.15.1.425; SIKPI MO, 1992, RADIAT RES, V130, P331, DOI 10.2307/3578378; SPEYER JF, 1965, BIOCHEM BIOPH RES CO, V21, P6, DOI 10.1016/0006-291X(65)90417-1; SPRINGGATE CF, 1973, P NATL ACAD SCI USA, V70, P245, DOI 10.1073/pnas.70.1.245; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STRONG LC, 1992, AM J EPIDEMIOL, V135, P190, DOI 10.1093/oxfordjournals.aje.a116271; STURZBECHER HW, 1988, ONCOGENE, V3, P405; TACK LC, 1989, J VIROL, V63, P1310, DOI 10.1128/JVI.63.3.1310-1317.1989; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG P, 1990, CANCER RES, V50, P7527; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WEINBERG DH, 1989, P NATL ACAD SCI USA, V86, P9742, DOI 10.1073/pnas.86.24.9742; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YAGI T, 1992, MUTAT RES, V273, P213, DOI 10.1016/0921-8777(92)90082-E; YAMAGUCHI M, 1986, P NATL ACAD SCI USA, V83, P1646, DOI 10.1073/pnas.83.6.1646; YANG JL, 1988, MOL CELL BIOL, V8, P3364, DOI 10.1128/MCB.8.8.3364; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	119	63	63	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2267	2278						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649766				2022-12-28	WOS:A1996UQ22000003
J	Fraser, SD; WilkesJohnston, J; Browder, LW				Fraser, SD; WilkesJohnston, J; Browder, LW			Effects of c-myc first exons and 5' synthetic hairpins on RNA translation in oocytes and early embryos of Xenopus laevis	ONCOGENE			English	Article						myc; translation; secondary structure; Xenopus	YEAST SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; SECONDARY STRUCTURE; ORNITHINE DECARBOXYLASE; INITIATION-FACTORS; NONCODING REGION; PROTO-ONCOGENE; EXPRESSION; GENE; INHIBITION	Mammalian c-myc transcripts have long G/C-rich 5' untranslated regions (UTRs) that may fold into secondary structural elements that may impede translation. We have examined the effects of different c-myc first exons, which produce most of the 5' UTR of c-myc transcripts, on translation in Xenopus oocytes and embryos, by placing these structures upstream of a chloramphenicol acetyltransferase (CAT) reporter. Our results demonstrate that the human c-myc first exon inhibits reporter translation in both oocytes and embryos. Unlike their mammalian counterparts, Xenopus c-mycI first exons initiated at either promoter 1 or promoter 2 do not impede translation. We conclude that translation inhibition reported in a previous investigation (Lazarus, 1992. Oncogene, 7:1037) utilizing Xenopus c-mycI 5' non-coding elements was due to the inclusion of non-relevant non-transcribed sequences. Previous investigators have reported that inhibition of translation in Xenopus oocytes by 5' secondary structure is alleviated after fertilization (Lazarus et al., 1988. Oncogene 3:517; Fu et al., 1991. Science 251:807). We repeated the experiments of Fu et al., examining the effects on translation by a highly stable synthetic hairpin. The hairpin severly restricted translation in both oocytes and embryos, indicating that highly stable 5' secondary structure is equally inhibitory in oocytes and embryos.	UNIV CALGARY, DEPT BIOL SCI, CALGARY, AB T2N 1N4, CANADA	University of Calgary								BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BETTANY AJE, 1989, YEAST, V5, P187, DOI 10.1002/yea.320050308; BUTNICK NZ, 1985, MOL CELL BIOL, V5, P3009, DOI 10.1128/MCB.5.11.3009; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EDERY I, 1995, MOL CELL BIOL, V15, P3363; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FU L, 1991, THESIS U CALGARY CAL; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GALILI G, 1988, J BIOL CHEM, V263, P5764; GRENS A, 1990, J BIOL CHEM, V265, P11810; HITCHCOCK MJM, 1980, ANAL BIOCHEM, V109, P338, DOI 10.1016/0003-2697(80)90657-0; JARAMILLO M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P134, DOI 10.1016/0167-4781(90)90154-T; Kay BK, 1991, METHODS CELL BIOL, V36; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KING MW, 1991, NUCLEIC ACIDS RES, V19, P5777, DOI 10.1093/nar/19.20.5777; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LAZARUS P, 1992, ONCOGENE, V7, P1037; LAZARUS P, 1988, ONCOGENE, V3, P517; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NILSEN TW, 1984, MOL CELL BIOL, V4, P2235, DOI 10.1128/MCB.4.10.2235; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TCHANG F, 1991, FEBS LETT, V291, P177, DOI 10.1016/0014-5793(91)81277-F; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; XU W, 1994, THESIS U CALGARY CAL; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	43	12	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1223	1230						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649824				2022-12-28	WOS:A1996UC06700007
J	Raj, GV; Ansari, SA; Khalili, K				Raj, GV; Ansari, SA; Khalili, K			Evidence for GEAPs, novel glial E2F1-associated proteins in hamster glioma cells induced by the human neurotropic polyomavirus, JCV	ONCOGENE			English	Article						cell cycle regulation; JCV; glioma; E2F family	RETINOBLASTOMA GENE-PRODUCT; TRANSCRIPTION FACTOR; GROWTH-REGULATION; BRAIN TUMORS; E2F; BINDING; VIRUS; DNA; PROMOTER; CYCLE	Injection of the human neurotropic polyomavirus, JCV, into neonatal hamsters causes tumors of glial origin. Previously, a rapidly proliferating cell line, HJC-15, which expresses high levels of the viral T-antigen, had been established from JCV-induced hamster glial tumors. In our analyses of the mechanisms involved in the control of glial cell proliferation in these tumor cells, we have focused our attention on E2F1, a DNA-binding transcription factor which modulates the activity of genes involved in the S-phase of the cell cycle. Here, we report the identification of a novel nucleo-protein complex that forms between select E2F1-binding sites and nuclear proteins from HJC-15 and normal hamster glial cells. In comparison to the previously characterized E2F1 complexes, this complex exhibited distinct mobility, binding, and biochemical characteristics. This slower migrating complex also contained several unique Glial E2F1-associated proteins, (GEAPs), which have a distinct molecular mass. Of particular, unlike the classical E2F1 whose DNA binding activity is increased during S-phase, the level of GEAPs remained constant throughout the cell cycle. GEAPs appeared to confer an increased basal transcriptional activity of promoters containing select E2F1 sites in HJC-15 cells. Interestingly, the increased transcriptional activity modulated by GEAPs in HJC-15 cells was overcome by overexpression of E2F1 in these cells. These data point to the presence of novel members of the E2F family in hamster glial cells with the potential to regulate expression of S-phase specific genes in glial tumors obtained upon intracerebral injection of JCV. The importance of these findings in the pathogenesis of viral-induced tumors and the role of cell cycle regulatory proteins in brain tumor formation is discussed.	THOMAS JEFFERSON UNIV,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,MOL NEUROVIROL SECT,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON CANC INST,DEPT MICROBIOL & IMMUNOL,PHILADELPHIA,PA 19107	Jefferson University; Jefferson University								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; DOU QP, 1994, J BIOL CHEM, V269, P1306; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FOSTER LM, 1993, DEV NEUROSCI-BASEL, V15, P100, DOI 10.1159/000111322; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KUNDU M, 1995, J VIROL, V69, P6940, DOI 10.1128/JVI.69.11.6940-6946.1995; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; MANFREDI JJ, 1994, BBA-REV CANCER, V1198, P65, DOI 10.1016/0304-419X(94)90006-X; MEANS AL, 1992, MOL CELL BIOL, V12, P1054, DOI 10.1128/MCB.12.3.1054; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NEVINS JR, 1992, SCIENCE, V258, P424; PADGETT BL, 1971, LANCET, V1, P1257; QIN XQ, 1995, MOL CELL BIOL, V15, P742; RAJ GV, 1995, INT J ONCOL, V7, P801; RAJ GV, 1994, MOL CELL BIOL, V14, P7770, DOI 10.1128/MCB.14.12.7770; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; SALA A, 1994, CANCER RES, V54, P1402; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Schilling Lynda J., 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P19; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WOOD WSM, 1980, J VIROL, V33, P1225; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XU GF, 1995, P NATL ACAD SCI USA, V92, P1357, DOI 10.1073/pnas.92.5.1357	44	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1279	1288						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649830				2022-12-28	WOS:A1996UC06700013
J	Lovric, J; Moelling, K				Lovric, J; Moelling, K			Activation of Mil/Raf protein kinases in mitotic cells	ONCOGENE			English	Article						Mil/Raf kinases; phosphorylation; cell cycle; mitosis	MAP-KINASE; TYROSINE PHOSPHORYLATION; RAF-1 KINASE; V-RAF; C-MYC; ONCOGENE; CYCLE; EXPRESSION; C-RAF-1; DOMAIN	The c-Raf-1 protein kinase is a major element of several signal transduction pathways and thought to be involved in entry into the S phase of the cell cycle. Here we show that c-Raf-1 as well as the transforming viral fusion protein Gag-Mil, in which most of the amino terminal regulatory region of the avian Raf homologue Mil is deleted, are activated five- to sixfold in mitotic cells. Mitotic activation of Mil/Raf kinase activity correlates with reduced electrophoretic mobility caused by hyperphosphorylation at serine/threonine residues located in the carboxy terminal part of c-Raf-1. Mitotic hyperphosphorylation occurs in various cell-lines indicating that it is ubiquitous. Our data suggest a novel function for Mil/Raf kinases in late stages of the cell cycle.	UNIV ZURICH, INST MED VIROL, CH-8028 ZURICH, SWITZERLAND	University of Zurich				Lovric, Josip/0000-0002-0338-6581				ALESSI DR, 1995, METHOD ENZYMOL, V255, P279; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; BOOTSMA D, 1964, EXP CELL RES, V33, P301, DOI 10.1016/S0014-4827(64)81035-1; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BUSCHER D, 1993, ONCOGENE, V8, P3323; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CLEVELAND JL, 1994, ONCOGENE, V9, P2217; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DURKIN JP, 1987, MOL CELL BIOL, V7, P444, DOI 10.1128/MCB.7.1.444; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GUILLOUF C, 1995, ONCOGENE, V10, P2263; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HIROYUKI T, 1992, J BIOL CHEM, V267, P20293; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAMAL S, 1995, ONCOGENE, V10, P2095; KASID U, 1989, SCIENCE, V243, P1354, DOI 10.1126/science.2466340; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; MAMON H, 1991, COLD SPRING HARB SYM, V56, P251; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MUSZYNSKI KW, 1995, J EXP MED, V181, P2189, DOI 10.1084/jem.181.6.2189; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; RAPP UR, 1988, HDB ONCOGENES, P213; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SETH A, 1993, MOL CELL BIOL, V13, P4125, DOI 10.1128/MCB.13.7.4125; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; TROPPMAIR J, 1994, J BIOL CHEM, V269, P7030; TURNER BC, 1993, P NATL ACAD SCI USA, V90, P5544, DOI 10.1073/pnas.90.12.5544; WARENIUS HM, 1994, EUR J CANCER, V30A, P369, DOI 10.1016/0959-8049(94)90258-5; WEDONG H, 1993, P NATL ACAD SCI USA, V90, P10947; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	44	24	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1109	1116						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649803				2022-12-28	WOS:A1996UA88400020
J	Chen, SL; Maroulakou, IG; Green, JE; RomanoSpica, V; Modi, W; Lautenberger, J; Bhat, NK				Chen, SL; Maroulakou, IG; Green, JE; RomanoSpica, V; Modi, W; Lautenberger, J; Bhat, NK			Isolation and characterization of a novel gene expressed in multiple cancers	ONCOGENE			English	Article						differential display; lung cancer; epithelial cells; leucine zipper; gene expression	CHAIN; CDNA; CELLS	Using differential display method, we have isolated and characterized a novel gene, N8, encoding a similar to 24 kDa protein. It is located on human chromosome 8q13 region. N8 gene is expressed at high levels in tumor derived cell lines from multiple cancers. It is also expressed at higher levels in lung tumors than normal lung tissue, NS is also differentially expressed in fetal and adult tissues. In adult, N8 is expressed at high levels in brain, kidney, prostate, pancreas and intestine and at very low levels in lung, liver, hematopoietic cells and gonads. During murine embryonic development N8 is expressed in the epithelium of the intestine, stomach, olfactory epithelium, neuronal layers of retina, kidney and salivary gland. Taken together, these results suggest that N8 may play different roles during embryogenesis and in the adult animals.	NCI,FREDERICK CANC RES & DEV CTR,SCI APPLICAT INT CORP,FREDERICK,MD 21702; NCI,FREDERICK CANC RES & DEV CTR,MOLEC ONCOL LAB,FREDERICK,MD 21702; CATHOLIC UNIV,INST HYG,ROME,ITALY	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli			Spica, Vincenzo Romano/V-5718-2019					AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARRETT JC, 1994, ENVIRON HEALTH PERSP, V102, P19, DOI 10.2307/3432053; BHAT NK, 1994, HYBRIDOMA, V13, P1, DOI 10.1089/hyb.1994.13.1; BILBE G, 1992, EMBO J, V11, P2103, DOI 10.1002/j.1460-2075.1992.tb05269.x; BUCHHAGEN DL, 1991, BIOCHIM BIOPHYS ACTA, V1072, P159; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; BUTTON E, 1995, CELL MOTIL CYTOSKEL, V30, P247, DOI 10.1002/cm.970300402; BYRNE JA, 1995, CANCER RES, V55, P2896; ELLER M, 1989, FEBS LETT, V256, P21, DOI 10.1016/0014-5793(89)81710-7; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; GAZDAR AF, 1994, ANTICANCER RES, V13, P261; JAYE M, 1987, AM J HUM GENET, V41, P605; KLEINSZANTO AJP, 1992, P NATL ACAD SCI USA, V89, P6693, DOI 10.1073/pnas.89.15.6693; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; MOLLO F, 1995, INT J CANCER, V60, P289; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; PIERRE P, 1992, CELL, V70, P887, DOI 10.1016/0092-8674(92)90240-D; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; TORY K, 1992, GENOMICS, V13, P275, DOI 10.1016/0888-7543(92)90243-L; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; 1988, HLTH EFFECTS RADON O, P24	27	60	82	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					741	751						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632896				2022-12-28	WOS:A1996TW68600005
J	Hoehn, GT; Stokland, T; Amin, S; Ramirez, M; Hawkins, AL; Griffin, CA; Small, D; Civin, CI				Hoehn, GT; Stokland, T; Amin, S; Ramirez, M; Hawkins, AL; Griffin, CA; Small, D; Civin, CI			Tnk1: A novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34(+)/Lin(-)/CD38(-) stem/progenitor cells	ONCOGENE			English	Article						Tnk1; tyrosine kinase; signal transduction; Ack; SH3 domain; stem cell	HUMAN-BONE MARROW; SIGNAL TRANSDUCTION; INSITU HYBRIDIZATION; HEMATOPOIETIC STEM; ANTIGENIC ANALYSIS; PROGENITOR CELLS; PROTO-ONCOGENE; W-LOCUS; RECEPTOR; P56LCK	Degenerate PCR was employed to identify novel tyrosine kinase genes from an enriched population of human umbilical cord blood hematopoietic stem/progenitor cells. One novel tyrosine kinase gene, designated Tnk1, was cloned, The sequence of the complete Tnk1 coding region predicts a 72 kD protein. Comparison of Tnk1 to available sequences in protein databases reveals that it is most homologous to Ack, an intracellular tyrosine kinase which associates with the GTP-bound form of p21cdc42Hs. Like Ack, Tnk1 consists of an N-terminal kinase domain, a putative SH3 domain immediately C-terminal to the kinase domain, and a proline-rich C-terminal region. Analysis of Tnk1 mRNA expression demonstrates that Tnk1 is expressed in all cord blood, bone marrow and adult blood sub-populations, as well as in most of the leukemia cell lines examined (16 of 20). Hybridization to fetal multi-tissue Northern blots detected several different Tnk1 transcripts in all fetal tissues examined. In contrast, a single Tnk1 transcript was detected in only five of 16 adult tissues examined (prostate, testis, ovary, small intestine and colon). Fluorescence in situ hybridization (FISH) analysis of metaphase chromosomes localized the Tnk1 gene to the short arm of chromosome 17 (17p13.1), near the p53 locus. Thus, Tnk1 is a novel tyrosine kinase that may be involved in signalling pathways utilized broadly during fetal development, more selectively in adult tissues and in cells of the lymphohematopoietic system.	JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21287 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21287 USA	Johns Hopkins University; Johns Hopkins University			Ramirez, Manuel/H-7710-2015	Ramirez, Manuel/0000-0003-0332-6973; Small, Donald/0000-0002-3072-243X	NATIONAL CANCER INSTITUTE [T32CA060441] Funding Source: NIH RePORTER; NCI NIH HHS [NIH CA60441] Funding Source: Medline; NHLBI NIH HHS [NIHCA-06973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMREIN KE, 1992, P NATL ACAD SCI USA, V89, P3343, DOI 10.1073/pnas.89.8.3343; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BIEGEL JA, 1992, CANCER RES, V52, P3391; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLEN JB, 1993, ONCOGENE, V8, P2025; BROXMEYER HE, 1992, P NATL ACAD SCI USA, V89, P4109, DOI 10.1073/pnas.89.9.4109; CARDOSO AA, 1993, P NATL ACAD SCI USA, V90, P8707, DOI 10.1073/pnas.90.18.8707; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVIN CI, 1984, J IMMUNOL, V133, P157; CIVIN CI, 1987, EXP HEMATOL, V15, P10; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DRWINGA HL, 1993, GENOMICS, V16, P311, DOI 10.1006/geno.1993.1190; DUBOIS BL, 1993, GENOMICS, V16, P315, DOI 10.1006/geno.1993.1191; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GORE SD, 1995, EXP HEMATOL, V23, P413; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HUANG S, 1992, NATURE, V360, P745, DOI 10.1038/360745a0; HUANG S, 1994, BLOOD, V83, P1515, DOI 10.1182/blood.V83.6.1515.bloodjournal8361515; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LOKEN MR, 1987, BLOOD, V70, P1316; LU L, 1993, BLOOD, V81, P41; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCDONALD JD, 1994, GENOMICS, V23, P229, DOI 10.1006/geno.1994.1481; MCGINNIS JF, 1995, J NEUROSCI RES, V40, P165, DOI 10.1002/jnr.490400204; MORRIS C, 1995, ONCOGENE, V10, P1009; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; OGAWA M, 1993, BLOOD, V81, P2844; OLIVEIRA L, 1994, GENOMICS, V22, P478, DOI 10.1006/geno.1994.1415; Sambrook J, 1989, MOL CLONING LABORATO; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHERR CJ, 1990, BLOOD, V75, P1; SMALL D, 1994, P NATL ACAD SCI USA, V91, P459, DOI 10.1073/pnas.91.2.459; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TOMBRANTINK J, 1994, GENOMICS, V19, P266, DOI 10.1006/geno.1994.1057; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; WHITNEY GS, 1993, DNA CELL BIOL, V12, P823, DOI 10.1089/dna.1993.12.823; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603	50	51	55	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					903	913						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632913				2022-12-28	WOS:A1996TW68600022
J	Mao, C; RayGallet, D; Tavitian, A; MoreauGachelin, F				Mao, C; RayGallet, D; Tavitian, A; MoreauGachelin, F			Differential phosphorylations of Spi-B and Spi-1 transcription factors	ONCOGENE			English	Article						Spi-1; PU.1 and Spi-B; pRb; SAP kinases; ERK1; affinity chromatography	PU.1 REGULATES EXPRESSION; PUTATIVE ONCOGENE SPI-1; DNA-BINDING MOTIF; ETS GENE FAMILY; RETINOBLASTOMA PROTEIN; ACTIVATION DOMAIN; CHAIN GENE; IDENTIFICATION; SEQUENCE; KINASE	Spi-1/PU-1 and Spi-B are hematopoietic transcription factors which, in vitro, display similar affinities for DNA target sequences containing the consensus binding site 5'GGAA-3'. While the role of Spi-1 in the transcriptional regulation of B cell and myeloid specific genes has been largely demonstrated, the biological function of Spi-B still remains to be elucidated. Since Spi-B and Spi-1 are very divergent in their transactivator domain, these domains might acquire functional specificity in vivo by interacting with different co-factors and/or by undergoing different phosphorylations. First, we observed that casein kinase II phosphorylates Spi-B as well as Spi-1, in vitro, Then. by affinity chromatographies and in vitro kinase assays with fusion proteins between glutathione-S-transferase and the transactivator domain of Spi-B, two kinases were identified on their ability to interact and phosphorylate this domain; the MAP kinase ERK1 and the stress activated protein kinase JNK1. The Threonine 56 was defined as the ERK1 phosphorylation site by using phosphoamino-acid analyses and a Spi-B mutant version with the substitution T56 to A56. Strikingly, ERK1 failed to phosphorylate Spi-1, in vitro, whereas JNK1, like CK II, phosphorylated Spi-B and Spi-1. In addition, other purified Spi-B-kinase activities, unidentified as yet, display similar specificity than ERK1 for Spi-B versus Spi-1. Furthermore, the evident interaction of pRb protein with the transactivator domain of Spi-B in an unphosphorylated state disappeared when this domain was first phosphorylated in vitro either by ERK1 or by the purified Spi-B-kinase activities. Our data revealed multiple phosphorylation sites within Spi-B whose some of them appeared specific for Spi-B versus Spi-1 and which may account for differential regulation of their activities.	FAC MED LARIBOISIERE, INSERM, U248, F-75010 PARIS, FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Ray-Gallet, Dominique/A-9224-2019					ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; BIRD TA, 1994, J BIOL CHEM, V269, P31836; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAGAN R, 1994, CELL, V78, P799, DOI 10.1016/S0092-8674(94)90522-3; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENKEL G, 1994, P NATL ACAD SCI USA, V91, P7737, DOI 10.1073/pnas.91.16.7737; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; RABAULT B, 1994, J BIOL CHEM, V269, P28143; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSS IL, 1994, ONCOGENE, V9, P121; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	55	48	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					863	873						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632909				2022-12-28	WOS:A1996TW68600018
J	LopezBarahona, M; Bustelo, XR; Barbacid, M				LopezBarahona, M; Bustelo, XR; Barbacid, M			The TC21 oncoprotein interacts with the rat guanosine nucleotide dissociation factor	ONCOGENE			English	Article						TC21; RalGDS; effector domain	COMPLEX-FORMATION; ESCHERICHIA-COLI; GENES; PROTEIN; GTPASE	TC21 is a highly oncogenic member of the Ras superfamily of small GTP binding proteins. We have used the yeast two hybrid system to identify proteins that interact with an oncogenic form of the TC21 protein. cDNA clones encoding the carboxy-terminal region of the RalGDS protein were isolated from human B-cell and HeLa cDNA libraries. RalGDS is an exchange factor that stimulates GDP dissociation from Ral, another member of the Ras superfamily of proteins. The interaction between RalGDS to TC21 is direct and appears to be mediated by the effector domain of TC21 and the carboxy-terminal region of RalGDS. Moreover, RalGDS only binds to TC21 in its active, GTP-loaded configuration. These results suggest that RalGDS might be an effector molecule for TC21 and may participate in cross-talking between Ral and TC21 signalling pathways.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOLEC ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb			Bustelo, Xose R./A-9526-2010	Bustelo, Xose R./0000-0001-9398-6072				ALAN J, 1990, ANAL BIOCHEM, V188, P245; ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CARBONI JM, 1995, ONCOGENE, V10, P1905; CAUDRADO A, 1990, CELL GROWTH DIFFER, V1, P9; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FEIG LA, 1993, RAS SUPERFAMILY GTPA, P247; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; MAINA CV, 1988, GENE, V74, P365, DOI 10.1016/0378-1119(88)90170-9; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; OLOFSSON B, 1988, ONCOGENE, V3, P231; PERONA R, 1993, ONCOGENE, V8, P1285; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SAEZ R, 1994, ONCOGENE, V9, P2977; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C	37	29	30	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					463	470						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637701				2022-12-28	WOS:A1996TV59700001
J	Zheng, S; Ramachandran, B; Haigh, JR; Palos, TP; Steger, K; Howard, BD				Zheng, S; Ramachandran, B; Haigh, JR; Palos, TP; Steger, K; Howard, BD			The induction of ret by Wnt-1 in PC12 cells is atypically dependent on continual Wnt-1 expression	ONCOGENE			English	Article						PC12; Wnt-1; ret; neu	NERVE GROWTH-FACTOR; MESSENGER-RNA; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; POSSIBLE INVOLVEMENT; INT-1 PROTOONCOGENE; MAMMARY ONCOGENE; GENE; LINE; TRANSFORMATION	Wild type PC12 pheochromocytoma cells that had been infected with a Wnt-1-carrying virus and thus express Wnt-1 (PC12/Wnt-1) are known to acquire the same hat cell phenotype as that of spontaneously occurring PC12 flat cell variants except that the latter do not presently express Wnt-1. Flat cell variants of PC12 cells exhibit markedly altered morphology and gene expression. In order to assess the possibility that the spontaneously occurring flat cell variants could have been induced in wild type PC12 cells by previous transient expression of the cell's endogenous Wnt-1, we have isolated PC12/Wnt-1 cells expressing little or no Wnt-1, In spite of absent Wnt-1 expression, they retained their flat cell morphology, glutamate/aspartate transporter activity, increased neu mRNA levels and lack of both norepinephrine transporter activity and nerve growth factor-induced differentiation, Thus, Wnt-1 expression is not required to maintain the flat cell phenotype, However, we identified one gene, ret, whose mRNA level in PC12 was not only increased by Wnt-1 expression, but whose increased mRNA level was also dependent on continual Wnt-1 expression, This finding suggests that the induction of vet by Wnt-1 can be used to elucidate the Wnt-induced signalling pathway in mammalian cells.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH038633, R01MH038633] Funding Source: NIH RePORTER; NIMH NIH HHS [MH38633] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSEN JK, 1990, J NEUROCHEM, V55, P559, DOI 10.1111/j.1471-4159.1990.tb04170.x; ANDERSON DJ, 1994, FASEB J, V8, P707, DOI 10.1096/fasebj.8.10.8050669; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOTHWELL MA, 1980, CELL, V21, P857, DOI 10.1016/0092-8674(80)90449-3; BUNONE G, 1995, EXP CELL RES, V217, P92, DOI 10.1006/excr.1995.1067; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DOUGALL WC, 1994, ONCOGENE, V9, P2109; ECHELARD Y, 1994, DEVELOPMENT, V120, P2213; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; GAMETT DC, 1994, FEBS LETT, V351, P335, DOI 10.1016/0014-5793(94)00855-8; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GOODFELLOW PJ, 1994, CURR OPIN GENET DEV, V4, P446, DOI 10.1016/0959-437X(94)90034-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1185, DOI 10.1016/0006-291X(88)90754-1; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HOEBEN RC, 1991, J VIROL, V65, P904, DOI 10.1128/JVI.65.2.904-912.1991; ISSACK PS, 1994, NEUR SOC ABSTR, V20, P1077; IWAMOTO T, 1993, ONCOGENE, V8, P1087; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MOON RT, 1993, DEVELOPMENT S, V118, P85; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Pestka S, 1981, Methods Enzymol, V78, P3; RAMACHANDRAN B, 1993, J BIOL CHEM, V268, P23891; Sambrook J., 1982, MOL CLONING LAB MANU, V1; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SUGIMOTO Y, 1988, J BIOL CHEM, V263, P12102; TAHIRA T, 1988, BIOCHEM BIOPH RES CO, V153, P1290, DOI 10.1016/S0006-291X(88)81368-8; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; VONDEIMLING A, 1995, BRAIN PATHOL, V5, P153; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	45	22	25	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					555	562						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637712				2022-12-28	WOS:A1996TV59700012
J	Dosch, J; Kaina, B				Dosch, J; Kaina, B			Induction of c-fos, c-jun, junB and junD mRNA and AP-1 by alkylating mutagens in cells deficient and proficient for the DNA repair protein O-6-methylguanine-DNA methyltransferase (MGMT) and its relationship to cell death, mutation induction and chromosomal instability	ONCOGENE			English	Article						Fos; Jun; alkyltransferase; DNA repair; inducible response	METHYLATION DAMAGE; MISMATCH BINDING; GENE; ACTIVATION; EXPRESSION; AGENTS; UV; DIFFERENTIATION; TRANSCRIPTION; METALLOTHIONEIN	An early and immediate response of cells upon irradiation with UV light and various other forms of genotoxic stress is the induction of the proto-oncogenes c-fos and c-jun, To address the questions of whether (a) methylating agents that are powerful carcinogens are effective in induction of fos and jun mRNAs, (b) induction is affected by the repair capacity of the cells, and (c) induction is accompanied by genotoxic effects, the levels of c-fos, c-jun, junB and junD mRNA were analysed in isogenic Chinese hamster cell lines deficient (phenotypically Mex(-)) and proficient (Mex(+)) for the DNA repair protein O-6-methylguanine-DNA methyltransferase (MGMT) after treatment with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and methyl methanesulfonate (MMS), Both methylating agents were very effective in inducing fos and jun mRNAs, although they differ markedly in their potency to induce O-6-methylguanine in DNA, Most responsive were c-fos and c-jun (up to 80-fold increases in mRNA level) whereas junB (up to ninefold) and junD (up to twofold) displayed an intermediate and weak response, respectively, No difference in the dose-dependence of induction of these mRNAs was observed between Mex(-) and Mex(+) cells indicating that the critical genotoxic and mutagenic lesion induced by MNNG, i.e. O-6-methylguanine, which is rapidly repaired by MGMT, does not act as a trigger for this response, Induction of fos and jun mRNAs by MNNG and MMS was accompanied by a dose-dependent increase in the activity of the transcription factor AP-1, To induce fos and jun mRNAs as well as AP-1, doses of MNNG were required which were more than 50-fold higher than those inducing gene mutations, recombination events (SCEs) and reproductive cell death, and fivefold higher than those inducing chromosomal aberrations in Mex(-) cells, Therefore, the immediate induction of fos and jun mRNAs and AP-1 in Mex(-) cells upon their exposure to MNNG appears not to be essential for the generation of MNNG-induced mutagenic and genotoxic effects, which is possibly due to the high genotoxic potential of non-repaired O-6-methylguanine, However, for MMS and UV light, which was included in this study for comparison, c-fos, c-jun, junB and junD mRNA as well as AP-1 induction paralleled the dose-response for induction of cell killing effects, recombination and chromosomal breakage indicating that increased expression of Fos and Jun is related to the generation of MMS and UV-induced genetic changes, These data are in line with a model according to which the induced c-Fos and Jun proteins are involved in defense against UV radiation and other DNA damaging agents.	UNIV MAINZ,INST TOXICOL,DIV APPL TOXICOL,D-55131 MAINZ,GERMANY	Johannes Gutenberg University of Mainz								ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; BUSCHER M, 1988, ONCOGENE, V3, P301; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; FRITZ G, 1993, J BIOL CHEM, V268, P21102; GRIFFIN S, 1994, BIOCHEMISTRY-US, V33, P4787, DOI 10.1021/bi00182a006; GROMBACHER T, 1995, BBA-MOL BASIS DIS, V1270, P63, DOI 10.1016/0925-4439(94)00073-Y; HAAS S, 1995, CARCINOGENESIS, V16, P985, DOI 10.1093/carcin/16.5.985; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HOLT J, 1986, P NATL ACAD SCI USA, P4794; KAINA B, 1993, ENVIRON MOL MUTAGEN, V22, P283, DOI 10.1002/em.2850220418; KAINA B, 1991, CARCINOGENESIS, V12, P1857; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEAF CD, 1989, CANCER SURV, V8, P323; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; NAKABEPPU Y, 1985, J BIOL CHEM, V260, P7281; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PEGG AE, 1992, FASEB J, V6, P2302, DOI 10.1096/fasebj.6.6.1544541; Peto R., 1984, IARC SCI PUBL, V57, P627; PRESTAYKO AW, 1981, NITROSOUREAS CURRENT; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SAFFHILL R, 1985, BIOCHIM BIOPHYS ACTA, V823, P111, DOI 10.1016/0304-419X(85)90009-5; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; ZHUKOVSKAYA N, 1994, CARCINOGENESIS, V15, P2189, DOI 10.1093/carcin/15.10.2189	38	47	48	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1927	1935						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934539				2022-12-28	WOS:A1996VR79500012
J	Davies, MPA; Rudland, PS; Robertson, L; Parry, EW; Jolicoeur, P; Barraclough, R				Davies, MPA; Rudland, PS; Robertson, L; Parry, EW; Jolicoeur, P; Barraclough, R			Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours	ONCOGENE			English	Article						p9Ka; S100A4; c-neu; breast cancer; metastasis; transgenic mice	HUMAN-BREAST-CANCER; NONMUSCLE MYOSIN; CELL-LINES; GENE; RAT; ONCOGENE; INDUCTION; MTS1; TUMORS; ADENOCARCINOMA	Increased levels of S100A4 (p9Ka) confer metastatic ability on a normally non-metastatic epithelial cell line. To find out whether S100A4 can induce metastasis in vivo, transgenic mice expressing high levels of S100A4, but which show no phenotypic effect, have been mated with MMTV-neu transgenic mice which succumb to stochastic mammary neoplasia related to expression of the MMTV-neu transgene. Resultant bitransgenic, multiparous, female progeny expressing both S100A4 and Neu have a slightly earlier incidence of palpable mammary tumours than the MMTV-neu offspring and specifically exhibit macroscopic metastatic lesions in the lungs. The S100A4 transgene is expressed in primary and secondary lesions of bitransgenic offspring and its expression is particularly associated with regions of invasion of primary lesions and metastases.	UNIV LIVERPOOL,DEPT BIOCHEM,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT HUMAN ANAT & CELL BIOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; CLIN RES INST MONTREAL,MONTREAL,PQ H2W 1R7,CANADA	University of Liverpool; University of Liverpool; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal			Davies, Michael/GWV-2527-2022; Barraclough, Roger/AAH-6516-2020	Davies, Michael Peter Alan/0000-0002-7609-4977; Barraclough, Roger/0000-0002-7203-1194				BARRACLOUGH R, 1987, J CELL PHYSIOL, V131, P393, DOI 10.1002/jcp.1041310311; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1994, EUR J CANCER, V30A, P1570, DOI 10.1016/0959-8049(94)00320-5; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V21, P8097; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOMBS LM, 1990, ANAL BIOCHEM, V188, P338, DOI 10.1016/0003-2697(90)90617-I; DAVIES BR, 1993, ONCOGENE, V8, P999; DAVIES M, 1995, DNA CELL BIOL, V14, P825, DOI 10.1089/dna.1995.14.825; DAVIES MPA, 1993, THESIS U LIVERPOOL; DEVOUGE MW, 1992, ONCOGENE, V7, P109; DUNNINGTON DJ, 1984, CANCER RES, V44, P5338; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FORD HL, 1995, ONCOGENE, V11, P2067; FORD HL, 1995, ONCOGENE, V10, P1597; GIBBS FEM, 1995, J HISTOCHEM CYTOCHEM, V43, P169, DOI 10.1177/43.2.7822773; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HOGAN B, 1986, MANIPULATING MOUSE E; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; LAEMMLI UK, 1970, NATURE, V227, P2678; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WATANABE Y, 1993, FEBS LETT, V324, P51, DOI 10.1016/0014-5793(93)81530-D	32	180	184	0	7	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1631	1637						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895508				2022-12-28	WOS:A1996VM88700007
J	Maity, A; Hwang, A; Janss, A; Phillips, P; McKenna, WG; Muschel, RJ				Maity, A; Hwang, A; Janss, A; Phillips, P; McKenna, WG; Muschel, RJ			Delayed cyclin B1 expression during the G2 arrest following DNA damage	ONCOGENE			English	Article						DNA damage; G2 delay; cyclin B1	CELL-CYCLE; IONIZING-RADIATION; HELA-CELLS; GENE-EXPRESSION; MESSENGER-RNA; NITROGEN-MUSTARD; ANTITUMOR DRUGS; TOPOISOMERASE-I; MAMMALIAN-CELLS; CDC25 PROTEIN	Exposure of cells to DNA damaging agents results in a G2 arrest. Exposure of HeLa cells to camptothecin, etoposide or nitrogen mustard for 1 h in S phase resulted in delayed expression of cyclin B1 mRNA during the G2 arrest. Initially the levels of cyclin B1 protein were low as well; however, with extended time the cells blocked in G2 regained higher levels of cyclin B1 protein. In the case of cells treated with nitrogen mustard the higher levels coincided with cells exiting the G2 block into G1. However, with camptothecin or etoposide treatment, while the accumulation of cyclin B1 protein was delayed, its levels eventually surpassed peak levels seen in control cells, in spite of the fact that cells were still blocked in G2. These cells did not continue to progress through the cell cycle indicating further complexity to the mechanisms underlying the G2 block. Decreased transcription and stability of cyclin B1 mRNA were shown to occur after treatment with these DNA damaging agents. These results indicate that suppression of cyclin B1 mRNA expression is one consequence of DNA damage in HeLa cells.	UNIV PENN, SCH MED, DEPT RADIAT ONCOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV ONCOL, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV NEUROL, PHILADELPHIA, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Childrens Hospital of Philadelphia				Maity, Amit/0000-0001-7151-2845	NATIONAL CANCER INSTITUTE [R01CA064227] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047439] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64227] Funding Source: Medline; NIGMS NIH HHS [GM 47439] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; CHEN GL, 1984, J BIOL CHEM, V259, P3560; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU CF, 1994, J CELL SCI, V107, P1833; DATTA R, 1992, CELL GROWTH DIFFER, V3, P637; DEAN SW, 1984, MUTAT RES, V132, P63, DOI 10.1016/0167-8817(84)90067-1; DELBINO G, 1990, CANCER RES, V50, P5746; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; GAZITT Y, 1993, CANCER RES, V53, P1899; GONG JP, 1995, CELL GROWTH DIFFER, V6, P1485; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; HEINTZ N, 1983, MOL CELL BIOL, V3, P539, DOI 10.1128/MCB.3.4.539; HENKEL AW, 1994, ANAL BIOCHEM, V223, P329, DOI 10.1006/abio.1994.1595; HERZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HSIANG YH, 1989, CANCER RES, V49, P5077; HWANG A, 1995, J BIOL CHEM, V270, P28419; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KASTAN MB, 1991, CANCER RES, V51, P6304; KATAYOSE D, 1995, BIOCHEM BIOPH RES CO, V215, P446, DOI 10.1006/bbrc.1995.2485; KOHN KW, 1994, J CELL BIOCHEM, V54, P440, DOI 10.1002/jcb.240540411; KRISHAN A, 1975, J CELL BIOL, V66, P521, DOI 10.1083/jcb.66.3.521; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LI LH, 1972, CANCER RES, V32, P2643; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; LOCK RB, 1993, INT J ONCOL, V3, P33; LOCK RB, 1994, CANCER RES, V54, P4933; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MAITY A, 1995, EMBO J, V14, P603, DOI 10.1002/j.1460-2075.1995.tb07036.x; MARKIEWICZ DA, 1994, INT J RADIAT ONCOL, V28, P135, DOI 10.1016/0360-3016(94)90151-1; MATEOS S, 1994, MUTAT RES-DNA REPAIR, V315, P181, DOI 10.1016/0921-8777(94)90017-5; McKenna WG, 1996, ONCOGENE, V12, P237; MEYUHAS O, 1980, GENE, V10, P113, DOI 10.1016/0378-1119(80)90129-8; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MUSCHEL RJ, 1991, CANCER RES, V51, P5113; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; OCONNOR PM, 1994, P NATL ACAD SCI USA, V91, P9480, DOI 10.1073/pnas.91.20.9480; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; RUSSELL P, 1986, CELL, V45, P145, DOI 10.1016/0092-8674(86)90546-5; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SMEETS MFMA, 1994, RADIOTHER ONCOL, V33, P217, DOI 10.1016/0167-8140(94)90357-3; STEWART N, 1995, ONCOGENE, V10, P109; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TOBEY RA, 1972, CANCER RES, V32, P2720; TODD DG, 1994, CANCER RES, V54, P5224; TSAO YP, 1992, CANCER RES, V52, P1823; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; WARD JF, 1994, INT J RADIAT BIOL, V66, P427, DOI 10.1080/09553009414551401; WOZNIAK AJ, 1983, CANCER RES, V43, P120; WU RS, 1971, P NATL ACAD SCI USA, V68, P3009, DOI 10.1073/pnas.68.12.3009	56	57	61	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	1996	13	8					1647	1657						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895510				2022-12-28	WOS:A1996VM88700009
J	Rachmilewitz, J; Elkin, M; Looijenga, LHJ; Verkerk, AJMH; Gonik, B; Lustig, G; Werner, D; deGroot, N; Hochberg, A				Rachmilewitz, J; Elkin, M; Looijenga, LHJ; Verkerk, AJMH; Gonik, B; Lustig, G; Werner, D; deGroot, N; Hochberg, A			Characterization of the imprinted IPW gene: Allelic expression in normal and tumorigenic human tissues	ONCOGENE			English	Article						IPW; imprinted genes; bi-allelic expression; testicular germ cell tumors; bladder carcinoma	GROWTH FACTOR-II; HUMAN H19 GENE; RELAXATION; INVITRO; REGION; LINE; IGF2	IPW (Imprinted gene in the Prader-Willi syndrome region) is a recently identified paternally expressed gene, Previous work has demonstrated IPW expression in the human fetus and adult, with monoallelic expression in adult lymphoblasts and fibroblasts, and in fetal tissues. To further examine the expression of IPW, a series of experiments were carried out using RT-PCR to measure IPW expression in placentae and various fetal and tumor tissues, Biallelic expression of IPW was found in testicular germ cell tumor and bladder cancer cells, suggesting loss of imprinting in the latter case. Both H19 and Insulin-like growth Factor 2 (IGF2), two additional imprinted genes, also showed biallelic expression in those same tumors that demonstrated IPW biallelic expression. Of note, the naturally occurring parthenogenetic-derived mature teratoma unexpectedly expressed large amounts of IPW, Lastly, the pluripotent embryonal cancer cell line Tera-2 expressed IPW at the same level before and after differentiation induced by retinoic acid, suggesting that this gene functions in a 'housekeeping' capacity throughout cell growth. This was in contradistinction to H19 and IGF2, both of which showed significant transcriptional upregulation after Tera-2 cell differentiation.	HEBREW UNIV JERUSALEM,SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL; UNIV ROTTERDAM HOSP,DR DANIEL DEN HOED CANC CTR,LAB EXPT PATHOONCOL,NL-3075 EA ROTTERDAM,NETHERLANDS; WAYNE STATE UNIV,SCH MED,GRACE HOSP,DEPT OBSTET & GYNECOL,DETROIT,MI; GERMAN CANC RES CTR,D-69120 HEIDELBERG,GERMANY	Hebrew University of Jerusalem; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Wayne State University; Helmholtz Association; German Cancer Research Center (DKFZ)			Looijenga, Leendert/B-8145-2019	Looijenga, Leendert/0000-0002-8146-1911; Verkerk, Annemieke JMH/0000-0002-7523-3656				ANDREWS PW, 1984, LAB INVEST, V50, P147; ARIEL I, 1994, GYNECOL ONCOL, V53, P212, DOI 10.1006/gyno.1994.1118; Ausubel F. M., 1993, CURRENT PROTOCOLS MO, V1; DoucRasy S, 1996, ONCOGENE, V12, P423; GIANNOUKAKIS N, 1993, NAT GENET, V4, P98, DOI 10.1038/ng0593-98; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LINDER D, 1975, NEW ENGL J MED, V292, P63, DOI 10.1056/NEJM197501092920202; MCDONALD RJ, 1987, METHOD ENZYMOL, V152, P221; MOSSELMAN S, 1994, CANCER RES, V54, P220; MOSTOFI FK, 1987, SEMIN DIAGN PATHOL, V4, P320; MUTTER GL, 1993, AM J HUM GENET, V53, P1096; OOSTERHUIS JW, 1989, LAB INVEST, V60, P14; POIRIER F, 1991, DEVELOPMENT, V113, P1105; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; SOLTER D, 1988, ANNU REV GENET, V22, P127; SURANI MAH, 1987, BIOL REPROD, V36, P1, DOI 10.1095/biolreprod36.1.1; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; SZULMAN AE, 1987, GESTATIONAL TROPHOBL, P27; TADOKORO K, 1991, NUCLEIC ACIDS RES, V19, P6967, DOI 10.1093/nar/19.24.6967; TYCKO B, 1994, AM J PATHOL, V144, P431; VANGURP RJH, 1994, JNCI-J NATL CANCER I, V14, P1070; VILLAR AJ, 1995, DEV BIOL, V172, P264, DOI 10.1006/dbio.1995.0021; WALSH C, 1994, MECH DEVELOP, V46, P55, DOI 10.1016/0925-4773(94)90037-X; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; Zhan SL, 1995, ONCOGENE, V11, P2503; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	27	26	27	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1687	1692						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895514				2022-12-28	WOS:A1996VM88700013
J	DeBenedetti, VMG; Radice, P; Mondini, P; Spatti, G; Conti, A; Illeni, MT; Caligo, MA; Cipollini, G; Bevilaqua, G; Pilotti, S; Pierotti, MA				DeBenedetti, VMG; Radice, P; Mondini, P; Spatti, G; Conti, A; Illeni, MT; Caligo, MA; Cipollini, G; Bevilaqua, G; Pilotti, S; Pierotti, MA			Screening for mutations in exon 11 of the BRCA1 gene in 70 Italian breast and ovarian cancer patients by protein truncation test	ONCOGENE			English	Article						breast cancer; ovarian cancer; hereditary tumours; BRCA1; PTT	SUSCEPTIBILITY GENE; FAMILIAL BREAST; HISTOPROGNOSTIC GRADE; TUMORS; LINKAGE	The most common mutations in the familial breast and ovarian cancer susceptibility gene BRCA1 are frameshift and nonsense mutations, which lead to the synthesis of truncated proteins. On this ground, we have analysed BRCA1 exon 11, which includes about 61% of coding region, in germline DNA from 70 Italian breast and/or ovarian cancer patients, using the protein truncation test (PTT). BRCA1 mutations were identified in nine of 29 (similar to 31%) patients with a family history of cancer and in three of 41 (similar to 7%) women with early-onset breast carcinomas, and were subsequently characterized by sequence analysis. In addition, BRCA1 mutations were also detected in six affected relatives of two positive index cases, The observed frequencies of mutations were not significantly different from those expected on the basis of the phenotypic characteristics of patients and their families, indicating that PTT is a rapid and sensitive method that can be used for a first BRCA1 mutational screening, The histological findings in BRCA1 mutated cases showed that eight of nine (similar to 89%) breast carcinomas were of grade III and nine of 9 (100%) ovarian carcinomas were of the endometrioid type (eight of grade III and one of grade II). This suggests that specific histological characteristics may represent additional criteria for selection of cases eligible to BRCA1 mutational analysis.	IST NAZL TUMORI, DIV EXPT ONCOL A, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV SURG GYNECOL ONCOL, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV SURG ONCOL C, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV IMMUNOHEMATOL, I-20133 MILAN, ITALY; IST NAZL TUMORI, DIV ANAT PATHOL & CITOL, I-20133 MILAN, ITALY; UNIV PISA, INST PATHOL ANAT, I-56126 PISA, ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Pisa			Radice, Paolo/O-3119-2013; Pierotti, Marco Alessandro/AAC-4728-2022; Caligo, Adelaide Maria/K-4289-2018	Radice, Paolo/0000-0001-6298-4111; Pierotti, Marco Alessandro/0000-0002-7431-8332; Caligo, Adelaide Maria/0000-0003-0589-1829				BIGNON YJ, 1995, LANCET, V346, P258, DOI 10.1016/S0140-6736(95)91310-6; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; EASTON DF, 1993, AM J HUM GENET, V52, P678; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, AM J HUM GENET, V57, P1457; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; HOULSTON RS, 1991, ANN HUM GENET, V55, P291, DOI 10.1111/j.1469-1809.1991.tb00856.x; JACQUEMIER J, 1995, LANCET, V345, P1503, DOI 10.1016/S0140-6736(95)91060-3; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; LINDBLOM A, 1995, BREAST CANCER RES TR, V34, P171, DOI 10.1007/BF00665789; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD S, 1994, LANCET, V343, P236, DOI 10.1016/S0140-6736(94)91021-9; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; PLUMMER SJ, 1995, HUM MOL GENET, V4, P1989, DOI 10.1093/hmg/4.10.1989; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; SANDER F, 1977, P NATL ACAD SCI USA, V74, P5463; Scully R. E, 1979, TUMORS OVARY MALDEVE; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; STRUEWING JP, 1995, AM J HUM GENET, V57, P1; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TAKAHASHI H, 1995, CANCER RES, V55, P2998; TORNOS C, 1995, AM J SURG PATHOL, V19, P1343, DOI 10.1097/00000478-199512000-00001; VANRENSBURG EJ, 1995, J CLIN PATHOL, V48, P789, DOI 10.1136/jcp.48.9.789; WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	32	26	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1353	1357						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808710				2022-12-28	WOS:A1996VJ20200027
J	Okuda, K; Golub, TR; Gilliland, DG; Griffin, JD				Okuda, K; Golub, TR; Gilliland, DG; Griffin, JD			p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell Lines	ONCOGENE			English	Article						leukemia; signal transduction; BCR/ABL	BCR-ABL ONCOGENE; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; TYROSINE KINASE; ADAPTER PROTEIN; TEL GENE; C-ABL; FUSION; PHOSPHORYLATION; TRANSFORMATION	The Philadelphia chromosome translocation generates a chimeric oncogene, BCR/ABL which causes chronic myelogenous leukemia, Two different fusion proteins can be produced, p190BCR/ABL and p210BCR/ABL, depending on the location of the breakpoint in BCR, Although the ABL tyrosine kinase activity of the resulting oncoprotein is essential for transformation, the exact functional contribution of BCR to transformation is unclear, A novel oncogene containing ABL is formed by the (9;12) translocation which fuses part of the ets-family member TEL to c-ABL in patients with acute leukemia, In an effort to compare the biological effects of various ABL oncogenes, rye transformed two different factor-dependent murine hematopoietic cell Lines with cDNA's encoding p210 BCR/ABL, p190 BCR/ABL, or TEL/ABL, Transfection of each of the three activated ABL oncogenes resulted in rapid emergence of growth factor-independence, and 2-4 sublines from each cell line with each oncogene were further studied, Each oncogene induced an increase in the tyrosine phosphorylation of cellular proteins and autophosphorylation of the oncoprotein itself, Overall, the pattern of increased tyrosine phosphorylation was similar in the cell lines, suggesting that many of the major substrates were identical, We specifically examined a series of proteins known to be p210 BCR/ABL substrates, including rasGAP, Shc, SH-PTP2, SH-PTP1, CRK-L, CBL, paxillin, and STATs, and found that each were also tyrosine phosphorylated in response to p190 BCR/ABL and TEL/ABL. These results suggest that the function of BCR can be largely replaced by the unrelated protein TEL with regards to transformation of murine hematopoietic cell lines to factor-independence, and support the hypothesis that a major contribution of both fusion partners is to activate the ABL tyrosine kinase.	DANA FARBER CANC INST,DIV HEMATOL MALIGNANCIES,BOSTON,MA 02115; DANA FARBER CANC INST,DEPT PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA066996] Funding Source: NIH RePORTER; NCI NIH HHS [CA66996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BUIJS A, 1995, ONCOGENE, V10, P1511; CAMPBELL ML, 1990, ONCOGENE, V5, P773; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1987, SCIENCE, V237, P532, DOI 10.1126/science.2440107; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DRUKER B, 1992, BLOOD, V79, P2215; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; GISHIZKY ML, 1992, SCIENCE, V256, P836, DOI 10.1126/science.1375394; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GOLUB TR, 1996, IN PRESS MOL CELL BI; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JANSSEN JWG, 1995, BRIT J HAEMATOL, V90, P222, DOI 10.1111/j.1365-2141.1995.tb03407.x; LANEUVILLE P, 1992, BLOOD, V80, P1788; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MATSUGUCHI T, 1994, J BIOL CHEM, V269, P5016; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; ODA T, 1994, J BIOL CHEM, V269, P22925; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RON D, 1991, NEW BIOL, V3, P372; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; SETH A, 1990, ONCOGENE, V5, P1761; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; TAUCHI T, 1994, J BIOL CHEM, V269, P15381; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1994, CANCER RES, V54, P2563; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	44	95	101	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1147	1152						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808688				2022-12-28	WOS:A1996VJ20200005
J	Yuan, ZM; Huang, YY; Kraeft, SK; Chen, LB; Kharbanda, S; Kufe, D				Yuan, ZM; Huang, YY; Kraeft, SK; Chen, LB; Kharbanda, S; Kufe, D			Interaction of cyclin-dependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-beta-D-arabinofuranosylctosine	ONCOGENE			English	Article						cyclin dependent kinase; protein tyrosine kinase; 1-beta-D-arabinofuranosylcytosine; DNA damage; cell cycle arrest	MYELOID-LEUKEMIA CELLS; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CATALYTIC SUBUNIT; ACTIVATING KINASE; HUMAN FIBROBLASTS; EPITHELIAL-CELLS; ANTIGEN RECEPTOR; MAMMALIAN-CELLS; SERINE KINASE	The cyclin dependent kinase 2 (Cdk2) is required for initiation and progression of DNA replication, Activation of Cdk2 involves binding to cyclin E or cyclin A and dephosphorylation of Tyr15, The present studies demonstrate that treatment of U-937 cells with 1-beta-D-arabinofuranosylcytosine (ara-C) is associated with tyrosine phosphorylation of Cdk2 and inhibition of Cdk2 activity, The results also demonstrate that Cdk2 directly associates with the Src-like tyrosine kinase Lyn as a consequence of ara-C-treatment, Confocal microscopy studies show that Lyn is detectable in the nucleus and that it colocalises with Cdk2, Subcellular fractionation and coimmunoprecipitation studies further demonstrate nuclear binding of Lyn and Cdk2, We also show that Lyn phosphorylates Tyr15 of Cdk2 and that incubation of Lyn with Cdk2 results in inhibition of Cdk2 activity, These findings suggest that the association of Lyn and Cdk2 in ara-C-treated cells may contribute to regulation of Cdk2-dependent cell cycle checkpoints.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CELLULAR & MOL BIOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NCI NIH HHS [CA29431] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; CICHOWSKI K, 1992, J BIOL CHEM, V267, P5025; DAVIDPFEUTY T, 1990, J CELL BIOL, V111, P3097, DOI 10.1083/jcb.111.6.3097; DRABEROVA L, 1993, P NATL ACAD SCI USA, V90, P3611, DOI 10.1073/pnas.90.8.3611; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FRAM RJ, 1982, CANCER RES, V42, P4050; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GUNJI H, 1991, CANCER RES, V51, P741; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KHARBANDA S, 1994, ONCOGENE, V9, P3005; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KUFE DW, 1984, MOL PHARMACOL, V26, P128; KUFE DW, 1980, J BIOL CHEM, V255, P8997; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MAJOR PP, 1981, P NATL ACAD SCI-BIOL, V78, P3235, DOI 10.1073/pnas.78.5.3235; MAJOR PP, 1982, BIOCHEM PHARMACOL, V31, P2937, DOI 10.1016/0006-2952(82)90266-0; MINOGUCHI K, 1994, J BIOL CHEM, V269, P5249; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; OHNO Y, 1988, CANCER RES, V48, P1494; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SCHEUERMANN RH, 1994, P NATL ACAD SCI USA, V91, P4048, DOI 10.1073/pnas.91.9.4048; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; STANLEY E, 1991, MOL CELL BIOL, V11, P3399, DOI 10.1128/MCB.11.7.3399; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YUAN ZM, 1995, BIOCHEMISTRY-US, V34, P1058, DOI 10.1021/bi00003a041; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	54	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					939	946						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806683				2022-12-28	WOS:A1996VG76600007
J	Crespo, P; Bustelo, XR; Aaronson, DS; Coso, OA; LopezBarahona, M; Barbacid, M; Gutkind, JS				Crespo, P; Bustelo, XR; Aaronson, DS; Coso, OA; LopezBarahona, M; Barbacid, M; Gutkind, JS			Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav	ONCOGENE			English	Article						Vav; signal transduction; JNK; MAP kinases; GTP-binding proteins	GUANINE-NUCLEOTIDE EXCHANGE; DBL-ONCOGENE PRODUCT; RECEPTOR TYROSINE KINASE; GTP-BINDING PROTEINS; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; MOLECULAR-CLONING; RAS; ACTIVATION; PHOSPHORYLATION	The protein product of the human vav oncogene, Vav, exhibits a number of structural motifs suggestive of a role in signal transduction pathways, including a leucine-rich region, a plekstrin homology (PH) domain, a cysteine-rich domain, two SH3 regions, an SH2 domain, and a central Dbl homology (DH) domain. However, the transforming pathway(s) activated by Vav has not yet been elucidated. Interestingly, DH domains are frequently found in guanine nucleotide-exchange factors for small GTP-binding proteins of the Ras and Rho families, and it has been recently shown that, whereas Ras controls the activation of mitogen activated kinases (MAPKs), two members of the Rho family of small GTPases, Rac 1 and Cdc42, regulate activity of stress activated protein kinases (SAPKs), also termed c-jun N-terminal kinases (JNKs). The structural similarity between Vav and other guanine nucleotide exchange factors for small GTP-binding proteins, together with the recent identification of biochemical routes specific for members of the Ras and Rho family of GTPases, prompted us to explore whether MAPK or JNK are downstream components of the Vav signaling pathways. Using the COS-7 cell transient expression system, we have found that neither Vav nor the product of the I,av proto-oncogene, proto-Vav, can enhance the enzymatic activity of a coexpressed, epitope tagged MAPK. On the other hand, we have observed that, whereas proto-Vav can slightly elevate JNK/SAPK activity, oncogenic Vav potently activates JNK/SAPK to an extent comparable to that elicited by two guanine-nucleotide exchange factors for Rho family members, Dbl and Ost. We also show that point mutations in conserved residues within the cysteine rich and DH domains of Vav both prevent its ability to activate JNK/SAPK and render Vav oncogenically inactive. In addition, we found that coexpression of the Rac-1 N17 dominant inhibitory mutant dramatically diminishes JNK/SAPK stimulation by Vav, as well as reduces the focus-forming ability of Vav in NIH3T3 murine fibroblasts. Taken together, these findings provide the first evidence that Rac-1 and JNK are integral components of the Vav signaling pathway.	NIDR,MOL SIGNALING UNIT,CELLULAR DEV & ONCOL LAB,NIH,BETHESDA,MD 20892; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT MOL BIOL,PRINCETON,NJ 08543	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Bristol-Myers Squibb			Bustelo, Xose R./AAD-2081-2022; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Bustelo, Xose R./A-9526-2010; Crespo, Piero/M-3273-2014	Bustelo, Xose R./0000-0001-9398-6072; Gutkind, J. Silvio/0000-0002-5150-4482; Bustelo, Xose R./0000-0001-9398-6072; Crespo, Piero/0000-0003-2825-7783				ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1993, CELL GROWTH DIFFER, V4, P297; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P177; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1991, NEW BIOL, V3, P372; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	41	154	155	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					455	460						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760286				2022-12-28	WOS:A1996VB32800002
J	Vadiveloo, PK; Vairo, G; Novak, U; Royston, AK; Whitty, G; Filonzi, EL; Cragoe, EJ; Hamilton, JA				Vadiveloo, PK; Vairo, G; Novak, U; Royston, AK; Whitty, G; Filonzi, EL; Cragoe, EJ; Hamilton, JA			Differential regulation of cell cycle machinery by various antiproliferative agents is linked to macrophage arrest at distinct G1 checkpoints	ONCOGENE			English	Article						cyclin; cdk; IFN gamma; dimethylamiloride; lipopolysaccharide; cAMP	STIMULATING FACTOR-I; DEPENDENT PROTEIN-KINASES; GROWTH-FACTOR-BETA; C-MYC EXPRESSION; S-PHASE ENTRY; TRANSCRIPTION FACTOR; TGF-BETA; RETINOBLASTOMA PROTEIN; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCTION	There is currently much interest in the mechanisms of action of antiproliferative agents and their effects on cell cycle machinery. In the present study we examined the mechanisms of action of four unrelated agents known to inhibit proliferation of CSF-1-stimulated bone marrow-derived macrophages (BMM). We report that 8-bromo-cAMP (8Br-cAMP) and lipopolysaccharide (LPS) potently reduced CSF-1-stimulated cyclin D1 protein, and cyclin-dependent kinase (cdk) 4 mRNA and protein levels, while the inhibitory effects of the Na+/ H+ antiport inhibitor 5-(N',N'-dimethyl) amiloride (DMA) and interferon gamma (IFN gamma) were only weak. All agents repressed CSF-1-stimulated retinoblastoma protein phosphorylation. Furthermore, 8Br-cAMP and to a lesser extent IFN gamma, also reduced CSF-1-stimulated levels of E2F DNA binding activity in a macrophage cell line, BAC1.2F5. An explanation for the different effects of the agents is that 8Br-cAMP and LPS were found to arrest BMM in early/mid-G1, while IFN gamma and DMA arrested cells in late G1 or early S phase. These data indicate that (1) different antiproliferative agents can arrest the same cell type at distinct checkpoints in G1 and (2) effects of antiproliferative agents on cell cycle machinery is Linked to the position at which they arrest cells in G1.	WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA	Walter & Eliza Hall Institute	Vadiveloo, PK (corresponding author), UNIV MELBOURNE,ROYAL MELBOURNE HOSP,DEPT MED,MELBOURNE,VIC 3050,AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; ANDO K, 1995, ONCOGENE, V10, P751; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BORTNER DM, 1991, GENE DEV, V5, P1777, DOI 10.1101/gad.5.10.1777; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKS BG, 1992, J BIOL CHEM, V267, P12307; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CRAGOE EJ, 1967, J MED CHEM, V10, P66, DOI 10.1021/jm00313a014; DEGREGORI J, 1995, MOL CELL BIOL, V15, P5846; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; GAGELIN C, 1994, BIOCHEM BIOPH RES CO, V205, P923, DOI 10.1006/bbrc.1994.2753; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HAMILTON JA, 1992, J IMMUNOL, V148, P4028; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KO TC, 1995, ONCOGENE, V10, P177; KREK W, 1995, METHOD ENZYMOL, V254, P114; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEVINS JR, 1992, SCIENCE, V258, P424; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NOVAK U, 1995, BLOOD, V86, P2948, DOI 10.1182/blood.V86.8.2948.bloodjournal8682948; OKAMOTO Y, 1993, BIOCHEM BIOPH RES CO, V195, P84, DOI 10.1006/bbrc.1993.2013; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PIETENPOL JA, 1991, P NATL ACAD SCI USA, V88, P10227, DOI 10.1073/pnas.88.22.10227; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; SCHWARZ JK, 1995, P NATL ACAD SCI USA, V92, P483, DOI 10.1073/pnas.92.2.483; SCHWARZBAUM S, 1984, J IMMUNOL, V132, P1158; SEWING A, 1993, J CELL SCI, V104, P545; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TUSHINSKI RJ, 1985, J CELL PHYSIOL, V122, P221, DOI 10.1002/jcp.1041220210; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; VAIRO G, 1991, J IMMUNOL, V146, P3469; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VAIRO G, 1995, ONCOGENE, V10, P1969; VAIRO G, 1992, J BIOL CHEM, V267, P19043; VAIRO G, 1990, J BIOL CHEM, V265, P16929; VAIRO G, 1991, IMMUNOL TODAY, V12, P362, DOI 10.1016/0167-5699(91)90067-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; XIE Y, 1993, BRIT J HAEMATOL, V84, P392, DOI 10.1111/j.1365-2141.1993.tb03092.x	68	47	47	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					599	608						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760301				2022-12-28	WOS:A1996VB32800017
J	Kessis, TD; Connolly, DC; Hedrick, L; Cho, KR				Kessis, TD; Connolly, DC; Hedrick, L; Cho, KR			Expression of HPV16 E6 or E7 increases integration of foreign DNA	ONCOGENE			English	Article						HPV; viral integration; cervical carcinoma; DNA damage; carcinogenesis	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; CERVICAL INTRAEPITHELIAL NEOPLASIA; CELL-CYCLE ARREST; GROWTH ARREST; ATAXIA-TELANGIECTASIA; GENE AMPLIFICATION; PHYSICAL STATE; SEQUENCES; CARCINOMA	In most invasive cervical carcinomas, high-risk human papillomavirus (HPV) DIVA is integrated into the host genome, while in pre-invasive cervical lesions the viral genome is typically maintained exclusively as an episome. In contrast, integration of low-risk HPV DIVA is rare, as is the association of low-risk HPVs with carcinomas. High-risk HPV integration is associated with a selective growth advantage of affected cells, and hence, integration is likely to be an important genetic alteration contributing to cervical tumor progression. Expression of high-risk, but not low-risk, HPV E6 or E7 proteins disrupts the p53-dependent G(1) arrest that cells normally display in response to DIVA damage. Absence of this cell cycle checkpoint may predispose cells containing high-risk HPVs to genetic instability and to the accumulation of the genetic alterations that appear to be required for HPV-associated cervical tumor progression. We hypothesized that integration of highrisk HPV DNA into the host cell genome may be facilitated by E6- and/or E7-mediated disruption of the normal DIVA damage response pathway. To test this hypothesis, we assessed the integration frequency of a reporter plasmid (pHyGal) in RKO cells expressing individual E6 or E7 genes of either high-risk (HPV16) or low-risk (HPV6, HPV11) type viruses. Cells expressing HPV16 E6 or HPV16 E7 exhibited a significantly increased frequency of pHyGal integration in comparison to RKO control cells or cells expressing low-risk HPV E6 or E7. Thus, expression of high-risk, but not low-risk, E6 and E7 proteins increases the frequency of foreign DNA integration into the host genome. These findings suggest that at least some of the difference in oncogenic potential observed between high-risk and low-risk HPV types may be determined by the increased ability of high-risk HPVs to integrate into host DNA.	JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, BALTIMORE, MD 21205 USA	Johns Hopkins University				Cho, Kathleen/0000-0003-0500-9998	NATIONAL CANCER INSTITUTE [R29CA064466] Funding Source: NIH RePORTER; NCI NIH HHS [CA64466] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARDER P, 1993, ONCOGENE, V8, P1397; CHEN SL, 1993, CANCER-AM CANCER SOC, V72, P1939, DOI 10.1002/1097-0142(19930915)72:6<1939::AID-CNCR2820720624>3.0.CO;2-2; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; CHOO KB, 1987, J MED VIROL, V21, P101, DOI 10.1002/jmv.1890210202; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FIRZLAFF JM, 1987, CANCER CELL, V5, P105; FOSTER SA, 1994, J VIROL, V68, P5698, DOI 10.1128/JVI.68.9.5698-5705.1994; FUKUSHIMA M, 1990, CANCER, V66, P2155, DOI 10.1002/1097-0142(19901115)66:10<2155::AID-CNCR2820661019>3.0.CO;2-Q; HALBERT CL, 1992, J VIROL, V66, P2125, DOI 10.1128/JVI.66.4.2125-2134.1992; HAVRE PA, 1995, CANCER RES, V55, P4420; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HICKMAN ES, 1994, ONCOGENE, V9, P2177; HIGGINS GD, 1992, J GEN VIROL, V73, P2047, DOI 10.1099/0022-1317-73-8-2047; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JENISON SA, 1990, J INFECT DIS, V162, P60, DOI 10.1093/infdis/162.1.60; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MANIAS DA, 1989, CANCER RES, V49, P2514; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; MORRIS JDH, 1993, ONCOGENE, V8, P893; MUNGER K, 1991, J VIROL, V65, P3943; MUNGER K, 1989, J VIROL, V63, P4417; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; ROMANCZUK H, 1992, P NATL ACAD SCI USA, V89, P3159, DOI 10.1073/pnas.89.7.3159; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SIEGEL J, 1995, ONCOGENE, V11, P1363; SLEBOS RJC, 1995, VIROLOGY, V208, P111, DOI 10.1006/viro.1995.1134; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; VOUSDEN KH, 1989, CANCER CELL-MON REV, V1, P43; WAHLS WP, 1990, SOMAT CELL MOLEC GEN, V16, P321, DOI 10.1007/BF01232460; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; XIA F, 1994, MOL CELL BIOL, V14, P5850, DOI 10.1128/MCB.14.9.5850; XIA F, 1995, CANCER RES, V55, P12; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	50	83	86	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					427	431						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710383				2022-12-28	WOS:A1996VA25200023
J	Bhatia, K; Raj, A; Gutierrez, MI; Judde, JG; Spangler, G; Venkatesh, H; Magrath, IT				Bhatia, K; Raj, A; Gutierrez, MI; Judde, JG; Spangler, G; Venkatesh, H; Magrath, IT			Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt's lymphomas	ONCOGENE			English	Article						EBV; EBNA-1; Burkitt's lymphoma; mutations; lymphomagenesis	CELLS; ASSOCIATION; EXPRESSION; TUMORS; EBV	We have examined sequence variations in the EBNA-1 protein of EBV in normal peripheral blood lymphocytes (PBL) and Burkitt's lymphomas (BL), We find two EBNA-1 strains P (prototype) and V (variant) which differ by 15 amino acids, Each strain has two subtypes defined by the amino acid at position 487 (P-ala, P-thr, V-pro and V-leu), In PBLs from 32 normal individuals, up to three of these subtypes were found in each sample, but the V strain did not occur in the absence of P strain viruses, nor was the V-leu subtype ever observed in normal PBL, In BLs only a single subtype was observed in each tumor, The P-thr and V-leu subtypes were more frequently seen than the P-ala and V-pro subtypes, which occurred in only two and one of the 36 tumor samples respectively, The P-thr was the most commonly observed peripheral blood of both American and as well as in African tumors, However, in 11 of 12 American tumors, the EBNA-1 subtype was V-leu, These data indicate that some EBNA-1 subtypes are more likely to lead to oncogenesis, and one subtype, V-leu, appears only to occur in tumors.			Bhatia, K (corresponding author), NATL CANC INST,LYMPHOMA BIOL SECT,PEDIAT BRANCH,NIH,BLDG 10,ROOM 13N240,10 CTR DR MSC 1928,BETHESDA,MD 20892, USA.							BHATIA KG, 1992, CANCER RES, V52, P4273; CHANG YS, 1990, J CLIN MICROBIOL, V28, P2398, DOI 10.1128/JCM.28.11.2398-2402.1990; COLES RE, 1994, ANN SURG ONCOL, V1, P405, DOI 10.1007/BF02303813; FRANK D, 1995, BLOOD, V85, P1396, DOI 10.1182/blood.V85.5.1396.bloodjournal8551396; GUTIERREZ MI, 1992, BLOOD, V79, P3261; HENLE W, 1967, J NATL CANCER I, V43, P1147; HENNESSY K, 1983, P NATL ACAD SCI-BIOL, V80, P5665, DOI 10.1073/pnas.80.18.5665; LABRECQUE LG, 1995, CANCER RES, V55, P39; Magrath I, 1992, Semin Cancer Biol, V3, P285; MURRAY RJ, 1992, J EXP MED, V176, P157, DOI 10.1084/jem.176.1.157; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; PIZZO PA, 1978, NATURE, V272, P629, DOI 10.1038/272629a0; ROGERS RP, 1992, ADV CANCER RES, V58, P1, DOI 10.1016/S0065-230X(08)60288-2; SAMPLE J, 1990, J VIROL, V64, P4084, DOI 10.1128/JVI.64.9.4084-4092.1990; SHIRAMIZU B, 1991, BLOOD, V77, P1516; SNUDDEN DK, 1995, ONCOGENE, V10, P1545; STRAUS SE, 1993, ANN INTERN MED, V118, P45, DOI 10.7326/0003-4819-118-1-199301010-00009; SUZUSHIMA H, 1995, BLOOD, V85, P480, DOI 10.1182/blood.V85.2.480.bloodjournal852480; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WRIGHTHAM MN, 1995, VIROLOGY, V208, P521, DOI 10.1006/viro.1995.1183	20	109	115	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 4	1996	13	1					177	181						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700544				2022-12-28	WOS:A1996UX31900020
J	Brown, MA; Xu, CF; Nicolai, H; Griffiths, B; Chambers, JA; Black, D; Solomon, E				Brown, MA; Xu, CF; Nicolai, H; Griffiths, B; Chambers, JA; Black, D; Solomon, E			The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21	ONCOGENE			English	Article						BRCA1; tumour-suppressor gene; breast/ovarian tumorigenesis; gene duplication; pseudogene	FAMILIAL BREAST; WILD-TYPE; HETEROZYGOSITY; EVOLUTION; CANCER	To begin to address the hypothesis that abnormal regulation of the breast/ovarian cancer susceptibility gene BRCA1 is a critical step in sporadic breast/ovarian tumorigenesis, we have determined the detailed structure of the BRCA1 genomic region, We show that this region of the genome contains a tandem duplication of approximately 30 kilobases, which results in two copies of BRCA1 exons 1 and 2, of exons 1 and 3 of the adjacent 1A1-3B gene and of the previously reported 295 base pair intergenic region. Sequence analysis of the duplicated exons of BRCA1 and 1A1-3B and flanking genomic DNA reveals maintenance of the intron-exon structure and a high degree of nucleotide sequence identity, suggesting that these are non-processed pseudogenes and that the duplication is a recent event in evolutionary terms, We also show that a processed pseudogene of the acidic ribosomal phosphoprotein P1 (ARPP1) is inserted directly upstream of pseudo-BRCA1 exon 1A, We believe that these findings could not only confound BRCA1 mutation analysis, but could have implications for the normal and abnormal regulation of BRCA1 transcription, translation and function.	BEATSON INST CANC RES, GLASGOW G61 1BD, LANARK, SCOTLAND	Beatson Institute	Brown, MA (corresponding author), IMPERIAL CANC RES FUND, SOMAT CELL GENET LAB, LONDON WC2A 3PX, ENGLAND.		Brown, Melissa A/F-1451-2010	Xu, Chun-Fang/0000-0002-8747-0683; Brown, Melissa/0000-0002-2830-9259				AHUJA SK, 1992, NAT GENET, V2, P31, DOI 10.1038/ng0992-31; BENARIE N, 1994, HUM MOL GENET, V3, P229, DOI 10.1093/hmg/3.2.229; BROWN MA, 1994, NATURE, V372, P733, DOI 10.1038/372733a0; BROWN MA, 1995, P NATL ACAD SCI USA, V92, P4362, DOI 10.1073/pnas.92.10.4362; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CORTESE JF, 1994, J BIOL CHEM, V269, P21898; CROPP CS, 1994, CANCER RES, V54, P2548; ERICKSON LM, 1992, GENOMICS, V14, P948, DOI 10.1016/S0888-7543(05)80116-8; FOULKES WD, 1993, INT J CANCER, V54, P220, DOI 10.1002/ijc.2910540210; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; JEFFREYS AJ, 1982, NATURE, V296, P9, DOI 10.1038/296009a0; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LINDBLOM A, 1993, HUM GENET, V91, P6; MARCHESE A, 1995, GENE, V154, P153, DOI 10.1016/0378-1119(94)00879-W; MATSUSHIMA M, 1995, HUM MOL GENET, V4, P1953, DOI 10.1093/hmg/4.10.1953; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RICH BE, 1987, MOL CELL BIOL, V7, P4065, DOI 10.1128/MCB.7.11.4065; SAPI E, 1994, GENOMICS, V22, P641, DOI 10.1006/geno.1994.1440; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SU LK, 1993, CANCER RES, V53, P2728; SUZUKI H, 1994, GENE, V147, P277, DOI 10.1016/0378-1119(94)90081-7; VANIN EF, 1985, ANNU REV GENET, V19, P253, DOI 10.1146/annurev.genet.19.1.253; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; XU CF, 1996, SEMINARS CANC BIOL	28	67	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2507	2513						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700509				2022-12-28	WOS:A1996UW48700004
J	Feinmesser, RL; Gray, K; Means, AR; Chantry, A				Feinmesser, RL; Gray, K; Means, AR; Chantry, A			HER-2/c-erbB2 is phosphorylated by calmodulin-dependent protein kinase II on a single site in the cytoplasmic tail at threonine-1172	ONCOGENE			English	Article						tyrosine kinases; HER-2/c-erbB2; calmodulin-dependent protein kinase; desensitisation	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; NEU ONCOGENE; CELLS; RESIDUES	Calmodulin-dependent protein kinase II (Cam kinase II) is known to desensitise epidermal growth factor receptor (HER-1) tyrosine kinase activity by a process involving phosphorylation at serines 1046/47 in the cytoplasmic tail, We have developed an experimental system to investigate phosphorylation of the related HER-2/cerbB2 proto-oncogene utilising purified Cam kinase II and recombinant glutathione-S-transferase (GST) fusion proteins, The cDNA for rat Cam kinase II-alpha was transfected into human embryonic kidney (HEK) 293 fibroblasts and the expressed protein purified to homogeneity by calmodulin-agarose affinity chromatography, A GST fusion protein comprising residues 1126-1255 of HER-2 was phosphorylated by purified Cam kinase II, in contrast to a GST protein comprising residues 1005-1125, Phosphoamino-acid analysis and site-directed mutagenesis indicated that HER-2 was phosphorylated on a single site at threonine-1172 which resides within a consensus Cam kinase II phosphorylation site (RAKT), HER-2 (threonine-1172-alanine), in the form of a ligand-inducible chimaera HER-1/2, was co-transfected into HEK-293 fibroblasts with a constitutively active form of Cam kinase II, followed by in vivo labelling of these cells with P-32-orthophosphate, Immunoprecipitation of ligand-activated receptors followed by two-dimensional phosphopeptide mapping indicated that threonine-1172 in HER-2 is a newly identified in vivo site which can be hyper-phosphorylated by constitutively active Cam kinase II, In addition, when over-expressed in HEK 293 fibroblasts, HER-1/2 (threonine-1172-alanine) showed a defect in desensitisation and underwent a more sustained EGF-induced receptor autophosphorylation compared to wild-type HER-1/2.	CHARING CROSS & WESTMINSTER MED SCH, DEPT BIOCHEM, LONDON W6 8RP, ENGLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT MED ONCOL, LONDON W6 8RP, ENGLAND; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA	Imperial College London; Imperial College London; Duke University					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIYAMA T, 1988, MOL CELL BIOL, V8, P1019, DOI 10.1128/MCB.8.3.1019; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COUNTAWAY JL, 1992, J BIOL CHEM, V267, P1129; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; CRUZALEGUI FH, 1992, P NATL ACAD SCI USA, V89, P12127, DOI 10.1073/pnas.89.24.12127; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; DOBASHI K, 1989, DNA-J MOLEC CELL BIO, V8, P723, DOI 10.1089/dna.1989.8.723; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KUPPUSWAMY D, 1993, J BIOL CHEM, V268, P19134; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; MORRISON P, 1993, J BIOL CHEM, V268, P15536; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THEROUX SJ, 1992, J BIOL CHEM, V267, P7967; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	24	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2725	2730						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700533				2022-12-28	WOS:A1996UW48700028
J	Guan, RJ; Moss, SF; Arber, N; Krajewski, S; Reed, JC; Holt, PR				Guan, RJ; Moss, SF; Arber, N; Krajewski, S; Reed, JC; Holt, PR			30 KDa phosphorylated form of Bcl-2 protein in human colon	ONCOGENE			English	Article						Bcl-2; protein phosphorylation; colon cancer; apoptosis; programmed cell death	CELL-DEATH; GENE	Bcl-2 expression was studied in a human colon cell line (HT-29) and in human colonic biopsies by Western and Northern blotting, Polyclonal antibodies raised against the Bcl-2 protein detected the expected 26 KDa protein in human colon, However, although Bcl-2 mRNA was present, the 26 KDa Bcl-2 protein was absent in HT-29 cells, Instead, a 30 KDa protein band strongly reacting with anti-Bcl-2 antibodies was found in HT-29 cells, and also in human colon, tonsil, and some other tissues, Alkaline phosphatase shifted the 30 KDa protein to the 26 KDa position in a time-dependent manner. P-32-labeling of HT-29 cells showed that the 30 KDa protein was phosphorylated, A 27 KDa phosphorylated protein was also immunoprecipitated by anti-Bcl-2 antibody, Phosphopeptide mapping showed that the 27 KDa protein contained a minimum of 3 and the 30 KDa protein at least an additional four phosphorylation sites, Phosphoamino acid analysis revealed that both the 30 KDa and 27 KDa proteins were phosphorylated on serine residues, These findings strongly suggest that the 30 KDa protein is a phosphorylated form of Bcl-2, which is widely distributed in human tissues.	UNIV COLOGNE, ST LUKES ROOSEVELT HOSP CTR, DEPT MED, DIV GASTROENTEROL, NEW YORK, NY 10025 USA; LA JOLLA CANC RES FDN, LA JOLLA, CA 92037 USA	Mount Sinai St. Luke's; Mount Sinai West; Sanford Burnham Prebys Medical Discovery Institute				holt, peter/0000-0002-8469-2766; Arber, Nadir/0000-0001-5283-6991				ALNEMRI ES, 1992, P NATL ACAD SCI USA, V89, P7295, DOI 10.1073/pnas.89.16.7295; BAXTER GD, 1992, J IMMUNOL, V148, P1949; BEDI A, 1995, CANCER RES, V55, P1811; BODRUG SE, 1995, CELL DEATH DIFFER, V2, P173; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; GEIER A, 1995, J CELL PHYSIOL, V163, P570, DOI 10.1002/jcp.1041630318; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; GUAN RJ, 1991, J BIOL CHEM, V266, P8262; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; KEMP BE, 1991, METHOD ENZYMOL, V200, P121; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P515; MAY WS, 1994, J BIOL CHEM, V269, P26865; MOSS SF, 1995, GASTROENTEROLOGY, V108, pA511, DOI 10.1016/0016-5085(95)26359-4; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROBAYE B, 1994, ELECTROPHORESIS, V15, P503, DOI 10.1002/elps.1150150168; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; WANG HG, 1994, ONCOGENE, V9, P2751; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	29	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2605	2609						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700519				2022-12-28	WOS:A1996UW48700014
J	Wang, HY; Lian, ZR; Lerch, MM; Chen, ZJ; Xie, WF; Ullrich, A				Wang, HY; Lian, ZR; Lerch, MM; Chen, ZJ; Xie, WF; Ullrich, A			Characterization of PCP-2, a novel receptor protein tyrosine phosphatase of the MAM domain family	ONCOGENE			English	Article						protein tyrosine phosphatase; cell contact; signal transduction; cell adhesion signals	CELL-ADHESION MOLECULE; NERVOUS-SYSTEM; IMMUNOGLOBULIN SUPERFAMILY; CHROMOSOMAL LOCALIZATION; EXTRACELLULAR REGION; HUMAN-PLACENTA; PURIFICATION; EXPRESSION; DROSOPHILA; CLEAVAGE	DNA sequences encoding a novel member of the receptor protein tyrosine phosphatase (R-PTP) family, termed PCP-2, were identified in a human pancreatic adenocarcinoma cDNA library, Human PCP-2 cDNA predicts a protein of 1430 amino acids with a calculated M(r) of 160 kDa, The predicted PCP-2 enzyme consists of a 740 amino acid extracellular region, a single transmembrane domain, and a 666 amino acid intracellular portion, The extracellular sequence contains a MAM (meprin/A5/PTP mu) domain, an immunoglobulin-like domain and four fibronectin type m-like repeats, suggesting that it is a member of the PTP kappa and PTP mu subfamily, The intracellular region contains two tandemly-repeated protein tyrosine phosphatase domains, Northern blot analyses revealed a single transcript of 5.5 kilobases, which is expressed at different levels in many human tissues except spleen and placenta, Upon transfection of PCP-2 cDNA into human embryonic kidney fibroblast 293 cells, a protein with an apparent M(r) of 180 000 was detected by immunoblot analysis, This size was reduced to the predicted M(r) upon treatment with endoglycosidase F, indicating that PCP-2 is glycosylated and, hence, expressed at the cell surface, A potential role of PCP-2 in cell-cell recognition and adhesion is supported by its co-localization with cell adhesion molecules, such as beta-catenin and E-cadherin, at sites of cell-cell contact.	MAX PLANCK INST BIOCHEM,DEPT MOLEC BIOL,D-82152 MARTINSRIED,GERMANY	Max Planck Society			Lerch, Markus M./E-2206-2016; Wang, Hongyang/B-1340-2010; Lian, Zhaorui/AAW-2379-2020	Lerch, Markus M./0000-0002-9643-8263; 				ALEXANDER D R, 1990, New Biologist, V2, P1049; BECKMANN G, 1993, TRENDS BIOCHEM SCI, V18, P40, DOI 10.1016/0968-0004(93)90049-S; BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BLASCHUK OW, 1990, J MOL BIOL, V211, P679, DOI 10.1016/0022-2836(90)90065-T; Brady-Kalnay S, 1994, ADV PROTEIN PHOSPHAT, V8, P241; CHARBONNEAU H, 1989, P NATL ACAD SCI USA, V86, P5252, DOI 10.1073/pnas.86.14.5252; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8345; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GEBBINK MFBG, 1995, J CELL BIOL, V131, P251, DOI 10.1083/jcb.131.1.251; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; GORBEA CM, 1993, J BIOL CHEM, V268, P21035; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; JIANG WP, 1992, J BIOL CHEM, V267, P9185; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRUEGER NX, 1990, EMBO J, V9, P3241, DOI 10.1002/j.1460-2075.1990.tb07523.x; LAMMERS R, 1993, J BIOL CHEM, V268, P22456; LAU KHW, 1993, CRIT REV ONCOGENESIS, V4, P451; MAURO VP, 1992, J CELL BIOL, V119, P191, DOI 10.1083/jcb.119.1.191; MIZUNO K, 1994, FEBS LETT, V355, P223, DOI 10.1016/0014-5793(94)01188-5; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; PALLEN CJ, 1991, BIOCHEM J, V276, P315, DOI 10.1042/bj2760315; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAP J, 1994, MOL CELL BIOL, V14, P1; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; STREULI M, 1989, P NATL ACAD SCI USA, V86, P8698, DOI 10.1073/pnas.86.22.8698; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TIAN SS, 1991, CELL, V67, P675, DOI 10.1016/0092-8674(91)90063-5; TONKS NK, 1988, J BIOL CHEM, V263, P6722; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4	42	40	51	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2555	2562						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700514				2022-12-28	WOS:A1996UW48700009
J	Miyazaki, T; Liu, ZJ; Taniguchi, T				Miyazaki, T; Liu, ZJ; Taniguchi, T			Selective cooperation of HTLV-1-encoded p40(tax-1) with cellular oncoproteins in the induction of hematopoietic cell proliferation	ONCOGENE			English	Article						HTLV-1; p40(tax-1); lck F505; c-myc; bcl-2; IL-2	VIRUS TYPE-I; RECEPTOR-BETA-CHAIN; LEUKEMIA-VIRUS; IL-2 RECEPTOR; HTLV-I; SIGNAL TRANSDUCTION; TRANS-ACTIVATION; LIGAND-BINDING; TAX PROTEIN; C-MYC	Human T cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T cell leukemia (ATL). The virus-encoded p40(tax-1), a nuclear oncoprotein, is known to promote transcription of its own as well as a variety of cellular genes, However, the mechanism by which p40(tax-1) promotes lymphocyte transformation is not fully understood, In the present study, we examined whether p40(tax-1) can induce hematopoietic cell proliferation by cooperating with the products of cellular proto-oncogenes; i.e. an activated form of the src-family protein tyrosine kinase p56(lck) (lck F505), c-Myc or Bcl-2, These oncoproteins are critical mediators of interleukin 2 (IL-2)-induced proliferative signals. We show that p40(tax-1) alone cannot render the hematopoietic cell line, BAF-B03, able to proliferate in the absence of cytokines, but it can do so in cooperation with lckF505, or c-Myc but not with Bcl-2.	UNIV TOKYO,FAC MED,DEPT IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; NIPPON BOEHRINGER INGELHEIM CO LTD,DEPT MOLEC & CELLULAR BIOL,KAWANISHI,HYOGO 66601,JAPAN	University of Tokyo; Osaka University; Boehringer Ingelheim			Miyazaki, Tadaaki/D-9368-2012					ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CARON C, 1993, EMBO J, V12, P4269, DOI 10.1002/j.1460-2075.1993.tb06111.x; DOI T, 1989, EUR J IMMUNOL, V19, P2375, DOI 10.1002/eji.1830191229; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3551; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1994, P NATL ACAD SCI USA, V91, P3584, DOI 10.1073/pnas.91.9.3584; HIRAI H, P NATL ACAD US, V91; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MINAMI Y, 1993, EMBO J, V12, P759, DOI 10.1002/j.1460-2075.1993.tb05710.x; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIBUYA H, 1992, CELL, V70, P57, DOI 10.1016/0092-8674(92)90533-I; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TANAKA Y, 1990, JPN J CANCER RES, V81, P225, DOI 10.1111/j.1349-7006.1990.tb02554.x; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WONGSTAAL F, 1983, NATURE, V302, P626, DOI 10.1038/302626a0; Yoshida M, 1993, Trends Microbiol, V1, P131, DOI 10.1016/0966-842X(93)90127-D; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	43	15	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2403	2408						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649781				2022-12-28	WOS:A1996UQ22000018
J	Bocco, JL; Bahr, A; Goetz, J; Hauss, C; Kallunki, T; Kedinger, C; Chatton, B				Bocco, JL; Bahr, A; Goetz, J; Hauss, C; Kallunki, T; Kedinger, C; Chatton, B			In vivo association of ATFa with JNK/SAP kinase activities	ONCOGENE			English	Article						ATF; Jun; kinase; interaction	DNA-BINDING PROTEINS; RESPONSE ELEMENT; LEUCINE ZIPPER; CYCLIC-AMP; JUN; FAMILY; ACTIVATION; CELLS; CREB; PHOSPHORYLATION	The human ATFa proteins belong to the CREB/ATF family of transcription factors. We have previously shown that the ATFa proteins may contribute to the modulation of the transcriptional activity of the Jun/Fos complexes (Chatton ed al. (1994). Oncogene, 9, 375-385). We now show that a protein kinase activity is strongly associated with ATFa in vivo, as revealed by coimmunoprecipitation of ATFa/kinase complexes from whole cell extracts, with antibodies against ATFa. Two independent regions were found to be implicated in kinase binding: a major interaction site is located within the N-terminal 82 residues comprising an important metal-chelating element; a weaker binding site corresponds to the basic sequence element preceding the C-terminal leucine-zipper of ATFa. Induction experiments suggest that each of these ATFa domains may interact with different kinases. The major activity is associated with the ATFa N-terminal domain. Based on its response to various inducers, on both in vitro and in vivo binding assays, and on its immunological properties, this activity most likely corresponds to the 54/55 kDa JNK2 protein. Taken together, these observations suggest that the ATFa proteins, among other CREB/ATF proteins, may be important effecters of cell signalling pathways.	ULP,INST GENET & BIOL MOL & CELLULAIRE,INSERM,CNRS,F-67404 ILLKIRCH GRAFFENS,FRANCE; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,CTR MOLEC GENET,PROGRAM BIOMED SCI,LA JOLLA,CA 92093	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); University of California System; University of California San Diego			CHATTON, Bruno/R-3813-2019	CHATTON, Bruno/0000-0003-4515-7119; Kallunki, Tuula/0000-0002-8571-383X; Bocco, Jose Luis/0000-0002-9682-1270				ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ADLER V, 1992, J BIOL CHEM, V267, P17001; BASU M, 1984, NATURE, V311, P477, DOI 10.1038/311477a0; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOCCO JL, 1993, ONCOGENE, V8, P2977; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHATTON B, 1994, ONCOGENE, V9, P375; CHATTON B, 1995, BIOTECHNIQUES, V18, P142; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN P, 1988, METHOD ENZYMOL, V159, P390; DAI TN, 1995, ONCOGENE, V10, P849; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FLINT KJ, 1991, ONCOGENE, V6, P2019; GAIRE M, 1990, NUCLEIC ACIDS RES, V18, P3467, DOI 10.1093/nar/18.12.3467; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE KAW, 1992, J CELL SCI, V103, P9; LIN YS, 1989, NATURE, V338, P39; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAEKAWA T, 1991, ONCOGENE, V6, P627; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TARTAGLIA J, 1992, AIDS RES HUM RETROV, V8, P1445, DOI 10.1089/aid.1992.8.1445; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Wiktor T J, 1992, Biotechnology, V24, P508; YAN MH, 1994, NATURE, V372, P798	44	27	27	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1971	1980						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649858				2022-12-28	WOS:A1996UK49800016
J	Leung, HY; Dickson, C; Robson, CN; Neal, DE				Leung, HY; Dickson, C; Robson, CN; Neal, DE			Over-expression of fibroblast growth factor-8 in human prostate cancer	ONCOGENE			English	Article						fibroblast growth factor-8, FGF-8; androgen induced growth factor; prostate cancer; in situ hybridisation			IMPERIAL CANC RES FUND,VIRAL CARCINOGENESIS LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	Leung, HY (corresponding author), UNIV NEWCASTLE UPON TYNE,SCH MED,DEPT SURG,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND.			Neal, David/0000-0002-6033-5086; Leung, Hing Y./0000-0002-3933-3975				DEARNALEY DP, 1994, BRIT MED J, V308, P780, DOI 10.1136/bmj.308.6931.780; LEUNG HY, 1994, INT J ONCOL, V4, P1219; LORENZI MV, 1995, ONCOGENE, V10, P2051; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MAHMOOD R, 1995, CURR BIOL, V5, P797, DOI 10.1016/S0960-9822(95)00157-6; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928	8	72	73	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1833	1835						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622905				2022-12-28	WOS:A1996UG45800027
J	Geng, Y; Eaton, EN; Picon, M; Roberts, JM; Lundberg, AS; Gifford, A; Sardet, C; Weinberg, RA				Geng, Y; Eaton, EN; Picon, M; Roberts, JM; Lundberg, AS; Gifford, A; Sardet, C; Weinberg, RA			Regulation of cyclin E transcription by E2Fs and retinoblastoma protein	ONCOGENE			English	Article						cell cycle; cyclin E transcription; E2F; retinoblastoma protein	CELL-CYCLE; DEPENDENT KINASES; BINDING PROTEIN; CDC2 GENE; EXPRESSION; REPRESSION; CLONING; PHOSPHORYLATION; TRANSACTIVATION; ASSOCIATION	Cyclin E is critical for the advance of cells through the G1 phase of their growth cycle. Transcription of the cyclin E gene is known to be cell cycle-dependent. We have shown previously that mRNA levels of cyclin E are regulated positively by mitogens and negatively by TGF-beta. Much circumstantial evidence implicates both E2F transcription factors and the retinoblastoma protein (pRB) in the control of cyclin E expression. However, the molecular basis of this control has remained unclear. We report here the cloning of the cyclin E promoter and the identification of several putative E2F binding sites within the promoter sequence. We have found that cell cycle regulation of cyclin E transcription is mediated by E2F binding sites present in the promoter. The activity of this promoter can be regulated negatively by pRB. Our results suggest the operation of a positive-feedback loop in late G1 that functions to ensure continued cyclin E expression and pRB inactivation.	WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139; FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104; DANA FARBER CANC INST,BOSTON,MA 02115	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Fred Hutchinson Cancer Center; Harvard University; Dana-Farber Cancer Institute					NCI NIH HHS [R35-CA39826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DURONIO RJ, 1995, GENE DEV, V9, P1456, DOI 10.1101/gad.9.12.1456; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAMEL PA, 1992, ONCOGENE, V7, P693; HARVEY RJ, 1991, NUCLEIC ACIDS RES, V19, P4002, DOI 10.1093/nar/19.14.4002; HATAKEYAMA M, 1994, GENE DEV, V8, P1759, DOI 10.1101/gad.8.15.1759; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HERRERA RE, 1995, UNPUB; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Sambrook J., 1989, MOL CLONING; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	50	360	372	0	17	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 21	1996	12	6					1173	1180						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649818				2022-12-28	WOS:A1996UC06700001
J	Hagmeyer, BM; Duyndam, MCA; Angel, P; deGroot, RP; Verlaan, M; Elfferich, P; vanderEb, AJ; Zantema, A				Hagmeyer, BM; Duyndam, MCA; Angel, P; deGroot, RP; Verlaan, M; Elfferich, P; vanderEb, AJ; Zantema, A			Altered AP-1/ATF complexes in adenovirus-E1-transformed cells due to E1A-dependent induction of ATF3	ONCOGENE			English	Article						LRF1; ATF; cJun; E1A	TRANSCRIPTION FACTOR E2F; JUN PROTO-ONCOGENE; C-JUN; DNA-BINDING; HETERODIMER FORMATION; RESPONSE ELEMENT; UP-REGULATION; E1A; PROTEINS; CREB	The adenovirus (Ad) E1A proteins alter the expression level and activity of AP-1/ATF transcription factors. Previously we have shown that in AdE1-transformed cells cJun is hyperphosphorylated in its N-terminal transactivation domain, which parallels enhanced transactivation function. To find out whether the interaction between cJun and other cellular proteins is altered, we have searched for proteins which would physically associate with cJun. In this report we show that in AdE1-transformed cells cJun specifically associates with two proteins of 21 and 23 kD. These proteins are not expressed at detectable levels in the parental cells or in cells transformed by oncogenes other than AdE1. The cJun-associated proteins represent different forms of the bZIP transcription factor ATF3, the human homolog of rat LRF1. The expression of ATF3 is induced in AdE1-transformed cells and is a direct effect of the expression of E1A. Through induction of ATF3 expression and the subsequent formation of cJun/ATF3 heterodimers, E1A alters the repertoire of AP-1/ATF factors and may thereby redirect the corresponding gene-expression program. Since the induction of ATF3 is a function of sequences within the transforming 12S-E1A protein, cJun/ATF3 complexes might be involved in establishing cellular transformation by AdE1A.	FORSCHUNGSZENTRUM KARLSRUHE, INST GENET, D-76021 KARLSRUHE, GERMANY; LEIDEN UNIV, MOLEC CARCINOGENESIS LAB, 2300 RA LEIDEN, NETHERLANDS	Helmholtz Association; Karlsruhe Institute of Technology; Leiden University; Leiden University - Excl LUMC			Piris, Miguel A/AAP-1445-2020	Piris, Miguel A/0000-0001-5839-3634				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BENBROOK DM, 1990, ONCOGENE, V5, P295; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARTER R, 1991, ONCOGENE, V6, P229; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHU HM, 1994, MOL ENDOCRINOL, V8, P59, DOI 10.1210/me.8.1.59; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DYSON N, 1992, CANCER SURV, V12, P161; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HAGMEYER BM, 1995, BIOESSAYS, V17, P621, DOI 10.1002/bies.950170708; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; HOEFFLER JP, 1992, J INVEST DERMATOL, V98, pS21, DOI 10.1111/1523-1747.ep12462126; HSU JC, 1993, CANCER RES, V53, P3789; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MEYER TE, 1993, ENDOCR REV, V14, P269, DOI 10.1210/er.14.3.269; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; SCHOLER H, 1986, SCIENCE, V232, P76, DOI 10.1126/science.3006253; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDEREB AJ, 1992, MALIGNANT TRANSFORMA, P115	39	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 7	1996	12	5					1025	1032						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649793				2022-12-28	WOS:A1996UA88400010
J	Wyllie, FS; Haughton, MF; Bond, JA; Rowson, JM; Jones, CJ; WynfordThomas, D				Wyllie, FS; Haughton, MF; Bond, JA; Rowson, JM; Jones, CJ; WynfordThomas, D			S phase cell-cycle arrest following DNA damage is independent of the p53/p21(WAF1) signalling pathway	ONCOGENE			English	Article						p53; p21(WAF-1); SDI1; CIP1; S phase; checkpoint	ATAXIA-TELANGIECTASIA; P53; REPLICATION; PROTEIN; CHECKPOINT; BLEOMYCIN; KINASES; CANCER	It is now likely that the cyclin-kinase inhibitor, p21(WAF1/SDI1), is,key effector of p53-mediated cell-cycle arrest at the G(1)/S checkpoint following DNA damage. More recently, however, in vitro data has suggested that this pathway may also mediate the acute inhibition of DNA synthesis seen in cells already in S phase. Here we address this question in an intact cell system using normal human diploid fibroblasts in which p53 function is manipulated by expression mutant (ala(143)) introduced vector. Induction of DNA strand breaks in normal control fibroblasts by exposure to bleomycin led as expected to G(1)/S cell cycle arrest, induction of p21(WAF1) and a rapid reduction in the rate of DNA synthesis in cells already in S phase. Stable expression of mutant p53 abrogated the G(1)/S (but not the G(1)/M) cell cycle checkpoint and abolished the induction of p21(WAF1), but had no significant effect on the inhibition of DNA replication in S phase nuclei. We conclude that, despite the in vitro evidence for inhibitory activity on PCNA/polymerase delta, p21(WAF1) induction does not appear to be essential for the acute inhibition of DNA synthesis in the intact cell following strand-break damage in S phase.	UNIV WALES COLL MED,DEPT PATHOL,CRC THYROID TUMOUR BIOL GRP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University				Jones, Christopher/0000-0002-5447-8187				BOND JA, 1994, ONCOGENE, V9, P1885; CANMAN CE, 1994, CANCER RES, V54, P5054; CLEAVER JE, 1992, RADIAT RES, V131, P338, DOI 10.2307/3578425; CRAMER P, 1981, NATURE, V291, P671, DOI 10.1038/291671a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAMB JR, 1989, INT J RADIAT BIOL, V56, P125, DOI 10.1080/09553008914551271; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI R, 1994, ONCOGENE, V9, P2261; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PINES J, 1994, NATURE, V369, P520, DOI 10.1038/369520a0; POVIRK LF, 1991, MUTAT RES, V257, P127, DOI 10.1016/0165-1110(91)90022-N; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WALTERS RA, 1975, BIOCHEM BIOPH RES CO, V65, P265, DOI 10.1016/S0006-291X(75)80088-X; WRIGHT PA, 1991, ONCOGENE, V6, P1693; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; WYLLIE FS, 1995, ONCOGENE, V10, P49; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	32	38	38	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1077	1082						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649799				2022-12-28	WOS:A1996UA88400016
J	Ren, ZP; Hedrum, A; Ponten, F; Nister, M; Ahmadian, A; Lundeberg, J; Uhlen, M; Ponten, J				Ren, ZP; Hedrum, A; Ponten, F; Nister, M; Ahmadian, A; Lundeberg, J; Uhlen, M; Ponten, J			Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes	ONCOGENE			English	Article						p53; skin; cancer; mutation; immunohistochemistry; LOH	XERODERMA-PIGMENTOSUM PATIENTS; SQUAMOUS-CELL CARCINOMA; SKIN CANCERS; HUMAN TUMORS; GENE; DNA; POLYMORPHISM; POPULATIONS; SUNLIGHT	Microdissection of biopsies with sequencing of exons 4-8 of the p53 gene permitted precise morphological identification of correlation between mutations and/or loss of heterozygosity, immunoreactivity of p53 and type of squamous neoplasia, Seventy-two specimens from ten lesions of sun-exposed sites including normal epidermis were analysed. Irrespective of p53 immunoreactivity and morphological grade dysplasia, in situ or invasive cancer, in each case, carried the identical mutation indicating that invasive skin cancer and its precursors derive from the same original neoplastic clone. Additionally, morphologically normal epidermis showed some sharply demarcated immunoreactive areas. These never had the same p53 mutation as that of the adjacent tumor, indicating that their mutations were separate events and ruling them out as common precursors of cancer, Nonimmunoreactive normal epidermis did not show p53 mutations, Our findings indicate that a large fraction of keratinocytes in sun-exposed human skin carry mutations of p53 and suggest that at least two options exist for such cells (i) innocuous clonal expansion with preserved morphology and normal differentiation or (ii) malignant transformation with the p53 mutation as an early event. Suggestive evidence existed that the p53 mutations were qualitatively different in the two respective groups of lesions.	ROYAL INST TECHNOL,DEPT BIOCHEM & BIOTECHNOL,S-10044 STOCKHOLM,SWEDEN	Royal Institute of Technology	Ren, ZP (corresponding author), UNIV UPPSALA HOSP,DEPT PATHOL,S-75185 UPPSALA,SWEDEN.		Uhlen, Mathias/AAV-8746-2021; Uhlen, Mathias/B-3262-2016	Uhlen, Mathias/0000-0002-4858-8056				BERG C, 1995, CLIN CHEM, V41, P1461; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAMPBELL C, 1993, J INVEST DERMATOL, V100, P746, DOI 10.1111/1523-1747.ep12475717; CAMPBELL C, 1993, BRIT J DERMATOL, V129, P235, DOI 10.1111/j.1365-2133.1993.tb11840.x; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DUMAZ N, 1993, P NATL ACAD SCI USA, V90, P10529, DOI 10.1073/pnas.90.22.10529; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FIALKOW PJ, 1976, BIOCHIM BIOPHYS ACTA, V458, P283, DOI 10.1016/0304-419X(76)90003-2; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; HEDRUM A, 1994, BIOTECHNIQUES, V17, P118; HULTMAN T, 1991, BIOTECHNIQUES, V10, P84; JIN YS, 1993, CANCER RES, V53, P2140; JONES MH, 1992, GENE CHROMOSOME CANC, V5, P89, DOI 10.1002/gcc.2870050113; KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988; KUBO Y, 1994, J INVEST DERMATOL, V102, P440, DOI 10.1111/1523-1747.ep12373002; LEITNER T, 1993, BIOTECHNIQUES, V15, P120; Lever W. F., 1990, HISTOPATHOLOGY SKIN; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MOLES JP, 1993, ONCOGENE, V8, P583; NAKAZAWA H, 1994, P NATL ACAD SCI USA, V91, P360, DOI 10.1073/pnas.91.1.360; NELSON MA, 1994, CANCER LETT, V85, P23, DOI 10.1016/0304-3835(94)90234-8; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; Potten C S, 1981, Int Rev Cytol, V69, P271; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; SATO M, 1993, CANCER RES, V53, P2944; STEPHENSON TJ, 1992, BRIT J DERMATOL, V127, P566, DOI 10.1111/j.1365-2133.1992.tb14866.x; TAGUCHI M, 1994, J INVEST DERMATOL, V103, P500, DOI 10.1111/1523-1747.ep12395643; WAINSCOAT JS, 1990, CANCER RES, V50, P1355; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	31	136	140	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					765	773						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632898				2022-12-28	WOS:A1996TW68600007
J	Erny, KM; Peli, J; Lambert, JF; Muller, V; Diggelmann, H				Erny, KM; Peli, J; Lambert, JF; Muller, V; Diggelmann, H			Involvement of the Tp1-2/cot oncogene in MMTV tumorigenesis	ONCOGENE			English	Article						MMTV; Tp1-2/cot; mammary tumor	MAMMARY-TUMOR VIRUS; T-CELL LYMPHOMAS; PROTEIN-KINASE; COT PROTOONCOGENE; TRANSFORMING GENE; SERINE KINASE; EXPRESSION; TPL-2; IDENTIFICATION; ACTIVATION	We report for the first time a relationship between the Tpl-2/cot oncogene and Mouse Mammary Tumor Virus (MMTV) associated transformation of mammary gland cells, A sub-genomic library generated from a primary mammary gland tumor yielded a novel MMTV integration site which disrupted the Tpl-2/cot proto-oncogene between exons 7 and 8, Comparison of a cell line derived from normal mammary gland (comma-D) and a cell line established from an MMTV induced mammary tumor (GR) demonstrated similar rearrangements within Tpl-2/cot for the GR cells but not in the comma-D cells, These rearrangements in the cell line were accompanied by an increase in the level of Tpl-2/cot specific mRNA, This data suggests that Tpl-2/cot expression may be important in epithelial cell transformation or tumor progression.	CHU VAUDOIS, INST MICROBIOL, CH-1011 LAUSANNE, SWITZERLAND; SWISS INST CANC RES, ISREC, EPALINGES, SWITZERLAND	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Swiss Institute Experimental Cancer Research				Erny-Albrecht, Katrina/0000-0003-3538-1475				AOKI M, 1993, J BIOL CHEM, V268, P22723; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; CHAN AML, 1993, ONCOGENE, V8, P1329; DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756; HELD W, 1993, CELL, V74, P529, DOI 10.1016/0092-8674(93)80054-I; HIGASHI T, 1990, P NATL ACAD SCI USA, V87, P2409, DOI 10.1073/pnas.87.7.2409; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; KOZAK C, 1987, J VIROL, V61, P1651, DOI 10.1128/JVI.61.5.1651-1654.1987; LAMBERT JF, 1993, MOL IMMUNOL, V30, P1399, DOI 10.1016/0161-5890(93)90101-G; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MIYOSHI J, 1991, MOL CELL BIOL, V11, P4088, DOI 10.1128/MCB.11.8.4088; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Nusse R, 1991, Curr Top Microbiol Immunol, V171, P43; OHARA R, 1995, J CELL SCI, V108, P97; OHARA R, 1993, JPN J CANCER RES, V84, P518, DOI 10.1111/j.1349-7006.1993.tb00170.x; PADMA R, 1991, CANCER RES, V51, P2486; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; PETERS G, 1983, CELL, V33, P369, DOI 10.1016/0092-8674(83)90418-X; RINGOLD G, 1975, VIROLOGY, V65, P135, DOI 10.1016/0042-6822(75)90014-8; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SELTEN G, 1986, CELL, V46, P603, DOI 10.1016/0092-8674(86)90886-X; Varmus H E, 1983, Prog Clin Biol Res, V119, P23; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078	25	59	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					2015	2020						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934549				2022-12-28	WOS:A1996VR79500022
J	Portella, G; Salvatore, D; Botti, G; Cerrato, A; Zhang, L; Mineo, A; Chiappetta, G; Santelli, G; Pozzi, L; Vecchio, G; Fusco, A; Santoro, M				Portella, G; Salvatore, D; Botti, G; Cerrato, A; Zhang, L; Mineo, A; Chiappetta, G; Santelli, G; Pozzi, L; Vecchio, G; Fusco, A; Santoro, M			Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene	ONCOGENE			English	Article						transgenic; oncogene; RET; mammary; thyroid	RET PROTO-ONCOGENE; TYROSINE KINASE; THYROID CARCINOMAS; METASTATIC DISEASE; NEU PROTOONCOGENE; RECEPTOR RET; HUMAN-BREAST; H4 D10S170; GENE; EXPRESSION	RET/PTC1 is a chimeric oncogene created by the fusion of the tyrosine kinase domain of RET to the 5'-terminal region of another gene named H4, So far, this oncogene has been found activated only in human papillary thyroid carcinomas, In order to investigate its transforming properties in vivo, we have produced transgenic mice carrying RET/PTC1 under the control of the H4 promoter, The transgene was expressed in several tissues, consistently with the ubiquitous expression of the wild type H4 gene, Mammary adenocarcinomas and, less frequently, hyperplasia of sebaceous glands and rare benign skin tumors, named pilomatrixomas, developed in these mice, The tumors were shown to express the transgene both at the RNA and protein level, These results demonstrate that the transforming ability of the RET/PTC1 oncogene is not restricted to the thyroid epithelium in vivo, Despite its ubiquitous expression, however, RET/PTC1 was able to induce only a limited number of tumor types; specifically mammary epithelium was affected by transgene expression, thus suggesting that RET/PTC1 is able to couple with transforming pathways specific for these glandular cells.	UNIV NAPLES,FAC MED & CHIRURG,DIPARTIMENTO BIOL & PATOL CELLULARE & MOL,CNR,I-80131 NAPLES,ITALY; FDN PASCALE,IST NAZL TUMORI NAPOLI,I-80131 NAPLES,ITALY; IST REGINA ELENA,I-00161 ROME,ITALY; UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Fondazione Pascale; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria			Cerrato, Aniello/AAY-1484-2020; Salvatore, Domenico/D-4881-2013; Portella, Giuseppe/AFU-6826-2022	SALVATORE, DOMENICO/0000-0002-4556-7620; Fusco, Alfredo/0000-0003-3332-5197; PORTELLA, Giuseppe/0000-0001-8276-9769; Botti, Gerardo/0000-0002-6287-733X				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; CHALSTRE.LJ, 1966, BRIT J CANCER, V20, P670, DOI 10.1038/bjc.1966.78; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUGAZZOLA L, 1995, CANCER RES, V55, P5617; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; GRIECO M, 1994, ONCOGENE, V9, P2531; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HEADINGTON JT, 1976, AM J PATHOL, V85, P480; HOGAN B, 1986, MANIPULATING MOUSE E, P79; ITO T, 1993, CANCER RES, V53, P2940; ITO T, 1994, LANCET, V344, P250; IWAMOTO T, 1991, EUR J IMMUNOL, V21, P1809, DOI 10.1002/eji.1830210805; IWAMOTO T, 1991, EMBO J, V10, P3167, DOI 10.1002/j.1460-2075.1991.tb04878.x; IWAMOTO T, 1990, ONCOGENE, V5, P533; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Klugbauer S, 1995, ONCOGENE, V11, P2459; LANZI C, 1992, ONCOGENE, V7, P2189; Mak YF, 1996, CURR OPIN GENET DEV, V6, P82, DOI 10.1016/S0959-437X(96)90015-5; MALLORY SB, 1995, DERMATOL CLIN, V13, P27, DOI 10.1016/S0733-8635(18)30103-7; MICHAELS RD, 1993, J ENDOCRINOL INVEST, V11, P909; MOROY T, 1990, EMBO J, V9, P3659, DOI 10.1002/j.1460-2075.1990.tb07577.x; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; RASSOULZADEGAN M, 1990, ONCOGENE, V5, P1507; ROMANO A, 1995, ONCOGENE, V9, P2923; RON E, 1984, BRIT J CANCER, V49, P87, DOI 10.1038/bjc.1984.13; SANTORO M, 1993, BRIT J CANCER, V68, P460, DOI 10.1038/bjc.1993.370; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1992, J CLIN INVEST, V89, P1517, DOI 10.1172/JCI115743; Santoro M, 1996, ONCOGENE, V12, P1821; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SUDA Y, 1987, EMBO J, V6, P4055, DOI 10.1002/j.1460-2075.1987.tb02751.x; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; TAKAHASHI M, 1988, ONCOGENE, V3, P571; TONG Q, 1995, ONCOGENE, V10, P1781	37	26	26	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2021	2026						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934550				2022-12-28	WOS:A1996VR79500023
J	Willumsen, BM; Cox, AD; Solski, PA; Der, CJ; Buss, JE				Willumsen, BM; Cox, AD; Solski, PA; Der, CJ; Buss, JE			Novel determinants of H-Ras plasma membrane localization and transformation	ONCOGENE			English	Article						palmitoylation; lipid modification; Ras transformation	POLYBASIC DOMAIN; CAAX MOTIF; PROTEINS; P21RAS; PALMITOYLATION; PALMITATE; ONCOGENE; PRODUCT; CYCLASE; SIGNAL	Although it is well-established that modification of Ras by farnesol is a critical step for its membrane association and transforming activity, the contribution of other C-terminal sequences and palmitate modification to Ras localization and function remains unclear, We have characterized H-Ras mutant proteins with alterations in the palmitoylated cysteines or in sequences flanking these residues, We found that non-palmitoylated proteins were impaired not only in membrane association but also in transforming activity, Mutations which drastically altered residues adjacent to the palmitoylated cysteine did not abolish palmitoylation, However, despite continued lipid modification the mutant proteins failed to bind to plasma membranes and instead accumulated on internal membranes and, importantly, were not transforming, Addition of an N-terminal myristoylation signal to these defective mutants, or to proteins entirely lacking the C-terminal 25 residues restored both plasma membrane association and transforming activity, Thus, H-Ras does not absolutely require prenylation or palmitoylation nor indeed its hypervariable domain in order to interact with effecters that ultimately cause transformation, However, in this native state, the C-terminus appears to provide a combination of lipids and a previously unrecognized signal for specific plasma membrane targeting that are essential for the correct localization and biological function of H-Ras.	UNIV N CAROLINA,DEPT RADIAT ONCOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PHARMACOL,CHAPEL HILL,NC 27599; IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Iowa State University	Willumsen, BM (corresponding author), UNIV COPENHAGEN,DEPT MOL CELL BIOL,OSTER FARIMAGSGADE 2A,DK-1353 COPENHAGEN,DENMARK.		Willumsen, Berthe M/H-1903-2012	Willumsen, Berthe M/0000-0002-2277-6999; Cox, Adrienne D./0000-0002-4901-2454; Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA052072, R29CA061951, R01CA042978] Funding Source: NIH RePORTER; NCI NIH HHS [CA52072, CA61951, CA42978] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Dudler T, 1996, J BIOL CHEM, V271, P11541, DOI 10.1074/jbc.271.19.11541; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; GRAND RJA, 1991, BIOCHEM J, V279, P609, DOI 10.1042/bj2790609; GUTIERREZ L, 1991, BIOCHIM BIOPHYS ACTA, V1078, P147, DOI 10.1016/0167-4838(91)99003-B; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HORIUCHI H, 1992, MOL CELL BIOL, V12, P4515, DOI 10.1128/MCB.12.10.4515; JHAPPAN C, 1986, J VIROL, V60, P750, DOI 10.1128/JVI.60.2.750-753.1986; Kato K, 1992, Semin Cancer Biol, V3, P179; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KURODA Y, 1993, SCIENCE, V259, P683, DOI 10.1126/science.8430318; LACAL PM, 1988, ONCOGENE, V2, P533; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LOWY DR, 1988, CELLULAR MOL BIOL TU, P203; LU JY, 1995, J BIOL CHEM, V270, P7251, DOI 10.1074/jbc.270.13.7251; NEWMAN CMH, 1992, J BIOL CHEM, V267, P12329; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; WILLUMSEN BM, 1985, EMBO J, V4, P2893, DOI 10.1002/j.1460-2075.1985.tb04019.x; WILLUMSEN BM, 1995, METHODS ENZYMOL LIPI, V220, P269; WILSON PT, 1995, J BIOL CHEM, V270, P9967	27	84	85	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1901	1909						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934536				2022-12-28	WOS:A1996VR79500009
J	Caligo, MA; Ghimenti, C; Cipollini, G; Ricci, S; Brunetti, I; Marchetti, V; Olsen, R; Neuhausen, S; ShattuckEidens, D; Conte, PF; Skolnick, MH; Bevilacqua, G				Caligo, MA; Ghimenti, C; Cipollini, G; Ricci, S; Brunetti, I; Marchetti, V; Olsen, R; Neuhausen, S; ShattuckEidens, D; Conte, PF; Skolnick, MH; Bevilacqua, G			BRCA1 germline mutational spectrum in Italian families from Tuscany: A high frequency of novel mutations	ONCOGENE			English	Article						hereditary breast ovarian cancer; BRCA1; mutation	CANCER SUSCEPTIBILITY GENE; OVARIAN-CANCER; BREAST-CANCER; LINKAGE; TUMORS; MAP	BRCA1 germline mutations confer susceptibility to familial breast and ovarian cancer, Mutational hot spots have never been detected in BRCA1 cDNA, Some mutations have been reported several times whereas some others appear to be population-related. In this study a group of 36 Italian families were analysed for BRCA1 germline mutations, All of them mere screened by allele-specific oligonucleotide hybridization (ASO) for three recurrent mutations (185delAG, 5382insC, nt332T>G), Twenty families, selected because of their high risk of carrying BRCA1 mutations, were subjected to analysis of the entire coding sequence of the gene, A total of eight mutations were found, ASO screening demonstrated only one known mutation in one patient, whereas cycle sequencing revealed five new mutations, Three of these new mutations were frameshifts: one occurred in exon 11 (1499insA), one in exon 16 (4873delCA) and one in the splice site of exon 3 (252delAAgt). Two were missense mutations (Cys64Arg; Asn158Tyr. The same frameshift mutation, 1499insA, was detected in three unrelated families, Haplotype analysis supported the hypothesis that two of these families may have had common ancestors, whereas in the third family the analysis was uninformative, BRCA1 germ line mutations mere found in one out of two families with ovarian cancer, in five out of eight families with breast-ovarian cancer, and in two out of 11 families with breast canter, All three families with 1499insA mutations included at least one case of ovarian cancer, The majority of the ovarian cancers (4/5) associated with detectable BRCA1 germline mutations were of serous histotype.	MYRIAD GENET, SALT LAKE CITY, UT USA; UNIV UTAH, DEPT MED INFORMAT, SALT LAKE CITY, UT 84112 USA; SANTA CHIARA HOSP, DEPT MED ONCOL, PISA, ITALY	Myriad Genetics, Inc; Utah System of Higher Education; University of Utah; Santa Chiara Hospital	Caligo, MA (corresponding author), UNIV PISA, INST PATHOL, PISA, ITALY.		Conte, PierFranco/F-7418-2014; Caligo, Adelaide Maria/K-4289-2018	Conte, PierFranco/0000-0002-5210-5344; Caligo, Adelaide Maria/0000-0003-0589-1829; BEVILACQUA, GENEROSO/0000-0001-8857-2609				BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1993, AM J HUM GENET, V52, P678; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, BRIT J CANCER, V72, P805, DOI 10.1038/bjc.1995.417; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GOLDGAR DE, 1994, J NATL CANCER I, V86, P200, DOI 10.1093/jnci/86.3.200; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NAROD SA, 1995, AM J HUM GENET, V56, P254; NAROD SA, 1991, LANCET, V338, P82; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; NEUHAUSEN SL, 1994, HUM MOL GENET, V3, P1919, DOI 10.1093/hmg/3.11.1919; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P582; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TAKAHASHI H, 1995, CANCER RES, V55, P2998; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	26	45	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1483	1488						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875986				2022-12-28	WOS:A1996VL38400013
J	Mangeney, M; Schmitt, JR; Leverrier, Y; Thomas, J; Marvel, J; Brun, G; Gillet, G				Mangeney, M; Schmitt, JR; Leverrier, Y; Thomas, J; Marvel, J; Brun, G; Gillet, G			The product of the v-src-inducible gene nr-13 is a potent anti-apoptotic factor	ONCOGENE			English	Article						v-src; apoptosis; cell transformation	QUAIL NEURORETINAL CELLS; BONE-MARROW CELLS; B-CELLS; DEATH; BCL-2; VIRUS; PROTEIN; TRANSFORMATION; INDUCTION; ONCOGENES	Tumorigenesis can be induced either by activating cell proliferation or by inhibiting metabolic pathways regulating programmed cell death (apoptosis). There is evidence suggesting that p60(v-src) and other tyrosine kinases protect cells against apoptosis. This effect could contribute to cell transformation by the Rous sarcoma virus, Mechanism of cell death inhibition by p60(v-src) remains Largely unknown, We have recently reported that in avian cells p60(v-src) activates the expression of nr-13, a bcl-2-related gene, In this paper, we demonstrate, using the bone marrow derived cell line Baf-3 as an experimental model, that the product of this avian gene (nr-13) is a potent anti-apoptotic factor, In addition, we report that, in quail neuroretinal cells, nr-13 expression is activated upon infection by the Rous sarcoma virus (RSV) but not by other oncogenic retroviruses like FSV or MH2, suggesting that nr-13 is a specific target of v-src. Activation of nr-13 expression may be a key step in cellular transformation by v-src.	ECOLE NORMALE SUPER LYON,UMR 49 CNRS,BIOL CELLULAIRE & MOL LAB,IMMUNOL CELLULAIRE GRP,F-69364 LYON 07,FRANCE; ECOLE NORMALE SUPER LYON,UMR 49 CNRS,BIOL CELLULAIRE & MOL LAB,BIOL REGULAT CELLULAIRES RES GRP,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON); Ecole Normale Superieure de Lyon (ENS de LYON)			marvel, jacqueline/H-8638-2014; LEVERRIER, Yann/M-3767-2014; gillet, germain/A-9095-2013	marvel, jacqueline/0000-0001-6241-459X; LEVERRIER, Yann/0000-0002-4227-5446; Mangeney, Marianne/0000-0002-9102-191X; Thomas, Joelle/0000-0002-0461-6131; GILLET, Germain/0000-0002-1514-327X				BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN J, 1994, J BIOL CHEM, V269, P7957; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GILLET G, 1993, ONCOGENE, V8, P565; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; HAECKER G, 1994, TRENDS BIOCHEM SCI, V19, P99, DOI 10.1016/0968-0004(94)90197-X; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; MARVEL J, 1994, ONCOGENE, V9, P1117; MICHEL D, 1989, ONCOGENE RES, V4, P127; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; PEARSON GR, 1987, VIROLOGY, V160, P151, DOI 10.1016/0042-6822(87)90055-9; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; SHEN YQ, 1995, CURR OPIN GENET DEV, V5, P105, DOI 10.1016/S0959-437X(95)90061-6; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; VAUX D, 1992, SCIENCE, V258, P1195; WIERDERRECHT G, 1993, ANN NY ACAD SCI, V696, P9; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5	33	25	25	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1441	1446						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875982				2022-12-28	WOS:A1996VL38400009
J	Wang, JW; Shackleford, GM				Wang, JW; Shackleford, GM			Murine Wnt10a and Wnt10b: Cloning and expression in developing limbs, face and skin of embryos and in adults	ONCOGENE			English	Article						breast neoplasms; oncogene; embryonic development; alternative splicing; limb development; Wnt	MAMMARY-TUMOR VIRUS; GENE FAMILY; TRANSGENIC MICE; CELL-LINE; INT-1 PROTOONCOGENE; PROVIRAL INSERTION; ONCOGENE INT-1; MOUSE; WNT-1; TRANSFORMATION	Wnt genes encode a family of secreted proteins having oncogenic potential and important roles in developmental processes, We report the isolation of cDNAs for a novel murine Wnt gene, Wnt10a, and for two alternatively spliced transcripts of Wnt10b, as well as analyses of the expression patterns of these genes in adult and embryonic tissues, Wnt10a and full length Wnt10b encode relatively closely related (62% identity) Wnt proteins containing the 24 cysteines characteristic of most Wnt proteins, The deduced protein encoded by the alternatively spliced Wnt10b transcript lacks a central region encompassing 25% of the full length isoform, Both Wnt genes were widely expressed in the adult, although the levels of expression varied significantly, Wnt10a RNA was most abundant in adult brain with a high concentration in the pituitary gland, and expression of Wnt10b was highest in adult lung and uterus, RNAs of both genes mere detected in thymus and spleen, tissues not previously reported as sites for Wnt gene expression, Wnt10a and Wnt10b expression broadly peaked at approximately 13.5 and 15.5 days of gestation, respectively, and Northern blot analyses of RNAs from dissected embryos revealed that expression of both genes was strongest in the face, limbs and skin and that Wnt10a was also expressed in the Liver, the major site of hematopoiesis in the embryo, These expression patterns suggest that Wnt10a and Wnt10b may function in various tissues of the adult and embryo with notable expression in tissues responsible for the formation and maturation of blood cells, in the pituitary gland (Wnt10a), and in the face, Limbs and skin of developing embryos.	CHILDRENS HOSP LOS ANGELES,DIV HEMATOL ONCOL,RES INST,LOS ANGELES,CA 90027; UNIV SO CALIF,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90033; UNIV SO CALIF,SCH MED,DEPT MOL MICROBIOL & IMMUNOL,LOS ANGELES,CA 90033	Children's Hospital Los Angeles; University of Southern California; University of Southern California					NATIONAL CANCER INSTITUTE [R01CA054436] Funding Source: NIH RePORTER; NCI NIH HHS [CA54436] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; BLASBAND A, 1992, ONCOGENE, V7, P153; BRADBURY JM, 1994, ONCOGENE, V9, P2597; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; BUHLER TA, 1993, DEV BIOL, V155, P87, DOI 10.1006/dbio.1993.1009; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; CHRISTIANSEN JH, 1995, MECH DEVELOP, V51, P341, DOI 10.1016/0925-4773(95)00383-5; CUI YZ, 1995, DEVELOPMENT, V121, P2177; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DONOHOWER LA, 1995, GENE DEV, V9, P882; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; IOZZO RV, 1995, CANCER RES, V55, P3495; KELLY GM, 1993, DEV BIOL, V158, P113, DOI 10.1006/dbio.1993.1172; KOZAK M, 1983, MICROBIOL REV, V47, P1; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; LEJEUNE S, 1995, CLIN CANCER RES, V1, P215; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1992, CIBA F SYMP, V165, P199; MOON RT, 1993, DEVELOPMENT, P85; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; RUGH R, 1968, MOUSE ITS REPRODUCTI; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SMOLICH BD, 1994, DEV BIOL, V166, P300, DOI 10.1006/dbio.1994.1316; SU SJ, 1995, MOL CELL BIOL, V15, P2625; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAUTZ D, 1992, IN SITU HYBRIDIZATIO, P61; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	49	79	84	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1537	1544						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875992				2022-12-28	WOS:A1996VL38400019
J	OHagan, RC; Tozer, RG; Symons, M; McCormick, F; Hassell, JA				OHagan, RC; Tozer, RG; Symons, M; McCormick, F; Hassell, JA			The activity of the ets transcription factor PEA3 is regulated by two distinct MAPK cascades	ONCOGENE			English	Article						PEA3; Ets; MAPK; Ras; transcription	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAYS; COMPLEX FACTOR ELK-1; DNA-BINDING MOTIF; C-JUN; RAS TRANSFORMATION; MAMMALIAN-CELLS; DOMAIN PROTEIN; PHOSPHORYLATION; GENE	PEA3, a member of the Ets family of transcriptional regulatory proteins, binds to the PEA3 promoter element and stimulates transcription through this site, The activity of the PEA3 element is regulated by mitogens, activated receptor tyrosine kinases, members Ras signal However, not clear whether transcriptional regulation by these agents because a number of different Ets proteins can functionally interact with the PEA3 element. To specifically learn whether the activity of PEA3 is regulated, we investigated the ability of constitutively-activated Ras (Ha-RasV12) and signaling proteins downstream of Ras to alter PEA3-dependent reporter gene expression in COS cells, Ha-RasV12 and activated proteins in both the extra-cellular regulated kinase (ERK) and the stress-activated protein kinase (SAPK) or Jun N-terminal kinase (JNK) cascades independently stimulated PEA3-mediated gene expression. Ha-RasV12 stimulation of PEA3 activity was reduced by dominant-negative mutants in each of these protein kinase cascades, suggesting that Ras activates PEA3 through both pathways. Furthermore, the ability of unique activators of each kinase cascade to stimulate PEA3-dependent gene expression was selectively reduced by dominant-negative mutants within the homologous but not the heterologous pathway. Hence two distinct mitogen-activated protein kinase (MAPK) cascades regulate PEA3 activity, PEA3 was phosphorylated in vivo at serine residues consistent with the possibility that it may be a direct target of MAPKs.	MCMASTER UNIV, CANC RES GRP, INST MOL BIOL & BIOTECHNOL, HAMILTON, ON L8S 4K1, CANADA; ONYX PHARMACEUT, RICHMOND, CA 94806 USA	McMaster University								BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; EDWARDS DR, 1992, BIOCHIM BIOPHYS ACTA, V1171, P41, DOI 10.1016/0167-4781(92)90138-P; FISHER RJ, 1991, ONCOGENE, V6, P2249; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1980, INTRO MACROMOLECULES, P3; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HIGASHINO F, 1995, ONCOGENE, V10, P1461; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KYRIAKIS JM, 1994, PROTEIN KINASES FRON, P85; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; POLVERINO A, 1995, J BIOL CHEM, V270, P26067, DOI 10.1074/jbc.270.44.26067; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1989, EMBO J, V8, P3371, DOI 10.1002/j.1460-2075.1989.tb08500.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WOODS DB, 1992, NUCLEIC ACIDS RES, V20, P699, DOI 10.1093/nar/20.4.699; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAN MH, 1994, NATURE, V372, P798; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	57	146	147	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	1996	13	6					1323	1333						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808707				2022-12-28	WOS:A1996VJ20200024
J	Juan, TSC; McNiece, IK; Jenkins, NA; Gilbert, DJ; Copeland, NG; Fletcher, FA				Juan, TSC; McNiece, IK; Jenkins, NA; Gilbert, DJ; Copeland, NG; Fletcher, FA			Molecular characterization of mouse and rat CPP32 beta gene encoding a cysteine protease resembling interleukin-1 beta converting enzyme and CED-3	ONCOGENE			English	Article						cysteine protease; apoptosis, CED-3; gene structure	PROGRAMMED CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; C-ELEGANS; POLY(ADP-RIBOSE) POLYMERASE; CAENORHABDITIS-ELEGANS; MAMMALIAN HOMOLOG; MICE DEFICIENT; APOPTOSIS; IDENTIFICATION; INDUCTION	Interleukin-1 beta converting enzyme (ICE) defines a new class of mammalian cysteine protease that shares strong homology with the Caenorhabditis elegans death gene ced-3, Both ICE and CED-3, when introduced into cultured cells, induce apoptosis, indicating that this type of cysteine protease may play an important role in the process of programmed cell death, Here, we report the cloning of a mouse and rat gene encoding a novel cysteine protease. The putative proteins encoded by these cDNAs contain the conserved sequence (QACRG) necessary for covalent linkage to the substrate as well as the three amino acids responsible for substrate binding and catalysis in ICE, Amino acid sequence analysis indicates that this rodent cysteine protease is the homolog of human CPP32 beta, Mouse CPP32 beta mRNA is highly expressed in spleen, and to a lesser degree in brain, lung, liver, and kidney, The mouse CPP32 beta genomic locus spans a region of approximately 20 kb, including seven exons and six introns, Mouse interspecific backcross mapping allowed localization of CPP32 beta to the central region of mouse chromosome 8, linked to Scvr, Lpl, Jund1 and Mlr.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Juan, TSC (corresponding author), AMGEN INC,DEPT DEV HEMATOL,1840 DEHAVILLAND DR,THOUSAND OAKS,CA 91320, USA.							BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Fichant Gwennaele A., 1992, Human Molecular Genetics, V1, P259, DOI 10.1093/hmg/1.4.259; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; Green EL, 1981, GENETICS PROBABILITY, P77; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HOFFMAN B, 1994, ONCOGENE, V9, P1807; JENKINS NA, 1981, J VIROL, V43, P269; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MOLINEAUX SM, 1993, P NATL ACAD SCI USA, V90, P1809, DOI 10.1073/pnas.90.5.1809; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; STEINGRIMSSON E, 1995, GENOMICS, V28, P179, DOI 10.1006/geno.1995.1129; TERAJIMA M, 1994, J BIOCHEM-TOKYO, V116, P1105, DOI 10.1093/oxfordjournals.jbchem.a124634; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	36	48	54	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					749	755						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761296				2022-12-28	WOS:A1996VD43300010
J	Dehbi, M; Ghahremani, M; Lechner, M; Dressler, G; Pelletier, J				Dehbi, M; Ghahremani, M; Lechner, M; Dressler, G; Pelletier, J			The paired-box transcription factor, PAX2, positively modulates expression of the Wilms' tumor suppressor gene (WT1)	ONCOGENE			English	Article						Wilms' tumor; WT1; Pax-2; kidney development; cancer genetics	FACTOR-A-CHAIN; ALVEOLAR RHABDOMYOSARCOMA; PROMOTER ACTIVITY; POINT MUTATIONS; PRODUCT; REPRESSION; PROTEIN; KIDNEY; BINDING; RECOGNITION	The Wilms' tumor suppressor gene, wt1, encodes a zinc finger protein which functions as a transcriptional regulator. Expression of the wt1 gene is developmentally regulated and restricted to a small set of tissues which include the fetal urogenital system, mesothelium, and spleen. In the developing kidney, induction of neprohogenesis by the ureter is accompanied by an increase in expression levels of the Pax-2 gene, a developmentally and spatially regulated paired-box member. This is followed by an increase in wt1 expression as mesenchymal cells condense and differentiate. In this report, we demonstrate that PAX2 isoforms are capable of transactivating the wt1 promoter. Deletion mutagenesis of the wt1 promoter identified an element responsible for mediating PAX2 responsiveness, located between nucleotides -33 and -71 relative to the first wt1 transcription start site. Consistent with its identity as a PAX responsive element, multimerization of this mofit upstream of a heterologous minimal promoter enhanced reporter activity when co-transfected with a Pax-2 expression vector. Finally, we demonstrate that PAX2 can stimulate expression of the endogenous wt1 gene. These results suggest that a role for mesenchyme-to-epithelium transition in ment is to induce wt1 expression.	MCGILL UNIV, DEPT BIOCHEM, MONTREAL, PQ H3G 1Y6, CANADA; UNIV MICHIGAN, HOWARD HUGHES MED INST, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PATHOL, ANN ARBOR, MI 48109 USA	McGill University; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan								ADAMS B, 1992, GENE DEV, V6, P1589, DOI 10.1101/gad.6.9.1589; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; BECKWITH J B, 1990, Pediatric Pathology, V10, P1; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; COPPES MJ, 1993, P NATL ACAD SCI USA, V90, P1416, DOI 10.1073/pnas.90.4.1416; CZERNY T, 1993, GENE DEV, V7, P2048, DOI 10.1101/gad.7.10.2048; DEY BR, 1994, MOL ENDOCRINOL, V8, P595, DOI 10.1210/me.8.5.595; DRESSLER GR, 1992, P NATL ACAD SCI USA, V89, P1179, DOI 10.1073/pnas.89.4.1179; DRESSLER GR, 1988, DEVELOPMENT, V104, P181; DRESSLER GR, 1993, NATURE, V362, P65, DOI 10.1038/362065a0; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; ECCLES MR, 1995, AM J PATHOL, V146, P40; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; FRAIZER GC, 1994, J BIOL CHEM, V269, P8892; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GNARRA JR, 1995, CANCER RES, V55, P4092; GOODYER P, 1995, ONCOGENE, V10, P1125; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARRINGTON MA, 1993, J BIOL CHEM, V268, P21271; HOFMANN W, 1993, ONCOGENE, V8, P3123; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; LITTLE MH, 1992, P NATL ACAD SCI USA, V89, P4791, DOI 10.1073/pnas.89.11.4791; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MATSUNAGA E, 1981, HUM GENET, V57, P231; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; POLEEV A, 1992, DEVELOPMENT, V116, P611; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; RYAN G, 1995, DEVELOPMENT, V121, P867; SHAPIRO DN, 1993, CANCER RES, V53, P5108; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; TAGGE EP, 1994, J PEDIATR SURG, V29, P134, DOI 10.1016/0022-3468(94)90308-5; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WU YJ, 1995, J BIOL CHEM, V270, P5944, DOI 10.1074/jbc.270.11.5944; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230	49	111	113	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	1996	13	3					447	453						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760285				2022-12-28	WOS:A1996VB32800001
J	Ishikawa, H; Ryseck, RP; Bravo, R				Ishikawa, H; Ryseck, RP; Bravo, R			Characterization of ES cells deficient for the p105 precursor (NF-kappa B1): Role of p50 NLS	ONCOGENE			English	Article						ES cells; gene targeting; I kappa B gamma; NF-kappa B; p50 NLS; p105 precursor	NF-KAPPA-B; NUCLEAR-LOCALIZATION SIGNAL; DNA-BINDING ACTIVITY; C-REL PROTOONCOGENE; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; 65-KD SUBUNIT; P65 SUBUNIT; STEM-CELLS; ACTIVATION	Proteolytic processing of the p105 precursor (NF-kappa B1) generates the p50 subunit of NF-kappa B. To address the function of p105 precursor, we have generated embryonic stem (ES) cells which lack the C-terminal inhibiting ankyrin-containing domain of p105 (I kappa B gamma) but contain a functional p50 by homologous recombination. Two forms of p50 were found in ES cells lacking p105. While one was a p50 molecule with the expected size of 415 amino acids, the other was an isoform of 358 amino acids generated by alternative splicing. This isoform lacked the C-terminal 62 amino acids of p50 including the putative nuclear localization signal (NLS), but included five unrelated amino acids. This p50 molecule lacking the NLS behaved similar to wild type p50. Importantly, the p50 isoform-RelA complex interacted efficiently with I kappa B alpha, implying that the NLS of p50 is not essential for these functions. Also, p50 isoform dimers were present in the nucleus. Loss of p105 and the augment of total p50 produced an increase in the nuclear kappa B-binding activity of p50-RelA and p50 dimers. In wild type ES cells, a significant proportion of total p50 is associated with p105. Therefore, the mutation introduced in NF-kappa B1 eliminates both the processing to generate p50 and the trapping of p50 by p105. In contrast to p50, only a small fraction of RelA is associated with p105. These findings indicate that p105 plays a unique role in controlling p50 dimer activity.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT ONCOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P4516, DOI 10.1093/nar/21.19.4516; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NAUMANN M, 1993, ONCOGENE, V8, P2275; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAGANO M, 1992, ONCOGENE, V7, P1681; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wurst W., 1993, Gene targeting: a practical approach., P33; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	61	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					255	263						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710364				2022-12-28	WOS:A1996VA25200004
J	Rutberg, SE; Saez, E; Glick, A; Dlugosz, AA; Spiegelman, BM; Yuspa, SH				Rutberg, SE; Saez, E; Glick, A; Dlugosz, AA; Spiegelman, BM; Yuspa, SH			Differentiation of mouse keratinocytes is accompanied by PKC-dependent changes in AP-1 proteins	ONCOGENE			English	Article						AP-1; keratinocytes; protein kinase C; mouse skin; differentiation; c-fos	TISSUE-SPECIFIC EXPRESSION; KINASE-C-DELTA; EPIDERMAL DIFFERENTIATION; SELECTIVE INHIBITOR; SKIN CARCINOGENESIS; BINDING-PROTEINS; GENE-EXPRESSION; PHORBOL ESTER; CYCLIC-AMP; FOS	The conversion of cultured basal keratinocytes to the spinous and granular cell phenotypes seen in the skin can be stimulated by raising the levels of extracellular calcium, Here me show that AP-1 DNA binding activity is very low in primary cultures of basal keratinocytes, but that this activity is induced 24-48 h after increasing the concentration of extracellular calcium from 0.05 to 0.12 mM. As such, the induction of AP-1 DNA binding activity correlates with events occurring during the terminal stages of keratinocyte differentiation, Calcium-induced AP-1 DNA binding complexes consist of Pra-1, Fra-2, c-Jun, JunB and JunD and are independent of c-Fos, since the induction of DNA binding activity and the composition of the AP-1 binding complexes are identical in differentiating keratinocytes derived from c-fos null and wild type mice, The formation of calcium-induced AP-1 binding complexes is regulated by protein kinase C (PKC) and requires a functional PKC alpha isozyme, as determined through pharmacological down-modulation of specific PKC isozymes in differentiating keratinocytes, Moreover, PKC activation is required for the increased expression of Fra-2, JunB and JunD in the nucleus of differentiating cells in vitro. This observation provides a link between the obligate activation of PKC during keratinocyte differentiation and the nuclear response required to alter gene expression, In vivo expression patterns suggest that the predominant AP-1 heterodimer in the granular layer consists of Fra-2 and JunB while a JunD and Fra-1 complex predominates the spinous layer of mouse epidermis, These findings suggest distinct functions for different AP-1 proteins in the regulation of events related to keratinocyte maturation.	NCI, CELLULAR CARCINOGENESIS & TUMOR PROMOT LAB, BETHESDA, MD 20892 USA; NCI, TUMOR VIRUS BIOL LAB, BETHESDA, MD 20892 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School								AN G, 1993, J BIOL CHEM, V268, P10977; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; AU YPT, 1994, CIRC RES, V75, P15, DOI 10.1161/01.RES.75.1.15; BASSETSEGUIN N, 1994, ONCOGENE, V9, P765; BASSETSEGUIN N, 1991, J INVEST DERMATOL, V97, P672, DOI 10.1111/1523-1747.ep12483807; Bernerd Francoise, 1993, Gene Expression, V3, P187; CARRASCO D, 1995, ONCOGENE, V10, P1069; CASATORRES J, 1994, J BIOL CHEM, V269, P20489; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; DISEPIO D, 1995, J BIOL CHEM, V270, P10792, DOI 10.1074/jbc.270.18.10792; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; DLUGOSZ AA, 1994, CANCER RES, V54, P6413; FISHER C, 1991, DEVELOPMENT, V111, P253; FRANZA BR, 1987, ONCOGENE, V1, P213; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; GANDARILLAS A, 1995, ONCOGENE, V11, P1403; GILLARDON F, 1994, ONCOGENE, V9, P3219; GRUDA MC, 1994, ONCOGENE, V9, P2537; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUFF CA, 1991, J INVEST DERMATOL, V96; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KULESH DA, 1988, MOL CELL BIOL, V8, P1540, DOI 10.1128/MCB.8.4.1540; LU B, 1994, J BIOL CHEM, V269, P7443; MALMQVIST KG, 1984, NUCL INSTRUM METH B, V3, P611, DOI 10.1016/0168-583X(84)90447-6; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; OSHIMA R G, 1992, Current Opinion in Cell Biology, V4, P110, DOI 10.1016/0955-0674(92)90067-M; PETTIT GR, 1991, CAN J CHEM, V69, P856, DOI 10.1139/v91-126; PRESLAND RB, 1992, J BIOL CHEM, V267, P23772; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; REDEMANNFIBI B, 1991, DIFFERENTIATION, V46, P43, DOI 10.1111/j.1432-0436.1991.tb00864.x; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; RODDEY PK, 1994, J INVEST DERMATOL, V102, P296, DOI 10.1111/1523-1747.ep12371785; ROOP DR, 1988, CANCER RES, V48, P3245; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; ROTHNAGEL JA, 1993, J INVEST DERMATOL, V101, P506, DOI 10.1111/1523-1747.ep12365886; ROTHNAGEL JA, 1987, J BIOL CHEM, V262, P15643; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; SAKO T, 1987, CANCER RES, V47, P5445; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; SONOBE MH, 1995, ONCOGENE, V10, P689; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Takahashi S., 1994, Journal of Dermatological Science, V7, P54, DOI 10.1016/0923-1811(94)90022-1; TANGUAY DA, 1994, CELL IMMUNOL, V158, P281, DOI 10.1006/cimm.1994.1276; TENNENBAUM T, 1993, CANCER RES, V53, P4803; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WOODGETT JR, 1993, ADV SEC MESS PHOSPH, V28, P261; YAMANISHI K, 1992, J BIOL CHEM, V267, P17858; YOON JK, 1994, MOL CELL BIOL, V14, P7731, DOI 10.1128/MCB.14.12.7731; YUSPA SH, 1994, CANCER RES, V54, P1178; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207	67	114	115	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	1996	13	1					167	176						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UX319	8700543				2022-12-28	WOS:A1996UX31900019
J	Rosenberger, SF; Bowden, GT				Rosenberger, SF; Bowden, GT			Okadaic acid stimulated TRE binding activity in a papilloma producing mouse keratinocyte cell line involves increased AP-1 expression	ONCOGENE			English	Article						okadaic acid; tumor promotion; AP-1; TRE binding; mouse keratinocytes	TUMOR PROMOTER; PROTEIN PHOSPHATASES; GENE-EXPRESSION; C-JUN; PHORBOL ESTERS; FOS; ACTIVATION; INDUCTION; ONCOGENE; PHOSPHORYLATION	The effects of the non-phorbol ester type tumor promoter okadaic acid, a serine-threonine phosphatase inhibitor, on activator protein 1 (AP-1) DNA binding activity were studied in papilloma producing 308 mouse keratinocytes. Okadaic acid increased AP-1 binding to a consensus TPA responsive element (TRE) within 2 h; maximum stimulation was observed at 6 h followed by a gradual decrease to basal levels within 24 h, Jun B, Jun D and Fos B proteins were identified as the major components of the AP-1 complex binding to the TRE element at 6 h, Inhibition of transcription with actinomycin D and inhibition of protein synthesis with cycloheximide abrogated the okadaic acid effect on AP-1 DNA binding, indicating that transcription and translation are required for okadaic acid increased TRE binding activity, Northern and Western blot analyses revealed a correlation between increased AP-1 binding activity and accumulation of jun B, jun D and fos B mRNAs and proteins, These data suggest increased AP-1 expression as principal mechanism of okadaic acid stimulated AP-1 activation in the mouse keratinocytes studied.			Rosenberger, SF (corresponding author), UNIV ARIZONA,HLTH SCI CTR,DEPT RADIAT ONCOL,1501 N CAMPBELL AVE,TUCSON,AZ 85724, USA.				NATIONAL CANCER INSTITUTE [R01CA040584] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40584] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BERNSTEIN LR, 1992, MOL CARCINOGEN, V6, P221, DOI 10.1002/mc.2940060308; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BROOKS JW, 1995, MOL IMMUNOL, V32, P779, DOI 10.1016/0161-5890(95)00055-J; CARTER R, 1994, ONCOGENE, V9, P2675; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COFFER P, 1994, ONCOGENE, V9, P911; COSENZA SC, 1994, J CELL BIOCHEM, V55, P503, DOI 10.1002/jcb.240550410; DATTA R, 1991, CELL GROWTH DIFFER, V2, P43; DICKINSON JA, 1995, CELL IMMUNOL, V165, P92, DOI 10.1006/cimm.1995.1191; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DOMANN FE, 1994, MOL CARCINOGEN, V9, P61, DOI 10.1002/mc.2940090202; DONG ZG, 1995, INT J ONCOL, V7, P359; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; FLEISCHMAN LF, 1993, ONCOGENE, V8, P771; GROVERBARDWICK A, 1994, CARCINOGENESIS, V15, P1667, DOI 10.1093/carcin/15.8.1667; GRUDA MC, 1994, ONCOGENE, V9, P2537; HABY C, 1994, BIOCHEM PHARMACOL, V48, P819, DOI 10.1016/0006-2952(94)90061-2; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HOLLADAY K, 1992, MOL CARCINOGEN, V5, P16, DOI 10.1002/mc.2940050106; HONKANEN RE, 1991, J BIOL CHEM, V266, P6614; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE JS, 1994, J BIOL CHEM, V269, P2887; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MURATA M, 1982, B JPN SOC SCI FISH, V48, P549; NAKAMURA T, 1991, CELL GROWTH DIFFER, V2, P267; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; PAI SR, 1994, ANTICANCER RES, V14, P985; REZZONICO R, 1995, ONCOGENE, V11, P1069; RIECKMANN P, 1992, BIOCHEM BIOPH RES CO, V187, P51, DOI 10.1016/S0006-291X(05)81457-3; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSA T, 1989, BIOCHEM BIOPH RES CO, V159, P939, DOI 10.1016/0006-291X(89)92199-2; SCHONTHAL A, 1991, ONCOGENE, V6, P423; SMITH MJ, 1992, BLOOD, V79, P2107; STRICKLAND JE, 1988, CANCER RES, V48, P165; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TANGUAY DA, 1994, CELL IMMUNOL, V158, P281, DOI 10.1006/cimm.1994.1276; THEVENIN C, 1991, J BIOL CHEM, V266, P9363; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WESTERMARCK J, 1994, CELL GROWTH DIFFER, V5, P1205; WU WS, 1992, ONCOGENE, V7, P2287; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; YOZA BK, 1992, CELL GROWTH DIFFER, V3, P677	56	38	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2301	2308						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649769				2022-12-28	WOS:A1996UQ22000006
J	Hu, YL; Bowtell, DDL				Hu, YL; Bowtell, DDL			Sos1 rapidly associates with Grb2 and is hypophosphorylated when complexed with the EGF receptor after EGF stimulation	ONCOGENE			English	Article						Sos; EGF receptor; Grb2; signal transduction	GUANINE-NUCLEOTIDE EXCHANGE; TYROSINE KINASES; RAS; PROTEIN; ACTIVATION; DOMAIN; BINDS; GENE; SH2	The Son of sevenless (Sos) protein, a guanine nucleotide exchange factor for ras proteins, appears to play a central role in signalling between protein tyrosine kinase receptors and ras. The C-terminal region of Sos binds an adaptor protein, Grb2, which in turn binds to activated receptors including the EGF receptor (EGFR). Although the Sos protein is rapidly phosphorylated following cytokine stimulation, there is no evidence that this alters the enzymatic activity of Sos for ras proteins. Therefore, we investigated whether the ability of Sos1 to form complexes with Grb2 and with the EGF receptor (EGFR) changes following EGF stimulation, as possible mechanism for regulating Sos activity. In contrast to earlier findings, we find that both the association and dissociation of Sos1 with Grb2 is responsive to EGF, Whilst the association of Sos1 and Grb2 following EGF stimulation is not cell type specific, we find that it is dependant on cell density and that the response to EGF differs to that induced by NGF. We find that following EGF stimulation, the Sos1 protein associated with the EGFR is markedly less phosphorylated than the majority of the Sos1 within the cell and there was reduced binding of Grb2 with phosphorylated Sos1 protein in a direct binding assay. A time course analysis showed that Sos1 dissociates from the EGFR more rapidly than does Grb2 following EGF stimulation. Collectively our findings are consistent with the notion that the phosphorylation of Sos1 affects its ability to complex with the EGFR and Grb2.	PETER MACCALLUM CANC INST, TRESCOWTHICK RES CTR, MELBOURNE, VIC 3000, AUSTRALIA; UNIV MELBOURNE, HOWARD FLOREY INST EXPTL PHYSIOL & MED, PARKVILLE, VIC 3052, AUSTRALIA	Peter Maccallum Cancer Center; Florey Institute of Neuroscience & Mental Health; University of Melbourne			Bowtell, David/H-1007-2016; Hu, Yinling/G-5682-2015	Bowtell, David/0000-0001-9089-7525; Hu, Yinling/0000-0002-4795-8537				ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHERNIACK AD, 1994, J BIOL CHEM, V269, P4717; CHERNIACK AD, 1995, J BIOL CHEM, V270, P1485, DOI 10.1074/jbc.270.4.1485; DEVRIESSMITS AMM, 1995, ONCOGENE, V10, P919; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GROSS E, 1992, NATURE, V360, P762, DOI 10.1038/360762a0; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LANGLOIS WJ, 1995, J BIOL CHEM, V270, P25320, DOI 10.1074/jbc.270.43.25320; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU BX, 1993, ONCOGENE, V8, P3081; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; RAABE T, 1995, EMBO J, V14, P2509, DOI 10.1002/j.1460-2075.1995.tb07248.x; RAVICHANDRAN KS, 1995, MOL CELL BIOL, V15, P593; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WATERS SB, 1995, MOL CELL BIOL, V15, P2791; WELHAM MJ, 1994, J BIOL CHEM, V269, P21165	32	27	27	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1865	1872						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649846				2022-12-28	WOS:A1996UK49800004
J	Sitzmann, J; NobenTrauth, K; Kamano, H; Klempnauer, KH				Sitzmann, J; NobenTrauth, K; Kamano, H; Klempnauer, KH			Expression of B-Myb during mouse embryogenesis	ONCOGENE			English	Article						B-myb; histone H4; mouse development; cell proliferation; spermatogenesis	C-MYB; A-MYB; HEMATOPOIETIC-CELLS; GENE; PROLIFERATION; TRANSCRIPTION; ACTIVATION; XENOPUS	B-myb is a member of the myb family of nuclear sequence-specific DNA-binding proteins which has been highly conserved among vertebrates. B-myb has been implicated in the control of cell proliferation, particularly at the G1/S transition of the cell cycle. So far, most of the work on B-myb has been performed in immortalized cell lines. Since these cells might show aberrant behavior of genes involved in proliferation control we have begun to investigate the role of B-myb in normal cells. As a first step, we have studied the expression of B-myb during mouse development. Here, we show the B-myb is expressed at similar levels during all stages of embryogenesis. In situ hybridization reveals a tight linkage between B-myb expression and proliferative activity (as assessed by the expression of the S-phase specific histone H4 gene) in most tissues and throughout embryonic development. However, B-myb and histone H4 expression are uncoupled during spermatogenesis in the adult mouse. Histone H4 is expressed at high levels in the early spermatogenic progenitor cells but not in successive stages of sperm cell development. By contrast, the highest levels of B-myb expression are found during the intermediate stages of spermatogenesis. Furthermore, we have found that B-myb mRNA isolated from the testis differs in size from that of other tissues. The data presented here strongly support the notion that B-myb plays a general role during proliferation of most cells. Furthermore, our results raise the possibility that the function of B-myb in cells undergoing meiosis may be different from its role in cells dividing mitotically.	MAX PLANCK INST IMMUNBIOL,HANS SPEMANN LAB,D-79108 FREIBURG,GERMANY	Max Planck Society								ARSURA M, 1992, BLOOD, V79, P2708; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; FOOS G, 1994, ONCOGENE, V9, P2481; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; GOLAY J, 1991, BLOOD, V77, P149; GOLAY J, 1994, ONCOGENE, V9, P2469; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; KAMANO H, 1996, ONCOGENE, V11, P2575; KLEMPNAUER KH, 1983, J VIROL, V48, P565, DOI 10.1128/JVI.48.3.565-572.1983; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1992, ONCOGENE, V7, P1185; LIN D, 1994, P NATL ACAD SCI USA, V91, P10079, DOI 10.1073/pnas.91.21.10079; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; METTUS RV, 1994, ONCOGENE, V9, P3077; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; OSLEY MA, 1991, ANNU REV BIOCHEM, V60, P827, DOI 10.1146/annurev.biochem.60.1.827; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SEILERTUYNS A, 1981, J MOL BIOL, V151, P607, DOI 10.1016/0022-2836(81)90426-5; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; Sitzmann J, 1995, ONCOGENE, V11, P2273; SITZMANN JH, 1993, J HISTOCHEM CYTOCHEM, V41, P773, DOI 10.1177/41.5.7682230; SITZMANN JH, 1995, BRIT J DERMATOL, V133, P241, DOI 10.1111/j.1365-2133.1995.tb02622.x; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WILKINSON DG, 1987, DEVELOPMENT, V99, P493	31	65	66	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1889	1894						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649849				2022-12-28	WOS:A1996UK49800007
J	Dolnikov, A; Ward, RL; Hawkins, NJ; Symonds, G				Dolnikov, A; Ward, RL; Hawkins, NJ; Symonds, G			Apoptosis in v-myc transformation of myelomonocytic cells and its modulation by CSF-1	ONCOGENE			English	Article						v-myc; apoptosis; CSF-1; transformation	C-MYC; ACTIVATES TRANSCRIPTION; PROTEIN; BCL-2; GENE; EXPRESSION; DEATH; LINE; INDUCTION; MAX	c-myc is a proto-oncogene essential for cell growth. When activated, its expression can lead to uncontrolled cell proliferation, transformation and tumorigenesis. The cell line tEMmyc4 is a murine myelomonocytic cell line that was established following transformation by v-myc. It has a high level of v-myc expression and constitutively expresses endogenous CSF-1, the monocytic growth and viability factor. Under growth restricting conditions (high cell density, serum deprivation, heat shock, or dexamethasone addition) cells of this line were found to undergo cell death through apoptosis. The induction of apoptosis by dexamethasone was associated with a decrease in constitutive CSF-1 expression without significant change in v-myc expression. Exogenous CSF-1 rescued these cells from dexamethasone induced-apoptosis. In vivo studies showed that tEMmyc4 cells were tumorigenic in syngeneic animals despite exhibiting some spontaneous apoptosis within the tumour mass. Co-administration of dexamethasone with the tumour cells significantly inhibited tumor development and the administration of dexamethasone to mice with established tumors resulted in tumor regression in all mice. This regression was associated with a high level of apoptosis and necrosis in the tumors. This study shows a correlation between the in vitro and in vivo induction of apoptosis and indicates that cancer cells bearing activated oncogenes may be more sensitive to apoptosis induction by chemotherapeutic agents.	ST VINCENTS HOSP, DEPT MED ONCOL, DARLINGHURST, NSW 2010, AUSTRALIA; ST VINCENTS HOSP, DEPT MED & HAEMATOL, DARLINGHURST, NSW 2010, AUSTRALIA; UNIV NEW S WALES, SCH PHYSIOL & PHARMACOL, SYDNEY, NSW 2052, AUSTRALIA; UNIV NEW S WALES, SCH PATHOL, SYDNEY, NSW 2052, AUSTRALIA	St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; University of New South Wales Sydney	Dolnikov, A (corresponding author), ST VINCENTS HOSP, DEPT CLIN PHARMACOL & TOXICOL, DARLINGHURST, NSW 2010, AUSTRALIA.		Hawkins, Nicholas J/A-8461-2008; Ward, Robyn L/I-2313-2013	Hawkins, Nicholas J/0000-0002-2204-3189; Ward, Robyn L/0000-0002-6877-8906				ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; ASKEW DS, 1991, ONCOGENE, V6, P1915; BAXTER JD, 1971, SCIENCE, V171, P189, DOI 10.1126/science.171.3967.189; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONHAM L, 1992, ONCOGENE, V7, P2219; BOURGEOIS S, 1977, CELL, V11, P423, DOI 10.1016/0092-8674(77)90060-5; BRADBURY D, 1992, BLOOD S1, V80, pA924; CHAMBERS SK, 1993, EXP HEMATOL, V21, P1328; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHISHOLM O, 1992, ONCOGENE, V7, P1827; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DAVIDOFF AN, 1993, EXP HEMATOL, V21, P922; DENG G, 1993, P NATL ACAD SCI USA, V90, P2189, DOI 10.1073/pnas.90.6.2189; DOLNIKOV A, 1995, INT J ONCOL, V6, P633; DOLNIKOV A, 1996, IN PRESS CANCER GENE; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FACCHINI LM, 1994, CELL GROWTH DIFFER, V5, P637; FUKASAWA Y, 1994, AM J PATHOL, V144, P480; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HOWLES KA, 1994, GENE DEV, V8, P1300; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LADNER MB, 1987, EMBO J, V6, P2693, DOI 10.1002/j.1460-2075.1987.tb02561.x; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; NORMAN MR, 1977, CANCER RES, V37, P3785; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SIBLEY CH, 1974, CELL, V2, P213, DOI 10.1016/0092-8674(74)90013-0; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STANLEY ER, 1977, J BIOL CHEM, V252, P4305; STAPLETON P, 1991, ONCOGENE, V6, P807; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991	49	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1189	1198						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649820				2022-12-28	WOS:A1996UC06700003
J	Goldberg, Y; Nassif, II; Pittas, A; Tsai, LL; Dynlacht, BD; Rigas, B; Shiff, SJ				Goldberg, Y; Nassif, II; Pittas, A; Tsai, LL; Dynlacht, BD; Rigas, B; Shiff, SJ			The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins	ONCOGENE			English	Article						NSAIDs; colon cancer; cyclin-dependent kinases; p21(WAF-1); cyclins; tumor suppressor proteins	SODIUM-BUTYRATE; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; P53 MUTATIONS; GENE; LINE; PHOSPHORYLATION; TRANSFORMATION; INDUCTION; POLYPOSIS	Nonsteroidal anti-inflammatory drugs lower the incidence of and mortality from colon cancer. Sulindac reduces the number and size of polyps in patients with. familial adenomatous polyposis. We have shown that sulindac and sulindac sulfide reversibly reduce the proliferation rate of HT-29 colon cancer cells, alter their morphology, induce them to accumulate in the G(0)/ G(1) phase of the cell cycle, and sulindac sulfide induces cell death by apoptosis. In this study we confirmed that sulindac and sulindac sulfide prevent HT-29 cells from progressing from the G(0)/G(1) into the S phase. This block in cell cycle progression is associated with an initial rise, then an abrupt decrease in the levels of p34(cdc2) protein. Sulindac and sulindac sulfide decrease the levels of mitotic cyclins, induce the levels of p21(WAF-1/cip1), and reduce the total levels of pRB, with a relative increase in the amount of the underphosphorylated form of pRB in a time- and concentration-dependent manner. In addition, these compounds reduce the levels of mutant p53. These responses are not associated with intestinal cell differentiation and occur independent of the ability of these compounds to induce apoptosis. We conclude that sulindac and sulindac sulfide reduce the levels of major components of the molecular cell cycle machinery and alter the levels of several tumor suppressor proteins in a manner consistent with cell cycle quiescence. These mechanisms may be operative in vivo to account, in part, for the anti-neoplastic effects of these compounds.	ROCKEFELLER UNIV HOSP,HUMAN BEHAV & METAB LAB,NEW YORK,NY 10021; CORNELL UNIV,COLL MED,DEPT MED,NEW YORK,NY 10021; HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Rockefeller University; Cornell University; Harvard University								CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1994, ONCOGENE, V9, P1767; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DUGGAN DE, 1980, DRUG METAB DISPOS, V8, P241; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FRITSCHE M, 1993, ONCOGENE, V8, P307; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GOPE R, 1993, CELL MOL BIOL, V39, P589; GOPE R, 1992, MOL CELL BIOCHEM, V110, P123, DOI 10.1007/BF02454189; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HALEVY O, 1990, SCIENCE, V250, P113, DOI 10.1126/science.2218501; HANIF R, 1995, GASTROENTEROLOGY, V108, pA478; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HERZ F, 1981, ARCH BIOCHEM BIOPHYS, V210, P581, DOI 10.1016/0003-9861(81)90224-1; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; INSEL P A, 1990, P638; JIANG HP, 1994, ONCOGENE, V9, P3397; JIANG HP, 1995, ONCOGENE, V10, P1855; KASTAN MB, 1991, CANCER RES, V51, P6304; KIM YS, 1980, CANCER-AM CANCER SOC, V45, P1185, DOI 10.1002/1097-0142(19800315)45:5+<1185::AID-CNCR2820451324>3.0.CO;2-W; LEVINE AJ, 1994, BRIT J CANCER, V69, P409, DOI 10.1038/bjc.1994.76; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAGANINHILL A, 1994, SEMIN SURG ONCOL, V10, P158, DOI 10.1002/ssu.2980100303; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PIAZZA GA, 1995, CANCER RES, V55, P3110; RAO CV, 1995, CANCER RES, V55, P1464; RAZVI ES, 1995, ADV VIRUS RES, V45, P1, DOI 10.1016/S0065-3527(08)60057-3; RIGAS B, 1993, J LAB CLIN MED, V122, P518; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SCHROY PC, 1994, J CELL PHYSIOL, V161, P111, DOI 10.1002/jcp.1041610114; SCHWALLER J, 1995, J CLIN INVEST, V95, P973, DOI 10.1172/JCI117806; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; SHIFF SJ, 1996, EXP CELL RES, V222; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TSAI LH, 1993, ONCOGENE, V8, P1593; TURNER D, 1993, CAN MED ASSOC J, V149, P595; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; WADDELL WR, 1983, J SURG ONCOL, V22, P197, DOI 10.1002/jso.2930220314; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG W, 1995, CANCER RES, V55, P668	62	181	186	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					893	901						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632912				2022-12-28	WOS:A1996TW68600021
J	Kurokawa, M; Tanaka, T; Tanaka, K; Ogawa, S; Mitani, K; Yazaki, Y; Hirai, H				Kurokawa, M; Tanaka, T; Tanaka, K; Ogawa, S; Mitani, K; Yazaki, Y; Hirai, H			Overexpression of the AML1 proto-oncoprotein in NIH3T3 cells leads to neoplastic transformation depending on the DNA-binding and transactivational potencies	ONCOGENE			English	Article						AML1; transformation; fibroblasts; DNA-binding; transactivational potencies	ACUTE MYELOID-LEUKEMIA; DROSOPHILA SEGMENTATION GENE; FUSION TRANSCRIPT; POLYOMAVIRUS ENHANCER; HEMATOPOIETIC-CELLS; ONCOGENIC ACTIVITY; NUCLEAR FACTOR; RUNT; EXPRESSION; RECEPTOR	The AML1 gene encodes DNA-binding proteins that contain the runt homology domain and is found at the breakpoints of t(8;21) and t(3;21) translocations associated with myelogenous leukemias. From the AML1 gene, two representative forms of proteins, AML1a and AML1b, are generated by alternative splicing. Both forms have the runt homology domain that possesses the DNA-binding ability but, unlike AML1b, AML1a lacks a putative transcriptional activation domain downstream of the runt homology domain. By using retroviral infection, we demonstrated that AML1b causes neoplastic transformation of NIH3T3 cells, AML1b-expressing cells form macroscopic colonies in soft agar and induce tumors in nude mice, indicating that AML1 can be a transforming gene when overexpressed in fibroblasts. Both the runt homology domain and the transactivational domain were required to transform NIH3T3 cells. By analysis of deletion mutants, it was shown that an element determining the transactivational potency exists between amino acids 288 and 396 within the region downstream of the runt homology domain. Furthermore, we demonstrated that this region was also required for fibroblast transformation, indicating that the transforming activity of AML1 is correlated with the transactivational potencies. These results suggest a role of AML1 in the regulation of cellular proliferation, as well as myeloid cell differentiation.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo			Tanaka, Tomoyuki U/A-4775-2008; Tanaka, Kozo/Y-6566-2018	Tanaka, Kozo/0000-0001-6086-2858				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAE SC, 1993, ONCOGENE, V8, P809; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAGA A, 1992, NATURE, V356, P484, DOI 10.1038/356484b0; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DUFFY JB, 1991, GENE DEV, V5, P2176, DOI 10.1101/gad.5.12a.2176; DUFFY JB, 1991, DEVELOPMENT, V113, P1223; EGAN SE, 1987, SCIENCE, V238, P202, DOI 10.1126/science.3659911; ERICKSON P, 1992, BLOOD, V80, P1825; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FURUKAWA K, 1990, CELL GROWTH DIFFER, V1, P135; GERGEN JP, 1988, GENE DEV, V2, P1179, DOI 10.1101/gad.2.9.1179; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P2090; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; KOZU T, 1993, BLOOD, V82, P1270; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LU J, 1995, MOL CELL BIOL, V15, P1651; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; SATAKE M, 1988, ONCOGENE, V3, P69; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; SETH A, 1989, P NATL ACAD SCI USA, V86, P7833, DOI 10.1073/pnas.86.20.7833; SETH A, 1990, ONCOGENE, V5, P1761; SUZOW J, 1993, MOL CELL BIOL, V13, P2141, DOI 10.1128/MCB.13.4.2141; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA K, 1995, BIOCHEM BIOPH RES CO, V211, P1023, DOI 10.1006/bbrc.1995.1913; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; TANAKA T, 1994, J BIOL CHEM, V269, P24020; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; ZHU XJ, 1994, MOL CELL BIOL, V14, P8051, DOI 10.1128/MCB.14.12.8051	54	59	60	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					883	892						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632911				2022-12-28	WOS:A1996TW68600020
J	Arbeit, JM; Olson, DC; Hanahan, D				Arbeit, JM; Olson, DC; Hanahan, D			Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice	ONCOGENE			English	Article						fibroblast growth factors; growth factor receptors; human papillomavirus; epidermal carcinogenesis	HUMAN PANCREATIC-CANCER; SQUAMOUS-CELL CARCINOMAS; HUMAN BREAST-CANCER; FACTOR EXPRESSION; FGF FAMILY; FACTOR-I; DIFFERENTIAL EXPRESSION; HUMAN PAPILLOMAVIRUS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS	Upregulation of acidic and factors (FGF-1 and -2), and FGFR-1 and -2, has been demonstrated in a variety of epithelial malignancies, However, the patterns of FGF/FGFR expression at specific stages of epithelial carcinogenesis have not been extensively characterized. In this report, the levels of FGF-1, FGF-2, FGF-7 mRNA and their receptors FGFR-1 and FGFR-2, were investigated during epidermal carcinogenesis in transgenic mice expressing the early region of the 'high risk' papillomavirus type 16 (HPV16) under control of the human keratin-14 enhancer/promoter (K14-HPV16 transgenic mice). FGF-1 was first upregulated in dysplasias, while FGF-2 was constitutively expressed in non-transgenic, neoplastic, and malignant keratinocytes throughout carcinogenesis. Expression of FGF-7 was undetectable in non-transgenic epidermis, and remained at threshold levels at all stages of progression. In well differentiated squamous cancers, FGFR-1 was upregulated and co-localized with angiogenic capillaries in the dermis underlying dysplastic lesions and within papillary fronds of invasive cancers. Tn contrast, FGFR-1 was upregulated specifically within the malignant squamous cells of moderate-poorly differentiated squamous cancers. The expression of FGFR-2 was essentially constitutive in both non-transgenic and neoplastic epidermis. Collectively the data suggest that the FGF/FGFR signaling pathways may potentially contribute to several facets of multi-stage epithelial carcinogenesis, including auto- or paracrine growth stimulation, upregulation of angiogenesis, and stromal remodeling.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Arbeit, JM (corresponding author), UNIV CALIF SAN FRANCISCO,HORMONE RES INST,503 PARNASSAS AVE,RM HSW 1090,SAN FRANCISCO,CA 94143, USA.		Arbeit, Jeffrey/K-6920-2019					ADNANE J, 1991, ONCOGENE, V6, P659; ARBEIT JM, 1994, J VIROL, V68, P4358, DOI 10.1128/JVI.68.7.4358-4368.1994; ARBEIT JM, 1996, CANC SURVEYS, V26, P1; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; Blasco MA, 1996, NAT GENET, V12, P200, DOI 10.1038/ng0296-200; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRICKARD K, 1994, GYNECOL ONCOL, V55, P277, DOI 10.1006/gyno.1994.1290; DIBLASIO AM, 1995, J STEROID BIOCHEM, V53, P375, DOI 10.1016/0960-0760(95)00082-B; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; HASEGAWA Y, 1994, BIOCHEM BIOPH RES CO, V200, P1435, DOI 10.1006/bbrc.1994.1611; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HOGAN B, 1994, MANIPULATING MOUSE E, P153; HUGHES CJ, 1994, AM J SURG, V168, P381, DOI 10.1016/S0002-9610(05)80080-7; Hurlin PJ, 1995, ONCOGENE, V11, P2487; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JACQUEMIER J, 1994, INT J CANCER, V59, P373, DOI 10.1002/ijc.2910590314; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; JAYSON GC, 1994, CANCER RES, V54, P5718; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KOBRIN MS, 1993, CANCER RES, V53, P4741; KULESZMARTIN M, 1985, CARCINOGENESIS, V6, P1245, DOI 10.1093/carcin/6.9.1245; LEUNG HY, 1994, INT J CANCER, V59, P667, DOI 10.1002/ijc.2910590515; LOWY DR, 1994, P NATL ACAD SCI USA, V91, P2436, DOI 10.1073/pnas.91.7.2436; LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256; MACIAG T, 1994, RECENT PROG HORM RES, V49, P105; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MORE JAW, 1991, DEVELOPMENT, V111, P741; MYOKEN Y, 1994, J ORAL PATHOL MED, V23, P451, DOI 10.1111/j.1600-0714.1994.tb00443.x; NAKAMOTO T, 1992, CANCER RES, V52, P571; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; PETERS KG, 1992, DEVELOPMENT, V114, P233; PEYRAT JP, 1992, J STEROID BIOCHEM, V43, P87, DOI 10.1016/0960-0760(92)90191-K; REED JA, 1994, AM J PATHOL, V144, P329; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; Sambrook J., 2002, MOL CLONING LAB MANU; SCHULTZHECTOR S, 1993, CANCER RES, V53, P1444; SINGH RK, 1994, AM J PATHOL, V145, P365; SLACK J, 1994, MOL REPROD DEV, V39, P118, DOI 10.1002/mrd.1080390118; SOUTTOU B, 1994, CELL GROWTH DIFFER, V5, P615; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; TAYLOR WR, 1993, EXP CELL RES, V204, P295, DOI 10.1006/excr.1993.1036; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAMAGUCHI TP, 1992, DEV BIOL, V152, P75, DOI 10.1016/0012-1606(92)90157-C; YAMANAKA Y, 1993, CANCER RES, V53, P5289; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513	62	57	61	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					1847	1857						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934530				2022-12-28	WOS:A1996VR79500003
J	Ribeiro, JCC; Hanley, JR; Russell, PJ				Ribeiro, JCC; Hanley, JR; Russell, PJ			Studies of X-irradiated bladder cancer cell lines showing differences in p53 status: Absence of a p53-dependent cell cycle checkpoint pathway	ONCOGENE			English	Article						p53; bladder cancer; cell lines; ionising irradiation; cell cycle; flow cytometry	WILD-TYPE P53; ATAXIA-TELANGIECTASIA CELLS; BRONCHIAL EPITHELIAL-CELLS; TUMOR-SUPPRESSOR GENE; KINASE INHIBITOR P21; DNA-DAMAGE; G(1) ARREST; NASOPHARYNGEAL CARCINOMA; P53-INDEPENDENT PATHWAY; IONIZING-RADIATION	Cell growth arrest is a common response to DNA damage by ionising irradiation and the p53 gene has been shown to play an important role in this mechanism, possibly in a tissue-specific manner. Mutations in the p53 gene are frequent in invasive bladder cancers, which are often treated by radiotherapy. In this paper we have investigated the growth response to X-irradiation of three bladder cancer cell lines with differing p53 status: UCRU-BL-17 overexpresses mutant p53, while UCRU-BL-13 and UCRU-BL-28 contain wt p53. We have also examined the expression of proteins reported to be part of the p53 control pathway in response to irradiation-induced DNA damage. No G1 arrest was detectable in any of the cell lines after ionising irradiation; furthermore, in a downstream event reported to be correlated with p53 function there was no increase in WAF-1 protein levels regardless of p53 status. Rather, ionising irradiation resulted in G2 arrest, but the extent of this was not related to p53 status. p16 levels were also not affected by irradiation, Our results suggest that the UCRU-BL-28 cell line may have a defect in the p53-cell control pathway upstream of p53, while UCRU-BL-13 cells may have a defect downstream between p53 and WAF-1.			Ribeiro, JCC (corresponding author), PRINCE WALES HOSP,ONCOL RES CTR,VILLA 1,HIGH ST,RANDWICK,NSW 2031,AUSTRALIA.		Russell, Pamela J/G-1685-2010; Russell, Pamela/O-8504-2019	Russell, Pamela J/0000-0002-3995-1239; 				AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bernhard E. J., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P602; CAAMANO J, 1991, AM J PATHOL, V139, P839; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; EBLEN ST, 1995, CANCER RES, V55, P1994; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESRIG D, 1993, AM J PATHOL, V143, P1389; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GIRINSKY T, 1995, CANCER RES, V55, P3726; GONG JP, 1993, CANCER RES, V53, P5096; GONG JP, 1994, CANCER RES, V54, P4285; GOZY M, 1993, INT J RADIAT ONCOL, V27, P83, DOI 10.1016/0360-3016(93)90424-T; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GRUIS NA, 1995, AM J PATHOL, V146, P1199; GUILLOUF C, 1995, ONCOGENE, V10, P2263; HAIN J, 1993, CANCER RES, V53, P1507; HARPER JW, 1993, CELL, V75, P805; JACKSON P, 1994, BIOCHEM BIOPH RES CO, V203, P133, DOI 10.1006/bbrc.1994.2159; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1993, ENVIRON HEALTH PERSP, V101, P55, DOI 10.2307/3431842; KASTAN MB, 1991, CANCER RES, V51, P6304; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAVIN MF, 1994, INT J RADIAT BIOL, V66, pS151; LI CY, 1995, ONCOGENE, V11, P1885; LI Y, 1994, ONCOGENE, V9, P2261; LICHTER AS, 1995, NEW ENGL J MED, V332, P371, DOI 10.1056/NEJM199502093320607; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MICHIELI P, 1994, CANCER RES, V54, P3391; MOLINARI M, 1995, ONCOGENE, V10, P1849; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NASRIN N, 1994, CANCER GENET CYTOGEN, V77, P14, DOI 10.1016/0165-4608(94)90142-2; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PAULES RS, 1995, CANCER RES, V55, P1763; PODUST N, 1995, CANCER RES, V34, P8869; PRICE BD, 1994, CANCER RES, V54, P896; REDDEL RR, 1988, CANCER RES, V48, P1904; RIBEIRO JC, 1994, J CELL BIOCHEM, V18, P196; RUSSELL PJ, 1988, INT J CANCER, V41, P74, DOI 10.1002/ijc.2910410115; RUSSELL PJ, 1989, INT J CANCER, V44, P276, DOI 10.1002/ijc.2910440216; RUSSELL PJ, 1993, J UROLOGY, V150, P1038, DOI 10.1016/S0022-5347(17)35682-3; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123; SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; SUN Y, 1993, P NATL ACAD SCI USA, V90, P2827, DOI 10.1073/pnas.90.7.2827; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WIMMEL A, 1994, ONCOGENE, V9, P995; YASUI W, 1993, INT J CANCER, V53, P36, DOI 10.1002/ijc.2910530108; ZHAN QM, 1994, CANCER RES, V54, P2755	62	6	6	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1269	1278						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808701				2022-12-28	WOS:A1996VJ20200018
J	Baasner, S; vonMelchner, H; Klenner, T; Hilgard, P; Beckers, T				Baasner, S; vonMelchner, H; Klenner, T; Hilgard, P; Beckers, T			Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase	ONCOGENE			English	Article						HER2/c-erbB2 receptor tyrosine kinase; tetracycline regulated gene expression; conditional mutant; nude mice xenotransplants; secreted human placental alkaline phosphatase	GROWTH-FACTOR-RECEPTOR; INDUCIBLE GENE-EXPRESSION; HIGHER EUKARYOTIC CELLS; MAMMALIAN-CELLS; NEU-ONCOGENE; TRANSGENIC MICE; REGULATED EXPRESSION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; HUMAN-BREAST	In the present study we describe the reversible transformation of NIH3T3 fibroblasts by overexpression of the HER2/c-erbB2 receptor tyrosine kinase. Cell lines expressing HER2 under control of a tetracycline-responsive promoter were isolated. Induction of HER2 expression resulted in cellular transformation in vitro as depicted by growth in soft agar and focus formation in tissue culture. Subsequent treatment of these cells with the effector anhydrotetracyline switched-off HER2 expression and induced morphological and functional changes characteristic for non-transformed cells. Subcutaneous transplantation of cells in nude mice resulted in the formation of solid tumors. Interestingly tumor formation was completely suppressed by treatment of the animals with anhydrotetracyline. Our findings indicate that overexpression of HER2 induces the transformed phenotype of NIH3T3 cells and is required for tumor formation and progression in nude mice. By linking the expression of the marker gene secreted placental alkaline phosphatase to the expression of HER2, a sensitive monitoring of tumor development in nude mice was feasible.	ASTA MED AG, DEPT CANC RES, D-60314 FRANKFURT, GERMANY; UNIV FRANKFURT, SCH MED, DEPT HEMATOL, LAB MOL HEMATOL, D-60596 FRANKFURT, GERMANY	Goethe University Frankfurt								ALIMANDI M, 1995, ONCOGENE, V10, P1813; Ausubel FM, 1988, MOL REPROD DEV; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BECKERS T, 1990, EUR J BIOCHEM, V189, P657, DOI 10.1111/j.1432-1033.1990.tb15534.x; BECKERS T, 1994, BIOTECHNIQUES, V16, P1074; BECKERS T, 1995, EUR J BIOCHEM, V231, P535, DOI 10.1111/j.1432-1033.1995.tb20729.x; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRANDTRAUF PW, 1994, CRIT REV ONCOGENESIS, V5, P313, DOI 10.1615/CritRevOncog.v5.i2-3.100; BRONSTEIN I, 1994, BIOTECHNIQUES, V17, P172; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DRUCKREY H, 1956, DRUG RES, V6, P539; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, NUCLEIC ACIDS RES, V21, P4411, DOI 10.1093/nar/21.18.4411; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; KIM HJ, 1995, J VIROL, V69, P2565, DOI 10.1128/JVI.69.4.2565-2573.1995; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LABOW MA, 1995, METHOD ENZYMOL, V254, P375; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; LONARDO F, 1990, New Biologist, V2, P992; PESCINI R, 1994, BIOCHEM BIOPH RES CO, V202, P1664, DOI 10.1006/bbrc.1994.2125; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RODER FT, 1994, MOL GEN GENET, V243, P32, DOI 10.1007/BF00283873; SCAHILL SJ, 1983, P NATL ACAD SCI-BIOL, V80, P4654, DOI 10.1073/pnas.80.15.4654; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCUDIERO DA, 1988, CANCER RES, V48, P4827; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WALKER AK, 1995, METHOD ENZYMOL, V254, P469; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; WIMMEL A, 1994, ONCOGENE, V9, P995; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yarranton Geoffrey T., 1992, Current Opinion in Biotechnology, V3, P506, DOI 10.1016/0958-1669(92)90078-W	56	35	39	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					901	911						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806679				2022-12-28	WOS:A1996VG76600003
J	Katoh, M; Hirai, M; Sugimura, T; Terada, M				Katoh, M; Hirai, M; Sugimura, T; Terada, M			Cloning, expression and chromosomal localization of Wnt-13, a novel member of the Wnt gene family	ONCOGENE			English	Article						Wnt gene family; human carcinogenesis; gastric cancer	RECEPTOR TYROSINE KINASE; TRANSGENIC MICE; MAMMARY CARCINOGENESIS; MOLECULAR-CLONING; SEQUENCE; INT-1; INT-2/FGF-3; ONCOGENE; WELL	The Wnt genes, encoding structurally-related secreted glycoproteins, are implicated in mammary carcinogenesis induced by mouse mammary tumor virus, In search of the Wnt gene(s) expressed in human gastric cancer, a WTGC1 cDNA fragment sharing 66.9% amino-acid homology with human and mouse Wnt-2 was isolated by degenerate polymerase chain reaction. The human gene corresponding to WTGC1 was designated as Wnt-13 and overlapping Wnt-13 cDNAs were cloned, Nucleotide sequence analysis indicated that the Wnt-13 gene encodes the protein of 372 amino acids, including a signal peptide, two potential N-glycosylation sites and 24 cystein residues highly conserved among members of the Wnt gene family, The Wnt-13 mRNA of 2.5 kb in size was detected in heart, brain, placenta, lung, prostate, testis, ovary, small intestine and colon of adult human and also in brain, lung and kidney of fetal human, Among various cancer cell lines, the Wnt-13 mRNA was detected in HeLa (cervical cancer), MKN28 and MKN74 (gastric cancer), The Wnt-13 gene has been mapped to human chromosome 1p13, These results suggest that the Wnt-13 gene may be involved in normal human development or differentiation as well as in human carcinogenesis.	NATL CANC CTR,RES INST,DIV GENET,CHUO KU,TOKYO 104,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT ANTHROPOL,BUNKYO KU,TOKYO 113,JAPAN	National Cancer Center - Japan; University of Tokyo								ADAMSON MC, 1994, GENOMICS, V24, P9, DOI 10.1006/geno.1994.1575; CLARK CC, 1993, GENOMICS, V18, P249, DOI 10.1006/geno.1993.1463; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; HUGUET EL, 1994, CANCER RES, V54, P2615; IOZZO RV, 1995, CANCER RES, V55, P3495; KATOH M, 1995, ONCOGENE, V10, P1447; KATOH M, 1992, P NATL ACAD SCI USA, V89, P2960, DOI 10.1073/pnas.89.7.2960; KATOH M, 1993, BIOCHEM BIOPH RES CO, V192, P1189, DOI 10.1006/bbrc.1993.1542; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; LEE FS, 1995, P NATL ACAD SCI USA, V92, P2268, DOI 10.1073/pnas.92.6.2268; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; NAKATANI H, 1990, JPN J CANCER RES, V81, P707, DOI 10.1111/j.1349-7006.1990.tb02631.x; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; ROELINK H, 1993, GENOMICS, V17, P790, DOI 10.1006/geno.1993.1412; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; WAINWRIGHT BJ, 1988, EMBO J, V7, P1743, DOI 10.1002/j.1460-2075.1988.tb03003.x; WOLDA SL, 1992, ONCOGENE, V7, P1941; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278	23	156	163	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					873	876						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761309				2022-12-28	WOS:A1996VD43300023
J	Meyers, S; Lenny, N; Sun, WH; Hiebert, SW				Meyers, S; Lenny, N; Sun, WH; Hiebert, SW			AML-2 is a potential target for transcriptional regulation by the t(8;21) and t(12;21) fusion proteins in acute leukemia	ONCOGENE			English	Article						AML-1; translocation; leukemia; transcription	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; RUNT DOMAIN; DNA-BINDING; GENE; EXPRESSION; IDENTIFICATION; CELLS; TRANSLOCATION; PROMOTER	AML-1B is targeted directly and indirectly in multiple chromosomal translocations in myeloid and B-cells. The AML-1/ETO and TEL/AML-1 fusion proteins, created by the t(8;21) and t(12;21) respectively, disrupt AML-1B-dependent transcription. Recently, two human members of the runt homology domain family of transcription factors have been identified, AML-2 and AML-3, which also regulate transcription through enhancer core motifs. If multiple factors regulate transcription through the same site, a dominant interfering protein may be required to promote leukemogenesis, rather than the inactivation of both AML1 alleles. To determine which AML family proteins are active in hematopoietic cells, we developed antisera specific to each family member for use in gel mobility shift assays. We have found that AML-1B is the major DNA binding activity in T-cell lines, while both AML-1B and AML-2 are expressed in myeloid and B-cell lines. AML-1B represents most of the active protein in the mouse thymus, whereas AML-1 and AML-2 are equally expressed in the mouse spleen. AML-3 is expressed at very low levels in a single myeloid cell line, 32D.3, and is the only core binding activity present in Buffalo rat liver cells. We demonstrate that AML-2-dependent transactivation mediated by enhancer core motifs is inhibited by the AML-1/ETO and TEL/AML-1 fusion proteins. This indicates that the t(8;21) and t(12;21) fusion proteins inhibit transcriptional activation by the AML-1 transcription factor family, and in so doing contributes to leukemogenesis.	ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN USA	St Jude Children's Research Hospital			Hiebert, Scott W/C-9979-2010		NATIONAL CANCER INSTITUTE [R01CA064140, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [5 P30 CA 21765, R01 CA-64140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAE SC, 1995, GENE, V159, P245, DOI 10.1016/0378-1119(95)00060-J; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Frank R, 1995, ONCOGENE, V11, P2667; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTTSCHALK LR, 1990, MOL CELL BIOL, V10, P5486, DOI 10.1128/MCB.10.10.5486; HIBERT SW, 1996, MOL CELL BIOL, V16, P1349; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1993, BLOOD, V81, P2728; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OGAWA E, 1993, VIROLOGY, V194, P314, DOI 10.1006/viro.1993.1262; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; ROMANA SP, 1995, BLOOD, V86, P4263, DOI 10.1182/blood.V86.11.4263.bloodjournal86114263; SATAKE M, 1995, MOL CELL BIOL, V15, P1662; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; TANAKA T, 1995, EMBO J, V14, P341, DOI 10.1002/j.1460-2075.1995.tb07008.x; WANG S, 1993, EMBO J, V13, P3324; WOTTON D, 1994, MOL CELL BIOL, V14, P840, DOI 10.1128/MCB.14.1.840; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085	38	118	120	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					303	312						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710369				2022-12-28	WOS:A1996VA25200009
J	Yasumoto, S; Kunimura, C; Kikuchi, K; Tahara, H; Ohji, H; Yamamoto, H; Ide, T; Utakoji, T				Yasumoto, S; Kunimura, C; Kikuchi, K; Tahara, H; Ohji, H; Yamamoto, H; Ide, T; Utakoji, T			Telomerase activity in normal human epithelial cells	ONCOGENE			English	Article						telomerase activity; normal human cells; epithelial cells	HUMAN-FIBROBLASTS; EPIDERMAL-CELLS; IMMORTAL CELLS; BURN WOUNDS; IN-VIVO; KERATINOCYTES; LYMPHOCYTES; TISSUES; RNA	Telomerase activity is found in most cancer tissues and many immortalized cell lines as well as in germ line cells but it is generally undetected in normal human somatic tissues. There is weak telomerase activity in some cell types of hematopoietic lineage in which a stem cell-like subpopulation may exist. Likewise, physiologically regenerating somatic tissues and organs such as skin, small intestine, and most other epithelia of the human body are supposed to contain similar cell lineages to maintain their renewal throughout the life span of individuals. It is therefore of interest whether telomerase activity is present in physiologically regenerating epithelial cells. Telomerase activity was detected, though very weakly, in cultured normal epidermal keratinocytes and at higher levels in a subpopulation that adhere rapidly on collagen IV-coated culture dishes. No telomerase activity was detected in a subpopulation that was less adherent on the coated dishes. The rapidly adherent subpopulation of keratinocytes was enriched in small proliferating cells with macrocolony forming potential. It was also passaged through more generations in culture, and expressed integrin beta 1 at higher levels than the less adherent subpopulation. Telomerase activity was similarly found in ectocervical keratinocytes as well as in simple endocervical epithelial cells. These findings provide the evidence of a telomerase-positive population among physiologically regenerating normal human epithelial cells. The identity of the telomerase-positive cells remains to be defined.	NISSHO COOPERAT,RES & DEV,KUSATU SHI,JAPAN; HIROSHIMA UNIV,SCH MED,DEPT CELLULAR & MOL BIOL,MINAMI KU,HIROSHIMA 734,JAPAN	Hiroshima University	Yasumoto, S (corresponding author), KANAGAWA CANC CTR,RES INST,MOL CELL BIOL LAB,ASAHI KU,54-2 NAKAO CHO,YOKOHAMA,KANAGAWA 241,JAPAN.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; BARRANDON Y, 1985, P NATL ACAD SCI USA, V82, P5390, DOI 10.1073/pnas.82.16.5390; CARTER WG, 1990, J CELL BIOL, V110, P1387, DOI 10.1083/jcb.110.4.1387; CHADENEAU C, 1995, ONCOGENE, V11, P893; COMPTON CC, 1989, LAB INVEST, V60, P600; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; GREEN H, 1988, NEWS PHYSIOL SCI, V3, P53; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASHIDA T, 1991, J GEN VIROL, V72, P1569, DOI 10.1099/0022-1317-72-7-1569; HIYAMA E, 1995, NAT MED, V1, P294; HIYAMA K, 1995, J NATL CANCER I, V87, P895, DOI 10.1093/jnci/87.12.895; HIYAMA K, 1995, J IMMUNOL, V155, P3711; JONES PH, 1995, CELL, V80, P83, DOI 10.1016/0092-8674(95)90453-0; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LEVY MZ, 1992, J MOL BIOL, V225, P114; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; NILSSON P, 1994, ONCOGENE, V9, P3043; Piatyszek Mieczyslaw A., 1995, Methods in Cell Science, V17, P1, DOI 10.1007/BF00981880; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; TAHARA H, 1995, CANCER RES, V55, P2734; Tahara H, 1995, CLIN CANCER RES, V1, P1245; TSUTSUMI K, 1993, AM J PATHOL, V143, P1150; YASUMOTO S, 1991, J VIROL, V65, P2000, DOI 10.1128/JVI.65.4.2000-2009.1991; YASUMOTO S, 1992, TISSUE CULT RES COMM, V11, P13; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	35	252	262	1	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					433	439						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710384				2022-12-28	WOS:A1996VA25200024
J	Berkowitz, EA; Hissong, MA; Lee, DC				Berkowitz, EA; Hissong, MA; Lee, DC			Transcriptional and post-transcriptional induction of the TGF alpha gene in transformed rat liver epithelial cells	ONCOGENE			English	Article						TGF alpha; transcription; DNase 1 hypersensitivity; mRNA stability	GROWTH-FACTOR-ALPHA; HUMAN PANCREATIC-CANCER; TRANSGENIC MICE; C-MYC; MESSENGER-RNA; HUMAN KERATINOCYTES; FACTOR RECEPTOR; PHORBOL ESTER; HEPATOCELLULAR-CARCINOMA; DEVELOPMENTAL EXPRESSION	Although TGF alpha mRNA and protein are frequently elevated in neoplastic cells, neither the level at which deregulation occurs nor the mechanism(s) responsible have been well characterized. As a first step, we examined the induction of TGF alpha mRNA in two series of clonally-derived rat liver epithelial cell lines that were transformed either by exposure to chemical carcinogen or stable transfection of activated Ha-ras. We found that steady-state levels of TGF alpha mRNA in both series of transformed lines were induced 25- to 50-fold over those in the respective normal parental cells. This induction, which occurred without amplification of the TGF alpha gene, was accompanied by at least a five- to 10-fold increase in transcription along the entire length of the gene with no evidence of a transcriptional attenuation or arrest mechanism in the normal cells. Analysis of the TGF alpha promoter and flanking regions did not support a correlation between the extent of methylation and the level of expression, but did reveal several DNase I hypersensitive sites spanning from -14 to +8 kilobases. Two of these sites were differentially observed in cells displaying high and low TGF alpha gene transcription, while a third site correlated with TPA-induced expression. Finally, measurement of TGF alpha mRNA decay in the presence of Actinomycin D revealed a consistent 1.5- to 3.2-fold increase in the half-life of the TGF alpha transcript in the various transformed cell lines. These results indicate that transformation-mediated induction of TGF alpha gene expression in rat liver epithelial cells occurs through both transcriptional and post-transcriptional mechanisms, but is primarily the result of TGF alpha promoter activation.	UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER; NCI NIH HHS [CA43793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BEDELL MA, 1995, GENE DEV, V9, P455, DOI 10.1101/gad.9.4.455; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BOCKMAN DE, 1992, GASTROENTEROLOGY, V103, P1883, DOI 10.1016/0016-5085(92)91448-D; CHEN XR, 1992, ONCOGENE, V7, P1805; CHEN XR, 1994, ONCOGENE, V9, P3179; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; DERYNCK R, 1987, CANCER RES, V47, P707; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; FILMUS J, 1993, ONCOGENE, V8, P1017; FINZI E, 1992, AM J PATHOL, V141, P643; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GODWIN AK, 1990, ONCOGENE, V5, P1231; GREWAL T, 1992, MOL CELL BIOL, V12, P2339, DOI 10.1128/MCB.12.5.2339; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALEY JD, 1991, J BIOL CHEM, V266, P1746; HALTER SA, 1992, AM J PATHOL, V140, P1131; HAMBURGER AW, 1993, P SOC EXP BIOL MED, V202, P64; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HU JM, 1992, CELL GROWTH DIFFER, V3, P577; HUBER BE, 1988, ONCOGENE, V3, P245; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JACK J, 1991, DEVELOPMENT, V113, P735; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; LAU JLT, 1988, J UROLOGY, V139, P170, DOI 10.1016/S0022-5347(17)42347-0; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE LW, 1991, CANCER RES, V51, P5238; LEE SW, 1991, J INVEST DERMATOL, V97, P106, DOI 10.1111/1523-1747.ep12478503; LIU C, 1988, CANCER RES, V48, P850; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; LYNCH MJ, 1993, CANCER RES, V53, P4041; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MURAKAMI H, 1993, CANCER RES, V53, P1719; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; NOVICKI DL, 1983, IN VITRO CELL DEV B, V19, P191; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RAYMOND VW, 1989, CANCER RES, V49, P3608; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAEKI T, 1991, MOL ENDOCRINOL, V5, P1955, DOI 10.1210/mend-5-12-1955; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; SOUTTOU B, 1994, CELL GROWTH DIFFER, V5, P615; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STROM SC, 1991, DIGEST DIS SCI, V36, P642, DOI 10.1007/BF01297033; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TAKAGI H, 1993, CANCER RES, V53, P4329; TANAKA S, 1991, AM J PATHOL, V139, P123; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TSAO MS, 1985, AM J PATHOL, V118, P306; TSAO MS, 1985, CANCER RES, V45, P5134; TWARDZIK DR, 1982, SCIENCE, V216, P894, DOI 10.1126/science.6177040; TWARDZIK DR, 1993, VIROLOGY, V124, P201; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YEH YC, 1987, CANCER RES, V47, P896	97	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1991	2002						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649860				2022-12-28	WOS:A1996UK49800018
J	Krane, IM; Leder, P				Krane, IM; Leder, P			NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice	ONCOGENE			English	Article						neu differentiation factor; heregulin; erbB; breast cancer	NEU ONCOGENE; TYROSINE KINASE; POINT MUTATION; TUMOR CELLS; LIGAND; PROTEIN; ACTIVATION; DIFFERENTIATION; GLYCOPROTEIN; ASSOCIATION	Neu differentiation factor (NDF), a member of the neuregulin family of ligands of erbB receptors, induces both differentiative and mitogenic effects on cultured human mammary epithelial cells, Since members of the epidermal growth factor receptor family, including Neu/erbB2, have been implicated in mammary carcinoma, we wished to know whether a potential ligand of this family, NDF, could induce such effects in the mammary gland in vivo, We therefore targeted expression of NDF to the mammary gland of transgenic mice using the mouse mammary tumor virus (MMTV) promoter in a fusion a clear, but subtle effect on adult virgin gland of female transgenic animals, Terminal end bud structures (TEBs), which normally disappear from the mammary gland at the age of similar to 8 weeks in wild type mice, persist in glands of virgin MMTV-NDF transgenic females, suggesting that NDF inhibits signals that normally lead to the terminal differentiation of these structures, Further, female mice, bred continuously to maximize expression of the transgene in the mammary gland,develop mammary adenocarcinomas at a median age of 12 months, Since these tumors arise in a solitary fashion, we infer that NDF is necessary, but not sufficient for their formation, In order to explore the signal transduction pathways potentially activated by NDF, we examined expression of the receptors erbB2, erbB3 and erbB4 in mammary epithelial cells established from induced tumor, All three receptors were though only the erbB3 receptor was phosphorylated, suggesting that overexpression of NDF might operate through this receptor, Additionally, about 50% of MMTV-NDF transgenic mice developed Harderian (lachrymal) gland hyperplasia, a benign tumor that does not progress to frank malignacy.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute								ALIMANDI M, 1995, ONCOGENE, V10, P1813; BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; CARDIFF RD, 1991, AM J PATHOL, V139, P495; CARRAWAY CAC, 1993, J BIOL CHEM, V268, P5582; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; Daniel CW, 1987, MAMMARY GLAND DEV RE; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Harlow E., 1988, ANTIBODIES LAB MANUA; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; KNIGHT CH, 1982, J REPROD FERTIL, V65, P521, DOI 10.1530/jrf.0.0650521; KRAUS MH, 1993, P NATL ACAD SCI USA, V90, P2900, DOI 10.1073/pnas.90.7.2900; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARIKOVSKY M, 1995, ONCOGENE, V10, P1403; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PELES E, 1991, EMBO J, V10, P2077, DOI 10.1002/j.1460-2075.1991.tb07739.x; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; RUSSO J, 1995, CANCER LETT, V90, P81, DOI 10.1016/0304-3835(94)03681-8; SAKAKURA T, 1976, SCIENCE, V194, P1439, DOI 10.1126/science.827022; Sambrook J., 2002, MOL CLONING LAB MANU; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056; STRANGE R, 1992, DEVELOPMENT, V115, P49; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WEN DZ, 1994, MOL CELL BIOL, V14, P1909, DOI 10.1128/MCB.14.3.1909; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	37	132	136	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 18	1996	12	8					1781	1788						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UG458	8622899				2022-12-28	WOS:A1996UG45800021
J	Han, DS; PottinClemenceau, C; Imro, MA; Scudeletti, M; Doucet, C; Puppo, F; BroutyBoye, D; Vedrenne, J; Sahraoui, Y; Brailly, H; Poggi, A; Jasmin, C; Azzarone, B; Indiveri, F				Han, DS; PottinClemenceau, C; Imro, MA; Scudeletti, M; Doucet, C; Puppo, F; BroutyBoye, D; Vedrenne, J; Sahraoui, Y; Brailly, H; Poggi, A; Jasmin, C; Azzarone, B; Indiveri, F			IL2 triggers a tumor progression process in a melanoma cell line MELP, derived from a patient whose metastasis increased in size during IL2/INF alpha biotherapy	ONCOGENE			English	Article						human melanomas; IL-2R; tumor progression	RECEPTOR GAMMA-CHAIN; INTERCELLULAR-ADHESION MOLECULE-1; COLONY-STIMULATING FACTOR; HIGH-DOSE INTERLEUKIN-2; FUNCTIONAL INTERLEUKIN-2; GROWTH INHIBITOR; EXPRESSION; FIBROBLASTS; P64	Human melanomas may express both in vivo and in vitro functional IL-Rs and may be expected to directly respond to injected IL2. This may generate biological situations which may be favourable for the patient, but also for tumor progression. Here, we analyse the latter hypothesis. MELP is a melanoma cell line derived from a patient whose metastasis increased in size during IL2 / IFN alpha. biotheraphy. These cells have been characterized in vitro for their phenotype and for their sensitivity to IL2. In vitro MELP cells express an IL2-R alpha(+)beta(+)gamma(-) phenotype and IL2 treatment induces the acquisition of new functional characteristics represented (i) by the increased surface expression of two markers of metastatic evolution (ICAM-1 and by the stable CD44); (ii) induction of the IL2-R gamma, with the appearance of functional IL2-R beta complex, which are also recognized by GM-CSF; (iii) by the inhibition of transcription of a regulatory cytokine such as IL6; (iv) by a differential effect of IL6 on CD44 surface expression in MELP cells treated or not with IL2 (MILG cells); (v) by the acquisition of faster growth rates and appearance of piling up and multilayer cellular organization; (vi) by the development of rapidly growing tumors in nude mice. IL2 induces in MELP cells a tumor progression process that could mimic the metastatic evolution observed in vivo during biotherapy. Therefore, MELP phenotype may help to define a subset of patients in which IL2 therapy may trigger unfavourable evolution.	HOP PAUL BROUSSE,INSERM,U268,F-94807 VILLEJUIF,FRANCE; UNIV GENOA,FAC MED,DIMI,I-16132 GENOA,ITALY; IMMUNOTECH SA,F-13288 MARSEILLE,FRANCE; SAN MARTINO HOSP,DEPT IMMUNOPATHOL ABC,I-16132 GENOA,ITALY	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Genoa; University of Genoa; IRCCS AOU San Martino IST			Indiveri, Francesco/AAE-9086-2020; Poggi, Alessandro/K-6664-2016; Azzarone, Bruno/AAH-9251-2019	Poggi, Alessandro/0000-0002-1860-430X; Azzarone, Bruno/0000-0002-5962-3849; Induveri, Francesco/0000-0002-9280-2232				ALILECHE A, 1993, ONCOGENE, V8, P1791; ALTOMONTE M, 1992, NEW ENGL J MED, V327, P959; BENVENISTE EN, 1986, NATURE, V321, P610, DOI 10.1038/321610a0; BIRCH M, 1991, CANCER RES, V51, P6660; BOSCO MC, 1994, BLOOD, V83, P2995, DOI 10.1182/blood.V83.10.2995.2995; BUCKLE AM, 1990, EUR J IMMUNOL, V20, P337, DOI 10.1002/eji.1830200216; BURTON JD, 1994, P NATL ACAD SCI USA, V91, P4935, DOI 10.1073/pnas.91.11.4935; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FRASIERSCOTT K, 1988, J CLIN INVEST, V82, P1877, DOI 10.1172/JCI113805; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GREEN JE, 1989, MOL CELL BIOL, V9, P4731, DOI 10.1128/MCB.9.11.4731; HERLYN M, 1990, CLIN EXP METASTAS, V8, P9; JOHNSON JP, 1989, P NATL ACAD SCI USA, V86, P641, DOI 10.1073/pnas.86.2.641; KANAKURA Y, 1993, CANCER RES, V53, P675; LU C, 1992, P NATL ACAD SCI USA, V89, P9215, DOI 10.1073/pnas.89.19.9215; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; MORIMOTO K, 1994, BLOOD, V83, P657; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; PLAISANCE S, 1992, INT IMMUNOL, V4, P739, DOI 10.1093/intimm/4.7.739; PLAISANCE S, 1993, INT IMMUNOL, V5, P843; PLAISANCE S, 1993, INT J CANCER, V55, P164, DOI 10.1002/ijc.2910550129; RIMOLDI D, 1993, ANTICANCER RES, V13, P555; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1989, ANN SURG, V210, P474, DOI 10.1097/00000658-198910000-00008; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SINGH RK, 1994, CANCER RES, V54, P3242; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; VOSS SD, 1993, P NATL ACAD SCI USA, V90, P2428, DOI 10.1073/pnas.90.6.2428; WALDMANN TA, 1993, IMMUNOL TODAY, V14, P264, DOI 10.1016/0167-5699(93)90043-K; WEIDMANN E, 1992, CANCER RES, V52, P5963	31	22	22	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1015	1023						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649792				2022-12-28	WOS:A1996UA88400009
J	Matsuda, S; Nakanishi, H; Sasaki, T; Takai, Y				Matsuda, S; Nakanishi, H; Sasaki, T; Takai, Y			A membrane-associated GDP/GTP exchange protein specific for Rho small GTP-binding protein - Partial purification and characterization from rat brain	ONCOGENE			English	Article						small G protein; Rho; mRho GEP; Rho GDI; dbl	SWISS 3T3 CELLS; ADP-RIBOSYLATION; CLOSTRIDIUM-BOTULINUM; REGULATORY PROTEIN; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; ONCOGENE PRODUCT; DBL ONCOGENE; SMG P21S; GDP	The Rho subfamily, consisting of three members (RhoA, -B and -C), belongs to the small GTP-binding protein superfamily. The Rho subfamily is implicated in regulation of various actin filament-dependent cell functions, such as cell aggregation, cell motility and cytokinesis. The Rho subfamily receives an upstream signal and is converted from the GDP-bound inactive form to the GTP-bound active form which transduces a signal to a downstream pathway. This conversion is regulated by GDP/GTP exchange proteins (GEPs) and several GEPs for the Rho subfamily have been identified. The GEPs thus far reported are mainly isolated from the cytosol fraction of various tissues and are not specific for the Rho subfamily. Here we have partially purified a membrane-associated GEP specific for the Rho subfamily (mRho GEP). mRho GEP was extracted from the crude synaptic membrane fraction of rat brain by a combination of detergent and NaCl, and partially purified by several column chromatographies. The partially purified mRho GEP was active on RhoA but was inactive on other small GTP-binding proteins including at least Rad, Ki-Ras and Rab3A. RhoA undergoes post-translational lipid modifications and mRho GEP required these lipid modifications for its GEP activity. mRho GEP was not active in the presence of Rho GDI, an inhibitory Rho GEP. These results indicate that there is a membrane-associated GEP specific for Rho and suggest that Rho is activated by this GEP on the membranes.	OSAKA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,SUITA,OSAKA 565,JAPAN; NATL INST PHYSIOL SCI,DEPT CELL PHYSIOL,OKAZAKI,AICHI 444,JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)				Nakanishi, Hiroyuki/0000-0002-9765-0266				BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GRAZIANI G, 1989, ONCOGENE, V4, P823; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIRATA K, 1992, J BIOL CHEM, V267, P8719; HORI Y, 1991, ONCOGENE, V6, P515; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; ISOMURA M, 1991, ONCOGENE, V6, P119; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; KAIBUCHI K, 1991, MOL CELL BIOL, V11, P2873, DOI 10.1128/MCB.11.5.2873; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KIKUCHI A, 1992, ONCOGENE, V7, P289; KIKUCHI A, 1995, METHOD ENZYMOL, V257, P57; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; LANG P, 1992, J BIOL CHEM, V267, P11677; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIURA Y, 1993, J BIOL CHEM, V268, P510; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MORII N, 1992, J BIOL CHEM, V267, P20921; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; NONAKA H, 1995, IN PRESS EMBO J; NORMAN JC, 1994, J CELL BIOL, V126, P1005, DOI 10.1083/jcb.126.4.1005; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SELF AJ, 1993, ONCOGENE, V8, P655; SHIMIZU K, 1991, BIOCHEM BIOPH RES CO, V175, P199, DOI 10.1016/S0006-291X(05)81220-3; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; STASIA MJ, 1991, BIOCHEM BIOPH RES CO, V180, P615, DOI 10.1016/S0006-291X(05)81110-6; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKAISHI K, 1995, ONCOGENE, V11, P39; TANAKA K, 1995, METHOD ENZYMOL, V256, P41; TOKSOZ D, 1994, ONCOGENE, V9, P621; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHANG J, 1993, J BIOL CHEM, V268, P22251; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	60	3	3	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					915	920						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632914				2022-12-28	WOS:A1996TW68600023
J	Shaw, P; Freeman, J; Bovey, R; Iggo, R				Shaw, P; Freeman, J; Bovey, R; Iggo, R			Regulation of specific DNA binding by p53: Evidence for a role for O-glycosylation and charged residues at the carboxy-terminus	ONCOGENE			English	Article						p53; transcription factor; DNA binding; PAb421; O-glycosylation; peptides	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CASEIN KINASE-II; MONOCLONAL-ANTIBODIES; TRANSCRIPTION FACTOR; PHOSPHORYLATION; EXPRESSION; FORMS; CELLS; SITE	The carboxy-terminus of p53 contains a basic region which represses DNA binding, and this repression can be relieved by PAb421, an antibody against the basic region. The EB-1 human cell line contains wild type p53 protein which fails to express the PAb421 epitope and is highly active both in biological assays and in DNA binding assays. We show by wheat germ agglutinin chromatography and galactosyl-transferase labelling that this p53 is O-glycosylated, and that at least one of the sugar residues masks the PAb421 epitope, as demonstrated by recovery of reactivity with PAb421 after digestion of Western blots of EB-1 cell extract with hexosaminidase. A minor population of p53 molecules in EB-1 cells lacks the modification, and there is a correlation between the ability to bind DNA with high affinity and masking of the PAb421 epitope. We also show that strongly positively charged peptides, including short peptides from the basic region of p53, can derepress DNA binding, probably by disruption of an intramolecular interaction involving the basic region. We propose that any intervention which prevents this intramolecular interaction, including addition of bulky residues such as sugar groups, can activate DNA binding by p53.	INST PATHOL, DIV EXPTL ONCOL, CH-1011 LAUSANNE, SWITZERLAND		Shaw, P (corresponding author), SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND.		Iggo, Richard/G-3546-2014					ABARZUA P, 1995, CANCER RES, V55, P3490; ANDERSON ME, 1995, BIOESSAYS, V17, P3, DOI 10.1002/bies.950170103; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FISCELLA M, 1994, ONCOGENE, V9, P3249; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLT GD, 1987, J BIOL CHEM, V262, P14847; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACOB GS, 1994, METHOD ENZYMOL, V230, P280; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MAYR GA, 1995, CANCER RES, V55, P2410; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MERCER WE, 1984, MOL CELL BIOL, V4, P276, DOI 10.1128/MCB.4.2.276; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1984, NATURE, V310, P143, DOI 10.1038/310143a0; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOMMER L, 1991, CELL, V67, P987, DOI 10.1016/0092-8674(91)90371-5; SOUSSI T, 1990, ONCOGENE, V5, P945; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; TARUNINA M, 1993, ONCOGENE, V8, P3165; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WU Y, 1994, EMBO J, V13, P4823, DOI 10.1002/j.1460-2075.1994.tb06808.x; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	62	199	207	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	1996	12	4					921	930						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632915				2022-12-28	WOS:A1996TW68600024
J	Wang, L; Li, WD; Wang, XQ; Zhang, CL; Zhang, T; Mao, XZ; Wu, M				Wang, L; Li, WD; Wang, XQ; Zhang, CL; Zhang, T; Mao, XZ; Wu, M			Genetic alterations on chromosomes 3 and 9 of esophageal cancer tissues from China	ONCOGENE			English	Article						tumor suppressor genes; esophageal cancer; loss of heterozygosity; microsatellite; genetic instability	SQUAMOUS-CELL CARCINOMA; HETEROZYGOSITY; ADENOCARCINOMA; HOMOLOG; LUNG	In previous studies, we had demonstrated that allelic losses in esophageal cancer (EC) tissues are frequently involved in chromosomes 3 and 9 acid that EC patients and their blood relatives have low capacity to repair damaged DNA and showed genetic instability. To better define the deleted chromosomal loci and understand the genetic instability in EC tissues, we selected 12 microsatellite markers (D3S1232, D3S1238, D3S1289, D3S1480, D3S647, D3S966, D3S1317, D3S659, D9S156, D9S171, D9S176 and GSN) to examine 36 paired EC tissues for loss of heterozygosity (LOH) and microsatellite instability (MIN) on chromosomes 3 and 9. The frequent LOH was found at D9S156(9p21), D3S647(3p23) and D3S1480(3p14.2), implying the possible existence of tumor suppressor genes near the deleted loci. Higher LOH incidence at D9S156 (9/18) and D3S1480 (8/19) was observed in EC tissues from Beijing, a low EC area. More frequent LOH at D3S647 (6/14) was found in EC tissues from Yangquan, a high EC area, This geographic difference of LOH occurrence was indicative of genetic heterogeneity in the etiology of EC. 24 of 36 (66.7%) EC tissues showed MIN at one or more chromosomal loci. The putative EC suppressor genes on chromosomes 3 and 9 and the molecular basis of the genetic instability associated with EC remain to be elucidated.	CHINESE ACAD MED SCI,INST CANC,NATL LAB MOLEC ONCOL,BEIJING 100021,PEOPLES R CHINA; BEIJING UNION MED COLL,BEIJING 100021,PEOPLES R CHINA; CANC INST HOSP,YANGQUAN,SHANXI,PEOPLES R CHINA	Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College				Li, Wei-Dong/0000-0003-0521-7412				ALLTONEN LA, 1993, SCIENCE, V260, P177; AOLI T, 1994, GENES CHROMOSOM CANC, V10, P177; BOYNTON RF, 1991, CANCER RES, V51, P5766; BOYNTON RF, 1992, P NATL ACAD SCI USA, V89, P3385, DOI 10.1073/pnas.89.8.3385; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAIRNS P, 1994, SCIENCE, V265, P415, DOI 10.1126/science.8023167; CARTER CL, 1992, J NATL CANCER I, V84, P771, DOI 10.1093/jnci/84.10.771; CHENG JQ, 1994, CANCER RES, V54, P5547; COLEMAN A, 1994, CANCER RES, V54, P344; DIAZ MO, 1990, NEW ENGL J MED, V322, P77, DOI 10.1056/NEJM199001113220202; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GIANI C, 1994, CANCER RES, V54, P6338; HU N, 1992, INT J EPIDEMIOL, V21, P877, DOI 10.1093/ije/21.5.877; HUANG DP, 1994, CANCER RES, V54, P4003; HUANG Y, 1992, CANCER RES, V52, P6525; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P236; KEEN AJ, 1994, ONCOGENE, V9, P2083; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Li J Y, 1982, Natl Cancer Inst Monogr, V62, P113; LI WB, 1994, PROG NATURAL SCI, V5, P602; LOEB LA, 1994, CANCER RES, V54, P5059; LUBINSKI J, 1994, CANCER RES, V54, P3710; MELTZER SJ, 1994, CANCER RES, V54, P3379; MERLO A, 1994, CANCER RES, V54, P640; MITRA S, 1993, PROG NUCLEIC ACID RE, V44, P109, DOI 10.1016/S0079-6603(08)60218-4; MORI T, 1994, CANCER RES, V54, P3396; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OGASAWARA S, 1995, CANCER RES, V55, P891; OLOPADE OL, 1994, CANCER RES, V54, P5547; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Sambrook J, 1989, MOL CLONING LABORATO; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; SPRUCK CH, 1994, NATURE, V370, P183, DOI 10.1038/370183a0; Su Y A, 1988, Proc Chin Acad Med Sci Peking Union Med Coll, V3, P84; TARMIN L, 1994, CANCER RES, V54, P6094; TSUCHIYA E, 1992, CANCER RES, V52, P2478; VANDERRIET P, 1994, CANCER RES, V54, P1156; WANGPENG J, 1990, CANCER GENET CYTOGEN, V45, P101; Weber J, 1989, AM J HUM GENET, V44, P338; WU DF, 1988, NATL MED J CHINA, V68, P128; WU M, 1989, GENETIC EPIDEMIOLOGY, P188; YANG CS, 1980, CANCER RES, V40, P2633; YOKOYAMA S, 1992, CANCER RES, V52, P873; ZHU D, 1994, CHINESE J MED GENET, V11, P354	47	31	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					699	703						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637728				2022-12-28	WOS:A1996TV59700028
J	Furuhata, T; Tokino, T; Urano, T; Nakamura, Y				Furuhata, T; Tokino, T; Urano, T; Nakamura, Y			Isolation of a novel GPI-anchored gene specifically regulated by p53; Correlation between its expression and anti-cancer drug sensitivity	ONCOGENE			English	Article						p53; GPI-anchored protein; anti-cancer drug; esophageal cancer	CELL-GROWTH; PROTEIN; SUPPRESSION; INHIBITOR; KINASES; THB; P21; DNA	We have identified a novel gene inducible by wild-type p53. A significant correlation between expression of this gene and p53 status in cells derived from esophageal cancers indicated that this gene is likely to be specifically regulated in a p53-dependent manner. As the predicted amino acid sequence showed a high degree of homology to the family of glycosyl-phosphatidylinositol (GPI)-anchored membrane proteins, we termed this gene GML (GPI-anchored molecule-like protein). Introduction of GML cDNA suppressed the growth of esophageal cancer cells in culture. A correlation between the presence of GML expression and the sensitivity of esophageal cancer cells to anti-cancer drugs implied that the gene product plays a significant role in the apoptotic pathway or cell-cycle regulation induced by p53 after DNA damage.	UNIV TOKYO, INST MED SCI, MOL MED LAB, TOKYO, JAPAN	University of Tokyo			Tokino, Takashi/AAI-9887-2021; Urano, Tomohiko/AFS-9574-2022					BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BRAKENHOFF RH, 1995, J CELL BIOL, V129, P1677, DOI 10.1083/jcb.129.6.1677; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GUMLEY TP, 1992, J IMMUNOL, V149, P2615; HARPER JW, 1993, CELL, V75, P805; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MIYASHITA T, 1995, CELL, V80, P293; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; ROCK KL, 1989, IMMUNOL REV, V111, P195, DOI 10.1111/j.1600-065X.1989.tb00547.x; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; TOKINO T, 1991, AM J HUM GENET, V48, P258; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	21	52	53	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1965	1970						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934543				2022-12-28	WOS:A1996VR79500016
J	Chen, JH; Vercamer, C; Li, ZL; Paulin, D; Vandenbunder, B; Stehelin, D				Chen, JH; Vercamer, C; Li, ZL; Paulin, D; Vandenbunder, B; Stehelin, D			PEA3 transactivates vimentin promoter in mammary epithelial and tumor cells	ONCOGENE			English	Article						PEA3; vimentin; promoter; mammary tumor	ETS-RELATED PROTEIN; DIFFERENTIAL DISPLAY; TRANSCRIPTION FACTOR; METASTATIC DISEASE; BREAST CARCINOMAS; MOLECULAR-CLONING; MOUSE EMBRYO; EXPRESSION; GENE; ONCOGENE	We have used differential display RT-PCR method to detect the genes specifically activated or repressed between mammary tumor and normal mammary epithelial cells, One of the genes identified is vimentin, The vimentin gene is abundantly expressed in both human and mouse mammary tumor cells and its expression decreased dramatically in normal mammary epithelial cells. The expression of vimentin gene correlates with the expression of transcription factor PEA3, Since the promoters of human and mouse vimentin genes contain one PEA3 binding site we investigated the ability of PEA3 to transactivate the vimentin promoter in mouse mammary epithelial cell CLS1, mouse mammary tumor MMT and human mammary tumor cell lines MCF7 and MDA231, Our results suggest that PEA3 specifically transactivates vimentin promoter through PEA3 site, Among members of the ETS transcription factor family only Erg showed ability to transactivate vimentin promoter besides PEA3, Our results also suggest that NFkB site on the vimentin promoter may act as positive regulatory element for the transcription of vimentin, In metastatic mammary tumors derived from mice carrying the polyoma middle T or neu transgene, PEA3 is overexpressed and vimentin has been shown to play a key role in the motility of cells, Our results suggest that one of the roles of PEA3 in mammary tumor is to participate the activation of vimentin gene whose gene product in turn contributes to the metastatic potential of mammary tumors.	TZU CHI COLL MED,INST MED RES,HUALIEN,TAIWAN; UNIV PARIS 07,F-75005 PARIS 15,FRANCE; INST PASTEUR,SERV CENT MICROSCOPIE ELECT,F-75005 PARIS 15,FRANCE	Tzu Chi University; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Chen, JH (corresponding author), INST PASTEUR,CNRS URA 1160,UNITE ONCOL MOL,F-59019 LILLE,FRANCE.		Li, Zhenlin/E-3937-2016	LI, Zhenlin/0000-0002-3706-4505				BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; BUTTICE G, 1993, J BIOL CHEM, V268, P7196; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1993, ONCOGENE, V8, P3375; COCHARD P, 1984, J NEUROSCI, V4, P2080; COCUCCIGUYON E, 1994, CELL, V79, P679; Crepieux Pascale, 1993, Gene Expression, V3, P215; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DOMAGALA W, 1990, AM J PATHOL, V136, P219; DOMAGALA W, 1990, AM J PATHOL, V137, P1059; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUERST D O, 1989, Journal of Cell Biology, V109, P517; GOULD VE, 1990, AM J PATHOL, V137, P1143; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; HIGASHINO F, 1995, ONCOGENE, V10, P1461; LANE EB, 1983, NATURE, V303, P701, DOI 10.1038/303701a0; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; LILIENBAUM A, 1993, J BIOL CHEM, V268, P2180; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MARCHIONI M, 1993, MOL CELL BIOL, V13, P7399; MONTE D, 1994, ONCOGENE, V9, P1397; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; RAYMOND WA, 1989, J PATHOL, V158, P107, DOI 10.1002/path.1711580205; RITTLING SR, 1987, MOL CELL BIOL, V7, P3908, DOI 10.1128/MCB.7.11.3908; SALVETTI A, 1993, MOL CELL BIOL, V13, P89, DOI 10.1128/MCB.13.1.89; SCOTT GK, 1994, J BIOL CHEM, V269, P19848; SOMMERS CL, 1994, CELL GROWTH DIFFER, V5, P839; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; STEINERT PM, 1990, CELL, V60, P521, DOI 10.1016/0092-8674(90)90651-T; STOVER DM, 1994, CANCER RES, V54, P3092; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; WASYLYKS B, 1993, NATURE, V234, P191; WERNERT N, 1994, CANCER RES, V54, P5683; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YONGANATHAN T, 1992, EUR J BIOCHEM, V207, P195; ZAPORI D, 1990, CANCER J, V3, P164	44	50	52	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1667	1675						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895512				2022-12-28	WOS:A1996VM88700011
J	Chen, Y; Knudsen, ES; Wang, JYJ				Chen, Y; Knudsen, ES; Wang, JYJ			The RB/p107/p130 phosphorylation pathway is not inhibited in rapamycin-induced G(1)-prolongation of NIH3T3 cells	ONCOGENE			English	Article						cdk2; cyclin A; cyclin E; p27(kip1)	ABL TYROSINE KINASE; HUMAN CYCLIN-E; S-PHASE ENTRY; RETINOBLASTOMA PROTEIN; MAMMALIAN FIBROBLASTS; GROWTH SUPPRESSION; TGF-BETA; EXPRESSION; G(1); ARREST	The immunosuppressant rapamycin has previously been shown to inhibit G(1)/S transition in several cell types. In Swiss-3T3 cells, rapamycin prolongs G(1) through the inhibition of the S6-kinase. In T-lymphocytes, rapamycin blocks the mitogen-induced down regulation of p27(Kip1), an inhibitor of the cdk/cyclin complexes. We show here that an NIH3T3 line (N-3T3) is also sensitive to the G(1)/S inhibitory effect of rapamycin. Unlike lymphocytes, rapamycin does not affect p27(Kip1) in these immortalized fibroblasts, nor does rapamycin affect the activity of cyclin D- or cyclin E-dependent kinases. As a result, rapamycin does not inhibit the phosphorylation of the retinoblastoma protein (RB) or two RB-related proteins, p107 and p130. Despite the phosphorylation of RB/p107/p130, the expression of cyclin A and its associated kinase activity is delayed in rapamycin-treated N-3T3 cells. Ectopic expression of cyclin A, but not cyclins D and E or E2F-1 and -4, can overcome the effect of rapamycin. Taken together, these results suggest that entry into S-phase is likely to involve rapamycin-sensitive pathways other than the phosphorylation of the pocket proteins.	UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,CTR GENET MOL,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320, CA58320, CA5028] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DOU QP, 1993, CANCER RES, V53, P1493; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; MORICE WG, 1993, J BIOL CHEM, V268, P22737; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NAKAMURA T, 1995, EXP CELL RES, V216, P422, DOI 10.1006/excr.1995.1053; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pines Jonathon, 1994, Seminars in Cell Biology, V5, P399, DOI 10.1006/scel.1994.1047; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1995, GENE DEV, V9, P31, DOI 10.1101/gad.9.1.31; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	47	16	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1765	1771						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895523				2022-12-28	WOS:A1996VM88700022
J	McConkey, DJ; Goodrich, D; Bucana, C; Klostergaard, J				McConkey, DJ; Goodrich, D; Bucana, C; Klostergaard, J			The human retinoblastoma gene product suppresses ceramide-induced apoptosis in human bladder tumor cells	ONCOGENE			English	Article						Rb; N-hexanoyl-D-sphingosine; DNA fragmentation; bladder carcinoma	ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; SIGNALING PATHWAY; CARCINOMA-CELLS; HL-60 CELLS; BCL-2; DIFFERENTIATION; INACTIVATION; EXPRESSION; MECHANISM	The retinoblastoma gene product, Rb, has previously been implicated as an obligatory component in the antiproliferative effects mediated by the lipid second messenger, ceramide. We have evaluated both the apoptotic effects and the effects on cell cycle distribution of the exogenous cell-permeable ceramide, N-hexanoyl-D-sphingosine, in an Rb-null human bladder tumor cell line, 5637, as well as in retrovirally infected, Rb(+) clones derived therefrom. These cell lines demonstrated comparable sensitivity to N-hexanoyl-D-sphingosine in a neutral red dye uptake assay. Exposure of the Rb-null parental cell line to 20 mu M N-hexanoyl-D-sphingosine for 24 h resulted in a classical pattern of DNA fragmentation that was accompanied by apoptotic nuclear morphological alterations, In contrast, the Rb(+) clones demonstrated suppression of DNA fragmentation in response to N-hexanoyl-D-sphingosine. Similarly, the frequency and degree of alteration of nuclear morphology in Rb(+) cells was also suppressed, Flow cytometric analysis of the parental and infected clones indicated that expression of Rb was without effect on their cell cycle distribution, with or without exposure to N-hexanoyl-D-sphingosine for 25 h; tunel assay confirmed that in this time frame apoptotic cells were far less frequent in the Rb(+) clones than in the parental 5637 cells, Human tumor cell lines derived from three other histological origins, breast and prostatic carcinomas and osteogenic sarcoma, also demonstrated very similar cytotoxic sensitivities to N-hexanoyl-D-sphingosine, irrespective of the expression of Rb, We conclude that Rb is not required for ceramide-induced apoptosis and that Rb can actually inhibit the DNA fragmentation and nuclear morphological changes associated with classical apoptosis.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT TUMOR BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	McConkey, DJ (corresponding author), UNIV TEXAS,MD ANDERSON CANC CTR,DEPT CELL BIOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030, USA.							BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chang Y, 1995, P NATL ACAD SCI USA, V92, P12275, DOI 10.1073/pnas.92.26.12275; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FERNANDEZ A, 1995, ONCOGENE, V10, P769; GILL BM, 1994, IMMUNOL REV, V142, P114; GOODRICH DW, 1992, CANCER RES, V52, P1968; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAUSER JML, 1994, J BIOL CHEM, V269, P6803; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jarvis WD, 1996, CLIN CANCER RES, V2, P1; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JAYADEV S, 1994, CMB, V1, P289; JOHNSTON DA, 1978, COMPUT BIOMED RES, V11, P393, DOI 10.1016/0010-4809(78)90020-4; JOSEPH CK, 1993, J BIOL CHEM, V268, P20002; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; KIM MY, 1991, J BIOL CHEM, V266, P484; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LIU J, 1994, J BIOL CHEM, V269, P3047; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MULLER HK, 1994, CELL IMMUNOL, V157, P263, DOI 10.1006/cimm.1994.1221; NEAMATI N, 1995, J IMMUNOL, V154, P3788; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBRHAMMER F, 1993, EMBO J, V120, P3679; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; OVERTON WR, 1988, CYTOMETRY, V9, P619, DOI 10.1002/cyto.990090617; SCHNIER JB, 1996, IN PRESS P NATL ACAD, V93; SHEW JY, 1990, P NATL ACAD SCI USA, V87, P6, DOI 10.1073/pnas.87.1.6; STECK KD, 1995, CYTOMETRY, V20, P154, DOI 10.1002/cyto.990200208; STRUM JC, 1994, J BIOL CHEM, V269, P15493; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; YANG ZH, 1993, J BIOL CHEM, V268, P20520	41	34	34	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1693	1700						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895515				2022-12-28	WOS:A1996VM88700014
J	Peled, A; Schwartz, D; Elkind, NB; Wolkowicz, R; Li, RZ; Rotter, V				Peled, A; Schwartz, D; Elkind, NB; Wolkowicz, R; Li, RZ; Rotter, V			The role of p53 in the induction of polyploidity of myelomonocytic leukemic M1/2 cells	ONCOGENE			English	Article						wild type p53; mutant p53; giant cells; ploidity	WILD-TYPE P53; C-TERMINAL DOMAIN; DNA-DAMAGE; CYCLE CONTROL; IONIZING-RADIATION; FLOW-CYTOMETRY; SINGLE STRANDS; PROTEIN; REPAIR; GENE	p53 was shown to play a central role in the maintenance of genomic integrity. The present experiments suggest that p53 is involved in the control of cell ploidity. Using a p53 non-producer cell line, M1/2, that was reconstituted to express either wild type or mutant p53 protein, by infection with the temperature sensitive (Ts) p53 Val135 virus, it was found that both loss of wild type p53 or overexpression of mutant p53, may be associated with the generation of cell polyploidity. Overexpression of mutant p53 protein enhanced the appearance of giant cells that further accumulated following gamma-irradiation. Expression of wild type p53 reduced the level of giant cells which accumulated in the parental M1/2 p53 nonproducer cells following gamma-irradiation. This activity of the wild type p53 seems to be mediated by either the reduction in the rate of giant cell generation, as observed in M1/2 derived cell lines expressing low levels of wild type p53 protein or by facilitating their apoptosis, as observed in wild type p53 high-producer cells. The latter conclusion is further supported by the observation that isolated giant cells are directly induced to undergo apoptosis following wild type p53 expression.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science								AFANASYEV VN, 1993, CYTOMETRY, V14, P603, DOI 10.1002/cyto.990140604; ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BELLOC F, 1994, CYTOMETRY, V17, P59, DOI 10.1002/cyto.990170108; BRAIN R, 1994, ONCOGENE, V9, P1775; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; FRIEDBERG EC, 1994, BIOESSAYS, V16, P645, DOI 10.1002/bies.950160909; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1995, CANCER RES, V55, P7; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LINDAHL T, 1994, CURR BIOL, V4, P249, DOI 10.1016/S0960-9822(00)00056-7; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MODRICH P, 1994, SCIENCE, V266, P1959, DOI 10.1126/science.7801122; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; PARSHAD R, 1994, CARCINOGENESIS, V15, P33, DOI 10.1093/carcin/15.1.33; Peled A, 1996, CANCER RES, V56, P2148; PELED A, 1995, UNPUB EXPT HEMAT; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; ROTTER V, 1993, P NATL ACAD SCI USA, V90, P9075, DOI 10.1073/pnas.90.19.9075; SCHWARTZ D, 1993, ONCOGENE, V8, P1487; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEWART N, 1995, ONCOGENE, V10, P109; WADEHARPER J, 1993, CELL, V75, P805; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1993, MOL CELL BIOL, V13, P1415, DOI 10.1128/MCB.13.3.1415; ZIPORI D, 1985, BLOOD, V66, P447	49	22	22	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 17	1996	13	8					1677	1685						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VM887	8895513				2022-12-28	WOS:A1996VM88700012
J	BirchenallRoberts, MC; Kim, SJ; Bertolette, DC; Turley, JM; Fu, T; Bang, OS; Kasper, JJ; Yoo, YD; Ruscetti, FW				BirchenallRoberts, MC; Kim, SJ; Bertolette, DC; Turley, JM; Fu, T; Bang, OS; Kasper, JJ; Yoo, YD; Ruscetti, FW			P120-v-Abl expression overcomes TGF-beta 1 negative regulation of c-myc transcription but not cell growth	ONCOGENE			English	Article						v-Abl; E2F-1; RB; c-myc; TGF-beta 1	RETINOBLASTOMA GENE-PRODUCT; MURINE LEUKEMIA-VIRUS; TUMOR-SUPPRESSOR PROTEIN; FACTOR-BETA; MOLECULAR-CLONING; TRANS-ACTIVATION; EPITHELIAL-CELLS; KINASE-ACTIVITY; E2F SITE; ABL	Transformation of interleukin-3 dependent (IL-3) 32D-123 myeloid cells by p120-v-Abl produced the factor-independent 32D-abl cell Line, In 32D-abl cells, myc expression was found to be significantly higher than in the parental cells and was correlated with increased E2F-1 protein expression and DNA binding ability, Surprisingly, in 32D-abl cells, TGF-beta 1, a potent G(1)/S inhibitor of 32D-123 and 32D-abl cell growth, increased E2F transactivation as shown by increased c-myc promoter-CAT and GAL4-E2F-1 activity, In addition, TGF-beta 1 was also found to increase E2F-1 protein levels but had no effect on steady-state retinoblastoma (RE) protein levels or phosphorylation state, In the absence of TGF-beta 1, transient expression of RE in v-Abl expressing cells resulted in decreased c-myc transcription, inhibition of GAL4-E2F-1 driven transactivation and inhibition of cellular proliferation, RE and v-Abl were found to physically asssociate in vivo and in vitro via v-Abl's ATP binding region, In summary, these studies established that in myeloid cells: (1) v-Abl binds RE resulting in increased E2F-1-driven c-myc transcription, and (2) an alternative pathway exists for TGF-beta 1-mediated growth inhibition of v-Abl-transformed cells, in which increased rather than decreased E2F-mediated c-myc transcription is observed.	NCI, FREDERICK CANC RES & DEV CTR, FREDERICK, MD 21702 USA; NCI, DIV BASIC SCI, CHEMOPREVENT LAB, BETHESDA, MD 20892 USA; NCI, FREDERICK CANC RES & DEV CTR, LAB LEUKOCYTE BIOL, DIV BASIC SCI, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	BirchenallRoberts, MC (corresponding author), SAIC FREDERICK, INTRAMURAL RES SUPPORT PROGRAM, FREDERICK, MD 21702 USA.							ABELSON HT, 1970, CANCER RES, V30, P2213; ARCINAS M, 1994, J BIOL CHEM, V269, P21919; Bang OS, 1996, J BIOL CHEM, V271, P7811, DOI 10.1074/jbc.271.13.7811; BIRCHENALLROBERTS MC, 1995, MOL CELL BIOL, V15, P6088; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BIRCHENALLROBERTS MC, 1991, J BIOL CHEM, V266, P9617; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAMBARD JC, 1988, J CELL PHYSIOL, V135, P101, DOI 10.1002/jcp.1041350114; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1988, MOL CELL BIOL, V8, P3088, DOI 10.1128/MCB.8.8.3088; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FALTYNEK CR, 1988, J BIOL CHEM, V263, P7112; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GREENBERGER JS, 1984, LEUKEMIA RES, V8, P363, DOI 10.1016/0145-2126(84)90076-6; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KELLER J, 1988, BLOOD, V75, P506; KELLER JR, 1990, ONCOGENE, V5, P549; KELLER JR, 1990, TRANSFORMING GROWTH; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KIM TA, 1994, J CELL PHYSIOL, V160, P1, DOI 10.1002/jcp.1041600102; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEOF EB, 1986, J CELL PHYSIOL, V127, P83, DOI 10.1002/jcp.1041270111; LONGSTREET M, 1992, ONCOGENE, V7, P1549; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MELILLO RM, 1994, MOL CELL BIOL, V14, P8241, DOI 10.1128/MCB.14.12.8241; MILLER TL, 1993, MOL CELL ENDOCRINOL, V91, P83, DOI 10.1016/0303-7207(93)90258-L; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1985, CANCER CELL, V3, P65; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NEVINS JR, 1992, SCIENCE, V258, P424; OSWALD F, 1994, ONCOGENE, V9, P2029; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SING GK, 1988, BLOOD, V72, P1504; SMELAND EB, 1987, EXP CELL RES, V171, P213, DOI 10.1016/0014-4827(87)90264-3; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WANG JYJ, 1984, CELL, V36, P349; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WONG KK, 1995, MOL CELL BIOL, V15, P6535; YAN ZF, 1992, ONCOGENE, V7, P801; ZAMMANIAN M, 1992, EMBO J, V11, P2603; ZENTELLA A, 1991, MOL CELL BIOL, V11, P4952, DOI 10.1128/MCB.11.10.4952	63	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 3	1996	13	7					1499	1509						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875988				2022-12-28	WOS:A1996VL38400015
J	DavidPfeuty, T; NouvianDooghe, Y				DavidPfeuty, T; NouvianDooghe, Y			Human cyclin B1 is targeted to the nucleus in G(1) phase prior to its accumulation in the cytoplasm	ONCOGENE			English	Article						cell-cycle regulation; cyclin B1; cyclin A; transformation	CDK-ACTIVATING KINASE; ROUS-SARCOMA VIRUS; HUMAN WEE1 KINASE; SEA-URCHIN EGGS; FISSION YEAST; CELL-CYCLE; SUBCELLULAR-LOCALIZATION; DNA-REPLICATION; PROTEIN-KINASE; S-PHASE	The immunolocalisation patterns of cyclin B1 have been investigated in various tumour-derived and untransformed human cells, using one polyclonal (B7/B8) and tao different monoclonal anti-human cyclin B1 antibodies, GNS1 and GNS11. In actively dividing cell populations, GNS11 reveals uniquely a cytoplasmic pool of cyclin B1 that rapidly increases after the onset of S phase; yet, B7/B8 and GNS1 detect, besides this cytoplasmic cyclin B1 population, a moderate but clear nuclear concentration of the protein in cells that have not yet entered S phase. As for confluent populations of untransformed and tumour cells, they become enriched in G(1)- and G(2)-arrested cells that characteristically display a discreet nuclear or an intense cytoplasmic GNS1 immunostaining respectively. Altogether, our immunofluorescence data conjugated with the results of a detailed biochemical analysis suggest that human cyclin B1 would exist in situ as two distinguishable molecular entities differentially susceptible to in vitro degradation and exhibiting different timing, kinetics and site of accumulation during the cell cycle: one form (recognized by the polyclonal and GNS1 antibodies but apparently not by GNS11) starts to build up inside the nucleus prior to entry in S phase and the other (in which both the GNS11 and GNS1 epitopes are readily accessible) emerges and accumulates in the cytoplasm beyond the G(1)/S boundary.			DavidPfeuty, T (corresponding author), CTR UNIV ORSAY, INST CURIE, SECT RECH, BATIMENT 110, F-91405 ORSAY, FRANCE.							AFLA CE, 1990, NATURE, V347, P680; ALFA CE, 1989, J CELL SCI, P9; BAILLY E, 1992, J CELL SCI, V101, P529; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BALDIN V, 1995, J CELL SCI, V108, P2425; BOOHER R, 1988, EMBO J, V7, P2321, DOI 10.1002/j.1460-2075.1988.tb03075.x; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BOOHER RN, 1989, CELL, V58, P485, DOI 10.1016/0092-8674(89)90429-7; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; DARBON JM, 1994, ONCOGENE, V9, P3127; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DAVIDPFEUTY T, 1993, J CELL SCI, V105, P613; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Fisher DL, 1996, EMBO J, V15, P850, DOI 10.1002/j.1460-2075.1996.tb00420.x; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GENEVIEREGARRIGUES AM, 1995, J CELL SCI, V108, P2693; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL M, 1988, CELL, V54, P739; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HAGAN I, 1988, J CELL SCI, V91, P587; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HAYLES J, 1995, EMBO J, V14, P2760, DOI 10.1002/j.1460-2075.1995.tb07276.x; HAYLES J, 1994, CELL, V78, P813, DOI 10.1016/S0092-8674(94)90542-8; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LABBE JC, 1994, EMBO J, V13, P5155, DOI 10.1002/j.1460-2075.1994.tb06845.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MARIDOR G, 1993, J CELL SCI, V106, P535; MCGOWAN CH, 1995, EMBO J, V14, P2166, DOI 10.1002/j.1460-2075.1995.tb07210.x; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1980, GENETICS, V96, P627; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1975, NATURE, V256, P547, DOI 10.1038/256547a0; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PIGGOTT JR, 1982, NATURE, V298, P391, DOI 10.1038/298391a0; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1991, TRENDS GENET, V7, P95, DOI 10.1016/0168-9525(91)90064-W; RESH MD, 1985, J CELL BIOL, V100, P409, DOI 10.1083/jcb.100.2.409; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERWOOD SW, 1994, EXP CELL RES, V211, P275, DOI 10.1006/excr.1994.1087; STANDART N, 1987, DEV BIOL, V124, P248, DOI 10.1016/0012-1606(87)90476-3; STARGER JM, 1978, J CELL BIOL, V78, P93, DOI 10.1083/jcb.78.1.93; SWENSON KI, 1986, CELL, V47, P861, DOI 10.1016/0092-8674(86)90801-9; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; WHITFIELD WGF, 1990, EMBO J, V9, P2563, DOI 10.1002/j.1460-2075.1990.tb07437.x; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	56	13	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1447	1460						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875983				2022-12-28	WOS:A1996VL38400010
J	Das, R; Vonderhaar, BK				Das, R; Vonderhaar, BK			Involvement of SHC, GRB2, SOS and RAS in prolactin signal transduction in mammary epithelial cells	ONCOGENE			English	Article						prolactin; breast cancer; JAK2; SHC; STAT5	HUMAN-BREAST-CANCER; ACTIVATED PROTEIN-KINASE; GROWTH-HORMONE RECEPTOR; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; GENE-EXPRESSION; LYMPHOMA-CELLS; MAP KINASE; ASSOCIATION; JAK2	The peptide hormone prolactin (Prl) regulates proliferation of normal and malignant mammary cells, In the present study me demonstrate that tate Prl responsive cell Lines, NOG-8 and T47D, activate the JAK2-SHC-MAPK pathway in a rapid and transient manner, Within 1 min of Prl treatment there was an increase in association of JAK2 with SHC, followed by rapid phosphorylation of both the 52 kDa and 46 kDa SHC proteins, Grb2 and Sos associated with the SHC proteins within 1-3 min of Prl treatment in these mammary cells, Within 5 min of hormone treatment we observe an increase in ras-GTP suggesting activation of ras, We also showed a rapid and transient tyrosine phosphorylation of STAT5 in proliferating T47D cells which reached its peak after 30 min of Prl treatment, These results indicate that Prl receptors, after binding the ligand, activate several pathways for signal transduction leading to mitogenesis.	NCI,TUMOR IMMUNOL & BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; BISWAS R, 1987, CANCER RES, V47, P3509; BONNETERRE J, 1982, EUR J CANCER CLIN ON, V18, P1157, DOI 10.1016/0277-5379(82)90097-9; BUCKLEY AR, 1994, BIOCHEM BIOPH RES CO, V204, P1158, DOI 10.1006/bbrc.1994.2584; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; CUTLER RL, 1993, J BIOL CHEM, V268, P21463; DAS R, 1996, IN PRESS BREAST CANC; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FINIDORI J, 1995, J ENDOCRINOL, V147, P11, DOI 10.1677/joe.0.1470011; GINSBURG E, 1995, CANCER RES, V55, P2591; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LEPROVOST F, 1994, NEUROENDOCRINOLOGY, V60, P305, DOI 10.1159/000126763; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MOLLER C, 1992, J BIOL CHEM, V267, P23403; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OHMICHI M, 1994, J BIOL CHEM, V269, P1143; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAO YP, 1995, CELL GROWTH DIFFER, V6, P1235; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUI H, 1994, J BIOL CHEM, V269, P5364; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SOTIROPOULOS A, 1994, ENDOCRINOLOGY, V135, P1292, DOI 10.1210/en.135.4.1292; STEINMETZ RW, 1993, J ENDOCRINOL, V136, P271, DOI 10.1677/joe.0.1360271; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; XIUWEN L, 1995, P NATL ACAD SCI USA, V92, P8831; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	40	87	87	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1139	1145						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808687				2022-12-28	WOS:A1996VJ20200004
J	Lanoix, J; DAgati, V; Szabolcs, M; Trudel, M				Lanoix, J; DAgati, V; Szabolcs, M; Trudel, M			Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease (ADPKD)	ONCOGENE			English	Article						ADPKD; proliferation; apoptosis	C-MYC; TRANSGENIC MICE; PROTOONCOGENE EXPRESSION; EPITHELIAL HYPERPLASIA; B-CELLS; DEATH; BCL-2; GENE; PROTEIN; P53	The proto-oncogene c-myc has been implicated in both cellular proliferation and apoptosis, and we have shown that overexpression of c-myc can induce polycystic kidney disease in transgenic mice, To elucidate the molecular and cellular defects underlying cystogenesis, we have investigated the potential roles of cell proliferation and apoptosis as they relate to c-myc and modulators of c-myc function in human autosomal dominant polycystic kidney disease (ADPKD), Renal c-myc expression was consistently elevated, up to 15-fold, in ADPKD, High levels of c-myc expression correlated with 10- to 100-fold increased proliferation index in cystic epithelium, Interestingly, steady-state levels of bcl-2 mRNA were also increased up to 20-fold and Bcl-2 protein was markedly elevated. In contrast, the expression of bax and p53 was virtually unchanged. However, apoptosis was consistently and significantly increased in ADPKD kidneys, unchecked by high levels of Bcl-2, Together with proliferation, apoptosis may thus represent a general mechanism for cyst growth and tissue remodeling. We conclude that both epithelial cell proliferation and apoptosis required for normal kidney homeostasis are deregulated in ADPKD, regulating the renal developmental program. Furthermore, abnormal expression of proto-oncogenes regulating these processes is an important mediator of cystogenesis in human ADPKD.	UNIV MONTREAL,FAC MED,INST RECH CLIN MONTREAL,MONTREAL,PQ,CANADA; COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Columbia University					NIDDK NIH HHS [DK 44864] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044864] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1994, CELL, V77, P881; [Anonymous], 1995, CELL, V81, P289; AVNER ED, 1992, P NATL ACAD SCI USA, V89, P7447, DOI 10.1073/pnas.89.16.7447; BARISONI L, 1995, AM J PATHOL, V147, P1728; BERNSTEIN J, 1987, AM J PATHOL, V129, P92; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BURN TC, 1995, HUM MOL GENET, V4, P575, DOI 10.1093/hmg/4.4.575; CHEN IT, 1986, P NATL ACAD SCI USA, V83, P6907, DOI 10.1073/pnas.83.18.6907; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COWLEY BD, 1987, P NATL ACAD SCI USA, V84, P8394, DOI 10.1073/pnas.84.23.8394; COWLEY BD, 1991, J AM SOC NEPHROL, V1, P1048; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Daoust Martin C., 1994, Clinical and Investigative Medicine, V17, pB97; EVAN AP, 1979, KIDNEY INT, V16, P743, DOI 10.1038/ki.1979.191; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; GRANTHAM JJ, 1987, KIDNEY INT, V31, P1145, DOI 10.1038/ki.1987.121; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; KIMBERLING WJ, 1993, GENOMICS, V18, P467, DOI 10.1016/S0888-7543(11)80001-7; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; MICHAUD J, 1994, AM J MED GENET, V51, P240, DOI 10.1002/ajmg.1320510314; MIYASHITA T, 1995, CELL, V80, P293; MUGRAUER G, 1991, J CELL BIOL, V112, P13, DOI 10.1083/jcb.112.1.13; NADASDY T, 1995, J AM SOC NEPHROL, V5, P1462; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PULENDRAN B, 1995, NATURE, V375, P331, DOI 10.1038/375331a0; REEDERS ST, 1985, NATURE, V317, P542, DOI 10.1038/317542a0; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Szabolcs Matthias J., 1993, Journal of the American Society of Nephrology, V4, P690; TRUDEL M, 1991, KIDNEY INT, V39, P665, DOI 10.1038/ki.1991.80; TRUDEL M, 1994, MAMM GENOME, V5, P149, DOI 10.1007/BF00352345; VANADELSBERG JS, 1995, NAT MED, V1, P359, DOI 10.1038/nm0495-359; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WILSON PD, 1991, KIDNEY INT, V39, P450, DOI 10.1038/ki.1991.56; WILSON PD, 1986, KIDNEY INT, V30, P371, DOI 10.1038/ki.1986.194; WOO D, 1995, NEW ENGL J MED, V333, P18, DOI 10.1056/NEJM199507063330104; Yin DX, 1996, P NATL ACAD SCI USA, V93, P3394, DOI 10.1073/pnas.93.8.3394	50	164	171	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1153	1160						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808689				2022-12-28	WOS:A1996VJ20200006
J	Amundadottir, LT; Nass, SJ; Berchem, GJ; Johnson, MD; Dickson, RB				Amundadottir, LT; Nass, SJ; Berchem, GJ; Johnson, MD; Dickson, RB			Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: Coordinated stimulation of growth and suppression of apoptosis	ONCOGENE			English	Article						c-Myc; TGF alpha; apoptosis; mammary tumorigenesis	HUMAN-BREAST-CANCER; PROGRAMMED CELL-DEATH; DNA STRAND BREAKS; TRANSGENIC MICE; EPITHELIAL-CELLS; FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; MEDIATED APOPTOSIS; FACTOR RECEPTOR; LEUKEMIA-CELLS	We have previously shown that TGF alpha and c-Myc interact in a strong, synergistic fashion to induce mammary gland tumors in double transgenic mice. Here we show this interaction can be explained, at least in part, by a cooperative growth stimulus by the two proteins, and by TGF alpha-mediated inhibition of c-Myc-induced apoptosis, We initially compared rapidly progressing mammary tumors from double transgenic mice to long latency tumors from single transgenic mice and observed a striking difference in the occurrence of apoptosis among the three groups, Tumors exhibiting apoptosis were derived exclusively from mice that expressed the c-myc transgene in the absence of the TGF alpha transgene, indicating that TGF alpha might protect c-Myc-overexpressing cells from programmed cell death, Cell lines were derived from single and double transgenic mammary tumors to examine further the mechanism underlying the cooperative interaction between the two gene products, In accordance with our in vivo data, apoptosis was only detected when the c-myc transgene was expressed without the TGF alpha transgene, Furthermore, exogenous addition of TGF alpha inhibited apoptosis in cells overexpressing c-Myc alone, In addition, tumor-derived cells that overexpressed both TGF alpha and c-Myc exhibited faster growth rates in vitro and in vivo and were less sensitive to the inhibitory effects of TGF beta in vitro compared to cell lines expressing only one of the transgenes, Based on our findings we propose that TGF alpha acts both as a proliferative and a survival factor for c-Myc-expressing tumor cells, Our results indicate that TGF alpha and c-Myc cooperate in tumorigenesis via a dual mechanism: TGF alpha can inhibit c-Myc-induced apoptosis and both proteins provide a growth stimulus.	GEORGETOWN UNIV,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,DEPT CELL BIOL,WASHINGTON,DC 20007; GEORGETOWN UNIV,DIV HEMATOL ONCOL,WASHINGTON,DC 20007	Georgetown University; Georgetown University; Georgetown University			Berchem, Guy/C-9364-2014; Amundadottir, Laufey T/L-7656-2016	Berchem, Guy/0000-0003-0157-2257; Amundadottir, Laufey T/0000-0003-1859-8971				AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; ARTEAGA CL, 1988, CANCER RES, V48, P5023; ASKEW DS, 1991, ONCOGENE, V6, P1915; BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONILLA M, 1988, J NATL CANCER I, V80, P665, DOI 10.1093/jnci/80.9.665; CATCHPOOLE DR, 1993, CANCER RES, V53, P4287; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANIEL CW, 1989, DEV BIOL, V135, P20, DOI 10.1016/0012-1606(89)90154-1; DERYNCK R, 1987, CANCER RES, V47, P707; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GARCIA I, 1989, CANCER RES, V49, P6675; GORSCH SM, 1992, CANCER RES, V52, P6949; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HAVRILESKY LJ, 1995, CANCER RES, V55, P944; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HSU B, 1995, ONCOGENE, V11, P175; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JHAPPAN C, 1993, EMBO J, V12, P1835, DOI 10.1002/j.1460-2075.1993.tb05832.x; KAMESAKI S, 1993, CANCER RES, V53, P4251; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KHAZAIE K, 1991, ONCOGENE, V6, P21; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963, DOI 10.1210/endo-127-6-2963; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MIYASHITA T, 1995, CELL, V80, P293; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; PERROTEAU I, 1986, BREAST CANCER RES TR, V7, P201, DOI 10.1007/BF01806251; PIERCE DF, 1993, GENE DEV, V7, P2308, DOI 10.1101/gad.7.12a.2308; ROTELLO RJ, 1991, P NATL ACAD SCI USA, V88, P3412, DOI 10.1073/pnas.88.8.3412; Sakamuro D, 1995, ONCOGENE, V11, P2411; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; SMITH GH, 1995, AM J PATHOL, V147, P1081; SOMMERS CL, 1992, CANCER RES, V52, P5190; SOMMERS CL, 1989, CANCER RES, V49, P4258; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAETLE R, 1993, CANCER RES, V53, P3386; TELANG NT, 1990, CELL REGUL, V1, P863, DOI 10.1091/mbc.1.11.863; TRAVERS MT, 1988, BRIT MED J, V296, P1621, DOI 10.1136/bmj.296.6637.1621; VALVERIUS EM, 1990, J CELL PHYSIOL, V145, P207, DOI 10.1002/jcp.1041450204; VALVERIUS EM, 1989, CANCER RES, V49, P6269; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WITKIEWICZ H, 1993, BIOTECHNIQUES, V14, P458; ZUGMAIER G, 1989, J CELL PHYSIOL, V141, P353, DOI 10.1002/jcp.1041410217	65	72	73	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					757	765						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761297				2022-12-28	WOS:A1996VD43300011
J	Jackers, P; Minoletti, F; Belotti, D; Clausse, N; Sozzi, G; Sobel, ME; Castronovo, V				Jackers, P; Minoletti, F; Belotti, D; Clausse, N; Sozzi, G; Sobel, ME; Castronovo, V			Isolation from a multigene family of the active human gene of the metastasis-associated multifunctional protein 37LRP/p40 at chromosome 3p21.3	ONCOGENE			English	Article						37 kD laminin receptor precursor; 3p21.3; Alu sequences; p40 ribosome-associated protein; small nuclear RNA E2 gene	AFFINITY LAMININ RECEPTOR; SMALL NUCLEOLAR RNAS; CELL LUNG-CANCER; RIBOSOMAL-PROTEIN; MESSENGER-RNA; TRANSLATIONAL CONTROL; BINDING-PROTEIN; MAMMALIAN-CELLS; CARCINOMA-CELLS; ALU RNA	The 37 kD precursor of the 67 kD laminin receptor (37LRP) is a polypeptide whose expression is consistently upregulated in aggressive carcinoma. Interestingly, the 37LRP appears to be a multifunctional protein involved in the translational machinery and has also been identified as p40 ribosome-associated protein. Although highly conserved cDNAs corresponding to this polypeptide have been isolated from several species including vertebrates, invertebrates, plants and prokaryotes, characterization of any of the corresponding active genes has never been reported. In this study, we have cloned an intron-containing fragment which permitted us to isolate the active 37LRP/p40 human gene. This gene contains seven exons and six introns. Ribonuclease protection experiments suggest multiple transcription start sites. The promoter area does not bear a TATA box but contains four Sp1 sites. The first intron is also GC rich containing five Sp1 sites. Intron 4 contains the full sequence of the small nuclear RNA E2 and two Alu sequences are found in intron 3. Fluorescent in situ hybridization localized the 37LRP/p40 active gene on chromosome 3 in the locus 3p21.3 which, interestingly, is a hot spot for genetic alterations in several cancers and particularly in small cell lung carcinoma.	IST TUMORI,MILAN,ITALY; NCI,MOL PATHOL SECT,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Belotti, Dorina/AAA-8077-2020; sozzi, gabriella/G-8259-2011	Belotti, Dorina/0000-0002-3868-9144; sozzi, gabriella/0000-0001-9360-6914				ANTOINE M, 1992, HUM MOL GENET, V1, P565, DOI 10.1093/hmg/1.8.565; AUTH D, 1992, P NATL ACAD SCI USA, V89, P4368, DOI 10.1073/pnas.89.10.4368; AXELOS M, 1993, PLANT PHYSIOL, V103, P299, DOI 10.1104/pp.103.1.299; BIGNON C, 1991, GENOMICS, V10, P481, DOI 10.1016/0888-7543(91)90336-D; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUCHHAGEN DL, 1994, INT J CANCER, V57, P473, DOI 10.1002/ijc.2910570406; CARRITT B, 1992, CANCER RES, V52, P1536; CASTRONOVO V, 1993, INVAS METAST, V13, P1; CASTRONOVO V, 1989, J NATL CANCER I, V81, P781, DOI 10.1093/jnci/81.10.781; CASTRONOVO V, 1991, BIOCHEM BIOPH RES CO, V177, P177, DOI 10.1016/0006-291X(91)91965-F; CHEN LC, 1994, CANCER RES, V54, P3021; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIES B, 1993, GENOMICS, V15, P68, DOI 10.1006/geno.1993.1011; DAVIS SC, 1992, J BIOL CHEM, V267, P5508; DEFALCO S, 1993, GENE, V126, P227, DOI 10.1016/0378-1119(93)90371-9; ELLIS S, 1994, FASEB J, V8, pA1312; ENGLANDER EW, 1995, J BIOL CHEM, V270, P10091, DOI 10.1074/jbc.270.17.10091; FAUTSCH MP, 1991, J BIOL CHEM, V266, P23288; FERNANDEZ MT, 1991, BIOCHEM BIOPH RES CO, V175, P84, DOI 10.1016/S0006-291X(05)81203-3; GROSSO LE, 1991, BIOCHEMISTRY-US, V30, P3346, DOI 10.1021/bi00227a026; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARIHARAN N, 1990, P NATL ACAD SCI USA, V87, P1526, DOI 10.1073/pnas.87.4.1526; HEPPELLPARTON AC, 1992, GENE CHROMOSOME CANC, V4, P228, DOI 10.1002/gcc.2870040307; HERNNDEZ MG, 1994, J BIOL CHEM, V269, P20744; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HIBI K, 1992, ONCOGENE, V7, P445; HIBI K, 1994, ONCOGENE, V9, P611; JACKERS P, 1996, IN PRESS BIOCH BIOPH; KEPPEL E, 1991, J CELL SCI, V100, P789; KROMER WJ, 1991, J BIOL CHEM, V266, P24573; LEVY S, 1991, P NATL ACAD SCI USA, V88, P3319, DOI 10.1073/pnas.88.8.3319; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; LOPEZRIBOT JL, 1994, INFECT IMMUN, V62, P742; LUBINSKI J, 1994, CANCER RES, V54, P3710; MAKRIDES S, 1988, NUCLEIC ACIDS RES, V16, P2349, DOI 10.1093/nar/16.5.2349; MARAIA RJ, 1993, MOL CELL BIOL, V13, P4233, DOI 10.1128/MCB.13.7.4233; MARIOTTINI P, 1990, MOL CELL BIOL, V10, P816, DOI 10.1128/MCB.10.2.816; MIOZZO M, 1990, GENE CHROMOSOME CANC, V2, P163, DOI 10.1002/gcc.2870020213; MOSCOW JA, 1994, CARCINOGENESIS, V15, P2769, DOI 10.1093/carcin/15.12.2769; NAG MK, 1993, P NATL ACAD SCI USA, V90, P9001, DOI 10.1073/pnas.90.19.9001; OUZOUNIS C, 1995, NUCLEIC ACIDS RES, V23, P565, DOI 10.1093/nar/23.4.565; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; RABACCHI SA, 1990, DEVELOPMENT, V109, P521; RAO CN, 1989, BIOCHEMISTRY-US, V28, P7476, DOI 10.1021/bi00444a047; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; ROSENTHAL ET, 1995, J CELL SCI, V108, P245; ROWE SM, 1995, CANCER RES, V55, P2743; RUFF EA, 1993, P NATL ACAD SCI USA, V90, P635, DOI 10.1073/pnas.90.2.635; SHIRAISHI M, 1995, ONCOGENE, V10, P1453; SINNETT D, 1992, J MOL BIOL, V226, P689, DOI 10.1016/0022-2836(92)90626-U; SIYANOVA EY, 1991, DOKL AKAD NAUK SSSR, V313, P227; SMITH R, 1988, EMBO J, V7, P1013, DOI 10.1002/j.1460-2075.1988.tb02908.x; TOHGO A, 1994, FEBS LETT, V340, P133, DOI 10.1016/0014-5793(94)80188-6; VANDENOUWELAND AMW, 1989, NUCLEIC ACIDS RES, V17, P3829, DOI 10.1093/nar/17.10.3829; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; WESTENDORF J M, 1990, Journal of Cell Biology, V111, p93A; WEWER UM, 1986, P NATL ACAD SCI USA, V83, P7137, DOI 10.1073/pnas.83.19.7137; XU L, 1994, NUCLEIC ACIDS RES, V22, P646, DOI 10.1093/nar/22.4.646; YOW HK, 1988, P NATL ACAD SCI USA, V85, P6394, DOI 10.1073/pnas.85.17.6394; ZINN AR, 1994, MOL CELL BIOL, V14, P2485, DOI 10.1128/MCB.14.4.2485	60	51	55	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					495	503						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760291				2022-12-28	WOS:A1996VB32800007
J	Chang, HW; Li, J; Vogt, PK				Chang, HW; Li, J; Vogt, PK			Domains of the qin protein required for oncogenic transformation	ONCOGENE			English	Article						winged helix domain; transcriptional repression; DNA binding; Qin	GENE FORK-HEAD; DNA-BINDING; FAMILY; MOUSE; HNF-3-BETA; BELONGS; EMBRYO; MOTIF	The gill oncogene is a cell-derived insert in the genome of avian sarcoma virus 31 (ASV 31) and functions as the oncogenic determinant of that virus. Overexpression of the viral and cellular versions of the Qin protein (v-Qin and c-Qin) induces oncogenic transformation of chicken embryo fibroblasts (CEF); v-Qin also rapidly induces fibrosarcomas in chickens. Qin proteins can bind to specific DNA sequences and act as transcriptional repressors. In this study, mutants of Qin were constructed in order to determine the molecular domains required for transformation of chicken embryo fibroblasts. Our data indicate that three regions required for transforming activity are located (i) between residues 74-141 at the amino terminus, (ii) in the winged helix domain and (iii) between residues 383-395 at the carboxyl terminus. A Qin mutant with 12 amino acids deleted from the carboxyl terminus (383-395) showed transforming activity that was lower than that of wild type Qin for CEF. Compare to wild type Qin transformants, the mutant transformed cells had a reduced ability for multilayered and for anchorage independent growth. Deletion of 48 amino acids from the carboxyl terminus of the Qin protein (347-395) completely abolished transforming activity. In contrast, deletion of 74 amino acids from the amino terminus did not affect transformation of CEF. However, further deletion of 68 amino acids (74-141) reduced but did not abolish transforming activity. Finally, deletion in the winged helix domain (218-295) completely abrogated oncogenic capacity in CEF. These results suggest that DIVA binding and transcriptional repression may be important in Qin-induced oncogenic transformation.	Scripps Res Inst, DEPT MOL & EXPT MED, LA JOLLA, CA 92037 USA	Scripps Research Institute			Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; FEDERSPIEL MJ, 1994, VIROLOGY, V203, P211, DOI 10.1006/viro.1994.1478; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; PELEG Y, 1994, MOL CELL BIOL, V14, P7816, DOI 10.1128/MCB.14.12.7816; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WONG WY, 1992, ONCOGENE, V7, P2077	15	20	20	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					441	444						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710385				2022-12-28	WOS:A1996VA25200025
J	Matoskova, B; Wong, WT; Seki, N; Nagase, T; Nomura, N; Robbins, KC; DiFiore, PP				Matoskova, B; Wong, WT; Seki, N; Nagase, T; Nomura, N; Robbins, KC; DiFiore, PP			RN-tre identifies a family of tre-related proteins displaying a novel potential protein binding domain	ONCOGENE			English	Article						eps8; SH3; tre; signal transduction	INSITU HYBRIDIZATION; CYTOGENETIC FINDINGS; GENE; ONCOGENE; CLONING; KINASE; GTPASE	Eps8 is a recently identified SH3-containing substrate for tyrosine kinase receptors, To understand the role of eps8 in receptor-mediated signaling, we cloned cDNAs encoding proteins that bind to its SH3 domain. One of these cDNAs predicts the synthesis of an 828 amino acid protein with homology to the N-terminal region of the tre oncogene. We designated this protein RN-tre for Related to the N-terminus of tre. RN-tre is ubiquitously expressed and maps to 10p13, a region known to be involved in translocations in various leukemias. Tn addition, a 10p13 monosomy syndrome, characterized by developmental alterations, has been reported, The regional homology between RN-tre and tre, which is limited to their N-terminal portion, prompted us to investigate the origin of the tre oncogene transcriptional unit. We were able to show that tre is the fusion product of a 5' genetic element, homologous to RN-tre and a 3' element, encoding a de-ubiquinating enzyme. Moreover, we identified, within the N-terminus of RN-tre and tre, a domain (named TrH, for Tre Homology), which is conserved within several proteins from yeast to mammals and has protein-binding properties in vitro.	EUROPEAN INST ONCOL, DEPT EXPTL ONCOL, IEO, I-20141 MILAN, ITALY; NIDR, NIH, CELLULAR DEV & ONCOL LAB, BETHESDA, MD 20892 USA; NCI, NIH, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; KAZASA DNA RES INST, CHIBA 292, JAPAN; IST MICROBIOL, FAC MED & CHIRURG, BARI, ITALY	IRCCS European Institute of Oncology (IEO); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				ABE R, 1983, CANCER GENET CYTOGEN, V9, P139, DOI 10.1016/0165-4608(83)90034-1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3583; BERGER R, 1988, CANCER GENET CYTOGEN, V36, P123, DOI 10.1016/0165-4608(88)90082-9; BIRGE RB, 1993, SCIENCE, V262, P1522, DOI 10.1126/science.7504323; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DALESSANDRO E, 1990, CANCER GENET CYTOGEN, V45, P231, DOI 10.1016/0165-4608(90)90087-Q; DAVIDOW LS, 1987, J BACTERIOL, V169, P4621, DOI 10.1128/jb.169.10.4621-4629.1987; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GREENBERG F, 1988, AM J HUM GENET, V43, P605; GUPTA K, 1993, ONCOGENE, V8, P2307; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HUEBNER K, 1988, ONCOGENE, V3, P449; KARLSSON T, 1995, ONCOGENE, V10, P1475; KRAUS MH, 1991, METHOD ENZYMOL, V200, P546; Matoskova B, 1996, ONCOGENE, V12, P2679; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PUI CH, 1987, BLOOD, V69, P1289; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARDSON PM, 1995, ONCOGENE, V11, P1139; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHAPIRA M, 1994, AM J MED GENET, V52, P34, DOI 10.1002/ajmg.1320520107; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; TAKAHASHI E, 1991, CYTOGENET CELL GENET, V57, P109, DOI 10.1159/000133124; TAKAHASHI E, 1990, HUM GENET, V86, P14; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG WT, 1994, ONCOGENE, V9, P3057; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	1996	12	12					2563	2571						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700515				2022-12-28	WOS:A1996UW48700010
J	Shimizu, S; Eguchi, Y; Kamiike, W; Matsuda, H; Tsujimoto, Y				Shimizu, S; Eguchi, Y; Kamiike, W; Matsuda, H; Tsujimoto, Y			Bcl-2 expression prevents activation of the ICE protease cascade	ONCOGENE			English	Article						bcl-2; bcl-x; ICE; CPP32; Yama; apoptosis	PROGRAMMED CELL-DEATH; HUMAN FOLLICULAR LYMPHOMA; CHROMOSOMAL BREAKPOINT; GROWTH-FACTOR; C-ELEGANS; GENE; SURVIVAL; ENZYME; CED-3	The Bcl-2 family and the ICE family of cysteine proteases play important roles in regulating cell death. We show here that induction of cell death by a Ca2+ ionophore or hypoxia results in increased levels and activity of active ICE(-like) proteases and the subsequent activation of CPP32/Yama(-like) proteases, and that inhibition of these protease activities reduces the extent of cell death, Overexpression of the anti-apoptotic proteins Bcl-2 or Bcl-x(L) inhibits the cell death and the activation of ICE(-like) and CPP32/Yama(-like) proteases, indicating that Bcl-2 and Bcl-x(L) act upstream of these proteases. We also show that specific inhibition of ICE(-like) proteases in vivo prevents activation of CPP32/Yama(-like) proteases, whereas inhibition of CPP32/Yama(-like) proteases does not prevent activation of TCE(-like) proteases, suggesting the existence of a protease cascade in vivo that requires ICE(-like)proteases for activation of CPP32/Yama(-like) proteases. Induction of necrotic cell death by KCN also induces activation of ICE(-like) proteases but not of CPP32/Yama(-like) proteases, and Bcl-2 and Bcl-x(L) inhibit the activation and the cell death, suggesting that the functional site of Bcl-2 and Bcl-x(L) is also upstream of ICE(-like) proteases in at least some forms of necrosis.	OSAKA UNIV, SCH MED, DEPT SURG 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT PHYSIOL 1, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MED GENET, SUITA, OSAKA 565, JAPAN	Osaka University; Osaka University; Osaka University								BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PEZZELLA F, 1990, AM J PATHOL, V137, P225; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHIMIZU S, 1996, IN PRESS CAN RES; SHIMIZU S, 1996, IN PRESS ONCOGENE; SINGER II, 1995, J EXP MED, V182, P1447, DOI 10.1084/jem.182.5.1447; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; YAUN J, 1993, CELL, V75, P641; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	39	275	281	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2251	2257						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649764				2022-12-28	WOS:A1996UQ22000001
J	Bao, JX; Zervos, AS				Bao, JX; Zervos, AS			Isolation and characterization of Nmi, a novel partner of Myc proteins	ONCOGENE			English	Article						Myc oncoproteins; transcription; two-hybrid screen	C-MYC; INCREASED EXPRESSION; DNA-BINDING; MAX; GENE; TRANSFORMATION; RECOGNITION; SEQUENCE; CLONING; TARGET	The Myc family of oncogenes is thought to play an important role In cell proliferation, differentiation, and neoplastic transformation. Although the structure and expression of Myc genes are well characterized, the function and biochemical properties of the Myc proteins are less well understood, Here, using a yeast genetic screen, we identified a novel gene, Nmi, that binds to N-myc and C-myc, It also interacts with other transcription factors in yeast. The carboxyl terminus of Nmi shows homology to an interferon-induced leucine zipper protein, IFP 35, whereas its amino terminus is homologous to a coiled-coil heptad repeat in the C. elegans protein, CEF59, Go-precipitation studies of Nmi with N-myc and C-myc confirmed the interaction in mammalian cells, Nmi mRNA is expressed at low levels in all fetal and adult human tissues tested, except brain, Among several cancer cell lines, high expression of Nmi was found in myeloid leukemias, which also express high levels of C-myc. Nmi gene is localized on human chromosome 22q13.3. Translocations of this region have been reported In some human leukemias.	HARVARD UNIV,SCH MED,MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital								ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANGE FC, 1994, J BIOL CHEM, V269, P1091; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; DU W, 1994, P NATL ACAD SCI USA, V91, P11318, DOI 10.1073/pnas.91.24.11318; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1992, FASEB J, V6, P30565; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LARSSON LG, 1987, P NATL ACAD SCI USA, V84, P223, DOI 10.1073/pnas.84.1.223; LU X, 1992, CELL, V70, P153, DOI 10.1016/0092-8674(92)90541-J; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAU MM, 1985, NATURE, V318, P69, DOI 10.1038/318069a0; NESSLINGER NJ, 1994, AM J HUM GENET, V54, P464; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; PRENDERGAST GC, 1991, CELL, V67, P641; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Sambrook J., 2002, MOL CLONING LAB MANU; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SCHREIBERAGUS N, 1995, CELL, V80, P77; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VINSON CR, 1992, NEW BIOL, V4, P396; WANG T, 1994, SCIENCE, V256, P674; ZERVOS AS, 1995, P NATL ACAD SCI USA, V92, P10531, DOI 10.1073/pnas.92.23.10531; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	45	99	103	0	12	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2171	2176						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668343				2022-12-28	WOS:A1996UP28300016
J	Wang, BL; Mysliwiec, T; Krainc, D; Jensen, RA; Sonoda, G; Testa, JR; Golemis, EA; Kruh, GD				Wang, BL; Mysliwiec, T; Krainc, D; Jensen, RA; Sonoda, G; Testa, JR; Golemis, EA; Kruh, GD			Identification of ArgBP1, an Arg protein tyrosine kinase binding protein that is the human homologue of a CNS-specific Xenopus gene	ONCOGENE			English	Article						Arg; Xlan4; Abl; SH3 domain; proline-rich motif	MURINE LEUKEMIA-VIRUS; FLUORESCENCE INSITU HYBRIDIZATION; C-ABL; CELL-CYCLE; SIGNAL-TRANSDUCTION; DROSOPHILA-ABL; DOMAIN; DNA; LOCALIZATION; PHOSPHATASE	Arg and c-Abl represent the mammalian members of the Abelson family of nonreceptor protein-tyrosine kinases. To gain insight into the biological role of Arg we used the two-hybrid approach to identify interacting proteins. Using a C-terminal segment of Arg we identified a novel protein, ArgBP1 (Arg binding protein 1). ArgBP1 contains a C-terminal SH3 domain, several PEST sequences, a serine rich domain and an SH3 binding site. ArgBP1 is ubiquitously expressed as two transcripts of similar to 2.2 kb and similar to 8kb with highest levels in brain, heart and testis. The association of ArgBP1 with Arg in living cells was confirmed by coimmunoprecipitation in cotransfected COS cells. Analysis of the mechanism of association indicated that the ArgBP1 SH3 domain binds to a C-terminal Arg SH3-binding site, and that an N-terminal ArgBP1 proline-rich sequence binds to the Arg SH3 domain. Immunostaining indicated that the subcellular localization of ArgBP1 is cytoplasmic. The similarity of the ArgPB1 expression pattern and subcellular localization to those of Arg and the potential for a highly specific and potentially strong association mediated by two pairs of SH3 domain/proline-rich motif interactions, suggest that ArgBP1 is likely to be a regulator and/or effector of Arg function.	FOX CHASE CANC CTR, DEPT MED ONCOL, PHILADELPHIA, PA 19111 USA; UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; FOX CHASE CANC CTR, DIV BASIC SCI, PHILADELPHIA, PA 19111 USA; HARVARD UNIV, CHILDRENS HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02115 USA; VANDERBILT UNIV, MED CTR, DEPT PATHOL, NASHVILLE, TN 37232 USA	Fox Chase Cancer Center; University of Pennsylvania; Fox Chase Cancer Center; Harvard University; Boston Children's Hospital; Harvard Medical School; Vanderbilt University				Golemis, Erica/0000-0003-3618-3673	NATIONAL CANCER INSTITUTE [P30CA006927, R29CA063366, R01CA057273, R55CA057273, R01CA063366] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA57273, CA63366] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; FAN YS, 1990, P NATL ACAD SCI USA, V87, P6223, DOI 10.1073/pnas.87.16.6223; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; GALLO KA, 1994, J BIOL CHEM, V269, P15092; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1989, CURR TOP MICROBIOL, V147, P1; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; LAEMMLI UK, 1968, MOL GEN GENET, V101, P333, DOI 10.1007/BF00436231; MATTIONI T, 1995, ONCOGENE, V10, P1325; MORRIS JF, 1991, ONCOGENE, V6, P2339; Mysliwiec T, 1996, ONCOGENE, V12, P631; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PEREGO R, 1991, ONCOGENE, V6, P1899; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; Rechsteiner M, 1990, Semin Cell Biol, V1, P433; REDDY BA, 1992, MECH DEVELOP, V39, P143, DOI 10.1016/0925-4773(92)90041-H; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; RENSHAW MW, 1988, MOL CELL BIOL, V8, P4547, DOI 10.1128/MCB.8.10.4547; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROSEN MK, 1995, NATURE, V374, P477, DOI 10.1038/374477a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; TESTA JR, 1992, CYTOGENET CELL GENET, V60, P247, DOI 10.1159/000133350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WANG JYJ, 1983, MOL CELL BIOL, V3, P773, DOI 10.1128/MCB.3.5.773; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E	46	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	1996	12	9					1921	1929						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649853				2022-12-28	WOS:A1996UK49800011
J	Lebel, M; Bertrand, R; MesMasson, AM				Lebel, M; Bertrand, R; MesMasson, AM			Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice	ONCOGENE			English	Article						transgenic mice; polyomavirus large T-antigen; Fas antigen receptor; testicular cells	VIRUS EARLY PROTEINS; DIFFERENTIAL DISPLAY; MOLECULAR-CLONING; SURFACE ANTIGEN; MESSENGER-RNAS; FIBROBLASTS; ONCOGENE; MEMBER; GENE; CDNA	MT-PVLT-10 transgenic mice express large T-antigen of polyomavirus under the control of the mouse metallothionein-1 promoter and males of this transgenic line develop testicular tumors at advanced ages. The differential display technique was employed to compare mRNA expression from immortalized cell lines derived from normal or adenomatous testis from MT-PVLT-10 transgenic males. Using this technique, a complementary DNA fragment corresponding to the mouse Fas antigen receptor was recovered from normal testicular cells but not from tumor cells. RNAse protection assays with the Fas antigen specific fragment confirmed its differential expression. Normal testicular cells from the transgenic animals responded to treatment of interferon-gamma by increasing the expression of Fas antigen specific mRNA and were sensitive to the proliferative inhibitory effect of anti-Fas antibody in vitro. This proliferative inhibition was characterized by an accumulation of cells in S phase of the cell cycle. In contrast, the testicular tumor cells did not respond to either interferon-gamma or to anti-Fas antibody in vitro. These results suggest that the loss of proliferative inhibitory effect mediated by the Fas antigen pathway in tumor cells may be an important step in testicular tumor progression in the MT-PVLT-10 transgenic mice.	UNIV MONTREAL,INST CANC MONTREAL,CTR RECH LOUIS CHARLES SIMARD,MONTREAL,PQ H2L 4M1,CANADA	Universite de Montreal				Mes-Masson, Anne-Marie/0000-0002-6498-266X				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; ASSELIN C, 1983, MOL CELL BIOL, V3, P1451, DOI 10.1128/MCB.3.8.1451; BAUTCH VL, 1989, MOL BIOL MED, V6, P309; BAUTCH VL, 1987, CELL, V51, P529, DOI 10.1016/0092-8674(87)90122-X; BONAVIDA B, 1995, OVARIAN CANC, V3, P295; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CHALIFOUR LE, 1990, ONCOGENE, V5, P1719; CHALIFOUR LE, 1992, MOL CARCINOGEN, V5, P178, DOI 10.1002/mc.2940050304; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V13, P2633; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; GRIEP AE, 1989, GENE DEV, V3, P1075, DOI 10.1101/gad.3.7.1075; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENSEN NA, 1989, MOL BIOL MED, V6, P493; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; LEBEL M, 1994, EXP CELL RES, V213, P12, DOI 10.1006/excr.1994.1167; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; MERCILLE S, 1994, BIOTECHNOL BIOENG, V44, P1140, DOI 10.1002/bit.260440916; MURAKAMI T, 1995, CANCER RES, V55, P3093; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; PERRAS JP, 1993, CYTOMETRY, V14, P441, DOI 10.1002/cyto.990140414; RASSOULZADEGAN M, 1983, P NATL ACAD SCI-BIOL, V80, P4354, DOI 10.1073/pnas.80.14.4354; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; RIMOLDI D, 1990, EXP CELL RES, V191, P76, DOI 10.1016/0014-4827(90)90038-C; SAKATSUME M, 1995, J BIOL CHEM, V270, P17528, DOI 10.1074/jbc.270.29.17528; Sambrook J., 2002, MOL CLONING LAB MANU; SMERDELY P, 1993, ENDOCRINOLOGY, V133, P2403, DOI 10.1210/en.133.5.2403; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; ZHENG DQ, 1994, ONCOGENE, V9, P3345	37	29	31	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1127	1135						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649805				2022-12-28	WOS:A1996UA88400022
J	Kojima, H; Nakajima, K; Hirano, T				Kojima, H; Nakajima, K; Hirano, T			IL-6-inducible complexes on an IL-6 response element of the junB promoter contain Stat3 and 36 kDa CRE-like site binding protein(s)	ONCOGENE			English	Article						interleukin-6; junB promoter; Stat; CRE-like site	SIGNAL TRANSDUCER GP130; GROWTH-FACTOR; INTERLEUKIN-6; RECEPTOR; ACTIVATION; DNA; TRANSCRIPTION; EXPRESSION; CLONING; FAMILY	The junB gene is one of immediate-early genes whose expression are regulated by a variety of extracellular stimuli and play important roles in cellular responses to the given stimuli. Interleukin-6 (IL-6) activates the junB promoter through an IL-6 response element, JRE-IL6, that is composed of two cooperative DNA motifs, a low affinity Stat-binding site overlapping with an Ets-binding site (JEBS) and a cAMP responsive element (CRE)-like site. This element is a target for the Jak-Stat signal transduction pathway. We showed that IL-6 induced novel complexes on JRE-IL6, termed JRE-IL6-BC1 and 2, which contained Stat3 but migrated more slowly than the complexes containing homo- or heterodimer of Stat3 and Stat1 in gel shift assays, These slow-migrating JRE-IL6-BCs appeared to contain CRE-like site binding proteins besides Stat3, since the formation of JRE-IL6-BCs required both the JEBS and CRE-like site of JRE-IL6 and oligonucleotides containing the CRE-like site or somatostatin CRE efficiently competed with JRE-IL6 for making JRE-IL6-BCs. The formation of the complexes correlated well with the responsiveness of JRE-IL6 to IL-6 signals. U.v.-cross linking study revealed that JRE-IL6 bound a 90 kDa protein, corresponding to Stat3, and a 36 kDa protein, most likely a CRE-like site binding protein(s), Furthermore, we showed that the IL-6/interferon gamma (IFN gamma) response element in the IRF-1 promoter (IR/IRF-1), which contains a Stat-binding site and an adjacent CRE-like site, also makes IL-6-induced binding complexes similar to JRE-IL6-BCs.	OSAKA UNIV, SCH MED, BIOMED RES CTR, DEPT MOLEC ONCOL, SUITA, OSAKA 565, JAPAN	Osaka University			Hirano, Toshio/C-8194-2009					AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; COFFER P, 1995, ONCOGENE, V10, P985; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FUJITANI Y, 1994, BIOCHEM BIOPH RES CO, V202, P1181, DOI 10.1006/bbrc.1994.2053; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HARROCH S, 1994, J BIOL CHEM, V269, P26191; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HIRANO T, 1992, CHEM IMMUNOL, V51, P153; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; JIANG CK, 1994, MOL CELL BIOL, V14, P4759, DOI 10.1128/MCB.14.7.4759; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1994, BIOCHEM BIOPH RES CO, V200, P821, DOI 10.1006/bbrc.1994.1525; MATSUDA T, 1988, EUR J IMMUNOL, V18, P951, DOI 10.1002/eji.1830180618; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Nakajima K, 1995, ANN NY ACAD SCI, V762, P55; NAKAJIMA K, 1993, MOL CELL BIOL, V13, P3027, DOI 10.1128/MCB.13.5.3027; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.immunol.8.1.253; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WIETZERBIN J, 1989, ANN NY ACAD SCI, V557, P162; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YIN TG, 1993, J IMMUNOL, V151, P2555; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	42	73	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					547	554						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637711				2022-12-28	WOS:A1996TV59700011
J	Joh, T; Kagami, Y; Yamamoto, K; Segawa, T; Takizawa, J; Takahashi, T; Ueda, R; Seto, M				Joh, T; Kagami, Y; Yamamoto, K; Segawa, T; Takizawa, J; Takahashi, T; Ueda, R; Seto, M			Identification of MLL and chimeric MLL gene products involved in 11q23 translocation and possible mechanisms of leukemogenesis by MLL truncation	ONCOGENE			English	Article						translocation; 11q23; MLL; AF9/LTG9; ENL/LTG19; leukemogenesis	ACUTE MYELOID LEUKEMIAS; PROLINE-RICH PROTEIN; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; ALL-1 GENE; EXPRESSION; CLONING; ABNORMALITIES; CELLS; HRX	11q23 chromosome aberrations are frequently observed in infantile as web as therapy-related leukemias, The target gene at 11q23, MLL, is disrupted by the translocation and becomes fused to various translocation partner genes such as AF4/FEL, LTG9/AF9 and LTG19/ENL, The resulting chimeric mRNAs are fused in frame and have been predicted to encode leukemia-specific chimeric proteins, In the present study, we raised antibodies against MLL, LTG9 and LTG19 and demonstrated that MLL and chimeric MLL-LTG9 and MLL-LTG19 products are synthesized in vivo and are localized in the nuclei, using immunofluorescence and cell fractionation studies, The truncated N-terminal portion of the MLL product common to the various types of 11q23 translocation was also localized in the nuclei in a similar fashion, Murine 32Dc13 cells stably expressing the truncated N-terminal MLL protein exhibited an inhibition of differentiation and a growth advantage following stimulation by granulocyte-colony stimulating factor, although the IL-3 dependency was not significantly changed in comparison to the parental cells, These results suggest that the N-terminal portion common to various MLL-chimeric products plays an important role in leukemogenesis.	AICHI CANC CTR, RES INST, LAB CHEMOTHERAPY, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR, RES INST, IMMUNOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR HOSP, DEPT HEMATOL & CHEMOTHERAPY, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BERNARD OA, 1994, ONCOGENE, V9, P1039; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DANIEL MT, 1993, BLOOD, V82, P1858; DENDEREN VJ, 1989, J EXP MED, V169, P87; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; KANEKO Y, 1986, BLOOD, V67, P484; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MAVILIO F, 1989, ONCOGENE, V4, P301; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRASAD R, 1993, CANCER RES, V53, P5624; PRASAD R, 1994, P NATL ACAD SCI USA, V90, P4631; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; RUBNITZ JE, 1994, BLOOD, V84, P1747; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TSE W, 1995, BLOOD, V85, P650, DOI 10.1182/blood.V85.3.650.bloodjournal853650; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; YAMAMOTO K, 1994, BLOOD, V83, P2912, DOI 10.1182/blood.V83.10.2912.2912; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	37	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1945	1953						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934541				2022-12-28	WOS:A1996VR79500014
J	Davis, P; Bazar, K; Huper, G; Lozano, G; Marks, J; Iglehart, JD				Davis, P; Bazar, K; Huper, G; Lozano, G; Marks, J; Iglehart, JD			Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells	ONCOGENE			English	Article						p53; transactivation; tumor suppressor	TUMOR-SUPPRESSOR P53; MUTANT P53; BINDING PROTEIN; CANCER CELLS; E6 PROTEINS; T-ANTIGEN; GENE; TRANSACTIVATION; MUTATIONS; TRANSFORMATION	The p53 gene is a recessive oncogene whose loss of function can result in cell transformation, Approximately 25% of human breast cancers contain missense mutations in one p53 allele, leading to inactivation of the mutated protein. In almost all of these cases, the wild-type allele is also lost, However, it remains uncertain whether mutant p53 acts in a dominant negative fashion over the wild-type protein, Two parameters of p53 function, transcriptional activation and transcriptional repression, were studied under a variety of experimental conditions within malignant and normal breast epithelial cells, Transient transfection of DNA encoding wild-type p53 was able to transactivate p53-responsive promoters, Wild-type p53 functioned equally wed in malignant cells which harbored an endogenous mutation in p53, in malignant cells containing normal p53 and in normal mammary epithelial cells, Co-transfection of cDNAs encoding mutant p53 proteins mere unable to inhibit the ability of wild-type p53 to transactivate the reporter constructs, Repression of viral promoters by normal p53 protein was not inhibited transfected mutant p53 proteins, regulated gene WBF1/CIP1/p21 was induced following gamma irradiation in normal mammary cells, containing endogenous wild-type p53 and in the same cells transfected with mutant p53 genes, From these experiments me conclude that mutant p53 proteins do not inactivate the transactivating (or repressing) function of a co-expressed normal p53 protein in these cells implying that complete loss of mild-type p53 is required to eliminate these functions in breast epithelium.	DUKE UNIV,MED CTR,SCH MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOL GENET,HOUSTON,TX 77030	Duke University; Duke University; Duke University; University of Texas System; UTMD Anderson Cancer Center	Davis, P (corresponding author), DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710, USA.				NCI NIH HHS [1P50-CA68438, R01-CA56749] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056749, P50CA068438] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BARTEK J, 1990, ONCOGENE, V5, P893; CASEY G, 1991, ONCOGENE, V6, P1791; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DAVIDOFF AM, 1991, SURGERY, V110, P259; DAVIDOFF AM, 1991, P NATL ACAD SCI USA, V88, P5006, DOI 10.1073/pnas.88.11.5006; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FAN SJ, 1995, CANCER RES, V55, P1649; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORRESTER K, 1995, ONCOGENE, V10, P2103; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPER G, 1992, IN VITRO CELL DEV-AN, V28A, P730; IGLEHART JD, 1990, CANCER RES, V50, P6701; JING H, 1994, ONCOGENE, V9, P3397; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MICHIELI P, 1994, CANCER RES, V54, P3391; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OROURKE RW, 1990, ONCOGENE, V5, P1829; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PARK DJ, 1994, ONCOGENE, V9, P1899; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RON D, 1994, P NATL ACAD SCI USA, V91, P10985; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10567; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SAYLORS RL, 1991, CANCER RES, V51, P4721; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; UNGER T, 1992, EMBO J, V11, P1393; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WALDMAN T, 1995, CANCER RES, V55, P5187; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WILLIAMS AC, 1995, ONCOGENE, V11, P141; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WYLLIE FS, 1996, ONCOGENE, V10, P1077; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0	57	14	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1315	1322						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808706				2022-12-28	WOS:A1996VJ20200023
J	Kaul, SC; Mitsui, Y; Komatsu, Y; Reddel, RR; Wadhwa, R				Kaul, SC; Mitsui, Y; Komatsu, Y; Reddel, RR; Wadhwa, R			A highly expressed 81 kDa protein in immortalized mouse fibroblasts: Its proliferative function and identity with ezrin	ONCOGENE			English	Article						ezrin; mouse fibroblasts; proliferation; contact inhibition	MEMBRANE-CYTOSKELETAL LINKER; ACTIN-BASED CYTOSKELETONS; ERM FAMILY MEMBERS; CELLULAR MORTALITY; APICAL MICROVILLI; PARIETAL-CELLS; IDENTIFICATION; PHOSPHORYLATION; ASSOCIATION; CLEAVAGE	An 81 kDa protein was found to be highly expressed in spontaneously immortalized CD1-ICR mouse fibroblasts, RS-4, as compared to normal fibroblasts. RS-4 cells have a reduced serum requirement and exhibit multilayered growth in vitro but are not tumorigenic, The protein was purified from RS-4 cell extracts and used to obtain a polyclonal antibody that specifically immunoprecipitated an 81 kDa protein from cell lysates. Immunocloning of its cDNA and sequence analysis revealed its identity with ezrin, an F-actin binding protein that is a component of the cortical cytoskeleton, Microinjection of the purified IgG fraction of the anti-p81 antiserum into the cytoplasm of RS-4 cells blocked their entry into S phase suggesting that the protein has a proliferative function, Immunostaining of normal mouse tissues showed that the expression of p81/ezrin was highest in proliferating cell populations. Unlike RS-4, NIH3T3 cells exhibit contact inhibition and express levels of p81/ezrin similar to those of normal fibroblasts, When NIH3T3 cells were transfected with p81/ezrin cDNA they lost contact inhibition and thus resembled RS-4 cells, The study demonstrates a proliferative function of p81/ezrin and suggests its involvement in pathways that negatively regulate contact inhibition.	CHILDRENS MED RES INST,SYDNEY,NSW 2145,AUSTRALIA; CHUGAI RES INST MOL MED,NIIHARI,IBARAKI 30041,JAPAN	Children's Medical Research Institute - Australia; University of Sydney	Kaul, SC (corresponding author), AGCY IND SCI & TECHNOL,NATL INST BIOSCI & HUMAN TECHNOL,1-1 HIGASHI,TSUKUBA,IBARAKI 305,JAPAN.		Reddel, Roger R/A-6635-2014; Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	Reddel, Roger R/0000-0002-6302-6107; Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192				ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; AMIEVA MR, 1994, EXP CELL RES, V210, P140, DOI 10.1006/excr.1994.1021; ARPIN M, 1994, CURR OPIN CELL BIOL, V6, P136, DOI 10.1016/0955-0674(94)90127-9; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; EDWARDS KA, 1994, P NATL ACAD SCI USA, V91, P4589, DOI 10.1073/pnas.91.10.4589; FAZIOLI F, 1993, ONCOGENE, V8, P1335; HANZEL D, 1991, EMBO J, V10, P2363, DOI 10.1002/j.1460-2075.1991.tb07775.x; HENRY M, 1995, 1995 M CYT CELL FUNC, P69; Herman IM, 1993, CURR OPIN CELL BIOL, V5, P48, DOI 10.1016/S0955-0674(05)80007-9; KAUL SC, 1994, BBA-GEN SUBJECTS, V1201, P389, DOI 10.1016/0304-4165(94)90067-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Sambrook J., 2002, MOL CLONING LAB MANU; SHUSTER CB, 1995, J CELL BIOL, V128, P837, DOI 10.1083/jcb.128.5.837; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAKEUCHI K, 1994, J CELL BIOL, V125, P1371, DOI 10.1083/jcb.125.6.1371; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; WADHWA R, 1991, MUTAT RES, V256, P243, DOI 10.1016/0921-8734(91)90015-4; WADHWA R, 1993, J BIOL CHEM, V268, P6615; WADHWA R, 1993, EXP CELL RES, V207, P442, DOI 10.1006/excr.1993.1213; WADHWA R, 1994, CELL STRUCT FUNCT, V19, P1, DOI 10.1247/csf.19.1; WADHWA R, 1991, BIOCHEM BIOPH RES CO, V178, P269, DOI 10.1016/0006-291X(91)91809-Q; YAO XB, 1993, AM J PHYSIOL, V265, pC36, DOI 10.1152/ajpcell.1993.265.1.C36; YONEMURA S, 1993, J CELL BIOL, V120, P437, DOI 10.1083/jcb.120.2.437	29	41	45	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1231	1237						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808697				2022-12-28	WOS:A1996VJ20200014
J	Ording, E; Bergholtz, S; Brendeford, EM; Jamin, N; Gabrielsen, OS				Ording, E; Bergholtz, S; Brendeford, EM; Jamin, N; Gabrielsen, OS			Flexibility in the second half-site sequence recognised by the c-Myb R(2) domain - In vitro and in vivo analysis	ONCOGENE			English	Article						c-Myb; DNA-binding; flexibility; yeast	DNA-BINDING DOMAIN; HELIX-RELATED MOTIF; V-MYB; TRANSCRIPTIONAL ACTIVATOR; PROTOONCOGENE PRODUCT; ONCOGENE PRODUCT; SACCHAROMYCES-CEREVISIAE; ONCOPROTEIN; PROTEIN; YEAST	The oncoprotein c-Myb is a transcription factor that recognises its specific target sequences through two subdomains. The R(3)-domain binds the first half-site, YAAC, and plays a dominant role in sequence recognition, while the homologous R(2)-domain interacts with a more loosely defined sequence in the second half-site, The difficulty in precisely defining a preferred second half-site sequence might reflect the flexible nature of R(2) which only attains its fully folded structure upon binding to DNA, a process that might allow the protein to adapt to different half-site sequences, Here we report that shifting the most conserved base in the second half-site, the G6, into position 5 resulted only in a minor reduction of complex stability in vitro. From an analysis of a series of second half-site variants by EMSA and DMS-interference, we conclude that the preferred recognition sequence should be revised to read [YAACNG or YAACGN], Modeling the structure of c-Myb R(2)R(3) in complex with a GT half-site variant revealed specific interactions with G5, When second half-site variants were tested in vivo using a sensitive yeast effector-reporter system, both the TG and GT half-site variants were functional mediating c-Myb-dependent transactivation, Unexpectedly, we observed large differences between the best second half-site variants at low levels of c-Myb-effector, the GG variant being five- to fifteen-fold more active in vivo than the single-G half-sites, the GH or HG variants.	UNIV OSLO,DEPT BIOCHEM,N-0316 OSLO,NORWAY; CEA SACLAY,DIEP,F-91191 GIF SUR YVETTE,FRANCE	University of Oslo; CEA; UDICE-French Research Universities; Universite Paris Saclay			Jamin, Nadege/AAA-7067-2021					BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BONNER JJ, 1991, GENE, V104, P113, DOI 10.1016/0378-1119(91)90475-Q; BRUNELLE A, 1987, P NATL ACAD SCI USA, V84, P6673, DOI 10.1073/pnas.84.19.6673; CHEN DC, 1992, CURR GENET, V21, P83, DOI 10.1007/BF00318659; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; DASGUPTA P, 1992, J VIROL, V66, P270, DOI 10.1128/JVI.66.1.270-276.1992; EKKER SC, 1992, EMBO J, V11, P4059, DOI 10.1002/j.1460-2075.1992.tb05499.x; ESS KC, 1995, MOL CELL BIOL, V15, P5705; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; FRIED MG, 1989, ELECTROPHORESIS, V10, P366, DOI 10.1002/elps.1150100515; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GRASSER FA, 1992, ONCOGENE, V7, P1005; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUEHMANN S, 1992, NUCLEIC ACIDS RES, V20, P2279, DOI 10.1093/nar/20.9.2279; HOVERING PI, 1994, J BIOL CHEM, V269, P17663; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JAMIN N, 1993, EUR J BIOCHEM, V216, P147, DOI 10.1111/j.1432-1033.1993.tb18126.x; KANEIISHII C, 1990, J BIOL CHEM, V265, P19990; KNEGTEL RMA, 1994, J MOL BIOL, V235, P318, DOI 10.1016/S0022-2836(05)80035-X; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; Miller J. H, 1972, EXPT MOL GENETICS; MYRSET AH, 1993, EMBO J, V12, P4625, DOI 10.1002/j.1460-2075.1993.tb06151.x; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; ORDING E, 1994, EUR J BIOCHEM, V222, P113, DOI 10.1111/j.1432-1033.1994.tb18848.x; PLAZA S, 1995, ONCOGENE, V10, P329; PUNYAMMALEE B, 1991, ONCOGENE, V6, P11; SAIKUMAR P, 1994, ONCOGENE, V9, P1279; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SOLANO R, 1995, EMBO J, V14, P1773, DOI 10.1002/j.1460-2075.1995.tb07166.x; STOBERGRASSER U, 1992, ONCOGENE, V7, P589; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WILLIAMSON JR, 1990, NUCLEIC ACIDS RES, V18, P379, DOI 10.1093/nar/18.2.379	42	17	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					1043	1051						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806694				2022-12-28	WOS:A1996VG76600018
J	White, DW; Gilmore, TD				White, DW; Gilmore, TD			Bcl-2 and CrmA have different effects on transformation, apoptosis and the stability of I kappa B-alpha in chicken spleen cells transformed by temperature-sensitive v-Rel oncoproteins	ONCOGENE			English	Article						v-Rel; Bcl-2; CrmA; I kappa B-alpha; malignant transformation; apoptosis	INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; UBIQUITIN-PROTEASOME PATHWAY; IL-1-BETA-CONVERTING ENZYME; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; RECOGNITION SEQUENCE; PRECURSOR PROTEIN; MAMMALIAN HOMOLOG; C-MYC	The retroviral oncoprotein v-Rel is a member of the Rel/ NF-kappa B family of transcription factors, We have previously characterized two v-Rel mutants (v-G37E and v-R273H) that are temperature-sensitive (ts) for transformation and immortalization of chicken spleen cells in vitro. We have now constructed vectors for the co-expression of wild-type or ts mutant v-Rel proteins and the anti-apoptosis proteins Bcl-2 or CrmA. The formation of v-Rel-transformed colonies is enhanced in the presence of overexpressed Bcl-2, Moreover, coexpression of Bcl-2 suppresses apoptosis that is induced when ts v-Rel-transformed cells are shifted to the nonpermissive temperature. However, co-expression of Bcl-2 in these cells does not affect ts functions of v-Rel, such as DNA binding and stabilization of I kappa B-alpha. In contrast, coexpression of CrmA does not suppress apoptosis, but does block an amino-terminal proteolysis of I kappa B-alpha that occurs in ts v-G37E-transformed cells shifted to the nonpermissive temperature, indicating that an ICE-like protease activity is not involved in apoptosis in these cells but is involved in proteolysis of I kappa B-alpha. In addition, CrmA can block cycloheximide-induced amino-terminal processing of I kappa B-alpha in spleen cells transformed by wild-type v-Rel. In summary, these results suggest that v-Rel immortalizes chicken spleen cells through a pathway that involves the Bcl-2 family of proteins, and suggest that one pathway of proteolysis of I kappa B-alpha involves an ICE-like protease.	BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215	Boston University					NCI NIH HHS [CA 47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAZELSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90200-A; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GIOMORE TD, 1995, DNA PROVIRUS H TEMIN, P109; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HRDLICKOVA R, 1995, J VIROL, V69, P403; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LU D, 1991, ONCOGENE, V6, P1235; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MORRISON LE, 1991, ONCOGENE, V6, P1657; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Sambrook J., 2002, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, MOL CELL BIOL, V16, P1169; WHITE DW, 1995, ONCOGENE, V10, P857; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605	73	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					891	899						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806678				2022-12-28	WOS:A1996VG76600002
J	Viglietto, G; Romano, A; Maglione, D; Rambaldi, M; Paoletti, I; Lago, CT; Califano, D; Monaco, C; Mineo, A; Santelli, G; Manzo, G; Botti, G; Chiappetta, G; Persico, MG				Viglietto, G; Romano, A; Maglione, D; Rambaldi, M; Paoletti, I; Lago, CT; Califano, D; Monaco, C; Mineo, A; Santelli, G; Manzo, G; Botti, G; Chiappetta, G; Persico, MG			Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor	ONCOGENE			English	Article						VEGF; PlGF; angiogenesis; germ cell tumors; vascular count	HUMAN COLON-CANCER; PERMEABILITY FACTOR; TYROSINE KINASE; STROMA GENERATION; BREAST-CARCINOMA; MESSENGER-RNAS; UP-REGULATION; FACTOR PIGF; IN-VIVO; ANGIOGENESIS	Neoangiogenesis is a prerequisite for tumor growth and metastasis. In germ cell cancer patients with the disease limited to the testicle (stage A), tumor-associated neovascularization is predictive of metastatic disease (stage B). To investigate the molecular mechanisms underlying neovascularization in human germ cell tumors (GCTs), we analysed the expression of two angiogenic growth factors, vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF), and of their receptors (FLT-1) and Flk-1/KDR) in a panel of testicular tumors. In this study we show a marked increase in VEGF expression in 36/44 (81.8%) primary testicular-derived GCTs, as compared to normal testis, that significantly correlates with a high density of intratumor microvessels (r = 0.72461, P < 0.001; n = 24). As determined by RT-PCR and/or Western blot, the predominant VEGF isoforms expressed in GCTs are the VEGF(121) and VEGF(165) which are more efficiently secreted by the cells, and thus more active in eliciting angiogenesis. Conversely, in the case of PIGF, only a weak correlation with the vascular density of tumors is observed (r = 0.26599, P < 0.05; n = 24). Northern blot analysis also revealed significant up-regulation of VEGF/ PIGF receptors in highly vascularized germ cell tumors, compared to normal testes. These findings suggest that VEGF may act in a paracrine manner to induce neovascularization, oedema extravasation and cyst formation in human germ cell tumors. The correlation between VEGF expression and the vascular density of tumors, suggest that the evaluation of VEGF expression may be of help in predicting patients at risk for metastatic diseases. Finally, we demonstrate that VEGF up-regulation may occur at the RNA level since no gene amplification is observed; conversely, in in vitro models such as the embryonal stem cell line NTERA-2 and the choriocarcinoma JEG-3 cell line, VEGF (but not PIGF) mRNA expression is regulated by hypoxic stress.	CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Viglietto, G (corresponding author), FDN SENATORE PASCALE,IST NAZL TUMORI,VIA M SEMMOLA,I-80131 NAPLES,ITALY.		Califano, Daniela/Y-6313-2018; Viglietto, Giuseppe/AAC-2852-2019	Califano, Daniela/0000-0001-6945-3209; Viglietto, Giuseppe/0000-0003-2327-7515; Botti, Gerardo/0000-0002-6287-733X				ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; BREIER G, 1992, DEVELOPMENT, V114, P521; BROWN LF, 1993, CANCER RES, V53, P4727; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; DVORAK HF, 1987, LAB INVEST, V57, P673; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HOUCK KA, 1991, MOL ENDOCRINOL, V5, P1806, DOI 10.1210/mend-5-12-1806; Jacobsen GK., 1989, ATLAS GERM CELL TUMO; KATO Y, 1991, ENDOCRINOLOGY, V128, P401, DOI 10.1210/endo-128-1-401; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KENDALL RL, 1994, BIOCHEM BIOPH RES CO, V201, P326, DOI 10.1006/bbrc.1994.1705; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; OLIVAREZ D, 1994, CANCER RES, V54, P2800; PARK JE, 1994, J BIOL CHEM, V269, P25646; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Sambrook J., 2002, MOL CLONING LAB MANU; SAMOTO K, 1995, CANCER RES, V55, P1189; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHIBUYA M, 1990, ONCOGENE, V5, P519; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIGEGRIST W, 1994, CANCER RES, V54, P2604; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; TAKAHASHI A, 1994, CANCER RES, V54, P4233; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; TERMAN BI, 1991, ONCOGENE, V6, P1677; Tisher E, 1991, J BIOL CHEM, V266, P11947; Toi M, 1995, CLIN CANCER RES, V1, P961; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	49	105	110	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					577	587						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760299				2022-12-28	WOS:A1996VB32800015
J	Jannot, CB; Beerli, RR; Mason, S; Gullick, WJ; Hynes, NE				Jannot, CB; Beerli, RR; Mason, S; Gullick, WJ; Hynes, NE			Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells	ONCOGENE			English	Article						ErbB receptor tyrosine kinases; single-chain antibody	HUMAN-BREAST-CANCER; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; PROTEINS; ERBB-2; HEREGULIN; SH2; DOMAINS; P185NEU	A gene encoding a single-chain antibody (scFv) which specifically binds the epidermal growth factor receptor (EGFR) has been constructed from hybridoma cells producing the R1 monoclonal antibody. The gene, designated scFv-R1R, was introduced into EGFR transformed NIH3T3 cells via retroviral infection. scFv-R1R was directed to the lumen of the endoplasmic reticulum (ER) where it bound the extracellular domain of the receptor inhibiting its appearance on the plasma membrane. In these cells, EGF induced tyrosine phosphorylation of the EGFR and several substrates was greatly reduced. Furthermore, intracellular retention of EGFR caused a partial inhibition in the transformed growth of the cells. Intracellular expression of receptor tyrosine kinase directed scFvs is a novel approach for affecting tumor cell growth. We have recently shown that scFv-5R directed to ErbB2, another member of the ErbB family, blocks the anchorage independent growth of ErbB2 transformed cells. In order to examine the effects of scFv-R1R and scFv-5R on the long-term growth of tumor cells overexpressing either EGFR or ErbB2, retroviruses encoding the two scFvs were used to infect various human tumor cell lines. Intracellular expression of the scFvs resulted in a marked inhibition of stable colony formation in some of the cell lines. In general, inhibition was observed when overexpressed receptor was targeted. However, in some cases expression of both scFvs was incompatible with long term cell growth suggesting that heterodimers of ErbB2 and EGFR are essential for the growth of some human tumor cell lines.	FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND; HAMMERSMITH HOSP,IMPERIAL CANC RES FUND,MOL ONCOL UNIT,LONDON W12 0NN,ENGLAND	Friedrich Miescher Institute for Biomedical Research; Cancer Research UK; Imperial College London								BARRETTLEE P, 1990, BRIT J CANCER, V61, P612, DOI 10.1038/bjc.1990.136; BEERLI RR, 1994, BIOCHEM BIOPH RES CO, V204, P666, DOI 10.1006/bbrc.1994.2511; BEERLI RR, 1994, J BIOL CHEM, V269, P23931; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BEERLI RR, 1996, J BIOL CHEM, V271, P3071; BIOCCA S, 1995, BIO-TECHNOL, V13, P1110, DOI 10.1038/nbt1095-1110; DESHANE J, 1994, GENE THER, V1, P332; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; DUAN LX, 1994, P NATL ACAD SCI USA, V91, P5075, DOI 10.1073/pnas.91.11.5075; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GULLICK WJ, 1984, ANAL BIOCHEM, V141, P253, DOI 10.1016/0003-2697(84)90454-8; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MARTE BM, 1995, ONCOGENE, V10, P167; MHASHILKAR AM, 1995, EMBO J, V14, P1542, DOI 10.1002/j.1460-2075.1995.tb07140.x; Murphy L C, 1990, Semin Cancer Biol, V1, P305; MURRAY PA, 1993, BRIT J CANCER, V67, P1408, DOI 10.1038/bjc.1993.261; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; WELS W, 1995, INT J CANCER, V60, P137, DOI 10.1002/ijc.2910600120; WELS W, 1992, BIO-TECHNOL, V10, P1128, DOI 10.1038/nbt1092-1128; WILDENHAIN Y, 1990, ONCOGENE, V5, P879; YARDEN Y, 1989, P NATL ACAD SCI USA, V86, P3179, DOI 10.1073/pnas.86.9.3179	37	85	91	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					275	282						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710366				2022-12-28	WOS:A1996VA25200006
J	Yao, R; Cooper, GM				Yao, R; Cooper, GM			Growth factor-dependent survival of rodent fibroblasts requires phosphatidylinositol 3-kinase but is independent of pp70(S6K) activity	ONCOGENE			English	Article						apoptosis; PI 3-kinase; S6 kinase	PROGRAMMED CELL-DEATH; PROTEIN-KINASE-C; S6 KINASE; DNA-SYNTHESIS; MAMMALIAN PROTEIN; ACTIVATION; RAPAMYCIN; INSULIN; WORTMANNIN; APOPTOSIS	A variety of mammalian cells undergo apoptosis when deprived of growth factors, but the intracellular signaling pathways responsible for cell survival remain to be characterized. In the present study, we have investigated the role of PI 3-kinase and pp70(S6K) in growth factor-dependent survival of rodent fibroblasts. As previously reported for PC12 pheochromocytoma cells, Rat-1 and REF52 cells underwent apoptosis following either serum-deprivation or treatment with the PI 3-kinase inhibitors wortmannin and LY294002. In contrast, NIH3T3 and BALB 3T3 cells were resistant to apoptosis induced by either serum-deprivation or PI 3-kinase inhibition. It thus appears that PI 3-kinase is specifically required to prevent apoptosis of fibroblast that are dependent upon growth factors survival. Consistent with this role of PI 3-kinase, serum and growth factors maintained steady state levels of PI 3-kinase activity that rapidly decreased following serum-deprivation. Serum and growth factors similarly maintained a steady state level of pp70(S6K), which is thought to be activated downstream of PI 3-kinase. However, inhibition of pp70(S6K) activation by rapamycin failed to induce apoptosis in either Rat-1 or PC12 cells. Cell survival thus appears to require a PI 3-kinase signaling pathway that is independent of pp70(S6K) activation.	DANA FARBER CANC INST,DIV MOL GENET,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School					NATIONAL CANCER INSTITUTE [R01CA018689] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA18689] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FINGAR DC, 1993, J BIOL CHEM, V268, P3005; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SOLTOFF SP, 1992, J BIOL CHEM, V267, P17472; TOKER A, 1994, J BIOL CHEM, V269, P32358; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YAMAMOTOHONDA R, 1995, J BIOL CHEM, V270, P2729, DOI 10.1074/jbc.270.6.2729; YANO H, 1993, J BIOL CHEM, V268, P25846; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	42	114	114	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					343	351						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710373				2022-12-28	WOS:A1996VA25200013
J	Franks, RR; Rencic, A; Gordon, J; Zoltick, PW; Curtis, M; Knobler, RL; Khalili, K				Franks, RR; Rencic, A; Gordon, J; Zoltick, PW; Curtis, M; Knobler, RL; Khalili, K			Formation of undifferentiated mesenteric tumors in transgenic mice expressing human neurotropic polyomavirus early protein	ONCOGENE			English	Article						T-antigen; JCV; animal model for CNS tumors	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; HUMAN PAPOVAVIRUS JC; DNA-BINDING PROTEIN; HUMAN-BRAIN; STIMULATES TRANSCRIPTION; EARLY REGION; VIRUS; PROMOTER; DYSMYELINATION; INDUCTION	The human polyomavirus, JCV, is the established etiologic agent of the human demyelinating disease, progressive multifocal leukoencephalopathy (PML) seen in immunosuppressed individuals. In PML patients, the viral early protein, which is produced exclusively in glial cells is responsible for initiation of the viral lytic cycle. The JCV early protein, T-antigen, has greater than 70% homology to the web characterized SV40 early protein which has established oncogenic properties. To investigate the role of JCV T-antigen in tumorigenesis, transgenic mice containing the viral early genome were produced. Of the four positive transgenic animals, one developed severe neurological abnormalities and succumbed to death at 3 weeks of age. Another animal died with no visible gross pathology and the cause of death was not determined. The remaining two founders developed massive, undifferentiated, solid mesenteric tumors with no obvious neurological symptoms. Results from histologic analysis demonstrated the presence of highly cellular, poorly differentiated neoplastic cells in the tumor tissue. Electron microscopic evaluation of the tumor revealed the presence of a small blue cell-like tumor of epithelial/neuroectodermal origin. Results from RNA analysis by non-quantitative and highly sensitive RT-PCR indicated the presence of the JCV early transcript in various tissues, including kidney, liver, spleen, heart, lung, and brain, as well as in the tumors. However, analysis of the viral early protein by Western blot and immunohistochemistry indicated high level production of JCV early protein in the tumor tissue, but not in any other tissues. These observations present the first evidence for the development of inheritable neuroectodermal tumors induced by the human polyomavirus, JCV, early protein in a whole animal system.	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,JEFFERSON INST MOLEC MED,MOLEC NEUROVIROL SECT,PHILADELPHIA,PA 19107; UNIV ILLINOIS,COLL MED,DEPT GENET,CHICAGO,IL 60612; THOMAS JEFFERSON UNIV,DEPT PATHOL,PHILADELPHIA,PA 19107; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT NEUROL,PHILADELPHIA,PA 19107	Jefferson University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Jefferson University; Jefferson University								AHMED S, 1990, J BIOL CHEM, V265, P13899; AMEMIYA K, 1989, J BIOL CHEM, V264, P7025; Ausubel FM, 1988, MOL REPROD DEV; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; CASTAIGNE P, 1974, REV NEUROL-FRANCE, V130, P379; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; FEIGENBAUM L, 1987, P NATL ACAD SCI USA, V84, P3695, DOI 10.1073/pnas.84.11.3695; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; Flint S. J, 1981, DNA TUMOR VIRUSES; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; GIARUSSO MH, 1978, J NEUROL SCI, V35, P391, DOI 10.1016/0022-510X(78)90019-9; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; HAAS S, 1994, VIROLOGY, V202, P89, DOI 10.1006/viro.1994.1325; HOUFF SA, 1983, POLYOMAVIRUSES NEURO, P223; KENNEY S, 1984, SCIENCE, V226, P1337, DOI 10.1126/science.6095453; KERR D, 1991, J BIOL CHEM, V266, P15876; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; MAJOR EO, 1992, CLIN MICROBIOL REV, V5, P49, DOI 10.1128/CMR.5.1.49-73.1992; OHSUMI S, 1986, ACTA PATHOL JAPON, V36, P815; PADGETT BL, 1977, CANCER RES, V37, P718; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; RAJ GV, 1994, MOL CELL BIOL, V14, P7770, DOI 10.1128/MCB.14.12.7770; RAJ GV, 1995, VIROLOGY, V213, P283, DOI 10.1006/viro.1995.0001; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; SMALL JA, 1986, CELL, V46, P13, DOI 10.1016/0092-8674(86)90855-X; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SOBRINHOSIMOES M, 1990, ARCH PATHOL LAB MED, V114, P369; TADA H, 1989, J VIROL, V63, P463, DOI 10.1128/JVI.63.1.463-466.1989; TADA H, 1991, VIROLOGY, V180, P327, DOI 10.1016/0042-6822(91)90037-C; TADA H, 1992, J VIROL, V66, P6885, DOI 10.1128/JVI.66.12.6885-6892.1992; TRAPP BD, 1988, ANN NEUROL, V23, P38, DOI 10.1002/ana.410230108; VARAKIS J, 1978, CANCER RES, V38, P1718; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	35	43	44	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2573	2578						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700516				2022-12-28	WOS:A1996UW48700011
J	Fotedar, R; Fitzgerald, P; Rousselle, T; Cannella, D; Doree, M; Messier, H; Fotedar, A				Fotedar, R; Fitzgerald, P; Rousselle, T; Cannella, D; Doree, M; Messier, H; Fotedar, A			p21 contains independent binding sites for cyclin and cdk2: Both sites are required to inhibit cdk2 kinase activity	ONCOGENE			English	Article						cell cycle; cyclin-dependent kinase; cyclin-dependent kinase inhibitor; domains of p21	DEPENDENT KINASES; PHOSPHORYLATION; PROTEIN; ACTIVATION; P34CDC2; SUBUNIT; CDC2; GENE; DNA	Cyclin dependent kinases regulate the progression of eukaryotic cells through the cell cycle, p21(Cip1/Waf1/Sdi1) is an inhibitor of cdk-cyclin kinase activity, and has been shown to form complexes with cdk-cyclins and with PCNA, an accessory protein of DNA polymerase delta, The kinase inhibitory domain maps to the N-terminus (1-82) and contains the cdk2 binding site (28-82), We have generated a panel of deletion mutants of p21, A functional characterization of p21 mutants in the N-terminal domain reveals that cyclins bind to this domain independently of cdk2, Correlating with these results we find that p21 can associate with cyclin-cdk kinases in two functionally distinct forms, one in which the kinase activity is inhibited and the other in which the kinase is still active, The cdk2 and cyclin binding sites on p21 are both required to inhibit kinase activity, The second type of interaction, in which an active cyclin-cdk complex only interacts with p21 either via the cyclin or the cdk2 binding site but not through both, does not lead to inhibition of cyclin kinase activity, These results thus provide a basis for understanding the mechanism by which p21, and perhaps other cdk-cyclin kinase inhibitory proteins, suppress kinase activity.	LA JOLLA INST ALLERGY & IMMUNOL,DIV MOLEC BIOL,LA JOLLA,CA 92037; CTR RECH BIOCHIM MACROMOL,CNRS UPR 9008,F-34033 MONTPELLIER,FRANCE	La Jolla Institute for Immunology; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Fotedar, R (corresponding author), INST BIOL STRUCT JP EBEL,41 AVE MARTYRS,F-38027 GRENOBLE 1,FRANCE.		Cannella, Dominique/F-4879-2019	Cannella, Dominique/0000-0002-1665-9833	NIAID NIH HHS [R01AI31453] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031453] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BRENOTBOSC F, 1995, CHROMOSOMA, V103, P517, DOI 10.1007/BF00355316; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDIERY WS, 1993, CELL, V75, P817; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FOTEDAR R, 1991, COLD SH Q B, V56, P325; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; FOTEDAR R, 1992, EMBO J, V11, P2177, DOI 10.1002/j.1460-2075.1992.tb05277.x; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOUBIN F, 1995, ONCOGENE, V10, P2281; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HU L, 1995, GENE DEV, V9, P1740; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI Y, 1994, ONCOGENE, V9, P2261; LORCA T, 1992, J CELL SCI, V102, P55; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MESSIER H, 1993, P NATL ACAD SCI USA, V90, P2685, DOI 10.1073/pnas.90.7.2685; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONDAVEN P, 1990, GENE DEV, V4, P9, DOI 10.1101/gad.4.1.9; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	50	93	94	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 16	1996	12	10					2155	2164						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UP283	8668341				2022-12-28	WOS:A1996UP28300014
J	Neyns, B; Katesuwanasing, D; Vermeij, J; Bourgain, C; Vandamme, B; Amfo, K; Lissens, W; DeSutter, P; HooghePeters, E; DeGreve, J				Neyns, B; Katesuwanasing, D; Vermeij, J; Bourgain, C; Vandamme, B; Amfo, K; Lissens, W; DeSutter, P; HooghePeters, E; DeGreve, J			Expression of the jun family of genes in human ovarian cancer and normal ovarian surface epithelium	ONCOGENE			English	Article						proto-oncogene; c-jun; jun-B; jun-D; ovarian cancer; normal ovarian surface epithelium	PROTO-ONCOGENE FAMILY; C-JUN; CELL-GROWTH; P53 GENE; FOS; AP-1; HER-2/NEU; MEMBER; TUMORS; MYC	The jun genes (c-jun, jun-B and jun-D) play a role in critical cell functions such as proliferation, differentiation and apoptosis. We documented jun expression at the mRNA and protein level in human ovarian cancer tissues (n = 28), surface epithelial cells of normal ovaries (n = 14) and ovarian cancer cell lines (n = 6). Almost all of ovarian tumors as well as normal ovaries concomitantly express c-jun, jun-B and jun-D mRNA. Immunohistochemistry was less sensitive and revealed nuclear c-Jun and Jun-B proteins in the malignant epithelial cells of respectively 38% and 11% of ovarian tumors and in the surface epithelium of a normal premenopausal ovary. In cultured ovarian cancer cells, c-jun and jun-B expression is inducible by serum and TPA and is therefore not constitutive. The c-jun and jun-B proteins therefore play a role both in differentiation of the normal ovarian surface epithelium, as well as in the proliferation of epithelial ovarian cancer cells. High jun-B expression relates to a more malignant phenotype both in vitro and in vivo. The jun-D gene is suppressed in ovarian cancer cells as compared to normal ovarian surface epithelial cells in situ and in vitro. Downregulation of jun-D might therefore be part of the malignant ovarian epithelial cell phenotype.	FREE UNIV BRUSSELS, LAB MED ONCOL, BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, DEPT HAEMATOL & MED ONCOL, BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, NFWO, BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, AKAD ZIEKENHUIS, EXPTL PATHOL LAB, B-1090 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, AKAD ZIEKENHUIS, MED GENET LAB, B-1090 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, AKAD ZIEKENHUIS, DEPT GYNECOL, B-1090 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, AKAD ZIEKENHUIS, LAB FUNDAMENTAL & CLIN PHARMACOL, B-1090 BRUSSELS, BELGIUM	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel			Lissens, Willy/B-2892-2013; De Greve, Jacques/J-4939-2012; Neyns, Bart/ABG-3145-2021; Neyns, Bart/AAA-8267-2021	Lissens, Willy/0000-0003-3875-9955; De Greve, Jacques/0000-0002-2389-0742; Neyns, Bart/0000-0003-0658-5903; 				ALLUM WH, 1987, BRIT J CANCER, V56, P785, DOI 10.1038/bjc.1987.288; AMFO K, 1995, ONCOGENE, V11, P351; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUERSPERG A, 1994, OVARIAN CANCER, V3; Ausubel FM, 1988, MOL REPROD DEV; AUWERX J, 1992, ONCOGENE, V7, P2271; BAUKNECHT T, 1993, CANCER, V71, P419, DOI 10.1002/1097-0142(19930115)71:2<419::AID-CNCR2820710224>3.0.CO;2-6; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BERCHUCK A, 1992, HEMATOL ONCOL CLIN N, V6, P813; BERCHUCK A, 1990, CANCER RES, V50, P4087; BERGER I, 1991, ONCOGENE, V6, P561; BIGSBY RM, 1994, ENDOCRINOLOGY, V134, P1820, DOI 10.1210/en.134.4.1820; BOSSYWETZEL E, 1992, GENE DEV, V6, P2340, DOI 10.1101/gad.6.12a.2340; CARTER R, 1994, ONCOGENE, V9, P2675; CASTELLAZZI M, 1991, P NATL ACAD SCI USA, V88, P8890, DOI 10.1073/pnas.88.20.8890; CHATTON B, 1994, ONCOGENE, V9, P375; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; COHEN DR, 1993, ONCOGENE, V8, P443; DEGREVE J, 1990, P AM ASSOC CANC RES, V31, P131; DEGROOT RP, 1992, ONCOGENE, V7, P2281; HEURTEAUX C, 1993, P NATL ACAD SCI USA, V90, P9431, DOI 10.1073/pnas.90.20.9431; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; ICHIKAWA Y, 1994, CANCER RES, V54, P33; JONES DJ, 1987, BRIT J CANCER, V56, P779, DOI 10.1038/bjc.1987.287; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KERPPOLA TK, 1994, ONCOGENE, V9, P675; KHAN I, 1993, PROSTAGLANDINS, V46, P139, DOI 10.1016/0090-6980(93)90039-A; KOO AS, 1992, J UROLOGY, V148, P1314, DOI 10.1016/S0022-5347(17)36899-4; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; KRUK PA, 1990, LAB INVEST, V63, P132; MAGRISSO IJ, 1993, LAB INVEST, V69, P674; MARTI A, 1994, ONCOGENE, V9, P1213; MATTEI MG, 1990, ONCOGENE, V5, P151; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MILNER BJ, 1993, CANCER RES, V53, P2128; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; MOTTA PM, 1980, J SUBMICR CYTOL PATH, V12, P407; NEPHEW KP, 1993, ENDOCRINOLOGY, V133, P419, DOI 10.1210/en.133.1.419; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; OKAMOTO A, 1991, CANCER RES, V51, P5171; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; RUBIN SC, 1994, CANCER, V73, P1456, DOI 10.1002/1097-0142(19940301)73:5<1456::AID-CNCR2820730522>3.0.CO;2-L; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SCHLINGENSIEPEN KH, 1993, DEV GENET, V14, P305, DOI 10.1002/dvg.1020140408; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SIEMENS CH, 1988, J CELL PHYSIOL, V134, P347, DOI 10.1002/jcp.1041340305; SINGLETON TP, 1994, CANCER-AM CANCER SOC, V73, P1460, DOI 10.1002/1097-0142(19940301)73:5<1460::AID-CNCR2820730523>3.0.CO;2-Z; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMITH MJ, 1992, BLOOD, V79, P2107; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; TASHIRO H, 1992, INT J CANCER, V50, P828, DOI 10.1002/ijc.2910500528; TSAO SW, 1991, ANTICANCER RES, V11, P1975; TYSON FL, 1991, AM J OBSTET GYNECOL, V165, P640, DOI 10.1016/0002-9378(91)90300-G; VANDAMME B, 1992, CANCER RES, V52, P6646; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; YAMITHEZI A, 1994, ONCOGENE, V9, P1065; Young R.C., 1993, CANC PRINCIPLES PRAC, P1226	58	51	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1247	1257						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649827				2022-12-28	WOS:A1996UC06700010
J	Lovric, J; Radziwill, G; Moelling, K				Lovric, J; Radziwill, G; Moelling, K			Specific association of Mil/Raf proteins with a 34 kDa phosphoprotein	ONCOGENE			English	Article						Mil/Raf kinase; phosphorylation; associated proteins; cell cycle; stimulation; cellular transformation	RAF-1 PROTEIN; MAP KINASE; PHOSPHORYLATION	Mil/Raf protein kinases are intermediates in signaling pathways leading to differentiation, mitogenesis and cellular transformation. To gain insight into the activity of Mil/Raf kinases at the molecular level we aimed to identify proteins specifically interacting with Mil/Raf proteins. A phosphoprotein of 34 kDa (pp34) was found to be associated with c-Raf as well as with viral and activated forms of Mil/Raf proteins in exponentially growing interphase cells. pp34 association was not detectable in mitotic cells. Serum stimulation or coexpression of activated Ras led to decreased electrophoretic mobility of pp34 complexed to Mil/Raf proteins while serum starvation rendered pp34 undetectable. Moreover, the association with pp34 became undetectable in parallel with the onset of morphological cellular transformation caused by overexpression of a constitutively activated mutant of c-Raf in an inducible expression system. Thus, the association of Mil/Raf proteins with pp34 is altered in the course of cell cycle progression, serum stimulation and cellular transformation. These events represent hallmarks of cellular Mil/Raf functions, rendering pp34 a candidate protein involved in Mil/Raf function.	UNIV ZURICH,INST MED VIROL,CH-8028 ZURICH,SWITZERLAND	University of Zurich				Lovric, Josip/0000-0002-0338-6581				BEIMLING P, 1994, BIOCHEM BIOPH RES CO, V204, P841, DOI 10.1006/bbrc.1994.2536; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1995, MOL CELL BIOL, V15, P4125; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; JAMAL S, 1995, ONCOGENE, V10, P2095; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LOVRIC J, 1994, FEBS LETT, V343, P15, DOI 10.1016/0014-5793(94)80598-9; LOVRIC J, 1996, IN PRESS ONCOGENE; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCGREW BR, 1992, ONCOGENE, V7, P33; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; RADZIWILL G, 1995, P NATL ACAD SCI USA, V92, P1421, DOI 10.1073/pnas.92.5.1421; Rommel C, 1996, ONCOGENE, V12, P609; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHRAMM K, 1994, BIOCHEM BIOPH RES CO, V201, P740, DOI 10.1006/bbrc.1994.1763; SCHRAVEN B, 1994, J BIOL CHEM, V269, P29102; SCHULTZ AM, 1985, VIROLOGY, V146, P78, DOI 10.1016/0042-6822(85)90054-6; SIGAL CT, 1993, MOL CELL BIOL, V13, P3084, DOI 10.1128/MCB.13.5.3084; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WILLIAMS NG, 1994, CANCER METAST REV, V13, P105, DOI 10.1007/BF00690421	30	2	2	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1145	1151						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649807				2022-12-28	WOS:A1996UA88400024
J	Takle, LA; Knowles, MA				Takle, LA; Knowles, MA			Deletion mapping implicates two tumour suppressor genes on chromosome 8p in the development of bladder cancer	ONCOGENE			English	Article						chromosome 8; loss of heterozygosity; bladder cancer; tumour suppressor gene; microsatellite polymorphism	TRANSITIONAL CELL-CARCINOMA; COLORECTAL-CANCER; POLYMORPHISMS; LOCI	Chromosome 8 loss of heterozygosity (LOH) in cancer of the urinary bladder is associated with high tumour grade and stage. We have screened 193 cases of transitional cell carcinoma (TCC) of the bladder using 30 microsatellite polymorphisms on chromosome 8. Forty three cases (22%) showed LOH on 8p, the majority of which (72%) had lost the entire short arm. Using 12 tumours with partial deletions of 8p, we have defined a minimum telomeric region of deletion between D8S264 and D8S133 (8p21.1-pter). We also found LOH in the region 8p11.2-12, where we have defined at least one centromeric target for deletion within a 4 cM interval. Two tumours were identified with loss of the telomeric region only, whereas all cases with loss in the centromeric region also had telomeric deletion. Chromosome 8p deletions have also been described in prostate, colorectal, hepatocellular, lung and endometrial carcinoma and collecting duct carcinoma of the kidney. It has been postulated that loss or inactivation of at least 2 tumour suppressor genes on 8p may play an important role in progression of both prostate and colorectal carcinomas. The regions of deletion eve have identified in bladder tumours are compatible with these, suggesting that at least two genes on 8p may play a role in the development of many common solid tumours. Our findings significantly refine the localisation of the more centromeric of these loci.	MARIE CURIE RES INST,MOLEC GENET LAB,OXTED RH8 0TL,SURREY,ENGLAND					Knowles, Margaret/0000-0002-9363-8657				ATKIN NB, 1985, CANCER GENET CYTOGEN, V15, P253, DOI 10.1016/0165-4608(85)90169-4; BABU VR, 1987, CANCER RES, V47, P6800; BERGER CS, 1986, CANCER GENET CYTOGEN, V23, P1, DOI 10.1016/0165-4608(86)90145-7; BOVA GS, 1993, CANCER RES, V53, P3869; CANNIZZARO LA, 1987, CYTOGENET CELL GENET, V46, P589; CARTWRIGHT RA, 1982, LANCET, V2, P842; CUNNINGHAM C, 1993, ONCOGENE, V8, P1391; CUNNINGHAM C, 1994, BRIT J CANCER, V70, P18, DOI 10.1038/bjc.1994.243; DOBASHI Y, 1994, CANCER RES, V54, P2827; EMI M, 1992, CANCER RES, V52, P5368; FRANKE S, 1994, BIOCHEM BIOPH RES CO, V199, P52, DOI 10.1006/bbrc.1994.1192; FUJINO T, 1994, CANCER RES, V54, P4294; FUJIWARA Y, 1994, GENE CHROMOSOME CANC, V10, P7, DOI 10.1002/gcc.2870100103; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUJIWARA Y, 1995, ONCOGENE, V10, P891; GIBAS Z, 1984, CANCER RES, V44, P1257; GIBAS Z, 1986, CANCER GENET CYTOGEN, V19, P229, DOI 10.1016/0165-4608(86)90051-8; GRANBERGOHMAN I, 1984, CANCER GENET CYTOGEN, V11, P69, DOI 10.1016/0165-4608(84)90100-6; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HICKMAN D, 1994, BIOCHEM J, V297, P441, DOI 10.1042/bj2970441; ICHIKAWA T, 1994, CANCER RES, V54, P2299; JONES TA, 1993, CYTOGENET CELL GENET, V63, P35, DOI 10.1159/000133497; KEEN AJ, 1994, ONCOGENE, V9, P2083; KELEMEN PR, 1994, GENE CHROMOSOME CANC, V11, P195, DOI 10.1002/gcc.2870110308; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KNOWLES MA, 1994, CANCER RES, V54, P531; KNOWLES MA, 1993, ONCOGENE, V8, P1357; MACGROGAN D, 1994, GENE CHROMOSOME CANC, V10, P151, DOI 10.1002/gcc.2870100302; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; PROCTOR AJ, 1991, ONCOGENE, V6, P789; RISCH A, 1995, HUM MOL GENET, V4, P231, DOI 10.1093/hmg/4.2.231; SCHOENBERG M, 1995, GENE CHROMOSOME CANC, V12, P76, DOI 10.1002/gcc.2870120115; Spurr N. K., 1995, Cytogenetics and Cell Genetics, V68, P147, DOI 10.1159/000133908; TOMFOHRDE J, 1992, GENOMICS, V14, P144, DOI 10.1016/S0888-7543(05)80297-6; TRAPMAN J, 1994, CANCER RES, V54, P6061; VANNI R, 1988, CANCER GENET CYTOGEN, V30, P35, DOI 10.1016/0165-4608(88)90090-8; WANG LM, 1992, CANCER RES, V52, P4824; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; YAREMKO ML, 1994, GENE CHROMOSOME CANC, V10, P1, DOI 10.1002/gcc.2870100102	39	81	82	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 7	1996	12	5					1083	1087						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UA884	8649800				2022-12-28	WOS:A1996UA88400017
J	Cano, E; Doza, YN; BenLevy, R; Cohen, P; Mahadevan, LC				Cano, E; Doza, YN; BenLevy, R; Cohen, P; Mahadevan, LC			Identification of anisomycin-activated kinases p45 and p55 in murine cells as MAPKAP kinase-2	ONCOGENE			English	Article						growth-factors; anisomycin; stress kinases; intracellular signalling; MAP kinases; MAPKAP kinase-2	DISTINCT MECHANISMS; PROTEIN-SYNTHESIS; PHOSPHORYLATION	We recently showed that EGF and anisomycin activate two kinases, p45 and p55, whose distinguishing feature is that their detection in in-gel kinase assays is enhanced by copolymerised poly-Glu/Tyr or poly-Glu/Phe (Cane E, Hazzalin CA and Mahadevan LC, Mol. Cell, Biol,, 20:117-121). Their activation characteristics and sizes are strikingly similar to those of JNK/SAPKs, which are also strongly activated by anisomycin. However, we show here that p45 and p55 are not JNK/SAPKs but murine forms of MAPKAP kinase-2 because: (i) Detection of immunoprecipitated JNK/SAPKs is completely dependent on the presence of c-Jun as substrate in the in-gel kinase assays, whereas detection of p45 and p55 is not, (ii) Detection of p45 and p55 activity is enhanced by the presence of poly-Glu/Tyr or poly-Glu/Phe, whereas JNK/SAPKs are not detectable under these conditions. (iii) Although the sizes of the murine JNK/SAPKs and MAPKAP K-2 are similar, human JNK/SAPKs migrate at 45 and 55 kDa whereas human MAPKAP K-2 migrates at 50 kDa; the poly-Glu/Tyr-enhanced activity in human cells migrates at 50 kDa. (iv) Purified rabbit muscle MAPKAP K-2 is detectable as two bands of activity on in-gel kinase assays and their detection is enhanced by poly-Glu/Tyr. (v) Finally, the anisomycin-activated poly-Glu/Tyr-enhanced p45 and p55 kinases can be immunoprecipitated from murine cells using an anti-MAPKAP K-2 antibody. Thus, EGF- and anisomycin-activated p45 and p55 are not JNK/SAPKs but MAPKAP K-2, implying that both these agents activate the p38/RK MAP kinase cascade.	UNIV LONDON KINGS COLL,RANDALL INST,DEV BIOL RES CTR,NUCL SIGNALLING LAB,LONDON WC2B 5RL,ENGLAND; UNIV DUNDEE,INST MED SCI,DEPT BIOCHEM,MRC,PROT PHOSPHORYLAT UNIT,DUNDEE DD1 4HN,SCOTLAND; INST CANC RES,CHESTER BEATTY LABS,CRC,LONDON SW3 6JB,ENGLAND	University of London; King's College London; University of Dundee; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Cano, Eva/A-2049-2010	Cano, Eva/0000-0003-2750-6135				BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BENLEVY R, IN PRESS EMBO J; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; CANO E, 1995, J CELL SCI, V108, P3599; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUOT J, 1995, EUR J BIOCHEM, V227, P416, DOI 10.1111/j.1432-1033.1995.tb20404.x; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KARDALINOU E, 1994, MOL CELL BIOL, V14, P1066, DOI 10.1128/MCB.14.2.1066; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MAHADEVAN LC, 1991, NATURE, V349, P747, DOI 10.1038/349747c0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; YAN MH, 1994, NATURE, V372, P798	30	83	83	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 15	1996	12	4					805	812						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TW686	8632902				2022-12-28	WOS:A1996TW68600011
J	Menke, AL; Riteco, N; vanHam, RCA; deBruyne, C; Rauscher, FJ; vanderEb, AJ; Jochemsen, AG				Menke, AL; Riteco, N; vanHam, RCA; deBruyne, C; Rauscher, FJ; vanderEb, AJ; Jochemsen, AG			Wilms' Tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells	ONCOGENE			English	Article						Wilm's tumor; WT1; adenovirus, tumorigenicity; serum-dependency	ZINC FINGER PROTEIN; GENE WT1; EXPRESSION; SUPPRESSOR; BINDING; LOCUS; P53; INDUCTION; ANTIGEN; PRODUCT	The Wilms' Tumor 1 gene (WT1) encodes a transcription factor of the zinc-finger family, As a result of alternative RNA splicing, the gene can be expressed as four polypeptides which differ in the presence or absence of two stretches of amino acids: one of 17 residues (17aa) just N-terminal of the four zinc-fingers and of three residues (K-T-S) between zinc finger 3 and 4. In this study, four human cDNA constructs encoding the Wilms' tumor 1 splice variants were stably transfected into adenovirus-transformed baby rat kidney (Ad-BRK) cells. The in vivo produced WT1 proteins that lacked the KTS residues were found to bind efficiently to both the Egr-1 consensus sequence and the recently described WTE DNA sequence, as determined by electrophoretic mobility shift assays. Our studies show distinct effects of the different WT1 isoforms. Expression of the WT1 (-/+) protein, lacking the 17aa insert, strongly suppressed the tumorigenic phenotype of the Ad-BRK cells. Intriguingly, expression of the WT1 (-/-) protein, lacking both inserts, increased the tumor growth rate. In contrast to the growth in vivo, the growth rate of the transfectants in tissue culture is not influenced by any of the WT1 isoforms. However, the suppression of tumorigenicity appears to be correlated with a reduced ability of the cells to grow in serum-free medium.	LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS; WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104	Leiden University; Leiden University - Excl LUMC; The Wistar Institute			Menke, Aswin/AAC-6809-2021	Menke, Aswin/0000-0002-0724-0897				AMIN KM, 1995, AM J PATHOL, V146, P344; BAUER M, 1987, J VIROL, V61, P1821, DOI 10.1128/JVI.61.6.1821-1827.1987; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER B, 1992, ONCOGENE, V7, P1431; BRENNER BM, 1990, J AM SOC NEPHROL, V1, P127; BRIEGER J, 1994, LEUKEMIA, V8, P2138; BRUENING W, 1992, NAT GENET, V1, P144, DOI 10.1038/ng0592-144; BRUENING W, 1993, CANCER INVEST, V11, P393, DOI 10.3109/07357909309018871; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; DRUMMOND IA, 1994, MOL CELL BIOL, V14, P3800, DOI 10.1128/MCB.14.6.3800; EKBLOM P, 1980, DEV BIOL, V74, P263, DOI 10.1016/0012-1606(80)90429-7; GESSLER M, 1992, GENOMICS, V12, P807, DOI 10.1016/0888-7543(92)90313-H; HABER DA, 1993, SCIENCE, V262, P2057, DOI 10.1126/science.8266105; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HASTIE ND, 1994, ANNU REV GENET, V28, P523; KONG A, 1993, HUM MOL GENET, V2, P1967; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LARSSON SH, 1995, CELL, V81, P1; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MENKE AL, 1995, INT J CANCER, V63, P76, DOI 10.1002/ijc.2910630115; MENSSEN HD, 1995, LEUKEMIA, V9, P1060; MIWA H, 1992, LEUKEMIA, V6, P405; MORRIS JF, 1991, ONCOGENE, V6, P2339; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; PRITCHARDJONES K, 1991, ONCOGENE, V6, P2211; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RAUSCHER FJ, 1993, FASEB J, V7, P896, DOI 10.1096/fasebj.7.10.8393820; REDDY JC, 1995, J BIOL CHEM, V270, P10878, DOI 10.1074/jbc.270.18.10878; RODECK U, 1994, INT J CANCER, V59, P78, DOI 10.1002/ijc.2910590116; RUPPRECHT HD, 1994, J BIOL CHEM, V269, P6198; SABATTINI P, 1995, MOL CELL BIOL, V15, P1060; SHARMA PM, 1992, CANCER RES, V52, P6407; STEEGENGA WT, 1995, VIROLOGY, V212, P543, DOI 10.1006/viro.1995.1512; STEWART CL, 1982, P NATL ACAD SCI-BIOL, V79, P4098, DOI 10.1073/pnas.79.13.4098; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; VANLEER EHG, 1993, EXP NEPHROL, V1, P292; WALKER C, 1994, CANCER RES, V54, P3101; WANG ZY, 1995, ONCOGENE, V10, P415; WANG ZY, 1995, ONCOGENE, V10, P1243; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165	48	42	46	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					537	546						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637710				2022-12-28	WOS:A1996TV59700010
J	Morris, C; Jeffs, A; Smith, T; McDonald, M; Board, P; Kennedy, M; Fitzgerald, P				Morris, C; Jeffs, A; Smith, T; McDonald, M; Board, P; Kennedy, M; Fitzgerald, P			BCR gene recombines with genomically distinct sites on band 11Q13 in complex BCR-ABL translocations of chronic myeloid leukemia	ONCOGENE			English	Article						CML (chronic myeloid leukemia); BCR; complex Ph; recombination	CHRONIC MYELOGENOUS LEUKEMIA; VARIANT PHILADELPHIA TRANSLOCATIONS; BREAKPOINT CLUSTER REGION; INTERPHASE CELL-NUCLEI; ALU-ALU RECOMBINATION; CHROMOSOME BANDS; MOLECULAR ANALYSIS; POSITIVE LEUKEMIA; HOMOLOGOUS RECOMBINATION; DNA-SEQUENCES	We have analysed a cloned 11q13/3'BCR junction fragment, one recombination product of a complex t(9;11;22) translocation in a patient with chronic myeloid leukemia. 3'M-Bcr recombined with chromosome band 11q13 at a specific point between two Alu elements lying in opposite orientation. We present new molecular data comparing the genomic location of the 11q13 breakpoint in our patient with that of one other recently reported to lie within the GSTP1 gene. This is the first time that specific breakpoint sites within a chromosomal region highly involved in complex Ph translocations have been relatively mapped. These early results argue against a precise site in 11q13 with which M-Bcr preferentially recombines and favour instead a larger recombination-prone domain. Both of the 11q13 breakpoint regions show Alu repeat elements in close proximity to the site of recombination.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,MOLEC GENET GRP,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research	Morris, C (corresponding author), CHRISTCHURCH SCH MED,DEPT PATHOL,CYTOGENET & MOLEC ONCOL UNIT,CHRISTCHURCH,NEW ZEALAND.		Kennedy, Martin A/A-4942-2008; Morris, Christine/G-1690-2011; Kennedy, Martin/O-4540-2019; Jeffs, Aaron/B-4324-2008	Kennedy, Martin A/0000-0002-6445-8526; Kennedy, Martin/0000-0002-6445-8526; 				BOARD PG, 1989, ANN HUM GENET, V53, P205, DOI 10.1111/j.1469-1809.1989.tb01786.x; BOARD PG, 1992, GENOMICS, V14, P470, DOI 10.1016/S0888-7543(05)80243-5; CHEN SJ, 1988, LEUKEMIA, V2, P634; CHEN SJ, 1989, ONCOGENE, V4, P195; CHEN SJ, 1989, BLOOD, V73, P1312; COWELL IG, 1988, BIOCHEM J, V255, P79, DOI 10.1042/bj2550079; CRAIG JM, 1993, BIOESSAYS, V15, P349, DOI 10.1002/bies.950150510; CRAIG JM, 1994, NATURE GENETIDS, V7, P367; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEBRAEKELEER M, 1986, CANCER GENET CYTOGEN, V23, P167, DOI 10.1016/0165-4608(86)90414-0; DEKLEIN A, 1986, NUCLEIC ACIDS RES, V14, P7071, DOI 10.1093/nar/14.17.7071; DENNY CT, 1989, P NATL ACAD SCI USA, V86, P4254, DOI 10.1073/pnas.86.11.4254; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAGEMEIJER A, 1984, CANCER GENET CYTOGEN, V13, P1, DOI 10.1016/0165-4608(84)90083-9; HEIM S, 1985, CANCER GENET CYTOGEN, V18, P205; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HEISTERKAMP N, 1985, NATURE, V315, P758, DOI 10.1038/315758a0; HEISTERKAMP N, 1988, NUCLEIC ACIDS RES, V16, P10069, DOI 10.1093/nar/16.21.10069; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; HURET JL, 1986, HUM GENETY, V4, P447; JIANG XY, 1990, BLOOD, V76, P597; JURKA J, 1991, J MOL EVOL, V32, P105, DOI 10.1007/BF02515383; KODURU PRK, 1993, ONCOGENE, V8, P3239; KORENBERG JR, 1988, CELL, V53, P391, DOI 10.1016/0092-8674(88)90159-6; LAWRENCE JB, 1990, SCIENCE, V249, P928, DOI 10.1126/science.2203143; LEFRANC MP, 1986, CELL, V45, P237, DOI 10.1016/0092-8674(86)90388-0; LI L, 1993, AM J HUM GENET, V53, P140; MARCUS S, 1993, HUM GENET, V90, P477; MARKERT ML, 1988, J CLIN INVEST, V81, P1323, DOI 10.1172/JCI113458; MITELMAN F, 1991, CATALOG CHROMOSOME A; MORRIS C, 1993, HUM GENET, V91, P31, DOI 10.1007/BF00230218; MORRIS CM, 1991, BLOOD, V78, P1078; MORRIS CM, 1988, CANCER GENET CYTOGEN, V35, P179, DOI 10.1016/0165-4608(88)90240-3; MORRIS CM, 1990, BLOOD, V76, P1812; NAKAMURA Y, 1993, BRIT J HAEMATOL, V83, P53, DOI 10.1111/j.1365-2141.1993.tb04630.x; ROUYER F, 1987, CELL, V51, P417, DOI 10.1016/0092-8674(87)90637-4; Sambrook J., 1989, MOL CLONING; SANDBERG AA, 1990, CHROMOSOMES HUMAN CA, P438; SOWERBY SJ, 1993, ONCOGENE, V8, P1679; STALLINGS RL, 1993, GENOME ANAL, V7, P59; TENHOEVE J, 1993, GENOMICS, V18, P588, DOI 10.1016/S0888-7543(05)80360-X; TENHOEVE J, 1993, ONCOGENE, V8, P2469; TOTH G, 1994, GENE, V140, P285, DOI 10.1016/0378-1119(94)90559-2; TRASK B, 1989, GENOMICS, V5, P710, DOI 10.1016/0888-7543(89)90112-2; TRASK BJ, 1991, AM J HUM GENET, V48, P1; ZHANG JG, 1995, BRIT J HAEMATOL, V90, P138, DOI 10.1111/j.1365-2141.1995.tb03392.x	48	15	16	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					677	685						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637725				2022-12-28	WOS:A1996TV59700025
J	Nandurkar, HH; Hilton, DJ; Nathan, P; Willson, T; Nicola, N; Begley, CG				Nandurkar, HH; Hilton, DJ; Nathan, P; Willson, T; Nicola, N; Begley, CG			The human IL-11 receptor requires gp130 for signalling: Demonstration by molecular cloning of the receptor	ONCOGENE			English	Article						cytokine receptor; interleukin-11 receptor	COLONY-STIMULATING FACTOR; LEUKEMIA-INHIBITORY FACTOR; MURINE HEMATOPOIETIC-CELLS; EXPRESSION CLONING; GM-CSF; CYTOKINE RECEPTORS; RECOMBINANT INTERLEUKIN-11; SYNERGISTIC INTERACTIONS; MARROW CULTURES; SOLUBLE FORM	We describe the molecular cloning of a cDNA for the alpha chain of the human IL-11 receptor (IL-11R alpha) and demonstrate the requirement of either the human or mouse gp130 molecule for signalling. cDNA clones encoding IL-11R alpha were isolated from a bone marrow cDNA library using a fragment from the murine IL-11R alpha as a probe, The human receptor was predicted to consist of 422 amino acids and was found to share 84% identity with the murine protein. In the extra-cellular region it exhibited a single hemopoietin domain with conserved cysteine residues and WSTWS motif. The transmembrane region was followed by a short cytoplasmic tail which did not contain a tyrosine kinase domain. Interaction of the human IL-11R alpha with murine gp130 was demonstrated: expression of the human IL-11R alpha in murine M1 cells which constitutively express murine gp130 (and murine LIF receptor), resulted in the generation of specific high-affinity binding sites for IL-11 (K-d=250 pM). In addition, expression of the human IL-11R alpha in these cells permitted the induction of macrophage differentiation in response to IL-11, These results suggested that the human IL-11R alpha chain was able to form a functional receptor complex in association with murine gp130. The requirement of gp130 for signalling was confirmed by expression of the human IL-11R alpha in Ba/F3 cells. BaF3 cells that expressed the human IL-11R alpha alone showed binding of radiolabelled IL-11 but no proliferative response. Introduction of human gp130 into these cells resulted in high-affinity IL-11 binding sites and IL-11 dependent cellular proliferation. Thus these results demonstrated the absolute requirement of gp130 for signalling.	ROYAL MELBOURNE HOSP, COOPERAT RES CTR CELLULAR GROWTH FACTORS, MELBOURNE, VIC 3050, AUSTRALIA; ROYAL MELBOURNE HOSP, ROTARY BONE MARROW RES LAB, MELBOURNE, VIC 3050, AUSTRALIA	Royal Melbourne Hospital; Royal Melbourne Hospital	Nandurkar, HH (corresponding author), ROYAL MELBOURNE HOSP, WALTER & ELIZA HALL INST MED RES, MELBOURNE, VIC 3050, AUSTRALIA.		Nicola, Nicos/D-2989-2011; Hilton, Douglas J/C-7250-2013; Nandurkar, Harshal/AAO-7443-2020	Nicola, Nicos/0000-0003-1054-7889; Hilton, Douglas J/0000-0002-7698-2392; Nandurkar, Harshal/0000-0002-8767-116X	NCI NIH HHS [CA 22556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA022556, R01CA022556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; BAUMANN H, 1991, J BIOL CHEM, V266, P20424; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BRUCE AG, 1992, J IMMUNOL, V149, P1271; BRUNO E, 1991, EXP HEMATOL, V19, P378; BURSTEIN SA, 1992, J CELL PHYSIOL, V153, P305, DOI 10.1002/jcp.1041530210; CAIRO MS, 1994, EXP HEMATOL, V22, P1118; CHEREL M, 1995, BLOOD, V86, P2534; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; DU XX, 1994, BLOOD, V83, P2023; FANN MJ, 1994, P NATL ACAD SCI USA, V91, P43, DOI 10.1073/pnas.91.1.43; FRIELING JTM, 1994, CYTOKINE, V6, P376, DOI 10.1016/1043-4666(94)90061-2; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; HANGOC G, 1993, BLOOD, V81, P965; HARA T, 1992, EMBO J, V11, P1875, DOI 10.1002/j.1460-2075.1992.tb05239.x; HILTON DJ, 1988, J BIOL CHEM, V263, P9238; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; HIRANO T, 1994, STEM CELLS, V12, P262, DOI 10.1002/stem.5530120303; HONDA M, 1992, J IMMUNOL, V148, P2175; ICHIKAWA Y, 1969, J CELL PHYSIOL, V74, P223, DOI 10.1002/jcp.1040740303; KAWASHIMA I, 1991, FEBS LETT, V283, P199, DOI 10.1016/0014-5793(91)80587-S; KELLER DC, 1993, BLOOD, V82, P1428; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LAYTON MJ, 1992, P NATL ACAD SCI USA, V89, P8616, DOI 10.1073/pnas.89.18.8616; METCALF D, 1990, P NATL ACAD SCI USA, V87, P4670, DOI 10.1073/pnas.87.12.4670; METCALF D, 1988, LEUKEMIA, V2, P216; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; METCALF D, 1984, HEMOPOIETIC COLONIES; MIYAJIMA A, 1992, TRENDS BIOCHEM SCI, V17, P378, DOI 10.1016/0968-0004(92)90004-S; MIYAJIMA A, 1993, BLOOD, V82, P1960; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MULLBERG J, 1992, BIOCHEM BIOPH RES CO, V189, P794, DOI 10.1016/0006-291X(92)92272-Y; MUSASHI M, 1991, BLOOD, V78, P1448; NAKAJIMA T, 1992, JPN J CANCER RES, V83, P373, DOI 10.1111/j.1349-7006.1992.tb00117.x; NICOLA NA, 1991, CELL, V67, P1, DOI 10.1016/0092-8674(91)90564-F; NICOLA NA, 1995, GROWTH FACTORS CYTOK; NOVICK D, 1989, J EXP MED, V170, P1409, DOI 10.1084/jem.170.4.1409; NOVOTNY JR, 1990, EXP HEMATOL, V18, P775; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIBLER KR, 1992, BLOOD, V80, P900; SCHOENHAUT DS, 1992, J IMMUNOL, V148, P3433; SHABO Y, 1988, BLOOD, V72, P2070; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SUGITA T, 1990, J EXP MED, V171, P2001, DOI 10.1084/jem.171.6.2001; TAGA T, 1992, FASEB J, V6, P3387, DOI 10.1096/fasebj.6.15.1334470; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; TANIGAWA T, 1993, P NATL ACAD SCI USA, V90, P7864, DOI 10.1073/pnas.90.16.7864; TANIGAWA T, 1995, BLOOD, V85, P379; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TERAMURA M, 1992, BLOOD, V79, P327; TSUJI K, 1992, BLOOD, V79, P2855; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; YANG YC, 1992, BIOFACTORS, V4, P15; YIN TG, 1993, J IMMUNOL, V151, P2555; YONEMURA Y, 1993, BRIT J HAEMATOL, V84, P16, DOI 10.1111/j.1365-2141.1993.tb03020.x; YONEMURA Y, 1992, EXP HEMATOL, V20, P1011	71	70	90	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 1	1996	12	3					585	593						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637716				2022-12-28	WOS:A1996TV59700016
